0000064803-22-000008.txt : 20220209 0000064803-22-000008.hdr.sgml : 20220209 20220209063735 ACCESSION NUMBER: 0000064803-22-000008 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 143 CONFORMED PERIOD OF REPORT: 20211231 FILED AS OF DATE: 20220209 DATE AS OF CHANGE: 20220209 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CVS HEALTH Corp CENTRAL INDEX KEY: 0000064803 STANDARD INDUSTRIAL CLASSIFICATION: RETAIL-DRUG STORES AND PROPRIETARY STORES [5912] IRS NUMBER: 050494040 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-01011 FILM NUMBER: 22603738 BUSINESS ADDRESS: STREET 1: ONE CVS DR. CITY: WOONSOCKET STATE: RI ZIP: 02895 BUSINESS PHONE: 4017651500 MAIL ADDRESS: STREET 1: ONE CVS DR. CITY: WOONSOCKET STATE: RI ZIP: 02895 FORMER COMPANY: FORMER CONFORMED NAME: CVS CAREMARK CORP DATE OF NAME CHANGE: 20070509 FORMER COMPANY: FORMER CONFORMED NAME: CVS/CAREMARK CORP DATE OF NAME CHANGE: 20070322 FORMER COMPANY: FORMER CONFORMED NAME: CVS CORP DATE OF NAME CHANGE: 19970128 10-K 1 cvs-20211231.htm 10-K cvs-20211231
00000648032021FYfalsehttp://fasb.org/us-gaap/2021-01-31#ProductMemberhttp://fasb.org/us-gaap/2021-01-31#ProductMemberhttp://fasb.org/us-gaap/2021-01-31#ProductMemberhttp://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201602Memberhttp://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201613MemberP3Yhttp://fasb.org/us-gaap/2021-01-31#LongTermDebtAndCapitalLeaseObligationshttp://fasb.org/us-gaap/2021-01-31#LongTermDebtAndCapitalLeaseObligationsP3Y00000648032021-01-012021-12-3100000648032021-06-30iso4217:USD00000648032022-02-02xbrli:shares0000064803us-gaap:ProductMember2021-01-012021-12-310000064803us-gaap:ProductMember2020-01-012020-12-310000064803us-gaap:ProductMember2019-01-012019-12-3100000648032020-01-012020-12-3100000648032019-01-012019-12-310000064803us-gaap:ServiceMember2021-01-012021-12-310000064803us-gaap:ServiceMember2020-01-012020-12-310000064803us-gaap:ServiceMember2019-01-012019-12-31iso4217:USDxbrli:shares00000648032021-12-3100000648032020-12-3100000648032019-12-3100000648032018-12-310000064803us-gaap:CommonStockMember2018-12-310000064803us-gaap:TreasuryStockMember2018-12-310000064803us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2018-12-310000064803us-gaap:RetainedEarningsMember2018-12-310000064803us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-12-310000064803us-gaap:ParentMember2018-12-310000064803us-gaap:NoncontrollingInterestMember2018-12-310000064803srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:RetainedEarningsMemberus-gaap:AccountingStandardsUpdate201602Member2018-12-310000064803srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:ParentMember2018-12-310000064803srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2018-12-310000064803us-gaap:RetainedEarningsMember2019-01-012019-12-310000064803us-gaap:ParentMember2019-01-012019-12-310000064803us-gaap:NoncontrollingInterestMember2019-01-012019-12-310000064803us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-01-012019-12-310000064803us-gaap:CommonStockMember2019-01-012019-12-310000064803us-gaap:TreasuryStockMember2019-01-012019-12-310000064803us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2019-01-012019-12-310000064803us-gaap:CommonStockMember2019-12-310000064803us-gaap:TreasuryStockMember2019-12-310000064803us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2019-12-310000064803us-gaap:RetainedEarningsMember2019-12-310000064803us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310000064803us-gaap:ParentMember2019-12-310000064803us-gaap:NoncontrollingInterestMember2019-12-310000064803srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:RetainedEarningsMember2019-12-310000064803srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:ParentMember2019-12-310000064803srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2019-12-310000064803us-gaap:RetainedEarningsMember2020-01-012020-12-310000064803us-gaap:ParentMember2020-01-012020-12-310000064803us-gaap:NoncontrollingInterestMember2020-01-012020-12-310000064803us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-12-310000064803us-gaap:CommonStockMember2020-01-012020-12-310000064803us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2020-01-012020-12-310000064803us-gaap:TreasuryStockMember2020-01-012020-12-310000064803us-gaap:CommonStockMember2020-12-310000064803us-gaap:TreasuryStockMember2020-12-310000064803us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2020-12-310000064803us-gaap:RetainedEarningsMember2020-12-310000064803us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310000064803us-gaap:ParentMember2020-12-310000064803us-gaap:NoncontrollingInterestMember2020-12-310000064803us-gaap:RetainedEarningsMember2021-01-012021-12-310000064803us-gaap:ParentMember2021-01-012021-12-310000064803us-gaap:NoncontrollingInterestMember2021-01-012021-12-310000064803us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-12-310000064803us-gaap:CommonStockMember2021-01-012021-12-310000064803us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2021-01-012021-12-310000064803us-gaap:TreasuryStockMember2021-01-012021-12-310000064803us-gaap:CommonStockMember2021-12-310000064803us-gaap:TreasuryStockMember2021-12-310000064803us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2021-12-310000064803us-gaap:RetainedEarningsMember2021-12-310000064803us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310000064803us-gaap:ParentMember2021-12-310000064803us-gaap:NoncontrollingInterestMember2021-12-310000064803us-gaap:AccountingStandardsUpdate201602Member2018-01-012018-12-310000064803us-gaap:AccountingStandardsUpdate201613Member2019-01-012019-12-310000064803srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:RetainedEarningsMemberus-gaap:AccountingStandardsUpdate201613Member2019-12-310000064803cvs:RetailLongTermCareSegmentMember2021-12-31cvs:storecvs:membercvs:peoplecvs:patientcvs:Segment0000064803cvs:HealthCareBenefitsSegmentMember2021-01-012021-12-31cvs:statecvs:clinic0000064803srt:MinimumMemberus-gaap:BuildingAndBuildingImprovementsMember2021-01-012021-12-310000064803srt:MaximumMemberus-gaap:BuildingAndBuildingImprovementsMember2021-01-012021-12-310000064803cvs:FixturesEquipmentAndInternallyDevelopedSoftwareMembersrt:MinimumMember2021-01-012021-12-310000064803cvs:FixturesEquipmentAndInternallyDevelopedSoftwareMembersrt:MaximumMember2021-01-012021-12-310000064803us-gaap:LandMember2021-12-310000064803us-gaap:LandMember2020-12-310000064803us-gaap:BuildingAndBuildingImprovementsMember2021-12-310000064803us-gaap:BuildingAndBuildingImprovementsMember2020-12-310000064803us-gaap:FurnitureAndFixturesMember2021-12-310000064803us-gaap:FurnitureAndFixturesMember2020-12-310000064803us-gaap:LeaseholdImprovementsMember2021-12-310000064803us-gaap:LeaseholdImprovementsMember2020-12-310000064803us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2021-12-310000064803us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2020-12-310000064803us-gaap:PropertyPlantAndEquipmentMembercvs:RetailLongTermCareSegmentMember2021-10-012021-12-310000064803srt:MaximumMember2021-01-012021-12-310000064803cvs:RetailLongTermCareSegmentMember2021-01-012021-12-310000064803cvs:LongTermCareReportingUnitMember2021-07-012021-09-3000000648032020-07-012020-09-3000000648032019-07-012019-09-300000064803srt:MinimumMember2021-01-012021-12-310000064803cvs:OtherInsuranceLiabilitiesMember2021-12-310000064803cvs:OtherLongTermInsuranceLiabilitiesMember2021-12-310000064803cvs:OtherInsuranceLiabilitiesMember2020-12-310000064803cvs:OtherLongTermInsuranceLiabilitiesMember2020-12-31xbrli:pure0000064803srt:MinimumMember2020-01-012020-12-310000064803srt:MaximumMember2020-01-012020-12-310000064803us-gaap:HealthInsuranceProductLineMember2021-12-310000064803us-gaap:HealthInsuranceProductLineMember2020-12-310000064803us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMemberus-gaap:DiscontinuedOperationsDisposedOfBySaleMembercvs:BrazilSubsidiaryMember2019-01-012019-12-310000064803us-gaap:OperatingSegmentsMembercvs:HealthCareBenefitsSegmentMembercvs:PharmacyRevenueMember2021-01-012021-12-310000064803us-gaap:OperatingSegmentsMembercvs:PharmacyServicesSegmentMembercvs:PharmacyRevenueMember2021-01-012021-12-310000064803us-gaap:OperatingSegmentsMembercvs:RetailLongTermCareSegmentMembercvs:PharmacyRevenueMember2021-01-012021-12-310000064803us-gaap:CorporateNonSegmentMembercvs:PharmacyRevenueMember2021-01-012021-12-310000064803us-gaap:IntersegmentEliminationMembercvs:PharmacyRevenueMember2021-01-012021-12-310000064803cvs:PharmacyRevenueMember2021-01-012021-12-310000064803us-gaap:OperatingSegmentsMembercvs:HealthCareBenefitsSegmentMembercvs:FrontStoreRevenueMember2021-01-012021-12-310000064803us-gaap:OperatingSegmentsMembercvs:FrontStoreRevenueMembercvs:PharmacyServicesSegmentMember2021-01-012021-12-310000064803us-gaap:OperatingSegmentsMembercvs:RetailLongTermCareSegmentMembercvs:FrontStoreRevenueMember2021-01-012021-12-310000064803cvs:FrontStoreRevenueMemberus-gaap:CorporateNonSegmentMember2021-01-012021-12-310000064803us-gaap:IntersegmentEliminationMembercvs:FrontStoreRevenueMember2021-01-012021-12-310000064803cvs:FrontStoreRevenueMember2021-01-012021-12-310000064803us-gaap:OperatingSegmentsMembercvs:HealthCareBenefitsSegmentMembercvs:PremiumsMember2021-01-012021-12-310000064803us-gaap:OperatingSegmentsMembercvs:PremiumsMembercvs:PharmacyServicesSegmentMember2021-01-012021-12-310000064803us-gaap:OperatingSegmentsMembercvs:RetailLongTermCareSegmentMembercvs:PremiumsMember2021-01-012021-12-310000064803cvs:PremiumsMemberus-gaap:CorporateNonSegmentMember2021-01-012021-12-310000064803us-gaap:IntersegmentEliminationMembercvs:PremiumsMember2021-01-012021-12-310000064803cvs:PremiumsMember2021-01-012021-12-310000064803us-gaap:OperatingSegmentsMembercvs:HealthCareBenefitsSegmentMember2021-01-012021-12-310000064803us-gaap:OperatingSegmentsMembercvs:PharmacyServicesSegmentMember2021-01-012021-12-310000064803us-gaap:OperatingSegmentsMembercvs:RetailLongTermCareSegmentMember2021-01-012021-12-310000064803us-gaap:CorporateNonSegmentMember2021-01-012021-12-310000064803us-gaap:IntersegmentEliminationMember2021-01-012021-12-310000064803us-gaap:OperatingSegmentsMembercvs:HealthCareBenefitsSegmentMemberus-gaap:ProductAndServiceOtherMember2021-01-012021-12-310000064803us-gaap:OperatingSegmentsMemberus-gaap:ProductAndServiceOtherMembercvs:PharmacyServicesSegmentMember2021-01-012021-12-310000064803us-gaap:OperatingSegmentsMembercvs:RetailLongTermCareSegmentMemberus-gaap:ProductAndServiceOtherMember2021-01-012021-12-310000064803us-gaap:ProductAndServiceOtherMemberus-gaap:CorporateNonSegmentMember2021-01-012021-12-310000064803us-gaap:IntersegmentEliminationMemberus-gaap:ProductAndServiceOtherMember2021-01-012021-12-310000064803us-gaap:ProductAndServiceOtherMember2021-01-012021-12-310000064803us-gaap:OperatingSegmentsMemberus-gaap:SalesChannelThroughIntermediaryMembercvs:PharmacyServicesSegmentMember2021-01-012021-12-310000064803us-gaap:OperatingSegmentsMemberus-gaap:SalesChannelDirectlyToConsumerMembercvs:PharmacyServicesSegmentMember2021-01-012021-12-310000064803cvs:SalesChannelOtherMemberus-gaap:OperatingSegmentsMembercvs:PharmacyServicesSegmentMember2021-01-012021-12-310000064803us-gaap:OperatingSegmentsMembercvs:HealthCareBenefitsSegmentMembercvs:PharmacyRevenueMember2020-01-012020-12-310000064803us-gaap:OperatingSegmentsMembercvs:PharmacyServicesSegmentMembercvs:PharmacyRevenueMember2020-01-012020-12-310000064803us-gaap:OperatingSegmentsMembercvs:RetailLongTermCareSegmentMembercvs:PharmacyRevenueMember2020-01-012020-12-310000064803us-gaap:CorporateNonSegmentMembercvs:PharmacyRevenueMember2020-01-012020-12-310000064803us-gaap:IntersegmentEliminationMembercvs:PharmacyRevenueMember2020-01-012020-12-310000064803cvs:PharmacyRevenueMember2020-01-012020-12-310000064803us-gaap:OperatingSegmentsMembercvs:HealthCareBenefitsSegmentMembercvs:FrontStoreRevenueMember2020-01-012020-12-310000064803us-gaap:OperatingSegmentsMembercvs:FrontStoreRevenueMembercvs:PharmacyServicesSegmentMember2020-01-012020-12-310000064803us-gaap:OperatingSegmentsMembercvs:RetailLongTermCareSegmentMembercvs:FrontStoreRevenueMember2020-01-012020-12-310000064803cvs:FrontStoreRevenueMemberus-gaap:CorporateNonSegmentMember2020-01-012020-12-310000064803us-gaap:IntersegmentEliminationMembercvs:FrontStoreRevenueMember2020-01-012020-12-310000064803cvs:FrontStoreRevenueMember2020-01-012020-12-310000064803us-gaap:OperatingSegmentsMembercvs:HealthCareBenefitsSegmentMembercvs:PremiumsMember2020-01-012020-12-310000064803us-gaap:OperatingSegmentsMembercvs:PremiumsMembercvs:PharmacyServicesSegmentMember2020-01-012020-12-310000064803us-gaap:OperatingSegmentsMembercvs:RetailLongTermCareSegmentMembercvs:PremiumsMember2020-01-012020-12-310000064803cvs:PremiumsMemberus-gaap:CorporateNonSegmentMember2020-01-012020-12-310000064803us-gaap:IntersegmentEliminationMembercvs:PremiumsMember2020-01-012020-12-310000064803cvs:PremiumsMember2020-01-012020-12-310000064803us-gaap:OperatingSegmentsMembercvs:HealthCareBenefitsSegmentMember2020-01-012020-12-310000064803us-gaap:OperatingSegmentsMembercvs:PharmacyServicesSegmentMember2020-01-012020-12-310000064803us-gaap:OperatingSegmentsMembercvs:RetailLongTermCareSegmentMember2020-01-012020-12-310000064803us-gaap:CorporateNonSegmentMember2020-01-012020-12-310000064803us-gaap:IntersegmentEliminationMember2020-01-012020-12-310000064803us-gaap:OperatingSegmentsMembercvs:HealthCareBenefitsSegmentMemberus-gaap:ProductAndServiceOtherMember2020-01-012020-12-310000064803us-gaap:OperatingSegmentsMemberus-gaap:ProductAndServiceOtherMembercvs:PharmacyServicesSegmentMember2020-01-012020-12-310000064803us-gaap:OperatingSegmentsMembercvs:RetailLongTermCareSegmentMemberus-gaap:ProductAndServiceOtherMember2020-01-012020-12-310000064803us-gaap:ProductAndServiceOtherMemberus-gaap:CorporateNonSegmentMember2020-01-012020-12-310000064803us-gaap:IntersegmentEliminationMemberus-gaap:ProductAndServiceOtherMember2020-01-012020-12-310000064803us-gaap:ProductAndServiceOtherMember2020-01-012020-12-310000064803us-gaap:OperatingSegmentsMemberus-gaap:SalesChannelThroughIntermediaryMembercvs:PharmacyServicesSegmentMember2020-01-012020-12-310000064803us-gaap:OperatingSegmentsMemberus-gaap:SalesChannelDirectlyToConsumerMembercvs:PharmacyServicesSegmentMember2020-01-012020-12-310000064803cvs:SalesChannelOtherMemberus-gaap:OperatingSegmentsMembercvs:PharmacyServicesSegmentMember2020-01-012020-12-310000064803us-gaap:OperatingSegmentsMembercvs:HealthCareBenefitsSegmentMembercvs:PharmacyRevenueMember2019-01-012019-12-310000064803us-gaap:OperatingSegmentsMembercvs:PharmacyServicesSegmentMembercvs:PharmacyRevenueMember2019-01-012019-12-310000064803us-gaap:OperatingSegmentsMembercvs:RetailLongTermCareSegmentMembercvs:PharmacyRevenueMember2019-01-012019-12-310000064803us-gaap:CorporateNonSegmentMembercvs:PharmacyRevenueMember2019-01-012019-12-310000064803us-gaap:IntersegmentEliminationMembercvs:PharmacyRevenueMember2019-01-012019-12-310000064803cvs:PharmacyRevenueMember2019-01-012019-12-310000064803us-gaap:OperatingSegmentsMembercvs:HealthCareBenefitsSegmentMembercvs:FrontStoreRevenueMember2019-01-012019-12-310000064803us-gaap:OperatingSegmentsMembercvs:FrontStoreRevenueMembercvs:PharmacyServicesSegmentMember2019-01-012019-12-310000064803us-gaap:OperatingSegmentsMembercvs:RetailLongTermCareSegmentMembercvs:FrontStoreRevenueMember2019-01-012019-12-310000064803cvs:FrontStoreRevenueMemberus-gaap:CorporateNonSegmentMember2019-01-012019-12-310000064803us-gaap:IntersegmentEliminationMembercvs:FrontStoreRevenueMember2019-01-012019-12-310000064803cvs:FrontStoreRevenueMember2019-01-012019-12-310000064803us-gaap:OperatingSegmentsMembercvs:HealthCareBenefitsSegmentMembercvs:PremiumsMember2019-01-012019-12-310000064803us-gaap:OperatingSegmentsMembercvs:PremiumsMembercvs:PharmacyServicesSegmentMember2019-01-012019-12-310000064803us-gaap:OperatingSegmentsMembercvs:RetailLongTermCareSegmentMembercvs:PremiumsMember2019-01-012019-12-310000064803cvs:PremiumsMemberus-gaap:CorporateNonSegmentMember2019-01-012019-12-310000064803us-gaap:IntersegmentEliminationMembercvs:PremiumsMember2019-01-012019-12-310000064803cvs:PremiumsMember2019-01-012019-12-310000064803us-gaap:OperatingSegmentsMembercvs:HealthCareBenefitsSegmentMember2019-01-012019-12-310000064803us-gaap:OperatingSegmentsMembercvs:PharmacyServicesSegmentMember2019-01-012019-12-310000064803us-gaap:OperatingSegmentsMembercvs:RetailLongTermCareSegmentMember2019-01-012019-12-310000064803us-gaap:CorporateNonSegmentMember2019-01-012019-12-310000064803us-gaap:IntersegmentEliminationMember2019-01-012019-12-310000064803us-gaap:OperatingSegmentsMembercvs:HealthCareBenefitsSegmentMemberus-gaap:ProductAndServiceOtherMember2019-01-012019-12-310000064803us-gaap:OperatingSegmentsMemberus-gaap:ProductAndServiceOtherMembercvs:PharmacyServicesSegmentMember2019-01-012019-12-310000064803us-gaap:OperatingSegmentsMembercvs:RetailLongTermCareSegmentMemberus-gaap:ProductAndServiceOtherMember2019-01-012019-12-310000064803us-gaap:ProductAndServiceOtherMemberus-gaap:CorporateNonSegmentMember2019-01-012019-12-310000064803us-gaap:IntersegmentEliminationMemberus-gaap:ProductAndServiceOtherMember2019-01-012019-12-310000064803us-gaap:ProductAndServiceOtherMember2019-01-012019-12-310000064803us-gaap:OperatingSegmentsMemberus-gaap:SalesChannelThroughIntermediaryMembercvs:PharmacyServicesSegmentMember2019-01-012019-12-310000064803us-gaap:OperatingSegmentsMemberus-gaap:SalesChannelDirectlyToConsumerMembercvs:PharmacyServicesSegmentMember2019-01-012019-12-310000064803cvs:SalesChannelOtherMemberus-gaap:OperatingSegmentsMembercvs:PharmacyServicesSegmentMember2019-01-012019-12-310000064803us-gaap:SettledLitigationMembercvs:USDepartmentOfHealthAndHumanServicesACARiskCorridorReceivablesMember2019-08-310000064803us-gaap:SettledLitigationMembercvs:USDepartmentOfHealthAndHumanServicesACARiskCorridorReceivablesMember2020-10-222020-10-220000064803us-gaap:SettledLitigationMembercvs:USDepartmentOfHealthAndHumanServicesACARiskCorridorReceivablesMember2020-12-310000064803cvs:RedOakMember2014-01-012014-12-310000064803cvs:RedOakMember2021-01-012021-12-310000064803us-gaap:HedgeFundsMemberus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2021-12-310000064803us-gaap:HedgeFundsMemberus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2020-12-310000064803us-gaap:PrivateEquityFundsMemberus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2021-12-310000064803us-gaap:PrivateEquityFundsMemberus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2020-12-310000064803us-gaap:RealEstateFundsMemberus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2021-12-310000064803us-gaap:RealEstateFundsMemberus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2020-12-310000064803us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2021-12-310000064803us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2020-12-310000064803cvs:HeartlandHealthcareServicesMember2021-12-310000064803cvs:CoventryHealthCareWorkersCompensationBusinessMemberus-gaap:DiscontinuedOperationsDisposedOfBySaleMembercvs:HealthCareBenefitsSegmentMember2020-07-312020-07-310000064803cvs:CoventryHealthCareWorkersCompensationBusinessMemberus-gaap:DiscontinuedOperationsDisposedOfBySaleMembercvs:HealthCareBenefitsSegmentMember2020-01-012020-12-310000064803us-gaap:DiscontinuedOperationsDisposedOfBySaleMembercvs:RetailLongTermCareSegmentMembercvs:BrazilSubsidiaryMember2019-07-010000064803us-gaap:DiscontinuedOperationsDisposedOfBySaleMembercvs:RetailLongTermCareSegmentMembercvs:DrogariaOnofreLtdaMember2019-01-012019-12-310000064803cvs:DebtAndEquitySecuritiesAvailableForSaleMember2021-12-310000064803cvs:DebtAndEquitySecuritiesAvailableForSaleMember2020-12-310000064803cvs:MortgageLoansMember2021-12-310000064803cvs:MortgageLoansMember2020-12-310000064803us-gaap:OtherInvestmentsMember2021-12-310000064803us-gaap:OtherInvestmentsMember2020-12-310000064803us-gaap:USGovernmentAgenciesDebtSecuritiesMember2021-12-310000064803us-gaap:USStatesAndPoliticalSubdivisionsMember2021-12-310000064803us-gaap:DomesticCorporateDebtSecuritiesMember2021-12-310000064803us-gaap:ForeignCorporateDebtSecuritiesMember2021-12-310000064803us-gaap:ResidentialMortgageBackedSecuritiesMember2021-12-310000064803us-gaap:CommercialMortgageBackedSecuritiesMember2021-12-310000064803cvs:OtherAssetBackedSecuritiesMember2021-12-310000064803us-gaap:RedeemablePreferredStockMember2021-12-310000064803us-gaap:USGovernmentAgenciesDebtSecuritiesMember2020-12-310000064803us-gaap:USStatesAndPoliticalSubdivisionsMember2020-12-310000064803us-gaap:DomesticCorporateDebtSecuritiesMember2020-12-310000064803us-gaap:ForeignCorporateDebtSecuritiesMember2020-12-310000064803us-gaap:ResidentialMortgageBackedSecuritiesMember2020-12-310000064803us-gaap:CommercialMortgageBackedSecuritiesMember2020-12-310000064803cvs:OtherAssetBackedSecuritiesMember2020-12-310000064803us-gaap:RedeemablePreferredStockMember2020-12-310000064803cvs:SupportingExperienceRatedProductsMember2021-12-310000064803cvs:SupportingExperienceRatedProductsMember2020-12-310000064803us-gaap:ResidentialMortgageBackedSecuritiesMember2021-01-012021-12-310000064803us-gaap:CommercialMortgageBackedSecuritiesMember2021-01-012021-12-310000064803cvs:OtherAssetBackedSecuritiesMember2021-01-012021-12-31cvs:security0000064803cvs:RedeemablePreferredSecuritiesMember2021-12-310000064803cvs:SupportingRemainingProductsMember2021-12-310000064803us-gaap:ResidentialMortgageBackedSecuritiesMembercvs:SupportingExperienceRatedProductsMember2021-12-310000064803cvs:SupportingRemainingProductsMemberus-gaap:ResidentialMortgageBackedSecuritiesMember2021-12-310000064803us-gaap:CommercialMortgageBackedSecuritiesMembercvs:SupportingExperienceRatedProductsMember2021-12-310000064803cvs:SupportingRemainingProductsMemberus-gaap:CommercialMortgageBackedSecuritiesMember2021-12-310000064803cvs:OtherAssetBackedSecuritiesMembercvs:SupportingExperienceRatedProductsMember2021-12-310000064803cvs:SupportingRemainingProductsMembercvs:OtherAssetBackedSecuritiesMember2021-12-310000064803us-gaap:CommercialRealEstateMember2021-01-012021-12-310000064803us-gaap:CommercialRealEstateMember2020-01-012020-12-310000064803us-gaap:CommercialRealEstateMembercvs:Category1Membercvs:YearOfOriginationPeriodOneMember2021-12-310000064803us-gaap:CommercialRealEstateMembercvs:Category1Membercvs:YearOfOriginationPeriodTwoMember2021-12-310000064803us-gaap:CommercialRealEstateMembercvs:YearOfOriginationPeriodThreeMembercvs:Category1Member2021-12-310000064803us-gaap:CommercialRealEstateMembercvs:Category1Membercvs:YearOfOriginationPeriodFourMember2021-12-310000064803us-gaap:CommercialRealEstateMembercvs:Category1Membercvs:YearOfOriginationPeriodFiveMember2021-12-310000064803us-gaap:CommercialRealEstateMembercvs:YearOfOriginationPriorToPeriodFiveMembercvs:Category1Member2021-12-310000064803us-gaap:CommercialRealEstateMembercvs:Category1Member2021-12-310000064803us-gaap:CommercialRealEstateMembercvs:Category2To4Membercvs:YearOfOriginationPeriodOneMember2021-12-310000064803us-gaap:CommercialRealEstateMembercvs:Category2To4Membercvs:YearOfOriginationPeriodTwoMember2021-12-310000064803us-gaap:CommercialRealEstateMembercvs:YearOfOriginationPeriodThreeMembercvs:Category2To4Member2021-12-310000064803us-gaap:CommercialRealEstateMembercvs:YearOfOriginationPeriodFourMembercvs:Category2To4Member2021-12-310000064803us-gaap:CommercialRealEstateMembercvs:Category2To4Membercvs:YearOfOriginationPeriodFiveMember2021-12-310000064803us-gaap:CommercialRealEstateMembercvs:YearOfOriginationPriorToPeriodFiveMembercvs:Category2To4Member2021-12-310000064803us-gaap:CommercialRealEstateMembercvs:Category2To4Member2021-12-310000064803us-gaap:CommercialRealEstateMembercvs:Categories5and6Membercvs:YearOfOriginationPeriodOneMember2021-12-310000064803us-gaap:CommercialRealEstateMembercvs:Categories5and6Membercvs:YearOfOriginationPeriodTwoMember2021-12-310000064803us-gaap:CommercialRealEstateMembercvs:YearOfOriginationPeriodThreeMembercvs:Categories5and6Member2021-12-310000064803us-gaap:CommercialRealEstateMembercvs:Categories5and6Membercvs:YearOfOriginationPeriodFourMember2021-12-310000064803us-gaap:CommercialRealEstateMembercvs:Categories5and6Membercvs:YearOfOriginationPeriodFiveMember2021-12-310000064803us-gaap:CommercialRealEstateMembercvs:Categories5and6Membercvs:YearOfOriginationPriorToPeriodFiveMember2021-12-310000064803us-gaap:CommercialRealEstateMembercvs:Categories5and6Member2021-12-310000064803us-gaap:CommercialRealEstateMembercvs:YearOfOriginationPeriodOneMembercvs:Category7Member2021-12-310000064803us-gaap:CommercialRealEstateMembercvs:Category7Membercvs:YearOfOriginationPeriodTwoMember2021-12-310000064803us-gaap:CommercialRealEstateMembercvs:YearOfOriginationPeriodThreeMembercvs:Category7Member2021-12-310000064803us-gaap:CommercialRealEstateMembercvs:YearOfOriginationPeriodFourMembercvs:Category7Member2021-12-310000064803us-gaap:CommercialRealEstateMembercvs:YearOfOriginationPeriodFiveMembercvs:Category7Member2021-12-310000064803us-gaap:CommercialRealEstateMembercvs:YearOfOriginationPriorToPeriodFiveMembercvs:Category7Member2021-12-310000064803us-gaap:CommercialRealEstateMembercvs:Category7Member2021-12-310000064803us-gaap:CommercialRealEstateMembercvs:YearOfOriginationPeriodOneMember2021-12-310000064803us-gaap:CommercialRealEstateMembercvs:YearOfOriginationPeriodTwoMember2021-12-310000064803us-gaap:CommercialRealEstateMembercvs:YearOfOriginationPeriodThreeMember2021-12-310000064803us-gaap:CommercialRealEstateMembercvs:YearOfOriginationPeriodFourMember2021-12-310000064803us-gaap:CommercialRealEstateMembercvs:YearOfOriginationPeriodFiveMember2021-12-310000064803us-gaap:CommercialRealEstateMembercvs:YearOfOriginationPriorToPeriodFiveMember2021-12-310000064803us-gaap:CommercialRealEstateMember2021-12-310000064803us-gaap:CommercialRealEstateMembercvs:Category1Membercvs:YearOfOriginationPeriodTwoMember2020-12-310000064803us-gaap:CommercialRealEstateMembercvs:YearOfOriginationPeriodThreeMembercvs:Category1Member2020-12-310000064803us-gaap:CommercialRealEstateMembercvs:Category1Membercvs:YearOfOriginationPeriodFourMember2020-12-310000064803us-gaap:CommercialRealEstateMembercvs:Category1Membercvs:YearOfOriginationPeriodFiveMember2020-12-310000064803us-gaap:CommercialRealEstateMembercvs:YearOfOriginationPriorToPeriodFiveMembercvs:Category1Member2020-12-310000064803us-gaap:CommercialRealEstateMembercvs:Category1Member2020-12-310000064803us-gaap:CommercialRealEstateMembercvs:Category2To4Membercvs:YearOfOriginationPeriodTwoMember2020-12-310000064803us-gaap:CommercialRealEstateMembercvs:YearOfOriginationPeriodThreeMembercvs:Category2To4Member2020-12-310000064803us-gaap:CommercialRealEstateMembercvs:YearOfOriginationPeriodFourMembercvs:Category2To4Member2020-12-310000064803us-gaap:CommercialRealEstateMembercvs:Category2To4Membercvs:YearOfOriginationPeriodFiveMember2020-12-310000064803us-gaap:CommercialRealEstateMembercvs:YearOfOriginationPriorToPeriodFiveMembercvs:Category2To4Member2020-12-310000064803us-gaap:CommercialRealEstateMembercvs:Category2To4Member2020-12-310000064803us-gaap:CommercialRealEstateMembercvs:Categories5and6Membercvs:YearOfOriginationPeriodTwoMember2020-12-310000064803us-gaap:CommercialRealEstateMembercvs:YearOfOriginationPeriodThreeMembercvs:Categories5and6Member2020-12-310000064803us-gaap:CommercialRealEstateMembercvs:Categories5and6Membercvs:YearOfOriginationPeriodFourMember2020-12-310000064803us-gaap:CommercialRealEstateMembercvs:Categories5and6Membercvs:YearOfOriginationPeriodFiveMember2020-12-310000064803us-gaap:CommercialRealEstateMembercvs:Categories5and6Membercvs:YearOfOriginationPriorToPeriodFiveMember2020-12-310000064803us-gaap:CommercialRealEstateMembercvs:Categories5and6Member2020-12-310000064803us-gaap:CommercialRealEstateMembercvs:Category7Membercvs:YearOfOriginationPeriodTwoMember2020-12-310000064803us-gaap:CommercialRealEstateMembercvs:YearOfOriginationPeriodThreeMembercvs:Category7Member2020-12-310000064803us-gaap:CommercialRealEstateMembercvs:YearOfOriginationPeriodFourMembercvs:Category7Member2020-12-310000064803us-gaap:CommercialRealEstateMembercvs:YearOfOriginationPeriodFiveMembercvs:Category7Member2020-12-310000064803us-gaap:CommercialRealEstateMembercvs:YearOfOriginationPriorToPeriodFiveMembercvs:Category7Member2020-12-310000064803us-gaap:CommercialRealEstateMembercvs:Category7Member2020-12-310000064803us-gaap:CommercialRealEstateMembercvs:YearOfOriginationPeriodTwoMember2020-12-310000064803us-gaap:CommercialRealEstateMembercvs:YearOfOriginationPeriodThreeMember2020-12-310000064803us-gaap:CommercialRealEstateMembercvs:YearOfOriginationPeriodFourMember2020-12-310000064803us-gaap:CommercialRealEstateMembercvs:YearOfOriginationPeriodFiveMember2020-12-310000064803us-gaap:CommercialRealEstateMembercvs:YearOfOriginationPriorToPeriodFiveMember2020-12-310000064803us-gaap:CommercialRealEstateMember2020-12-310000064803us-gaap:DebtSecuritiesMember2021-01-012021-12-310000064803us-gaap:DebtSecuritiesMember2020-01-012020-12-310000064803us-gaap:DebtSecuritiesMember2019-01-012019-12-310000064803cvs:MortgageLoansMember2021-01-012021-12-310000064803cvs:MortgageLoansMember2020-01-012020-12-310000064803cvs:MortgageLoansMember2019-01-012019-12-310000064803us-gaap:OtherInvestmentsMember2021-01-012021-12-310000064803us-gaap:OtherInvestmentsMember2020-01-012020-12-310000064803us-gaap:OtherInvestmentsMember2019-01-012019-12-310000064803cvs:SupportingExperienceRatedProductsMember2021-01-012021-12-310000064803cvs:SupportingExperienceRatedProductsMember2020-01-012020-12-310000064803cvs:SupportingExperienceRatedProductsMember2019-01-012019-12-310000064803us-gaap:FairValueMeasurementsRecurringMember2020-12-310000064803us-gaap:FairValueMeasurementsRecurringMember2021-12-310000064803us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-12-310000064803us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000064803us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2021-12-310000064803us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2021-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2021-12-310000064803us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2021-12-310000064803us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USStatesAndPoliticalSubdivisionsMemberus-gaap:FairValueInputsLevel1Member2021-12-310000064803us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USStatesAndPoliticalSubdivisionsMember2021-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USStatesAndPoliticalSubdivisionsMember2021-12-310000064803us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USStatesAndPoliticalSubdivisionsMember2021-12-310000064803us-gaap:FairValueMeasurementsRecurringMemberus-gaap:DomesticCorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2021-12-310000064803us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:DomesticCorporateDebtSecuritiesMember2021-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:DomesticCorporateDebtSecuritiesMember2021-12-310000064803us-gaap:FairValueMeasurementsRecurringMemberus-gaap:DomesticCorporateDebtSecuritiesMember2021-12-310000064803us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:ForeignCorporateDebtSecuritiesMember2021-12-310000064803us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignCorporateDebtSecuritiesMember2021-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignCorporateDebtSecuritiesMember2021-12-310000064803us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignCorporateDebtSecuritiesMember2021-12-310000064803us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ResidentialMortgageBackedSecuritiesMemberus-gaap:FairValueInputsLevel1Member2021-12-310000064803us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ResidentialMortgageBackedSecuritiesMember2021-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ResidentialMortgageBackedSecuritiesMember2021-12-310000064803us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ResidentialMortgageBackedSecuritiesMember2021-12-310000064803us-gaap:CommercialMortgageBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-12-310000064803us-gaap:CommercialMortgageBackedSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:CommercialMortgageBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000064803us-gaap:CommercialMortgageBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000064803cvs:OtherAssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-12-310000064803us-gaap:FairValueInputsLevel2Membercvs:OtherAssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000064803us-gaap:FairValueInputsLevel3Membercvs:OtherAssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000064803cvs:OtherAssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000064803us-gaap:FairValueMeasurementsRecurringMemberus-gaap:RedeemablePreferredStockMemberus-gaap:FairValueInputsLevel1Member2021-12-310000064803us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:RedeemablePreferredStockMember2021-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:RedeemablePreferredStockMember2021-12-310000064803us-gaap:FairValueMeasurementsRecurringMemberus-gaap:RedeemablePreferredStockMember2021-12-310000064803us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2020-12-310000064803us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000064803us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2020-12-310000064803us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2020-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2020-12-310000064803us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2020-12-310000064803us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USStatesAndPoliticalSubdivisionsMemberus-gaap:FairValueInputsLevel1Member2020-12-310000064803us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USStatesAndPoliticalSubdivisionsMember2020-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USStatesAndPoliticalSubdivisionsMember2020-12-310000064803us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USStatesAndPoliticalSubdivisionsMember2020-12-310000064803us-gaap:FairValueMeasurementsRecurringMemberus-gaap:DomesticCorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2020-12-310000064803us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:DomesticCorporateDebtSecuritiesMember2020-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:DomesticCorporateDebtSecuritiesMember2020-12-310000064803us-gaap:FairValueMeasurementsRecurringMemberus-gaap:DomesticCorporateDebtSecuritiesMember2020-12-310000064803us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:ForeignCorporateDebtSecuritiesMember2020-12-310000064803us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignCorporateDebtSecuritiesMember2020-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignCorporateDebtSecuritiesMember2020-12-310000064803us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignCorporateDebtSecuritiesMember2020-12-310000064803us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ResidentialMortgageBackedSecuritiesMemberus-gaap:FairValueInputsLevel1Member2020-12-310000064803us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ResidentialMortgageBackedSecuritiesMember2020-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ResidentialMortgageBackedSecuritiesMember2020-12-310000064803us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ResidentialMortgageBackedSecuritiesMember2020-12-310000064803us-gaap:CommercialMortgageBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2020-12-310000064803us-gaap:CommercialMortgageBackedSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:CommercialMortgageBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000064803us-gaap:CommercialMortgageBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000064803cvs:OtherAssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2020-12-310000064803us-gaap:FairValueInputsLevel2Membercvs:OtherAssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000064803us-gaap:FairValueInputsLevel3Membercvs:OtherAssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000064803cvs:OtherAssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000064803us-gaap:FairValueMeasurementsRecurringMemberus-gaap:RedeemablePreferredStockMemberus-gaap:FairValueInputsLevel1Member2020-12-310000064803us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:RedeemablePreferredStockMember2020-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:RedeemablePreferredStockMember2020-12-310000064803us-gaap:FairValueMeasurementsRecurringMemberus-gaap:RedeemablePreferredStockMember2020-12-310000064803us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentShorttermDebtSecuritiesMember2020-12-310000064803us-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquitySecuritiesMember2020-12-310000064803us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USStatesAndPoliticalSubdivisionsMember2021-01-012021-12-310000064803us-gaap:FairValueMeasurementsRecurringMemberus-gaap:DomesticCorporateDebtSecuritiesMember2021-01-012021-12-310000064803us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentShorttermDebtSecuritiesMember2021-01-012021-12-310000064803cvs:OtherAssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-01-012021-12-310000064803us-gaap:FairValueMeasurementsRecurringMemberus-gaap:RedeemablePreferredStockMember2021-01-012021-12-310000064803us-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquitySecuritiesMember2021-01-012021-12-310000064803us-gaap:FairValueMeasurementsRecurringMember2021-01-012021-12-310000064803us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentShorttermDebtSecuritiesMember2021-12-310000064803us-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquitySecuritiesMember2021-12-310000064803us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USStatesAndPoliticalSubdivisionsMember2019-12-310000064803us-gaap:FairValueMeasurementsRecurringMemberus-gaap:DomesticCorporateDebtSecuritiesMember2019-12-310000064803us-gaap:FairValueMeasurementsRecurringMemberus-gaap:RedeemablePreferredStockMember2019-12-310000064803us-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquitySecuritiesMember2019-12-310000064803us-gaap:FairValueMeasurementsRecurringMember2019-12-310000064803us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USStatesAndPoliticalSubdivisionsMember2020-01-012020-12-310000064803us-gaap:FairValueMeasurementsRecurringMemberus-gaap:DomesticCorporateDebtSecuritiesMember2020-01-012020-12-310000064803us-gaap:FairValueMeasurementsRecurringMemberus-gaap:RedeemablePreferredStockMember2020-01-012020-12-310000064803us-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquitySecuritiesMember2020-01-012020-12-310000064803us-gaap:FairValueMeasurementsRecurringMember2020-01-012020-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-01-012021-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-01-012020-12-310000064803us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsNonrecurringMember2021-12-310000064803us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsNonrecurringMember2021-12-310000064803us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsNonrecurringMember2021-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsNonrecurringMember2021-12-310000064803us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsNonrecurringMember2021-12-310000064803us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsNonrecurringMember2020-12-310000064803us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsNonrecurringMember2020-12-310000064803us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsNonrecurringMember2020-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsNonrecurringMember2020-12-310000064803us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsNonrecurringMember2020-12-310000064803us-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-12-310000064803us-gaap:FairValueInputsLevel2Memberus-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000064803us-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000064803us-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2020-12-310000064803us-gaap:FairValueInputsLevel2Memberus-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000064803us-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000064803us-gaap:DebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-12-310000064803us-gaap:FairValueInputsLevel2Memberus-gaap:DebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:DebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000064803us-gaap:DebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000064803us-gaap:DebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2020-12-310000064803us-gaap:FairValueInputsLevel2Memberus-gaap:DebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:DebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000064803us-gaap:DebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000064803us-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-12-310000064803us-gaap:FairValueInputsLevel2Memberus-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000064803us-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000064803us-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2020-12-310000064803us-gaap:FairValueInputsLevel2Memberus-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000064803us-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000064803cvs:CommonAndCollectiveTrustsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-12-310000064803cvs:CommonAndCollectiveTrustsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000064803us-gaap:FairValueInputsLevel3Membercvs:CommonAndCollectiveTrustsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000064803cvs:CommonAndCollectiveTrustsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000064803cvs:CommonAndCollectiveTrustsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2020-12-310000064803cvs:CommonAndCollectiveTrustsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000064803us-gaap:FairValueInputsLevel3Membercvs:CommonAndCollectiveTrustsMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000064803cvs:CommonAndCollectiveTrustsMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000064803us-gaap:AccountsReceivableMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000064803us-gaap:AccountsReceivableMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMembercvs:SeparateAccountFinancialAssetsMember2020-01-012020-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMembercvs:SeparateAccountFinancialAssetsMember2021-01-012021-12-310000064803cvs:HealthCareBenefitsSegmentMember2019-12-310000064803cvs:PharmacyServicesSegmentMember2019-12-310000064803cvs:RetailLongTermCareSegmentMember2019-12-310000064803cvs:HealthCareBenefitsSegmentMember2020-01-012020-12-310000064803cvs:PharmacyServicesSegmentMember2020-01-012020-12-310000064803cvs:RetailLongTermCareSegmentMember2020-01-012020-12-310000064803cvs:HealthCareBenefitsSegmentMember2020-12-310000064803cvs:PharmacyServicesSegmentMember2020-12-310000064803cvs:RetailLongTermCareSegmentMember2020-12-310000064803cvs:PharmacyServicesSegmentMember2021-01-012021-12-310000064803cvs:HealthCareBenefitsSegmentMember2021-12-310000064803cvs:PharmacyServicesSegmentMember2021-12-310000064803cvs:LongTermCareReportingUnitMember2021-12-310000064803us-gaap:CustomerListsMembercvs:LongTermCareReportingUnitMember2021-12-310000064803us-gaap:CustomerRelatedIntangibleAssetsMember2021-12-310000064803us-gaap:CustomerRelatedIntangibleAssetsMember2021-01-012021-12-310000064803us-gaap:TechnologyBasedIntangibleAssetsMember2021-12-310000064803us-gaap:TechnologyBasedIntangibleAssetsMember2021-01-012021-12-310000064803cvs:ProviderNetworksMember2021-12-310000064803cvs:ProviderNetworksMember2021-01-012021-12-310000064803cvs:ValueOfBusinessAcquiredMember2021-12-310000064803cvs:ValueOfBusinessAcquiredMember2021-01-012021-12-310000064803us-gaap:OtherIntangibleAssetsMember2021-12-310000064803us-gaap:OtherIntangibleAssetsMember2021-01-012021-12-310000064803us-gaap:CustomerRelatedIntangibleAssetsMember2020-12-310000064803us-gaap:CustomerRelatedIntangibleAssetsMember2020-01-012020-12-310000064803us-gaap:TechnologyBasedIntangibleAssetsMember2020-12-310000064803us-gaap:TechnologyBasedIntangibleAssetsMember2020-01-012020-12-310000064803cvs:ProviderNetworksMember2020-12-310000064803cvs:ProviderNetworksMember2020-01-012020-12-310000064803cvs:ValueOfBusinessAcquiredMember2020-12-310000064803cvs:ValueOfBusinessAcquiredMember2020-01-012020-12-310000064803us-gaap:OtherIntangibleAssetsMember2020-12-310000064803us-gaap:OtherIntangibleAssetsMember2020-01-012020-12-310000064803us-gaap:BuildingMembersrt:MinimumMember2021-12-310000064803us-gaap:BuildingMembersrt:MaximumMember2021-12-310000064803us-gaap:EquipmentMembersrt:MinimumMember2021-12-310000064803us-gaap:EquipmentMembersrt:MaximumMember2021-12-310000064803cvs:RetailLongTermCareSegmentMember2021-10-012021-12-310000064803cvs:RetailLongTermCareSegmentMemberus-gaap:PropertySubjectToOperatingLeaseMember2021-10-012021-12-310000064803cvs:RetailLongTermCareSegmentMemberus-gaap:PropertySubjectToOperatingLeaseMember2021-12-310000064803us-gaap:PropertyPlantAndEquipmentMembercvs:RetailLongTermCareSegmentMember2021-12-310000064803cvs:RetailLongTermCareSegmentMember2019-01-012019-12-310000064803us-gaap:ShortDurationInsuranceContractAccidentYear2019Memberus-gaap:HealthInsuranceProductLineMember2020-12-310000064803us-gaap:ShortDurationInsuranceContractAccidentYear2019Memberus-gaap:HealthInsuranceProductLineMember2021-12-310000064803us-gaap:HealthInsuranceProductLineMemberus-gaap:ShortDurationInsuranceContractAccidentYear2020Member2021-12-310000064803us-gaap:HealthInsuranceProductLineMember2019-12-310000064803us-gaap:HealthInsuranceProductLineMember2018-12-310000064803us-gaap:HealthInsuranceProductLineMember2021-01-012021-12-310000064803us-gaap:HealthInsuranceProductLineMember2020-01-012020-12-310000064803us-gaap:HealthInsuranceProductLineMember2019-01-012019-12-310000064803cvs:HealthCareBenefitsSegmentMember2019-01-012019-12-310000064803us-gaap:CorporateAndOtherMember2021-01-012021-12-310000064803us-gaap:CorporateAndOtherMember2020-01-012020-12-310000064803us-gaap:CorporateAndOtherMember2019-01-012019-12-310000064803cvs:SeniorNotes3.35DueMarch2021Memberus-gaap:SeniorNotesMember2021-12-310000064803cvs:SeniorNotes3.35DueMarch2021Memberus-gaap:SeniorNotesMember2020-12-310000064803us-gaap:NotesPayableToBanksMembercvs:FloatingRateNotesDueMarch2021Member2020-12-310000064803us-gaap:NotesPayableToBanksMembercvs:FloatingRateNotesDueMarch2021Member2021-12-310000064803cvs:SeniorNotes4.125DueMay2021Memberus-gaap:SeniorNotesMember2021-12-310000064803cvs:SeniorNotes4.125DueMay2021Memberus-gaap:SeniorNotesMember2020-12-310000064803us-gaap:SeniorNotesMembercvs:SeniorNotes2.125June2021Member2021-12-310000064803us-gaap:SeniorNotesMembercvs:SeniorNotes2.125June2021Member2020-12-310000064803cvs:SeniorNotes4.125DueJune2021Memberus-gaap:SeniorNotesMember2021-12-310000064803cvs:SeniorNotes4.125DueJune2021Memberus-gaap:SeniorNotesMember2020-12-310000064803cvs:SeniorNotes5.45DueJune2021Memberus-gaap:SeniorNotesMember2021-12-310000064803cvs:SeniorNotes5.45DueJune2021Memberus-gaap:SeniorNotesMember2020-12-310000064803us-gaap:SeniorNotesMembercvs:SeniorNotes3.5DueJuly2022Member2021-12-310000064803us-gaap:SeniorNotesMembercvs:SeniorNotes3.5DueJuly2022Member2020-12-310000064803cvs:SeniorNotes2.75DueNovember2022Memberus-gaap:SeniorNotesMember2021-12-310000064803cvs:SeniorNotes2.75DueNovember2022Memberus-gaap:SeniorNotesMember2020-12-310000064803cvs:SeniorNotes2.75DueDecember2022Memberus-gaap:SeniorNotesMember2021-12-310000064803cvs:SeniorNotes2.75DueDecember2022Memberus-gaap:SeniorNotesMember2020-12-310000064803cvs:SeniorNotes4.75DueDecember2022Memberus-gaap:SeniorNotesMember2021-12-310000064803cvs:SeniorNotes4.75DueDecember2022Memberus-gaap:SeniorNotesMember2020-12-310000064803us-gaap:SeniorNotesMembercvs:SeniorNotes3.7DueMarch2023Member2021-12-310000064803us-gaap:SeniorNotesMembercvs:SeniorNotes3.7DueMarch2023Member2020-12-310000064803cvs:SeniorNotes2.8DueJune2023Memberus-gaap:SeniorNotesMember2021-12-310000064803cvs:SeniorNotes2.8DueJune2023Memberus-gaap:SeniorNotesMember2020-12-310000064803cvs:SeniorNotes4DueDecember2023Memberus-gaap:SeniorNotesMember2021-12-310000064803cvs:SeniorNotes4DueDecember2023Memberus-gaap:SeniorNotesMember2020-12-310000064803us-gaap:SeniorNotesMembercvs:SeniorNotes3.375DueAugust2024Member2021-12-310000064803us-gaap:SeniorNotesMembercvs:SeniorNotes3.375DueAugust2024Member2020-12-310000064803cvs:SeniorNotes2.625DueAugust2024Memberus-gaap:SeniorNotesMember2021-12-310000064803cvs:SeniorNotes2.625DueAugust2024Memberus-gaap:SeniorNotesMember2020-12-310000064803us-gaap:SeniorNotesMembercvs:SeniorNotes3.5DueNovember2024Member2021-12-310000064803us-gaap:SeniorNotesMembercvs:SeniorNotes3.5DueNovember2024Member2020-12-310000064803us-gaap:SeniorNotesMembercvs:SeniorNotes5DueDecember2024Member2021-12-310000064803us-gaap:SeniorNotesMembercvs:SeniorNotes5DueDecember2024Member2020-12-310000064803us-gaap:SeniorNotesMembercvs:SeniorNotes4.1DueMarch2025Member2021-12-310000064803us-gaap:SeniorNotesMembercvs:SeniorNotes4.1DueMarch2025Member2020-12-310000064803us-gaap:SeniorNotesMembercvs:SeniorNotes3.875DueJuly2025Member2021-12-310000064803us-gaap:SeniorNotesMembercvs:SeniorNotes3.875DueJuly2025Member2020-12-310000064803cvs:SeniorNotes2.875DueJune2026Memberus-gaap:SeniorNotesMember2021-12-310000064803cvs:SeniorNotes2.875DueJune2026Memberus-gaap:SeniorNotesMember2020-12-310000064803us-gaap:SeniorNotesMembercvs:SeniorNotes3DueAugust2026Member2021-12-310000064803us-gaap:SeniorNotesMembercvs:SeniorNotes3DueAugust2026Member2020-12-310000064803cvs:SeniorNotes3Point625PercentApril2027Memberus-gaap:SeniorNotesMember2021-12-310000064803cvs:SeniorNotes3Point625PercentApril2027Memberus-gaap:SeniorNotesMember2020-12-310000064803us-gaap:SeniorNotesMembercvs:SeniorNotes6.25DueJune2027Member2021-12-310000064803us-gaap:SeniorNotesMembercvs:SeniorNotes6.25DueJune2027Member2020-12-310000064803cvs:SeniorNotes1Point3PercentAugust2027Memberus-gaap:SeniorNotesMember2021-12-310000064803cvs:SeniorNotes1Point3PercentAugust2027Memberus-gaap:SeniorNotesMember2020-12-310000064803cvs:SeniorNotes4.3DueMarch2028Memberus-gaap:SeniorNotesMember2021-12-310000064803cvs:SeniorNotes4.3DueMarch2028Memberus-gaap:SeniorNotesMember2020-12-310000064803cvs:SeniorNotes3.25DueAugust2029Memberus-gaap:SeniorNotesMember2021-12-310000064803cvs:SeniorNotes3.25DueAugust2029Memberus-gaap:SeniorNotesMember2020-12-310000064803us-gaap:SeniorNotesMembercvs:SeniorNotes3Point75PercentApril2030Member2021-12-310000064803us-gaap:SeniorNotesMembercvs:SeniorNotes3Point75PercentApril2030Member2020-12-310000064803cvs:SeniorNotes1Point75PercentAugust2030Memberus-gaap:SeniorNotesMember2021-12-310000064803cvs:SeniorNotes1Point75PercentAugust2030Memberus-gaap:SeniorNotesMember2020-12-310000064803us-gaap:SeniorNotesMembercvs:SeniorNotes1Point875PercentFebruary2031Member2021-12-310000064803us-gaap:SeniorNotesMembercvs:SeniorNotes1Point875PercentFebruary2031Member2020-12-310000064803us-gaap:SeniorNotesMembercvs:SeniorNotes2Point125PercentDueSeptember2031Member2021-12-310000064803us-gaap:SeniorNotesMembercvs:SeniorNotes2Point125PercentDueSeptember2031Member2020-12-310000064803us-gaap:SeniorNotesMembercvs:SeniorNotes4.875DueJuly2035Member2021-12-310000064803us-gaap:SeniorNotesMembercvs:SeniorNotes4.875DueJuly2035Member2020-12-310000064803us-gaap:SeniorNotesMembercvs:SeniorNotes6.625DueJune2036Member2021-12-310000064803us-gaap:SeniorNotesMembercvs:SeniorNotes6.625DueJune2036Member2020-12-310000064803cvs:SeniorNotes6.75DueDecember2037Memberus-gaap:SeniorNotesMember2021-12-310000064803cvs:SeniorNotes6.75DueDecember2037Memberus-gaap:SeniorNotesMember2020-12-310000064803cvs:SeniorNotes4.78DueMarch2038Memberus-gaap:SeniorNotesMember2021-12-310000064803cvs:SeniorNotes4.78DueMarch2038Memberus-gaap:SeniorNotesMember2020-12-310000064803us-gaap:SeniorNotesMembercvs:SeniorNotes6.125DueSeptember2039Member2021-12-310000064803us-gaap:SeniorNotesMembercvs:SeniorNotes6.125DueSeptember2039Member2020-12-310000064803us-gaap:SeniorNotesMembercvs:SeniorNotes4Point125PercentApril2040Member2021-12-310000064803us-gaap:SeniorNotesMembercvs:SeniorNotes4Point125PercentApril2040Member2020-12-310000064803us-gaap:SeniorNotesMembercvs:SeniorNotes2Point7PercentAugust2040Member2021-12-310000064803us-gaap:SeniorNotesMembercvs:SeniorNotes2Point7PercentAugust2040Member2020-12-310000064803us-gaap:SeniorNotesMembercvs:SeniorNotes5.75DueMay2041Member2021-12-310000064803us-gaap:SeniorNotesMembercvs:SeniorNotes5.75DueMay2041Member2020-12-310000064803us-gaap:SeniorNotesMembercvs:SeniorNotes4.5DueMay2042Member2021-12-310000064803us-gaap:SeniorNotesMembercvs:SeniorNotes4.5DueMay2042Member2020-12-310000064803cvs:SeniorNotes4.125DueNovember2042Memberus-gaap:SeniorNotesMember2021-12-310000064803cvs:SeniorNotes4.125DueNovember2042Memberus-gaap:SeniorNotesMember2020-12-310000064803us-gaap:SeniorNotesMembercvs:SeniorNotes5.3DueDecember2043Member2021-12-310000064803us-gaap:SeniorNotesMembercvs:SeniorNotes5.3DueDecember2043Member2020-12-310000064803cvs:SeniorNotes4.75DueMarch2044Memberus-gaap:SeniorNotesMember2021-12-310000064803cvs:SeniorNotes4.75DueMarch2044Memberus-gaap:SeniorNotesMember2020-12-310000064803us-gaap:SeniorNotesMembercvs:SeniorNotes5.125DueJuly2045Member2021-12-310000064803us-gaap:SeniorNotesMembercvs:SeniorNotes5.125DueJuly2045Member2020-12-310000064803us-gaap:SeniorNotesMembercvs:SeniorNotes3.875DueAugust2047Member2021-12-310000064803us-gaap:SeniorNotesMembercvs:SeniorNotes3.875DueAugust2047Member2020-12-310000064803us-gaap:SeniorNotesMembercvs:SeniorNotes5.05DueMarch2048Member2021-12-310000064803us-gaap:SeniorNotesMembercvs:SeniorNotes5.05DueMarch2048Member2020-12-310000064803cvs:SeniorNotes4Point25PercentApril2050Memberus-gaap:SeniorNotesMember2021-12-310000064803cvs:SeniorNotes4Point25PercentApril2050Memberus-gaap:SeniorNotesMember2020-12-310000064803us-gaap:OtherDebtSecuritiesMember2021-12-310000064803us-gaap:OtherDebtSecuritiesMember2020-12-310000064803us-gaap:CommercialPaperMember2021-12-310000064803us-gaap:LineOfCreditMembercvs:RevolvingCreditFacilityExpiringMay172023Member2021-12-310000064803us-gaap:LineOfCreditMembercvs:RevolvingCreditFacilityExpiringMay172023Member2021-01-012021-12-310000064803us-gaap:LineOfCreditMembercvs:RevolvingCreditFacilityExpiringMay162024Member2021-12-310000064803us-gaap:LineOfCreditMembercvs:RevolvingCreditFacilityExpiringMay162024Member2021-01-012021-12-310000064803us-gaap:LineOfCreditMembercvs:RevolvingCreditFacilityExpiringMay112026Member2021-12-310000064803us-gaap:LineOfCreditMembercvs:RevolvingCreditFacilityExpiringMay112026Member2021-01-012021-12-310000064803cvs:BackUpCreditFacilitiesMemberus-gaap:LineOfCreditMember2021-01-012021-12-310000064803cvs:BackUpCreditFacilitiesMemberus-gaap:LineOfCreditMember2020-12-310000064803cvs:BackUpCreditFacilitiesMemberus-gaap:LineOfCreditMember2021-12-310000064803us-gaap:FederalHomeLoanBankAdvancesMember2021-12-310000064803us-gaap:FederalHomeLoanBankAdvancesMember2020-12-310000064803us-gaap:SeniorNotesMembercvs:SeniorNotes2Point125PercentDueSeptember2031Member2021-08-1800000648032021-08-182021-08-180000064803us-gaap:SeniorNotesMembercvs:SeniorNotes13DueAugust2027Member2020-12-160000064803us-gaap:SeniorNotesMembercvs:SeniorNotes1875DueFebruary2031Member2020-12-160000064803us-gaap:SeniorNotesMembercvs:SeniorNotes1875DueFebruary2031Member2020-12-162020-12-160000064803us-gaap:SeniorNotesMembercvs:SeniorNotes13DueAugust2027Member2020-08-210000064803us-gaap:SeniorNotesMembercvs:SeniorNotes175DueAugust2030Member2020-08-210000064803us-gaap:SeniorNotesMembercvs:SeniorNotes27DueAugust2040Member2020-08-2100000648032020-08-212020-08-210000064803us-gaap:SeniorNotesMembercvs:SeniorNotes3625DueApril2027Member2020-03-310000064803us-gaap:SeniorNotesMembercvs:SeniorNotes375DueApril2030Member2020-03-310000064803us-gaap:SeniorNotesMembercvs:SeniorNotes4125DueApril2040Member2020-03-310000064803us-gaap:SeniorNotesMembercvs:SeniorNotes425DueApril2050Member2020-03-310000064803us-gaap:SeniorNotesMembercvs:SeniorNotes425DueApril2050Member2020-01-012020-03-3100000648032020-01-012020-03-310000064803cvs:SeniorNotes3Point70PercentDue2023Memberus-gaap:SeniorNotesMember2021-12-012021-12-310000064803cvs:SeniorNotes3Point70PercentDue2023Memberus-gaap:SeniorNotesMember2021-12-3100000648032021-12-012021-12-310000064803us-gaap:SeniorNotesMembercvs:SeniorNotes4PointThreePercentDue2028Member2021-08-012021-08-310000064803us-gaap:SeniorNotesMembercvs:SeniorNotes4PointThreePercentDue2028Member2021-08-3100000648032021-08-012021-08-310000064803cvs:OutstandingSeniorNotesMemberus-gaap:SeniorNotesMember2020-12-012020-12-310000064803cvs:SeniorNotes4DueDecember2023Memberus-gaap:SeniorNotesMember2020-12-012020-12-310000064803us-gaap:SeniorNotesMembercvs:SeniorNotes3.7DueMarch2023Member2020-12-012020-12-310000064803us-gaap:SeniorNotesMembercvs:SeniorNotes4.1DueMarch2025Member2020-12-012020-12-310000064803us-gaap:SeniorNotesMembercvs:SeniorNotes43Due2028Member2020-12-012020-12-310000064803us-gaap:SeniorNotesMembercvs:SeniorNotes43Due2028Member2020-12-3100000648032020-12-012020-12-310000064803cvs:OutstandingSeniorNotesMemberus-gaap:SeniorNotesMember2020-08-012020-08-310000064803cvs:SeniorNotes4DueDecember2023Memberus-gaap:SeniorNotesMember2020-08-012020-08-310000064803cvs:SeniorNotes4DueDecember2023Memberus-gaap:SeniorNotesMember2020-08-310000064803us-gaap:SeniorNotesMembercvs:SeniorNotes3.7DueMarch2023Member2020-08-012020-08-310000064803us-gaap:SeniorNotesMembercvs:SeniorNotes3.7DueMarch2023Member2020-08-310000064803us-gaap:SeniorNotesMembercvs:SeniorNotes4.1DueMarch2025Member2020-08-012020-08-310000064803us-gaap:SeniorNotesMembercvs:SeniorNotes4.1DueMarch2025Member2020-08-3100000648032020-08-012020-08-310000064803cvs:OutstandingSeniorNotesMemberus-gaap:SeniorNotesMember2019-08-012019-08-310000064803cvs:SeniorNotes3.125DueMarch2020Memberus-gaap:SeniorNotesMember2019-08-012019-08-310000064803cvs:SeniorNotes3.125DueMarch2020Memberus-gaap:SeniorNotesMember2019-08-310000064803cvs:FloatingRateNotesMembercvs:FloatingRateNotesDueMarch2020Member2019-08-012019-08-310000064803cvs:SeniorNotes4.125DueMay2021Memberus-gaap:SeniorNotesMember2019-08-012019-08-310000064803cvs:SeniorNotes4.125DueMay2021Memberus-gaap:SeniorNotesMember2019-08-310000064803cvs:SeniorNotes4.125DueJune2021Memberus-gaap:SeniorNotesMember2019-08-012019-08-310000064803cvs:SeniorNotes4.125DueJune2021Memberus-gaap:SeniorNotesMember2019-08-310000064803cvs:SeniorNotes5.45DueJune2021Memberus-gaap:SeniorNotesMember2019-08-012019-08-310000064803cvs:SeniorNotes5.45DueJune2021Memberus-gaap:SeniorNotesMember2019-08-310000064803cvs:SeniorNotes3.35DueMarch2021Memberus-gaap:SeniorNotesMember2019-08-012019-08-310000064803cvs:SeniorNotes3.35DueMarch2021Memberus-gaap:SeniorNotesMember2019-08-3100000648032019-08-012019-08-310000064803us-gaap:PensionPlansDefinedBenefitMember2020-12-310000064803us-gaap:PensionPlansDefinedBenefitMember2019-12-310000064803us-gaap:PensionPlansDefinedBenefitMember2021-01-012021-12-310000064803us-gaap:PensionPlansDefinedBenefitMember2020-01-012020-12-310000064803us-gaap:PensionPlansDefinedBenefitMember2021-12-310000064803us-gaap:PensionPlansDefinedBenefitMember2019-01-012019-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel1Member2021-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel2Member2021-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2021-12-310000064803us-gaap:FairValueInputsLevel12And3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2021-12-310000064803us-gaap:USTreasuryAndGovernmentMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Member2021-12-310000064803us-gaap:USTreasuryAndGovernmentMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Member2021-12-310000064803us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000064803us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel12And3Memberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:USStatesAndPoliticalSubdivisionsMemberus-gaap:FairValueInputsLevel1Member2021-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Memberus-gaap:USStatesAndPoliticalSubdivisionsMember2021-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:USStatesAndPoliticalSubdivisionsMember2021-12-310000064803us-gaap:FairValueInputsLevel12And3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:USStatesAndPoliticalSubdivisionsMember2021-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:DomesticCorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2021-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Memberus-gaap:DomesticCorporateDebtSecuritiesMember2021-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DomesticCorporateDebtSecuritiesMember2021-12-310000064803us-gaap:FairValueInputsLevel12And3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DomesticCorporateDebtSecuritiesMember2021-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignCorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2021-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignCorporateDebtSecuritiesMember2021-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignCorporateDebtSecuritiesMember2021-12-310000064803us-gaap:FairValueInputsLevel12And3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignCorporateDebtSecuritiesMember2021-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ResidentialMortgageBackedSecuritiesMemberus-gaap:FairValueInputsLevel1Member2021-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ResidentialMortgageBackedSecuritiesMember2021-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ResidentialMortgageBackedSecuritiesMember2021-12-310000064803us-gaap:FairValueInputsLevel12And3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ResidentialMortgageBackedSecuritiesMember2021-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Memberus-gaap:CommercialMortgageBackedSecuritiesMember2021-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CommercialMortgageBackedSecuritiesMember2021-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CommercialMortgageBackedSecuritiesMember2021-12-310000064803us-gaap:FairValueInputsLevel12And3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CommercialMortgageBackedSecuritiesMember2021-12-310000064803us-gaap:AssetBackedSecuritiesMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Member2021-12-310000064803us-gaap:AssetBackedSecuritiesMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Member2021-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:AssetBackedSecuritiesMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000064803us-gaap:FairValueInputsLevel12And3Memberus-gaap:AssetBackedSecuritiesMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000064803us-gaap:PensionPlansDefinedBenefitMembercvs:RedeemablePreferredSecuritiesMemberus-gaap:FairValueInputsLevel1Member2021-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Membercvs:RedeemablePreferredSecuritiesMember2021-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMembercvs:RedeemablePreferredSecuritiesMember2021-12-310000064803us-gaap:FairValueInputsLevel12And3Memberus-gaap:PensionPlansDefinedBenefitMembercvs:RedeemablePreferredSecuritiesMember2021-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:DebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2021-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Memberus-gaap:DebtSecuritiesMember2021-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DebtSecuritiesMember2021-12-310000064803us-gaap:FairValueInputsLevel12And3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DebtSecuritiesMember2021-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanEquitySecuritiesUsMemberus-gaap:FairValueInputsLevel1Member2021-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Memberus-gaap:DefinedBenefitPlanEquitySecuritiesUsMember2021-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanEquitySecuritiesUsMember2021-12-310000064803us-gaap:FairValueInputsLevel12And3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanEquitySecuritiesUsMember2021-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMemberus-gaap:FairValueInputsLevel1Member2021-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Memberus-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember2021-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember2021-12-310000064803us-gaap:FairValueInputsLevel12And3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember2021-12-310000064803us-gaap:PensionPlansDefinedBenefitMembercvs:EquitySecuritiesDomesticRealEstateMemberus-gaap:FairValueInputsLevel1Member2021-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Membercvs:EquitySecuritiesDomesticRealEstateMember2021-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMembercvs:EquitySecuritiesDomesticRealEstateMember2021-12-310000064803us-gaap:FairValueInputsLevel12And3Memberus-gaap:PensionPlansDefinedBenefitMembercvs:EquitySecuritiesDomesticRealEstateMember2021-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel1Member2021-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EquitySecuritiesMember2021-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:EquitySecuritiesMember2021-12-310000064803us-gaap:FairValueInputsLevel12And3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:EquitySecuritiesMember2021-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMemberus-gaap:FairValueInputsLevel1Member2021-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Memberus-gaap:DefinedBenefitPlanRealEstateMember2021-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMember2021-12-310000064803us-gaap:FairValueInputsLevel12And3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMember2021-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCommonCollectiveTrustMemberus-gaap:FairValueInputsLevel1Member2021-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Memberus-gaap:DefinedBenefitPlanCommonCollectiveTrustMember2021-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCommonCollectiveTrustMember2021-12-310000064803us-gaap:FairValueInputsLevel12And3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCommonCollectiveTrustMember2021-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherInvestmentsMemberus-gaap:FairValueInputsLevel1Member2021-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Memberus-gaap:OtherInvestmentsMember2021-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherInvestmentsMember2021-12-310000064803us-gaap:FairValueInputsLevel12And3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherInvestmentsMember2021-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Member2021-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Member2021-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000064803us-gaap:FairValueInputsLevel12And3Memberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000064803us-gaap:PensionPlansDefinedBenefitMembercvs:DefinedBenefitPlanCommonCollectiveTrustEquitySecuritiesMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2021-12-310000064803us-gaap:PensionPlansDefinedBenefitMembercvs:DefinedBenefitPlanCommonCollectiveTrustDebtSecuritiesMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2021-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:AccountsReceivableMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2021-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:PrivateEquityFundsMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2021-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:HedgeFundsMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2021-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel1Member2020-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel2Member2020-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2020-12-310000064803us-gaap:FairValueInputsLevel12And3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2020-12-310000064803us-gaap:USTreasuryAndGovernmentMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Member2020-12-310000064803us-gaap:USTreasuryAndGovernmentMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Member2020-12-310000064803us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMember2020-12-310000064803us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel12And3Memberus-gaap:PensionPlansDefinedBenefitMember2020-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:USStatesAndPoliticalSubdivisionsMemberus-gaap:FairValueInputsLevel1Member2020-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Memberus-gaap:USStatesAndPoliticalSubdivisionsMember2020-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:USStatesAndPoliticalSubdivisionsMember2020-12-310000064803us-gaap:FairValueInputsLevel12And3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:USStatesAndPoliticalSubdivisionsMember2020-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:DomesticCorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2020-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Memberus-gaap:DomesticCorporateDebtSecuritiesMember2020-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DomesticCorporateDebtSecuritiesMember2020-12-310000064803us-gaap:FairValueInputsLevel12And3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DomesticCorporateDebtSecuritiesMember2020-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignCorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2020-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignCorporateDebtSecuritiesMember2020-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignCorporateDebtSecuritiesMember2020-12-310000064803us-gaap:FairValueInputsLevel12And3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignCorporateDebtSecuritiesMember2020-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ResidentialMortgageBackedSecuritiesMemberus-gaap:FairValueInputsLevel1Member2020-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ResidentialMortgageBackedSecuritiesMember2020-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ResidentialMortgageBackedSecuritiesMember2020-12-310000064803us-gaap:FairValueInputsLevel12And3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ResidentialMortgageBackedSecuritiesMember2020-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Memberus-gaap:CommercialMortgageBackedSecuritiesMember2020-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CommercialMortgageBackedSecuritiesMember2020-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CommercialMortgageBackedSecuritiesMember2020-12-310000064803us-gaap:FairValueInputsLevel12And3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CommercialMortgageBackedSecuritiesMember2020-12-310000064803us-gaap:AssetBackedSecuritiesMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Member2020-12-310000064803us-gaap:AssetBackedSecuritiesMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Member2020-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:AssetBackedSecuritiesMemberus-gaap:PensionPlansDefinedBenefitMember2020-12-310000064803us-gaap:FairValueInputsLevel12And3Memberus-gaap:AssetBackedSecuritiesMemberus-gaap:PensionPlansDefinedBenefitMember2020-12-310000064803us-gaap:PensionPlansDefinedBenefitMembercvs:RedeemablePreferredSecuritiesMemberus-gaap:FairValueInputsLevel1Member2020-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Membercvs:RedeemablePreferredSecuritiesMember2020-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMembercvs:RedeemablePreferredSecuritiesMember2020-12-310000064803us-gaap:FairValueInputsLevel12And3Memberus-gaap:PensionPlansDefinedBenefitMembercvs:RedeemablePreferredSecuritiesMember2020-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:DebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2020-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Memberus-gaap:DebtSecuritiesMember2020-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DebtSecuritiesMember2020-12-310000064803us-gaap:FairValueInputsLevel12And3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DebtSecuritiesMember2020-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanEquitySecuritiesUsMemberus-gaap:FairValueInputsLevel1Member2020-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Memberus-gaap:DefinedBenefitPlanEquitySecuritiesUsMember2020-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanEquitySecuritiesUsMember2020-12-310000064803us-gaap:FairValueInputsLevel12And3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanEquitySecuritiesUsMember2020-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMemberus-gaap:FairValueInputsLevel1Member2020-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Memberus-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember2020-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember2020-12-310000064803us-gaap:FairValueInputsLevel12And3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember2020-12-310000064803us-gaap:PensionPlansDefinedBenefitMembercvs:EquitySecuritiesDomesticRealEstateMemberus-gaap:FairValueInputsLevel1Member2020-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Membercvs:EquitySecuritiesDomesticRealEstateMember2020-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMembercvs:EquitySecuritiesDomesticRealEstateMember2020-12-310000064803us-gaap:FairValueInputsLevel12And3Memberus-gaap:PensionPlansDefinedBenefitMembercvs:EquitySecuritiesDomesticRealEstateMember2020-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel1Member2020-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EquitySecuritiesMember2020-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:EquitySecuritiesMember2020-12-310000064803us-gaap:FairValueInputsLevel12And3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:EquitySecuritiesMember2020-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMemberus-gaap:FairValueInputsLevel1Member2020-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Memberus-gaap:DefinedBenefitPlanRealEstateMember2020-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMember2020-12-310000064803us-gaap:FairValueInputsLevel12And3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMember2020-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCommonCollectiveTrustMemberus-gaap:FairValueInputsLevel1Member2020-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Memberus-gaap:DefinedBenefitPlanCommonCollectiveTrustMember2020-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCommonCollectiveTrustMember2020-12-310000064803us-gaap:FairValueInputsLevel12And3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCommonCollectiveTrustMember2020-12-310000064803us-gaap:DefinedBenefitPlanDerivativeMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Member2020-12-310000064803us-gaap:DefinedBenefitPlanDerivativeMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Member2020-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:DefinedBenefitPlanDerivativeMemberus-gaap:PensionPlansDefinedBenefitMember2020-12-310000064803us-gaap:FairValueInputsLevel12And3Memberus-gaap:DefinedBenefitPlanDerivativeMemberus-gaap:PensionPlansDefinedBenefitMember2020-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherInvestmentsMemberus-gaap:FairValueInputsLevel1Member2020-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Memberus-gaap:OtherInvestmentsMember2020-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherInvestmentsMember2020-12-310000064803us-gaap:FairValueInputsLevel12And3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherInvestmentsMember2020-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Member2020-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Member2020-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMember2020-12-310000064803us-gaap:FairValueInputsLevel12And3Memberus-gaap:PensionPlansDefinedBenefitMember2020-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Membercvs:DefinedBenefitPlanCommonCollectiveTrustEquitySecuritiesMember2020-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Membercvs:DefinedBenefitPlanCommonCollectiveTrustDebtSecuritiesMember2020-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:AccountsReceivableMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2020-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:PrivateEquityFundsMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2020-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:HedgeFundsMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2020-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMember2021-01-012021-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMember2021-01-012021-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMember2019-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DomesticCorporateDebtSecuritiesMember2019-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMember2019-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMember2020-01-012020-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DomesticCorporateDebtSecuritiesMember2020-01-012020-12-310000064803us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMember2020-01-012020-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:EquitySecuritiesMember2021-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:DebtSecuritiesMember2021-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:RealEstateInvestmentMember2021-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:PrivateEquityFundsMember2021-12-310000064803us-gaap:PensionPlansDefinedBenefitMemberus-gaap:HedgeFundsMember2021-12-310000064803us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-12-310000064803us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2020-12-310000064803us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-01-012021-12-310000064803us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2020-01-012020-12-310000064803us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2019-01-012019-12-310000064803cvs:CVSHealth2017IncentiveCompensationPlanMember2021-12-310000064803cvs:AetnaInc2010StockIncentivePlanMember2018-11-280000064803cvs:EmployeeStockOptionsandStockAppreciationRightsMember2021-01-012021-12-310000064803cvs:EmployeeStockOptionsandStockAppreciationRightsMember2020-01-012020-12-310000064803cvs:EmployeeStockOptionsandStockAppreciationRightsMember2019-01-012019-12-310000064803cvs:RestrictedStockUnitsandPerformanceShareUnitsMember2021-01-012021-12-310000064803cvs:RestrictedStockUnitsandPerformanceShareUnitsMember2020-01-012020-12-310000064803cvs:RestrictedStockUnitsandPerformanceShareUnitsMember2019-01-012019-12-310000064803us-gaap:EmployeeStockMember2021-12-310000064803us-gaap:EmployeeStockMember2021-01-012021-12-310000064803us-gaap:EmployeeStockMember2020-01-012020-12-310000064803us-gaap:EmployeeStockMember2019-01-012019-12-310000064803cvs:RestrictedStockUnitsandPerformanceShareUnitsMember2021-12-310000064803cvs:RestrictedStockUnitsandPerformanceShareUnitsMember2020-12-310000064803us-gaap:EmployeeStockOptionMember2021-01-012021-12-310000064803cvs:ShareBasedPaymentArrangementOptionGrantedPriorThrough2018Member2021-01-012021-12-310000064803cvs:ShareBasedPaymentArrangementOptionGrantedSubsequentTo2018Member2021-01-012021-12-310000064803us-gaap:StockAppreciationRightsSARSMember2021-01-012021-12-310000064803us-gaap:EmployeeStockOptionMember2020-01-012020-12-310000064803us-gaap:EmployeeStockOptionMember2019-01-012019-12-310000064803cvs:EmployeeStockOptionsandStockAppreciationRightsMember2021-12-310000064803cvs:EmployeeStockOptionsandStockAppreciationRightsMember2020-12-310000064803cvs:A2021RepurchaseProgramMember2021-12-090000064803cvs:A2021RepurchaseProgramMember2021-12-310000064803cvs:A2016RepurchaseProgramMember2016-11-020000064803cvs:A2016RepurchaseProgramMember2021-12-310000064803cvs:BarclaysBankMembercvs:A2021AcceleratedRepurchaseProgramMemberus-gaap:SubsequentEventMember2022-01-040000064803cvs:BarclaysBankMembercvs:A2021AcceleratedRepurchaseProgramMemberus-gaap:SubsequentEventMember2022-01-042022-01-0400000648032020-09-3000000648032020-03-3100000648032020-06-3000000648032021-09-3000000648032021-03-310000064803srt:ScenarioForecastMember2022-12-310000064803cvs:InsuranceAndHmoMember2021-01-012021-12-310000064803cvs:InsuranceAndHmoMember2020-01-012020-12-310000064803cvs:InsuranceAndHmoMember2019-01-012019-12-310000064803cvs:InsuranceAndHmoMember2021-12-310000064803cvs:InsuranceAndHmoMember2020-12-310000064803cvs:InsuranceAndHmoMember2019-12-310000064803us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember2020-12-310000064803us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember2019-12-310000064803us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember2018-12-310000064803us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember2021-01-012021-12-310000064803us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember2020-01-012020-12-310000064803us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember2019-01-012019-12-310000064803us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember2021-12-310000064803us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2020-12-310000064803us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2019-12-310000064803us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2018-12-310000064803us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2021-01-012021-12-310000064803us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2020-01-012020-12-310000064803us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2019-01-012019-12-310000064803us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2021-12-310000064803us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2020-12-310000064803us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2019-12-310000064803us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2018-12-310000064803us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2021-01-012021-12-310000064803us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2020-01-012020-12-310000064803us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2019-01-012019-12-310000064803us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2021-12-310000064803us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember2020-12-310000064803us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember2019-12-310000064803us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember2018-12-310000064803us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember2021-01-012021-12-310000064803us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember2020-01-012020-12-310000064803us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember2019-01-012019-12-310000064803us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember2021-12-310000064803us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2020-12-310000064803us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2019-12-310000064803us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2018-12-310000064803us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2021-12-310000064803us-gaap:EmployeeStockOptionMember2021-01-012021-12-310000064803us-gaap:EmployeeStockOptionMember2020-01-012020-12-310000064803us-gaap:EmployeeStockOptionMember2019-01-012019-12-310000064803us-gaap:SubsequentEventMember2022-01-012022-01-31cvs:reinsurance_agreement0000064803cvs:HartfordLifeAndAccidentInsuranceCompanyMember2021-12-310000064803cvs:HartfordLifeAndAccidentInsuranceCompanyMember2020-12-310000064803cvs:LincolnLifeAnnuityCompanyOfNewYorkMember2021-12-310000064803cvs:LincolnLifeAnnuityCompanyOfNewYorkMember2020-12-310000064803cvs:VOYARetirementInsuranceAndAnnuityCompanyMember2021-12-310000064803cvs:VOYARetirementInsuranceAndAnnuityCompanyMember2020-12-310000064803cvs:AllOtherReinsurersMember2021-12-310000064803cvs:AllOtherReinsurersMember2020-12-31cvs:lease00000648032012-01-012012-12-310000064803cvs:RadcliffAndFlaimVAetnaIncEtAlMemberus-gaap:PendingLitigationMember2020-12-31cvs:claim0000064803us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMembercvs:USFederalGovernmentMember2021-01-012021-12-310000064803us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMembercvs:USFederalGovernmentMember2020-01-012020-12-310000064803us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMembercvs:USFederalGovernmentMember2019-01-012019-12-310000064803us-gaap:IntersegmentEliminationMembercvs:HealthCareBenefitsSegmentMember2021-01-012021-12-310000064803us-gaap:IntersegmentEliminationMembercvs:PharmacyServicesSegmentMember2021-01-012021-12-310000064803us-gaap:IntersegmentEliminationMembercvs:RetailLongTermCareSegmentMember2021-01-012021-12-310000064803us-gaap:IntersegmentEliminationMembercvs:HealthCareBenefitsSegmentMember2020-01-012020-12-310000064803us-gaap:IntersegmentEliminationMembercvs:PharmacyServicesSegmentMember2020-01-012020-12-310000064803us-gaap:IntersegmentEliminationMembercvs:RetailLongTermCareSegmentMember2020-01-012020-12-310000064803us-gaap:IntersegmentEliminationMembercvs:HealthCareBenefitsSegmentMember2019-01-012019-12-310000064803us-gaap:IntersegmentEliminationMembercvs:PharmacyServicesSegmentMember2019-01-012019-12-310000064803us-gaap:IntersegmentEliminationMembercvs:RetailLongTermCareSegmentMember2019-01-012019-12-310000064803cvs:HealthCareBenefitsSegmentMember2021-06-012021-06-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
        (Mark One)
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2021
or
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _________ to_________
Commission file number: 001-01011
cvs-20211231_g1.jpg
CVS HEALTH CORPORATION
(Exact name of registrant as specified in its charter)
Delaware05-0494040
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)
One CVS Drive, Woonsocket,Rhode Island02895
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code:(401)765-1500
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.01 per shareCVSNew York Stock Exchange
Securities registered pursuant to Section 12(g) of the Act:None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.YesNo
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.YesNo
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.YesNo
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).YesNo
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer Accelerated filer
Non-accelerated filerSmaller reporting company
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C 7262(b)) by the registered public accounting firm that prepared or issued its audit report.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).YesNo
The aggregate market value of the registrant’s common stock held by non-affiliates was approximately $109,651,334,285 as of June 30, 2021, based on the closing price of the common stock on the New York Stock Exchange. For purposes of this calculation, only executive officers and directors are deemed to be affiliates of the registrant.
As of February 2, 2022, the registrant had 1,312,510,426 shares of common stock outstanding.
DOCUMENTS INCORPORATED BY REFERENCE

The following materials are incorporated by reference into this Form 10-K:
Information contained in the definitive proxy statement for CVS Health Corporation’s 2022 Annual Meeting of Stockholders, to be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year ended December 31, 2021 (the “Proxy Statement”), is incorporated by reference in Parts III and IV to the extent described therein.



TABLE OF CONTENTS

Page
Part I
Item 1:
Item 1A:
Item 1B:
Item 2:
Item 3:
Item 4:
Part II
Item 5:
Item 6:
Item 7:
Item 7A:
Item 8:
Item 9:
Item 9A:
Item 9B:
Part III
Item 10:
Item 11:
Item 12:
Item 13:
Item 14:
Part IV
Item 15:
Item 16:




Unless the context otherwise requires, references to the terms “we,” “our” or “us” used throughout this Annual Report on Form 10-K (this “10-K”) refer to CVS Health Corporation (a Delaware corporation), together with its subsidiaries (collectively, “CVS Health” or the “Company”). References to competitors and other companies throughout this 10-K, including the information incorporated herein by reference, are for illustrative or comparison purposes only and are not identifying that these companies are the only competitors or closest competitors of the Company or any of the Company’s businesses, products, or services.

CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS

The Private Securities Litigation Reform Act of 1995 (the “Reform Act”) provides a “safe harbor” for forward-looking statements, so long as (1) those statements are identified as forward-looking, and (2) the statements are accompanied by meaningful cautionary statements that identify important factors that could cause actual results to differ materially from those discussed in the statement. We are taking advantage of these safe harbor provisions.

Certain information contained in this 10-K is forward-looking within the meaning of the Reform Act or SEC rules. This information includes, but is not limited to: “Outlook for 2022” of Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) included in Item 7, “Quantitative and Qualitative Disclosures About Market Risk” included in Item 7A, “Government Regulation” included in Item 1, and “Risk Factors” included in Item 1A. In addition, throughout this 10-K and our other reports and communications, we use the following words or variations or negatives of these words and similar expressions when we intend to identify forward-looking statements:

·Anticipates·Believes·Can·Continue·Could
·Estimates·Evaluate·Expects·Explore·Forecast
·Guidance·Intends·Likely·May·Might
·Outlook·Plans·Potential·Predict·Probable
·Projects·Seeks·Should·View·Will

All statements addressing the future operating performance of CVS Health or any segment or any subsidiary and/or future events or developments, including statements relating to the projected impact of coronavirus disease 2019 (“COVID-19”) and its emerging new variants on the Company’s businesses, investment portfolio, operating results, cash flows and/or financial condition, statements relating to corporate strategy, statements relating to future revenue, operating income or adjusted operating income, earnings per share or adjusted earnings per share, Health Care Benefits segment business, sales results and/or trends, medical cost trends, medical membership, Medicare Part D membership, medical benefit ratios and/or operations, Pharmacy Services segment business, sales results and/or trends and/or operations, Retail/LTC segment business, sales results and/or trends and/or operations, incremental investment spending, interest expense, effective tax rate, weighted-average share count, cash flow from operations, net capital expenditures, cash available for debt repayment, integration synergies, net synergies, integration costs, enterprise modernization, transformation, leverage ratio, cash available for enhancing shareholder value, inventory reduction, turn rate and/or loss rate, debt ratings, the Company’s ability to attract or retain customers and clients, store development and/or relocations, new product development, and the impact of industry and regulatory developments, as well as statements expressing optimism or pessimism about future operating results or events, are forward-looking statements within the meaning of the Reform Act.

Forward-looking statements rely on a number of estimates, assumptions and projections concerning future events, and are subject to a number of significant risks and uncertainties and other factors that could cause actual results to differ materially from those statements. Many of these risks and uncertainties and other factors are outside our control. Certain of these risks and uncertainties and other factors are described under “Risk Factors” included in Item 1A of this 10-K; these are not the only risks and uncertainties we face. There can be no assurance that the Company has identified all the risks that may affect it. Additional risks and uncertainties not presently known to the Company or that the Company currently believes to be immaterial also may adversely affect the Company’s businesses. If any of those risks or uncertainties develops into actual events, those events or circumstances could have a material adverse effect on the Company’s businesses, operating results, cash flows, financial condition and/or stock price, among other effects.

You should not put undue reliance on forward-looking statements. Any forward-looking statement speaks only as of the date of this 10-K, and we disclaim any intention or obligation to update or revise forward-looking statements, whether as a result of new information, future events, uncertainties or otherwise.

1

PART I

Item 1. Business.

Overview

CVS Health Corporation, together with its subsidiaries (collectively, “CVS Health,” the “Company,” “we,” “our” or “us”), is a leading diversified health solutions company, making healthier happen now. In an increasingly connected and digital world, we are meeting people wherever they are and changing health care to meet their needs. The Company has more than 9,900 retail locations, nearly 1,200 walk-in medical clinics, a leading pharmacy benefits manager with approximately 110 million plan members with expanding specialty pharmacy solutions and a dedicated senior pharmacy care business serving more than one million patients per year. The Company also serves an estimated 35 million people through traditional, voluntary and consumer-directed health insurance products and related services, including expanding Medicare Advantage offerings and a leading standalone Medicare Part D prescription drug plan (“PDP”). The Company believes its innovative health care model increases access to quality care, delivers better health outcomes and lowers overall health care costs.

The Company has four reportable segments: Health Care Benefits, Pharmacy Services, Retail/LTC and Corporate/Other.

Business Strategy

The Company seeks to improve access, lower costs and enhance health outcomes by engaging with consumers when, where and how they desire. This means delivering solutions that are personalized, seamless, connected and increasingly digital. CVS Health is also shifting from transaction-based primary care to addressing holistic health – physical, emotional, social, economic – which will lead to higher quality of care and lower medical costs. The Company is a leader in key segments of health care today through foundational businesses and is seeking to create new sources of value by expanding into next generation primary care delivery and health services, with a goal of improving satisfaction levels for both providers and consumers. The Company believes its consumer-centric strategy will drive sustainable long-term growth and deliver value for all stakeholders.

COVID-19

The COVID-19 pandemic and its emerging new variants continue to impact the U.S. and other countries around the world. Our strong local presence and scale in communities across the country has enabled us to play an indispensable role in the national response to COVID-19, as well as provide seamless support for our customers wherever they need us: in our CVS locations, in their homes, and virtually.

The Company offered COVID-19 diagnostic testing at more than 4,800 CVS Pharmacy® locations, at community-based testing sites in underserved areas and through its Return ReadySM solution as of December 31, 2021. During 2021, the Company also began selling over-the-counter (“OTC”) test kits in its retail locations and online. The Company began administering COVID-19 vaccinations in long-term care facilities and in certain of its retail pharmacies during December 2020 and February 2021, respectively, and began the administration of COVID-19 boosters and pediatric vaccines during the fourth quarter of 2021. The Company offered COVID-19 vaccinations at more than 9,800 CVS Pharmacy locations as of December 31, 2021. During the year ended December 31, 2021, the Company administered more than 32 million COVID-19 tests and more than 59 million COVID-19 vaccines. The Company expects to continue to play a significant role in COVID-19 testing and vaccine administration in the future, while maintaining a strong commitment to testing and vaccine equity by optimizing site locations and targeting outreach initiatives to reach vulnerable populations.

The impact of COVID-19 on the Company’s businesses, operating results, cash flows and financial condition in the years ended December 31, 2021 and 2020, as well as information regarding certain expected impacts of COVID-19 on the Company, is discussed throughout this 10-K.

Health Care Benefits Segment

The Health Care Benefits segment operates as one of the nation’s leading diversified health care benefits providers, serving an estimated 35 million people as of December 31, 2021. The Health Care Benefits segment has the information and resources to help members, in consultation with their health care professionals, make more informed decisions about their health care. The Health Care Benefits segment offers a broad range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, medical management capabilities, Medicare Advantage and Medicare Supplement plans, PDPs, Medicaid health care management services and health information
2


technology (“HIT”) products and services. The Health Care Benefits segment also provided workers’ compensation administrative services through its Coventry Health Care Workers’ Compensation business (“Workers’ Compensation business”) prior to the sale of this business on July 31, 2020. The Health Care Benefits segment’s customers include employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers (“providers”), governmental units, government-sponsored plans, labor groups and expatriates.

Health Care Benefits Products and Services

The Company refers to insurance products (where it assumes all or a majority of the risk for medical and dental care costs) as “Insured” and administrative services contract products (where the plan sponsor assumes all or a majority of the risk of medical and dental care costs) as “ASC.” Health Care Benefits products and services consist of the following:

Commercial Medical: The Health Care Benefits segment offers point-of-service (“POS”), preferred provider organization (“PPO”), health maintenance organization (“HMO”) and indemnity benefit (“Indemnity”) plans. Commercial medical products also include health savings accounts (“HSAs”) and consumer-directed health plans that combine traditional POS or PPO and/or dental coverage, subject to a deductible, with an accumulating benefit account (which may be funded by the plan sponsor and/or the member in the case of HSAs). With the launch of Aetna Virtual Primary CareTM in 2021, eligible members now have access to health services remotely, paired with access to in-person visits with providers in the Company’s network, including at MinuteClinic® and CVS HealthHUB® locations. Principal products and services are targeted specifically to large multi-site national, mid-sized and small employers, individual insureds and expatriates. The Company offers medical stop loss insurance coverage for certain employers who elect to self-insure their health benefits. Under medical stop loss insurance products, the Company assumes risk for costs associated with large individual claims and/or aggregate loss experience within an employer’s plan above a pre-set annual threshold. The segment also has a portfolio of additional health products and services that complement its medical products such as dental plans, behavioral health and employee assistance products, provider network access and vision products.
Government Medical: In select geographies, the Health Care Benefits segment offers Medicare Advantage plans, Medicare Supplement plans and prescription drug coverage for Medicare beneficiaries; participates in Medicaid and subsidized Children’s Health Insurance Programs (“CHIP”); and participates in demonstration projects for members who are eligible for both Medicare and Medicaid (“Duals”). These Government Medical products are further described below:
Medicare Advantage: Through annual contracts with the U.S. Centers for Medicare & Medicaid Services (“CMS”), the Company offers HMO and PPO products for eligible individuals in certain geographic areas through the Medicare Advantage program. Members typically receive enhanced benefits over traditional fee-for-service Medicare coverage (“Original Medicare”), including reduced cost-sharing for preventive care, vision and other services. The Company offered network-based HMO and/or PPO plans in 46 states and Washington, D.C. in 2021. For certain qualifying employer groups, the Company offers Medicare PPO products nationally. When combined with the Company’s PDP product, these national PPO plans form an integrated national Insured Medicare product for employers that provides medical and pharmacy benefits.
Medicare PDP: The Company is a national provider of drug benefits under the Medicare Part D prescription drug program. All Medicare eligible individuals are eligible to participate in this voluntary prescription drug plan. Members typically receive coverage for certain prescription drugs, usually subject to a deductible, co-insurance and/or co-payment. The Company offered PDP plans in all 50 states and Washington, D.C. in 2021. On November 30, 2018, the Company completed the sale of the standalone PDPs of Aetna, Inc. (“Aetna”) to WellCare Health Plans, Inc. effective December 31, 2018. The Company provided administrative services to, and retained the financial results of, the divested plans through 2019. Subsequent to 2019, the Company no longer retains the financial results of the divested plans.
Medicare Supplement: For certain Medicare eligible members, the Company offers supplemental coverage for certain health care costs not covered by Original Medicare. The products included in the Medicare Supplement portfolio help to cover some of the gaps in Original Medicare, and include coverage for Medicare deductibles and coinsurance amounts. The Company offered a wide selection of Medicare Supplement products in 49 states and Washington, D.C. in 2021.
Medicaid and CHIP: The Company offers health care management services to individuals eligible for Medicaid and CHIP under multi-year contracts with government agencies in various states that are subject to annual appropriations. CHIP are state-subsidized insurance programs that provide benefits for families with uninsured children. The Company offered these services on an Insured or ASC basis in 16 states in 2021.
Duals: The Company provides health coverage to beneficiaries who are dually eligible for both Medicare and Medicaid coverage. These members must meet certain income and resource requirements in order to qualify for
3


this coverage. The Company coordinates 100% of the care for these members and may provide them with additional services in order to manage their health care costs.

The Company also has a portfolio of transformative products and services aimed at creating a holistic and integrated approach to individual health and wellness. These products and services complement the Commercial Medical and Government Medical products and aim to provide innovative solutions, create integrated experience offerings and enable enhanced care delivery to customers.

Health Care Benefits Provider Networks

The Company contracts with physicians, hospitals and other providers for services they provide to the Company’s members. The Company uses a variety of techniques designed to help encourage appropriate utilization of medical services (“utilization”) and maintain affordability of quality coverage. In addition to contracts with providers for negotiated rates of reimbursement, these techniques include creating risk sharing arrangements that align economic incentives with providers, the development and implementation of guidelines for the appropriate utilization and the provision of data to providers to enable them to improve health care quality. At December 31, 2021, the Company’s underlying nationwide provider network had approximately 1.5 million participating providers. Other providers in the Company’s provider networks also include laboratory, imaging, urgent care and other freestanding health facilities.

Health Care Benefits Quality Assessment

CMS uses a 5-star rating system to monitor Medicare health care and drug plans and ensure that they meet CMS’s quality standards. CMS uses this rating system to provide Medicare beneficiaries with a tool that they can use to compare the overall quality of care and level of customer service of companies that provide Medicare health care and drug plans. The rating system considers a variety of measures adopted by CMS, including quality of preventative services, chronic illness management and overall customer satisfaction. See “Health Care Benefits Pricing” below in this Item 1 for further discussion of star ratings. The Company seeks Health Plan accreditation for Aetna HMO plans from the National Committee for Quality Assurance (“NCQA”), a private, not-for-profit organization that evaluates, accredits and certifies a wide range of health care organizations. Health care plans seeking accreditation must pass a rigorous, comprehensive review and must annually report on their performance.

Aetna Life Insurance Company (“ALIC”), a wholly-owned subsidiary of the Company, has received nationwide NCQA PPO Health Plan accreditation. As of December 31, 2021, all of the Company’s Commercial HMO and all of ALIC’s PPO members who were eligible participated in HMOs or PPOs that are accredited by the NCQA.

The Company’s provider selection and credentialing/re-credentialing policies and procedures are consistent with NCQA and URAC, a health care accrediting organization that establishes quality standards for the health care industry, as well as state and federal, requirements. In addition, the Company is certified under the NCQA Credentials Verification Organization (“CVO”) certification program for all certification options and has URAC CVO accreditation.

Quality assessment programs for contracted providers who participate in the Company’s networks begin with the initial review of health care practitioners. Practitioners’ licenses and education are verified, and their work history is collected by the Company or in some cases by the practitioner’s affiliated group or organization. The Company generally requires participating hospitals to be certified by CMS or accredited by The Joint Commission, the American Osteopathic Association, or Det Norske Veritas Healthcare.

The Company also offers quality and outcome measurement programs, quality improvement programs, and health care data analysis systems to providers and purchasers of health care services.

Health Care Benefits Information Systems

The Health Care Benefits segment currently operates and supports an end-to-end suite of information technology platforms to support member engagement, enrollment, health benefit administration, care management, service operations, financial reporting and analytics. The multiple platforms are supported by an integration layer to facilitate the transfer of real-time data. There is continued focus and investment in enterprise data platforms, cloud capabilities, digital products to offer innovative solutions and a seamless experience to the Company’s members through mobile and web channels. The Company is making concerted investments in emerging technology capabilities such as voice, artificial intelligence and robotics to further automate, reduce cost and improve the experience for all of its constituents. The Health Care Benefits segment is utilizing the
4


full breadth of the Company’s assets to build enterprise technology that will help guide our members through their health care journey, provide them a high level of service, enable healthier outcomes and encourage them to take next best actions to lead healthier lives.

Health Care Benefits Customers

Medical membership is dispersed throughout the United States, and the Company also serves medical members in certain countries outside the United States. The Company offers a broad range of traditional, voluntary and consumer-directed health insurance products and related services, many of which are available nationwide. Depending on the product, the Company markets to a range of customers including employer groups, individuals, college students, part-time and hourly workers, health plans, providers, governmental units, government-sponsored plans, labor groups and expatriates. For additional information on medical membership, see “Health Care Benefits Segment” in the Management’s Discussion and Analysis of Financial Condition and Results of Operations (the “MD&A”) included in Item 7 of this 10-K.

The Company markets both Commercial Insured and ASC products and services primarily to employers that sponsor the Company’s products for the benefit of their employees and their employees’ dependents. Frequently, larger employers offer employees a choice among coverage options, from which the employee makes his or her selection during a designated annual open enrollment period. Typically, employers pay all of the monthly premiums to the Company and, through payroll deductions, obtain reimbursement from employees for a percentage of the premiums that is determined by each employer. Some Health Care Benefits products are sold directly to employees of employer groups on a fully employee-funded basis. In some cases, the Company bills the covered individual directly. In addition, effective January 2022, the Company entered the individual public health insurance exchanges (“Public Exchanges”) in eight states through which it sells Insured plans directly to individual consumers.

The Company offers Insured Medicare coverage on an individual basis as well as through employer groups to their retirees. Medicaid and CHIP members are enrolled on an individual basis. The Company also offers Insured health care coverage to members who are dually-eligible for both Medicare and Medicaid.

Health Care Benefits products are sold through: the Company’s sales personnel; independent brokers, agents and consultants who assist in the production and servicing of business; as well as private health insurance exchanges (“Private Exchanges”) and Public Exchanges (together with Private Exchanges, “Insurance Exchanges”). For large employers or other entities that sponsor the Company’s products (“plan sponsors”), independent consultants and brokers are frequently involved in employer health plan selection decisions and sales. In some instances, the Company may pay commissions, fees and other amounts to brokers, agents, consultants and sales representatives who place business with the Company. In certain cases, the customer pays the broker for services rendered, and the Company may facilitate that arrangement by collecting the funds from the customer and transmitting them to the broker. The Company supports marketing and sales efforts with an advertising program that may include television, radio, billboards, print media and social media, supplemented by market research and direct marketing efforts.

The U.S. federal government is a significant customer of the Health Care Benefits segment through contracts with CMS for coverage of Medicare-eligible individuals and federal employee-related benefit programs. Other than the contracts with CMS, the Health Care Benefits segment is not dependent upon a single customer or a few customers the loss of which would have a significant effect on the earnings of the segment. The loss of business from any one, or a few, independent brokers or agents would not have a material adverse effect on the earnings of the Health Care Benefits segment. In 2021, 2020 and 2019, Health Care Benefits segment revenues from the federal government accounted for 14%, 13% and 13%, respectively, of the Company’s consolidated total revenues. Contracts with CMS for coverage of Medicare-eligible individuals in the Health Care Benefits segment accounted for approximately 79%, 78% and 76%, respectively, of the Company’s consolidated revenues from the federal government in 2021, 2020 and 2019.

Health Care Benefits Pricing

For Commercial Insured plans, contracts containing the pricing and other terms of the relationship are generally established in advance of the policy period and typically have a duration of one year. Fees under ASC plans are generally fixed for a period of one year.

Generally, a fixed premium rate is determined at the beginning of the policy period for Commercial Insured plans. The Company typically cannot recover unanticipated increases in health care and other benefit costs in the current policy period; however, it may consider prior experience for a product in the aggregate or for a specific customer, among other factors, in
5


determining premium rates for future policy periods. Where required by state laws, premium rates are filed and approved by state regulators prior to contract inception. Future operating results could be adversely affected if the premium rates requested are not approved or are adjusted downward or their approval is delayed by state or federal regulators.

The Company has Medicare Advantage and PDP contracts with CMS to provide HMO, PPO and prescription drug coverage to Medicare beneficiaries in certain geographic areas. Under these annual contracts, CMS pays the Company a fixed per member (or “capitation”) payment and/or a portion of the premium, both of which are based on membership and adjusted for demographic and health risk factors. CMS also considers inflation, changes in utilization patterns and average per capita fee-for-service Medicare costs in the calculation of the fixed capitation payment or premium. PDP contracts also provide a risk-sharing arrangement with CMS to limit the Company’s exposure to unfavorable expenses or benefit from favorable expenses. Amounts payable to the Company under the Medicare arrangements are subject to annual revision by CMS, and the Company elects to participate in each Medicare service area or region on an annual basis. Premiums paid to the Company for Medicare products are subject to federal government reviews and audits, which can result, and have resulted, in retroactive and prospective premium adjustments and refunds to the government and/or members. In addition to payments received from CMS, some Medicare Advantage products and all PDP products require a supplemental premium to be paid by the member or sponsoring employer. In some cases these supplemental premiums are adjusted based on the member’s income and asset levels. Compared to Commercial Medical products, Medicare contracts generate higher per member per month revenues and higher health care and other benefit costs.

The Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010 (collectively, the “ACA”) ties a portion of each Medicare Advantage plan’s reimbursement to the plan’s “star ratings.” Plans must have a star rating of four or higher (out of five) to qualify for bonus payments. CMS released the Company’s 2022 star ratings in October 2021. The Company’s 2022 star ratings will be used to determine which of the Company’s Medicare Advantage plans have ratings of four stars or higher and qualify for bonus payments in 2023. Based on the Company’s membership at December 31, 2021, 87% of the Company’s Medicare Advantage members were in plans with 2022 star ratings of at least 4.0 stars, compared to 83% of the Company’s Medicare Advantage members being in plans with 2021 star ratings of at least 4.0 stars based on the Company’s membership at December 31, 2020.

Rates for Medicare Supplement products are regulated at the state level and vary by state and plan.

Under Insured Medicaid contracts, state government agencies pay the Company fixed monthly rates per member that vary by state, line of business and demographics; and the Company arranges, pays for and manages the health care services provided to Medicaid beneficiaries. These rates are subject to change by each state, and, in some instances, provide for adjustment for health risk factors. CMS requires these rates to be actuarially sound. The Company also receives fees from customers where it provides services under ASC Medicaid contracts. ASC Medicaid contracts generally are for periods of more than one year, and certain of them contain performance incentives and limited financial risk sharing with respect to certain medical, financial and operational metrics. Under these arrangements, performance is evaluated annually, with associated financial incentive opportunities, and financial risk share obligations are typically limited to a percentage of the fees otherwise payable to the Company. Payments to the Company under Medicaid contracts are subject to the annual appropriation process in the applicable state.

Under Duals contracts, the rate setting process is generally established by CMS in partnership with the state government agency participating in the demonstration project. Both CMS and the state government agency may seek premium and other refunds under certain circumstances, including if the Company fails to comply with CMS regulations or other contractual requirements.

The Company offers HMO and consumer-directed medical and dental plans to federal employees under the Federal Employees Health Benefits (“FEHB”) Program and the Federal Employees Dental and Vision Insurance Program. Premium rates and fees for those plans are subject to federal government review and audit, which can result, and have resulted, in retroactive and prospective premium and fee adjustments and refunds to the government and/or members.

Beginning in 2014, the ACA imposed significant new industry-wide fees, assessments and taxes, including an annual levy known as the health insurer fee (the “HIF”). The HIF applied for 2020 and was temporarily suspended for 2019. In December 2019, the HIF was repealed for calendar years after 2020. For additional information on the ACA fees, assessments and taxes, see Note 1 ‘‘Significant Accounting Policies’’ included in Item 8 of this 10-K. The Company’s goal is to collect premiums and fees where possible, or solve for, all of the ACA-related fees, assessments and taxes.


6


Health Care Benefits Seasonality

The Health Care Benefits segment’s quarterly operating income progression is also impacted by (i) the seasonality of benefit costs which generally increase during the year as Insured members progress through their annual deductibles and out-of-pocket expense limits and (ii) the seasonality of operating expenses, which are generally the highest during the fourth quarter due primarily to spending to support readiness for the start of the upcoming plan year and marketing associated with Medicare annual enrollment.

During the year ended December 31, 2021, the customary quarterly operating income progression was impacted by COVID-19. While overall medical costs in the first quarter were generally consistent with historical baseline levels in the aggregate, the segment experienced increased COVID-19 testing and treatment costs and lower Medicare risk-adjusted revenue. During the second quarter, COVID-19 testing and treatment costs persisted, however at levels significantly lower than those observed during the first quarter. Beginning in the third quarter, medical costs once again increased primarily driven by the spread of the emerging new variants of COVID-19, which resulted in increased testing and treatment costs that continued throughout the fourth quarter.

During the year ended December 31, 2020, the customary quarterly operating income progression was also impacted by COVID-19. Beginning in mid-March, the health care system experienced a significant reduction in utilization that is discretionary and the cancellation of elective medical procedures. Utilization remained below historical levels through April, began to recover in May and June and reached more normal levels in the third and fourth quarters, with select geographies impacted by COVID-19 waves. The impact of the deferral of non-essential care was partially offset by COVID-19 testing and treatment costs, as well as planned COVID-19 related investments.

Health Care Benefits Competition

The health care benefits industry is highly competitive, primarily due to a large number of for-profit and not-for-profit competitors, competitors’ marketing and pricing and a proliferation of competing products, including new products that are continually being introduced into the marketplace. New entrants into the marketplace, as well as consolidation within the industry, have contributed to and are expected to intensify the competitive environment. In addition, the rapid pace of change as the industry evolves towards a consumer-focused retail marketplace, including Insurance Exchanges, and the increased use of technology to interact with members, providers and customers, increase the risks the Company currently faces from new entrants and disruptive actions by existing competitors compared to prior periods.

The Company believes that the significant factors that distinguish competing health plans include the perceived overall quality (including accreditation status), quality of service, comprehensiveness of coverage, cost (including premium rates, provider discounts and member out-of-pocket costs), product design, financial stability and ratings, breadth and quality of provider networks, ability to offer different provider network options, providers available in such networks, and quality of member support and care management programs. The Company believes that it is competitive on each of these factors. The Company’s ability to increase the number of persons covered by its health plans or to increase Health Care Benefits segment revenues is affected by its ability to differentiate itself from its competitors on these factors. Competition may also affect the availability of services from providers, including primary care physicians, specialists and hospitals.

Insured products compete with local and regional health care benefits plans, health care benefits and other plans sponsored by other large commercial health care benefit insurance companies, health system owned health plans, new entrants into the marketplace and numerous for-profit and not-for-profit organizations operating under licenses from the Blue Cross and Blue Shield Association. The largest competitor in Medicare products is Original Medicare. Additional Health Care Benefits segment competitors include other types of medical and dental provider organizations, various specialty service providers (including pharmacy benefit management (“PBM”) services providers), health care consultants, financial services companies, integrated health care delivery organizations (networks of providers who also coordinate administrative services for and assume insurance risk of their members), third party administrators (“TPAs”), HIT companies and, for certain plans, programs sponsored by the federal or state governments. Emerging competitors include start up health care benefits plans, technology companies, provider-owned health plans, new joint ventures (including not-for-profit joint ventures among firms from multiple industries), technology firms, financial services firms that are distributing competing products on their proprietary Private Exchanges, and consulting firms that are distributing competing products on their proprietary Private Exchanges, as well as non-traditional distributors such as retail companies. The Company’s ability to increase the number of persons enrolled in Insured Commercial Medical products also is affected by the desire and ability of employers to self-fund their health coverage.

7


The Health Care Benefits segment’s ASC plans compete primarily with other large commercial health care benefit companies, numerous for-profit and not-for-profit organizations operating under licenses from the Blue Cross and Blue Shield Association and TPAs.

The Health Care Benefits segment’s international products compete with local, global and U.S.-based health plans and commercial health care benefit insurance companies, many of whom are licensed in more geographies and have a longer operating history, better brand recognition and greater marketplace presence in one or more geographies.

The provider solutions and HIT marketplaces and products are evolving rapidly. The Company competes for provider solutions and HIT business with other large health plans and commercial health care benefit insurance companies as well as information technology companies and companies that specialize in provider solutions and HIT. Many information technology product competitors have longer operating histories, better brand recognition, greater marketplace presence and more experience in developing innovative products.

In addition to competitive pressures affecting the Company’s ability to obtain new customers or retain existing customers, the Health Care Benefits segment’s medical membership has been and may continue to be adversely affected by adverse and/or uncertain economic conditions and reductions in workforce by existing customers due to adverse and/or uncertain general economic conditions, especially in the United States and industries where such membership is concentrated.

Health Care Benefits Reinsurance

The Company currently has several reinsurance agreements with non-affiliated insurers that relate to Health Care Benefits insurance policies. The Company entered into these contracts to reduce the risk of catastrophic losses which in turn reduces capital and surplus requirements. The Company frequently evaluates reinsurance opportunities and refines its reinsurance and risk management strategies on a regular basis.

Pharmacy Services Segment

The Pharmacy Services segment provides a full range of PBM solutions, including plan design offerings and administration, formulary management, retail pharmacy network management services and mail order pharmacy. In addition, through the Pharmacy Services segment, the Company provides specialty pharmacy and infusion services, clinical services, disease management services, medical spend management and pharmacy and/or other administrative services for providers and federal 340B drug pricing program covered entities (“Covered Entities”). The Pharmacy Services segment’s clients are primarily employers, insurance companies, unions, government employee groups, health plans, PDPs, Medicaid managed care (“Managed Medicaid”) plans, plans offered on Insurance Exchanges and other sponsors of health benefit plans throughout the United States and Covered Entities. The Pharmacy Services segment includes retail specialty pharmacy stores, specialty mail order pharmacies, mail order dispensing pharmacies, compounding pharmacies and branches for infusion and enteral nutrition services. During the year ended December 31, 2021, the Company’s PBM filled or managed 2.2 billion prescriptions on a 30-day equivalent basis.

PBM Services

The Company dispenses prescription drugs directly through its mail order dispensing and specialty mail order pharmacies and through pharmacies in its retail network. All prescriptions processed by the Company are analyzed, processed and documented by the Company’s proprietary prescription management systems. These systems provide essential features and functionality to allow plan members to utilize their prescription drug benefits. These systems also streamline the process by which prescriptions are processed by staff and network pharmacists by enhancing review of various items through automation, including plan eligibility, early refills, duplicate dispensing, appropriateness of dosage, drug interactions or allergies, over-utilization and potential fraud.

Plan Design Offerings and Administration
The Company assists its PBM clients in designing pharmacy benefit plans that help improve health outcomes while minimizing the costs to the client. The Company also assists PBM clients in monitoring the effectiveness of their plans through frequent, informal communications, the use of proprietary software, as well as through formal annual, quarterly and sometimes monthly performance reviews. The Company administers pharmacy benefit plans for clients who contract with it to facilitate prescription drug coverage and claims processing for their eligible plan members. The Company also provides administrative services for Covered Entities.

8


The Company makes recommendations to help PBM clients design benefit plans that promote the use of lower cost, clinically appropriate drugs and helps its PBM clients control costs by recommending plan designs that encourage the use of generic equivalents of brand name drugs when such equivalents are available. Clients also have the option, through plan design, to further lower their pharmacy benefit plan costs by setting different member payment levels for different products on their drug lists or “formularies,” which helps guide members to choose lower cost alternatives through appropriate financial incentives.

Formulary Management
The Company utilizes an independent panel of doctors, pharmacists and other medical experts, referred to as the CVS Caremark National Pharmacy and Therapeutics Committee, to review and approve the selection of drugs that meet the Company’s standards of safety and efficacy for inclusion on one of the Company’s template formularies. The Company’s formularies provide recommended products in numerous drug classes to help ensure member access to clinically appropriate drugs with alternatives within a class under the client’s pharmacy benefit plan, while helping to drive the lowest net cost for clients that select one of the Company’s formularies. To help improve clinical outcomes for members and clients, the Company conducts ongoing, independent reviews of all drugs, including those appearing on the formularies and generic equivalent products. Many of the Company’s clients choose to adopt a template formulary offering as part of their plan design. PBM clients are given capabilities to offer real time benefits information for a member’s specific plan design, provided digitally at the point of prescribing, at the CVS pharmacy and directly to members.

Retail Pharmacy Network Management Services
The Company maintains a national network of approximately 66,000 retail pharmacies, consisting of approximately 40,000 chain pharmacies (which includes CVS Pharmacy locations) and approximately 26,000 independent pharmacies, in the United States, including Puerto Rico, the District of Columbia, Guam and the U.S. Virgin Islands. When a customer fills a prescription in a retail pharmacy, the pharmacy sends prescription data electronically to the Company from the point-of-sale. This data interfaces with the Company’s proprietary prescription management systems, which verify relevant plan member data and eligibility, while also performing a drug utilization review to help evaluate clinical appropriateness and safety and confirming that the pharmacy will receive payment for the prescription. The Company also offers a performance program for non-Medicare customers, which can be implemented with either the Company’s broad, national network or with any managed network (as allowed by applicable laws and regulations). Under the program, high performing pharmacies are eligible to receive an incremental positive performance payment. The program aligns with key Healthcare Effectiveness Data Information Set measures utilized by CMS and is funded by client fees. 

Mail Order Pharmacy Services
The Pharmacy Services segment operates mail order dispensing pharmacies in the United States. Plan members or their prescribers submit prescriptions or refill requests, primarily for maintenance medications, to these pharmacies, and staff pharmacists review these prescriptions and refill requests with the assistance of the Company’s prescription management systems. This review may involve communications with the prescriber and, with the prescriber’s approval when required, can result in generic substitution, therapeutic interchange or other actions designed to help reduce cost and/or improve quality of treatment. The Company’s mail order dispensing pharmacies have been awarded Mail Service Pharmacy accreditation from URAC.

Specialty Pharmacy and Infusion Services
The Pharmacy Services segment operates specialty mail order pharmacies, retail specialty pharmacy stores and branches for infusion and enteral nutrition services in the United States. The specialty mail order pharmacies are used for delivery of advanced medications to individuals with chronic or genetic diseases and disorders. The Company’s specialty mail order pharmacies have been awarded Specialty Pharmacy accreditation from URAC. Substantially all of the Company’s specialty mail order pharmacies also have been accredited by The Joint Commission and the Accreditation Commission for Health Care (“ACHC”), which are independent, not-for-profit organizations that accredit and certify health care programs and organizations in the United States. The ACHC accreditation includes an additional accreditation by the Pharmacy Compounding Accreditation Board, which certifies compliance with the highest level of pharmacy compounding standards.

Clinical Services
The Company offers multiple clinical programs and services to help clients manage overall pharmacy and health care costs in a clinically appropriate manner. These programs are primarily designed to promote better health outcomes and to help target inappropriate medication utilization and non-adherence to medication, each of which may result in adverse medical events that negatively affect member health and client pharmacy and medical spend. These programs include utilization management (“UM”), medication management, quality assurance, adherence and counseling programs to complement the client’s plan design and clinical strategies. To help address prescription opioid abuse and misuse, the Company introduced an industry-leading UM approach that limits to seven days the supply of opioids dispensed for certain acute prescriptions for patients who
9


are new to therapy, limits the daily dosage of opioids dispensed based on the strength of the opioid and requires the use of immediate-release formulations of opioids before extended-release opioids are dispensed. The Company’s Pharmacy Advisor® program facilitates pharmacist counseling, both face-to-face and over the telephone, to help participating plan members with certain chronic diseases, such as diabetes and cardiovascular conditions, to identify gaps in care, adhere to their prescribed medications and manage their health conditions. The Company also has digital connectivity that helps to lower drug costs for patients by providing expanded visibility to lower cost alternatives through enhanced analytics and data sharing.

Disease Management Programs
The Company’s clinical programs and services utilize advanced protocols and offer clients convenience in working with providers and other third parties. The Company’s care management program covers diseases such as rheumatoid arthritis, Parkinson’s disease, epilepsy and multiple sclerosis and is accredited by the NCQA. The Company’s UM program covers similar diseases and is accredited by the NCQA and URAC.

Medical Benefit Management
The Company’s NovoLogix® online preauthorization tool helps identify and capture cost savings opportunities for specialty drugs billed under the medical benefit by identifying outliers to appropriate dosages and costs, and helps to ensure clinically appropriate use of specialty drugs.

Group Purchasing Organization Services
The Company operates a group purchasing organization that negotiates pricing for the purchase of pharmaceuticals and rebates with pharmaceutical manufacturers on behalf of its participants. The Company also provides various administrative, management and reporting services to pharmaceutical manufacturers.

Pharmacy Services Information Systems

The Pharmacy Services segment’s claim adjudication platform incorporates architecture that centralizes the data generated from filling mail order prescriptions, adjudicating retail pharmacy claims and delivering other solutions to PBM clients. The Health Engagement Engine® technology and proprietary clinical algorithms help connect the various parts of the enterprise and serve an essential role in cost management and health improvement, leveraging cloud-native technologies and practices. This capability transforms pharmacy data into actionable interventions at key points of care, including in retail, mail and specialty pharmacies as well as in customer care call center operations, leveraging our enterprise data platform to improve the quality of care. The technology leverages assisted artificial intelligence to deliver insights to the business and bring automation to otherwise manual tasks. Specialty services also connects with our claim adjudication platform and various health plan adjudication platforms with a centralized architecture servicing many clients and members. Operating services, such as Specialty Expedite®, provide an interconnected onboarding solution for specialty medications and branding solutions ranging from fulfillment to total patient management. These services are managed through our new innovative specialty workflow and web platform.

Pharmacy Services Clients

The Company’s Pharmacy Services clients are primarily employers, insurance companies, unions, government employee groups, health plans, Medicare Part D plans, Managed Medicaid plans and plans offered on Insurance Exchanges and other sponsors of health benefit plans throughout the United States and Covered Entities. Pharmaceuticals are provided to eligible members in benefit plans maintained by clients and utilize the Company’s information systems, among other things, to help perform safety checks, drug interaction screening and identify opportunities for generic substitution. Substantially all of the Pharmacy Services segment’s revenues are generated from dispensing and managing prescription drugs to eligible members in benefit plans maintained by clients.

Pharmacy Services Seasonality

The majority of Pharmacy Services segment revenues are not seasonal in nature.

Pharmacy Services Competition

The Company believes the primary competitive factors in the pharmacy services industry include: (i) the ability to negotiate favorable discounts from drug manufacturers as well as to negotiate favorable discounts from, and access to, retail pharmacy networks; (ii) the ability to identify and apply effective cost management programs utilizing clinical strategies, including the development and utilization of preferred formularies; (iii) the ability to market PBM products and services; (iv) the commitment
10


to provide flexible, clinically-oriented services to clients and be responsive to clients’ needs; (v) the quality, scope and costs of products and services offered to clients and their members; and (vi) operational excellence in delivering services. The Pharmacy Services segment has a significant number of competitors offering PBM services, including large, national PBM companies (e.g., Prime Therapeutics and MedImpact), PBMs owned by large national health plans (e.g., the Express Scripts business of Cigna Corporation and the OptumRx business of UnitedHealth) and smaller standalone PBMs.

Retail/LTC Segment

The Retail/LTC segment sells prescription drugs and a wide assortment of health and wellness products and general merchandise, provides health care services through its MinuteClinic walk-in medical clinics, provides medical diagnostic testing, administers vaccinations for illnesses such as influenza, COVID-19 and shingles and conducts long-term care pharmacy (“LTC”) operations, which distribute prescription drugs and provide related pharmacy consulting and other ancillary services to long-term care facilities and other care settings. As of December 31, 2021, the Retail/LTC segment operated more than 9,900 retail locations, nearly 1,200 MinuteClinic locations as well as online retail pharmacy websites, LTC pharmacies and on-site pharmacies. During the year ended December 31, 2021, the Retail/LTC segment filled 1.6 billion prescriptions on a 30-day equivalent basis. For the year ended December 31, 2021, the Company dispensed approximately 26.4% of the total retail pharmacy prescriptions in the United States.

Retail/LTC Products and Services

A typical retail store sells prescription drugs and a wide assortment of high-quality, nationally advertised brand name and proprietary brand merchandise. Pharmacy locations may also contract with Covered Entities under the federal 340B drug pricing program. Front store categories include over-the-counter drugs, consumer health products, beauty products and personal care products. LTC operations include distribution of prescription drugs and related consulting and ancillary services. The Company purchases merchandise from numerous manufacturers and distributors. The Company believes that competitive sources are readily available for substantially all of the products carried in its retail stores and the loss of any one supplier would not likely have a material effect on the Retail/LTC segment. The Company’s MinuteClinic locations offer a variety of health care services.

Retail/LTC revenues by major product group are as follows:
Percentage of Revenues
202120202019
Pharmacy (1)
76.0 %76.9 %76.7 %
Front store and other (2)
24.0 %23.1 %23.3 %
100.0 %100.0 %100.0 %
_____________________________________________
(1)Pharmacy includes LTC sales and sales in pharmacies within Target Corporation (“Target”) and other retail stores.
(2)“Other” represents less than 12% of the “Front store and other” revenue category in all periods presented.

Pharmacy
Pharmacy revenues represented approximately three-fourths of Retail/LTC segment revenues in each of 2021, 2020 and 2019. The Company believes that retail pharmacy operations will continue to represent a critical part of the Company’s business due to industry demographics, e.g., an aging American population consuming a greater number of prescription drugs, prescription drugs being used more often as the first line of defense for managing illness, the introduction of new pharmaceutical products, the need for vaccinations, including the COVID-19 vaccination, and Medicare Part D growth. The Company believes the retail pharmacy business benefits from investment in both people and technology, as well as innovative collaborations with health plans, PBMs and providers. Given the nature of prescriptions, consumers want their prescriptions filled accurately by professional pharmacists using the latest tools and technology, and ready when promised. Consumers also need medication management programs and better information to help them get the most out of their health care dollars. To assist consumers with these needs, the Company has introduced integrated pharmacy health care services that provide an earlier, easier and more effective approach to engaging consumers in behaviors that can help lower costs, improve health and save lives.

Front Store
Front store revenues reflect the Company’s strategy of innovating with new and unique products and services, using innovative personalized marketing and adjusting the mix of merchandise to match customers’ needs and preferences. A key component of the front store strategy is the ExtraCare® card program, which is one of the largest and most successful retail loyalty programs in the United States. The ExtraCare program allows the Company to balance marketing efforts so it can reward its best
11


customers by providing them with automatic sale prices, customized coupons, ExtraBucks® rewards and other benefits. The Company also offers a subscription-based membership program, CarePass®, under which members are entitled to a suite of benefits delivered over the course of the subscription period, as well as a promotional reward that can be redeemed for future goods and services. The Company continues to launch and enhance new and exclusive brands to create unmatched offerings in beauty products and deliver other unique product offerings, including a full range of high-quality CVS Health® and other proprietary brand products that are only available through CVS stores. The Company currently carries approximately 6,000 CVS Health and proprietary items, which accounted for approximately 22% of front store revenues during 2021.

MinuteClinic
As of December 31, 2021, the Company operated nearly 1,200 MinuteClinic locations in the United States. The clinics are staffed by nurse practitioners and physician assistants who utilize nationally established guidelines to deliver a variety of health care services. Payors value these clinics because they provide convenient, high-quality, cost-effective care, in many cases offering an attractive alternative to more expensive sites of care. MinuteClinic is collaborating with the Health Care Benefits and Pharmacy Services segments to help meet the needs of the Company’s health plan members and CVS Caremark’s client plan members by offering programs that can improve member health and lower costs. MinuteClinic also maintains relationships with leading hospitals, clinics and physicians in the communities we serve to support and enhance quality, access and continuity of care.

On-site Pharmacies
The Company also operates a limited number of pharmacies located at client sites, which provide certain health plan members and customers with a convenient alternative for filling their prescriptions and receiving vaccinations, including the COVID-19 vaccination.

Medical Diagnostic Testing
The Company offers medical diagnostic testing primarily through its COVID-19 testing sites located at CVS Pharmacy locations, in its MinuteClinic locations, at community-based testing sites in underserved areas and through its Return Ready solution.

Long-term Care Pharmacy Operations
The Retail/LTC segment provides LTC pharmacy services through the Omnicare® business. Omnicare’s customers consist of skilled nursing facilities, assisted living facilities, independent living communities, hospitals, correctional facilities, and other health care service providers. The Company provides pharmacy consulting, including monthly patient drug therapy evaluations, to assist in compliance with state and federal regulations and provide proprietary clinical and health management programs. It also provides pharmaceutical case management services for retirees, employees and dependents who have drug benefits under corporate-sponsored health care programs.

Community Location Development

CVS Health’s community health destinations are an integral part of its ability to meet the needs of consumers and maintain its leadership position in the changing health care landscape. When paired with its rapidly expanding digital presence, the Company’s physical presence in thousands of communities across the country represents a competitive advantage by allowing it to develop deep and trusted relationships through everyday engagement in consumer health. The Company’s community health destinations have played, and will continue to play, a key role in the Company’s continued growth and success. During 2021, the Company opened approximately 55 new community locations, relocated approximately 15 locations, converted approximately 300 locations into CVS HealthHUB locations and closed approximately 80 locations.

The Company’s continuous assessment of its national footprint is an essential component of competing effectively in the current health care environment. On an ongoing basis, the Company evaluates changes in population, consumer buying patterns and future health needs to assess the ability of its existing stores and locations to meet the needs of its consumers and the business. During the fourth quarter of 2021, the Company completed a strategic review of its retail business and announced its plans to reduce store density in certain locations through the closure of approximately 900 stores between 2022 and 2024.

As part of the Company’s strategic review of its retail business, CVS Health will also create new store formats to drive higher engagement with consumers. Three distinct models will serve as community health destinations: (a) sites dedicated to offering primary care services; (b) an enhanced version of CVS HealthHUB locations with products and services designed for everyday health and wellness needs; and (c) traditional CVS Pharmacy stores that provide prescription services and health, wellness, personal care and other convenient retail offerings.

12


Retail/LTC Information Systems

The Company has continued to invest in information systems to enable it to deliver exceptional customer service, enhance safety and quality, and expand patient care services while lowering operating costs. The proprietary WeCARE Workflow tool supports pharmacy teams by prioritizing work to meet customer expectations, facilitating prescriber outreach, and seamlessly integrating clinical programs. This solution delivers improved efficiency and enhances customer experience, as well as provides a framework to accommodate the evolution of pharmacy practice and the expansion of clinical programs. Our Health Engagement Engine technology and data science clinical algorithms enable the Company to help identify opportunities for pharmacists to deliver face-to-face counseling regarding patient health and safety matters, including medication adherence issues, gaps in care and management of certain chronic health conditions. The Company’s digital strategy is to empower the consumer to navigate their pharmacy experience and manage their condition through integrated online and mobile solutions that offer utility and convenience. The Company’s LTC digital technology suite, Omniview®, improves the efficiency of customers’ operations with tools that include executive dashboards, pre-admission pricing, electronic ordering of prescription refills, proof-of-delivery tracking, access to patient profiles, receipt and management of facility bills, and real-time validation of Medicare Part D coverage, among other capabilities.

Through the collaboration of its digital and technical teams, the Company has established critical tools which enable patients to schedule COVID-19 diagnostic testing and vaccination appointments through CVS.com and MinuteClinic.com. Key elements of the offerings include landing pages which highlight services and answer common questions, screening capabilities to determine patient eligibility, service location locator and appointment selection tools to efficiently identify the requested service on a specified date, time, and location and registration pages to collect required patient information, accelerating the administration of the test or vaccine once at the store. Once scheduled, the tools provide the user with instructions and notifications including SMS text message and email reminders, and, following administration, also provide digital results for tests and records for vaccinations, enabling patients to view and save their medical records for convenient access at a later point.

Retail/LTC Customers

The success of the Retail/LTC segment’s businesses is dependent upon the Company’s ability to establish and maintain contractual relationships with pharmacy benefit managers and other payors on acceptable terms. Substantially all of the Retail/LTC segment’s pharmacy revenues are derived from pharmacy benefit managers, managed care organizations (“MCOs”), government funded health care programs, commercial employers and other third-party payors. No single Retail/LTC payor accounted for 10% or more of the Company’s consolidated total revenues in 2021, 2020 or 2019.

Retail/LTC Seasonality

The majority of Retail/LTC segment revenues, particularly pharmacy revenues, generally are not seasonal in nature. However, front store revenues tend to be higher during the December holiday season. In addition, both pharmacy and front store revenues are affected by the timing and severity of the cough, cold and flu season. Uncharacteristic or extreme weather conditions also can adversely affect consumer shopping patterns and Retail/LTC revenues, expenses and operating results.

During the year ended December 31, 2021, the customary quarterly operating income progression continued to be impacted by COVID-19. During the first quarter, the Company experienced reduced customer traffic in its retail pharmacies, which reflected the impact of a weak cough, cold and flu season, while it administered the highest quarterly volume of COVID-19 diagnostic tests. During the second quarter, the segment generated earnings from COVID-19 vaccinations and saw improved customer traffic as vaccinated customers began more actively shopping in CVS locations. During the third and fourth quarters, emerging new variants drove the continued administration of COVID-19 vaccinations (including booster shots), which reached their highest levels of the year during the fourth quarter, and diagnostic testing. During the third and fourth quarters, the segment also generated earnings from the sale of OTC test kits in the front store.

During the year ended December 31, 2020, the customary quarterly operating income progression was also impacted by COVID-19. During March 2020, the Company experienced greater use of 90-day prescriptions, early refills of maintenance medications and increased front store volume as consumers prepared for the COVID-19 pandemic. Subsequent to March 2020, the Company experienced reduced customer traffic in its retail pharmacies and MinuteClinic locations due to shelter-in-place orders as well as reduced new therapy prescriptions as a result of the COVID-19 pandemic. Beginning in the third quarter, the Company saw an increase in diagnostic testing related to the COVID-19 pandemic and in December 2020, the Company began administering COVID-19 vaccinations in long-term care facilities.

13


Retail/LTC Competition

The retail pharmacy business is highly competitive. The Company believes that it competes principally on the basis of: (i) store location and convenience, (ii) customer service and satisfaction, (iii) product selection and variety, and (iv) price. In the areas it serves, the Company competes with other drugstore chains (e.g., Walgreens and Rite Aid), supermarkets, discount retailers (e.g., Walmart), independent pharmacies, restrictive pharmacy networks, internet companies (e.g., Amazon), membership clubs, retail health clinics, urgent care and primary care offices, as well as mail order dispensing pharmacies.

LTC pharmacy services are highly regional or local in nature, and within a given geographic area of operation, highly competitive. The Company’s largest LTC pharmacy competitor nationally is PharMerica. The Company also competes with numerous local and regional institutional pharmacies, pharmacies owned by long-term care facilities and local retail pharmacies. Some states have enacted “freedom of choice” or “any willing provider” requirements as part of their state Medicaid programs or in separate legislation, which may increase the competition that the Company faces in providing services to long-term care facility residents in these states.

Corporate/Other Segment

The Company presents the remainder of its financial results in the Corporate/Other segment, which primarily consists of:

Management and administrative expenses to support the Company’s overall operations, which include certain aspects of executive management and the corporate relations, legal, compliance, human resources, information technology and finance departments, expenses associated with the Company’s investments in its transformation and enterprise modernization programs and acquisition-related integration costs; and
Products for which the Company no longer solicits or accepts new customers such as large case pensions and long-term care insurance products.


14


Generic Sourcing Venture

The Company and Cardinal Health, Inc. (“Cardinal”) each have a 50% ownership in Red Oak Sourcing, LLC (“Red Oak”), a generic pharmaceutical sourcing entity. Under this arrangement, the Company and Cardinal contributed their sourcing and supply chain expertise to Red Oak and agreed to source and negotiate generic pharmaceutical supply contracts for both companies through Red Oak. Red Oak does not own or hold inventory on behalf of either company.

Working Capital Practices

The Company funds the growth of its businesses through a combination of cash flow from operations, commercial paper and other short-term borrowings, proceeds from sale-leaseback transactions and long-term borrowings. For additional information on the Company’s working capital practices, see “Liquidity and Capital Resources” in the MD&A included in Item 7 of this 10-K. Employer groups, individuals, college students, part-time and hourly workers, health plans, providers, governmental units, government-sponsored plans (with the exception of Medicare Part D services, which are described below), labor groups and expatriates, which represent the vast majority of Health Care Benefits segment revenues, typically settle in less than 30 days. As a provider of Medicare Part D services, the Company contracts annually with CMS. Utilization of services each plan year results in the accumulation of either a receivable from or a payable to CMS. The timing of settlement of the receivable or payable with CMS takes several quarters, which impacts working capital from year to year. The majority of the Retail/LTC segment non-pharmacy revenues are paid in cash, or with debit or credit cards. Managed care organizations, pharmacy benefit managers, government funded health care programs, commercial employers and other third party insurance programs, which represent the vast majority of the Company’s consolidated pharmacy revenues, typically settle in less than 30 days. The remainder of the Company’s consolidated pharmacy revenues are paid in cash, or with debit or credit cards.

Human Capital

Overview

At CVS Health, we share a single, clear purpose: bringing our heart to every moment of your health. We devote significant time and attention to the attraction, development and retention of talent to deliver high levels of service to our customers. Our commitment to them includes a competitive rewards package and programs that support our diverse range of colleagues in rewarding and fulfilling careers. As of December 31, 2021, we employed approximately 300,000 colleagues primarily in the United States including in all 50 states, the District of Columbia and Puerto Rico, approximately 72% of whom were full-time.

We believe engaged colleagues produce stronger business results and are more likely to build a career with the Company. Each year we conduct an internal engagement survey that provides colleagues with an opportunity to share their opinions and experiences with respect to their role, their team and the enterprise to help our Board and our management identify areas where we can improve colleague experience. The survey covers a broad range of topics including development and opportunities, diversity management, recognition, performance, well-being, compliance and continuous improvement. In 2021, greater than 80% of our colleagues participated in the engagement survey, of which greater than 75% responded that they were actively engaged.

The Board and our chief executive officer (“CEO”) provide oversight of our human capital strategy, which consists of the following categories: total rewards; diversity, equity and inclusion; colleague development; and health and safety.

Total Rewards

We recognize how vital our colleagues are to our success and strive to offer comprehensive and competitive wages and benefits to meet the varying needs of our colleagues and their families. The benefits and programs include annual bonuses, 401(k) plans, stock awards, an employee stock purchase plan, health care and insurance benefits, paid time off, flexible work schedules, family leave, dependent care resources, colleague assistance programs and tuition assistance, among many others, depending on eligibility.

In recognition of the critical role that the attraction and retention of talent plays in the success of our business, during 2021, we also announced a significant investment in our employees through an increase in the Company’s minimum hourly wage to $15.00 an hour effective July 2022, with incremental increases to the Company’s competitive hourly rates beginning in August 2021. The new wage structure also incorporates additional increases beyond the $15.00 minimum, with higher starting hourly rates for roles such as pharmacy technicians and call center representatives. In addition, during 2021 we awarded incremental
15


bonuses to select colleague groups in recognition of their ongoing contributions throughout the COVID-19 pandemic, the most significant of which included bonuses to our pharmacist and distribution center colleagues.

Diversity, Equity & Inclusion

We believe that a diverse workforce creates a healthier, stronger and more sustainable company. We aim to attract, develop, retain and support a diverse workforce that reflects the many customers, patients, members and communities we serve. Our Diversity Management Leadership Council, a cross-functional group of senior leaders appointed by our CEO, works with our Strategic Diversity Management leadership team to intentionally embed diversity across all facets of our business. For our efforts, we have been recognized as a DiversityInc Top 50 Company, a LatinaStyle Top 50 Company for Latinas and earned a 100 percent score on both the Human Rights Campaign Corporate Equality Index as well as the Disability Equality Index, meaning the company is recognized as a “Best Place to Work for Disability Inclusion.” The Company discloses information on our diversity, equity and inclusion strategy and programs in our annual Corporate Social Responsibility (“CSR”) Report.

As a foundation of diversity and inclusion, we continuously focus on increasing underrepresented populations across our business. In 2021, 71% of our total colleague population and 55% of our colleagues at the manager level and above self-reported as female. In addition, in 2021 our colleagues reported their race/ethnicity as: White (49%), Black/African American (17%), Hispanic/Latino (15%), Asian (11%) and Other (8%). The appendix to our CSR Report, our Strategic Diversity Management Report and our EEO-1 Employer Information Report include additional information on the diversity of our workforce.

Our diversity management strategy emphasizes workplace representation, inclusion and belonging, talent acquisition and management and a diverse marketplace. We incorporated a diversity metric into our 2021 annual cash incentive program for our most senior leaders who have the greatest ability to influence the overall hiring, development and promotion of our colleagues. We also continued the deployment of conscious inclusion training for colleagues designed to enhance awareness of biases and support inclusive behaviors. Our CSR Report includes additional information with respect to our conscious inclusion training. We support 16 Colleague Resource Groups (“CRGs”) that include more than 26,000 colleagues across the enterprise. These groups represent a wide range of professional, cultural, ethical and personal affinities and interests, as well as formal mentoring programs. Our CRGs provide our colleagues with an opportunity to connect and network with one another through a particular affinity, culture or interest. Each of our CRGs is sponsored by a senior leader.

Colleague Development

The Company offers a number of resources and programs that attract, engage, develop, advance and retain colleagues. Training and development provides colleagues the support they need to perform well in their current role while planning and preparing for future roles. We offer an online orientation program that pairs new hires with seasoned colleagues and the training continues throughout a colleague’s career through in-person, virtual and self-paced learning at all levels. We also provide mentoring, tools and workshops for colleagues to manage their career development. We offer a variety of management and leadership programs that develop incumbent diverse and other high potential colleagues. Our broad training practices include updated, tech-enabled tools and keep our colleagues informed of new developments in our industry that are relevant to their roles. During the year ended December 31, 2021, our colleagues invested more than 13 million hours in learning and development courses.

Our colleague development program also promotes the importance of compliance across our business. Our colleagues demonstrate this commitment through our annual Code of Conduct training, which 100% of active colleagues completed in 2021. In 2021, we launched more than 70 different training courses as part of our annual Enterprise Compliance Training Program.

Health & Safety

We have a strong commitment to providing a safe working environment. We have implemented an environmental health and safety management system to support adherence and monitoring of programs designed to make our various business operations compliant with applicable occupational safety and health regulations and requirements. Our Environmental Health and Safety Department oversees the implementation and adherence to programs like Powered Industrial Truck training, materials handling and storage, selection of personal protective equipment and workplace violence prevention.

We utilize Safety Service Plans to analyze data and concentrate on key areas of risk to reduce the chance of workplace incidents. We focus on identifying causes and improving performance when workplace incidents occur. We also engage leaders
16


in promoting a culture of safety. With safety task forces in place at each distribution center, we empower leaders and safety business partners to identify policies, procedures and processes that could improve their own operations.

From the outset of the COVID-19 pandemic, we took a comprehensive approach to managing occupational health and safety challenges presented by the pandemic, including implementing facial covering requirements for our workplaces and providing face masks to colleagues, providing sick leave, implementing symptom screening measures and implementing additional protocols in accordance with applicable Occupational Safety and Health Administration (“OSHA”) requirements and guidance and Centers for Disease Control and Prevention (“CDC”) guidelines for workplaces. We have emphasized the importance of taking immediate steps toward full vaccination.

Environmental, Social and Governance (“ESG”) Strategy

Overview

CVS Health believes the health of our people, communities and planet are linked to the health of our business. Our ESG strategy is designed to use our assets to transform the health care experience and invest in community health at the local level, while working to reduce the environmental impact of our operations. Our ESG strategy includes a set of goals we hope to achieve in 2030 or earlier. We believe these goals are achievable without materially adversely affecting our businesses, operating results, cash flows and/or prospects. Our ESG strategy consists of four pillars: Healthy People, Healthy Business, Healthy Community and Healthy Planet.

Healthy People

Through physical and virtual interactions, we provide convenient, personalized and integrated access to health care support and services. We continue to implement and expand initiatives that build on our innovative health care model, with the ultimate aim to transform the health care experience for every person we reach to improve health outcomes. These include helping to improve chronic disease prevention and management, helping to reduce and prevent prescription drug misuse, and improving the social determinants of health, which include education, transportation and behavioral health. Through our ESG strategy we are focused on our interaction with individuals across all our touchpoints to increase the likelihood that these initiatives will succeed.

Healthy Business

As we work to transform health care, we are committed to operating a healthy business for all our stakeholders, including our patients, customers, stockholders, clients, partners, communities and colleagues. Throughout our large operational footprint and including our supply chain, we are committed to acting responsibly with respect for human rights, privacy, information security, public policy, marketing and advertising. We focus on diversity, equity and inclusion as well as colleague development, health and safety. Through our ESG strategy we will be investing in colleague mentoring, sponsorship, development and advancement; workforce initiatives that provide employment services and training to the underserved; and providing access to health care while addressing health disparities.

Healthy Community

By working with community-focused organizations and through innovative programs that can be tailored to and executed across different communities, we are driving positive health outcomes and reducing overall health care costs. Through our recently announced Health Zones initiative, CVS Health and our nonprofit partners are working together to create a model that reduces health disparities, promotes and enhances equity and ensures at-risk communities can thrive. Through our ESG strategy we are building healthier communities through social impact investments, such as supporting health care professionals, reducing food insecurity, engaging our customers in community health, and coordinating care for the underserved.

Healthy Planet

Our work to improve the planet is aligned with our commitment to the communities we serve and to help protect our businesses from the negative impacts of climate change. All of our businesses, including our community locations, corporate offices and operation centers, distribution centers, and specialty pharmacy and PBM mail pharmacy locations, can be impacted by climate change-related extreme weather events and we are doing our part to reduce our environmental impacts. We are focused on identifying resource efficiencies across our operations and supply chain. We are proud to be recognized as a leader in addressing climate-related issues and are working closely with key stakeholders to make and deliver meaningful progress. Key
17


priorities include the advancement of our greenhouse gas (“GHG”) emissions-reduction targets, reduction in our energy consumption, the advancement of sustainability in transportation, logistics and our physical locations, which includes retrofitting community and corporate locations with LED lighting, exploring investments in renewable energy, reducing water use, focusing on smarter consumption through a “digital first” approach and the reduction of our use of paper and plastic. In October 2021, CVS Health’s science-based net zero GHG emissions targets were validated by the Science Based Targets initiatives (“SBTi”). We continue to make meaningful progress to reduce our environmental impact.

Intellectual Property

The Company has registered and/or applied to register a variety of trademarks and service marks used throughout its businesses, as well as domain names, and relies on a combination of copyright, patent, trademark and trade secret laws, in addition to contractual restrictions, to establish and protect the Company’s proprietary rights. The Company regards its intellectual property as having significant value in the Health Care Benefits, Pharmacy Services and Retail/LTC segments. The Company is not aware of any facts that could materially impact the continuing use of any of its intellectual property.

Government Regulation

Overview

The Company’s operations are subject to comprehensive federal, state and local laws and regulations and comparable multiple levels of international regulation in the jurisdictions in which it does business. There also continues to be a heightened level of review and/or audit by federal, state and international regulators of the health and related benefits industry’s business and reporting practices. In addition, many of the Company’s PBM clients and the Company’s payors in the Retail/LTC segment, including insurers, Medicare plans, Managed Medicaid plans and MCOs, are themselves subject to extensive regulations that affect the design and implementation of prescription drug benefit plans that they sponsor. Similarly, the Company’s LTC clients, such as skilled nursing facilities, are subject to government regulations, including many of the same government regulations to which the Company is subject.

The laws and rules governing the Company’s businesses and interpretations of those laws and rules continue to expand and become more restrictive each year and are subject to frequent change. The application of these complex legal and regulatory requirements to the detailed operation of the Company’s businesses creates areas of uncertainty. Further, there are numerous proposed health care, financial services and other laws and regulations at the federal, state and international levels, some of which could adversely affect the Company’s businesses if they are enacted. The Company cannot predict whether pending or future federal or state legislation or court proceedings will change aspects of how it operates in the specific markets in which it competes or the health care industry generally, but if changes occur, the impact of any such changes could have a material adverse impact on the Company’s businesses, operating results, cash flows and/or stock price. Possible regulatory or legislative changes include the federal or one or more state governments fundamentally restructuring the Commercial, Medicare or Medicaid marketplace; reducing payments to the Company in connection with Medicare, Medicaid, dual eligible or special needs programs; increasing its involvement in drug reimbursement, pricing, purchasing, and/or importation; or changing the laws governing PBMs.

The Company has internal control policies and procedures and conducts training and compliance programs for its employees to help prevent, detect and correct prohibited practices. However, if the Company’s employees or agents fail to comply with applicable laws governing its international or other operations, it may face investigations, prosecutions and other legal proceedings and actions which could result in civil penalties, administrative remedies and criminal sanctions. Any failure or alleged failure to comply with applicable laws and regulations summarized below, or any adverse applications or interpretations of, or changes in, the laws and regulations affecting the Company and/or its businesses, could have a material adverse effect on the Company’s operating results, financial condition, cash flows and/or stock price. See Item 3 of this 10-K, “Legal Proceedings,” for further information.

The Company can give no assurance that its businesses, financial condition, operating results and/or cash flows will not be materially adversely affected, or that the Company will not be required to materially change its business practices, based on: (i) future enactment of new health care or other laws or regulations; (ii) the interpretation or application of existing laws or regulations, including the laws and regulations described in this Government Regulation section, as they may relate to one or more of the Company’s businesses, one or more of the industries in which the Company competes and/or the health care industry generally; (iii) pending or future federal or state governmental investigations of one or more of the Company’s businesses, one or more of the industries in which the Company competes and/or the health care industry generally; (iv) pending or future government audits, investigations or enforcement actions against the Company; or (v) adverse developments
18

in pending or future legal proceedings against or affecting the Company, including qui tam lawsuits, or affecting one or more of the industries in which the Company competes and/or the health care industry generally.

Laws and Regulations Related to COVID-19

The Families First Coronavirus Response Act (the “Families First Act”) and the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) were enacted in March 2020. Each of the Families First Act and the CARES Act requires the Company to provide coverage for COVID-19 related medical services, in many cases without member cost-sharing, in its Insured Health Care Benefits products.

The CARES Act also provides relief funding to providers to reimburse them for health care related expenses incurred in preventing, preparing for and/or responding to COVID-19 (provided no other source is obligated to reimburse those expenses) or lost health care related revenues that are attributable to COVID-19. Under the CARES Act, the Company receives reimbursement for uninsured patients in connection with COVID-19 testing and vaccination as well as monoclonal antibody treatment. Aside from such reimbursement, the Company has not requested any funding under the CARES Act. However, in the second quarter of 2020, the Company received $43 million from the CARES Act provider relief fund, all of which was returned to the U.S. Department of Health and Human Services (“HHS”) during the second quarter of 2020.

The CARES Act also allows for the deferral of the payment of the employer share of Social Security taxes effective March 27, 2020 by permitting them to remit the associated payments in two equal installments on or about December 31, 2021 and December 31, 2022. The Company elected to defer approximately $670 million of its Social Security tax payments during the year ended December 31, 2020. The Company paid the first of two equal installments in December 2021 and will remit the second installment on or about December 31, 2022, as required under the CARES Act.

Congress enacted the American Rescue Plan Act in March 2021. Among other changes, as a result of this legislation, Public Exchange plan premium subsidies increased for low-income individuals and became available to people with incomes higher than 400% of the federal poverty limit. These changes are currently in effect through the remainder of 2022, and Congress may extend, or potentially make permanent, these policies in subsequent legislation, which could cause continued shifts in enrollment into Public Exchange plans.

In addition to the Families First Act, the CARES Act, and the American Rescue Plan Act, the Company continues to experience new legislation, regulation, directives, orders and other requirements from federal, state, county and municipal authorities related to the COVID-19 pandemic. These governmental actions have included, but are not limited to, requirements to waive member cost-sharing associated with COVID-19 testing and treatment, provide coverage for additional COVID-19-related services, expand the use of telemedicine, extend grace periods for payments of premiums or limit coverage termination based on non-payment of premiums or fees, modify health benefits coverage eligibility rules to help maintain employee eligibility, and facilitate, accelerate or advance payments to providers, and other requirements related to the public health emergency. These requirements may impact different areas of our business differently and for different lengths of time, and present financial implications with respect to implementing and unwinding our compliance with these new requirements.

The Company has operations that fall within the scope of COVID-19 vaccine requirements for federal contractors, certain health care workers, and the requirements of certain jurisdictions such as New York City. Several of these are subject to judicial challenges. We are continuing to closely monitor and update our practices in response to developments or changes in the COVID-19 vaccination policies established by various federal agencies as well as the several state- and municipal-specific COVID-19 vaccine mandates that provide expanded exemptions, modifications, requirements or restrictions regarding employee vaccinations. We have a process for employees to request a reasonable accommodation if they are unable to get vaccinated due to a medical condition, sincerely held religious belief, or any other legally recognized exemption. Employees must apply and be approved for a reasonable accommodation in order to be exempt from the vaccination requirement.

Additionally, in December 2021, the Biden administration reiterated CARES Act guidance noting commercial health insurers are not required to cover workplace or surveillance testing and announced several new directives and actions to combat COVID-19, including the expansion of free at-home testing to be covered by commercial health insurers for the remainder of the public health emergency. On January 10, 2022, the HHS announced that commercial health insurers must cover the costs of up to eight rapid OTC COVID-19 test kits per individual per 30-day period. This requirement will likely impact multiple business operations, including increasing benefit costs in our commercial health insurance business and increasing revenues in our retail business. The requirement may also result in a decrease in more expensive tests and treatments, which could partially mitigate the increase in benefit costs in our commercial health insurance business. These impacts will be highly dependent on the overall supply of testing products.
19


The impact of this governmental activity on the U.S. economy, consumer, customer and health care provider behavior and health care utilization patterns is beyond our knowledge and control. As a result, the financial and/or operational impact these COVID-19 related governmental actions and inactions will have on our businesses, operating results, cash flows and/or financial condition is uncertain, but the collective impact could be material and adverse.

Laws and Regulations Related to Multiple Segments of the Company’s Business

Laws Related to Reimbursement by Government Programs - The Company is subject to various federal and state laws concerning its submission of claims and other information to Medicare, Medicaid and other federal and state government-sponsored health care programs. Potential sanctions for violating these laws include recoupment or reduction of government reimbursement amounts, civil penalties, treble damages, and exclusion from participation in government health care programs. Such laws include the federal False Claims Act (the “False Claims Act”), the federal anti-kickback statute (the “AKS”), state false claims acts and anti-kickback statutes in most states, the federal “Stark Law” and related state laws. In particular, the False Claims Act prohibits intentionally submitting, conspiring to submit, or causing to be submitted, false claims, records, or statements to the federal government, or intentionally failing to return overpayments, in connection with reimbursement by federal government programs. In addition, any claim for government reimbursement also violates the False Claims Act where it results from a violation of the AKS.

Both federal and state false claims laws permit private individuals to file qui tam or “whistleblower” lawsuits on behalf of the federal or state government. Participants in the health and related benefits industry, including the Company, frequently are subject to actions under the False Claims Act or similar state laws. The federal Stark Law generally prohibits physicians from referring Medicare or Medicaid beneficiaries for certain services, including outpatient prescription drugs, to any entity with which the physician, or an immediate family member of the physician, has a financial relationship. The Stark Law further prohibits the entity receiving a prohibited referral from presenting a claim for reimbursement by Medicare or Medicaid for services furnished pursuant to the prohibited referral. Various states have enacted similar laws.

The ACA - The ACA significantly increased federal and state oversight of health plans. Among other requirements, it specifies minimum medical loss ratios (“MLRs”) for Commercial and Medicare Insured products, specifies features required to be included in commercial benefit designs, limits commercial individual and small group rating and pricing practices, encourages additional competition (including potential incentives for new participants to enter the marketplace), and includes regulations and processes that could delay or limit the Company’s ability to appropriately increase its health plan premium rates. This in turn could adversely affect the Company’s ability to continue to participate in certain product lines and/or geographies that it serves today.

In June 2021, the United States Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety and issued an opinion preserving the ACA and its consumer protections in its current form. Even though the ACA was deemed constitutional, there may nevertheless be continued efforts to invalidate, modify, repeal or replace portions of it. In addition to litigation, parts of the ACA continue to evolve through the promulgation of executive orders, legislation, regulations and guidance at the federal or state level. The Company expects the ACA, including potential changes thereto, to continue to significantly impact its business operations and operating results, including pricing, medical benefit ratios (“MBRs”) and the geographies in which the Company’s products are available.

Medicare Regulation - The Company’s Medicare Advantage products compete directly with Original Medicare and Medicare Advantage products offered by other Medicare Advantage organizations and Medicare Supplement products offered by other insurers. The Company’s Medicare PDP and Medicare Supplement products are products that Medicare beneficiaries who are enrolled in Original Medicare purchase to enhance their Original Medicare coverage.

The Company continues to expand the number of counties in which it offers Medicare products. The Company has expanded its Medicare service area and products in 2022 and is seeking to substantially grow its Medicare membership, revenue and operating results over the next several years, including through growth in Medicare Supplement products. The anticipated organic expansion of the Medicare service area and Medicare products offered and the Medicare-related provisions of the ACA significantly increase the Company’s exposure to funding and regulation of, and changes in government policy with respect to and/or funding or regulation of, the various Medicare programs in which the Company participates, including changes in the amounts payable to us under those programs and/or new reforms or surcharges on existing programs. For example, the ACA requires minimum MLRs for Medicare Advantage and Medicare Part D plans of 85%. If a Medicare Advantage or Medicare Part D contract pays minimum MLR rebates for three consecutive years, it will become ineligible to enroll new members. If a Medicare Advantage or Medicare Part D contract pays such rebates for five consecutive years, it will be terminated by CMS.
20

Due to potential lower utilization of medical services by Medicare beneficiaries during the COVID-19 pandemic, it is possible certain Medicare Advantage contracts may not meet the 85% MLR for consecutive years.

The Company’s Medicare Advantage and PDP products are heavily regulated by CMS. The regulations and contractual requirements applicable to the Company and other private participants in Medicare programs are complex, expensive to comply with and subject to change. For example, the Medicare Advantage Overpayment Rule, issued in 2014, implemented the ACA requirements that Medicare Advantage and PDP plans report and refund to CMS overpayments that those plans receive from CMS. Failure to notify overpayments to CMS could result in liability under the False Claims Act. The precise interpretation, impact and legality of this rule are subject to pending litigation. Payments the Company receives from CMS for its Medicare Advantage and Part D businesses also are subject to risk adjustment based on the health status of the individuals enrolled. Elements of that risk adjustment mechanism continue to be challenged by the U.S. Department of Justice (the “DOJ”), the Office of the Inspector General of the HHS (the “OIG”) and CMS itself. Substantial changes in the risk adjustment mechanism, including changes that result from enforcement or audit actions, could materially affect the amount of the Company’s Medicare reimbursement, require the Company to raise prices or reduce the benefits offered to Medicare beneficiaries, and potentially limit the Company’s (and the industry’s) participation in the Medicare program.

The Company has invested significant resources to comply with Medicare standards, and its Medicare compliance efforts will continue to require significant resources. CMS may seek premium and other refunds, prohibit the Company from continuing to market and/or enroll members in or refuse to passively enroll members in one or more of the Company’s Medicare or Medicare-Medicaid demonstration (historically known as “dual eligible”) plans, exclude us from participating in one or more Medicare, dual eligible or dual eligible special needs plan programs and/or institute other sanctions and/or civil monetary penalties against the Company if it fails to comply with CMS regulations or its Medicare contractual requirements. The Company’s Medicare Supplement products are regulated at the state level and subject to similar significant compliance requirements and risks.

In addition, in November 2020, the HHS released the final Rebate Rule (the “Rebate Rule”), which eliminates the regulatory safe harbor from prosecution under the AKS for rebates from pharmaceutical companies to PBMs in Medicare Part D, replacing it with two far narrower safe harbors designed to directly benefit patients with high out-of-pocket costs and to change the way PBMs are compensated. The new safe harbors are (i) for rebates which are passed on to the patient at the point of sale and (ii) for flat service fee payments made to PBMs which cannot be tied to the list prices of drugs. It is unclear whether the Rebate Rule will be enforceable, whether pharmaceutical companies will respond by reducing list prices, whether list prices in the private market may also be reduced, and what the resulting impact will be to PBMs or the Company. The Pharmaceutical Care Management Association (the “PCMA”), which represents PBMs, has filed a suit in an effort to block the Rebate Rule, claiming that the Rebate Rule would lead to higher premiums in Medicare Part D and was adopted in an unlawful manner. The Bipartisan Infrastructure Act of 2021 delays the effective date of the rebate rule to January 2026, and pending Reconciliation legislation would fully repeal the Rebate Rule.

In December 2021, President Biden signed the Protecting Medicare and American Farmers from Sequester Cuts Act. The legislation extends the suspension of the 2% Medicare sequester cuts until March 2022. Starting in April 2022, the Medicare sequester cuts will be phased back in with a 1% cut that will continue through June. Absent any further changes by Congress, the 2% Medicare sequester would be fully implemented again effective July 1, 2022. Congress suspended the Medicare sequester cuts due to the COVID-19 pandemic, providing a continued increase in Medicare Advantage and Part D plan payments, as well as Medicare fee-for-service provider payments. The legislation also includes a 3% increase in the Medicare Physician Fee Schedule payments for 2022. Congress enacted a similar increase of 3.75% for 2021 which was set to expire. As a result of this increase, Medicare Advantage plans who have contracts with providers based on the Medicare Physician Fee Schedule will need to increase their payment rates by 3%. This increase became effective in January 2022 and does not include any allowance for the increased Medicare Advantage costs that result from the provision. Taken together, the two provisions represent a modest increase in Medicare Advantage costs relative to our expectations for 2022.

Currently, Congress is considering legislation to add additional benefits to Medicare Part B, such as dental, hearing and vision benefits. The Congressional Budget Office has not yet scored any of the proposals.

Going forward, the Company expects CMS, the OIG, the DOJ, other federal agencies and the U.S. Congress to continue to scrutinize closely each component of the Medicare program (including Medicare Advantage, PDPs, demonstration projects such as Medicare-Medicaid plans and provider network access and adequacy), modify the terms and requirements of the program and possibly seek to recast or limit private insurers’ roles. It is also possible that Congress may reform the structure of the Medicare Part D program and may consider changes to Medicare Advantage payment policies due to recent recommendations by the Medicare Payment Advisory Commission and to reduce the potential added cost burden of costly new
21

benefits, or policies that impact drug pricing such as price controls and inflationary rebates applied to pharmaceutical manufacturers.

It is not possible to predict the outcome of such regulatory or Congressional activity, any of which could materially and adversely affect the Company.

Medicare Audits - CMS regularly audits the Company’s performance to determine its compliance with CMS’s regulations and its contracts with CMS and to assess the quality of services it provides to Medicare Advantage and PDP beneficiaries. For example, CMS conducts risk adjustment data validation (“RADV”) audits of a subset of Medicare Advantage contracts for each contract year. Since 2011, CMS has selected certain of the Company’s Medicare Advantage contracts for various years for RADV audit, and the number of RADV audits continues to increase. The OIG also is auditing the Company’s risk adjustment data and that of other companies, and the Company expects CMS and the OIG to continue auditing risk adjustment data. The Company also has received Civil Investigative Demands (“CIDs”) from, and provided documents and information to, the Civil Division of the DOJ in connection with a current investigation of its patient chart review processes in connection with risk adjustment data submissions under Parts C and D of the Medicare program.

In October 2018, CMS issued proposed rules related to, among other things, changes to the RADV audit methodology established by CMS in 2012. CMS projects that the changes to the RADV audit methodology would increase its recoveries from Medicare Advantage plans as a result of RADV audits. CMS has requested comments on the proposed rules, including whether the proposed RADV rule change should apply retroactively to audits of Medicare Advantage plans for contract year 2011 and forward, and gave notice that it has extended the timeline for publication of the final rules until November 2022. While the Company submitted timely comments to the proposed rules, if they are adopted as proposed there may be potential adverse effects, which could be material, on the Company’s operating results, financial condition, and cash flows. CMS also has announced that its goal is to subject all Medicare Advantage contracts to either a comprehensive or a targeted RADV audit for each contract year.

Medicare Star Ratings - A portion of each Medicare Advantage plan’s reimbursement is tied to the plan’s “star ratings.” The star rating system considers a variety of measures adopted by CMS, including quality of preventative services, chronic illness management, compliance and overall customer satisfaction. Only Medicare Advantage plans with an overall star rating of four or more stars (out of five stars) are eligible for a quality bonus in their basic premium rates. As a result, the Company’s Medicare Advantage plans’ operating results in 2022 and going forward will be significantly affected by their star ratings. The Company’s star ratings and past performance scores are adversely affected by the compliance issues that arise each year in its Medicare operations. CMS released the Company’s 2022 star ratings in October 2021. The Company’s 2022 star ratings will be used to determine which of its Medicare Advantage plans have ratings of four stars or higher and qualify for bonus payments in 2023. Based on the Company’s membership at December 31, 2021, 87% of the Company’s Medicare Advantage members were in plans with 2022 star ratings of at least 4.0 stars. CMS also gives PDPs star ratings which affect each PDP’s enrollment. Medicare Advantage and PDP plans that are rated less than three stars for three consecutive years are subject to contract termination by CMS. CMS continues to revise its star ratings system to make it harder to achieve four stars or more. Despite the Company’s success in achieving high 2022 star ratings and other quality measures and the continuation of its improvement efforts, there can be no assurances that it will be successful in maintaining or improving its star ratings in future years. Accordingly, the Company’s Medicare Advantage plans may not be eligible for full level quality bonuses, which could adversely affect the benefits such plans can offer, reduce membership and/or reduce profit margins.

Medicare Benchmark Rates - In January 2021, CMS issued its final notice detailing final 2022 Medicare Advantage benchmark payment rates. Final 2022 Medicare Advantage rates resulted in an increase in industry benchmark rates of approximately 4.1%. This rate increase only partially offsets the challenge the Company faces from the impact of the increasing cost of medical care (including prescription medications) and CMS local and national coverage decisions that require the Company to pay for services and supplies that are not factored into the Company’s bids. The federal government may seek to impose restrictions on the configuration of pharmacy or other provider networks for Medicare Advantage and/or PDP plans, or otherwise restrict the ability of these plans to alter benefits, negotiate prices or establish other terms to improve affordability or maintain viability of products. The Company currently believes that the payments it has received and will receive in the near term are adequate to justify the Company’s continued participation in the Medicare Advantage and PDP programs, although there are economic and political pressures to continue to reduce spending on the program, and this outlook could change.

340B Drug Pricing Program – The 340B Drug Pricing Program allows eligible Covered Entities to purchase prescription drugs from manufacturers at a steep discount, and is overseen by the HHS and the Health Resources and Services Administration (“HRSA”). In 2020, a number of pharmaceutical manufacturers began programs that limited Covered Entities’ participation in the program through contract pharmacies arrangements. In May 2021, HRSA sent enforcement letters to
22

multiple manufacturers to curb these practices. In September 2021, HRSA forwarded the enforcement actions to the OIG for potential imposition of civil monetary penalties. Those enforcement actions are currently subject to ongoing litigation. A reduction in Covered Entities’ participation in contract pharmacy arrangements, as a result of the pending enforcement actions or otherwise, a reduction in the use of the Company’s administrative services by Covered Entities, or a reduction in drug manufacturers’ participation in the program could materially and adversely affect the Company.

Anti-Remuneration Laws - Federal law prohibits, among other things, an entity from knowingly and willfully offering, paying, soliciting or receiving, subject to certain exceptions and “safe harbors,” any remuneration to induce the referral of individuals or the purchase, lease or order of items or services for which payment may be made under Medicare, Medicaid or certain other federal and state health care programs. A number of states have similar laws, some of which are not limited to services paid for with government funds. Sanctions for violating these federal and state anti-remuneration laws may include imprisonment, criminal and civil fines, and exclusion from participation in Medicare, Medicaid and other federal and state government-sponsored health care programs. Companies involved in public health care programs such as Medicare and/or Medicaid are required to maintain compliance programs to detect and deter fraud, waste and abuse, and are often the subject of fraud, waste and abuse investigations and audits. The Company has invested significant resources to comply with Medicare and Medicaid program standards. Ongoing vigorous law enforcement and the highly technical regulatory scheme mean that the Company’s compliance efforts in this area will continue to require significant resources.

Antitrust and Unfair Competition - The U.S. Federal Trade Commission (“FTC”) investigates and prosecutes practices that are “unfair trade practices” or “unfair methods of competition.” Numerous lawsuits have been filed throughout the United States against pharmaceutical manufacturers, retail pharmacies and/or PBMs under various federal and state antitrust and unfair competition laws challenging, among other things: (i) brand name drug pricing and rebate practices of pharmaceutical manufacturers, (ii) the maintenance of retail or specialty pharmacy networks by PBMs, and (iii) various other business practices of PBMs and retail pharmacies. In July 2021, the FTC approved several resolutions that direct agency staff to use compulsory process, such as subpoenas, to investigate seven specific enforcement priorities. Priority targets include, among other businesses, health care businesses, such as pharmaceutical companies, pharmacy benefits managers and hospitals. To the extent that the Company appears to have actual or potential market power in a relevant market or CVS Pharmacy, CVS Specialty or MinuteClinic plays a unique or expanded role in a Health Care Benefits or Pharmacy Services segment product offering, the Company’s business arrangements and uses of confidential information may be subject to heightened scrutiny from an anti-competitive perspective and possible challenge by state and/or federal regulators and/or private parties.

Privacy and Confidentiality Requirements - Many of the Company’s activities involve the receipt, use and disclosure by the Company of personally identifiable information (“PII”) as permitted in accordance with applicable federal and state privacy and data security laws, which require organizations to provide appropriate privacy and security safeguards for such information. In addition to PII, the Company uses and discloses de-identified data for analytical and other purposes when permitted. Additionally, there are industry standards for handling credit card data known as the Payment Card Industry Data Security Standard, which are a set of requirements designed to help ensure that entities that process, store or transmit credit card information maintain a secure environment. Certain states have incorporated these requirements into state laws or enacted other requirements relating to the use and/or disclosure of PII.

The federal Health Insurance Portability and Accountability Act of 1996 and the regulations issued thereunder (collectively, “HIPAA”), as further modified by the American Recovery and Reinvestment Act of 2009 (“ARRA”) impose extensive requirements on the way in which health plans, providers, health care clearinghouses (known as “covered entities”) and their business associates use, disclose and safeguard protected health information (“PHI”). Further, ARRA requires the Company and other covered entities to report any breaches of PHI to impacted individuals and to the HHS and to notify the media in any states where 500 or more people are impacted by the unauthorized release or use of or access to PHI. Criminal penalties and civil sanctions may be imposed for failing to comply with HIPAA standards. The Health Information Technology for Economic and Clinical Health Act (the “HITECH Act”), enacted as part of ARRA, amended HIPAA to impose additional restrictions on third-party funded communications using PHI and the receipt of remuneration in exchange for PHI. The HITECH Act also extended HIPAA privacy and security requirements and penalties directly to business associates. HHS has begun to audit health plans, providers and other parties to enforce HIPAA compliance, including with respect to data security.

In addition to HIPAA, state health privacy laws apply to the extent they are more protective of individual privacy than is HIPAA, including laws that place stricter controls on the release of information relating to specific diseases or conditions and requirements to notify members of unauthorized release or use of or access to PHI. States also have adopted regulations to implement provisions of the Financial Modernization Act of 1999 (also known as the Gramm-Leach-Bliley Act (“GLBA”)) which generally require insurers, including health insurers, to provide customers with notice regarding how their non-public personal health and financial information is used and the opportunity to “opt out” of certain disclosures before the insurer
23

shares such information with a non-affiliated third party. Like HIPAA, GLBA sets a “floor” standard, allowing states to adopt more stringent requirements governing privacy protection. Complying with additional state requirements requires us to make additional investments beyond those the Company has made to comply with HIPAA and GLBA.

The Cybersecurity Information Sharing Act of 2015 encourages organizations to share cyber threat indicators with the federal government and, among other things, directs HHS to develop a set of voluntary cybersecurity best practices for organizations in the health care industry. In addition, states have begun to enact more comprehensive privacy laws and regulations addressing consumer rights to data access, deletion, protection or transparency, such as the California Consumer Privacy Act (“CCPA”). States also are starting to issue regulations and proposed regulations specifically related to cybersecurity, such as the regulations issued by the New York Department of Financial Services. Complying with conflicting cybersecurity regulations, which may differ from state to state, requires significant resources. In addition, differing approaches to state privacy and/or cyber-security regulation and varying enforcement philosophies may materially and adversely affect the Company’s ability to standardize its products and services across state lines. Widely-reported large scale commercial data breaches in the United States and abroad increase the likelihood that additional data security legislation will be considered by additional states. These legislative and regulatory developments will impact the design and operation of the Company’s businesses, its privacy and security strategy and its web-based and mobile assets.

Finally, each Public Exchange is required to adhere to privacy and security standards with respect to PII, and to impose privacy and security standards that are at least as protective of PII as those the Public Exchange has implemented for itself or non-Public Exchange entities, which include insurers offering plans through the Public Exchange and their designated downstream entities, including PBMs and other business associates. These standards may differ from, and be more stringent than, HIPAA.

Consumer Protection Laws - The federal government has many consumer protection laws, such as the Federal Trade Commission Act, the Federal Postal Service Act and the Consumer Product Safety Act. Most states also have similar consumer protection laws and a growing number of states regulate subscription programs. In addition, the federal government and most states have adopted laws and/or regulations requiring places of public accommodation, health care services and other goods and services to be accessible to people with disabilities. These consumer protection and accessibility laws and regulations have been the basis for investigations, lawsuits and multistate settlements relating to, among other matters, the marketing of loyalty programs, and health care products and services, pricing accuracy, expired front store products, financial incentives provided by drug manufacturers to pharmacies in connection with therapeutic interchange programs, disclosures related to how personal data is used and protected and the accessibility of goods and services to people with disabilities. As a result of the Company’s direct-to-consumer activities, including mobile and web-based solutions offered to members and to other consumers, the Company also is subject to federal and state regulations applicable to electronic communications and to other general consumer protection laws and regulations. For example, the CCPA became effective in 2020, and additional federal and state regulation of consumer privacy protection may be proposed or enacted in 2020. The Company expects these new laws and regulations to impact the design of its products and services and the management and operation of its businesses and to increase its compliance costs.

Transparency in Coverage Rule - In October 2020, the HHS, the U.S. Department of Labor (“DOL”) and the U.S. Internal Revenue Service (“IRS,” and together with the HHS and DOL, the “Tri-Departments”) released a final rule requiring health insurers to disclose negotiated prices of drugs, medical services, supplies and other covered items. The rule requires group health plans and health insurance issuers in the individual and group markets to disclose cost-sharing information upon request, to a participant, beneficiary, or enrollee and require plans and issuers to publicly disclose in-network provider rates, historical out-of-network allowed amounts and the associated billed charges, and negotiated rates and historical net prices for prescription drugs. Disclosure of data in a machine readable file is required beginning in January 2022, and insurers are required to have a consumer tool in place by January 2023. In August 2021, the federal government delayed enforcement of the requirement to publish machine-readable files for in-network rates, out-of-network allowed amounts and billed charges until July 2022. It also delayed enforcement of machine-readable files related to prescription drug pricing until further rulemaking occurs. The public disclosure of insurer- or PBM-negotiated price concessions may result in drug manufacturers lowering discounts or rebates, resulting in higher drug costs for patients and impacting the ability of the Company to negotiate drug prices and provide competitive products and services to consumers.

Additionally, the Consolidated Appropriations Act of 2021 was signed into law in December 2020 and contains further transparency provisions requiring group health plans and health insurance issuers to report certain prescription drug costs, overall spending on health services and prescription drugs, and information about premiums and the impact of rebates and other remuneration on premiums and out-of-pocket costs to the Tri-Departments. No later than 18 months after the first submission and bi-annually thereafter, the Tri-Departments will release a public report on drug pricing trends, drug reimbursement, and the
24

impact of drug prices on premiums. In August, the Tri-Departments deferred enforcement of both the December 2021 deadline for reporting 2020 plan year data and the June 2022 deadline for reporting 2021 plan year data to December 2022.

Telemarketing and Other Outbound Contacts - Certain federal and state laws, such as the Telephone Consumer Protection Act and the Telemarketing Sales Rule, give the FTC, the Federal Communications Commission and state attorneys general the ability to regulate, and bring enforcement actions relating to, telemarketing practices and certain automated outbound contacts such as phone calls, texts or emails. Under certain circumstances, these laws provide consumers with a private right of action. Violations of these laws could result in substantial statutory penalties and other sanctions.

Pharmacy and Professional Licensure and Regulation - The Company is subject to a variety of intersecting federal and state statutes and regulations that govern the wholesale distribution of drugs; operation of retail, specialty, infusion, LTC and mail order pharmacies; licensure of facilities and professionals, including pharmacists, technicians, nurses and other health care professionals; registration of facilities with the U.S. Drug Enforcement Administration (the “DEA”) and analogous state agencies that regulate controlled substances; packaging, storing, shipping and tracking of pharmaceuticals; repackaging of drug products; labeling, medication guides and other consumer disclosures; interactions with prescribers and health care professionals; compounding of prescription medications; dispensing of controlled and non-controlled substances; counseling of patients; transfers of prescriptions; advertisement of prescription products and pharmacy services; security; inventory control; recordkeeping; reporting to Boards of Pharmacy, the U.S. Food and Drug Administration (the “FDA”), the U.S. Consumer Product Safety Commission, the DEA and related state agencies; and other elements of pharmacy practice. Pharmacies are highly regulated and have contact with a wide variety of federal, state and local agencies with various powers to investigate, inspect, audit or solicit information, including Boards of Pharmacy and Nursing, the DEA, the FDA, the DOJ, HHS and others. Many of these agencies have broad enforcement powers, conduct audits on a regular basis, can impose substantial fines and penalties, and may revoke the license, registration or program enrollment of a facility or professional.

State Insurance, HMO and Insurance Holding Company Regulation - A number of states regulate affiliated groups of insurers and HMOs such as the Company under holding company statutes. These laws may, among other things, require prior regulatory approval of dividends and material intercompany transfers of assets and transactions between the regulated companies and their affiliates, including their parent holding companies. The Company expects the states in which its insurance and HMO subsidiaries are licensed to continue to expand their regulation of the corporate governance and internal control activities of its insurance companies and HMOs. Changes to state insurance, HMO and/or insurance holding company laws or regulations or changes to the interpretation of those laws or regulations, including due to regulators’ increasing concerns regarding insurance company and/or HMO solvency due, among other things, to past and expected payor insolvencies, could negatively affect the Company’s businesses in various ways, including through increases in solvency fund assessments, requirements that the Company hold greater levels of capital and/or delays in approving dividends from regulated subsidiaries.

PBM offerings of prescription drug coverage under certain risk arrangements may be subject to laws and regulations in various states. Such laws may require that the party at risk become licensed as an insurer, establish reserves or otherwise demonstrate financial viability. Laws that may apply in such cases include insurance laws and laws governing MCOs and limited prepaid health service plans. In addition, several states require that PBMs become directly registered or licensed with the department of insurance or similar government oversight agency regardless of any arrangements they have with clients. PBM licensure laws may include oversight of certain PBM activities and operations and may include auditing of those activities.

The states of domicile of the Company’s regulated subsidiaries have statutory risk-based capital (“RBC”) requirements for health and other insurance companies and HMOs based on the National Association of Insurance Commissioners’ (the “NAIC”) Risk-Based Capital for Insurers Model Act (the “RBC Model Act”). These RBC requirements are intended to assess the capital adequacy of life and health insurers and HMOs, taking into account the risk characteristics of a company’s investments and products. The RBC Model Act sets forth the formula for calculating RBC requirements, which are designed to take into account asset risks, insurance risks, interest rate risks and other relevant risks with respect to an individual company’s business. In general, under these laws, an insurance company or HMO must submit a report of its RBC level to the insurance department or insurance commissioner of its state of domicile for each calendar year. At December 31, 2021, the RBC level of each of the Company’s insurance and HMO subsidiaries was above the level that would require regulatory action.

For information regarding restrictions on certain payments of dividends or other distributions by the Company’s HMO and insurance company subsidiaries, see Note 12 ‘‘Shareholders’ Equity’’ included in Item 8 of this 10-K.

The holding company laws for the states of domicile of certain of the Company’s subsidiaries also restrict the ability of any person to obtain control of an insurance company or HMO without prior regulatory approval. Under those statutes, without such approval (or an exemption), no person may acquire any voting security of an insurance holding company (such as the
25

Company’s ultimate parent company, CVS Health Corporation) that controls an insurance company or HMO, or merge with such a holding company, if as a result of such transaction such person would control the insurance holding company. Control is generally defined as the direct or indirect power to direct or cause the direction of the management and policies of a person and is presumed to exist if a person directly or indirectly owns or controls 10% or more of the voting securities of another person.

Certain states have laws that prohibit submitting a false claim or making a false record or statement in order to secure reimbursement from an insurance company. These state laws vary, and violation of them may lead to the imposition of civil or criminal penalties.

Government Agreements and Mandates - From time to time, the Company and/or its various affiliates are subject to certain consent decrees, settlement and other agreements, corrective action plans and corporate integrity agreements with various federal, state and local authorities relating to such matters as privacy practices, controlled substances, PDPs, expired products, environmental and safety matters, marketing and advertising practices, PBM, LTC and other pharmacy operations and various other business practices. Certain of these agreements contain ongoing reporting, monitoring and/or other compliance requirements for the Company. Failure to meet the Company’s obligations under these agreements could result in civil or criminal remedies, financial penalties, administrative remedies, and/or exclusion from participation in federal health care programs.

Environmental and Safety Regulation - The Company’s businesses are subject to various federal, state and local laws, regulations and other requirements pertaining to protection of the environment, public health and employee safety, including, for example, regulations governing the management of hazardous substances, the cleaning up of contaminated sites, and the maintenance of safe working conditions in the Company’s retail locations, distribution centers and other facilities. Governmental agencies at the federal, state and local levels continue to focus on the retail and health care sectors’ compliance with such laws and regulations, and have at times pursued enforcement activities. Any failure to comply with these regulations could result in fines or other sanctions by government authorities.

ERISA Regulation - The Employee Retirement Income Security Act of 1974 (“ERISA”), provides for comprehensive federal regulation of certain employee pension and benefit plans, including private employer and union sponsored health plans and certain other plans that contract with us to provide PBM services. In general, the Company assists plan sponsors in the administration of their health benefit plans, including the prescription drug benefit portion of those plans, in accordance with the plan designs adopted by the plan sponsors. In addition, the Company may have fiduciary duties where it has specifically contracted with a plan sponsor to accept limited fiduciary responsibility, such as for the adjudication of initial prescription drug benefit claims and/or the appeals of denied claims under a plan. In addition to its fiduciary provisions, ERISA imposes civil and criminal liability on service providers to health plans and certain other persons if certain forms of illegal remuneration are made or received. These provisions of ERISA are broadly written and their application to specific business practices is often uncertain.

Some of the Company’s health and related benefits and large case pensions products and services and related fees also are subject to potential issues raised by judicial interpretations relating to ERISA. Under those interpretations, together with DOL regulations, the Company may have ERISA fiduciary duties with respect to PBM members and/or certain general account assets held under contracts that are not guaranteed benefit policies. As a result, certain transactions related to those general account assets are subject to conflict of interest and other restrictions, and the Company must provide certain disclosures to policyholders annually. The Company must comply with these restrictions or face substantial penalties.

In addition, ERISA generally preempts all state and local laws that relate to employee benefit plans, but the extent of the pre-emption continues to be reviewed by courts, including the U.S. Supreme Court. For example, in December 2020, the U.S. Supreme Court upheld an Arkansas law that, among other things, mandates a particular pricing methodology, establishes an appeals process for a pharmacy when the reimbursement is below the pharmacy’s acquisition cost, permits a pharmacy to reverse and rebill if they cannot procure the drug from its wholesaler at a price equal to or less than the reimbursement rate, prohibits a PBM from reimbursing a pharmacy less than the amount it reimburses an affiliate on a per unit basis, and permits a pharmacy to decline to dispense if the reimbursement is lower than the pharmacy’s acquisition cost. Also, in November 2021, the U.S. Court of Appeals for the Eighth Circuit upheld a North Dakota law that regulates employer-sponsored ERISA health plans and certain PBM practices within Medicare.

Other Legislative Initiatives and Regulatory Initiatives - The U.S. federal and state governments, as well as governments in other countries where the Company does business, continue to enact and seriously consider many broad-based legislative and regulatory proposals that have had a material impact on or could materially impact various aspects of the health care and related benefits system and the Company’s businesses, operating results and/or cash flows. For example:
26


Under the Budget Control Act of 2011 and the American Taxpayer Relief Act of 2012 significant, automatic across-the-board budget cuts (known as sequestration) began in March 2013, including Medicare spending cuts of not more than 2% of total program costs per year through 2024. Since then, Congress has extended and modified sequestration a number of times. The CARES Act temporarily suspended Medicare sequestration from May 2020 to the end of December 2020 and extended mandatory sequestration to 2030. Several subsequent acts have extended the temporary suspension of Medicare sequestration through the end of March 2022, at which point a 1% sequestration will take effect April 2022 through June 2022, with the full 2% sequestration due to resume in July 2022. Significant uncertainty remains as to whether and how the U.S. Congress will proceed with actions that create additional federal revenue and/or with entitlement reform. The Company cannot predict future federal Medicare or federal or state Medicaid funding levels or the impact that future federal or state budget actions or entitlement program reform, if it occurs, will have on the Company’s businesses, operations or operating results, but the effects could be materially adverse, particularly on the Company’s Medicare and/or Medicaid revenues, MBRs and operating results.
The European Union’s (“EU’s”) General Data Protection Regulation (“GDPR”) began to apply across the EU during 2018.
Other significant legislative and/or regulatory measures which are or recently have been under consideration include the following:
Increasing the corporate tax rate.
Eliminating payment of manufacturer’s rebates on prescription drugs to PBMs, PDPs and Managed Medicaid organizations in connection with federally funded health care programs.
Imposing requirements and restrictions on the design and/or administration of pharmacy benefit plans offered by the Company’s and its clients’ health plans and/or its PBM clients and/or the services the Company provides to those clients, including prohibiting “differential” or “spread” pricing in PBM contracts; restricting or eliminating the use of formularies for prescription drugs; restricting the Company’s ability to require members to obtain drugs through a home delivery or specialty pharmacy; restricting the Company’s ability to place certain specialty or other drugs in the higher cost tiers of its pharmacy formularies; restricting the Company’s ability to make changes to drug formularies and/or clinical programs; limiting or eliminating rebates on pharmaceuticals; requiring the use of up front purchase price discounts on pharmaceuticals in lieu of rebates; restricting the Company’s ability to configure and reimburse its health plan and retail pharmacy provider networks, including use of CVS Pharmacy locations; and restricting or eliminating the use of certain drug pricing methodologies.
Increasing federal or state government regulation of, or involvement in, the pricing and/or purchasing of drugs.
Restricting the Company’s ability to limit providers’ participation in its networks and/or remove providers from its networks by imposing network adequacy requirements or otherwise (including in its Medicare and Commercial Health Care Benefits products).
Imposing assessments on (or to be collected by) health plans or health carriers that may or may not be passed through to their customers. These assessments may include assessments for insolvency, the uninsured, uncompensated care, Medicaid funding or defraying health care provider medical malpractice insurance costs.
Mandating coverage by the Company’s and its clients’ health plans for additional conditions and/or specified procedures, drugs or devices (e.g., high cost pharmaceuticals, experimental pharmaceuticals and oral chemotherapy regimens).
Regulating electronic connectivity.
Mandating or regulating the disclosure of provider fee schedules, manufacturer’s rebates and other data about the Company’s payments to providers and/or payments the Company receives from pharmaceutical manufacturers.
Mandating or regulating disclosure of provider outcome and/or efficiency information.
Prescribing or limiting members’ financial responsibility for health care or other covered services they utilize, including restricting “surprise” bills by providers and by specifying procedures for resolving “surprise” bills.
Prescribing payment levels for health care and other covered services rendered to the Company’s members by providers who do not have contracts with the Company.
Assessing the medical device status of home infusion therapy products and/or solutions, mobile consumer wellness tools and clinical decision support tools, which may require compliance with FDA requirements in relation to some of these products, solutions and/or tools.
Restricting the ability of employers and/or health plans to establish or impose member financial responsibility.
Proposals to expand benefits under Original Medicare.
Amending or supplementing ERISA to impose greater requirements on PBMs or the administration of employer-funded benefit plans or limit the scope of current ERISA pre-emption, which would among other things expose
27

the Company and other health plans to expanded liability for punitive and other extra-contractual damages and additional state regulation.

It is uncertain whether the Company can counter the potential adverse effects of such potential legislation or regulation on its operating results or cash flows, including whether it can recoup, through higher premium rates, expanded membership or other measures, the increased costs of mandated coverage or benefits, assessments, fees, taxes or other increased costs, including the cost of modifying its systems to implement any enacted legislation or regulations.

The Company’s businesses also may be affected by other legislation and regulations. The Dodd-Frank Wall Street Reform and Consumer Protection Act creates incentives for whistleblowers to speak directly to the government rather than utilizing internal compliance programs and reduces the burden of proof under the Foreign Corrupt Practices Act of 1977 (the “FCPA”). There also are laws and regulations that set standards for the escheatment of funds to states.

Health savings accounts, health reimbursement arrangements and flexible spending accounts and certain of the tax, fee and subsidy provisions of the ACA also are regulated by the U.S. Department of the Treasury and the Internal Revenue Service.

The Company also may be adversely affected by court and regulatory decisions that expand or revise the interpretations of existing statutes and regulations or impose medical malpractice or bad faith liability. Federal and state courts, including the U.S. Supreme Court, continue to consider cases, and federal and state regulators continue to issue regulations and interpretations, addressing bad faith liability for denial of medical claims, the scope of ERISA’s fiduciary duty requirements, the scope of the False Claims Act and the pre-emptive effect of ERISA and Medicare Part D on state laws.

Contract Audits - The Company is subject to audits of many of its contracts, including its PBM client contracts, its PBM rebate contracts, its PBM network contracts, its contracts relating to Medicare Advantage and/or Medicare Part D, the agreements the Company’s pharmacies enter into with other payors, its Medicaid contracts and its customer contracts. Because some of the Company’s contracts are with state or federal governments or with entities contracted with state or federal agencies, audits of these contracts are often regulated by the federal or state agencies responsible for administering federal or state benefits programs, including those which operate Medicaid fee for service plans, Managed Medicaid plans, Medicare Part D plans or Medicare Advantage organizations.

Federal Employee Health Benefits Program - The Company’s subsidiaries contract with the Office of Personnel Management (the “OPM”) to provide managed health care services under the FEHB program in their service areas. These contracts with the OPM and applicable government regulations establish premium rating arrangements for this program. In addition to other requirements, such as the Transparency in Coverage Rule note above, OPM regulations require that community-rated FEHB plans meet a FEHB program-specific minimum MLR by plan code and market. Managing to these rules is complicated by the simultaneous application of the minimum MLR standards and associated premium rebate requirements of the ACA. The Company also has a contractual arrangement with carriers for the FEHB program, such as the BlueCross BlueShield Association, to provide pharmacy services to federal employees, postal workers, annuitants, and their dependents under the Government-wide Service Benefit Plan, as authorized by the FEHB Act and as part of the FEHB program. Additionally, the Company manages certain FEHB plans on a “cost-plus” basis. These arrangements subject the Company to certain aspects of the FEHB Act, and other federal regulations, such as the FEHB Acquisition Regulation, that otherwise would not be applicable to the Company. The OPM also is auditing the Company and its other contractors to, among other things, verify that plans meet their applicable FEHB program-specific MLR and the premiums established under the OPM’s Insured contracts and costs allocated pursuant to the OPM’s cost-based contracts are in compliance with the requirements of the applicable FEHB program. The OPM may seek premium refunds or institute other sanctions against the Company if it fails to comply with the FEHB program requirements.

Clinical Services Regulation - The Company provides clinical services to health plans, PBMs and providers for a variety of complex and common medical conditions, including arranging for certain members to participate in disease management programs. State laws regulate the practice of medicine, the practice of pharmacy, the practice of nursing and certain other clinical activities. Clinicians engaged in a professional practice in connection with the provision of clinical services must satisfy applicable state licensing requirements and must act within their scope of practice.

Third Party Administration and Other State Licensure Laws - Many states have licensure or registration laws governing certain types of administrative organizations, such as PPOs, TPAs and companies that provide utilization review services. Several states also have licensure or registration laws governing the organizations that provide or administer consumer card programs (also known as cash card or discount card programs).

28

International Regulation - The Company has insurance licenses in several foreign jurisdictions and does business directly or through local affiliations in numerous countries around the world. The Company has taken steps to be able to continue to serve customers in the European Economic Area following the United Kingdom’s exit from the EU (“Brexit”).

The Company’s international operations are subject to different, and sometimes more stringent, legal and regulatory requirements, which vary widely by jurisdiction, including anti-corruption laws; economic sanctions laws; various privacy, insurance, tax, tariff and trade laws and regulations; corporate governance, privacy, data protection (including the EU’s General Data Protection Regulation which began to apply across the EU during 2018), data mining, data transfer, labor and employment, intellectual property, consumer protection and investment laws and regulations; discriminatory licensing procedures; compulsory cessions of reinsurance; required localization of records and funds; higher premium and income taxes; limitations on dividends and repatriation of capital; and requirements for local participation in an insurer’s ownership. In addition, the expansion of the Company’s operations into foreign countries increases the Company’s exposure to the anti-bribery, anti-corruption and anti-money laundering provisions of U.S. law, including the FCPA, and corresponding foreign laws, including the U.K. Bribery Act 2010 (the “UK Bribery Act”).

Anti-Corruption Laws - The FCPA prohibits offering, promising or authorizing others to give anything of value to a foreign government official to obtain or retain business or otherwise secure a business advantage. The Company also is subject to applicable anti-corruption laws of the jurisdictions in which it operates. In many countries outside the United States, health care professionals are employed by the government. Therefore, the Company’s dealings with them are subject to regulation under the FCPA. Violations of the FCPA and other anti-corruption laws may result in severe criminal and civil sanctions as well as other penalties, and there continues to be a heightened level of FCPA enforcement activity by the U.S. Securities and Exchange Commission (the “SEC”) and the DOJ. The UK Bribery Act is an anti-corruption law that is broader in scope than the FCPA and applies to all companies with a nexus to the United Kingdom. Disclosures of FCPA violations may be shared with the UK authorities, thus potentially exposing companies to liability and potential penalties in multiple jurisdictions.

Anti-Money Laundering Regulations - Certain lines of the Company’s businesses are subject to Treasury anti-money laundering regulations. Those lines of business have implemented anti-money laundering policies designed to ensure their compliance with the regulations. The Company also is subject to anti-money laundering laws in non-U.S. jurisdictions where it operates.

Office of Foreign Assets Control - The Company also is subject to regulation by the Office of Foreign Assets Control of the U.S. Department of Treasury (“OFAC”). OFAC administers and enforces economic and trade sanctions based on U.S. foreign policy and national security goals against targeted foreign countries and regimes, terrorists, international narcotics traffickers, those engaged in activities related to the proliferation of weapons of mass destruction, and other threats to the national security, foreign policy or economy of the United States. In addition, the Company is subject to similar regulations in the non-U.S. jurisdictions in which it operates.

FDA Regulation - The FDA regulates the Company’s compounding pharmacy and clinical research operations. The FDA also generally has authority to, among other things, regulate the manufacture, distribution, sale and labeling of medical devices (including hemodialysis devices such as the device the Company is developing and mobile medical devices) and many products sold through retail pharmacies, including prescription drugs, over-the-counter medications, cosmetics, dietary supplements and certain food items. In addition, the FDA regulates the Company’s activities as a distributor of store brand products.

Laws and Regulations Related to the Health Care Benefits Segment

In addition to the laws and regulations discussed above that may affect multiple segments of the Company’s business, the Company is subject to federal, state, local and international statutes and regulations governing its Health Care Benefits segment specifically.

Overview - Differing approaches to state insurance regulation and varying enforcement philosophies may materially and adversely affect the Company’s ability to standardize its Health Care Benefits products and services across state lines. These laws and regulations, including the ACA, restrict how the Company conducts its business and result in additional burdens and costs to the Company. Significant areas of governmental regulation include premium rates and rating methodologies, underwriting rules and procedures, required benefits, sales and marketing activities, provider rates of payment, restrictions on health plans’ ability to limit providers’ participation in their networks and/or remove providers from their networks and financial condition (including reserves and minimum capital or risk based capital requirements). These laws and regulations are different in each jurisdiction and vary from product to product.

29

Each health insurer and HMO must file periodic financial and operating reports with the states in which it does business. In addition, health insurers and HMOs are subject to state examination and periodic license renewal. Applicable laws also restrict the ability of the Company’s regulated subsidiaries to pay dividends, and certain dividends require prior regulatory approval. In addition, some of the Company’s businesses and related activities may be subject to PPO, MCO, utilization review or TPA-related licensure requirements and regulations. These licensure requirements and regulations differ from state to state, but may contain provider network, contracting, product and rate, financial and reporting requirements. There also are laws and regulations that set specific standards for the Company’s delivery of services, payment of claims, fraud prevention, protection of consumer health information, and payment for covered benefits and services.

Required Regulatory Approvals - The Company must obtain and maintain regulatory approvals to price, market and administer many of its Health Care Benefits products. Supervisory agencies, including CMS, the Center for Consumer Information and Insurance Oversight and the DOL, as well as state health, insurance, managed care and Medicaid agencies, have broad authority to take one or more of the following actions:

Grant, suspend and revoke the Company’s licenses to transact business;
Suspend or exclude the Company from participation in government programs;
Suspend or limit the Company’s authority to market products;
Regulate many aspects of the products and services the Company offers, including the pricing and underwriting of many of its products and services;
Assess damages, fines and/or penalties;
Terminate the Company’s contract with the government agency and/or withhold payments from the government agency to the Company;
Impose retroactive adjustments to premiums and require the Company to pay refunds to the government, customers and/or members;
Restrict the Company’s ability to conduct acquisitions or dispositions;
Require the Company to maintain minimum capital levels in its subsidiaries and monitor its solvency and reserve adequacy;
Regulate the Company’s investment activities on the basis of quality, diversification and other quantitative criteria; and/or
Exclude the Company’s plans from participating in Public Exchanges if they are deemed to have a history of “unreasonable” premium rate increases or fail to meet other criteria set by HHS or the applicable state.

The Company’s operations, current and past business practices, current and past contracts, and accounts and other books and records are subject to routine, regular and special investigations, audits, examinations and reviews by, and from time to time the Company receives subpoenas and other requests for information from, federal, state and international supervisory and enforcement agencies, attorneys general and other state, federal and international governmental authorities and legislators.

Commercial Product Pricing and Underwriting Restrictions - Pricing and underwriting regulation by states limits the Company’s underwriting and rating practices and those of other health insurers, particularly for small employer groups, and varies by state. In general, these limitations apply to certain customer segments and limit the Company’s ability to set prices for new or renewing groups, or both, based on specific characteristics of the group or the group’s prior claim experience. In some states, these laws and regulations restrict the Company’s ability to price for the risk it assumes and/or reflect reasonable costs in the Company’s pricing.

The ACA expanded the premium rate review process by, among other things, requiring the Company’s Commercial Insured rates to be reviewed for “reasonableness” at either the state or the federal level. HHS established a federal premium rate review process that generally applies to proposed premium rate increases equal to or exceeding a federally (or lower state) specified threshold. HHS’s rate review process imposes additional public disclosure requirements as well as additional review on filings requesting premium rate increases equal to or exceeding this “reasonableness” threshold. These combined state and federal review requirements may prevent, further delay or otherwise affect the Company’s ability to price for the risk it assumes, which could adversely affect its MBRs and operating results, particularly during periods of increased utilization of medical services and/or medical cost trend or when such utilization and/or trend exceeds the Company’s projections.

The ACA also specifies minimum MLRs of 85% for large group Commercial products and 80% for individual and small group Commercial products. Because the ACA minimum MLRs are structured as “floors” for many of their requirements, states have the latitude to enact more stringent rules governing these restrictions. For Commercial products, states have and may adopt higher minimum MLR requirements, use more stringent definitions of “medical loss ratio,” incorporate minimum MLR
30

requirements into prospective premium rate filings, require prior approval of premium rates or impose other requirements related to minimum MLR. Minimum MLR requirements and similar actions further limit the level of margin the Company can earn in its Insured Commercial products while leaving the Company exposed to medical costs that are higher than those reflected in its pricing. The Company also may be subject to significant fines, penalties, premium refunds and litigation if it fails to comply with minimum MLR laws and regulations.

In addition, the Company requested increases in its premium rates in its Commercial Health Care Benefits business for 2022 and expects to continue to request increases in those rates for 2023 and beyond in order to adequately price for projected medical cost trends, required expansions of coverage and rating limits, and significant assessments, fees and taxes imposed by the federal and state governments, including as a result of the ACA. The Company’s rates also must be adequate to reflect adverse selection in its products, particularly in small group Commercial products. These rate increases may be significant and thus heighten the risks of adverse publicity, adverse regulatory action and adverse selection and the likelihood that the Company’s requested premium rate increases will be denied, reduced or delayed, which could lead to operating margin compression.

Many of the laws and regulations governing the Company’s pricing and underwriting practices also limit the differentials in premium rates insurers and other carriers may charge between new and renewal business, and/or between groups based on differing characteristics. They may also require that carriers disclose to customers the basis on which the carrier establishes new business and renewal premium rates and limit the ability of a carrier to terminate customers’ coverage.

Recently, with respect to quality improvement activities (“QIAs”) that health plans report to HHS, revised regulations no longer provide insurers the option of reporting a flat amount equal to 0.8 percent of earned premium in lieu of reporting the insurers' actual itemized QIA expenditures. This change will impact the Company’s future MLR calculations and reporting since we have utilized the 0.8 percent premium election.

Medicaid Regulation - The Company is seeking to substantially grow its Medicaid, dual eligible and dual eligible special needs plan businesses over the next several years. As a result, the Company also is increasing its exposure to changes in government policy with respect to and/or regulation of the various Medicaid, dual eligible and dual eligible special needs plan programs in which the Company participates, including changes in the amounts payable to the Company under those programs.

Since 2017, Managed Medicaid products, including those the Company offers, are subject to a minimum federal MLR of 85%. A Medicaid managed care quality rating system and provider network adequacy requirements also apply to Medicaid products. Because the federal minimum MLR is structured as a “floor,” states have the latitude to enact more stringent rules governing these restrictions. For Managed Medicaid products, states may adopt higher minimum MLR requirements, use more stringent definitions of “medical loss ratio” or impose other requirements related to minimum MLR. Minimum MLR requirements and similar actions further limit the level of margin the Company can earn in its Insured Medicaid products while leaving the Company exposed to medical costs that are higher than those reflected in its pricing. The Company also may be subject to significant fines, penalties, premium refunds and litigation if it fails to comply with minimum MLR laws and regulations.

States continue to consider Medicaid expansion; however, 12 states have still not decided to expand as of 2022. States may opt out of the elements of the ACA requiring expansion of Medicaid coverage without losing their current federal Medicaid funding. In addition, the election of new governors and/or state legislatures may impact states’ previous decisions regarding Medicaid expansion. Although Congress enacted incentives for states that had not yet done so to expand Medicaid, this incentive alone may not persuade holdout states to expand.

In 2021, Medicaid MCOs faced new requirements and state flexibility that were finalized in the 2020 Medicaid managed care final rule. States now have flexibility related to rate setting and provider network adequacy that could adversely or positively impact our Medicaid plans. Other changes related to managed care operations include beneficiary communications, appeals and grievances, and provider directories.

The economic aspects of the Medicaid, dual eligible and dual eligible special needs plan business vary from state to state and are subject to frequent change. Medicaid premiums are paid by each state and differ from state to state. The federal government and certain states also are considering proposals and legislation for Medicaid and dual eligible program reforms or redesigns, including restrictions on the collection of manufacturer’s rebates on pharmaceuticals by Medicaid MCOs and their contracted PBMs, further program, population and/or geographic expansions of risk-based managed care, increasing beneficiary cost-sharing or payment levels, and changes to benefits, reimbursement, eligibility criteria, provider network adequacy requirements (including requiring the inclusion of specified high cost providers in the Company’s networks) and program structure. In some states, current Medicaid and dual eligible funding and premium revenue may not be adequate for the Company to continue
31

program participation. The Company’s Medicaid and dual eligible contracts with states (or sponsors of Medicaid managed care plans) are subject to cancellation by the state (or the sponsors of the managed care plans) after a short notice period without cause (e.g., when a state discontinues a managed care program) or in the event of insufficient state funding.

The Company’s Medicaid, dual eligible and dual eligible special needs plan products also are heavily regulated by CMS and state Medicaid agencies, which have the right to audit the Company’s performance to determine compliance with CMS contracts and regulations. The Company’s Medicaid products, dual eligible products and CHIP contracts also are subject to complex federal and state regulations and oversight by state Medicaid agencies regarding the services provided to Medicaid enrollees, payment for those services, network requirements (including mandatory inclusion of specified high-cost providers), and other aspects of these programs, and by external review organizations which audit Medicaid plans on behalf of state Medicaid agencies. The laws, regulations and contractual requirements applicable to the Company and other participants in Medicaid and dual eligible programs, including requirements that the Company submit encounter data to the applicable state agency, are extensive, complex and subject to change. The Company has invested significant resources to comply with these standards, and its Medicaid and dual eligible program compliance efforts will continue to require significant resources. CMS and/or state Medicaid agencies may fine the Company, withhold payments to the Company, seek premium and other refunds, terminate the Company’s existing contracts, elect not to award the Company new contracts or not to renew the Company’s existing contracts, prohibit the Company from continuing to market and/or enroll members in or refuse to automatically assign members to one or more of the Company’s Medicaid or dual eligible products, exclude the Company from participating in one or more Medicaid or dual eligible programs and/or institute other sanctions and/or civil monetary penalties against the Company if it fails to comply with CMS or state regulations or contractual requirements.

The Company cannot predict whether pending or future federal or state legislation or court proceedings will change various aspects of the Medicaid program, nor can it predict the impact those changes will have on its business operations or operating results, but the effects could be materially adverse.

Federal and State Reporting - The Company is subject to extensive financial and business reporting requirements, including penalties for inaccuracies and/or omissions, at both the federal and state level. The Company’s ability to comply with certain of these requirements depends on receipt of information from third parties that may not be readily available or reliably provided in all instances. The Company is and will continue to be required to modify its information systems, dedicate significant resources and incur significant expenses to comply with these requirements. However, the Company cannot eliminate the risks of unavailability of or errors in its reports.

Product Design and Administration and Sales Practices - State and/or federal regulatory scrutiny of health care benefit product design and administration and marketing and advertising practices, including the filing of insurance policy forms, the adequacy of provider networks, the accuracy of provider directories, and the adequacy of disclosure regarding products and their administration, is increasing as are the penalties being imposed for inappropriate practices. Medicare, Medicaid and dual eligible products and products offering more limited benefits in particular continue to attract increased regulatory scrutiny.

Guaranty Fund Assessments/Solvency Protection - Under guaranty fund laws existing in all states, insurers doing business in those states can be assessed (in most states up to prescribed limits) for certain obligations of insolvent insurance companies to policyholders and claimants. The life and health insurance guaranty associations in which the Company participates that operate under these laws respond to insolvencies of long-term care insurers as well as health insurers. The Company’s assessments generally are based on a formula relating to the Company’s health care premiums in the state compared to the premiums of other insurers. Certain states allow assessments to be recovered over time as offsets to premium taxes. Some states have similar laws relating to HMOs and/or other payors such as not-for-profit consumer governed health plans established under the ACA. While historically the Company has ultimately recovered more than half of guaranty fund assessments through statutorily permitted premium tax offsets, significant increases in assessments could lead to legislative and/or regulatory actions that limit future offsets.

Laws and Regulations Related to the Pharmacy Services Segment

In addition to the laws and regulations discussed above that may affect multiple segments of the Company’s business, the Company is subject to federal, state and local statutes and regulations governing the operation of its Pharmacy Services segment specifically. Among these are the following:

PBM Laws and Regulation - Legislation and/or regulations seeking to regulate PBM activities in a comprehensive manner have been proposed or enacted in a number of states. This legislation could adversely affect the Company’s ability to conduct business on commercially reasonable terms in states where the legislation is in effect and the Company’s ability to standardize
32

its PBM products and services across state lines. In addition, certain quasi-regulatory organizations, including the National Association of Boards of Pharmacy and the NAIC and the National Council of Insurance Legislators, have issued model regulations or may propose future regulations concerning PBMs and/or PBM activities. Similarly, credentialing organizations such as URAC have established voluntary standards regarding PBM, mail order pharmacy and/or specialty pharmacy activities. While the actions of these quasi-regulatory or standard-setting organizations do not have the force of law, they may influence states to adopt their requirements or recommendations and influence client requirements for PBM, mail order pharmacy and/or specialty pharmacy services. Moreover, any standards established by these organizations could also impact the Company’s health plan clients and/or the services provided to those clients and/or the Company’s health plans.

The Company’s PBM activities also are regulated directly and indirectly at the federal and state levels, including being subject to the False Claims Act and state false claims acts and the AKS and state anti-kickback laws. These laws and regulations govern, and proposed legislation and regulations may govern and/or further restrict, critical PBM practices, including disclosure, receipt and retention of rebates and other payments received from pharmaceutical manufacturers; use of, administration of and/or changes to drug formularies, maximum allowable cost (“MAC”) list pricing, average wholesale prices (“AWP”) and/or clinical programs; the offering to plan sponsors of pricing that includes retail network “differential” or “spread” (i.e., a difference between the drug price charged to the plan sponsor by a PBM and the price paid by the PBM to the dispensing provider); reconciliation to pricing guarantees; disclosure of data to third parties; drug UM practices; the level of duty a PBM owes its customers; configuration of pharmacy networks; the operations of the Company’s pharmacies (including audits of its pharmacies); disclosure of negotiated provider reimbursement rates; disclosure of fees associated with administrative service agreements and patient care programs that are attributable to members’ drug utilization; and registration or licensing of PBMs. Failure by the Company or one of its PBM services suppliers to comply with these laws or regulations could result in material fines and/or sanctions and could have a material adverse effect on the Company’s operating results and/or cash flows.

The Company’s PBM service contracts, including those in which the Company assumes certain risks under performance guarantees or similar arrangements, are generally not subject to insurance regulation by the states. However, state departments of insurance are increasing their oversight of PBM activities due to legislation passing in a number of states requiring PBMs to register or obtain a license with the department, including through market conduct examinations and other audits our licensed entities. In addition, rulemaking is either underway or has already taken place in a number of states with the areas of focus on licensure requirements, pharmacy reimbursement for generics (MAC reimbursement) and pharmacy audits - most of which fall under the state insurance code.

Most-Favored-Nation Rule - In November 2020, HHS released the Most-Favored-Nation Rule (the “MFN Rule”), which requires CMS to take a most-favored-nation approach in calculating payment for Medicare Part B drugs. The MFN Rule will test paying Part B drugs at comparable amounts to the lowest adjusted price paid by any country in the Organization for Economic Co-operation and Development that has a Gross Domestic Product (“GDP”) per capita that is at least 60% of the U.S. GDP per capita. The MFN Rule will also test a redesign of the percentage add-on payment structure under Medicare Part B to remove incentives for use of higher-cost drugs through a flat per-dose add-on payment, and will include a financial hardship exemption for participants. The mandatory MFN Rule will operate for seven years, from January 1, 2021 to December 31, 2027. Over the course of the model, CMS will monitor and evaluate the impact of the MFN Rule on beneficiary access to drugs, program costs, and the quality of care for beneficiaries. Further, CMS commits to assess initial impacts of the MFN Rule on quality of care, including access to drugs, prior to beginning performance year 5. Multiple pharmaceutical manufacturers have sued HHS over the rule, and it is currently delayed due to a temporary restraining order prohibiting CMS from implementing it. If implemented, the MFN Rule may impact the ability of the Company to negotiate drug prices and provide competitive products and services to consumers. In August 2021, CMS published a proposed rule to rescind the MFN Rule. It is unclear whether this rescission may be followed by regulatory or legislative alternatives that present similar, or even more substantial, patient access, provider reimbursement, and other concerns.

Pharmacy Network Access Legislation - Medicare Part D and a majority of states now have some form of legislation affecting the Company’s (and its health plans’ and its health plan clients’) ability to limit access to a pharmacy provider network or remove pharmacy network providers. For example, certain “any willing provider” legislation may require the Company or its clients to admit a nonparticipating pharmacy if such pharmacy is willing and able to meet the plan’s price and other applicable terms and conditions for network participation. These laws could negatively affect the services and economic benefits achievable through a limited pharmacy provider network. Also, a majority of states now have some form of legislation affecting the Company’s ability (and the Company’s and its client health plans’ ability) to conduct audits of network pharmacies regarding claims submitted to the Company for payment. These laws could negatively affect the Company’s ability to recover overpayments of claims submitted by network pharmacies that the Company identifies through pharmacy audits.
33

Finally, several states have passed legislation that limits the ability of PBMs and health insurers to provide special benefit structures for use with affiliated pharmacies, which could result in reduced savings to clients and consumers.

Pharmacy Pricing Legislation - A number of states have passed legislation regulating the Company’s ability to manage and establish MACs for generic prescription drugs. MAC methodology is a common cost management practice used by private and public payors (including CMS) to pay pharmacies for dispensing generic prescription drugs. MAC prices specify the allowable reimbursement by a PBM for a particular strength and dosage of a generic drug that is available from multiple manufacturers but sold at different prices. State legislation can regulate the disclosure of MAC prices and MAC price methodologies, the kinds of drugs that a PBM can pay for at a MAC price, and the rights of pharmacies to appeal a MAC price established by a PBM. These laws could negatively affect the Company’s ability to establish MAC prices for generic drugs. Additionally, some states have passed legislation that would create a reimbursement benchmark mandate, such as the national average drug acquisition cost and/or the wholesale acquisition cost (“WAC”), plus a set dispensing fee, for pharmacies in the network.

Formulary and Plan Design Regulation - A number of government entities regulate the administration of prescription drug benefits. HHS regulates how Medicare Part D formularies are developed and administered, including requiring the inclusion of all drugs in certain classes and categories, subject to limited exceptions. Under the ACA, CMS imposes drug coverage requirements for health plans required to cover essential health benefits, including plans offered through federal or state Public Exchanges. Additionally, the NAIC and health care accreditation agencies like NCQA and URAC have developed model acts and standards for formulary development that are often incorporated into government requirements. Many states regulate the scope of prescription drug coverage, as well as the delivery channels to receive prescriptions, for insurers, MCOs and Medicaid managed care plans. The increasing government regulation of formularies could significantly affect the Company’s ability to develop and administer formularies, pharmacy networks and other plan design features. Similarly, some states prohibit health plan sponsors from implementing certain restrictive pharmacy benefit plan design features. This regulation could limit or preclude (i) limited networks, (ii) a requirement to use particular providers, (iii) copayment differentials among providers and (iv) formulary tiering practices.

Laws and Regulations Related to the Retail/LTC Segment

In addition to the laws and regulations discussed above that may affect multiple segments of the Company’s business, the Company is subject to federal, state and local statutes and regulations governing the operation of its Retail/LTC segment specifically. Among these are the following:

Retail Medical Clinics - States regulate retail medical clinics operated by nurse practitioners or physician assistants through physician oversight, clinic and lab licensure requirements and the prohibition of the corporate practice of medicine. A number of states have implemented or proposed laws or regulations that impact certain components of retail medical clinic operations such as physician oversight, signage, third party contracting requirements, bathroom facilities, and scope of services. These laws and regulations may affect the operation and expansion of the Company’s owned and managed retail medical clinics.

Other Laws - Other federal, state and local laws and regulations also impact the Company’s retail operations, including laws and regulations governing the practice of optometry, the practice of audiology, the provision of dietician services and the sale of durable medical equipment, contact lenses, eyeglasses, hearing aids and alcohol.

Available Information

CVS Health Corporation was incorporated in Delaware in 1996. The corporate office is located at One CVS Drive, Woonsocket, Rhode Island 02895, telephone (401) 765-1500. CVS Health Corporation’s common stock is listed on the New York Stock Exchange under the trading symbol “CVS.” General information about the Company is available through the Company’s website at http://www.cvshealth.com. The Company’s financial press releases and filings with the SEC are available free of charge within the Investors section of the Company’s website at http://investors.cvshealth.com. In addition, the SEC maintains an internet site that contains reports, proxy and information statements and other information regarding issuers, such as the Company, that file electronically with the SEC. The address of that website is http://www.sec.gov. The information on or linked to the Company’s website is neither a part of nor incorporated by reference in this 10-K or any of the Company’s other SEC filings.

In accordance with guidance provided by the SEC regarding use by a company of its websites and social media channels as a means to disclose material information to investors and to comply with its disclosure obligations under SEC Regulation FD, CVS Health Corporation (the “Registrant”) hereby notifies investors, the media and other interested parties that it intends to continue to use its media and investor relations website (http://investors.cvshealth.com/) and its Twitter feed (@CVSHealthIR)
34

to publish important information about the Registrant, including information that may be deemed material to investors. The list of social media channels that the Registrant uses may be updated on its media and investor relations website from time to time. The Registrant encourages investors, the media, and other interested parties to review the information the Registrant posts on its website and social media channels as described above, in addition to information announced by the Registrant through its SEC filings, press releases and public conference calls and webcasts.

Item 1A. Risk Factors.

You should carefully consider each of the following risks and uncertainties and all of the other information set forth in this 10-K. These risks and uncertainties and other factors may affect forward-looking statements, including those we make in this 10-K or elsewhere, such as in news releases or investor or analyst calls, meetings or presentations, on our websites or through our social media channels. The risks and uncertainties described below are not the only ones we face. There can be no assurance that we have identified all the risks that affect us. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial also may adversely affect our businesses. Any of these risks or uncertainties could cause our actual results to differ materially from our expectations and the expected results discussed in our forward-looking statements. You should not consider past results to be an indication of future performance.

If any of the following risks or uncertainties develops into actual events or if the circumstances described in the risks or uncertainties occur or continue to occur, those events or circumstances could have a material adverse effect on our businesses, operating results, cash flows, financial condition and/or stock price, among other effects on us. You should read the following section in conjunction with the MD&A, included in Item 7 of this 10-K, our consolidated financial statements and the related notes, included in Item 8 of this 10-K, and our “Cautionary Statement Concerning Forward-Looking Statements” in this 10-K.

Summary

The following is a summary of the principal risks we face that could negatively impact our businesses, operating results, cash flows and/or financial condition:

Risks Relating to Our Businesses

The impact COVID-19 will have on our businesses, operating results, cash flows and/or financial condition is uncertain, but the impact could be material and adverse.
We may not be able to accurately forecast health care and other benefit costs.
Adverse economic conditions in the U.S. and abroad can materially and adversely impact our businesses, operating results, cash flows and financial condition.
Each of our segments operates in a highly competitive and evolving business environment.
A change in our Health Care Benefits product mix may adversely affect our profit margins.
We can provide no assurance that we will be able to compete successfully and profitably on Public Exchanges.
Negative public perception of the industries in which we operate can adversely affect our businesses, operating results, cash flows and prospects.
We must maintain and improve our relationships with our customers and increase the demand for our products and services.
We face risks relating to the availability, pricing and safety profiles of prescription drugs that we purchase and sell.
The reserves we hold for expected claims in our Insured Health Care Benefits products are based on estimates that involve an extensive degree of judgment and are inherently variable, and any reserve, including a premium deficiency reserve, may be insufficient.
We are exposed to risks relating to the solvency of other insurers.

Risks From Changes in Public Policy and Other Legal and Regulatory Risks

We are subject to potential changes in public policy, laws and regulations, including reform of the U.S. health care system and entitlement programs.
If we fail to comply with applicable laws and regulations we could be subject to significant adverse regulatory actions.
If our compliance or other systems and processes fail or are deemed inadequate, we may suffer brand and reputational harm and become subject to regulatory actions and/or litigation.
35


We routinely are subject to litigation and other adverse legal proceedings, including class actions and qui tam actions. Many of these proceedings seek substantial damages which may not be covered by insurance.
We frequently are subject to regular and special governmental audits, investigations and reviews that could result in changes to our business practices and also could result in material refunds, fines, penalties, civil liabilities, criminal liabilities and other sanctions.
Our litigation and regulatory risk profiles are changing as we offer new products and services and expand in business areas beyond our historical core businesses.
We face unique regulatory and other challenges in our Medicare and Medicaid businesses.
Programs funded in whole or in part by the U.S. federal government account for a significant portion of our revenues.
We may not be able to obtain adequate premium rate increases in our Insured Health Care Benefits products, MBRs and operating results and could magnify the adverse impact of increases in health care and other benefit costs and of ACA assessments, fees and taxes.
Minimum MLR rebate requirements limit the level of margin we can earn in our Insured Health Care Benefits products while leaving us exposed to higher than expected medical costs. Challenges to our minimum MLR rebate methodology and/or reports could adversely affect our operating results.
Our operating results may be adversely affected by changes in laws and policies governing employers and by union organizing activity.

Risks Associated with Mergers, Acquisitions, and Divestitures

We may be unable to successfully integrate companies we acquire.
We expect to continue to pursue acquisitions, joint ventures, strategic alliances and other inorganic growth opportunities, which may be unsuccessful, cause us to assume unanticipated liabilities, disrupt our existing businesses, be dilutive or lead us to assume significant debt, among other things.

Risks Related to Our Operations

Failure to meet customer and investor expectations, including with respect to environmental, social and governance goals, may harm our brand and reputation, our ability to retain and grow our customer base and membership.
We and our vendors have experienced and continue to experience information security incidents. We can provide no assurance that we or our vendors will be able to contain detect or prevent incident.
Data governance failures or the failure or disruption of our information technology or infrastructure can adversely affect our reputation, businesses and prospects. Our use and disclosure of members’, customers’ and other constituents’ sensitive information is subject to complex regulations at multiple levels.
Product liability, product recall or personal injury issues could damage our reputation.
We face significant competition in attracting and retaining talented employees. Further, managing succession for, and retention of, key executives is critical to our success.
Sales of our products and services are dependent on our ability to attract and motivate internal sales personnel and independent third-party brokers, consultants and agents. We may be subject to penalties or other regulatory actions as a result of the marketing practices of brokers and agents selling our products.
Failure of our businesses to effectively collaborate could prevent us from maximizing our operating results.
Pursuing multiple information technology improvement initiatives simultaneously could make continued development and implementation significantly more challenging.
We are subject to payment-related risks that could increase our operating costs, expose us to fraud or theft, subject us to potential liability and disrupt our business operations.
Both our and our vendors’ operations are subject to a variety of business continuity hazards and risks that could interrupt our operations or otherwise adversely affect our performance and operating results.

Financial Risks

We would be adversely affected by downgrades or potential downgrades in our credit ratings, should they occur, or if we do not effectively deploy our capital.
Goodwill and other intangible assets could, in the future, become impaired.
36


Adverse conditions in the U.S. and global capital markets can significantly and adversely affect the value of our investments in debt and equity securities, mortgage loans, alternative instruments and other investments.

Risks Related to Our Relationships with Manufacturers, Providers, Suppliers and Vendors

We face risks relating to the market availability, pricing, suppliers and safety profiles of prescription drugs and other products that we purchase and sell.
We need to be able to maintain our ability to contract with providers on competitive terms and develop and maintain attractive networks with high quality providers.
If our suppliers or service providers fail to meet their contractual obligations to us or to comply with applicable laws or regulations, we may be exposed to brand and reputational harm, litigation and/or regulatory action.
We may experience increased medical and other benefit costs, litigation risk and customer and member dissatisfaction when providers that do not have contracts with us render services to our Health Care Benefits members.
Continuing consolidation and integration among providers and other suppliers may increase our costs and increase competition.

Risks Related to COVID-19

The spread of, impact of and response to COVID-19 underscores and amplifies certain risks we face. The impact COVID-19 will have on our businesses, operating results, cash flows and/or financial condition is uncertain, but the impact could be material and adverse.

COVID-19 has spread to every state in the U.S., has been declared a pandemic by the World Health Organization and has severely impacted, and is expected to continue to severely impact, the economies of the U.S. and other countries around the world.

The legislative and regulatory environment governing our businesses is dynamic and changing frequently, including the Families First Act, the CARES Act, the American Rescue Plan Act and mandated increases to the medical services we must pay for without a corresponding increase in the premiums we receive in our Health Care Benefits Insured products. As a result of COVID-19, including legislative and/or regulatory responses to COVID-19, the premiums we charge in our Insured Health Care Benefits products may prove to be insufficient to cover the cost of medical services delivered to our Insured medical members, which may increase significantly as a result of higher utilization rates of medical facilities and services and other increases in associated hospital and pharmaceutical costs.

Federal, state and local governmental policies and initiatives to reduce the transmission of COVID-19, including existing and new variants, such as mask and vaccination mandates, restrictions on large gatherings and social distancing directives, may not effectively combat the severity and/or duration of the COVID-19 pandemic and have resulted in, among other things, a reduction in utilization that is discretionary, the cancellation of elective medical procedures, reduced customer traffic and front store sales in our retail pharmacies, our customers being ordered to close or severely curtail their operations, the adoption of work-from-home policies and a reduction in diagnostic reporting due to reductions in health care provider visits and restrictions on our access to providers’ medical records, all of which impact our businesses. Among other impacts of these policies and initiatives on our businesses, there may be changes in medical claims submission patterns and an adverse impact on (i) drug utilization due to the reduction in discretionary visits with providers; (ii) front store sales as a result of reduced customer traffic in our retail pharmacies; (iii) medical membership in our Health Care Benefits segment and covered lives in our PBM clients due to reductions in workforce at our existing customers (including due to business failures) as well as reduced willingness to change benefits providers by prospective customers; (iv) benefit costs due to COVID-19 related support programs we have put in place for our medical members and mandated increases to the medical services we must pay for without a corresponding increase in the premiums we receive in our Insured Health Care Benefits products; and (v) the amount, timing and collectability of payments to the Company from customers, clients, government payers and members as a result of the impact of COVID-19 on them. Over time, these policies and initiatives also may cause us to experience increased benefit costs and/or decreased revenues in our Health Care Benefits segment if, as a result of our medical members not seeing their providers as a result of COVID-19, we are unable to implement clinical initiatives to manage benefit costs and chronic conditions of our medical members and appropriately document their risk profiles.

In addition, in response to COVID-19, during the first half of 2020, we began to offer our medical members expanded benefit coverage and became obligated by governmental action to provide other additional coverage. This expanded benefit coverage continued to be provided without a corresponding increase in the premiums we receive in our Insured Health Care Benefits
37


products. We also are taking actions designed to help provide financial and administrative relief for the health care provider community. Such measures and any further steps we take or are required to take to expand or otherwise modify the services delivered to our Health Care Benefits members, provide relief for the health care provider community, or in connection with the relaxation of social distancing directives and other restrictions on movement and economic activity intended to reduce the spread of COVID-19, including the potential for widespread testing and vaccination, including boosters, as a component of lifting those measures, could adversely impact our benefit costs, MBR and operating results.

The various initiatives we have implemented to slow and/or reduce the impact of COVID-19 and the COVID-19-related support programs we have put in place for our customers, medical members and colleagues have increased our operating expenses and reduced the efficiency of our operations. Our operating results will continue to be adversely affected so long as these initiatives continue or if they are expanded. In addition, any adverse economic conditions that could be caused by COVID-19 may have an adverse impact on our net investment income and the value of our investment portfolio.

The spread of COVID-19, or actions taken to mitigate its spread, could have material and adverse effects on our ability to operate our businesses effectively, including as a result of the complete or partial closure of facilities, labor shortages and/or financial difficulties experienced by third-party service providers. Disruptions in our supply chains, our distribution chains and/or public and private infrastructure, including those caused by industry capacity constraints, material availability, global logistics delays and constraints arising from, among other things, the transportation capacity of ocean shipping containers, and labor availability constraints, could materially and adversely impact our business operations. We have transitioned a significant subset of our colleagues to a remote work environment in an effort to mitigate the spread of COVID-19, as have a significant number of our third-party service providers, which may amplify certain risks to our businesses, including an increased demand for information technology resources, increased risk of phishing and other cybersecurity attacks, increased risk of unauthorized dissemination of sensitive personal information or proprietary or confidential information about us or our medical members or other third-parties and increased risk of business interruptions.

The COVID-19 pandemic continues to evolve and the severity and duration of the pandemic and scope and intensity of the governmental response to it are unknown at this time. We believe COVID-19’s impact on our businesses, operating results, cash flows and/or financial condition primarily will be driven by the geographies impacted and the severity and duration of the pandemic; vaccination rates; the severity of any new COVID-19 variants and whether vaccines are effective in combating them; the pandemic’s impact on the U.S. and global economies and consumer behavior and health care utilization patterns; and the timing, scope and impact of any additional stimulus legislation as well as other federal, state and local governmental responses to the pandemic. Those primary drivers are beyond our knowledge and control. As a result, the impact COVID-19 will have on our businesses, operating results, cash flows and/or financial condition is uncertain, but the impact could be adverse and material. COVID-19 also may result in legal and regulatory proceedings, investigations and claims against us.

Risks Relating to Our Businesses

We may not be able to accurately forecast health care and other benefit costs, which could adversely affect our Health Care Benefits segment’s operating results. There can be no assurance that future health care and other benefits costs will not exceed our projections.

As a result of COVID-19, the current economic environment is adverse and less predictable than recently experienced, which has caused and may continue to cause unanticipated and significant volatility in our health care and other benefits costs, including COVID-19 related testing and vaccination and post-acute care skilled nursing facility and behavioral health costs. In January 2021, the President of the United States issued an executive order to support government efforts to expand access, availability and use of COVID-19 diagnostic, screening and surveillance and addressed the cost of COVID-19 testing by facilitating COVID-19 testing free of charge to those who lack comprehensive health insurance and clarifying group health plans’ and health insurance issuers’ obligations to provide coverage for COVID-19 testing. In January 2022, the HHS announced that commercial health insurers must cover the cost of up to eight rapid COVID-19 OTC test kits per individual per 30-day period. In addition, the timing of vaccine administration to the general public and related costs as well as the identification of new, more infectious strains of the COVID-19 virus and whether the vaccines will be effective against such new strains are uncertain and may impact our MBR. Premiums for our Insured Health Care Benefits products, which comprised 93% of our Health Care Benefits revenues for 2021, are priced in advance based on our forecasts of health care and other benefit costs during a fixed premium period, which is generally twelve months. These forecasts are typically developed several months before the fixed premium period begins, are influenced by historical data (and recent historical data in particular), are dependent on our ability to anticipate and detect medical cost trends and changes in our members’ behavior and health care utilization patterns and medical claim submission patterns and require a significant degree of judgment. For example, our revenue on Medicare policies is based on bids submitted in June of the year before the contract year. Cost increases in excess of
38


our projections cannot be recovered in the fixed premium period through higher premiums. As a result, our profits are particularly sensitive to the accuracy of our forecasts of the increases in health care and other benefit costs that we expect to occur and our ability to anticipate and detect medical cost trends. For 2022, those forecasts include adjustments made to pricing based on prospective expectations for liabilities due to testing, vaccines, direct COVID-19 treatment and deferred care. Risk-adjusted revenue has been adjusted for deferred care, and forecasted enrollment considers assumptions about the economic environment, though COVID-19 related impacts remain uncertain. During periods when health care and other benefit costs, utilization and/or medical costs trends experience significant volatility and medical claim submission patterns are changing rapidly as a result of COVID-19, accurately detecting, forecasting, managing, reserving and pricing for our (and our self-insured customers’) medical cost trends and incurred and future health care and other benefits costs is more challenging. There can be no assurance regarding the accuracy of the health care or other benefit cost projections reflected in our pricing, and our health care and other benefit costs (including COVID-19 related testing and vaccination and post-acute care skilled nursing facility and behavioral health costs) are affected by COVID-19 and other external events over which we have no control. Even relatively small differences between predicted and actual health care and other benefit costs as a percentage of premium revenues can result in significant adverse changes in our Health Care Benefits segment’s operating results.

A number of factors contribute to rising health care and other benefit costs, including COVID-19, previously uninsured members entering the health care system, changes in members’ behavior and health care utilization patterns, turnover in our membership, additional government mandated benefits or other regulatory changes (including under the Families First Act, the CARES Act, and the American Rescue Plan Act), changes in the health status of our members, the aging of the population and other changing demographic characteristics, advances in medical technology, increases in the number and cost of prescription drugs (including specialty pharmacy drugs and ultra-high cost drugs and therapies), direct-to-consumer marketing by drug manufacturers, the increasing influence of social media on our members’ health care utilization and other behaviors, changes in health care practices and general economic conditions (such as inflation and employment levels). In addition, government-imposed limitations on Medicare and Medicaid reimbursements to health plans and providers have caused the private sector to bear a greater share of increasing health care and other benefits costs over time, and future amendments to the ACA that increase the uninsured population may amplify this problem. Other factors that affect our health care and other benefit costs include epidemics or other pandemics, changes as a result of the ACA, changes to the ACA and other changes in the regulatory environment, the evolution toward a consumer driven business model, new technologies, influenza-related health care costs (which may be substantial and higher than we expected), clusters of high-cost cases, health care provider and member fraud, and numerous other factors that are or may be beyond our control. For example, the 2020-2021 influenza season was impacted by efforts taken to reduce the spread of COVID-19; and the 2019-2020 influenza season had an earlier than average start and had a higher incidence of influenza than the 2018-2019 influenza season.

Our Health Care Benefits segment’s operating results and competitiveness depend in large part on our ability to appropriately manage future health care and other benefit costs through underwriting criteria, product design, provider network configuration, negotiation of favorable provider contracts and medical management programs. Our medical cost management programs may not be successful and may have a smaller impact on health care and benefit costs than we expect. The factors described above may adversely affect our ability to predict and manage health care and other benefit costs, which can adversely affect our competitiveness and operating results.

Furthermore, if we are not able to accurately and promptly anticipate and detect medical cost trends or accurately estimate the cost of incurred but not yet reported claims or reported claims that have not been paid, our ability to take timely corrective actions to limit future health care costs and reflect our current benefit cost experience in our pricing process may be limited, which would further amplify the extent of any adverse impact on our operating results. These risks are particularly acute during periods when health care and other benefit costs, utilization and/or medical cost trends experience significant volatility and medical claim submission patterns are changing rapidly as a result of COVID-19. Such risks are further magnified by the ACA and other existing and future legislation and regulations that limit our ability to price for our projected and/or experienced increases in utilization and/or medical cost trends.

There can be no assurance that future health care and other benefits costs will not exceed our projections.

Adverse economic conditions in the U.S. and abroad can materially and adversely impact our businesses, operating results, cash flows and financial condition, and we do not expect these conditions to improve in the near future.

Adverse economic conditions in the U.S. and abroad, including those caused by COVID-19, can materially and adversely impact our businesses, operating results, cash flows and financial condition, including:

39


In our Pharmacy Services segment, by causing drug utilization to decline, reducing demand for PBM services and adversely affecting the financial health of our PBM clients.
In our Retail/LTC segment, by causing drug utilization to decline, changing consumer purchasing power, preferences and/or spending patterns leading to reduced consumer demand for products sold in our stores and adversely affecting the financial health of our LTC pharmacy customers.
By causing our existing customers to reduce workforces (including due to business failures), which would reduce our revenues, the number of covered lives in our PBM clients and/or the number of members our Health Care Benefits segment serves.
By causing our clients and customers and potential clients and customers, particularly those with the most employees or members, and state and local governments, to force us to compete more vigorously on factors such as price and service, including service, discount and other performance guarantees, to retain or obtain their business.
By causing customers and potential customers of our Health Care Benefits and Retail/LTC segments to purchase fewer products and/or products that generate less profit for us than the ones they currently purchase or otherwise would have purchased.
By causing customers and potential customers of our Health Care Benefits segment, particularly smaller employers and individuals, to forego obtaining or renewing their health and other coverage with us.
In our Health Care Benefits segment, by causing unanticipated increases and volatility in utilization of medical and other covered services, including COVID-19 related testing, vaccination and behavioral health services, by our medical members, changes in medical claim submission patterns and/or increases in medical unit costs and/or provider behavior, each of which would increase our costs and limit our ability to accurately detect, forecast, manage, reserve and price for our (and our self-insured customers’) medical cost trends and incurred and future health care and other benefits costs.
By increasing medical unit costs and causing changes in provider behavior in our Health Care Benefits segment as hospitals and other providers attempt to maintain revenue levels in their efforts to adjust to their own COVID-19-related and other economic challenges.
By weakening the ability or perceived ability of the issuers and/or guarantors of the debt or other securities we hold in our investment portfolio to perform on their obligations to us, which could result in defaults in those securities and has reduced, and may further reduce, the value of those securities and has created, and may continue to create, net realized capital losses for us that reduce our operating results.
By weakening the ability of our customers, including self-insured customers in our Health Care Benefits segment, medical providers and the other companies with which we do business as well as our medical members to perform their obligations to us or causing them not to perform those obligations, either of which could reduce our operating results.
By weakening the ability of our former subsidiaries and/or their purchasers to satisfy their lease obligations that we have guaranteed and causing the Company to be required to satisfy those obligations.
By weakening the financial condition of other insurers, including long-term care insurers and life insurers, which increases the risk that we will receive significant assessments for obligations of insolvent insurers to policyholders and claimants.
By causing, over time, inflation that could cause interest rates to increase and thereby increase our interest expense and reduce our operating results, as well as decrease the value of the debt securities we hold in our investment portfolio, which would reduce our operating results and/or adversely affect our financial condition.

Furthermore, reductions in workforce by our customers can cause unanticipated increases in the health care and other benefits costs of our Health Care Benefits segment. For example, our business associated with members who have elected to receive benefits under Consolidated Omnibus Budget Reconciliation Act (known as “COBRA”) typically has an MBR that is significantly higher than our overall Commercial MBR.

Each of our segments operates in a highly competitive and evolving business environment; and operating income in the industries in which we compete may decline.

Each of our segments, Health Care Benefits, Pharmacy Services, which includes our PBM business, and Retail/LTC, operates in a highly competitive and evolving business environment. Specifically:

As competition increases in the geographies in which we operate, including competition from new entrants, a significant increase in price compression and/or reimbursement pressures could occur, and this could require us to reevaluate our pricing structures to remain competitive.
In our Health Care Benefits segment we are seeking to substantially grow our Medicaid, dual eligible and dual eligible special needs plan membership over the next several years. In many instances, to acquire and retain our government
40


customers’ business, we must bid against our competitors in a highly competitive environment. Winning bids often are challenged successfully by unsuccessful bidders, and may also be withdrawn or cancelled by the issuing agency.
Customer contracts in our Health Care Benefits segment are generally for a period of one year, and our customers have considerable flexibility in moving between us and our competitors. One of the key factors on which we compete for customers, especially in uncertain economic environments, is overall cost. We are therefore under pressure to contain premium price increases despite being faced with increasing health care and other benefit costs and increasing operating costs. If we are unable to increase our prices to reflect, or otherwise mitigate the impact of, increasing costs, our profitability will be adversely affected. If we are unable to limit our price increases, we may lose members to competitors with more favorable pricing, adversely affecting our revenues and operating results. In response to rising prices, our customers may elect to self-insure or to reduce benefits in order to limit increases in their benefit costs. Alternatively, our customers may purchase different types of products from us that are less profitable. Such elections may result in reduced membership in our more profitable Insured products and/or lower premiums for our Insured products, which may adversely affect our revenues and operating results, although such elections also may reduce our health care and other benefit costs. In addition, our Medicare, Medicaid and CHIP products are subject to termination without cause, periodic re-bid, rate adjustment and program redesign, as customers seek to contain their benefit costs, particularly in an uncertain economy, and our exposure to this risk is increasing as we grow our Government products membership. These actions may adversely affect our membership, revenues and operating results.
We requested increases in our premium rates in our Commercial Health Care Benefits business for 2021 and expect to request increases in those rates for 2022 and beyond in order to adequately price for projected medical cost trends, required expansions of coverage and rating limits, and significant assessments, fees and taxes imposed by federal and state governments, including as a result of the ACA. Our rates also must be adequate to reflect the risk that our products will be selected by people with a higher risk profile or utilization rate than the pool of participants we anticipated when we established pricing for the applicable products (also known as “adverse selection”), particularly in small group Commercial products. These rate increases may be significant and thus heighten the risks of adverse publicity, adverse regulatory action and adverse selection and the likelihood that our requested premium rate increases will be denied, reduced or delayed, which could lead to operating margin compression.
The competitive success of our Pharmacy Services segment is dependent on our ability to establish and maintain contractual relationships with network pharmacies as PBM clients evaluate adopting narrow or restricted retail pharmacy networks.
The competitive success of our Retail/LTC segment and our specialty pharmacy operations is dependent on our ability to establish and maintain contractual relationships with PBMs and other payors on acceptable terms as the payors’ clients evaluate adopting narrow or restricted retail pharmacy networks.
In our PBM business, we maintain contractual relationships with brand name drug manufacturers that provide for purchase discounts and/or rebates on drugs dispensed by pharmacies in our retail network and by our specialty and mail order pharmacies (all or a portion of which may be passed on to clients). Manufacturer’s rebates often depend on a PBM’s ability to meet contractual requirements, including the placement of a manufacturer’s products on the PBM’s formularies. If we lose our relationship with one or more drug manufacturers, or if the discounts or rebates provided by drug manufacturers decline, our operating results, cash flows and/or prospects could be adversely affected.
The PBM industry has been experiencing price compression as a result of competitive pressures and increased client demands for lower prices, increased revenue sharing, including sharing in a larger portion of rebates received from drug manufacturers, enhanced service offerings and/or higher service levels. Marketplace dynamics and regulatory changes also have adversely affected our ability to offer plan sponsors pricing that includes the use of retail “differential” or “spread,” which could adversely affect our future profitability, and we expect these trends to continue.
Our retail pharmacy, specialty pharmacy and LTC pharmacy operations have been affected by reimbursement pressure caused by competition, including client demands for lower prices, generic drug pricing, earlier than expected generic drug introductions and network reimbursement pressure. If we are unable to increase our prices to reflect, or otherwise mitigate the impact of, increasing costs, our profitability will be adversely affected. If we are unable to limit our price increases, we may lose customers to competitors with more favorable pricing, adversely affecting our revenues and operating results.
A shift in the mix of our pharmacy prescription volume towards programs offering lower reimbursement rates as a result of competition or otherwise could adversely affect our margins, including the ongoing shift in pharmacy mix towards 90-day prescriptions at retail and the ongoing shift in pharmacy mix towards Medicare Part D prescriptions.
PBM client contracts often are for a period of approximately three years. However, PBM clients may require early or periodic re-negotiation of pricing prior to contract expiration. PBM clients are generally well informed, can move between us and our competitors and often seek competing bids prior to expiration of their contracts. We are therefore under pressure to contain price increases despite being faced with increasing drug costs and increasing operating costs. If we are unable to increase our prices to reflect, or otherwise mitigate the impact of, increasing costs, our profitability will be adversely
41


affected. If we are unable to limit our price increases, we may lose customers to competitors with more favorable pricing, adversely affecting our revenues and operating results.
The operating results and margins of our LTC business are further affected by the increased efforts of health care payors to negotiate reduced or capitated pricing arrangements and by the financial health of, and purchases and sales of, our LTC customers.

In addition, competitors in each of our businesses may offer services and pricing terms that we may not be willing or able to offer. Competition also may come from new entrants and other sources in the future. Unless we can demonstrate enhanced value to our clients through innovative product and service offerings in the rapidly changing health care industry, we may be unable to remain competitive.

Disruptive innovation by existing or new competitors could alter the competitive landscape in the future and require us to accurately identify and assess such alterations and make timely and effective changes to our strategies and business model to compete effectively. For example, decisions to buy our Health Care Benefits and Pharmacy Services products and services increasingly are made or influenced by consumers, either through direct purchasing (e.g., Medicare Advantage plans and PDPs) or through Public Exchanges and private health insurance exchanges that allow individual choice. Consumers also are increasingly seeking to access consumer goods and health care products and services locally and through other direct channels such as mobile devices and websites. To compete effectively in the consumer-driven marketplace, we will be required to develop or acquire new capabilities, attract new talent and develop new service and distribution relationships that respond to consumer needs and preferences.

Changes in marketplace dynamics or the actions of competitors or manufacturers, including industry consolidation, the emergence of new competitors and strategic alliances, and decisions to exclude us from new narrow or restricted retail pharmacy networks could materially and adversely affect our businesses, operating results, cash flows and/or prospects.

We can provide no assurance that we will be able to compete successfully on Public Exchanges or that our pricing or other actions will result in the profitability of our Public Exchange products.

In January 2022, we entered into the Public Exchanges in eight states. To compete effectively on Public Exchanges, we have developed or acquired the technology, systems, tools and talent necessary to interact with Public Exchanges and engage Public Exchange consumers through enhanced consumer-focused sales, marketing channels and customer interfaces. We have also created new customer service programs and product offerings. While participating on the Public Exchanges, we will have to respond to pricing and other actions taken by existing competitors and regulators as well as potentially disruptive new entrants, which could reduce our profit margins. Due to the price transparency provided by Public Exchanges, when we market products we face competitive pressures from existing and new competitors who may have lower cost structures. Our competitors may bring their Public Exchange and other consumer products to market more quickly, have greater experience marketing to consumers and/or may be targeting the higher margin portions of our business. We can provide no assurance that we will be able to compete successfully or profitably on Public Exchanges or that we will be able to benefit from any opportunities presented by Public Exchanges.

In addition, there can be no assurance that our pricing or other actions will result in the profitability of our Public Exchange products in 2022 or any future year. We have set 2022 premium rates for our Public Exchange products based on our projections, including as to the health status and quantity of membership and utilization of medical and/or other covered services by members. The accuracy of the projections reflected in our pricing may be impacted by (i) adverse selection among individuals who require or utilize more expensive medical and/or other covered services, (ii) other plans’ withdrawals from participation in the Public Exchanges we serve and (iii) legislation, regulations, enforcement activity and/or judicial decisions that cause Public Exchanges to operate in a manner different than what we projected in setting our premium rates.

A change in our Health Care Benefits product mix may adversely affect our profit margins.

Our Insured Health Care Benefits products that involve greater potential risk generally tend to be more profitable than our ASC products. Historically, smaller employer groups have been more likely to purchase Insured Health Care Benefits products because such purchasers are generally unable or unwilling to bear greater liability for health care expenditures, although over the last several years even relatively small employers have moved to ASC products. We also serve, and expect to grow our business with, government-sponsored programs, including Medicare and Medicaid, that are subject to competitive bids and have lower profit margins than our Commercial Insured Health Care Benefits products. A shift of enrollees from more profitable products to less profitable products could have a material adverse effect on the Health Care Benefits segment’s operating results.
42



Negative public perception of the industries in which we operate, or of our industries’ or our practices, can adversely affect our businesses, operating results, cash flows and prospects.

Our brand and reputation are two of our most important assets, and the industries in which we operate have been and are negatively perceived by the public from time to time. Negative publicity may come as a result of adverse media coverage, litigation against us and other industry participants, the ongoing public debates over drug pricing, PBMs, government involvement in drug pricing and purchasing, changes to the ACA, “surprise” medical bills, governmental hearings and/or investigations, actual or perceived shortfalls regarding our industries’ or our own products and/or business practices (including PBM operations, drug pricing and insurance coverage determinations) and social media and other media relations activities. Negative publicity also may come from a failure to meet customer expectations for consistent, high quality and accessible care. This risk may increase as we continue to offer products and services that make greater use of data and as our business model becomes more focused on delivering health care to consumers.

In addition, by working with the U.S. government in the distribution and administration of the COVID-19 vaccine, the Company may be subject to negative publicity related to the government’s actions in response to COVID-19 that are outside of the ability of the Company to control.

Negative public perception and/or publicity of our industries in general, or of us or our key vendors, brokers or product distribution networks in particular, can further increase our costs of doing business and adversely affect our operating results and our stock price by:

adversely affecting our brand and reputation;
adversely affecting our ability to market and sell our products and/or services and/or retain our existing customers and members;
requiring us to change our products and/or services;
reducing or restricting the revenue we can receive for our products and/or services; and/or
increasing or significantly changing the regulatory and legislative requirements with which we must comply.

We must maintain and improve our relationships with our retail and specialty pharmacy customers and increase the demand for our products and services, including proprietary brands.

The success of our businesses depends in part on customer loyalty, superior customer service and our ability to persuade customers to frequent our retail stores and online sites and to purchase products in additional categories and our proprietary brands. Failure to timely identify or effectively respond to changing consumer preferences and spending patterns, and evolving demographic mixes in the communities we serve, an inability to expand the products being purchased by our clients and customers, or the failure or inability to obtain or offer particular categories of products could adversely affect our relationship with our customers and clients and the demand for our products and services and could result in excess inventories of products.

We offer our retail customers proprietary brand products that are available exclusively at our retail stores and through our online retail sites. The sale of proprietary products subjects us to unique risks including potential product liability risks, mandatory or voluntary product recalls, potential supply chain and distribution chain disruptions for raw materials and finished products, our ability to successfully protect our intellectual property rights and the rights of applicable third parties, and other risks generally encountered by entities that source, market and sell private-label products. We also face similar risks for the other products we sell in our retail operations, including supply chain and distribution chain disruption risk. Any failure to adequately address some or all of these risks could have an adverse effect on our retail business, operating results, cash flows and/or financial condition. Additionally, an increase in the sales of our proprietary brands may adversely affect our sales of products owned by our suppliers and adversely impact certain of our supplier relationships. Our ability to locate qualified, economically stable suppliers who satisfy our requirements, and to acquire sufficient products in a timely and effective manner, is critical to ensuring, among other things, that customer confidence is not diminished. Any failure to develop sourcing relationships with a broad and deep supplier base could adversely affect our operating results and erode customer loyalty.

We also could be adversely affected if we fail to identify or effectively respond to changes in marketplace dynamics. For example, specialty pharmacy represents a significant and growing proportion of prescription drug spending in the U.S., a significant portion of which is dispensed outside of traditional retail pharmacies. Because our specialty pharmacy business focuses on complex and high-cost medications, many of which are made available by manufacturers to a limited number of pharmacies (so-called limited distribution drugs) that serve a relatively limited universe of patients, the future growth of our
43


specialty pharmacy business depends largely upon expanding our access to key drugs and penetration in certain treatment categories. Any contraction of our base of patients or reduction in demand for the prescriptions we currently dispense could have an adverse effect on our specialty pharmacy business, operating results and cash flows.

We face risks relating to the availability, pricing and safety profiles of prescription drugs that we purchase and sell.

The profitability of our Retail/LTC and Pharmacy Services segments is dependent upon the utilization of prescription drug products. We dispense significant volumes of brand name and generic drugs from our retail, LTC, specialty and mail order pharmacies, and the retail pharmacies in our PBM’s network also dispense significant volumes of brand name and generic drugs. Our revenues, operating results and cash flows may decline if physicians cease writing prescriptions for drugs or the utilization of drugs is reduced, including due to:

increased safety risk profiles or regulatory restrictions;
manufacturing or other supply issues;
a reduction in drug manufacturers’ participation in federal programs;
certain products being withdrawn by their manufacturers or transitioned to over-the-counter products;
future FDA rulings restricting the supply or increasing the cost of products;
the introduction of new and successful prescription drugs or lower-priced generic alternatives to existing brand name products; or
inflation in the price of drugs.

In addition, increased utilization of generic drugs (which normally yield a higher gross profit rate than equivalent brand name drugs) has resulted in pressure to decrease reimbursement payments to retail, mail order, specialty and LTC pharmacies for generic drugs, causing a reduction in our margins on sales of generic drugs. Consolidation within the generic drug manufacturing industry and other external factors may enhance the ability of manufacturers to sustain or increase pricing of generic drugs and diminish our ability to negotiate reduced generic drug acquisition costs. Any inability to offset increased brand name or generic prescription drug acquisition costs or to modify our activities to lessen the financial impact of such increased costs could have a significant adverse effect on our operating results.

The reserves we hold for expected claims in our Insured Health Care Benefits products are based on estimates that involve an extensive degree of judgment and are inherently variable. Any reserve, including a premium deficiency reserve, may be insufficient. If actual claims exceed our estimates, our operating results could be materially adversely affected, and our ability to take timely corrective actions to limit future costs may be limited.

A large portion of health care claims are not submitted to us until after the end of the quarter in which services are rendered by providers to our members. Our reported health care costs payable for any particular period reflect our estimates of the ultimate cost of such claims as well as claims that have been reported to us but not yet paid. We also must estimate the amount of rebates payable under the MLR rules of the ACA, CMS and the OPM and the amounts payable by us to, and receivable by us from, the United States federal government under the ACA’s remaining premium stabilization program.

Our estimates of health care costs payable are based on a number of factors, including those derived from historical claim experience, but this estimation process also makes use of extensive judgment. Considerable variability is inherent in such estimates, and the accuracy of the estimates is highly sensitive to changes in medical claims submission and processing patterns and/or procedures, turnover and other changes in membership, changes in product mix, changes in the utilization of medical and/or other covered services, including prescription drugs, changes in medical cost trends, changes in our medical management practices and the introduction of new benefits and products. We estimate health care costs payable periodically, and any resulting adjustments, including premium deficiency reserves, are reflected in current-period operating results within benefit costs. For example, as of December 31, 2021 and 2020, we established a premium deficiency reserve of $16 million and $11 million, respectively, related to Medicaid products in the Health Care Benefits segment. A worsening (or improvement) of health care cost trend rates or changes in claim payment patterns from those that we assumed in estimating health care costs payable as of December 31, 2021 would cause these estimates to change in the near term, and such a change could be material.

Furthermore, if we are not able to accurately and promptly anticipate and detect medical cost trends or accurately estimate the cost of incurred but not yet reported claims or reported claims that have not been paid, our ability to take timely corrective actions to limit future health care costs and reflect our current benefit cost experience in our pricing process may be limited, which would further exacerbate the extent of any adverse impact on our operating results. These risks are particularly acute during and following periods when utilization of medical and/or other covered services and/or medical cost trends are below
44


recent historical levels and in products where there is significant turnover in our membership each year, and such risks are further magnified by the ACA and other legislation and regulations that limit our ability to price for our projected and/or experienced increases in utilization and/or medical cost trends.

Our operating results are affected by the health of the economy in general and in the geographies we serve.

Our businesses are affected by the U.S. economy and consumer confidence in general and in the geographies we serve, including various economic factors, including inflation and changes in consumer purchasing power, preferences and/or spending patterns. An unfavorable, uncertain or volatile economic environment could cause a decline in drug utilization, an increase in health care utilization and dampen demand for PBM services as well as consumer demand for products sold in our retail stores.

If our customers’ operating and financial performance deteriorates, or they are unable to make scheduled payments or obtain adequate financing, our customers may not be able to pay timely, or may delay payment of, amounts owed to us. Any inability of our customers to pay us for our products and services may adversely affect our businesses, operating results and cash flows. In addition, both state and federal government sponsored payers, as a result of budget deficits or spending reductions, may suspend payments or seek to reduce their health care expenditures resulting in our customers delaying payments to us or renegotiating their contracts with us.

Further, economic conditions including interest rate fluctuations, changes in capital market conditions and regulatory changes may affect our ability to obtain necessary financing on acceptable terms, our ability to secure suitable store locations under acceptable terms, our ability to execute sale-leaseback transactions under acceptable terms and the value of our investment portfolio. Adverse changes in the U.S. economy, consumer confidence and economic conditions could have an adverse effect on our businesses and financial results. This adverse effect could be further exacerbated by the increasing prevalence of high deductible health plans and health plan designs favoring co-insurance over co-payments as members and other consumers may decide to postpone, or not to seek, medical treatment which may lead them to incur more expensive medical treatment in the future and/or decrease our prescription volumes.

In addition, our Health Care Benefits membership remains concentrated in certain U.S. geographies and in certain industries. Unfavorable changes in health care or other benefit costs or reimbursement rates or increased competition in those geographic areas where our membership is concentrated could therefore have a disproportionately adverse effect on our Health Care Benefits segment’s operating results. Our Health Care Benefits membership has been and may continue to be affected by workforce reductions by our customers due to adverse and/or uncertain general economic conditions, especially in the U.S. geographies and industries where our membership is concentrated. As a result, we may not be able to profitably grow and diversify our Health Care Benefits membership geographically, by product type or by customer industry, and our revenues and operating results may be disproportionately affected by adverse changes affecting our customers.

We are exposed to risks relating to the solvency of other insurers.

We are subject to assessments under guaranty fund laws existing in all states for obligations of insolvent insurance companies (including long-term care insurers), HMOs, ACA co-ops and other payors to policyholders and claimants. For example, in the first quarter of 2017, Aetna recorded a discounted estimated liability expense of $231 million pretax for our estimated share of future assessments for long-term care insurer Penn Treaty Network America Insurance Company and one of its subsidiaries. Guaranty funds are maintained by state insurance commissioners to protect policyholders and claimants in the event that an insurer, HMO, ACA co-op and/or other payor becomes insolvent or is unable to meet its financial obligations. These funds are usually financed by assessments against insurers regulated by a state. Future assessments may have an adverse effect on our operating results and cash flows.

Extreme events, or the threat of extreme events, could materially impact our businesses and health care (including behavioral health) costs.

Nuclear, biological or other attacks, or other acts of violence, including active shooter situations, whether as a result of war or terrorism or otherwise; other man-made disasters; natural disasters, such as hurricanes, tropical storms, floods, fires, earthquakes, tsunamis, cyclones, typhoons or extreme weather conditions such as major or extended winter storms, droughts and tornados, whether as a result of climate change or otherwise; epidemics; pandemics and other extreme events can affect the U.S. economy in general, our industries and us specifically. In particular, such extreme events or the threat of such extreme events could result in significant health care (including behavioral health) costs, which also would be affected by the government’s actions and the responsiveness of public health agencies and other insurers. Such extreme events or the threat of
45


such extreme events also could disrupt our supply chains and/or our distribution chains for the products we sell. In addition, our employees and those of our vendors are concentrated in certain large, metropolitan areas which may be particularly exposed to these events. Such events could adversely affect our businesses, operating results and cash flows, and, in the event of extreme circumstances, our financial condition or viability, particularly if our responses to such events are less adequate than those of our competitors.

We may be unable to achieve our environmental, social and governance goals.
We are dedicated to corporate social responsibility and sustainability and face pressures from our colleagues, customers, and stockholders to make significant advancements in environmental, social and governance matters. In part to address these concerns, we established certain goals as part of our ESG strategy. Achievement of our goals is subject to risks and uncertainties, many of which are outside of our control, and it is possible that we may fail to achieve these goals or that our colleagues, customers, or stockholders might not be satisfied with our efforts. These risks and uncertainties include, but are not limited to: our ability to execute our operational strategies and achieve our goals within the currently projected costs and the expected timeframes; the availability and cost of renewable energy and other materials; compliance with, and changes or additions to, global and regional regulations, taxes, charges, mandates or requirements relating to climate-related goals; labor-related regulations and requirements that restrict or prohibit our ability to impose requirements on third party contractors; the actions of competitors and competitive pressures; an acquisition of or merger with another company that has not adopted similar goals or whose progress towards reaching its goals is not as advanced as ours; and the pace of regional and global recovery from the COVID-19 pandemic. A failure to meet our goals could adversely affect public perception of our business, employee morale or customer or stockholder support.

Further, an increasing percentage of colleagues, customers, and stockholders considers sustainability factors in making employment, consumer health care and investment decisions. If we are unable to meet our goals, we may lose colleagues, and have difficulty recruiting new colleagues, investors, customers, or partners, our stock price may be negatively impacted, our reputation may be negatively affected, and it may be more difficult for us to compete effectively, all of which would have an adverse effect on our business, operating results, and financial condition.

Risks From Changes in Public Policy and Other Legal and Regulatory Risks

We are subject to potential changes in public policy, laws and regulations, including reform of the U.S. health care system, which can adversely affect our businesses. Entitlement program reform, if it occurs, could have a material adverse effect on our businesses, operations and/or operating results.

The political environment in which we operate remains uncertain. It is reasonably possible that our business operations and operating results could be materially adversely affected by legislative, regulatory and public policy changes at the federal or state level, increased government involvement in drug reimbursement, pricing, purchasing and/or importation and/or increased regulation of PBMs, including: changes to the regulatory environment for health care and related benefits, including Medicare, the ACA, and related Public Exchange regulations; changes to laws or regulations governing drug reimbursement and/or pricing; changes to the laws and regulations governing PBMs’, PDPs’ and/or Managed Medicaid organizations’ interactions with government funded health care programs; changes to laws and/or regulations governing drug manufacturers’ rebates; changes to laws and/or regulations governing reimbursements paid to pharmacists by and/or reporting required by PBMs; changes to immigration policies and/or other public policy initiatives. It is not possible to predict whether or when any such changes will occur or what form any such changes may take (including through the use of U.S. Presidential Executive Orders). Other significant changes to health care and related benefits system legislation or regulation as well as changes with respect to tax and trade policies, tariffs and other government regulations affecting trade between the United States and other countries also are possible and could adversely affect our businesses. If we fail to respond adequately to such changes, including by implementing strategic and operational initiatives, or do not respond as effectively as our competitors, our businesses, operations and operating results may be materially adversely affected.

Efforts to amend the ACA and related regulations are possible. It is also possible that federal and state governments will continue to enact and seriously consider many broad-based legislative and regulatory proposals that will or could materially impact various aspects of the health care and related benefits system and our businesses. Further changes to federal health care and related benefits laws, including the ACA, drug reimbursement and pricing laws, laws governing PBMs and/or laws governing PBMs’, PDPs’ and/or Managed Medicaid organizations’ interactions with government funded health care programs, are probable. We cannot predict the effect, if any, that new health care and related benefits legislation, future changes to the ACA or the implementation of or failure to implement the outstanding provisions of ACA, may have on our Health Care Benefits, Pharmacy Services and/or retail pharmacy, LTC pharmacy operations and/or operating results. The federal and many
46


state governments also are considering changes in the interpretation, enforcement and/or application of existing programs, laws and regulations, including changes to payments under and funding of Medicare and Medicaid programs and increased regulation of PBMs.

Further, changes in existing federal or state laws or regulations or the adoption of new laws or regulations relating to additional regulation of PBMs (including network restrictions, formulary management affiliate reimbursement, contractual guarantees and reconciliations, or other PBM services), drug pricing or purchasing, patent term extensions and/or purchase discount and/or rebate arrangements with drug manufacturers also could reduce the discounts or rebates we receive. Changes in existing federal or state laws or regulations or the adoption of new laws or regulations relating to claims processing and billing, including our ability to use MAC lists and collect transmission fees, also could adversely affect our profitability. For example, on October 29, 2020, the HHS released a final rule requiring health insurers to disclose drug pricing and cost-sharing information. The final rule requires group health plans and health insurance issuers in the individual and group markets to disclose cost-sharing information upon request, to a participant, beneficiary, or enrollee, which, unless otherwise indicated, for the purpose of the final rules includes an authorized representative, and requires plans and issuers to disclose in-network provider rates, historical out-of-network allowed amounts and the associated billed charges, and negotiated rates for prescription drugs. While the specific regulation requiring PBMs to disclose negotiated price concessions was paused under federal guidance released in August 2021, if it resurfaces, the regulation may result in drug manufacturers lowering discounts or rebates, resulting in higher drug costs for patients and impacting the ability of the Company to negotiate drug prices and provide competitive products and services to consumers.

In addition, in November 2020, the HHS released the Rebate Rule, which eliminates the regulatory safe harbor from prosecution under the AKS for rebates from pharmaceutical companies to PBMs in Medicare Part D and in Medicaid MCOs, replacing it with two far narrower safe harbors designed to directly benefit patients with high out-of-pocket costs and to change the way PBMs are compensated. The new safe harbors are (i) for rebates which are passed on to the patient at the point of sale and (ii) for flat service fee payments made to PBMs which cannot be tied to the list prices of drugs. The PCMA, which represents PBMs, has filed a suit in an effort to block the Rebate Rule, claiming that the Rebate Rule would lead to higher premiums in Medicare Part D and was adopted in an unlawful manner. It is unclear whether the Rebate Rule will be enforceable, whether pharmaceutical companies will respond by reducing list prices, whether list prices in the private market may also be reduced, and what the resulting impact will be to PBMs or the Company. The Bipartisan Infrastructure Act of 2021 delays the effective date of the rebate rule to January 2026, and pending Reconciliation legislation would fully repeal the Rebate Rule.

Additionally, the Consolidated Appropriations Act of 2021 was signed into law in December 2020 and contains transparency provisions requiring group health plans and health insurance issuers to report certain prescription drug costs, overall spending on health services and prescription drugs, and information about premiums and the impact of rebates and other remuneration on premiums and out-of-pocket costs to the Tri-Departments. No later than 18 months after the first submission and bi-annually thereafter, the Tri-Departments will release a public report on drug pricing trends, drug reimbursement, and the impact of drug prices on premiums. In August, the Tri-Departments deferred enforcement of both the December 2021 deadline for reporting 2020 plan year data and the June 2022 deadline for reporting 2021 plan year data to December 2022.

We cannot predict the enactment or content of new legislation or regulations or changes to existing laws or regulations or their enforcement, interpretation or application, or the effect they will have on our business operations or operating results, which could be materially adverse. Even if we could predict such matters, it is not possible to eliminate the adverse impact of public policy changes that would fundamentally change the dynamics of one or more of the industries in which we compete. Examples of such changes include: the federal or one or more state governments fundamentally restructuring or reducing the funding available for Medicare, Medicaid, dual eligible or dual eligible special needs plan programs, increasing its involvement in drug reimbursement, pricing, purchasing and/or importation, changing the laws and regulations governing PBMs’, PDPs’ and/or Managed Medicaid organizations’ interactions with government funded health care programs, changing the tax treatment of health or related benefits, or significantly altering the ACA. The likelihood of adverse changes remains high due to state and federal budgetary pressures, and our businesses and operating results could be materially and adversely affected by such changes, even if we correctly predict their occurrence.

For more information on these matters, see “Government Regulation” included in Item 1 of this 10-K.

If we fail to comply with applicable laws and regulations, many of which are highly complex, we could be subject to significant adverse regulatory actions, including monetary penalties, or suffer brand and reputational harm.

47


Our businesses are subject to extensive regulation and oversight by state, federal and international governmental authorities. The laws and regulations governing our operations and interpretations of those laws and regulations, including those related to human capital and climate change, are increasing in number and complexity, change frequently and can be inconsistent or conflict with one another. In general, these laws and regulations are designed to benefit and protect customers, members and providers rather than us or our investors. In addition, the governmental authorities that regulate our businesses have broad latitude to make, interpret and enforce the laws and regulations that govern us and continue to interpret and enforce those laws and regulations more strictly and more aggressively each year. We also must follow various restrictions on certain of our businesses and the payment of dividends by certain of our subsidiaries put in place by certain state regulators.

Certain of our Pharmacy Services and Retail/LTC operations, products and services are subject to:

the clinical quality, patient safety and other risks inherent in the dispensing, packaging and distribution of drugs and other health care products and services, including claims related to purported dispensing and other operational errors (any failure by our Pharmacy Services and/or Retail/LTC operations to adhere to the laws and regulations applicable to the dispensing of drugs could subject us to civil and criminal penalties);
federal and state anti-kickback and other laws that govern our relationship with drug manufacturers, customers and consumers;
compliance requirements under ERISA, including fiduciary obligations in connection with the development and implementation of items such as drug formularies and preferred drug listings; and
federal and state legislative proposals and/or regulatory activity that could adversely affect pharmacy benefit industry practices.

Our Health Care Benefits products are highly regulated, particularly those that serve Medicare, Medicaid, dual eligible, dual eligible special needs and small group Commercial customers and members. The laws and regulations governing participation in Medicare Advantage (including dual eligible special needs plans), Medicare Part D, Medicaid, and managed Medicaid plans are complex, are subject to interpretation and can expose us to penalties for non-compliance.

The scope of the practices and activities that are prohibited by federal and state false claims acts is the subject of pending litigation. Claims under federal and state false claims acts can be brought by the government or by private individuals on behalf of the government through a qui tam or “whistleblower” suit, and we are a defendant in a number of such proceedings. If we are convicted of fraud or other criminal conduct in the performance of a government program or if there is an adverse decision against us under the False Claims Act, we may be temporarily or permanently suspended from participating in government health care programs, including Medicare Advantage, Medicare Part D, Medicaid, dual eligible and dual eligible special needs plan programs, and we also may be required to pay significant fines and/or other monetary penalties. Whistleblower suits have resulted in significant settlements between governmental agencies and health care companies. The significant incentives and protections provided to whistleblowers under applicable law increase the risk of whistleblower suits.

If we fail to comply with laws and regulations that apply to government programs, we could be subject to criminal fines, civil penalties, premium refunds, prohibitions on marketing or active or passive enrollment of members, corrective actions, termination of our contracts or other sanctions which could have a material adverse effect on our ability to participate in Medicare Advantage, Medicare Part D, Medicaid, dual eligible, dual eligible special needs plan and other programs and on our operating results, cash flows and financial condition.

Our businesses, profitability and growth also may be adversely affected by (i) judicial and regulatory decisions that change and/or expand the interpretations of existing statutes and regulations, impose medical or bad faith liability, increase our responsibilities under ERISA or the remedies available under ERISA, or reduce the scope of ERISA pre-emption of state law claims or (ii) other legislation and regulations. For example, in December 2020, the U.S. Supreme Court upheld an Arkansas law that, among other things, mandates a particular pricing methodology, establishes an appeals process for a pharmacy when the reimbursement is below the pharmacy’s acquisition cost, permits a pharmacy to reverse and rebill if they cannot procure the drug from its wholesaler at a price equal to or less than the reimbursement rate, prohibits a PBM from reimbursing a pharmacy less than the amount it reimburses an affiliate on a per unit basis, and permits a pharmacy to decline to dispense if the reimbursement is lower than the pharmacy’s acquisition cost. Also, in November 2021, the U.S. Court of Appeals for the Eighth Circuit upheld a North Dakota law that regulates employer-sponsored ERISA health plans and certain PBM practices within Medicare.

If our compliance or other systems and processes fail or are deemed inadequate, we may suffer brand and reputational harm and become subject to regulatory actions and/or litigation.
48



In addition to being subject to extensive and complex regulations, many of our contracts with customers include detailed requirements. In order to be eligible to offer certain products or bid on certain contracts, we must demonstrate that we have robust systems and processes in place that are designed to maintain compliance with all applicable legal, regulatory and contractual requirements. These systems and processes frequently are reviewed and audited by our customers and regulators. If our systems and processes designed to maintain compliance with applicable legal and contractual requirements, and to prevent and detect instances of, or the potential for, non-compliance fail or are deemed inadequate, we may suffer brand and reputational harm and be subject to regulatory actions, litigation and other proceedings which may result in damages, fines, suspension or loss of licensure, suspension or exclusion from participation in government programs and/or other penalties, any of which could adversely affect our businesses, operating results, cash flows and/or financial condition.

We routinely are subject to litigation and other adverse legal proceedings, including class actions and qui tam actions. Many of these proceedings seek substantial damages which may not be covered by insurance. These proceedings are costly to defend, may result in changes in our business practices, harm our brand and reputation and adversely affect our businesses and operating results.

PBM, retail pharmacy, mail order pharmacy, specialty pharmacy, LTC pharmacy and health care and related benefits are highly regulated industries whose participants frequently are subject to litigation and other adverse legal proceedings. We are currently subject to various litigation and arbitration matters, investigations, regulatory audits, inspections, government inquiries, and regulatory and other legal proceedings, both inside and outside the U.S. Outside the U.S., contractual rights, tax positions and applicable regulations may be subject to interpretation or uncertainty to a greater degree than in the U.S. Litigation related to our provision of professional services in our medical clinics, pharmacies and LTC operations is increasing as we expand our services along the continuum of health care.

Litigation, and particularly securities, derivative, collective or class action and qui tam litigation, is often expensive and disruptive. Many of the legal proceedings against us seek substantial damages (including non-economic or punitive damages and treble damages), and certain of these proceedings also seek changes in our business practices. While we currently have insurance coverage for some potential liabilities, other potential liabilities may not be covered by insurance, insurers may dispute coverage and/or the amount of our insurance may not be enough to cover the damages awarded or costs incurred. In addition, some types of damages, like punitive damages, may not be covered by insurance, and in some jurisdictions the coverage of punitive damages is prohibited. Insurance coverage for all or some forms of liability also may become unavailable or prohibitively expensive in the future.

The outcome of litigation and other adverse legal proceedings is always uncertain, and outcomes that are not justifiable by the evidence or existing law or regulation can and do occur, and the costs incurred frequently are substantial regardless of the outcome. Litigation and other adverse legal proceedings could materially adversely affect our businesses, operating results and/or cash flows because of brand and reputational harm to us caused by such proceedings, the cost of defending such proceedings, the cost of settlement or judgments against us, or the changes in our operations that could result from such proceedings. See Item 3 of this 10-K for additional information.

We frequently are subject to regular and special governmental audits, investigations and reviews that could result in changes to our business practices and also could result in material refunds, fines, penalties, civil liabilities, criminal liabilities and other sanctions.

As one of the largest national retail, mail order, specialty and LTC pharmacy, PBM and health care and related benefits providers, we frequently are subject to regular and special governmental market conduct and other audits, investigations and reviews by, and we receive subpoenas and other requests for information from, various federal and state agencies, regulatory authorities, attorneys general, committees, subcommittees and members of the U.S. Congress and other state, federal and international governmental authorities. For example, we have received CIDs from, and provided documents and information to, the Civil Division of the DOJ in connection with a current investigation of our patient chart review processes in connection with risk adjustment data submissions under Parts C and D of the Medicare program. CMS and the OIG also are auditing the risk adjustment-related data of certain of our Medicare Advantage plans, and the number of such audits continues to increase. Several such audits, investigations and reviews by governmental authorities currently are pending, some of which may be resolved in 2022, the results of which may be adverse to us.

Federal and state governments have made investigating and prosecuting health care and other insurance fraud, waste and abuse a priority. Fraud, waste and abuse prohibitions encompass a wide range of activities, including kickbacks for referral of members, billing for unnecessary medical and/or other covered services, improper marketing and violations of patient privacy
49


rights. The regulations and contractual requirements applicable to us and other industry participants are complex and subject to change, making it necessary for us to invest significant resources in complying with our regulatory and contractual requirements. Ongoing vigorous law enforcement and the highly technical regulatory scheme mean that our compliance efforts in this area will continue to require significant resources. In addition, our medical costs and the medical expenses of our Health Care Benefits ASC customers may be adversely affected if we do not prevent or detect fraudulent activity by providers and/or members.

Regular and special governmental audits, investigations and reviews by federal, state and international regulators could result in changes to our business practices, and also could result in significant or material premium refunds, fines, penalties, civil liabilities, criminal liabilities or other sanctions, including suspension or exclusion from participation in government programs and suspension or loss of licensure. Any of these audits, investigations or reviews could have a material adverse effect on our businesses, operating results, cash flows and/or financial condition or result in significant liabilities and negative publicity for us.

See “Legal and Regulatory Proceedings” in Note 16 ‘‘Commitments and Contingencies’’ included in Item 8 of this 10-K for additional information.

Our litigation and regulatory risk profile are changing as we offer new products and services and expand in business areas beyond our historical core businesses of Health Care Benefits, Pharmacy Services and Retail/LTC.

Historically, we focused primarily on providing Health Care Benefits, Pharmacy Services and Retail/LTC products and services. As a result of our transformation program and other innovation initiatives, we are expanding our presence in the health care space and plan to offer new products and services (such as the home hemodialysis device we are developing) which present a different litigation and regulatory risk profile than the products and services that we historically have offered.

The increased volume of business in areas beyond our historical core businesses and new products and services subject us to litigation and regulatory risks that are different from the risks of providing Health Care Benefits, Pharmacy Services and Retail/LTC products and services and increase significantly our exposure to other risks.

We face unique regulatory and other challenges in our Medicare and Medicaid businesses.

We are seeking to substantially grow the Medicare and Medicaid membership in our Health Care Benefits segment in 2022 and over the next several years. We face unique regulatory and other challenges that may inhibit the growth and profitability of those businesses.

In January 2021, CMS issued its final notice detailing final 2022 Medicare Advantage benchmark payment rates. Final 2022 Medicare Advantage rates resulted in an increase in industry benchmark rates of approximately 4.1%. We cannot predict future Medicare funding levels, the impact of future federal budget actions or ensure that such changes or actions will not have an adverse effect on our Medicare operating results.
The organic expansion of our Medicare Advantage and Medicare Part D service area is subject to the ability of CMS to process our requests for service area expansions and our ability to build cost competitive provider networks in the expanded service areas that meet applicable network adequacy requirements. CMS’ decisions on our requests for service area expansions also may be affected adversely by compliance issues that arise each year in our Medicare operations.
CMS regularly audits our performance to determine our compliance with CMS’s regulations and our contracts with CMS and to assess the quality of the services we provide to our Medicare members. As a result of these audits, we may be subject to significant or material retroactive adjustments to and/or withholding of certain premiums and fees, fines, criminal liability, civil monetary penalties, CMS imposed sanctions (including suspension or exclusion from participation in government programs) or other restrictions on our Medicare, Medicaid and other businesses, including suspension or loss of licensure.
“Star ratings” from CMS for our Medicare Advantage plans will continue to have a significant effect on our plans’ operating results. Only Medicare Advantage plans with a star rating of four or higher (out of five) are eligible for a quality bonus in their basic premium rates. CMS continues to change its rating system to make achieving and maintaining a four or higher star rating more difficult. Our star ratings and past performance scores are adversely affected by the compliance issues that arise each year in our Medicare operations. If our star ratings fall below four for a significant portion of our Medicare Advantage membership or do not match the performance of our competitors or the star rating quality bonuses are reduced or eliminated, our revenues, operating results and cash flows may be significantly adversely affected.
50


Payments we receive from CMS for our Medicare Advantage and Medicare Part D businesses also are subject to risk adjustment based on the health status of the individuals we enroll. Elements of that risk adjustment mechanism continue to be challenged by the DOJ, the OIG and CMS itself. Substantial changes in the risk adjustment mechanism, including changes that result from enforcement or audit actions, could materially affect the amount of our Medicare reimbursement, require us to raise prices or reduce the benefits we offer to Medicare beneficiaries, and potentially limit our (and the industry’s) participation in the Medicare program.
Changes to the ability of PBMs to have pharmacy performance programs in place for clients and report payments via direct and indirect reporting mechanisms could impact the Pharmacy Services business.
Medicare Part D has resulted in increased utilization of prescription medications and puts pressure on our pharmacy gross margin rates due to regulatory and competitive pressures. Further, as a result of the ACA and changes to the retiree drug subsidy rules, clients of our PBM business could decide to discontinue providing prescription drug benefits to their Medicare-eligible members. To the extent this phenomenon occurs, the adverse effects of increasing customer migration into Medicare Part D may outweigh the benefits we realize from growth of our Medicare Part D products.
Our Medicare Part D operating results and our ability to expand our Medicare Part D business could be adversely affected if: the cost and complexity of Medicare Part D exceed management’s expectations or prevent effective program implementation or administration; changes to the regulations regarding how drug costs are reported for Medicare Part D are implemented in a manner that adversely affects the profitability of our Medicare Part D business; changes to the applicable regulations impact our ability to retain fees from third parties including network pharmacies; the government alters Medicare Part D program requirements or reduces funding because of the higher-than-anticipated cost to taxpayers of Medicare Part D or for other reasons; the government mandated use of point-of-sale manufacturer’s rebates effective in 2022 continues; the government enacts price controls on certain pharmaceutical products in Medicare Part D; the government makes changes to how pharmacy pay-for-performance is calculated; or reinsurance thresholds are reduced below their current levels.
We have experienced challenges in obtaining complete and accurate encounter data for our Medicaid products due to difficulties with providers and third-party vendors submitting claims in a timely fashion in the proper format, and with state agencies in coordinating such submissions. As states increase their reliance on encounter data, these difficulties could affect the Medicaid premium rates we receive and how Medicaid membership is assigned to us, which could have a material adverse effect on our Medicaid operating results and cash flows and/or our ability to bid for, and continue to participate in, certain Medicaid programs.
If we fail to report and correct errors discovered through our own auditing procedures or during a CMS audit or otherwise fail to comply with the applicable laws and regulations, we could be subject to fines, civil monetary penalties or other sanctions, including fines and penalties under the False Claims Act, which could have a material adverse effect on our ability to participate in Medicare Advantage, Medicare Part D or other government programs, and on our operating results, cash flows and financial condition.
Certain of our Medicaid contracts require the submission of complete and correct encounter data. The accurate and timely reporting of encounter data is increasingly important to the success of our Medicaid programs because more states are using encounter data to determine compliance with performance standards and, in part, to set premium rates. We have expended and may continue to expend additional effort and incur significant additional costs to collect accurate, or to correct inaccurate or incomplete, encounter data and have been and could be exposed to premium withholding, operating sanctions and financial fines and penalties for noncompliance. We have experienced challenges in obtaining complete and accurate encounter data due to difficulties with providers and third-party vendors submitting claims in a timely fashion in the proper format, and with state agencies in coordinating such submissions. As states increase their reliance on encounter data, these difficulties could affect the Medicaid premium rates we receive and how Medicaid membership is assigned to us, which could have a material adverse effect on our Medicaid operating results and cash flows and/or our ability to successfully bid for, and continue to participate in, certain Medicaid programs.

Programs funded in whole or in part by the U.S. federal government account for a significant portion of our revenues, and we expect that percentage to increase.

Programs funded in whole or in part by the U.S. federal government account for a significant portion of our revenues, and we expect that percentage to increase. As our government funded businesses grow, our exposure to changes in federal and state government policy with respect to and/or regulation of the various government funded programs in which we participate also increases.

The laws and regulations governing participation in Medicare Advantage (including dual eligible special needs plans), Medicare Part D, Medicaid, and managed Medicaid plans are complex, are subject to interpretation and can expose us to penalties for non-compliance. Federal, state and local governments have the right to cancel or not to renew their contracts with
51


us on short notice without cause or if funds are not available. Funding for these programs is dependent on many factors outside our control, including general economic conditions, continuing government efforts to contain health care costs and budgetary constraints at the federal or applicable state or local level and general political issues and priorities.

The U.S. federal government and our other government customers also may reduce funding for health care or other programs, cancel or decline to renew contracts with us, or make changes that adversely affect the number of persons eligible for certain programs, the services provided to enrollees in such programs, our premiums and our administrative and health care and other benefit costs, any of which could have a material adverse effect on our businesses, operating results and cash flows. When federal funding is delayed, suspended or curtailed, we continue to receive, and we remain liable for and are required to fund, claims from providers for providing services to beneficiaries of federally funded health benefits programs in which we participate. An extended federal government shutdown or a delay by Congress in raising the federal government’s debt ceiling also could lead to a delay, reduction, suspension or cancellation of federal government spending and a significant increase in interest rates that could, in turn, have a material adverse effect on the value of our investment portfolio, our ability to access the capital markets and our businesses, operating results, cash flows and liquidity.

Possible changes in industry pricing benchmarks and drug pricing generally can adversely affect our PBM and Retail/LTC businesses.

It is possible that the pharmaceutical industry, regulators, or federal policymakers may evaluate and/or develop an alternative pricing reference to replace AWP or WAC, which are the pricing references used for many of our PBM and LTC client contracts, drug purchase agreements, retail network contracts, specialty payor agreements and other contracts with third party payors in connection with the reimbursement of drug payments. In addition, many state Medicaid fee-for-service programs have established pharmacy network payments on the basis of Actual Acquisition Cost (“AAC”). The use of an AAC basis in fee for service Medicaid could have an impact on reimbursement practices in Health Care Benefits’ Commercial and other Government products. It is also possible that Congress may enact some limited form of price negotiation for Medicare. In addition, CMS also publishes the National Average Drug Acquisition Cost (“NADAC”) for certain drugs; NADAC pricing is being adopted in an increasing number of states.

Future changes to the use of AWP, WAC or to other published pricing benchmarks used to establish drug pricing, including changes in the basis for calculating reimbursement by federal and state health care programs and/or other payors, could impact the reimbursement we receive from Medicare and Medicaid programs, the reimbursement we receive from our PBM clients and other payors and/or our ability to negotiate rebates and/or discounts with drug manufacturers, wholesalers, PBMs and retail pharmacies. A failure or inability to fully offset any increased prices or costs or to modify our operations to mitigate the impact of such increases could have a material adverse effect on our operating results. Additionally, any future changes in drug prices could be significantly different than our projections. We cannot predict the effect of these possible changes on our businesses.

We may not be able to obtain adequate premium rate increases in our Insured Health Care Benefits products, which would have an adverse effect on our revenues, MBRs and operating results and could magnify the adverse impact of increases in health care and other benefit costs and of ACA assessments, fees and taxes.

Premium rates for our Insured Health Care Benefits products generally must be filed with state insurance regulators and are subject to their approval, which creates risk for us in the current political and regulatory environment. The ACA generally requires a review by HHS in conjunction with state regulators of premium rate increases that exceed a federally specified threshold (or lower state-specific thresholds set by states determined by HHS to have adequate processes). Rate reviews can magnify the adverse impact on our operating margins, MBRs and operating results of increases in health care and other benefit costs, increased utilization of covered services, and ACA assessments, fees and taxes, by restricting our ability to reflect these increases and/or these assessments, fees and taxes in our pricing. Further, our ability to reflect ACA assessments, fees and taxes in our Medicare, Medicaid and CHIP premium rates is limited.

Since 2013, HHS has issued determinations to health plans that their premium rate increases were “unreasonable,” and we continue to experience challenges to appropriate premium rate increases in certain states. Regulators or legislatures in several states have implemented or are considering limits on premium rate increases, either by enforcing existing legal requirements more stringently or proposing different regulatory standards. Regulators or legislatures in several states also have conducted hearings on proposed premium rate increases, which can result, and in some instances have resulted, in substantial delays in implementing proposed rate increases even if they ultimately are approved. Our plans can be excluded from participating in small group Public Exchanges if they are deemed to have a history of “unreasonable” rate increases. Any significant rate increases we may request heighten the risks of adverse publicity, adverse regulatory action and adverse selection and the
52


likelihood that our requested premium rate increases will be denied, reduced or delayed, which could adversely affect our MBRs and lead to operating margin compression.

We anticipate continued regulatory and legislative action to increase regulation of premium rates in our Insured Health Care Benefits products. We may not be able to obtain rates that are actuarially justified or that are sufficient to make our policies profitable in one or more product lines or geographies. If we are unable to obtain adequate premium rates and/or premium rate increases, it could materially and adversely affect our operating margins and MBRs and our ability to earn adequate returns on Insured Health Care Benefits products in one or more states or cause us to withdraw from certain geographies and/or products.

Minimum MLR rebate requirements limit the level of margin we can earn in our Insured Health Care Benefits products while leaving us exposed to higher than expected medical costs. Challenges to our minimum MLR rebate methodology and/or reports could adversely affect our operating results.

The ACA’s minimum MLR rebate requirements limit the level of margin we can earn in Health Care Benefits’ Commercial Insured and Medicare Insured businesses. CMS minimum MLR rebate regulations limit the level of margin we can earn in our Medicaid Insured business. Certain portions of our Health Care Benefits Medicaid and FEHB program business also are subject to minimum MLR rebate requirements in addition to but separate from those imposed by the ACA. Minimum MLR rebate requirements leave us exposed to medical costs that are higher than those reflected in our pricing. The process supporting the management and determination of the amount of MLR rebates payable is complex and requires judgment, and the minimum MLR reporting requirements are detailed. CMS has also proposed, but not yet finalized, a definition of “prescription drug price concessions” for commercial MLR calculation purposes, which would make additional PBM information available to plans and the HHS, potentially further complicating the MLR calculation process. Federal and state auditors are challenging our Commercial Health Care Benefits business’ compliance with the ACA’s minimum MLR requirements as well as our FEHB plans’ compliance with OPM’s FEHB program-specific minimum MLR requirements. Our Medicare and Medicaid contracts also are subject to minimum MLR audits. If a Medicare Advantage or Medicare Part D contract pays minimum MLR rebates for three consecutive years, it will become ineligible to enroll new members. If a Medicare Advantage or Medicare Part D contract pays such rebates for five consecutive years, it will be terminated by CMS. Additional challenges to our methodology and/or reports relating to minimum MLR and related rebates by federal and state regulators and private litigants are reasonably possible. The outcome of these audits and additional challenges could adversely affect our operating results.

Our operating results may be adversely affected by changes in laws and policies governing employers and by union organizing activity.

Congress and certain state legislatures continue to consider and pass legislation that increases our costs of doing business, including increased minimum wages and requiring employers to provide paid sick leave or paid family leave. In addition, our employee-related operating costs may be increased by union organizing activity and it is possible that the National Labor Relations Board may adopt regulatory changes through re-making or case law that could facilitate union organizing. If we are unable to reflect these increased expenses in our pricing or otherwise modify our operations to mitigate the effects of such increases, our operating results will be adversely affected.

We face international political, legal and compliance, operational, regulatory, economic and other risks that may be more significant than in our domestic operations.

Our international operations present political, legal, compliance, operational, regulatory, economic and other risks that we do not face or that are more significant than in our domestic operations. These risks vary widely by country and include varying regional and geopolitical business conditions and demands, government intervention and censorship, discriminatory regulation, climate change regulation, nationalization or expropriation of assets and pricing constraints. Our international products need to meet country-specific customer and member preferences as well as country-specific legal requirements, including those related to licensing, data privacy, data storage and data protection.

Our international operations increase our exposure to, and require us to devote significant management resources to implement controls and systems to comply with, the privacy and data protection laws of non-U.S. jurisdictions, such as the EU’s GDPR, and the anti-bribery, anti-corruption and anti-money laundering laws of the United States (including the FCPA) and the United Kingdom (including the UK Bribery Act) and similar laws in other jurisdictions. Implementing our compliance policies, internal controls and other systems upon our expansion into new countries and geographies may require the investment of considerable management time and financial and other resources over several years before any significant revenues or profits are generated. Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers or employees, restrictions or outright prohibitions on the conduct of our business, and significant brand and reputational harm. We
53


must regularly reassess the size, capability and location of our global infrastructure and make appropriate changes, and must have effective change management processes and internal controls in place to address changes in our businesses and operations. Our success depends, in part, on our ability to anticipate these risks and manage these difficulties, and the failure to do so could have a material adverse effect on our brand, reputation, businesses, operating results and/or financial condition.

Our international operations require us to overcome logistical and other challenges based on differing languages, cultures, legal and regulatory schemes and time zones. Our international operations encounter labor laws, standards and customs that can be difficult and make employee relationships less flexible than in our domestic operations and expensive to modify or terminate. In some countries we are required to, or choose to, operate with local business associates, which requires us to manage our relationships with these third parties and may reduce our operational flexibility and ability to quickly respond to business challenges.

In some countries we may be exposed to currency exchange controls or other restrictions that prevent us from transferring funds internationally or converting local currencies into U.S. dollars or other currencies. Fluctuations in foreign currency exchange rates may adversely affect our revenues, operating results and cash flows from our international operations. Some of our operations are, and are increasingly likely to be, in emerging markets where these risks are heightened. Any measures we may implement to reduce the effect of volatile currencies and other risks on our international operations may not be effective.

Risks Associated with Mergers, Acquisitions, and Divestitures

We may be unable to successfully integrate companies we acquire.

Upon the closing of any acquisition we complete, we will need to successfully integrate the products, services and related assets, as well as internal controls into our business operations. If an acquisition is consummated, the integration of the acquired business, its products, services and related assets into our company also may be complex and time-consuming and, if the integration is not fully successful, we may not achieve the anticipated benefits, operating and cost synergies and/or growth opportunities of an acquisition. Potential difficulties that may be encountered in the integration process include the following:

Integrating personnel, operations and systems (including internal control environments and compliance policies), while maintaining focus on producing and delivering consistent, high quality products and services;
Coordinating geographically dispersed organizations;
Disrupting management’s attention from our ongoing business operations;
Retaining existing customers and attracting new customers;
Managing inefficiencies associated with integrating our operations; and
Reconciling post-acquisition costs and liabilities between buyer and seller.

An inability to realize the full extent of the anticipated benefits, operating and cost synergies, innovations and operations efficiencies or growth opportunities of an acquisition, as well as any delays or additional expenses encountered in the integration process, could have a material adverse effect on our businesses and operating results. Furthermore, acquisitions, even if successfully integrated, may fail to further our business strategy as anticipated, expose us to increased competition or challenges with respect to our products, services or service areas, and expose us to additional liabilities associated with an acquired business including risks and liabilities associated with litigation involving the acquired business. Any one of these challenges or risks could impair our ability to realize any benefit from our acquisitions after we have expended resources on them.

We expect to continue to pursue acquisitions, joint ventures, strategic alliances and other inorganic growth opportunities, which may be unsuccessful, cause us to assume unanticipated liabilities, disrupt our existing businesses, be dilutive or lead us to assume significant debt, among other things.

We expect to continue to pursue acquisitions, joint ventures, strategic alliances and other inorganic growth opportunities as part of our growth strategy. In addition to the integration risks noted above, some other risks we face with respect to acquisitions and other inorganic growth strategies include:

we frequently compete with other firms, some of which may have greater financial and other resources and a greater tolerance for risk, to acquire attractive companies;
the acquired, alliance and/or joint venture businesses may not perform as projected;
54


the goodwill or other intangible assets established as a result of our acquisitions may be incorrectly valued or may become impaired;
we may assume unanticipated liabilities, including those that were not disclosed to us or which we underestimated;
the acquired businesses, or the pursuit of other inorganic growth strategies, could disrupt or compete with our existing businesses, distract management, result in the loss of key employees, divert resources, result in tax costs or inefficiencies and make it difficult to maintain our current business standards, controls, information technology systems, policies, procedures and performance;
we may finance future acquisitions and other inorganic growth strategies by issuing common stock for some or all of the purchase price, which would dilute the ownership interests of our stockholders;
we may incur significant debt in connection with acquisitions (whether to finance acquisitions or by assuming debt from the businesses we acquire);
we may not have the expertise to manage and profitably grow the businesses we acquire, and we may need to rely on the retention of key personnel and other suppliers of businesses we acquire, which may be difficult or impossible to accomplish;
we may enter into merger or purchase agreements but, due to reasons within or outside our control, fail to complete the related transactions, which could result in termination fees or other penalties that could be material, cause material disruptions to our businesses and operations and adversely affect our brand and reputation;
in order to complete a proposed acquisition, we may be required to divest certain portions of our business, for which we may not be able to obtain favorable pricing;
we may be involved in litigation related to mergers or acquisitions, including for matters that occurred prior to the applicable closing, which may be costly to defend and may result in adverse rulings against us that could be material; and
the integration into our businesses of the businesses and entities we acquire may affect the way in which existing laws and regulations apply to us, including subjecting us to laws and regulations that did not previously apply to us.

In addition, joint ventures present risks that are different from acquisitions, including selection of appropriate joint venture parties, initial and ongoing governance of the joint venture, joint venture compliance activities (including compliance with applicable CMS requirements), growing the joint venture’s business in a manner acceptable to all the parties, including other providers in the networks that include joint ventures, maintaining positive relationships among the joint venture parties and the joint venture’s customers, and member and business disruption that may occur upon joint venture termination.

Risks Related to Our Operations

Failure to meet customer expectations may harm our brand and reputation, our ability to retain and grow our customer base and membership and our operating results and cash flows.

Our ability to attract and retain customers and members is dependent upon providing cost effective, quality customer service operations (such as call center operations, PBM functions, retail pharmacy and LTC services, retail, mail order and specialty pharmacy prescription delivery, claims processing, customer case installation and online access and tools) that meet or exceed our customers’ and members’ expectations, either directly or through vendors. As we seek to reduce general and administrative expenses, we must balance the potential impact of cost-saving measures on our customers and other services and performances. If we misjudge the effects of such measures, customers and other services may be adversely affected. We depend on third parties for certain of our customer service, PBM and prescription delivery operations. If we or our vendors fail to provide service that meets our customers’ and members’ expectations, we may have difficulty retaining or profitably growing our customer base and/or membership, which could adversely affect our operating results. For example, noncompliance with any privacy or security laws or regulations or any security breach involving us or one of our third-party vendors could have a material adverse effect on our businesses, operating results, brand and reputation.

We and our vendors have experienced and continue to experience cyber attacks. We can provide no assurance that we or our vendors will be able to detect, prevent or contain the effects of such attacks or other information security (including cybersecurity) risks or threats in the future.

We and our vendors have experienced diverse cyber attacks and expect to continue to experience cyber attacks going forward. As examples, the Company and its vendors have experienced attempts to gain access to systems, denial of service attacks, attempted malware infections, account takeovers, scanning activity, and phishing emails. Attacks can originate from external criminals, terrorists, nation states, or internal actors. The Company is dedicating and will continue to dedicate significant resources and incur significant expenses to maintain and update on an ongoing basis the systems and processes that are
55


designed to mitigate the information security risks it faces and protect the security of its computer systems, software, networks and other technology assets against attempts by unauthorized parties to obtain access to confidential information, disrupt or degrade service, or cause other damage. The impact of cyber attacks has not been material to the Company’s operations or operating results through December 31, 2021. The Board and its Audit Committee and Nominating and Corporate Governance Committee are regularly informed regarding the Company’s information security policies, practices and status.

A compromise of our information security controls or of those businesses with whom we interact, which results in confidential information being accessed, obtained, damaged, or used by unauthorized or improper persons, could harm our reputation and expose us to regulatory actions and claims from customers and clients, financial institutions, payment card associations and other persons, any of which could adversely affect our businesses, operating results and financial condition. Because the techniques used to obtain unauthorized access, disable or degrade service, or sabotage systems change frequently and may not immediately produce signs of intrusion, we may be unable to anticipate these techniques or to implement adequate preventative measures. Moreover, a data security breach could require that we expend significant resources related to our information systems and infrastructure, and could distract management and other key personnel from performing their primary operational duties. We also could be adversely affected by any significant disruption in the systems of third parties we interact with, including key payors and vendors.

The costs of attempting to protect against the foregoing risks and the costs of responding to an information security incident are significant. Large scale data breaches at other entities increase the challenge we and our vendors face in maintaining the security of our information technology systems and proprietary information and of our customers’, members’ and other constituents’ sensitive information. Following an information security incident, our and/or our vendors’ remediation efforts may not be successful, and could result in interruptions, delays or cessation of service, and loss of existing or potential customers and members. In addition, breaches of our and/or our vendors’ security measures and the unauthorized access to or dissemination of sensitive personal information or proprietary information or confidential information about us, our customers, our members or other third-parties, could expose our customers’, members’ and other constituents’ private information and our customers, members and other constituents to the risk of financial or medical identity theft, or expose us or other third parties to a risk of loss or misuse of this information, and result in investigations, regulatory enforcement actions, material fines and penalties, loss of customers, litigation or other actions which could have a material adverse effect on our brand, reputation, businesses, operating results and cash flows.

Data governance failures can adversely affect our reputation, businesses and prospects. Our use and disclosure of members’, customers’ and other constituents’ sensitive information is subject to complex regulations at multiple levels. We would be adversely affected if we or our business associates or other vendors fail to adequately protect members’, customers’ or other constituents’ sensitive information.

Our information systems are critical to the operation of our businesses. We collect, process, maintain, retain, evaluate, utilize and distribute large amounts of personal health and financial information and other confidential and sensitive data about our customers, members and other constituents in the ordinary course of our businesses. Some of our information systems rely upon third party systems, including cloud service providers, to accomplish these tasks. The use and disclosure of such information is regulated at the federal, state and international levels, and these laws, rules and regulations are subject to change and increased enforcement activity, such as the California Consumer Privacy Act which went into effect January 1, 2020, the EU’s GDPR which began to apply across the EU during 2018 and the audit program implemented by HHS under HIPAA. In some cases, such laws, rules and regulations also apply to our vendors and/or may hold us liable for any violations by our vendors. International laws, rules and regulations governing the use and disclosure of such information are generally more stringent than U.S. laws and regulations, and they vary from jurisdiction to jurisdiction. Noncompliance with any privacy or security laws or regulations, or any security breach, information security incident, and any other incident involving the theft, misappropriation, loss or other unauthorized disclosure of, or access to, sensitive or confidential customer, member or other constituent information, whether by us, by one of our business associates or vendors or by another third party, could require us to expend significant resources to remediate any damage, could interrupt our operations and could adversely affect our brand and reputation, membership and operating results and also could expose and/or has exposed us to mandatory disclosure to the media, litigation (including class action litigation), governmental investigations and enforcement proceedings, material fines, penalties and/or remediation costs, and compensatory, special, punitive and statutory damages, consent orders, adverse actions against our licenses to do business and/or injunctive relief, any of which could adversely affect our businesses, operating results, cash flows or financial condition.

Our businesses depend on our customers’, members’ and other constituents’ willingness to entrust us with their health related and other sensitive personal information. Events that adversely affect that trust, including inadequate disclosure to our members or customers of our uses of their information, failing to keep our information technology systems and our customers’, members’
56


and other constituents’ sensitive information secure from significant attack, theft, damage, loss or unauthorized disclosure or access, whether as a result of our action or inaction (including human error) or that of our business associates, vendors or other third parties, could adversely affect our brand and reputation, membership and operating results and also could expose and/or has exposed us to mandatory disclosure to the media, litigation (including class action litigation), governmental investigations and enforcement proceedings, material fines, penalties and/or remediation costs, and compensatory, special, punitive and statutory damages, consent orders, adverse actions against our licenses to do business and/or injunctive relief, any of which could adversely affect our businesses, operating results, cash flows or financial condition. Large scale data breaches at other entities increase the challenge we and our vendors face in maintaining the security of our information technology systems and proprietary information and of our customers’, members’ and other constituents’ sensitive information. There can be no assurance that additional such failures will not occur, or if any do occur, that we will detect them or that they can be sufficiently remediated.

Product liability, product recall or personal injury issues could damage our reputation and have a significant adverse effect on our businesses, operating results, cash flows and/or financial condition.

The products that we sell could become subject to contamination, product tampering, mislabeling, recall or other damage. In addition, errors in the dispensing, packaging or administration of drugs or other products and consuming drugs in a manner that is not prescribed could lead to serious injury or death. Product liability or personal injury claims may be asserted against us with respect to any of the drugs or other products we sell or services we provide. For example, we are a defendant in hundreds of litigation proceedings relating to opioids and the sale of products containing talc. Our businesses involve the provision of professional services, including by pharmacists, physician assistants, nurses and nurse practitioners, which exposes us to professional liability claims. Should a product or other liability issue arise, the coverage available under our insurance programs and the indemnification amounts available to us from third parties may not be adequate to protect us against the financial impact of the related claims. We also may not be able to maintain our existing levels of insurance on acceptable terms in the future. A product liability or personal injury issue or judgment against us or a product recall, tampering, or mislabeling could damage our reputation and have a significant adverse effect on our businesses, operating results and/or financial condition.

We face significant competition in attracting and retaining talented employees. Further, managing succession for, and retention of, key executives is critical to our success, and our failure to do so could adversely affect our businesses, operating results and/or future performance.

Our ability to attract and retain qualified and experienced employees is essential to meet our current and future goals and objectives. There is no guarantee we will be able to attract and retain such employees or that competition among potential employers will not result in increased compensation and/or benefits costs. If we are unable to retain existing employees or attract additional employees, or we experience an unexpected loss of leadership, we could experience a material adverse effect on our businesses, operating results and/or future performance.

In addition, our failure to adequately plan for succession of senior management and other key management roles or the failure of key employees to successfully transition into new roles could have a material adverse effect on our businesses, operating results and/or future performance. The succession plans we have in place and our employment arrangements with certain key executives do not guarantee the services of these executives will continue to be available to us.

Sales of our products and services are dependent on our ability to attract and motivate internal sales personnel and independent third-party brokers, consultants and agents. New distribution channels create new disintermediation risk. We may be subject to penalties or other regulatory actions as a result of the marketing practices of brokers and agents selling our products.

Our products are sold primarily through our sales personnel, who frequently work with independent brokers, consultants and agents who assist in the production and servicing of business. The independent brokers, consultants and agents generally are not dedicated to us exclusively and may frequently recommend and/or market health care benefits products of our competitors. Accordingly, we must compete intensely for their services and allegiance. Our sales could be adversely affected if we are unable to attract, retain or motivate sales personnel and third-party brokers, consultants and agents, or if we do not adequately provide support, training and education to this sales network regarding our complex product portfolio, or if our sales strategy is not appropriately aligned across distribution channels. This risk is heightened as we develop, operate and expand our consumer-oriented products and services and we expand in the health care space and our business model evolves to include a greater focus on consumers and direct-to-consumer sales, such as competing for sales on Insurance Exchanges.

57


New distribution channels for our products and services continue to emerge, including Private Exchanges operated by health care consultants and technology companies. These channels may make it more difficult for us to directly engage consumers and other customers in the selection and management of their health care benefits, in health care utilization and in the effective navigation of the health care system. We also may be challenged by new technologies and marketplace entrants that could interfere with our existing relationships with customers and health plan members in these areas.

In addition, there have been several investigations regarding the marketing practices of brokers and agents selling health care and other insurance products and the payments they receive. These investigations have resulted in enforcement actions against companies in our industry and brokers and agents marketing and selling those companies’ products. For example, CMS and state departments of insurance have increased their scrutiny of the marketing practices of brokers and agents who market Medicare products. These investigations and enforcement actions could result in penalties and the imposition of corrective action plans and/or changes to industry practices, which could adversely affect our ability to market our products.

Failure of our businesses to effectively collaborate could prevent us from maximizing our operating results.

To maximize our overall enterprise value, our various businesses need to collaborate effectively. Our businesses need to be aligned in order to prioritize goals and coordinate the design of new products intended to utilize the offerings of multiple businesses, including our transformation and enterprise modernization programs. In addition, misaligned incentives, information siloes, ineffective product development and failure of our corporate governance policies or procedures, for example significant financial decisions being made at an inappropriate level in our organization, also could prevent us from maximizing our operating results and/or achieving our financial and other projections.

The failure or disruption of our information technology systems or the failure of our information technology infrastructure to support our businesses could adversely affect our reputation, businesses, operating results and cash flows.

Our information systems are subject to damage or interruption from power outages, facility damage, computer and telecommunications failures, computer viruses, security breaches (including credit card or personally identifiable information breaches), cyber attacks, vandalism, catastrophic events and human error. If our information systems are damaged, fail to work properly or otherwise become unavailable, we may incur substantial costs to repair or replace them, and may experience reputational damage, loss of critical information, customer disruption and interruptions or delays in our ability to perform essential functions and implement new and innovative services. In addition, compliance with changes in U.S. and foreign laws and regulations, including privacy and information security laws and standards, may cause us to incur significant expense due to increased investment in technology and the development of new operational processes.

Our business success and operating results depend in part on effective information technology systems and on continuing to develop and implement improvements in technology. Pursuing multiple initiatives simultaneously could make this continued development and implementation significantly more challenging.

Many aspects of our operations are dependent on our information systems and the information collected, processed, stored, and handled by these systems. We rely heavily on our computer systems to manage our ordering, pricing, point-of-sale, pharmacy fulfillment, inventory replenishment, claims processing, customer loyalty and subscription programs, finance and other processes. Throughout our operations, we collect, process, maintain, retain, evaluate, utilize and distribute large amounts of confidential and sensitive data and information, including personally identifiable information and protected health information, that our customers, members and other constituents provide to purchase products or services, enroll in programs or services, register on our websites, interact with our personnel, or otherwise communicate with us. In addition, for these operations, we depend in part on the secure transmission of confidential information over public networks.

We have many different information and other technology systems supporting our businesses (including as a result of our acquisitions). Our businesses depend in large part on these systems to adequately price our products and services; accurately establish reserves, process claims and report operating results; and interact with providers, employer plan sponsors, customers, members, consumers and vendors in an efficient and uninterrupted fashion. In addition, recent trends toward greater consumer engagement in health care require new and enhanced technologies, including more sophisticated applications for mobile devices. Certain of our technology systems (including software) are older, legacy systems that are less flexible, less efficient and require a significant ongoing commitment of capital and human resources to maintain, protect and enhance them and to integrate them with our other systems. We must re-engineer and reduce the number of these systems to meet changing consumer and vendor preferences and needs, improve our productivity and reduce our operating expenses. We also need to develop or acquire new technology systems, contract with new vendors or modify certain of our existing systems to support the consumer-oriented and transformation products and services we are developing, operating and expanding and/or to meet current
58


and developing industry and regulatory standards, including to keep pace with continuing changes in information processing technology and emerging cybersecurity risks and threats. If we fail to achieve these objectives, our ability to profitably grow our business and/or our operating results may be adversely affected.

In addition, information technology and other technology and process improvement projects, including our transformation and enterprise modernization programs, frequently are long-term in nature and may take longer to complete and cost more than we expect and may not deliver the benefits we project once they are complete. If we do not effectively and efficiently secure, manage, integrate and enhance our technology portfolio (including vendor sourced systems), we could, among other things, have problems determining health care and other benefit cost estimates and/or establishing appropriate pricing, meeting the needs of customers, consumers, providers, members and vendors, developing and expanding our consumer-oriented products and services or keeping pace with industry and regulatory standards, and our operating results may be adversely affected.

We are subject to payment-related risks that could increase our operating costs, expose us to fraud or theft, subject us to potential liability and disrupt our business operations.

We accept payments using a variety of methods, including cash, checks, credit cards, debit cards, gift cards, mobile payments and potentially other technologies in the future. Acceptance of these payment methods subjects us to rules, regulations, contractual obligations and compliance requirements, including payment network rules and operating guidelines, data security standards and certification requirements, and rules governing electronic funds transfers. These requirements may change in the future, which could make compliance more difficult or costly. For certain payment options, including credit and debit cards, we pay interchange and other fees, which could increase periodically thereby raising our operating costs. We rely on third parties to provide payment processing services, including the processing of credit cards, debit cards, and various other forms of electronic payment. If these vendors are unable to provide these services to us, or if their systems are compromised, our operations could be disrupted. The payment methods that we offer also expose us to potential fraud and theft by persons seeking to obtain unauthorized access to, or exploit any weaknesses in, the payment systems we use. If we fail to abide by applicable rules or requirements, or if data relating to our payment systems is compromised due to a breach or misuse, we may be responsible for any costs incurred by payment card issuing banks and other third parties or subject to fines and higher transaction fees. In addition, our reputation and ability to accept certain types of payments could each be harmed resulting in reduced sales and adverse effects on our operating results.

Both our and our vendors’ operations are subject to a variety of business continuity hazards and risks, any of which could interrupt our operations or otherwise adversely affect our performance and operating results.

We and our vendors are subject to business continuity hazards and other risks, including natural disasters, utility and other mechanical failures, acts of war or terrorism, acts of civil unrest, disruption of communications, data security and preservation, disruption of supply or distribution, safety regulation and labor difficulties. The occurrence of any of these or other events to us or our vendors might disrupt or shut down our operations or otherwise adversely affect our operations. We also may be subject to certain liability claims in the event of an injury or loss of life, or damage to property, resulting from such events. Although we have developed procedures for crisis management and disaster recovery and business continuity plans and maintain insurance policies that we believe are customary and adequate for our size and industry, our insurance policies include limits and exclusions and, as a result, our coverage may be insufficient to protect against all potential hazards and risks incident to our businesses. In addition, our crisis management and disaster recovery procedures and business continuity plans may not be effective. Should any such hazards or risks occur, or should our insurance coverage be inadequate or unavailable, our businesses, operating results, cash flows and financial condition could be adversely affected.

Financial Risks

We would be adversely affected if we do not effectively deploy our capital. Downgrades or potential downgrades in our credit ratings, should they occur, could adversely affect our brand and reputation, businesses, operating results, cash flows and financial condition.

Our operations generate significant capital, and we have the ability to raise additional capital. The manner in which we deploy our capital, including investments in our businesses, our operations (such as information technology and other strategic and capital projects), dividends, acquisitions, share and/or debt repurchases, repayment of debt, reinsurance or other capital uses, impacts our financial strength, claims paying ability and credit ratings issued by nationally-recognized statistical rating organizations. Credit ratings issued by nationally-recognized statistical rating organizations are broadly distributed and generally used throughout our industries. Our ratings reflect each rating organization’s opinion of our financial strength, operating performance and ability to meet our debt obligations or obligations to our insureds. We believe our credit ratings and
59


the financial strength and claims paying ability of our principal insurance and HMO subsidiaries are important factors in marketing our Health Care Benefits products to certain of our customers.

Each of the ratings organizations reviews our ratings periodically, and there can be no assurance that our current ratings will be maintained in the future. Downgrades in our ratings could adversely affect our businesses, operating results, cash flows and financial condition.

Goodwill and other intangible assets could, in the future, become impaired.

As of December 31, 2021 and December 31, 2020, we had $108.1 billion and $110.7 billion, respectively, of goodwill and other intangible assets. Goodwill and indefinite-lived intangible assets are subject to annual impairment reviews, or more frequent reviews if events or circumstances indicate that the carrying value may not be recoverable. When evaluating goodwill for potential impairment, we compare the fair value of our reporting units to their respective carrying amounts. We estimate the fair value of our reporting units using a combination of a discounted cash flow method and a market multiple method. If the carrying amount of a reporting unit exceeds its estimated fair value, a goodwill impairment loss is recognized in an amount equal to the excess to the extent of the goodwill balance. Indefinite-lived intangible assets are tested for impairment by comparing the estimated fair value of the asset to its carrying value. The Company estimates the fair value of its indefinite-lived trademarks using the relief from royalty method under the income approach. If the carrying value of the asset exceeds its estimated fair value, an impairment loss is recognized, and the asset is written down to its estimated fair value. Definite-lived intangible assets are tested for impairment whenever events or changes in circumstances indicate that the carrying value of such an asset may not be recoverable. If indicators of impairment are present, the Company first compares the carrying amount of the asset group to the estimated future cash flows associated with the asset group (undiscounted). If the estimated future cash flows used in this analysis are less than the carrying amount of the asset group, an impairment loss calculation is prepared. The impairment loss calculation compares the carrying amount of the asset group to the asset group’s estimated future cash flows (discounted).

Estimated fair values could change if, for example, there are changes in the business climate, industry-wide changes, changes in the competitive environment, adverse legal or regulatory actions or developments, changes in capital structure, cost of debt, interest rates, capital expenditure levels, operating cash flows or market capitalization. Because of the significance of our goodwill and intangible assets, any future impairment of these assets could require material noncash charges to our operating results, which also could have a material adverse effect on our financial condition.

Adverse conditions in the U.S. and global capital markets can significantly and adversely affect the value of our investments in debt and equity securities, mortgage loans, alternative investments and other investments, and our operating results and/or our financial condition.

The global capital markets, including credit markets, continue to experience volatility and uncertainty. As an insurer, we have a substantial investment portfolio that supports our policy liabilities and surplus and is comprised largely of debt securities of issuers located in the U.S. As a result, the income we earn from our investment portfolio is largely driven by the level of interest rates in the U.S., and to a lesser extent the international financial markets; and volatility, uncertainty and/or disruptions in the global capital markets, particularly the U.S. credit markets, and governments’ monetary policy, particularly U.S. monetary policy, can significantly and adversely affect the value of our investment portfolio, our operating results and/or our financial condition by:

significantly reducing the value and/or liquidity of the debt securities we hold in our investment portfolio and creating realized capital losses that reduce our operating results and/or unrealized capital losses that reduce our shareholders’ equity;
keeping interest rates low on high-quality short-term or medium-term debt securities (such as we have experienced during recent years) and thereby materially reducing our net investment income and operating results as the proceeds from securities in our investment portfolio that mature or are otherwise disposed of continue to be reinvested in lower yielding securities;
reducing the fair values of our investments if interest rates rise;
causing non-performance of or defaults on their obligations to us by third parties, including customers, issuers of securities in our investment portfolio, mortgage borrowers and/or reinsurance and/or derivatives counterparties;
making it more difficult to value certain of our investment securities, for example if trading becomes less frequent, which could lead to significant period-to-period changes in our estimates of the fair values of those securities and cause period-to-period volatility in our net income and shareholders’ equity;
60


reducing our ability to issue short-term debt securities at attractive interest rates, thereby increasing our interest expense and decreasing our operating results; and
reducing our ability to issue other securities.

Although we seek, within guidelines we deem appropriate, to match the duration of our assets and liabilities and to manage our credit and counterparty exposures, a failure adequately to do so could adversely affect our net income and our financial condition and, in extreme circumstances, our cash flows.

Risks Related to Our Relationships with Manufacturers, Providers, Suppliers and Vendors

We face risks relating to the market availability, pricing, suppliers and safety profiles of prescription drugs and other products that we purchase and sell.

Our Retail/LTC segment and our mail order and specialty pharmacy operations generate revenues in significant part by dispensing prescription drugs. Our PBM business generates revenues primarily by contracting with clients to provide prescription drugs and related health care services to plan members. As a result, we are dependent on our relationships with prescription drug manufacturers and suppliers. We acquire a substantial amount of our mail order and specialty pharmacies’ prescription drug supply from a limited number of suppliers. Certain of our agreements with such suppliers are short-term and cancelable by either party without cause. In addition, these agreements may allow the supplier to distribute through channels other than us. Certain of these agreements also allow pricing and other terms to be adjusted periodically for changing market conditions or required service levels. A termination or modification to any of these relationships could adversely affect our prescription drug supply and have a material adverse effect on our businesses, operating results and financial condition. Moreover, many products distributed by our pharmacies are manufactured with ingredients that are susceptible to supply shortages. In some cases, we depend upon a single source of supply. Any such supply shortages or loss of any such single source of supply could adversely affect our operating results and cash flows.

Much of the branded and generic drug product that we sell in our pharmacies, and much of the other merchandise we sell, is manufactured in whole or in substantial part outside of the United States. In most cases, the products or merchandise are imported by others and sold to us. As a result, significant changes in tax or trade policies, tariffs or trade relations between the United States and other countries, such as the imposition of unilateral tariffs on imported products, could result in significant increases in our costs, restrict our access to suppliers, depress economic activity, and have a material adverse effect on our businesses, operating results and cash flows. In addition, other countries may change their business and trade policies and such changes, as well as any negative sentiments towards the United States in response to increased import tariffs and other changes in U.S. trade regulations, could adversely affect our businesses.

Our suppliers are independent entities subject to their own operational and financial risks that are outside our control. If our current suppliers were to stop selling prescription drugs to us or delay delivery, including as a result of supply shortages, supplier production disruptions, supplier quality issues, closing or bankruptcies of our suppliers, or for other reasons, we may be unable to procure alternatives from other suppliers in a timely and efficient manner and on acceptable terms, or at all.

Our operating results may be adversely affected if we are unable to contract with providers on competitive terms and develop and maintain attractive networks with high quality providers.

We are seeking to enhance our health care provider networks by entering into joint ventures and other collaborative risk-sharing arrangements with providers. Providers’ willingness to enter these arrangements with us depends upon, among other things, our ability to provide them with up to date quality of care data to support these value-based contracts. These arrangements are designed to give providers incentives to engage in population health management and optimize delivery of health care to our members. These arrangements also may allow us to expand into new geographies, target new customer groups, increase membership and reduce medical costs and, if we provide technology or other services to the relevant health system or provider organization, may contribute to our revenue and earnings from alternative sources. If such arrangements do not result in the lower medical costs that we project or if we fail to attract providers to such arrangements, or are less successful at implementing such arrangements than our competitors, our medical costs may not be competitive and may be higher than we project, our attractiveness to customers may be reduced, we may lose or be unable to grow medical membership, and our ability to profitably grow our business and/or our operating results may be adversely affected.

While we believe joint ventures, accountable care organizations (“ACOs”) and other non-traditional health care provider organizational structures present opportunities for us, the implementation of our joint ventures and other non-traditional structure strategies may not achieve the intended results, which could adversely affect our operating results and cash flows.
61


Among other things, joint ventures require us to maintain collaborative relationships with our counterparties, continue to gain access to provider rates that make the joint ventures economically sustainable and devote significant management time to the operation and management of the joint ventures. We may not be able to achieve these objectives in one or more of our joint ventures, which could adversely affect our operating results and cash flows.

If our suppliers or service providers fail to meet their contractual obligations to us or to comply with applicable laws or regulations, we may be exposed to brand and reputational harm, litigation and/or regulatory action. This risk is particularly high in our Medicare, Medicaid, dual eligible and dual eligible special needs plan programs.

In addition to our suppliers, we contract with various third parties to perform certain functions and services and provide us with certain information technology systems. Our arrangements with suppliers and these third parties may expose us to public scrutiny, adversely affect our brand and reputation, expose us to litigation or regulatory action, and otherwise make our operations vulnerable if we fail to adequately oversee, monitor and regulate their performance or if they fail to meet their contractual obligations to us or to comply with applicable laws or regulations, including those related to human capital and climate change. For example, certain of our vendors have been responsible for releases of sensitive information of our members and employees, which has caused us to incur additional expenses and given rise to regulatory actions and litigation against us.

These risks are particularly high in our in Medicare Advantage (including dual eligible special needs plans), Medicare Part D, Medicaid, and managed Medicaid plans, where third parties may perform medical management and other member related services for us. Any failure of our or these third parties’ prevention, detection or control systems related to regulatory compliance, compliance with our internal policies, data security and/or cybersecurity or any incident involving the theft, misappropriation, loss or other unauthorized disclosure of, or access to, members’, customers’ or other constituents’ sensitive information could require us to expend significant resources to remediate any damage, interrupt our operations and adversely affect our brand and reputation and also expose us to whistleblower, class action and other litigation, other proceedings, prohibitions on marketing or active or passive enrollment of members, corrective actions, fines, sanctions and/or penalties, any of which could adversely affect our businesses, operating results, cash flows and/or financial condition.

We may experience increased medical and other benefit costs, litigation risk and customer and member dissatisfaction when providers that do not have contracts with us render services to our Health Care Benefits members.

Some providers that render services to our Health Care Benefits members do not have contracts with us. In those cases, we do not have a pre-established understanding with these providers as to the amount of compensation that is due to them for services rendered to our members. In some states, the amount of compensation due to these nonparticipating providers is defined by law or regulation, but in most instances it is either not defined or it is established by a standard that is not clearly translatable into dollar terms. In such instances providers may believe that they are underpaid for their services and may either litigate or arbitrate their dispute with us or try to recover the difference between what we have paid them and the amount they charged us from our members, which may result in customer and member dissatisfaction. For example, in October 2018, an arbitrator awarded certain claimant hospitals approximately $150 million in a proceeding relating to Aetna’s out-of-network benefit payment and administration practices, and in March 2019 that award was reduced to approximately $86 million. Such disputes may cause us to pay higher medical or other benefit costs than we projected.

Continuing consolidation and integration among providers and other suppliers may increase our medical and other covered benefits costs, make it difficult for us to compete in certain geographies and create new competitors.

Hospitals and other providers and health systems continue to consolidate across the health care industry. While this consolidation could increase efficiency and has the potential to improve the delivery of health care services, it also reduces competition and the number of potential contracting parties in certain geographies. These health systems also are increasingly forming and considering forming health plans to directly offer health insurance in competition with us, a process that has been accelerated by the ACA. In addition, ACOs (including Commercial and Medicaid-only ACOs developed as a result of state Medicaid laws), practice management companies, consolidation among and by integrated health systems and other changes in the organizational structures that physicians, hospitals and other providers adopt continues to change the way these providers interact with us and the competitive landscape in which we operate. These changes may increase our medical and other covered benefits costs, may affect the way we price our products and services and estimate our medical and other covered benefits costs and may require us to change our operations, including by withdrawing from certain geographies where we do not have a significant presence across our businesses or are unable to collaborate or contract with providers on acceptable terms. Each of these changes may adversely affect our businesses and operating results.
62


Item 1B. Unresolved Staff Comments.

There are no unresolved SEC Staff Comments.

Item 2. Properties.

The Company’s principal office is an owned building complex located in Woonsocket, Rhode Island, which totals approximately one million square feet. The Company also leases office space in other locations in the United States.

Health Care Benefits Segment

The Health Care Benefits segment’s principal office is an owned building complex located in Hartford, Connecticut, which totals approximately 1.7 million square feet. The Health Care Benefits segment also owns or leases office space in other locations in the United States and several other countries.

Pharmacy Services Segment

The Pharmacy Services segment includes owned or leased mail service dispensing pharmacies, call centers, on-site pharmacy stores, retail specialty pharmacy stores, specialty mail service pharmacies and branches for infusion and enteral services throughout the United States.

Retail/LTC Segment

As of December 31, 2021, the Retail/LTC segment operated the following properties:

Approximately 8,075 retail stores, of which approximately 5% were owned. Net selling space for retail stores was approximately 79.8 million square feet as of December 31, 2021.
Approximately 1,865 retail pharmacies within retail chains, as well as approximately 80 clinics in Target Corporation (“Target”) stores;
Owned distribution centers and leased distribution facilities throughout the United States totaling approximately 10.7 million square feet; and
Owned and leased LTC pharmacies throughout the United States and an owned LTC repackaging facility.

In connection with certain business dispositions completed between 1995 and 1997, the Company continues to guarantee lease obligations for 72 former stores. The Company is indemnified for these guarantee obligations by the respective initial purchasers. These guarantees generally remain in effect for the initial lease term and any extension thereof pursuant to a renewal option provided for in the lease prior to the time of the disposition. For additional information on these guarantees, see “Lease Guarantees” in Note 16 ‘‘Commitments and Contingencies’’ included in Item 8 of this 10-K.

Management believes that the Company’s owned and leased facilities are suitable and adequate to meet the Company’s anticipated needs. At the end of the existing lease terms, management believes the leases can be renewed or replaced by alternative space. For additional information on the right-of-use assets and lease liabilities associated with the Company’s leases, see Note 6 ‘‘Leases’’ included in Item 8 of this 10-K.

Item 3. Legal Proceedings.

The information contained in Note 16 ‘‘Commitments and Contingencies’’ included in Item 8 of this 10-K is incorporated herein by reference.

Item 4. Mine Safety Disclosures.

Not applicable.

63

Information about our Executive Officers

The following sets forth the name, age and biographical information for each of the Registrant’s executive officers as of February 9, 2022. In each case the officer’s term of office extends to the date of the meeting of the Board following the next annual meeting of stockholders of CVS Health Corporation. Previous positions and responsibilities held by each of the executive officers over the past five years or more are indicated below:

    Troyen A. Brennan, M.D., age 67, Executive Vice President and Chief Medical Officer of CVS Health Corporation since November 2008; Executive Vice President and Chief Medical Officer of Aetna Inc. from February 2006 through November 2008.

    James D. Clark, age 57, Senior Vice President - Controller and Chief Accounting Officer of CVS Health Corporation since November 2018; Vice President - Finance and Accounting of CVS Pharmacy, Inc. from September 2009 through October 2018.

    Daniel P. Finke, age 51, Executive Vice President of CVS Health Corporation and President of Health Care Benefits since February 2021; Executive Vice President, Commercial Business and Markets of Aetna Inc. from February 2020 through January 2021; Executive Vice President, Consumer Health and Service of Aetna Inc. from June 2018 through January 2020; Senior Vice President, Network and Clinical Services of Aetna Inc. from January 2016 through May 2018.

    Shawn M. Guertin, age 58, Executive Vice President and Chief Financial Officer of CVS Health Corporation since May 2021; Executive Vice President, Chief Financial Officer and Chief Enterprise Risk Officer of Aetna Inc. from February 2013 through May 2019; Senior Vice President, Finance of Aetna Inc. from April 2011 through January 2013.

    Laurie P. Havanec, age 61, Executive Vice President and Chief People Officer of CVS Health Corporation since February 2021; Executive Vice President and Chief People Officer, Otis Worldwide Corporation, an elevator, escalator and moving walkway manufacturer, from October 2019 through January 2021; Corporate Vice President, Talent of United Technologies Corporation, a multinational manufacturing conglomerate, from April 2017 through October 2019; Vice President - Human Resources, Institution Businesses of Aetna Inc. from 2013 through March 2017.

    Alan M. Lotvin, M.D., age 60, Executive Vice President of CVS Health Corporation and President of CVS Caremark since March 2020; Executive Vice President - Transformation of CVS Health Corporation from June 2018 through February 2020; Executive Vice President - Specialty Pharmacy, CVS Caremark from November 2012 through May 2018.

    Karen S. Lynch, age 59, President and Chief Executive Officer of CVS Health Corporation since February 2021; Executive Vice President of CVS Health Corporation from November 2018 through January 2021; President of Aetna Inc. from January 2015 through January 2021; and a director of CVS Health Corporation since February 2021. Ms. Lynch is also a member of the board of directors of U.S. Bancorp, a banking and financial services company.

    Thomas M. Moriarty, age 58, Executive Vice President and General Counsel of CVS Health Corporation since October 2012; Chief Policy and External Affairs Officer since March 2017; Chief Strategy Officer from March 2014 through February 2017.

    Michelle A. Peluso, age 49, Executive Vice President and Chief Customer Officer of CVS Health Corporation since January 2021 and Co-President of Retail since January 2022; Senior Vice President, Digital Sales and Chief Marketing Officer, IBM, a multinational technology corporation, from February 2016 through January 2021; Chief Executive Officer, Gilt Groupe, Inc., an online shopping destination, from 2013 through February 2016. Ms. Peluso is also a member of the board of directors of Nike, Inc., an athletic footwear and clothing manufacturer.

    Jonathan C. Roberts, age 66, Executive Vice President and Chief Operating Officer of CVS Health Corporation since March 2017; Executive Vice President of CVS Health Corporation and President of CVS Caremark from September 2012 through February 2017.

    Prem Shah, age 42, Executive Vice President and Chief Pharmacy Officer of CVS Health Corporation since November 2021 and Co-President of Retail since January 2022; Executive Vice President, Specialty and Product Innovation , CVS Caremark from August 2018 through November 2021; Vice President - Specialty Pharmacy, CVS Caremark from February 2013 through July 2018.
64

PART II

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

Market Information

CVS Health Corporation’s common stock is listed on the New York Stock Exchange under the symbol “CVS.”

Dividends

During 2021, 2020 and 2019, the quarterly cash dividend was $0.50 per share. In December 2021, the Board authorized a 10% increase in the quarterly cash dividend to $0.55 per share effective in 2022. CVS Health Corporation has paid cash dividends every quarter since becoming a public company. Future dividends will depend on the Company’s earnings, capital requirements, financial condition and other factors considered relevant by the Board.

See Note 12 ‘‘Shareholders’ Equity’’ included in Item 8 of this 10-K for information regarding CVS Health Corporation’s dividends.

Holders of Common Stock

As of February 2, 2022, there were 24,946 registered holders of the registrant’s common stock according to the records maintained by the registrant’s transfer agent.

Issuer Purchases of Equity Securities

The following share repurchase programs have been authorized by the Board:
In billions
Authorization Date
AuthorizedRemaining as of
December 31, 2021
December 9, 2021 (“2021 Repurchase Program”)$10.0 $10.0 
November 2, 2016 (“2016 Repurchase Program”)15.0 — 

Each of the share Repurchase Programs was effective immediately. The 2016 Repurchase program was terminated effective December 9, 2021. The 2021 Repurchase Program permits the Company to effect repurchases from time to time through a combination of open market repurchases, privately negotiated transactions, accelerated share repurchase (“ASR”) transactions, and/or other derivative transactions. The 2021 Repurchase Program can be modified or terminated by the Board at any time. During the three months ended December 31, 2021, the Company did not repurchase any shares of common stock.

Pursuant to the authorization under the 2021 Repurchase Program, the Company entered into a $1.5 billion fixed dollar ASR with Barclays Bank PLC (“Barclays”). Upon payment of the $1.5 billion purchase price on January 4, 2022, the Company received a number of shares of CVS Health Corporation’s common stock equal to 80% of the $1.5 billion notional amount of the ASR or approximately 11.6 million shares at a price of $103.34 per share, which were placed into treasury stock in January 2022. At the conclusion of the ASR, the Company may receive additional shares equal to the remaining 20% of the $1.5 billion notional amount. The ultimate number of shares the Company may receive will depend on the daily volume-weighted average price of the Company’s stock over an averaging period, less a discount. It is also possible, depending on such weighted average price, that the Company will have an obligation to Barclays which, at the Company’s option, could be settled in additional cash or by issuing shares. Under the terms of the ASR, the maximum number of shares that could be delivered to the Company is 29.0 million.

See Note 12 ‘‘Shareholders’ Equity’’ included in Item 8 of this 10-K for additional information regarding the Company’s share repurchases.

65

Stock Performance Graph

The following graph compares the cumulative total shareholder return on CVS Health Corporation’s common stock (assuming reinvestment of dividends) with the cumulative total return on the S&P 500 Index, the S&P 500 Food and Staples Retailing Industry Group Index and the S&P 500 Healthcare Sector Group Index from December 31, 2016 through December 31, 2021. The graph assumes a $100 investment in shares of CVS Health Corporation’s common stock on December 31, 2016.
cvs-20211231_g2.jpg
December 31,
201620172018201920202021
CVS Health Corporation$100 $94 $88 $103 $97 $151 
S&P 500 (1)
100 122 116 153 181 233 
S&P 500 Food & Staples Retailing Group Index (2)
100 113 115 146 170 213 
S&P 500 Health Care Group Index (1) (3)
100 122 130 157 178 225 
_____________________________________________
(1)Includes CVS Health Corporation.
(2)Includes five companies (COST, KR, SYY, WBA, WMT).
(3)Includes 64 companies.

The year-ended values of each investment shown in the preceding graph are based on share price appreciation plus dividends, with the dividends reinvested as of the last business day of the month during which such dividends were ex-dividend. The calculations exclude trading commissions and taxes. Total shareholder returns from each investment can be calculated from the year-end investment values shown beneath the graph.

Item 6. Reserved

Not applicable.
66

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations. (“MD&A”)

The following discussion and analysis should be read in conjunction with the audited consolidated financial statements and related notes included in Item 8 of this Annual Report on Form 10-K (this “10-K”), “Risk Factors” included in Item 1A of this 10-K and the “Cautionary Statement Concerning Forward-Looking Statements” in this 10-K.

Overview of Business

CVS Health Corporation, together with its subsidiaries (collectively, “CVS Health,” the “Company,” “we,” “our” or “us”), is a diversified health solutions company united around a common purpose of helping people on their path to better health. In an increasingly connected and digital world, we are meeting people wherever they are and changing health care to meet their needs. The Company has more than 9,900 retail locations, nearly 1,200 walk-in medical clinics, a leading pharmacy benefits manager with approximately 110 million plan members with expanding specialty pharmacy solutions and a dedicated senior pharmacy care business serving more than one million patients per year. The Company also serves an estimated 35 million people through traditional, voluntary and consumer-directed health insurance products and related services, including expanding Medicare Advantage offerings and a leading standalone Medicare Part D prescription drug plan (“PDP”). The Company believes its innovative health care model increases access to quality care, delivers better health outcomes and lowers overall health care costs.

The Company has four reportable segments: Health Care Benefits, Pharmacy Services, Retail/LTC and Corporate/Other, which are described below.

Overview of the Health Care Benefits Segment

The Health Care Benefits segment operates as one of the nation’s leading diversified health care benefits providers. The Health Care Benefits segment has the information and resources to help members, in consultation with their health care professionals, make more informed decisions about their health care. The Health Care Benefits segment offers a broad range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, medical management capabilities, Medicare Advantage and Medicare Supplement plans, PDPs, Medicaid health care management services, and health information technology products and services. The Health Care Benefits segment also provided workers’ compensation administrative services through its Coventry Health Care Workers’ Compensation business (“Workers’ Compensation business”) prior to the sale of this business on July 31, 2020. The Health Care Benefits segment’s customers include employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers (“providers”), governmental units, government-sponsored plans, labor groups and expatriates. The Company refers to insurance products (where it assumes all or a majority of the risk for medical and dental care costs) as “Insured” and administrative services contract products (where the plan sponsor assumes all or a majority of the risk for medical and dental care costs) as “ASC.” In addition, effective January 2022, the Company entered the individual public health insurance exchanges (“Public Exchanges”) in eight states through which it sells Insured plans directly to individual consumers.

Overview of the Pharmacy Services Segment

The Pharmacy Services segment provides a full range of pharmacy benefit management (“PBM”) solutions, including plan design offerings and administration, formulary management, retail pharmacy network management services and mail order pharmacy. In addition, through the Pharmacy Services segment, the Company provides specialty pharmacy and infusion services, clinical services, disease management services, medical spend management and pharmacy and/or other administrative services for providers and federal 340B drug pricing program covered entities (“Covered Entities”). The Pharmacy Services segment’s clients are primarily employers, insurance companies, unions, government employee groups, health plans, PDPs, Medicaid managed care plans, plans offered on Public Exchanges and private health insurance exchanges, other sponsors of health benefit plans throughout the United States and Covered Entities. The Pharmacy Services segment operates retail specialty pharmacy stores, specialty mail order pharmacies, mail order dispensing pharmacies, compounding pharmacies and branches for infusion and enteral nutrition services.

Overview of the Retail/LTC Segment

The Retail/LTC segment sells prescription drugs and a wide assortment of health and wellness products and general merchandise, provides health care services through its MinuteClinic® walk-in medical clinics, provides medical diagnostic testing, administers vaccinations for illnesses such as influenza, coronavirus disease 2019 (“COVID-19”) and shingles and conducts long-term care pharmacy (“LTC”) operations, which distribute prescription drugs and provide related pharmacy
67


consulting and other ancillary services to long-term care facilities and other care settings. As of December 31, 2021, the Retail/LTC segment operated more than 9,900 retail locations, nearly 1,200 MinuteClinic locations as well as online retail pharmacy websites, LTC pharmacies and onsite pharmacies. For the year ended December 31, 2021, the Company dispensed approximately 26.4% of the total retail pharmacy prescriptions in the United States.

Overview of the Corporate/Other Segment

The Company presents the remainder of its financial results in the Corporate/Other segment, which primarily consists of:

Management and administrative expenses to support the Company’s overall operations, which include certain aspects of executive management and the corporate relations, legal, compliance, human resources, information technology and finance departments, expenses associated with the Company’s investments in its transformation and enterprise modernization programs and acquisition-related integration costs; and
Products for which the Company no longer solicits or accepts new customers such as large case pensions and long-term care insurance products.
68


COVID-19

The COVID-19 pandemic and its emerging new variants continue to impact the U.S. and other countries around the world. Our strong local presence and scale in communities across the country has enabled us to continue to play an indispensable role in the national response to COVID-19, as well as provide seamless support for our customers wherever they need us: in our CVS locations, in their homes, and virtually. The COVID-19 pandemic had a significant impact on the Company’s operating results for the years ended December 31, 2021 and 2020, primarily in the Company’s Health Care Benefits and Retail/LTC segments.

Health Care Benefits Segment

Beginning in mid-March 2020, the health system experienced a significant reduction in utilization of medical services (“utilization”) that is discretionary and the cancellation of elective medical procedures. Utilization remained below historical levels through April 2020, began to recover in May and June 2020 and reached more normal levels in the third and fourth quarters of 2020, with select geographies impacted by COVID-19 waves. In response to COVID-19, the Company provided expanded benefit coverage to its members, including cost-sharing waivers for COVID-19 related treatments, as well as assistance to members through premium credits, telehealth cost-sharing waivers and other investments. During 2020, COVID-19 also resulted in a shift in the Company’s medical membership. The Company experienced declines in Commercial membership due to reductions in workforce at our existing customers, substantially offset by increases in Medicaid membership primarily as a result of the suspension of eligibility redeterminations and increased unemployment.

During the year ended December 31, 2021, overall medical costs in the first quarter were generally consistent with historical baseline levels in the aggregate, however the segment experienced increased COVID-19 testing and treatment costs and lower Medicare risk-adjusted revenue. During the second quarter, COVID-19 testing and treatment costs persisted, however at levels significantly lower than those observed during the first quarter. Beginning in the third quarter of 2021, medical costs once again increased primarily driven by the spread of emerging new variants of COVID-19, which resulted in increased testing and treatment costs throughout the remainder of the year.

Retail/LTC Segment

During March 2020, the Company experienced increased prescription volume due to the greater use of 90-day prescriptions and early refills of maintenance medications, as well as increased front store volume as consumers prepared for the COVID-19 pandemic. Beginning in the second quarter and continuing throughout the remainder of the year, the Company experienced reduced customer traffic in its retail pharmacies and MinuteClinic locations due to shelter-in-place orders as well as reduced new therapy prescriptions and decreased long-term care prescription volume as a result of the COVID-19 pandemic. In addition, the Company incurred incremental operating expenses associated with the Company’s COVID-19 pandemic response efforts and waived fees associated with prescription home delivery and associated front store products. During 2020, the Company also played a key role in supporting the local communities in which it operates through the administration of diagnostic testing at its CVS Pharmacy® locations, as well as in long-term care facilities, at community-based testing sites in underserved areas and through its Return ReadySM solution. The Company also began administering COVID-19 vaccinations in long-term care facilities during December 2020.

During the first quarter of 2021, the Company experienced reduced customer traffic in its retail pharmacies, which reflected the impact of a weak cough, cold and flu season, while it administered the highest quarterly volume of COVID-19 diagnostic tests. The Company began administering COVID-19 vaccines in its retail pharmacies during February 2021. During the second quarter, the segment generated earnings from COVID-19 vaccines and saw improved customer traffic as vaccinated customers began more actively shopping in CVS locations. During the third and fourth quarters, emerging new variants drove the continued administration of COVID-19 vaccinations (including boosters) and diagnostic testing, while the segment also generated earnings from the sale of over-the-counter (“OTC”) test kits in the front store. During the year ended December 31, 2021, the Company administered more than 32 million COVID-19 tests and more than 59 million COVID-19 vaccines and sold more than 22 million OTC test kits.

The COVID-19 pandemic continues to evolve. We believe COVID-19’s impact on our businesses, operating results, cash flows and/or financial condition primarily will be driven by the geographies impacted and the severity and duration of the pandemic; the pandemic’s impact on the U.S. and global economies and consumer behavior and health care utilization patterns; and the timing, scope and impact of stimulus legislation as well as other federal, state and local governmental responses to the pandemic. Those primary drivers are beyond our knowledge and control. As a result, the impact COVID-19 will have on our businesses, operating results, cash flows and/or financial condition is uncertain, but the impact could be adverse and material.

69


Results of Operations

The following information summarizes the Company’s results of operations for 2021 compared to 2020. For discussion of the Company’s results of operations for 2020 compared to 2019, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 filed with the U.S. Securities and Exchange Commission (the “SEC”) on February 16, 2021.

Summary of Consolidated Financial Results
Change
Year Ended December 31, 2021 vs. 20202020 vs. 2019
In millions202120202019$%$%
Revenues:
Products$203,738 $190,688 $185,236 $13,050 6.8 %$5,452 2.9 %
Premiums76,132 69,364 63,122 6,768 9.8 %6,242 9.9 %
Services11,042 7,856 7,407 3,186 40.6 %449 6.1 %
Net investment income1,199 798 1,011 401 50.3 %(213)(21.1)%
Total revenues292,111 268,706 256,776 23,405 8.7 %11,930 4.6 %
Operating costs:
Cost of products sold175,803 163,981 158,719 11,822 7.2 %5,262 3.3 %
Benefit costs64,260 55,679 52,529 8,581 15.4 %3,150 6.0 %
Store impairments 1,358 — 231 1,358 100.0 %(231)(100.0)%
Goodwill impairment431 — — 431 100.0 %— — %
Operating expenses37,066 35,135 33,310 1,931 5.5 %1,825 5.5 %
Total operating costs278,918 254,795 244,789 24,123 9.5 %10,006 4.1 %
Operating income13,193 13,911 11,987 (718)(5.2)%1,924 16.1 %
Interest expense2,503 2,907 3,035 (404)(13.9)%(128)(4.2)%
Loss on early extinguishment of debt452 1,440 79 (988)(68.6)%1,361 1,722.8 %
Other income(182)(206)(124)24 11.7 %(82)(66.1)%
Income before income tax provision10,420 9,770 8,997 650 6.7 %773 8.6 %
Income tax provision2,522 2,569 2,366 (47)(1.8)%203 8.6 %
Income from continuing operations7,898 7,201 6,631 697 9.7 %570 8.6 %
Loss from discontinued operations, net of tax— (9)— 100.0 %(9)(100.0)%
Net income7,898 7,192 6,631 706 9.8 %561 8.5 %
Net (income) loss attributable to noncontrolling interests12 (13)25 192.3 %(16)(533.3)%
Net income attributable to CVS Health$7,910 $7,179 $6,634 $731 10.2 %$545 8.2 %

Commentary - 2021 compared to 2020

Revenues
Total revenues increased $23.4 billion or 8.7% in 2021 compared to 2020. The increase in total revenues was primarily driven by growth across all segments.
Please see “Segment Analysis” later in this MD&A for additional information about the revenues of the Company’s segments.

Operating expenses
Operating expenses increased $1.9 billion or 5.5% in 2021 compared to 2020. The increase in operating expenses was primarily due to incremental costs associated with growth in the business, including costs associated with the administration of COVID-19 vaccinations and diagnostic testing in the Retail/LTC segment. The increase in operating expenses was partially offset by the repeal of the non-deductible health insurer fee (“HIF”) for 2021 and gains from anti-trust legal settlements of $263 million recorded in 2021.
70


Operating expenses as a percentage of total revenues decreased to 12.7% in 2021 compared to 13.1% in 2020. The decrease in operating expenses as a percentage of total revenues was primarily due to the increases in total revenues referred to above.
Please see “Segment Analysis” later in this MD&A for additional information about the operating expenses of the Company’s segments.

Operating income
Operating income decreased $718 million or 5.2% in 2021 compared to 2020. The decrease in operating income was primarily due to:
A store impairment charge of approximately $1.4 billion recorded in the fourth quarter of 2021 related to planned retail store closures over the next three years;
Decreased operating income in the Health Care Benefits segment, driven by higher COVID-19 related costs in 2021 compared to the prior year, including the impact of the deferral of elective procedures and other discretionary utilization in response to the COVID-19 pandemic during 2020, as well as the absence of pre-tax income of $307 million associated with the receipt of amounts owed to the Company under the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010 (collectively, the “ACA”) risk corridor program (“ACA risk corridor receipt”); and
A $431 million goodwill impairment charge associated with the LTC business in the Retail/LTC segment recorded during the third quarter of 2021, partially offset by:
Increased prescription and front store volume and the administration of COVID-19 vaccinations and diagnostic testing in the Retail/LTC segment;
Improved purchasing economics and growth in specialty pharmacy in the Pharmacy Services segment;
Gains from anti-trust legal settlements of $263 million recorded in 2021; and
Lower acquisition-related integration costs in 2021 compared to the prior year.
Please see “Segment Analysis” later in this MD&A for additional information about the operating income of the Company’s segments.

Interest expense
Interest expense decreased $404 million in 2021 compared to 2020, due to lower debt in the year ended December 31, 2021. See “Liquidity and Capital Resources” later in this report for additional information.

Loss on early extinguishment of debt
During 2021, the loss on early extinguishment of debt relates to the Company’s repayment of approximately $2.3 billion of its outstanding senior notes in December 2021 pursuant to its early redemption make-whole provision for such senior notes, which resulted in a loss on early extinguishment of debt of $89 million, and the repayment of approximately $2.0 billion of its outstanding senior notes pursuant to its tender offer for such notes in August 2021, which resulted in a loss on early extinguishment of debt of $363 million. During 2020, the loss on early extinguishment of debt relates to the Company’s repayment of $6.0 billion of its outstanding senior notes pursuant to its tender offers for such senior notes in August 2020, which resulted in a loss on early extinguishment of debt of $766 million, and the repayment of $4.5 billion of its outstanding senior notes pursuant to its tender offers for such senior notes in December 2020, which resulted in a loss on early extinguishment of debt of $674 million. See Note 8 ‘‘Borrowings and Credit Agreements’’ included in Item 8 of this 10-K for additional information.

Income tax provision
The Company’s effective income tax rate decreased to 24.2% in 2021 compared to 26.3% in the prior year primarily due to the repeal of the non-deductible HIF for 2021 and the favorable impact of a prior year refund claim approved by the Internal Revenue Service during the fourth quarter of 2021. The decrease was partially offset by the absence of the favorable resolution of certain tax matters in the fourth quarter of 2020.

Loss from discontinued operations
In connection with certain business dispositions completed between 1995 and 1997, the Company retained guarantees on store lease obligations for a number of former subsidiaries, including Linens ‘n Things and Bob’s Stores, each of which subsequently filed for bankruptcy. The Company’s loss from discontinued operations in 2020 primarily included lease-related costs required to satisfy these lease guarantees.
71


See “Discontinued Operations” in Note 1 ‘‘Significant Accounting Policies’’ and “Lease Guarantees” in Note 16 ‘‘Commitments and Contingencies’’ included in Item 8 of this 10-K for additional information about the Company’s discontinued operations and the Company’s lease guarantees, respectively.

72


Outlook for 2022

With respect to 2022, the Company believes you should consider the following important information:

The Health Care Benefits segment is expected to benefit from Medicare and Commercial membership growth, partially offset by membership declines in its Medicaid products. The projected MBR is expected to decrease compared to 2021, reflecting a combination of expected improved pricing and a reduction in COVID-19 related medical costs. While the Company still expects a net negative impact from COVID-19 in 2022 within the Health Care Benefits segment, the expectation is the impact will be less adverse than what was experienced in 2021.
The Pharmacy Services segment is expected to benefit from the Company’s ability to drive further improvements in purchasing economics and continued growth in specialty pharmacy, partially offset by continued price compression and state regulation of pharmacy pricing.
The Retail/LTC segment is expected to continue to benefit from increased prescription volume and improved generic drug purchasing, partially offset by continued pharmacy reimbursement pressure and incremental operating expenses associated with the Company’s minimum wage investment. The Company expects that COVID-19 vaccinations and diagnostic testing will continue in 2022, albeit at lower levels than those experienced during 2021. The Company expects to see continued strength in Front Store sales, including sales of OTC test kits, in 2022. The extent of COVID-19 vaccinations, diagnostic testing and OTC test kit sales will be dependent upon various factors including vaccine hesitancy, the emergence of new variants, government testing initiatives and the availability and administration of pediatric and booster vaccinations.
The Company is expected to benefit from the continuation of its enterprise-wide cost savings initiatives, which aim to reduce the Company’s operating cost structure in a way that improves the consumer experience and is sustainable. Key drivers include:
Investments in digital, technology and analytics capabilities that will streamline processes and improve outcomes,
Implementing workforce and workplace strategies, and
Deploying vendor and procurement strategies.
The Company expects changes to its business environment to continue as elected and other government officials at the national and state levels continue to propose and enact significant modifications to public policy and existing laws and regulations that govern or impact the Company’s businesses.
The COVID-19 pandemic continues to impact the economies of the U.S. and other countries around the world. The Company believes COVID-19’s impact on its businesses, operating results, cash flows and/or financial condition primarily will be driven by the geographies impacted and the severity and duration of the pandemic, as well as the pandemic’s impact on the U.S. and global economies, global supply chain, consumer behavior, and health care utilization patterns. In addition, as described in the “Government Regulation” section of this Form 10-K, federal, state and local governmental policies and initiatives designed to reduce the transmission of COVID-19 and emerging new variants may not effectively combat the severity and/or duration of the COVID-19 pandemic, and have resulted in a myriad of impacts on the Company’s businesses. Those primary drivers are beyond the Company’s knowledge and control. As a result, the impact COVID-19 will have on the Company’s businesses, operating results, cash flows and/or financial condition is uncertain, but the impact could be adverse and material.

The Company’s current expectations described above are forward-looking statements. Please see “Risk Factors” included in Item 1A of this 10-K and the “Cautionary Statement Concerning Forward-Looking Statements” in this 10-K for information regarding important factors that may cause the Company’s actual results to differ from those currently projected and/or otherwise materially affect the Company.

73


Segment Analysis

The following discussion of segment operating results is presented based on the Company’s reportable segments in accordance with the accounting guidance for segment reporting and is consistent with the segment disclosure in Note 17 ‘‘Segment Reporting’’ included in Item 8 of this 10-K.

The Company has three operating segments, Health Care Benefits, Pharmacy Services and Retail/LTC, as well as a Corporate/Other segment. The Company’s segments maintain separate financial information, and the Company’s chief operating decision maker (the “CODM”) evaluates the segments’ operating results on a regular basis in deciding how to allocate resources among the segments and in assessing segment performance. The CODM evaluates the performance of the Company’s segments based on adjusted operating income, which is defined as operating income (GAAP measure) excluding the impact of amortization of intangible assets and other items, if any, that neither relate to the ordinary course of the Company’s business nor reflect the Company’s underlying business performance. See the reconciliations of operating income (GAAP measure) to adjusted operating income below for further context regarding the items excluded from operating income in determining adjusted operating income. The Company uses adjusted operating income as its principal measure of segment performance as it enhances the Company’s ability to compare past financial performance with current performance and analyze underlying business performance and trends. Non-GAAP financial measures the Company discloses, such as consolidated adjusted operating income, should not be considered a substitute for, or superior to, financial measures determined or calculated in accordance with GAAP.

The following is a reconciliation of financial measures of the Company’s segments to the consolidated totals:
In millionsHealth Care
Benefits
Pharmacy
Services (1)
Retail/
LTC
Corporate/
Other
Intersegment
Eliminations (2)
Consolidated
Totals
2021
Total revenues $82,186 $153,022 $100,105 $721 $(43,923)$292,111 
Adjusted operating income (loss)5,012 6,859 7,623 (1,471)(711)17,312 
2020
Total revenues75,467 141,938 91,198 426 (40,323)268,706 
Adjusted operating income (loss)6,188 5,688 6,146 (1,306)(708)16,008 
2019
Total revenues69,604 141,491 86,608 512 (41,439)256,776 
Adjusted operating income (loss)5,202 5,129 6,705 (1,000)(697)15,339 
_____________________________________________
(1)Total revenues of the Pharmacy Services segment include approximately $11.6 billion, $10.9 billion and $11.5 billion of retail co-payments for 2021, 2020 and 2019, respectively. See Note 1 ‘‘Significant Accounting Policies’’ included in Item 8 of this 10-K for additional information about retail co-payments.
(2)Intersegment revenue eliminations relate to intersegment revenue generating activities that occur between the Health Care Benefits segment, the Pharmacy Services segment, and/or the Retail/LTC segment. Intersegment adjusted operating income eliminations occur when members of Pharmacy Services Segment clients (“PSS members”) enrolled in Maintenance Choice® elect to pick up maintenance prescriptions at one of the Company’s retail pharmacies instead of receiving them through the mail. When this occurs, both the Pharmacy Services and Retail/LTC segments record the adjusted operating income on a stand-alone basis.

74


The following are reconciliations of consolidated operating income (GAAP measure) to consolidated adjusted operating income, as well as reconciliations of segment GAAP operating income to segment adjusted operating income:
Year Ended December 31, 2021
In millionsHealth Care
Benefits
Pharmacy 
Services
Retail/
LTC
Corporate/
Other
Intersegment
Eliminations
Consolidated
Totals
Operating income (loss) (GAAP measure)$3,521 $6,667 $5,322 $(1,606)$(711)$13,193 
Amortization of intangible assets (1)
1,552 192 512 — 2,259 
Acquisition-related integration costs (2)
— — — 132 — 132 
Store impairments (3)
— — 1,358 — — 1,358 
Goodwill impairment (4)
— — 431 — — 431 
Acquisition purchase price adjustment outside of measurement period (5)
(61)— — — — (61)
Adjusted operating income (loss)$5,012 $6,859 $7,623 $(1,471)$(711)$17,312 

Year Ended December 31, 2020
In millionsHealth Care
Benefits
Pharmacy 
Services
Retail/
LTC
Corporate/
Other
Intersegment
Eliminations
Consolidated
Totals
Operating income (loss) (GAAP measure)$5,166 $5,454 $5,640 $(1,641)$(708)$13,911 
Amortization of intangible assets (1)
1,598 234 506 — 2,341 
Acquisition-related integration costs (2)
— — — 332 — 332 
Gain on divestiture of subsidiary (6)
(269)— — — — (269)
Receipt of fully reserved ACA risk corridor receivable (7)
(307)— — — — (307)
Adjusted operating income (loss)$6,188 $5,688 $6,146 $(1,306)$(708)$16,008 

Year Ended December 31, 2019
In millionsHealth Care
Benefits
Pharmacy 
Services
Retail/
LTC
Corporate/
Other
Intersegment
Eliminations
Consolidated
Totals
Operating income (loss) (GAAP measure)$3,639 $4,735 $5,793 $(1,483)$(697)$11,987 
Amortization of intangible assets (1)
1,563 394 476 — 2,436 
Acquisition-related integration costs (2)
— — — 480 — 480 
Store impairments (3)
— — 231 — — 231 
Loss on divestiture of subsidiary (6)
— — 205 — — 205 
Adjusted operating income (loss)$5,202 $5,129 $6,705 $(1,000)$(697)$15,339 
_____________________________________________
(1)The Company’s acquisition activities have resulted in the recognition of intangible assets as required under the acquisition method of accounting which consist primarily of trademarks, customer contracts/relationships, covenants not to compete, technology, provider networks and value of business acquired. Definite-lived intangible assets are amortized over their estimated useful lives and are tested for impairment when events indicate that the carrying value may not be recoverable. The amortization of intangible assets is reflected in the Company’s GAAP consolidated statements of operations in operating expenses within each segment. Although intangible assets contribute to the Company’s revenue generation, the amortization of intangible assets does not directly relate to the underwriting of the Company’s insurance products, the services performed for the Company’s customers or the sale of the Company’s products or services. Additionally, intangible asset amortization expense typically fluctuates based on the size and timing of the Company’s acquisition activity. Accordingly, the Company believes excluding the amortization of intangible assets enhances the Company’s and investors’ ability to compare the Company’s past financial performance with its current performance and to analyze underlying business performance and trends. Intangible asset amortization excluded from the related non-GAAP financial measure represents the entire amount recorded within the Company’s GAAP financial statements, and the revenue generated by the associated intangible assets has not been excluded from the related non-GAAP financial measure. Intangible asset amortization is excluded from the related non-GAAP financial measure because the amortization, unlike the related revenue, is not affected by operations of any particular period unless an intangible asset becomes impaired or the estimated useful life of an intangible asset is revised.
(2)In 2021, 2020 and 2019, acquisition-related integration costs relate to the Company’s acquisition (“Aetna Acquisition”) of Aetna Inc. (“Aetna”). The acquisition-related integration costs are reflected in the Company’s GAAP consolidated statements of operations in operating expenses within the Corporate/Other segment.
(3)During the year ended December 31, 2021, the store impairment charge relates to the write down of operating lease right-of-use assets and property and equipment in connection with the planned closure of approximately 900 retail stores between 2022 and 2024. During the year ended December 31, 2019, the store impairment charges related to the write down of operating lease right-of-use assets in connection with the planned closure of 68 underperforming retail pharmacy stores in 2019 and 2020. The store impairment charges are reflected in the Company’s GAAP consolidated statements of operations within the Retail/LTC segment.
75


(4)During the year ended December 31, 2021, the goodwill impairment charge relates to the LTC reporting unit within the Retail/LTC segment.
(5)In June 2021, the Company received $61 million related to a purchase price working capital adjustment for an acquisition completed during the first quarter of 2020. The resolution of this matter occurred subsequent to the acquisition accounting measurement period and is reflected in the Company’s GAAP consolidated statement of operations for the year ended December 31, 2021 as a reduction of operating expenses within the Health Care Benefits segment.
(6)In 2020, the gain on divestiture of subsidiary represents the pre-tax gain on the sale of the Workers’ Compensation business, which the Company sold on July 31, 2020 for approximately $850 million. The gain on divestiture is reflected as a reduction of operating expenses in the Company’s GAAP consolidated statement of operations within the Health Care Benefits segment. In 2019, the loss on divestiture of subsidiary represents the pre-tax loss on the sale of Onofre, which occurred on July 1, 2019. The loss on divestiture primarily relates to the elimination of the cumulative translation adjustment from accumulated other comprehensive income and is reflected in the Company’s GAAP consolidated statement of operations in operating expenses within the Retail/LTC segment.
(7)In 2020, the Company received $313 million owed to it under the ACA’s risk corridor program that was previously fully reserved for as payment was uncertain. After considering offsetting items such as the ACA’s minimum medical loss ratio (“MLR”) rebate requirements and premium taxes, the Company recognized pre-tax income of $307 million in the Company’s GAAP consolidated statement of operations within the Health Care Benefits segment.



76


Health Care Benefits Segment

The following table summarizes the Health Care Benefits segment’s performance for the respective periods:
Change
Year Ended December 31,2021 vs. 20202020 vs. 2019
In millions, except percentages and basis points (“bps”)202120202019$%$%
Revenues:
Premiums$76,064$69,301$63,031$6,7639.8 %$6,270 9.9 %
Services5,5365,6835,974(147)(2.6)%(291)(4.9)%
Net investment income58648359910321.3 %(116)(19.4)%
Total revenues82,18675,46769,6046,7198.9 %5,863 8.4 %
Benefit costs64,66256,08353,0928,57915.3 %2,991 5.6 %
MBR (Benefit costs as a % of premium revenues)
85.0 %80.9 %84.2%410bps(330)bps
Operating expenses$14,003$14,218$12,873$(215)(1.5)%$1,345 10.4 %
Operating expenses as a % of total revenues17.0 %18.8 %18.5 %
Operating income$3,521$5,166$3,639$(1,645)(31.8)%$1,527 42.0 %
Operating income as a % of total revenues4.3 %6.8 %5.2 %
Adjusted operating income (1)
$5,012$6,188$5,202$(1,176)(19.0)%$986 19.0 %
Adjusted operating income as a % of total revenues6.1 %8.2 %7.5 %
Premium revenues (by business):
Government$55,739$48,928$41,818$6,81113.9 %$7,11017.0 %
Commercial20,32520,37321,213(48)(0.2)%(840)(4.0)%
_____________________________________________
(1)See “Segment Analysis” above in this MD&A for a reconciliation of operating income (GAAP measure) to adjusted operating income for the Health Care Benefits segment, which represents the Company’s principal measure of segment performance.

Commentary - 2021 compared to 2020

Revenues
Total revenues increased $6.7 billion, or 8.9%, to $82.2 billion in 2021 compared to 2020 primarily driven by growth in the Government Services business, partially offset by the unfavorable impact of the repeal of the HIF for 2021 and the absence of the ACA risk corridor receipt.

Medical Benefit Ratio (“MBR”)
Medical benefit ratio is calculated as benefit costs divided by premium revenues and represents the percentage of premium revenues spent on medical benefits for the Company’s Insured members. Management uses MBR to assess the underlying business performance and underwriting of its insurance products, understand variances between actual results and expected results and identify trends in period-over-period results. MBR provides management and investors with information useful in assessing the operating results of the Company’s Insured Health Care Benefits products.
The MBR increased from 80.9% to 85.0% in 2021 compared to the prior year. The increase was primarily driven by higher COVID-19 related costs in 2021 compared to the prior year, including the impact of the deferral of elective procedures and other discretionary utilization in response to the COVID-19 pandemic during 2020 and the repeal of the HIF for 2021, partially offset by improved underlying performance in the current year.

Operating expenses
Operating expenses in the Health Care Benefits segment include selling, general and administrative expenses and depreciation and amortization expenses.
Operating expenses decreased $215 million, or 1.5%, in 2021 compared to 2020. The decrease in operating expenses was primarily due to the repeal of the HIF for 2021, partially offset by incremental operating expenses to support the growth in the Government Services business described above and the net impact of the sale of the Workers’ Compensation business sold on July 31, 2020.
77



Adjusted operating income
Adjusted operating income decreased $1.2 billion, or 19.0%, in 2021 compared to 2020. The decrease in adjusted operating income was primarily driven by higher COVID-19 related costs in 2021 compared to the prior year, including the impact of the deferral of elective procedures and other discretionary utilization in response to the COVID-19 pandemic during 2020. The decrease was partially offset by improved performance in the underlying Government Services business and higher favorable development of prior-years’ health care cost estimates in 2021 compared to the prior year.

The following table summarizes the Health Care Benefits segment’s medical membership as of December 31, 2021 and 2020:
20212020
In thousandsInsured
ASC
TotalInsuredASCTotal
Medical membership:
Commercial3,258 13,530 16,788 3,258 13,644 16,902 
Medicare Advantage2,971 — 2,971 2,705 — 2,705 
Medicare Supplement1,285 — 1,285 1,082 — 1,082 
Medicaid2,333 471 2,804 2,100 623 2,723 
Total medical membership9,847 14,001 23,848 9,145 14,267 23,412 
Supplemental membership information:
Medicare Prescription Drug Plan (standalone)5,777 5,490 

Medical Membership
Medical membership represents the number of members covered by the Company’s Insured and ASC medical products and related services at a specified point in time. Management uses this metric to understand variances between actual medical membership and expected amounts as well as trends in period-over-period results. This metric provides management and investors with information useful in understanding the impact of medical membership on segment total revenues and operating results.
Medical membership as of December 31, 2021 of 23.8 million increased 436,000 compared with December 31, 2020, primarily reflecting increases in Medicare and Medicaid products, partially offset by declines in Commercial self-insured membership.

Medicare Update
On January 15, 2021, the U.S. Centers for Medicare & Medicaid Services (“CMS”) issued its final notice detailing final 2022 Medicare Advantage benchmark payment rates. Final 2022 Medicare Advantage rates resulted in an increase in industry benchmark rates of approximately 4.1%.

The ACA ties a portion of each Medicare Advantage plan’s reimbursement to the plan’s “star ratings.” Plans must have a star rating of four or higher (out of five) to qualify for bonus payments. CMS released the Company’s 2022 star ratings in October 2021. The Company’s 2022 star ratings will be used to determine which of the Company’s Medicare Advantage plans have ratings of four stars or higher and qualify for bonus payments in 2023. Based on the Company’s membership at December 31, 2021, 87% of the Company’s Medicare Advantage members were in plans with 2022 star ratings of at least 4.0 stars, compared to 83% of the Company’s Medicare Advantage members being in plans with 2021 star ratings of at least 4.0 stars based on the Company’s membership at December 31, 2020.

78


Pharmacy Services Segment

The following table summarizes the Pharmacy Services segment’s performance for the respective periods:
Change
Year Ended December 31,2021 vs. 20202020 vs. 2019
In millions, except percentages202120202019$%$%
Revenues:
Products$151,851$140,950$140,946$10,901 7.7 %$— %
Services1,171988545183 18.5 %443 81.3 %
Total revenues153,022141,938141,49111,084 7.8 %447 0.3 %
Cost of products sold144,894135,045135,2459,849 7.3 %(200)(0.1)%
Operating expenses1,4611,4391,51122 1.5 %(72)(4.8)%
Operating expenses as a % of total revenues1.0 %1.0 %1.1 %
Operating income$6,667$5,454$4,735$1,213 22.2 %$719 15.2 %
Operating income as a % of total revenues4.4 %3.8 %3.3 %
Adjusted operating income (1)
$6,859$5,688$5,129$1,171 20.6 %$559 10.9 %
Adjusted operating income as a % of total revenues4.5 %4.0 %3.6 %
Revenues (by distribution channel):
Pharmacy network (2)
$91,715$85,045$88,755$6,670 7.8 %$(3,710)(4.2)%
Mail choice (3)
60,54756,07152,1414,476 8.0 %3,930 7.5 %
Other760822595(62)(7.5)%227 38.2 %
Pharmacy claims processed: (4)
Total2,244.72,112.92,014.2131.8 6.2 %98.7 4.9 %
Pharmacy network (2)
1,914.01,790.11,704.0123.9 6.9 %86.1 5.1 %
Mail choice (3)
330.7322.8310.27.9 2.4 %12.6 4.1 %
Generic dispensing rate: (4)
Total86.8 %88.2 %88.2 %
Pharmacy network (2)
87.0 %88.7 %88.7 %
Mail choice (3)
85.6 %85.3 %85.1 %
_____________________________________________
(1)See “Segment Analysis” above in this MD&A for a reconciliation of operating income (GAAP measure) to adjusted operating income for the Pharmacy Services segment, which represents the Company’s principal measure of segment performance.
(2)Pharmacy network is defined as claims filled at retail and specialty retail pharmacies, including the Company’s retail pharmacies and LTC pharmacies, but excluding Maintenance Choice® activity, which is included within the mail choice category. Maintenance Choice permits eligible client plan members to fill their maintenance prescriptions through mail order delivery or at a CVS Pharmacy retail store for the same price as mail order.
(3)Mail choice is defined as claims filled at a Pharmacy Services mail order facility, which includes specialty mail claims inclusive of Specialty Connect® claims picked up at a retail pharmacy, as well as prescriptions filled at the Company’s retail pharmacies under the Maintenance Choice program.
(4)Includes an adjustment to convert 90-day prescriptions to the equivalent of three 30-day prescriptions. This adjustment reflects the fact that these prescriptions include approximately three times the amount of product days supplied compared to a normal prescription.

Commentary - 2021 compared to 2020

Revenues
Total revenues increased $11.1 billion, or 7.8%, to $153.0 billion in 2021 compared to 2020. The increase was primarily driven by increased pharmacy claims volume, growth in specialty pharmacy and brand inflation, partially offset by continued price compression.
79


Operating expenses
Operating expenses in the Pharmacy Services segment include selling, general and administrative expenses; depreciation and amortization expense; and expenses related to specialty retail pharmacies, which include store and administrative payroll, employee benefits and occupancy costs.
Operating expenses as a percentage of total revenues remained consistent at 1.0% in both 2021 and 2020.

Adjusted operating income
Adjusted operating income increased $1.2 billion, or 20.6%, in 2021 compared to 2020. The increase in adjusted operating income was primarily driven by improved purchasing economics which reflected increased contributions from the products and services of the Company’s group purchasing organization and specialty pharmacy (including pharmacy and/or administrative services for providers and Covered Entities). These increases were partially offset by continued price compression.
As you review the Pharmacy Services segment’s performance in this area, you should consider the following important information about the business:
The Company’s efforts to (i) retain existing clients, (ii) obtain new business and (iii) maintain or improve the rebates, fees and/or discounts the Company receives from manufacturers, wholesalers and retail pharmacies continue to have an impact on adjusted operating income. In particular, competitive pressures in the PBM industry have caused the Company and other PBMs to continue to share with clients a larger portion of rebates, fees and/or discounts received from pharmaceutical manufacturers. In addition, marketplace dynamics and regulatory changes have limited the Company’s ability to offer plan sponsors pricing that includes retail network “differential” or “spread,” and the Company expects these trends to continue. The “differential” or “spread” is any difference between the drug price charged to plan sponsors, including Medicare Part D plan sponsors, by a PBM and the price paid for the drug by the PBM to the dispensing provider.

Pharmacy claims processed
Total pharmacy claims processed represents the number of prescription claims processed through our pharmacy benefits manager and dispensed by either our retail network pharmacies or our own mail and specialty pharmacies. Management uses this metric to understand variances between actual claims processed and expected amounts as well as trends in period-over-period results. This metric provides management and investors with information useful in understanding the impact of pharmacy claim volume on segment total revenues and operating results.
The Company’s pharmacy network claims processed on a 30-day equivalent basis increased 6.9% to 1.9 billion claims in 2021 compared to 1.8 billion claims in 2020. The increase in pharmacy network claims processed was primarily driven by net new business and COVID-19 vaccinations, as well as increased new therapy prescriptions, which were adversely impacted by the COVID-19 pandemic during 2020.
The Company’s mail choice claims processed on a 30-day equivalent basis increased 2.4% to 330.7 million claims in 2021 compared to 322.8 million claims in 2020. The increase in mail choice claims was primarily driven by net new business and the continued adoption of Maintenance Choice offerings.
Excluding the impact of COVID-19 vaccinations, total pharmacy claims processed increased 4.2%, on a 30-day equivalent basis, in 2021 compared to the prior year.

Generic dispensing rate
Generic dispensing rate is calculated by dividing the Pharmacy Services segment’s generic drug prescriptions processed or filled by its total prescriptions processed or filled. Management uses this metric to evaluate the effectiveness of the business at encouraging the use of generic drugs when they are available and clinically appropriate, which aids in decreasing costs for client members and retail customers. This metric provides management and investors with information useful in understanding trends in segment total revenues and operating results.
The Pharmacy Services segment’s total generic dispensing rate decreased to 86.8% in 2021 compared to 88.2% in the prior year. The decrease in the segment’s generic dispensing rate was primarily driven by an increase in brand prescriptions, largely attributable to COVID-19 vaccinations in 2021. Excluding the impact of COVID-19 vaccinations, the segment’s total generic dispensing rate increased to 88.5% in 2021.
80


Retail/LTC Segment

The following table summarizes the Retail/LTC segment’s performance for the respective periods:
Change
Year Ended December 31,2021 vs. 20202020 vs. 2019
In millions, except percentages202120202019$%$%
Revenues:
Products$95,652$89,944$85,729$5,708 6.3 %$4,215 4.9 %
Services4,4361,2548793,182 253.7 %375 42.7 %
Net investment income1717 100.0 %— — %
Total revenues100,10591,19886,6088,907 9.8 %4,590 5.3 %
Cost of products sold 72,83267,28462,6885,548 8.2 %4,596 7.3 %
Store impairments1,3582311,358 100.0 %(231)(100.0)%
Goodwill impairment431431 100.0 %— — %
Operating expenses20,16218,27417,8961,888 10.3 %378 2.1 %
Operating expenses as a % of total revenues20.1 %20.0 %20.7 %
Operating income$5,322$5,640$5,793$(318)(5.6)%$(153)(2.6)%
Operating income as a % of total revenues5.3 %6.2 %6.7 %
Adjusted operating income (1)
$7,623$6,146$6,705$1,477 24.0 %$(559)(8.3)%
Adjusted operating income as a % of total revenues7.6 %6.7 %7.7 %
Revenues (by major goods/service lines):
Pharmacy$76,121$70,176$66,442$5,945 8.5 %$3,734 5.6 %
Front Store21,31519,65519,4221,660 8.4 %233 1.2 %
Other2,6521,3677441,285 94.0 %623 83.7 %
Net investment income1717 100.0 %— — %
Prescriptions filled (2)
1,587.61,465.21,417.2122.4 8.4 %48.0 3.4 %
Same store sales increase: (3)
Total8.9 %5.6 %3.7 %
Pharmacy9.3 %7.0 %4.5 %
Front Store7.6 %0.9 %1.1 %
Prescription volume (2)
9.3 %4.7 %7.2 %
Generic dispensing rate (2)
85.7 %88.3 %88.3 %
_____________________________________________
(1)See “Segment Analysis” above in this MD&A for a reconciliation of operating income (GAAP measure) to adjusted operating income for the Retail/LTC segment, which represents the Company’s principal measure of segment performance.
(2)Includes an adjustment to convert 90‑day prescriptions to the equivalent of three 30‑day prescriptions. This adjustment reflects the fact that these prescriptions include approximately three times the amount of product days supplied compared to a normal prescription.
(3)Same store sales and prescription volume represent the change in revenues and prescriptions filled in the Company’s retail pharmacy stores that have been operating for greater than one year, expressed as a percentage that indicates the increase or decrease relative to the comparable prior period. Same store metrics exclude revenues from MinuteClinic, revenues and prescriptions from LTC operations and, in 2019, revenues and prescriptions from stores in Brazil. Management uses these metrics to evaluate the performance of existing stores on a comparable basis and to inform future decisions regarding existing stores and new locations. Same-store metrics provide management and investors with information useful in understanding the portion of current revenues and prescriptions resulting from organic growth in existing locations versus the portion resulting from opening new stores.

Commentary - 2021 compared to 2020

Revenues
Total revenues increased $8.9 billion, or 9.8%, to $100.1 billion in 2021 compared to 2020. The increase was primarily driven by increased prescription and front store volume, the administration of COVID-19 vaccinations and diagnostic testing, as well as brand inflation. These increases were partially offset by continued pharmacy reimbursement pressure and the impact of recent generic introductions. COVID-19 vaccinations, diagnostic testing and OTC test kit sales contributed approximately 45% of the increase in the segment’s revenues in 2021 compared to the prior year. The prior year reflected
81


the ongoing expansion of the Company’s diagnostic testing program which began in April 2020, an immaterial impact from COVID-19 vaccinations which began in December 2020 and no OTC test kit sales.
Pharmacy same store sales increased 9.3% in 2021 compared to 2020. The increase was driven by the 9.3% increase in pharmacy same store prescription volume on a 30-day equivalent basis and brand inflation. These increases were partially offset by continued pharmacy reimbursement pressure and the impact of recent generic introductions.
Front store same store sales increased 7.6% in 2021 compared to 2020. The increase was primarily due to strength in consumer health, including the sale of OTC test kits, as well as increased beauty and personal care sales in 2021.
Other revenues increased 94.0% in 2021 compared to 2020. The increase was primarily due to increased COVID-19 diagnostic testing in 2021.

Store impairments
During 2021, the Company recorded a store impairment charge of approximately $1.4 billion related to the write-down of operating lease right-of-use assets and property and equipment in connection with the planned closure of approximately 900 retail stores between 2022 and 2024. See Note 6 ‘‘Leases’’ included in Item 8 of this 10-K for additional information.

Goodwill impairment
During 2021, the Company recorded a $431 million goodwill impairment charge related to the LTC reporting unit within the Retail/LTC segment. See Note 5 ‘‘Goodwill and Other Intangibles’’ included in Item 8 of this 10-K for additional information.

Operating expenses
Operating expenses in the Retail/LTC segment include store payroll, store employee benefits, store occupancy costs, selling expenses, advertising expenses, depreciation and amortization expense and certain administrative expenses.
Operating expenses increased $1.9 billion, or 10.3%, in 2021 compared to 2020. The increase was primarily due to incremental costs associated with increased volume including COVID-19 vaccinations and diagnostic testing, as well as increased investments in the segment’s capabilities and colleague compensation and benefits. These increases were partially offset by gains from anti-trust legal settlements of $231 million recorded in 2021, the absence of incremental expenses associated with the Company’s initial COVID-19 pandemic mitigation efforts incurred in 2020 and the impact of cost savings initiatives in 2021.
Operating expenses as a percentage of total revenues remained relatively consistent at 20.1% and 20.0% in 2021 and 2020, respectively.

Adjusted operating income
Adjusted operating income increased $1.5 billion, or 24.0%, in 2021 compared to 2020. The increase in adjusted operating income was primarily driven by the administration of COVID-19 vaccinations and diagnostic testing, the increased prescription and front store volume described above, improved generic drug purchasing and gains from anti-trust legal settlements of $231 million recorded in 2021. These increases were partially offset by continued pharmacy reimbursement pressure and increased investments in the segment’s capabilities and colleague compensation and benefits.
As you review the Retail/LTC segment’s performance in this area, you should consider the following important information about the business:
The segment’s adjusted operating income benefited from the administration of COVID-19 vaccinations, diagnostic testing and OTC test kit sales which contributed approximately 30% of the segment’s adjusted operating income in 2021.
The segment’s adjusted operating income has been adversely affected by the efforts of managed care organizations, PBMs and governmental and other third-party payors to reduce their prescription drug costs, including the use of restrictive networks, as well as changes in the mix of business within the pharmacy portion of the Retail/LTC segment. If the pharmacy reimbursement pressure accelerates, the segment may not be able to grow revenues, and its adjusted operating income could be adversely affected.
The increased use of generic drugs has positively impacted the segment’s adjusted operating income but has resulted in third-party payors augmenting their efforts to reduce reimbursement payments to retail pharmacies for prescriptions. This trend, which the Company expects to continue, reduces the benefit the segment realizes from brand-to-generic drug conversions.

Prescriptions filled
Prescriptions filled represents the number of prescriptions dispensed through the Retail/LTC segment’s pharmacies. Management uses this metric to understand variances between actual prescriptions dispensed and expected amounts as well
82


as trends in period-over-period results. This metric provides management and investors with information useful in understanding the impact of prescription volume on segment total revenues and operating results.
Prescriptions filled increased 8.4%, on a 30-day equivalent basis, in 2021 compared to 2020 primarily driven by COVID-19 vaccinations and the continued adoption of patient care programs, as well as increased new therapy prescriptions, which were adversely impacted by the COVID-19 pandemic in 2020. Excluding the impact of COVID-19 vaccinations, prescriptions filled increased 4.3%, on a 30-day equivalent basis, in 2021 compared to the prior year.

Generic dispensing rate
Generic dispensing rate is calculated by dividing the Retail/LTC segment’s generic drug prescriptions filled by its total prescriptions filled. Management uses this metric to evaluate the effectiveness of the business at encouraging the use of generic drugs when they are available and clinically appropriate, which aids in decreasing costs for client members and retail customers. This metric provides management and investors with information useful in understanding trends in segment total revenues and operating results.
The Retail/LTC segment’s generic dispensing rate decreased to 85.7% in 2021 compared to 88.3% in the prior year. The decrease in the segment’s generic dispensing rate was primarily driven by an increase in brand prescriptions, largely attributable to COVID-19 vaccinations in 2021. Excluding the impact of COVID-19 vaccinations, the segment’s total generic dispensing rate increased to 89.0% in 2021.


83


Corporate/Other Segment

The following table summarizes the Corporate/Other segment’s performance for the respective periods:

Change
Year Ended December 31,2021 vs. 20202020 vs. 2019
In millions, except percentages202120202019$%$%
Revenues:
Premiums$68 $63$91$7.9 %$(28)(30.8)%
Services57 48918.8 %39 433.3 %
Net investment income596 315412281 89.2 %(97)(23.5)%
Total revenues721 426512295 69.2 %(86)(16.8)%
Cost of products sold37 37 100.0 %— — %
Benefit costs212 221285(9)(4.1)%(64)(22.5)%
Operating expenses2,078 1,8461,710232 12.6 %136 8.0 %
Operating loss(1,606)(1,641)(1,483)35 2.1 %(158)(10.7)%
Adjusted operating loss (1)
(1,471)(1,306)(1,000)(165)(12.6)%(306)(30.6)%
_____________________________________________
(1)See “Segment Analysis” above in this MD&A for a reconciliation of Corporate/Other segment operating loss (GAAP measure) to adjusted operating loss, which represents the Company’s principal measure of segment performance.

Commentary - 2021 compared to 2020

Revenues
Revenues primarily relate to products for which the Company no longer solicits or accepts new customers, such as large case pensions and long-term care insurance products.
Total revenues increased $295 million in 2021 compared to 2020. The increase was primarily driven by higher net investment income, primarily driven by private equity investments and increased net realized capital gains in 2021 compared to 2020.

Adjusted operating loss
Adjusted operating loss increased $165 million in 2021 compared to 2020. The increase was primarily driven by higher employee benefit costs and incremental operating expenses associated with the Company’s investments in transformation, partially offset by the increase in net investment income in 2021 described above.


84


Liquidity and Capital Resources

Cash Flows

The Company maintains a level of liquidity sufficient to allow it to meet its cash needs in the short-term. Over the long term, the Company manages its cash and capital structure to maximize shareholder return, maintain its financial condition and maintain flexibility for future strategic initiatives. The Company continuously assesses its regulatory capital requirements, working capital needs, debt and leverage levels, debt maturity schedule, capital expenditure requirements, dividend payouts, potential share repurchases and future investments or acquisitions. The Company believes its operating cash flows, commercial paper program, credit facilities, as well as any potential future borrowings, will be sufficient to fund these future payments and long-term initiatives. As of December 31, 2021, the Company had approximately $9.4 billion in cash and cash equivalents, approximately $3.8 billion of which was held by the parent company or nonrestricted subsidiaries.

The net change in cash, cash equivalents and restricted cash for the years ended December 31, 2021, 2020 and 2019 was as follows:
Change
Year Ended December 31,2021 vs. 20202020 vs. 2019
In millions202120202019$%$%
Net cash provided by operating activities$18,265 $15,865 $12,848 $2,400 15.1 %$3,017 23.5 %
Net cash used in investing activities(5,261)(5,534)(3,339)273 4.9 %(2,195)(65.7)%
Net cash used in financing activities(11,356)(7,696)(7,654)(3,660)(47.6)%(42)(0.5)%
Net increase in cash, cash equivalents and restricted cash$1,648 $2,635 $1,855 $(987)(37.5)%$780 42.0 %

Commentary - 2021 compared to 2020

Net cash provided by operating activities increased by $2.4 billion in 2021 compared to 2020 due primarily to the timing of payments and higher operating income in the Retail/LTC segment. The increase was partially offset by reduced benefit costs due to the deferral of elective procedures and other discretionary utilization in the Health Care Benefits segment as a result of the COVID-19 pandemic, which favorably impacted operating cash flows in 2020 and did not recur during the current year.
Net cash used in investing activities decreased by $273 million in 2021 compared to 2020 primarily due to increased proceeds from the sale and maturity of investments and a decrease in cash used for acquisitions, partially offset by the absence of $840 million in proceeds from the sale of the Workers’ Compensation business in 2020 and increased purchases of investments during 2021 compared to the prior year. In addition, cash used in investing activities reflected the following activity:
Gross capital expenditures remained relatively consistent at approximately $2.5 billion and $2.4 billion in 2021 and 2020, respectively. During 2021, approximately 64% of the Company’s total capital expenditures were for technology, digital and other strategic initiatives and 36% were for store, fulfillment and support facilities expansion and improvements.
Net cash used in financing activities increased to $11.4 billion in 2021 compared to $7.7 billion in 2020. The increase in cash used in finance activities primarily related to lower proceeds from the issuance of long-term debt, partially offset by lower repayments of long-term debt during 2021 compared to the prior year.

Included in net cash used in investing activities for the years ended December 31, 2021, 2020 and 2019 was the following store development activity: (1)
202120202019
Total stores (beginning of year)9,962 9,896 9,921 
New and acquired stores (2)
58 156 102 
Closed stores (2)
(81)(90)(127)
Total stores (end of year)9,939 9,962 9,896 
Relocated stores (2)
17 18 23 
_____________________________________________
(1)Includes retail drugstores and pharmacies within retail chains, primarily in Target Corporation (“Target”) stores.
85


(2)Relocated stores are not included in new and acquired stores or closed stores totals.

Short-term Borrowings

Commercial Paper and Back-up Credit Facilities
The Company did not have any commercial paper outstanding as of December 31, 2021 or 2020. In connection with its commercial paper program, the Company maintains a $2.0 billion, five-year unsecured back-up revolving credit facility, which expires on May 17, 2023, a $2.0 billion, five-year unsecured back-up revolving credit facility, which expires on May 16, 2024, and a $2.0 billion, five-year unsecured back-up revolving credit facility, which expires on May 11, 2026. The credit facilities allow for borrowings at various rates that are dependent, in part, on the Company’s public debt ratings and require the Company to pay a weighted average quarterly facility fee of approximately 0.03%, regardless of usage. As of December 31, 2021 and 2020, there were no borrowings outstanding under any of the Company’s back-up credit facilities.

Federal Home Loan Bank of Boston (“FHLBB”)
A subsidiary of the Company is a member of the FHLBB. As a member, the subsidiary has the ability to obtain cash advances, subject to certain minimum collateral requirements. The maximum borrowing capacity available from the FHLBB as of December 31, 2021 was approximately $995 million. At both December 31, 2021 and 2020, there were no outstanding advances from the FHLBB.

Long-term Borrowings

2021 Notes
On August 18, 2021, the Company issued $1.0 billion aggregate principal amount of 2.125% unsecured senior notes due September 15, 2031 for total proceeds of $987 million, net of discounts, underwriting fees and offering expenses. The net proceeds of this offering were used for the purchase of senior notes in connection with the Company’s cash tender offer in August 2021 as described below.

2020 Notes
On December 16, 2020, the Company issued $750 million aggregate principal amount of 1.3% unsecured senior notes due August 21, 2027 and $1.25 billion aggregate principal amount of 1.875% unsecured senior notes due February 28, 2031 for total proceeds of approximately $1.99 billion, net of discounts and underwriting fees. The $750 million aggregate principal amount of 1.3% unsecured senior notes represent a further issuance of the Company’s 1.3% unsecured senior notes due August 21, 2027 initially issued in an aggregate principal amount of $1.5 billion on August 21, 2020.

On August 21, 2020, the Company issued $1.5 billion aggregate principal amount of 1.3% unsecured senior notes due August 21, 2027, $1.25 billion aggregate principal amount of 1.75% unsecured senior notes due August 21, 2030 and $1.25 billion aggregate principal amount of 2.7% unsecured senior notes due August 21, 2040 (collectively, the “August 2020 Notes”) for total proceeds of approximately $3.97 billion, net of discounts and underwriting fees.

On March 31, 2020, the Company issued $750 million aggregate principal amount of 3.625% unsecured senior notes due April 1, 2027, $1.5 billion aggregate principal amount of 3.75% unsecured senior notes due April 1, 2030, $1.0 billion aggregate principal amount of 4.125% unsecured senior notes due April 1, 2040 and $750 million aggregate principal amount of 4.25% unsecured senior notes due April 1, 2050 (collectively, the “March 2020 Notes”) for total proceeds of approximately $3.95 billion, net of discounts and underwriting fees.

The net proceeds of these offerings were used for general corporate purposes, which may include working capital, capital expenditures, as well as the repurchase and/or repayment of indebtedness.

During March 2020, the Company entered into several interest rate swap transactions to manage interest rate risk. These agreements were designated as cash flow hedges and were used to hedge the exposure to variability in future cash flows resulting from changes in interest rates related to the anticipated issuance of the March 2020 Notes. In connection with the issuance of the March 2020 Notes, the Company terminated all outstanding cash flow hedges. The Company paid a net amount of $7 million to the hedge counterparties upon termination, which was recorded as a loss, net of tax, of $5 million in accumulated other comprehensive income and will be reclassified as interest expense over the life of the March 2020 Notes. See Note 13 ‘‘Other Comprehensive Income’’ included in Item 8 of this 10-K for additional information.



86


Early Extinguishments of Debt
In December 2021, the Company redeemed for cash the remaining $2.3 billion of its outstanding 3.7% senior notes due 2023. In connection with the early redemption of such senior notes, the Company paid a make-whole premium of $80 million in excess of the aggregate principal amount of the senior notes that were redeemed, wrote-off $8 million of unamortized deferred financing costs and incurred $1 million in fees, for a total loss on early extinguishment of debt of $89 million.

In August 2021, the Company purchased approximately $2.0 billion of its outstanding 4.3% senior notes due 2028 through a cash tender offer. In connection with the purchase of such senior notes, the Company paid a premium of $332 million in excess of the aggregate principal amount of the senior notes that were purchased, wrote-off $26 million of unamortized deferred financing costs and incurred $5 million in fees, for a total loss on early extinguishment of debt of $363 million.

In December 2020, the Company purchased $4.5 billion of its outstanding senior notes through cash tender offers. The senior notes purchased included the following: $113 million of its 4.0% senior notes due 2023, $1.4 billion of its 3.7% senior notes due 2023, $1.0 billion of its 4.1% senior notes due 2025 and $2.0 billion of its 4.3% senior notes due 2028. In connection with the purchase of such senior notes, the Company paid a premium of $619 million in excess of the aggregate principal amount of the senior notes that were purchased, wrote-off $45 million of unamortized deferred financing costs and incurred $10 million in fees, for a total loss on early extinguishment of debt of $674 million.

In August 2020, the Company purchased $6.0 billion of its outstanding senior notes through cash tender offers. The senior notes purchased included the following: $723 million of its 4.0% senior notes due 2023, $2.3 billion of its 3.7% senior notes due 2023 and $3.0 billion of its 4.1% senior notes due 2025. In connection with the purchase of such senior notes, the Company paid a premium of $706 million in excess of the aggregate principal amount of the senior notes that were purchased, wrote-off $47 million of unamortized deferred financing costs and incurred $13 million in fees, for a total loss on early extinguishment of debt of $766 million.

In August 2019, the Company purchased $4.0 billion of its outstanding senior notes through cash tender offers. The senior notes purchased included the following: $1.3 billion of its 3.125% senior notes due 2020, $723 million of its floating rate notes due 2020, $328 million of its 4.125% senior notes due 2021, $297 million of 4.125% senior notes due 2021 issued by Aetna, $413 million of 5.45% senior notes due 2021 issued by Coventry Health Care, Inc., a wholly-owned subsidiary of Aetna, and $962 million of its 3.35% senior notes due 2021. In connection with the purchase of such senior notes, the Company paid a premium of $76 million in excess of the aggregate principal amount of the senior notes that were purchased, incurred $8 million in fees and recognized a net gain of $5 million on the write-off of net unamortized deferred financing premiums, for a net loss on early extinguishment of debt of $79 million.

See Note 8 ‘‘Borrowings and Credit Agreements’’ and Note 12 ‘‘Shareholders’ Equity’’ included in Item 8 of this 10-K for additional information about debt issuances, debt repayments, share repurchases and dividend payments.

Derivative Financial Instruments

The Company uses derivative financial instruments in order to manage interest rate and foreign exchange risk and credit exposure. The Company’s use of these derivatives is generally limited to hedging risk and has principally consisted of using interest rate swaps, treasury rate locks, forward contracts, futures contracts, warrants, put options and credit default swaps.

Debt Covenants

The Company’s back-up revolving credit facilities, unsecured senior notes and unsecured floating rate notes (see Note 8 ‘‘Borrowings and Credit Agreements’’ included in Item 8 of this 10-K) contain customary restrictive financial and operating covenants. These covenants do not include an acceleration of the Company’s debt maturities in the event of a downgrade in the Company’s credit ratings. The Company does not believe the restrictions contained in these covenants materially affect its financial or operating flexibility. As of December 31, 2021, the Company was in compliance with all of its debt covenants.

Debt Ratings 

As of December 31, 2021, the Company’s long-term debt was rated “Baa2” by Moody’s Investors Service, Inc. (“Moody’s”) and “BBB” by Standard & Poor’s Financial Services LLC (“S&P”), and its commercial paper program was rated “P-2” by Moody’s and “A-2” by S&P. The outlook on the Company’s long-term debt is “Stable” by Moody’s and “Positive” by S&P. In assessing the Company’s credit strength, the Company believes that both Moody’s and S&P considered, among other things, the Company’s capital structure and financial policies as well as its consolidated balance sheet, its historical acquisition activity
87


and other financial information. Although the Company currently believes its long-term debt ratings will remain investment grade, it cannot guarantee the future actions of Moody’s and/or S&P. The Company’s debt ratings have a direct impact on its future borrowing costs, access to capital markets and new store operating lease costs.

Share Repurchase Programs

During the years ended December 31, 2021, 2020 and 2019, the Company did not repurchase any shares of common stock. See Note 12 ‘‘Shareholders’ Equity’’ included in Item 8 of this 10-K for additional information on the Company’s share repurchase program.

Quarterly Cash Dividend

During 2021, 2020 and 2019, the quarterly cash dividend was $0.50 per share. In December 2021, CVS Health Corporation’s Board of Directors (the “Board”) authorized a 10% increase in the quarterly cash dividend to $0.55 per share effective in 2022. CVS Health Corporation has paid cash dividends every quarter since becoming a public company. Future dividends will depend on the Company’s earnings, capital requirements, financial condition and other factors considered relevant by the Board.

Future Cash Requirements

The following table summarizes certain estimated future cash requirements under the Company’s various contractual obligations at December 31, 2021, in total and disaggregated into current and long-term obligations. The table below does not include future payments of claims to health care providers or pharmacies because certain terms of these payments are not determinable at December 31, 2021 (for example, the timing and volume of future services provided under fee-for-service arrangements and future membership levels for capitated arrangements).
In millionsTotalCurrentLong-Term
Operating lease liabilities (1)
$26,070 $2,685 $23,385 
Finance lease liabilities (1)
2,068 122 1,946 
Contractual lease obligations with Target (2)
2,419 — 2,419 
Long-term debt (3)
55,443 4,154 51,289 
Interest payments on long-term debt (3)
31,668 2,196 29,472 
Other long-term liabilities on the consolidated balance sheets (4)
Future policy benefits (5)
5,553 416 5,137 
Unpaid claims (5)
1,589 324 1,265 
Policyholders’ funds (5) (6)
1,761 1,266 495 
Total$126,571 $11,163 $115,408 
_____________________________________________
(1)Refer to Note 6 ‘‘Leases’’ included in Item 8 of this 10-K for additional information regarding the maturity of lease liabilities under operating and finance leases.
(2)The Company leases pharmacy and clinic space from Target. See Note 6 ‘‘Leases’’ included in Item 8 of this 10-K for additional information regarding the lease arrangements with Target. Amounts related to such operating and finance leases are reflected within the operating lease liabilities and finance lease liabilities in the table above. Pharmacy lease amounts due in excess of the remaining estimated economic life of the buildings are reflected in the table above assuming equivalent stores continue to operate through the term of the arrangements.
(3)Refer to Note 8 ‘‘Borrowings and Credit Agreements’’ included in Item 8 of this 10-K for additional information regarding the maturities of debt principal. Interest payments on long-term debt are calculated using outstanding balances and interest rates in effect on December 31, 2021.
(4)Payments of other long-term liabilities exclude Separate Accounts liabilities of approximately $5.1 billion because these liabilities are supported by assets that are legally segregated and are not subject to claims that arise out of the Company’s business.
(5)Total payments of future policy benefits, unpaid claims and policyholders’ funds include $728 million, $1.6 billion and $186 million, respectively, of reserves for contracts subject to reinsurance. The Company expects the assuming reinsurance carrier to fund these obligations and has reflected these amounts as reinsurance recoverable assets on the consolidated balance sheets.
(6)Customer funds associated with group life and health contracts of approximately $3.0 billion have been excluded from the table above because such funds may be used primarily at the customer’s discretion to offset future premiums and/or for refunds, and the timing of the related cash flows cannot be determined. Additionally, net unrealized capital gains on debt securities supporting experience-rated products of $92 million, before tax, have been excluded from the table above.

Restrictions on Certain Payments

In addition to general state law restrictions on payments of dividends and other distributions to stockholders applicable to all corporations, health maintenance organizations (“HMOs”) and insurance companies are subject to further regulations that, among other things, may require those companies to maintain certain levels of equity (referred to as surplus) and restrict the
88


amount of dividends and other distributions that may be paid to their equity holders. These regulations are not directly applicable to CVS Health Corporation as a holding company, since CVS Health Corporation is not an HMO or an insurance company. In addition, in connection with the Aetna Acquisition, the Company made certain undertakings that require prior regulatory approval of dividends by certain of its HMOs and insurance companies. The additional regulations and undertakings applicable to the Company’s HMO and insurance company subsidiaries are not expected to affect the Company’s ability to service the Company’s debt, meet other financing obligations or pay dividends, or the ability of any of the Company’s subsidiaries to service their debt or other financing obligations. Under applicable regulatory requirements and undertakings, at December 31, 2021, the maximum amount of dividends that may be paid by the Company’s insurance and HMO subsidiaries without prior approval by regulatory authorities was $2.9 billion in the aggregate.

The Company maintains capital levels in its operating subsidiaries at or above targeted and/or required capital levels and dividends amounts in excess of these levels to meet liquidity requirements, including the payment of interest on debt and stockholder dividends. In addition, at the Company’s discretion, it uses these funds for other purposes such as funding share and debt repurchase programs, investments in new businesses and other purposes considered advisable.

At December 31, 2021 and 2020, the Company held investments of $450 million and $524 million, respectively, that are not accounted for as Separate Accounts assets but are legally segregated and are not subject to claims that arise out of the Company’s business. See Note 3 ‘‘Investments’’ included in Item 8 of this 10-K for additional information on investments related to the 2012 conversion of an existing group annuity contract from a participating to a non-participating contract.

Solvency Regulation

The National Association of Insurance Commissioners (the “NAIC”) utilizes risk-based capital (“RBC”) standards for insurance companies that are designed to identify weakly-capitalized companies by comparing each company’s adjusted surplus to its required surplus (the “RBC Ratio”). The RBC Ratio is designed to reflect the risk profile of insurance companies. Within certain ratio ranges, regulators have increasing authority to take action as the RBC Ratio decreases. There are four levels of regulatory action, ranging from requiring an insurer to submit a comprehensive financial plan for increasing its RBC to the state insurance commissioner to requiring the state insurance commissioner to place the insurer under regulatory control. At December 31, 2021, the RBC Ratio of each of the Company’s primary insurance subsidiaries was above the level that would require regulatory action. The RBC framework described above for insurers has been extended by the NAIC to health organizations, including HMOs. Although not all states had adopted these rules at December 31, 2021, at that date, each of the Company’s active HMOs had a surplus that exceeded either the applicable state net worth requirements or, where adopted, the levels that would require regulatory action under the NAIC’s RBC rules. External rating agencies use their own capital models and/or RBC standards when they determine a company’s rating.

89


Critical Accounting Policies

The Company prepares the consolidated financial statements in conformity with generally accepted accounting principles, which require management to make certain estimates and apply judgment. Estimates and judgments are based on historical experience, current trends and other factors that management believes to be important at the time the consolidated financial statements are prepared. On a regular basis, the Company reviews its accounting policies and how they are applied and disclosed in the consolidated financial statements. While the Company believes the historical experience, current trends and other factors considered by management support the preparation of the consolidated financial statements in conformity with generally accepted accounting principles, actual results could differ from estimates, and such differences could be material.

Significant accounting policies are discussed in Note 1 ‘‘Significant Accounting Policies’’ included in Item 8 of this 10-K. Management believes the following accounting policies include a higher degree of judgment and/or complexity and, thus, are considered to be critical accounting policies. The Company has discussed the development and selection of these critical accounting policies with the Audit Committee of the Board (the “Audit Committee”), and the Audit Committee has reviewed the disclosures relating to them.

Revenue Recognition

Health Care Benefits Segment
Health Care Benefits revenue is principally derived from insurance premiums and fees billed to customers. Revenue is recognized based on customer billings, which, in the Company’s Commercial business, reflect contracted rates per member and the number of covered members recorded in the Company’s records at the time the billings are prepared. Billings are generally sent monthly for coverage during the following month. Revenue related to the Company’s Government business is collected monthly from the U.S. federal government and various government agencies based on fixed payment rates and member eligibility.

The Company’s billings may be subsequently adjusted to reflect enrollment changes due to member terminations or other factors. These adjustments are known as retroactivity adjustments. In each period, the Company estimates the amount of future retroactivity and adjusts the recorded revenue accordingly. As information regarding actual retroactivity amounts becomes known, the Company refines its estimates and records any required adjustments to revenues in the period in which they arise. A significant difference in the actual level of retroactivity compared to estimated levels would have a significant effect on the Company’s operating results.

Premium Revenue
Premiums are recognized as revenue in the month in which the enrollee is entitled to receive health care services. Premiums are reported net of an allowance for estimated terminations and uncollectible amounts. Additionally, premium revenue subject to the MLR rebate requirements of the ACA is recorded net of the estimated minimum MLR rebates for the current calendar year. Premiums related to unexpired contractual coverage periods (unearned premiums) are reported as other insurance liabilities on the consolidated balance sheets and recognized as revenue when earned.

Some of the Company’s contracts allow for premiums to be adjusted to reflect actual experience or the relative health status of Insured members. Such adjustments are reasonably estimable at the outset of the contract, and adjustments to those estimates are made based on actual experience of the customer emerging under the contract and the terms of the underlying contract.

Services Revenue
Services revenue relates to contracts that can include various combinations of services or series of services which generally are capable of being distinct and accounted for as separate performance obligations. The Health Care Benefits segment’s services revenue primarily consists of ASC fees received in exchange for performing certain claim processing and member services for ASC members. ASC fee revenue is recognized over the period the service is provided. Some of the Company’s administrative services contracts include guarantees with respect to certain functions, such as customer service response time, claim processing accuracy and claim processing turnaround time, as well as certain guarantees that a plan sponsor’s benefit claim experience will fall within a certain range. With any of these guarantees, the Company is financially at risk if the conditions of the arrangements are not met, although the maximum amount at risk typically is limited to a percentage of the fees otherwise payable to the Company by the customer involved. Each period the Company estimates its obligations under the terms of these guarantees and records its estimate as an offset to services revenues.



90


Accounting for Medicare Part D
Revenues include insurance premiums earned by the Company’s PDPs, which are determined based on the PDP’s annual bid and related contractual arrangements with CMS. The insurance premiums include a beneficiary premium, which is the responsibility of the PDP member, and can be subsidized by CMS in the case of low-income members, and a direct premium paid by CMS. Premiums collected in advance are initially recorded within other insurance liabilities and are then recognized ratably as revenue over the period in which members are entitled to receive benefits.

Revenues also include a risk-sharing feature of the Medicare Part D program design referred to as the risk corridor. The Company estimates variable consideration in the form of amounts payable to, or receivable from, CMS under the risk corridor, and adjusts revenue based on calculations of additional subsidies to be received from or owed to CMS at the end of the reporting year.

In addition to Medicare Part D premiums, the Company receives additional payments each month from CMS related to catastrophic reinsurance, low-income cost-sharing subsidies and coverage gap benefits. If the subsidies received differ from the amounts earned from actual prescriptions transferred, the difference is recorded in either accounts receivable, net or accrued expenses.

Pharmacy Services Segment
The Pharmacy Services segment sells prescription drugs directly through its mail service dispensing pharmacies and indirectly through the Company’s retail pharmacy network. The Company’s pharmacy benefit arrangements are accounted for in a manner consistent with a master supply arrangement as there are no contractual minimum volumes and each prescription is considered a separate purchasing decision and distinct performance obligation transferred at a point in time. PBM services performed in connection with each prescription claim are considered part of a single performance obligation which culminates in the dispensing of prescription drugs.

The Company recognizes revenue using the gross method at the contract price negotiated with its clients when the Company has concluded it controls the prescription drug before it is transferred to the client plan members. The Company controls prescriptions dispensed indirectly through its retail pharmacy network because it has separate contractual arrangements with those pharmacies, has discretion in setting the price for the transaction and assumes primary responsibility for fulfilling the promise to provide prescription drugs to its client plan members while also performing the related PBM services.

Revenues include (i) the portion of the price the client pays directly to the Company, net of any discounts earned on brand name drugs or other discounts and refunds paid back to the client (see “Drug Discounts” and “Guarantees” below), (ii) the price paid to the Company by client plan members for mail order prescriptions and the price paid to retail network pharmacies by client plan members for retail prescriptions (“retail co-payments”), and (iii) claims based administrative fees for retail pharmacy network contracts. Sales taxes are not included in revenues.

The Company recognizes revenue when control of the prescription drugs is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to receive in exchange for those prescription drugs. The Company has established the following revenue recognition policies for the Pharmacy Services segment:

Revenues generated from prescription drugs sold by mail service dispensing pharmacies are recognized when the prescription drug is delivered to the client plan member. At the time of delivery, the Company has performed substantially all of its performance obligations under its client contracts and does not experience a significant level of returns or reshipments.
Revenues generated from prescription drugs sold by third party pharmacies in the Company’s retail pharmacy network and associated administrative fees are recognized at the Company’s point-of-sale, which is when the claim is adjudicated by the Company’s online claims processing system and the Company has transferred control of the prescription drug and completed all of its performance obligations.

For contracts under which the Company acts as an agent or does not control the prescription drugs prior to transfer to the client plan member, revenue is recognized using the net method.

Drug Discounts
The Company records revenue net of manufacturers’ rebates earned by its clients based on their plan members’ utilization of brand-name formulary drugs. The Company estimates these rebates at period-end based on actual and estimated claims data and its estimates of the manufacturers’ rebates earned by its clients. The estimates are based on the best available data at period-end and recent history for the various factors that can affect the amount of rebates due to the client. The Company adjusts its rebates
91


payable to clients to the actual amounts paid when these rebates are paid or as significant events occur. Any cumulative effect of these adjustments is recorded against revenues at the time it is identified. Adjustments generally result from contract changes with clients or manufacturers that have retroactive rebate adjustments, differences between the estimated and actual product mix subject to rebates, or whether the brand name drug was included in the applicable formulary. The effect of adjustments between estimated and actual manufacturers’ rebate amounts has not been material to the Company’s operating results or financial condition.

Guarantees
The Company also adjusts revenues for refunds owed to clients resulting from pricing guarantees and performance against defined service and performance metrics. The inputs to these estimates are not subject to a high degree of subjectivity or volatility. The effect of adjustments between estimated and actual pricing and performance refund amounts has not been material to the Company’s operating results or financial condition.

Retail/LTC Segment
Retail Pharmacy
The Company’s retail drugstores recognize revenue at the time the customer takes possession of the merchandise. For pharmacy sales, each prescription claim is its own arrangement with the customer and is a performance obligation, separate and distinct from other prescription claims under other retail network arrangements. Revenues are adjusted for refunds owed to third party payers resulting from pricing guarantees and performance against defined value-based service and performance metrics. The inputs to these estimates are not subject to a high degree of subjectivity or volatility. The effect of adjustments between estimated and actual pricing and performance refund amounts has not been material to the Company’s operating results or financial condition.

Revenue from Company gift cards purchased by customers is deferred as a contract liability until goods or services are transferred. Any amounts not expected to be redeemed by customers (i.e., breakage) are recognized based on historical redemption patterns.

Customer returns are not material to the Company’s operating results or financial condition. Sales taxes are not included in revenues.

Loyalty and Other Programs
The Company’s customer loyalty program, ExtraCare®, consists of two components, ExtraSavingsTM and ExtraBucks® Rewards. ExtraSavings are coupons that are recorded as a reduction of revenue when redeemed as the Company concluded that they do not represent a promise to the customer to deliver additional goods or services at the time of issuance because they are not tied to a specific transaction or spending level.

ExtraBucks Rewards are accumulated by customers based on their historical spending levels. Thus, the Company has determined that there is an additional performance obligation to those customers at the time of the initial transaction. The Company allocates the transaction price to the initial transaction and the ExtraBucks Rewards transaction based upon the relative standalone selling price, which considers historical redemption patterns for the rewards. Revenue allocated to ExtraBucks Rewards is recognized as those rewards are redeemed. At the end of each period, unredeemed ExtraBucks Rewards are reflected as a contract liability.

The Company also offers a subscription-based membership program, CarePass®, under which members are entitled to a suite of benefits delivered over the course of the subscription period, as well as a promotional reward that can be redeemed for future goods and services. Subscriptions are paid for on a monthly or annual basis at the time of or in advance of the Company delivering the goods and services. Revenue from these arrangements is recognized as the performance obligations are satisfied.

Long-term Care
Revenue is recognized when control of the promised goods or services is transferred to customers in an amount that reflects the consideration the Company expects to be entitled to receive in exchange for those goods or services. Each prescription claim represents a separate performance obligation of the Company, separate and distinct from other prescription claims under customer arrangements. A significant portion of long-term care revenue from sales of pharmaceutical and medical products is reimbursed by the federal Medicare Part D program and, to a lesser extent, state Medicaid programs. The Company monitors its revenues and receivables from these reimbursement sources, as well as long-term care facilities and other third party insurance payors, and reduces revenue at the revenue recognition date to properly account for the variable consideration due to anticipated differences between billed and reimbursed amounts. Accordingly, the total revenues and receivables reported in the Company’s consolidated financial statements are recorded at the amount expected to be ultimately received from these payors.
92



Patient co-payments associated with Medicare Part D, certain state Medicaid programs, Medicare Part B and certain third party payors typically are not collected at the time products are delivered or services are rendered, but are billed to the individuals as part of normal billing procedures and subject to normal accounts receivable collections procedures.

Walk-In Medical Clinics
For services provided by the Company’s walk-in medical clinics, revenue recognition occurs for completed services provided to patients, with adjustments taken for third party payor contractual obligations and patient direct bill historical collection rates.

Impairments of Debt Securities

The Company regularly reviews its debt securities to determine whether a decline in fair value below the cost basis or carrying value has occurred. If a debt security is in an unrealized loss position and the Company has the intent to sell the security, or it is more likely than not that the Company will have to sell the security before recovery of its amortized cost basis, the amortized cost basis of the security is written down to its fair value and the difference is recognized in net income. If a debt security is in an unrealized loss position and the Company does not have the intent to sell and it is more likely than not that the Company will not have to sell such security before recovery of its amortized cost basis, the Company bifurcates the impairment into credit-related and non-credit related components. The amount of the credit-related component is recorded as an allowance for credit losses and recognized in net income, and the amount of the non-credit related component is included in other comprehensive income. The Company analyzes all facts and circumstances believed to be relevant for each investment when performing this analysis, in accordance with applicable accounting guidance.

In evaluating whether a credit related loss exists, the Company considers a variety of factors including: the extent to which the fair value is less than the amortized cost basis; adverse conditions specifically related to the issuer of a security, an industry or geographic area; the payment structure of the security; the failure of the issuer of the security to make scheduled interest or principle payments; and any changes to the rating of the security by a rating agency.

During the years ended December 31, 2021 and 2020, the Company recorded yield-related impairment losses on debt securities of $42 million and $49 million, respectively. During the years ended December 31, 2021 and 2020, the Company did not record credit-related impairment losses on debt securities. During the year ended December 31, 2019, the Company recorded other-than-temporary impairment (“OTTI”) losses on debt securities of $24 million.

The risks inherent in assessing the impairment of a debt security include the risk that market factors may differ from projections and the risk that facts and circumstances factored into the Company’s assessment may change with the passage of time. Unexpected changes to market factors and circumstances that were not present in past reporting periods are among the factors that may result in a current period decision to sell debt securities that were not impaired in prior reporting periods.

Vendor Allowances and Purchase Discounts

Vendor and manufacturer receivables were $10.6 billion and $9.8 billion as of December 31, 2021 and 2020, respectively, the majority of which relate to purchase discounts and vendor allowances as described below.

Pharmacy Services Segment
The Pharmacy Services segment receives purchase discounts on products purchased. Contractual arrangements with vendors, including manufacturers, wholesalers and retail pharmacies, normally provide for the Pharmacy Services segment to receive purchase discounts from established list prices in one, or a combination, of the following forms: (i) a direct discount at the time of purchase, (ii) a discount for the prompt payment of invoices or (iii) when products are purchased indirectly from a manufacturer (e.g., through a wholesaler or retail pharmacy), a discount (or rebate) paid subsequent to dispensing. These rebates are recognized when prescriptions are dispensed and are generally calculated and billed to manufacturers within 30 days of the end of each completed quarter. Historically, the effect of adjustments resulting from the reconciliation of rebates recognized to the amounts billed and collected has not been material to the Company’s operating results or financial condition. The Company accounts for the effect of any such differences as a change in accounting estimate in the period the reconciliation is completed. The Pharmacy Services segment also receives additional discounts under its wholesaler contracts if it exceeds contractually defined purchase volumes. In addition, the Pharmacy Services segment receives fees from pharmaceutical manufacturers for administrative services. Purchase discounts and administrative service fees are recorded as a reduction of cost of products sold.

93


Retail/LTC Segment
Vendor allowances received by the Retail/LTC segment reduce the carrying cost of inventory and are recognized in cost of products sold when the related inventory is sold, unless they are specifically identified as a reimbursement of incremental costs for promotional programs and/or other services provided. Amounts that are directly linked to advertising commitments are recognized as a reduction of advertising expense (included in operating expenses) when the related advertising commitment is satisfied. Any such allowances received in excess of the actual cost incurred also reduce the carrying cost of inventory. The total value of any upfront payments received from vendors that are linked to purchase commitments is initially deferred. The deferred amounts are then amortized to reduce cost of products sold over the life of the contract based upon sales volume. The total value of any upfront payments received from vendors that are not linked to purchase commitments is also initially deferred. The deferred amounts are then amortized to reduce cost of products sold on a straight-line basis over the life of the related contract.

The Company establishes a receivable for vendor income that is earned but not yet received based on historical trends and data. The majority of vendor receivables are collected within the following fiscal quarter. Historically, adjustments to the Company’s vendor receivables resulting from the reconciliation of receivables recognized to the amounts collected have not been material to the Company’s operating results or financial condition.

There have not been any material changes in the way the Company accounts for vendor allowances or purchase discounts during the past three years.

Inventory

Inventories are valued at the lower of cost or net realizable value using the weighted average cost method.

The value of ending inventory is reduced for estimated inventory losses that have occurred during the interim period between physical inventory counts. Physical inventory counts are taken on a regular basis in each retail store and LTC pharmacy, and a continuous cycle count process is the primary procedure used to validate the inventory balances on hand in each distribution center and mail facility to ensure that the amounts reflected in the consolidated financial statements are properly stated. The Company’s accounting for inventory contains uncertainty since management must use judgment to estimate the inventory losses that have occurred during the interim period between physical inventory counts. When estimating these losses, a number of factors are considered which include historical physical inventory results on a location-by-location basis and current physical inventory loss trends.

The total reserve for estimated inventory losses covered by this critical accounting policy was $522 million and $369 million as of December 31, 2021 and 2020, respectively. Although management believes there is sufficient current and historical information available to record reasonable estimates for estimated inventory losses, it is possible that actual results could differ. In order to help investors assess the aggregate risk, if any, associated with the inventory-related uncertainties discussed above, a ten percent (10%) pre-tax change in estimated inventory losses, which is a reasonably likely change, would increase or decrease the total reserve for estimated inventory losses by approximately $52 million as of December 31, 2021.

Although management believes that the estimates discussed above are reasonable and the related calculations conform to generally accepted accounting principles, actual results could differ from such estimates, and such differences could be material.

Right-of-Use Assets and Lease Liabilities

The Company determines if an arrangement contains a lease at the inception of a contract. Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at the commencement date of the lease, renewal date of the lease or significant remodeling of the lease space based on the present value of the remaining future minimum lease payments. As the interest rate implicit in the Company’s leases is not readily determinable, the Company utilizes its incremental borrowing rate, determined by class of underlying asset, to discount the lease payments. The operating lease right-of-use assets also include lease payments made before commencement and are reduced by lease incentives. The Company evaluates the recoverability of its right-of-use assets as described in “Long-Lived Asset Impairment” below.

The Company’s real estate leases typically contain options that permit renewals for additional periods of up to five years each. For real estate leases, the options to extend are not considered reasonably certain at lease commencement because the Company reevaluates each lease on a regular basis to consider the economic and strategic incentives of exercising the renewal options and
94


regularly opens or closes stores to align with its operating strategy. Generally, the renewal option periods are not included within the lease term and the associated payments are not included in the measurement of the right-of-use asset and lease liability. Similarly, renewal options are not included in the lease term for non-real estate leases because they are not considered reasonably certain of being exercised at lease commencement. Leases with an initial term of 12 months or less are not recorded on the balance sheets, and lease expense is recognized on a straight-line basis over the term of the short-term lease.
For real estate leases, the Company accounts for lease components and nonlease components as a single lease component. Certain real estate leases require additional payments based on sales volume, as well as reimbursement for real estate taxes, common area maintenance and insurance, which are expensed as incurred as variable lease costs. Other real estate leases contain one fixed lease payment that includes real estate taxes, common area maintenance and insurance. These fixed payments are considered part of the lease payment and included in the right-of-use assets and lease liabilities.

Long-Lived Asset Impairment

Recoverability of Definite-Lived Assets
The Company evaluates the recoverability of long-lived assets, excluding goodwill and indefinite-lived intangible assets, which are tested for impairment using separate tests described below, whenever events or changes in circumstances indicate that the carrying value of such an asset may not be recoverable. The Company groups and evaluates these long-lived assets for impairment at the lowest level at which individual cash flows can be identified. If indicators of impairment are present, the Company first compares the carrying amount of the asset group to the estimated future cash flows associated with the asset group (undiscounted). If the estimated future cash flows used in this analysis are less than the carrying amount of the asset group, an impairment loss calculation is prepared. The impairment loss calculation compares the carrying amount of the asset group to the asset group’s estimated future cash flows (discounted). If required, an impairment loss is recorded for the portion of the asset group’s carrying value that exceeds the asset group’s estimated future cash flows (discounted).

The long-lived asset impairment loss calculation contains uncertainty since management must use judgment to estimate each asset group’s future sales, profitability and cash flows. When preparing these estimates, the Company considers historical results and current operating trends and consolidated sales, profitability and cash flow results and forecasts. These estimates can be affected by a number of factors including general economic and regulatory conditions, efforts of third party organizations to reduce their prescription drug costs and/or increased member co-payments, the continued efforts of competitors to gain market share and consumer spending patterns.

During the fourth quarter of 2021, the Company completed a strategic review of its retail business and announced the creation of new formats for its stores to continue to drive higher engagement with customers. As part of this review, the Company evaluated changes in population, consumer buying patterns and future health needs to ensure it has the right kinds of stores in the right locations for consumers and for the business. In connection with this initiative, on November 17, 2021, the Board of Directors of CVS Health Corporation (the “Board”) authorized the closing of approximately 900 stores over the next three years. The Company expects to close approximately 300 stores each year between 2022 and 2024. As a result, management determined that there were indicators of impairment with respect to the impacted stores’ asset groups, including the associated operating lease right-of-use assets and property and equipment. A long-lived asset impairment test was performed during the fourth quarter of 2021 and the results of the impairment test indicated that the fair value of certain retail store asset groups were lower than their respective carrying values. Accordingly, in the three months ended December 31, 2021, the Company recorded a store impairment charge of approximately $1.4 billion, consisting of a write down of approximately $1.1 billion related to operating lease right-of-use assets and $261 million related to property and equipment, within the Retail/LTC segment.

There were no material impairment charges recognized on long-lived assets in the year ended December 31, 2020. During the year ended December 31, 2019, the Company recorded store impairment charges of $231 million, primarily related to operating lease right-of-use asset impairment charges.

Recoverability of Goodwill
Goodwill represents the excess of amounts paid for acquisitions over the fair value of the net identifiable assets acquired. Goodwill is subject to annual impairment reviews, or more frequent reviews if events or circumstances indicate that the carrying value may not be recoverable. Goodwill is tested for impairment on a reporting unit basis. The impairment test is performed by comparing the reporting unit’s fair value with its net book value (or carrying amount), including goodwill. The fair value of the reporting units is estimated using a combination of a discounted cash flow method and a market multiple method. If the net book value (carrying amount) of the reporting unit exceeds its fair value, the reporting unit’s goodwill is considered to be impaired, and an impairment is recognized in an amount equal to the excess.

95


The determination of the fair value of the reporting units requires the Company to make significant assumptions and estimates. These assumptions and estimates primarily include the selection of appropriate peer group companies; control premiums and valuation multiples appropriate for acquisitions in the industries in which the Company competes; discount rates; terminal growth rates; and forecasts of revenue, operating income, depreciation and amortization, income taxes, capital expenditures and future working capital requirements. When determining these assumptions and preparing these estimates, the Company considers each reporting unit’s historical results and current operating trends; consolidated revenues, profitability and cash flow results and forecasts; and industry trends. The Company’s estimates can be affected by a number of factors, including general economic and regulatory conditions; the risk-free interest rate environment; the Company’s market capitalization; efforts of customers and payers to reduce costs, including their prescription drug costs, and/or increase member co-payments; the continued efforts of competitors to gain market share, consumer spending patterns and the Company’s ability to achieve its revenue growth projections and execute on its cost reduction initiatives.

2021 Goodwill Impairment Test
During the third quarter of 2021, the Company performed its required annual impairment tests of goodwill. The results of the impairment tests indicated an impairment of the goodwill associated with the LTC reporting unit, as the reporting unit’s carrying value exceeded its fair value as of the testing date. The results of the impairment tests of the remaining reporting units indicated that there was no impairment of goodwill as of the testing date. The fair values of the reporting units with goodwill exceeded their carrying values by significant margins, with the exception of the Commercial Business reporting unit, which exceeded its carrying value by approximately 3%.

As discussed in Note 5 ‘‘Goodwill and Other Intangibles’’ included in Item 8 of this 10-K, during 2021, the LTC reporting unit has continued to face challenges that have impacted the Company’s ability to grow the LTC reporting unit’s business at the rate estimated when its 2020 goodwill impairment test was performed. These challenges include lower net facility admissions, net long-term care facility customer losses and the prolonged adverse impact of the COVID-19 pandemic and the emerging new variants, which resulted in more significant declines in occupancy rates experienced by the Company’s long-term care facility customers than previously anticipated. During the third quarter of 2021, LTC management updated their 2021 annual forecast and submitted their long-term plan which showed deterioration in the financial results for the remainder of 2021 and beyond. The Company utilized these updated projections in performing its annual impairment test, which indicated that the fair value of the LTC reporting unit was lower than its carrying value, resulting in a $431 million goodwill impairment charge in the third quarter of 2021. The fair value of the LTC reporting unit was determined using a combination of a discounted cash flow method and a market multiple method. Subsequent to the impairment charge recorded in the third quarter of 2021, there is no remaining goodwill balance in the LTC reporting unit.

The Company has experienced declines in its Commercial Insured medical membership subsequent to the closing date of the Aetna Acquisition and may continue to do so for a number of reasons, including as a result of the competitive Commercial business environment. In addition, COVID-19 and the emerging new variants have had and may continue to have an adverse impact on medical membership in the Commercial business due to reductions in workforce at existing customers (including due to business failures) as well as reduced willingness to change benefit providers by prospective customers. The Company’s fair value estimate is sensitive to significant assumptions including changes in medical membership, revenue growth rate, operating income and the discount rate. Although the Company believes the financial projections used to determine the fair value of the Commercial Business reporting unit in the third quarter of 2021 were reasonable and achievable, the challenges described above may affect the Company’s ability to increase medical membership or operating income in the Commercial Business reporting unit at the rate estimated when such goodwill impairment test was performed and may continue to do so. As of December 31, 2021, the goodwill balance in the Commercial Business reporting unit was $26.5 billion.

2020 Goodwill Impairment Test
During the third quarter of 2020, the Company performed its required annual impairment test of goodwill. The results of this impairment test indicated that there was no impairment of goodwill as of the testing date. The goodwill impairment test resulted in the fair values of all of the Company’s reporting units exceeding their carrying values by significant margins, with the exception of the Commercial Business and LTC reporting units, which exceeded their carrying values by approximately 6% and 12%, respectively.

2019 Goodwill Impairment Test
During the third quarter of 2019, the Company performed its required annual impairment test of goodwill. The results of this impairment test indicated that there was no impairment of goodwill as of the testing date. The goodwill impairment test resulted in the fair values of all of the Company’s reporting units exceeding their carrying values by significant margins, with the exception of the Commercial Business and LTC reporting units, which exceeded their carrying values by approximately 4% and 9%, respectively.
96



Recoverability of Indefinite-Lived Intangible Assets
Indefinite-lived intangible assets are subject to annual impairment reviews, or more frequent reviews if events or circumstances indicate that their carrying value may not be recoverable. Indefinite-lived intangible assets are tested by comparing the estimated fair value of the asset to its carrying value. If the carrying value of the asset exceeds its estimated fair value, an impairment loss is recognized, and the asset is written down to its estimated fair value.

The indefinite-lived intangible asset impairment loss calculation contains uncertainty since management must use judgment to estimate fair value based on the assumption that, in lieu of ownership of an intangible asset, the Company would be willing to pay a royalty in order to utilize the benefits of the asset. Fair value is estimated by discounting the hypothetical royalty payments to their present value over the estimated economic life of the asset. These estimates can be affected by a number of factors including general economic conditions, availability of market information and the profitability of the Company. There were no impairment losses recognized on indefinite-lived intangible assets in any of the years ended December 31, 2021, 2020 or 2019.

Health Care Costs Payable

At December 31, 2021 and 2020, 75% and 77% respectively, of health care costs payable are estimates of the ultimate cost of (i) services rendered to the Company’s Insured members but not yet reported to the Company and (ii) claims which have been reported to the Company but not yet paid (collectively, “IBNR”). Health care costs payable also include an estimate of the cost of services that will continue to be rendered after the financial statement date if the Company is obligated to pay for such services in accordance with contractual or regulatory requirements. The remainder of health care costs payable is primarily comprised of pharmacy and capitation payables, other amounts due to providers pursuant to risk sharing agreements and accruals for state assessments. The Company develops its estimate of IBNR using actuarial principles and assumptions that consider numerous factors. See Note 1 ‘‘Significant Accounting Policies’’ included in Item 8 of this 10-K for additional information on the Company’s reserving methodology.

During 2021 and 2020, the Company observed an increase in completion factors relative to those assumed at the prior year end. After considering the claims paid in 2021 and 2020 with dates of service prior to the fourth quarter of the previous year, the Company observed assumed incurred claim weighted average completion factors that were 21 and 4 basis points higher, respectively, than previously estimated, resulting in a decrease of $207 million and $35 million in 2021 and 2020, respectively, in health care costs payable that related to the prior year. The Company has considered the pattern of changes in its completion factors when determining the completion factors used in its estimates of IBNR as of December 31, 2021. However, based on historical claim experience, it is reasonably possible that the Company’s estimated weighted average completion factors may vary by plus or minus 13 basis points from the Company’s assumed rates, which could impact health care costs payable by approximately plus or minus $186 million pretax.

Also during 2021 and 2020, the Company observed that health care costs for claims with claim incurred dates of three months or less before the financial statement date were lower than previously estimated. Specifically, after considering the claims paid in 2021 and 2020 with claim incurred dates for the fourth quarter of the previous year, the Company observed health care costs that were 5.0% and 4.0% lower, respectively, for each fourth quarter than previously estimated, resulting in a reduction of $581 million and $394 million in 2021 and 2020, respectively, in health care costs payable that related to prior year.

Management considers historical health care cost trend rates together with its knowledge of recent events that may impact current trends when developing estimates of current health care cost trend rates. When establishing reserves as of December 31, 2021, the Company increased its assumed health care cost trend rates for the most recent three months by 1.8% from health care cost trend rates recently observed. Health care cost trend rates during the past two years have been impacted by utilization changes driven by the COVID-19 pandemic. The impact has not been uniform, with products and select geographies experiencing utilization impacts due to COVID-19 waves. Based on historical claim experience, it is reasonably possible that the Company’s estimated health care cost trend rates may vary by plus or minus 3.5% from the assumed rates, which could impact health care costs payable by plus or minus $450 million pretax.

Income Taxes

The Company accounts for income taxes using the asset and liability method. Deferred tax assets and liabilities are established for any temporary differences between financial and tax reporting bases and are adjusted as needed to reflect changes in the enacted tax rates expected to be in effect when the temporary differences reverse. Such adjustments are recorded in the period
97


in which changes in tax laws are enacted, regardless of when they are effective. Deferred tax assets are reduced, if necessary, by a valuation allowance to the extent future realization of those losses, deductions or other tax benefits is sufficiently uncertain.
Significant judgment is required in determining the provision for income taxes and the related taxes payable and deferred tax assets and liabilities since, in the ordinary course of business, there are transactions and calculations where the ultimate tax outcome is uncertain. Additionally, the Company’s tax returns are subject to audit by various domestic and foreign tax authorities that could result in material adjustments based on differing interpretations of the tax laws. Although management believes that its estimates are reasonable and are based on the best available information at the time the provision is prepared, actual results could differ from these estimates resulting in a final tax outcome that may be materially different from that which is reflected in the consolidated financial statements.

The tax benefit from an uncertain tax position is recognized only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the consolidated financial statements from such positions are then measured based on the largest benefit that has a greater than 50% likelihood of being realized upon settlement with the related tax authority. Interest and/or penalties related to uncertain tax positions are recognized in the income tax provision. Significant judgment is required in determining uncertain tax positions. The Company has established accruals for uncertain tax positions using its judgment and adjusts these accruals, as warranted, due to changing facts and circumstances.

New Accounting Pronouncements

See Note 1 ‘‘Significant Accounting Policies’’ included in Item 8 of this 10-K for a description of new accounting pronouncements applicable to the Company.

98

Item 7A. Quantitative and Qualitative Disclosures About Market Risk.

The Company’s earnings and financial condition are exposed to interest rate risk, credit quality risk, market valuation risk, foreign currency risk, commodity risk and operational risk.

Evaluation of Interest Rate and Credit Quality Risk

The Company manages interest rate risk by seeking to maintain a tight match between the durations of assets and liabilities when appropriate. The Company manages credit quality risk by seeking to maintain high average credit quality ratings and diversified sector exposure within its debt securities portfolio. In connection with its investment and risk management objectives, the Company also uses derivative financial instruments whose market value is at least partially determined by, among other things, levels of or changes in interest rates (short-term or long-term), duration, prepayment rates, equity markets or credit ratings/spreads. The Company’s use of these derivatives is generally limited to hedging risk and has principally consisted of using interest rate swaps, treasury rate locks, forward contracts, futures contracts, warrants, put options and credit default swaps. These instruments, viewed separately, subject the Company to varying degrees of interest rate, equity price and credit risk. However, when used for hedging, the Company expects these instruments to reduce overall risk.

Investments
The Company’s investment portfolio supported the following products at December 31, 2021 and 2020:
In millions20212020
Experience-rated products $957 $1,037 
Remaining products25,185 22,775 
Total investments$26,142 $23,812 

Investment risks associated with experience-rated products generally do not impact the Company’s operating results. The risks associated with investments supporting experience-rated pension and annuity products in the large case pensions business in the Company’s Corporate/Other segment are assumed by the contract holders and not by the Company (subject to, among other things, certain minimum guarantees). Assets supporting experience-rated products may be subject to contract holder or participant withdrawals.

The debt securities in the Company’s investment portfolio had an average credit quality rating of A at both December 31, 2021 and 2020, with a fair value of approximately $6.7 billion and $6.3 billion rated AAA at December 31, 2021 and 2020, respectively. The fair value of debt securities that were rated below investment grade (that is, having a credit quality rating below BBB-/Baa3) was $2.3 billion and $1.9 billion at December 31, 2021 and 2020, respectively (of which 2% at both December 31, 2021 and 2020 supported experience-rated products).

At December 31, 2021 and 2020, the Company held $305 million and $321 million, respectively, of municipal debt securities that were guaranteed by third parties, representing 1% of total investments at both December 31, 2021 and 2020. These securities had an average credit quality rating of AA at both December 31, 2021 and 2020 with the guarantee. These securities had an average credit quality rating of A at both December 31, 2021 and 2020, respectively, without the guarantee. The Company does not have any significant concentration of investments with third party guarantors (either direct or indirect).

The Company generally classifies debt securities as available for sale, and carries them at fair value on the consolidated balance sheets. At both December 31, 2021 and 2020, less than 1% of debt securities were valued using inputs that reflect the Company’s assumptions (categorized as Level 3 inputs in accordance with accounting principles generally accepted in the United States of America). See Note 4 ‘‘Fair Value’’ included in Item 8 of this 10-K for additional information on the methodologies and key assumptions used to determine the fair value of investments. For additional information related to investments, see Note 3 ‘‘Investments’’ included in Item 8 of this 10-K.

The Company regularly reviews debt securities in its portfolio to determine whether a decline in fair value below the cost basis or carrying value has occurred. If a debt security is in an unrealized loss position and the Company has the intent to sell the security, or it is more likely than not that the Company will have to sell the security before recovery of its amortized cost basis, the amortized cost basis of the security is written down to its fair value and the difference is recognized in net income. If a debt security is in an unrealized loss position and the Company does not have the intent to sell and it is more likely than not that the Company will not have to sell such security before recovery of its amortized cost basis, the Company bifurcates the impairment into credit-related and non-credit related components. The amount of the credit-related component is recorded as an allowance
99


for credit losses and recognized in net income, and the amount of the non-credit related component is included in other comprehensive income. The impairment of debt securities is considered a critical accounting policy. See ‘‘Critical Accounting Policies - Impairments of Debt Securities” in the MD&A included in Item 7 of this 10-K for additional information.

Evaluation of Market Valuation Risks

The Company regularly evaluates its risk from market-sensitive instruments by examining, among other things, levels of or changes in interest rates (short-term or long-term), duration, prepayment rates, equity markets and/or credit ratings/spreads. The Company also regularly evaluates the appropriateness of investments relative to management-approved investment guidelines (and operates within those guidelines) and the business objectives of its portfolios.

On a quarterly basis, the Company reviews the impact of hypothetical net losses in its investment portfolio on the Company’s consolidated near-term financial condition, operating results and cash flows assuming the occurrence of certain reasonably possible changes in near-term market rates and prices. Interest rate changes (whether resulting from changes in treasury yields or credit spreads or other factors) represent the most material risk exposure category for the Company. The Company has estimated the impact on the fair value of market sensitive instruments based on the net present value of cash flows using a representative set of likely future interest rate scenarios. The assumptions used were as follows: an immediate increase of 100 basis points in interest rates (which the Company believes represents a moderately adverse scenario) for long-term debt issued by the Company, as well as its interest rate sensitive investments and an immediate decrease of 15% in prices for publicly traded domestic equity securities in the Company’s investment portfolio.

Assuming an immediate increase of 100 basis points in interest rates, the theoretical decline in the fair values of market sensitive instruments at December 31, 2021 is as follows:

The fair value of long-term debt issued by the Company would decline by approximately $4.6 billion ($5.8 billion pretax). Changes in the fair value of long-term debt do not impact the Company’s operating results or financial condition.
The theoretical reduction in the fair value of interest rate sensitive investments partially offset by the theoretical reduction in the fair value of interest rate sensitive liabilities would result in a net decline in fair value of approximately $680 million ($860 million pretax) related to continuing non-experience-rated products. Reductions in the fair value of investment securities would be reflected as an unrealized loss in equity, as the Company classifies these debt securities as available for sale. The Company does not record liabilities at fair value.

If the value of the Company’s publicly traded domestic equity securities held within its investment portfolio were to decline by 15%, this would result in a net decline in fair value of $14 million ($18 million pretax).

Based on overall exposure to interest rate risk and equity price risk, the Company believes that these changes in market rates and prices would not materially affect consolidated near-term financial condition, operating results or cash flows as of December 31, 2021.

Evaluation of Foreign Currency and Commodity Risk

At December 31, 2021 and 2020, the Company did not have any material foreign currency exchange rate or commodity derivative instruments in place and believes its exposure to foreign currency exchange rate risk is not material.

Evaluation of Operational Risks

The Company also faces certain operational risks. Those risks include risks related to the COVID-19 pandemic and risks related to information security, including cybersecurity.

The spread of COVID-19, or actions taken to mitigate its spread, could have material and adverse effects on our ability to operate our businesses effectively, including as a result of the complete or partial closure of facilities or labor shortages. Disruptions in our supply chains, our distribution chains and/or public and private infrastructure, including communications, financial services and supply chains, could materially and adversely impact our business operations. We have transitioned a significant subset of our colleagues to a remote work environment in an effort to mitigate the spread of COVID-19, as have a significant number of our third-party service providers, which may amplify certain risks to our businesses, including an increased demand for information technology resources, increased risk of phishing and other cyber attacks, increased risk of unauthorized dissemination of sensitive personal information or proprietary or confidential information about us or our medical members or other third-parties and increased risk of business interruptions.
100



The Company and its vendors have experienced diverse cyber attacks and expect to continue to experience cyber attacks going forward. As examples, the Company and its vendors have experienced attempts to gain access to systems, denial of service attacks, attempted malware infections, account takeovers, scanning activity and phishing emails. Attacks can originate from external criminals, terrorists, nation states or internal actors. The Company is dedicating and will continue to dedicate significant resources and incur significant expenses to maintain and update on an ongoing basis the systems and processes that are designed to mitigate the information security risks it faces and protect the security of its computer systems, software, networks and other technology assets against attempts by unauthorized parties to obtain access to confidential information, disrupt or degrade service or cause other damage. The impact of cyber attacks has not been material to the Company’s operations or operating results through December 31, 2021. The Board and its Audit Committee and Nominating and Corporate Governance Committee are regularly informed regarding the Company’s information security policies, practices and status.

101

Item 8. Financial Statements and Supplementary Data.


Index to Consolidated Financial Statements

102

Consolidated Statements of Operations
For the Years Ended December 31,
In millions, except per share amounts202120202019
Revenues:   
Products
$203,738 $190,688 $185,236 
Premiums
76,132 69,364 63,122 
Services
11,042 7,856 7,407 
Net investment income
1,199 798 1,011 
Total revenues292,111 268,706 256,776 
Operating costs:
Cost of products sold
175,803 163,981 158,719 
Benefit costs
64,260 55,679 52,529 
Store impairments1,358  231 
Goodwill impairment431   
Operating expenses37,066 35,135 33,310 
Total operating costs278,918 254,795 244,789 
Operating income13,193 13,911 11,987 
Interest expense2,503 2,907 3,035 
Loss on early extinguishment of debt452 1,440 79 
Other income(182)(206)(124)
Income before income tax provision10,420 9,770 8,997 
Income tax provision2,522 2,569 2,366 
Income from continuing operations7,898 7,201 6,631 
Loss from discontinued operations, net of tax (9) 
Net income7,898 7,192 6,631 
Net (income) loss attributable to noncontrolling interests12 (13)3 
Net income attributable to CVS Health$7,910 $7,179 $6,634 
Basic earnings per share:
Income from continuing operations attributable to CVS Health$6.00 $5.49 $5.10 
Loss from discontinued operations attributable to CVS Health$ $(0.01)$ 
Net income attributable to CVS Health$6.00 $5.48 $5.10 
Weighted average basic shares outstanding1,319 1,309 1,301 
Diluted earnings per share:
Income from continuing operations attributable to CVS Health$5.95 $5.47 $5.08 
Loss from discontinued operations attributable to CVS Health$ $(0.01)$ 
Net income attributable to CVS Health$5.95 $5.46 $5.08 
Weighted average diluted shares outstanding1,329 1,314 1,305 
Dividends declared per share$2.00 $2.00 $2.00 

See accompanying notes to consolidated financial statements.
103

Consolidated Statements of Comprehensive Income
For the Years Ended December 31,
In millions202120202019
Net income$7,898 $7,192 $6,631 
Other comprehensive income (loss), net of tax:
Net unrealized investment gains (losses)(436)440 677 
Foreign currency translation adjustments(7)3 162 
Net cash flow hedges(26)(31)(33)
Pension and other postretirement benefits 20 (17)111 
Other comprehensive income (loss)(449)395 917 
Comprehensive income7,449 7,587 7,548 
Comprehensive (income) loss attributable to noncontrolling interests12 (13)3 
Comprehensive income attributable to CVS Health$7,461 $7,574 $7,551 

See accompanying notes to consolidated financial statements.
104

Consolidated Balance Sheets
At December 31,
In millions, except per share amounts20212020
Assets: 
Cash and cash equivalents$9,408 $7,854 
Investments3,117 3,000 
Accounts receivable, net24,431 21,742 
Inventories17,760 18,496 
Other current assets5,292 5,277 
Total current assets60,008 56,369 
Long-term investments23,025 20,812 
Property and equipment, net12,896 12,606 
Operating lease right-of-use assets19,122 20,729 
Goodwill79,121 79,552 
Intangible assets, net29,026 31,142 
Separate accounts assets5,087 4,881 
Other assets4,714 4,624 
Total assets$232,999 $230,715 
Liabilities:
Accounts payable$12,544 $11,138 
Pharmacy claims and discounts payable17,330 15,795 
Health care costs payable 8,808 7,936 
Policyholders’ funds4,301 4,270 
Accrued expenses17,670 14,243 
Other insurance liabilities1,303 1,557 
Current portion of operating lease liabilities1,646 1,638 
Current portion of long-term debt4,205 5,440 
Total current liabilities67,807 62,017 
Long-term operating lease liabilities18,177 18,757 
Long-term debt51,971 59,207 
Deferred income taxes6,270 6,794 
Separate accounts liabilities5,087 4,881 
Other long-term insurance liabilities6,402 7,007 
Other long-term liabilities1,904 2,351 
Total liabilities157,618 161,014 
Commitments and contingencies (Note 16)
Shareholders’ equity:
Preferred stock, par value $0.01: 0.1 shares authorized; none issued or outstanding
  
Common stock, par value $0.01: 3,200 shares authorized; 1,744 shares issued and 1,322 shares outstanding at December 31, 2021 and 1,733 shares issued and 1,310 shares outstanding at December 31, 2020 and capital surplus
47,377 46,513 
Treasury stock, at cost: 422 and 423 shares at December 31, 2021 and 2020
(28,173)(28,178)
Retained earnings54,906 49,640 
Accumulated other comprehensive income965 1,414 
Total CVS Health shareholders’ equity75,075 69,389 
Noncontrolling interests306 312 
Total shareholders’ equity75,381 69,701 
Total liabilities and shareholders’ equity$232,999 $230,715 

See accompanying notes to consolidated financial statements.
105

Consolidated Statements of Cash Flows
For the Years Ended December 31,
In millions202120202019
Cash flows from operating activities:  
Cash receipts from customers$284,219 $264,327 $248,393 
Cash paid for inventory and prescriptions dispensed by retail network pharmacies(165,783)(158,636)(149,655)
Insurance benefits paid (63,598)(55,124)(52,242)
Cash paid to other suppliers and employees(31,652)(29,763)(28,932)
Interest and investment income received743 894 955 
Interest paid(2,469)(2,904)(2,954)
Income taxes paid(3,195)(2,929)(2,717)
Net cash provided by operating activities18,265 15,865 12,848 
Cash flows from investing activities:
Proceeds from sales and maturities of investments7,246 6,467 7,049 
Purchases of investments(9,963)(9,639)(7,534)
Purchases of property and equipment(2,520)(2,437)(2,457)
Proceeds from sale-leaseback transactions 101 5 
Acquisitions (net of cash acquired)(146)(866)(444)
Proceeds from sale of subsidiary 840  
Other122  42 
Net cash used in investing activities(5,261)(5,534)(3,339)
Cash flows from financing activities:
Net repayments of short-term debt  (720)
Proceeds from issuance of long-term debt987 9,958 3,736 
Repayments of long-term debt(10,254)(15,631)(8,336)
Derivative settlements (7)(25)
Dividends paid(2,625)(2,624)(2,603)
Proceeds from exercise of stock options549 264 210 
Payments for taxes related to net share settlement of equity awards(168)(88)(112)
Other155 432 196 
Net cash used in financing activities(11,356)(7,696)(7,654)
Net increase in cash, cash equivalents and restricted cash1,648 2,635 1,855 
Cash, cash equivalents and restricted cash at the beginning of the period11,043 8,408 6,553 
Cash, cash equivalents and restricted cash at the end of the period$12,691 $11,043 $8,408 
106

For the Years Ended December 31,
In millions202120202019
Reconciliation of net income to net cash provided by operating activities:
Net income$7,898 $7,192 $6,631 
Adjustments required to reconcile net income to net cash provided by operating activities:
Depreciation and amortization4,512 4,441 4,371 
Store impairments1,358  231 
Goodwill impairment431   
Stock-based compensation484 400 453 
(Gain) loss on sale of subsidiaries (269)205 
Loss on early extinguishment of debt452 1,440 79 
Deferred income taxes(428)(570)(654)
Other noncash items(390)72 33 
Change in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable, net(2,703)(1,510)(2,158)
Inventories735 (973)(1,075)
Other assets(3)364 (614)
Accounts payable and pharmacy claims and discounts payable2,898 2,769 3,550 
Health care costs payable and other insurance liabilities169 (231)320 
Other liabilities2,852 2,740 1,476 
Net cash provided by operating activities$18,265 $15,865 $12,848 

See accompanying notes to consolidated financial statements.
107

Consolidated Statements of Shareholders’ Equity
Attributable to CVS Health
Number of shares
outstanding
Common
Stock and
Capital
Surplus (2)
Accumulated
Other
Comprehensive
Income
Total
CVS Health
Shareholders’
Equity
Total
Shareholders’
Equity
In millionsCommon
Shares
Treasury
Shares (1)
Treasury
Stock (1)
Retained
Earnings
Noncontrolling
Interests
Balance at December 31, 20181,720 (425)$45,440 $(28,228)$40,911 $102 $58,225 $318 $58,543 
Adoption of new accounting standards (3)
— — — — 178 — 178 — 178 
Net income— — — — 6,634 — 6,634 (3)6,631 
Other comprehensive income (Note 13)— — — — — 917 917 — 917 
Stock option activity, stock awards and other7 2 532 — — — 532 — 532 
Purchase of treasury shares, net of ESPP issuances— (2)— (7)— — (7)— (7)
Common stock dividends— — — — (2,615)— (2,615)— (2,615)
Other decreases in noncontrolling interests       (9)(9)
Balance at December 31, 20191,727 (425)45,972 (28,235)45,108 1,019 63,864 306 64,170 
Adoption of new accounting standard (4)
— — — — (3)— (3)— (3)
Net income— — — — 7,179 — 7,179 13 7,192 
Other comprehensive income (Note 13)— — — — — 395 395 — 395 
Stock option activity, stock awards and other6 — 541 — — — 541 — 541 
ESPP issuances, net of purchase of treasury shares— 2 — 57 — — 57 — 57 
Common stock dividends— — — — (2,644)— (2,644)— (2,644)
Other decreases in noncontrolling interests— — — — — — — (7)(7)
Balance at December 31, 20201,733 (423)46,513 (28,178)49,640 1,414 69,389 312 69,701 
Net income— — — — 7,910 — 7,910 (12)7,898 
Other comprehensive loss (Note 13)— — — — — (449)(449)— (449)
Stock option activity, stock awards and other11 — 864 — — — 864 — 864 
ESPP issuances, net of purchase of treasury shares— 1 — 5 — — 5 — 5 
Common stock dividends— — — — (2,644)— (2,644)— (2,644)
Other increases in noncontrolling interests— — — — — — — 6 6 
Balance at December 31, 20211,744 (422)$47,377 $(28,173)$54,906 $965 $75,075 $306 $75,381 
_____________________________________________
(1)Treasury shares include 1 million shares held in trust for each of the years ended December 31, 2021, 2020 and 2019. Treasury stock includes $29 million related to shares held in trust for each of the years ended December 31, 2021, 2020 and 2019. See Note 1 ‘‘Significant Accounting Policies’’ for additional information.
(2)Common stock and capital surplus includes the par value of common stock of $17 million as of December 31, 2021, 2020 and 2019.
(3)Reflects the adoption of Accounting Standards Update (“ASU”) 2016-02, Leases (Topic 842), which resulted in an increase to retained earnings of $178 million during the year ended December 31, 2019.
(4)Reflects the adoption of ASU 2016-13, Financial Instruments - Credit Losses (Topic 326), which resulted in a reduction to retained earnings of $3 million during the year ended December 31, 2020.

See accompanying notes to consolidated financial statements.
108

Notes to Consolidated Financial Statements

1.Significant Accounting Policies

Description of Business 

CVS Health Corporation, together with its subsidiaries (collectively, “CVS Health” or the “Company”), has more than 9,900 retail locations, nearly 1,200 walk-in medical clinics, a leading pharmacy benefits manager with approximately 110 million plan members with expanding specialty pharmacy solutions and a dedicated senior pharmacy care business serving more than one million patients per year. The Company also serves an estimated 35 million people through traditional, voluntary and consumer-directed health insurance products and related services, including expanding Medicare Advantage offerings and a leading standalone Medicare Part D prescription drug plan (“PDP”). The Company believes its innovative health care model increases access to quality care, delivers better health outcomes and lowers overall health care costs.

The coronavirus disease 2019 (“COVID-19”) and its emerging new variants continue to impact the economies of the U.S. and other countries around the world. The impact of COVID-19 on the Company’s businesses, operating results, cash flows and financial condition in the years ended December 31, 2021 and 2020, as well as information regarding certain expected impacts of COVID-19 on the Company, is discussed throughout this Annual Report on Form 10-K.

The Company has four reportable segments: Health Care Benefits, Pharmacy Services, Retail/LTC and Corporate/Other, which are described below.

Health Care Benefits Segment
The Health Care Benefits segment operates as one of the nation’s leading diversified health care benefits providers. The Health Care Benefits segment has the information and resources to help members, in consultation with their health care professionals, make more informed decisions about their health care. The Health Care Benefits segment offers a broad range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, medical management capabilities, Medicare Advantage and Medicare Supplement plans, PDPs, Medicaid health care management services and health information technology products and services. The Health Care Benefits segment also provided workers’ compensation administrative services through its Coventry Health Care Workers’ Compensation business (“Workers’ Compensation business”) prior to the sale of this business on July 31, 2020. The Health Care Benefits segment’s customers include employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers (“providers”), governmental units, government-sponsored plans, labor groups and expatriates. The Company refers to insurance products (where it assumes all or a majority of the risk for medical and dental care costs) as “Insured” and administrative services contract products (where the plan sponsor assumes all or a majority of the risk for medical and dental care costs) as “ASC.” In addition, effective January 2022, the Company entered the individual public health insurance exchanges (“Public Exchanges”) in eight states through which it sells Insured plans directly to individual consumers.

Pharmacy Services Segment
The Pharmacy Services segment provides a full range of pharmacy benefit management (“PBM”) solutions, including plan design offerings and administration, formulary management, retail pharmacy network management services and mail order pharmacy. In addition, through the Pharmacy Services segment, the Company provides specialty pharmacy and infusion services, clinical services, disease management services, medical spend management and pharmacy and/or other administrative services for providers and federal 340B drug pricing program covered entities (“Covered Entities”). The Pharmacy Services segment’s clients are primarily employers, insurance companies, unions, government employee groups, health plans, PDPs, Medicaid managed care plans, plans offered on Public Exchanges and private health insurance exchanges, other sponsors of health benefit plans throughout the United States and Covered Entities. The Pharmacy Services segment operates retail specialty pharmacy stores, specialty mail order pharmacies, mail order dispensing pharmacies, compounding pharmacies and branches for infusion and enteral nutrition services.

Retail/LTC Segment
The Retail/LTC segment sells prescription drugs and a wide assortment of health and wellness products and general merchandise, provides health care services through its MinuteClinic® walk-in medical clinics, provides medical diagnostic testing, administers vaccinations for illnesses such as influenza, COVID-19 and shingles and conducts long-term care pharmacy (“LTC”) operations, which distribute prescription drugs and provide related pharmacy consulting and other ancillary services to long-term care facilities and other care settings. As of December 31, 2021, the Retail/LTC segment operated more than 9,900 retail locations, nearly 1,200 MinuteClinic locations as well as online retail pharmacy websites, LTC pharmacies and on-site pharmacies.
109



Corporate/Other Segment
The Company presents the remainder of its financial results in the Corporate/Other segment, which primarily consists of:

Management and administrative expenses to support the Company’s overall operations, which include certain aspects of executive management and the corporate relations, legal, compliance, human resources, information technology and finance departments, expenses associated with the Company’s investments in its transformation and enterprise modernization programs and acquisition-related transaction and integration costs; and
Products for which the Company no longer solicits or accepts new customers such as its large case pensions and long-term care insurance products.

Basis of Presentation

The accompanying consolidated financial statements of CVS Health and its subsidiaries have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The consolidated financial statements include the accounts of the Company and its majority-owned subsidiaries and variable interest entities (“VIEs”) for which the Company is the primary beneficiary. All material intercompany balances and transactions have been eliminated.

Reclassifications

Certain prior year amounts have been reclassified to conform with the current year presentation.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates.

Cash and Cash Equivalents

Cash and cash equivalents consist of cash and temporary investments with maturities of three months or less when purchased. The Company invests in short-term money market funds, commercial paper and time deposits, as well as other debt securities that are classified as cash equivalents within the accompanying consolidated balance sheets, as these funds are highly liquid and readily convertible to known amounts of cash.

Restricted Cash

Restricted cash (included in other current assets) represents funds held on behalf of members, including health savings account (“HSA”) funds associated with high deductible health plans. Beginning in 2021, the Company began presenting these funds held on behalf of members in restricted cash and, for statement of cash flow purposes, retrospectively adjusted the 2020 and 2019 balances by the amounts shown in the table below in the line item “restricted cash (included in other current assets)” to conform with the current year presentation. Restricted cash (included in other assets) represents amounts held in a trust in one of the Company’s captive insurance companies to satisfy collateral requirements associated with the assignment of certain insurance policies. All restricted cash is invested in time deposits, money market funds or commercial paper.

The following is a reconciliation of cash and cash equivalents on the consolidated balance sheets to total cash, cash equivalents and restricted cash on the consolidated statements of cash flows as of December 31, 2021, 2020 and 2019:
In millions202120202019
Cash and cash equivalents$9,408 $7,854 $5,683 
Restricted cash (included in other current assets)3,065 2,913 2,454 
Restricted cash (included in other assets)218 276 271 
Total cash, cash equivalents and restricted cash in the consolidated statements of cash flows$12,691 $11,043 $8,408 



110


Investments

Debt Securities
Debt securities consist primarily of U.S. Treasury and agency securities, mortgage-backed securities, corporate and foreign bonds and other debt securities. Debt securities are classified as either current or long-term investments based on their contractual maturities unless the Company intends to sell an investment within the next twelve months, in which case it is classified as current on the consolidated balance sheets. Debt securities are classified as available for sale and are carried at fair value. See Note 4 ‘‘Fair Value’’ for additional information on how the Company estimates the fair value of these investments.

If a debt security is in an unrealized loss position and the Company has the intent to sell the security, or it is more likely than not that the Company will have to sell the security before recovery of its amortized cost basis, the amortized cost basis of the security is written down to its fair value and the difference is recognized in net income. If a debt security is in an unrealized loss position and the Company does not have the intent to sell and it is more likely than not that the Company will not have to sell such security before recovery of its amortized cost basis, the Company bifurcates the impairment into credit-related and non-credit related components. In evaluating whether a credit related loss exists, the Company considers a variety of factors including: the extent to which the fair value is less than the amortized cost basis; adverse conditions specifically related to the issuer of a security, an industry or geographic area; the payment structure of the security; the failure of the issuer of the security to make scheduled interest or principal payments; and any changes to the rating of the security by a rating agency. The amount of the credit-related component is recorded as an allowance for credit losses and recognized in net income, and the amount of the non-credit related component is included in other comprehensive income. Interest is not accrued on debt securities when management believes the collection of interest is unlikely.

The credit-related component is determined by comparing the present value of cash flows expected to be collected from the security, considering all reasonably available information relevant to the collectability of the security, with the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis of the security, the Company records an allowance for credit losses, which is limited by the amount that the fair value is less than amortized cost basis.

For mortgage-backed and other asset-backed securities, the Company recognizes income using an effective yield based on anticipated prepayments and the estimated economic life of the securities. When estimates of prepayments change, the effective yield is recalculated to reflect actual payments to date and anticipated future payments. The Company’s investment in the security is adjusted to the amount that would have existed had the new effective yield been applied since the acquisition of the security, with adjustments recognized in net income.

Equity Securities
Equity securities with readily available fair values are measured at fair value with changes in fair value recognized in net income (loss).

Mortgage Loans
Mortgage loan investments on the consolidated balance sheets are valued at the unpaid principal balance, net of an allowance for credit losses. Mortgage loans with a maturity date or a committed prepayment date within twelve months are classified as current on the consolidated balance sheets. The Company assesses whether its loans share similar risk characteristics and, if so, groups such loans in a risk pool when measuring expected credit losses. The Company considers the following characteristics when evaluating whether its loans share similar risk characteristics: loan-to-value ratios, property type (e.g., office, retail, apartment, industrial), geographic location, vacancy rates and property condition.

Credit loss reserves are determined using a loss rate method that multiplies the unpaid principal balance of each loan within a risk pool group by an estimated loss rate percentage. The loss rate percentage considers both the expected loan loss severity and the probability of loan default. For periods where the Company is able to make or obtain reasonable and supportable forecasts of expected economic conditions (e.g., gross domestic product, employment), the Company adjusts its expected loss rates to reflect these forecasted economic conditions. For periods beyond which the Company is able to make or obtain reasonable and supportable forecasts of expected economic conditions, the Company reverts to historical loss rates in determining expected credit losses.

Interest income on a potential problem loan (i.e., high probability of default) or restructured loan is accrued to the extent it is deemed to be collectible and the loan continues to perform under its original or restructured terms. Interest income on problem loans (i.e., more than 60 days delinquent, in bankruptcy or in process of foreclosure) is recognized on a cash basis. Cash payments on loans in the process of foreclosure are treated as a return of principal.
111


Other Investments
Other investments consist primarily of the following:

Private equity and hedge fund limited partnerships, which are accounted for using the equity method of accounting. Under this method, the carrying value of the investment is based on the value of the Company’s equity ownership of the underlying investment funds provided by the general partner or manager of the investments, the financial statements of which generally are audited. As a result of the timing of the receipt of the valuation information provided by the fund managers, these investments are generally reported on up to a three month lag. The Company reviews investments for impairment at least quarterly and monitors their performance throughout the year through discussions with the administrators, managers and/or general partners. If the Company becomes aware of an impairment of a limited partnership’s investments through its review or prior to receiving the limited partnership’s financial statements at the financial statement date, an impairment will be recognized by recording a reduction in the carrying value of the limited partnership with a corresponding charge to net investment income.
Investment real estate, which is carried on the consolidated balance sheets at depreciated cost, including capital additions, net of write-downs for other-than-temporary declines in fair value. Depreciation is calculated using the straight-line method based on the estimated useful life of each asset. If any real estate investment is considered held-for-sale, it is carried at the lower of its carrying value or fair value less estimated selling costs. The Company generally estimates fair value using net operating income and applying a capitalization rate in conjunction with comparable sales information. At the time of the sale, the difference between the sales price and the carrying value is recorded as a realized capital gain or loss.
Privately-placed equity securities, which are carried on the consolidated balance sheets at cost less impairments, plus or minus subsequent adjustments for observable price changes. Additionally, as a member of the Federal Home Loan Bank of Boston (“FHLBB”), a subsidiary of the Company is required to purchase and hold shares of the FHLBB. These shares are restricted and carried at cost.

Net Investment Income
Net investment income on the Company’s investments is recorded when earned and is reflected in the Company’s net income (other than net investment income on assets supporting experience-rated products). Experience-rated products are products in the large case pensions business where the contract holder, not the Company, assumes investment and other risks, subject to, among other things, minimum guarantees provided by the Company. The effect of investment performance on experience-rated products is allocated to contract holders’ accounts daily, based on the underlying investment experience and, therefore, does not impact the Company’s net income (as long as the contract’s minimum guarantees are not triggered). Net investment income on assets supporting large case pensions’ experience-rated products is included in net investment income in the consolidated statements of operations and is credited to contract holders’ accounts through a charge to benefit costs. The contract holders’ accounts are reflected in policyholders’ funds on the consolidated balance sheets.

Realized capital gains and losses on investments (other than realized capital gains and losses on investments supporting experience-rated products) are included as a component of net investment income in the consolidated statements of operations. Realized capital gains and losses are determined on a specific identification basis. Purchases and sales of debt and equity securities and alternative investments are reflected on the trade date. Purchases and sales of mortgage loans and investment real estate are reflected on the closing date.

Realized capital gains and losses on investments supporting large case pensions’ experience-rated products are not included in realized capital gains and losses in the consolidated statements of operations and instead are credited directly to contract holders’ accounts. The contract holders’ accounts are reflected in policyholders’ funds on the consolidated balance sheets.

Unrealized capital gains and losses on investments (other than unrealized capital gains and losses on investments supporting experience-rated products) are reflected in shareholders’ equity, net of tax, as a component of accumulated other comprehensive income. Unrealized capital gains and losses on investments supporting large case pensions’ experience-rated products are credited directly to contract holders’ accounts. The contract holders’ accounts are reflected in policyholders’ funds on the consolidated balance sheets.

Derivative Financial Instruments

The Company uses derivative financial instruments in order to manage interest rate and foreign exchange risk and credit exposure. The Company’s use of these derivatives is generally limited to hedging risk and has principally consisted of using interest rate swaps, treasury rate locks, forward contracts, futures contracts, warrants, put options and credit default swaps.


112


Accounts Receivable

Accounts receivable are stated net of allowances for credit losses, customer credit allowances, contractual allowances and estimated terminations. Accounts receivable, net is composed of the following at December 31, 2021 and 2020:
In millions20212020
Trade receivables$7,932 $7,101 
Vendor and manufacturer receivables10,573 9,815 
Premium receivables2,537 2,628 
Other receivables3,389 2,198 
   Total accounts receivable, net $24,431 $21,742 

The Company’s allowance for credit losses was $339 million and $358 million as of December 31, 2021 and 2020, respectively. When developing an estimate of the Company’s expected credit losses, the Company considers all available relevant information regarding the collectability of cash flows, including historical information, current conditions and reasonable and supportable forecasts of future economic conditions over the contractual life of the receivable. The Company’s accounts receivable are short duration in nature and typically settle in less than 30 days.

Inventories

Inventories are valued at the lower of cost or net realizable value using the weighted average cost method. Physical inventory counts are taken on a regular basis in each retail store and LTC pharmacy, and a continuous cycle count process is the primary procedure used to validate the inventory balances on hand in each distribution center and mail facility to ensure that the amounts reflected in the consolidated financial statements are properly stated. During the interim period between physical inventory counts, the Company accrues for anticipated physical inventory losses on a location-by-location basis based on historical results and current physical inventory trends.

Reinsurance Recoverables

The Company utilizes reinsurance agreements primarily to: (a) reduce required capital and (b) facilitate the acquisition or disposition of certain insurance contracts. Ceded reinsurance agreements permit the Company to recover a portion of its losses from reinsurers, although they do not discharge the Company’s primary liability as the direct insurer of the risks reinsured. Failure of reinsurers to indemnify the Company could result in losses; however, the Company does not expect charges for unrecoverable reinsurance to have a material effect on its consolidated operating results or financial condition. The Company evaluates the financial condition of its reinsurers and monitors concentrations of credit risk arising from similar geographic regions, activities or economic characteristics of its reinsurers. At December 31, 2021, the Company’s reinsurance recoverables consisted primarily of amounts due from third parties that are rated consistent with companies that are considered to have the ability to meet their obligations. Reinsurance recoverables are recorded as other current assets or other assets on the consolidated balance sheets.

Health Care Contract Acquisition Costs

Insurance products included in the Health Care Benefits segment are cancellable by either the customer or the member monthly upon written notice. Acquisition costs related to prepaid health care and health indemnity contracts are generally expensed as incurred. Acquisition costs for certain long-duration insurance contracts are deferred and are recorded as other current assets or other assets on the consolidated balance sheets and are amortized over the estimated life of the contracts. The amortization of deferred acquisition costs is recorded in operating expenses in the consolidated statements of operations. At December 31, 2021 and 2020, the balance of deferred acquisition costs was $895 million and $546 million, respectively, comprised primarily of commissions paid on Medicare Supplement products within the Health Care Benefits segment.

Property and Equipment

Property and equipment is reported at historical cost, net of accumulated depreciation. Property, equipment and improvements to leased premises are depreciated using the straight-line method over the estimated useful lives of the assets, or when applicable, the term of the lease, whichever is shorter. Estimated useful lives generally range from 1 to 40 years for buildings, building improvements and leasehold improvements and 3 to 10 years for fixtures, equipment and internally developed software. Repair and maintenance costs are charged directly to expense as incurred. Major renewals or replacements that
113


substantially extend the useful life of an asset are capitalized and depreciated. Application development stage costs for significant internally developed software projects are capitalized and depreciated.

Property and equipment consists of the following at December 31, 2021 and 2020:
In millions20212020
Land$2,038 $2,134 
Building and improvements4,225 3,950 
Fixtures and equipment13,619 13,125 
Leasehold improvements6,242 6,077 
Software7,426 6,020 
Total property and equipment33,550 31,306 
Accumulated depreciation and amortization(20,654)(18,700)
Property and equipment, net$12,896 $12,606 

Depreciation expense (which includes the amortization of property and equipment under finance or capital leases) totaled $2.3 billion, $2.1 billion and $1.9 billion for the years ended December 31, 2021, 2020 and 2019, respectively. During the year ended December 31, 2021, the Company recorded an impairment on property and equipment of $261 million in connection with the planned closure of certain retail stores. See Note 6 ‘‘Leases’’ for additional information about this impairment charge as well as the Company’s finance leases.

Right-of-Use Assets and Lease Liabilities

The Company determines if an arrangement contains a lease at the inception of a contract. Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at the commencement date of the lease, renewal date of the lease or significant remodeling of the lease space based on the present value of the remaining future minimum lease payments. As the interest rate implicit in the Company’s leases is not readily determinable, the Company utilizes its incremental borrowing rate, determined by class of underlying asset, to discount the lease payments. The operating lease right-of-use assets also include lease payments made before commencement and are reduced by lease incentives.

The Company’s real estate leases typically contain options that permit renewals for additional periods of up to five years each. For real estate leases, the options to extend are not considered reasonably certain at lease commencement because the Company reevaluates each lease on a regular basis to consider the economic and strategic incentives of exercising the renewal options and regularly opens or closes stores to align with its operating strategy. Generally, the renewal option periods are not included within the lease term and the associated payments are not included in the measurement of the right-of-use asset and lease liability. Similarly, renewal options are not included in the lease term for non-real estate leases because they are not considered reasonably certain of being exercised at lease commencement. Leases with an initial term of 12 months or less are not recorded on the balance sheets, and lease expense is recognized on a straight-line basis over the term of the short-term lease.

For real estate leases, the Company accounts for lease components and nonlease components as a single lease component. Certain real estate leases require additional payments based on sales volume, as well as reimbursement for real estate taxes, common area maintenance and insurance, which are expensed as incurred as variable lease costs. Other real estate leases contain one fixed lease payment that includes real estate taxes, common area maintenance and insurance. These fixed payments are considered part of the lease payment and included in the right-of-use assets and lease liabilities.

See Note 6 ‘‘Leases’’ for additional information about right-of-use assets and lease liabilities.

Goodwill

The Company accounts for business combinations using the acquisition method of accounting, which requires the excess cost of an acquisition over the fair value of net assets acquired and identifiable intangible assets to be recorded as goodwill. Goodwill is not amortized, but is subject to impairment reviews annually, or more frequently if necessary, as further described in “Long-Lived Asset Impairment” below. See Note 5 ‘‘Goodwill and Other Intangibles’’ for additional information about goodwill.


114


Intangible Assets

The Company’s identifiable intangible assets consist primarily of trademarks, trade names, customer contracts/relationships, covenants not to compete, technology, provider networks and value of business acquired (“VOBA”). These intangible assets arise primarily from the determination of their respective fair market values at the date of acquisition. Amounts assigned to identifiable intangible assets, and their related useful lives, are derived from established valuation techniques and management estimates.

The Company’s definite-lived intangible assets are amortized over their estimated useful lives based upon the pattern of future cash flows attributable to the asset. Other than VOBA, definite-lived intangible assets are amortized using the straight-line method. VOBA is amortized over the expected life of the acquired contracts in proportion to estimated premiums. Indefinite-lived intangible assets are not amortized but are tested for impairment annually, or more frequently if necessary, as further described in “Long-Lived Asset Impairment” below.

See Note 5 ‘‘Goodwill and Other Intangibles’’ for additional information about intangible assets.

Long-Lived Asset Impairment

The Company evaluates the recoverability of long-lived assets, excluding goodwill and indefinite-lived intangible assets, which are tested for impairment using separate tests described below, whenever events or changes in circumstances indicate that the carrying value of such asset may not be recoverable. The Company groups and evaluates these long-lived assets for impairment at the lowest level at which individual cash flows can be identified. If indicators of impairment are present, the Company first compares the carrying amount of the asset group to the estimated future cash flows associated with the asset group (undiscounted). If the estimated future cash flows used in this analysis are less than the carrying amount of the asset group, an impairment loss calculation is prepared. The impairment loss calculation compares the carrying amount of the asset group to the asset group’s estimated future cash flows (discounted). If required, an impairment loss is recorded for the portion of the asset group’s carrying value that exceeds the asset group’s estimated future cash flows (discounted). During the year ended December 31, 2021, the Company recorded a store impairment charge of approximately $1.4 billion primarily related to the write down of operating lease right-of-use assets and property and equipment in connection with the planned closure of approximately 900 retail stores between 2022 and 2024. There were no material impairment charges recognized on long-lived assets in the year ended 2020. During the year ended December 31, 2019 the Company recorded a store impairment charge of $231 million primarily related to operating lease right-of-use assets. See Note 6 ‘‘Leases’’ for additional information about the right-of-use asset impairment charges.

When evaluating goodwill for potential impairment, the Company compares the fair value of its reporting units to their respective carrying amounts. The Company estimates the fair value of its reporting units using a combination of a discounted cash flow method and a market multiple method. If the carrying amount of a reporting unit exceeds its estimated fair value, an impairment loss is recognized in an amount equal to that excess. During the third quarter of 2021, the Company performed its required annual impairment tests of goodwill, the results of which indicated an impairment of the goodwill associated with the LTC reporting unit. Accordingly, during the third quarter of 2021, the Company recorded a $431 million goodwill impairment charge. The results of the impairment tests indicated that there was no impairment of goodwill of the remaining reporting units as of the testing date or during the year ended December 31, 2021. During the third quarter of both 2020 and 2019, the Company performed its required annual goodwill impairment tests and concluded there were no goodwill impairments as of the testing dates or during the years ended December 31, 2020 and 2019. See Note 5 ‘‘Goodwill and Other Intangibles’’ for additional information about the goodwill impairment charge recorded during the year ended December 31, 2021.

Indefinite-lived intangible assets are tested for impairment by comparing the estimated fair value of the asset to its carrying value. The Company estimates the fair value of its indefinite-lived trademarks using the relief from royalty method under the income approach. If the carrying value of the asset exceeds its estimated fair value, an impairment loss is recognized, and the asset is written down to its estimated fair value. There were no impairment losses recognized on indefinite-lived intangible assets in any of the years ended December 31, 2021, 2020 or 2019.

Separate Accounts

Separate Accounts assets and liabilities related to large case pensions products represent funds maintained to meet specific objectives of contract holders who bear the investment risk. These assets and liabilities are carried at fair value. Net investment income (including net realized capital gains and losses) accrue directly to such contract holders. The assets of each account are legally segregated and are not subject to claims arising from the Company’s other businesses. Deposits, withdrawals and net
115


investment income (including net realized and net unrealized capital gains and losses) on Separate Accounts assets are not reflected in the consolidated statements of operations or cash flows. Management fees charged to contract holders are included in services revenue and recognized over the period earned.

Health Care Costs Payable

Health care costs payable consist principally of unpaid fee-for-service medical, dental and pharmacy claims, capitation costs, other amounts due to providers pursuant to risk-sharing arrangements related to the Health Care Benefits segment’s Insured Commercial, Medicare and Medicaid products and accruals for state assessments. Unpaid health care claims include an estimate of payments the Company will make for (i) services rendered to the Company’s Insured members but not yet reported to the Company and (ii) claims which have been reported to the Company but not yet paid, each as of the financial statement date (collectively, “IBNR”). Health care costs payable also include an estimate of the cost of services that will continue to be rendered after the financial statement date if the Company is obligated to pay for such services in accordance with contractual or regulatory requirements. Such estimates are developed using actuarial principles and assumptions which consider, among other things, historical and projected claim submission and processing patterns, assumed and historical medical cost trends, historical utilization of medical services, claim inventory levels, changes in Insured membership and product mix, seasonality and other relevant factors. The Company reflects changes in these estimates in benefit costs in the Company’s consolidated operating results in the period they are determined. Capitation costs represent contractual monthly fees paid to participating physicians and other medical providers for providing medical care, regardless of the volume of medical services provided to the Insured member. Amounts due under risk-sharing arrangements are based on the terms of the underlying contracts with the providers and consider claims experience under the contracts through the financial statement date.

The Company develops its estimate of IBNR using actuarial principles and assumptions that consider numerous factors. Of those factors, the Company considers the analysis of historical and projected claim payment patterns (including claims submission and processing patterns) and the assumed health care cost trend rate (the year-over-year change in per member per month health care costs) to be the most critical assumptions. In developing its IBNR estimate, the Company consistently applies these actuarial principles and assumptions each period, with consideration to the variability of related factors. There have been no significant changes to the methodologies or assumptions used to develop the Company’s estimate of IBNR in 2021.

The Company analyzes historical claim payment patterns by comparing claim incurred dates (i.e., the date services were provided) to claim payment dates to estimate “completion factors.” The Company uses completion factors predominantly to estimate the ultimate cost of claims incurred more than three months before the financial statement date. The Company estimates completion factors by aggregating claim data based on the month of service and month of claim payment and estimating the percentage of claims incurred for a given month that are complete by each month thereafter. For any given month, substantially all claims are paid within six months of the date of service, but it can take up to 48 months or longer after the date of service before all of the claims are completely resolved and paid. These historically-derived completion factors are then applied to claims paid through the financial statement date to estimate the ultimate claim cost for a given month’s incurred claim activity. The difference between the estimated ultimate claim cost and the claims paid through the financial statement date represents the Company’s estimate of claims remaining to be paid as of the financial statement date and is included in the Company’s health care costs payable. The completion factors the Company uses reflect judgments and possible adjustments based on data such as claim inventory levels, claim submission and processing patterns and, to a lesser extent, other factors such as changes in health care cost trend rates, changes in Insured membership and changes in product mix. If claims are submitted or processed on a faster (slower) pace than prior periods, the actual claims may be more (less) complete than originally estimated using the Company’s completion factors, which may result in reserves that are higher (lower) than the ultimate cost of claims.

Because claims incurred within three months before the financial statement date are less mature, the Company uses a combination of historically-derived completion factors and the assumed health care cost trend rate to estimate the ultimate cost of claims incurred for these months. The Company applies its actuarial judgment and places a greater emphasis on the assumed health care cost trend rate for the most recent claim incurred dates as these months may be influenced by seasonal patterns and changes in membership and product mix.

The Company’s health care cost trend rate is affected by changes in per member utilization of medical services as well as changes in the unit cost of such services. Many factors influence the health care cost trend rate, including the Company’s ability to manage benefit costs through product design, negotiation of favorable provider contracts and medical management programs, as well as the mix of the Company’s business. The health status of the Company’s Insured members, aging of the population and other demographic characteristics, advances in medical technology and other factors continue to contribute to rising per member utilization and unit costs. Changes in health care practices, inflation, new technologies, increases in the cost of
116


prescription drugs (including specialty pharmacy drugs), direct-to-consumer marketing by pharmaceutical companies, clusters of high-cost cases, claim intensity, changes in the regulatory environment, health care provider or member fraud and numerous other factors also contribute to the cost of health care and the Company’s health care cost trend rate.

For each reporting period, the Company uses an extensive degree of judgment in the process of estimating its health care costs payable. As a result, considerable variability and uncertainty is inherent in such estimates, particularly with respect to claims with claim incurred dates of three months or less before the financial statement date; and the adequacy of such estimates is highly sensitive to changes in assumed completion factors and the assumed health care cost trend rates. For each reporting period the Company recognizes the actuarial best estimate of health care costs payable considering the potential volatility in assumed completion factors and health care cost trend rates, as well as other factors. The Company believes its estimate of health care costs payable is reasonable and adequate to cover its obligations at December 31, 2021; however, actual claim payments may differ from the Company’s estimates. A worsening (or improvement) of the Company’s health care cost trend rates or changes in completion factors from those that the Company assumed in estimating health care costs payable at December 31, 2021 would cause these estimates to change in the near term, and such a change could be material.

Each quarter, the Company re-examines previously established health care costs payable estimates based on actual claim payments for prior periods and other changes in facts and circumstances. Given the extensive degree of judgment in this estimate, it is possible that the Company’s estimates of health care costs payable could develop either favorably (that is, its actual benefit costs for the period were less than estimated) or unfavorably. The changes in the Company’s estimate of health care costs payable may relate to a prior quarter, prior year or earlier periods. For a roll forward of the Company’s health care costs payable, see Note 7 ‘‘Health Care Costs Payable.’’ The Company’s reserving practice is to consistently recognize the actuarial best estimate of its ultimate liability for health care costs payable.

Other Insurance Liabilities

Unpaid Claims
Unpaid claims consist primarily of reserves associated with certain short-duration group disability and term life insurance contracts, including an estimate for IBNR as of the financial statement date. Reserves associated with certain short-duration group disability and term life insurance contracts are based upon the Company’s estimate of the present value of future benefits, which is based on assumed investment yields and assumptions regarding mortality, morbidity and recoveries from the U.S. Social Security Administration. The Company develops its estimate of IBNR using actuarial principles and assumptions which consider, among other things, contractual requirements, claim incidence rates, claim recovery rates, seasonality and other relevant factors. The Company discounts certain claim liabilities related to group long-term disability and life insurance waiver of premium contracts. The discount rates generally reflect the Company’s expected investment returns for the investments supporting all incurral years of these liabilities. The discount rates for retrospectively-rated contracts are set at contractually specified levels. The Company’s estimates of unpaid claims are subject to change due to changes in the underlying experience of the insurance contracts, changes in investment yields or other factors, and these changes are recorded in current and future benefits in the consolidated statements of operations in the period they are determined. The Company estimates its reserve for claims IBNR for life products largely based on completion factors. The completion factors used are based on the Company’s historical experience and reflect judgments and possible adjustments based on data such as claim inventory levels, claim payment patterns, changes in business volume and other factors. If claims are submitted or processed on a faster (slower) pace than historical periods, the actual claims may be more (less) complete than originally estimated using completion factors, which may result in reserves that are higher (lower) than required to cover future life benefit payments. There have been no significant changes to the methodologies or assumptions used to develop the Company’s estimate of unpaid claims IBNR in 2021. As of December 31, 2021, unpaid claims balances of $324 million and $1.3 billion were recorded in other insurance liabilities and other long-term insurance liabilities, respectively. As of December 31, 2020, unpaid claims balances of $532 million and $1.5 billion were recorded in other insurance liabilities and other long-term insurance liabilities, respectively.

Substantially all life and disability insurance liabilities have been fully ceded to unrelated third parties through indemnity reinsurance agreements; however, the Company remains directly obligated to the policyholders.

Future Policy Benefits
Future policy benefits consist primarily of reserves for limited payment pension and annuity contracts and long-term care insurance contracts. Reserves for limited payment pension and annuity contracts are computed using actuarial principles that consider, among other things, assumptions reflecting anticipated mortality, retirement, expense and interest rate experience. Such assumptions generally vary by plan, year of issue and policy duration. Assumed interest rates on such contracts ranged from 3.0% to 11.3% in the year ended December 31, 2021 and from 3.3% to 11.3% in the year ended December 31, 2020. The Company periodically reviews mortality assumptions against both industry standards and its experience. Reserves for long-
117


duration long-term care contracts represent the Company’s estimate of the present value of future benefits and essential maintenance expenses to be paid to or on behalf of policyholders less the present value of future gross premiums. The assumed interest rate on such contracts was 5.1% in both the years ended December 31, 2021 and 2020. The Company’s estimate of the present value of future benefits under such contracts is based upon mortality, morbidity and interest rate assumptions. As of December 31, 2021, future policy benefits balances of $416 million and $5.1 billion were recorded in other insurance liabilities and other long-term insurance liabilities, respectively. As of December 31, 2020, future policy benefits balances of $462 million and $5.5 billion were recorded in other insurance liabilities and other long-term insurance liabilities, respectively.

Premium Deficiency Reserves

The Company evaluates its insurance contracts to determine if it is probable that a loss will be incurred. A premium deficiency loss is recognized when it is probable that expected future claims, including maintenance costs (for example, direct costs such as claim processing costs), will exceed existing reserves plus anticipated future premiums and reinsurance recoveries. Anticipated investment income is not considered in the calculation of premium deficiency losses for short-duration contracts. For purposes of determining premium deficiency losses, contracts are grouped consistent with the Company’s method of acquiring, servicing and measuring the profitability of such contracts. As of December 31, 2021 and 2020, the Company established a premium deficiency reserve of $16 million and $11 million, respectively, related to Medicaid products in the Health Care Benefits segment.

Policyholders’ Funds

Policyholders’ funds consist primarily of reserves for pension and annuity investment contracts and customer funds associated with certain health contracts. Reserves for such contracts are equal to cumulative deposits less withdrawals and charges plus interest credited thereon, net of experience-rated adjustments. In 2021, interest rates for pension and annuity investment contracts ranged from 3.5% to 4.8%. In 2020, interest rates for pension and annuity investment contracts ranged from 4.1% to 5.1%. Reserves for contracts subject to experience rating reflect the Company’s rights as well as the rights of policyholders and plan participants. The Company also holds funds for HSAs on behalf of members associated with high deductible health plans. These amounts are held to pay for qualified health care expenses incurred by these members. The HSA balances were approximately $2.9 billion and $2.7 billion at December 31, 2021 and 2020, respectively, and are reflected in other current assets with a corresponding liability in policyholders’ funds. These assets are considered restricted cash for cash flow statement purposes.

Policyholders’ funds liabilities that are expected to be paid within twelve months from the balance sheet date are classified as current on the consolidated balance sheets. Policyholders’ funds liabilities that are expected to be paid greater than twelve months from the balance sheet date are included in other long-term liabilities on the consolidated balance sheets.

Self-Insurance Liabilities

The Company is self-insured for certain losses related to general liability, workers’ compensation and auto liability. The Company obtains third party insurance coverage to limit exposure from these claims. The Company is also self-insured for certain losses related to health and medical liabilities. The Company’s self-insurance accruals, which include reported claims and claims incurred but not reported, are calculated using standard insurance industry actuarial assumptions and the Company’s historical claims experience. At December 31, 2021 and 2020, self-insurance liabilities totaled $1.1 billion and $927 million, respectively, and were recorded as accrued expenses on the consolidated balance sheets.

Foreign Currency Translation and Transactions

For non-U.S. dollar functional currency locations, (i) assets and liabilities are translated at end-of-period exchange rates, (ii) revenues and expenses are translated at average exchange rates in effect during the period and (iii) equity is translated at historical exchange rates. The resulting cumulative translation adjustments are included as a component of accumulated other comprehensive income.

For U.S. dollar functional currency locations, foreign currency assets and liabilities are remeasured into U.S. dollars at end-of-period exchange rates, except for nonmonetary balance sheet accounts which are remeasured at historical exchange rates. Revenues and expenses are remeasured at average exchange rates in effect during each period, except for those expenses related to the nonmonetary balance sheet amounts which are remeasured at historical exchange rates. Gains or losses from foreign currency remeasurement are included in net income.

118


Gains and losses from foreign currency transactions and the effects of foreign currency remeasurements were not material in the years ended December 31, 2021 or 2020. On July 1, 2019, the Company sold its Brazilian subsidiary, Drogaria Onofre Ltda. (“Onofre”) for an immaterial amount. The Company recorded a loss on the divestiture, which included the elimination of the subsidiary’s $154 million cumulative translation adjustment from accumulated other comprehensive income during the year ended December 31, 2019.

Revenue Recognition

Health Care Benefits Segment
Health Care Benefits revenue is principally derived from insurance premiums and fees billed to customers. Revenue is recognized based on customer billings, which, in the Company’s Commercial business, reflect contracted rates per member and the number of covered members recorded in the Company’s records at the time the billings are prepared. Billings are generally sent monthly for coverage during the following month. Revenue related to the Company’s Government business is collected monthly from the U.S. federal government and various government agencies based on fixed payment rates and member eligibility.

The Company’s billings may be subsequently adjusted to reflect enrollment changes due to member terminations or other factors. These adjustments are known as retroactivity adjustments. In each period, the Company estimates the amount of future retroactivity and adjusts the recorded revenue accordingly. As information regarding actual retroactivity amounts becomes known, the Company refines its estimates and records any required adjustments to revenues in the period in which they arise.

Premium Revenue
Premiums are recognized as revenue in the month in which the enrollee is entitled to receive health care services. Premiums are reported net of an allowance for estimated terminations and uncollectible amounts. Additionally, premium revenue subject to the minimum medical loss ratio (“MLR”) rebate requirements of the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010 (as amended, collectively, the “ACA”) is recorded net of the estimated minimum MLR rebates for the current calendar year. Premiums related to unexpired contractual coverage periods (unearned premiums) are reported as other insurance liabilities on the consolidated balance sheets and recognized as revenue when earned.

Some of the Company’s contracts allow for premiums to be adjusted to reflect actual experience or the relative health status of Insured members. Such adjustments are reasonably estimable at the outset of the contract, and adjustments to those estimates are made based on actual experience of the customer emerging under the contract and the terms of the underlying contract.

Services Revenue
Services revenue relates to contracts that can include various combinations of services or series of services which generally are capable of being distinct and accounted for as separate performance obligations. The Health Care Benefits segment’s services revenue primarily consists of ASC fees received in exchange for performing certain claim processing and member services for ASC members. ASC fee revenue is recognized over the period the service is provided. Some of the Company’s administrative services contracts include guarantees with respect to certain functions, such as customer service response time, claim processing accuracy and claim processing turnaround time, as well as certain guarantees that a plan sponsor’s benefit claim experience will fall within a certain range. With any of these guarantees, the Company is financially at risk if the conditions of the arrangements are not met, although the maximum amount at risk typically is limited to a percentage of the fees otherwise payable to the Company by the customer involved. Each period the Company estimates its obligations under the terms of these guarantees and records its estimate as an offset to services revenues.

Accounting for Medicare Part D
Revenues include insurance premiums earned by the Company’s PDPs, which are determined based on the PDP’s annual bid and related contractual arrangements with the U.S. Centers for Medicare & Medicaid Services (“CMS”). The insurance premiums include a beneficiary premium, which is the responsibility of the PDP member, and can be subsidized by CMS in the case of low-income members, and a direct premium paid by CMS. Premiums collected in advance are initially recorded within other insurance liabilities and are then recognized ratably as revenue over the period in which members are entitled to receive benefits.

Revenues also include a risk-sharing feature of the Medicare Part D program design referred to as the risk corridor. The Company estimates variable consideration in the form of amounts payable to, or receivable from, CMS under the risk corridor, and adjusts revenue based on calculations of additional subsidies to be received from or owed to CMS at the end of the reporting year.

119


In addition to Medicare Part D premiums, the Company receives additional payments each month from CMS related to catastrophic reinsurance, low-income cost-sharing subsidies and coverage gap benefits. If the subsidies received differ from the amounts earned from actual prescriptions transferred, the difference is recorded in either accounts receivable, net or accrued expenses.

Pharmacy Services Segment
The Pharmacy Services segment sells prescription drugs directly through its mail service dispensing pharmacies and indirectly through the Company’s retail pharmacy network. The Company’s pharmacy benefit arrangements are accounted for in a manner consistent with a master supply arrangement as there are no contractual minimum volumes and each prescription is considered a separate purchasing decision and distinct performance obligation transferred at a point in time. PBM services performed in connection with each prescription claim are considered part of a single performance obligation which culminates in the dispensing of prescription drugs.

The Company recognizes revenue using the gross method at the contract price negotiated with its clients when the Company has concluded it controls the prescription drug before it is transferred to the client plan members. The Company controls prescriptions dispensed indirectly through its retail pharmacy network because it has separate contractual arrangements with those pharmacies, has discretion in setting the price for the transaction and assumes primary responsibility for fulfilling the promise to provide prescription drugs to its client plan members while also performing the related PBM services.

Revenues include (i) the portion of the price the client pays directly to the Company, net of any discounts earned on brand name drugs or other discounts and refunds paid back to the client (see “Drug Discounts” and “Guarantees” below), (ii) the price paid to the Company by client plan members for mail order prescriptions and the price paid to retail network pharmacies by client plan members for retail prescriptions (“retail co-payments”), and (iii) claims based administrative fees for retail pharmacy network contracts. Sales taxes are not included in revenues.

The Company recognizes revenue when control of the prescription drugs is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to receive in exchange for those prescription drugs. The Company has established the following revenue recognition policies for the Pharmacy Services segment:

Revenues generated from prescription drugs sold by mail service dispensing pharmacies are recognized when the prescription drug is delivered to the client plan member. At the time of delivery, the Company has performed substantially all of its performance obligations under its client contracts and does not experience a significant level of returns or reshipments.
Revenues generated from prescription drugs sold by third party pharmacies in the Company’s retail pharmacy network and associated administrative fees are recognized at the Company’s point-of-sale, which is when the claim is adjudicated by the Company’s online claims processing system and the Company has transferred control of the prescription drug and completed all of its performance obligations.

For contracts under which the Company acts as an agent or does not control the prescription drugs prior to transfer to the client plan member, revenue is recognized using the net method.

Drug Discounts
The Company records revenue net of manufacturers’ rebates earned by its clients based on their plan members’ utilization of brand-name formulary drugs. The Company estimates these rebates at period-end based on actual and estimated claims data and its estimates of the manufacturers’ rebates earned by its clients. The estimates are based on the best available data at period-end and recent history for the various factors that can affect the amount of rebates due to the client. The Company adjusts its rebates payable to clients to the actual amounts paid when these rebates are paid or as significant events occur. Any cumulative effect of these adjustments is recorded against revenues at the time it is identified. Adjustments generally result from contract changes with clients or manufacturers that have retroactive rebate adjustments, differences between the estimated and actual product mix subject to rebates, or whether the brand name drug was included in the applicable formulary. The effect of adjustments between estimated and actual manufacturers’ rebate amounts has not been material to the Company’s operating results or financial condition.

Guarantees
The Company also adjusts revenues for refunds owed to clients resulting from pricing guarantees and performance against defined service and performance metrics. The inputs to these estimates are not subject to a high degree of subjectivity or volatility. The effect of adjustments between estimated and actual pricing and performance refund amounts has not been material to the Company’s operating results or financial condition.
120



Retail/LTC Segment
Retail Pharmacy
The Company’s retail drugstores recognize revenue at the time the customer takes possession of the merchandise. For pharmacy sales, each prescription claim is its own arrangement with the customer and is a performance obligation, separate and distinct from other prescription claims under other retail network arrangements. Revenues are adjusted for refunds owed to third party payers resulting from pricing guarantees and performance against defined value-based service and performance metrics. The inputs to these estimates are not subject to a high degree of subjectivity or volatility. The effect of adjustments between estimated and actual pricing and performance refund amounts has not been material to the Company’s operating results or financial condition.

Revenue from Company gift cards purchased by customers is deferred as a contract liability until goods or services are transferred. Any amounts not expected to be redeemed by customers (i.e., breakage) are recognized based on historical redemption patterns.

Customer returns are not material to the Company’s operating results or financial condition. Sales taxes are not included in revenues.

Loyalty and Other Programs
The Company’s customer loyalty program, ExtraCare®, consists of two components, ExtraSavingsTM and ExtraBucks® Rewards. ExtraSavings are coupons that are recorded as a reduction of revenue when redeemed as the Company concluded that they do not represent a promise to the customer to deliver additional goods or services at the time of issuance because they are not tied to a specific transaction or spending level.

ExtraBucks Rewards are accumulated by customers based on their historical spending levels. Thus, the Company has determined that there is an additional performance obligation to those customers at the time of the initial transaction. The Company allocates the transaction price to the initial transaction and the ExtraBucks Rewards transaction based upon the relative standalone selling price, which considers historical redemption patterns for the rewards. Revenue allocated to ExtraBucks Rewards is recognized as those rewards are redeemed. At the end of each period, unredeemed ExtraBucks Rewards are reflected as a contract liability.

The Company also offers a subscription-based membership program, CarePass®, under which members are entitled to a suite of benefits delivered over the course of the subscription period, as well as a promotional reward that can be redeemed for future goods and services. Subscriptions are paid for on a monthly or annual basis at the time of or in advance of the Company delivering the goods and services. Revenue from these arrangements is recognized as the performance obligations are satisfied.

Long-term Care
Revenue is recognized when control of the promised goods or services is transferred to customers in an amount that reflects the consideration the Company expects to be entitled to receive in exchange for those goods or services. Each prescription claim represents a separate performance obligation of the Company, separate and distinct from other prescription claims under customer arrangements. A significant portion of long-term care revenue from sales of pharmaceutical and medical products is reimbursed by the federal Medicare Part D program and, to a lesser extent, state Medicaid programs. The Company monitors its revenues and receivables from these reimbursement sources, as well as long-term care facilities and other third party insurance payors, and reduces revenue at the revenue recognition date to properly account for the variable consideration due to anticipated differences between billed and reimbursed amounts. Accordingly, the total revenues and receivables reported in the Company’s consolidated financial statements are recorded at the amount expected to be ultimately received from these payors.

Patient co-payments associated with Medicare Part D, certain state Medicaid programs, Medicare Part B and certain third party payors typically are not collected at the time products are delivered or services are rendered, but are billed to the individuals as part of normal billing procedures and subject to normal accounts receivable collections procedures.

Walk-In Medical Clinics
For services provided by the Company’s walk-in medical clinics, revenue recognition occurs for completed services provided to patients, with adjustments taken for third party payor contractual obligations and patient direct bill historical collection rates.


121


Disaggregation of Revenue
The following table disaggregates the Company’s revenue by major source in each segment for the years ended December 31, 2021, 2020 and 2019:
In millionsHealth Care
Benefits
Pharmacy
Services
Retail/
LTC
Corporate/
Other
Intersegment
Eliminations
Consolidated
Totals
2021
Major goods/services lines:
Pharmacy$ $152,262 $76,121 $ $(43,765)$184,618 
Front Store  21,315   21,315 
Premiums76,064   68  76,132 
Net investment income586  17 596  1,199 
Other5,536 760 2,652 57 (158)8,847 
Total$82,186 $153,022 $100,105 $721 $(43,923)$292,111 
Pharmacy Services distribution channel:
Pharmacy network (1)
$91,715 
Mail choice (2)
60,547 
Other760 
Total$153,022 
2020
Major goods/services lines:
Pharmacy$ $141,116 $70,176 $ $(40,003)$171,289 
Front Store  19,655   19,655 
Premiums69,301   63  69,364 
Net investment income483   315  798 
Other5,683 822 1,367 48 (320)7,600 
Total$75,467 $141,938 $91,198 $426 $(40,323)$268,706 
Pharmacy Services distribution channel:
Pharmacy network (1)
$85,045 
Mail choice (2)
56,071 
Other822 
Total$141,938 
2019
Major goods/services lines:
Pharmacy$ $140,896 $66,442 $ $(41,413)$165,925 
Front Store  19,422   19,422 
Premiums63,031   91  63,122 
Net investment income599   412  1,011 
Other5,974 595 744 9 (26)7,296 
Total$69,604 $141,491 $86,608 $512 $(41,439)$256,776 
Pharmacy Services distribution channel:
Pharmacy network (1)
$88,755 
Mail choice (2)
52,141 
Other595 
Total$141,491 
_____________________________________________
122


(1)Pharmacy Services pharmacy network is defined as claims filled at retail and specialty retail pharmacies, including the Company’s retail pharmacies and LTC pharmacies, but excluding Maintenance Choice® activity, which is included within the mail choice category. Maintenance Choice permits eligible client plan members to fill their maintenance prescriptions through mail order delivery or at a CVS Pharmacy retail store for the same price as mail order.
(2)Pharmacy Services mail choice is defined as claims filled at a Pharmacy Services mail order facility, which includes specialty mail claims inclusive of Specialty Connect® claims picked up at a retail pharmacy, as well as prescriptions filled at the Company’s retail pharmacies under the Maintenance Choice program.

Contract Balances
Contract liabilities primarily represent the Company’s obligation to transfer additional goods or services to a customer for which the Company has received consideration, and include ExtraBucks Rewards and unredeemed Company gift cards. The consideration received remains a contract liability until goods or services have been provided to the customer. In addition, the Company recognizes breakage on Company gift cards based on historical redemption patterns.

The following table provides information about receivables and contract liabilities from contracts with customers as of December 31, 2021 and 2020:
In millions20212020
Trade receivables (included in accounts receivable, net)$7,932 $7,101 
Contract liabilities (included in accrued expenses)87 71 

During the years ended December 31, 2021 and 2020, the contract liabilities balance includes increases related to customers’ earnings in ExtraBucks Rewards or issuances of Company gift cards and decreases for revenues recognized during the period as a result of the redemption of ExtraBucks Rewards or Company gift cards and breakage of Company gift cards. Below is a summary of such changes:
In millions20212020
Contract liabilities, beginning of period$71 $73 
Rewards earnings and gift card issuances387 357 
Redemption and breakage(371)(359)
Contract liabilities, end of period$87 $71 

Cost of Products Sold

The Company accounts for cost of products sold as follows:

Pharmacy Services Segment
Cost of products sold includes: (i) the cost of prescription drugs sold during the reporting period directly through the Company’s mail service dispensing pharmacies and indirectly through the Company’s retail pharmacy network, (ii) shipping and handling costs, and (iii) the operating costs of the Company’s mail service dispensing pharmacies and client service operations and related information technology support costs including depreciation and amortization. The cost of prescription drugs sold component of cost of products sold includes: (i) the cost of the prescription drugs purchased from manufacturers or distributors and shipped to members in clients’ benefit plans from the Company’s mail service dispensing pharmacies, net of any volume-related or other discounts (see “Vendor Allowances and Purchase Discounts” below) and (ii) the cost of prescription drugs sold (including retail co-payments) through the Company’s retail pharmacy network under contracts where the Company is the principal, net of any volume-related or other discounts.

Retail/LTC Segment
Cost of products sold includes: the cost of merchandise sold during the reporting period, including prescription drug costs, and the related purchasing costs, warehousing and delivery costs (including depreciation and amortization) and actual and estimated inventory losses.

Vendor Allowances and Purchase Discounts

The Company accounts for vendor allowances and purchase discounts as follows:

Pharmacy Services Segment
The Pharmacy Services segment receives purchase discounts on products purchased. Contractual arrangements with vendors, including manufacturers, wholesalers and retail pharmacies, normally provide for the Pharmacy Services segment to receive
123


purchase discounts from established list prices in one, or a combination, of the following forms: (i) a direct discount at the time of purchase, (ii) a discount for the prompt payment of invoices or (iii) when products are purchased indirectly from a manufacturer (e.g., through a wholesaler or retail pharmacy), a discount (or rebate) paid subsequent to dispensing. These rebates are recognized when prescriptions are dispensed and are generally calculated and billed to manufacturers within 30 days of the end of each completed quarter. Historically, the effect of adjustments resulting from the reconciliation of rebates recognized to the amounts billed and collected has not been material to the Company’s operating results or financial condition. The Company accounts for the effect of any such differences as a change in accounting estimate in the period the reconciliation is completed. The Pharmacy Services segment also receives additional discounts under its wholesaler contracts if it exceeds contractually defined purchase volumes. In addition, the Pharmacy Services segment receives fees from pharmaceutical manufacturers for administrative services. Purchase discounts and administrative service fees are recorded as a reduction of cost of products sold.

Retail/LTC Segment
Vendor allowances received by the Retail/LTC segment reduce the carrying cost of inventory and are recognized in cost of products sold when the related inventory is sold, unless they are specifically identified as a reimbursement of incremental costs for promotional programs and/or other services provided. Amounts that are directly linked to advertising commitments are recognized as a reduction of advertising expense (included in operating expenses) when the related advertising commitment is satisfied. Any amounts received in excess of the actual cost incurred also reduce the carrying cost of inventory. The total value of any upfront payments received from vendors that are linked to purchase commitments is initially deferred. The deferred amounts are then amortized to reduce cost of products sold over the life of the contract based upon sales volume. The total value of any upfront payments received from vendors that are not linked to purchase commitments is also initially deferred. The deferred amounts are then amortized to reduce cost of products sold on a straight-line basis over the life of the related contract. The total amortization of these upfront payments was not material to the Company’s consolidated financial statements in any of the periods presented.

Health Care Reform

Health Insurer Fee
Since January 1, 2014, the ACA has imposed an annual premium-based health insurer fee (“HIF”) for each calendar year, payable in September, which was not deductible for tax purposes. The Company has been required to estimate a liability for the HIF at the beginning of the calendar year in which the fee was payable with a corresponding deferred asset that was amortized ratably to operating expenses over the calendar year. The Company recorded the liability for the HIF in accrued expenses and recorded the deferred asset in other current assets. In December 2019, the HIF was repealed for calendar years after 2020, therefore there was no expense related to the HIF in the year ended December 31, 2021. In the year ended December 31, 2020, operating expenses included $1.0 billion related to the Company’s share of the HIF. There was no expense related to the HIF in 2019, since there was a one-year suspension of the HIF for 2019.

Risk Adjustment
The ACA established a permanent risk adjustment program to transfer funds from qualified individual and small group insurance plans with below average risk scores to plans with above average risk scores. Based on the risk of the Company’s qualified plan members relative to the average risk of members of other qualified plans in comparable markets, as defined by the ACA, the Company estimates its ultimate risk adjustment receivable (recorded in accounts receivable) or payable (recorded in accrued expenses) for the current calendar year and reflects the pro-rata year-to-date impact as an adjustment to premium revenue.

Risk Corridor
The ACA established a temporary risk corridor program, which expired at the end of 2016, for qualified individual and small group health insurance plans. Under this program, health insurance companies were to make payments to, or receive payments from, the U.S. Department of Health and Human Services (“HHS”) based on their ratio of allowable costs to target costs (as defined by the ACA).

The Company filed a lawsuit in August 2019 to recover the $313 million it was owed under the ACA’s risk corridor program, which had been stayed pending the Supreme Court decision. In April 2020, the U.S. Supreme Court ruled that health insurance companies may sue the federal government for amounts owed as calculated under the ACA’s temporary risk corridor program.

In October 2020, the Company received the $313 million it was owed under the ACA’s risk corridor program. The Company recorded the risk corridor payment as an increase to premium revenue in the year ended December 31, 2020. After considering
124


offsetting items such as the ACA’s minimum MLR rebate requirements and premium taxes, the Company recorded pre-tax income of $307 million and after-tax income of $223 million during the year ended December 31, 2020.

Advertising Costs

Advertising costs, which are reduced by the portion funded by vendors, are expensed when the related advertising takes place. Net advertising costs, which are included in operating expenses, were $523 million, $461 million and $396 million in 2021, 2020 and 2019, respectively.

Stock-Based Compensation

Stock-based compensation is measured at the grant date based on the fair value of the award and is recognized as expense over the requisite service period of the stock award (generally three to five years) using the straight-line method.

Income Taxes

The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year or years in which the differences are expected to reverse. The effect of a change in the tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date of such change.

The Company recognizes deferred tax assets to the extent that it believes these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies, and the Company’s recent operating results. The Company establishes a valuation allowance when it does not consider it more likely than not that a deferred tax asset will be recovered.

The Company records uncertain tax positions on the basis of a two-step process whereby (1) the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority.

Interest and/or penalties related to uncertain tax positions are recognized in the income tax provision.

Measurement of Defined Benefit Pension and Other Postretirement Employee Benefit Plans

The Company sponsors defined benefit pension plans (“pension plans”) and other postretirement employee benefit plans (“OPEB plans”) for its employees and retirees. The Company recognizes the funded status of its pension and OPEB plans on the consolidated balance sheets based on the year-end measurements of plan assets and benefit obligations. When the fair value of plan assets are in excess of the plan benefit obligations, the amounts are reported in other current assets and other assets. When the fair value of plan benefit obligations are in excess of plan assets, the amounts are reported in accrued expenses and other long-term liabilities based on the amount by which the actuarial present value of benefits payable in the next twelve months included in the benefit obligation exceeds the fair value of plan assets. The net periodic benefit cost (income) for the Company’s pension and OPEB plans do not contain a service cost component as these plans have been frozen for an extended period of time. Non-service cost components of pension and postretirement net periodic benefit cost (income) are included in other income in the consolidated statements of operations.

Earnings per Share

Earnings per share is computed using the two-class method. The Company calculates basic earnings per share based on the weighted average number of common shares outstanding for the period. See Note 14 ‘‘Earnings Per Share’’ for additional information.




125


Shares Held in Trust

The Company maintains grantor trusts, which held approximately one million shares of its common stock at both December 31, 2021 and 2020. These shares are designated for use under various employee compensation plans. Since the Company holds these shares, they are excluded from the computation of basic and diluted shares outstanding.

Variable Interest Entities

The Company has investments in (i) a generic pharmaceutical sourcing entity, (ii) certain hedge fund and private equity investments and (iii) certain real estate partnerships that are considered VIEs. The Company does not have a future obligation to fund losses or debts on behalf of these investments; however, it may voluntarily contribute funds. In evaluating whether the Company is the primary beneficiary of a VIE, the Company considers several factors, including whether the Company has (a) the power to direct the activities that most significantly impact the VIE’s economic performance and (b) the obligation to absorb losses and the right to receive benefits that could potentially be significant to the VIE.

Variable Interest Entities - Primary Beneficiary
In 2014, the Company and Cardinal Health, Inc. (“Cardinal”) established Red Oak Sourcing, LLC (“Red Oak”), a generic pharmaceutical sourcing entity in which the Company and Cardinal each own 50%. The Red Oak arrangement had an initial term of ten years. In 2021, the Red Oak arrangement was amended to extend the initial term an additional five years, for a total term of 15 years. Under this arrangement, the Company and Cardinal contributed their sourcing and supply chain expertise to Red Oak and agreed to source and negotiate generic pharmaceutical supply contracts for both companies through Red Oak; however, Red Oak does not own or hold inventory on behalf of either company. No physical assets (e.g., property and equipment) were contributed to Red Oak by either company, and minimal funding was provided to capitalize Red Oak. The Company has determined that it is the primary beneficiary of this VIE because it has the ability to direct the activities of Red Oak. Consequently, the Company consolidates Red Oak in its consolidated financial statements within the Retail/LTC segment.

Cardinal is required to pay the Company quarterly payments, which began in October 2014 and will extend through June 2029. As milestones are met, the quarterly payments increase. The Company received $183 million from Cardinal during each of the years ended December 31, 2021, 2020 and 2019. The payments reduce the Company’s carrying value of inventory and are recognized in cost of products sold when the related inventory is sold. Amounts reimbursed by Cardinal for the years ended December 31, 2021, 2020 and 2019, and amounts due to or due from Cardinal at December 31, 2021 and 2020 were immaterial.

Variable Interest Entities - Other Variable Interest Holder
The Company has invested in certain VIEs for which it has determined that it is not the primary beneficiary, consisting of the following:

Hedge fund and private equity investments - The Company invests in hedge fund and private equity investments in order to generate investment returns for its investment portfolio supporting its insurance businesses.
Real estate partnerships - The Company invests in various real estate partnerships, including those that construct, own and manage low-income housing developments. For the low income housing development investments, substantially all of the projected benefits to the Company are from tax credits and other tax benefits.

The Company is not the primary beneficiary of these VIEs because the nature of the Company’s involvement with the activities of these VIEs does not give the Company the power to direct the activities that most significantly impact their economic performance. The Company records the amount of its investment in these VIEs as long-term investments on the consolidated balance sheets and recognizes its share of each VIE’s income or losses in net income (loss). The Company’s maximum exposure to loss from these VIEs is limited to its investment balances as disclosed below and the risk of recapture of previously recognized tax credits related to the real estate partnerships, which the Company does not consider significant.

The total amount of other variable interest holder VIE assets included in long-term investments on the consolidated balance sheets at December 31, 2021 and 2020 was as follows:
In millions20212020
Hedge fund investments$463 $342 
Private equity investments601 547 
Real estate partnerships225 200 
Total$1,289 $1,089 
126


Related Party Transactions

The Company has an equity method investment in SureScripts, LLC (“SureScripts”), which operates a clinical health information network. The Company utilizes this clinical health information network in providing services to its client plan members and retail customers. The Company expensed fees for the use of this network of $52 million, $56 million and $32 million in the years ended December 31, 2021, 2020 and 2019, respectively. The Company’s investment in and equity in the earnings of SureScripts for all periods presented is immaterial.

The Company has an equity method investment in Heartland Healthcare Services, LLC (“Heartland”). Heartland operates several LTC pharmacies in four states. Heartland paid the Company $79 million, $77 million and $96 million for pharmaceutical inventory purchases during the years ended December 31, 2021, 2020 and 2019, respectively. Additionally, the Company performs certain collection functions for Heartland and then transfers those customer cash collections to Heartland. The Company’s investment in and equity in the earnings of Heartland for all periods presented is immaterial.

During the years ended December 31, 2021, 2020 and 2019, the Company made charitable contributions of $50 million, $50 million and $30 million, respectively, to the CVS Health Foundation, a non-profit entity that focuses on health, education and community involvement programs. The charitable contributions were recorded as operating expenses in the consolidated statements of operations within the Corporate/Other segment for the years ended December 31, 2021, 2020 and 2019.

Discontinued Operations

In connection with certain business dispositions completed between 1995 and 1997, the Company retained guarantees on store lease obligations for a number of former subsidiaries, including Linens ‘n Things and Bob’s Stores, each of which subsequently filed for bankruptcy. The Company’s loss from discontinued operations includes lease-related costs that the Company believes it will likely be required to satisfy pursuant to these lease guarantees. See “Lease Guarantees” in Note 16 ‘‘Commitments and Contingencies’’ for additional information.

Below is a summary of the results of discontinued operations for the year ended December 31, 2020.
In millions2020
Loss from discontinued operations$(12)
Income tax benefit3 
Loss from discontinued operations, net of tax$(9)

Results from discontinued operations were immaterial for the years ended December 31, 2021 and 2019.

New Accounting Pronouncements Recently Adopted

Simplifying the Accounting for Income Taxes
In December 2019, the Financial Accounting Standards Board (“FASB”) issued ASU 2019-12, Simplifying the Accounting for Income Taxes (Topic 740). This standard simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in Accounting Standards Codification 740 related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The standard also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The Company adopted this new accounting standard on January 1, 2021. The adoption of this standard did not have a material impact on the Company’s consolidated operating results, cash flows, financial condition or related disclosures.

New Accounting Pronouncements Not Yet Adopted

Targeted Improvements to the Accounting for Long-Duration Insurance Contracts
In August 2018, the FASB issued ASU 2018-12, Targeted Improvements to the Accounting for Long-Duration Contracts (Topic 944). This standard requires the Company to review cash flow assumptions for its long-duration insurance contracts at least annually and recognize the effect of changes in future cash flow assumptions in net income. This standard also requires the Company to update discount rate assumptions quarterly and recognize the effect of changes in these assumptions in other comprehensive income. The rate used to discount the Company’s liability for future policy benefits will be based on an estimate of the yield for an upper-medium grade fixed-income instrument with a duration profile matching that of the Company’s
127


liabilities. In addition, this standard changes the amortization method for deferred acquisition costs and requires additional disclosures regarding the long duration insurance contract liabilities in the Company’s interim and annual financial statements. The standard is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022. The Company will adopt the new standard on January 1, 2023, using the modified retrospective transition method as of the earliest period presented for changes to the liability for future policy benefits and deferred acquisition costs. While the Company is still evaluating the impact of the new standard on its financial statements, the Company anticipates an increase to its liability for future policy benefits with a corresponding change in accumulated other comprehensive income as a result of updating the rate used to discount the liabilities to reflect the yield for an upper-medium grade fixed-income instrument compared to the Company’s expected investment yield under the existing guidance.

2.Divestitures

Divestiture of Workers’ Compensation Business

On July 31, 2020, the Company sold its Workers’ Compensation business for approximately $850 million. The results of this business were reported within the Health Care Benefits segment. The Company recorded a pre-tax gain on the divestiture of $269 million in the year ended December 31, 2020, which is reflected as a reduction in operating expenses in the Company’s consolidated statement of operations within the Health Care Benefits segment.

Divestiture of Brazilian Subsidiary

On July 1, 2019, the Company sold its Brazilian subsidiary, Onofre, for an immaterial amount. Onofre operated 50 retail pharmacy stores, the results of which historically had been reported within the Retail/LTC segment. The Company recorded a pre-tax loss on the divestiture of $205 million in the year ended December 31, 2019, which primarily relates to the elimination of the cumulative translation adjustment from accumulated other comprehensive income and is reflected in operating expenses in the Company’s consolidated statement of operations within the Retail/LTC segment.

3.Investments

Total investments at December 31, 2021 and 2020 were as follows:
20212020
In millionsCurrentLong-termTotalCurrentLong-termTotal
Debt securities available for sale$3,009 $20,231 $23,240 $2,774 $18,414 $21,188 
Mortgage loans58 844 902 226 821 1,047 
Other investments50 1,950 2,000  1,577 1,577 
Total investments$3,117 $23,025 $26,142 $3,000 $20,812 $23,812 

At December 31, 2021 and 2020, the Company held investments of $450 million and $524 million, respectively, related to the 2012 conversion of an existing group annuity contract from a participating to a non-participating contract. These investments are included in the total investments of large case pensions supporting non-experience-rated products. Although these investments are not accounted for as Separate Accounts assets, they are legally segregated and are not subject to claims that arise out of the Company’s business and only support future policy benefits obligations under that group annuity contract.






128


Debt Securities

Debt securities available for sale at December 31, 2021 and 2020 were as follows:
In millions
Amortized
Cost (1)
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Fair
Value
December 31, 2021   
Debt securities:   
U.S. government securities$2,349 $70 $(3)$2,416 
States, municipalities and political subdivisions2,947 148 (4)3,091 
U.S. corporate securities9,093 682 (40)9,735 
Foreign securities2,821 196 (24)2,993 
Residential mortgage-backed securities870 15 (10)875 
Commercial mortgage-backed securities1,278 44 (12)1,310 
Other asset-backed securities2,791 14 (13)2,792 
Redeemable preferred securities25 3  28 
Total debt securities (2)
$22,174 $1,172 $(106)$23,240 
December 31, 2020
Debt securities:
U.S. government securities$2,341 $128 $ $2,469 
States, municipalities and political subdivisions2,556 172  2,728 
U.S. corporate securities7,879 1,023 (8)8,894 
Foreign securities2,595 324 (1)2,918 
Residential mortgage-backed securities673 32  705 
Commercial mortgage-backed securities962 84  1,046 
Other asset-backed securities2,369 36 (2)2,403 
Redeemable preferred securities21 4  25 
Total debt securities (2)
$19,396 $1,803 $(11)$21,188 
_____________________________________________
(1)There was no allowance for expected credit losses recorded on available-for-sale debt securities at December 31, 2021 or 2020.
(2)Investment risks associated with the Company’s experience-rated products generally do not impact the Company’s consolidated operating results. At December 31, 2021, debt securities with a fair value of $864 million, gross unrealized capital gains of $94 million and gross unrealized capital losses of $2 million and at December 31, 2020, debt securities with a fair value of $919 million, gross unrealized capital gains of $135 million and no gross unrealized capital losses were included in total debt securities, but support experience-rated products. Changes in net unrealized capital gains (losses) on these securities are not reflected in accumulated other comprehensive income.


129


The amortized cost and fair value of debt securities at December 31, 2021 are shown below by contractual maturity.  Actual maturities may differ from contractual maturities because securities may be restructured, called or prepaid, or the Company intends to sell a security prior to maturity.
In millions Amortized
Cost
Fair
Value
Due to mature: 
Less than one year$1,205 $1,218 
One year through five years6,965 7,142 
After five years through ten years4,733 4,910 
Greater than ten years4,332 4,993 
Residential mortgage-backed securities870 875 
Commercial mortgage-backed securities1,278 1,310 
Other asset-backed securities2,791 2,792 
Total$22,174 $23,240 

Mortgage-Backed and Other Asset-Backed Securities
All of the Company’s residential mortgage-backed securities at December 31, 2021 were issued by the Government National Mortgage Association, the Federal National Mortgage Association or the Federal Home Loan Mortgage Corporation and carry agency guarantees and explicit or implicit guarantees by the U.S. Government. At December 31, 2021, the Company’s residential mortgage-backed securities had an average credit quality rating of AAA and a weighted average duration of 4.7 years.

The Company’s commercial mortgage-backed securities have underlying loans that are dispersed throughout the United States. Significant market observable inputs used to value these securities include loss severity and probability of default. At December 31, 2021, these securities had an average credit quality rating of AAA and a weighted average duration of 6.1 years.

The Company’s other asset-backed securities have a variety of underlying collateral (e.g., automobile loans, credit card receivables, home equity loans and commercial loans). Significant market observable inputs used to value these securities include the unemployment rate, loss severity and probability of default. At December 31, 2021, these securities had an average credit quality rating of AA and a weighted average duration of 1.0 year.

130


Summarized below are the debt securities the Company held at December 31, 2021 and 2020 that were in an unrealized capital loss position, aggregated by the length of time the investments have been in that position:
Less than 12 monthsGreater than 12 monthsTotal
In millions, except number of securitiesNumber
of
 Securities
Fair
Value
Unrealized
Losses
Number
of
 Securities
Fair
Value
Unrealized
Losses
Number
of
 Securities
Fair
Value
Unrealized
Losses
December 31, 2021
Debt securities:  
U.S. government securities43 $242 $2 10 $40 $1 53 $282 $3 
States, municipalities and political subdivisions233 428 3 13 33 1 246 461 4 
U.S. corporate securities1,610 2,296 31 165 238 9 1,775 2,534 40 
Foreign securities449 747 20 57 91 4 506 838 24 
Residential mortgage-backed securities165 593 9 10 36 1 175 629 10 
Commercial mortgage-backed securities188 462 7 35 112 5 223 574 12 
Other asset-backed securities1,011 2,030 12 26 31 1 1,037 2,061 13 
Redeemable preferred securities1 2  1 3  2 5  
Total debt securities3,700 $6,800 $84 317 $584 $22 4,017 $7,384 $106 
December 31, 2020
Debt securities:
U.S. government securities32 $205 $  $ $ 32 $205 $ 
States, municipalities and political subdivisions49 83     49 83  
U.S. corporate securities145 155 8 2   147 155 8 
Foreign securities41 69 1 5 5  46 74 1 
Residential mortgage-backed securities23 26  3   26 26  
Commercial mortgage-backed securities22 75     22 75  
Other asset-backed securities156 256 1 49 41 1 205 297 2 
Total debt securities468 $869 $10 59 $46 $1 527 $915 $11 

The Company reviewed the securities in the table above and concluded that they are performing assets generating investment income to support the needs of the Company’s business. In performing this review, the Company considered factors such as the quality of the investment security based on research performed by the Company’s internal credit analysts and external rating agencies and the prospects of realizing the carrying value of the security based on the investment’s current prospects for recovery. Unrealized capital losses at December 31, 2021 were generally caused by interest rate increases and not by unfavorable changes in the credit quality associated with these securities. As of December 31, 2021, the Company did not intend to sell these securities, and did not believe it was more likely than not that it would be required to sell these securities prior to the anticipated recovery of their amortized cost basis.

131


The maturity dates for debt securities in an unrealized capital loss position at December 31, 2021 were as follows:
 Supporting experience-
rated products
Supporting remaining
products
Total
In millionsFair
Value
Unrealized
Losses
Fair
Value
Unrealized
Losses
Fair
Value
Unrealized
Losses
Due to mature:      
Less than one year$2 $ $49 $1 $51 $1 
One year through five years13 1 2,229 32 2,242 33 
After five years through ten years33 1 1,332 26 1,365 27 
Greater than ten years17  445 10 462 10 
Residential mortgage-backed securities4  625 10 629 10 
Commercial mortgage-backed securities6  568 12 574 12 
Other asset-backed securities4  2,057 13 2,061 13 
Total$79 $2 $7,305 $104 $7,384 $106 

Mortgage Loans

The Company’s mortgage loans are collateralized by commercial real estate. During the years ended December 31, 2021 and 2020, the Company had the following activity in its mortgage loan portfolio:
In millions20212020
New mortgage loans$262 $63 
Mortgage loans fully repaid373 187 
Mortgage loans foreclosed  

The Company assesses mortgage loans on a regular basis for credit impairments, and assigns a credit quality indicator to each loan. The Company’s credit quality indicator is internally developed and categorizes each loan in its portfolio on a scale from 1 to 7. These indicators are based upon several factors, including current loan-to-value ratios, current and future property cash flow, property condition, market trends, creditworthiness of the borrower and deal structure.

Category 1 - Represents loans of superior quality.
Categories 2 to 4 - Represent loans where credit risk is minimal to acceptable; however, these loans may display some susceptibility to economic changes.
Categories 5 and 6 - Represent loans where credit risk is not substantial, but these loans warrant management’s close attention.
Category 7 - Represents loans where collections are potentially at risk; if necessary, an impairment is recorded.


132


Based upon the Company’s assessments at December 31, 2021 and 2020, the amortized cost basis of the Company’s mortgage loans within each credit quality indicator by year of origination was as follows:

Amortized Cost Basis by Year of Origination
In millions, except credit quality indicator20212020201920182017PriorTotal
December 31, 2021
1$ $ $ $ $ $28 $28 
2 to 4255 48 40 72 97 349 861 
5 and 6   3 4 6 13 
7       
Total$255 $48 $40 $75 $101 $383 $902 
December 31, 2020
1$ $ $ $22 $37 $59 
2 to 446 96 91 124 595 952 
5 and 6  3 4 29 36 
7      
Total$46 $96 $94 $150 $661 $1,047 

At December 31, 2021 scheduled mortgage loan principal repayments were as follows:
In millions
2022$58 
2023100 
2024210 
202576 
2026177 
Thereafter281 
Total$902 

Net Investment Income

Sources of net investment income for the years ended December 31, 2021, 2020 and 2019 were as follows:
In millions202120202019
Debt securities$634 $598 $589 
Mortgage loans55 60 71 
Other investments381 123 194 
Gross investment income1,070 781 854 
Investment expenses(47)(35)(42)
Net investment income (excluding net realized capital gains or losses)1,023 746 812 
Net realized capital gains (1)
176 52 199 
Net investment income (2)
$1,199 $798 $1,011 
_____________________________________________
(1)Net realized capital gains are net of yield-related impairment losses on debt securities of $42 million and $49 million for the years ended December 31, 2021 and 2020, respectively. There were no credit-related losses on debt securities in the years ended December 31, 2021 and 2020. Net realized capital gains are net of other-than-temporary impairment (“OTTI”) losses on debt securities of $24 million for the year ended December 31, 2019.
(2)Net investment income includes $38 million, $42 million and $44 million for the years ended December 31, 2021, 2020 and 2019, respectively, related to investments supporting experience-rated products.


133


Capital gains and losses recognized during the year ended December 31, 2021 related to investments in equity securities held as of December 31, 2021 were not material.

Excluding amounts related to experience-rated products, proceeds from the sale of available-for-sale debt securities and the related gross realized capital gains and losses in the years ended December 31, 2021, 2020 and 2019 were as follows:
In millions202120202019
Proceeds from sales$3,572 $3,913 $4,773 
Gross realized capital gains72 80 146 
Gross realized capital losses14 62 17 

4.Fair Value

The preparation of the Company’s consolidated financial statements in accordance with GAAP requires certain assets and liabilities to be reflected at their fair value and others to be reflected on another basis, such as an adjusted historical cost basis. In this note, the Company provides details on the fair value of financial assets and liabilities and how it determines those fair values. The Company presents this information for those financial instruments that are measured at fair value for which the change in fair value impacts net income attributable to CVS Health or other comprehensive income separately from other financial assets and liabilities.

Financial Instruments Measured at Fair Value on the Consolidated Balance Sheets

Certain of the Company’s financial instruments are measured at fair value on the consolidated balance sheets. The fair values of these instruments are based on valuations that include inputs that can be classified within one of three levels of a hierarchy established by GAAP.  The following are the levels of the hierarchy and a brief description of the type of valuation information (“valuation inputs”) that qualifies a financial asset or liability for each level:

Level 1 – Unadjusted quoted prices for identical assets or liabilities in active markets.
Level 2 – Valuation inputs other than Level 1 that are based on observable market data. These include: quoted prices for similar assets in active markets, quoted prices for identical assets in inactive markets, valuation inputs that are observable that are not prices (such as interest rates and credit risks) and valuation inputs that are derived from or corroborated by observable markets.
Level 3 – Developed from unobservable data, reflecting the Company’s assumptions.

Financial assets and liabilities are classified based upon the lowest level of input that is significant to the valuation. When quoted prices in active markets for identical assets and liabilities are available, the Company uses these quoted market prices to determine the fair value of financial assets and liabilities and classifies these assets and liabilities in Level 1. In other cases where a quoted market price for identical assets and liabilities in an active market is either not available or not observable, the Company estimates fair value using valuation methodologies based on available and observable market information or by using a matrix pricing model. These financial assets and liabilities are classified in Level 2. If quoted market prices are not available, the Company determines fair value using broker quotes or an internal analysis of each investment’s financial performance and cash flow projections. Thus, financial assets and liabilities may be classified in Level 3 even though there may be some significant inputs that may be observable.

The following is a description of the valuation methodologies used for the Company’s financial assets and liabilities that are measured at fair value, including the general classification of such assets and liabilities pursuant to the valuation hierarchy.

Cash and Cash Equivalents The carrying value of cash and cash equivalents approximates fair value as maturities are less than three months. When quoted prices are available in an active market, cash equivalents are classified in Level 1 of the fair value hierarchy. Fair values of cash equivalent instruments that do not trade on a regular basis in active markets are classified as Level 2.

Debt Securities Where quoted prices are available in an active market, debt securities are classified in Level 1 of the fair value hierarchy. The Company’s Level 1 debt securities consist primarily of U.S. Treasury securities.

The fair values of the Company’s Level 2 debt securities are obtained using models, such as matrix pricing, which use quoted market prices of debt securities with similar characteristics or discounted cash flows to estimate fair value. The
134


Company reviews these prices to ensure they are based on observable market inputs that include quoted prices for similar assets in active markets, quoted prices for identical assets in inactive markets and inputs that are observable that are not prices (such as interest rates and credit risks). The Company also reviews the methodologies and the assumptions used to calculate prices from these observable inputs. On a quarterly basis, the Company selects a sample of its Level 2 debt securities’ prices and compares them to prices provided by a secondary source. Variances over a specified threshold are identified and reviewed to confirm the price provided by the primary source represents an appropriate estimate of fair value. In addition, the Company’s internal investment team consistently compares the prices obtained for select Level 2 debt securities to the team’s own independent estimates of fair value for those securities. The Company obtained one price for each of its Level 2 debt securities and did not adjust any of those prices at December 31, 2021 or 2020.

The Company also values certain debt securities using Level 3 inputs. For Level 3 debt securities, fair values are determined by outside brokers or, in the case of certain private placement securities, are priced internally. Outside brokers determine the value of these debt securities through a combination of their knowledge of the current pricing environment and market flows. The Company did not have any broker quoted debt securities for the years ended December 31, 2021 and 2020. For some private placement securities, the Company’s internal staff determines the value of these debt securities by analyzing spreads of corporate and sector indices as well as interest spreads of comparable public bonds. Examples of these private placement Level 3 debt securities include certain U.S. and foreign securities and certain tax-exempt municipal securities.

Equity Securities The Company currently has two classifications of equity securities: those that are publicly traded and those that are privately placed. Publicly-traded equity securities are classified in Level 1 because quoted prices are available for these securities in an active market. For privately placed equity securities, there is no active market; therefore, these securities are classified in Level 3 because the Company prices these securities through an internal analysis of each investment’s financial statements and cash flow projections. Significant unobservable inputs consist of earnings and revenue multiples, discount for lack of marketability and comparability adjustments. An increase or decrease in any of these unobservable inputs would have resulted in a change in the fair value measurement.


135


There were no financial liabilities measured at fair value on a recurring basis on the consolidated balance sheets at December 31, 2021 or 2020. Financial assets measured at fair value on a recurring basis on the consolidated balance sheets at December 31, 2021 and 2020 were as follows:
In millionsLevel 1Level 2Level 3Total
December 31, 2021    
Cash and cash equivalents$4,954 $4,454 $ $9,408 
Debt securities:    
U.S. government securities2,372 44  2,416 
States, municipalities and political subdivisions 3,086 5 3,091 
U.S. corporate securities 9,697 38 9,735 
Foreign securities 2,983 10 2,993 
Residential mortgage-backed securities 875  875 
Commercial mortgage-backed securities 1,310  1,310 
Other asset-backed securities 2,789 3 2,792 
Redeemable preferred securities 28  28 
Total debt securities2,372 20,812 56 23,240 
Equity securities114  55 169 
Total$7,440 $25,266 $111 $32,817 
December 31, 2020    
Cash and cash equivalents$3,985 $3,869 $ $7,854 
Debt securities:
U.S. government securities2,370 99  2,469 
States, municipalities and political subdivisions 2,727 1 2,728 
U.S. corporate securities 8,842 52 8,894 
Foreign securities 2,918  2,918 
Residential mortgage-backed securities 705  705 
Commercial mortgage-backed securities 1,046  1,046 
Other asset-backed securities 2,403  2,403 
Redeemable preferred securities 24 1 25 
Total debt securities2,370 18,764 54 21,188 
Equity securities17  30 47 
Total$6,372 $22,633 $84 $29,089 

136


The changes in the balances of Level 3 financial assets during the year ended December 31, 2021 were as follows:
In millionsStates,
municipalities
 and political
subdivisions
U.S.
corporate
securities
Foreign
securities
Other asset-
backed
securities
Redeemable
preferred
securities
Equity
securities
Total
Beginning balance$1 $52 $ $ $1 $30 $84 
Net realized and unrealized capital gains (losses):
Included in earnings  (10)  2 13 5 
Included in other comprehensive income (3)  (1) (4)
Purchases 1  3  13 17 
Sales(1)(1)  (2)(1)(5)
Settlements (1)    (1)
Transfers into Level 3, net5  10    15 
Ending balance$5 $38 $10 $3 $ $55 $111 

The change in unrealized capital losses included in other comprehensive income associated with Level 3 financial assets which were held as of December 31, 2021 was $4 million during the year ended December 31, 2021.

The changes in the balances of Level 3 financial assets during the year ended December 31, 2020 were as follows:
In millionsStates,
municipalities
 and political
subdivisions
U.S.
corporate
securities
Redeemable
preferred
securities
Equity
securities
Total
Beginning balance$ $37 $12 $39 $88 
Net realized and unrealized capital gains (losses):
Included in earnings  (11)18 (3)4 
Included in other comprehensive income  (5) (5)
Purchases 27  3 30 
Sales  (24)(9)(33)
Settlements (1)  (1)
Transfers into Level 3, net1    1 
Ending balance$1 $52 $1 $30 $84 

The change in unrealized capital losses included in other comprehensive income associated with Level 3 financial assets which were held as of December 31, 2020 was $4 million during the year ended December 31, 2020.

The total gross transfers into (out of) Level 3 during the years ended December 31, 2021 and 2020 were as follows:
In millions20212020
Gross transfers into Level 3$15 $1 
Gross transfers out of Level 3  
Net transfers into Level 3$15 $1 


137


Financial Instruments Not Measured at Fair Value on the Consolidated Balance Sheets

The carrying value and estimated fair value classified by level of fair value hierarchy for financial instruments carried on the consolidated balance sheets at adjusted cost or contract value at December 31, 2021 and 2020 were as follows:
Carrying
Value
 Estimated Fair Value
In millionsLevel 1Level 2Level 3Total
December 31, 2021
Assets: 
Mortgage loans$902 $ $ $907 $907 
Equity securities (1)
126 N/AN/AN/AN/A
Liabilities:
Investment contract liabilities:
With a fixed maturity5   5 5 
Without a fixed maturity336   373 373 
Long-term debt56,176 64,157   64,157 
December 31, 2020
Assets:
Mortgage loans$1,047 $ $ $1,070 $1,070 
Equity securities (1)
145 N/AN/AN/AN/A
Liabilities:
Investment contract liabilities:
With a fixed maturity5   5 5 
Without a fixed maturity322   371 371 
Long-term debt64,647 75,940   75,940 
_____________________________________________
(1)It was not practical to estimate the fair value of these cost-method investments as it represents shares of unlisted companies. See Note 1 ‘‘Significant Accounting Policies’’ for additional information regarding the valuation of cost method investments.

Separate Accounts Measured at Fair Value on the Consolidated Balance Sheets

Separate Accounts assets relate to the Company’s large case pensions products which represent funds maintained to meet specific objectives of contract holders. Since contract holders bear the investment risk of these assets, a corresponding Separate Accounts liability has been established equal to the assets. These assets and liabilities are carried at fair value. Net investment income and capital gains and losses on Separate Accounts assets accrue directly to such contract holders. The assets of each account are legally segregated and are not subject to claims arising from the Company’s other businesses. Deposits, withdrawals, net investment income and realized and unrealized capital gains and losses on Separate Accounts assets are not reflected in the consolidated statements of operations, shareholders’ equity or cash flows.

Separate Accounts assets include debt and equity securities. The valuation methodologies used for these assets are similar to the methodologies described above in this Note 4 ‘‘Fair Value.’’ Separate Accounts assets also include investments in common/collective trusts that are carried at fair value. Common/collective trusts invest in other investment funds otherwise known as the underlying funds. The Separate Accounts’ interests in the common/collective trust funds are based on the fair values of the investments of the underlying funds and therefore are classified in Level 2. The assets in the underlying funds primarily consist of equity securities. Investments in common/collective trust funds are valued at their respective net asset value (“NAV”) per share/unit on the valuation date.


138


Separate Accounts financial assets at December 31, 2021 and 2020 were as follows:
December 31, 2021December 31, 2020
In millionsLevel 1Level 2Level 3TotalLevel 1Level 2Level 3Total
Cash and cash equivalents$2 $186 $ $188 $2 $186 $ $188 
Debt securities1,233 3,048  4,281 1,465 2,634  4,099 
Equity securities 1  1  2  2 
Common/collective trusts 547  547  563  563 
Total (1)
$1,235 $3,782 $ $5,017 $1,467 $3,385 $ $4,852 
_____________________________________________
(1)Excludes $70 million and $29 million of other receivables at December 31, 2021 and 2020, respectively.

During the years ended December 31, 2021 and 2020, the Company had no gross transfers of Separate Accounts financial assets into or out of Level 3.

5.Goodwill and Other Intangibles

Goodwill

Below is a summary of the changes in the carrying amount of goodwill by segment for the years ended December 31, 2021 and 2020:
In millionsHealth Care
Benefits
Pharmacy
Services
Retail/
LTC
Total
Balance at December 31, 2019$45,361 $23,581 $10,807 $79,749 
Acquisitions274 34  308 
Divestiture of Workers’ Compensation business(505)  (505)
Balance at December 31, 202045,130 23,615 10,807 79,552 
Impairment  (431)(431)
Balance at December 31, 2021$45,130 $23,615 $10,376 $79,121 

During the year ended December 31, 2021, the decrease in the carrying amount of goodwill was primarily driven by a goodwill impairment charge related to the LTC reporting unit within the Retail/LTC segment. During the year ended December 31, 2020, the decrease in the carrying amount of goodwill was primarily driven by the divestiture of the Workers’ Compensation business, partially offset by goodwill associated with immaterial acquisitions. See Note 2 ‘‘Divestitures’’ for further discussion regarding the Workers’ Compensation business divestiture.

During the third quarter of 2021, the Company performed its required annual impairment tests of goodwill. The results of the impairment tests indicated an impairment of the goodwill associated with the LTC reporting unit, as the reporting unit’s carrying value exceeded its fair value as of the testing date. The results of the impairment tests of the remaining reporting units indicated that there was no impairment of goodwill as of the testing date.

During 2021, the LTC reporting unit has continued to face challenges that have impacted the Company’s ability to grow the LTC reporting unit’s business at the rate estimated when its 2020 goodwill impairment test was performed. These challenges include lower net facility admissions, net long-term care facility customer losses and the prolonged adverse impact of the COVID-19 pandemic and the emerging new variants, which resulted in more significant declines in occupancy rates experienced by the Company’s long-term care facility customers than previously anticipated. During the third quarter of 2021, LTC management updated their 2021 annual forecast and submitted their long-term plan which showed deterioration in the financial results for the remainder of 2021 and beyond. The Company utilized these updated projections in performing its annual impairment test, which indicated that the fair value of the LTC reporting unit was lower than its carrying value, resulting in a $431 million goodwill impairment charge in the third quarter of 2021. The fair value of the LTC reporting unit was determined using a combination of a discounted cash flow method and a market multiple method. As of December 31, 2021, there was no remaining goodwill balance in the LTC reporting unit. During the third quarter of 2021, the Company also performed an impairment test of the intangible assets of the LTC reporting unit and concluded these assets were not impaired. As of December 31, 2021, there was $2.7 billion of intangible assets related to customer lists in the LTC reporting unit.

139


During the third quarter of 2020, the Company performed its required annual impairment tests of goodwill. The results of the impairment tests indicated that there was no impairment of goodwill.

At December 31, 2021 and 2020, cumulative goodwill impairments were $6.6 billion and $6.1 billion, respectively.

Intangible Assets

The following table is a summary of the Company’s intangible assets as of December 31, 2021 and 2020:
In millions, except weighted average lifeGross
Carrying
Amount
Accumulated
Amortization
Net
Carrying
Amount
Weighted
Average
Life (years)
2021
Trademarks (indefinite-lived)$10,498 $— $10,498 N/A
Customer contracts/relationships and covenants not to compete25,084 (10,564)14,520 15.0
Technology1,060 (1,060) 3.0
Provider networks4,203 (651)3,552 20.0
Value of Business Acquired 590 (173)417 20.0
Other318 (279)39 8.4
Total $41,753 $(12,727)$29,026 15.3
2020
Trademarks (indefinite-lived)$10,498 $— $10,498 N/A
Customer contracts/relationships and covenants not to compete24,952 (8,923)16,029 14.9
Technology1,060 (739)321 3.0
Provider networks4,203 (440)3,763 20.0
Value of Business Acquired 590 (119)471 20.0
Other320 (260)60 7.7
Total$41,623 $(10,481)$31,142 15.2

Amortization expense for intangible assets totaled $2.3 billion, $2.3 billion and $2.4 billion for the years ended December 31, 2021, 2020 and 2019, respectively. The projected annual amortization expense for the Company’s intangible assets for the next five years is as follows:
In millions
2022$1,858 
20231,826 
20241,785 
20251,734 
20261,494 

6.Leases

The Company leases most of its retail stores and mail order facilities and certain distribution centers and corporate offices under operating or finance leases, typically with initial terms of 15 to 25 years. The Company also leases certain equipment and other assets under operating or finance leases, typically with initial terms of 3 to 10 years.

In addition, the Company leases pharmacy space at the stores of another retail chain for which the noncancelable contractual term of the pharmacy lease arrangement exceeds the remaining estimated economic life of the buildings. For these pharmacy lease arrangements, the Company concluded that for accounting purposes the lease term was the remaining estimated economic life of the buildings. Consequently, most of these individual pharmacy leases are finance leases.



140


The following table is a summary of the components of net lease cost for the years ended December 31, 2021, 2020 and 2019:
In millions202120202019
Operating lease cost$2,633 $2,670 $2,720 
Finance lease cost:
Amortization of right-of-use assets62 56 38 
Interest on lease liabilities62 58 44 
Total finance lease costs124 114 82 
Short-term lease costs25 22 24 
Variable lease costs604 599 581 
Less: sublease income59 55 50 
Net lease cost$3,327 $3,350 $3,357 

Supplemental cash flow information related to leases for the years ended December 31, 2021, 2020 and 2019 is as follows:
In millions202120202019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows paid for operating leases$2,714 $2,724 $2,701 
Operating cash flows paid for interest portion of finance leases62 58 44 
Financing cash flows paid for principal portion of finance leases50 34 26 
Right-of-use assets obtained in exchange for lease obligations:
Operating leases1,254 1,679 1,824 
Finance leases278 313 283 


141


Supplemental balance sheet information related to leases as of December 31, 2021 and 2020 is as follows:
In millions, except remaining lease term and discount rate20212020
Operating leases:
Operating lease right-of-use assets$19,122$20,729
Current portion of operating lease liabilities$1,646$1,638
Long-term operating lease liabilities18,17718,757
Total operating lease liabilities$19,823$20,395
Finance leases:
Property and equipment, gross$1,375$1,107
Accumulated depreciation(188)(106)
Property and equipment, net$1,187$1,001
Current portion of long-term debt$50$33
Long-term debt1,2501,050
Total finance lease liabilities$1,300$1,083
Weighted average remaining lease term (in years)
Operating leases12.813.3
Finance leases20.020.3
Weighted average discount rate
Operating leases4.4 %4.5 %
Finance leases5.0 %5.6 %

The following table summarizes the maturity of lease liabilities under finance and operating leases as of December 31, 2021:
In millionsFinance
Leases
Operating
Leases
(1)
Total
2022$122 $2,685 $2,807 
2023121 2,613 2,734 
2024111 2,398 2,509 
2025110 2,217 2,327 
2026109 2,054 2,163 
Thereafter1,495 14,103 15,598 
Total lease payments (2)
2,068 26,070 28,138 
Less: imputed interest(768)(6,247)(7,015)
Total lease liabilities$1,300 $19,823 $21,123 
_____________________________________________
(1)Future operating lease payments have not been reduced by minimum sublease rentals of $311 million due in the future under noncancelable subleases.
(2)The Company leases pharmacy and clinic space from Target Corporation. Amounts related to such finance and operating leases are reflected above. Pharmacy lease amounts due in excess of the remaining estimated economic life of the buildings of approximately $2.4 billion are not reflected in this table since the estimated economic life of the buildings is shorter than the contractual term of the pharmacy lease arrangement.

Sale-Leaseback Transactions
The Company finances a portion of its store development program through sale-leaseback transactions. The properties are generally sold at net book value, which generally approximates fair value, and the resulting leases generally qualify and are accounted for as operating leases. The operating leases that resulted from these transactions are included in the tables above. The Company does not have any retained or contingent interests in the stores and does not provide any guarantees, other than a
142


guarantee of lease payments, in connection with the sale-leaseback transactions. There were no sale-leaseback transactions in 2021. Proceeds from sale-leaseback transactions totaled $101 million and $5 million in the years ended December 31, 2020 and 2019, respectively. Gains from sale-leaseback transactions totaled $3 million in the year ended December 31, 2020. There were no material gains from sale-leaseback transactions in the year ended December 31, 2019.

Store Impairment Charges
The Company evaluates its retail store right-of-use and property and equipment assets for impairment at the retail store level, which is the lowest level at which cash flows can be identified. For retail stores where there is an indicator of impairment present, the Company first compares the carrying amount of the asset group to the estimated future cash flows associated with the asset group (undiscounted). If the estimated undiscounted future cash flows used in the analysis are less than the carrying amount of the asset group, an impairment loss calculation is prepared. The impairment loss calculation compares the carrying amount of the asset group to its estimated fair value which is the greater of the asset group’s estimated future cash flows (discounted), or the consideration of what a market participant would pay to lease the assets, net of leasing costs. The Company’s estimate of fair value considers historical results, current operating trends, consolidated sales, profitability and cash flow results and forecasts. For assets which the Company has determined it will be able to sublease, the estimated future cash flows include the estimated sublease income, net of estimated leasing costs.

When the carrying value of an asset group exceeds its estimated fair value, an impairment loss is recorded to reduce the value of the asset group to its estimated fair value. As the impaired assets are measured at fair value on a nonrecurring basis primarily using unobservable inputs as of the measurement date, the assets are classified in Level 3 of the fair value hierarchy.

During the fourth quarter of 2021, the Company completed a strategic review of its retail business and announced the creation of new formats for its stores to continue to drive higher engagement with customers. As part of this review, the Company evaluated changes in population, consumer buying patterns and future health needs to ensure it has the right kinds of stores in the right locations for consumers and for the business. In connection with this initiative, on November 17, 2021, the Board of Directors of CVS Health Corporation (the “Board”) authorized the closing of approximately 900 retail stores over the next three years. The Company expects to close approximately 300 stores each year between 2022 and 2024. As a result, management determined that there were indicators of impairment with respect to the impacted stores’ asset groups, including the associated operating lease right-of-use assets and property and equipment. A long-lived asset impairment test was performed during the fourth quarter of 2021 and the results of the impairment test indicated that the fair value of certain retail store asset groups was lower than their respective carrying values. Accordingly, in the three months ended December 31, 2021, the Company recorded a store impairment charge of approximately $1.4 billion, consisting of a write down of approximately $1.1 billion related to operating lease right-of-use assets and $261 million related to property and equipment, within the Retail/LTC segment. Subsequent to the impairment loss, the fair value of the associated operating lease right-of use assets and property and equipment were $356 million and $185 million, respectively.

During 2019, the Company performed reviews of its retail stores and determined it would close 68 underperforming retail pharmacy stores. As a result, management determined that there were indicators of impairment with respect to the impacted stores, including the associated operating lease right-of-use assets. Long-lived asset impairment tests were performed and the results indicated that the fair value of those underperforming retail stores were lower than their respective carrying values. Accordingly, the Company recorded store impairment charges of $231 million during the year ended December 31, 2019, primarily related to these operating lease right-of-use asset impairment charges, within the Retail/LTC segment.
143



7.Health Care Costs Payable

The following is information about incurred and cumulative paid health care claims development as of December 31, 2021, net of reinsurance, and the total IBNR liabilities plus expected development on reported claims included within the net incurred claims amounts. See Note 1 ‘‘Significant Accounting Policies’’ for information on how the Company estimates IBNR reserves and health care costs payable as well as changes to those methodologies, if any. The Company’s estimate of IBNR liabilities is primarily based on trend and completion factors. Claim frequency is not used in the calculation of the Company’s liability. In addition, it is impracticable to disclose claim frequency information for health care claims due to the Company’s inability to gather consistent claim frequency information across its multiple claims processing systems. Any claim frequency count disclosure would not be comparable across the Company’s different claim processing systems and would not be consistent from period to period based on the volume of claims processed through each system. As a result, health care claim count frequency is not included in the disclosures below.

The information about incurred and paid health care claims development for the year ended December 31, 2020 is presented as required unaudited supplemental information.
In millionsIncurred Health Care Claims,
Net of Reinsurance
For the Years Ended December 31,
Date of Service20202021
(Unaudited)
2020$54,529 $53,804 
202162,830 
Total$116,634 
In millionsCumulative Paid Health Care Claims,
Net of Reinsurance
For the Years Ended December 31,
Date of Service20202021
(Unaudited)
2020$47,567 $53,590 
202154,600 
Total$108,190 
All outstanding liabilities for health care costs payable prior to 2020, net of reinsurance130 
Total outstanding liabilities for health care costs payable, net of reinsurance$8,574 

At December 31, 2021, the Company’s liabilities for IBNR plus expected development on reported claims totaled approximately $6.6 billion. Substantially all of the Company’s liabilities for IBNR plus expected development on reported claims at December 31, 2021 related to the current calendar year.

The reconciliation of the December 31, 2021 health care net incurred and paid claims development tables to the health care costs payable liability on the consolidated balance sheet is as follows:
In millionsDecember 31, 2021
Short-duration health care costs payable, net of reinsurance$8,574 
Reinsurance recoverables8 
Premium deficiency reserve16 
Insurance lines other than short duration210 
Total health care costs payable$8,808 

144


The following table shows the components of the change in health care costs payable during the years ended December 31, 2021, 2020 and 2019:
In millions202120202019
Health care costs payable, beginning of period $7,936 $6,879 $6,147 
Less: Reinsurance recoverables10 5 4 
Health care costs payable, beginning of period, net7,926 6,874 6,143 
Acquisitions, net 414  
Add: Components of incurred health care costs
  Current year64,761 55,835 52,723 
  Prior years(788)(429)(524)
Total incurred health care costs (1)
63,973 55,406 52,199 
Less: Claims paid
  Current year56,323 48,770 46,158 
  Prior years6,792 6,009 5,314 
Total claims paid63,115 54,779 51,472 
Add: Premium deficiency reserve16 11 4 
Health care costs payable, end of period, net8,800 7,926 6,874 
Add: Reinsurance recoverables8 10 5 
Health care costs payable, end of period$8,808 $7,936 $6,879 
_____________________________________________
(1)Total incurred health care costs for the years ended December 31, 2021, 2020 and 2019 in the table above exclude (i) $16 million, $11 million and $4 million, respectively, for a premium deficiency reserve related to the Company’s Medicaid products, (ii) $59 million, $41 million and $41 million, respectively, of benefit costs recorded in the Health Care Benefits segment that are included in other insurance liabilities on the consolidated balance sheets and (iii) $212 million, $221 million and $285 million, respectively, of benefit costs recorded in the Corporate/Other segment that are included in other insurance liabilities on the consolidated balance sheets.

The Company’s estimates of prior years’ health care costs payable decreased by $788 million, $429 million and $524 million in 2021, 2020 and 2019, respectively, because claims were settled for amounts less than originally estimated (i.e., the amount of claims incurred was lower than originally estimated), primarily due to lower health care cost trends as well as the actual claim submission time being faster than originally assumed (i.e., the Company’s completion factors were higher than originally assumed) in estimating health care costs payable at the end of the prior year. This development does not directly correspond to an increase in the Company’s operating results as these reductions were offset by estimated current period health care costs when the Company established the estimate of the current year health care costs payable.
145



8.Borrowings and Credit Agreements
The following table is a summary of the Company’s borrowings as of December 31, 2021 and 2020:
In millions20212020
Long-term debt
3.35% senior notes due March 2021
$ $2,038 
Floating rate notes due March 2021 (0.950% at December 31, 2020)
 1,000 
4.125% senior notes due May 2021
 222 
2.125% senior notes due June 2021
 1,750 
4.125% senior notes due June 2021
 203 
5.45% senior notes due June 2021
 187 
3.5% senior notes due July 2022
1,500 1,500 
2.75% senior notes due November 2022
1,000 1,000 
2.75% senior notes due December 2022
1,250 1,250 
4.75% senior notes due December 2022
399 399 
3.7% senior notes due March 2023
 2,336 
2.8% senior notes due June 2023
1,300 1,300 
4% senior notes due December 2023
414 414 
3.375% senior notes due August 2024
650 650 
2.625% senior notes due August 2024
1,000 1,000 
3.5% senior notes due November 2024
750 750 
5% senior notes due December 2024
299 299 
4.1% senior notes due March 2025
950 950 
3.875% senior notes due July 2025
2,828 2,828 
2.875% senior notes due June 2026
1,750 1,750 
3% senior notes due August 2026
750 750 
3.625% senior notes due April 2027
750 750 
6.25% senior notes due June 2027
372 372 
1.3% senior notes due August 2027
2,250 2,250 
4.3% senior notes due March 2028
5,000 7,050 
3.25% senior notes due August 2029
1,750 1,750 
3.75% senior notes due April 2030
1,500 1,500 
1.75% senior notes due August 2030
1,250 1,250 
1.875% senior notes due February 2031
1,250 1,250 
2.125% senior notes due September 2031
1,000  
4.875% senior notes due July 2035
652 652 
6.625% senior notes due June 2036
771 771 
6.75% senior notes due December 2037
533 533 
4.78% senior notes due March 2038
5,000 5,000 
6.125% senior notes due September 2039
447 447 
4.125% senior notes due April 2040
1,000 1,000 
2.7% senior notes due August 2040
1,250 1,250 
5.75% senior notes due May 2041
133 133 
4.5% senior notes due May 2042
500 500 
4.125% senior notes due November 2042
500 500 
5.3% senior notes due December 2043
750 750 
4.75% senior notes due March 2044
375 375 
5.125% senior notes due July 2045
3,500 3,500 
3.875% senior notes due August 2047
1,000 1,000 
5.05% senior notes due March 2048
8,000 8,000 
4.25% senior notes due April 2050
750 750 
Finance lease liabilities1,300 1,083 
Other320 326 
Total debt principal56,743 65,318 
Debt premiums219 238 
Debt discounts and deferred financing costs(786)(909)
56,176 64,647 
Less:
Current portion of long-term debt(4,205)(5,440)
Long-term debt$51,971 $59,207 
146


The following is a summary of the Company’s required repayments of debt principal due during each of the next five years and thereafter, as of December 31, 2021:
In millions
2022$4,154 
20231,719 
20242,706 
20253,785 
20262,507 
Thereafter40,572 
Subtotal55,443 
Finance lease liabilities (1)
1,300 
Total debt principal$56,743 
_____________________________________________
(1)See Note 6 ‘‘Leases’’ for a summary of maturities of the Company’s finance lease liabilities.

Short-term Borrowings

Commercial Paper and Back-up Credit Facilities
The Company did not have any commercial paper outstanding as of December 31, 2021 or 2020. In connection with its commercial paper program, the Company maintains a $2.0 billion, five-year unsecured back-up revolving credit facility, which expires on May 17, 2023, a $2.0 billion, five-year unsecured back-up revolving credit facility, which expires on May 16, 2024, and a $2.0 billion, five-year unsecured back-up revolving credit facility, which expires on May 11, 2026. The credit facilities allow for borrowings at various rates that are dependent, in part, on the Company’s public debt ratings and require the Company to pay a weighted average quarterly facility fee of approximately 0.03%, regardless of usage. As of December 31, 2021 and 2020, there were no borrowings outstanding under any of the Company’s back-up credit facilities.

Federal Home Loan Bank of Boston (“FHLBB”)
A subsidiary of the Company is a member of the FHLBB. As a member, the subsidiary has the ability to obtain cash advances, subject to certain minimum collateral requirements. The maximum borrowing capacity available from the FHLBB as of December 31, 2021 was approximately $995 million. At both December 31, 2021 and 2020, there were no outstanding advances from the FHLBB.

Long-term Borrowings

2021 Notes
On August 18, 2021, the Company issued $1.0 billion aggregate principal amount of 2.125% unsecured senior notes due September 15, 2031 for total proceeds of $987 million, net of discounts, underwriting fees and offering expenses. The net proceeds of this offering were used for the purchase of senior notes in connection with the Company’s cash tender offer in August 2021 as described below.

2020 Notes
On December 16, 2020, the Company issued $750 million aggregate principal amount of 1.3% unsecured senior notes due August 21, 2027 and $1.25 billion aggregate principal amount of 1.875% unsecured senior notes due February 28, 2031 for total proceeds of approximately $1.99 billion, net of discounts and underwriting fees. The $750 million aggregate principal amount of 1.3% unsecured senior notes represent a further issuance of the Company’s 1.3% unsecured senior notes due August 21, 2027 initially issued in an aggregate principal amount of $1.5 billion on August 21, 2020.

On August 21, 2020, the Company issued $1.5 billion aggregate principal amount of 1.3% unsecured senior notes due August 21, 2027, $1.25 billion aggregate principal amount of 1.75% unsecured senior notes due August 21, 2030 and $1.25 billion aggregate principal amount of 2.7% unsecured senior notes due August 21, 2040 (collectively, the “August 2020 Notes”) for total proceeds of approximately $3.97 billion, net of discounts and underwriting fees.

On March 31, 2020, the Company issued $750 million aggregate principal amount of 3.625% unsecured senior notes due April 1, 2027, $1.5 billion aggregate principal amount of 3.75% unsecured senior notes due April 1, 2030, $1.0 billion aggregate principal amount of 4.125% unsecured senior notes due April 1, 2040 and $750 million aggregate principal amount of 4.25%
147


unsecured senior notes due April 1, 2050 (collectively, the “March 2020 Notes”) for total proceeds of approximately $3.95 billion, net of discounts and underwriting fees.

The net proceeds of these offerings were used for general corporate purposes, which may include working capital, capital expenditures, as well as the repurchase and/or repayment of indebtedness.

During March 2020, the Company entered into several interest rate swap transactions to manage interest rate risk. These agreements were designated as cash flow hedges and were used to hedge the exposure to variability in future cash flows resulting from changes in interest rates related to the anticipated issuance of the March 2020 Notes. In connection with the issuance of the March 2020 Notes, the Company terminated all outstanding cash flow hedges. The Company paid a net amount of $7 million to the hedge counterparties upon termination, which was recorded as a loss, net of tax, of $5 million in accumulated other comprehensive income and will be reclassified as interest expense over the life of the March 2020 Notes. See Note 13 ‘‘Other Comprehensive Income’’ for additional information.

Early Extinguishments of Debt
In December 2021, the Company redeemed for cash the remaining $2.3 billion of its outstanding 3.7% senior notes due 2023. In connection with the early redemption of such senior notes, the Company paid a make-whole premium of $80 million in excess of the aggregate principal amount of the senior notes that were redeemed, wrote-off $8 million of unamortized deferred financing costs and incurred $1 million in fees, for a total loss on early extinguishment of debt of $89 million.

In August 2021, the Company purchased approximately $2.0 billion of its outstanding 4.3% senior notes due 2028 through a cash tender offer. In connection with the purchase of such senior notes, the Company paid a premium of $332 million in excess of the aggregate principal amount of the senior notes that were purchased, wrote-off $26 million of unamortized deferred financing costs and incurred $5 million in fees, for a total loss on early extinguishment of debt of $363 million.

In December 2020, the Company purchased $4.5 billion of its outstanding senior notes through cash tender offers. The senior notes purchased included the following: $113 million of its 4.0% senior notes due 2023, $1.4 billion of its 3.7% senior notes due 2023, $1.0 billion of its 4.1% senior notes due 2025 and $2.0 billion of its 4.3% senior notes due 2028. In connection with the purchase of such senior notes, the Company paid a premium of $619 million in excess of the aggregate principal amount of the senior notes that were purchased, wrote-off $45 million of unamortized deferred financing costs and incurred $10 million in fees, for a total loss on early extinguishment of debt of $674 million.

In August 2020, the Company purchased $6.0 billion of its outstanding senior notes through cash tender offers. The senior notes purchased included the following: $723 million of its 4.0% senior notes due 2023, $2.3 billion of its 3.7% senior notes due 2023 and $3.0 billion of its 4.1% senior notes due 2025. In connection with the purchase of such senior notes, the Company paid a premium of $706 million in excess of the aggregate principal amount of the senior notes that were purchased, wrote-off $47 million of unamortized deferred financing costs and incurred $13 million in fees, for a total loss on early extinguishment of debt of $766 million.

In August 2019, the Company purchased $4.0 billion of its outstanding senior notes through cash tender offers. The senior notes purchased included the following: $1.3 billion of its 3.125% senior notes due 2020, $723 million of its floating rate notes due 2020, $328 million of its 4.125% senior notes due 2021, $297 million of 4.125% senior notes due 2021 issued by Aetna Inc. (“Aetna”), $413 million of 5.45% senior notes due 2021 issued by Coventry Health Care, Inc., a wholly-owned subsidiary of Aetna, and $962 million of its 3.35% senior notes due 2021. In connection with the purchase of such senior notes, the Company paid a premium of $76 million in excess of the aggregate principal amount of the senior notes that were purchased, incurred $8 million in fees and recognized a net gain of $5 million on the write-off of net unamortized deferred financing premiums, for a net loss on early extinguishment of debt of $79 million.

Debt Covenants

The Company’s back-up revolving credit facilities, unsecured senior notes and unsecured floating rate notes contain customary restrictive financial and operating covenants. These covenants do not include an acceleration of the Company’s debt maturities in the event of a downgrade in the Company’s credit ratings. The Company does not believe the restrictions contained in these covenants materially affect its financial or operating flexibility. As of December 31, 2021, the Company was in compliance with all of its debt covenants.



148


9.Pension Plans and Other Postretirement Benefits

Defined Contribution Plans

As of December 31, 2021, the Company sponsors several active 401(k) savings plans that cover all employees who meet plan eligibility requirements.

The Company makes matching contributions consistent with the provisions of the respective plans. At the participant’s option, account balances, including the Company’s matching contribution, can be invested among various investment options under each plan. The CVS Health Future Fund 401(k) Plan offers CVS Health Corporation’s common stock fund as an investment option. The Company also maintains nonqualified, unfunded deferred compensation plans for certain key employees. The plans provide participants the opportunity to defer portions of their eligible compensation and for certain nonqualified plans, participants receive matching contributions equivalent to what they could have received under the CVS Health Future Fund 401(k) Plan absent certain restrictions and limitations under the Internal Revenue Code. The Company’s contributions under its defined contribution plans were $552 million, $520 million and $550 million in the years ended December 31, 2021, 2020 and 2019, respectively. The Company’s contributions for the year ended December 31, 2019 include contributions to the Aetna 401(k) Plan, which was merged into the CVS Health Future Fund 401(k) Plan on January 1, 2020.

Defined Benefit Pension Plans

The Company sponsors a tax-qualified defined benefit pension plan that was frozen in 2010 and a nonqualified supplemental pension plan that was frozen in 2007. The Company also sponsors several other defined benefit pension plans that are unfunded nonqualified supplemental retirement plans.

Pension Benefit Obligation and Plan Assets
The following tables outline the change in pension benefit obligation and plan assets over the specified periods:
In millions20212020
Change in benefit obligation:
Benefit obligation, beginning of year$6,462 $6,239 
Interest cost110 168 
Actuarial (gain) loss(102)413 
Benefit payments(408)(358)
Settlements(53) 
Benefit obligation, end of year6,009 6,462 
Change in plan assets:
Fair value of plan assets, beginning of year6,845 6,395 
Actual return on plan assets215 783 
Employer contributions78 25 
Benefit payments(408)(358)
Settlements(53) 
Fair value of plan assets, end of year6,677 6,845 
Funded status$668 $383 

The change in the pension benefit obligation during the years ended December 31, 2021 and 2020 was primarily driven by the change in the discount rate during each respective period.


149


The assets (liabilities) recognized on the consolidated balance sheets at December 31, 2021 and 2020 for the defined benefit pension plans consisted of the following:
In millions20212020
Noncurrent assets reflected in other assets$946 $744 
Current liabilities reflected in accrued expenses(28)(76)
Noncurrent liabilities reflected in other long-term liabilities(250)(285)
Net assets$668 $383 

Net Periodic Benefit Cost (Income)
The components of net periodic benefit cost (income) for the years ended December 31, 2021, 2020 and 2019 are shown below:
In millions202120202019
Components of net periodic benefit cost (income):
Interest cost$110 $168 $225 
Expected return on plan assets(317)(388)(357)
Amortization of net actuarial loss5 2 1 
Settlement losses16   
Net periodic benefit cost (income)$(186)$(218)$(131)

Pension Plan Assumptions
The Company uses a series of actuarial assumptions to determine its benefit obligation and net periodic benefit cost (income), the most significant of which include discount rates and expected return on plan assets assumptions.

Discount Rates - The discount rate is determined using a yield curve as of the annual measurement date. The yield curve consists of a series of individual discount rates, with each discount rate corresponding to a single point in time, based on high-quality bonds. Projected benefit payments are discounted to the measurement date using the corresponding rate from the yield curve that is consistent with the maturity profile of the expected liability cash flows.

Expected Return on Plan Assets - The expected long-term rate of return on plan assets is determined by using the plan’s target allocation and return expectations based on many factors including forecasted long-term capital market real returns and the inflationary outlook on a plan by plan basis. See “Pension Plan Assets” below for additional details regarding the pension plan assets as of December 31, 2021 and 2020.

The Company also considers other assumptions including mortality, interest crediting rate, termination and retirement rates and cost of living adjustments.

The Company determined its benefit obligation based on the following weighted average assumptions as of December 31, 2021 and 2020:
20212020
Discount rate2.8 %2.5 %

The Company determined its net periodic benefit cost (income) based on the following weighted average assumptions for the years ended December 31, 2021, 2020 and 2019:
202120202019
Discount rate1.8 %2.9 %4.0 %
Expected long-term rate of return on plan assets4.8 %6.3 %6.5 %


150


Pension Plan Assets
The Company’s pension plan assets primarily include debt and equity securities held in separate accounts, common/collective trusts and real estate investments. The valuation methodologies used to value these debt and equity securities and common/collective trusts are similar to the methodologies described in Note 4 “Fair Value.” Pension plan assets also include investments in other assets that are carried at fair value. The following is a description of the valuation methodologies used to value real estate investments and these additional investments, including the general classification pursuant to the fair value hierarchy.

Real Estate - Real estate investments are valued by independent third party appraisers. The appraisals comply with the Uniform Standards of Professional Appraisal Practice, which include, among other things, the income, cost, and sales comparison approaches to estimating property value. Therefore, these investments are classified in Level 3.

Private equity and hedge fund limited partnerships - Private equity and hedge fund limited partnerships are carried at fair value which is estimated using the NAV per unit as reported by the administrator of the underlying investment fund as a practical expedient to fair value. Therefore, these investments have been excluded from the fair value table below.

Pension plan assets with changes in fair value measured on a recurring basis at December 31, 2021 were as follows:
In millionsLevel 1Level 2Level 3Total
Cash and cash equivalents$60 $97 $ $157 
Debt securities:
    U.S. government securities1,223 1  1,224 
    States, municipalities and political subdivisions 150  150 
    U.S. corporate securities 2,458  2,458 
    Foreign securities 202  202 
    Residential mortgage-backed securities 277  277 
    Commercial mortgage-backed securities 76  76 
    Other asset-backed securities 162  162 
    Redeemable preferred securities 4  4 
Total debt securities1,223 3,330  4,553 
Equity securities:
    U.S. domestic201   201 
    International81   81 
    Domestic real estate1   1 
Total equity securities283   283 
Other investments:
    Real estate  378 378 
    Common/collective trusts (1)
 410  410 
Total other investments 410 378 788 
Total pension investments (2)
$1,566 $3,837 $378 $5,781 
_____________________________________________
(1)The assets in the underlying funds of common/collective trusts consist of $261 million of equity securities and $149 million of debt securities.
(2)Excludes $76 million of other receivables as well as $583 million of private equity limited partnership investments and $237 million of hedge fund limited partnership investments as these amounts are measured at NAV per share or an equivalent and are not subject to leveling within the fair value hierarchy.
151


Pension plan assets with changes in fair value measured on a recurring basis at December 31, 2020 were as follows:
In millionsLevel 1Level 2Level 3Total
Cash and cash equivalents$118 $81 $ $199 
Debt securities:
    U.S. government securities575 36  611 
    States, municipalities and political subdivisions 170  170 
    U.S. corporate securities 2,006  2,006 
    Foreign securities 167  167 
    Residential mortgage-backed securities 287  287 
    Commercial mortgage-backed securities 83  83 
    Other asset-backed securities 133  133 
    Redeemable preferred securities 5  5 
Total debt securities575 2,887  3,462 
Equity securities:
    U.S. domestic1,046   1,046 
    International537   537 
    Domestic real estate15   15 
Total equity securities1,598   1,598 
Other investments:
    Real estate  343 343 
    Common/collective trusts (1)
 266  266 
    Derivatives (3) (3)
Total other investments 263 343 606 
Total pension investments (2)
$2,291 $3,231 $343 $5,865 
_____________________________________________
(1)The assets in the underlying funds of common/collective trusts consist of $84 million of equity securities and $182 million of debt securities.
(2)Excludes $142 million of other receivables as well as $624 million of private equity limited partnership investments and $214 million of hedge fund limited partnership investments as these amounts are measured at NAV per share or an equivalent and are not subject to leveling within the fair value hierarchy.

The changes in the balances of Level 3 pension plan assets during the year ended December 31, 2021 were as follows:
In millionsReal estateTotal
Beginning balance$343 $343 
Actual return on plan assets43 43 
Purchases, sales and settlements(8)(8)
Transfers out of Level 3  
Ending balance$378 $378 

The changes in the balances of Level 3 pension plan assets during the year ended December 31, 2020 were as follows:

In millionsReal estateU.S. corporate
securities
Total
Beginning balance$353 $1 $354 
Actual return on plan assets(2) (2)
Purchases, sales and settlements(8) (8)
Transfers out of Level 3 (1)(1)
Ending balance$343 $ $343 

152


The Company’s pension plan invests in a diversified mix of assets designed to generate returns that will enable the plan to meet its future benefit obligations. The risk of unexpected investment and actuarial outcomes is regularly evaluated. This evaluation is performed through forecasting and assessing ranges of investment outcomes over short- and long-term horizons and by assessing the pension plan’s liability characteristics. Complementary investment styles and strategies are utilized by professional investment management firms to further improve portfolio and operational risk characteristics. Public and private equity investments are used primarily to increase overall plan returns. Real estate investments are viewed favorably for their diversification benefits and above-average dividend generation. Fixed income investments provide diversification benefits and liability hedging attributes that are desirable, especially in falling interest rate environments.

At December 31, 2021, target investment allocations for the Company’s pension plan were: 12% in equity securities, 77% in fixed income and debt securities, 5% in real estate, 3% in private equity limited partnerships and 3% in hedge funds. Actual asset allocations may differ from target allocations due to tactical decisions to overweight or underweight certain assets or as a result of normal fluctuations in asset values. Asset allocations are consistent with stated investment policies and, as a general rule, periodically rebalanced back to target asset allocations. Asset allocations and investment performance are formally reviewed periodically throughout the year by the pension plan’s Investment Subcommittee. Forecasting of asset and liability growth is performed at least annually.

Cash Flows
The Company generally contributes to its tax-qualified pension plan based on minimum funding requirements determined under applicable federal laws and regulations. Employer contributions related to the nonqualified supplemental pension plans generally represent payments to retirees for current benefits. The Company contributed $78 million, $25 million and $25 million to its pension plans during 2021, 2020 and 2019, respectively. No contributions are required for the tax-qualified pension plan in 2022. The Company expects to make an immaterial amount of contributions for all other pension plans in 2022.

The Company estimates the following future benefit payments, which are calculated using the same actuarial assumptions used to measure the pension benefit obligation as of December 31, 2021:
In millions
2022$371 
2023371 
2024371 
2025371 
2026368 
2027-20311,776 

Multiemployer Pension Plans
The Company also contributes to a number of multiemployer pension plans under the terms of collective-bargaining agreements that cover its union-represented employees. The risks of participating in these multiemployer plans are different from single-employer pension plans in the following respects: (i) assets contributed to the multiemployer plan by one employer may be used to provide benefits to employees of other participating employers, (ii) if a participating employer stops contributing to the plan, the unfunded obligations of the plan may be borne by the remaining participating employers, and (iii) if the Company chooses to stop participating in some of its multiemployer plans, the Company may be required to pay those plans an amount based on the underfunded status of the applicable plan, which is referred to as a withdrawal liability.

None of the multiemployer pension plans in which the Company participates are individually significant to the Company. The Company’s contributions to multiemployer pension plans were $19 million, $19 million and $18 million in 2021, 2020 and 2019, respectively.

Other Postretirement Benefits

The Company provides postretirement health care and life insurance benefits to certain retirees who meet eligibility requirements. The Company’s funding policy is generally to pay covered expenses as they are incurred. For retiree medical plan accounting, the Company reviews external data and its own historical trends for health care costs to determine the health care cost trend rates. As of December 31, 2021 and 2020, the Company’s other postretirement benefits had an accumulated postretirement benefit obligation of $207 million and $226 million, respectively. Net periodic benefit costs related to these other postretirement benefits were $4 million, $12 million and $7 million in 2021, 2020 and 2019, respectively.

153


The Company estimates the following future benefit payments, which are calculated using the same actuarial assumptions used to measure the accumulated other postretirement benefit obligation as of December 31, 2021:
In millions
2022$12 
202312 
202412 
202512 
202612 
2027-203160 

Pursuant to various collective bargaining agreements, the Company also contributes to multiemployer health and welfare plans that cover certain union-represented employees. The plans provide postretirement health care and life insurance benefits to certain employees who meet eligibility requirements. The Company’s contributions to multiemployer health and welfare plans totaled $60 million, $54 million and $57 million in 2021, 2020 and 2019, respectively.

10.Income Taxes

The income tax provision for continuing operations consisted of the following for the years ended December 31, 2021, 2020 and 2019:
In millions202120202019
Current:
Federal$2,285 $2,615 $2,450 
State665 518 565 
2,950 3,133 3,015 
Deferred:
Federal(306)(450)(535)
State(122)(114)(114)
(428)(564)(649)
Total$2,522 $2,569 $2,366 

The following table is a reconciliation of the statutory income tax rate to the Company’s effective income tax rate for continuing operations for the years ended December 31, 2021, 2020 and 2019:
202120202019
Statutory income tax rate21.0 %21.0 %21.0 %
State income taxes, net of federal tax benefit4.1 3.2 4.0 
Health insurer fee 2.2  
Basis difference upon disposition of subsidiary (1.2) 
Prior year refund claim (1.2)  
Other0.3 1.1 1.3 
Effective income tax rate24.2 %26.3 %26.3 %









154


The following table is a summary of the components of the Company’s deferred income tax assets and liabilities as of December 31, 2021 and 2020:
In millions20212020
Deferred income tax assets:
Lease and rents$5,563 $5,742 
Inventory99 80 
Employee benefits193 238 
Bad debts and other allowances489 395 
Net operating loss and capital loss carryforwards416 568 
Deferred income78 43 
Insurance reserves501 489 
Payroll tax deferral87 173 
Other396 500 
Valuation allowance(325)(454)
Total deferred income tax assets7,497 7,774 
Deferred income tax liabilities:
Retirement benefits(105)(29)
Investments(334)(421)
Lease and rents(4,947)(5,368)
Depreciation and amortization(8,381)(8,750)
Total deferred income tax liabilities(13,767)(14,568)
Net deferred income tax liabilities$(6,270)$(6,794)

As of December 31, 2021, the Company had net operating and capital loss carryovers of $416 million, which expire between 2022 and 2041. The Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and the Company’s recent operating results. The Company established a valuation allowance of $325 million as of December 31, 2021 because it does not consider it more likely than not that these deferred tax assets will be recovered.

A reconciliation of the beginning and ending balance of unrecognized tax benefits in 2021, 2020 and 2019 is as follows:
In millions202120202019
Beginning balance$768 $655 $661 
Additions based on tax positions related to the current year3 3 4 
Additions based on tax positions related to prior years52 182 115 
Reductions for tax positions of prior years(33)(56)(111)
Expiration of statutes of limitation(1)(2)(7)
Settlements(7)(14)(7)
Ending balance$782 $768 $655 

CVS Health Corporation and most of its subsidiaries are subject to U.S. federal income tax as well as income tax of numerous state and local jurisdictions. CVS Health Corporation participated in the Compliance Assurance Process through 2019, which is a program made available by the U.S. Internal Revenue Service (“IRS”) to certain qualifying large taxpayers, under which participants work collaboratively with the IRS to identify and resolve potential tax issues through open, cooperative and transparent interaction prior to the annual filing of their federal income tax returns. The IRS has completed its examinations of the Company’s consolidated U.S. federal income tax returns for tax years through and including 2013 and 2018. The IRS has substantially completed its examinations of the Company’s consolidated U.S. federal income tax returns for tax years 2014 through 2017 and 2019.

155


CVS Health Corporation and its subsidiaries are also currently under income tax examinations by a number of state and local tax authorities. As of December 31, 2021, no examination has resulted in any proposed adjustments that would result in a material change to the Company’s operating results, financial condition or liquidity.

Substantially all material state and local income tax matters have been concluded for fiscal years through 2014. Certain state exams are likely to be concluded and certain state statutes of limitations will lapse in 2022, but the change in the balance of the Company’s uncertain tax positions is projected to be immaterial. In addition, it is reasonably possible that the Company’s unrecognized tax benefits could change within the next twelve months due to the anticipated conclusion of various examinations with the IRS for various years. An estimate of the range of the possible change cannot be made at this time.

The Company records interest expense related to unrecognized tax benefits and penalties in the income tax provision. The Company accrued interest expense of approximately $40 million, $34 million and $49 million in 2021, 2020 and 2019, respectively. The Company had approximately $151 million and $121 million accrued for interest and penalties as of December 31, 2021 and 2020, respectively.

As of December 31, 2021, the total amount of unrecognized tax benefits that, if recognized, would affect the Company’s effective income tax rate is approximately $669 million, after considering the federal benefit of state income taxes.

11.Stock Incentive Plans

The terms of the CVS Health 2017 Incentive Compensation Plan (“ICP”) provide for grants of annual incentive and long-term performance awards to executive officers and other officers and employees of the Company or any subsidiary of the Company, as well as equity compensation to outside directors of CVS Health Corporation. Payment of such annual incentive and long-term performance awards will be in cash, stock, other awards or other property, at the discretion of the Management Planning and Development Committee (the “MP&D Committee”) of the Board. The ICP allows for a maximum of 58 million shares of CVS Health Corporation common stock to be reserved and available for grants. As of December 31, 2021, there were approximately 30 million shares of CVS Health Corporation common stock available for future grants under the ICP.

Upon the acquisition of Aetna (the “Aetna Acquisition”) on November 28, 2018, approximately 22 million shares of Aetna common stock subject to awards outstanding under the Amended Aetna Inc. 2010 Stock Incentive Plan (“SIP”) were assumed by CVS Health Corporation. In addition, in accordance with the merger agreement, shares which were available for future issuance under the SIP were converted into approximately 32 million shares of CVS Health Corporation common stock reserved and available for issuance pursuant to future awards. Subsequent to the expiration of the SIP on May 21, 2020, the ICP is the only compensation plan under which the Company grants stock options, restricted stock and other stock-based awards to its employees.

Stock-Based Compensation Expense

Stock-based compensation is measured at the grant date based on the fair value of the award and is recognized as expense over the requisite service period of the stock award (generally three to five years) using the straight-line method. The following table is a summary of stock-based compensation for the years ended December 31, 2021, 2020 and 2019:
In millions202120202019
Stock options and stock appreciation rights (“SARs”) (1)
$80 $71 $76 
Restricted stock units and performance stock units
404 329 377 
Total stock-based compensation$484 $400 $453 
_____________________________________________
(1)Includes the ESPP.

ESPP

The Company’s Employee Stock Purchase Plan (“ESPP”) provides for the purchase of up to 60 million shares of CVS Health Corporation common stock. Under the ESPP, eligible employees may purchase common stock at the end of each six month offering period at a purchase price equal to 90% of the lower of the fair market value on the first day or the last day of the offering period. During 2021, approximately 3 million shares of common stock were purchased under the provisions of the ESPP at an average price of $60.51 per share. As of December 31, 2021, approximately 31 million shares of common stock were available for issuance under the ESPP.

156


The fair value of stock-based compensation associated with the ESPP is estimated on the date of grant (the first day of the six month offering period) using the Black-Scholes option pricing model.

The following table is a summary of the assumptions used to value the ESPP awards for the years ended December 31, 2021, 2020 and 2019:
202120202019
Dividend yield (1)
1.34 %1.46 %1.70 %
Expected volatility (2)
25.27 %37.21 %27.96 %
Risk-free interest rate (3)
0.08 %0.81 %2.27 %
Expected life (in years) (4)
0.50.50.5
Weighted-average grant date fair value$12.55 $13.85 $10.51 
_____________________________________________
(1)The dividend yield is calculated based on semi-annual dividends paid and the fair market value of CVS Health Corporation stock at the grant date.
(2)The expected volatility is estimated based on the historical volatility of CVS Health Corporation’s daily stock price over the previous six month period.
(3)The risk-free interest rate is selected based on the Treasury constant maturity interest rate whose term is consistent with the expected term of ESPP purchases (i.e., six months).
(4)The expected life is based on the semi-annual purchase period.

Restricted Stock Units and Performance Stock Units

The Company’s restricted stock units and performance stock units are considered nonvested share awards and require no payment from the employee. The fair value of the restricted stock units is based on the market price of CVS Health Corporation common stock on the grant date and is recognized on a straight-line basis over the vesting period. For each restricted stock unit granted, employees receive one share of common stock, net of taxes, at the end of the vesting period.

The Company’s performance stock units contain performance vesting conditions in addition to a service vesting condition. Vesting of the Company’s performance stock units is dependent upon the degree to which the Company achieves its performance goals, which are generally set for a three-year performance period and are approved at the time of grant by the MP&D Committee.

The fair value of performance stock units granted with service and performance vesting conditions is based on the market price of CVS Health Corporation common stock on the grant date and is recognized over the vesting period. Certain of the performance stock units also contain a market vesting condition based on the performance of CVS Health Corporation common stock relative to a comparator group. The fair value of these performance stock units is determined using a Monte Carlo simulation as of the grant date and is recognized over the vesting period.

As of December 31, 2021, there was $529 million of total unrecognized compensation cost related to the Company’s restricted stock units and performance stock units that are expected to vest. These costs are expected to be recognized over a weighted-average period of 2.1 years. The total fair value of restricted stock units vested during 2021, 2020 and 2019 was $406 million, $229 million and $265 million, respectively.

The following table is a summary of the restricted stock unit and performance stock unit activity for the year ended December 31, 2021:
In thousands, except weighted average grant date fair valueUnitsWeighted Average
Grant Date
Fair Value
Outstanding at beginning of year, nonvested14,824 $58.12 
Granted6,190 $74.39 
Vested(5,448)$74.47 
Forfeited(1,236)$63.40 
Outstanding at end of year, nonvested14,330 $63.02 

Stock Options and SARs

All stock option grants are awarded at fair value on the date of grant. The fair value of stock options is estimated using the Black-Scholes option pricing model, and stock-based compensation is recognized on a straight-line basis over the requisite
157


service period. Stock options granted generally become exercisable over a four-year period from the grant date. Stock options granted through 2018 generally expire seven years after the grant date. Stock options granted subsequent to 2018 generally expire ten years after the grant date.

All unvested Aetna SARs outstanding upon the acquisition of Aetna were converted into replacement CVS Health Corporation SARs. The replacement SARs granted are settled in CVS Health Corporation common stock, net of taxes, based on the appreciation of the stock price on the exercise date over the market price on the date of grant. The fair value of SARs is estimated using the Black-Scholes option pricing model, and stock-based compensation is recognized on a straight-line basis over the requisite service period. SARs generally become exercisable over a three-year period from the grant date. SARs generally expire ten years after the grant date. No SARs have been granted subsequent to the Aetna Acquisition.

The following table is a summary of stock option and SAR activity that occurred for the years ended December 31, 2021, 2020 and 2019:
In millions202120202019
Cash received from stock options exercised (including ESPP)
$549 $264 $210 
Payments for taxes for net share settlement of equity awards
168 88 112 
Intrinsic value of stock options and SARs exercised
105 24 30 
Fair value of stock options and SARs vested
224 252 467 

The fair value of each stock option is estimated using the Black-Scholes option pricing model based on the following assumptions at the time of grant:
202120202019
Dividend yield (1)
2.68 %3.42 %3.68 %
Expected volatility (2)
27.10 %25.22 %21.76 %
Risk-free interest rate (3)
1.13 %0.61 %0.56 %
Expected life (in years) (4)
6.36.36.3
Weighted-average grant date fair value$14.57 $8.78 $6.27 
_____________________________________________
(1)The dividend yield is based on annual dividends paid and the fair market value of CVS Health Corporation stock at the grant date.
(2)The expected volatility is estimated based on the historical volatility of CVS Health Corporation’s daily stock price over a period equal to the expected life of each option grant after adjustments for infrequent events such as stock splits.
(3)The risk-free interest rate is selected based on yields from U.S. Treasury zero-coupon issues with a remaining term equal to the expected term of the options being valued.
(4)The expected life represents the number of years the options are expected to be outstanding from grant date based on historical option or SAR holder exercise experience.

As of December 31, 2021, unrecognized compensation expense related to unvested stock options totaled $38 million, which the Company expects to be recognized over a weighted-average period of 2.0 years. After considering anticipated forfeitures, the Company expects approximately 9 million of the unvested stock options to vest over the requisite service period.


158


The following table is a summary of the Company’s stock option and SAR activity for the year ended December 31, 2021:
In thousands, except weighted average exercise price and remaining contractual termSharesWeighted
Average
Exercise
 Price
Weighted
Average
Remaining
Contractual
Term
Aggregate
Intrinsic
Value
Outstanding at beginning of year23,955 $69.62 
Granted3,322 $74.66 
Exercised(6,366)$63.41 
Forfeited(694)$62.66 
Expired(1,156)$87.42 
Outstanding at end of year19,061 $71.74 4.75$603,137 
Exercisable at end of year9,704 $79.99 2.61229,034 
Vested at end of year and expected to vest in the future18,709 $71.82 4.69590,514 

12.Shareholders’ Equity

Share Repurchases

The following share repurchase programs have been authorized by the Board:
In billions
Authorization Date
AuthorizedRemaining as of
December 31, 2021
December 9, 2021 (“2021 Repurchase Program”)
$10.0 $10.0 
November 2, 2016 (“2016 Repurchase Program”)15.0  

Each of the share Repurchase Programs was effective immediately. The 2016 Repurchase program was terminated effective December 9, 2021. The 2021 Repurchase Program permits the Company to effect repurchases from time to time through a combination of open market repurchases, privately negotiated transactions, accelerated share repurchase (“ASR”) transactions, and/or other derivative transactions. The 2021 Repurchase Program can be modified or terminated by the Board at any time.

During the years ended December 31, 2021, 2020 and 2019, the Company did not repurchase any shares of common stock pursuant to the 2016 or 2021 Repurchase Programs.

Pursuant to the authorization under the 2021 Repurchase Program, the Company entered into a $1.5 billion fixed dollar ASR with Barclays Bank PLC (“Barclays”). Upon payment of the $1.5 billion purchase price on January 4, 2022, the Company received a number of shares of CVS Health Corporation’s common stock equal to 80% of the $1.5 billion notional amount of the ASR or approximately 11.6 million shares at a price of $103.34 per share, which were placed into treasury stock in January 2022. At the conclusion of the ASR, the Company may receive additional shares equal to the remaining 20% of the $1.5 billion notional amount. The ultimate number of shares the Company may receive will depend on the daily volume-weighted average price of the Company’s stock over an averaging period, less a discount. It is also possible, depending on such weighted average price, that the Company will have an obligation to Barclays which, at the Company’s option, could be settled in additional cash or by issuing shares. Under the terms of the ASR, the maximum number of shares that could be delivered to the Company is 29.0 million.

Dividends

The quarterly cash dividend declared by the Board was $0.50 per share in 2021 and 2020. In December 2021, the Board authorized a 10% increase in the quarterly cash dividend to $0.55 per share effective in 2022. CVS Health Corporation has paid cash dividends every quarter since becoming a public company. Future dividend payments will depend on the Company’s earnings, capital requirements, financial condition and other factors considered relevant by the Board.

Regulatory Requirements

The Company’s insurance business operations are conducted through subsidiaries that principally consist of health maintenance organizations (“HMOs”) and insurance companies. The Company’s HMO and insurance subsidiaries report their financial
159


statements in accordance with accounting practices prescribed by state regulatory authorities which may differ from GAAP. The combined statutory net income for the years ended and estimated combined statutory and capital surplus at December 31, 2021, 2020 and 2019 for the Company’s insurance and HMO subsidiaries were as follows:
In millions202120202019
Statutory net income
$3,302 $3,667 $2,842 
Estimated statutory capital and surplus
14,879 13,238 10,975 

The Company’s insurance and HMO subsidiaries paid $1.6 billion of gross dividends to the Company for the year ended December 31, 2021.

In addition to general state law restrictions on payments of dividends and other distributions to stockholders applicable to all corporations, HMOs and insurance companies are subject to further regulations that, among other things, may require those companies to maintain certain levels of equity and restrict the amount of dividends and other distributions that may be paid to their equity holders. In addition, in connection with the Aetna Acquisition, the Company made certain undertakings that require prior regulatory approval of dividends by certain of its HMOs and insurance companies. At December 31, 2021, these amounts were as follows:
In millions
Estimated minimum statutory surplus required by regulators$7,261 
Investments on deposit with regulatory bodies794 
Estimated maximum dividend distributions permitted in 2022 without prior regulatory approval2,939 

Noncontrolling Interests

At December 31, 2021 and 2020, noncontrolling interests were $306 million and $312 million, respectively, primarily related to third party interests in the Company’s operating entities. The noncontrolling entities’ share is included in total shareholders equity on the consolidated balance sheets.

160


13.Other Comprehensive Income

Shareholders’ equity included the following activity in accumulated other comprehensive income in 2021, 2020 and 2019:
At December 31,
In millions202120202019
Net unrealized investment gains (losses):
Beginning of year balance$1,214 $774 $97 
Other comprehensive income (loss) before reclassifications ($(489), $497 and $927 pretax)
(410)415 763 
Amounts reclassified from accumulated other comprehensive income ($(32), $31 and $(105) pretax) (1)
(26)25 (86)
Other comprehensive income (loss)(436)440 677 
End of year balance778 1,214 774 
Foreign currency translation adjustments:
Beginning of year balance7 4 (158)
Other comprehensive income (loss) before reclassifications(7)3 8 
Amounts reclassified from accumulated other comprehensive income (loss) (2)
  154 
Other comprehensive income (loss)(7)3 162 
End of year balance 7 4 
Net cash flow hedges:
Beginning of year balance248 279 312 
Other comprehensive loss before reclassifications ($0, $(7) and $(25) pretax)
 (5)(18)
Amounts reclassified from accumulated other comprehensive income ($(34), $(35) and $(20) pretax) (3)
(26)(26)(15)
Other comprehensive loss(26)(31)(33)
End of year balance222 248 279 
Pension and other postretirement benefits:
Beginning of year balance(55)(38)(149)
Other comprehensive income (loss) before reclassifications ($20, $(30) and $162 pretax)
15 (22)120 
Amounts reclassified from accumulated other comprehensive loss ($6, $7 and $(12) pretax) (4)
5 5 (9)
Other comprehensive income (loss) 20 (17)111 
End of year balance(35)(55)(38)
Total beginning of year accumulated other comprehensive income1,414 1,019 102 
Total other comprehensive income (loss)(449)395 917 
Total end of year accumulated other comprehensive income$965 $1,414 $1,019 
_____________________________________________
(1)Amounts reclassified from accumulated other comprehensive income for specifically identified debt securities are included in net investment income in the consolidated statements of operations.
(2)Amounts reclassified from accumulated other comprehensive income (loss) represent the elimination of the cumulative translation adjustment associated with the sale of Onofre, which was sold on July 1, 2019. The loss on the divestiture of Onofre is reflected in operating expenses in the consolidated statements of operations.
(3)Amounts reclassified from accumulated other comprehensive income for specifically identified cash flow hedges are included within interest expense in the consolidated statements of operations. The Company expects to reclassify approximately $11 million, net of tax, in net gains associated with its cash flow hedges into net income within the next 12 months.
(4)Amounts reclassified from accumulated other comprehensive loss for specifically identified pension and other postretirement benefits are included in other income in the consolidated statements of operations.



161


14.Earnings Per Share

Earnings per share is computed using the two-class method. SARs and options to purchase 7 million, 15 million, and 17 million shares of common stock were outstanding, but were excluded from the calculation of diluted earnings per share for the years ended December 31, 2021, 2020 and 2019, respectively, because their exercise prices were greater than the average market price of the common shares and, therefore, the effect would be antidilutive.

The following is a reconciliation of basic and diluted earnings per share from continuing operations for the years ended December 31, 2021, 2020 and 2019:
In millions, except per share amounts202120202019
Numerator for earnings per share calculation:
Income from continuing operations$7,898 $7,201 $6,631 
Income allocated to participating securities  (5)
Net (income) loss attributable to noncontrolling interests12 (13)3 
Income from continuing operations attributable to CVS Health$7,910 $7,188 $6,629 
Denominator for earnings per share calculation:
Weighted average shares, basic1,319 1,309 1,301 
Effect of dilutive securities10 5 4 
Weighted average shares, diluted1,329 1,314 1,305 
Earnings per share from continuing operations:
Basic$6.00 $5.49 $5.10 
Diluted$5.95 $5.47 $5.08 

15.Reinsurance

The Company utilizes reinsurance agreements primarily to: (a) reduce required capital and (b) facilitate the acquisition or disposition of certain insurance contracts. Ceded reinsurance agreements permit the Company to recover a portion of its losses from reinsurers, although they do not discharge the Company’s primary liability as the direct insurer of the risks reinsured.

On November 30, 2018, the Company completed the sale of Aetna’s standalone Medicare Part D prescription drug plans to a subsidiary of WellCare Health Plans, Inc. (“WellCare”), effective December 31, 2018. In connection with that sale, subsidiaries of WellCare and Aetna entered into reinsurance agreements under which WellCare ceded to Aetna 100% of the insurance risk related to the divested standalone Medicare Part D prescription drug plans for the 2019 PDP plan year.

In January 2022, the Company entered into two four-year reinsurance agreements with an unrelated reinsurer that allow it to reduce required capital and provide collateralized excess of loss reinsurance coverage on a portion of the Health Care Benefits segment’s group Commercial Insured business.

Reinsurance recoverables (recorded as other current assets or other assets on the consolidated balance sheets) at December 31, 2021 and 2020 were as follows:
In millions20212020
Reinsurer
Hartford Life and Accident Insurance Company$1,887 $2,364 
Lincoln Life & Annuity Company of New York395 406 
VOYA Retirement Insurance and Annuity Company 167 170 
All Other100 115 
Total$2,549 $3,055 


162


Direct, assumed and ceded premiums earned for the years ended December 31, 2021, 2020 and 2019 were as follows:
In millions202120202019
Direct$76,320 $69,711 $62,968 
Assumed492 478 2,108 
Ceded(680)(825)(1,954)
Net premiums$76,132 $69,364 $63,122 

The impact of reinsurance on benefit costs for the years ended December 31, 2021, 2020 and 2019 were as follows:
In millions202120202019
Direct$64,414 $56,077 $52,592 
Assumed398 329 1,562 
Ceded(552)(727)(1,625)
Net benefit costs$64,260 $55,679 $52,529 

There is not a material difference between premiums on a written basis versus an earned basis.

The Company also has various agreements with unrelated reinsurers that do not qualify for reinsurance accounting under GAAP, and consequently are accounted for using deposit accounting. The Company entered into these contracts to reduce the risk of catastrophic loss which in turn reduces the Company’s capital and surplus requirements. Total deposit assets and liabilities related to reinsurance agreements that do not qualify for reinsurance accounting under GAAP were not material as of December 31, 2021 or 2020.

16.Commitments and Contingencies

COVID-19

The COVID-19 pandemic continues to evolve. The Company believes COVID-19’s impact on its businesses, operating results, cash flows and/or financial condition primarily will be driven by the geographies impacted and the severity and duration of the pandemic; the pandemic’s impact on the U.S. and global economies and consumer behavior and health care utilization patterns; and the timing, scope and impact of stimulus legislation as well as other federal, state and local governmental responses to the pandemic. Those primary drivers are beyond the Company’s knowledge and control. As a result, the impact COVID-19 will have on the Company’s businesses, operating results, cash flows and/or financial condition is uncertain, but the impact could be adverse and material. COVID-19 also may result in legal and regulatory proceedings, investigations and claims against the Company.

Guarantees

The Company has the following significant guarantee arrangements at December 31, 2021:

ASC Claim Funding Accounts - The Company has arrangements with certain banks for the processing of claim payments for its ASC customers. The banks maintain accounts to fund claims of the Company’s ASC customers. The customer is responsible for funding the amount paid by the bank each day. In these arrangements, the Company guarantees that the banks will not sustain losses if the responsible ASC customer does not properly fund its account. The aggregate maximum exposure under these arrangements is generally limited to $250 million. The Company can limit its exposure to these guarantees by suspending the payment of claims for ASC customers that have not adequately funded the amount paid by the bank.
Separate Accounts Assets - Certain Separate Accounts assets associated with the large case pensions business in the Corporate/Other segment represent funds maintained as a contractual requirement to fund specific pension annuities that the Company has guaranteed. Minimum contractual obligations underlying the guaranteed benefits in these Separate Accounts were approximately $1.3 billion and $1.4 billion at December 31, 2021 and 2020, respectively. See Note 1 ‘‘Significant Accounting Policies’’ for additional information on Separate Accounts. Contract holders assume all investment and mortality risk and are required to maintain Separate Accounts balances at or above a specified level. The level of required funds is a function of the risk underlying the Separate Account’s investment strategy. If contract holders do not maintain the required level of Separate Accounts assets to meet the annuity guarantees, the Company would
163


establish an additional liability. Contract holders’ balances in the Separate Accounts at December 31, 2021 exceeded the value of the guaranteed benefit obligation. As a result, the Company was not required to maintain any additional liability for its related guarantees at December 31, 2021.

Lease Guarantees

Between 1995 and 1997, the Company sold or spun off a number of subsidiaries, including Bob’s Stores and Linens ‘n Things, each of which subsequently filed for bankruptcy, and Marshalls. In many cases, when a former subsidiary leased a store, the Company provided a guarantee of the former subsidiary’s lease obligations for the initial lease term and any extension thereof pursuant to a renewal option provided for in the lease prior to the time of the disposition. When the subsidiaries were disposed of and accounted for as discontinued operations, the Company’s guarantees remained in place, although each initial purchaser agreed to indemnify the Company for any lease obligations the Company was required to satisfy. If any of the purchasers or any of the former subsidiaries fail to make the required payments under a store lease, the Company could be required to satisfy those obligations, and any significant adverse impact of COVID-19 on such purchasers and/or former subsidiaries increases the risk that the Company will be required to satisfy those obligations. As of December 31, 2021, the Company guaranteed 72 such store leases (excluding the lease guarantees related to Linens ‘n Things, which have been recorded as a liability on the consolidated balance sheets), with the maximum remaining lease term extending through 2030.

Guaranty Fund Assessments, Market Stabilization and Other Non-Voluntary Risk Sharing Pools

Under guaranty fund laws existing in all states, insurers doing business in those states can be assessed (in most states up to prescribed limits) for certain obligations of insolvent insurance companies to policyholders and claimants. The life and health insurance guaranty associations in which the Company participates that operate under these laws respond to insolvencies of long-term care insurers and life insurers as well as health insurers. The Company’s assessments generally are based on a formula relating to the Company’s health care premiums in the state compared to the premiums of other insurers. Certain states allow assessments to be recovered over time as offsets to premium taxes. Some states have similar laws relating to HMOs and/or other payors such as not-for-profit consumer-governed health plans established under the ACA.

In 2009, the Pennsylvania Insurance Commissioner placed long-term care insurer Penn Treaty Network America Insurance Company and one of its subsidiaries (collectively, “Penn Treaty”) in rehabilitation, an intermediate action before insolvency, and subsequently petitioned a state court to convert the rehabilitation into a liquidation. Penn Treaty was placed in liquidation in March 2017. The Company has recorded a liability for its estimated share of future assessments by applicable life and health insurance guaranty associations. It is reasonably possible that in the future the Company may record a liability and expense relating to other insolvencies which could have a material adverse effect on the Company’s operating results, financial condition and cash flows, and the risk is heightened by any significant adverse impact of the COVID-19 pandemic on the solvency of other insurers, including long-term care and life insurers. While historically the Company has ultimately recovered more than half of guaranty fund assessments through statutorily permitted premium tax offsets, significant increases in assessments could lead to legislative and/or regulatory actions that limit future offsets.

HMOs in certain states in which the Company does business are subject to assessments, including market stabilization and other risk-sharing pools, for which the Company is assessed charges based on incurred claims, demographic membership mix and other factors. The Company establishes liabilities for these assessments based on applicable laws and regulations. In certain states, the ultimate assessments the Company pays are dependent upon the Company’s experience relative to other entities subject to the assessment, and the ultimate liability is not known at the financial statement date. While the ultimate amount of the assessment is dependent upon the experience of all pool participants, the Company believes it has adequate reserves to cover such assessments.

The Company’s total guaranty fund assessments liability was immaterial at both December 31, 2021 and 2020.

Litigation and Regulatory Proceedings

The Company has been involved or is currently involved in numerous legal proceedings, including litigation, arbitration, government investigations, audits, reviews and claims. These include routine, regular and special investigations, audits and reviews by CMS, state insurance and health and welfare departments, the U.S. Department of Justice (the “DOJ”), state attorneys general, the U.S. Drug Enforcement Administration (the “DEA”) and other governmental authorities.

Legal proceedings, in general, and securities, class action and multi-district litigation, in particular, and governmental special investigations, audits and reviews can be expensive and disruptive. Some of the litigation matters may purport or be determined
164


to be class actions and/or involve parties seeking large and/or indeterminate amounts, including punitive or exemplary damages, and may remain unresolved for several years. The Company also may be named from time to time in qui tam actions initiated by private third parties that could also be separately pursued by a governmental body. The results of legal proceedings, including government investigations, are often uncertain and difficult to predict, and the costs incurred in these matters can be substantial, regardless of the outcome.

The Company records accruals for outstanding legal matters when it believes it is probable that a loss will be incurred and the amount can be reasonably estimated. The Company evaluates, on a quarterly basis, developments in legal matters that could affect the amount of any accrual and developments that would make a loss contingency both probable and reasonably estimable. If a loss contingency is not both probable and reasonably estimable, the Company does not establish an accrued liability. None of the Company’s accruals for outstanding legal matters are material individually or in the aggregate to the Company’s financial condition.

Except as otherwise noted, the Company cannot predict with certainty the timing or outcome of the legal matters described below, and the Company is unable to reasonably estimate a possible loss or range of possible loss in excess of amounts already accrued for these matters. The Company believes that its defenses and assertions in pending legal proceedings have merit and does not believe that any of these pending matters, after consideration of applicable reserves and rights to indemnification, will have a material adverse effect on the Company’s financial position. Substantial unanticipated verdicts, fines and rulings, however, do sometimes occur, which could result in judgments against the Company, entry into settlements or a revision to its expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on its results of operations. In addition, as a result of governmental investigations or proceedings, the Company may be subject to damages, civil or criminal fines or penalties, or other sanctions including possible suspension or loss of licensure and/or exclusion from participating in government programs. The outcome of such governmental investigations of proceedings could be material to the Company.

Usual and Customary Pricing Litigation

The Company and certain current and former directors and officers are named as a defendant in a number of lawsuits that allege that the Company’s retail pharmacies overcharged for prescription drugs by not submitting the correct usual and customary price during the claims adjudication process. These actions are brought by a number of different types of plaintiffs, including plan members, private payors, government payors, and shareholders based on different legal theories. Some of these cases are brought as putative class actions, and in some instances, classes have been certified. The Company is defending itself against these claims.

PBM Litigation and Investigations

The Company is named as a defendant in a number of lawsuits and is subject to a number of investigations concerning its PBM practices.
The Company is facing multiple lawsuits, including by a State Attorney General, governmental subdivisions and several putative class actions, regarding drug pricing and its rebate arrangements with drug manufacturers. These complaints, brought by a number of different types of plaintiffs under a variety of legal theories, generally allege that rebate agreements between the drug manufacturers and PBMs caused inflated prices for certain drug products. The Company is defending itself against these claims. The Company has also received subpoenas, civil investigative demands (“CIDs”) and other requests for documents and information from, and is being investigated by, Attorneys General of multiple states and the District of Columbia regarding its PBM practices, including pricing and rebates. The Company has been providing documents and information in response to these subpoenas, CIDs and requests for information.

United States ex rel. Behnke v. CVS Caremark Corporation, et al. (U.S. District Court for the Eastern District of Pennsylvania). In April 2018, the Court unsealed a complaint filed in February 2014. The government has declined to intervene in this case. The relator alleges that the Company submitted, or caused to be submitted, to Part D of the Medicare program Prescription Drug Event data and/or Direct and Indirect Remuneration reports that misrepresented true prices paid by the Company’s PBM to pharmacies for drugs dispensed to Part D beneficiaries with prescription benefits administered by the Company’s PBM. The Company is defending itself against these claims.

165


Controlled Substances Litigation, Audits and Subpoenas

In December 2017, the U.S. Judicial Panel on Multidistrict Litigation consolidated numerous cases filed against various defendants by plaintiffs such as counties, cities, hospitals, Indian tribes and third-party payors, alleging claims generally concerning the impacts of widespread prescription opioid abuse. The consolidated multidistrict litigation captioned In re National Prescription Opiate Litigation (MDL No. 2804) is pending in the U.S. District Court for the Northern District of Ohio. This multidistrict litigation presumptively includes hundreds of relevant federal court cases that name the Company as a defendant. A significant number of similar cases that name the Company as a defendant in some capacity are pending in state courts. In addition, the Company has been named as a defendant in similar cases brought by certain state Attorneys General. The Company is defending itself against all such claims. Additionally, the Company has received subpoenas, CIDs and/or other requests for information regarding opioids from state Attorneys General and insurance and other regulators of several U.S. jurisdictions. The Company has been cooperating with the government with respect to these subpoenas, CIDs and other requests for information. In November 2021, the Company was among the chain pharmacies found liable by a jury in a trial in federal court in Ohio; the remedy pursuant to that verdict has not been determined and the Company plans to appeal.

In January 2020, the DOJ served the Company with a DEA administrative subpoena. The subpoena seeks documents relating to practices with respect to prescription opioids and other controlled substances at CVS Pharmacy locations concerning potential violations of the federal Controlled Substances Act and the federal False Claims Act. In January 2022, the DOJ served the Company with a CID regarding similar subjects. The Company is providing documents and information in response to these matters.

Prescription Processing Litigation and Investigations

The Company is named as a defendant in a number of lawsuits and is subject to a number of investigations concerning its prescription processing practices, including the following:

U.S. ex rel. Bassan et al. v. Omnicare, Inc. and CVS Health Corp. (U.S. District Court for the Southern District of New York). In December 2019, the U.S. Attorney’s Office for the Southern District of New York (the “SDNY”) filed a complaint-in-intervention in this previously sealed qui tam case. The complaint alleges that for certain non-skilled nursing facilities, Omnicare improperly filled prescriptions beyond one year where a valid prescription did not exist and that these dispensing events violated the federal False Claims Act. The Company is defending itself against these claims.

In July 2017, the Company also received a subpoena from the California Department of Insurance requesting documents concerning the Company’s Omnicare pharmacies’ cycle fill process for assisted living facilities. The Company has been cooperating with the California Department of Insurance and providing documents and information in response to this subpoena.

In December 2016, the Company received a CID from the U.S. Attorney’s Office for the Northern District of New York requesting documents and information in connection with a federal False Claims Act investigation concerning whether the Company’s retail pharmacies improperly submitted certain insulin claims to Part D of the Medicare program rather than Part B of the Medicare program. The Company has been cooperating with the government and providing documents and information in response to this CID.

Provider Proceedings

The Company is named as a defendant in purported class actions and individual lawsuits arising out of its practices related to the payment of claims for services rendered to its members by providers with whom the Company has a contract and with whom the Company does not have a contract (“out-of-network providers”). Among other things, these lawsuits allege that the Company paid too little to its health plan members and/or providers for out-of-network services and/or otherwise allege that the Company failed to timely or appropriately pay or administer out-of-network claims and benefits (including the Company’s post payment audit and collection practices and reductions in payments to providers due to sequestration). Other major health insurers are the subject of similar litigation or have settled similar litigation.

The Company also has received subpoenas and/or requests for documents and other information from, and been investigated by, state Attorneys General and other state and/or federal regulators, legislators and agencies relating to, and the Company is involved in other litigation regarding, its out-of-network benefit payment and administration practices. It is reasonably possible that others could initiate additional litigation or additional regulatory action against the Company with respect to its out-of-network benefit payment and/or administration practices.
166



CMS Actions

CMS regularly audits the Company’s performance to determine its compliance with CMS’s regulations and its contracts with CMS and to assess the quality of services it provides to Medicare beneficiaries. CMS uses various payment mechanisms to allocate and adjust premium payments to the Company’s and other companies’ Medicare plans by considering the applicable health status of Medicare members as supported by information prepared, maintained and provided by providers. The Company collects claim and encounter data from providers and generally relies on providers to appropriately code their submissions to the Company and document their medical records, including the diagnosis data submitted to the Company with claims. CMS pays increased premiums to Medicare Advantage plans and Medicare PDP plans for members who have certain medical conditions identified with specific diagnosis codes. Federal regulators review and audit the providers’ medical records to determine whether those records support the related diagnosis codes that determine the members’ health status and the resulting risk-adjusted premium payments to the Company. In that regard, CMS has instituted risk adjustment data validation (“RADV”) audits of various Medicare Advantage plans, including certain of the Company’s plans, to validate coding practices and supporting medical record documentation maintained by providers and the resulting risk adjusted premium payments to the plans. CMS may require the Company to refund premium payments if the Company’s risk adjusted premiums are not properly supported by medical record data. The Office of the Inspector General of the HHS (the “OIG”) also is auditing the Company’s risk adjustment-related data and that of other companies. The Company expects CMS and the OIG to continue these types of audits.

In 2012, CMS revised its audit methodology for RADV audits to determine refunds payable by Medicare Advantage plans for contract year 2011 and forward. Under the revised methodology, among other things, CMS will extrapolate the error rate identified in the audit sample of approximately 200 members to all risk adjusted premium payments made under the contract being audited. For contract years prior to 2011, CMS did not extrapolate sample error rates to the entire contract. As a result, the revised methodology may increase the Company’s exposure to premium refunds to CMS based on incomplete medical records maintained by providers. Since 2013, CMS has selected certain of the Company’s Medicare Advantage contracts for various contract years for RADV audit, and the number of RADV audits continues to increase. The Company is currently unable to predict which of its Medicare Advantage contracts will be selected for future audit, the amounts of any retroactive refunds of, or prospective adjustments to, Medicare Advantage premium payments made to the Company, the effect of any such refunds or adjustments on the actuarial soundness of the Company’s Medicare Advantage bids, or whether any RADV audit findings would require the Company to change its method of estimating future premium revenue in future bid submissions to CMS or compromise premium assumptions made in the Company’s bids for prior contract years, the current contract year or future contract years. Any premium or fee refunds or adjustments resulting from regulatory audits, whether as a result of RADV, Public Exchange related or other audits by CMS, the OIG or otherwise, including audits of the Company’s MLR rebates, methodology and/or reports, could be material and could adversely affect the Company’s operating results, cash flows and/or financial condition.

Medicare and Medicaid CIDs

The Company has received CIDs from the Civil Division of the DOJ in connection with a current investigation of the Company’s patient chart review processes in connection with risk adjustment data submissions under Parts C and D of the Medicare program. The Company has been cooperating with the government and providing documents and information in response to these CIDs.

In May 2017, the Company received a CID from the SDNY requesting documents and information concerning possible false claims submitted to Medicare in connection with reimbursements for prescription drugs under the Medicare Part D program. The Company has been cooperating with the government and providing documents and information in response to this CID.

Stockholder Matters

Beginning in February 2019, multiple class action complaints, as well as a derivative complaint, were filed by putative plaintiffs against the Company and certain current and former officers and directors. The plaintiffs in these cases assert a variety of causes of action under federal securities laws that are premised on allegations that the defendants made certain omissions and misrepresentations relating to the performance of the Company’s LTC business unit. The Company and its current and former officers and directors are defending themselves against these claims. Since filing, several of the cases have been consolidated, and the first-filed federal case, City of Miami Fire Fighters’ and Police Officers’ Retirement Trust, et al. (formerly known as Anarkat), was dismissed with prejudice in February 2021. Plaintiffs have appealed that decision to the First Circuit after their motion for reconsideration was denied. In re CVS Health Corp. Securities Act Litigation (formerly known as Waterford) and In
167


re CVS Health Corp. Securities Litigation (formerly known as City of Warren and Freundlich) have been stayed pending the outcome of the First Circuit appeal.

In August and September 2020, two class actions under the Employee Retirement Income Security Act of 1974 (“ERISA”) were filed in the U.S. District Court for the District of Connecticut against CVS Health, Aetna, and several current and former executives, directors and/or members of Aetna’s Compensation and Talent Management Committee: Radcliffe v. Aetna Inc., et al. and Flaim v. Aetna Inc., et al. The plaintiffs in these cases assert a variety of causes of action premised on allegations that the defendants breached fiduciary duties and engaged in prohibited transactions relating to participants in the Aetna 401(k) Plan’s investment in company stock between December 3, 2017 and February 20, 2019, claiming losses related to the performance of the Company’s LTC business unit. The district court consolidated the actions and the Company is defending itself against these claims. In October 2021, the consolidated case was dismissed without prejudice. Plaintiffs may seek leave to file an amended complaint. The Company also received a related document request pursuant to ERISA § 104(b), to which the Company has responded.

In December 2021, the Company received a demand for inspection of books and records pursuant to Delaware Corporation Law Section 220 (the “Demand”). The Demand purports to be related to potential breaches of fiduciary duties by the Board in relation to certain matters concerning opioids.

Other Legal and Regulatory Proceedings

The Company is also a party to other legal proceedings and is subject to government investigations, inquiries and audits and has received and is cooperating with the government in response to CIDs, subpoenas or similar process from various governmental agencies requesting information. These other legal proceedings and government actions include claims of or relating to bad faith, medical or professional malpractice, breach of fiduciary duty, claims processing, dispensing of medications, non-compliance with state and federal regulatory regimes, marketing misconduct, denial of or failure to timely or appropriately pay or administer claims and benefits, provider network structure (including the use of performance-based networks and termination of provider contracts), rescission of insurance coverage, improper disclosure or use of personal information, anticompetitive practices, general contractual matters, product liability, intellectual property litigation and employment litigation. Some of these other legal proceedings are or are purported to be class actions or derivative claims. The Company is defending itself against the claims brought in these matters.

Awards to the Company and others of certain government contracts, particularly Medicaid contracts and other contracts with government customers in the Company’s Health Care Benefits segment, frequently are subject to protests by unsuccessful bidders. These protests may result in awards to the Company being reversed, delayed or modified. The loss or delay in implementation of any government contract could adversely affect the Company’s operating results. The Company will continue to defend contract awards it receives.

There also continues to be a heightened level of review and/or audit by regulatory authorities and legislators of, and increased litigation regarding, the Company’s and the rest of the health care and related benefits industry’s business and reporting practices, including premium rate increases, utilization management, development and application of medical policies, complaint, grievance and appeal processing, information privacy, provider network structure (including provider network adequacy, the use of performance-based networks and termination of provider contracts), provider directory accuracy, calculation of minimum medical loss ratios and/or payment of related rebates, delegated arrangements, rescission of insurance coverage, limited benefit health products, student health products, pharmacy benefit management practices (including manufacturers’ rebates, pricing, the use of narrow networks and the placement of drugs in formulary tiers), sales practices, customer service practices, vendor oversight and claim payment practices (including payments to out-of-network providers).

As a leading national health solutions company, the Company regularly is the subject of government actions of the types described above. These government actions may prevent or delay the Company from implementing planned premium rate increases and may result, and have resulted, in restrictions on the Company’s businesses, changes to or clarifications of the Company’s business practices, retroactive adjustments to premiums, refunds or other payments to members, beneficiaries, states or the federal government, withholding of premium payments to the Company by government agencies, assessments of damages, civil or criminal fines or penalties, or other sanctions, including the possible suspension or loss of licensure and/or suspension or exclusion from participation in government programs.

The Company can give no assurance that its businesses, financial condition, operating results and/or cash flows will not be materially adversely affected, or that the Company will not be required to materially change its business practices, based on: (i) future enactment of new health care or other laws or regulations; (ii) the interpretation or application of existing laws or
168


regulations as they may relate to one or more of the Company’s businesses, one or more of the industries in which the Company competes and/or the health care industry generally; (iii) pending or future federal or state government investigations of one or more of the Company’s businesses, one or more of the industries in which the Company competes and/or the health care industry generally; (iv) pending or future government audits, investigations or enforcement actions against the Company; (v) adverse developments in any pending qui tam lawsuit against the Company, whether sealed or unsealed, or in any future qui tam lawsuit that may be filed against the Company; or (vi) adverse developments in pending or future legal proceedings against the Company or affecting one or more of the industries in which the Company competes and/or the health care industry generally.

17.Segment Reporting

The Company has three operating segments, Health Care Benefits, Pharmacy Services and Retail/LTC, as well as a Corporate/Other segment. The Company’s segments maintain separate financial information, and the Company’s chief operating decision maker (the “CODM”) evaluates the segments’ operating results on a regular basis in deciding how to allocate resources among the segments and in assessing segment performance. The CODM evaluates the performance of the Company’s segments based on adjusted operating income, which is defined as operating income (GAAP measure) excluding the impact of amortization of intangible assets and other items, if any, that neither relate to the ordinary course of the Company’s business nor reflect the Company’s underlying business performance. See the reconciliation of consolidated operating income (GAAP measure) to consolidated adjusted operating income below for further context regarding the items excluded from operating income in determining adjusted operating income. The Company uses adjusted operating income as its principal measure of segment performance as it enhances the Company’s ability to compare past financial performance with current performance and analyze underlying business performance and trends. Non-GAAP financial measures the Company discloses, such as consolidated adjusted operating income, should not be considered a substitute for, or superior to, financial measures determined or calculated in accordance with GAAP.

In 2021, 2020 and 2019, revenues from the federal government accounted for 17%, 16% and 16%, respectively, of the Company’s consolidated total revenues, primarily related to contracts with CMS for coverage of Medicare-eligible individuals within the Health Care Benefits segment.










169


The following is a reconciliation of financial measures of the Company’s segments to the consolidated totals:
In millionsHealth Care
Benefits
Pharmacy 
Services
(1)
Retail/
LTC
Corporate/
Other
Intersegment
Eliminations (2)
Consolidated
Totals
2021:
Revenues from external customers$81,515 $143,194 $66,078 $125 $— $290,912 
Intersegment revenues85 9,828 34,010 — (43,923)— 
Net investment income 586  17 596  1,199 
Total revenues82,186 153,022 100,105 721 (43,923)292,111 
  Adjusted operating income (loss) 5,012 6,859 7,623 (1,471)(711)17,312 
Depreciation and amortization1,837 576 1,884 215  4,512 
2020:
Revenues from external customers74,926 132,663 60,208 111 — 267,908 
Intersegment revenues58 9,275 30,990 — (40,323)— 
Net investment income483   315  798 
Total revenues 75,467 141,938 91,198 426 (40,323)268,706 
  Adjusted operating income (loss) 6,188 5,688 6,146 (1,306)(708)16,008 
Depreciation and amortization1,832 612 1,801 196  4,441 
2019:
Revenues from external customers68,979 130,428 56,258 100 — 255,765 
Intersegment revenues26 11,063 30,350 — (41,439)— 
Net investment income599   412  1,011 
Total revenues69,604 141,491 86,608 512 (41,439)256,776 
  Adjusted operating income (loss) 5,202 5,129 6,705 (1,000)(697)15,339 
Depreciation and amortization1,721 766 1,723 161  4,371 
_____________________________________________
(1)Total revenues of the Pharmacy Services segment include approximately $11.6 billion, $10.9 billion and $11.5 billion of retail co-payments for 2021, 2020 and 2019, respectively. See Note 1 ‘‘Significant Accounting Policies’’ for additional information about retail co-payments.
(2)Intersegment revenue eliminations relate to intersegment revenue generating activities that occur between the Health Care Benefits segment, the Pharmacy Services segment, and/or the Retail/LTC segment. Intersegment adjusted operating income eliminations occur when members of Pharmacy Services Segment clients (“PSS members”) enrolled in Maintenance Choice® elect to pick up maintenance prescriptions at one of the Company’s retail pharmacies instead of receiving them through the mail. When this occurs, both the Pharmacy Services and Retail/LTC segments record the adjusted operating income on a stand-alone basis.

170


The following is a reconciliation of consolidated operating income to adjusted operating income for the years ended December 31, 2021, 2020 and 2019:
In millions202120202019
Operating income (GAAP measure)$13,193 $13,911 $11,987 
Amortization of intangible assets (1)
2,259 2,341 2,436 
Acquisition-related integration costs (2)
132 332 480 
Store impairments (3)
1,358  231 
Goodwill impairment (4)
431   
Acquisition purchase price adjustment outside of measurement period (5)
(61)  
(Gain) loss on divestiture of subsidiary (6)
 (269)205 
Receipt of fully reserved ACA risk corridor receivable (7)
 (307) 
Adjusted operating income$17,312 $16,008 $15,339 
_____________________________________________
(1)The Company’s acquisition activities have resulted in the recognition of intangible assets as required under the acquisition method of accounting which consist primarily of trademarks, customer contracts/relationships, covenants not to compete, technology, provider networks and value of business acquired. Definite-lived intangible assets are amortized over their estimated useful lives and are tested for impairment when events indicate that the carrying value may not be recoverable. The amortization of intangible assets is reflected in the Company’s GAAP consolidated statements of operations in operating expenses within each segment. Although intangible assets contribute to the Company’s revenue generation, the amortization of intangible assets does not directly relate to the underwriting of the Company’s insurance products, the services performed for the Company’s customers or the sale of the Company’s products or services. Additionally, intangible asset amortization expense typically fluctuates based on the size and timing of the Company’s acquisition activity. Accordingly, the Company believes excluding the amortization of intangible assets enhances the Company’s and investors’ ability to compare the Company’s past financial performance with its current performance and to analyze underlying business performance and trends. Intangible asset amortization excluded from the related non-GAAP financial measure represents the entire amount recorded within the Company’s GAAP financial statements, and the revenue generated by the associated intangible assets has not been excluded from the related non-GAAP financial measure. Intangible asset amortization is excluded from the related non-GAAP financial measure because the amortization, unlike the related revenue, is not affected by operations of any particular period unless an intangible asset becomes impaired or the estimated useful life of an intangible asset is revised.
(2)In 2021, 2020 and 2019, acquisition-related integration costs relate to the Aetna Acquisition. The acquisition-related integration costs are reflected in the Company’s GAAP consolidated statements of operations in operating expenses within the Corporate/Other segment.
(3)During the year ended December 31, 2021, the store impairment charge relates to the write down of operating lease right-of-use assets and property and equipment in connection with the planned closure of approximately 900 retail stores between 2022 and 2024. During the year ended December 31, 2019, the store impairment charges related to the write down of operating lease right-of-use assets in connection with the planned closure of 68 underperforming retail pharmacy stores in 2019 and 2020. The store impairment charges are reflected in the Company’s GAAP consolidated statements of operations within the Retail/LTC segment.
(4)During the year ended December 31, 2021, the goodwill impairment charge relates to the LTC reporting unit within the Retail/LTC segment.
(5)In June 2021, the Company received $61 million related to a purchase price working capital adjustment for an acquisition completed during the first quarter of 2020. The resolution of this matter occurred subsequent to the acquisition accounting measurement period and is reflected in the Company’s GAAP consolidated statement of operations for the year ended December 31, 2021 as a reduction of operating expenses within the Health Care Benefits segment.
(6)In 2020, the gain on divestiture of subsidiary represents the pre-tax gain on the sale of the Workers’ Compensation business, which the Company sold on July 31, 2020 for approximately $850 million. The gain on divestiture is reflected as a reduction of operating expenses in the Company’s GAAP consolidated statement of operations within the Health Care Benefits segment. In 2019, the loss on divestiture of subsidiary represents the pre-tax loss on the sale of Onofre, which occurred on July 1, 2019. The loss on divestiture primarily relates to the elimination of the cumulative translation adjustment from accumulated other comprehensive income and is reflected in the Company’s GAAP consolidated statement of operations in operating expenses within the Retail/LTC segment.
(7)In 2020, the Company received $313 million owed to it under the ACA’s risk corridor program that was previously fully reserved for as payment was uncertain. After considering offsetting items such as the ACA’s minimum MLR rebate requirements and premium taxes, the Company recognized pre-tax income of $307 million in the Company’s GAAP consolidated statement of operations within the Health Care Benefits segment.




171

Report of Independent Registered Public Accounting Firm

To the Shareholders and the Board of Directors of CVS Health Corporation

Opinion on Internal Control over Financial Reporting

We have audited CVS Health Corporation’s internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, CVS Health Corporation (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2021, based on the COSO criteria.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the 2021 consolidated financial statements of the Company and our report dated February 9, 2022, expressed an unqualified opinion thereon.

Basis for Opinion

The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management’s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.

Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

Definition and Limitations of Internal Control over Financial Reporting

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/ Ernst & Young LLP

Boston, Massachusetts
February 9, 2022
172


Report of Independent Registered Public Accounting Firm

To the Shareholders and the Board of Directors of CVS Health Corporation

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of CVS Health Corporation (the Company) as of December 31, 2021 and 2020, the related consolidated statements of operations, comprehensive income, shareholders’ equity and cash flows for each of the three years in the period ended December 31, 2021, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2021, in conformity with U.S. generally accepted accounting principles.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company’s internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February 9, 2022, expressed an unqualified opinion thereon.

Basis for Opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matters

The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.
173


Annual goodwill impairment test of the Commercial Business reporting unit
Description of the Matter
At December 31, 2021, the Company’s goodwill related to the Commercial Business reporting unit was $26.5 billion. As discussed in Note 1 to the consolidated financial statements, goodwill is not amortized, but rather is subject to an annual impairment review, or more frequent reviews, if events and circumstances indicate an impairment exists.

Auditing management's annual goodwill impairment test related to the Commercial Business reporting unit was complex and highly judgmental due to the significant estimation required to determine the fair value of the reporting unit. In particular, the fair value estimate was sensitive to changes in significant assumptions, such as the discount rate, projected revenue and projected operating income that are forward-looking and affected by future economic and market conditions.
How We Addressed the Matter in Our AuditWe obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the Company’s annual goodwill impairment review process, including controls over management’s review of the significant assumptions described above.

To test the estimated fair value of the Commercial Business reporting unit, we performed audit procedures that included, among others, assessing methodologies and testing the significant assumptions discussed above and the underlying data used by the Company in its analysis. We compared the significant assumptions to the reporting unit’s historical results and third-party industry data. We performed sensitivity analyses of significant assumptions to evaluate the changes in the fair value of the reporting unit that would result from changes in the key assumptions. We involved valuation specialists to assist in our assessment of the methodology and significant assumptions (such as the discount rate) used by the Company. In addition, we tested management’s reconciliation of the fair value of all reporting units to the market capitalization of the Company.
Valuation of health care costs payable
Description of the Matter
At December 31, 2021, the incurred but not reported (“IBNR”) liabilities represented $6.6 billion of $8.8 billion of health care costs payable. As discussed in Note 1 to the consolidated financial statements, the Company’s liability for health care costs payable includes estimated payments for (1) services rendered to members but not yet reported and (2) claims that have been reported but not yet paid, each as of the financial statement date (collectively, “IBNR”). The estimated IBNR liability is developed utilizing actuarial principles and assumptions that include historical and projected claim submission and processing patterns, historical and assumed medical cost trends, historical utilization of medical services, claim inventory levels, changes in membership and product mix, seasonality and other relevant factors to record the actuarial best estimate of health care costs payable. There is significant uncertainty inherent in determining management’s actuarial best estimate of health care costs payable. In particular, the estimate is sensitive to the assumed completion factors and the assumed health care cost trend rates.

Auditing management’s actuarial best estimate of IBNR reserves for health care costs payable for its products and services involved a high degree of subjectivity in evaluating management’s assumptions used in the valuation process.
How We Addressed the Matter in Our Audit
We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the process for estimating IBNR reserves. This included, among others, controls over the completeness and accuracy of data used in the actuarial projections, the transfer of data between underlying source systems, and the review and approval processes that management has in place for the actuarial principles and assumptions used in estimating the health care costs payable.

To test IBNR reserves, our audit procedures included, among others, testing the completeness and accuracy of the underlying claim and membership data used in the calculation of IBNR reserves. We involved actuarial specialists to assist with our audit procedures, which included, among others, evaluating the methodologies applied by the Company in determining the actuarially determined liability, evaluating management’s actuarial principles and assumptions used in their analysis based on historical claim experience, and independently calculating a range of reserve estimates for comparison to management’s actuarial best estimate of the liability for health care costs payable. Additionally, we performed a review of the prior period liabilities for incurred but not paid claims to subsequent claims development.
174


/s/ Ernst & Young LLP

We have served as the Company’s auditor since 2007.

Boston, Massachusetts
February 9, 2022

175

Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.

None.

Item 9A. Controls and Procedures.

Evaluation of disclosure controls and procedures

The Company’s Chief Executive Officer and Chief Financial Officer, after evaluating the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Rules 13a-15 (f) and 15d-15(f) under the Securities Exchange Act of 1934) as of December 31, 2021, have concluded that as of such date the Company’s disclosure controls and procedures were adequate and effective at a reasonable assurance level and designed to ensure that material information relating to the Company and its consolidated subsidiaries would be made known to such officers on a timely basis.

Management’s report on internal control over financial reporting

Management is responsible for establishing and maintaining adequate internal control over financial reporting. The Company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of the Company’s consolidated financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company’s assets that could have a material effect on the Company’s consolidated financial statements. In order to ensure the Company’s internal control over financial reporting is effective, management regularly assesses such control and did so most recently for its financial reporting as of December 31, 2021.

Management conducted an assessment of the effectiveness of the Company’s internal control over financial reporting based on the criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 Framework). This evaluation included review of the documentation, evaluation of the design effectiveness and testing of the operating effectiveness of controls. The Companys system of internal control over financial reporting is enhanced by periodic reviews by the Company’s internal auditors, written policies and procedures and a written Code of Conduct adopted by CVS Health Corporation’s Board of Directors, applicable to all employees of the Company. In addition, the Company has an internal Disclosure Committee, comprised of management from each functional area within the Company, which performs a separate review of disclosure controls and procedures. There are inherent limitations in the effectiveness of any system of internal control over financial reporting.

Based on management’s assessment, management concluded that the Company’s internal control over financial reporting is effective and provides reasonable assurance that assets are safeguarded and that the financial records are reliable for preparing financial statements as of December 31, 2021.

Ernst & Young LLP, the Company’s independent registered public accounting firm, is appointed by CVS Health Corporation’s Board of Directors and ratified by CVS Health Corporation’s stockholders. They were engaged to render an opinion regarding the fair presentation of the Companys consolidated financial statements as well as conducting an audit of internal control over financial reporting. Their reports included in Item 8 of this Form 10-K are based upon audits conducted in accordance with the standards of the Public Company Accounting Oversight Board (United States).

Changes in internal control over financial reporting

There has been no change in the Company’s internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Rule 13a-15 or Rule 15d-15 that occurred during the fourth quarter ended December 31, 2021 that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

176

Item 9B. Other Information.

No events have occurred during the fourth quarter ended December 31, 2021 that would require disclosure under this item.

PART III

Item 10. Directors, Executive Officers and Corporate Governance.

Information concerning the Executive Officers of CVS Health Corporation is included in Part I of this 10-K pursuant to General Instruction G to Form 10-K.

The sections of the Proxy Statement under the captions “Committees of the Board as of the Annual Meeting,” “Code of Conduct,” “Audit Committee Report,” and “Biographies of our Incumbent Board Nominees” are incorporated herein by reference.

Item 11. Executive Compensation.

The sections of the Proxy Statement under the captions “Non-Employee Director Compensation” and “Executive Compensation and Related Matters,” including “Letter from the Management Planning and Development Committee,” “Compensation Committee Report,” “Compensation Discussion and Analysis” and “Compensation of Named Executive Officers” are incorporated herein by reference.

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

The sections of the Proxy Statement under the captions “Share Ownership of Directors and Certain Executive Officers” and “Share Ownership of Principal Stockholders” are incorporated herein by reference. Those sections contain information concerning security ownership of certain beneficial owners and management and related stockholder matters.

The following table summarizes information about the registrant’s common stock that may be issued upon the exercise of options, warrants and rights under all of the Company’s equity compensation plans as of December 31, 2021:
Number of
securities to be
issued upon
exercise of
outstanding
options, warrants
and rights (1) (2)
(a)
Weighted
average exercise
price of
outstanding
options, warrants
and rights
(b)
Number of securities
remaining available for
future issuance under
equity compensation
plans (excluding
securities reflected in
first column) (1)
(c)
Equity compensation plans approved by stockholders (3)
29,075 $74.09 29,585 
Equity compensation plans not approved by stockholders (4)
5,064 43.63 — 
Total34,139 $72.68 29,585 
_____________________________________________
(1)Shares in thousands.
(2)Consists of: (i) 17,575 shares of common stock underlying outstanding options, (ii) 854 shares of common stock issuable upon the exercise of outstanding stock appreciation rights (“SARs”) and (iii) 15,710 shares of common stock issuable on the vesting of outstanding restricted stock units, deferred stock units and performance stock units, assuming target level performance in the case of performance stock units. The number of shares included with respect to outstanding SARs is the number of shares of CVS Health Corporation common stock that would have been issued had the SARs been exercised based on the closing price per share of CVS Health Corporation common stock on December 31, 2021, as reported on the NYSE, which was $103.16.
(3)Consists of the CVS Health 2017 Incentive Compensation Plan.
(4)Consists of the Amended Aetna Inc. 2010 Stock Incentive Plan (the “Aetna Stock Plan”). The Aetna Stock Plan expired on May 21, 2020, therefore there are no securities available for future issuance under this plan.

The Aetna Stock Plan was last approved by Aetna’s shareholders at Aetna’s 2017 Annual Meeting on May 19, 2017. The Company elected to continue to grant awards under the Aetna Stock Plan to employees of Aetna and its subsidiaries following the completion of the Company’s acquisition of Aetna. The Aetna Stock Plan was designed to promote the Company’s interests and those of its stockholders and to further align the interests of stockholders and employees by tying awards to total return to stockholders, enabling plan participants to acquire additional equity interests in the Company and providing compensation opportunities dependent upon the Company’s performance. The Aetna Stock Plan was not submitted to the Company’s stockholders and expired on May 21, 2020. Under the Aetna Stock Plan, eligible participants could be granted stock options to
177

purchase shares of CVS Health Corporation common stock, SARs, time-vesting and/or performance-vesting incentive stock or incentive units and other stock-based awards.

Item 13. Certain Relationships and Related Transactions, and Director Independence.

The sections of the Proxy Statement under the captions “Independence Determinations for Directors” and “Related Person Transaction Policy” are incorporated herein by reference.

Item 14. Principal Accountant Fees and Services.

The section of the Proxy Statement under the caption “Item 2: Ratification of Appointment of Independent Registered Public Accounting Firm for 2021” is incorporated herein by reference.

178

PART IV

Item 15. Exhibits, Financial Statement Schedules.

The following documents are filed as part of this 10-K:

1.Financial Statements. See “Index to Consolidated Financial Statements” in Item 8 of this 10-K.

2.Financial Statement Schedules. All financial statement schedules are omitted because they are not applicable, not required under the instructions, or the information is included in the consolidated financial statements or related notes.

3.Exhibits. The exhibits listed in the “Index to Exhibits” in this Item 15 are filed or incorporated by reference as part of this 10-K. Exhibits marked with an asterisk (*) are management contracts or compensatory plans or arrangements. Exhibits other than those listed are omitted because they are not required to be listed or are not applicable. Pursuant to Item 601(b)(4)(iii) of Regulation S-K, the Registrant hereby agrees to furnish to the Securities and Exchange Commission a copy of any omitted instrument that is not required to be listed.

INDEX TO EXHIBITS

ExhibitDescription
3Articles of Incorporation and Bylaws
3.1
3.2
4Instruments defining the rights of security holders, including indentures
4.1
4.2
4.3
4.4
4.5
4.6
4.7
4.8
4.9
4.10
4.11
4.12
4.13
4.14
4.15
179


4.16
4.17
4.18
4.19
4.20
4.21
4.22
4.23
10Material Contracts
10.1
10.2
10.3
10.4
10.5*
10.6*
10.7*
10.8*
10.9*
10.10*
10.11*
10.12*
10.13*
10.14*
10.15*
10.16*
10.17*
180


10.18*
10.19*
10.20*
10.21*
10.22*
10.23*
10.24*
10.25*
10.26*
10.27*
10.28*
10.29*
10.30*
10.31*
10.32*
10.33*
10.34*
10.35*
10.36*
10.37*
10.38*
10.39*
181


10.40*
10.41*
10.42*
10.43*
10.44*
10.45*
10.46*
10.47*
10.48*
10.49*
10.50*
10.51*
10.52*
10.53*
10.54*
10.55*
10.56*Descriptions of certain arrangements not embodied in formal documents as described under the heading “Non-Employee Director Compensation” are incorporated herein by reference to the Proxy Statement (when filed).
21Subsidiaries of the registrant
21.1
23Consents of experts and counsel
23.1
31Rule 13a-14(a)/15d-14(a) Certifications
31.1
31.2
32Section 1350 Certifications
32.1
182

32.2
101Interactive Data File
101The following materials from the CVS Health Corporation Annual Report on Form 10-K for the fiscal year ended December 31, 2021 formatted in Inline XBRL: (i) the Consolidated Statements of Operations, (ii) the Consolidated Statements of Comprehensive Income, (iii) the Consolidated Balance Sheets, (iv) the Consolidated Statements of Cash Flows, (v) the Consolidated Statements of Shareholders’ Equity and (vi) the related Notes to Consolidated Financial Statements. The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
104
104Cover Page Interactive Data File - The cover page from the Company's Annual Report on Form 10-K for the year ended December 31, 2021, formatted in Inline XBRL (included as Exhibit 101).

Item 16. Form 10-K Summary.

None.

183

SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
CVS HEALTH CORPORATION
Date:February 9, 2022By:/s/ SHAWN M. GUERTIN
Shawn M. Guertin
Executive Vice President and Chief Financial Officer
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
SignatureTitle(s)Date
/s/ FERNANDO AGUIRREDirectorFebruary 9, 2022
Fernando Aguirre
/s/ C. DAVID BROWN IIDirectorFebruary 9, 2022
C. David Brown II
/s/ JAMES D. CLARKSenior Vice President - Controller and ChiefFebruary 9, 2022
James D. ClarkAccounting Officer (Principal Accounting Officer)
/s/ ALECIA A. DECOUDREAUXDirectorFebruary 9, 2022
Alecia A. DeCoudreaux
/s/ NANCY-ANN M. DEPARLEDirectorFebruary 9, 2022
Nancy-Ann M. DeParle
/s/ DAVID W. DORMANChair of the Board and DirectorFebruary 9, 2022
David W. Dorman
/s/ ROGER N. FARAHDirectorFebruary 9, 2022
Roger N. Farah
/s/ ANNE M. FINUCANEDirectorFebruary 9, 2022
Anne M. Finucane
/s/ SHAWN M. GUERTINExecutive Vice President and Chief FinancialFebruary 9, 2022
Shawn M. GuertinOfficer (Principal Financial Officer)
/s/ EDWARD J. LUDWIGDirectorFebruary 9, 2022
Edward J. Ludwig
/s/ KAREN S. LYNCHPresident and Chief Executive OfficerFebruary 9, 2022
Karen S. Lynch(Principal Executive Officer) and Director
/s/ JEAN-PIERRE MILLONDirectorFebruary 9, 2022
Jean-Pierre Millon
/s/ MARY L. SCHAPIRODirectorFebruary 9, 2022
Mary L. Schapiro
/s/ WILLIAM C. WELDONDirectorFebruary 9, 2022
William C. Weldon
/s/ TONY L. WHITEDirectorFebruary 9, 2022
Tony L. White

EX-4.23 2 exhibit423-2021.htm EX-4.23 Document
Exhibit 4.23
DESCRIPTION OF COMMON STOCK REGISTERED UNDER SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934

The following description (this “Description”) of the terms of the common stock of CVS Health Corporation (“CVS Health”) is a summary only and is qualified by reference to the relevant provisions of Delaware law and the Restated Certificate of Incorporation (the “Charter”) and the By-Laws (the “By-Laws”) of CVS Health. Copies of the Charter and the By-Laws are incorporated by reference as exhibits to the Annual Report on Form 10-K to which this Description is an exhibit.

Authorized Capital Stock
Under the Charter as of February 9, 2022, the authorized capital stock of CVS Health consisted of (i) 3,200,000,000 shares of common stock, par value of $0.01 per share (“common stock”), (ii) 120,619 shares of cumulative preferred stock, par value $0.01 per share (“preferred stock”), and (iii) 50,000,000 shares of preference stock, par value $1.00 per share (“preference stock”).

Common Stock
The holders of shares of common stock are entitled to one vote per share on all matters voted on by CVS Health stockholders, including elections of directors. Except as otherwise required by law, or by the provisions of the preferred stock or the preference stock, or provided in any resolution adopted by the CVS Health board of directors (the “board”) with respect to any subsequently created class or series of shares of CVS Health, the holders of the shares of common stock exclusively possess all voting power. The Charter precludes cumulative voting in the election of directors. The Charter provides for a majority vote standard for uncontested elections of directors, and a plurality of votes standard for contested elections of directors. Subject to any rights of any outstanding series of preferred stock or preference stock, (i) the holders of shares of common stock are entitled to such dividends as may be declared from time to time by the board from funds available therefor, (ii) no dividends may be declared, paid, or set aside for payment on shares of common stock unless full cumulative dividends are paid on any outstanding preference stock and any other preferred stock issued and outstanding at such time that is designated to have such dividend preference and (iii) upon dissolution the holders of shares of common stock are entitled to receive pro rata all assets of CVS Health available for distribution to such holders, subject to any liquidation preferences designated to any preferred stock or preference stock that may be issued and outstanding at such time of liquidation.

No Preemptive Rights
The Charter provides that no holder of any shares of CVS Health of any class or series may have any preemptive right to purchase or subscribe to any shares of CVS Health or any security convertible into shares of CVS Health of any class or series.

Provisions Relating to Amendments to CVS Health’s Charter and By-Laws
Under Delaware law, stockholders have the right to adopt, amend or repeal the certificate of incorporation and by-laws of a corporation. However, Delaware law requires that any amendment to the Charter also be approved by the board. Under Delaware law, unless a higher vote is required in a corporation’s certificate of incorporation, amendments to the corporation’s certificate of incorporation will be adopted upon receiving at a properly convened meeting the affirmative vote of a majority of the votes cast by all stockholders entitled to vote thereon, and if any class or series is entitled to vote thereon as a class, the affirmative vote of a majority of the votes cast in each class vote.

In addition, the By-Laws may be amended by the board with respect to all matters not exclusively reserved by law to the stockholders. Amendments to the By-Laws may be adopted and approved by the affirmative vote of the holders of record of a majority of the outstanding shares of stock of CVS Health entitled to vote at any annual or special meeting, or by the affirmative vote of a majority of the directors cast at any regular or special meeting, at which a quorum is present.
1


Certain Statutory and Charter Provisions
Certain provisions of the Charter and By-Laws summarized in the following paragraphs may be deemed to have an antitakeover effect and may delay, defer or prevent a tender offer or takeover attempt.

Potential Issuances of Preferred Stock and Preference Stock
As of February 9, 2022, the Charter authorized 120,619 shares of preferred stock, par value $0.01 per share and 50,000,000 shares of preference stock, par value $1.00 per share. The Charter also authorizes the board to issue shares of preferred stock or preference stock, from time to time, in such class or classes, and such series within any class, and with such designations, preferences and relative, participating, optional or other special rights, and qualifications, limitations or restrictions thereof as the board may determine, including, for example, (i) the designation of the class or series; (ii) the number of shares of the class or series, which number the board may thereafter (except where otherwise provided in the designation of any subsequently authorized class or series) increase or decrease (but not below the number of shares thereof then outstanding); (iii) whether dividends, if any, will be cumulative or noncumulative and the dividend rate of the class or series; (iv) the dates on which dividends, if any, will be payable; (v) the redemption rights and price or prices, if any, for shares of the class or series; (vi) the terms and amounts of any sinking fund provided for the purchase or redemption of shares of the class or series; (vii) the amounts payable on shares of the class or series in the event of any voluntary or involuntary liquidation, dissolution or winding up of the affairs of CVS Health; (viii) whether the shares of the class or series will be convertible into shares of any other class or series, or any other security, of CVS Health or any other corporation, and, if so, the specification of such other class or series or such other security, the conversion price or prices or rate or rates, any adjustments thereof, the date or dates as of which such shares will be convertible and all other terms and conditions upon which such conversion may be made; (ix) restrictions on the issuance of shares of the same class or series or of any other class or series; and (x) the voting rights, if any, of the holders of such class or series. The authorized capital stock of CVS Health, including preferred stock, preference stock and common stock, will be available for issuance without further action by CVS Health stockholders, unless such action is required by applicable law or the rules of any stock exchange or automated quotation system on which CVS Health’s securities may be listed or traded. If the approval of CVS Health stockholders is not so required, the board does not intend to seek stockholder approval.
Although the board has no intention at the present time of doing so, it could issue a class or series of preferred stock or preference stock that could, depending on the terms of such class or series, impede completion of a merger, tender offer or other takeover attempt that the holders of some, or a majority, of CVS Health shares might believe to be in their best interests or in which CVS Health stockholders might receive a premium for their shares over the then-current market price of such shares.

Potential Issuances of Rights to Purchase Securities
CVS Health does not currently have a stockholder rights plan, although the board retains the right to adopt a new plan at a future date. The Charter grants the board exclusive authority to create and issue rights entitling the holders thereof to purchase from CVS Health shares of capital stock or other securities and to elect to repurchase, redeem, terminate or amend any such rights. The times at which and terms upon which such rights are to be issued, repurchased, redeemed, terminated or amended are to be determined exclusively by the board and set forth in the contracts or instruments that evidence any such rights. The authority of the board with respect to such rights includes determining, for example, (i) the purchase price of the capital stock or other securities or property to be purchased upon exercise of such rights; (ii) provisions relating to the times at which and the circumstances under which such rights may be exercised or sold or otherwise transferred, either together with or separately from any other shares or other securities of CVS Health; (iii) provisions which adjust the number or exercise price of such rights or the amount or nature of the shares, other securities or other property receivable upon exercise of such rights in the event of a combination, split or recapitalization of any shares of CVS Health, a change in ownership of CVS Health’s shares or other securities or a reorganization, merger, consolidation, sale of assets or other occurrence relating to CVS Health or any shares of CVS Health, and provisions restricting the ability of CVS Health to enter into any such transaction absent an assumption by the other party or parties thereto of the obligations of CVS Health under such rights; (iv) provisions which deny the holder of a specified percentage of the outstanding securities of CVS Health the right to exercise such rights and/or cause such rights held by such holder to become void; (v) provisions which
2


permit CVS Health to redeem or exchange such rights; and (vi) the appointment of the rights agent with respect to such rights. This provision is intended to confirm the board’s exclusive authority to issue, repurchase, redeem, terminate or amend share purchase rights or other rights to purchase shares or securities of CVS Health or any other corporation.

Stockholder Action by Written Consent
The Charter provides that stockholder action may be taken at an annual or special meeting of stockholders or by written consent in lieu of a meeting, but only if such action is taken in accordance with the provisions of the Charter and By-Laws. Any person other than CVS Health seeking to have the CVS Health stockholders authorize or take corporate action by written consent without a meeting is required to deliver a written notice signed by holders of record of at least twenty-five percent (25%) of the voting power of the outstanding capital stock of CVS Health entitled to express consent on the relevant action and request that a record date be fixed for such purpose.

Stockholder Vote on Fundamental or Extraordinary Corporate Transactions
Under Delaware law, a sale, lease or exchange of all or substantially all of CVS Health’s assets, an amendment to the Charter, a merger or consolidation of CVS Health with another corporation or a dissolution of CVS Health generally requires the affirmative vote of the board and, with limited exceptions, the affirmative vote of a majority of the aggregate voting power of the outstanding stock entitled to vote on the transaction.
With respect to transactions with related persons (persons who own at least 10% of the outstanding capital stock of CVS Health), the Charter provides that a majority of outstanding shares (excluding those owned by the related person) voting as a single class is required to approve a business combination transaction with a related person, unless (i) such transaction is approved by a majority of continuing directors (directors who are not the related person, or an affiliate or associate thereof (or a representative or nominee of the related person or such affiliate or associate), that is involved in the relevant business combination and (a) who were members of the board immediately prior to the time that such related person became a related person or (b) whose initial election as a director was recommended by the affirmative vote of a least a majority of the continuing directors then in office, provided that, in either such case, such continuing director has continued in office after becoming a continuing director) or (ii) certain fair price requirements are met.

State Anti-Takeover Provisions
CVS Health has not opted out of Section 203 of the Delaware General Corporation Law, which provides that, if a person acquires 15% or more of the outstanding voting stock of a Delaware corporation, thereby becoming an “interested stockholder,” that person may not engage in certain “business combinations” with the corporation, including mergers, purchases and sales of 10% or more of its assets, stock purchases and other transactions pursuant to which the percentage of the corporation’s stock owned by the interested stockholder increases (other than on a pro rata basis) or pursuant to which the interested stockholder receives a financial benefit from the corporation, for a period of three years after becoming an interested stockholder unless one of the following exceptions applies: (i) the board approved the acquisition of stock pursuant to which the person became an interested stockholder or the transaction that resulted in the person becoming an interested stockholder prior to the time that the person became an interested stockholder; (ii) upon consummation of the transaction that resulted in the person becoming an interested stockholder such person owned at least 85% of the outstanding voting stock of CVS Health, excluding, for purposes of determining the voting stock outstanding, voting stock owned by directors who are also officers and certain employee stock plans; or (iii) the transaction is approved by the board and by the affirmative vote of two-thirds of the outstanding voting stock which is not owned by the interested stockholder. An “interested stockholder” also includes the affiliates and associates of a 15% or more owner and any affiliate or associate of CVS Health who was the owner of 15% or more of the outstanding voting stock within the three-year period prior to determine whether a person is an interested stockholder.

3
EX-10.10 3 exhibit1010-2021.htm EX-10.10 Document
Exhibit 10.10
cvshealthlogob.jpg


















CVS HEALTH CORPORATION

DEFERRED COMPENSATION PLAN







Amended and Restated Effective January 1, 2022















Proprietary


CVS HEALTH CORPORATION
Deferred Compensation Plan

PAGE
ARTICLE I –INTRODUCTION............................................................................................................
1.1
Name of Plan.........................................................................................................................
1.2
Purpose of Plan.....................................................................................................................
5
1.3
“Top Hat” Pension Benefit Plan..............................................................................................
5
1.4
Funding..................................................................................................................................
5
1.5
Effective Date.........................................................................................................................
5
1.6
Administration........................................................................................................................
5
1.7
Number and Gender..............................................................................................................
5
1.8
Headings................................................................................................................................
5
ARTICLE II – DEFINITIONS..............................................................................................................
6
2.1
Account..................................................................................................................................
2.2
Aetna Plans...........................................................................................................................
2.3
Affiliate...................................................................................................................................
2.4
Annual Cash Incentive...........................................................................................................
2.5
Annual Cash Incentive Deferral.............................................................................................
2.6
Base Salary............................................................................................................................
2.7
Base Salary Deferral..............................................................................................................
2.8
Beneficiary.............................................................................................................................
2.9
Board.....................................................................................................................................
2.10
Change in Control..................................................................................................................
2.11
Code......................................................................................................................................
7
2.12
Commissions.........................................................................................................................
7
2.13
Commissions Deferral...........................................................................................................
7
2.14
Committee.............................................................................................................................
7
2.15
Company Account..................................................................................................................
7
2.16
Company Contribution...........................................................................................................
7
2.17
CVS Caremark Retention Payment.......................................................................................
8
2.18
Deferrals................................................................................................................................
8
2.19
Deferral Account....................................................................................................................
8
Proprietary
Page | i



2.20
Deferred Compensation Election...........................................................................................
8
2.21
Disability.................................................................................................................................
8
2.22
Distribution Date....................................................................................................................
8
2.23
Effective Date.........................................................................................................................
8
2.24
Elective Deferrals...................................................................................................................
8
2.25
Eligible Executive...................................................................................................................
8
2.26
Employee...............................................................................................................................
8
2.27
ERISA....................................................................................................................................
9
2.28
Executive...............................................................................................................................
9
2.29
Future Fund...........................................................................................................................
9
2.30
Grandfathered Company Account.........................................................................................
9
2.31
Grandfathered Deferral Account............................................................................................
9
2.32
Lost Matching Contributions..................................................................................................
9
2.33
Participant..............................................................................................................................
9
2.34
Plan Administrator..................................................................................................................
9
2.35
Plan Year................................................................................................................................
9
2.36
Qualified Future Fund Matching Contribution........................................................................
9
2.37
Retirement.............................................................................................................................
9
2.38
Specified Employee...............................................................................................................
10
2.39
Specific Future Year...............................................................................................................
10
2.40
Termination of Employment...................................................................................................
2.41
Total Pay................................................................................................................................
2.42
Universal 409A Definition Document.....................................................................................
2.43
Valuation Date........................................................................................................................
2.44
Year of Service.......................................................................................................................
ARTICLE III – ELIGIBILITY AND PARTICIPATION..........................................................................
11
3.1
Eligibility.................................................................................................................................
3.2
Commencement of Participation............................................................................................
3.3
Termination of Participation...................................................................................................
ARTICLE IV – DEFERRALS & COMPANY CONTRIBUTIONS........................................................
4.1
Deferrals................................................................................................................................
4.2
Filing Requirements of Deferred Compensation Elections....................................................
4.3
Modification or Revocation of Election by Participant............................................................
4.4
Company Contributions and Other Deferrals.........................................................................
4.5
Deferral and Contribution Timing...........................................................................................
Proprietary
Page | ii



ARTICLE V – ACCOUNTS................................................................................................................
5.1
Establishment of Bookkeeping Accounts...............................................................................
5.2
Subaccounts..........................................................................................................................
5.3
Hypothetical Nature of Accounts............................................................................................
5.4
Vesting...................................................................................................................................
5.5
Deferral Crediting Options.....................................................................................................
5.6
Hypothetical Gains or Losses................................................................................................
ARTICLE VI – DISTRIBUTION OF ACCOUNT.................................................................................
6.1
Distribution Elections – Timing of Payment...........................................................................
6.2
Disability Distributions............................................................................................................
6.3
Distributions in the Event of Death........................................................................................
6.4
Distributions Upon Termination of Employment Other Than Retirement, Death or Disability
6.5
Change in Control..................................................................................................................
6.6
Form of Payment...................................................................................................................
6.7
Change of Distribution Election.............................................................................................
6.8
Account Valuation upon a Distribution...................................................................................
6.9
Designation of Beneficiary.....................................................................................................
6.10
Unclaimed Account................................................................................................................
6.11
Hardship Withdrawals............................................................................................................
6.12
ARTICLE VII – ADMINISTRATION....................................................................................................
7.1
Plan Administrator..................................................................................................................
7.2
General Powers of Administration.........................................................................................
7.3
Costs of Administration..........................................................................................................
7.4
Indemnification.......................................................................................................................
7.5
409A Compliance...................................................................................................................
ARTICLE VIII – CLAIMS PROCEDURE............................................................................................
8.1
Claims....................................................................................................................................
8.2
Claim Decision.......................................................................................................................
8.3
8.4
Review of Decision...............................................................................................................
8.5
Time Limit for Bringing Legal Action......................................................................................
ARTICLE IX – MISCELLANEOUS.....................................................................................................
9.1
Not Contract of Employment..................................................................................................
9.2
Non-Assignability of Benefits.................................................................................................
Proprietary
Page | iii



9.3
Withholding and Deduction and Taxes..................................................................................
9.4
Amendment and Termination.................................................................................................
9.5
Compliance with Securities and Other Laws.........................................................................
9.6
No Trust Created...................................................................................................................
9.7
Unsecured General Creditor Status of Employee..................................................................
9.8
Limitation...............................................................................................................................
9.9
Payment to Minors and Incompetents...................................................................................
9.10
9.11
Severability.............................................................................................................................
9.12
Governing Laws.....................................................................................................................
9.13
Binding Effect.........................................................................................................................
Article I – Definitions.........................................................................................................................
Article IV – Deferrals and Company Contributions...........................................................................
Article V – Maintenance of Accounts................................................................................................
Article VI – Payment of Benefit.........................................................................................................
Article 2: Participation.......................................................................................................................
Article 3: Contributions & Deferral Elections.....................................................................................
APPENDIX C APPENDIX C – PROVISIONS APPLICABLE TO A PARTICIPANT’S ACCOUNT UNDER THE AETNA SUPPLEMENTAL 401(K) PLAN AND AETNA DEFERRED COMPENSATION PROGRAM...........................................................................................................



Proprietary
Page | iv



ARTICLE I – INTRODUCTION
1.1Name of Plan.
CVS Health Corporation (the “Company”) hereby adopts the CVS Health Deferred Compensation Plan as amended and restated as of January 1, 2022 (the “Plan”).
1.2Purpose of Plan.
The purpose of the Plan is to provide certain eligible employees of the Company or an Affiliate authorized by the Committee to participate in the Plan the opportunity to defer elements of his or her compensation which might not otherwise be deferrable under other plans maintained by the Company or an Affiliate and to make deferrals and receive contributions that would be obtainable under the CVS Health Future Fund 401(k) Plan (“Future Fund”) in the absence of certain restrictions and limitations in the Internal Revenue Code.
1.3“Top Hat” Pension Benefit Plan.
The Plan is an “employee pension benefit plan” within the meaning of ERISA. However, the Plan is unfunded and maintained for a select group of management or highly compensated employees and, therefore, it is intended that the Plan will be exempt from Parts 2, 3 and 4 of Title I of ERISA. The Plan is not intended to qualify under Section 401(a) of the Code.
1.4Funding.
The Plan is unfunded. All benefits will be paid from the general assets of the Company. Participants in the Plan shall have the status of general unsecured creditors of the Company.
1.5Effective Date.
The Plan was originally effective as of January 1, 1997, and amended and restated in its entirety effective as of December 31, 2008, to comply with the provisions of Section 409A of the Internal Revenue Code and regulations promulgated thereunder and as of December 17, 2014, October 1, 2015, November 1, 2016, and January 1, 2020 to reflect certain design and administrative changes desired by the Company.
1.6Administration.
The Plan shall be administered by the Deferred Compensation Plans Committee, as defined in Article VII.
1.7Number and Gender.
Wherever appropriate herein, words used in the singular shall be considered to include the plural and words used in the plural shall be considered to include the singular. The masculine gender, where appearing in the Plan, shall be deemed to include the feminine gender. The feminine gender, where appearing in the Plan, shall be deemed to include the masculine gender.
1.8Headings.
The headings of Articles and Sections herein are included solely for convenience, and if there is any conflict between such headings and the text of the Plan, the text shall control.


Proprietary
Page | 1



ARTICLE II – DEFINITIONS
For purposes of the Plan, the following words and phrases shall have the meanings set forth below, unless their context clearly requires a different meaning:
2.1Account.
The Company Account, Deferral Account, Grandfathered Company Account, and the Grandfathered Deferral Account maintained by the Company on behalf of each Participant pursuant to the Plan.
2.2Aetna Plans.
The Aetna Deferred Compensation Program (“Aetna Program”) and the Aetna Supplemental 401K Plan (“Aetna Supplemental Plan”).
2.3Affiliate.
A subsidiary of the Company, as defined in the Company’s Universal 409A Definition Document.
2.4Annual Cash Incentive.
The amount awarded to a Participant in cash for a Plan Year under a regular (annual) incentive plan (other than an exceptional performance award program or a one-time incentive plan or program) maintained by the Company or an Affiliate, and any other amount otherwise included in Annual Cash Incentive for purposes of the Plan under rules as are adopted by the Committee.
Effective January 1, 2015, Operation Production Incentives shall be excluded from the definition of Annual Cash Incentive.
2.5Annual Cash Incentive Deferral.
The amount of a Participant’s Annual Cash Incentive which a Participant elects to have withheld on a pre-tax basis from his or her Annual Cash Incentive and credited to his or her Deferral Account pursuant to the Plan.
2.6Base Salary.
The base rate of cash compensation paid by the Company or an Affiliate to or for the benefit of a Participant for services rendered or labor performed while a Participant, including deferrals pursuant to the Plan and any pre-tax contribution to be made on the Participant’s behalf to any qualified plan maintained by the Company or an Affiliate pursuant to a cash or deferred arrangement maintained by the Company or an Affiliate (as defined under Section 401(k) of the Code) or under any cafeteria plan (as defined under Section 125 of the Code) or under a qualified transportation fringe (as defined under Section 132(f) of the Code). Base Salary shall exclude any overtime, premium pay, shift differentials, bonuses, commissions or any other form of supplemental cash compensation, except to the extent otherwise deemed “Base Salary” for purposes of the Plan under rules as are adopted by the Committee.
2.7Base Salary Deferral.
The amount of a Participant’s Base Salary which the Participant elects to have withheld on a pre- tax basis from his or her Base Salary and credited to his or her Deferral Account pursuant to the Plan.
Proprietary
Page | 2



2.8Beneficiary.
The person or persons (which may include trusts) designated in writing (either by hand or electronic submission) by the Participant on the beneficiary designation form prescribed by the Plan Administrator to receive the amounts, if any, payable under the Plan upon the death of the Participant. In the absence of such written designation by the Participant, the Beneficiary shall mean, in the following order, the Participant’s spouse, if any; the person named as the Participant’s beneficiary under the Company’s life insurance program; or the Participant’s estate.
2.9Board.
The Board of Directors of the Company.
2.10Change in Control.
“Change in Control” as such term is defined in the Universal 409A Definition Document.
2.11Code.
The Internal Revenue Code of 1986, as amended. References to any provision of the Code or regulation (including a proposed regulation) thereunder shall include any successor provisions or regulations.
2.12Commissions.
The amount of a Participant’s sales commissions or other commissions payable under a sales commissions or other commissions plan maintained by the Company or an Affiliate. (Sales commissions for purposes of the Plan shall mean sales commissions as defined in Treas. Reg. Section 1.409A-2(a)(12)(i) and any subsequent guidance and such sales commissions are considered to be earned in the taxable year of the Participant in which the sale is completed so that the amount of the Commissions are reasonably determinable.)
2.13Commissions Deferral.
The amount of a Participant’s Commissions that a Participant elects to have withheld on a pre-tax basis from his or her Commissions and credited to his or her Deferral Account pursuant to the Plan.
2.14Committee.
The Management Planning and Development Committee of the Board of Directors of the Company or any other directors of the Company designated as the Committee.
2.15Company Account.
The bookkeeping account (or subaccount(s) thereof) maintained for each Participant to record the amount of Company Contributions that are either (i) credited on his or her behalf under Section 4.4 on or after January 1, 2005 or (ii) were credited on his or her behalf under Section 4.4 prior to January 1, 2005, but became vested on or after January 1, 2005, as adjusted pursuant to Section 5.6.
2.16Company Contribution.
The amount, as determined by the Company on an annual basis based on the provisions of the Plan, which is credited on the Participant’s behalf by the Company to his or her Company Account pursuant to the provisions of Section 4.4(a) of the Plan.
Proprietary
Page | 3



2.17CVS Caremark Retention Payment.
The amount granted to an Eligible Executive, as defined in and provided for under the provisions of the employment term sheet agreement entered into between the Company or an Affiliate and said Eligible Executive, as a former employee of Caremark Rx, Inc., in connection with the merger involving Caremark, Rx, Inc. and the Company.
2.18Deferrals.
The amount of deferrals credited to a Participant pursuant to Section 4.1.
2.19Deferral Account.
The bookkeeping account (or subaccount(s) thereof) maintained for each Participant to record any and all deferrals made under the Plan.
2.20Deferred Compensation Election.
The written election (either by hand or electronic submission) including any amendments, attachments and appendices thereto as prescribed by the Plan Administrator, regardless of how it may be titled, under which the Participant agrees to defer a portion of his or her Base Salary and/or Annual Cash Incentive or Commissions under the Plan (or any other cash remuneration payable to a Participant that he or she may elect to defer under the provisions of the Plan, including but not limited to awards under the Company’s Long Term Incentive Plan (LTIP). This election as to deferral and the related form and timing of distribution is made by the Participant and constitutes the agreement entered into between the Company and a Participant for participation in the Plan. The Participant elects the terms of his or her deferral pursuant to the provisions of this Plan and the administrative procedures established by the Plan Administrator.
2.21Disability.
“Disability” as defined in the Company’s Long-Term Disability Plan.
2.22Distribution Date.
The date on which a Participant’s distribution is scheduled to be paid with respect to his or her Account under the Plan pursuant to his or her Deferred Compensation Election, which date shall take into account any processing period.
2.23Effective Date.
January 1, 1997.
2.24Elective Deferrals.
Elective Deferrals as defined in the Future Fund.
2.25Eligible Executive.
An Executive who is eligible to participate in the Plan as provided in Section 3.1(a).
2.26Employee.
Any common-law full-time salaried exempt employee of the Company or an Affiliate, other than a store manager, pharmacist or MinuteClinic practitioner, who has been authorized by the Committee to participate in the Plan.
Proprietary
Page | 4



2.27ERISA.
The Employee Retirement Income Security Act of 1974, as amended.
2.28Executive.
An Employee whose Base Salary (determined on the basis of a maximum forty (40) hour work week) equals or exceeds $175,000 (as adjusted from time to time by the Committee).
2.29Future Fund.
The CVS Health Future Fund 401(k) Plan.
2.30Grandfathered Company Account.
The bookkeeping account (or subaccount(s)) maintained for each Participant to record the amount of Company Contributions credited on a Participant’s behalf under Section 4.4, which were vested as of December 31, 2004, adjusted as provided in Section 5.6.
2.31Grandfathered Deferral Account.
The bookkeeping account (or subaccount(s)) maintained for each Participant to record (i) the amount of Base Salary and/or Annual Cash Incentive or Commissions deferred in accordance with Section 4.1, (ii) the amount of LTIP deferrals deferred in accordance with Section 4.4, and/or (iii) the amount of cash retention award deferrals deferred in accordance with Section 4.4, as of December 31, 2004, adjusted pursuant to Section 5.6.
2.32Lost Matching Contributions.
The amounts credited on a Participant’s behalf to his or her Company Account pursuant to the provisions of Section 4.4(a).
2.33Participant.
Each Eligible Executive participating in the Plan as set forth in Section 3.2.
2.34Plan Administrator.
The Deferred Compensation Plans Committee appointed pursuant to Section 7.1 to administer the Plan.
2.35Plan Year.
A calendar year ending on December 31.
2.36Qualified Future Fund Matching Contribution.
The total of all matching contributions that could have been made by the Company or an Affiliate with respect to a Plan Year for the benefit of a Participant under and in accordance with the terms of Future Fund.
2.37Retirement.
Termination of Employment with the Company and all Affiliates on or after (i) age fifty-five (55) and the completion of ten (10) or more Years of Service or, if earlier, (ii) age sixty (60) and the completion of five (5) or more Years of Service.
Proprietary
Page | 5



2.38Specified Employee.
“Specified Employee” as such term is defined in the Universal 409A Definition Document.
2.39Specific Future Year.
A calendar year in the future elected by a Participant with respect to the distribution of his or her Account(s) (or subaccount(s) thereof) pursuant to the Plan.
2.40Termination of Employment.
“Termination of employment” as such term is defined in the Universal 409A Definition Document.
2.41Total Pay
The total of Base Salary, Annual Cash Incentive and Commissions.
2.42Universal 409A Definition Document.
The document developed by the Company for the purpose of defining terms relating to benefits or amounts in all plans covered by Section 409A of the Code and sponsored by the Company or any Affiliate.
2.43Valuation Date.
The date on which an Account is valued under the Plan, as determined by the Committee, by reference to the New York Stock Exchange.
2.44Year of Service.
Year of Participation Service as defined in Future Fund.
























Proprietary
Page | 6



ARTICLE III – ELIGIBILITY AND PARTICIPATION
3.1Eligibility.
(a)An Employee who is an Executive on October 1st of a calendar year (or such other date in the calendar year as designated by the Committee) shall be eligible to participate in the Plan. The Committee may, in its sole discretion, designate other key employees of the Company or an Affiliate who are members of a select group of management or highly compensated employees as eligible to participate in the Plan.
(b)Notwithstanding any Plan provision to the contrary, Employees must also be subject to the income tax laws of the United States in order to be eligible for participation in the Plan.
(c)Subject to the provisions of Sections 3.3 and Section 4.1, an Eligible Executive shall remain eligible to continue participation in the Plan for each Plan Year following his or her initial year of participation in the Plan.
(d)A Participant who ceases to be an Executive can continue to be eligible to participate unless and until such Participant fails to make an annual deferral election under the Plan or under the CVS Health Corporation Deferred Stock Compensation Plan, at which point the Employee must meet the threshold compensation level in order to be eligible to participate for a future Plan Year.
(e)Deferred Compensation Plan Participants who made a deferral under the Deferred Compensation Plan with respect to the two most recent enrollment periods shall, regardless of compensation threshold, be eligible to participate in the Deferred Compensation Plan for the 2020 Plan Year.
(f)Active Aetna employees who elected to defer in either of the Aetna Plans in the two most recent enrollment periods shall, regardless of compensation threshold, be eligible to participate in the Deferred Compensation Plan for the 2020 Plan Year.
3.2Commencement of Participation.
An Eligible Executive shall become a Participant effective as of the date that the Eligible Executive’s first Deferred Compensation Election becomes effective, provided that the Eligible Executive has provided such information as the Plan Administrator deems necessary to properly administer the Plan.
3.3Termination of Participation.
(a)Participation shall cease when the benefits that have been credited to a Participant’s Deferral Account have been distributed to him or her.
(b)Subject to the provisions of Section 4.3(c), a Participant shall only be eligible to make Deferrals under the Plan for as long as he or she remains an Eligible Executive.
(c)If a former Participant who has incurred a Termination of Employment with the Company and all Affiliates and whose participation in the Plan ceased under Section 3.3(a) is reemployed as an Executive, the former Participant may again become eligible to participate in accordance with the provisions of Section 3.1(a).
Proprietary
Page | 7



ARTICLE IV – DEFERRALS & COMPANY CONTRIBUTIONS
4.1Deferrals.
(a)Subject to the following provisions of this Article IV, an Eligible Executive may defer for any Plan Year: (i) up to fifty percent (50%) of Base Salary otherwise earned and payable in that Plan Year, and/or (ii) up to eighty percent (80%) of Annual Cash Incentive otherwise earned in that Plan Year and payable in that Plan Year or in the first calendar quarter of the following Plan Year, and/or (iii) with respect to Deferred Compensation Elections made prior to November 1, 2021, up to eighty percent (80%) of Commissions otherwise earned in that Plan Year and payable in that Plan Year or in the first calendar quarter of the following Plan Year, and with respect to Deferred Compensation Elections made on or after November 1, 2021, up to eighty percent (80%) of Commissions otherwise payable in the applicable Plan Year in accordance with Section 4.2. The Plan Administrator may, as it deems appropriate, establish maximum or minimum limits on the amounts which may be deferred for a Plan Year and/or the times of such Deferred Compensation Elections. An Eligible Executive shall be given advance notice of any such limits. Notwithstanding anything in the Plan to the contrary, a previously submitted Participant’s Deferred Compensation Election (with respect to Base Salary, Annual Cash Incentive and/or Commissions) shall be disregarded following the Participant’s Termination of Employment.
(b)Deferrals under the Plan shall be calculated with respect to the gross cash compensation payable to the Participant prior to any deductions (e.g., 401(k) deferrals) or withholdings. However, the Deferrals shall be reduced by the Plan Administrator as necessary if it is later determined, after Deferrals are made under the Plan and after additional deduction of all required income and employment taxes, 401(k) and other employee benefit deductions, and other deductions required by law, that all such total deferrals will exceed one hundred percent (100%) of the cash compensation of the Participant available under Section 4.1(a). Changes to payroll withholdings that affect the amount of compensation being deferred to the Plan shall be allowed only to the extent permissible under Section 409A of the Code.
4.2Filing Requirements of Deferred Compensation Elections.
Subject to the following provisions of this Section, during an annual enrollment period established by the Plan Administrator in any Plan Year, an Eligible Executive described in Section 3.1 may elect, subject to Section 4.1 above, to defer: (a) a portion of his or her Base Salary that is otherwise earned and payable in the next Plan Year, and/or (b) a portion of his or her Annual Cash Incentive otherwise earned in the next Plan Year and payable in that Plan Year or in the first calendar quarter of the subsequent Plan Year, and/or (c) with respect to Deferred Compensation Elections made prior to November 1, 2021, a portion of his or her Commissions otherwise earned in the next Plan Year and payable in that Plan Year or in the first calendar quarter of the subsequent Plan Year, and with respect to Deferred Compensation Elections made on or after November 1, 2021, a portion of his or her Commissions payable in the second succeeding Plan Year following the calendar year in which such Deferred Compensation Election is made. The aforementioned Deferred Compensation Elections are to be made by submitting a Deferred Compensation Election during such annual enrollment period. If an Executive becomes an Eligible Executive after October 1 (or such later date as prescribed by the Plan Administrator) in any calendar year, he or she may not make a Deferred Compensation Election for Base Salary, Annual Cash Incentive or Commissions earned in the next Plan Year (and on or after November 1, 2021, for Commissions payable in the second succeeding Plan Year).
A Participant shall submit a Deferred Compensation Election in the manner specified by the Plan Administrator and a Deferred Compensation Election that is not timely filed shall be considered void and have no effect. If a Participant does not file a Deferred Compensation Election applicable to his or her Base Salary, Annual Cash Incentive or Commissions earned in a Plan Year on or before the close of the applicable annual enrollment period (or such later date prescribed by the
Proprietary
Page | 8



Plan Administrator), the Participant shall be deemed to have elected not to make a Deferred Compensation Election for such Plan Year. The Plan Administrator shall establish procedures that govern deferral elections under the Plan, including the ability to make separate elections for Base Salary, Annual Cash Incentive or Commissions, and any other cash remuneration payable to the Participant that the Committee or Plan Administrator permits a Participant to defer under the Plan.
Subject to the provisions of this Article, an Eligible Executive must file a new Deferred Compensation Election for each Plan Year that the Eligible Executive is eligible to participate in the Plan if the Eligible Executive intends to make a deferral under the Plan for such Plan Year.
4.3Modification or Revocation of Election by Participant.
(a)A Participant’s Deferred Compensation Election for a Plan Year shall become irrevocable as of the close of business on the date established by the Plan Administrator, but not later than the applicable date described below.
i.In the case of a deferral of Base Salary and/or Annual Cash Incentives and with respect to Commissions, Deferred Compensation Elections made before November 1, 2021, on the last day of the calendar year preceding the Plan Year in which such Base Salary or Annual Cash Incentive or Commissions applicable to that Deferred Compensation Election is earned. Such Deferred Compensation Elections shall become effective as of the first day of the Plan Year in which such Base Salary and/or Annual Cash Incentive and/or Commission is earned.
ii.In the case of a deferral of Commissions, for Deferred Compensation Elections made on or after November 1, 2021, on the last day of the second calendar year preceding the Plan Year in which such Commissions applicable to that Deferred Compensation Election are paid. Such Deferred Compensation Elections shall become effective as of the first day of the Plan Year that precedes the Plan Year in which such Commission is paid.
Notwithstanding the foregoing, the Plan Administrator may cancel a Participant’s Deferred Compensation Elections for the balance of a Plan Year if the Participant submits evidence of an unforeseeable emergency (as defined in the Universal 409A Definition Document) to the Plan Administrator. Any Base Salary, Annual Cash Incentive, Commissions or other cash remuneration which would have been deferred pursuant to that cancelled Deferred Compensation Election shall be paid to the Eligible Executive as if he or she had not made that election.
A Participant may revoke or change a Deferred Compensation Election any time prior to the date such election becomes irrevocable. Any such change or revocation shall be made in a form and manner determined by the Plan Administrator. Under no circumstances may a Participant’s Deferred Compensation Election be made, modified or revoked retroactively.
(b)If a Participant’s Deferred Compensation Election applicable to his or her Base Salary and/or Annual Cash Incentive or Commissions is cancelled for a Plan Year, he or she will not be permitted to elect to make Deferrals again until the next Plan Year.
(c)If a Participant ceases to be an Executive after the date a Deferred Compensation Election becomes effective but continues to be employed by the Company or an Affiliate, his or her Deferred Compensation Election currently in effect shall remain in force.
(d)Notwithstanding anything in the Plan to the contrary, if an Eligible Executive:
Proprietary
Page | 9



i.receives a withdrawal of deferred cash contributions on account of hardship from any plan which is maintained by the Company or an Affiliate and which meets the requirements of Section 401(k) of the Code (or any successor thereto); and
ii.is precluded from making contributions to such 401(k) plan for at least six (6) months after receipt of the hardship withdrawal,
the Eligible Executive’s Deferred Compensation Election with respect to Base Salary, Annual Cash Incentive or Commissions in effect at that time shall be cancelled. Any Base Salary, Annual Cash Incentive or Commissions payment which would have been deferred pursuant to that Deferred Compensation Election but for the application of this Section 4.3(d) shall be paid to the Eligible Executive as if he or she had not made that election.
4.4Company Contributions and Other Deferrals.
(a)Company Contributions – Restoration of Lost Matching Contribution.
The amount of Lost Matching Contributions credited under the Plan on a Participant’s behalf each calendar year shall be equal to (i) minus (ii) where:
i.is the lesser of (a) total Qualified Future Fund Matching Contribution that would have been allocated on the Participant’s behalf under Future Fund for the Plan Year, without giving effect to any reductions or limitations required by Sections 401(a)(17), 401(k), 402(g) and/or 415 of the Code (i.e., 5% of Total Pay), and (b) the Future Fund matching contribution that would have been allocated on the participants behalf, had the participant contributed the maximum amount permissible by law for that plan year, plus his or her Deferral under Section 4.1 for the Plan Year; and
ii.If the Participant is eligible to contribute to Future Fund (whether pre-tax or after-tax) during the Plan Year, (ii) is the maximum amount of matching contributions that could have been made on the participants behalf to Future Fund had the participant contributed the maximum amount permissible by law for that Plan Year.
In addition, if the Participant is not eligible to contribute to Future Fund during the Plan Year but is eligible to contribute to another qualified defined contribution plan (whether pre-tax or after-tax) maintained by the Company or an Affiliate during that Plan Year, the amount under this clause (ii) shall equal, unless otherwise provided by the Committee, the maximum amount of matching contributions the Participant would have received under the provisions of Future Fund for that Plan Year had he or she been eligible to contribute to Future Fund during that Plan Year, based on his or her Base Salary and/or Annual Cash Incentive or Commissions otherwise earned and payable in that Plan Year.
For purposes of this subsection (a), for the Plan Year in which the requirement to complete one (1) Year of Service is met, Total Compensation for the entire Plan Year shall be taken into account.
Notwithstanding the foregoing, for purposes of determining the Lost Matching Contributions to be credited under this Section 4.4(a), Years of Service with respect to a Participant employed by Red Oak Sourcing, LLC, the limited liability corporation formed pursuant to the Framework Agreement between CVS Pharmacy, Inc. and Cardinal Health 110 Inc., dated December 10, 2013 (“Cardinal”), who immediately prior to becoming employed by Red Oak Sourcing, LLC was employed by Cardinal, shall include the period of such Participant’s employment rendered with Cardinal.
Proprietary
Page | 10



Lost Matching Contributions shall be credited under this Section 4.4(a) with respect to a Participant who made a Bonus Deferral Contribution election under the Omnicare, Inc. Deferred Compensation Plan with respect to the 2016 Plan Year but such Lost Matching Contributions shall be subject to the Participant’s distribution election and the distribution provisions of the Omnicare, Inc. Deferred Compensation Plan in effect on the date of such Participant’s election.
Notwithstanding anything in the Plan to the contrary, a Participant shall not be eligible to receive a Lost Matching Contribution following the Participant’s Termination of Employment, unless the Participant terminates due to Retirement.
For purposes of clarification, in no event shall a Participant be eligible to receive a Lost Matching Contribution if the Participant does not make an actual deferral into the Plan for the Plan Year.
(b)LTIP Deferrals.
At the sole discretion of the Committee, all or a portion of a Participant’s cash award under the LTIP may be deferred under the Plan. Such election shall be made in accordance with the procedures established by the Plan Administrator. The deferral election applicable to an LTIP cash award shall be made prior to the close of the calendar year preceding the first day of the performance period applicable to that award. Notwithstanding the foregoing, such election shall become irrevocable as of the close of business of the last day of the calendar year preceding the first day of the performance period applicable to that award. However, if such award meets the definition of performance-based compensation (as defined under Treas. Reg. Section 1.409A-1(e) and any subsequent guidance), the Plan Administrator may permit such election to be made in accordance with the provisions under Treas. Reg. Section 1.409A-2(a)(8) and subsequent guidance. Notwithstanding anything in the Plan to the contrary, a previously submitted deferral election of a Participant’s cash award under the LTIP shall be disregarded following the Participant’s Termination of Employment.
(c)Cash Retention Award Deferrals.
At the sole discretion of the Committee and subject to the procedures established by the Plan Administrator, an Eligible Executive may elect to defer all or a portion of a cash retention award that may be otherwise paid under a cash retention program maintained by the Company or an Affiliate. The deferral election applicable to such cash retention award shall be made in accordance with the provisions of Treasury Regulations Section 1.409A- 2(a)(5). Notwithstanding anything in the Plan to the contrary, a previously submitted deferral election of a Participant’s cash retention award shall be disregarded following the Participant’s Termination of Employment.
4.5Deferral and Contribution Timing.
Base Salary Deferrals will be credited to the Account of each Participant as of the date of the paycheck from which the deferral was withheld. A Participant whose employment terminates during a payroll period will cease deferral withholding effective as of the first day of the following payroll period.
Annual Cash Incentive Deferrals and Commission Deferrals will be credited to the Account of each Participant as of the day on which such Annual Cash Incentive or Commissions, whichever is applicable, otherwise would have been paid to the Participant in cash.
Company Contributions for the Restoration of Lost Matching Contribution pursuant to Section 4.4(a)
Proprietary
Page | 11



above will generally be credited to the Participant’s Company Account as of the last day of each Plan Year following the Participant’s completion of one (1) Year of Participation Service (as defined in Future Fund).
LTIP deferrals shall be credited to the Account of the Participant at the time designated by the Plan Administrator.
Cash retention awards Deferrals will be credited to the Account of the Participant as of the day on which such cash retention award otherwise would have been paid to the Participant in cash.















































Proprietary
Page | 12



ARTICLE V– ACCOUNTS
5.1Establishment of Bookkeeping Accounts.
Separate bookkeeping accounts shall be maintained for each Participant. Said accounts (or subaccount(s) thereof) shall be credited with the deferrals and contributions made by or on behalf of the Participant pursuant to the Plan and credited (or charged, as the case may be) with the hypothetical investment results determined pursuant to this Article of the Plan.
5.2Subaccounts.
Within each Participant’s bookkeeping account, separate subaccount(s) shall be maintained to the extent necessary for the administration of the Plan. Generally, subaccount(s) will be set up for each year, for each Deferred Compensation Election the Participant makes, and for the Company Contribution credited each year on behalf of a Participant.
5.3Hypothetical Nature of Accounts.
The accounts established under this Article shall be hypothetical in nature and shall be maintained for bookkeeping purposes only so that hypothetical gains or losses on the deferrals or contributions made to the Plan can be credited (or charged, as the case may be).
Neither the Plan nor any of the accounts, or subaccount(s), established hereunder shall hold any actual funds or assets. The right of any person to receive one or more payments under the Plan shall be an unsecured claim against the general assets of the Company. Any liability of the Company to any Participant, former Participant, or Beneficiary with respect to a right to payment shall be based solely upon contractual obligations created by the Plan. The Company, an Affiliate, the Board, the Committee, or any other person shall not be deemed to be a trustee of any amounts to be paid under the Plan. Nothing contained in the Plan, and no action taken pursuant to its provisions, shall create or be construed to create a trust of any kind, or a fiduciary relationship, between the Company, an Affiliate, the Board, the Committee, the Plan Administrator, or any other person and a Participant or any other person.
5.4Vesting.
Deferral Account. A Participant shall be one hundred percent (100%) vested in his or her Deferral Account and Grandfathered Deferral Account at all times. A Participant shall be one hundred percent (100%) vested in the LTIP deferrals credited on his or her behalf pursuant to Section 4.4(b) and any cash retention award deferrals credited on his or her behalf pursuant to Section 4.4(c).
Company Account. A Participant shall be one hundred percent (100%) vested in his or her Company Account and Grandfathered Company Account at all times.
5.5Deferral Crediting Options.
Deferral Crediting Options are similar to investment choices in a qualified defined contribution plan, except that they are hypothetical in nature and no funds are actually held in the Plan. Deferral Crediting Options determine the hypothetical gain or loss to be reflected in the Participant Accounts and shall be elected by Participants in the manner determined by the Plan Administrator.
The Deferral Crediting Options offered to Participants are determined by the Plan Administrator at its sole discretion. The Plan Administrator specifically retains the right to change the Deferral Crediting Options at any time, in its sole discretion.
In the event the Plan Administrator designates more than one Deferral Crediting Option, each Participant shall electronically submit a Deferral Crediting Option election during each annual
Proprietary
Page | 13



enrollment period, which shall be used to measure the hypothetical investment performance of his or her Accounts, within such time period and on such form as the Plan Administrator may prescribe. The designation of a Deferral Crediting Option shall not require the Company to invest or earmark their general assets in any manner. If a Participant fails to make a Deferral Crediting Option, his or her Accounts shall be deemed invested in a Deferral Crediting Option as determined by the Plan Administrator.
A Participant may change his or her election of a Deferral Crediting Option used to measure the hypothetical investment performance of his or her Account balance within such time periods and in such manner prescribed by the Plan Administrator. The election shall be effective as soon as administratively practicable after the date on which the election is submitted in the manner specified by the Plan Administrator.
Any amounts added to or subtracted from a Participant’s Account on any given Valuation Date will be converted to hypothetical unit equivalents (“Hypothetical Units”) with a value per Hypothetical Unit (“Unit Price”) based on the daily closing price on said date (“Unit Price”) for any given Deferral Crediting Option.
5.6Hypothetical Gains or Losses.
Any hypothetical dividends, capital gains and any other income or unit activity will be reflected in the Deferral Crediting Options. The timing of these will be the same as for the funds on which each Deferral Crediting Option is based.
The gain or loss on Participant Accounts will be calculated each Valuation Date. The Unit Price shall determine each Deferral Crediting Option’s hypothetical value, based on the number of units within the Account for any given Deferral Crediting Option. Account balances on a given day will be based on the previous day’s New York Stock Exchange closing price.
Proprietary
Page | 14



ARTICLE VI – DISTRIBUTION OF ACCOUNT
6.1Distribution Elections – Timing of Payment.
(a)Subject to the limitations set forth in this Article VI, each time a Participant makes a Deferred Compensation Election with respect to a Plan Year beginning on or after January 1, 2016, the Participant shall designate on that applicable Deferred Compensation Election, separately for Participant deferrals and Company Contributions, as adjusted pursuant to Article V, that the distribution of such deferrals shall be made or commence, as the case may be, pursuant to Section 6.6, as of (i) the Participant’s Retirement; or (ii) a Specific Future Year not later than the Plan Year in which the Participant attains age seventy-one (71).
A Participant may choose different options with respect to each Deferred Compensation Election. A Participant may not change the election made pursuant to the provisions of this Section 6.1, except as otherwise provided in Section 6.7 below.
i.Retirement. The distribution of the portion of a Participant’s Deferral or Company Account (or subaccount(s)) that is deferred to Retirement under this Section shall commence on the first business day in the January next following his or her Retirement, pursuant to the provisions of Section 6.6, provided, however, that with respect to a Participant who is a Specified Employee as of the date of his or her Retirement, payment of any portion of his or her Deferral or Company Account (or any subaccount(s) thereof) that is subject to Section 409A of the Code will be delayed until the first business day of the seventh (7th) month following the date such Retirement occurs.
ii.Specific Future Year. In the event a Participant elects to have the distribution of such deferrals made or commence as of a Specific Future Year, subject to rules established by the Plan Administrator, the deferral period must be at least five (5) Plan Years. The distribution of the portion of a Participant’s Deferral or Company Account (or subaccount(s)) that is deferred to a Specific Future Year shall commence on the first business day of January in that specific year pursuant to the provisions of Section 6.6.
(b)Company Contributions shall be distributed pursuant to the Participant’s distribution election. In the event a Participant has not made a distribution election for the Company Contributions for that Plan Year, such distribution shall mirror his or her distribution election made with respect to his or her Base Salary Deferral or Annual Cash Incentive or Commissions Deferral for that Plan Year, if any, in such order; otherwise, such distribution shall be made at the Participant’s Retirement.
6.2Disability Distributions.
Notwithstanding the foregoing, if a Participant has a Termination of Employment because he or she has become Disabled, as determined by the Plan Administrator, such Participant will receive the balance of his or her Deferral Account and Company Account paid out in five (5) annual substantially equal installments with the first payment to be made within seventy-five (75) days from the date of the Participant’s Termination of Employment. Subsequent annual payments will be paid as of the first business day in January of each subsequent year of the installment period.
6.3Distributions in the Event of Death.
Notwithstanding the foregoing, in the event of a Participant’s death, the Participant’s Beneficiary will receive the remaining balance of the Participant’s Deferral Account and Company Account paid
Proprietary
Page | 15



in two (2) annual installments with the first payment to be made within seventy-five (75) days of the Participant’s date of death. The second annual payment will be paid as of the first business day in January of the subsequent calendar year.
6.4Distributions Upon Termination of Employment Other Than Retirement, Death or Disability.
Notwithstanding the foregoing, in the event a Participant incurs a Termination of Employment from the Company and all Affiliates for any reason other than Retirement, death or Disability, said Participant will receive his or her entire Deferral Account and Company Account balance in a single lump sum payment. Such payment shall be made within seventy-five (75) days of the date the Participant’s Termination of Employment occurs; provided, however, that with respect to a Participant who is a Specified Employee as of the date of his or her Termination of Employment for reasons other than death, payment of any portion of his or her Deferral or Company Account (or any subaccount(s) thereof) pursuant to the provisions of this Section 6.4 will be delayed until the first business day of the seventh (7th) month following the date such Termination of Employment occurs.
6.5Change in Control.
Notwithstanding the foregoing provisions of this Article VI, upon the occurrence of a Change in Control, a Participant who has a valid change in control election(s) in effect shall automatically receive the balance of his or her Deferral Account and Company Account related to that election, in cash, in a single lump sum payment. Such lump sum payment shall be paid within forty-five (45) business days after the Change in Control occurs. If such Participant dies after such Change in Control event occurs, but before receiving such payment, it shall be made to his or her Beneficiary.
6.6Form of Payment.
(a)Installments. Subject to the limitations set forth in Article VI, distributions will be made in annual (or quarterly, if the election was made prior to October 1, 2008) installments, as elected by the Participant, for up to, and including, ten (10) years (fifteen (15) years for an election made prior to October 1, 2008). The initial installment of an annual or quarterly payment stream will begin as of the first business day of the January (a) next following the Participant’s date of Retirement or (b) of the Specific Future Year, as the case may be, in accordance with the provisions of set forth in Section 6.1. Subsequent annual or quarterly payments will be as of the first business day of each subsequent calendar year or quarter of the installment period.
Each installment will be equal to a fraction of the Account balance (or subaccount(s) thereof) as of the date the installment is paid, with the numerator of the fraction being “1” and the denominator being the number of payments remaining in the payment schedule.
Notwithstanding the foregoing provisions of this paragraph (a), if a Participant dies before receiving payment of the entire balance of his or her Deferral and Company Accounts under the provisions of this Section, the remaining value of such Accounts shall be payable to his or her Beneficiary in accordance with the provisions of Section 6.9.
(b)Lump sum. A Participant may elect distribution in the form of a single lump sum payment. Except for Specified Employees, distribution shall be made as of the first business day of the January (a) next following the Participant’s date of Retirement or (b) of the Specific Future Year, as the case may be, in accordance with the provisions of set forth in Section 6.1.


Proprietary
Page | 16



(c)Distributions to a Participant made pursuant to Section 6.1 will occur pursuant to the Participant’s payment elections at the time he or she submits the applicable Deferred Compensation Election. A Participant may choose different forms of payment with respect to each Deferred Compensation Election. Company Contributions, adjusted pursuant to Article V, shall be distributed pursuant to the Participant’s form of payment election made with respect to his or her Company Contributions for that year. If the Participant has not made an election with respect to his or her Company Contributions, the portion of his or her Company Account attributable to such Company contributions will be distributed in accordance with his or her form of payment election with respect to his or her Base Salary Deferral, Annual Cash Incentive or Commissions Deferrals for that year, if any, in that order; otherwise payment will be made in a lump sum payment. In the absence of an election of the form of payment by a Participant on a Deferred Compensation Election, the portion of the Participant’s Account deferred pursuant to that Deferred Compensation Election, adjusted pursuant to the provisions of Article V, shall be paid in a single lump sum.
(d)A Participant shall not change his or her form of payment election, except as otherwise provided in Section 6.7 below.
6.7Change of Distribution Election.
(a)In accordance with such procedures as the Plan Administrator may prescribe, a Participant may elect to change his or her Specific Future Year election under Section 6.1(a)(ii) with respect to a portion of his or her Deferral Account (or an Interim Distribution date election applicable to a portion of his or her Deferral Account or Company Account made pursuant to the provisions of the Plan as in effect prior to December 31, 2008) to a later Specific Future Year (or, if applicable, a later Interim Distribution date) by duly completing, executing and filing with the Plan Administrator a new Specific Future Year election (or Interim Distribution date election) applicable to such Deferrals, subject to the following limitations:
i.such election must be made at least twelve (12) months prior to the Specific Future Year (or Interim Distribution date) then in effect with respect to that portion of his or her Deferral or Company Account (or subaccount(s) thereof), and such election will not become effective until at least twelve (12) months after the date on which the election is made; and
ii.the new Specific Future Year (or Interim Distribution date) shall be a calendar year that is not less than five (5) years from the Specific Future Year (or Interim Distribution date) then in effect.
Notwithstanding the foregoing, effective for election changes made on or after January 1, 2021, a Participant may elect to delay his or her distribution from an elected Specific Future Year to a new Specific Future Year that is at least five (5) years from the Specific Future Year then in effect, provided the election is made in accordance with the foregoing provisions of this Section 6.7(a). A Participant may elect to delay his or her distribution from an elected Specific Future Year (or Interim Distribution date) pursuant to this Section 6.7(a) more than once, provided that all such elections comply with the provisions of this Section 6.7(a).
(b)In accordance with such procedures as the Plan Administrator may prescribe, a Participant may elect to delay the payment of a portion of his or her Deferral or Company Account (or any subaccount(s) thereof) scheduled to be paid at his or her Retirement to his or her Retirement plus five (5) calendar years by duly completing, executing and filing with the Plan Administrator a new Retirement election applicable to such deferrals; provided,
Proprietary
Page | 17



however such election must be made at least twelve (12) months prior to Retirement and shall not become effective until at least twelve (12) months after the date on which the election is made.
(c)In accordance with such procedures as the Plan Administrator may prescribe, a Participant may elect to change the form of payment election under Section 6.6 applicable to his or her distribution under Section 6.1(a)(i) or (ii) by duly completing, executing and filing with the Plan Administrator a new form of payment election applicable to such deferrals, subject to the following limitations:
i.such election must be made at least twelve (12) months prior to the Specific Future Year then in effect with respect to that portion of his or her Deferral or Company Account (or subaccount(s) thereof), and such election will not become effective until at least twelve (12) months after the date on which the election is made; and
ii.the distribution of that portion of his or her Deferral or Company Account (or subaccount(s) thereof) shall be deferred for five (5) years from the date such amount would otherwise have been paid absent this election.
Notwithstanding the foregoing or any provision of any Appendix to this Plan, effective for election changes made on or after January 1, 2021, in no case may a Participant elect to change the form of payment election to an installment form that includes payments for a period in excess of ten (10) years.
(d)It is the Company’s intent that the provisions of Sections 6.7(a), (b) and (c) comply with the subsequent election provisions in Section 409A(a)(4)(C) of the Code, related regulations and other applicable guidance, and this Section 6.7 shall be interpreted accordingly. The Plan Administrator may impose additional restrictions or conditions on a Participant’s ability to make an election pursuant to this Section 6.7. For avoidance of doubt, a Participant may not elect to alter the distribution of any portion of his or her Deferral or Company Accounts (or any subaccount(s) thereof) from Retirement to a Specific Future Year or, except as provided in paragraph (a) above, from a Specific Future Year to Retirement.
6.8Account Valuation upon a Distribution.
With respect to a distribution made pursuant to this Article, the Valuation Date of a Participant’s Account shall be the day immediately preceding the Distribution Date.
6.9Designation of Beneficiary.
Each Participant shall have the right to designate a Beneficiary to receive payment of his or her Account in the event of death. Any such designation may be changed at any time by executing and submitting (either by hand or electronic submission) a new designation on a form prescribed by the Plan Administrator.
6.10Unclaimed Account.
If the Plan Administrator is unable to locate a Participant or Beneficiary to whom an Account is payable, such Account may be forfeited to the Company upon the Plan Administrator’s determination. Notwithstanding the foregoing, if subsequent to any such forfeiture, the Participant or Beneficiary to whom such Account is payable makes a valid claim, such forfeited Account shall be restored to the Plan and paid by the Company.
6.11Hardship Withdrawals.
A Participant may apply in writing to the Plan Administrator for, and the Plan Administrator may
Proprietary
Page | 18



grant, a hardship withdrawal of all or any part of a Participant’s Deferral or Company Account if the Plan Administrator, in its sole discretion, determines that the Participant has incurred an Unforeseeable Emergency, as defined in the Universal 409A Definition Document.

The Plan Administrator shall determine whether an event qualifies as a hardship within this Section, in its sole and absolute discretion. Such request shall be made in a time and manner determined by the Plan Administrator. The payment made from a Participant’s Deferral or Company Account (or any subaccount(s) thereof) pursuant to the provisions of this Section 6.11 shall not be in excess of the amount necessary to meet such financial hardship of the Participant, including amounts necessary to pay any federal, state or local income taxes with respect to the payment and shall not be available unless all other financial resources of the Participant have been exhausted. Payment shall be made in the month following the date the Plan Administrator determines that the Participant has incurred an unforeseeable severe financial hardship and grants the right to a withdrawal pursuant to this Section 6.11.
6.12Distribution of Grandfathered Deferral Account and the Grandfathered Company Account.
Notwithstanding the foregoing provisions of this Article VI, the distribution from a Participant’s Grandfathered Deferral Account and Grandfathered Company Account (or subaccount(s)) shall be made pursuant to the provisions of the Plan as set forth on October 3, 2004, without regard to any amendments after October 3, 2004 which would constitute a material modification for Section 409A of the Code, as modified in Appendix A attached hereto.

Proprietary
Page | 19




ARTICLE VI — ADMINISTRATION
7.1Plan Administrator.
The Plan shall be administered by the Deferred Compensation Plans Committee, appointed by the Committee as Plan Administrator. The Plan Administrator shall be responsible for the general operation and administration of the Plan and for carrying out the provisions thereof. The Plan Administrator may delegate to others certain aspects of the management and operations of the Plan including the employment of advisors and the delegation of ministerial duties to qualified individuals, provided that such delegation is in writing.
7.2General Powers of Administration.
The Plan Administrator shall have the exclusive responsibility and complete discretionary authority to control the operation, management and administration of the Plan, with all powers necessary to enable it properly to carry out such responsibilities, including, but not limited to, the power to interpret the Plan and any related documents, to establish procedures for making any elections called for under the Plan, to make factual determinations regarding any and all matters arising hereunder, including, but not limited to, the right to determine eligibility for benefits, the right to construe the terms of the Plan, the right to remedy possible ambiguities, inequities, inconsistencies or omissions, and the right to resolve all interpretive, equitable or other questions arising under the Plan. The decisions of the Plan Administrator or such other party as is authorized under the terms of any grantor trust on all matters shall be final, binding and conclusive on all persons to the extent permitted by law. The Plan Administrator shall have all powers necessary or appropriate to enable it to carry out its administrative duties. Not in limitation, but in application of the foregoing, the Plan Administrator shall have the duty and power to interpret the Plan and determine all questions that may raise hereunder as to the status and rights of Employees, Participants, Beneficiaries, and any other person. The Plan Administrator may exercise the powers hereby granted in its sole and absolute discretion. No member of the Deferred Compensation Plans Committee shall be personally liable for any actions taken by the Plan Administrator unless the member’s action involves gross negligence or willful misconduct.
7.3Costs of Administration.
The costs of administering the Plan shall be borne by the Company unless and until the Participant receives written notice of the imposition of such administrative costs; with such costs to begin with the next Plan Year and none may be assessed retroactively for prior Plan Years.
Such costs shall be charged against the Participant’s Account and shall be uniform or proportional for all Participants. Such costs shall not exceed the standard rates for similarly designed nonqualified plans under administration by high quality third party administrators at the time such costs are initially imposed and thereafter.
7.4Indemnification.
The Company shall indemnify each director, officer or employee of the Company or any Affiliate and each member of the Committee and Deferred Compensation Plans Committee, including any subcommittee or delegates thereof, against any and all claims, losses, damages, expenses, including attorney’s fees, incurred by them, and any liability, including any amounts paid in settlement with their approval, arising from their action or failure to act, except when the same is judicially determined to be attributable to their gross negligence or willful misconduct, as a result of the fact that he or she is or was serving the Plan in any capacity at the request of the Company.

Proprietary
Page | 20



7.5409A Compliance.
With respect to the accounts subject to Section 409A of the Code, the Plan is intended to comply with the requirements of Section 409A of the Code and the provisions hereof shall be interpreted in a manner that satisfies the requirements of Section 409A of the Code and the regulations thereunder, and the Plan shall be operated accordingly. Regardless of, and superseding any other provision of the Plan to the contrary, if any provision of the Plan would otherwise frustrate or conflict with this intent, the provision will be interpreted and deemed amended so as to avoid this conflict.
















































Proprietary
Page | 21




ARTICLE VIII – CLAIMS PROCEDURE
8.1Claims.
A person who believes that he or she is being denied a benefit to which he or she is entitled under the Plan (hereinafter referred to as a “Claimant”) may file a written request for such benefit with the Plan Administrator, setting forth his or her claim. The request must be addressed to the Senior Vice President, Compensation and Benefits, at the Company’s then principal place of business.
8.2Claim Decision.
Upon receipt of a claim, the Plan Administrator or its delegate shall review and determine the claim within ninety (90) days. If the Plan Administrator determines that additional time is needed to review the claim, the Plan Administrator will provide the Claimant with a notice of the extension before the end of the initial ninety (90)-day period. The notice of extension will provide the date by which the Plan Administrator expects to make a decision.
If the claim is denied in whole or in part, the Plan Administrator shall notify the Claimant in writing of the following:
(a)The reason or reasons for such denial;
(b)The pertinent provisions of the Plan;
(c)Appropriate information as to the steps to be taken if the Claimant wishes to submit the claim for review; and
(d)The time limits for requesting a review under this Section.
8.3Request for Review/Appeal.
Within sixty (60) days after the receipt by the Claimant of the initial written notice of a denial, the Claimant may request in writing that the initial determination be reviewed. Such request must be addressed to the Senior Vice President, Compensation and Benefits, at the Company’s then principal place of business. The Claimant or his or her duly authorized representative may, but need not, submit issues and comments in writing for consideration by the Appeals Committee, a subcommittee of the Deferred Compensation Plans Committee. If the Claimant does not request a review of the initial determination within such sixty (60)-day period, he or she shall be barred and stopped from challenging the Plan Administrator’s initial determination.
8.4Review of Decision.
Within sixty (60) days after the Plan Administrator’s receipt of a request for review, the Appeals Committee of the Plan Administrator will review the Plan Administrator’s initial determination. After considering all materials presented by the Claimant, the Appeals Committee will render a written decision, setting forth the reasons for the decision and containing references to the pertinent provisions of the Plan. If the Appeals Committee requires an extension of the sixty (60)-day time period, the Appeals Committee will so notify the Claimant and will render the decision as soon as possible, but no later than one hundred twenty (120) days after receipt of the request for review.
8.5Time Limit for Bringing Legal Action.
Any legal action by the Claimant must be brought within ninety (90) days following the date of the decision on the final review under Section 8.4 above.
Proprietary
Page | 22



ARTICLE IX – MISCELLANEOUS
9.1Not Contract of Employment.
The adoption and maintenance of the Plan shall not be deemed to be a contract between the Company or an Affiliate and any person and shall not be consideration for the employment of any person. Nothing herein contained shall be deemed to give any person the right to be retained in the employ of the Company or an Affiliate or to restrict the right of the Company or an Affiliate to discharge any person at any time nor shall the Plan be deemed to give the Company or an Affiliate the right to require any person to remain in the employ of the Company or an Affiliate or to restrict any person’s right to terminate his or her employment at any time.
9.2Non-Assignability of Benefits.
No Participant, Beneficiary or distributees of benefits under the Plan shall have any power or right to transfer, assign, anticipate, hypothecate or otherwise encumber any part or all of the amounts payable hereunder, which are expressly declared to be unassignable and nontransferable. Any such attempted assignment or transfer shall be void. No amount payable hereunder shall, prior to actual payment thereof, be subject to seizure by any creditor of any such Participant, Beneficiary or other distributees for the payment of any debt judgment or other obligation, by a proceeding at law or in equity, nor transferable by operation of law in the event of the bankruptcy, insolvency or death of such Participant, Beneficiary or other distributee hereunder.
9.3Withholding and Deduction and Taxes.
All deferrals and payments provided for hereunder shall be subject to applicable withholding and other deductions as shall be required of the Company under any applicable local, state or federal law. The Company may require that the Participant or Beneficiary making a deferral or receiving payments pay to the Company the amount of any federal, state or local taxes, if any, that the Company or any Affiliate is required to withhold with respect to such deferrals or payments or the Company or any Affiliate may deduct from other wages paid by the Company or any Affiliate the amount of any withholding taxes due with respect to such deferrals or payments. A Participant or Beneficiary shall be solely responsible for any tax consequences related to deferrals or payments made under the Plan. The Company shall have no obligation to make any payment under the Plan until the Company’s or any Affiliate’s tax withholding obligations have been satisfied by the Participant or Beneficiary.
9.4Amendment and Termination.
The Committee or its delegate may from time to time, in its discretion, amend, in whole or in part, any or all of the provisions of the Plan; provided, however, that no amendment may be made that would impair the rights of a Participant with respect to amounts already allocated to his or her Account without the Participant’s consent. To the extent consistent with the rules relating to plan terminations and liquidations in Treas. Reg. Section 1.409A-3(j)(4)(ix) or otherwise consistent with Section 409A of the Code, the Committee, in its sole discretion, may terminate the Plan and any related Deferred Compensation Election at any time and in that event the Committee may provide that, without the prior written consent of Participants, the Participants’ Accounts shall be distributed in a single cash lump sum upon termination of the Plan. Unless so distributed in accordance with the preceding sentence, in the event of a Plan termination, the Plan Administrator shall continue to maintain the Participants’ Accounts until distributed pursuant to the terms of the Plan and Participants shall remain one hundred percent (100%) vested in all amounts credited to their Accounts. In the event of a Plan termination, the distribution of a Participant’s Grandfathered Deferral Account and Grandfathered Company Account shall be made pursuant to the provisions of the Plan as set forth on October 3, 2004, without regard to any amendments after October 3,
Proprietary
Page | 23



2004 which would constitute a material modification for Section 409A of the Code, as modified in Appendix A attached hereto.
9.5Compliance with Securities and Other Laws.
Notwithstanding any Plan provision to the contrary, the Committee may at any time impose such restrictions on the Plan and participation therein, including limiting the amount of any deferral or the timing thereof, as the Committee may deem advisable from time to time in order to comply or preserve compliance with any applicable laws, including any applicable state and federal securities laws and exemptions from registration available thereunder.
9.6No Trust Created.
Nothing contained in the Plan and no action taken pursuant to its provisions by the Company or any person, shall create, nor be construed to create, a trust of any kind or a fiduciary relationship between the Company or an Affiliate and the Participant, Beneficiary, or any other person.
9.7Unsecured General Creditor Status of Employee.
The payments to the Participant, Beneficiary or any other distributees hereunder shall be made from assets which shall continue, for all purposes, to be a part of the general, unrestricted assets of the Company. No person shall have or acquire any interest in any such assets by virtue of the provisions of the Plan. The Company’s obligation hereunder shall be an unfunded and unsecured promise to pay money in the future. To the extent that the Participant, Beneficiary or other distributees acquire a right to receive payments from the Company under the provisions hereof, such right shall be no greater than the right of any unsecured general creditor of the Company. No such person shall have or acquire any legal or equitable right, interest or claim in or to any property or assets of the Company.
In the event that, in its discretion, the Company purchases an insurance policy, or policies, insuring the life of the Employee, or any other property, to allow the Company to recover the cost of providing the benefits, in whole, or in part, hereunder, neither the Participant, Beneficiary or other distributee shall have or acquire any rights whatsoever therein or in the proceeds therefrom. The Company shall be the sole owner and beneficiary of any such policy or policies and, as such, shall possess and, may exercise all incidents of ownership therein. No such policy, policies or other property shall be held in any trust for a Participant, Beneficiary or other distributee or held as collateral security for any obligation of the Company hereunder. An Employee’s participation in the underwriting or other steps necessary to acquire such policy or policies may be required by the Company and, if required, shall not be a suggestion of any beneficial interest in such policy or policies to a Participant.
9.8Limitation.
A Participant and his or her Beneficiary shall assume all risk in connection with any decrease in value of his or her Account, and neither the Company nor the Committee or the Plan Administrator shall be liable or responsible therefor.
9.9Payment to Minors and Incompetents.
If any Participant, spouse, or Beneficiary entitled to receive any benefits hereunder is a minor or is deemed by the Plan Administrator or is adjudicated to be legally incapable of giving a valid receipt and discharge for such benefits, the benefits will be paid to the person or entity as the Plan Administrator determines has been appointed or established to receive such payment on behalf of such person. Such payment shall, to the extent made, be deemed a complete discharge of any payment obligation under the Plan.
Proprietary
Page | 24




9.10Acceleration of or Delay in Payments.
The Plan Administrator, in its sole and absolute discretion, may elect to accelerate the time or form of payment of a benefit owed to the Participant hereunder, provided such acceleration is permitted under Treas. Reg. Section 1.409A-3(j)(4) and any subsequent guidance. The Plan Administrator may also, in its sole and absolute discretion, delay the time for payment of a benefit owed to the Participant hereunder, to the extent permitted under Treas. Reg. Section 1.409A- 2(b)(7) and any subsequent guidance.
9.11Severability.
If any provision of the Plan shall be held illegal or invalid for any reason, said illegality or invalidity shall not affect the remaining provisions hereof; instead, each provision shall be fully severable and the Plan shall be construed and enforced as if said illegal or invalid provision had never been included herein.
9.12Governing Laws.
All provisions of the Plan shall be construed in accordance with the laws of Rhode Island, except to the extent preempted by federal law.
9.13Binding Effect.
The terms of the Plan shall be binding on each Participant and his or her heirs and legal representatives and on the Company and its successors and assigns.
Proprietary
Page | 25



APPENDIX A – PROVISIONS APPLICABLE TO A PARTICIPANT’S GRANDFATHERED DEFERRAL ACCOUNT AND GRANDFATHERED COMPANY ACCOUNT
This Appendix A constitutes an integral part of the Plan and is applicable with respect to the Grandfathered Deferral Account and the Grandfathered Company Account of those individuals who were Participants in the Plan on December 31, 2004. The Grandfathered Deferral Account and Grandfathered Company Account are subject to all the terms and conditions of the Plan as set forth on October 3, 2004, without regard to any Plan amendments after October 3, 2004 which would constitute a material modification for Section 409A of the Code, as modified below. Section references in this Appendix A correspond to appropriate Sections of the Plan as set forth on October 3, 2004.
Article I – Definitions
Section 2.15. Company Account means the Participant’s Grandfathered Company Account as set forth in Section 2.28.
Section 2.19. Deferral Account means the Participant’s Grandfathered Deferral Account as set forth in Section 2.29 of the foregoing provisions of the Plan.
For purposes of a Participant’s Grandfathered Deferral Account and Grandfathered Company Account, the term Change in Control shall have the meaning set forth in the 1997 Incentive Compensation Plan as in effect on October 3, 2004.
Article IV – Deferrals and Company Contributions
The provisions of Section 4.03 shall continue to apply to a Participant’s Grandfathered Deferral Account, Grandfathered Company Account and amounts transferred from the Melville Deferred Compensation Plan that were vested on or earlier than December 31, 2004.
Article V – Maintenance of Accounts
The provisions of Section V as set forth in the foregoing provisions of the Plan as amended and restated effective as of December 31, 2008 shall be applicable to a Participant’s Grandfathered Deferral Account and Grandfathered Company Account on and after January 1, 2009.
Article VI – Payment of Benefit
For purposes of this Article VI – Payment of Benefit, the term “termination of employment” or any other similar language means with respect to a Participant the complete cessation of providing service to the Company and any Affiliate as an employee.
6.2.Form of Payment
Effective on or after October 1, 2008, a Participant shall not elect installments in excess of ten (10) years or quarterly installments.
6.3.Disability Distributions
A Participant shall be entitled to distribution under this Section if such Participant becomes “Disabled” as such term is defined under Section 6.03 of the Plan.
6.6.Change of Distribution Election
On and after January 1, 2009, a change in a Specific Future Year distribution date or an Interim distribution date shall be effective only if the new Specific Future Year distribution date or an Interim
Proprietary
Page | 26



distribution date is not less than five (5) years later then the date in effect prior to the change election.
Notwithstanding the foregoing, the forms of distribution election available to Participants covered by this Appendix A shall be limited to the forms of distribution described in Section 6.6 of the Plan, but in no case may a Participant elect to change the form of payment election to an installment form that includes payments for a period of in excess of ten (10) years
Proprietary
Page | 27



APPENDIX B – PROVISIONS APPLICABLE TO A PARTICIPANT’S ACCOUNT UNDER THE OMNICARE, INC. DEFERRED COMPENSATION PLAN
This Appendix B constitutes an integral part of the Plan and is applicable with respect to a Participant’s Account (“Omnicare Account”) under the Omnicare, Inc. Deferred Compensation Plan, effective January 1, 2017. The Participants’ Omnicare Accounts are subject to all the terms and conditions of the Omnicare Plan as set forth on January 1, 2013. Section references in this Appendix B correspond to appropriate Sections of the Omnicare Plan as set forth on January 1, 2013.
Article 2: Participation
Effective December 31, 2016, there shall be no new Participants in the Plan.
Article 3: Contributions & Deferral Elections
3.1Elections to Defer Compensation.
Effective December 31, 2016 there shall be no new Elections to defer Compensation.
3.2Company Contributions.
Effective December 31, 2016 there shall be no Discretionary Company Contributions or Company Matching Contributions.
3.3Investment Elections.
Effective January 1, 2017, a Participant shall be eligible to designate the investment of his or her Omnicare Account solely in accordance with the Deferral Crediting Options of the CVS Health Corporation Deferred Compensation Plan.
Proprietary
Page | 28




APPENDIX C APPENDIX C – PROVISIONS APPLICABLE TO A PARTICIPANT’S ACCOUNT UNDER THE AETNA SUPPLEMENTAL 401(K) PLAN AND AETNA DEFERRED COMPENSATION PROGRAM
This Appendix C constitutes an integral part of the Plan and is applicable with respect to a Participant’s accounts under the Aetna Supplemental 401(k) Plan and Aetna Deferred Compensation Program (collectively, the “Aetna Accounts”), effective January 1, 2020, which have been merged into the Plan. The Participants’ Aetna Accounts are subject to all the terms and conditions of the Plan except that the Aetna Accounts shall remain subject to the distribution provisions of the Supplemental 401(k) Plan as set forth on January 1, 2009, as amended, and the Deferred Compensation Program as set forth on January 1, 2008, as applicable, and as set forth below:
AETNA SUPPLEMENTAL 401(K) PLAN
Payment of Deferred Amounts
1.Timing of Payment for Participants whose Termination from Service Occurs on or after January 1, 2005.
The vested Account balance of any Participant whose Termination from Service (“separation from service” as defined Code Section 409A) occurs on or after January 1, 2005 shall be paid in a lump sum no later than thirty [30] days after later of (a) the date that is six (6) months following the Participant’s Termination from Service Date; or (b) the January 1 next following the Participant’s Termination from Service Date.
2.Election as to Time of Payment – Prior Participants.
Each Participant who incurred a Termination from Service prior to January 1, 2005 shall have had an opportunity to make an election, on a form and in the manner prescribed by the Company for this purpose, specifying the time at which his or her vested Account balance is to be paid.
Except as otherwise provided in paragraph 3 and 4 below, payment of any such Participant’s vested Account balance shall be made to the Participant in a lump sum as soon as practicable after the Valuation Date on or next following the time specified for payment in the election made by the Participant under this paragraph 2.
In the absence of an election which complies with either paragraph 2 or 3, any such Participant’s vested Account balance shall be paid in a lump sum as soon as practicable after the Valuation Date on or next following the Participant’s Termination from Service.
3.Time of Payment-Certain Prior Participants.
This paragraph 3 applies to Participants who ceased to be Employees prior to October 1, 1996 without having made an election pursuant to paragraph 2 hereof. Payment of the Account balance of any such Participant shall be made in a lump sum at the earlier of the commencement of the Participant’s (i) final distribution from the Aetna 401(k) Plan; or (ii) required minimum distributions following attainment of age 70½, unless the Participant has otherwise elected, prior to termination of employment, to receive payment at a later date.
4.Payment in the Event of Participant’s Death.
Notwithstanding any election that may have been made by a Participant pursuant to paragraph 2 or 3, and notwithstanding the provisions of paragraph 1, any vested Account balance that has not been paid to the Participant as of the date of the Participant’s death shall be paid to the Participant’s Beneficiary in a lump sum on the Valuation Date on or next following the Participant’s death.Acceleration of Payment.
Proprietary
Page | 29



If a Participant experiences an “unforeseeable emergency” as defined in Section 409A, the Participant may submit to the Administrator a written request for a distribution, including such documentation as the Administrator may require. The Administrator shall review the request and make a determination approving or denying the requested distribution. If approved, distribution shall be made on the first business day of the month following the approval and shall be limited to such amount as is reasonably necessary to alleviate the Participant’s emergency need, taking into account other assets available to the Participant to the extent required by Section 409A. In addition, and notwithstanding any other provision of this Plan to the contrary, the Company, in its sole discretion, may accelerate the payment of vested Account balances in any other circumstances permitted under Section 409A.
5.Change of Distribution Election.
The provisions of Section 6.7(c) shall apply to Aetna Accounts.
AETNA DEFERRED COMPENSATION PROGRAM
Payment
1.Payment will begin on the specified date or event elected by the Participant for each year’s deferrals. The form of payment(s) will be made according to the option(s) elected by the Participant for each year’s deferred funds. If the Participant failed to specify the time and form of payment on an election form, payment shall be made in accordance with: (a) if applicable, the time and form specified by the Company in the separate written arrangement providing for the compensation or (b) if not so specified, the time of payment shall be the Participant’s separation from service and the form of payment shall be a single lump sum. Payments are subject to such deductions as may be required in accordance with federal and state tax regulations.
2.Notwithstanding the preceding paragraph, if a Participant is a “Specified Employee” within the meaning of Section 409A at the time of termination of employment, any payment of “deferred compensation” hereunder to which the participant would otherwise be entitled, due to such termination of employment, during the first six months following termination of employment, shall remain in the Participant’s bookkeeping account and be paid in a lump sum on the six-month anniversary of the Specified Employee’s termination of employment date (or, if earlier, death). This requirement shall only apply to the extent required by Section 409A.
3.The payment of “deferred compensation” (within the meaning of Section 409A) under this program may not be accelerated in violation of Section 409A.
4.Unless otherwise noted in the deferral election form, in the event of the Participant’s “disability” i(within the meaning of Section 409A) or death during the deferral period, payment shall be made to the Participant or the Participant’s beneficiary upon such event.
5.In case of an “unforeseeable emergency,” within the meaning of Section 409A, a Participant may submit a request for payment of amounts already deferred to be advanced and/or a deferral election to be canceled, to the extent permitted under Section 409A. The Company shall make the determination of unforeseeable emergency in its sole discretion consistent with the requirements of Section 409A. If approved, payment shall be made on the first day of the month following approval and shall be limited to such amount as is reasonably necessary to alleviate the Participant’s emergency need, taking into account other assets available to the Participant to the extent required by Section 409A.
6.The provisions of Section 6.7(c) shall apply to Aetna Accounts.
Proprietary
Page | 30

EX-10.25 4 exhibit1025-2021.htm EX-10.25 Document

Exhibit 10.25

CVS HEALTH SEVERANCE PLAN FOR
NON-STORE EMPLOYEES
(Amended and Restated as of October 11, 2021)









Proprietary


CVS HEALTH SEVERANCE PLAN
FOR NON-STORE EMPLOYEES
(Amended and Restated as of October 11, 2021)

WHEREAS, CVS Health Corporation (the “Company”) has established the CVS Health Severance Plan for Non-Store Employees (the “Plan”) to provide financial assistance to employees in non-store positions who are involuntarily terminated and are eligible within the terms and conditions of the Plan;

WHEREAS, it is intended that the Plan constitute an employee welfare benefit plan within the scope of Section 3(1) of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”), that the Plan constitute a separation pay plan within the scope of Department of Labor (“DOL”) Regulation Section 2510.3- 2(b), and that all payments made under the Plan be deductible by the Company under Section 162(a) of the Internal Revenue Code of 1986, as amended (the “Code”);

WHEREAS, the benefits provided under the Plan are intended to constitute separation pay within the meaning of Treasury Regulation Section 1.409A-1(b)(9)(iii);

WHEREAS, this document is the official plan document; and

WHEREAS, the Company wishes to make certain amendments to the Plan, effective as of October 11, 2021 (the “Effective Date”);

NOW, THEREFORE, as of the Effective Date, the Company does hereby amend the Plan to provide as follows:
ARTICLE 1
DEFINITIONS

For purposes of the Plan, the following terms, when used with an initial capital letter, shall have the meaning set forth below unless a different meaning is plainly required by the context.

1.1     “Affiliate” shall mean (a) any corporation which is required to be aggregated with the Company under Code Section 414(b), (c), (m), or (o) and (b) any other entity in which the Company has an ownership interest and which the Company designates as an Affiliate for purposes of the Plan.

1.2     Cause” shall refer to a termination of an Eligible Employee’s employment because of the
Eligible Employee’s (a) failure to satisfactorily perform under a performance improvement plan of the Employer; (b) acts of unethical business activity, including but not limited to fraud, misappropriation, embezzlement, dishonesty, harassment, discrimination in violation of Employer policies, or willful or negligent destruction of property of an Employer or an Affiliate; (c) misconduct that could cause damage (monetary, reputational or otherwise) to the Employer, an Affiliate, or any personnel thereof; (d) conviction of or a plea of guilty or nolo contendere to any felony, whether or not any right to appeal has been or may be exercised; (e) negligence of duty; (f) insubordination; or (g) a violation of the Employer’s policy, procedure, or practice.

1.3      Code” shall mean the Internal Revenue Code of 1986, as amended.

1.4      Eligible Employee” shall mean an individual who is employed by the Employer on a regular basis in a non-store position and has been employed by the Employer in any position for a minimum of ninety (90) days prior to the individual’s separation of employment. For purposes of the Plan, distribution warehouse employees, field managers and employees employed by CVS ProCare, Inc. working at Company headquarters, shall be treated as working in a non-store location and therefore not subject to exclusion from eligibility. For purposes of the Plan, individuals in the following categories will not be considered Eligible Employees:

2
Proprietary


(a)individuals who are covered by a collective bargaining agreement, provided welfare benefits were the subject of bargaining, unless the terms of the collective bargaining agreement provide for participation in the Plan;

(b)individuals who are seasonal employees, leased employees, independent contractors, temporary employees, or consultants;


(c)individuals who work for the Employer or an Affiliate in a store location of the Company or an Affiliate, or whose compensation is paid through or according to a store payroll, including but not limited to: pharmacists, store managers, assistant store managers, crew, and pharmacy staff;

(d)individuals employed by MinuteClinic, L.L.C. or by any practitioner-owned entity managed by MinuteClinic, L.L.C.;


(e)the President and CEO of CVS Health Corporation;

(f)individuals employed in Puerto Rico; and

(g)individuals employed outside the United States of America.

The decision of whether an individual falls into one of these categories and whether an individual is employed by an Employer on a regular basis in a non-store position for a minimum of ninety (90) days shall be made by the Employer in its sole discretion. Any individual who is excluded from being considered an Eligible Employee under the Plan shall be excluded from the Plan regardless of the individual’s reclassification by a government agency, including a reclassification by the Internal Revenue Service for tax withholding purposes.

1.5Employer” shall mean CVS Pharmacy, Inc., Caremark Rx, L.L.C. and Aetna Inc. and any current or future Affiliate thereof that does not maintain its own severance plan for employees of that Affiliate.

1.6ERISA” shall mean the Employee Retirement Income Security Act of 1974, as amended.

1.7Exempt Employee” shall mean an Eligible Employee who is paid on a salaried basis for payroll purposes and classified in the sole discretion of the Employer under its normal classification procedures as an exempt employee under the Fair Labor Standards Act.

1.8Involuntary Termination” shall mean an Eligible Employee’s termination of employment with the Employer due to the unilateral action of the Employer, including but not limited to a termination as a result of the elimination of an Eligible Employee’s position due to a reorganization or changes in responsibilities, a reduction in force, or a closing of the business unit in which the Eligible Employee works; provided, however, that such Involuntary Termination constitutes a separation from service under Treasury Regulation Section 1.409A-1(h). Notwithstanding the foregoing, an Eligible Employee will not have an Involuntary Termination if the Eligible Employee: (a) is terminated for Cause, as determined by the Employer in its sole discretion; (b) voluntarily terminates his or her employment at any time or resigns prior to an Involuntary Termination; (c) takes a leave of absence; (d) is administratively terminated for failure to return from a leave of absence upon expiration of his or her leave; (e) terminates employment due to his or her death or disability; (f) transfers to an Affiliate; (g) transfers to a new employer in connection with the sale of an Employer facility; or (h) fails to accept an offer for a job with the Employer that is comparable to the job that he or she is performing for the Employer at the time of the offer. For purposes of Subsection (h) of this Section 1.8, whether a job is considered “comparable” shall be determined in the sole discretion of the Employer, taking into account whether the new job is located 50 or fewer miles from the Eligible Employee’s job at the time of the offer, whether the compensation offered is materially less than the Eligible Employee’s compensation at the time of the offer, and
3
Proprietary


whether the new job will result in a substantial change of duties from the Eligible Employee’s job at the time of the offer. The determination of whether an Eligible Employee’s termination of employment is an Involuntary Termination shall be made in the sole discretion of the Employer. If an Employer deems an Eligible Employee’s termination of employment to be an Involuntary Termination and, Employer later learns of facts and circumstances that, had the Employer known such facts and circumstances at the time of termination, would have resulted in a termination of employment for Cause, the Eligible Employee’s termination shall be deemed as of the date of termination to not have been an Involuntary Termination.

1.9Non-exempt Employee” shall mean an Eligible Employee who is paid on an hourly basis for time worked and classified in the sole discretion of the Employer under its normal classification procedures as a non-exempt employee under the Fair Labor Standards Act.

1.10Plan Administrator” shall mean the Senior Vice President of Human Resources of CVS Pharmacy, Inc., or such other person, designated by the Chief People Officer of the Company to act as the Plan Administrator.

1.11Rehire Date” shall mean the date an Eligible Employee accepts reemployment with any Employer.

1.12Severance Pay” shall mean the pay an Eligible Employee is eligible to receive under Subsection (b) of Section 2.1 of the Plan upon his or her Involuntary Termination.

1.13Severance Period” shall mean the period of time during which an Eligible Employee is eligible to receive Severance Pay

1.14Weekly Rate” shall mean, (a) with respect to an Eligible Employee paid on a salaried basis, an Eligible Employee’s annual base salary (as determined by the Employer), as of the date of the Eligible Employee’s Involuntary Termination, expressed on a weekly basis (as determined in the sole discretion of the Employer), and (b) with respect to an Eligible Employee paid on an hourly basis, the hourly wage rate of the Eligible Employee as of the date of the Eligible Employee’s Involuntary Termination multiplied by the Eligible Employee’s regularly scheduled number of hours of service per week (as determined by the Employer), not in excess of 40 hours. Weekly Rate shall exclude any overtime, incentive, and bonus payments, unless otherwise required by law.

1.15Year of Service” shall mean each full year of service performed by the Eligible Employee for an Employer as reflected in the records of the Employer and as determined as of the Eligible Employee’s date of termination of employment, based on the Employer’s policies and procedures for determining periods of service, and the applicable law.


ARTICLE 2
SEVERANCE PAY AND ELIGIBLE EMPLOYEE BENEFITS

2.1     (a)     Eligibility. Upon his or her Involuntary Termination, an Eligible Employee may, in the discretion of the Plan Administrator, be granted Severance Pay and benefits provided under Subsections (b), (c), and (d) of this Section 2.1, provided the conditions of Section 2.2 are satisfied. The determination of whether Severance Pay is payable under the Plan, and the form and amount of such pay, shall be made in the sole discretion of the Plan Administrator.

(b)Severance Pay. The Severance Pay payable to an Eligible Employee in the event of Involuntary Termination shall be determined by the Plan Administrator in its, his or her sole discretion, using the guidelines set forth in Appendix A for the applicable Eligible Employee’s grade, as determined by the Employer. Notwithstanding such referenced guidelines, the Plan Administrator may increase or decrease (including, to zero) the amount of Severance Pay with respect to any Eligible Employee for reasons it, he or
4
Proprietary


she deems appropriate in its sole discretion at any time, whether before or after payments of Severance Pay have commenced (including, but not limited to, a decrease to take into account any debts owed to an Employer or a decrease if an Eligible Employee fails to satisfactorily perform his or her duties and is not on or has not completed a performance improvement plan at the time of termination of employment), at any time, whether before or after payments of Severance Pay have commenced. A special one-time lump sum payment shall be made with respect to each Eligible Employee who experienced an Involuntary Termination on or after January 1, 2021 and prior to October 11, 2021 equal to the difference, if any, between the Severance Pay payable to such Eligible Employee under Appendix A as in effect upon his or her Involuntary Termination and the Severance Pay that would have been paid to him or her under Appendix A as in effect as of October 11, 2021.

(c)COBRA Assistance. In the event an Eligible Employee who has an Involuntary Termination
(i) is eligible to elect continuation coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985 as amended (“COBRA”) in accordance with the terms of the medical and prescription drug plan and/or dental plan of the Employer and (ii) properly and timely elects such continuation coverage, the Employer may pay for a portion of the cost of COBRA coverage equivalent to the contribution which the Employer makes on behalf of similarly situated active employees under such plan for the appropriate tier of coverage selected and in place immediately prior to the date of the Eligible Employee’s Involuntary Termination (e.g., employee-only, family coverage), for a period determined in the sole discretion of the Plan Administrator, which generally shall be the Severance Period but in any event no longer than eighteen (18) months from the date of the Involuntary Termination. Any COBRA assistance provided under this Subsection (c) shall be paid by the Employer directly to the insurance carrier, if applicable. The portion of the COBRA premium not covered by the COBRA assistance specified in this Subsection (c) must be paid by the Eligible Employee directly to the insurance carrier or service provider that administers COBRA, as applicable, based on the standard rules under the respective plan for payment of COBRA premiums. This Subsection (c) does not provide COBRA assistance in the event the Eligible Employee fails to properly and timely elect COBRA continuation coverage, regardless of whether his or her covered dependents elect COBRA continuation coverage.

(d)     Outplacement Services. Upon an Involuntary Termination, the outplacement services provided to an Eligible Employee shall be provided in the sole discretion of the Plan Administrator based on the guidelines contained in this Subsection (d).

(i)If an Eligible Employee so desires, he or she may be eligible for outplacement services for assistance in obtaining new employment, provided through a vendor selected by the Employer, with the Employer directly providing payment to such vendor. The provision of outplacement services is contingent upon the Eligible Employee’s cooperation with the outplacement service vendor, upon the active efforts of the Eligible Employee to locate a new position, and upon the Eligible Employee initiating outplacement services during the Severance Period.

(ii)Subject to the requirements of Paragraph (i) of this Subsection (d), outplacement services shall be offered for a period of time determined in the sole discretion of the Plan Administrator, based on the guidelines set forth in Appendix A for the applicable Eligible Employee’s grade, as determined by the Employer, provided that in no event shall such services extend beyond twelve (12) months following the Involuntary Termination of the Eligible Employee.

(e)Form and Timing of Payment. In the event an Eligible Employee is awarded Severance Pay under the terms of Subsection (a) of this Section 2.1, such Severance Pay shall be paid following an Eligible Employee’s Involuntary Termination (except as provided in Section 2.3, below), as follows: No Severance Pay shall commence (with respect to salary continuation payments) or be paid (with respect to a lump sum) (i) prior to the expiration of the later of a period that is identified in a severance agreement with the Eligible Employee during which he or she may consider the execution of the release of claims form (the “Consideration Period”) or a period ending at least seven (7) days following the execution of the release of claims form (the “Revocation Period”), or (ii) later than sixty (60) days following the date of Eligible Employee’s Involuntary Termination. Severance Pay that is paid in the form of salary continuation shall
5
Proprietary


commence as soon as feasible following expiration of the later of the Consideration Period or the Revocation Period, which generally shall be the first regularly scheduled payroll date following the expiration of the Consideration Period or the Revocation Period, as the case may be, and shall thereafter be paid in substantially equal installments in accordance with the Employer’s regular payroll practice, except as provided in Section 2.3 of the Plan, except that the first installment paid after the expiration of the later of the Consideration Period or the Revocation Period shall include, on a retroactive basis, all installments that would have been paid had they started as soon as administratively feasible after the date of the Eligible Employee’s Involuntary Termination. It is the intent of the Plan that the Severance Period in all cases be measured from the date of the Eligible Employee’s Involuntary Termination. Further, in the Plan Administrator’s sole discretion, Severance Pay may be paid to any Eligible Employees in a single lump sum, in which event Severance Pay shall be paid within the period that satisfies the 409A requirements for short-term deferrals under Section 409A of the Code.

(f)Withholding. Any payment of Severance Pay to an Eligible Employee shall be subject to normal withholding for state and federal income taxes and Social Security taxes.

(g)Death.    Upon the death of the Eligible Employee who had an Involuntary Termination and who has not received all Severance Pay payable under the Plan, the Severance Pay otherwise payable under Section 2.1(b) of the Plan shall be paid in the form of a lump sum to the Eligible Employee’s surviving legal spouse or, if there is no surviving legal spouse, to the Eligible Employee’s estate as soon as practicable, but in no event later than 60 days following death. Any other severance benefits provided under this Section 2.1 (COBRA assistance and outplacement services) shall cease upon the Eligible Employee’s death.

2.2    Conditions on Payment of Severance Pay and Benefits. Payment of the Severance Pay and benefits provided in Section 2.1 of the Plan shall be subject to and conditioned upon the following:

(a)to the extent an Eligible Employee receives notice of a date selected by the Employer (in its sole discretion) on which the Eligible Employee’s Involuntary Termination shall occur (a “Designated Termination Date”), the Eligible Employee must continue to work in a satisfactory manner until his or her Designated Termination Date;

(b)the Eligible Employee must cooperate in transitioning all of the Eligible Employee’s work in consultation with the Eligible Employee’s supervisor or other designated employee;

(c)the Eligible Employee must execute and deliver a severance agreement that includes a release of claims, which agreement shall be in a form specified by the Employer from time to time, which may include restrictive covenants and a waiver as described in Subsection (d) of this Section 2.2) within the time period specified under the terms of the applicable severance offer. Further, in no event will Severance Pay be paid with respect to an Eligible Employee in the event the release of claims form is revoked during the Revocation Period (described in Section 2.1(e) of the Plan); and

(d)the Eligible Employee must waive the right to receive any other severance payment relating to salary continuation or salary replacement the Eligible Employee may otherwise be eligible to receive upon termination of employment under any employment agreement, severance plan, practice, policy or program of the Employer or an Affiliate.

2.3     Maximum Severance Pay. Notwithstanding any other provisions to the contrary, benefits
paid hereunder (a) shall not exceed two times the lesser of (i) the Eligible Employee’s Compensation (as defined in this Section 2.3) during the calendar year immediately preceding the Eligible Employee’s Involuntary Termination or (ii) the maximum amount that may be taken into account under a qualified plan pursuant to Section 401(a)(17) of the Code for the calendar year in which the Eligible Employee’s Involuntary Termination occurs and (b) shall be paid in full within twenty-four (24) months after the date the Eligible Employee’s Involuntary Termination occurs. In the event that any Severance Pay payable to an Eligible Employee would exceed the twenty-four (24) month period provided in the foregoing sentence if the Severance Pay continued to
6
Proprietary


be paid in accordance with the Employer’s regular payroll practice, any Severance Pay that would otherwise exceed the twenty-four (24) month time period will be paid to the Eligible Employee in a lump sum on the last regular payroll date within the twenty-four (24) month period. For purposes of this Section 2.3, “Compensation” shall mean the Eligible Employee’s total annualized compensation, based upon the annual rate of pay for services provided to the Employer for the calendar year preceding the calendar year in which the Eligible Employee’s Involuntary Termination occurs, adjusted for any increase in such preceding calendar year that was expected to continue indefinitely if the Eligible Employee had not had an Involuntary Termination.

2.4     Cessation of Severance Pay Upon Reemployment. If an Eligible Employee who had an Involuntary Termination and who is receiving Severance Pay thereafter accepts reemployment with any Employer during the Severance Period, such Employee’s Severance Pay shall cease on the Rehire Date and any remaining Severance Pay shall be forfeited.

2.5     Cessation of Severance Pay After Commencement of Payments. If an Eligible Employee is deemed to have an Involuntary Termination and begins to receive Severance Pay under the Plan and the Employer or the Plan Administrator becomes aware of facts and circumstances that, had the Employer known same at the time of the Eligible Employee’s termination of employment, would have affected the Employer’s determination as to whether such Employee’s termination was an Involuntary Termination, the Plan Administrator may suspend any future Severance Pay payments to the Eligible Employee while the Employer investigates the facts and circumstances and finalizes such investigation, and, if the Employer determines that the Eligible Employee should have been terminated for Cause, such Eligible Employee’s Severance Pay shall cease as of the suspension date, any remaining Severance Pay shall be forfeited and any Severance Pay that has been paid shall be subject to repayment by the Eligible Employee.

2.6     Impact of Debt on Severance Pay. In the event an Eligible Employee is indebted to the Company or Employer (determined in the sole discretion of the Company or Employer, as applicable), the Plan Administrator reserves the right to reduce, offset, withhold, and/or forfeit the Severance Pay otherwise payable under the Plan.

2.7     Employee Benefits. As of the date of an Eligible Employee’s Involuntary Termination, the Eligible Employee’s active participation in any benefit plan, program, or policy sponsored or subsidized by the Employer shall cease, unless otherwise continued pursuant to the terms of such plan, program or policy.

2.8     Awards. Any award or grant made to the Eligible Employee under any stock option, stock purchase, or stock appreciation rights plan of the Company or Employer shall be administered and interpreted in accordance with the terms of the applicable plan documents.

2.9     Paid Time Off. Any pay for accrued paid time off shall be determined under the terms of the Employer's applicable policies

2.10     Bonuses. Whether any bonuses or other incentive payments are payable to an Eligible Employee shall be determined based on the terms of any applicable bonus or incentive program, plan, or policy.

2.11     Benefits Not Vested. No one under any circumstance is automatically entitled to Severance Pay or benefits described in Section 2.1 of the Plan. Notwithstanding anything in the Plan to the contrary, the Plan Administrator reserves the right, at its, his or her sole discretion, to increase, decrease, or eliminate Severance Pay and benefits under the Plan.

ARTICLE 3
ADMINISTRATION OF THE PLAN

3.1     Control and Administration. Notwithstanding any other provision in the Plan, and to the full extent permitted under ERISA and the Internal Revenue Code, the Plan Administrator shall have the exclusive right, power and final authority, in its, his or her sole and absolute discretion, to administer, apply, construe and
7
Proprietary


interpret the terms of the Plan and all related plan documents and all facts surrounding claims for benefits under the Plan and shall determine all questions arising in the administration, interpretation and application of the Plan, including, but not limited to, those concerning eligibility for benefits. Accordingly, benefits under the Plan shall be paid only if the Plan Administrator decides in its, his or her sole discretion that an Eligible Employee is entitled to benefits, and the Plan Administrator shall decide all questions regarding the form, amount and duration of benefits. The Plan Administrator may consult with attorneys, consultants and other persons for advice, counsel and reports to make determinations under the Plan, and the Plan Administrator may delegate its administrative duties and responsibilities to persons or entities of its choice, in all cases who may be employees of the Company. All determinations of the Plan Administrator shall be conclusive and binding on all parties. The Plan Administrator shall be the named fiduciary of the Plan for purposes of ERISA.


3.2     Claim Procedures.

(a)Procedure for Granting or Denying Claims. An Eligible Employee, or his or her duly authorized representative, may file a claim for payment of benefits under the Plan within 30 days after termination of employment. Such a claim must be made in writing and be delivered to the Plan Administrator, in person or by mail, postage paid. Within 90 days after receipt of such claim, the Plan Administrator shall notify the claimant of the granting or denying, in whole or in part, of such claim, unless special circumstances require an extension of time for processing the claim. In no event may the extension exceed 90 days from the end of the initial 90-day period. If such extension is necessary, the claimant will be given a written notice to this effect prior to the expiration of the initial 90-day period. The Plan Administrator shall have full discretion to deny or grant a claim in whole or in part.

(b)Requirement for Notice of Claim Denial. The Plan Administrator shall provide to every claimant who is denied a claim for benefits a written or electronic notice setting forth in a manner calculated to be understood by the claimant:

(i)The specific reason or reasons for the denial;

(ii)Specific reference to pertinent Plan provisions on which the denial is based;

(iii)A description of any additional material or information necessary for the claimant to perfect the claim and an explanation of why such material is necessary; and

(iv)An explanation of the Plan’s claim review procedures and the time limits applicable to such procedures, including a statement of the claimant’s right to bring a civil action under Section 502(a) of ERISA following an adverse determination on review.

(c)Right to Appeal on Claim Denial. Within 60 days after receipt by the claimant of written or electronic notification of the denial (in whole or in part) of his or her claim, the claimant or his or her duly authorized representative may make a written application to the Plan Administrator, in person or by certified mail, postage prepaid, to be afforded a full and fair review of such denial. The claimant or his or her duly authorized representative may submit written comments, documents, records, and other information relating to the claim for benefits. Moreover, the claimant or his or her duly authorized representative shall be provided, upon request and free of charge, reasonable access to, and copies of, all documents, records, and other information relevant to the claimant’s claim for benefits.

(d)Disposition of Disputed Claims. Upon receipt of a request for review, the Plan Administrator shall make a decision on the claim. The review shall take into account all comments, documents, records, and other information submitted by the claimant relating to the claim, without regard to whether such information was submitted or considered in the initial benefit determination. The decision on review shall be made not later than 60 days after the Plan Administrator's receipt of a request for a review, unless special circumstances require an extension of time for processing, in which case a decision shall be rendered not later than 120 days after receipt of
8
Proprietary


the request for review. If an extension is necessary, the claimant shall be given written notice of the extension prior to the expiration of the initial 60-day period.

The Plan Administrator shall provide the claimant or his or her duly authorized representative with written or electronic notification of the Plan Administrator’s determination on review. In the case of an adverse determination, the notification shall set forth, in a manner calculated to be understood by the claimant, the specific reason or reasons for the decision as well as specific references to the Plan provisions on which the decision was based. The decision shall also include a statement that the claimant is entitled to receive, upon request and free of charge, reasonable access to, and copies of, all documents, records, and other information relevant to the claimant’s claim for benefits. Moreover, the decision shall contain a statement of the claimant’s right to bring an action under Section 502(a) of ERISA.

3.3Conditions to Legal Action. No legal action may be commenced or maintained against the Plan, the Company or any Employer prior to the claimant’s exhaustion of the claims procedures set forth in Section 3.2 of the Plan. In addition, no legal action may be commenced against the Plan more than ninety (90) days after the Plan Administrator’s final claim determination on review pursuant to Section 3.2(d) of the Plan. Any legal action must be conducted in the United States District Court for Rhode Island.

3.4Named Fiduciary. The Plan Administrator of the Plan shall be the Named Fiduciary of the Plan for purposes of ERISA Section 402(a)(1).
ARTICLE 4
MISCELLANEOUS

4.1      Amendment or Termination. The Plan may be amended, terminated, withdrawn or suspended at any time in writing by the Management Planning and Development Committee of the Company or any individual designated by such Committee to take such actions.

4.2      Choice of Law. The validity, interpretation, construction and performance of the obligations created under the Plan shall be governed by ERISA, and to the extent not preempted by federal law, the laws of the State of Rhode Island without regard to its conflicts of law principles.

4.3     Validity. The invalidity or unenforceability of any provision of the Plan shall not affect the validity or enforceability of any other provision of the Plan, which shall remain in full force and effect.

4.4     Plan Exclusive Source of Rights. The Plan contains all of the terms and conditions with respect to the benefits provided hereunder, and no employee or former employee of the Company or any Employer may rely on any other communication or representation, whether oral or written, of the Company or any Employer or any of its subsidiaries, or any officer or employee thereof, as creating any right or obligation not expressly provided by the Plan.

4.5     Non-assignability. No benefit which shall be payable under the Plan to any Eligible Employee shall be subject in any manner to anticipation, alienation, sale, transfer, assignment, pledge, encumbrance, or charge (except as required by law), and any attempt to anticipate, alienate, sell, transfer, assign, pledge, encumber, or charge a benefit shall be null and void. No benefit shall in any manner be liable for, or subject to, the debts, contracts, liabilities, engagements, or torts of any Eligible Employee. No benefit shall be subject to legal attachment or legal process for, or against, the Eligible Employee and the same shall not be recognized under the Plan. Notwithstanding the preceding sentence, the Employer retains the discretion, in accordance with federal and/or state laws, to reduce the amount of benefits payable under the Plan to any Eligible Employee to recover any amounts that the Eligible Employee owes to the Employer.

4.6     No Employment Rights. The Plan shall not give any Eligible Employee any right or claim except to the extent that the right is specifically provided under the terms of the Plan. The establishment of the Plan shall not be construed (a) to give any Eligible Employee a right to continue in the employ of the Employer
9
Proprietary


or (b) to interfere with the right of the Employer to terminate the employment of any Eligible Employee at any time.

4.7     Headings. Article and section headings are for convenience only and the language of the Plan itself will be controlling.

4.8     Gender and Numbers. Masculine pronouns include the feminine as well as the neuter genders, and the singular shall include the plural, unless indicated otherwise by the context.

4.9     Code Section 409A. The benefits provided under the terms of the Plan are intended to fall
within the short-term deferral exception, the separation pay exception or another exception to the application of Section 409A of the Code and the applicable guidance issued thereunder. In furtherance of this intent, the Plan shall be interpreted, operated and administered in a manner consistent with this intention. To the extent the benefits provided under the Plan become subject to Code Section 409A and applicable guidance issued thereunder, the Plan shall be construed, and benefits paid hereunder, as necessary to comply with Section 409A of the Code and such guidance. Further, to the extent that an Eligible Employee becomes entitled to receive Severance Pay under the terms of the Plan, and, at the time of the Eligible Employee’s Involuntary Termination, he or she is a “specified employee” within the meaning of Treasury Regulation Section 1.409A- 1(i), any portion of Severance Pay payable to such Eligible Employee that is subject to Code Section 409A and applicable guidance thereunder shall be delayed until the date that is the earlier of (i) the Eligible Employee’s death or (ii) six months following the date of the Eligible Employee’s Involuntary Termination, at which time the payments that were delayed for such six month period shall be paid in a lump sum on the date of the next occurring regular payroll date of the Employer, and any remaining payments shall be paid according to the original schedule provided herein. In addition, each payment of a salary continuation stream of installment payments hereunder shall be a separate payment for purposes of Section 409A of the Code.
4.10     Funding. The Plan is not funded, and Severance Pay and benefits under the Plan are paid from the general assets of the Employer.
4.11     Plan Year. The Plan’s records shall be maintained on the basis of the calendar year.
IN WITNESS WHEREOF, the Management Planning and Development Committee of the Company, or its duly authorized delegate, has amended the Plan as of the Effective Date pursuant to the execution hereof on its behalf by a duly authorized officer on October 11, 2021.

CVS HEALTH CORPORATION
By: /s/ Laurie P. Havanec
Date: October, 26, 2021Title:EVP and Chief People Officer













10
Proprietary


Appendix A
Amount of Severance Pay and Outplacement
Services, effective as of October 11, 2021

Severance Pay is the Weekly Rate payable for the number of weeks listed below, determined by Grade and Years of Service (YOS)
 
 
Tier 1
 
 
Tier 2
 
 
Tier 3
 
 
Tier 4
 
 
Executive Tier 1
 
 
Executive Tier 2
Grades 101, 102, 103, 104, 105, 106, 550, 551, 552, 652, 752
Grades 107, 108, 201, 202, 203, 301, 302, 405, 406, 407, 408, 553, 554, 653, 753, 654, 754
Grades 109, 110, 111, 204, 205, 303, 304, 409, 410, 411, 555, 556, 557, 558, 655, 656, 657, 658, 755, 756, 757, 758
Grades 112, 206, 305, 412, 559, 560, 659, 759
Grades 36 A-Z, 70G
Grades 38 A-Z, 39 A-Z, 71G, 72G
Full
YOS
Number of Weeks
Number of Weeks
 
Number of Weeks
Number of Weeks
Number of Weeks
Number of Weeks
0
2
4
13
26
52
52
1
4
6
13
26
52
*52 or 78
2
6
8
13
26
52
78
3
8
10
13
26
52
78
4
10
12
13
26
52
78
5
12
14
14
26
52
78
6
13
16
16
26
52
78
7
13
18
18
26
52
78
8
13
20
20
26
52
78
9
13
20
20
26
52
78
10
13
20
20
26
52
78
11
13
20
21
26
52
78
12
13
20
22
26
52
78
13
13
20
23
26
52
78
14
14
20
24
26
52
78
15
15
20
25
28
52
78
16
16
21
26
29
52
78
17
17
22
26
30
52
78
18
18
23
26
31
52
78
19
19
24
26
32
52
78
20
20
25
26
33
52
78
21
21
26
26
34
52
78
22
22
26
26
35
52
78
23
23
26
26
36
52
78
24
24
26
26
37
52
78
25
25
26
26
38
52
78
26
26
26
27
39
52
78
27
26
26
28
39
52
78
28
26
26
29
39
52
78
11
Proprietary


29
26
26
30
39
52
78

 
 
Tier 1
 
 
Tier 2
 
 
Tier 3
 
 
Tier 4
 
 
Executive Tier 1
 
 
Executive Tier 2

Grades 101, 102, 103, 104, 105, 106, 550, 551, 552, 652, 752
Grades 107, 108, 201, 202, 203, 301, 302, 405, 406, 407, 408, 553, 554, 653, 753, 654, 754
Grades 109, 110, 111, 204, 205, 303, 304, 409, 410, 411, 555, 556, 557, 558, 655, 656, 657, 658, 755, 756, 757, 758
Grades 112, 206, 305, 412, 559, 560, 659, 759
Grades 36 A-Z, 70G
Grades 38 A-Z, 39 A-Z, 71G, 72G
Full YOS
Number of Weeks
Number of Weeks
Number of Weeks
Number of Weeks
Number of Weeks
Number of Weeks
30
26
26
31
39
52
78
31
26
26
32
39
52
78
32
26
26
33
39
52
78
33
26
26
34
39
52
78
34
26
26
35
39
52
78
35
26
26
36
39
52
78
36+
26
26
39
39
52
78
 
  6-Week Virtual
Outplacement
 
3-Month Virtual
Outplacement
 
3-Month Professional Outplacement
3-Month
Professional
Outplacement
6-Month
Executive
Outplacement
6-Month
Executive
Outplacement

* Under 18 months of service receives 52 weeks
    
12
Proprietary
EX-10.55 5 exhibit1055-2021.htm EX-10.55 Document

Exhibit 10.55
cvshealthlogo1.jpg


CVS HEALTH CORPORATION
NONQUALIFIED STOCK OPTION AGREEMENT
GRANT DATE: [MERGED FIELD]

1.     GRANT OF AWARD. Pursuant and subject to the provisions of the [MERGED FIELD] of CVS Health Corporation (the “Plan”), on the date set forth above (the “Grant Date”), CVS Health Corporation (the ”Company”) has granted and hereby evidences the Grant to the person named below (the “Participant”), subject to the terms and conditions set forth or incorporated in this Nonqualified Stock Option Agreement (“Agreement”), the right, and option, to purchase from the Company the aggregate number of shares of Common Stock ($.01 par value) of the Company (“Shares”) set forth below, at the purchase price indicated below (the “Option”), such Option to be exercised as hereinafter provided. The Plan is hereby made a part hereof and Participant agrees to be bound by all the provisions of the Plan. Capitalized terms not otherwise defined herein shall have the meaning assigned to such term(s) in the Plan. The Option is a nonqualified option as defined in the Plan.

Participant:[MERGED FIELD]
Employee ID:[MERGED FIELD]
Shares:[MERGED FIELD]
Option Price:[MERGED FIELD]

2.    TERM OF OPTION. The term of this Option shall be for a period of ten (10) years from the Grant Date, subject to the earlier termination of the Option, as set forth in the Plan and in this Agreement. No portion of the Option shall be exercisable after the term of the Option.

3.    EXERCISE OF OPTION. (a)    The Option, subject to the provisions of the Plan, shall be exercised by submitting a request to exercise to the Company’s stock option administrator, in accordance with the Company’s current exercise policies and procedures, specifying the number of Shares to be purchased, which number may not be less than one hundred (100) Shares (unless the number of Shares purchased is the total balance which is then exercisable). An exercise by Participant of all or part of this Option shall be effected through the Company’s “cashless exercise” procedures. Otherwise, at the time of exercise, Participant shall tender to the Company cash or cash equivalent for the aggregate option price of the Shares Participant has elected to purchase or certificates for Shares of Common Stock of the Company owned by Participant for at least six (6) months with a fair market value at least equal to the aggregate option price of the Shares Participant has elected to purchase, or a combination of the foregoing.

    (b)    Prior to its expiration or termination and except as otherwise provided herein, the Option will become vested in accordance with the vesting schedule set forth below, each date on which vesting occurs a “Vesting Date”, and any vested Option will be exercisable by Participant prior to the expiration of its term so long as Participant has maintained continuous employment with the Company or a subsidiary of the Company from the Grant Date through the exercise date:

(i)    25% of the Option shall vest on the 1st anniversary of the Grant Date.
(ii)    25% of the Option shall vest on the 2nd anniversary of the Grant Date.
(iii)    25% of the Option shall vest on the 3rd anniversary of the Grant Date.
(iv)    25% of the Option shall vest on the 4th anniversary of the Grant Date.




1





4.    TAXES. Upon a cashless exercise of the Option the Company shall withhold from the proceeds of the exercise of the Option any required taxes. If the Option is exercised other than through a cashless exercise Company shall have the right to require Participant to pay the amount of any withholding taxes immediately, upon notification from the Company, before the proceeds from the exercise of the Option are delivered to Participant. Furthermore, the Company may elect to deduct such taxes from any other amounts then payable to Participant in cash or in Shares or from any other amounts payable any time thereafter to Participant to the extent allowed under applicable law.

5.    NON-TRANSFERABILITY. The Option shall not be transferable by Participant other than by will or by the laws of descent and distribution, and during Participant’s lifetime shall be exercised only by the Participant during the continuance of Participant’s employment with the Company and any of its subsidiaries.

6.    FORFEITURE OF OPTION UPON TERMINATION OF EMPLOYMENT. Unless otherwise provided for in the Plan or in this Agreement, as of the date on which Participant’s employment with the Company and its subsidiaries terminates, the Option, to the extent unexercised as of the employment termination date, shall be forfeited immediately in its entirety, provided that, if the Participant’s employment with the Company and its subsidiaries terminates without Cause, the Option, to the extent vested and unexercised, shall be exercisable at any time on or before the ninetieth (90th) day immediately following the employment termination date and, to the extent unvested, shall be forfeited immediately.

7.    TERMINATION OF PARTICIPANT’S EMPLOYMENT WITHOUT CAUSE. In the event that Participant’s employment with the Company and its subsidiaries is terminated without Cause and Participant receives severance pay following Participant’s employment pursuant to a written agreement, vesting of the Option shall continue through the end of the severance period set forth in the agreement providing for such severance pay. To the extent vested, the Option shall be exercisable at any time during the severance period and on or before the ninetieth (90th) day following the last day of the severance period, as long as no government regulations or rules are violated by such continued vesting or exercise period; provided, however, that in no event will the Option be exercisable beyond its original term. Any portion of the Option not vested as of the last day of the severance period shall be forfeited as of the last day of the severance period. In the event that Participant returns to employment with the Company or any subsidiary prior to the expiration of the severance period, Participant shall be treated as if his or her employment with the Company or any subsidiary of the Company had continued through the severance period for purposes of determining eligibility for continued vesting.

8.    RETIREMENT OF PARTICIPANT. In the event Participant’s employment with the Company and any subsidiary of the Company terminates by reason of a Qualified Retirement, Participant (a) shall continue to vest in the Option, to the extent unvested as of the retirement date, for a period of three (3) years following Participant’s retirement date and (b) may exercise the Option, to the extent vested, at any time within the period of three (3) years following Participant’s retirement date, but not beyond the original term of the Option, in both cases as long as no government regulations or rules are violated by such continued vesting or exercise period. To the extent unvested or unexercised at the end of the three (3) year period following Participant’s retirement date, the Option shall be forfeited. In the event Participant’s termination of employment qualifies as a Qualified Retirement and Participant also enters into a severance agreement with the Company, the terms of this Section 8 shall apply with respect to the vesting and exercise of the Option as of the Participant’s employment termination date. “Qualified Retirement” shall mean termination of employment on or after attainment of age fifty-five (55) with at least ten (10) years of continuous service, or attainment of age sixty (60) with at least five (5) years of continuous service, provided that:  (i) if Participant elects to terminate his or her employment voluntarily, Participant has provided the Company with at least twelve (12) months advance notice, in accordance with the provisions of Section 13 below, of his or her retirement date or such other term of advance notice as is determined by the Chief Human Resources Officer of the Company; or (ii) if the Company elects to terminate Participant’s employment, such termination is without cause.  A Participant shall also be deemed to have

2




experienced a Qualified Retirement if the Company elects to terminate Participant’s employment without Cause and Participant shall meet the age and service requirement set forth above during the severance period set forth in a severance agreement with the Company.

9.    DISABILITY OF PARTICIPANT. In the event Participant’s employment with the Company and any subsidiary of the Company terminates by reason of total and permanent disability (as defined in the Company’s Long-Term Disability Plan, or, if not defined in such Plan, as defined by the Social Security Administration), the Option shall vest as of the employment termination date on a pro-rata basis as follows: the Option shall vest with respect to a total number of Shares as of the employment termination date (which is the last day that Participant is employed by the Company and any subsidiary of the Company) equal to (i) the number of Shares subject to the Option on the Grant Date multiplied by the following fraction: (A) the numerator shall be the whole number of months elapsed as of the employment termination date since the Grant Date and (B) the denominator shall be forty-eight (48), minus (ii) the number of Shares with respect to which the Option vested prior to the employment termination date (whether or not the Option was previously exercised). For purposes of this calculation, the number of months in the numerator in sub-section (A) above shall include any partial month in which Participant has worked. For example, if the time elapsed between the Grant Date and the employment termination date is eight months and five days, the numerator in sub-section (A) above shall be nine. The Option may be exercised to the extent vested at any time within one (1) year of Participant’s employment termination date but not beyond the original term of the Option. The prorated Option shall vest on the Participant’s employment termination date.

10.    DEATH OF PARTICIPANT. In the event of Participant’s death while Participant is employed with the Company and any subsidiary of the Company, the Option shall immediately vest in full, and the Option shall remain exercisable for a period of one (1) year after Participant’s death, or until the Option expiration date, whichever occurs first, by Participant’s Beneficiary. At the end of said one (1)-year time period, all rights with respect to any Option that is unexercised shall terminate and the Option shall be cancelled.

11.    TRANSFER OF EMPLOYMENT.     Transfer of Participant’s employment from the Company to a subsidiary of the Company, among or between subsidiaries of the Company, or from a subsidiary of the Company to the Company shall not be treated as termination of employment.

12.    REQUIRED ACCEPTANCE OF AWARD. The Option may not be exercised unless and until the Company has received the Participant’s acceptance of the terms and conditions set forth herein. Acceptance shall be submitted electronically as required by the Company.

13.    NOTICE. Any notice required to be given hereunder to the Company shall be in writing. If by regular mail, any required notice shall be addressed to: CVS Health Corporation, Attention: Senior Director, Executive Compensation, One CVS Drive, Woonsocket, RI 02895. If by electronic mail, any notice required shall be sent to: equityadministration@cvshealth.com, with “Retirement Notice” in the subject line. Any notice required to be given hereunder to Participant shall be addressed to Participant at his or her address as shown on the records of the Company, subject to the right of either party hereafter to designate in writing to the other some other address.

14.    RECOUPMENT OF OPTION AWARD. The Option subject to this Agreement under the Plan shall be subject to the terms of the Company’s Recoupment Policy as it exists from time to time, which may require the Participant to immediately repay to the Company the value of any pre-tax economic benefit that he or she may derive from the Award. By accepting this Award, Participant acknowledges that a copy of the Company’s Recoupment Policy has been made available for the Participant’s reference.

15.    COMMITTEE AUTHORITY. The Committee shall have the authority, in its sole discretion, to make any interpretations, determinations, and/or take any administrative actions with respect to the Plan and this Agreement, including whether any post-termination payments to Participant shall be deemed severance pay, the duration of any severance period, and/or whether a termination was without cause.

3





16.    GOVERNING LAW. This Nonqualified Stock Option Agreement and the Option evidenced hereby shall be governed by the laws of Delaware, without giving effect to principles of conflict of laws.

17.    ACKNOWLEDGEMENT.     This Agreement shall be fully effective only upon the Participant’s formal acceptance of the terms and conditions set forth above as required by the Company.





BY:
Executive Vice President, Chief Human Resources Officer
CVS Health Corporation            
                    










































Stock Option Agreement



4

EX-21.1 6 exhibit211-2021.htm EX-21.1 Document

Exhibit 21.1


Subsidiaries of CVS Health Corporation
Listed below are subsidiaries under CVS Health Corporation at December 31, 2021 with their jurisdictions of organization shown in parentheses. Subsidiaries excluded from the list below are not insurance companies and would not, in the aggregate, constitute a “significant subsidiary” of CVS Health Corporation, as that term is defined in Rule 1-02(w) of Regulation S-X.

CVS Foreign, Inc. (New York)
CVS Caremark Indemnity Ltd. (Bermuda)
CVS International, L.L.C. (Delaware)

CVS Pharmacy, Inc. (Rhode Island)
Aetna Inc. (Pennsylvania)
Aetna Health Holdings, LLC (Delaware)
Aetna Health of California Inc. (California)
Aetna Health Inc. (Connecticut)
Aetna Health Inc. (Florida)
Aetna Health Inc. (Georgia)
Aetna Health Inc. (Maine)
Aetna Health of Michigan Inc. (Michigan)
Aetna Health Inc. (New Jersey)
Aetna Health Inc. (New York)
Aetna Better Health Inc. (New York)
Aetna Health Inc. (Pennsylvania)
Aetna Health Inc. (Texas)
Aetna Better Health of California Inc. (California)
Aetna Health of Ohio Inc. (Ohio)Aetna Better Health of Texas Inc. (Texas)
Aetna Better Health of Washington, Inc. (Washington)
Aetna Better Health Inc. (Georgia)
Aetna HealthAssurance Pennsylvania, Inc. (Pennsylvania)
Aetna Dental of California Inc. (California)
Aetna Dental Inc. (New Jersey)
Aetna Dental Inc. (Texas)
Aetna Rx Home Delivery, LLC (Delaware)
Aetna Health Management, LLC (Delaware)
Aetna Ireland Inc. (Delaware)
Aetna Specialty Pharmacy, LLC (Delaware)
Cofinity, Inc. (Delaware)
@Credentials Inc. (Delaware)
Aetna Better Health Inc. (Pennsylvania)
Aetna Better Health Inc. (Connecticut)
Aetna Better Health of Illinois Inc. (Illinois)
Aetna Better Health Premier Plan MMAI Inc. (Illinois)
Aetna Better Health of Kansas Inc. (Kansas)
Aetna Better Health, Inc. (Louisiana)
Aetna Florida Inc. (Florida)
Aetna Better Health of Indiana Inc. (Indiana)

1






Aetna Better Health Inc. (Ohio)
Aetna Better Health of Oklahoma Inc. (Oklahoma)
Aetna Better Health of Nevada Inc. (Nevada)
Aetna Better Health Inc. (New Jersey)
Aetna Better Health of North Carolina Inc. (North Carolina)
Aetna Network Services LLC (Connecticut)
Aetna Risk Assurance Company of Connecticut Inc. (Connecticut)
Aetna Student Health Agency Inc. (Massachusetts)
Delaware Physicians Care, Incorporated (Delaware)
Schaller Anderson Medical Administrators, Incorporated (Delaware)
Aetna Medicaid Administrators LLC (Arizona)
iTriage, LLC (Delaware)
Medical Examinations of New York, P.C. (New York)
bswift LLC (Illinois)
Prodigy Health Group, Inc. (Delaware)
Niagara Re, Inc. (New York)
Performax, Inc. (Delaware)
Scrip World, LLC (Utah)
Precision Benefit Services, Inc. (Delaware)
American Health Holding, Inc. (Ohio)
Meritain Health, Inc. (New York)
Administrative Enterprises, Inc. (Arizona)
U.S Healthcare Holdings, LLC (Ohio)
Prime Net, Inc. (Ohio)
Professional Risk Management, Inc. (Ohio)
ADMINCO, Inc. (Arizona)
Aetna ACO Holdings Inc. (Delaware)
Aetna Pharmacy Management Services LLC (Delaware)
Coventry Transplant Network, Inc. (Delaware)
Aetna Health of Iowa Inc. (Iowa)
Coventry Health Care of Nebraska, Inc. (Nebraska)
Aetna Health Inc. (Louisiana)
HealthAssurance Pennsylvania, Inc. (Pennsylvania)
Coventry Prescription Management Services Inc. (Nevada)
Coventry Health and Life Insurance Company (Missouri)
Aetna Better Health of Kentucky Insurance Company (Kentucky)
Coventry Health Care of Virginia, Inc. (Virginia)
Coventry Health Care of Missouri, Inc. (Missouri)
Aetna Better Health of Missouri LLC (Missouri)
Coventry Health Care of Illinois, Inc. (Illinois)
Coventry Health Care of West Virginia, Inc. (West Virginia)
Coventry HealthCare Management Corporation (Delaware)
Coventry Health Care of Kansas, Inc. (Kansas)
Coventry Health Care National Accounts, Inc. (Delaware)
Aetna Better Health of Michigan Inc. (Michigan)
Aetna Health of Utah Inc. (Utah)
Aetna Better Health of Tennessee Inc. (Tennessee)

2






Coventry Health Care National Network, Inc. (Delaware)
Coventry Consumer Advantage, Inc. (Delaware)
MHNet Specialty Services, LLC (Maryland)
Mental Health Network of New York IPA, Inc. (New York)
Mental Health Associates, Inc. (Louisiana)
MHNet of Florida, Inc. (Florida)
Group Dental Service, Inc. (Maryland)
Group Dental Service of Maryland, Inc. (Maryland)
Florida Health Plan Administrators, LLC (Florida)
Aetna Better Health of Florida Inc. (Florida)
Carefree Insurance Services, Inc. (Florida)
Coventry Health Plan of Florida, Inc. (Florida)
First Health Group Corp. (Delaware)
First Health Life & Health Insurance Company (Texas)
Claims Administration Corp. (Maryland)
First Choice of the Midwest LLC (South Dakota)
Continental Life Insurance Company of Brentwood, Tennessee (Tennessee)
American Continental Insurance Company (Tennessee)
Aetna Life Insurance Company (Connecticut)
AHP Holdings, Inc. (Connecticut)
Aetna Insurance Company of Connecticut (Connecticut)
AE Fourteen, Incorporated (Connecticut)
Aetna Life Assignment Company (Connecticut)
Aetna ACO Holdings Inc. (Delaware)
Innovation Health Holdings, LLC (Delaware)
Innovation Health Insurance Company (Virginia)
Innovation Health Plan, Inc. (Virginia)
Texas Health + Aetna Health Insurance Holding Company LLC (Texas)
Texas Health + Aetna Health Insurance Company (Texas)
Texas Health + Aetna Health Plan Inc. (Texas)
Banner Health and Aetna Health Insurance Holding Company LLC (Delaware)
Banner Health and Aetna Health Insurance Company (Arizona)
Banner Health and Aetna Health Plan Inc. (Arizona)
Sutter Health and Aetna Insurance Holding Company LLC (Delaware)
Sutter Health and Aetna Administrative Services LLC (Delaware)
Sutter Health and Aetna Insurance Company (California)
Allina Health and Aetna Insurance Holding Company LLC (Delaware)
Allina Health and Aetna Insurance Company (Minnesota)
Allina Health and Aetna Health Plan Inc. (Minnesota)
Aetna International LLC (Connecticut)
Aetna Life & Casualty (Bermuda) Ltd. (Bermuda)
Aetna International Ex Pat LLC (Delaware)
Aetna Global Holdings Limited (England & Wales)
Aetna Insurance (Hong Kong) Limited (Hong Kong)
Virtual Home Healthcare LLC (Dubai)
Minor Health Enterprise Co, Ltd. (Thailand)
Health Care Management Co. Ltd. (Thailand)

3






Aetna Services (Thailand) Limited (Thailand)
Aetna Health Insurance (Thailand) Public Company Limited (Thailand)
Aetna Health Insurance (Thailand) Public Company Limited (Thailand)
Aetna Holdings (Thailand) Limited (Thailand)
Health Care Management Co. Ltd. (Thailand)
Minor Health Enterprise Co, Ltd. (Thailand)
Aetna Health Insurance (Thailand) Public Company Limited (Thailand)
Aetna Global Benefits (Bermuda) Limited (Bermuda)
Goodhealth Worldwide (Global) Limited (Bermuda)
Aetna Global Benefits (Europe) Limited (England & Wales)
Aetna Global Benefits (Asia Pacific) Limited (Hong Kong)
PT Aetna Management Consulting (Indonesia)
Goodhealth Worldwide (Asia) Limited (Hong Kong)
Aetna Global Benefits Limited (DIFC, UAE)
Aetna Global Benefits (Middle East) LLC (UAE)
Pt. Aetna Global Benefits Indonesia (Indonesia)
Spinnaker Topco Limited (Bermuda)
Spinnaker Bidco Limited (England and Wales)
Aetna Holdco (UK) Limited (England and Wales)
Aetna Global Benefits (UK) Limited (England and Wales)
Aetna Insurance Company Limited (England and Wales)
Aetna Insurance (Singapore) Pte. Ltd. (Singapore)
Aetna Health Insurance Company of Europe DAC (Ireland)
Aetna (Shanghai) Enterprise Services Co. Ltd. (China)
Aetna (Beijing) Enterprise Management Services Co., Ltd. (China)
Aetna Global Benefits (Singapore) PTE. LTD. (Singapore)
Indian Health Organisation Private Limited (India)
PT Aetna Management Consulting (Indonesia)
PE Holdings, LLC (Connecticut)
Aetna Resources LLC (Delaware)
Canal Place, LLC (Delaware)
Aetna Ventures, LLC (Delaware)
Phoenix Data Solutions LLC (Delaware)
Aetna Financial Holdings, LLC (Delaware)
Aetna Asset Advisors, LLC (Delaware)
U.S. Healthcare Properties, Inc. (Pennsylvania)
Aetna Capital Management, LLC (Delaware)
Aetna Partners Diversified Fund, LLC (Delaware)
Aetna Workers’ Comp Access, LLC (Delaware)
Aetna Behavioral Health, LLC (Delaware)
Managed Care Coordinators, Inc. (Delaware)
Horizon Behavioral Services, LLC (Delaware)
Employee Assistance Services, LLC (Kentucky)
Health and Human Resource Center, Inc. (California)
Resources for Living, LLC (Texas)
The Vasquez Group Inc. (Illinois)
Work and Family Benefits, Inc. (New Jersey)

4






Aetna Card Solutions, LLC (Connecticut)
PayFlex Holdings, Inc. (Delaware)
PayFlex Systems USA, Inc. (Nebraska)
Aetna Health and Life Insurance Company (Connecticut)
Aetna Health Insurance Company (Pennsylvania)
Aetna Health Insurance Company of New York (New York)
AUSHC Holdings, Inc. (Connecticut)
PHPSNE Parent Corporation (Delaware)
Active Health Management, Inc. (Delaware)
Health Data & Management Solutions, Inc. (Delaware)
Aetna Integrated Informatics, Inc. (Pennsylvania)
Health Re, Inc. (Vermont)
ASI Wings, LLC (Delaware)
Aetna Corporate Services LLC (Delaware)
Echo Merger Sub, Inc. (Delaware)

CVS Pharmacy, Inc. (continued)

Alabama CVS Pharmacy, L.L.C. (Alabama)
Alaska CVS Pharmacy, L.L.C. (Alaska)
American Drug Stores Delaware, L.L.C. (Delaware)
Arkansas CVS Pharmacy, L.L.C. (Arkansas)
CareCenter Pharmacy, L.L.C. (Delaware)
Caremark Rx, L.L.C. (Delaware)
ACS ACQCO CORP. (Delaware)
Advanced Care Scripts, Inc. (Florida)
CaremarkPCS, L.L.C. (Delaware)
CaremarkPCS Health, L.L.C. (Delaware)
Caremark IPA, L.L.C. (New York)
Accordant Health Services, L.L.C. (Delaware)
AdvancePCS SpecialtyRx, LLC (Delaware)
AdvanceRx.com, L.L.C. (Delaware)
Caremark PhC, L.L.C. (Delaware)
Caremark Ulysses Holding Corp. (New York)
MemberHealth LLC (Delaware)
UAC Holding, Inc. (Delaware)
Caremark, L.L.C. (California)
Caremark Arizona Mail Pharmacy, LLC (Arizona)
Caremark Arizona Specialty Pharmacy, L.L.C. (Arizona)
Caremark California Specialty Pharmacy, L.L.C. (California)
Caremark Florida Mail Pharmacy, LLC (Florida)
Caremark Florida Specialty Pharmacy, LLC (Florida)
Caremark Hawaii Mail Pharmacy, L.L.C. (Hawaii)
Caremark Hawaii Specialty Pharmacy, LLC (Hawaii)
Caremark Illinois Mail Pharmacy, LLC (Illinois)
CVS Caremark Advanced Technology Pharmacy, L.L.C. (Illinois)
Caremark Illinois Specialty Pharmacy, LLC (Illinois)

5






Caremark Irving Resource Center, LLC (Texas)
Caremark Kansas Specialty Pharmacy, LLC (Kansas)
Caremark Logistics, LLC (Delaware)
Caremark Louisiana Specialty Pharmacy, LLC (Louisiana)
Caremark Maryland Specialty Pharmacy, LLC (Maryland)
Caremark Massachusetts Specialty Pharmacy, L.L.C. (Massachusetts)
Caremark Michigan Specialty Pharmacy, LLC (Michigan)
Caremark Minnesota Specialty Pharmacy, LLC (Minnesota)
Caremark New Jersey Specialty Pharmacy, LLC (New Jersey)
Caremark North Carolina Specialty Pharmacy, LLC (North Carolina)
Caremark Ohio Specialty Pharmacy, L.L.C. (Ohio)
Caremark Pennsylvania Specialty Pharmacy, LLC (Pennsylvania)
Caremark Redlands Pharmacy, L.L.C. (California)
Caremark Repack, LLC (Illinois)
Caremark Tennessee Specialty Pharmacy, LLC (Tennessee)
Caremark Texas Mail Pharmacy, LLC (Texas)
Caremark Texas Specialty Pharmacy, LLC (Texas)
Caremark Washington Specialty Pharmacy, LLC (Washington)
Central Rx Services, LLC (Nevada)
CVS Caremark TN SUTA, LLC (Delaware)
Generation Health, L.L.C. (Delaware)
NovoLogix, LLC (Delaware)
CaremarkPCS Alabama Mail Pharmacy, LLC (Alabama)
CVS Caremark Part D Services, L.L.C. (Delaware)
Eckerd Corporation of Florida, Inc. (Florida)
Express Pharmacy Services of PA, L.L.C. (Delaware)
Ocean Acquisition Sub, L.L.C. (Delaware)
Coram LLC (Delaware)
T2 Medical, Inc. (Delaware)
Coram Healthcare Corporation of Alabama (Delaware)
Coram Healthcare Corporation of Florida (Delaware)
Coram Healthcare Corporation of Greater D.C. (Delaware)
Coram Healthcare Corporation of Greater New York (New York)
Coram Healthcare Corporation of Indiana (Delaware)
Coram Healthcare Corporation of Mississippi (Delaware)
Coram Healthcare Corporation of Nevada (Delaware)
Coram Healthcare Corporation of Northern California (Delaware)
Coram Healthcare Corporation of Southern California (Delaware)
Coram Healthcare Corporation of Southern Florida (Delaware)
Coram Specialty Infusion Services, L.L.C. (Delaware)
Coram Rx, LLC (Delaware)
Coram Healthcare Corporation of North Texas (Delaware)
Coram Healthcare Corporation of Utah (Delaware)
Coram Healthcare Corporation of Massachusetts (Delaware)
Coram Alternate Site Services, Inc. (Delaware)
Geneva Woods Management, LLC (Delaware)


6






Part D Holding Company, L.L.C. (Delaware)
Accendo Insurance Company (Utah)
Silverscript Insurance Company (Tennessee)
Connecticut CVS Pharmacy, L.L.C. (Connecticut)
Coram Clinical Trials, Inc. (Delaware)*
CVS Cabot Holdings Inc. (Delaware)*
CVS Shaw Holdings Inc. (Delaware)*
Omnicare, LLC (Delaware)*
Evergreen Pharmaceutical of California, LLC (California)
JHC Acquisition, LLC (Delaware)
Geneva Woods Pharmacy, LLC (Alaska)
Geneva Woods Health Services, LLC (Delaware)
Geneva Woods Retail Pharmacy LLC (Delaware)
Geneva Woods LTC Pharmacy, LLC
Geneva Woods Pharmacy Wyoming, LLC (Delaware)
Geneva Woods Pharmacy Washington, LLC (Delaware)
Geneva Woods Pharmacy Alaska, LLC (Delaware)
AMC - Tennessee, LLC (Delaware)
CHP Acquisition, LLC (Delaware)
Home Pharmacy Services, LLC (Missouri)
CP Acquisition, LLC (Oklahoma)
Managed Healthcare, LLC (Delaware)
Medical Arts Health Care, LLC (Georgia)
NIV Acquisition, LLC (Delaware)
OCR Services, LLC (Delaware)
Shore Pharmaceutical Providers, LLC (Delaware)
Omnicare of Nevada, LLC (Delaware)
Omnicare Pharmacies of the Great Plains Holding, LLC (Delaware)
Omnicare of Nebraska LLC (Delaware)
Pharmacy Associates of Glenn Falls, LLC (New York)
Sterling Healthcare Services, LLC (Delaware)
Superior Care Pharmacy, LLC (Delaware)
TCPI Acquisition, LLC (Delaware)
UC Acquisition, LLC (Delaware)
Weber Medical Systems LLC (Delaware)
Williamson Drug Company, LLC (Virginia)
Med World Acquisition Corp. (Delaware)
MHHP Acquisition Company, LLC (Delaware)


______________________
*Coram Clinical Trials, Inc. – CVS Pharmacy, Inc. 75%/Aetna Life Insurance Company 25%
* CVS Cabot Holdings, Inc. – Coram Clinical Trials, Inc. 99.72%/Aetna Inc. .28%
*CVS Shaw Holdings, Inc. – Coram Clinical Trials, Inc. 99.72%/Aetna Inc. .28%
*Omnicare, LLC – Aetna Inc 0.28%/CVS Cabot Holdings, Inc. 49.86%/CVS Shaw Holdings, Inc. 49.86%

7






Omnicare, LLC (continued)

NeighborCare Pharmacy Services, LLC (Delaware)
APS Acquisition LLC (Delaware)
ASCO HealthCare, LLC (Maryland)
Badger Acquisition LLC (Delaware)
Badger Acquisition of Minnesota LLC (Delaware)
Merwin Long Term Care, LLC (Minnesota)
Badger Acquisition of Ohio LLC (Delaware)
Badger Acquisition of Kentucky LLC (Delaware)
Best Care LTC Acquisition Company, LLC (Delaware)
Care Pharmaceutical Services, LP (Delaware)
CCRx Holdings, LLC (Delaware)
Continuing Care Rx, LLC (Pennsylvania)
CCRx of North Carolina LLC (Delaware)
Compscript, LLC (Florida)
Campo’s Medical Pharmacy, LLC (Louisiana)
D & R Pharmaceutical Services LLC (Kentucky)
Enloe Drugs, LLC (Delaware)
Evergreen Pharmaceutical, LLC (Washington)
Home Care Pharmacy, LLC (Delaware)
Interlock Pharmacy Systems, LLC (Missouri)
Langsam Health Services, LLC (Delaware)
LCPS Acquisition, LLC (Delaware)
Omnicare Pharmacy of Tennessee LLC (Delaware)
Lobos Acquisition, LLC (Delaware)
Lo-Med Prescription Services, LLC (Ohio)
ZS Acquisition Company, LLC (Delaware)
Main Street Pharmacy, L.L.C. (Maryland)
NCS Healthcare of Illinois, LLC (Ohio)
NCS Healthcare of Iowa, LLC (Ohio)
Martin Health Services, LLC (Delaware)
NCS Healthcare of Kansas, LLC (Ohio)
NCS Healthcare of Kentucky, LLC (Ohio)
NCS Healthcare of Montana, LLC (Ohio)
NCS Healthcare of New Mexico, LLC (Ohio)
NCS Healthcare of South Carolina, LLC (Ohio)
NCS Healthcare of Tennessee, LLC (Ohio)
NCS Healthcare of Ohio, LLC (Ohio)
NCS Healthcare of Wisconsin, LLC (Ohio)
North Shore Pharmacy Services LLC (Delaware)
Omnicare Indiana Partnership Holding Company LLC (Delaware)
Omnicare of New York, LLC (Delaware)
NeighborCare of Indiana, LLC (Indiana)
Grandview Pharmacy, LLC (Indiana)
NeighborCare of Virginia, LLC (Virginia)
Omnicare Pharmacies of Pennsylvania West LLC (Pennsylvania)

8






Omnicare Pharmacy and Supply Services LLC (South Dakota)
Omnicare Pharmacy of the Midwest, LLC (Delaware)
Omnicare Property Management, LLC (Delaware)
Pharmacy Consultants, LLC (South Carolina)
PRN Pharmaceutical Services, LP (Delaware)
Roeschen’s Healthcare LLC (Wisconsin)
PP Acquisition Company LLC (Delaware)
Specialized Pharmacy Services, LLC (Michigan)
Value Health Care Services LLC (Delaware)
VAPS Acquisition Company, LLC (Delaware)
Westhaven Services Co, LLC (Ohio)
Three Forks Apothecary, LLC (Kentucky)
UNI-Care Health Services of Maine, LLC (New Hampshire)

CVS Pharmacy, Inc. (continued)

CVS 2948 Henderson, L.L.C. (Nevada)
CVS AL Distribution, L.L.C. (Alabama)
CVS Albany, L.L.C. (New York)
CVS AOC Services, L.L.C. (Delaware)
CVS AOC Corporation (California)
CVS Care Concierge, LLC (Delaware)
CVS Health Applications, LLC (Rhode Island)
CVS Health Clinical Trial Services LLC (Connecticut)
CVS Health Solutions LLC (Delaware)
CVS Health Ventures Management, LLC (Delaware)
CVS Health Ventures Fund GP, LLC (Delaware)
CVS Health Ventures Fund, LP (Delaware)
CVS Indiana, L.L.C. (Indiana)
CVS International, L.L.C. (Delaware)
CCI Foreign, S.à R.L. (R.C.S. Luxembourg)
Beauty Holdings, L.L.C. (Delaware)
Pamplona Saúde e Beleza LTDA (Brazil)
CVS Kidney Care, LLC (Delaware)
CVS Kidney Care Health Services LLC (Delaware)
CVS Kidney Care Advanced Technologies LLC (Delaware)
CVS Kidney Care Home Dialysis LLC (Delaware)
CVS-SHC Kidney Care Home Dialysis of Austin LLC (Delaware)
CVS-SHC Kidney Care Home Dialysis of Los Angeles LLC (Delaware)
CVS-SHC Kidney Care Home Dialysis of Philadelphia LLC (Delaware)
CVS-SHC Renal Holdings LLC (Delaware)
CVS Management Support, LLC (Delaware)
CVS Manchester NH, L.L.C. (New Hampshire)
CVS Media Exchange LLC (Delaware)
CVS Michigan, L.L.C. (Michigan)
CVS Orlando FL Distribution, L.L.C. (Florida)

9






CVS PA Distribution, L.L.C. (Pennsylvania)
CVS Pharmacy Overseas Online, LLC
CVS PR Center, Inc. (Delaware)
Puerto Rico CVS Pharmacy, L.L.C. (Puerto Rico)
Caremark Puerto Rico, L.L.C. (Puerto Rico)
Caremark Puerto Rico Specialty Pharmacy, L.L.C. (Puerto Rico)
CVS RS Arizona, L.L.C. (Arizona)
Arizona CVS Stores, L.L.C. (Arizona)
CVS 3268 Gilbert, L.L.C. (Arizona)
CVS 3745 Peoria, L.L.C. (Arizona)
CVS Gilbert 3272, L.L.C. (Arizona)
CVS Rx Services, Inc. (New York)
Busse CVS, L.L.C. (Illinois)
Goodyear CVS, L.L.C. (Arizona)
Sheffield Avenue CVS, L.L.C. (Illinois)
South Wabash CVS, L.L.C. (Illinois)
Thomas Phoenix CVS, L.L.C. (Arizona)
Washington Lamb CVS, L.L.C. (Nevada)
CVS SC Distribution, L.L.C. (South Carolina)
CVS State Capital, L.L.C. (Maine)
CVS TN Distribution, L.L.C. (Tennessee)
CVS Transportation, L.L.C. (Indiana)
CVS Vero FL Distribution, L.L.C. (Florida)
D.A.W., LLC (Massachusetts)
Delaware CVS Pharmacy, L.L.C. (Delaware)
District of Columbia CVS Pharmacy, L.L.C. (District of Columbia)
Enterprise Patient Safety Organization, LLC (Rhode Island)
E.T.B., Inc. (Texas)
Garfield Beach CVS, L.L.C. (California)
Georgia CVS Pharmacy, L.L.C. (Georgia)
German Dobson CVS, L.L.C. (Arizona)
Grand St. Paul CVS, L.L.C. (Minnesota)
Highland Park CVS, L.L.C. (Illinois)
Holiday CVS, L.L.C. (Florida)
Hook-SupeRx, L.L.C. (Delaware)
Idaho CVS Pharmacy, L.L.C. (Idaho)
Iowa CVS Pharmacy, L.L.C. (Iowa)
Kansas CVS Pharmacy, L.L.C. (Kansas)
Kentucky CVS Pharmacy, L.L.C. (Kentucky)
Longs Drug Stores California, L.L.C. (California)
Louisiana CVS Pharmacy, L.L.C. (Louisiana)
Maryland CVS Pharmacy, L.L.C. (Maryland)
Melville Realty Company, Inc. (New York)
CVS Bellmore Avenue, L.L.C. (New York)
MinuteClinic, L.L.C. (Delaware)
MinuteClinic Diagnostic of Alabama, L.L.C. (Alabama)
MinuteClinic Diagnostic of Arkansas, LLC (Arkansas)

10






MinuteClinic Diagnostic of Arizona, LLC (Minnesota)
MinuteClinic Diagnostic of Colorado LLC (Colorado)
MinuteClinic Diagnostic of Florida, LLC (Minnesota)
MinuteClinic Diagnostic of Georgia, LLC (Minnesota)
MinuteClinic Diagnostic of Hawaii, L.L.C. (Hawaii)
MinuteClinic Diagnostic of Illinois, LLC (Delaware)
MinuteClinic Diagnostic of Kentucky, L.L.C. (Kentucky)
MinuteClinic Diagnostic of Louisiana, L.L.C. (Louisiana)
MinuteClinic Diagnostic of Maine, L.L.C. (Maine)
MinuteClinic Diagnostic of Maryland, LLC (Minnesota)
MinuteClinic Diagnostic of Massachusetts, LLC (Massachusetts)
MinuteClinic Diagnostic of Nebraska, L.L.C. (Nebraska)
MinuteClinic Diagnostic of New Hampshire, L.L.C. (New Hampshire)
MinuteClinic Diagnostic of New Mexico, L.L.C. (New Mexico)
MinuteClinic Diagnostic of Ohio, LLC (Ohio)
MinuteClinic Diagnostic of Oklahoma, LLC (Oklahoma)
MinuteClinic Diagnostic of Oregon, LLC (Oregon)
MinuteClinic Diagnostic of Pennsylvania, LLC (Minnesota)
MinuteClinic Diagnostic of Rhode Island, LLC (Minnesota)
MinuteClinic Diagnostic of South Carolina, L.L.C. (South Carolina)
MinuteClinic Diagnostic of Texas, LLC (Minnesota)
MinuteClinic Diagnostic of Utah, L.L.C. (Utah)
MinuteClinic Diagnostic of Virginia, LLC (Virginia)
MinuteClinic Diagnostic of Washington, LLC (Oregon)
MinuteClinic Diagnostic of Wisconsin, L.L.C. (Wisconsin)
MinuteClinic Online Diagnostic Services, LLC (Delaware)
MinuteClinic Physician Practice of Texas (Texas)
MinuteClinic Telehealth Services, LLC (Delaware)
MinuteClinic Telehealth Services of Texas Association (Texas)
Mississippi CVS Pharmacy, L.L.C. (Mississippi)
Missouri CVS Pharmacy, L.L.C. (Missouri)
Montana CVS Pharmacy, L.L.C. (Montana)
Nebraska CVS Pharmacy, L.L.C. (Nebraska)
New Jersey CVS Pharmacy, L.L.C. (New Jersey)
North Carolina CVS Pharmacy, L.L.C. (North Carolina)
Ohio CVS Stores, L.L.C. (Ohio)
Oklahoma CVS Pharmacy, L.L.C. (Oklahoma)
Oregon CVS Pharmacy, L.L.C. (Oregon)
Pennsylvania CVS Pharmacy, L.L.C. (Pennsylvania)
ProCare Pharmacy Direct, L.L.C. (Ohio)
ProCare Pharmacy, L.L.C. (Rhode Island)
Red Oak Sourcing, LLC (Delaware)
Rhode Island CVS Pharmacy, L.L.C. (Rhode Island)
South Carolina CVS Pharmacy, L.L.C. (South Carolina)
Tennessee CVS Pharmacy, L.L.C. (Tennessee)
Utah CVS Pharmacy, L.L.C. (Utah)
Vermont CVS Pharmacy, L.L.C. (Vermont)

11






Virginia CVS Pharmacy, L.L.C. (Virginia)
Warm Springs Road CVS, L.L.C. (Nevada)
Washington CVS Pharmacy, L.L.C. (Washington)
Wellpartner, LLC (Delaware)
West Virginia CVS Pharmacy, L.L.C. (West Virginia)
Wisconsin CVS Pharmacy, L.L.C. (Wisconsin)
Woodward Detroit CVS, L.L.C. (Michigan)
Zinc Health Ventures, LLC (Delaware)
Zinc Health Services, LLC (Delaware)

12

EX-23.1 7 exhibit231-2021.htm EX-23.1 Document

Exhibit 23.1
Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the following Registration Statements:
(1)Registration Statement (Form S-3ASR No. 333-238506) of CVS Health Corporation, and
(2)Registration Statements (Form S-8 Nos. 333-238507, 333-230035, 333-228622, 333-167746, 333-217853, 333-208805, 333-141481, 333-139470, 333-63664, 333-91253, 333-49407, 333-34927, and 333-28043) of CVS Health Corporation;
of our reports dated February 9, 2022, with respect to the consolidated financial statements of CVS Health Corporation and the effectiveness of internal control over financial reporting of CVS Health Corporation included in this Annual Report (Form 10-K) of CVS Health Corporation for the year ended December 31, 2021.

/s/ Ernst & Young LLP

Boston, Massachusetts
February 9, 2022



EX-31.1 8 exhibit311-2021.htm EX-31.1 Document

Exhibit 31.1

Certification

I, Karen S. Lynch, President and Chief Executive Officer of CVS Health Corporation, certify that:

1.    I have reviewed this annual report on Form 10-K of CVS Health Corporation;
2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.     The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)    Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.    The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date:February 9, 2022
/S/     KAREN S. LYNCH
Karen S. Lynch
President and Chief Executive Officer


EX-31.2 9 exhibit312-2021.htm EX-31.2 Document

Exhibit 31.2

Certification
I, Shawn M. Guertin, Executive Vice President and Chief Financial Officer of CVS Health Corporation, certify that:

1.    I have reviewed this annual report on Form 10-K of CVS Health Corporation;
2.     Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.     Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.     The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)    Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.    The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date:February 9, 2022
/S/     SHAWN M. GUERTIN
Shawn M. Guertin
Executive Vice President and Chief Financial Officer



EX-32.1 10 exhibit321-2021.htm EX-32.1 Document

Exhibit 32.1
CERTIFICATION

The certification set forth below is being submitted in connection with the Annual Report of CVS Health Corporation (the "Company") on Form 10-K for the period ended December 31, 2021 (the “Report”) solely for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code.
I, Karen S. Lynch, President and Chief Executive Officer of the Company, certify that, to the best of my knowledge:
1. the Report fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act; and
2. the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date:February 9, 2022
/S/    KAREN S. LYNCH
Karen S. Lynch
President and Chief Executive Officer


EX-32.2 11 exhibit322-2021.htm EX-32.2 Document

Exhibit 32.2

CERTIFICATION

The certification set forth below is being submitted in connection with the Annual Report of CVS Health Corporation (the "Company") on Form 10-K for the period ended December 31, 2021 (the “Report”) solely for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code.
I, Shawn M. Guertin, Executive Vice President and Chief Financial Officer of the Company, certify that, to the best of my knowledge:
1. the Report fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act; and
2. the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date:February 9, 2022
/S/    SHAWN M. GUERTIN
Shawn M. Guertin
Executive Vice President and Chief Financial Officer



EX-101.SCH 12 cvs-20211231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 000010001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 000020002 - Document - Audit Information link:presentationLink link:calculationLink link:definitionLink 100010003 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 100020004 - Statement - Consolidated Statements of Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 100030005 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 100040006 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100050007 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 100050007 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 100060008 - Statement - Consolidated Statements of Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 100070009 - Statement - Consolidated Statements of Shareholders' Equity (Parentheticals) link:presentationLink link:calculationLink link:definitionLink 210011001 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 220022001 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 230033001 - Disclosure - Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 240044001 - Disclosure - Significant Accounting Policies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 240054002 - Disclosure - Significant Accounting Policies - Restricted Cash (Details) link:presentationLink link:calculationLink link:definitionLink 240064003 - Disclosure - Significant Accounting Policies - Accounts Receivable (Details) link:presentationLink link:calculationLink link:definitionLink 240074004 - Disclosure - Significant Accounting Policies - Property Plant and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 240084005 - Disclosure - Significant Accounting Policies - Disaggregation of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 240094006 - Disclosure - Significant Accounting Policies - Receivables and Contracted Balances (Details) link:presentationLink link:calculationLink link:definitionLink 240104007 - Disclosure - Significant Accounting Policies - Contract Balances (Details) link:presentationLink link:calculationLink link:definitionLink 240114008 - Disclosure - Significant Accounting Policies - Variable Interest Entities (Details) link:presentationLink link:calculationLink link:definitionLink 240124009 - Disclosure - Significant Accounting Policies - Discontinued Operations (Details) link:presentationLink link:calculationLink link:definitionLink 210131002 - Disclosure - Divestitures link:presentationLink link:calculationLink link:definitionLink 240144010 - Disclosure - Divestitures - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 210151003 - Disclosure - Investments link:presentationLink link:calculationLink link:definitionLink 230163002 - Disclosure - Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 240174011 - Disclosure - Investments - Schedule of Total Investments (Details) link:presentationLink link:calculationLink link:definitionLink 240184012 - Disclosure - Investments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 240194013 - Disclosure - Investments - Debt Securities (Details) link:presentationLink link:calculationLink link:definitionLink 240204014 - Disclosure - Investments - Debt Securities by Maturity (Details) link:presentationLink link:calculationLink link:definitionLink 240214015 - Disclosure - Investments - Unrealized Loss Position (Details) link:presentationLink link:calculationLink link:definitionLink 240224016 - Disclosure - Investments - Unrealized Loss Position Maturities (Details) link:presentationLink link:calculationLink link:definitionLink 240234017 - Disclosure - Investments - Mortgage Loans (Details) link:presentationLink link:calculationLink link:definitionLink 240244018 - Disclosure - Investments - Mortgage Loans Credit Ratings Indicator (Details) link:presentationLink link:calculationLink link:definitionLink 240254019 - Disclosure - Investments - Schedule of Mortgage Loan Principal Repayments (Details) link:presentationLink link:calculationLink link:definitionLink 240264020 - Disclosure - Investments - Net Investment Income (Details) link:presentationLink link:calculationLink link:definitionLink 240274021 - Disclosure - Investments - Realized Gains (Details) link:presentationLink link:calculationLink link:definitionLink 210281004 - Disclosure - Fair Value link:presentationLink link:calculationLink link:definitionLink 230293003 - Disclosure - Fair Value (Tables) link:presentationLink link:calculationLink link:definitionLink 240304022 - Disclosure - Fair Value - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 240314023 - Disclosure - Fair Value - Changes in Level 3 Financial Assets (Details) link:presentationLink link:calculationLink link:definitionLink 240324024 - Disclosure - Fair Value - Gross Transfers Into (Out Of) Level 3 (Details) link:presentationLink link:calculationLink link:definitionLink 240334025 - Disclosure - Fair Value - Carrying Value and Fair Value Classified by Level (Details) link:presentationLink link:calculationLink link:definitionLink 240344026 - Disclosure - Fair Value - Separate Accounts Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 240354027 - Disclosure - Fair Value - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 210361005 - Disclosure - Goodwill and Other Intangibles link:presentationLink link:calculationLink link:definitionLink 230373004 - Disclosure - Goodwill and Other Intangibles (Tables) link:presentationLink link:calculationLink link:definitionLink 240384028 - Disclosure - Goodwill and Other Intangibles - Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 240394029 - Disclosure - Goodwill and Other Intangibles - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 240404030 - Disclosure - Goodwill and Other Intangibles - Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 240414031 - Disclosure - Goodwill and Other Acquired Intangibles - Future Amortization Expense (Details) link:presentationLink link:calculationLink link:definitionLink 210421006 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 230433005 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 240444032 - Disclosure - Leases - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 240454033 - Disclosure - Leases - Summary of the Components of Net Lease Cost (Details) link:presentationLink link:calculationLink link:definitionLink 240464034 - Disclosure - Leases - Supplemental Cash Flow Information (Details) link:presentationLink link:calculationLink link:definitionLink 240474035 - Disclosure - Leases - Supplemental Balance Sheet Information (Details) link:presentationLink link:calculationLink link:definitionLink 240484036 - Disclosure - Leases - Maturities of Operating and Finance Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 240484036 - Disclosure - Leases - Maturities of Operating and Finance Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 210491007 - Disclosure - Health Care Costs Payable link:presentationLink link:calculationLink link:definitionLink 230503006 - Disclosure - Health Care Costs Payable (Tables) link:presentationLink link:calculationLink link:definitionLink 240514037 - Disclosure - Health Care Costs Payable - Incurred and Paid Health Care Claims Development (Details) link:presentationLink link:calculationLink link:definitionLink 240524038 - Disclosure - Health Care Costs Payable - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 240534039 - Disclosure - Health Care Costs Payable - Reconciliation of Health Care Net Incurred and Paid Claims Development to Health Care Costs Payable Liability (Details) link:presentationLink link:calculationLink link:definitionLink 240544040 - Disclosure - Health Care Costs Payable - Reconciliation of Health Care Costs Payable (Details) link:presentationLink link:calculationLink link:definitionLink 210551008 - Disclosure - Borrowings and Credit Arrangements link:presentationLink link:calculationLink link:definitionLink 230563007 - Disclosure - Borrowings and Credit Arrangements (Tables) link:presentationLink link:calculationLink link:definitionLink 240574041 - Disclosure - Borrowings and Credit Arrangements - Schedule of Debt (Details) link:presentationLink link:calculationLink link:definitionLink 240584042 - Disclosure - Borrowings and Credit Arrangements - Debt Maturities (Details) link:presentationLink link:calculationLink link:definitionLink 240594043 - Disclosure - Borrowings and Credit Arrangements - Short-term Borrowings (Details) link:presentationLink link:calculationLink link:definitionLink 240604044 - Disclosure - Borrowings and Credit Arrangements - Long-Term Borrowings (Details) link:presentationLink link:calculationLink link:definitionLink 210611009 - Disclosure - Pension Plans and Other Postretirement Benefits link:presentationLink link:calculationLink link:definitionLink 230623008 - Disclosure - Pension Plans and Other Postretirement Benefits (Tables) link:presentationLink link:calculationLink link:definitionLink 240634045 - Disclosure - Pension Plans and Other Postretirement Benefits - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 240644046 - Disclosure - Pension Plans and Other Postretirement Benefits - Benefit Obligations and Plan Assets (Details) link:presentationLink link:calculationLink link:definitionLink 240654047 - Disclosure - Pension Plans and Other Postretirement Benefits - Net Periodic Benefit Costs (Details) link:presentationLink link:calculationLink link:definitionLink 240664048 - Disclosure - Pension Plans and Other Postretirement Benefits - Weighted Average Assumptions Used (Details) link:presentationLink link:calculationLink link:definitionLink 240674049 - Disclosure - Pension Plans and Other Postretirement Benefits - Fair Value of Pension Plan Assets (Details) link:presentationLink link:calculationLink link:definitionLink 240684050 - Disclosure - Pension Plans and Other Postretirement Benefits - Changes in Level 3 Pension Plan Assets (Details) link:presentationLink link:calculationLink link:definitionLink 240694051 - Disclosure - Pension Plans and Other Postretirement Benefits - Defined Benefit Plans Expected Benefit (Details) link:presentationLink link:calculationLink link:definitionLink 210701010 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 230713009 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 240724052 - Disclosure - Income Taxes - Income Tax Provision (Details) link:presentationLink link:calculationLink link:definitionLink 240734053 - Disclosure - Income Taxes - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 240744054 - Disclosure - Income Taxes - Effective Tax Rate Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 240754055 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 240764056 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Details) link:presentationLink link:calculationLink link:definitionLink 210771011 - Disclosure - Stock Incentive Plans link:presentationLink link:calculationLink link:definitionLink 230783010 - Disclosure - Stock Incentive Plans (Tables) link:presentationLink link:calculationLink link:definitionLink 240794057 - Disclosure - Stock Incentive Plans - Stock-Based Compensation Expense and ESPP (Details) link:presentationLink link:calculationLink link:definitionLink 240804058 - Disclosure - Stock Incentive Plans - Valuation and Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 240814059 - Disclosure - Stock Incentive Plans - Restricted Stock Activity (Details) link:presentationLink link:calculationLink link:definitionLink 240824060 - Disclosure - Stock Incentive Plans - Stock Option and SAR Activity (Details) link:presentationLink link:calculationLink link:definitionLink 210831012 - Disclosure - Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 230843011 - Disclosure - Shareholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 240854061 - Disclosure - Shareholders' Equity - Share Repurchases (Details) link:presentationLink link:calculationLink link:definitionLink 240864062 - Disclosure - Shareholders' Equity - Accelerated Share Repurchases (Details) link:presentationLink link:calculationLink link:definitionLink 240874063 - Disclosure - Shareholders' Equity - Dividends (Details) link:presentationLink link:calculationLink link:definitionLink 240884064 - Disclosure - Shareholders' Equity - Regulatory Requirements (Details) link:presentationLink link:calculationLink link:definitionLink 240894065 - Disclosure - Shareholders' Equity - Noncontrolling Interests (Details) link:presentationLink link:calculationLink link:definitionLink 210901013 - Disclosure - Other Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 230913012 - Disclosure - Other Comprehensive Income (Tables) link:presentationLink link:calculationLink link:definitionLink 240924066 - Disclosure - Other Comprehensive Income (Details) link:presentationLink link:calculationLink link:definitionLink 210931014 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 230943013 - Disclosure - Earnings Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 240954067 - Disclosure - Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 210961015 - Disclosure - Reinsurance link:presentationLink link:calculationLink link:definitionLink 230973014 - Disclosure - Reinsurance (Tables) link:presentationLink link:calculationLink link:definitionLink 240984068 - Disclosure - Reinsurance - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 240994069 - Disclosure - Reinsurance - Reinsurance Recoverables (Details) link:presentationLink link:calculationLink link:definitionLink 241004070 - Disclosure - Reinsurance - Effects of Reinsurance (Details) link:presentationLink link:calculationLink link:definitionLink 211011016 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 241024071 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 211031017 - Disclosure - Segment Reporting link:presentationLink link:calculationLink link:definitionLink 231043015 - Disclosure - Segment Reporting (Tables) link:presentationLink link:calculationLink link:definitionLink 241054072 - Disclosure - Segment Reporting - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 241064073 - Disclosure - Segment Reporting - Reconciliation of Financial Measures of Segments to Consolidated Totals (Details) link:presentationLink link:calculationLink link:definitionLink 241074074 - Disclosure - Segment Reporting - Reconciliation from Operating Income to Adjusted Operating Income (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 13 cvs-20211231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 14 cvs-20211231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 15 cvs-20211231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Customer [Domain] Customer [Domain] Amounts reclassified, pre-tax Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax Actuarial (gain) loss Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss) Other asset-backed securities Other Asset-Backed Securities [Member] Securities collateralized by a variety of assets such as automobile loans, credit card receivables, home equity loans, etc. Vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period State Current State and Local Tax Expense (Benefit) Leasehold improvements Leasehold Improvements [Member] Consolidated Entities [Axis] Consolidated Entities [Axis] Effective Income Tax Rate Reconciliation, Amount [Abstract] Effective Income Tax Rate Reconciliation, Amount [Abstract] 4.125% senior notes due May 2021 Senior Notes, 4.125%, Due May 2021 [Member] Senior Notes, 4.125%, Due May 2021 [Member] Total finance lease costs Finance Lease Cost Finance Lease Cost Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Other Other Intangible Assets [Member] 4.125% senior notes due June 2021 Senior Notes, 4.125%, Due June 2021 [Member] Senior Notes, 4.125%, Due June 2021 [Member] Security Exchange Name Security Exchange Name Direct Direct Premiums Earned Equity securities Equity Securities, FV-NI, Current OTTI losses, investments, portion recognized in earnings, net Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Recognized in Earnings Redemption and breakage Contract With Customer Liability Redemption And Breakage Contract With Customer Liability Redemption And Breakage Forfeited (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Schedule of contract with customer assets and liabilities Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Common stock, par value $0.01: 3,200 shares authorized; 1,744 shares issued and 1,322 shares outstanding at December 31, 2021 and 1,733 shares issued and 1,310 shares outstanding at December 31, 2020 and capital surplus Common Stocks, Including Additional Paid in Capital Shares forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Operating leases Operating Lease, Weighted Average Remaining Lease Term Foreign Currency Translation and Transactions Foreign Currency Transactions and Translations Policy [Policy Text Block] Current liabilities reflected in accrued expenses Liability, Defined Benefit Plan, Current 5.05% senior notes due March 2048 Senior Notes, 5.05%, Due March 2048 [Member] Senior Notes, 5.05%, Due March 2048 [Member] Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table] Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table] Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract] Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] 3.5% senior notes due July 2022 Senior Notes, 3.5%, Due July 2022 [Member] Senior Notes, 3.5%, Due July 2022 [Member] Investment, Name [Axis] Investment, Name [Axis] Derivative Financial Instruments Derivatives, Policy [Policy Text Block] Number of shares available for grant Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Net increase in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Incurred Health Care Claims, Net of Reinsurance Short-duration Insurance Contracts, Incurred Claims and Allocated Claim Adjustment Expense, Net 7 Category 7 [Member] Mortgage loan credit quality indicator - Category 7 Expected volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 2023 Long-Term Debt, Maturity, Year Two Intrinsic value of stock options and SARs exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 2.7% senior notes due August 2040 Senior Notes, 2 Point 7 Percent, August 2040 [Member] Senior Notes, 2 Point 7 Percent, August 2040 Net realized and unrealized capital gains (losses): Fair Value, Assets Measured On Recurring Basis, Unobservable Unput Reconciliation, Net Realized And Unrealized Capital Gaines (Losses) [Abstract] Fair Value, Assets Measured On Recurring Basis, Unobservable Unput Reconciliation, Net Realized And Unrealized Capital Gaines (Losses) [Abstract] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Foreign currency translation adjustments Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member] Amortization of intangible assets Amortization of Intangible Assets 2022 Lessee, Liability, Payments, Year One Lessee, Liability, Payments, Year One Remaining as of December 31, 2021 Stock Repurchase Program, Remaining Authorized Repurchase Amount Settlements Defined Benefit Plan, Benefit Obligation, Payment for Settlement Additions based on tax positions related to prior years Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Antidilutive securities excluded from computation of EPS (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Operating leases Operating Lease, Weighted Average Discount Rate, Percent Components of change in health care costs payable Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table Text Block] Total deferred income tax assets Deferred Tax Assets, Net of Valuation Allowance Business Combination and Asset Acquisition [Abstract] Number of states in which entity operates Number of States in which Entity Operates Cash and Cash Equivalents and Restricted Cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Revolving Credit Facility, Expiring May 11, 2026 Revolving Credit Facility, Expiring May 11, 2026 [Member] Revolving Credit Facility, Expiring May 11, 2026 Numerator for earnings per share calculation: Numerator For Earnings Per Share Calculation [Abstract] Numerator For Earnings Per Share Calculation [Abstract] Included in earnings  Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings Award Type [Domain] Award Type [Domain] Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] Local Phone Number Local Phone Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Nonrecurring Fair Value, Nonrecurring [Member] Shares exercisable at end of year (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Amortization of net actuarial loss Defined Benefit Plan, Amortization of Gain (Loss) Separate Accounts Policyholder Accounts, Policy [Policy Text Block] Investment contracts without a fixed maturity Investment Contracts Without A Fixed Maturity, Fair Value Disclosure Investment Contracts Without A Fixed Maturity, Fair Value Disclosure. Fair value of debt securities by contractual maturity Investments Classified by Contractual Maturity Date [Table Text Block] Federal Home Loan Bank Advances Federal Home Loan Bank Advances [Member] Significant Accounting Policies [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Preferred stock, par value $0.01: 0.1 shares authorized; none issued or outstanding Preferred Stock, Value, Issued Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward] Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward] Variable Interest Entity, Not Primary Beneficiary Variable Interest Entity, Not Primary Beneficiary [Member] Retained Earnings Retained Earnings [Member] Assumptions used to determine net benefit costs Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract] Long-term debt Debt Instrument, Fair Value Disclosure Separate Account Asset Category [Domain] Separate Account Asset Category [Domain] Lease and rents Deferred Tax Liabilities, Leasing Arrangements Debt securities Debt Securities [Member] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] VIE, ownership percentage Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage Mortgage loans SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate Real estate partnerships Real Estate Funds [Member] Credit-related impairment loss Credit Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings Credit Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings Accounts receivable, net Increase (Decrease) in Accounts Receivable Separate accounts liabilities Separate Account, Liability 2 to 4 Category 2 to 4 [Member] Mortgage Loan Credit Quality Indicator - Category 2 to 4 [Member]. 5.3% senior notes due December 2043 Senior Notes, 5.3%, Due December 2043 [Member] Senior Notes, 5.3%, Due December 2043 [Member] 2024 Mortgage Loans On Real Estate Collections Of Principal In Year Three Mortgage Loans On Real Estate Collections Of Principal In Year Three Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Comprehensive income Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Financing cash flows paid for principal portion of finance leases Finance Lease, Principal Payments 2021 Repurchase Program 2021 Repurchase Program [Member] 2021 Repurchase Program Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Decrease in prior years' healthcare costs payable Prior Year Claims and Claims Adjustment Expense Net income attributable to CVS Health (in dollars per share) Earnings Per Share, Basic Less: sublease income Sublease Income Mortgage Loans On Real Estate Year Of Origination [Domain] Mortgage Loans On Real Estate Year Of Origination [Domain] Mortgage Loans On Real Estate Year Of Origination Unvested at beginning of period (in shares) Unvested at end of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Separate Account Asset Category [Axis] Separate Account Asset Category [Axis] 2022 Long-Term Debt, Maturity, Year One Amortized Cost Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract] Reporting Unit [Domain] Reporting Unit [Domain] Total Investments [Domain] Total Investments [Domain] Fair Value Measurement [Domain] Fair Value Measurement [Domain] Diluted earnings per share: Earnings Per Share, Diluted [Abstract] Prior Year Of Origination Prior To Period Five [Member] Year Of Origination Prior To Period Five Cumulative Effect, Period of Adoption, Adjustment Cumulative Effect, Period of Adoption, Adjustment [Member] Noncurrent assets reflected in other assets Assets for Plan Benefits, Defined Benefit Plan Commercial Paper Commercial Paper [Member] Net deferred income tax liabilities Deferred Tax Liabilities, Net Other noncash items Other Noncash Income (Expense) Ceded Credit Risk, Reinsurer [Axis] Ceded Credit Risk, Reinsurer [Axis] Number of retail locations (more than) Number of stores Number of Stores 3% senior notes due August 2026 Senior Notes, 3%, Due August 2026 [Member] Senior Notes, 3%, Due August 2026 [Member] Less: imputed interest Lessee, Liability, Undiscounted Excess Amount Lessee, Liability, Undiscounted Excess Amount Entity Voluntary Filers Entity Voluntary Filers Defined Benefit Plan, Plan Assets, Category [Domain] Defined Benefit Plan, Plan Assets, Category [Domain] Current portion of long-term debt Current portion of long-term debt Long-term Debt and Lease Obligation, Current Plan Name [Axis] Plan Name [Axis] Combined statutory net income Statutory Accounting Practices, Statutory Net Income Amount Discontinued Operations Discontinued Operations, Policy [Policy Text Block] Ceded Credit Risk [Line Items] Ceded Credit Risk [Line Items] Level 1 Fair Value, Inputs, Level 1 [Member] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Goodwill impairment Impairment Goodwill, Impairment Loss US Federal Government US Federal Government [Member] US Federal Government Number of leases guaranteed Guarantor Obligations, Number of Leases Guarantor Obligations, Number of Leases Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Entity Small Business Entity Small Business Operating Leases Lessee, Operating Lease, Liability, Payment, Due [Abstract] Cash and cash equivalents Cash and Cash Equivalents [Member] Additions based on tax positions related to the current year Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Employee benefits Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation Pending Litigation Pending Litigation [Member] International Defined Benefit Plan, Equity Securities, Non-US [Member] Revolving Credit Facility, Expiring May 17, 2023 Revolving Credit Facility, Expiring May 17, 2023 [Member] Revolving Credit Facility, Expiring May 17, 2023 [Member] Scenario [Axis] Scenario [Axis] Greater than ten years Debt Securities, Available-For-Sale, Allocated And Single Maturity Date, Maturity, After 10 Years, Amortized Cost, Net Debt Securities, Available-For-Sale, Allocated And Single Maturity Date, Maturity, After 10 Years, Amortized Cost, Net Pharmacy Services Pharmacy Services Segment [Member] Pharmacy Services Segment [Member] Front Store Front Store Revenue [Member] Front Store Revenue [Member] Four years reinsurance agreement with unrelated insurer Four Years Reinsurance Agreement With Unrelated Insurer This line item represents the four years of a reinsurance agreement with an unrelated insurer. Impairment of intangible assets, indefinite-lived Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) Unrecognized tax benefits that would impact effective tax rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Schedule of Investment Income, Reported Amounts, by Category [Table] Investment Income [Table] Accounts payable and pharmacy claims and discounts payable Increase (Decrease) in Accounts Payable Entity Interactive Data Current Entity Interactive Data Current Thereafter Long-Term Debt, Maturity, after Year Five 2025 Finite-Lived Intangible Asset, Expected Amortization, Year Four Insurance benefits paid Payments for Insurance Benefits Payments for Insurance Benefits Settlements Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities Stock option activity, stock awards and other Stock Issued During Period, Value, Stock Options Exercised Settlement losses Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement Gross realized capital gains Debt Securities, Available-for-sale, Realized Gain Health insurer fee Health Insurer Fee Represents the estimated amount of the health insurer fee accrued during the reporting period, as required by Health Care Reform. Number of stores, planned closure period (in years) Number of Stores, Planned Closure Period Number of Stores, Planned Closure Period Balance Sheet Location [Domain] Balance Sheet Location [Domain] Cash paid for inventory and prescriptions dispensed by retail network pharmacies Payments for Inventory and Prescriptions Dispensed by Retail Network Pharmacies Payments for Inventory and Prescriptions Dispensed by Retail Network Pharmacies Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items] Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items] Beginning balance Ending balance Unrecognized Tax Benefits Debt securities, maturity, without single maturity date, unrealized losses Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, without Single Maturity Date, Amortized Cost Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, without Single Maturity Date, Amortized Cost Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Gross Unrealized Gains Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Entity Address, State or Province Entity Address, State or Province Leases Lessee, Finance Leases [Text Block] Drogaria onofre Ltda. Drogaria onofre Ltda. [Member] Drogaria onofre Ltda. Lincoln Life & Annuity Company of New York Lincoln Life & Annuity Company Of New York [Member] Lincoln Life & Annuity Company Of New York [Member] Right-of-use assets obtained in exchange for lease obligations: Right-Of-Use Asset Obtained In Exchange For Lease Liability [Abstract] Right-Of-Use Asset Obtained In Exchange For Lease Liability [Abstract] Yield-related impairment loss Yield Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings Yield Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings 2023 Mortgage Loans On Real Estate Collections Of Principal In Year Two Mortgage Loans On Real Estate Collections Of Principal In Year Two Balance at beginning of period (in shares) Balance at end of period (in shares) Shares, Outstanding Weighted average exercise price exercisable at end of year ($ per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Income tax penalties and interest accrued Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Senior Notes, 4.3%, Due 2028 Senior Notes, 4 Point Three Percent, Due 2028 [Member] Senior Notes, 4 Point Three Percent, Due 2028 Equity securities Equity Securities [Member] Accounting Policies [Abstract] Accounting Policies [Abstract] 2025 Defined Benefit Plan, Expected Future Benefit Payment, Year Four Weighted average contractual term, outstanding at end of year Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term 3.875% senior notes due August 2047 Senior Notes, 3.875%, Due August 2047 [Member] Senior Notes, 3.875%, Due August 2047 [Member] Federal Current Federal Tax Expense (Benefit) Total operating lease liabilities Total operating lease liabilities Operating Lease, Liability 5.125% senior notes due July 2045 Senior Notes, 5.125%, Due July 2045 [Member] Senior Notes, 5.125%, Due July 2045 [Member] Document Transition Report Document Transition Report Income from continuing operations attributable to CVS Health Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent Common stock Common Stock, Value, Issued Finance leases Finance Lease, Weighted Average Discount Rate, Percent Insurance reserves Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Reserves Compensation not yet recognized, period for recognition Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Customer Concentration Risk Customer Concentration Risk [Member] Unvested at beginning of year (in dollars per share) Unvested at end of year (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Leases Lessee, Operating Leases [Text Block] Cash dividend declared (USD per share) Dividends Payable, Amount Per Share Real Estate Investment Real Estate Investment [Member] Carrying value and estimated fair value of certain financial instruments Fair Value, by Balance Sheet Grouping [Table Text Block] Amortization of right-of-use assets Finance Lease, Right-of-Use Asset, Amortization Commercial mortgage-backed securities Commercial Mortgage Backed Securities [Member] Debt securities, maturity, without single maturity date Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value Funded status Defined Benefit Plan, Funded (Unfunded) Status of Plan Schedule of reinsurance recoverables Ceded Credit Risk [Table Text Block] ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Schedule of valuation assumptions Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Investments Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] 3.625% senior notes due April 2027 Senior Notes, 3 Point 625 Percent, April 2027 [Member] Senior Notes, 3 Point 625 Percent, April 2027 Legal Entity [Axis] Legal Entity [Axis] 6.625% senior notes due June 2036 Senior Notes, 6.625%, Due June 2036 [Member] Senior Notes, 6.625%, Due June 2036 [Member] U.S. Department of Health and Human Services, ACA Risk Corridor Receivables U.S. Department of Health and Human Services, ACA Risk Corridor Receivables [Member] U.S. Department of Health and Human Services, ACA Risk Corridor Receivables Goodwill [Line Items] Goodwill [Line Items] 2022 Mortgage Loans On Real Estate Collections Of Principal In Next Twelve Months Mortgage Loans On Real Estate Collections Of Principal In Next Twelve Months Other Long-Term Insurance Liabilities Other Long-Term Insurance Liabilities [Member] Other Long-Term Insurance Liabilities [Member] Fair Value Debt Securities, Available-For-Sale, Unrealized Loss Position, Fair Value [Abstract] Debt Securities, Available-For-Sale, Unrealized Loss Position, Fair Value [Abstract] Retirement benefits Deferred Tax Liabilities, Retirement Benefits Deferred Tax Liabilities, Retirement Benefits Cost, Product and Service [Extensible List] Cost, Product and Service [Extensible Enumeration] Treasury shares held in trust (in shares) Treasury Stock, Shares, Held in Trust Treasury Stock, Shares, Held in Trust VOYA Retirement Insurance and Annuity Company VOYA Retirement Insurance And Annuity Company [Member] VOYA Retirement Insurance And Annuity Company [Member] Health care costs payable Health care costs payable, beginning of period, net Health care costs payable, end of period, net Liability for Unpaid Claims and Claims Adjustment Expense, Net Thereafter Finance Lease, Liability, to be Paid, after Year Five Changes in level 3 financial assets Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] 3.125% senior notes due March 2020 Senior Notes, 3.125%, Due March 2020 [Member] Senior Notes, 3.125%, Due March 2020 [Member] Entity [Domain] Entity [Domain] Accrued expenses Accrued Liabilities, Current Dividends declared per share (in dollars per share) Common Stock, Dividends, Per Share, Declared Revenues Revenues Revenue from Contract with Customer, Excluding Assessed Tax Cash receipts from customers Proceeds from Customers Cash paid for amounts included in the measurement of lease liabilities: Cash Flow, Lessee [Abstract] Cash Flow, Lessee [Abstract] Employee Stock Option Stock Options Share-based Payment Arrangement, Option [Member] Equity [Abstract] Equity [Abstract] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Consolidation Items [Domain] Consolidation Items [Domain] After five years through ten years Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, After Five Through Ten Years Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, After Five Through Ten Years Fair Value, Less than 12 months Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months Segment Reporting Segment Reporting Disclosure [Text Block] Finance leases Finance Lease, Weighted Average Remaining Lease Term Payments for ASR, amount Payments for Accelerated Share Repurchases, Amount Payments for Accelerated Share Repurchases, Amount Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Long-term debt and lease obligations Long-term Debt and Lease Obligation, Including Current Maturities Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-sale [Line Items] One year through five years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Document Fiscal Year Focus Document Fiscal Year Focus Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Gross transfers out of Level 3 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3 2027-2031 Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years Amount awarded from other party Litigation Settlement, Amount Awarded from Other Party Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Back-Up Credit Facilities Back-Up Credit Facilities [Member] Back-Up Credit Facilities [Member] U.S. corporate securities U.S. corporate securities Debt Security, Corporate, US [Member] Related Party Transactions Equity Method Investments [Policy Text Block] Long-Term Care Reporting Unit Long-Term Care Reporting Unit [Member] Long-Term Care Reporting Unit [Member] Other income Other Nonoperating Income (Expense) Other liabilities Increase (Decrease) in Other Operating Liabilities Expected to vest (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Number Other Payments for (Proceeds from) Other Investing Activities Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table] Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table] Deferred income Deferred Tax Assets, Deferred Income Maximum Maximum [Member] Share-based Payment Arrangement [Abstract] Share-based Payment Arrangement [Abstract] Components of Income Tax Expense (Benefit), Continuing Operations [Abstract] Components of Income Tax Expense (Benefit), Continuing Operations [Abstract] Charitable contribution to CVS Health Foundation Related Party Transaction, Charitable Contribution To Non-Profit Entity Related Party Transaction, Charitable Contribution To Non-Profit Entity Award Type [Axis] Award Type [Axis] Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Maturities of operating lease liabilities Lessee, Operating Lease, Liability, Maturity [Table Text Block] Total CVS Health shareholders’ equity Stockholders' Equity Attributable to Parent Settled Litigation Settled Litigation [Member] Common/collective trusts, Equity Securities Defined Benefit Plan, Common Collective Trust, Equity Securities [Member] Defined Benefit Plan, Common Collective Trust, Equity Securities [Member] 2023 Lessee, Liability, Payments, Due Year Two Lessee, Liability, Payments, Due Year Two One year through five years Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, After One Through Five Years, Accumulated Loss Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, After One Through Five Years, Accumulated Loss City Area Code City Area Code Ceded Ceded Premiums Earned HSA balances Heath Savings Account Balance Heath Savings Account Balance Aggregate intrinsic value exercisable at end of year Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value 2.75% senior notes due November 2022 Senior Notes, 2.75%, Due November 2022 [Member] Senior Notes, 2.75%, Due November 2022 [Member] Schedule of reconciliation of cash and cash equivalents Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Redeemable preferred securities Redeemable Preferred Stock [Member] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Redeemable preferred securities Redeemable Preferred Securities [Member] Redeemable Preferred Securities [Member] Useful life of property plant and equipment Property, Plant and Equipment, Useful Life Fair Value Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract] Changes in Accumulated Other Comprehensive Income (Loss) by Component AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] Equity, Class of Treasury Stock [Line Items] Equity, Class of Treasury Stock [Line Items] Estimated maximum dividend distributions permitted in 2022 without prior regulatory approval Statutory Accounting Practices, Statutory Amount Available for Dividend Payments without Regulatory Approval Net investment income Investment Income, Net Long-term operating lease liabilities Long-term operating lease liabilities Operating Lease, Liability, Noncurrent Total lease payments Finance Lease, Liability, Payment, Due Adjustments for New Accounting Pronouncements [Axis] Accounting Standards Update [Axis] Total current taxes Current Income Tax Expense (Benefit) Debt face amount Debt Instrument, Face Amount Net periodic benefit cost Net periodic benefit cost (income) Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Policyholder Benefits and Claims Incurred, Net [Abstract] Policyholder Benefits and Claims Incurred, Net [Abstract] Share price (in dollars per share) Share Price Schedule of Defined Benefit Plans Disclosures [Table] Schedule of Defined Benefit Plans Disclosures [Table] Operating Segments Operating Segments [Member] Operating lease term (in years) Lessee, Operating Lease, Term of Contract Total finance lease liabilities Total finance lease liabilities Finance lease liabilities Finance Lease, Liability Total deferred income tax liabilities Deferred Tax Liabilities, Gross Business Acquisition [Line Items] Business Acquisition [Line Items] Share Repurchase Program [Axis] Share Repurchase Program [Axis] Income Statement [Abstract] Income Statement [Abstract] Entity Registrant Name Entity Registrant Name Number of plan members Number Of Plan Members Number Of Plan Members Components of Deferred Tax Assets and Liabilities [Abstract] Components of Deferred Tax Assets and Liabilities [Abstract] 2024 Finance Lease, Liability, to be Paid, Year Three 2025 Finance Lease, Liability, to be Paid, Year Four Schedule of impact of reinsurance on benefit costs Effects of Reinsurance [Table Text Block] 1.875%, senior notes due February 2031 Senior Notes, 1.875%, Due February 2031 [Member] Senior Notes, 1.875%, Due February 2031 4% senior notes due December 2023 Senior Notes, 4%, Due December 2023 [Member] Senior Notes, 4%, Due December 2023 [Member] Significant Accounting Policies Basis of Presentation and Significant Accounting Policies [Text Block] Weighted average exercise price, forfeited ($ per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Income tax provision Total Income Tax Expense (Benefit) 2024 Defined Benefit Plan, Expected Future Benefit Payment, Year Three Accounts receivable, net Total accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Inventory Deferred Tax Assets, Inventory Floating Rate Notes Floating Rate Notes [Member] Floating Rate Notes Insurance [Abstract] Insurance [Abstract] Dividends Payable [Table] Dividends Payable [Table] Entity Tax Identification Number Entity Tax Identification Number Hedge fund investments Hedge Funds Hedge Funds [Member] Change in plan assets: Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] Investment Type [Axis] Investment Type [Axis] Document Fiscal Period Focus Document Fiscal Period Focus Total current assets Assets, Current Dividends paid SEC Schedule, 12-04, Cash Dividends Paid to Registrant, Consolidated Subsidiaries Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] Total lease payments Lessee, Operating Lease, Liability, to be Paid Other receivables Accounts Receivable [Member] Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 3.375% senior notes due August 2024 Senior Notes, 3.375%, Due August 2024 [Member] Senior Notes, 3.375%, Due August 2024 [Member] Share-Based Compensation Share-based Payment Arrangement [Policy Text Block] Fair Value Debt Securities, Available-for-sale, Fair Value, Fiscal Year Maturity [Abstract] Schedule of Variable Interest Entities [Table] Schedule of Variable Interest Entities [Table] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] 1.3% senior notes due August 2027 Senior Notes, 1.3%, Due August 2027 [Member] Senior Notes, 1.3%, Due August 2027 Change in Contract with Customer, Liability [Roll Forward] Change in Contract with Customer, Liability [Roll Forward] Change in Contract with Customer, Liability Compensation not yet recognized, options Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount 4.75% senior notes due March 2044 Senior Notes, 4.75%, Due March 2044 [Member] Senior Notes, 4.75%, Due March 2044 [Member] Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] ESPP issuances, net of purchase of treasury shares ESPP Issuance, Net of Treasury Stock, Value, Acquired, Cost Method ESPP Issuance, Net of Treasury Stock, Value, Acquired, Cost Method Debt discounts and deferred financing costs Debt Instrument, Unamortized Discount and Debt Issuance Costs, Net Debt Instrument, Unamortized Discount and Debt Issuance Costs, Net Compensation not yet recognized, other than options Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Employee Stock Options and Stock Appreciation Rights Employee Stock Options and Stock Appreciation Rights [Member] Employee Stock Options and Stock Appreciation Rights [Member] Revenues Revenue Benchmark [Member] Equity Component [Domain] Equity Component [Domain] Gains from sale-leaseback transactions Sale and Leaseback Transaction, Gain (Loss), Net Total lease payments Lessee, Liability, Payments, Due Lessee, Liability, Payments, Due Mortgage loans Mortgage Loans [Member] Represents mortgage loans for the reporting period measured at carrying value. We carry the value of our mortgage loan investments on our balance sheet at the unpaid principal balance, net of impairment reserves. 2024 Lessee, Liability, Payments, Due Year Three Lessee, Liability, Payments, Due Year Three 2022 Lessee, Operating Lease, Liability, to be Paid, Year One Disposal Group Name [Domain] Disposal Group Name [Domain] Total Mortgage Loans on Real Estate, Commercial and Consumer, Net Variable Interest Entity [Line Items] Variable Interest Entity [Line Items] Defined Benefit Plan, Plan Assets, Category [Axis] Defined Benefit Plan, Plan Assets, Category [Axis] Deferred income tax assets: Components of Deferred Tax Assets [Abstract] Litigation Case [Axis] Litigation Case [Axis] Proceeds from VIE Proceeds From Variable Interest Entity Proceeds From Variable Interest Entity 4.3% senior notes due 2028 Senior Notes, 4.3%, Due 2028 [Member] Senior Notes, 4.3%, Due 2028 Floating rate notes due March 2021 Floating Rate Notes Due March 2021 [Member] Floating Rate Notes Due March 2021 [Member] Restricted cash (included in other assets) Restricted Cash, Noncurrent Total Investments [Line Items] Total Investments [Line Items] Purchases of investments Payments to Acquire Investments Other Insurance Liabilities Other Insurance Liabilities [Member] Other Insurance Liabilities [Member] Short-term Debt, Type [Axis] Short-term Debt, Type [Axis] Liabilities: Liabilities [Abstract] Transfers out of Level 3 Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Assets Transferred into (out of) Level 3 Schedule of changes in fair value of plan assets Schedule of Allocation of Plan Assets [Table Text Block] 3.35% senior notes due March 2021 Senior Notes, 3.35%, Due March 2021 [Member] Senior Notes, 3.35%, Due March 2021 [Member] Schedule of changes in benefit obligations Schedule of Changes in Projected Benefit Obligations [Table Text Block] Counterparty Name [Domain] Counterparty Name [Domain] 2025 Lessee, Operating Lease, Liability, to be Paid, Year Four Intangible assets, gross Intangible Assets, Gross (Excluding Goodwill) Foreign securities Foreign Government Short-term Debt Securities [Member] Barclays Bank Barclays Bank [Member] Barclays Bank Other increases (decreases) in noncontrolling interest Noncontrolling interest, Other Period Increase (Decrease) Noncontrolling interest, Other Period Increase (Decrease) Current portion of long-term debt Finance Lease, Liability, Current 4.125% senior notes due April 2040 Senior Notes, 4.125%, Due April 2040 [Member] Senior Notes, 4.125%, Due April 2040 Income before income tax provision Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Level 2 Fair Value, Inputs, Level 2 [Member] Type of Adoption [Domain] Accounting Standards Update [Domain] Assumed interest rates on limited payment pension contracts on large case pension business (in hundredths) Limited Payments Contracts Minimum assumed interest rates on limited payment contracts on large case pensions business. Auditor Location Auditor Location Fair Value Debt Securities, Available-for-sale, Unrealized Loss Position Segment Reporting [Abstract] Segment Reporting [Abstract] Finance lease term (in years) Lessee, Finance Lease, Term of Contract Acquisitions, net Liability for Unpaid Claims and Claims Adjustment Expense, Business Acquisitions Debt securities available for sale Debt And Equity Securities Available For Sale [Member] Investments in debt and equity securities which are categorized neither as trading securities nor held-to-maturity securities. Such securities are reported at fair value; unrealized gains and losses related to Available-for-sale securities are excluded from earnings and reported in a separate component of shareholders' equity (other comprehensive income) Interest on lease liabilities Finance Lease, Interest Expense Use of Estimates Use of Estimates, Policy [Policy Text Block] Reconciliation of basic and diluted earnings (loss) per share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Finance Leases Finance Lease, Liability, Payment, Due [Abstract] Premiums Earned, Net [Abstract] Premiums Earned, Net [Abstract] Title of 12(b) Security Title of 12(b) Security Net realized capital gains Realized Investment Gains (Losses) Investment, Name [Domain] Investment, Name [Domain] Deferred income taxes Deferred Income Taxes and Tax Credits Common stock, shares authorized (in shares) Common Stock, Shares Authorized Document Type Document Type Accumulated depreciation Finance Lease, Right-Of-Use Asset, Accumulated Depreciation Finance Lease, Right-Of-Use Asset, Accumulated Depreciation Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Product and Service [Domain] Product and Service [Domain] Schedule of liability for unpaid claims and claims adjustment expense Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block] Debt interest rate Debt Instrument, Interest Rate, Stated Percentage 6.75% senior notes due December 2037 Senior Notes, 6.75%, Due December 2037 [Member] Senior Notes, 6.75%, Due December 2037 [Member] Net (income) loss attributable to noncontrolling interests Comprehensive (income) loss attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Weighted Average Life (years) Finite-Lived Intangible Asset, Weighted Average Period before Next Renewal or Extension Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Audit methodology sample size Loss Contingency, Audit Methodology Sample Size Loss Contingency, Audit Methodology Sample Size Measurement Frequency [Axis] Measurement Frequency [Axis] Real Estate [Domain] Real Estate [Domain] Value of Business Acquired Value Of Business Acquired [Member] Value Of Business Acquired [Member] 3.875% senior notes due July 2025 Senior Notes, 3.875%, Due July 2025 [Member] Senior Notes, 3.875%, Due July 2025 [Member] Lease costs and supplemental cash flow information Lease, Cost [Table Text Block] Assumed Policyholder Benefits and Claims Incurred, Assumed Thereafter Lessee, Liability, Payments, Due After Year Five Lessee, Liability, Payments, Due After Year Five Weighted average discount rate Leases, Weighted Average Discount Rate [Abstract] Leases, Weighted Average Discount Rate [Abstract] Other investments Other Investments [Member] 5.45% senior notes due June 2021 Senior Notes, 5.45%, Due June 2021 [Member] This item represents senior notes due 2021 with a coupon rate of 5.45%. Brazil Subsidiary Brazil Subsidiary [Member] Brazil Subsidiary [Member] Products Product [Member] 2.125% senior notes due September 2031 Senior Notes, 2 Point 125 Percent, Due September 2031 [Member] Senior Notes, 2 Point 125 Percent, Due September 2031 Financial liabilities fair value on a recurring basis Financial Liabilities Fair Value Disclosure Divestitures Mergers, Acquisitions and Dispositions Disclosures [Text Block] Number of people served Number Of People Served Number Of People Served Investments Investment, Policy [Policy Text Block] Weighted average duration of securities Debt Securities, Available-For-Sale, Weighted Average Duration Of Securities Debt Securities, Available-For-Sale, Weighted Average Duration Of Securities Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Treasury stock, at cost: 422 and 423 shares at December 31, 2021 and 2020 Treasury Stock, Value Separate Accounts, financial assets Separate Account, Financial Assets [Member] Separate Account, Financial Assets Investment contracts with a fixed maturity Investment Contracts With Fixed Maturity, Fair Value Disclosure Investment Contracts With Fixed Maturity, Fair Value Disclosure. Award vesting period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Income tax penalties and interest expense Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense 3.5% senior notes due November 2024 Senior Notes, 3.5%, Due November 2024 [Member] Senior Notes, 3.5%, Due November 2024 [Member] Former gain contingency, recognized in current period, net of tax Former Gain Contingency, Recognized in Current Period, Net of Tax Former Gain Contingency, Recognized in Current Period, Net of Tax Maturities of financing lease liabilities Finance Lease, Liability, Fiscal Year Maturity [Table Text Block] Fair Value Fair Value Disclosures [Text Block] 2021 ASR 2021 Accelerated Repurchase Program [Member] 2021 Accelerated Repurchase Program Concentration Risk Type [Axis] Concentration Risk Type [Axis] Other insurance liabilities Other Insurance Liabilities, Current Other Insurance Liabilities, Current 2.75% senior notes due December 2022 Senior Notes, 2.75%, Due December 2022 [Member] Senior Notes, 2.75%, Due December 2022 [Member] Fair Value, Separate Account Investment [Line Items] Fair Value, Separate Account Investment [Line Items] Derivative settlements Proceeds from derivative instruments Payments for (Proceeds from) Derivative Instrument, Financing Activities 2024 Finite-Lived Intangible Asset, Expected Amortization, Year Three Loss from discontinued operations attributable to CVS Health (in dollars per share) Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share Auditor Information [Abstract] Auditor Information [Abstract] Premium deficiency reserve Add: Premium deficiency reserve Premium Deficiency Reserve Liability The amount of reserves related to expected future claims, including maintenance costs (for example, direct costs such as claim processing costs), in excess of existing reserves plus anticipated future premiums and reinsurance recoveries. Other revenues from transactions with related party Related Party Transaction, Other Revenues from Transactions with Related Party 1.875% senior notes due February 2031 Senior Notes, 1 Point 875 Percent, February 2031 [Member] Senior Notes, 1 Point 875 Percent, February 2031 Total lease liabilities Lease, Liability Lease, Liability Revenues: Revenues [Abstract] Goodwill Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Document Period End Date Document Period End Date 2025 Lessee, Liability, Payments, Due Year Four Lessee, Liability, Payments, Due Year Four Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Aetna Inc 2010 Stock Incentive Plan Aetna Inc 2010 Stock Incentive Plan [Member] Aetna Inc 2010 Stock Incentive Plan [Member] 4.125% senior notes due November 2042 Senior Notes, 4.125%, Due November 2042 [Member] This item represents senior notes due 2042 with a coupon rate of 4.125%. Total Fair Value, Inputs, Level 1, 2 and 3 Fair Value, Inputs, Level 1, 2 and 3 [Member] Direct Policyholder Benefits and Claims Incurred, Direct Co-payments Net Revenues, Retail CoPayments Net Revenues, Retail CoPayments Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Consolidated Entities [Domain] Consolidated Entities [Domain] State income taxes, net of federal tax benefit Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent State Deferred State and Local Income Tax Expense (Benefit) Schedule of property and equipment Property, Plant and Equipment [Table Text Block] Debt instrument term Debt Instrument, Term Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-sale [Table] Fixtures, equipment and internally developed software Fixtures, Equipment And Internally Developed Software [Member] Fixtures, Equipment And Internally Developed Software [Member] Net investment income Net Investment Income Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net AOCI Including Portion Attributable to Noncontrolling Interest AOCI Including Portion Attributable to Noncontrolling Interest [Member] Mortgage loans Mortgages Held-for-sale, Fair Value Disclosure One year through five years Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, After One Through Five Years Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, After One Through Five Years Estimated annual pretax amortization for other acquired intangible assets over the next five years Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Included in other comprehensive income Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss) Repayments of long-term debt Repayments of Long-term Debt Earnings Per Share [Abstract] Earnings Per Share [Abstract] Loss from discontinued operations attributable to CVS Health (in dollars per share) Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share Total property and equipment Property, Plant and Equipment, Gross Allowance for credit loss Accounts Receivable, Allowance for Credit Loss Total revenues Revenues Cumulative translation adjustment from AOCI eliminated upon divestiture Amounts reclassified from accumulated other comprehensive loss, net of tax Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Liability for unpaid claims Liability for Unpaid Claims Represents the total liability on the balance sheet for unpaid claims for both short-duration and long-duration insurance contracts after reinsurance. Purchase of treasury shares, net of ESPP issuances Treasury Stock, Value, Acquired, Cost Method, Net Of ESPP Issuance Treasury Stock, Value, Acquired, Cost Method, Net Of ESPP Issuance Federal home loan bank advances maximum amount available Federal Home Loan Bank, Advances, General Debt Obligations, Maximum Amount Available Schedule of stock options and stock appreciation rights award activity Share-based Payment Arrangement, Option and Stock Appreciation Rights, Activity [Table Text Block] Estimated minimum statutory surplus required by regulators Statutory Accounting Practices, Statutory Capital and Surplus Required Weighted average exercise price, outstanding at beginning of year ($ per share) Weighted average exercise price, outstanding at end of year ($ per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Number of Securities Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions Supporting remaining products Supporting Remaining Products [Member] Debt securities in an unrealized capital loss position supporting remaining products. Number of states the Company has submitted regulatory filings for a January 2022 entrance into the individual public health insurance exchange Individual Public Health Insurance Exchanges, Submitted Regulatory Filings, Number of States Individual Public Health Insurance Exchanges, Submitted Regulatory Filings, Number of States Entity Current Reporting Status Entity Current Reporting Status Weighted average grant date fair value (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Beginning balance Ending balance Fair value of plan assets Defined Benefit Plan, Plan Assets, Amount Premiums Premiums [Member] Premiums [Member] Effective income tax rate Effective Income Tax Rate Reconciliation, Percent 5.75% senior notes due May 2041 Senior Notes, 5.75%, Due May 2041 [Member] Senior Notes, 5.75%, Due May 2041 [Member] Other Debt Obligations Other Debt Obligations [Member] Leases, amount due in excess of remaining estimated economic life Operating And Capital Leases, Amount Due In Excess Of Remaining Estimated Economic Life Operating And Capital Leases, Amount Due In Excess Of Remaining Estimated Economic Life Counterparty Name [Axis] Counterparty Name [Axis] Proceeds from sales and maturities of investments Proceeds from Sale and Maturity of Marketable Securities Trade receivables Contract with Customer, Asset, after Allowance for Credit Loss, Current Capital shares reserved for future issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Leases [Abstract] Leases [Abstract] Income Taxes Income Tax, Policy [Policy Text Block] Intangible Assets Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block] Total health care costs payable Health care costs payable, beginning of period Health care costs payable, end of period Liability for Claims and Claims Adjustment Expense Disposal Group Classification [Domain] Disposal Group Classification [Domain] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Weighted average diluted shares outstanding (in shares) Weighted average shares, diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted 2020 Short-Duration Insurance Contract, Accident Year 2019 [Member] Income Taxes Income Tax Disclosure [Text Block] Lease renewal term Lessee, Operating And Finance Leases, Renewal Term Lessee, Operating And Finance Leases, Renewal Term Radcliff and Flaim v Aetna Inc., et al Radcliff and Flaim v Aetna Inc., et al [Member] Radcliff and Flaim v Aetna Inc., et al 3.75% senior notes due April 2030 Senior Notes, 3 Point 75 Percent, April 2030 [Member] Senior Notes, 3 Point 75 Percent, April 2030 Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Greater than ten years Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, After Ten Years, Accumulated Loss Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, After Ten Years, Accumulated Loss Schedule of net periodic benefit cost Schedule of Net Benefit Costs [Table Text Block] Less than one year Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, Within One Year Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, Within One Year Total incurred health care costs Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims Ceded Credit Risk [Table] Ceded Credit Risk [Table] Investment expenses Investment Income, Investment Expense Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Total Investments [Axis] Total Investments [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Entity Address, Address Line One Entity Address, Address Line One Accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Amended contract term (in years) Variable Interest Entity, Amended Contract Term Variable Interest Entity, Amended Contract Term Net unrealized investment gains (losses) Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Other long-term insurance liabilities Other Insurance Liabilities, Noncurrent Other Insurance Liabilities, Noncurrent Entity Shell Company Entity Shell Company Deferred acquisition costs Deferred Policy Acquisition Cost Expected life (in years) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Total current liabilities Liabilities, Current Employee Stock Employee Stock [Member] Payments for taxes related to net share settlement of equity awards Payments for taxes for net share settlement of equity awards Payment, Tax Withholding, Share-based Payment Arrangement Intersegment Eliminations Intersegment Eliminations [Member] Assumed interest rates on long-duration group life and long-term care contracts Assumed Interest Rates On Long Duration Group Life And Long Term Care Contracts Assumed Interest Rates On Long Duration Group Life And Long Term Care Contracts Litigation Status [Domain] Litigation Status [Domain] Ceded Policyholder Benefits and Claims Incurred, Ceded Operating lease, right-of-use asset, fair value Operating lease, Right-of-Use Asset, Fair Value Disclosure Operating lease, Right-of-Use Asset, Fair Value Disclosure Amended contract extension term Variable Interest Entity, Amended Contract Extension Term Variable Interest Entity, Amended Contract Extension Term Premium Deficiency Reserves Insurance Premium Deficiency Reserve [Policy Text Block] Insurance Premium Deficiency Reserve [Policy Text Block] Accounts payable Accounts Payable, Trade, Current Loss Contingencies [Table] Loss Contingencies [Table] Aggregate intrinsic value vested at end of year and expected to vest in the future Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Current Fiscal Year End Date Current Fiscal Year End Date 2020 Year Of Origination Period Two [Member] Year Of Origination Period Two Statement [Table] Statement [Table] Total claims paid Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid Net investment income Investment Income [Table Text Block] New Accounting Pronouncements Recently Adopted and Not Yet Adopted New Accounting Pronouncements, Policy [Policy Text Block] Other Deferred Tax Assets, Other Number of Securities, Greater than 12 months Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions 2026 Defined Benefit Plan, Expected Future Benefit Payment, Year Five Mortgage loans foreclosed SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate, Foreclosure Statistical Measurement [Axis] Statistical Measurement [Axis] Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration] Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration] Subsequent Event Subsequent Event [Member] Long-term debt Finance Lease, Liability, Noncurrent Loss from discontinued operations Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax 4.5% senior notes due May 2042 Senior Notes, 4.5%, Due May 2042 [Member] Senior Notes, 4.5%, Due May 2042 [Member] Finite-lived intangible assets, net carrying amount Finite-Lived Intangible Assets, Net Goodwill Balance, beginning of the period Balance, end of the period Goodwill Cash and cash equivalents Defined Benefit Plan, Cash and Cash Equivalents [Member] Noncontrolling interests Stockholders' Equity Attributable to Noncontrolling Interest Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Unrealized Losses, Less than 12 months Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss Hartford Life and Accident Insurance Company Hartford Life And Accident Insurance Company [Member] Hartford Life And Accident Insurance Company [Member] Fair Value Measured at Net Asset Value Per Share Fair Value Measured at Net Asset Value Per Share [Member] Other Intangible Assets[Line Items] Other Acquired Intangible Assets [Line Items] -- None. No documentation exists for this element. -- Scenario [Domain] Scenario [Domain] Change in goodwill Schedule of Goodwill [Table Text Block] Adjustments required to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Reinsurance Recoverables Reinsurance Accounting Policy [Policy Text Block] Operating lease cost Operating Lease, Cost Derivatives Defined Benefit Plan, Derivative [Member] Schedule of Investment Income, Reported Amounts, by Category [Line Items] Net Investment Income [Line Items] Unrealized Losses, Greater than 12 months Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss Cash paid to other suppliers and employees Payments to Suppliers and Employees Total deferred income taxes Deferred Income Tax Expense (Benefit) Common Stock and Capital Surplus Common Stock Including Additional Paid in Capital [Member] Weighted average remaining contractual term vested at end of year and expected to vest in the future Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Assets: Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract] Authorized Stock Repurchase Program, Authorized Amount Share repurchase programs Class of Treasury Stock [Table Text Block] Statutory income tax rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Separate account financial assets Fair Value, Separate Account Investment [Table Text Block] Earnings per Common Share Earnings Per Share, Policy [Policy Text Block] Acquisition-related integration costs Business Combination, Integration Related Costs Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Net income attributable to CVS Health Net Income (Loss) Attributable to Parent Accounts Receivable Receivable [Policy Text Block] New mortgage loans SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate, New Mortgage Loan Operating lease right-of-use assets Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Measurement of Defined Benefit Pension and Other Postretirement Employee Benefit (OPEB) Plans Pension and Other Postretirement Plans, Policy [Policy Text Block] Net operating loss and capital loss carryforwards Deferred Tax Assets, Operating Loss Carryforwards Interest cost Defined Benefit Plan, Interest Cost Finite-lived intangible assets, accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Statistical Measurement [Domain] Statistical Measurement [Domain] Cash proceeds received and tax benefit from share-based payment awards Cash Proceeds Received and Tax Benefit from Share-based Payment Awards [Table Text Block] Liability for Claims and Claims Adjustment Expense [Line Items] Liability for Claims and Claims Adjustment Expense [Line Items] Schedule of maturities of long-term debt Schedule of Maturities of Long-term Debt [Table Text Block] Payroll tax deferral Deferred Tax Assets, Payroll Tax Deferral Deferred Tax Assets, Payroll Tax Deferral Provider networks Provider networks [Member] Acquired in a business combination or other transaction. This item represents the value ascribed to the relationships with the acquiree's physicians, hospitals and other health care providers network. Segment Policy Segment Reporting, Policy [Policy Text Block] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Average purchase price of shares purchased (in dollars per share) Stock Issued During Period, Employee Stock Purchase Plan, Average Purchase Price of Shares Purchased Stock Issued During Period, Employee Stock Purchase Plan, Average Purchase Price of Shares Purchased Shares Held in Trust Shares Held In Trust [Policy Text Block] Shares Held In Trust [Policy Text Block] Other assets Other Assets, Noncurrent ASR, maximum amount of shares received or delivered Accelerated Share Repurchase Program, Maximum Number of Shares Accelerated Share Repurchase Program, Maximum Number of Shares Expected return on plan assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Segments [Axis] Segments [Axis] Health Care Contract Acquisition Costs Deferred Policy Acquisition Costs, Policy [Policy Text Block] Receipt related purchase price adjustment from acquisition Receipt from Business Combination, Purchase Price Adjustment, Outside of Measurement Period Receipt from Business Combination, Purchase Price Adjustment, Outside of Measurement Period Dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Retirement Benefits [Abstract] Retirement Benefits [Abstract] Amortized Cost Debt Securities, Available For Sale, Amortized Cost, Net Debt Securities, Available For Sale, Amortized Cost, Net 2025 Mortgage Loans On Real Estate Collections Of Principal In Year Four Mortgage Loans On Real Estate Collections Of Principal In Year Four Entity File Number Entity File Number Senior Notes, 3 Point 70 Percent, Due 2023 Senior Notes, 3 Point 70 Percent, Due 2023 [Member] Senior Notes, 3 Point 70 Percent, Due 2023 Expenses from transactions with related party Related Party Transaction, Expenses from Transactions with Related Party Debt securities available for sale Debt Securities, Available-for-sale [Table Text Block] Total Lessee, Leases Liabilities Payments Due [Abstract] Lessee, Leases Liabilities Payments Due [Abstract] ESPP issuances, net of purchase of treasury shares (in shares) ESPP Issuance, Net of Treasury Stock, Shares, Acquired, Cost Method ESPP Issuance, Net of Treasury Stock, Shares, Acquired, Cost Method Floating rate notes due March 2020 Floating Rate Notes Due March 2020 [Member] Floating Rate Notes Due March 2020 [Member] Variable lease costs Variable Lease, Cost Long-term debt Long-term Debt and Lease Obligation Insurance and HMO Insurance and HMO [Member] Insurance and HMO subsidiaries [Member]. Distribution centers and Corporate offices Building [Member] Retail/ LTC Retail Long-Term Care Segment [Member] Retail Long-Term Care Segment [Member] After five years through ten years Debt Securities, Available-For-Sale, Maturity, Allocated And Single Maturity Date, after Five Through Ten Years, Amortized Cost, Net Debt Securities, Available-For-Sale, Maturity, Allocated And Single Maturity Date, after Five Through Ten Years, Amortized Cost, Net Weighted-average grant date fair value (in dollars per share) Granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Vested in period, fair value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Commitment fee percentage Line of Credit Facility, Commitment Fee Percentage Actual return on plan assets Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss) Health Care Reform Health Care Entities, Policy [Policy Text Block] Pharmacy network Sales Channel, Through Intermediary [Member] ASR percent of notional amount received in shares Accelerated Share Repurchases, Percent of Notional Amount Received in Shares Accelerated Share Repurchases, Percent of Notional Amount Received in Shares 4.75% senior notes due December 2022 Senior Notes, 4.75%, Due December 2022 [Member] Senior Notes, 4.75%, Due December 2022 [Member] Schedule of Operating Leased Assets [Table] Schedule of Operating Leased Assets [Table] Disposal Group Name [Axis] Disposal Group Name [Axis] Noncurrent liabilities reflected in other long-term liabilities Liability, Defined Benefit Plan, Noncurrent Debt securities, maturity, without single maturity date Debt Securities, Available-For-sale, Maturity, Without Single Maturity Date, Amortized Cost, Net Debt Securities, Available-For-sale, Maturity, Without Single Maturity Date, Amortized Cost, Net Denominator for earnings per share calculation: Denominator For Earnings Per Share Calculation [Abstract] Denominator For Earnings Per Share Calculation [Abstract] Cumulative Paid Health Care Claims, Net of Reinsurance Short-duration Insurance Contracts, Cumulative Paid Claims and Allocated Claim Adjustment Expense, Net Share Repurchase Program [Domain] Share Repurchase Program [Domain] 6.125% senior notes due September 2039 Senior Notes, 6.125%, Due September 2039 [Member] Senior Notes, 6.125%, Due September 2039 [Member] Assets: Assets [Abstract] 2024 Long-Term Debt, Maturity, Year Three Cumulative goodwill impairments Goodwill, Impaired, Accumulated Impairment Loss Land Land [Member] Weighted average exercise price vested at end of year and expected to vest in the future ($ per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Ceded Credit Risk, Reinsurer [Domain] Ceded Credit Risk, Reinsurer [Domain] Finance leases Right-of-Use Asset Obtained in Exchange for Finance Lease Liability States, municipalities and political subdivisions States, municipalities and political subdivisions US States and Political Subdivisions Debt Securities [Member] Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Fair Value, Separate Account Investment [Table] Fair Value, Separate Account Investment [Table] Concentration risk, percent Concentration Risk, Percentage ASR agreement, amount Accelerated Share Repurchases Agreement, Amount Accelerated Share Repurchases Agreement, Amount Goodwill and Other Intangibles Goodwill and Intangible Assets Disclosure [Text Block] Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Significant Accounting Policies [Table] Accounting Standards Update and Change in Accounting Principle [Table] Shares, Outstanding at beginning of year (in shares) Shares, Outstanding at end of year (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number 3.75% senior notes due April 2030 Senior Notes, 3.75%, Due April 2030 [Member] Senior Notes, 3.75%, Due April 2030 Discount rate Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate Debt Instrument [Axis] Debt Instrument [Axis] Commercial Real Estate Commercial Real Estate [Member] Reinsurance Disclosures [Abstract] Reinsurance Disclosures [Abstract] Advertising Costs Advertising Cost [Policy Text Block] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Number of Securities Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Number of Positions [Abstract] Bad debts and other allowances Deferred Tax Assets, Tax Deferred Expense, Reserves And Accruals, Bad Debts And Other Allowances Deferred Tax Assets, Tax Deferred Expense, Reserves And Accruals, Bad Debts And Other Allowances Income tax benefit Discontinued Operation, Tax Effect of Discontinued Operation Contract with Customer, Sales Channel [Axis] Contract with Customer, Sales Channel [Axis] Finance leases: Finance Lease, Assets And Liabilities, Lessee [Abstract] Finance Lease, Assets And Liabilities, Lessee [Abstract] Operating leases Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3.25% senior notes due August 2029 Senior Notes, 3.25%, Due August 2029 [Member] Senior Notes, 3.25%, Due August 2029 [Member] Schedule of deferred tax assets and liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] 5% senior notes due December 2024 Senior Notes, 5%, Due December 2024 [Member] Senior Notes, 5%, Due December 2024 [Member] Prior years Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years Internal Credit Assessment [Domain] Internal Credit Assessment [Domain] Target investment allocations Defined Benefit Plan, Plan Assets, Target Allocation, Percentage Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Amount expected to be reclassified Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Number of operating segments Number of Operating Segments (Gain) loss on sale of subsidiaries Gain (loss) on sale of subsidiaries Gain (Loss) on Disposition of Business Number of claims Loss Contingency, Pending Claims, Number Number of reinsurance contracts entered into Number of Reinsurance Contracts Entered Into Number of reinsurance contracts entered into with an unrelated insurer. Pension and other postretirement benefits Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax U.S. government securities US Treasury and Government [Member] 2024 Lessee, Operating Lease, Liability, to be Paid, Year Three 2026 Finite-Lived Intangible Asset, Expected Amortization, after Year Five Prior year refund claim Effective Income Tax Rate Reconciliation, Tax Settlement, Domestic, Percent Initial contractual term (in years) Initial contractual term Variable Interest Entity, Initial Contractual Term Former gain contingency, recognized in current period, before tax Former Gain Contingency, Recognized in Current Period, Before Tax Former Gain Contingency, Recognized in Current Period, Before Tax Schedule of disaggregation of revenue Disaggregation of Revenue [Table Text Block] 2026 Long-Term Debt, Maturity, Year Five Units Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Debt securities, maturity, without single maturity date, fair value Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, without Single Maturity Date, Fair Value Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, without Single Maturity Date, Fair Value RSU and performance share unit activity Schedule of Nonvested Share Activity [Table Text Block] Gross investment income Investment Income, Interest and Dividend 5 and 6 Categories 5 and 6 [Member] Mortgage loan credit quality indicator - Categories 5 and 6 Purchase of treasury shares, net of ESPP issuances (in shares) Treasury Stock, Shares, Acquired, Cost Method, Net Of ESPP Issuance Treasury Stock, Shares, Acquired, Cost Method, Net Of ESPP Issuance Number of shares authorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Operating cash flows paid for operating leases Operating Lease, Payments Net repayments of short-term debt Proceeds from (Repayments of) Short-term Debt All outstanding liabilities for health care costs payable prior to 2020, net of reinsurance Short-duration Insurance Contracts, Liability for Unpaid Claims and Allocated Claim Adjustment Expense, Net, Not Separately Presented Receipt of fully reserved ACA risk corridor receivable Accounts Receivable, Allowance for Credit Loss, Recovery 1.75% senior notes due August 2030 Senior Notes, 1 Point 75 Percent, August 2030 [Member] Senior Notes, 1 Point 75 Percent, August 2030 Reinsurance recoverables Less: Reinsurance recoverables Add: Reinsurance recoverables Reinsurance Recoverable for Unpaid Claims and Claims Adjustments Property and equipment, net Finance Lease, Right-Of-Use Asset, Net Finance Lease, Right-Of-Use Asset, Net Statutory Accounting Practices [Line Items] Statutory Accounting Practices [Line Items] 4.875% senior notes due July 2035 Senior Notes, 4.875%, Due July 2035 [Member] Senior Notes, 4.875%, Due July 2035 [Member] Long-term debt Subtotal Amount outstanding Long-term Debt, Gross Goodwill [Roll Forward] Goodwill [Roll Forward] Reporting Unit [Axis] Reporting Unit [Axis] Claims Development [Line Items] Claims Development [Line Items] Income from continuing operations attributable to CVS Health (in dollars per share) Earnings (loss) per share from continuing operations, diluted (USD per share) Income (Loss) from Continuing Operations, Per Diluted Share 6.25% senior notes due June 2027 Senior Notes, 6.25%, Due June 2027 [Member] Senior Notes, 6.25%, Due June 2027 [Member] Total Assets, Fair Value Disclosure Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Red Oak Red Oak [Member] Red Oak Pharmacy Pharmacy Revenue [Member] Pharmacy Revenue [Member] Liabilities: Financial Instruments, Financial Liabilities, Balance Sheet Groupings [Abstract] Total liabilities and shareholders’ equity Liabilities and Equity Other Effective Income Tax Rate Reconciliation, Other Adjustments, Percent Investments, Debt and Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] Net cash flow hedges Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax 1.3% senior notes due August 2027 Senior Notes, 1 Point 3 Percent, August 2027 [Member] Senior Notes, 1 Point 3 Percent, August 2027 Future noncancelable subleases, future minimum payments Lessor, Operating Lease, Payments to be Received Contract liabilities (included in accrued expenses) Contract liabilities, beginning of period Contract liabilities, end of period Contract with Customer, Liability, Current 3.7% senior notes due March 2023 Senior Notes, 3.7%, Due March 2023 [Member] Senior Notes, 3.7%, Due March 2023 [Member] 2026 Lessee, Operating Lease, Liability, to be Paid, Year Five Weighted average remaining lease term (in years) Weighted Average Remaining Lease Term [Abstract] Weighted Average Remaining Lease Term [Abstract] Weighted average exercise price, exercised ($ per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Services Service [Member] Benefit payments Defined Benefit Plan, Plan Assets, Benefits Paid 4.25% senior notes due April 2050 Senior Notes, 4 Point 25 Percent, April 2050 [Member] Senior Notes, 4 Point 25 Percent, April 2050 U.S. government securities US Government Agencies Debt Securities [Member] 2.7% senior notes due August 2040 Senior Notes, 2.7%, Due August 2040 [Member] Senior Notes, 2.7%, Due August 2040 Concentration Risk [Line Items] Concentration Risk [Line Items] Operating leases: Operating Lease, Assets And Liabilities, Lessee [Abstract] Operating Lease, Assets And Liabilities, Lessee [Abstract] Purchases, sales and settlements Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Purchase, Sale, and Settlement Number of stores, annual planned closures for closure period Number of Stores, Annual Planned Closures For Closure Period Number of Stores, Annual Planned Closures For Closure Period Short-term Debt, Type [Domain] Short-term Debt, Type [Domain] Reconciliation of net income to net cash provided by operating activities: Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Contractual obligations underlying the guaranteed benefits Contractual Obligations To Maintain Levels Of Separate Accounts Represents the contractual obligation to maintain the required level of funding in Separate Accounts necessary to fund specific guaranteed pensions annuities. Earnings Per Share Earnings Per Share [Text Block] Operating costs: Operating Expenses [Abstract] Supporting experience- rated products Supporting Experience Rated Products [Member] Supporting discontinued and experience-rated products. Total outstanding liabilities for health care costs payable, net of reinsurance Short-duration health care costs payable, net of reinsurance Short-duration Insurance Contracts, Liability for Unpaid Claims and Allocated Claim Adjustment Expense, Net Statutory accounting practices disclosure Statutory Accounting Practices Disclosure [Table Text Block] 2023 Defined Benefit Plan, Expected Future Benefit Payment, Year Two Minimum Minimum [Member] Plan assets, investment within plan asset category, amount Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount 2023 Lessee, Operating Lease, Liability, to be Paid, Year Two Less than one year Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, Within One Year, Accumulated Loss Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, Within One Year, Accumulated Loss Depreciation and amortization Deferred Tax Liabilities, Depreciation and Amortization Deferred Tax Liabilities, Depreciation and Amortization - Amount of deferred tax liability attributable to taxable temporary differences from depreciation and amortization Reclassifications Reclassification, Comparability Adjustment [Policy Text Block] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Proceeds and related gross realized capital gains and losses from the sale of debt securities Proceeds And Related Gross Realized Capital Gains Losses From Sale Of Debt Securities [Table Text Block] This item includes proceeds from the sale of debt securities and the related gross realized capital gains and losses, excluding amounts related to experience-rated and discontinued products. Gain contingency, unrecorded amount Gain Contingency, Unrecorded Amount 2.875% senior notes due June 2026 Senior Notes, 2.875%, Due June 2026 [Member] Senior Notes, 2.875%, Due June 2026 [Member] Greater than ten years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10 Cumulative Effect, Period of Adoption [Axis] Cumulative Effect, Period of Adoption [Axis] OCI before Reclass, pre-tax Other Comprehensive Income (Loss), before Reclassifications, before Tax Fair Value, Greater than 12 months Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer Thereafter Mortgage Loans On Real Estate Collections Of Principal After Year Five Mortgage Loans On Real Estate Collections Of Principal After Year Five Schedule of change in level 3 plan assets Defined Benefit Plan, Plan Assets, Category [Table Text Block] 2025 Long-Term Debt, Maturity, Year Four Acquisitions (net of cash acquired) Payments to Acquire Businesses, Net of Cash Acquired Borrowings and Credit Arrangements Debt Disclosure [Text Block] Assets (liabilities) recognized on the consolidated balance sheet Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract] All Other All Other Reinsurers [Member] All Other Reinsurers [Member] Schedule of components of income tax expense (benefit) Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] 4.3% senior notes due March 2028 Senior Notes, 4.3%, Due March 2028 [Member] Senior Notes, 4.3%, Due March 2028 [Member] Line of Credit Line of Credit [Member] Stock Incentive Plans Share-based Payment Arrangement [Text Block] Senior Notes Senior Notes [Member] Common/collective trusts Defined Benefit Plan, Common Collective Trust [Member] Level 3 Fair Value, Inputs, Level 3 [Member] Right-of-Use Assets and Lease Liabilities Lessee, Leases [Policy Text Block] Premium receivables Premiums Receivable, Net Investments Deferred Tax Liabilities, Investments Number of reportable segments Number of Reportable Segments Fair value of stock options and SARs vested Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Vested In Period, Fair Value Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Vested In Period, Fair Value Total debt principal Total debt principal Long-term Debt, Gross And Lease Obligation Long-term Debt, Gross And Lease Obligation Supplemental balance sheet information Lessee, Lease [Table Text Block] Lessee, Lease [Table Text Block] Health Care Benefits Health Care Benefits Segment [Member] Health Care Benefits Segment [Member] Net investment income (excluding net realized capital gains or losses) Investment Income, Excluding Capital Gains or Losses Investment Income, Excluding Capital Gains or Losses Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Reinsurance Reinsurance [Text Block] Acquisitions Goodwill, Acquired During Period Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Other Postretirement Benefits Other Postretirement Benefits Plan [Member] Commitments and contingencies (Note 16) Commitments and Contingencies Long-term Debt, Fiscal Year Maturity [Abstract] Long-term Debt, Fiscal Year Maturity [Abstract] Health care costs payable and other insurance liabilities Increase (Decrease) in Insurance Liabilities Subsequent Event [Table] Subsequent Event [Table] Other Insurance Liabilities Unpaid Policy Claims and Claims Adjustment Expense, Policy [Policy Text Block] Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Emerging Growth Company Entity Emerging Growth Company Class of Treasury Stock [Table] Class of Treasury Stock [Table] Proceeds from debt Proceeds from Debt, Net of Issuance Costs Future policy benefits Liability for Future Policy Benefit, before Reinsurance Real Estate, Type of Property [Axis] Real Estate, Type of Property [Axis] Disposal Group Classification [Axis] Disposal Group Classification [Axis] Common/collective trusts Common and Collective Trusts [Member] The total amount of Common/Collective Trusts held by the company, primarily related to investment funds otherwise known as underlying funds. ASU 2016-13 Accounting Standards Update 2016-13 [Member] Auditor Name Auditor Name Cover [Abstract] Cover [Abstract] Operating lease assets Property Subject to Operating Lease [Member] Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) claims liability, net Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net Property and equipment, gross Finance Lease, Right-Of-Use Asset, Gross Finance Lease, Right-Of-Use Asset, Gross Total operating costs Costs and Expenses Loss on net cash flow hedges Other comprehensive income (loss) before reclassifications Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Treasury stock, shares (in shares) Treasury Stock, Shares Debt securities in an unrealized capital loss position Schedule of Unrealized Loss on Investments [Table Text Block] Less: imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Total reinsurance recoverables Reinsurance Recoverable for Paid and Unpaid Claims and Claims Adjustments CVS Health 2017 Incentive Compensation Plan CVS Health 2017 Incentive Compensation Plan [Member] CVS Health 2017 Incentive Compensation Plan [Member] Financial Instrument [Axis] Financial Instrument [Axis] Short-term Debt [Line Items] Short-term Debt [Line Items] Less: imputed interest Finance Lease, Liability, Undiscounted Excess Amount Dividends paid Payments of Dividends Current: Current Income Tax Expense (Benefit), Continuing Operations [Abstract] Outstanding Senior Notes Outstanding Senior Notes [Member] Outstanding Senior Notes [Member] Carrying Value Reported Value Measurement [Member] 2026 Lessee, Liability, Payments, Due Year Five Lessee, Liability, Payments, Due Year Five 2026 Finance Lease, Liability, to be Paid, Year Five Common Shares Common Stock [Member] Less: Claims paid Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid [Abstract] Revenues Revenues from external customers Premiums Earned, Net And Revenue From Contract With Customer, Excluding Assessed Tax Premiums Earned, Net And Revenue From Contract With Customer, Excluding Assessed Tax Operating income Operating income (GAAP measure) Operating Income (Loss) Defined contribution plan, employer contributions Defined Contribution Plan, Employer Discretionary Contribution Amount 3.625% senior notes due April 2027 Senior Notes, 3.625%, Due April 2027 [Member] Senior Notes, 3.625%, Due April 2027 Current portion of operating lease liabilities Current portion of operating lease liabilities Operating Lease, Liability, Current Gross Unrealized Losses Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Shares repurchased (in shares) Treasury Stock, Common, Shares 2023 Finite-Lived Intangible Asset, Expected Amortization, Year Two Stock-based compensation Share-based Payment Arrangement, Noncash Expense Policyholders' Funds Allocations to Policyholders, Policies [Policy Text Block] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Depreciation Depreciation Investments on deposit with regulatory bodies Assets Held by Insurance Regulators Mail choice Sales Channel, Directly to Consumer [Member] Technology Technology-Based Intangible Assets [Member] Treasury Shares Treasury Stock [Member] Real estate Defined Benefit Plan, Real Estate [Member] Benefit payments Defined Benefit Plan, Benefit Obligation, Benefits Paid 4.25% senior notes due April 2050 Senior Notes, 4.25%, Due April 2050 [Member] Senior Notes, 4.25%, Due April 2050 Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Property and equipment Property, Plant and Equipment [Member] Short-duration Insurance Contracts, Accident Year [Domain] Short-duration Insurance Contracts, Accident Year [Domain] Employer contributions Employer contributions Defined Benefit Plan, Plan Assets, Contributions by Employer Less than one year Debt Securities, Available-For-Sale, Maturity, Allocated And Single Maturity Date, Within One Year, Amortized Cost, Net Debt Securities, Available-For-Sale, Maturity, Allocated And Single Maturity Date, Within One Year, Amortized Cost, Net Total liabilities Liabilities Internal Credit Assessment [Axis] Internal Credit Assessment [Axis] 2022 Finite-Lived Intangible Asset, Expected Amortization, Year One Weighted average exercise price, granted ($ per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Aggregate Intrinsic value outstanding at end of year Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Mortgage Loans On Real Estate Year Of Origination [Axis] Mortgage Loans On Real Estate Year Of Origination [Axis] Mortgage Loans On Real Estate Year Of Origination Shares expired (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 4.125% senior notes due April 2040 Senior Notes, 4 Point 125 Percent, April 2040 [Member] Senior Notes, 4 Point 125 Percent, April 2040 2019 Year Of Origination Period Three [Member] Year Of Origination Period Three Consolidation Items [Axis] Consolidation Items [Axis] Current year Current Year Claims and Claims Adjustment Expense Common stock, shares issued (in shares) Common Stock, Shares, Issued Schedule of changes in plan assets Schedule of Changes in Fair Value of Plan Assets [Table Text Block] Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Weighted average assumptions used in determining benefit obligations and net benefit costs Defined Benefit Plan, Assumptions [Table Text Block] Entity Address, City or Town Entity Address, City or Town Loss on early extinguishment of debt Gain (Loss) on Extinguishment of Debt Gross realized capital losses Debt Securities, Available-for-sale, Realized Loss Variable Interest Entities Consolidation, Variable Interest Entity, Policy [Policy Text Block] Schedule of expected future benefits payments Schedule of Expected Benefit Payments [Table Text Block] Schedule of Accumulated Other Comprehensive Income (Loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Retirement Plan Type [Axis] Retirement Plan Type [Axis] Schedule of unrecognized tax benefits roll forward Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] Software Software and Software Development Costs [Member] Rewards earnings and gift card issuances Contract With Customer Liability Loyalty Program Earnings And Gift Card Issuance Amount of increase (decrease) in contract liability recognized for loyalty program earnings and gift card issuance. Balance Sheet Location [Axis] Balance Sheet Location [Axis] Other Comprehensive Income Comprehensive Income (Loss) Note [Text Block] Schedule of Short-term Debt [Table] Schedule of Short-term Debt [Table] Measurement Frequency [Domain] Measurement Frequency [Domain] ASU 2016-02 Accounting Standards Update 2016-02 [Member] Interest expense Interest Expense 2022 Finance Lease, Liability, to be Paid, Year One Deferred: Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract] Expected long-term rate of return on plan assets Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets 2022 Defined Benefit Plan, Expected Future Benefit Payment, Year One Retained earnings Retained Earnings (Accumulated Deficit) Expiration period Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Number of patients served per year (more than) Number of Patients Served per Year Number of Patients Served per Year Litigation Case [Domain] Litigation Case [Domain] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Shares issued employee stock purchase plan (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Entity Filer Category Entity Filer Category Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Concentration Risk [Table] Concentration Risk [Table] Health Care Costs Payable Health Care Costs, Policy [Policy Text Block] Estimated Fair Value Estimate of Fair Value Measurement [Member] Common/collective trusts, Debt Securities Defined Benefit Plan, Common Collective Trust, Debt Securities [Member] Defined Benefit Plan, Common Collective Trust, Debt Securities [Member] Transfers into Level 3, net Net transfers into Level 3 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net Combined statutory capital and surplus Statutory Accounting Practices, Statutory Capital and Surplus, Balance Stock options granted subsequent to 2018 Share-Based Payment Arrangement, Option, Granted Subsequent to 2018 [Member] Share-Based Payment Arrangement, Option, Granted Subsequent to 2018 Mortgage Loans on Real Estate [Line Items] SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items] Indefinite-lived intangible assets, Trademarks Indefinite-lived Intangible Assets (Excluding Goodwill) 1 Category 1 [Member] Mortgage Loan Credit Quality Indicator - Category 1 [Member]. Proceeds from exercise of stock options Cash received from stock options exercised (including ESPP) Proceeds from Stock Options Exercised Investments Current Short-term Investments 2023 Finance Lease, Liability, to be Paid, Year Two Proceeds from sale-leaseback transactions Proceeds from Lease Payment, Sales-Type and Direct Financing Leases, Investing Activity Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Total shareholders’ equity Beginning of year balance End of year balance Cumulative adjustment to retained earnings as a result of new accounting standard adoption Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Amendment Flag Amendment Flag Benefit costs recorded in other insurance liabilities Liability For Unpaid Claims And Claims Adjustment Expense, Claims Paid, Excluded From Total Incurred Health Care Costs Liability For Unpaid Claims And Claims Adjustment Expense, Claims Paid, Excluded From Total Incurred Health Care Costs Proceeds from issuance of long-term debt Proceeds from Issuance of Long-term Debt Other intangible assets Finite lived and indefinite lived intangible assets [Table Text Block] Tabular disclosure of the cost, accumulated amortization and net balance of intangibles assets and amortization period, in total and by major class. Finite-lived intangible assets have a stated useful life over which their gross carrying value is amortized. Indefinite intangible assets have a projected indefinite period of benefit (hence are not amortized). Interest rate for pension and annuity investment contracts Pension And Annuity Investment Contracts Interest Pension And Annuity Investment Contracts Interest Equity Components [Axis] Equity Components [Axis] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Premium paid in excess of debt principal Gain (Loss) on Extinguishment of Debt, before Write off of Debt Issuance Cost Concentration Risk Type [Domain] Concentration Risk Type [Domain] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Sales Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Sales ASR, shares to be received at the end of program as a percent of notional amount Accelerated Share Repurchases, Percent of Notional Amount in Shares to be Received at End of Program Accelerated Share Repurchases, Percent of Notional Amount in Shares to be Received at End of Program Inventories Inventory, Net Add: Components of incurred health care costs Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims [Abstract] Summarized financial information of segments Schedule of Segment Reporting Information, by Segment [Table Text Block] Federal Deferred Federal Income Tax Expense (Benefit) Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Weighted average exercise price, expired ($ per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five Investments related to 2012 contract conversion Restricted Investments, at Fair Value Settlements Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements Product and Service [Axis] Product and Service [Axis] One year through five years Debt Securities, Available-For-Sale, Maturity, Allocated And Single Maturity Date, After One Through Five Years, Amortized Cost, Net Debt Securities, Available-For-Sale, Maturity, Allocated And Single Maturity Date, After One Through Five Years, Amortized Cost, Net Equity securities Equity Securities without Readily Determinable Fair Value, Amount Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Entity Public Float Entity Public Float Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Short-term lease costs Short-term Lease, Cost Discontinued Operations, Disposed of by Sale Discontinued Operations, Disposed of by Sale [Member] Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Notes Payable Notes Payable to Banks [Member] Adjusted operating income (loss) Adjusted operating income Adjusted Operating Income (Loss) Adjusted Operating Income (Loss) 1.75% senior notes due August 2030 Senior Notes, 1.75%, Due August 2030 [Member] Senior Notes, 1.75%, Due August 2030 Investments [Abstract] Investments [Abstract] Statement [Line Items] Statement [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Dividends Payable [Line Items] Dividends Payable [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Total Investments Retirement Plan Type [Domain] Retirement Plan Type [Domain] Fair Value Total Debt securities Debt Securities, Available-for-sale Information about incurred and paid health care claims development Short-duration Insurance Contracts, Claims Development [Table Text Block] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Purchase price of common stock percent Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent 2026 Mortgage Loans On Real Estate Collections Of Principal In Year Five Mortgage Loans On Real Estate Collections Of Principal In Year Five Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Valuation allowance Valuation allowance Deferred Tax Assets, Valuation Allowance Vendor and manufacturer receivables Vendor and Manufacturer Receivables Vendor and Manufacturer Receivables Corporate/ Other Corporate, Non-Segment [Member] Net gain on write-off of net unamortized deferred financing premiums on early extinguishment of debt Net Gain from Write Off of Deferred Debt Issuance Costs Net Gain from Write Off of Deferred Debt Issuance Costs Customer [Axis] Customer [Axis] Pension Plans and Other Postretirement Benefits Retirement Benefits [Text Block] Shares granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Document Annual Report Document Annual Report Forecast Forecast [Member] Stock-based compensation Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Net unrealized investment gains (losses) AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Including Noncontrolling Interest [Member] Divestiture of Workers’ Compensation business Goodwill, Written off Related to Sale of Business Unit Lease and rents Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Deferred Rent Total assets Assets 2.625% senior notes due August 2024 Senior Notes, 2.625%, Due August 2024 [Member] Senior Notes, 2.625%, Due August 2024 [Member] Plan Name [Domain] Plan Name [Domain] Deferred income tax liabilities: Components of Deferred Tax Liabilities [Abstract] U.S. domestic Defined Benefit Plan, Equity Securities, US [Member] Interest paid Interest Paid, Excluding Capitalized Interest, Operating Activities Basis difference upon disposition of subsidiary Effective Income Tax Rate Reconciliation, Disposition of Business, Percent Noncontrolling Interests Noncontrolling Interest [Member] Statutory Accounting Practices [Table] Statutory Accounting Practices [Table] Schedule of accounts receivable, net Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Premiums Net premiums Premiums Earned, Net 2.8% senior notes due June 2023 Senior Notes, 2.8%, Due June 2023 [Member] Senior Notes, 2.8%, Due June 2023 [Member] Short-duration Insurance Contracts, Accident Year [Axis] Short-duration Insurance Contracts, Accident Year [Axis] Cumulative Effect, Period of Adoption [Domain] Cumulative Effect, Period of Adoption [Domain] Short-term debt Short-term Debt Property and equipment, fair value Property, Plant, and Equipment, Fair Value Disclosure Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Litigation Status [Axis] Litigation Status [Axis] Health Care Costs Payable Short-Duration Insurance and Deposit Contracts [Text Block] Other Intangible Assets [Table] Other Acquired Intangible Assets [Table] -- None. No documentation exists for this element. -- Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Fixtures and equipment Furniture and Fixtures [Member] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Subsequent Event [Line Items] Subsequent Event [Line Items] Basic earnings per share: Earnings Per Share, Basic [Abstract] Net benefit costs Policyholder Benefits and Claims Incurred, Net Foreign securities Debt Security, Corporate, Non-US [Member] Other receivables Other Receivables, Net, Current Corporate/ Other Corporate and Other [Member] Net income attributable to CVS Health (in dollars per share) Earnings Per Share, Diluted Weighted average basic shares outstanding (in shares) Weighted average shares, basic (in shares) Weighted Average Number of Shares Outstanding, Basic Mortgage loans fully repaid Mortgage Loans on Real Estate, Loans Fully Repaid Pertains to amount of mortgage loans fully repaid. Segments [Domain] Segments [Domain] Effect of dilutive securities (in shares) Weighted Average Number Diluted Shares Outstanding Adjustment 2018 Year Of Origination Period Four [Member] Year Of Origination Period Four Income taxes paid Income Taxes Paid, Net Accounting Standards Update [Extensible List] Accounting Standards Update [Extensible Enumeration] Finance lease cost: Lease, Cost [Abstract] Intangible assets, net Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Comprehensive income attributable to CVS Health Comprehensive Income (Loss), Net of Tax, Attributable to Parent Income allocated to participating securities Participating Securities, Distributed and Undistributed Earnings (Loss), Diluted Other comprehensive income (loss), net of tax: Other Comprehensive Income (Loss), Net of Tax [Abstract] Pension and OPEB plans Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Including Portion Attributable to Noncontrolling Interest [Member] Schedule of assets (liabilities) recognized in Balance Sheet Schedule of Amounts Recognized in Balance Sheet [Table Text Block] Deferred income taxes Deferred Income Tax Liabilities, Net Multiemployer plans, plan contributions Multiemployer Plan, Pension, Insignificant, Plan Contribution Number of stores, planned closure Number of Stores, Planned Closure Number of Stores, Planned Closure 2021 Short-Duration Insurance Contract, Accident Year 2020 [Member] Income from continuing operations attributable to CVS Health (in dollars per share) Earnings (loss) per share from continuing operations, basic (USD per share) Income (Loss) from Continuing Operations, Per Basic Share 4.1% senior notes due March 2025 Senior Notes, 4.1%, Due March 2025 [Member] Senior Notes, 4.1%, Due March 2025 [Member] Loss from discontinued operations, net of tax Loss from discontinued operations, net of tax Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Schedule of effective income tax rate reconciliation Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Total CVS Health Shareholders’ Equity Parent [Member] Depreciation and amortization Depreciation, Depletion and Amortization Fair value of financial assets and liabilities Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Common stock dividends Dividends, Common Stock Actual return on plan assets Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Actual Return (Loss) on Plan Assets Still Held Schedule of variable interest entities Schedule of Variable Interest Entities [Table Text Block] Accumulated Other Comprehensive Income AOCI Attributable to Parent [Member] Inventories Increase (Decrease) in Inventories Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Gross transfers into Level 3 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3 Long-term investments Long-term Long-term Investments Financial Instruments [Domain] Financial Instruments [Domain] After five years through ten years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10 Pharmacy rebate period Pharmacy Rebate Period Pharmacy Rebate Period Cost of products sold Cost of Goods and Services Sold Number of Securities, Less than 12 months Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions Proceeds from sale of subsidiary Proceeds from Divestiture of Businesses Entity Central Index Key Entity Central Index Key Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Treasury shares held in trust Treasury Stock, Value, Shares Held In Trust Treasury Stock, Value, Shares Held In Trust Change in Contract with Customer, Liability [Abstract] Change in Contract with Customer, Liability [Abstract] Other Product and Service, Other [Member] Lease, Cost, Total Lease, Cost Quarterly dividends declared, percent increase Dividends Payable, Quarterly Dividends Declared, Increase Amount, Percent Dividends Payable, Quarterly Dividends Declared, Increase Amount, Percent Shareholders’ equity: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Reductions for tax positions of prior years Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Other Sales Channel, Other [Member] Sales Channel, Other [Member] Operating expenses Operating Expenses, Excluding Store Impairments and Goodwill Impairments Operating Expenses, Excluding Store Impairments and Goodwill Impairments Loss Contingencies [Line Items] Loss Contingencies [Line Items] Other long-term liabilities Other Liabilities, Noncurrent Greater than ten years Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, After Ten Years Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, After Ten Years Unrealized Losses Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract] Residential mortgage-backed securities Residential Mortgage Backed Securities [Member] 2.125% senior notes due June 2021 Senior Notes, 2.125%, June 2021 [Member] Senior Notes, 2.125%, June 2021 [Member] Benefit obligation Benefit obligation, beginning of year Benefit obligation, end of year Defined Benefit Plan, Benefit Obligation Carrying value of long-term debt Schedule of Long-term Debt Instruments [Table Text Block] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Debt Instrument [Line Items] Debt Instrument [Line Items] Trading Symbol Trading Symbol Customer contracts/relationships and covenants not to compete Customer-Related Intangible Assets [Member] Health Insurance Product Line Health Insurance Product Line [Member] Benefit costs Policyholder Benefits and Claims Incurred, Net, Health Unrealized Losses Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss Other assets Increase (Decrease) in Other Operating Assets Net cash flow hedges Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member] Equipment Equipment [Member] Debt premiums Debt Instrument, Unamortized Premium Shares vested at end of year and expected to vest in the future (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Stock options granted through 2018 Share-Based Payment Arrangement, Option, Granted Prior Through 2018 [Member] Share-Based Payment Arrangement, Option, Granted Prior Through 2018 Proceeds from sales Proceeds from Sale of Debt Securities, Available-for-sale Assumptions used to determine benefit obligations Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract] Pharmacy claims and discounts payable Pharmacy Claims and Discounts Payable, Current Pharmacy Claims and Discounts Payable, Current Reclassification out of Accumulated Other Comprehensive Income [Table] Reclassification out of Accumulated Other Comprehensive Income [Table] Long-Lived Asset Impairment Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block] Domestic real estate Equity Securities Domestic Real Estate [Member] This category includes information about ownership interests or the right to acquire ownership interests in domestic real estate whose ownership interest is represented by shares of common or preferred stock (which is neither mandatorily redeemable no redeemable at the option of the holder), convertible securities, stock rights, or stock warrants categorized by other type. Schedule of Goodwill [Table] Schedule of Goodwill [Table] Debt extinguishment fees Debt Extinguishment Fees Debt Extinguishment Fees Schedule of regulatory Requirements Schedule of Regulatory Assets [Table Text Block] Stock-based compensation expense Share-based Payment Arrangement, Expense Cost of Products Sold Cost of Goods and Service [Policy Text Block] Weighted average remaining contractual term exercisable at end of year Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Earnings per share from continuing operations: Earnings Per Share, Basic and Diluted [Abstract] Settlements Defined Benefit Plan, Plan Assets, Payment for Settlement 2021 Year Of Origination Period One [Member] Year Of Origination Period One Net income Net income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Investments [Domain] Investments [Domain] Restricted cash (included in other current assets) Restricted Cash, Current Liability for Claims and Claims Adjustment Expense [Table] Liability for Claims and Claims Adjustment Expense [Table] Cash, cash equivalents and restricted cash at the beginning of the period Cash, cash equivalents and restricted cash at the end of the period Total cash, cash equivalents and restricted cash in the consolidated statements of cash flows Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Health insurer fee Health Insurer Fee Tax Effect, Percent Represents the tax effect of the health care reform's non-tax deductible health insurer fee. Revolving Credit Facility, Expiring May 16, 2024 Revolving Credit Facility, Expiring May 16, 2024 [Member] Revolving Credit Facility, Expiring May 16, 2024 [Member] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Allowance for credit loss Debt Securities, Available-for-sale, Allowance for Credit Loss Guarantor obligations, maximum exposure Guarantor Obligations, Maximum Exposure, Undiscounted Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Other Proceeds from (Payments for) Other Financing Activities Intangible assets related to customer lists Finite-lived intangible assets, gross carrying amount Finite-Lived Intangible Assets, Gross Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items] Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items] Vendor Allowances And Purchase Discounts Vendor Allowances And Purchase Discounts [Policy Text Block] Vendor Allowances And Purchase Discounts Cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Short-duration Insurance Contracts, Claims Development [Table] Short-duration Insurance Contracts, Claims Development [Table] Contract with Customer, Sales Channel [Domain] Contract with Customer, Sales Channel [Domain] Stock option activity, stock awards and other (in shares) Shares exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 4.78% senior notes due March 2038 Senior Notes, 4.78%, Due March 2038 [Member] Senior Notes, 4.78%, Due March 2038 [Member] Beginning balance Ending balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value Other comprehensive income (loss) Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax Recurring Fair Value, Recurring [Member] Self-Insurance Liabilities Self Insurance Reserve [Policy Text Block] Shareholders' Equity Stockholders' Equity Note Disclosure [Text Block] Private equity investments Private Equity Funds [Member] Schedule of discontinued operations Disposal Groups, Including Discontinued Operations [Table Text Block] Expiration of statutes of limitation Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations Measurement Basis [Axis] Measurement Basis [Axis] Auditor Firm ID Auditor Firm ID Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Reconciliation of operating earnings to net income Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] Change in benefit obligation: Defined Benefit Plan, Change in Benefit Obligation [Roll Forward] Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Building, building improvements and leasehold improvements Building and improvements Building and Building Improvements [Member] Change in operating assets and liabilities, net of effects from acquisitions: Increase (Decrease) in Operating Capital [Abstract] Vested (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Assumed Assumed Premiums Earned Activity in mortgage loan portfolio Activity in mortgage loan portfolio [Table Text Block] Table representing activities in mortgage loan portfolio during the period. After five years through ten years Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, After Five Through Ten Years, Accumulated Loss Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, After Five Through Ten Years, Accumulated Loss Separate accounts assets Separate Account Asset Period after date of service a claim is paid Health Care Costs Payable, Period After Date Of Services Claims Are Paid Health Care Costs Payable, Period After Date Of Services Claims Are Paid Number of walk-in medical clinics Number of Walk In Medical Clinics Number of Walk In Medical Clinics Restricted Stock Units and Performance Share Units Restricted Stock Units and Performance Share Units [Member] Restricted Stock Units and Performance Share Units [Member] Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Operating cash flows paid for interest portion of finance leases Finance Lease, Interest Payment on Liability Mortgage Loans on Real Estate [Table] SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate Schedule [Table] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Mortgage loan internal credit rating Schedule Of Mortgage Loan Internal Credit Ratings [Table Text Block] Schedule detailing credit quality information related to financing receivables by credit quality indicator and by class of financing receivable. Total Investments [Table] Total Investments [Table] Discount rate Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate Change in unrealized capital losses included in OCI associated with Level 3 financial assets Fair Value, Asset, Recurring Basis, Still Held, Unrealized Gain (Loss), OCI Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Total investments Total Investments [Table Text Block] This item includes total investments, both current and long-term. Operating Leased Assets [Line Items] Operating Leased Assets [Line Items] Other current assets Other Assets, Current Customer Lists Customer Lists [Member] Other asset-backed securities Asset-backed Securities [Member] Advertising costs Advertising Expense Net assets Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position Coventry Health Care Workers Compensation Business Coventry Health Care Workers Compensation Business [Member] Coventry Health Care Workers Compensation Business Schedule of direct, assumed and ceded premiums earned SEC Schedule, 12-17, Insurance Companies, Reinsurance [Text Block] Heartland Healthcare Services Heartland Healthcare Services [Member] Heartland Healthcare Services [Member] Aggregate principal of debt extinguished Extinguishment of Debt, Amount Interest and investment income received Proceeds from Interest and Dividends Received 2016 Repurchase Program 2016 Repurchase Program [Member] 2016 Repurchase Program [Member] Offsetting [Abstract] Offsetting [Abstract] Acquisition purchase price adjustments outside of measurement period Business Combination, Purchase Price Adjustment, Outside of Measurement Period Business Combination, Purchase Price Adjustment, Outside of Measurement Period Income from continuing operations Income from continuing operations Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Write off of deferred debt issuance cost Write off of Deferred Debt Issuance Cost Policyholders’ funds Other Policyholder Funds Inventories Inventory, Policy [Policy Text Block] 2017 Year Of Origination Period Five [Member] Year Of Origination Period Five Self insurance liabilities Self Insurance Reserve Pension Plan Pension Plan [Member] Store impairments Store impairment charges Store Impairment Charges Store Impairment Charges Less than one year Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Insurance lines other than short duration Short-duration Insurance Contracts, Liability for Unpaid Claims and Claim Adjustment Expense, Other Reconciling Item Purchases Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases Schedule ESPP valuation assumptions Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block] Current year Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year EX-101.PRE 16 cvs-20211231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 17 cvs-20211231_g1.jpg CVS HEALTH LOGO begin 644 cvs-20211231_g1.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# (! 0(! 0(" @(" @(" P4# P,# M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_ MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P, M# P,# P,# P,# P,# P,# P,# P,# S_P 1" < )T# 2( A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#]#?\ @KK_ M ,%;8/V'M)B\%^#([/5OBEJT*S(LZ&6UT*W;($\PW+OD;!$<61T+MP%63YV_ M9&_X.-6T;X/>)K?XP:6VK>,-(M_/T&YTFV\F/Q 6X%M, "L$BLV[S0 AC!^4 M.H62S_P7L_X)B:[XL\2:I\>/!,$VKJUI$OBG3$3S)HXX8Q&MY".=R+&JK(O5 M0F\<;S7Y-(_G#TXRTO#RB]5YK7?;],OV0/\ @XC\:6WQV:/XR0:+-X%UZ;:TVF6# M12^&G)PKCYV,T"CAP0TF/G5C@QM]T_\ !2[_ (*B:'^PA\$M%U;2[>U\5^)_ M&ZN/#EJEP?LDT:HK/=R.N !T:9P&")GG#$X4,1[M_P %^OAM'\&OVC/AKX0T ME;I/"_ACX<6.EZ2LSEMJPW-S$06/!(1+ORCU%7A\SQD<#.M5?:S?JOP.? MB/PYX/K\:X/*<&E%VE*K3@]+1C>-WT9Y90W63_'A/]=N#?+P>OHWCS_@X3^*&O?L\:#XF\)Z' MX+TK7=+U'^QO%EK>V<]U;M+/"9;*XM=LT96*06]X&1B[1M&HW,"K-]V_LKKX M ?\ X))>#U\3?8?^%=M\-H/[>.6$?V3^SE^V;S'\^[ EW[?GW!OXA7QOKOP5 M_9(_:8_9A^,7A7]FF&2;Q\OAH:SY44&K;Y$LYXYXHU^V#RP9''E?+A\3/CC= M7;.ABZM?'/Q%%HO_ DOA?3]5?4K*V#QVK7=J\H@B 9B1YJB MW(&XG,U?%7PD_P"#A'XR1^!O&/B;Q9H?@C5+/28;;3=+M;&PGM/.U:[:1X3* M[32?N([>UNW<#:S,D:@KO+#Y ^''[7-SX/\ ^"?7Q$^$$7$/C3Q-I6J1D [C M;JI:Y8'D##V5@OJ1*W!"FOLK]G;_ ()=Z7\;?^".>DQZIXFT;P5XS\:>()/& M>C3ZQ)';VTGEQ/:P02'&]H9+;]Z" 61K@-M8 JW)',,1B>14)VY8MN_5['T& M*X#X3>!?!OQL\*SVEI,VKVMQ?:'&))$;[3Y,7+"ERJ(7)22/DLJ@M^ M:T7PL_:X_P"">/A2^UGP[>>)[/P+')---J/A_4(==\/2 <23F ^;&@R@#230 MH?D.=HXK]&_^")W_ 4BUC]MWPAXK\.^+M+TFV\4>$8K:=K[38/L\6JVTWF( M':,$A)4:(AMI"L'0J%^8+OE.,J/$*E7F^9K9K1^C/%\4N%\N>25TWPWI5S9W&G"TO;VSNA&F_:I_:L'_!:Z']GL M>(O@BW@63PU_PLX3?\([?_V@?#O]N&P_L[S/M.S[=Y()\[9Y>[G;CY3\[?\ M! #X'?M5>,O^"27PGU+X;?'KX=^"_!=U_;!T[1M2^'?]K7=IMUJ^67?<_:X_ M,WS"1Q\@VJRKR5R?0/V=/#OQ/^$G_!QY=?\ "Y_'WA_XAZ];_LT3WB:GHWAP MZ)#!8CQ*-L+0>;,7=765MX9#M0^+7[;WC_XA>+OB%XMUB[O-*\%V]AXMC\/_ ZL(KAX MK6TL3I4*PRN8T21YMS,Q9=P$JRM)W'P;_P""O^L?L<_LH_MF:9\-/''B_P"+ M?@#X3:7H^J?"3Q+XKT^^35-+75;B'3I+.X:_BC>>.QNKB)H5=#N2-QN*LJ1@ M'[M#FOFC_@KA\;/BE^S3^PSXP^)'PEU#P78ZY\/[6;Q!J,?B739[ZWO["WMI MWD@B6*6,I,T@A*NQ*@*P(R01\_?#+_@W<\ Q?"VQ\0^*O'7Q7OOVEKG3UFO? MBS!XWU)=8L=3*J7:WC$PMS;(X*)%)$^8OE+$_/7QW^QC\-]8_P"'!O[(?BE?3^+O#WB'4)]6N)K23[%&6VP6[-Y$($TTQ!CB0E6"] H !^G&E_ M\%(M%^&?[.G[+_B+XA66I2>(OVC9/#^AVG]A60-I;:MJ5BEQEP\H:.WW[P#F M1E!'!P2.+_:0_:[^,7P$_P""P'[//PK:\\!WOPB^.XUY([<:3.-W['O@KXH?!'_@F;XDU9/$+:EXRUKP#X,U M/[+KU[:0OI[::93Y4<4JK!/N8_OX@LV, .!7JO\ P5C_ &0+37O^"A'_ 3E M^#?A7Q1XN\#Z+%#XVTI-5TW5IVUB'3H=*T]KF);N1FF$D]LDT!E+%AYQ;)(Y M /UF3CKG/H?6G9S7Y/?M7?L8>#?^"*WQ_P#V;?B-^SRWB7P38?$KXN:/\./& M_AF7Q#J.K:5XGL]4$X:YE2[GD(NH!"3$ZL "YSD##?J_'N ^:@".6 RQ[3T/ M%?E7^W5_P;TW'Q._:+TO7OA+?:-X9\+>++PCQ)I\X*Q>'R07>ZM(E&'1\$?9 MP5"RLFUEC8F']6J*Y<5@Z6(AR55='U'"O&.;<.XF6*RJKR2DFGU33[IZ.VZ[ M,\S_ &5?V5/!_P"QW\'M/\%>"=-^PZ79?O)I9<-%7EFT34)T9K9Q(%\RVG"_-Y3 ME(SN +(R*P##XNF\$7$VZ6SA\9[="F)?>7-N6!.7^A0J>TC=OI?6WH?:<3>+F>9W@I9?75.G3G+FG[." MBYM6UD^NJ1^'WQA_X-V?C%?_ !L\2+X3D\%6O@N\UF=](DFU%Q+:6,DK-$K1 M^426BC8*?F.2@K]#/^"@'_!+G1?VNOV.M!^&^@SVOAV^\!I;OX6EECWV]N88 M#"+>7 W")XSM+*"58(^U]FQOK6BJHY1AJ2FH+26YSYQXK<0YE4PE;$5%S87X M&EUTUE_,[*VO2_<_"FP_X)/?MJ> _!&H?#/2;B=/ NH2.MS9V'BV./2+D..54DR2R>6 V3N!).?L_]@G_@FU\3/^":G[,GCW7/#%KX/\>_'#Q6UDL6 MEWFHRV.AP013[3%]J\HREA%+-(7\L!F2) N$WO\ H/12PN3T*%158MMK:[V- MN)?%K.\ZP,\NKJG3IS:E/V<%%S:U]Y]=5<^'_P#@@O\ LL?&S]AC]BG3?@U\ M7/#_ (,TVS\"F7^PM2T/6I-0FU7[7?WMY<>?&T*+"8S-"B%6?<"Q.TC!X:;] MFK]J:7_@MK'\?O\ A7_PJ_X5^GA;_A5A4^+)FO/[!.NF].J"+[-C[7Y!/^C$ M^7GCS.J?F)^;W[.7[._[5'_!(K0]8^%OPE^''@G]H3X%_VQ=7_@F& MZ\9CPOKW@ZVNIFGELKIIX)HKJ&.61RDB_O&)=FP&2*/TV/\ 8.^+G[;O[&GQ MD\#_ +57C'P_7"SI#/*T[&,O"$ MC"IN+_:E% 'YY_#36?\ @H=\//A)9_".Z\ _!G7?$6EV4>E6GQEG\82_V>\* M(B)=7&D-;FYFO-@+/ATB>7MLR&\Z_82_X))_'+X/?\$S?VCOV8?&UQX5:U\> M)K^M_*)@'[J%V*R2G]ZX&64,?U1HH _+KXA_L)?M M/?%[]@O]F^QO/"/PYT?XK?LL^.]"U;3=&/B>2?3/%VFZ38);K)]H$.;>>:4L M1&P941"2S$A:V?VLO@#^UY\=?VX?V9_C-H_PJ^$]O_PH^PU6YGTF[\=SK]KO M-9TR"VN[=I%LSM6UD1]LBA_-Z[5'%?I910!\'_\ !:3]EWX]?M9:K\$[/X2^ M$_ NL:3\,?B!I/Q)N;G7/$)=/L=)\17%A;R:I965V;NUM+MHU,T<4K(C2(LA95 GRAPHIC 18 cvs-20211231_g2.jpg STOCK PERFORMANCE GRAPH begin 644 cvs-20211231_g2.jpg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end GRAPHIC 19 cvshealthlogo1.jpg CVS HEALTH LOGO begin 644 cvshealthlogo1.jpg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end GRAPHIC 20 cvshealthlogob.jpg CVS HEALTH LOGO begin 644 cvshealthlogob.jpg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end XML 21 R1.htm IDEA: XBRL DOCUMENT v3.22.0.1
Cover Page - USD ($)
12 Months Ended
Dec. 31, 2021
Feb. 02, 2022
Jun. 30, 2021
Cover [Abstract]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2021    
Current Fiscal Year End Date --12-31    
Document Transition Report false    
Entity File Number 001-01011    
Entity Registrant Name CVS HEALTH CORPORATION    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 05-0494040    
Entity Address, Address Line One One CVS Drive,    
Entity Address, City or Town Woonsocket,    
Entity Address, State or Province RI    
Entity Address, Postal Zip Code 02895    
City Area Code (401)    
Local Phone Number 765-1500    
Title of 12(b) Security Common Stock, par value $0.01 per share    
Trading Symbol CVS    
Security Exchange Name NYSE    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag true    
Entity Shell Company false    
Entity Public Float     $ 109,651,334,285
Entity Common Stock, Shares Outstanding   1,312,510,426  
Documents Incorporated by Reference
The following materials are incorporated by reference into this Form 10-K:
Information contained in the definitive proxy statement for CVS Health Corporation’s 2022 Annual Meeting of Stockholders, to be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year ended December 31, 2021 (the “Proxy Statement”), is incorporated by reference in Parts III and IV to the extent described therein.
   
Entity Central Index Key 0000064803    
Document Fiscal Year Focus 2021    
Document Fiscal Period Focus FY    
Amendment Flag false    
XML 22 R2.htm IDEA: XBRL DOCUMENT v3.22.0.1
Audit Information
12 Months Ended
Dec. 31, 2021
Auditor Information [Abstract]  
Auditor Name Ernst & Young LLP
Auditor Location Boston, Massachusetts
Auditor Firm ID 42
XML 23 R3.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Operations - USD ($)
shares in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Revenues:      
Premiums $ 76,132,000,000 $ 69,364,000,000 $ 63,122,000,000
Net investment income 1,199,000,000 798,000,000 1,011,000,000
Total revenues 292,111,000,000 268,706,000,000 256,776,000,000
Operating costs:      
Cost of products sold 175,803,000,000 163,981,000,000 158,719,000,000
Benefit costs 64,260,000,000 55,679,000,000 52,529,000,000
Store impairments 1,358,000,000 0 231,000,000
Goodwill impairment 431,000,000 0 0
Operating expenses 37,066,000,000 35,135,000,000 33,310,000,000
Total operating costs 278,918,000,000 254,795,000,000 244,789,000,000
Operating income 13,193,000,000 13,911,000,000 11,987,000,000
Interest expense 2,503,000,000 2,907,000,000 3,035,000,000
Loss on early extinguishment of debt 452,000,000 1,440,000,000 79,000,000
Other income (182,000,000) (206,000,000) (124,000,000)
Income before income tax provision 10,420,000,000 9,770,000,000 8,997,000,000
Income tax provision 2,522,000,000 2,569,000,000 2,366,000,000
Income from continuing operations 7,898,000,000 7,201,000,000 6,631,000,000
Loss from discontinued operations, net of tax 0 (9,000,000) 0
Net income 7,898,000,000 7,192,000,000 6,631,000,000
Net (income) loss attributable to noncontrolling interests 12,000,000 (13,000,000) 3,000,000
Net income attributable to CVS Health $ 7,910,000,000 $ 7,179,000,000 $ 6,634,000,000
Basic earnings per share:      
Income from continuing operations attributable to CVS Health (in dollars per share) $ 6.00 $ 5.49 $ 5.10
Loss from discontinued operations attributable to CVS Health (in dollars per share) 0 (0.01) 0
Net income attributable to CVS Health (in dollars per share) $ 6.00 $ 5.48 $ 5.10
Weighted average basic shares outstanding (in shares) 1,319 1,309 1,301
Diluted earnings per share:      
Income from continuing operations attributable to CVS Health (in dollars per share) $ 5.95 $ 5.47 $ 5.08
Loss from discontinued operations attributable to CVS Health (in dollars per share) 0 (0.01) 0
Net income attributable to CVS Health (in dollars per share) $ 5.95 $ 5.46 $ 5.08
Weighted average diluted shares outstanding (in shares) 1,329 1,314 1,305
Dividends declared per share (in dollars per share) $ 2.00 $ 2.00 $ 2.00
Cost, Product and Service [Extensible List] Products Products Products
Products      
Revenues:      
Revenues $ 203,738,000,000 $ 190,688,000,000 $ 185,236,000,000
Services      
Revenues:      
Revenues $ 11,042,000,000 $ 7,856,000,000 $ 7,407,000,000
XML 24 R4.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Comprehensive Income - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Statement of Comprehensive Income [Abstract]      
Net income $ 7,898 $ 7,192 $ 6,631
Other comprehensive income (loss), net of tax:      
Net unrealized investment gains (losses) (436) 440 677
Foreign currency translation adjustments (7) 3 162
Net cash flow hedges (26) (31) (33)
Pension and other postretirement benefits 20 (17) 111
Other comprehensive income (loss) (449) 395 917
Comprehensive income 7,449 7,587 7,548
Comprehensive (income) loss attributable to noncontrolling interests 12 (13) 3
Comprehensive income attributable to CVS Health $ 7,461 $ 7,574 $ 7,551
XML 25 R5.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Balance Sheets - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Assets:    
Cash and cash equivalents $ 9,408 $ 7,854
Investments 3,117 3,000
Accounts receivable, net 24,431 21,742
Inventories 17,760 18,496
Other current assets 5,292 5,277
Total current assets 60,008 56,369
Long-term investments 23,025 20,812
Property and equipment, net 12,896 12,606
Operating lease right-of-use assets 19,122 20,729
Goodwill 79,121 79,552
Intangible assets, net 29,026 31,142
Separate accounts assets 5,087 4,881
Other assets 4,714 4,624
Total assets 232,999 230,715
Liabilities:    
Accounts payable 12,544 11,138
Pharmacy claims and discounts payable 17,330 15,795
Health care costs payable 8,808 7,936
Policyholders’ funds 4,301 4,270
Accrued expenses 17,670 14,243
Other insurance liabilities 1,303 1,557
Current portion of operating lease liabilities 1,646 1,638
Current portion of long-term debt 4,205 5,440
Total current liabilities 67,807 62,017
Long-term operating lease liabilities 18,177 18,757
Long-term debt 51,971 59,207
Deferred income taxes 6,270 6,794
Separate accounts liabilities 5,087 4,881
Other long-term insurance liabilities 6,402 7,007
Other long-term liabilities 1,904 2,351
Total liabilities 157,618 161,014
Commitments and contingencies (Note 16)
Shareholders’ equity:    
Preferred stock, par value $0.01: 0.1 shares authorized; none issued or outstanding 0 0
Common stock, par value $0.01: 3,200 shares authorized; 1,744 shares issued and 1,322 shares outstanding at December 31, 2021 and 1,733 shares issued and 1,310 shares outstanding at December 31, 2020 and capital surplus 47,377 46,513
Treasury stock, at cost: 422 and 423 shares at December 31, 2021 and 2020 (28,173) (28,178)
Retained earnings 54,906 49,640
Accumulated other comprehensive income 965 1,414
Total CVS Health shareholders’ equity 75,075 69,389
Noncontrolling interests 306 312
Total shareholders’ equity 75,381 69,701
Total liabilities and shareholders’ equity $ 232,999 $ 230,715
XML 26 R6.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Balance Sheets (Parenthetical) - $ / shares
Dec. 31, 2021
Dec. 31, 2020
Statement of Financial Position [Abstract]    
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, shares authorized (in shares) 100,000 100,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, shares authorized (in shares) 3,200,000,000 3,200,000,000
Common stock, shares issued (in shares) 1,744,000,000 1,733,000,000
Common stock, shares outstanding (in shares) 1,322,000,000 1,310,000,000
Treasury stock, shares (in shares) 422,000,000 423,000,000
XML 27 R7.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Cash Flows - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Cash flows from operating activities:      
Cash receipts from customers $ 284,219,000,000 $ 264,327,000,000 $ 248,393,000,000
Cash paid for inventory and prescriptions dispensed by retail network pharmacies (165,783,000,000) (158,636,000,000) (149,655,000,000)
Insurance benefits paid (63,598,000,000) (55,124,000,000) (52,242,000,000)
Cash paid to other suppliers and employees (31,652,000,000) (29,763,000,000) (28,932,000,000)
Interest and investment income received 743,000,000 894,000,000 955,000,000
Interest paid (2,469,000,000) (2,904,000,000) (2,954,000,000)
Income taxes paid (3,195,000,000) (2,929,000,000) (2,717,000,000)
Net cash provided by operating activities 18,265,000,000 15,865,000,000 12,848,000,000
Cash flows from investing activities:      
Proceeds from sales and maturities of investments 7,246,000,000 6,467,000,000 7,049,000,000
Purchases of investments (9,963,000,000) (9,639,000,000) (7,534,000,000)
Purchases of property and equipment (2,520,000,000) (2,437,000,000) (2,457,000,000)
Proceeds from sale-leaseback transactions 0 101,000,000 5,000,000
Acquisitions (net of cash acquired) (146,000,000) (866,000,000) (444,000,000)
Proceeds from sale of subsidiary 0 840,000,000 0
Other 122,000,000 0 42,000,000
Net cash used in investing activities (5,261,000,000) (5,534,000,000) (3,339,000,000)
Cash flows from financing activities:      
Net repayments of short-term debt 0 0 (720,000,000)
Proceeds from issuance of long-term debt 987,000,000 9,958,000,000 3,736,000,000
Repayments of long-term debt (10,254,000,000) (15,631,000,000) (8,336,000,000)
Derivative settlements 0 (7,000,000) (25,000,000)
Dividends paid (2,625,000,000) (2,624,000,000) (2,603,000,000)
Proceeds from exercise of stock options 549,000,000 264,000,000 210,000,000
Payments for taxes related to net share settlement of equity awards (168,000,000) (88,000,000) (112,000,000)
Other 155,000,000 432,000,000 196,000,000
Net cash used in financing activities (11,356,000,000) (7,696,000,000) (7,654,000,000)
Net increase in cash, cash equivalents and restricted cash 1,648,000,000 2,635,000,000 1,855,000,000
Cash, cash equivalents and restricted cash at the beginning of the period 11,043,000,000 8,408,000,000 6,553,000,000
Cash, cash equivalents and restricted cash at the end of the period 12,691,000,000 11,043,000,000 8,408,000,000
Reconciliation of net income to net cash provided by operating activities:      
Net income 7,898,000,000 7,192,000,000 6,631,000,000
Adjustments required to reconcile net income to net cash provided by operating activities:      
Depreciation and amortization 4,512,000,000 4,441,000,000 4,371,000,000
Store impairments 1,358,000,000 0 231,000,000
Goodwill impairment 431,000,000 0 0
Stock-based compensation 484,000,000 400,000,000 453,000,000
(Gain) loss on sale of subsidiaries 0 (269,000,000) 205,000,000
Loss on early extinguishment of debt 452,000,000 1,440,000,000 79,000,000
Deferred income taxes (428,000,000) (570,000,000) (654,000,000)
Other noncash items (390,000,000) 72,000,000 33,000,000
Change in operating assets and liabilities, net of effects from acquisitions:      
Accounts receivable, net (2,703,000,000) (1,510,000,000) (2,158,000,000)
Inventories 735,000,000 (973,000,000) (1,075,000,000)
Other assets (3,000,000) 364,000,000 (614,000,000)
Accounts payable and pharmacy claims and discounts payable 2,898,000,000 2,769,000,000 3,550,000,000
Health care costs payable and other insurance liabilities 169,000,000 (231,000,000) 320,000,000
Other liabilities 2,852,000,000 2,740,000,000 1,476,000,000
Net cash provided by operating activities $ 18,265,000,000 $ 15,865,000,000 $ 12,848,000,000
XML 28 R8.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Shareholders' Equity - USD ($)
shares in Millions, $ in Millions
Total
Cumulative Effect, Period of Adoption, Adjustment
Common Shares
Treasury Shares
Common Stock and Capital Surplus
[3]
Retained Earnings
Retained Earnings
Cumulative Effect, Period of Adoption, Adjustment
[4]
Accumulated Other Comprehensive Income
Total CVS Health Shareholders’ Equity
Total CVS Health Shareholders’ Equity
Cumulative Effect, Period of Adoption, Adjustment
Noncontrolling Interests
Balance at beginning of period (in shares) at Dec. 31, 2018     1,720 (425) [1]              
Beginning of year balance at Dec. 31, 2018 $ 58,543 $ 178 [2]   $ (28,228) [1] $ 45,440 $ 40,911   $ 102 $ 58,225 $ 178 [2] $ 318
Stockholders' Equity [Roll Forward]                      
Net income 6,631         6,634     6,634   (3)
Other comprehensive income (loss) 917             917 917    
Stock option activity, stock awards and other (in shares)     7 2 [1]              
Stock option activity, stock awards and other 532       532       532    
Purchase of treasury shares, net of ESPP issuances (in shares) [1]       2              
Purchase of treasury shares, net of ESPP issuances (7)     $ (7) [1]         (7)    
Common stock dividends (2,615)         (2,615)     (2,615)    
Other increases (decreases) in noncontrolling interest (9)                   (9)
Balance at end of period (in shares) at Dec. 31, 2019     1,727 (425) [1]              
End of year balance at Dec. 31, 2019 64,170 $ (3) [4]   $ (28,235) [1] 45,972 45,108 $ (3) 1,019 63,864 $ (3) [4] 306
Stockholders' Equity [Roll Forward]                      
Net income 7,192         7,179     7,179   13
Other comprehensive income (loss) 395             395 395    
Stock option activity, stock awards and other (in shares)     6                
Stock option activity, stock awards and other 541       541       541    
ESPP issuances, net of purchase of treasury shares (in shares) [1]       2              
ESPP issuances, net of purchase of treasury shares 57     $ 57 [1]         57    
Common stock dividends (2,644)         (2,644)     (2,644)    
Other increases (decreases) in noncontrolling interest (7)                   (7)
Balance at end of period (in shares) at Dec. 31, 2020     1,733 (423) [1]              
End of year balance at Dec. 31, 2020 69,701     $ (28,178) [1] 46,513 49,640   1,414 69,389   312
Stockholders' Equity [Roll Forward]                      
Net income 7,898         7,910     7,910   (12)
Other comprehensive income (loss) (449)             (449) (449)    
Stock option activity, stock awards and other (in shares)     11                
Stock option activity, stock awards and other 864       864       864    
ESPP issuances, net of purchase of treasury shares (in shares) [1]       1              
ESPP issuances, net of purchase of treasury shares 5     $ 5 [1]         5    
Common stock dividends (2,644)         (2,644)     (2,644)    
Other increases (decreases) in noncontrolling interest 6                   6
Balance at end of period (in shares) at Dec. 31, 2021     1,744 (422) [1]              
End of year balance at Dec. 31, 2021 $ 75,381     $ (28,173) [1] $ 47,377 $ 54,906   $ 965 $ 75,075   $ 306
[1] Treasury shares include 1 million shares held in trust for each of the years ended December 31, 2021, 2020 and 2019. Treasury stock includes $29 million related to shares held in trust for each of the years ended December 31, 2021, 2020 and 2019. See Note 1 ‘‘Significant Accounting Policies’’ for additional information.
[2] Reflects the adoption of Accounting Standards Update (“ASU”) 2016-02, Leases (Topic 842), which resulted in an increase to retained earnings of $178 million during the year ended December 31, 2019.
[3] Common stock and capital surplus includes the par value of common stock of $17 million as of December 31, 2021, 2020 and 2019.
[4] Reflects the adoption of ASU 2016-13, Financial Instruments - Credit Losses (Topic 326), which resulted in a reduction to retained earnings of $3 million during the year ended December 31, 2020.
XML 29 R9.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Shareholders' Equity (Parentheticals) - USD ($)
shares in Millions, $ in Millions
12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2021
Dec. 31, 2020
Treasury shares held in trust (in shares) 1   1 1
Treasury shares held in trust $ 29   $ 29 $ 29
Common stock 17   17 17
Cumulative adjustment to retained earnings as a result of new accounting standard adoption $ 64,170 $ 58,543 75,381 69,701
ASU 2016-02        
Accounting Standards Update [Extensible List]   ASU 2016-02    
ASU 2016-13        
Accounting Standards Update [Extensible List] ASU 2016-13      
Retained Earnings        
Cumulative adjustment to retained earnings as a result of new accounting standard adoption $ 45,108 $ 40,911 $ 54,906 $ 49,640
Cumulative Effect, Period of Adoption, Adjustment        
Cumulative adjustment to retained earnings as a result of new accounting standard adoption (3) [1] 178 [2]    
Cumulative Effect, Period of Adoption, Adjustment | Retained Earnings        
Cumulative adjustment to retained earnings as a result of new accounting standard adoption [1] (3)      
Cumulative Effect, Period of Adoption, Adjustment | Retained Earnings | ASU 2016-02        
Cumulative adjustment to retained earnings as a result of new accounting standard adoption [2]   $ 178    
Cumulative Effect, Period of Adoption, Adjustment | Retained Earnings | ASU 2016-13        
Cumulative adjustment to retained earnings as a result of new accounting standard adoption $ (3)      
[1] Reflects the adoption of ASU 2016-13, Financial Instruments - Credit Losses (Topic 326), which resulted in a reduction to retained earnings of $3 million during the year ended December 31, 2020.
[2] Reflects the adoption of Accounting Standards Update (“ASU”) 2016-02, Leases (Topic 842), which resulted in an increase to retained earnings of $178 million during the year ended December 31, 2019.
XML 30 R10.htm IDEA: XBRL DOCUMENT v3.22.0.1
Significant Accounting Policies
12 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
Significant Accounting Policies Significant Accounting Policies
Description of Business 

CVS Health Corporation, together with its subsidiaries (collectively, “CVS Health” or the “Company”), has more than 9,900 retail locations, nearly 1,200 walk-in medical clinics, a leading pharmacy benefits manager with approximately 110 million plan members with expanding specialty pharmacy solutions and a dedicated senior pharmacy care business serving more than one million patients per year. The Company also serves an estimated 35 million people through traditional, voluntary and consumer-directed health insurance products and related services, including expanding Medicare Advantage offerings and a leading standalone Medicare Part D prescription drug plan (“PDP”). The Company believes its innovative health care model increases access to quality care, delivers better health outcomes and lowers overall health care costs.

The coronavirus disease 2019 (“COVID-19”) and its emerging new variants continue to impact the economies of the U.S. and other countries around the world. The impact of COVID-19 on the Company’s businesses, operating results, cash flows and financial condition in the years ended December 31, 2021 and 2020, as well as information regarding certain expected impacts of COVID-19 on the Company, is discussed throughout this Annual Report on Form 10-K.

The Company has four reportable segments: Health Care Benefits, Pharmacy Services, Retail/LTC and Corporate/Other, which are described below.

Health Care Benefits Segment
The Health Care Benefits segment operates as one of the nation’s leading diversified health care benefits providers. The Health Care Benefits segment has the information and resources to help members, in consultation with their health care professionals, make more informed decisions about their health care. The Health Care Benefits segment offers a broad range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, medical management capabilities, Medicare Advantage and Medicare Supplement plans, PDPs, Medicaid health care management services and health information technology products and services. The Health Care Benefits segment also provided workers’ compensation administrative services through its Coventry Health Care Workers’ Compensation business (“Workers’ Compensation business”) prior to the sale of this business on July 31, 2020. The Health Care Benefits segment’s customers include employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers (“providers”), governmental units, government-sponsored plans, labor groups and expatriates. The Company refers to insurance products (where it assumes all or a majority of the risk for medical and dental care costs) as “Insured” and administrative services contract products (where the plan sponsor assumes all or a majority of the risk for medical and dental care costs) as “ASC.” In addition, effective January 2022, the Company entered the individual public health insurance exchanges (“Public Exchanges”) in eight states through which it sells Insured plans directly to individual consumers.

Pharmacy Services Segment
The Pharmacy Services segment provides a full range of pharmacy benefit management (“PBM”) solutions, including plan design offerings and administration, formulary management, retail pharmacy network management services and mail order pharmacy. In addition, through the Pharmacy Services segment, the Company provides specialty pharmacy and infusion services, clinical services, disease management services, medical spend management and pharmacy and/or other administrative services for providers and federal 340B drug pricing program covered entities (“Covered Entities”). The Pharmacy Services segment’s clients are primarily employers, insurance companies, unions, government employee groups, health plans, PDPs, Medicaid managed care plans, plans offered on Public Exchanges and private health insurance exchanges, other sponsors of health benefit plans throughout the United States and Covered Entities. The Pharmacy Services segment operates retail specialty pharmacy stores, specialty mail order pharmacies, mail order dispensing pharmacies, compounding pharmacies and branches for infusion and enteral nutrition services.

Retail/LTC Segment
The Retail/LTC segment sells prescription drugs and a wide assortment of health and wellness products and general merchandise, provides health care services through its MinuteClinic® walk-in medical clinics, provides medical diagnostic testing, administers vaccinations for illnesses such as influenza, COVID-19 and shingles and conducts long-term care pharmacy (“LTC”) operations, which distribute prescription drugs and provide related pharmacy consulting and other ancillary services to long-term care facilities and other care settings. As of December 31, 2021, the Retail/LTC segment operated more than 9,900 retail locations, nearly 1,200 MinuteClinic locations as well as online retail pharmacy websites, LTC pharmacies and on-site pharmacies.
Corporate/Other Segment
The Company presents the remainder of its financial results in the Corporate/Other segment, which primarily consists of:

Management and administrative expenses to support the Company’s overall operations, which include certain aspects of executive management and the corporate relations, legal, compliance, human resources, information technology and finance departments, expenses associated with the Company’s investments in its transformation and enterprise modernization programs and acquisition-related transaction and integration costs; and
Products for which the Company no longer solicits or accepts new customers such as its large case pensions and long-term care insurance products.

Basis of Presentation

The accompanying consolidated financial statements of CVS Health and its subsidiaries have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The consolidated financial statements include the accounts of the Company and its majority-owned subsidiaries and variable interest entities (“VIEs”) for which the Company is the primary beneficiary. All material intercompany balances and transactions have been eliminated.

Reclassifications

Certain prior year amounts have been reclassified to conform with the current year presentation.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates.

Cash and Cash Equivalents

Cash and cash equivalents consist of cash and temporary investments with maturities of three months or less when purchased. The Company invests in short-term money market funds, commercial paper and time deposits, as well as other debt securities that are classified as cash equivalents within the accompanying consolidated balance sheets, as these funds are highly liquid and readily convertible to known amounts of cash.

Restricted Cash

Restricted cash (included in other current assets) represents funds held on behalf of members, including health savings account (“HSA”) funds associated with high deductible health plans. Beginning in 2021, the Company began presenting these funds held on behalf of members in restricted cash and, for statement of cash flow purposes, retrospectively adjusted the 2020 and 2019 balances by the amounts shown in the table below in the line item “restricted cash (included in other current assets)” to conform with the current year presentation. Restricted cash (included in other assets) represents amounts held in a trust in one of the Company’s captive insurance companies to satisfy collateral requirements associated with the assignment of certain insurance policies. All restricted cash is invested in time deposits, money market funds or commercial paper.

The following is a reconciliation of cash and cash equivalents on the consolidated balance sheets to total cash, cash equivalents and restricted cash on the consolidated statements of cash flows as of December 31, 2021, 2020 and 2019:
In millions202120202019
Cash and cash equivalents$9,408 $7,854 $5,683 
Restricted cash (included in other current assets)3,065 2,913 2,454 
Restricted cash (included in other assets)218 276 271 
Total cash, cash equivalents and restricted cash in the consolidated statements of cash flows$12,691 $11,043 $8,408 
Investments

Debt Securities
Debt securities consist primarily of U.S. Treasury and agency securities, mortgage-backed securities, corporate and foreign bonds and other debt securities. Debt securities are classified as either current or long-term investments based on their contractual maturities unless the Company intends to sell an investment within the next twelve months, in which case it is classified as current on the consolidated balance sheets. Debt securities are classified as available for sale and are carried at fair value. See Note 4 ‘‘Fair Value’’ for additional information on how the Company estimates the fair value of these investments.

If a debt security is in an unrealized loss position and the Company has the intent to sell the security, or it is more likely than not that the Company will have to sell the security before recovery of its amortized cost basis, the amortized cost basis of the security is written down to its fair value and the difference is recognized in net income. If a debt security is in an unrealized loss position and the Company does not have the intent to sell and it is more likely than not that the Company will not have to sell such security before recovery of its amortized cost basis, the Company bifurcates the impairment into credit-related and non-credit related components. In evaluating whether a credit related loss exists, the Company considers a variety of factors including: the extent to which the fair value is less than the amortized cost basis; adverse conditions specifically related to the issuer of a security, an industry or geographic area; the payment structure of the security; the failure of the issuer of the security to make scheduled interest or principal payments; and any changes to the rating of the security by a rating agency. The amount of the credit-related component is recorded as an allowance for credit losses and recognized in net income, and the amount of the non-credit related component is included in other comprehensive income. Interest is not accrued on debt securities when management believes the collection of interest is unlikely.

The credit-related component is determined by comparing the present value of cash flows expected to be collected from the security, considering all reasonably available information relevant to the collectability of the security, with the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis of the security, the Company records an allowance for credit losses, which is limited by the amount that the fair value is less than amortized cost basis.

For mortgage-backed and other asset-backed securities, the Company recognizes income using an effective yield based on anticipated prepayments and the estimated economic life of the securities. When estimates of prepayments change, the effective yield is recalculated to reflect actual payments to date and anticipated future payments. The Company’s investment in the security is adjusted to the amount that would have existed had the new effective yield been applied since the acquisition of the security, with adjustments recognized in net income.

Equity Securities
Equity securities with readily available fair values are measured at fair value with changes in fair value recognized in net income (loss).

Mortgage Loans
Mortgage loan investments on the consolidated balance sheets are valued at the unpaid principal balance, net of an allowance for credit losses. Mortgage loans with a maturity date or a committed prepayment date within twelve months are classified as current on the consolidated balance sheets. The Company assesses whether its loans share similar risk characteristics and, if so, groups such loans in a risk pool when measuring expected credit losses. The Company considers the following characteristics when evaluating whether its loans share similar risk characteristics: loan-to-value ratios, property type (e.g., office, retail, apartment, industrial), geographic location, vacancy rates and property condition.

Credit loss reserves are determined using a loss rate method that multiplies the unpaid principal balance of each loan within a risk pool group by an estimated loss rate percentage. The loss rate percentage considers both the expected loan loss severity and the probability of loan default. For periods where the Company is able to make or obtain reasonable and supportable forecasts of expected economic conditions (e.g., gross domestic product, employment), the Company adjusts its expected loss rates to reflect these forecasted economic conditions. For periods beyond which the Company is able to make or obtain reasonable and supportable forecasts of expected economic conditions, the Company reverts to historical loss rates in determining expected credit losses.

Interest income on a potential problem loan (i.e., high probability of default) or restructured loan is accrued to the extent it is deemed to be collectible and the loan continues to perform under its original or restructured terms. Interest income on problem loans (i.e., more than 60 days delinquent, in bankruptcy or in process of foreclosure) is recognized on a cash basis. Cash payments on loans in the process of foreclosure are treated as a return of principal.
Other Investments
Other investments consist primarily of the following:

Private equity and hedge fund limited partnerships, which are accounted for using the equity method of accounting. Under this method, the carrying value of the investment is based on the value of the Company’s equity ownership of the underlying investment funds provided by the general partner or manager of the investments, the financial statements of which generally are audited. As a result of the timing of the receipt of the valuation information provided by the fund managers, these investments are generally reported on up to a three month lag. The Company reviews investments for impairment at least quarterly and monitors their performance throughout the year through discussions with the administrators, managers and/or general partners. If the Company becomes aware of an impairment of a limited partnership’s investments through its review or prior to receiving the limited partnership’s financial statements at the financial statement date, an impairment will be recognized by recording a reduction in the carrying value of the limited partnership with a corresponding charge to net investment income.
Investment real estate, which is carried on the consolidated balance sheets at depreciated cost, including capital additions, net of write-downs for other-than-temporary declines in fair value. Depreciation is calculated using the straight-line method based on the estimated useful life of each asset. If any real estate investment is considered held-for-sale, it is carried at the lower of its carrying value or fair value less estimated selling costs. The Company generally estimates fair value using net operating income and applying a capitalization rate in conjunction with comparable sales information. At the time of the sale, the difference between the sales price and the carrying value is recorded as a realized capital gain or loss.
Privately-placed equity securities, which are carried on the consolidated balance sheets at cost less impairments, plus or minus subsequent adjustments for observable price changes. Additionally, as a member of the Federal Home Loan Bank of Boston (“FHLBB”), a subsidiary of the Company is required to purchase and hold shares of the FHLBB. These shares are restricted and carried at cost.

Net Investment Income
Net investment income on the Company’s investments is recorded when earned and is reflected in the Company’s net income (other than net investment income on assets supporting experience-rated products). Experience-rated products are products in the large case pensions business where the contract holder, not the Company, assumes investment and other risks, subject to, among other things, minimum guarantees provided by the Company. The effect of investment performance on experience-rated products is allocated to contract holders’ accounts daily, based on the underlying investment experience and, therefore, does not impact the Company’s net income (as long as the contract’s minimum guarantees are not triggered). Net investment income on assets supporting large case pensions’ experience-rated products is included in net investment income in the consolidated statements of operations and is credited to contract holders’ accounts through a charge to benefit costs. The contract holders’ accounts are reflected in policyholders’ funds on the consolidated balance sheets.

Realized capital gains and losses on investments (other than realized capital gains and losses on investments supporting experience-rated products) are included as a component of net investment income in the consolidated statements of operations. Realized capital gains and losses are determined on a specific identification basis. Purchases and sales of debt and equity securities and alternative investments are reflected on the trade date. Purchases and sales of mortgage loans and investment real estate are reflected on the closing date.

Realized capital gains and losses on investments supporting large case pensions’ experience-rated products are not included in realized capital gains and losses in the consolidated statements of operations and instead are credited directly to contract holders’ accounts. The contract holders’ accounts are reflected in policyholders’ funds on the consolidated balance sheets.

Unrealized capital gains and losses on investments (other than unrealized capital gains and losses on investments supporting experience-rated products) are reflected in shareholders’ equity, net of tax, as a component of accumulated other comprehensive income. Unrealized capital gains and losses on investments supporting large case pensions’ experience-rated products are credited directly to contract holders’ accounts. The contract holders’ accounts are reflected in policyholders’ funds on the consolidated balance sheets.

Derivative Financial Instruments

The Company uses derivative financial instruments in order to manage interest rate and foreign exchange risk and credit exposure. The Company’s use of these derivatives is generally limited to hedging risk and has principally consisted of using interest rate swaps, treasury rate locks, forward contracts, futures contracts, warrants, put options and credit default swaps.
Accounts Receivable

Accounts receivable are stated net of allowances for credit losses, customer credit allowances, contractual allowances and estimated terminations. Accounts receivable, net is composed of the following at December 31, 2021 and 2020:
In millions20212020
Trade receivables$7,932 $7,101 
Vendor and manufacturer receivables10,573 9,815 
Premium receivables2,537 2,628 
Other receivables3,389 2,198 
   Total accounts receivable, net $24,431 $21,742 

The Company’s allowance for credit losses was $339 million and $358 million as of December 31, 2021 and 2020, respectively. When developing an estimate of the Company’s expected credit losses, the Company considers all available relevant information regarding the collectability of cash flows, including historical information, current conditions and reasonable and supportable forecasts of future economic conditions over the contractual life of the receivable. The Company’s accounts receivable are short duration in nature and typically settle in less than 30 days.

Inventories

Inventories are valued at the lower of cost or net realizable value using the weighted average cost method. Physical inventory counts are taken on a regular basis in each retail store and LTC pharmacy, and a continuous cycle count process is the primary procedure used to validate the inventory balances on hand in each distribution center and mail facility to ensure that the amounts reflected in the consolidated financial statements are properly stated. During the interim period between physical inventory counts, the Company accrues for anticipated physical inventory losses on a location-by-location basis based on historical results and current physical inventory trends.

Reinsurance Recoverables

The Company utilizes reinsurance agreements primarily to: (a) reduce required capital and (b) facilitate the acquisition or disposition of certain insurance contracts. Ceded reinsurance agreements permit the Company to recover a portion of its losses from reinsurers, although they do not discharge the Company’s primary liability as the direct insurer of the risks reinsured. Failure of reinsurers to indemnify the Company could result in losses; however, the Company does not expect charges for unrecoverable reinsurance to have a material effect on its consolidated operating results or financial condition. The Company evaluates the financial condition of its reinsurers and monitors concentrations of credit risk arising from similar geographic regions, activities or economic characteristics of its reinsurers. At December 31, 2021, the Company’s reinsurance recoverables consisted primarily of amounts due from third parties that are rated consistent with companies that are considered to have the ability to meet their obligations. Reinsurance recoverables are recorded as other current assets or other assets on the consolidated balance sheets.

Health Care Contract Acquisition Costs

Insurance products included in the Health Care Benefits segment are cancellable by either the customer or the member monthly upon written notice. Acquisition costs related to prepaid health care and health indemnity contracts are generally expensed as incurred. Acquisition costs for certain long-duration insurance contracts are deferred and are recorded as other current assets or other assets on the consolidated balance sheets and are amortized over the estimated life of the contracts. The amortization of deferred acquisition costs is recorded in operating expenses in the consolidated statements of operations. At December 31, 2021 and 2020, the balance of deferred acquisition costs was $895 million and $546 million, respectively, comprised primarily of commissions paid on Medicare Supplement products within the Health Care Benefits segment.

Property and Equipment

Property and equipment is reported at historical cost, net of accumulated depreciation. Property, equipment and improvements to leased premises are depreciated using the straight-line method over the estimated useful lives of the assets, or when applicable, the term of the lease, whichever is shorter. Estimated useful lives generally range from 1 to 40 years for buildings, building improvements and leasehold improvements and 3 to 10 years for fixtures, equipment and internally developed software. Repair and maintenance costs are charged directly to expense as incurred. Major renewals or replacements that
substantially extend the useful life of an asset are capitalized and depreciated. Application development stage costs for significant internally developed software projects are capitalized and depreciated.

Property and equipment consists of the following at December 31, 2021 and 2020:
In millions20212020
Land$2,038 $2,134 
Building and improvements4,225 3,950 
Fixtures and equipment13,619 13,125 
Leasehold improvements6,242 6,077 
Software7,426 6,020 
Total property and equipment33,550 31,306 
Accumulated depreciation and amortization(20,654)(18,700)
Property and equipment, net$12,896 $12,606 

Depreciation expense (which includes the amortization of property and equipment under finance or capital leases) totaled $2.3 billion, $2.1 billion and $1.9 billion for the years ended December 31, 2021, 2020 and 2019, respectively. During the year ended December 31, 2021, the Company recorded an impairment on property and equipment of $261 million in connection with the planned closure of certain retail stores. See Note 6 ‘‘Leases’’ for additional information about this impairment charge as well as the Company’s finance leases.

Right-of-Use Assets and Lease Liabilities

The Company determines if an arrangement contains a lease at the inception of a contract. Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at the commencement date of the lease, renewal date of the lease or significant remodeling of the lease space based on the present value of the remaining future minimum lease payments. As the interest rate implicit in the Company’s leases is not readily determinable, the Company utilizes its incremental borrowing rate, determined by class of underlying asset, to discount the lease payments. The operating lease right-of-use assets also include lease payments made before commencement and are reduced by lease incentives.

The Company’s real estate leases typically contain options that permit renewals for additional periods of up to five years each. For real estate leases, the options to extend are not considered reasonably certain at lease commencement because the Company reevaluates each lease on a regular basis to consider the economic and strategic incentives of exercising the renewal options and regularly opens or closes stores to align with its operating strategy. Generally, the renewal option periods are not included within the lease term and the associated payments are not included in the measurement of the right-of-use asset and lease liability. Similarly, renewal options are not included in the lease term for non-real estate leases because they are not considered reasonably certain of being exercised at lease commencement. Leases with an initial term of 12 months or less are not recorded on the balance sheets, and lease expense is recognized on a straight-line basis over the term of the short-term lease.

For real estate leases, the Company accounts for lease components and nonlease components as a single lease component. Certain real estate leases require additional payments based on sales volume, as well as reimbursement for real estate taxes, common area maintenance and insurance, which are expensed as incurred as variable lease costs. Other real estate leases contain one fixed lease payment that includes real estate taxes, common area maintenance and insurance. These fixed payments are considered part of the lease payment and included in the right-of-use assets and lease liabilities.

See Note 6 ‘‘Leases’’ for additional information about right-of-use assets and lease liabilities.

Goodwill

The Company accounts for business combinations using the acquisition method of accounting, which requires the excess cost of an acquisition over the fair value of net assets acquired and identifiable intangible assets to be recorded as goodwill. Goodwill is not amortized, but is subject to impairment reviews annually, or more frequently if necessary, as further described in “Long-Lived Asset Impairment” below. See Note 5 ‘‘Goodwill and Other Intangibles’’ for additional information about goodwill.
Intangible Assets

The Company’s identifiable intangible assets consist primarily of trademarks, trade names, customer contracts/relationships, covenants not to compete, technology, provider networks and value of business acquired (“VOBA”). These intangible assets arise primarily from the determination of their respective fair market values at the date of acquisition. Amounts assigned to identifiable intangible assets, and their related useful lives, are derived from established valuation techniques and management estimates.

The Company’s definite-lived intangible assets are amortized over their estimated useful lives based upon the pattern of future cash flows attributable to the asset. Other than VOBA, definite-lived intangible assets are amortized using the straight-line method. VOBA is amortized over the expected life of the acquired contracts in proportion to estimated premiums. Indefinite-lived intangible assets are not amortized but are tested for impairment annually, or more frequently if necessary, as further described in “Long-Lived Asset Impairment” below.

See Note 5 ‘‘Goodwill and Other Intangibles’’ for additional information about intangible assets.

Long-Lived Asset Impairment

The Company evaluates the recoverability of long-lived assets, excluding goodwill and indefinite-lived intangible assets, which are tested for impairment using separate tests described below, whenever events or changes in circumstances indicate that the carrying value of such asset may not be recoverable. The Company groups and evaluates these long-lived assets for impairment at the lowest level at which individual cash flows can be identified. If indicators of impairment are present, the Company first compares the carrying amount of the asset group to the estimated future cash flows associated with the asset group (undiscounted). If the estimated future cash flows used in this analysis are less than the carrying amount of the asset group, an impairment loss calculation is prepared. The impairment loss calculation compares the carrying amount of the asset group to the asset group’s estimated future cash flows (discounted). If required, an impairment loss is recorded for the portion of the asset group’s carrying value that exceeds the asset group’s estimated future cash flows (discounted). During the year ended December 31, 2021, the Company recorded a store impairment charge of approximately $1.4 billion primarily related to the write down of operating lease right-of-use assets and property and equipment in connection with the planned closure of approximately 900 retail stores between 2022 and 2024. There were no material impairment charges recognized on long-lived assets in the year ended 2020. During the year ended December 31, 2019 the Company recorded a store impairment charge of $231 million primarily related to operating lease right-of-use assets. See Note 6 ‘‘Leases’’ for additional information about the right-of-use asset impairment charges.

When evaluating goodwill for potential impairment, the Company compares the fair value of its reporting units to their respective carrying amounts. The Company estimates the fair value of its reporting units using a combination of a discounted cash flow method and a market multiple method. If the carrying amount of a reporting unit exceeds its estimated fair value, an impairment loss is recognized in an amount equal to that excess. During the third quarter of 2021, the Company performed its required annual impairment tests of goodwill, the results of which indicated an impairment of the goodwill associated with the LTC reporting unit. Accordingly, during the third quarter of 2021, the Company recorded a $431 million goodwill impairment charge. The results of the impairment tests indicated that there was no impairment of goodwill of the remaining reporting units as of the testing date or during the year ended December 31, 2021. During the third quarter of both 2020 and 2019, the Company performed its required annual goodwill impairment tests and concluded there were no goodwill impairments as of the testing dates or during the years ended December 31, 2020 and 2019. See Note 5 ‘‘Goodwill and Other Intangibles’’ for additional information about the goodwill impairment charge recorded during the year ended December 31, 2021.

Indefinite-lived intangible assets are tested for impairment by comparing the estimated fair value of the asset to its carrying value. The Company estimates the fair value of its indefinite-lived trademarks using the relief from royalty method under the income approach. If the carrying value of the asset exceeds its estimated fair value, an impairment loss is recognized, and the asset is written down to its estimated fair value. There were no impairment losses recognized on indefinite-lived intangible assets in any of the years ended December 31, 2021, 2020 or 2019.

Separate Accounts

Separate Accounts assets and liabilities related to large case pensions products represent funds maintained to meet specific objectives of contract holders who bear the investment risk. These assets and liabilities are carried at fair value. Net investment income (including net realized capital gains and losses) accrue directly to such contract holders. The assets of each account are legally segregated and are not subject to claims arising from the Company’s other businesses. Deposits, withdrawals and net
investment income (including net realized and net unrealized capital gains and losses) on Separate Accounts assets are not reflected in the consolidated statements of operations or cash flows. Management fees charged to contract holders are included in services revenue and recognized over the period earned.

Health Care Costs Payable

Health care costs payable consist principally of unpaid fee-for-service medical, dental and pharmacy claims, capitation costs, other amounts due to providers pursuant to risk-sharing arrangements related to the Health Care Benefits segment’s Insured Commercial, Medicare and Medicaid products and accruals for state assessments. Unpaid health care claims include an estimate of payments the Company will make for (i) services rendered to the Company’s Insured members but not yet reported to the Company and (ii) claims which have been reported to the Company but not yet paid, each as of the financial statement date (collectively, “IBNR”). Health care costs payable also include an estimate of the cost of services that will continue to be rendered after the financial statement date if the Company is obligated to pay for such services in accordance with contractual or regulatory requirements. Such estimates are developed using actuarial principles and assumptions which consider, among other things, historical and projected claim submission and processing patterns, assumed and historical medical cost trends, historical utilization of medical services, claim inventory levels, changes in Insured membership and product mix, seasonality and other relevant factors. The Company reflects changes in these estimates in benefit costs in the Company’s consolidated operating results in the period they are determined. Capitation costs represent contractual monthly fees paid to participating physicians and other medical providers for providing medical care, regardless of the volume of medical services provided to the Insured member. Amounts due under risk-sharing arrangements are based on the terms of the underlying contracts with the providers and consider claims experience under the contracts through the financial statement date.

The Company develops its estimate of IBNR using actuarial principles and assumptions that consider numerous factors. Of those factors, the Company considers the analysis of historical and projected claim payment patterns (including claims submission and processing patterns) and the assumed health care cost trend rate (the year-over-year change in per member per month health care costs) to be the most critical assumptions. In developing its IBNR estimate, the Company consistently applies these actuarial principles and assumptions each period, with consideration to the variability of related factors. There have been no significant changes to the methodologies or assumptions used to develop the Company’s estimate of IBNR in 2021.

The Company analyzes historical claim payment patterns by comparing claim incurred dates (i.e., the date services were provided) to claim payment dates to estimate “completion factors.” The Company uses completion factors predominantly to estimate the ultimate cost of claims incurred more than three months before the financial statement date. The Company estimates completion factors by aggregating claim data based on the month of service and month of claim payment and estimating the percentage of claims incurred for a given month that are complete by each month thereafter. For any given month, substantially all claims are paid within six months of the date of service, but it can take up to 48 months or longer after the date of service before all of the claims are completely resolved and paid. These historically-derived completion factors are then applied to claims paid through the financial statement date to estimate the ultimate claim cost for a given month’s incurred claim activity. The difference between the estimated ultimate claim cost and the claims paid through the financial statement date represents the Company’s estimate of claims remaining to be paid as of the financial statement date and is included in the Company’s health care costs payable. The completion factors the Company uses reflect judgments and possible adjustments based on data such as claim inventory levels, claim submission and processing patterns and, to a lesser extent, other factors such as changes in health care cost trend rates, changes in Insured membership and changes in product mix. If claims are submitted or processed on a faster (slower) pace than prior periods, the actual claims may be more (less) complete than originally estimated using the Company’s completion factors, which may result in reserves that are higher (lower) than the ultimate cost of claims.

Because claims incurred within three months before the financial statement date are less mature, the Company uses a combination of historically-derived completion factors and the assumed health care cost trend rate to estimate the ultimate cost of claims incurred for these months. The Company applies its actuarial judgment and places a greater emphasis on the assumed health care cost trend rate for the most recent claim incurred dates as these months may be influenced by seasonal patterns and changes in membership and product mix.

The Company’s health care cost trend rate is affected by changes in per member utilization of medical services as well as changes in the unit cost of such services. Many factors influence the health care cost trend rate, including the Company’s ability to manage benefit costs through product design, negotiation of favorable provider contracts and medical management programs, as well as the mix of the Company’s business. The health status of the Company’s Insured members, aging of the population and other demographic characteristics, advances in medical technology and other factors continue to contribute to rising per member utilization and unit costs. Changes in health care practices, inflation, new technologies, increases in the cost of
prescription drugs (including specialty pharmacy drugs), direct-to-consumer marketing by pharmaceutical companies, clusters of high-cost cases, claim intensity, changes in the regulatory environment, health care provider or member fraud and numerous other factors also contribute to the cost of health care and the Company’s health care cost trend rate.

For each reporting period, the Company uses an extensive degree of judgment in the process of estimating its health care costs payable. As a result, considerable variability and uncertainty is inherent in such estimates, particularly with respect to claims with claim incurred dates of three months or less before the financial statement date; and the adequacy of such estimates is highly sensitive to changes in assumed completion factors and the assumed health care cost trend rates. For each reporting period the Company recognizes the actuarial best estimate of health care costs payable considering the potential volatility in assumed completion factors and health care cost trend rates, as well as other factors. The Company believes its estimate of health care costs payable is reasonable and adequate to cover its obligations at December 31, 2021; however, actual claim payments may differ from the Company’s estimates. A worsening (or improvement) of the Company’s health care cost trend rates or changes in completion factors from those that the Company assumed in estimating health care costs payable at December 31, 2021 would cause these estimates to change in the near term, and such a change could be material.

Each quarter, the Company re-examines previously established health care costs payable estimates based on actual claim payments for prior periods and other changes in facts and circumstances. Given the extensive degree of judgment in this estimate, it is possible that the Company’s estimates of health care costs payable could develop either favorably (that is, its actual benefit costs for the period were less than estimated) or unfavorably. The changes in the Company’s estimate of health care costs payable may relate to a prior quarter, prior year or earlier periods. For a roll forward of the Company’s health care costs payable, see Note 7 ‘‘Health Care Costs Payable.’’ The Company’s reserving practice is to consistently recognize the actuarial best estimate of its ultimate liability for health care costs payable.

Other Insurance Liabilities

Unpaid Claims
Unpaid claims consist primarily of reserves associated with certain short-duration group disability and term life insurance contracts, including an estimate for IBNR as of the financial statement date. Reserves associated with certain short-duration group disability and term life insurance contracts are based upon the Company’s estimate of the present value of future benefits, which is based on assumed investment yields and assumptions regarding mortality, morbidity and recoveries from the U.S. Social Security Administration. The Company develops its estimate of IBNR using actuarial principles and assumptions which consider, among other things, contractual requirements, claim incidence rates, claim recovery rates, seasonality and other relevant factors. The Company discounts certain claim liabilities related to group long-term disability and life insurance waiver of premium contracts. The discount rates generally reflect the Company’s expected investment returns for the investments supporting all incurral years of these liabilities. The discount rates for retrospectively-rated contracts are set at contractually specified levels. The Company’s estimates of unpaid claims are subject to change due to changes in the underlying experience of the insurance contracts, changes in investment yields or other factors, and these changes are recorded in current and future benefits in the consolidated statements of operations in the period they are determined. The Company estimates its reserve for claims IBNR for life products largely based on completion factors. The completion factors used are based on the Company’s historical experience and reflect judgments and possible adjustments based on data such as claim inventory levels, claim payment patterns, changes in business volume and other factors. If claims are submitted or processed on a faster (slower) pace than historical periods, the actual claims may be more (less) complete than originally estimated using completion factors, which may result in reserves that are higher (lower) than required to cover future life benefit payments. There have been no significant changes to the methodologies or assumptions used to develop the Company’s estimate of unpaid claims IBNR in 2021. As of December 31, 2021, unpaid claims balances of $324 million and $1.3 billion were recorded in other insurance liabilities and other long-term insurance liabilities, respectively. As of December 31, 2020, unpaid claims balances of $532 million and $1.5 billion were recorded in other insurance liabilities and other long-term insurance liabilities, respectively.

Substantially all life and disability insurance liabilities have been fully ceded to unrelated third parties through indemnity reinsurance agreements; however, the Company remains directly obligated to the policyholders.

Future Policy Benefits
Future policy benefits consist primarily of reserves for limited payment pension and annuity contracts and long-term care insurance contracts. Reserves for limited payment pension and annuity contracts are computed using actuarial principles that consider, among other things, assumptions reflecting anticipated mortality, retirement, expense and interest rate experience. Such assumptions generally vary by plan, year of issue and policy duration. Assumed interest rates on such contracts ranged from 3.0% to 11.3% in the year ended December 31, 2021 and from 3.3% to 11.3% in the year ended December 31, 2020. The Company periodically reviews mortality assumptions against both industry standards and its experience. Reserves for long-
duration long-term care contracts represent the Company’s estimate of the present value of future benefits and essential maintenance expenses to be paid to or on behalf of policyholders less the present value of future gross premiums. The assumed interest rate on such contracts was 5.1% in both the years ended December 31, 2021 and 2020. The Company’s estimate of the present value of future benefits under such contracts is based upon mortality, morbidity and interest rate assumptions. As of December 31, 2021, future policy benefits balances of $416 million and $5.1 billion were recorded in other insurance liabilities and other long-term insurance liabilities, respectively. As of December 31, 2020, future policy benefits balances of $462 million and $5.5 billion were recorded in other insurance liabilities and other long-term insurance liabilities, respectively.

Premium Deficiency Reserves

The Company evaluates its insurance contracts to determine if it is probable that a loss will be incurred. A premium deficiency loss is recognized when it is probable that expected future claims, including maintenance costs (for example, direct costs such as claim processing costs), will exceed existing reserves plus anticipated future premiums and reinsurance recoveries. Anticipated investment income is not considered in the calculation of premium deficiency losses for short-duration contracts. For purposes of determining premium deficiency losses, contracts are grouped consistent with the Company’s method of acquiring, servicing and measuring the profitability of such contracts. As of December 31, 2021 and 2020, the Company established a premium deficiency reserve of $16 million and $11 million, respectively, related to Medicaid products in the Health Care Benefits segment.

Policyholders’ Funds

Policyholders’ funds consist primarily of reserves for pension and annuity investment contracts and customer funds associated with certain health contracts. Reserves for such contracts are equal to cumulative deposits less withdrawals and charges plus interest credited thereon, net of experience-rated adjustments. In 2021, interest rates for pension and annuity investment contracts ranged from 3.5% to 4.8%. In 2020, interest rates for pension and annuity investment contracts ranged from 4.1% to 5.1%. Reserves for contracts subject to experience rating reflect the Company’s rights as well as the rights of policyholders and plan participants. The Company also holds funds for HSAs on behalf of members associated with high deductible health plans. These amounts are held to pay for qualified health care expenses incurred by these members. The HSA balances were approximately $2.9 billion and $2.7 billion at December 31, 2021 and 2020, respectively, and are reflected in other current assets with a corresponding liability in policyholders’ funds. These assets are considered restricted cash for cash flow statement purposes.

Policyholders’ funds liabilities that are expected to be paid within twelve months from the balance sheet date are classified as current on the consolidated balance sheets. Policyholders’ funds liabilities that are expected to be paid greater than twelve months from the balance sheet date are included in other long-term liabilities on the consolidated balance sheets.

Self-Insurance Liabilities

The Company is self-insured for certain losses related to general liability, workers’ compensation and auto liability. The Company obtains third party insurance coverage to limit exposure from these claims. The Company is also self-insured for certain losses related to health and medical liabilities. The Company’s self-insurance accruals, which include reported claims and claims incurred but not reported, are calculated using standard insurance industry actuarial assumptions and the Company’s historical claims experience. At December 31, 2021 and 2020, self-insurance liabilities totaled $1.1 billion and $927 million, respectively, and were recorded as accrued expenses on the consolidated balance sheets.

Foreign Currency Translation and Transactions

For non-U.S. dollar functional currency locations, (i) assets and liabilities are translated at end-of-period exchange rates, (ii) revenues and expenses are translated at average exchange rates in effect during the period and (iii) equity is translated at historical exchange rates. The resulting cumulative translation adjustments are included as a component of accumulated other comprehensive income.

For U.S. dollar functional currency locations, foreign currency assets and liabilities are remeasured into U.S. dollars at end-of-period exchange rates, except for nonmonetary balance sheet accounts which are remeasured at historical exchange rates. Revenues and expenses are remeasured at average exchange rates in effect during each period, except for those expenses related to the nonmonetary balance sheet amounts which are remeasured at historical exchange rates. Gains or losses from foreign currency remeasurement are included in net income.
Gains and losses from foreign currency transactions and the effects of foreign currency remeasurements were not material in the years ended December 31, 2021 or 2020. On July 1, 2019, the Company sold its Brazilian subsidiary, Drogaria Onofre Ltda. (“Onofre”) for an immaterial amount. The Company recorded a loss on the divestiture, which included the elimination of the subsidiary’s $154 million cumulative translation adjustment from accumulated other comprehensive income during the year ended December 31, 2019.

Revenue Recognition

Health Care Benefits Segment
Health Care Benefits revenue is principally derived from insurance premiums and fees billed to customers. Revenue is recognized based on customer billings, which, in the Company’s Commercial business, reflect contracted rates per member and the number of covered members recorded in the Company’s records at the time the billings are prepared. Billings are generally sent monthly for coverage during the following month. Revenue related to the Company’s Government business is collected monthly from the U.S. federal government and various government agencies based on fixed payment rates and member eligibility.

The Company’s billings may be subsequently adjusted to reflect enrollment changes due to member terminations or other factors. These adjustments are known as retroactivity adjustments. In each period, the Company estimates the amount of future retroactivity and adjusts the recorded revenue accordingly. As information regarding actual retroactivity amounts becomes known, the Company refines its estimates and records any required adjustments to revenues in the period in which they arise.

Premium Revenue
Premiums are recognized as revenue in the month in which the enrollee is entitled to receive health care services. Premiums are reported net of an allowance for estimated terminations and uncollectible amounts. Additionally, premium revenue subject to the minimum medical loss ratio (“MLR”) rebate requirements of the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010 (as amended, collectively, the “ACA”) is recorded net of the estimated minimum MLR rebates for the current calendar year. Premiums related to unexpired contractual coverage periods (unearned premiums) are reported as other insurance liabilities on the consolidated balance sheets and recognized as revenue when earned.

Some of the Company’s contracts allow for premiums to be adjusted to reflect actual experience or the relative health status of Insured members. Such adjustments are reasonably estimable at the outset of the contract, and adjustments to those estimates are made based on actual experience of the customer emerging under the contract and the terms of the underlying contract.

Services Revenue
Services revenue relates to contracts that can include various combinations of services or series of services which generally are capable of being distinct and accounted for as separate performance obligations. The Health Care Benefits segment’s services revenue primarily consists of ASC fees received in exchange for performing certain claim processing and member services for ASC members. ASC fee revenue is recognized over the period the service is provided. Some of the Company’s administrative services contracts include guarantees with respect to certain functions, such as customer service response time, claim processing accuracy and claim processing turnaround time, as well as certain guarantees that a plan sponsor’s benefit claim experience will fall within a certain range. With any of these guarantees, the Company is financially at risk if the conditions of the arrangements are not met, although the maximum amount at risk typically is limited to a percentage of the fees otherwise payable to the Company by the customer involved. Each period the Company estimates its obligations under the terms of these guarantees and records its estimate as an offset to services revenues.

Accounting for Medicare Part D
Revenues include insurance premiums earned by the Company’s PDPs, which are determined based on the PDP’s annual bid and related contractual arrangements with the U.S. Centers for Medicare & Medicaid Services (“CMS”). The insurance premiums include a beneficiary premium, which is the responsibility of the PDP member, and can be subsidized by CMS in the case of low-income members, and a direct premium paid by CMS. Premiums collected in advance are initially recorded within other insurance liabilities and are then recognized ratably as revenue over the period in which members are entitled to receive benefits.

Revenues also include a risk-sharing feature of the Medicare Part D program design referred to as the risk corridor. The Company estimates variable consideration in the form of amounts payable to, or receivable from, CMS under the risk corridor, and adjusts revenue based on calculations of additional subsidies to be received from or owed to CMS at the end of the reporting year.
In addition to Medicare Part D premiums, the Company receives additional payments each month from CMS related to catastrophic reinsurance, low-income cost-sharing subsidies and coverage gap benefits. If the subsidies received differ from the amounts earned from actual prescriptions transferred, the difference is recorded in either accounts receivable, net or accrued expenses.

Pharmacy Services Segment
The Pharmacy Services segment sells prescription drugs directly through its mail service dispensing pharmacies and indirectly through the Company’s retail pharmacy network. The Company’s pharmacy benefit arrangements are accounted for in a manner consistent with a master supply arrangement as there are no contractual minimum volumes and each prescription is considered a separate purchasing decision and distinct performance obligation transferred at a point in time. PBM services performed in connection with each prescription claim are considered part of a single performance obligation which culminates in the dispensing of prescription drugs.

The Company recognizes revenue using the gross method at the contract price negotiated with its clients when the Company has concluded it controls the prescription drug before it is transferred to the client plan members. The Company controls prescriptions dispensed indirectly through its retail pharmacy network because it has separate contractual arrangements with those pharmacies, has discretion in setting the price for the transaction and assumes primary responsibility for fulfilling the promise to provide prescription drugs to its client plan members while also performing the related PBM services.

Revenues include (i) the portion of the price the client pays directly to the Company, net of any discounts earned on brand name drugs or other discounts and refunds paid back to the client (see “Drug Discounts” and “Guarantees” below), (ii) the price paid to the Company by client plan members for mail order prescriptions and the price paid to retail network pharmacies by client plan members for retail prescriptions (“retail co-payments”), and (iii) claims based administrative fees for retail pharmacy network contracts. Sales taxes are not included in revenues.

The Company recognizes revenue when control of the prescription drugs is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to receive in exchange for those prescription drugs. The Company has established the following revenue recognition policies for the Pharmacy Services segment:

Revenues generated from prescription drugs sold by mail service dispensing pharmacies are recognized when the prescription drug is delivered to the client plan member. At the time of delivery, the Company has performed substantially all of its performance obligations under its client contracts and does not experience a significant level of returns or reshipments.
Revenues generated from prescription drugs sold by third party pharmacies in the Company’s retail pharmacy network and associated administrative fees are recognized at the Company’s point-of-sale, which is when the claim is adjudicated by the Company’s online claims processing system and the Company has transferred control of the prescription drug and completed all of its performance obligations.

For contracts under which the Company acts as an agent or does not control the prescription drugs prior to transfer to the client plan member, revenue is recognized using the net method.

Drug Discounts
The Company records revenue net of manufacturers’ rebates earned by its clients based on their plan members’ utilization of brand-name formulary drugs. The Company estimates these rebates at period-end based on actual and estimated claims data and its estimates of the manufacturers’ rebates earned by its clients. The estimates are based on the best available data at period-end and recent history for the various factors that can affect the amount of rebates due to the client. The Company adjusts its rebates payable to clients to the actual amounts paid when these rebates are paid or as significant events occur. Any cumulative effect of these adjustments is recorded against revenues at the time it is identified. Adjustments generally result from contract changes with clients or manufacturers that have retroactive rebate adjustments, differences between the estimated and actual product mix subject to rebates, or whether the brand name drug was included in the applicable formulary. The effect of adjustments between estimated and actual manufacturers’ rebate amounts has not been material to the Company’s operating results or financial condition.

Guarantees
The Company also adjusts revenues for refunds owed to clients resulting from pricing guarantees and performance against defined service and performance metrics. The inputs to these estimates are not subject to a high degree of subjectivity or volatility. The effect of adjustments between estimated and actual pricing and performance refund amounts has not been material to the Company’s operating results or financial condition.
Retail/LTC Segment
Retail Pharmacy
The Company’s retail drugstores recognize revenue at the time the customer takes possession of the merchandise. For pharmacy sales, each prescription claim is its own arrangement with the customer and is a performance obligation, separate and distinct from other prescription claims under other retail network arrangements. Revenues are adjusted for refunds owed to third party payers resulting from pricing guarantees and performance against defined value-based service and performance metrics. The inputs to these estimates are not subject to a high degree of subjectivity or volatility. The effect of adjustments between estimated and actual pricing and performance refund amounts has not been material to the Company’s operating results or financial condition.

Revenue from Company gift cards purchased by customers is deferred as a contract liability until goods or services are transferred. Any amounts not expected to be redeemed by customers (i.e., breakage) are recognized based on historical redemption patterns.

Customer returns are not material to the Company’s operating results or financial condition. Sales taxes are not included in revenues.

Loyalty and Other Programs
The Company’s customer loyalty program, ExtraCare®, consists of two components, ExtraSavingsTM and ExtraBucks® Rewards. ExtraSavings are coupons that are recorded as a reduction of revenue when redeemed as the Company concluded that they do not represent a promise to the customer to deliver additional goods or services at the time of issuance because they are not tied to a specific transaction or spending level.

ExtraBucks Rewards are accumulated by customers based on their historical spending levels. Thus, the Company has determined that there is an additional performance obligation to those customers at the time of the initial transaction. The Company allocates the transaction price to the initial transaction and the ExtraBucks Rewards transaction based upon the relative standalone selling price, which considers historical redemption patterns for the rewards. Revenue allocated to ExtraBucks Rewards is recognized as those rewards are redeemed. At the end of each period, unredeemed ExtraBucks Rewards are reflected as a contract liability.

The Company also offers a subscription-based membership program, CarePass®, under which members are entitled to a suite of benefits delivered over the course of the subscription period, as well as a promotional reward that can be redeemed for future goods and services. Subscriptions are paid for on a monthly or annual basis at the time of or in advance of the Company delivering the goods and services. Revenue from these arrangements is recognized as the performance obligations are satisfied.

Long-term Care
Revenue is recognized when control of the promised goods or services is transferred to customers in an amount that reflects the consideration the Company expects to be entitled to receive in exchange for those goods or services. Each prescription claim represents a separate performance obligation of the Company, separate and distinct from other prescription claims under customer arrangements. A significant portion of long-term care revenue from sales of pharmaceutical and medical products is reimbursed by the federal Medicare Part D program and, to a lesser extent, state Medicaid programs. The Company monitors its revenues and receivables from these reimbursement sources, as well as long-term care facilities and other third party insurance payors, and reduces revenue at the revenue recognition date to properly account for the variable consideration due to anticipated differences between billed and reimbursed amounts. Accordingly, the total revenues and receivables reported in the Company’s consolidated financial statements are recorded at the amount expected to be ultimately received from these payors.

Patient co-payments associated with Medicare Part D, certain state Medicaid programs, Medicare Part B and certain third party payors typically are not collected at the time products are delivered or services are rendered, but are billed to the individuals as part of normal billing procedures and subject to normal accounts receivable collections procedures.

Walk-In Medical Clinics
For services provided by the Company’s walk-in medical clinics, revenue recognition occurs for completed services provided to patients, with adjustments taken for third party payor contractual obligations and patient direct bill historical collection rates.
Disaggregation of Revenue
The following table disaggregates the Company’s revenue by major source in each segment for the years ended December 31, 2021, 2020 and 2019:
In millionsHealth Care
Benefits
Pharmacy
Services
Retail/
LTC
Corporate/
Other
Intersegment
Eliminations
Consolidated
Totals
2021
Major goods/services lines:
Pharmacy$— $152,262 $76,121 $— $(43,765)$184,618 
Front Store— — 21,315 — — 21,315 
Premiums76,064 — — 68 — 76,132 
Net investment income586 — 17 596 — 1,199 
Other5,536 760 2,652 57 (158)8,847 
Total$82,186 $153,022 $100,105 $721 $(43,923)$292,111 
Pharmacy Services distribution channel:
Pharmacy network (1)
$91,715 
Mail choice (2)
60,547 
Other760 
Total$153,022 
2020
Major goods/services lines:
Pharmacy$— $141,116 $70,176 $— $(40,003)$171,289 
Front Store— — 19,655 — — 19,655 
Premiums69,301 — — 63 — 69,364 
Net investment income483 — — 315 — 798 
Other5,683 822 1,367 48 (320)7,600 
Total$75,467 $141,938 $91,198 $426 $(40,323)$268,706 
Pharmacy Services distribution channel:
Pharmacy network (1)
$85,045 
Mail choice (2)
56,071 
Other822 
Total$141,938 
2019
Major goods/services lines:
Pharmacy$— $140,896 $66,442 $— $(41,413)$165,925 
Front Store— — 19,422 — — 19,422 
Premiums63,031 — — 91 — 63,122 
Net investment income599 — — 412 — 1,011 
Other5,974 595 744 (26)7,296 
Total$69,604 $141,491 $86,608 $512 $(41,439)$256,776 
Pharmacy Services distribution channel:
Pharmacy network (1)
$88,755 
Mail choice (2)
52,141 
Other595 
Total$141,491 
_____________________________________________
(1)Pharmacy Services pharmacy network is defined as claims filled at retail and specialty retail pharmacies, including the Company’s retail pharmacies and LTC pharmacies, but excluding Maintenance Choice® activity, which is included within the mail choice category. Maintenance Choice permits eligible client plan members to fill their maintenance prescriptions through mail order delivery or at a CVS Pharmacy retail store for the same price as mail order.
(2)Pharmacy Services mail choice is defined as claims filled at a Pharmacy Services mail order facility, which includes specialty mail claims inclusive of Specialty Connect® claims picked up at a retail pharmacy, as well as prescriptions filled at the Company’s retail pharmacies under the Maintenance Choice program.

Contract Balances
Contract liabilities primarily represent the Company’s obligation to transfer additional goods or services to a customer for which the Company has received consideration, and include ExtraBucks Rewards and unredeemed Company gift cards. The consideration received remains a contract liability until goods or services have been provided to the customer. In addition, the Company recognizes breakage on Company gift cards based on historical redemption patterns.

The following table provides information about receivables and contract liabilities from contracts with customers as of December 31, 2021 and 2020:
In millions20212020
Trade receivables (included in accounts receivable, net)$7,932 $7,101 
Contract liabilities (included in accrued expenses)87 71 

During the years ended December 31, 2021 and 2020, the contract liabilities balance includes increases related to customers’ earnings in ExtraBucks Rewards or issuances of Company gift cards and decreases for revenues recognized during the period as a result of the redemption of ExtraBucks Rewards or Company gift cards and breakage of Company gift cards. Below is a summary of such changes:
In millions20212020
Contract liabilities, beginning of period$71 $73 
Rewards earnings and gift card issuances387 357 
Redemption and breakage(371)(359)
Contract liabilities, end of period$87 $71 

Cost of Products Sold

The Company accounts for cost of products sold as follows:

Pharmacy Services Segment
Cost of products sold includes: (i) the cost of prescription drugs sold during the reporting period directly through the Company’s mail service dispensing pharmacies and indirectly through the Company’s retail pharmacy network, (ii) shipping and handling costs, and (iii) the operating costs of the Company’s mail service dispensing pharmacies and client service operations and related information technology support costs including depreciation and amortization. The cost of prescription drugs sold component of cost of products sold includes: (i) the cost of the prescription drugs purchased from manufacturers or distributors and shipped to members in clients’ benefit plans from the Company’s mail service dispensing pharmacies, net of any volume-related or other discounts (see “Vendor Allowances and Purchase Discounts” below) and (ii) the cost of prescription drugs sold (including retail co-payments) through the Company’s retail pharmacy network under contracts where the Company is the principal, net of any volume-related or other discounts.

Retail/LTC Segment
Cost of products sold includes: the cost of merchandise sold during the reporting period, including prescription drug costs, and the related purchasing costs, warehousing and delivery costs (including depreciation and amortization) and actual and estimated inventory losses.

Vendor Allowances and Purchase Discounts

The Company accounts for vendor allowances and purchase discounts as follows:

Pharmacy Services Segment
The Pharmacy Services segment receives purchase discounts on products purchased. Contractual arrangements with vendors, including manufacturers, wholesalers and retail pharmacies, normally provide for the Pharmacy Services segment to receive
purchase discounts from established list prices in one, or a combination, of the following forms: (i) a direct discount at the time of purchase, (ii) a discount for the prompt payment of invoices or (iii) when products are purchased indirectly from a manufacturer (e.g., through a wholesaler or retail pharmacy), a discount (or rebate) paid subsequent to dispensing. These rebates are recognized when prescriptions are dispensed and are generally calculated and billed to manufacturers within 30 days of the end of each completed quarter. Historically, the effect of adjustments resulting from the reconciliation of rebates recognized to the amounts billed and collected has not been material to the Company’s operating results or financial condition. The Company accounts for the effect of any such differences as a change in accounting estimate in the period the reconciliation is completed. The Pharmacy Services segment also receives additional discounts under its wholesaler contracts if it exceeds contractually defined purchase volumes. In addition, the Pharmacy Services segment receives fees from pharmaceutical manufacturers for administrative services. Purchase discounts and administrative service fees are recorded as a reduction of cost of products sold.

Retail/LTC Segment
Vendor allowances received by the Retail/LTC segment reduce the carrying cost of inventory and are recognized in cost of products sold when the related inventory is sold, unless they are specifically identified as a reimbursement of incremental costs for promotional programs and/or other services provided. Amounts that are directly linked to advertising commitments are recognized as a reduction of advertising expense (included in operating expenses) when the related advertising commitment is satisfied. Any amounts received in excess of the actual cost incurred also reduce the carrying cost of inventory. The total value of any upfront payments received from vendors that are linked to purchase commitments is initially deferred. The deferred amounts are then amortized to reduce cost of products sold over the life of the contract based upon sales volume. The total value of any upfront payments received from vendors that are not linked to purchase commitments is also initially deferred. The deferred amounts are then amortized to reduce cost of products sold on a straight-line basis over the life of the related contract. The total amortization of these upfront payments was not material to the Company’s consolidated financial statements in any of the periods presented.

Health Care Reform

Health Insurer Fee
Since January 1, 2014, the ACA has imposed an annual premium-based health insurer fee (“HIF”) for each calendar year, payable in September, which was not deductible for tax purposes. The Company has been required to estimate a liability for the HIF at the beginning of the calendar year in which the fee was payable with a corresponding deferred asset that was amortized ratably to operating expenses over the calendar year. The Company recorded the liability for the HIF in accrued expenses and recorded the deferred asset in other current assets. In December 2019, the HIF was repealed for calendar years after 2020, therefore there was no expense related to the HIF in the year ended December 31, 2021. In the year ended December 31, 2020, operating expenses included $1.0 billion related to the Company’s share of the HIF. There was no expense related to the HIF in 2019, since there was a one-year suspension of the HIF for 2019.

Risk Adjustment
The ACA established a permanent risk adjustment program to transfer funds from qualified individual and small group insurance plans with below average risk scores to plans with above average risk scores. Based on the risk of the Company’s qualified plan members relative to the average risk of members of other qualified plans in comparable markets, as defined by the ACA, the Company estimates its ultimate risk adjustment receivable (recorded in accounts receivable) or payable (recorded in accrued expenses) for the current calendar year and reflects the pro-rata year-to-date impact as an adjustment to premium revenue.

Risk Corridor
The ACA established a temporary risk corridor program, which expired at the end of 2016, for qualified individual and small group health insurance plans. Under this program, health insurance companies were to make payments to, or receive payments from, the U.S. Department of Health and Human Services (“HHS”) based on their ratio of allowable costs to target costs (as defined by the ACA).

The Company filed a lawsuit in August 2019 to recover the $313 million it was owed under the ACA’s risk corridor program, which had been stayed pending the Supreme Court decision. In April 2020, the U.S. Supreme Court ruled that health insurance companies may sue the federal government for amounts owed as calculated under the ACA’s temporary risk corridor program.

In October 2020, the Company received the $313 million it was owed under the ACA’s risk corridor program. The Company recorded the risk corridor payment as an increase to premium revenue in the year ended December 31, 2020. After considering
offsetting items such as the ACA’s minimum MLR rebate requirements and premium taxes, the Company recorded pre-tax income of $307 million and after-tax income of $223 million during the year ended December 31, 2020.

Advertising Costs

Advertising costs, which are reduced by the portion funded by vendors, are expensed when the related advertising takes place. Net advertising costs, which are included in operating expenses, were $523 million, $461 million and $396 million in 2021, 2020 and 2019, respectively.

Stock-Based Compensation

Stock-based compensation is measured at the grant date based on the fair value of the award and is recognized as expense over the requisite service period of the stock award (generally three to five years) using the straight-line method.

Income Taxes

The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year or years in which the differences are expected to reverse. The effect of a change in the tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date of such change.

The Company recognizes deferred tax assets to the extent that it believes these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies, and the Company’s recent operating results. The Company establishes a valuation allowance when it does not consider it more likely than not that a deferred tax asset will be recovered.

The Company records uncertain tax positions on the basis of a two-step process whereby (1) the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority.

Interest and/or penalties related to uncertain tax positions are recognized in the income tax provision.

Measurement of Defined Benefit Pension and Other Postretirement Employee Benefit Plans

The Company sponsors defined benefit pension plans (“pension plans”) and other postretirement employee benefit plans (“OPEB plans”) for its employees and retirees. The Company recognizes the funded status of its pension and OPEB plans on the consolidated balance sheets based on the year-end measurements of plan assets and benefit obligations. When the fair value of plan assets are in excess of the plan benefit obligations, the amounts are reported in other current assets and other assets. When the fair value of plan benefit obligations are in excess of plan assets, the amounts are reported in accrued expenses and other long-term liabilities based on the amount by which the actuarial present value of benefits payable in the next twelve months included in the benefit obligation exceeds the fair value of plan assets. The net periodic benefit cost (income) for the Company’s pension and OPEB plans do not contain a service cost component as these plans have been frozen for an extended period of time. Non-service cost components of pension and postretirement net periodic benefit cost (income) are included in other income in the consolidated statements of operations.

Earnings per Share

Earnings per share is computed using the two-class method. The Company calculates basic earnings per share based on the weighted average number of common shares outstanding for the period. See Note 14 ‘‘Earnings Per Share’’ for additional information.
Shares Held in Trust

The Company maintains grantor trusts, which held approximately one million shares of its common stock at both December 31, 2021 and 2020. These shares are designated for use under various employee compensation plans. Since the Company holds these shares, they are excluded from the computation of basic and diluted shares outstanding.

Variable Interest Entities

The Company has investments in (i) a generic pharmaceutical sourcing entity, (ii) certain hedge fund and private equity investments and (iii) certain real estate partnerships that are considered VIEs. The Company does not have a future obligation to fund losses or debts on behalf of these investments; however, it may voluntarily contribute funds. In evaluating whether the Company is the primary beneficiary of a VIE, the Company considers several factors, including whether the Company has (a) the power to direct the activities that most significantly impact the VIE’s economic performance and (b) the obligation to absorb losses and the right to receive benefits that could potentially be significant to the VIE.

Variable Interest Entities - Primary Beneficiary
In 2014, the Company and Cardinal Health, Inc. (“Cardinal”) established Red Oak Sourcing, LLC (“Red Oak”), a generic pharmaceutical sourcing entity in which the Company and Cardinal each own 50%. The Red Oak arrangement had an initial term of ten years. In 2021, the Red Oak arrangement was amended to extend the initial term an additional five years, for a total term of 15 years. Under this arrangement, the Company and Cardinal contributed their sourcing and supply chain expertise to Red Oak and agreed to source and negotiate generic pharmaceutical supply contracts for both companies through Red Oak; however, Red Oak does not own or hold inventory on behalf of either company. No physical assets (e.g., property and equipment) were contributed to Red Oak by either company, and minimal funding was provided to capitalize Red Oak. The Company has determined that it is the primary beneficiary of this VIE because it has the ability to direct the activities of Red Oak. Consequently, the Company consolidates Red Oak in its consolidated financial statements within the Retail/LTC segment.

Cardinal is required to pay the Company quarterly payments, which began in October 2014 and will extend through June 2029. As milestones are met, the quarterly payments increase. The Company received $183 million from Cardinal during each of the years ended December 31, 2021, 2020 and 2019. The payments reduce the Company’s carrying value of inventory and are recognized in cost of products sold when the related inventory is sold. Amounts reimbursed by Cardinal for the years ended December 31, 2021, 2020 and 2019, and amounts due to or due from Cardinal at December 31, 2021 and 2020 were immaterial.

Variable Interest Entities - Other Variable Interest Holder
The Company has invested in certain VIEs for which it has determined that it is not the primary beneficiary, consisting of the following:

Hedge fund and private equity investments - The Company invests in hedge fund and private equity investments in order to generate investment returns for its investment portfolio supporting its insurance businesses.
Real estate partnerships - The Company invests in various real estate partnerships, including those that construct, own and manage low-income housing developments. For the low income housing development investments, substantially all of the projected benefits to the Company are from tax credits and other tax benefits.

The Company is not the primary beneficiary of these VIEs because the nature of the Company’s involvement with the activities of these VIEs does not give the Company the power to direct the activities that most significantly impact their economic performance. The Company records the amount of its investment in these VIEs as long-term investments on the consolidated balance sheets and recognizes its share of each VIE’s income or losses in net income (loss). The Company’s maximum exposure to loss from these VIEs is limited to its investment balances as disclosed below and the risk of recapture of previously recognized tax credits related to the real estate partnerships, which the Company does not consider significant.

The total amount of other variable interest holder VIE assets included in long-term investments on the consolidated balance sheets at December 31, 2021 and 2020 was as follows:
In millions20212020
Hedge fund investments$463 $342 
Private equity investments601 547 
Real estate partnerships225 200 
Total$1,289 $1,089 
Related Party Transactions

The Company has an equity method investment in SureScripts, LLC (“SureScripts”), which operates a clinical health information network. The Company utilizes this clinical health information network in providing services to its client plan members and retail customers. The Company expensed fees for the use of this network of $52 million, $56 million and $32 million in the years ended December 31, 2021, 2020 and 2019, respectively. The Company’s investment in and equity in the earnings of SureScripts for all periods presented is immaterial.

The Company has an equity method investment in Heartland Healthcare Services, LLC (“Heartland”). Heartland operates several LTC pharmacies in four states. Heartland paid the Company $79 million, $77 million and $96 million for pharmaceutical inventory purchases during the years ended December 31, 2021, 2020 and 2019, respectively. Additionally, the Company performs certain collection functions for Heartland and then transfers those customer cash collections to Heartland. The Company’s investment in and equity in the earnings of Heartland for all periods presented is immaterial.

During the years ended December 31, 2021, 2020 and 2019, the Company made charitable contributions of $50 million, $50 million and $30 million, respectively, to the CVS Health Foundation, a non-profit entity that focuses on health, education and community involvement programs. The charitable contributions were recorded as operating expenses in the consolidated statements of operations within the Corporate/Other segment for the years ended December 31, 2021, 2020 and 2019.

Discontinued Operations

In connection with certain business dispositions completed between 1995 and 1997, the Company retained guarantees on store lease obligations for a number of former subsidiaries, including Linens ‘n Things and Bob’s Stores, each of which subsequently filed for bankruptcy. The Company’s loss from discontinued operations includes lease-related costs that the Company believes it will likely be required to satisfy pursuant to these lease guarantees. See “Lease Guarantees” in Note 16 ‘‘Commitments and Contingencies’’ for additional information.

Below is a summary of the results of discontinued operations for the year ended December 31, 2020.
In millions2020
Loss from discontinued operations$(12)
Income tax benefit
Loss from discontinued operations, net of tax$(9)

Results from discontinued operations were immaterial for the years ended December 31, 2021 and 2019.

New Accounting Pronouncements Recently Adopted

Simplifying the Accounting for Income Taxes
In December 2019, the Financial Accounting Standards Board (“FASB”) issued ASU 2019-12, Simplifying the Accounting for Income Taxes (Topic 740). This standard simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in Accounting Standards Codification 740 related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The standard also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The Company adopted this new accounting standard on January 1, 2021. The adoption of this standard did not have a material impact on the Company’s consolidated operating results, cash flows, financial condition or related disclosures.

New Accounting Pronouncements Not Yet Adopted

Targeted Improvements to the Accounting for Long-Duration Insurance Contracts
In August 2018, the FASB issued ASU 2018-12, Targeted Improvements to the Accounting for Long-Duration Contracts (Topic 944). This standard requires the Company to review cash flow assumptions for its long-duration insurance contracts at least annually and recognize the effect of changes in future cash flow assumptions in net income. This standard also requires the Company to update discount rate assumptions quarterly and recognize the effect of changes in these assumptions in other comprehensive income. The rate used to discount the Company’s liability for future policy benefits will be based on an estimate of the yield for an upper-medium grade fixed-income instrument with a duration profile matching that of the Company’s
liabilities. In addition, this standard changes the amortization method for deferred acquisition costs and requires additional disclosures regarding the long duration insurance contract liabilities in the Company’s interim and annual financial statements. The standard is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022. The Company will adopt the new standard on January 1, 2023, using the modified retrospective transition method as of the earliest period presented for changes to the liability for future policy benefits and deferred acquisition costs. While the Company is still evaluating the impact of the new standard on its financial statements, the Company anticipates an increase to its liability for future policy benefits with a corresponding change in accumulated other comprehensive income as a result of updating the rate used to discount the liabilities to reflect the yield for an upper-medium grade fixed-income instrument compared to the Company’s expected investment yield under the existing guidance.
XML 31 R11.htm IDEA: XBRL DOCUMENT v3.22.0.1
Divestitures
12 Months Ended
Dec. 31, 2021
Business Combination and Asset Acquisition [Abstract]  
Divestitures Divestitures
Divestiture of Workers’ Compensation Business

On July 31, 2020, the Company sold its Workers’ Compensation business for approximately $850 million. The results of this business were reported within the Health Care Benefits segment. The Company recorded a pre-tax gain on the divestiture of $269 million in the year ended December 31, 2020, which is reflected as a reduction in operating expenses in the Company’s consolidated statement of operations within the Health Care Benefits segment.

Divestiture of Brazilian Subsidiary

On July 1, 2019, the Company sold its Brazilian subsidiary, Onofre, for an immaterial amount. Onofre operated 50 retail pharmacy stores, the results of which historically had been reported within the Retail/LTC segment. The Company recorded a pre-tax loss on the divestiture of $205 million in the year ended December 31, 2019, which primarily relates to the elimination of the cumulative translation adjustment from accumulated other comprehensive income and is reflected in operating expenses in the Company’s consolidated statement of operations within the Retail/LTC segment.
XML 32 R12.htm IDEA: XBRL DOCUMENT v3.22.0.1
Investments
12 Months Ended
Dec. 31, 2021
Investments [Abstract]  
Investments Investments
Total investments at December 31, 2021 and 2020 were as follows:
20212020
In millionsCurrentLong-termTotalCurrentLong-termTotal
Debt securities available for sale$3,009 $20,231 $23,240 $2,774 $18,414 $21,188 
Mortgage loans58 844 902 226 821 1,047 
Other investments50 1,950 2,000 — 1,577 1,577 
Total investments$3,117 $23,025 $26,142 $3,000 $20,812 $23,812 

At December 31, 2021 and 2020, the Company held investments of $450 million and $524 million, respectively, related to the 2012 conversion of an existing group annuity contract from a participating to a non-participating contract. These investments are included in the total investments of large case pensions supporting non-experience-rated products. Although these investments are not accounted for as Separate Accounts assets, they are legally segregated and are not subject to claims that arise out of the Company’s business and only support future policy benefits obligations under that group annuity contract.
Debt Securities

Debt securities available for sale at December 31, 2021 and 2020 were as follows:
In millions
Amortized
Cost (1)
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Fair
Value
December 31, 2021   
Debt securities:   
U.S. government securities$2,349 $70 $(3)$2,416 
States, municipalities and political subdivisions2,947 148 (4)3,091 
U.S. corporate securities9,093 682 (40)9,735 
Foreign securities2,821 196 (24)2,993 
Residential mortgage-backed securities870 15 (10)875 
Commercial mortgage-backed securities1,278 44 (12)1,310 
Other asset-backed securities2,791 14 (13)2,792 
Redeemable preferred securities25 — 28 
Total debt securities (2)
$22,174 $1,172 $(106)$23,240 
December 31, 2020
Debt securities:
U.S. government securities$2,341 $128 $— $2,469 
States, municipalities and political subdivisions2,556 172 — 2,728 
U.S. corporate securities7,879 1,023 (8)8,894 
Foreign securities2,595 324 (1)2,918 
Residential mortgage-backed securities673 32 — 705 
Commercial mortgage-backed securities962 84 — 1,046 
Other asset-backed securities2,369 36 (2)2,403 
Redeemable preferred securities21 — 25 
Total debt securities (2)
$19,396 $1,803 $(11)$21,188 
_____________________________________________
(1)There was no allowance for expected credit losses recorded on available-for-sale debt securities at December 31, 2021 or 2020.
(2)Investment risks associated with the Company’s experience-rated products generally do not impact the Company’s consolidated operating results. At December 31, 2021, debt securities with a fair value of $864 million, gross unrealized capital gains of $94 million and gross unrealized capital losses of $2 million and at December 31, 2020, debt securities with a fair value of $919 million, gross unrealized capital gains of $135 million and no gross unrealized capital losses were included in total debt securities, but support experience-rated products. Changes in net unrealized capital gains (losses) on these securities are not reflected in accumulated other comprehensive income.
The amortized cost and fair value of debt securities at December 31, 2021 are shown below by contractual maturity.  Actual maturities may differ from contractual maturities because securities may be restructured, called or prepaid, or the Company intends to sell a security prior to maturity.
In millions Amortized
Cost
Fair
Value
Due to mature: 
Less than one year$1,205 $1,218 
One year through five years6,965 7,142 
After five years through ten years4,733 4,910 
Greater than ten years4,332 4,993 
Residential mortgage-backed securities870 875 
Commercial mortgage-backed securities1,278 1,310 
Other asset-backed securities2,791 2,792 
Total$22,174 $23,240 

Mortgage-Backed and Other Asset-Backed Securities
All of the Company’s residential mortgage-backed securities at December 31, 2021 were issued by the Government National Mortgage Association, the Federal National Mortgage Association or the Federal Home Loan Mortgage Corporation and carry agency guarantees and explicit or implicit guarantees by the U.S. Government. At December 31, 2021, the Company’s residential mortgage-backed securities had an average credit quality rating of AAA and a weighted average duration of 4.7 years.

The Company’s commercial mortgage-backed securities have underlying loans that are dispersed throughout the United States. Significant market observable inputs used to value these securities include loss severity and probability of default. At December 31, 2021, these securities had an average credit quality rating of AAA and a weighted average duration of 6.1 years.

The Company’s other asset-backed securities have a variety of underlying collateral (e.g., automobile loans, credit card receivables, home equity loans and commercial loans). Significant market observable inputs used to value these securities include the unemployment rate, loss severity and probability of default. At December 31, 2021, these securities had an average credit quality rating of AA and a weighted average duration of 1.0 year.
Summarized below are the debt securities the Company held at December 31, 2021 and 2020 that were in an unrealized capital loss position, aggregated by the length of time the investments have been in that position:
Less than 12 monthsGreater than 12 monthsTotal
In millions, except number of securitiesNumber
of
 Securities
Fair
Value
Unrealized
Losses
Number
of
 Securities
Fair
Value
Unrealized
Losses
Number
of
 Securities
Fair
Value
Unrealized
Losses
December 31, 2021
Debt securities:  
U.S. government securities43 $242 $10 $40 $53 $282 $
States, municipalities and political subdivisions233 428 13 33 246 461 
U.S. corporate securities1,610 2,296 31 165 238 1,775 2,534 40 
Foreign securities449 747 20 57 91 506 838 24 
Residential mortgage-backed securities165 593 10 36 175 629 10 
Commercial mortgage-backed securities188 462 35 112 223 574 12 
Other asset-backed securities1,011 2,030 12 26 31 1,037 2,061 13 
Redeemable preferred securities— — — 
Total debt securities3,700 $6,800 $84 317 $584 $22 4,017 $7,384 $106 
December 31, 2020
Debt securities:
U.S. government securities32 $205 $— — $— $— 32 $205 $— 
States, municipalities and political subdivisions49 83 — — — — 49 83 — 
U.S. corporate securities145 155 — — 147 155 
Foreign securities41 69 — 46 74 
Residential mortgage-backed securities23 26 — — — 26 26 — 
Commercial mortgage-backed securities22 75 — — — — 22 75 — 
Other asset-backed securities156 256 49 41 205 297 
Total debt securities468 $869 $10 59 $46 $527 $915 $11 

The Company reviewed the securities in the table above and concluded that they are performing assets generating investment income to support the needs of the Company’s business. In performing this review, the Company considered factors such as the quality of the investment security based on research performed by the Company’s internal credit analysts and external rating agencies and the prospects of realizing the carrying value of the security based on the investment’s current prospects for recovery. Unrealized capital losses at December 31, 2021 were generally caused by interest rate increases and not by unfavorable changes in the credit quality associated with these securities. As of December 31, 2021, the Company did not intend to sell these securities, and did not believe it was more likely than not that it would be required to sell these securities prior to the anticipated recovery of their amortized cost basis.
The maturity dates for debt securities in an unrealized capital loss position at December 31, 2021 were as follows:
 Supporting experience-
rated products
Supporting remaining
products
Total
In millionsFair
Value
Unrealized
Losses
Fair
Value
Unrealized
Losses
Fair
Value
Unrealized
Losses
Due to mature:      
Less than one year$$— $49 $$51 $
One year through five years13 2,229 32 2,242 33 
After five years through ten years33 1,332 26 1,365 27 
Greater than ten years17 — 445 10 462 10 
Residential mortgage-backed securities— 625 10 629 10 
Commercial mortgage-backed securities— 568 12 574 12 
Other asset-backed securities— 2,057 13 2,061 13 
Total$79 $$7,305 $104 $7,384 $106 

Mortgage Loans

The Company’s mortgage loans are collateralized by commercial real estate. During the years ended December 31, 2021 and 2020, the Company had the following activity in its mortgage loan portfolio:
In millions20212020
New mortgage loans$262 $63 
Mortgage loans fully repaid373 187 
Mortgage loans foreclosed— — 

The Company assesses mortgage loans on a regular basis for credit impairments, and assigns a credit quality indicator to each loan. The Company’s credit quality indicator is internally developed and categorizes each loan in its portfolio on a scale from 1 to 7. These indicators are based upon several factors, including current loan-to-value ratios, current and future property cash flow, property condition, market trends, creditworthiness of the borrower and deal structure.

Category 1 - Represents loans of superior quality.
Categories 2 to 4 - Represent loans where credit risk is minimal to acceptable; however, these loans may display some susceptibility to economic changes.
Categories 5 and 6 - Represent loans where credit risk is not substantial, but these loans warrant management’s close attention.
Category 7 - Represents loans where collections are potentially at risk; if necessary, an impairment is recorded.
Based upon the Company’s assessments at December 31, 2021 and 2020, the amortized cost basis of the Company’s mortgage loans within each credit quality indicator by year of origination was as follows:

Amortized Cost Basis by Year of Origination
In millions, except credit quality indicator20212020201920182017PriorTotal
December 31, 2021
1$— $— $— $— $— $28 $28 
2 to 4255 48 40 72 97 349 861 
5 and 6— — — 13 
7— — — — — — — 
Total$255 $48 $40 $75 $101 $383 $902 
December 31, 2020
1$— $— $— $22 $37 $59 
2 to 446 96 91 124 595 952 
5 and 6— — 29 36 
7— — — — — — 
Total$46 $96 $94 $150 $661 $1,047 

At December 31, 2021 scheduled mortgage loan principal repayments were as follows:
In millions
2022$58 
2023100 
2024210 
202576 
2026177 
Thereafter281 
Total$902 

Net Investment Income

Sources of net investment income for the years ended December 31, 2021, 2020 and 2019 were as follows:
In millions202120202019
Debt securities$634 $598 $589 
Mortgage loans55 60 71 
Other investments381 123 194 
Gross investment income1,070 781 854 
Investment expenses(47)(35)(42)
Net investment income (excluding net realized capital gains or losses)1,023 746 812 
Net realized capital gains (1)
176 52 199 
Net investment income (2)
$1,199 $798 $1,011 
_____________________________________________
(1)Net realized capital gains are net of yield-related impairment losses on debt securities of $42 million and $49 million for the years ended December 31, 2021 and 2020, respectively. There were no credit-related losses on debt securities in the years ended December 31, 2021 and 2020. Net realized capital gains are net of other-than-temporary impairment (“OTTI”) losses on debt securities of $24 million for the year ended December 31, 2019.
(2)Net investment income includes $38 million, $42 million and $44 million for the years ended December 31, 2021, 2020 and 2019, respectively, related to investments supporting experience-rated products.
Capital gains and losses recognized during the year ended December 31, 2021 related to investments in equity securities held as of December 31, 2021 were not material.

Excluding amounts related to experience-rated products, proceeds from the sale of available-for-sale debt securities and the related gross realized capital gains and losses in the years ended December 31, 2021, 2020 and 2019 were as follows:
In millions202120202019
Proceeds from sales$3,572 $3,913 $4,773 
Gross realized capital gains72 80 146 
Gross realized capital losses14 62 17 
XML 33 R13.htm IDEA: XBRL DOCUMENT v3.22.0.1
Fair Value
12 Months Ended
Dec. 31, 2021
Fair Value Disclosures [Abstract]  
Fair Value Fair Value
The preparation of the Company’s consolidated financial statements in accordance with GAAP requires certain assets and liabilities to be reflected at their fair value and others to be reflected on another basis, such as an adjusted historical cost basis. In this note, the Company provides details on the fair value of financial assets and liabilities and how it determines those fair values. The Company presents this information for those financial instruments that are measured at fair value for which the change in fair value impacts net income attributable to CVS Health or other comprehensive income separately from other financial assets and liabilities.

Financial Instruments Measured at Fair Value on the Consolidated Balance Sheets

Certain of the Company’s financial instruments are measured at fair value on the consolidated balance sheets. The fair values of these instruments are based on valuations that include inputs that can be classified within one of three levels of a hierarchy established by GAAP.  The following are the levels of the hierarchy and a brief description of the type of valuation information (“valuation inputs”) that qualifies a financial asset or liability for each level:

Level 1 – Unadjusted quoted prices for identical assets or liabilities in active markets.
Level 2 – Valuation inputs other than Level 1 that are based on observable market data. These include: quoted prices for similar assets in active markets, quoted prices for identical assets in inactive markets, valuation inputs that are observable that are not prices (such as interest rates and credit risks) and valuation inputs that are derived from or corroborated by observable markets.
Level 3 – Developed from unobservable data, reflecting the Company’s assumptions.

Financial assets and liabilities are classified based upon the lowest level of input that is significant to the valuation. When quoted prices in active markets for identical assets and liabilities are available, the Company uses these quoted market prices to determine the fair value of financial assets and liabilities and classifies these assets and liabilities in Level 1. In other cases where a quoted market price for identical assets and liabilities in an active market is either not available or not observable, the Company estimates fair value using valuation methodologies based on available and observable market information or by using a matrix pricing model. These financial assets and liabilities are classified in Level 2. If quoted market prices are not available, the Company determines fair value using broker quotes or an internal analysis of each investment’s financial performance and cash flow projections. Thus, financial assets and liabilities may be classified in Level 3 even though there may be some significant inputs that may be observable.

The following is a description of the valuation methodologies used for the Company’s financial assets and liabilities that are measured at fair value, including the general classification of such assets and liabilities pursuant to the valuation hierarchy.

Cash and Cash Equivalents The carrying value of cash and cash equivalents approximates fair value as maturities are less than three months. When quoted prices are available in an active market, cash equivalents are classified in Level 1 of the fair value hierarchy. Fair values of cash equivalent instruments that do not trade on a regular basis in active markets are classified as Level 2.

Debt Securities Where quoted prices are available in an active market, debt securities are classified in Level 1 of the fair value hierarchy. The Company’s Level 1 debt securities consist primarily of U.S. Treasury securities.

The fair values of the Company’s Level 2 debt securities are obtained using models, such as matrix pricing, which use quoted market prices of debt securities with similar characteristics or discounted cash flows to estimate fair value. The
Company reviews these prices to ensure they are based on observable market inputs that include quoted prices for similar assets in active markets, quoted prices for identical assets in inactive markets and inputs that are observable that are not prices (such as interest rates and credit risks). The Company also reviews the methodologies and the assumptions used to calculate prices from these observable inputs. On a quarterly basis, the Company selects a sample of its Level 2 debt securities’ prices and compares them to prices provided by a secondary source. Variances over a specified threshold are identified and reviewed to confirm the price provided by the primary source represents an appropriate estimate of fair value. In addition, the Company’s internal investment team consistently compares the prices obtained for select Level 2 debt securities to the team’s own independent estimates of fair value for those securities. The Company obtained one price for each of its Level 2 debt securities and did not adjust any of those prices at December 31, 2021 or 2020.

The Company also values certain debt securities using Level 3 inputs. For Level 3 debt securities, fair values are determined by outside brokers or, in the case of certain private placement securities, are priced internally. Outside brokers determine the value of these debt securities through a combination of their knowledge of the current pricing environment and market flows. The Company did not have any broker quoted debt securities for the years ended December 31, 2021 and 2020. For some private placement securities, the Company’s internal staff determines the value of these debt securities by analyzing spreads of corporate and sector indices as well as interest spreads of comparable public bonds. Examples of these private placement Level 3 debt securities include certain U.S. and foreign securities and certain tax-exempt municipal securities.

Equity Securities The Company currently has two classifications of equity securities: those that are publicly traded and those that are privately placed. Publicly-traded equity securities are classified in Level 1 because quoted prices are available for these securities in an active market. For privately placed equity securities, there is no active market; therefore, these securities are classified in Level 3 because the Company prices these securities through an internal analysis of each investment’s financial statements and cash flow projections. Significant unobservable inputs consist of earnings and revenue multiples, discount for lack of marketability and comparability adjustments. An increase or decrease in any of these unobservable inputs would have resulted in a change in the fair value measurement.
There were no financial liabilities measured at fair value on a recurring basis on the consolidated balance sheets at December 31, 2021 or 2020. Financial assets measured at fair value on a recurring basis on the consolidated balance sheets at December 31, 2021 and 2020 were as follows:
In millionsLevel 1Level 2Level 3Total
December 31, 2021    
Cash and cash equivalents$4,954 $4,454 $— $9,408 
Debt securities:    
U.S. government securities2,372 44 — 2,416 
States, municipalities and political subdivisions— 3,086 3,091 
U.S. corporate securities— 9,697 38 9,735 
Foreign securities— 2,983 10 2,993 
Residential mortgage-backed securities— 875 — 875 
Commercial mortgage-backed securities— 1,310 — 1,310 
Other asset-backed securities— 2,789 2,792 
Redeemable preferred securities— 28 — 28 
Total debt securities2,372 20,812 56 23,240 
Equity securities114 — 55 169 
Total$7,440 $25,266 $111 $32,817 
December 31, 2020    
Cash and cash equivalents$3,985 $3,869 $— $7,854 
Debt securities:
U.S. government securities2,370 99 — 2,469 
States, municipalities and political subdivisions— 2,727 2,728 
U.S. corporate securities— 8,842 52 8,894 
Foreign securities— 2,918 — 2,918 
Residential mortgage-backed securities— 705 — 705 
Commercial mortgage-backed securities— 1,046 — 1,046 
Other asset-backed securities— 2,403 — 2,403 
Redeemable preferred securities— 24 25 
Total debt securities2,370 18,764 54 21,188 
Equity securities17 — 30 47 
Total$6,372 $22,633 $84 $29,089 
The changes in the balances of Level 3 financial assets during the year ended December 31, 2021 were as follows:
In millionsStates,
municipalities
 and political
subdivisions
U.S.
corporate
securities
Foreign
securities
Other asset-
backed
securities
Redeemable
preferred
securities
Equity
securities
Total
Beginning balance$$52 $— $— $$30 $84 
Net realized and unrealized capital gains (losses):
Included in earnings — (10)— — 13 
Included in other comprehensive income— (3)— — (1)— (4)
Purchases— — — 13 17 
Sales(1)(1)— — (2)(1)(5)
Settlements— (1)— — — — (1)
Transfers into Level 3, net— 10 — — — 15 
Ending balance$$38 $10 $$— $55 $111 

The change in unrealized capital losses included in other comprehensive income associated with Level 3 financial assets which were held as of December 31, 2021 was $4 million during the year ended December 31, 2021.

The changes in the balances of Level 3 financial assets during the year ended December 31, 2020 were as follows:
In millionsStates,
municipalities
 and political
subdivisions
U.S.
corporate
securities
Redeemable
preferred
securities
Equity
securities
Total
Beginning balance$— $37 $12 $39 $88 
Net realized and unrealized capital gains (losses):
Included in earnings — (11)18 (3)
Included in other comprehensive income— — (5)— (5)
Purchases— 27 — 30 
Sales— — (24)(9)(33)
Settlements— (1)— — (1)
Transfers into Level 3, net— — — 
Ending balance$$52 $$30 $84 

The change in unrealized capital losses included in other comprehensive income associated with Level 3 financial assets which were held as of December 31, 2020 was $4 million during the year ended December 31, 2020.

The total gross transfers into (out of) Level 3 during the years ended December 31, 2021 and 2020 were as follows:
In millions20212020
Gross transfers into Level 3$15 $
Gross transfers out of Level 3— — 
Net transfers into Level 3$15 $
Financial Instruments Not Measured at Fair Value on the Consolidated Balance Sheets

The carrying value and estimated fair value classified by level of fair value hierarchy for financial instruments carried on the consolidated balance sheets at adjusted cost or contract value at December 31, 2021 and 2020 were as follows:
Carrying
Value
 Estimated Fair Value
In millionsLevel 1Level 2Level 3Total
December 31, 2021
Assets: 
Mortgage loans$902 $— $— $907 $907 
Equity securities (1)
126 N/AN/AN/AN/A
Liabilities:
Investment contract liabilities:
With a fixed maturity— — 
Without a fixed maturity336 — — 373 373 
Long-term debt56,176 64,157 — — 64,157 
December 31, 2020
Assets:
Mortgage loans$1,047 $— $— $1,070 $1,070 
Equity securities (1)
145 N/AN/AN/AN/A
Liabilities:
Investment contract liabilities:
With a fixed maturity— — 
Without a fixed maturity322 — — 371 371 
Long-term debt64,647 75,940 — — 75,940 
_____________________________________________
(1)It was not practical to estimate the fair value of these cost-method investments as it represents shares of unlisted companies. See Note 1 ‘‘Significant Accounting Policies’’ for additional information regarding the valuation of cost method investments.

Separate Accounts Measured at Fair Value on the Consolidated Balance Sheets

Separate Accounts assets relate to the Company’s large case pensions products which represent funds maintained to meet specific objectives of contract holders. Since contract holders bear the investment risk of these assets, a corresponding Separate Accounts liability has been established equal to the assets. These assets and liabilities are carried at fair value. Net investment income and capital gains and losses on Separate Accounts assets accrue directly to such contract holders. The assets of each account are legally segregated and are not subject to claims arising from the Company’s other businesses. Deposits, withdrawals, net investment income and realized and unrealized capital gains and losses on Separate Accounts assets are not reflected in the consolidated statements of operations, shareholders’ equity or cash flows.

Separate Accounts assets include debt and equity securities. The valuation methodologies used for these assets are similar to the methodologies described above in this Note 4 ‘‘Fair Value.’’ Separate Accounts assets also include investments in common/collective trusts that are carried at fair value. Common/collective trusts invest in other investment funds otherwise known as the underlying funds. The Separate Accounts’ interests in the common/collective trust funds are based on the fair values of the investments of the underlying funds and therefore are classified in Level 2. The assets in the underlying funds primarily consist of equity securities. Investments in common/collective trust funds are valued at their respective net asset value (“NAV”) per share/unit on the valuation date.
Separate Accounts financial assets at December 31, 2021 and 2020 were as follows:
December 31, 2021December 31, 2020
In millionsLevel 1Level 2Level 3TotalLevel 1Level 2Level 3Total
Cash and cash equivalents$$186 $— $188 $$186 $— $188 
Debt securities1,233 3,048 — 4,281 1,465 2,634 — 4,099 
Equity securities— — — — 
Common/collective trusts— 547 — 547 — 563 — 563 
Total (1)
$1,235 $3,782 $— $5,017 $1,467 $3,385 $— $4,852 
_____________________________________________
(1)Excludes $70 million and $29 million of other receivables at December 31, 2021 and 2020, respectively.

During the years ended December 31, 2021 and 2020, the Company had no gross transfers of Separate Accounts financial assets into or out of Level 3.
XML 34 R14.htm IDEA: XBRL DOCUMENT v3.22.0.1
Goodwill and Other Intangibles
12 Months Ended
Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Other Intangibles Goodwill and Other Intangibles
Goodwill

Below is a summary of the changes in the carrying amount of goodwill by segment for the years ended December 31, 2021 and 2020:
In millionsHealth Care
Benefits
Pharmacy
Services
Retail/
LTC
Total
Balance at December 31, 2019$45,361 $23,581 $10,807 $79,749 
Acquisitions274 34 — 308 
Divestiture of Workers’ Compensation business(505)— — (505)
Balance at December 31, 202045,130 23,615 10,807 79,552 
Impairment— — (431)(431)
Balance at December 31, 2021$45,130 $23,615 $10,376 $79,121 

During the year ended December 31, 2021, the decrease in the carrying amount of goodwill was primarily driven by a goodwill impairment charge related to the LTC reporting unit within the Retail/LTC segment. During the year ended December 31, 2020, the decrease in the carrying amount of goodwill was primarily driven by the divestiture of the Workers’ Compensation business, partially offset by goodwill associated with immaterial acquisitions. See Note 2 ‘‘Divestitures’’ for further discussion regarding the Workers’ Compensation business divestiture.

During the third quarter of 2021, the Company performed its required annual impairment tests of goodwill. The results of the impairment tests indicated an impairment of the goodwill associated with the LTC reporting unit, as the reporting unit’s carrying value exceeded its fair value as of the testing date. The results of the impairment tests of the remaining reporting units indicated that there was no impairment of goodwill as of the testing date.

During 2021, the LTC reporting unit has continued to face challenges that have impacted the Company’s ability to grow the LTC reporting unit’s business at the rate estimated when its 2020 goodwill impairment test was performed. These challenges include lower net facility admissions, net long-term care facility customer losses and the prolonged adverse impact of the COVID-19 pandemic and the emerging new variants, which resulted in more significant declines in occupancy rates experienced by the Company’s long-term care facility customers than previously anticipated. During the third quarter of 2021, LTC management updated their 2021 annual forecast and submitted their long-term plan which showed deterioration in the financial results for the remainder of 2021 and beyond. The Company utilized these updated projections in performing its annual impairment test, which indicated that the fair value of the LTC reporting unit was lower than its carrying value, resulting in a $431 million goodwill impairment charge in the third quarter of 2021. The fair value of the LTC reporting unit was determined using a combination of a discounted cash flow method and a market multiple method. As of December 31, 2021, there was no remaining goodwill balance in the LTC reporting unit. During the third quarter of 2021, the Company also performed an impairment test of the intangible assets of the LTC reporting unit and concluded these assets were not impaired. As of December 31, 2021, there was $2.7 billion of intangible assets related to customer lists in the LTC reporting unit.
During the third quarter of 2020, the Company performed its required annual impairment tests of goodwill. The results of the impairment tests indicated that there was no impairment of goodwill.

At December 31, 2021 and 2020, cumulative goodwill impairments were $6.6 billion and $6.1 billion, respectively.

Intangible Assets

The following table is a summary of the Company’s intangible assets as of December 31, 2021 and 2020:
In millions, except weighted average lifeGross
Carrying
Amount
Accumulated
Amortization
Net
Carrying
Amount
Weighted
Average
Life (years)
2021
Trademarks (indefinite-lived)$10,498 $— $10,498 N/A
Customer contracts/relationships and covenants not to compete25,084 (10,564)14,520 15.0
Technology1,060 (1,060)— 3.0
Provider networks4,203 (651)3,552 20.0
Value of Business Acquired 590 (173)417 20.0
Other318 (279)39 8.4
Total $41,753 $(12,727)$29,026 15.3
2020
Trademarks (indefinite-lived)$10,498 $— $10,498 N/A
Customer contracts/relationships and covenants not to compete24,952 (8,923)16,029 14.9
Technology1,060 (739)321 3.0
Provider networks4,203 (440)3,763 20.0
Value of Business Acquired 590 (119)471 20.0
Other320 (260)60 7.7
Total$41,623 $(10,481)$31,142 15.2

Amortization expense for intangible assets totaled $2.3 billion, $2.3 billion and $2.4 billion for the years ended December 31, 2021, 2020 and 2019, respectively. The projected annual amortization expense for the Company’s intangible assets for the next five years is as follows:
In millions
2022$1,858 
20231,826 
20241,785 
20251,734 
20261,494 
XML 35 R15.htm IDEA: XBRL DOCUMENT v3.22.0.1
Leases
12 Months Ended
Dec. 31, 2021
Leases [Abstract]  
Leases Leases
The Company leases most of its retail stores and mail order facilities and certain distribution centers and corporate offices under operating or finance leases, typically with initial terms of 15 to 25 years. The Company also leases certain equipment and other assets under operating or finance leases, typically with initial terms of 3 to 10 years.

In addition, the Company leases pharmacy space at the stores of another retail chain for which the noncancelable contractual term of the pharmacy lease arrangement exceeds the remaining estimated economic life of the buildings. For these pharmacy lease arrangements, the Company concluded that for accounting purposes the lease term was the remaining estimated economic life of the buildings. Consequently, most of these individual pharmacy leases are finance leases.
The following table is a summary of the components of net lease cost for the years ended December 31, 2021, 2020 and 2019:
In millions202120202019
Operating lease cost$2,633 $2,670 $2,720 
Finance lease cost:
Amortization of right-of-use assets62 56 38 
Interest on lease liabilities62 58 44 
Total finance lease costs124 114 82 
Short-term lease costs25 22 24 
Variable lease costs604 599 581 
Less: sublease income59 55 50 
Net lease cost$3,327 $3,350 $3,357 

Supplemental cash flow information related to leases for the years ended December 31, 2021, 2020 and 2019 is as follows:
In millions202120202019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows paid for operating leases$2,714 $2,724 $2,701 
Operating cash flows paid for interest portion of finance leases62 58 44 
Financing cash flows paid for principal portion of finance leases50 34 26 
Right-of-use assets obtained in exchange for lease obligations:
Operating leases1,254 1,679 1,824 
Finance leases278 313 283 
Supplemental balance sheet information related to leases as of December 31, 2021 and 2020 is as follows:
In millions, except remaining lease term and discount rate20212020
Operating leases:
Operating lease right-of-use assets$19,122$20,729
Current portion of operating lease liabilities$1,646$1,638
Long-term operating lease liabilities18,17718,757
Total operating lease liabilities$19,823$20,395
Finance leases:
Property and equipment, gross$1,375$1,107
Accumulated depreciation(188)(106)
Property and equipment, net$1,187$1,001
Current portion of long-term debt$50$33
Long-term debt1,2501,050
Total finance lease liabilities$1,300$1,083
Weighted average remaining lease term (in years)
Operating leases12.813.3
Finance leases20.020.3
Weighted average discount rate
Operating leases4.4 %4.5 %
Finance leases5.0 %5.6 %

The following table summarizes the maturity of lease liabilities under finance and operating leases as of December 31, 2021:
In millionsFinance
Leases
Operating
Leases
(1)
Total
2022$122 $2,685 $2,807 
2023121 2,613 2,734 
2024111 2,398 2,509 
2025110 2,217 2,327 
2026109 2,054 2,163 
Thereafter1,495 14,103 15,598 
Total lease payments (2)
2,068 26,070 28,138 
Less: imputed interest(768)(6,247)(7,015)
Total lease liabilities$1,300 $19,823 $21,123 
_____________________________________________
(1)Future operating lease payments have not been reduced by minimum sublease rentals of $311 million due in the future under noncancelable subleases.
(2)The Company leases pharmacy and clinic space from Target Corporation. Amounts related to such finance and operating leases are reflected above. Pharmacy lease amounts due in excess of the remaining estimated economic life of the buildings of approximately $2.4 billion are not reflected in this table since the estimated economic life of the buildings is shorter than the contractual term of the pharmacy lease arrangement.

Sale-Leaseback Transactions
The Company finances a portion of its store development program through sale-leaseback transactions. The properties are generally sold at net book value, which generally approximates fair value, and the resulting leases generally qualify and are accounted for as operating leases. The operating leases that resulted from these transactions are included in the tables above. The Company does not have any retained or contingent interests in the stores and does not provide any guarantees, other than a
guarantee of lease payments, in connection with the sale-leaseback transactions. There were no sale-leaseback transactions in 2021. Proceeds from sale-leaseback transactions totaled $101 million and $5 million in the years ended December 31, 2020 and 2019, respectively. Gains from sale-leaseback transactions totaled $3 million in the year ended December 31, 2020. There were no material gains from sale-leaseback transactions in the year ended December 31, 2019.

Store Impairment Charges
The Company evaluates its retail store right-of-use and property and equipment assets for impairment at the retail store level, which is the lowest level at which cash flows can be identified. For retail stores where there is an indicator of impairment present, the Company first compares the carrying amount of the asset group to the estimated future cash flows associated with the asset group (undiscounted). If the estimated undiscounted future cash flows used in the analysis are less than the carrying amount of the asset group, an impairment loss calculation is prepared. The impairment loss calculation compares the carrying amount of the asset group to its estimated fair value which is the greater of the asset group’s estimated future cash flows (discounted), or the consideration of what a market participant would pay to lease the assets, net of leasing costs. The Company’s estimate of fair value considers historical results, current operating trends, consolidated sales, profitability and cash flow results and forecasts. For assets which the Company has determined it will be able to sublease, the estimated future cash flows include the estimated sublease income, net of estimated leasing costs.

When the carrying value of an asset group exceeds its estimated fair value, an impairment loss is recorded to reduce the value of the asset group to its estimated fair value. As the impaired assets are measured at fair value on a nonrecurring basis primarily using unobservable inputs as of the measurement date, the assets are classified in Level 3 of the fair value hierarchy.

During the fourth quarter of 2021, the Company completed a strategic review of its retail business and announced the creation of new formats for its stores to continue to drive higher engagement with customers. As part of this review, the Company evaluated changes in population, consumer buying patterns and future health needs to ensure it has the right kinds of stores in the right locations for consumers and for the business. In connection with this initiative, on November 17, 2021, the Board of Directors of CVS Health Corporation (the “Board”) authorized the closing of approximately 900 retail stores over the next three years. The Company expects to close approximately 300 stores each year between 2022 and 2024. As a result, management determined that there were indicators of impairment with respect to the impacted stores’ asset groups, including the associated operating lease right-of-use assets and property and equipment. A long-lived asset impairment test was performed during the fourth quarter of 2021 and the results of the impairment test indicated that the fair value of certain retail store asset groups was lower than their respective carrying values. Accordingly, in the three months ended December 31, 2021, the Company recorded a store impairment charge of approximately $1.4 billion, consisting of a write down of approximately $1.1 billion related to operating lease right-of-use assets and $261 million related to property and equipment, within the Retail/LTC segment. Subsequent to the impairment loss, the fair value of the associated operating lease right-of use assets and property and equipment were $356 million and $185 million, respectively.

During 2019, the Company performed reviews of its retail stores and determined it would close 68 underperforming retail pharmacy stores. As a result, management determined that there were indicators of impairment with respect to the impacted stores, including the associated operating lease right-of-use assets. Long-lived asset impairment tests were performed and the results indicated that the fair value of those underperforming retail stores were lower than their respective carrying values. Accordingly, the Company recorded store impairment charges of $231 million during the year ended December 31, 2019, primarily related to these operating lease right-of-use asset impairment charges, within the Retail/LTC segment.
Leases Leases
The Company leases most of its retail stores and mail order facilities and certain distribution centers and corporate offices under operating or finance leases, typically with initial terms of 15 to 25 years. The Company also leases certain equipment and other assets under operating or finance leases, typically with initial terms of 3 to 10 years.

In addition, the Company leases pharmacy space at the stores of another retail chain for which the noncancelable contractual term of the pharmacy lease arrangement exceeds the remaining estimated economic life of the buildings. For these pharmacy lease arrangements, the Company concluded that for accounting purposes the lease term was the remaining estimated economic life of the buildings. Consequently, most of these individual pharmacy leases are finance leases.
The following table is a summary of the components of net lease cost for the years ended December 31, 2021, 2020 and 2019:
In millions202120202019
Operating lease cost$2,633 $2,670 $2,720 
Finance lease cost:
Amortization of right-of-use assets62 56 38 
Interest on lease liabilities62 58 44 
Total finance lease costs124 114 82 
Short-term lease costs25 22 24 
Variable lease costs604 599 581 
Less: sublease income59 55 50 
Net lease cost$3,327 $3,350 $3,357 

Supplemental cash flow information related to leases for the years ended December 31, 2021, 2020 and 2019 is as follows:
In millions202120202019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows paid for operating leases$2,714 $2,724 $2,701 
Operating cash flows paid for interest portion of finance leases62 58 44 
Financing cash flows paid for principal portion of finance leases50 34 26 
Right-of-use assets obtained in exchange for lease obligations:
Operating leases1,254 1,679 1,824 
Finance leases278 313 283 
Supplemental balance sheet information related to leases as of December 31, 2021 and 2020 is as follows:
In millions, except remaining lease term and discount rate20212020
Operating leases:
Operating lease right-of-use assets$19,122$20,729
Current portion of operating lease liabilities$1,646$1,638
Long-term operating lease liabilities18,17718,757
Total operating lease liabilities$19,823$20,395
Finance leases:
Property and equipment, gross$1,375$1,107
Accumulated depreciation(188)(106)
Property and equipment, net$1,187$1,001
Current portion of long-term debt$50$33
Long-term debt1,2501,050
Total finance lease liabilities$1,300$1,083
Weighted average remaining lease term (in years)
Operating leases12.813.3
Finance leases20.020.3
Weighted average discount rate
Operating leases4.4 %4.5 %
Finance leases5.0 %5.6 %

The following table summarizes the maturity of lease liabilities under finance and operating leases as of December 31, 2021:
In millionsFinance
Leases
Operating
Leases
(1)
Total
2022$122 $2,685 $2,807 
2023121 2,613 2,734 
2024111 2,398 2,509 
2025110 2,217 2,327 
2026109 2,054 2,163 
Thereafter1,495 14,103 15,598 
Total lease payments (2)
2,068 26,070 28,138 
Less: imputed interest(768)(6,247)(7,015)
Total lease liabilities$1,300 $19,823 $21,123 
_____________________________________________
(1)Future operating lease payments have not been reduced by minimum sublease rentals of $311 million due in the future under noncancelable subleases.
(2)The Company leases pharmacy and clinic space from Target Corporation. Amounts related to such finance and operating leases are reflected above. Pharmacy lease amounts due in excess of the remaining estimated economic life of the buildings of approximately $2.4 billion are not reflected in this table since the estimated economic life of the buildings is shorter than the contractual term of the pharmacy lease arrangement.

Sale-Leaseback Transactions
The Company finances a portion of its store development program through sale-leaseback transactions. The properties are generally sold at net book value, which generally approximates fair value, and the resulting leases generally qualify and are accounted for as operating leases. The operating leases that resulted from these transactions are included in the tables above. The Company does not have any retained or contingent interests in the stores and does not provide any guarantees, other than a
guarantee of lease payments, in connection with the sale-leaseback transactions. There were no sale-leaseback transactions in 2021. Proceeds from sale-leaseback transactions totaled $101 million and $5 million in the years ended December 31, 2020 and 2019, respectively. Gains from sale-leaseback transactions totaled $3 million in the year ended December 31, 2020. There were no material gains from sale-leaseback transactions in the year ended December 31, 2019.

Store Impairment Charges
The Company evaluates its retail store right-of-use and property and equipment assets for impairment at the retail store level, which is the lowest level at which cash flows can be identified. For retail stores where there is an indicator of impairment present, the Company first compares the carrying amount of the asset group to the estimated future cash flows associated with the asset group (undiscounted). If the estimated undiscounted future cash flows used in the analysis are less than the carrying amount of the asset group, an impairment loss calculation is prepared. The impairment loss calculation compares the carrying amount of the asset group to its estimated fair value which is the greater of the asset group’s estimated future cash flows (discounted), or the consideration of what a market participant would pay to lease the assets, net of leasing costs. The Company’s estimate of fair value considers historical results, current operating trends, consolidated sales, profitability and cash flow results and forecasts. For assets which the Company has determined it will be able to sublease, the estimated future cash flows include the estimated sublease income, net of estimated leasing costs.

When the carrying value of an asset group exceeds its estimated fair value, an impairment loss is recorded to reduce the value of the asset group to its estimated fair value. As the impaired assets are measured at fair value on a nonrecurring basis primarily using unobservable inputs as of the measurement date, the assets are classified in Level 3 of the fair value hierarchy.

During the fourth quarter of 2021, the Company completed a strategic review of its retail business and announced the creation of new formats for its stores to continue to drive higher engagement with customers. As part of this review, the Company evaluated changes in population, consumer buying patterns and future health needs to ensure it has the right kinds of stores in the right locations for consumers and for the business. In connection with this initiative, on November 17, 2021, the Board of Directors of CVS Health Corporation (the “Board”) authorized the closing of approximately 900 retail stores over the next three years. The Company expects to close approximately 300 stores each year between 2022 and 2024. As a result, management determined that there were indicators of impairment with respect to the impacted stores’ asset groups, including the associated operating lease right-of-use assets and property and equipment. A long-lived asset impairment test was performed during the fourth quarter of 2021 and the results of the impairment test indicated that the fair value of certain retail store asset groups was lower than their respective carrying values. Accordingly, in the three months ended December 31, 2021, the Company recorded a store impairment charge of approximately $1.4 billion, consisting of a write down of approximately $1.1 billion related to operating lease right-of-use assets and $261 million related to property and equipment, within the Retail/LTC segment. Subsequent to the impairment loss, the fair value of the associated operating lease right-of use assets and property and equipment were $356 million and $185 million, respectively.

During 2019, the Company performed reviews of its retail stores and determined it would close 68 underperforming retail pharmacy stores. As a result, management determined that there were indicators of impairment with respect to the impacted stores, including the associated operating lease right-of-use assets. Long-lived asset impairment tests were performed and the results indicated that the fair value of those underperforming retail stores were lower than their respective carrying values. Accordingly, the Company recorded store impairment charges of $231 million during the year ended December 31, 2019, primarily related to these operating lease right-of-use asset impairment charges, within the Retail/LTC segment.
XML 36 R16.htm IDEA: XBRL DOCUMENT v3.22.0.1
Health Care Costs Payable
12 Months Ended
Dec. 31, 2021
Insurance [Abstract]  
Health Care Costs Payable Health Care Costs Payable
The following is information about incurred and cumulative paid health care claims development as of December 31, 2021, net of reinsurance, and the total IBNR liabilities plus expected development on reported claims included within the net incurred claims amounts. See Note 1 ‘‘Significant Accounting Policies’’ for information on how the Company estimates IBNR reserves and health care costs payable as well as changes to those methodologies, if any. The Company’s estimate of IBNR liabilities is primarily based on trend and completion factors. Claim frequency is not used in the calculation of the Company’s liability. In addition, it is impracticable to disclose claim frequency information for health care claims due to the Company’s inability to gather consistent claim frequency information across its multiple claims processing systems. Any claim frequency count disclosure would not be comparable across the Company’s different claim processing systems and would not be consistent from period to period based on the volume of claims processed through each system. As a result, health care claim count frequency is not included in the disclosures below.

The information about incurred and paid health care claims development for the year ended December 31, 2020 is presented as required unaudited supplemental information.
In millionsIncurred Health Care Claims,
Net of Reinsurance
For the Years Ended December 31,
Date of Service20202021
(Unaudited)
2020$54,529 $53,804 
202162,830 
Total$116,634 
In millionsCumulative Paid Health Care Claims,
Net of Reinsurance
For the Years Ended December 31,
Date of Service20202021
(Unaudited)
2020$47,567 $53,590 
202154,600 
Total$108,190 
All outstanding liabilities for health care costs payable prior to 2020, net of reinsurance130 
Total outstanding liabilities for health care costs payable, net of reinsurance$8,574 

At December 31, 2021, the Company’s liabilities for IBNR plus expected development on reported claims totaled approximately $6.6 billion. Substantially all of the Company’s liabilities for IBNR plus expected development on reported claims at December 31, 2021 related to the current calendar year.

The reconciliation of the December 31, 2021 health care net incurred and paid claims development tables to the health care costs payable liability on the consolidated balance sheet is as follows:
In millionsDecember 31, 2021
Short-duration health care costs payable, net of reinsurance$8,574 
Reinsurance recoverables
Premium deficiency reserve16 
Insurance lines other than short duration210 
Total health care costs payable$8,808 
The following table shows the components of the change in health care costs payable during the years ended December 31, 2021, 2020 and 2019:
In millions202120202019
Health care costs payable, beginning of period $7,936 $6,879 $6,147 
Less: Reinsurance recoverables10 
Health care costs payable, beginning of period, net7,926 6,874 6,143 
Acquisitions, net— 414 — 
Add: Components of incurred health care costs
  Current year64,761 55,835 52,723 
  Prior years(788)(429)(524)
Total incurred health care costs (1)
63,973 55,406 52,199 
Less: Claims paid
  Current year56,323 48,770 46,158 
  Prior years6,792 6,009 5,314 
Total claims paid63,115 54,779 51,472 
Add: Premium deficiency reserve16 11 
Health care costs payable, end of period, net8,800 7,926 6,874 
Add: Reinsurance recoverables10 
Health care costs payable, end of period$8,808 $7,936 $6,879 
_____________________________________________
(1)Total incurred health care costs for the years ended December 31, 2021, 2020 and 2019 in the table above exclude (i) $16 million, $11 million and $4 million, respectively, for a premium deficiency reserve related to the Company’s Medicaid products, (ii) $59 million, $41 million and $41 million, respectively, of benefit costs recorded in the Health Care Benefits segment that are included in other insurance liabilities on the consolidated balance sheets and (iii) $212 million, $221 million and $285 million, respectively, of benefit costs recorded in the Corporate/Other segment that are included in other insurance liabilities on the consolidated balance sheets.

The Company’s estimates of prior years’ health care costs payable decreased by $788 million, $429 million and $524 million in 2021, 2020 and 2019, respectively, because claims were settled for amounts less than originally estimated (i.e., the amount of claims incurred was lower than originally estimated), primarily due to lower health care cost trends as well as the actual claim submission time being faster than originally assumed (i.e., the Company’s completion factors were higher than originally assumed) in estimating health care costs payable at the end of the prior year. This development does not directly correspond to an increase in the Company’s operating results as these reductions were offset by estimated current period health care costs when the Company established the estimate of the current year health care costs payable.
XML 37 R17.htm IDEA: XBRL DOCUMENT v3.22.0.1
Borrowings and Credit Arrangements
12 Months Ended
Dec. 31, 2021
Debt Disclosure [Abstract]  
Borrowings and Credit Arrangements Borrowings and Credit Agreements
The following table is a summary of the Company’s borrowings as of December 31, 2021 and 2020:
In millions20212020
Long-term debt
3.35% senior notes due March 2021
$— $2,038 
Floating rate notes due March 2021 (0.950% at December 31, 2020)
— 1,000 
4.125% senior notes due May 2021
— 222 
2.125% senior notes due June 2021
— 1,750 
4.125% senior notes due June 2021
— 203 
5.45% senior notes due June 2021
— 187 
3.5% senior notes due July 2022
1,500 1,500 
2.75% senior notes due November 2022
1,000 1,000 
2.75% senior notes due December 2022
1,250 1,250 
4.75% senior notes due December 2022
399 399 
3.7% senior notes due March 2023
— 2,336 
2.8% senior notes due June 2023
1,300 1,300 
4% senior notes due December 2023
414 414 
3.375% senior notes due August 2024
650 650 
2.625% senior notes due August 2024
1,000 1,000 
3.5% senior notes due November 2024
750 750 
5% senior notes due December 2024
299 299 
4.1% senior notes due March 2025
950 950 
3.875% senior notes due July 2025
2,828 2,828 
2.875% senior notes due June 2026
1,750 1,750 
3% senior notes due August 2026
750 750 
3.625% senior notes due April 2027
750 750 
6.25% senior notes due June 2027
372 372 
1.3% senior notes due August 2027
2,250 2,250 
4.3% senior notes due March 2028
5,000 7,050 
3.25% senior notes due August 2029
1,750 1,750 
3.75% senior notes due April 2030
1,500 1,500 
1.75% senior notes due August 2030
1,250 1,250 
1.875% senior notes due February 2031
1,250 1,250 
2.125% senior notes due September 2031
1,000 — 
4.875% senior notes due July 2035
652 652 
6.625% senior notes due June 2036
771 771 
6.75% senior notes due December 2037
533 533 
4.78% senior notes due March 2038
5,000 5,000 
6.125% senior notes due September 2039
447 447 
4.125% senior notes due April 2040
1,000 1,000 
2.7% senior notes due August 2040
1,250 1,250 
5.75% senior notes due May 2041
133 133 
4.5% senior notes due May 2042
500 500 
4.125% senior notes due November 2042
500 500 
5.3% senior notes due December 2043
750 750 
4.75% senior notes due March 2044
375 375 
5.125% senior notes due July 2045
3,500 3,500 
3.875% senior notes due August 2047
1,000 1,000 
5.05% senior notes due March 2048
8,000 8,000 
4.25% senior notes due April 2050
750 750 
Finance lease liabilities1,300 1,083 
Other320 326 
Total debt principal56,743 65,318 
Debt premiums219 238 
Debt discounts and deferred financing costs(786)(909)
56,176 64,647 
Less:
Current portion of long-term debt(4,205)(5,440)
Long-term debt$51,971 $59,207 
The following is a summary of the Company’s required repayments of debt principal due during each of the next five years and thereafter, as of December 31, 2021:
In millions
2022$4,154 
20231,719 
20242,706 
20253,785 
20262,507 
Thereafter40,572 
Subtotal55,443 
Finance lease liabilities (1)
1,300 
Total debt principal$56,743 
_____________________________________________
(1)See Note 6 ‘‘Leases’’ for a summary of maturities of the Company’s finance lease liabilities.

Short-term Borrowings

Commercial Paper and Back-up Credit Facilities
The Company did not have any commercial paper outstanding as of December 31, 2021 or 2020. In connection with its commercial paper program, the Company maintains a $2.0 billion, five-year unsecured back-up revolving credit facility, which expires on May 17, 2023, a $2.0 billion, five-year unsecured back-up revolving credit facility, which expires on May 16, 2024, and a $2.0 billion, five-year unsecured back-up revolving credit facility, which expires on May 11, 2026. The credit facilities allow for borrowings at various rates that are dependent, in part, on the Company’s public debt ratings and require the Company to pay a weighted average quarterly facility fee of approximately 0.03%, regardless of usage. As of December 31, 2021 and 2020, there were no borrowings outstanding under any of the Company’s back-up credit facilities.

Federal Home Loan Bank of Boston (“FHLBB”)
A subsidiary of the Company is a member of the FHLBB. As a member, the subsidiary has the ability to obtain cash advances, subject to certain minimum collateral requirements. The maximum borrowing capacity available from the FHLBB as of December 31, 2021 was approximately $995 million. At both December 31, 2021 and 2020, there were no outstanding advances from the FHLBB.

Long-term Borrowings

2021 Notes
On August 18, 2021, the Company issued $1.0 billion aggregate principal amount of 2.125% unsecured senior notes due September 15, 2031 for total proceeds of $987 million, net of discounts, underwriting fees and offering expenses. The net proceeds of this offering were used for the purchase of senior notes in connection with the Company’s cash tender offer in August 2021 as described below.

2020 Notes
On December 16, 2020, the Company issued $750 million aggregate principal amount of 1.3% unsecured senior notes due August 21, 2027 and $1.25 billion aggregate principal amount of 1.875% unsecured senior notes due February 28, 2031 for total proceeds of approximately $1.99 billion, net of discounts and underwriting fees. The $750 million aggregate principal amount of 1.3% unsecured senior notes represent a further issuance of the Company’s 1.3% unsecured senior notes due August 21, 2027 initially issued in an aggregate principal amount of $1.5 billion on August 21, 2020.

On August 21, 2020, the Company issued $1.5 billion aggregate principal amount of 1.3% unsecured senior notes due August 21, 2027, $1.25 billion aggregate principal amount of 1.75% unsecured senior notes due August 21, 2030 and $1.25 billion aggregate principal amount of 2.7% unsecured senior notes due August 21, 2040 (collectively, the “August 2020 Notes”) for total proceeds of approximately $3.97 billion, net of discounts and underwriting fees.

On March 31, 2020, the Company issued $750 million aggregate principal amount of 3.625% unsecured senior notes due April 1, 2027, $1.5 billion aggregate principal amount of 3.75% unsecured senior notes due April 1, 2030, $1.0 billion aggregate principal amount of 4.125% unsecured senior notes due April 1, 2040 and $750 million aggregate principal amount of 4.25%
unsecured senior notes due April 1, 2050 (collectively, the “March 2020 Notes”) for total proceeds of approximately $3.95 billion, net of discounts and underwriting fees.

The net proceeds of these offerings were used for general corporate purposes, which may include working capital, capital expenditures, as well as the repurchase and/or repayment of indebtedness.

During March 2020, the Company entered into several interest rate swap transactions to manage interest rate risk. These agreements were designated as cash flow hedges and were used to hedge the exposure to variability in future cash flows resulting from changes in interest rates related to the anticipated issuance of the March 2020 Notes. In connection with the issuance of the March 2020 Notes, the Company terminated all outstanding cash flow hedges. The Company paid a net amount of $7 million to the hedge counterparties upon termination, which was recorded as a loss, net of tax, of $5 million in accumulated other comprehensive income and will be reclassified as interest expense over the life of the March 2020 Notes. See Note 13 ‘‘Other Comprehensive Income’’ for additional information.

Early Extinguishments of Debt
In December 2021, the Company redeemed for cash the remaining $2.3 billion of its outstanding 3.7% senior notes due 2023. In connection with the early redemption of such senior notes, the Company paid a make-whole premium of $80 million in excess of the aggregate principal amount of the senior notes that were redeemed, wrote-off $8 million of unamortized deferred financing costs and incurred $1 million in fees, for a total loss on early extinguishment of debt of $89 million.

In August 2021, the Company purchased approximately $2.0 billion of its outstanding 4.3% senior notes due 2028 through a cash tender offer. In connection with the purchase of such senior notes, the Company paid a premium of $332 million in excess of the aggregate principal amount of the senior notes that were purchased, wrote-off $26 million of unamortized deferred financing costs and incurred $5 million in fees, for a total loss on early extinguishment of debt of $363 million.

In December 2020, the Company purchased $4.5 billion of its outstanding senior notes through cash tender offers. The senior notes purchased included the following: $113 million of its 4.0% senior notes due 2023, $1.4 billion of its 3.7% senior notes due 2023, $1.0 billion of its 4.1% senior notes due 2025 and $2.0 billion of its 4.3% senior notes due 2028. In connection with the purchase of such senior notes, the Company paid a premium of $619 million in excess of the aggregate principal amount of the senior notes that were purchased, wrote-off $45 million of unamortized deferred financing costs and incurred $10 million in fees, for a total loss on early extinguishment of debt of $674 million.

In August 2020, the Company purchased $6.0 billion of its outstanding senior notes through cash tender offers. The senior notes purchased included the following: $723 million of its 4.0% senior notes due 2023, $2.3 billion of its 3.7% senior notes due 2023 and $3.0 billion of its 4.1% senior notes due 2025. In connection with the purchase of such senior notes, the Company paid a premium of $706 million in excess of the aggregate principal amount of the senior notes that were purchased, wrote-off $47 million of unamortized deferred financing costs and incurred $13 million in fees, for a total loss on early extinguishment of debt of $766 million.

In August 2019, the Company purchased $4.0 billion of its outstanding senior notes through cash tender offers. The senior notes purchased included the following: $1.3 billion of its 3.125% senior notes due 2020, $723 million of its floating rate notes due 2020, $328 million of its 4.125% senior notes due 2021, $297 million of 4.125% senior notes due 2021 issued by Aetna Inc. (“Aetna”), $413 million of 5.45% senior notes due 2021 issued by Coventry Health Care, Inc., a wholly-owned subsidiary of Aetna, and $962 million of its 3.35% senior notes due 2021. In connection with the purchase of such senior notes, the Company paid a premium of $76 million in excess of the aggregate principal amount of the senior notes that were purchased, incurred $8 million in fees and recognized a net gain of $5 million on the write-off of net unamortized deferred financing premiums, for a net loss on early extinguishment of debt of $79 million.

Debt Covenants

The Company’s back-up revolving credit facilities, unsecured senior notes and unsecured floating rate notes contain customary restrictive financial and operating covenants. These covenants do not include an acceleration of the Company’s debt maturities in the event of a downgrade in the Company’s credit ratings. The Company does not believe the restrictions contained in these covenants materially affect its financial or operating flexibility. As of December 31, 2021, the Company was in compliance with all of its debt covenants.
XML 38 R18.htm IDEA: XBRL DOCUMENT v3.22.0.1
Pension Plans and Other Postretirement Benefits
12 Months Ended
Dec. 31, 2021
Retirement Benefits [Abstract]  
Pension Plans and Other Postretirement Benefits Pension Plans and Other Postretirement Benefits
Defined Contribution Plans

As of December 31, 2021, the Company sponsors several active 401(k) savings plans that cover all employees who meet plan eligibility requirements.

The Company makes matching contributions consistent with the provisions of the respective plans. At the participant’s option, account balances, including the Company’s matching contribution, can be invested among various investment options under each plan. The CVS Health Future Fund 401(k) Plan offers CVS Health Corporation’s common stock fund as an investment option. The Company also maintains nonqualified, unfunded deferred compensation plans for certain key employees. The plans provide participants the opportunity to defer portions of their eligible compensation and for certain nonqualified plans, participants receive matching contributions equivalent to what they could have received under the CVS Health Future Fund 401(k) Plan absent certain restrictions and limitations under the Internal Revenue Code. The Company’s contributions under its defined contribution plans were $552 million, $520 million and $550 million in the years ended December 31, 2021, 2020 and 2019, respectively. The Company’s contributions for the year ended December 31, 2019 include contributions to the Aetna 401(k) Plan, which was merged into the CVS Health Future Fund 401(k) Plan on January 1, 2020.

Defined Benefit Pension Plans

The Company sponsors a tax-qualified defined benefit pension plan that was frozen in 2010 and a nonqualified supplemental pension plan that was frozen in 2007. The Company also sponsors several other defined benefit pension plans that are unfunded nonqualified supplemental retirement plans.

Pension Benefit Obligation and Plan Assets
The following tables outline the change in pension benefit obligation and plan assets over the specified periods:
In millions20212020
Change in benefit obligation:
Benefit obligation, beginning of year$6,462 $6,239 
Interest cost110 168 
Actuarial (gain) loss(102)413 
Benefit payments(408)(358)
Settlements(53)— 
Benefit obligation, end of year6,009 6,462 
Change in plan assets:
Fair value of plan assets, beginning of year6,845 6,395 
Actual return on plan assets215 783 
Employer contributions78 25 
Benefit payments(408)(358)
Settlements(53)— 
Fair value of plan assets, end of year6,677 6,845 
Funded status$668 $383 

The change in the pension benefit obligation during the years ended December 31, 2021 and 2020 was primarily driven by the change in the discount rate during each respective period.
The assets (liabilities) recognized on the consolidated balance sheets at December 31, 2021 and 2020 for the defined benefit pension plans consisted of the following:
In millions20212020
Noncurrent assets reflected in other assets$946 $744 
Current liabilities reflected in accrued expenses(28)(76)
Noncurrent liabilities reflected in other long-term liabilities(250)(285)
Net assets$668 $383 

Net Periodic Benefit Cost (Income)
The components of net periodic benefit cost (income) for the years ended December 31, 2021, 2020 and 2019 are shown below:
In millions202120202019
Components of net periodic benefit cost (income):
Interest cost$110 $168 $225 
Expected return on plan assets(317)(388)(357)
Amortization of net actuarial loss
Settlement losses16 — — 
Net periodic benefit cost (income)$(186)$(218)$(131)

Pension Plan Assumptions
The Company uses a series of actuarial assumptions to determine its benefit obligation and net periodic benefit cost (income), the most significant of which include discount rates and expected return on plan assets assumptions.

Discount Rates - The discount rate is determined using a yield curve as of the annual measurement date. The yield curve consists of a series of individual discount rates, with each discount rate corresponding to a single point in time, based on high-quality bonds. Projected benefit payments are discounted to the measurement date using the corresponding rate from the yield curve that is consistent with the maturity profile of the expected liability cash flows.

Expected Return on Plan Assets - The expected long-term rate of return on plan assets is determined by using the plan’s target allocation and return expectations based on many factors including forecasted long-term capital market real returns and the inflationary outlook on a plan by plan basis. See “Pension Plan Assets” below for additional details regarding the pension plan assets as of December 31, 2021 and 2020.

The Company also considers other assumptions including mortality, interest crediting rate, termination and retirement rates and cost of living adjustments.

The Company determined its benefit obligation based on the following weighted average assumptions as of December 31, 2021 and 2020:
20212020
Discount rate2.8 %2.5 %

The Company determined its net periodic benefit cost (income) based on the following weighted average assumptions for the years ended December 31, 2021, 2020 and 2019:
202120202019
Discount rate1.8 %2.9 %4.0 %
Expected long-term rate of return on plan assets4.8 %6.3 %6.5 %
Pension Plan Assets
The Company’s pension plan assets primarily include debt and equity securities held in separate accounts, common/collective trusts and real estate investments. The valuation methodologies used to value these debt and equity securities and common/collective trusts are similar to the methodologies described in Note 4 “Fair Value.” Pension plan assets also include investments in other assets that are carried at fair value. The following is a description of the valuation methodologies used to value real estate investments and these additional investments, including the general classification pursuant to the fair value hierarchy.

Real Estate - Real estate investments are valued by independent third party appraisers. The appraisals comply with the Uniform Standards of Professional Appraisal Practice, which include, among other things, the income, cost, and sales comparison approaches to estimating property value. Therefore, these investments are classified in Level 3.

Private equity and hedge fund limited partnerships - Private equity and hedge fund limited partnerships are carried at fair value which is estimated using the NAV per unit as reported by the administrator of the underlying investment fund as a practical expedient to fair value. Therefore, these investments have been excluded from the fair value table below.

Pension plan assets with changes in fair value measured on a recurring basis at December 31, 2021 were as follows:
In millionsLevel 1Level 2Level 3Total
Cash and cash equivalents$60 $97 $— $157 
Debt securities:
    U.S. government securities1,223 — 1,224 
    States, municipalities and political subdivisions— 150 — 150 
    U.S. corporate securities— 2,458 — 2,458 
    Foreign securities— 202 — 202 
    Residential mortgage-backed securities— 277 — 277 
    Commercial mortgage-backed securities— 76 — 76 
    Other asset-backed securities— 162 — 162 
    Redeemable preferred securities— — 
Total debt securities1,223 3,330 — 4,553 
Equity securities:
    U.S. domestic201 — — 201 
    International81 — — 81 
    Domestic real estate— — 
Total equity securities283 — — 283 
Other investments:
    Real estate— — 378 378 
    Common/collective trusts (1)
— 410 — 410 
Total other investments— 410 378 788 
Total pension investments (2)
$1,566 $3,837 $378 $5,781 
_____________________________________________
(1)The assets in the underlying funds of common/collective trusts consist of $261 million of equity securities and $149 million of debt securities.
(2)Excludes $76 million of other receivables as well as $583 million of private equity limited partnership investments and $237 million of hedge fund limited partnership investments as these amounts are measured at NAV per share or an equivalent and are not subject to leveling within the fair value hierarchy.
Pension plan assets with changes in fair value measured on a recurring basis at December 31, 2020 were as follows:
In millionsLevel 1Level 2Level 3Total
Cash and cash equivalents$118 $81 $— $199 
Debt securities:
    U.S. government securities575 36 — 611 
    States, municipalities and political subdivisions— 170 — 170 
    U.S. corporate securities— 2,006 — 2,006 
    Foreign securities— 167 — 167 
    Residential mortgage-backed securities— 287 — 287 
    Commercial mortgage-backed securities— 83 — 83 
    Other asset-backed securities— 133 — 133 
    Redeemable preferred securities— — 
Total debt securities575 2,887 — 3,462 
Equity securities:
    U.S. domestic1,046 — — 1,046 
    International537 — — 537 
    Domestic real estate15 — — 15 
Total equity securities1,598 — — 1,598 
Other investments:
    Real estate— — 343 343 
    Common/collective trusts (1)
— 266 — 266 
    Derivatives— (3)— (3)
Total other investments— 263 343 606 
Total pension investments (2)
$2,291 $3,231 $343 $5,865 
_____________________________________________
(1)The assets in the underlying funds of common/collective trusts consist of $84 million of equity securities and $182 million of debt securities.
(2)Excludes $142 million of other receivables as well as $624 million of private equity limited partnership investments and $214 million of hedge fund limited partnership investments as these amounts are measured at NAV per share or an equivalent and are not subject to leveling within the fair value hierarchy.

The changes in the balances of Level 3 pension plan assets during the year ended December 31, 2021 were as follows:
In millionsReal estateTotal
Beginning balance$343 $343 
Actual return on plan assets43 43 
Purchases, sales and settlements(8)(8)
Transfers out of Level 3— — 
Ending balance$378 $378 

The changes in the balances of Level 3 pension plan assets during the year ended December 31, 2020 were as follows:

In millionsReal estateU.S. corporate
securities
Total
Beginning balance$353 $$354 
Actual return on plan assets(2)— (2)
Purchases, sales and settlements(8)— (8)
Transfers out of Level 3— (1)(1)
Ending balance$343 $— $343 
The Company’s pension plan invests in a diversified mix of assets designed to generate returns that will enable the plan to meet its future benefit obligations. The risk of unexpected investment and actuarial outcomes is regularly evaluated. This evaluation is performed through forecasting and assessing ranges of investment outcomes over short- and long-term horizons and by assessing the pension plan’s liability characteristics. Complementary investment styles and strategies are utilized by professional investment management firms to further improve portfolio and operational risk characteristics. Public and private equity investments are used primarily to increase overall plan returns. Real estate investments are viewed favorably for their diversification benefits and above-average dividend generation. Fixed income investments provide diversification benefits and liability hedging attributes that are desirable, especially in falling interest rate environments.

At December 31, 2021, target investment allocations for the Company’s pension plan were: 12% in equity securities, 77% in fixed income and debt securities, 5% in real estate, 3% in private equity limited partnerships and 3% in hedge funds. Actual asset allocations may differ from target allocations due to tactical decisions to overweight or underweight certain assets or as a result of normal fluctuations in asset values. Asset allocations are consistent with stated investment policies and, as a general rule, periodically rebalanced back to target asset allocations. Asset allocations and investment performance are formally reviewed periodically throughout the year by the pension plan’s Investment Subcommittee. Forecasting of asset and liability growth is performed at least annually.

Cash Flows
The Company generally contributes to its tax-qualified pension plan based on minimum funding requirements determined under applicable federal laws and regulations. Employer contributions related to the nonqualified supplemental pension plans generally represent payments to retirees for current benefits. The Company contributed $78 million, $25 million and $25 million to its pension plans during 2021, 2020 and 2019, respectively. No contributions are required for the tax-qualified pension plan in 2022. The Company expects to make an immaterial amount of contributions for all other pension plans in 2022.

The Company estimates the following future benefit payments, which are calculated using the same actuarial assumptions used to measure the pension benefit obligation as of December 31, 2021:
In millions
2022$371 
2023371 
2024371 
2025371 
2026368 
2027-20311,776 

Multiemployer Pension Plans
The Company also contributes to a number of multiemployer pension plans under the terms of collective-bargaining agreements that cover its union-represented employees. The risks of participating in these multiemployer plans are different from single-employer pension plans in the following respects: (i) assets contributed to the multiemployer plan by one employer may be used to provide benefits to employees of other participating employers, (ii) if a participating employer stops contributing to the plan, the unfunded obligations of the plan may be borne by the remaining participating employers, and (iii) if the Company chooses to stop participating in some of its multiemployer plans, the Company may be required to pay those plans an amount based on the underfunded status of the applicable plan, which is referred to as a withdrawal liability.

None of the multiemployer pension plans in which the Company participates are individually significant to the Company. The Company’s contributions to multiemployer pension plans were $19 million, $19 million and $18 million in 2021, 2020 and 2019, respectively.

Other Postretirement Benefits

The Company provides postretirement health care and life insurance benefits to certain retirees who meet eligibility requirements. The Company’s funding policy is generally to pay covered expenses as they are incurred. For retiree medical plan accounting, the Company reviews external data and its own historical trends for health care costs to determine the health care cost trend rates. As of December 31, 2021 and 2020, the Company’s other postretirement benefits had an accumulated postretirement benefit obligation of $207 million and $226 million, respectively. Net periodic benefit costs related to these other postretirement benefits were $4 million, $12 million and $7 million in 2021, 2020 and 2019, respectively.
The Company estimates the following future benefit payments, which are calculated using the same actuarial assumptions used to measure the accumulated other postretirement benefit obligation as of December 31, 2021:
In millions
2022$12 
202312 
202412 
202512 
202612 
2027-203160 
Pursuant to various collective bargaining agreements, the Company also contributes to multiemployer health and welfare plans that cover certain union-represented employees. The plans provide postretirement health care and life insurance benefits to certain employees who meet eligibility requirements. The Company’s contributions to multiemployer health and welfare plans totaled $60 million, $54 million and $57 million in 2021, 2020 and 2019, respectively.
XML 39 R19.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes
12 Months Ended
Dec. 31, 2021
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
The income tax provision for continuing operations consisted of the following for the years ended December 31, 2021, 2020 and 2019:
In millions202120202019
Current:
Federal$2,285 $2,615 $2,450 
State665 518 565 
2,950 3,133 3,015 
Deferred:
Federal(306)(450)(535)
State(122)(114)(114)
(428)(564)(649)
Total$2,522 $2,569 $2,366 

The following table is a reconciliation of the statutory income tax rate to the Company’s effective income tax rate for continuing operations for the years ended December 31, 2021, 2020 and 2019:
202120202019
Statutory income tax rate21.0 %21.0 %21.0 %
State income taxes, net of federal tax benefit4.1 3.2 4.0 
Health insurer fee— 2.2 — 
Basis difference upon disposition of subsidiary— (1.2)— 
Prior year refund claim (1.2)— — 
Other0.3 1.1 1.3 
Effective income tax rate24.2 %26.3 %26.3 %
The following table is a summary of the components of the Company’s deferred income tax assets and liabilities as of December 31, 2021 and 2020:
In millions20212020
Deferred income tax assets:
Lease and rents$5,563 $5,742 
Inventory99 80 
Employee benefits193 238 
Bad debts and other allowances489 395 
Net operating loss and capital loss carryforwards416 568 
Deferred income78 43 
Insurance reserves501 489 
Payroll tax deferral87 173 
Other396 500 
Valuation allowance(325)(454)
Total deferred income tax assets7,497 7,774 
Deferred income tax liabilities:
Retirement benefits(105)(29)
Investments(334)(421)
Lease and rents(4,947)(5,368)
Depreciation and amortization(8,381)(8,750)
Total deferred income tax liabilities(13,767)(14,568)
Net deferred income tax liabilities$(6,270)$(6,794)

As of December 31, 2021, the Company had net operating and capital loss carryovers of $416 million, which expire between 2022 and 2041. The Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and the Company’s recent operating results. The Company established a valuation allowance of $325 million as of December 31, 2021 because it does not consider it more likely than not that these deferred tax assets will be recovered.

A reconciliation of the beginning and ending balance of unrecognized tax benefits in 2021, 2020 and 2019 is as follows:
In millions202120202019
Beginning balance$768 $655 $661 
Additions based on tax positions related to the current year
Additions based on tax positions related to prior years52 182 115 
Reductions for tax positions of prior years(33)(56)(111)
Expiration of statutes of limitation(1)(2)(7)
Settlements(7)(14)(7)
Ending balance$782 $768 $655 

CVS Health Corporation and most of its subsidiaries are subject to U.S. federal income tax as well as income tax of numerous state and local jurisdictions. CVS Health Corporation participated in the Compliance Assurance Process through 2019, which is a program made available by the U.S. Internal Revenue Service (“IRS”) to certain qualifying large taxpayers, under which participants work collaboratively with the IRS to identify and resolve potential tax issues through open, cooperative and transparent interaction prior to the annual filing of their federal income tax returns. The IRS has completed its examinations of the Company’s consolidated U.S. federal income tax returns for tax years through and including 2013 and 2018. The IRS has substantially completed its examinations of the Company’s consolidated U.S. federal income tax returns for tax years 2014 through 2017 and 2019.
CVS Health Corporation and its subsidiaries are also currently under income tax examinations by a number of state and local tax authorities. As of December 31, 2021, no examination has resulted in any proposed adjustments that would result in a material change to the Company’s operating results, financial condition or liquidity.

Substantially all material state and local income tax matters have been concluded for fiscal years through 2014. Certain state exams are likely to be concluded and certain state statutes of limitations will lapse in 2022, but the change in the balance of the Company’s uncertain tax positions is projected to be immaterial. In addition, it is reasonably possible that the Company’s unrecognized tax benefits could change within the next twelve months due to the anticipated conclusion of various examinations with the IRS for various years. An estimate of the range of the possible change cannot be made at this time.

The Company records interest expense related to unrecognized tax benefits and penalties in the income tax provision. The Company accrued interest expense of approximately $40 million, $34 million and $49 million in 2021, 2020 and 2019, respectively. The Company had approximately $151 million and $121 million accrued for interest and penalties as of December 31, 2021 and 2020, respectively.

As of December 31, 2021, the total amount of unrecognized tax benefits that, if recognized, would affect the Company’s effective income tax rate is approximately $669 million, after considering the federal benefit of state income taxes.
XML 40 R20.htm IDEA: XBRL DOCUMENT v3.22.0.1
Stock Incentive Plans
12 Months Ended
Dec. 31, 2021
Share-based Payment Arrangement [Abstract]  
Stock Incentive Plans Stock Incentive Plans
The terms of the CVS Health 2017 Incentive Compensation Plan (“ICP”) provide for grants of annual incentive and long-term performance awards to executive officers and other officers and employees of the Company or any subsidiary of the Company, as well as equity compensation to outside directors of CVS Health Corporation. Payment of such annual incentive and long-term performance awards will be in cash, stock, other awards or other property, at the discretion of the Management Planning and Development Committee (the “MP&D Committee”) of the Board. The ICP allows for a maximum of 58 million shares of CVS Health Corporation common stock to be reserved and available for grants. As of December 31, 2021, there were approximately 30 million shares of CVS Health Corporation common stock available for future grants under the ICP.

Upon the acquisition of Aetna (the “Aetna Acquisition”) on November 28, 2018, approximately 22 million shares of Aetna common stock subject to awards outstanding under the Amended Aetna Inc. 2010 Stock Incentive Plan (“SIP”) were assumed by CVS Health Corporation. In addition, in accordance with the merger agreement, shares which were available for future issuance under the SIP were converted into approximately 32 million shares of CVS Health Corporation common stock reserved and available for issuance pursuant to future awards. Subsequent to the expiration of the SIP on May 21, 2020, the ICP is the only compensation plan under which the Company grants stock options, restricted stock and other stock-based awards to its employees.

Stock-Based Compensation Expense

Stock-based compensation is measured at the grant date based on the fair value of the award and is recognized as expense over the requisite service period of the stock award (generally three to five years) using the straight-line method. The following table is a summary of stock-based compensation for the years ended December 31, 2021, 2020 and 2019:
In millions202120202019
Stock options and stock appreciation rights (“SARs”) (1)
$80 $71 $76 
Restricted stock units and performance stock units
404 329 377 
Total stock-based compensation$484 $400 $453 
_____________________________________________
(1)Includes the ESPP.

ESPP

The Company’s Employee Stock Purchase Plan (“ESPP”) provides for the purchase of up to 60 million shares of CVS Health Corporation common stock. Under the ESPP, eligible employees may purchase common stock at the end of each six month offering period at a purchase price equal to 90% of the lower of the fair market value on the first day or the last day of the offering period. During 2021, approximately 3 million shares of common stock were purchased under the provisions of the ESPP at an average price of $60.51 per share. As of December 31, 2021, approximately 31 million shares of common stock were available for issuance under the ESPP.
The fair value of stock-based compensation associated with the ESPP is estimated on the date of grant (the first day of the six month offering period) using the Black-Scholes option pricing model.

The following table is a summary of the assumptions used to value the ESPP awards for the years ended December 31, 2021, 2020 and 2019:
202120202019
Dividend yield (1)
1.34 %1.46 %1.70 %
Expected volatility (2)
25.27 %37.21 %27.96 %
Risk-free interest rate (3)
0.08 %0.81 %2.27 %
Expected life (in years) (4)
0.50.50.5
Weighted-average grant date fair value$12.55 $13.85 $10.51 
_____________________________________________
(1)The dividend yield is calculated based on semi-annual dividends paid and the fair market value of CVS Health Corporation stock at the grant date.
(2)The expected volatility is estimated based on the historical volatility of CVS Health Corporation’s daily stock price over the previous six month period.
(3)The risk-free interest rate is selected based on the Treasury constant maturity interest rate whose term is consistent with the expected term of ESPP purchases (i.e., six months).
(4)The expected life is based on the semi-annual purchase period.

Restricted Stock Units and Performance Stock Units

The Company’s restricted stock units and performance stock units are considered nonvested share awards and require no payment from the employee. The fair value of the restricted stock units is based on the market price of CVS Health Corporation common stock on the grant date and is recognized on a straight-line basis over the vesting period. For each restricted stock unit granted, employees receive one share of common stock, net of taxes, at the end of the vesting period.

The Company’s performance stock units contain performance vesting conditions in addition to a service vesting condition. Vesting of the Company’s performance stock units is dependent upon the degree to which the Company achieves its performance goals, which are generally set for a three-year performance period and are approved at the time of grant by the MP&D Committee.

The fair value of performance stock units granted with service and performance vesting conditions is based on the market price of CVS Health Corporation common stock on the grant date and is recognized over the vesting period. Certain of the performance stock units also contain a market vesting condition based on the performance of CVS Health Corporation common stock relative to a comparator group. The fair value of these performance stock units is determined using a Monte Carlo simulation as of the grant date and is recognized over the vesting period.

As of December 31, 2021, there was $529 million of total unrecognized compensation cost related to the Company’s restricted stock units and performance stock units that are expected to vest. These costs are expected to be recognized over a weighted-average period of 2.1 years. The total fair value of restricted stock units vested during 2021, 2020 and 2019 was $406 million, $229 million and $265 million, respectively.

The following table is a summary of the restricted stock unit and performance stock unit activity for the year ended December 31, 2021:
In thousands, except weighted average grant date fair valueUnitsWeighted Average
Grant Date
Fair Value
Outstanding at beginning of year, nonvested14,824 $58.12 
Granted6,190 $74.39 
Vested(5,448)$74.47 
Forfeited(1,236)$63.40 
Outstanding at end of year, nonvested14,330 $63.02 

Stock Options and SARs

All stock option grants are awarded at fair value on the date of grant. The fair value of stock options is estimated using the Black-Scholes option pricing model, and stock-based compensation is recognized on a straight-line basis over the requisite
service period. Stock options granted generally become exercisable over a four-year period from the grant date. Stock options granted through 2018 generally expire seven years after the grant date. Stock options granted subsequent to 2018 generally expire ten years after the grant date.

All unvested Aetna SARs outstanding upon the acquisition of Aetna were converted into replacement CVS Health Corporation SARs. The replacement SARs granted are settled in CVS Health Corporation common stock, net of taxes, based on the appreciation of the stock price on the exercise date over the market price on the date of grant. The fair value of SARs is estimated using the Black-Scholes option pricing model, and stock-based compensation is recognized on a straight-line basis over the requisite service period. SARs generally become exercisable over a three-year period from the grant date. SARs generally expire ten years after the grant date. No SARs have been granted subsequent to the Aetna Acquisition.

The following table is a summary of stock option and SAR activity that occurred for the years ended December 31, 2021, 2020 and 2019:
In millions202120202019
Cash received from stock options exercised (including ESPP)
$549 $264 $210 
Payments for taxes for net share settlement of equity awards
168 88 112 
Intrinsic value of stock options and SARs exercised
105 24 30 
Fair value of stock options and SARs vested
224 252 467 

The fair value of each stock option is estimated using the Black-Scholes option pricing model based on the following assumptions at the time of grant:
202120202019
Dividend yield (1)
2.68 %3.42 %3.68 %
Expected volatility (2)
27.10 %25.22 %21.76 %
Risk-free interest rate (3)
1.13 %0.61 %0.56 %
Expected life (in years) (4)
6.36.36.3
Weighted-average grant date fair value$14.57 $8.78 $6.27 
_____________________________________________
(1)The dividend yield is based on annual dividends paid and the fair market value of CVS Health Corporation stock at the grant date.
(2)The expected volatility is estimated based on the historical volatility of CVS Health Corporation’s daily stock price over a period equal to the expected life of each option grant after adjustments for infrequent events such as stock splits.
(3)The risk-free interest rate is selected based on yields from U.S. Treasury zero-coupon issues with a remaining term equal to the expected term of the options being valued.
(4)The expected life represents the number of years the options are expected to be outstanding from grant date based on historical option or SAR holder exercise experience.

As of December 31, 2021, unrecognized compensation expense related to unvested stock options totaled $38 million, which the Company expects to be recognized over a weighted-average period of 2.0 years. After considering anticipated forfeitures, the Company expects approximately 9 million of the unvested stock options to vest over the requisite service period.
The following table is a summary of the Company’s stock option and SAR activity for the year ended December 31, 2021:
In thousands, except weighted average exercise price and remaining contractual termSharesWeighted
Average
Exercise
 Price
Weighted
Average
Remaining
Contractual
Term
Aggregate
Intrinsic
Value
Outstanding at beginning of year23,955 $69.62 
Granted3,322 $74.66 
Exercised(6,366)$63.41 
Forfeited(694)$62.66 
Expired(1,156)$87.42 
Outstanding at end of year19,061 $71.74 4.75$603,137 
Exercisable at end of year9,704 $79.99 2.61229,034 
Vested at end of year and expected to vest in the future18,709 $71.82 4.69590,514 
XML 41 R21.htm IDEA: XBRL DOCUMENT v3.22.0.1
Shareholders' Equity
12 Months Ended
Dec. 31, 2021
Equity [Abstract]  
Shareholders' Equity Shareholders’ Equity
Share Repurchases

The following share repurchase programs have been authorized by the Board:
In billions
Authorization Date
AuthorizedRemaining as of
December 31, 2021
December 9, 2021 (“2021 Repurchase Program”)
$10.0 $10.0 
November 2, 2016 (“2016 Repurchase Program”)15.0 — 

Each of the share Repurchase Programs was effective immediately. The 2016 Repurchase program was terminated effective December 9, 2021. The 2021 Repurchase Program permits the Company to effect repurchases from time to time through a combination of open market repurchases, privately negotiated transactions, accelerated share repurchase (“ASR”) transactions, and/or other derivative transactions. The 2021 Repurchase Program can be modified or terminated by the Board at any time.

During the years ended December 31, 2021, 2020 and 2019, the Company did not repurchase any shares of common stock pursuant to the 2016 or 2021 Repurchase Programs.

Pursuant to the authorization under the 2021 Repurchase Program, the Company entered into a $1.5 billion fixed dollar ASR with Barclays Bank PLC (“Barclays”). Upon payment of the $1.5 billion purchase price on January 4, 2022, the Company received a number of shares of CVS Health Corporation’s common stock equal to 80% of the $1.5 billion notional amount of the ASR or approximately 11.6 million shares at a price of $103.34 per share, which were placed into treasury stock in January 2022. At the conclusion of the ASR, the Company may receive additional shares equal to the remaining 20% of the $1.5 billion notional amount. The ultimate number of shares the Company may receive will depend on the daily volume-weighted average price of the Company’s stock over an averaging period, less a discount. It is also possible, depending on such weighted average price, that the Company will have an obligation to Barclays which, at the Company’s option, could be settled in additional cash or by issuing shares. Under the terms of the ASR, the maximum number of shares that could be delivered to the Company is 29.0 million.

Dividends

The quarterly cash dividend declared by the Board was $0.50 per share in 2021 and 2020. In December 2021, the Board authorized a 10% increase in the quarterly cash dividend to $0.55 per share effective in 2022. CVS Health Corporation has paid cash dividends every quarter since becoming a public company. Future dividend payments will depend on the Company’s earnings, capital requirements, financial condition and other factors considered relevant by the Board.

Regulatory Requirements

The Company’s insurance business operations are conducted through subsidiaries that principally consist of health maintenance organizations (“HMOs”) and insurance companies. The Company’s HMO and insurance subsidiaries report their financial
statements in accordance with accounting practices prescribed by state regulatory authorities which may differ from GAAP. The combined statutory net income for the years ended and estimated combined statutory and capital surplus at December 31, 2021, 2020 and 2019 for the Company’s insurance and HMO subsidiaries were as follows:
In millions202120202019
Statutory net income
$3,302 $3,667 $2,842 
Estimated statutory capital and surplus
14,879 13,238 10,975 

The Company’s insurance and HMO subsidiaries paid $1.6 billion of gross dividends to the Company for the year ended December 31, 2021.

In addition to general state law restrictions on payments of dividends and other distributions to stockholders applicable to all corporations, HMOs and insurance companies are subject to further regulations that, among other things, may require those companies to maintain certain levels of equity and restrict the amount of dividends and other distributions that may be paid to their equity holders. In addition, in connection with the Aetna Acquisition, the Company made certain undertakings that require prior regulatory approval of dividends by certain of its HMOs and insurance companies. At December 31, 2021, these amounts were as follows:
In millions
Estimated minimum statutory surplus required by regulators$7,261 
Investments on deposit with regulatory bodies794 
Estimated maximum dividend distributions permitted in 2022 without prior regulatory approval2,939 

Noncontrolling Interests

At December 31, 2021 and 2020, noncontrolling interests were $306 million and $312 million, respectively, primarily related to third party interests in the Company’s operating entities. The noncontrolling entities’ share is included in total shareholders equity on the consolidated balance sheets.
XML 42 R22.htm IDEA: XBRL DOCUMENT v3.22.0.1
Other Comprehensive Income
12 Months Ended
Dec. 31, 2021
Other Comprehensive Income (Loss), Net of Tax [Abstract]  
Other Comprehensive Income Other Comprehensive Income
Shareholders’ equity included the following activity in accumulated other comprehensive income in 2021, 2020 and 2019:
At December 31,
In millions202120202019
Net unrealized investment gains (losses):
Beginning of year balance$1,214 $774 $97 
Other comprehensive income (loss) before reclassifications ($(489), $497 and $927 pretax)
(410)415 763 
Amounts reclassified from accumulated other comprehensive income ($(32), $31 and $(105) pretax) (1)
(26)25 (86)
Other comprehensive income (loss)(436)440 677 
End of year balance778 1,214 774 
Foreign currency translation adjustments:
Beginning of year balance(158)
Other comprehensive income (loss) before reclassifications(7)
Amounts reclassified from accumulated other comprehensive income (loss) (2)
— — 154 
Other comprehensive income (loss)(7)162 
End of year balance— 
Net cash flow hedges:
Beginning of year balance248 279 312 
Other comprehensive loss before reclassifications ($0, $(7) and $(25) pretax)
— (5)(18)
Amounts reclassified from accumulated other comprehensive income ($(34), $(35) and $(20) pretax) (3)
(26)(26)(15)
Other comprehensive loss(26)(31)(33)
End of year balance222 248 279 
Pension and other postretirement benefits:
Beginning of year balance(55)(38)(149)
Other comprehensive income (loss) before reclassifications ($20, $(30) and $162 pretax)
15 (22)120 
Amounts reclassified from accumulated other comprehensive loss ($6, $7 and $(12) pretax) (4)
(9)
Other comprehensive income (loss) 20 (17)111 
End of year balance(35)(55)(38)
Total beginning of year accumulated other comprehensive income1,414 1,019 102 
Total other comprehensive income (loss)(449)395 917 
Total end of year accumulated other comprehensive income$965 $1,414 $1,019 
_____________________________________________
(1)Amounts reclassified from accumulated other comprehensive income for specifically identified debt securities are included in net investment income in the consolidated statements of operations.
(2)Amounts reclassified from accumulated other comprehensive income (loss) represent the elimination of the cumulative translation adjustment associated with the sale of Onofre, which was sold on July 1, 2019. The loss on the divestiture of Onofre is reflected in operating expenses in the consolidated statements of operations.
(3)Amounts reclassified from accumulated other comprehensive income for specifically identified cash flow hedges are included within interest expense in the consolidated statements of operations. The Company expects to reclassify approximately $11 million, net of tax, in net gains associated with its cash flow hedges into net income within the next 12 months.
(4)Amounts reclassified from accumulated other comprehensive loss for specifically identified pension and other postretirement benefits are included in other income in the consolidated statements of operations.
XML 43 R23.htm IDEA: XBRL DOCUMENT v3.22.0.1
Earnings Per Share
12 Months Ended
Dec. 31, 2021
Earnings Per Share [Abstract]  
Earnings Per Share Earnings Per Share
Earnings per share is computed using the two-class method. SARs and options to purchase 7 million, 15 million, and 17 million shares of common stock were outstanding, but were excluded from the calculation of diluted earnings per share for the years ended December 31, 2021, 2020 and 2019, respectively, because their exercise prices were greater than the average market price of the common shares and, therefore, the effect would be antidilutive.

The following is a reconciliation of basic and diluted earnings per share from continuing operations for the years ended December 31, 2021, 2020 and 2019:
In millions, except per share amounts202120202019
Numerator for earnings per share calculation:
Income from continuing operations$7,898 $7,201 $6,631 
Income allocated to participating securities— — (5)
Net (income) loss attributable to noncontrolling interests12 (13)
Income from continuing operations attributable to CVS Health$7,910 $7,188 $6,629 
Denominator for earnings per share calculation:
Weighted average shares, basic1,319 1,309 1,301 
Effect of dilutive securities10 
Weighted average shares, diluted1,329 1,314 1,305 
Earnings per share from continuing operations:
Basic$6.00 $5.49 $5.10 
Diluted$5.95 $5.47 $5.08 
XML 44 R24.htm IDEA: XBRL DOCUMENT v3.22.0.1
Reinsurance
12 Months Ended
Dec. 31, 2021
Reinsurance Disclosures [Abstract]  
Reinsurance Reinsurance
The Company utilizes reinsurance agreements primarily to: (a) reduce required capital and (b) facilitate the acquisition or disposition of certain insurance contracts. Ceded reinsurance agreements permit the Company to recover a portion of its losses from reinsurers, although they do not discharge the Company’s primary liability as the direct insurer of the risks reinsured.

On November 30, 2018, the Company completed the sale of Aetna’s standalone Medicare Part D prescription drug plans to a subsidiary of WellCare Health Plans, Inc. (“WellCare”), effective December 31, 2018. In connection with that sale, subsidiaries of WellCare and Aetna entered into reinsurance agreements under which WellCare ceded to Aetna 100% of the insurance risk related to the divested standalone Medicare Part D prescription drug plans for the 2019 PDP plan year.

In January 2022, the Company entered into two four-year reinsurance agreements with an unrelated reinsurer that allow it to reduce required capital and provide collateralized excess of loss reinsurance coverage on a portion of the Health Care Benefits segment’s group Commercial Insured business.

Reinsurance recoverables (recorded as other current assets or other assets on the consolidated balance sheets) at December 31, 2021 and 2020 were as follows:
In millions20212020
Reinsurer
Hartford Life and Accident Insurance Company$1,887 $2,364 
Lincoln Life & Annuity Company of New York395 406 
VOYA Retirement Insurance and Annuity Company 167 170 
All Other100 115 
Total$2,549 $3,055 
Direct, assumed and ceded premiums earned for the years ended December 31, 2021, 2020 and 2019 were as follows:
In millions202120202019
Direct$76,320 $69,711 $62,968 
Assumed492 478 2,108 
Ceded(680)(825)(1,954)
Net premiums$76,132 $69,364 $63,122 

The impact of reinsurance on benefit costs for the years ended December 31, 2021, 2020 and 2019 were as follows:
In millions202120202019
Direct$64,414 $56,077 $52,592 
Assumed398 329 1,562 
Ceded(552)(727)(1,625)
Net benefit costs$64,260 $55,679 $52,529 

There is not a material difference between premiums on a written basis versus an earned basis.

The Company also has various agreements with unrelated reinsurers that do not qualify for reinsurance accounting under GAAP, and consequently are accounted for using deposit accounting. The Company entered into these contracts to reduce the risk of catastrophic loss which in turn reduces the Company’s capital and surplus requirements. Total deposit assets and liabilities related to reinsurance agreements that do not qualify for reinsurance accounting under GAAP were not material as of December 31, 2021 or 2020.
XML 45 R25.htm IDEA: XBRL DOCUMENT v3.22.0.1
Commitments and Contingencies
12 Months Ended
Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
COVID-19

The COVID-19 pandemic continues to evolve. The Company believes COVID-19’s impact on its businesses, operating results, cash flows and/or financial condition primarily will be driven by the geographies impacted and the severity and duration of the pandemic; the pandemic’s impact on the U.S. and global economies and consumer behavior and health care utilization patterns; and the timing, scope and impact of stimulus legislation as well as other federal, state and local governmental responses to the pandemic. Those primary drivers are beyond the Company’s knowledge and control. As a result, the impact COVID-19 will have on the Company’s businesses, operating results, cash flows and/or financial condition is uncertain, but the impact could be adverse and material. COVID-19 also may result in legal and regulatory proceedings, investigations and claims against the Company.

Guarantees

The Company has the following significant guarantee arrangements at December 31, 2021:

ASC Claim Funding Accounts - The Company has arrangements with certain banks for the processing of claim payments for its ASC customers. The banks maintain accounts to fund claims of the Company’s ASC customers. The customer is responsible for funding the amount paid by the bank each day. In these arrangements, the Company guarantees that the banks will not sustain losses if the responsible ASC customer does not properly fund its account. The aggregate maximum exposure under these arrangements is generally limited to $250 million. The Company can limit its exposure to these guarantees by suspending the payment of claims for ASC customers that have not adequately funded the amount paid by the bank.
Separate Accounts Assets - Certain Separate Accounts assets associated with the large case pensions business in the Corporate/Other segment represent funds maintained as a contractual requirement to fund specific pension annuities that the Company has guaranteed. Minimum contractual obligations underlying the guaranteed benefits in these Separate Accounts were approximately $1.3 billion and $1.4 billion at December 31, 2021 and 2020, respectively. See Note 1 ‘‘Significant Accounting Policies’’ for additional information on Separate Accounts. Contract holders assume all investment and mortality risk and are required to maintain Separate Accounts balances at or above a specified level. The level of required funds is a function of the risk underlying the Separate Account’s investment strategy. If contract holders do not maintain the required level of Separate Accounts assets to meet the annuity guarantees, the Company would
establish an additional liability. Contract holders’ balances in the Separate Accounts at December 31, 2021 exceeded the value of the guaranteed benefit obligation. As a result, the Company was not required to maintain any additional liability for its related guarantees at December 31, 2021.

Lease Guarantees

Between 1995 and 1997, the Company sold or spun off a number of subsidiaries, including Bob’s Stores and Linens ‘n Things, each of which subsequently filed for bankruptcy, and Marshalls. In many cases, when a former subsidiary leased a store, the Company provided a guarantee of the former subsidiary’s lease obligations for the initial lease term and any extension thereof pursuant to a renewal option provided for in the lease prior to the time of the disposition. When the subsidiaries were disposed of and accounted for as discontinued operations, the Company’s guarantees remained in place, although each initial purchaser agreed to indemnify the Company for any lease obligations the Company was required to satisfy. If any of the purchasers or any of the former subsidiaries fail to make the required payments under a store lease, the Company could be required to satisfy those obligations, and any significant adverse impact of COVID-19 on such purchasers and/or former subsidiaries increases the risk that the Company will be required to satisfy those obligations. As of December 31, 2021, the Company guaranteed 72 such store leases (excluding the lease guarantees related to Linens ‘n Things, which have been recorded as a liability on the consolidated balance sheets), with the maximum remaining lease term extending through 2030.

Guaranty Fund Assessments, Market Stabilization and Other Non-Voluntary Risk Sharing Pools

Under guaranty fund laws existing in all states, insurers doing business in those states can be assessed (in most states up to prescribed limits) for certain obligations of insolvent insurance companies to policyholders and claimants. The life and health insurance guaranty associations in which the Company participates that operate under these laws respond to insolvencies of long-term care insurers and life insurers as well as health insurers. The Company’s assessments generally are based on a formula relating to the Company’s health care premiums in the state compared to the premiums of other insurers. Certain states allow assessments to be recovered over time as offsets to premium taxes. Some states have similar laws relating to HMOs and/or other payors such as not-for-profit consumer-governed health plans established under the ACA.

In 2009, the Pennsylvania Insurance Commissioner placed long-term care insurer Penn Treaty Network America Insurance Company and one of its subsidiaries (collectively, “Penn Treaty”) in rehabilitation, an intermediate action before insolvency, and subsequently petitioned a state court to convert the rehabilitation into a liquidation. Penn Treaty was placed in liquidation in March 2017. The Company has recorded a liability for its estimated share of future assessments by applicable life and health insurance guaranty associations. It is reasonably possible that in the future the Company may record a liability and expense relating to other insolvencies which could have a material adverse effect on the Company’s operating results, financial condition and cash flows, and the risk is heightened by any significant adverse impact of the COVID-19 pandemic on the solvency of other insurers, including long-term care and life insurers. While historically the Company has ultimately recovered more than half of guaranty fund assessments through statutorily permitted premium tax offsets, significant increases in assessments could lead to legislative and/or regulatory actions that limit future offsets.

HMOs in certain states in which the Company does business are subject to assessments, including market stabilization and other risk-sharing pools, for which the Company is assessed charges based on incurred claims, demographic membership mix and other factors. The Company establishes liabilities for these assessments based on applicable laws and regulations. In certain states, the ultimate assessments the Company pays are dependent upon the Company’s experience relative to other entities subject to the assessment, and the ultimate liability is not known at the financial statement date. While the ultimate amount of the assessment is dependent upon the experience of all pool participants, the Company believes it has adequate reserves to cover such assessments.

The Company’s total guaranty fund assessments liability was immaterial at both December 31, 2021 and 2020.

Litigation and Regulatory Proceedings

The Company has been involved or is currently involved in numerous legal proceedings, including litigation, arbitration, government investigations, audits, reviews and claims. These include routine, regular and special investigations, audits and reviews by CMS, state insurance and health and welfare departments, the U.S. Department of Justice (the “DOJ”), state attorneys general, the U.S. Drug Enforcement Administration (the “DEA”) and other governmental authorities.

Legal proceedings, in general, and securities, class action and multi-district litigation, in particular, and governmental special investigations, audits and reviews can be expensive and disruptive. Some of the litigation matters may purport or be determined
to be class actions and/or involve parties seeking large and/or indeterminate amounts, including punitive or exemplary damages, and may remain unresolved for several years. The Company also may be named from time to time in qui tam actions initiated by private third parties that could also be separately pursued by a governmental body. The results of legal proceedings, including government investigations, are often uncertain and difficult to predict, and the costs incurred in these matters can be substantial, regardless of the outcome.

The Company records accruals for outstanding legal matters when it believes it is probable that a loss will be incurred and the amount can be reasonably estimated. The Company evaluates, on a quarterly basis, developments in legal matters that could affect the amount of any accrual and developments that would make a loss contingency both probable and reasonably estimable. If a loss contingency is not both probable and reasonably estimable, the Company does not establish an accrued liability. None of the Company’s accruals for outstanding legal matters are material individually or in the aggregate to the Company’s financial condition.

Except as otherwise noted, the Company cannot predict with certainty the timing or outcome of the legal matters described below, and the Company is unable to reasonably estimate a possible loss or range of possible loss in excess of amounts already accrued for these matters. The Company believes that its defenses and assertions in pending legal proceedings have merit and does not believe that any of these pending matters, after consideration of applicable reserves and rights to indemnification, will have a material adverse effect on the Company’s financial position. Substantial unanticipated verdicts, fines and rulings, however, do sometimes occur, which could result in judgments against the Company, entry into settlements or a revision to its expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on its results of operations. In addition, as a result of governmental investigations or proceedings, the Company may be subject to damages, civil or criminal fines or penalties, or other sanctions including possible suspension or loss of licensure and/or exclusion from participating in government programs. The outcome of such governmental investigations of proceedings could be material to the Company.

Usual and Customary Pricing Litigation

The Company and certain current and former directors and officers are named as a defendant in a number of lawsuits that allege that the Company’s retail pharmacies overcharged for prescription drugs by not submitting the correct usual and customary price during the claims adjudication process. These actions are brought by a number of different types of plaintiffs, including plan members, private payors, government payors, and shareholders based on different legal theories. Some of these cases are brought as putative class actions, and in some instances, classes have been certified. The Company is defending itself against these claims.

PBM Litigation and Investigations

The Company is named as a defendant in a number of lawsuits and is subject to a number of investigations concerning its PBM practices.
The Company is facing multiple lawsuits, including by a State Attorney General, governmental subdivisions and several putative class actions, regarding drug pricing and its rebate arrangements with drug manufacturers. These complaints, brought by a number of different types of plaintiffs under a variety of legal theories, generally allege that rebate agreements between the drug manufacturers and PBMs caused inflated prices for certain drug products. The Company is defending itself against these claims. The Company has also received subpoenas, civil investigative demands (“CIDs”) and other requests for documents and information from, and is being investigated by, Attorneys General of multiple states and the District of Columbia regarding its PBM practices, including pricing and rebates. The Company has been providing documents and information in response to these subpoenas, CIDs and requests for information.

United States ex rel. Behnke v. CVS Caremark Corporation, et al. (U.S. District Court for the Eastern District of Pennsylvania). In April 2018, the Court unsealed a complaint filed in February 2014. The government has declined to intervene in this case. The relator alleges that the Company submitted, or caused to be submitted, to Part D of the Medicare program Prescription Drug Event data and/or Direct and Indirect Remuneration reports that misrepresented true prices paid by the Company’s PBM to pharmacies for drugs dispensed to Part D beneficiaries with prescription benefits administered by the Company’s PBM. The Company is defending itself against these claims.
Controlled Substances Litigation, Audits and Subpoenas

In December 2017, the U.S. Judicial Panel on Multidistrict Litigation consolidated numerous cases filed against various defendants by plaintiffs such as counties, cities, hospitals, Indian tribes and third-party payors, alleging claims generally concerning the impacts of widespread prescription opioid abuse. The consolidated multidistrict litigation captioned In re National Prescription Opiate Litigation (MDL No. 2804) is pending in the U.S. District Court for the Northern District of Ohio. This multidistrict litigation presumptively includes hundreds of relevant federal court cases that name the Company as a defendant. A significant number of similar cases that name the Company as a defendant in some capacity are pending in state courts. In addition, the Company has been named as a defendant in similar cases brought by certain state Attorneys General. The Company is defending itself against all such claims. Additionally, the Company has received subpoenas, CIDs and/or other requests for information regarding opioids from state Attorneys General and insurance and other regulators of several U.S. jurisdictions. The Company has been cooperating with the government with respect to these subpoenas, CIDs and other requests for information. In November 2021, the Company was among the chain pharmacies found liable by a jury in a trial in federal court in Ohio; the remedy pursuant to that verdict has not been determined and the Company plans to appeal.

In January 2020, the DOJ served the Company with a DEA administrative subpoena. The subpoena seeks documents relating to practices with respect to prescription opioids and other controlled substances at CVS Pharmacy locations concerning potential violations of the federal Controlled Substances Act and the federal False Claims Act. In January 2022, the DOJ served the Company with a CID regarding similar subjects. The Company is providing documents and information in response to these matters.

Prescription Processing Litigation and Investigations

The Company is named as a defendant in a number of lawsuits and is subject to a number of investigations concerning its prescription processing practices, including the following:

U.S. ex rel. Bassan et al. v. Omnicare, Inc. and CVS Health Corp. (U.S. District Court for the Southern District of New York). In December 2019, the U.S. Attorney’s Office for the Southern District of New York (the “SDNY”) filed a complaint-in-intervention in this previously sealed qui tam case. The complaint alleges that for certain non-skilled nursing facilities, Omnicare improperly filled prescriptions beyond one year where a valid prescription did not exist and that these dispensing events violated the federal False Claims Act. The Company is defending itself against these claims.

In July 2017, the Company also received a subpoena from the California Department of Insurance requesting documents concerning the Company’s Omnicare pharmacies’ cycle fill process for assisted living facilities. The Company has been cooperating with the California Department of Insurance and providing documents and information in response to this subpoena.

In December 2016, the Company received a CID from the U.S. Attorney’s Office for the Northern District of New York requesting documents and information in connection with a federal False Claims Act investigation concerning whether the Company’s retail pharmacies improperly submitted certain insulin claims to Part D of the Medicare program rather than Part B of the Medicare program. The Company has been cooperating with the government and providing documents and information in response to this CID.

Provider Proceedings

The Company is named as a defendant in purported class actions and individual lawsuits arising out of its practices related to the payment of claims for services rendered to its members by providers with whom the Company has a contract and with whom the Company does not have a contract (“out-of-network providers”). Among other things, these lawsuits allege that the Company paid too little to its health plan members and/or providers for out-of-network services and/or otherwise allege that the Company failed to timely or appropriately pay or administer out-of-network claims and benefits (including the Company’s post payment audit and collection practices and reductions in payments to providers due to sequestration). Other major health insurers are the subject of similar litigation or have settled similar litigation.

The Company also has received subpoenas and/or requests for documents and other information from, and been investigated by, state Attorneys General and other state and/or federal regulators, legislators and agencies relating to, and the Company is involved in other litigation regarding, its out-of-network benefit payment and administration practices. It is reasonably possible that others could initiate additional litigation or additional regulatory action against the Company with respect to its out-of-network benefit payment and/or administration practices.
CMS Actions

CMS regularly audits the Company’s performance to determine its compliance with CMS’s regulations and its contracts with CMS and to assess the quality of services it provides to Medicare beneficiaries. CMS uses various payment mechanisms to allocate and adjust premium payments to the Company’s and other companies’ Medicare plans by considering the applicable health status of Medicare members as supported by information prepared, maintained and provided by providers. The Company collects claim and encounter data from providers and generally relies on providers to appropriately code their submissions to the Company and document their medical records, including the diagnosis data submitted to the Company with claims. CMS pays increased premiums to Medicare Advantage plans and Medicare PDP plans for members who have certain medical conditions identified with specific diagnosis codes. Federal regulators review and audit the providers’ medical records to determine whether those records support the related diagnosis codes that determine the members’ health status and the resulting risk-adjusted premium payments to the Company. In that regard, CMS has instituted risk adjustment data validation (“RADV”) audits of various Medicare Advantage plans, including certain of the Company’s plans, to validate coding practices and supporting medical record documentation maintained by providers and the resulting risk adjusted premium payments to the plans. CMS may require the Company to refund premium payments if the Company’s risk adjusted premiums are not properly supported by medical record data. The Office of the Inspector General of the HHS (the “OIG”) also is auditing the Company’s risk adjustment-related data and that of other companies. The Company expects CMS and the OIG to continue these types of audits.

In 2012, CMS revised its audit methodology for RADV audits to determine refunds payable by Medicare Advantage plans for contract year 2011 and forward. Under the revised methodology, among other things, CMS will extrapolate the error rate identified in the audit sample of approximately 200 members to all risk adjusted premium payments made under the contract being audited. For contract years prior to 2011, CMS did not extrapolate sample error rates to the entire contract. As a result, the revised methodology may increase the Company’s exposure to premium refunds to CMS based on incomplete medical records maintained by providers. Since 2013, CMS has selected certain of the Company’s Medicare Advantage contracts for various contract years for RADV audit, and the number of RADV audits continues to increase. The Company is currently unable to predict which of its Medicare Advantage contracts will be selected for future audit, the amounts of any retroactive refunds of, or prospective adjustments to, Medicare Advantage premium payments made to the Company, the effect of any such refunds or adjustments on the actuarial soundness of the Company’s Medicare Advantage bids, or whether any RADV audit findings would require the Company to change its method of estimating future premium revenue in future bid submissions to CMS or compromise premium assumptions made in the Company’s bids for prior contract years, the current contract year or future contract years. Any premium or fee refunds or adjustments resulting from regulatory audits, whether as a result of RADV, Public Exchange related or other audits by CMS, the OIG or otherwise, including audits of the Company’s MLR rebates, methodology and/or reports, could be material and could adversely affect the Company’s operating results, cash flows and/or financial condition.

Medicare and Medicaid CIDs

The Company has received CIDs from the Civil Division of the DOJ in connection with a current investigation of the Company’s patient chart review processes in connection with risk adjustment data submissions under Parts C and D of the Medicare program. The Company has been cooperating with the government and providing documents and information in response to these CIDs.

In May 2017, the Company received a CID from the SDNY requesting documents and information concerning possible false claims submitted to Medicare in connection with reimbursements for prescription drugs under the Medicare Part D program. The Company has been cooperating with the government and providing documents and information in response to this CID.

Stockholder Matters

Beginning in February 2019, multiple class action complaints, as well as a derivative complaint, were filed by putative plaintiffs against the Company and certain current and former officers and directors. The plaintiffs in these cases assert a variety of causes of action under federal securities laws that are premised on allegations that the defendants made certain omissions and misrepresentations relating to the performance of the Company’s LTC business unit. The Company and its current and former officers and directors are defending themselves against these claims. Since filing, several of the cases have been consolidated, and the first-filed federal case, City of Miami Fire Fighters’ and Police Officers’ Retirement Trust, et al. (formerly known as Anarkat), was dismissed with prejudice in February 2021. Plaintiffs have appealed that decision to the First Circuit after their motion for reconsideration was denied. In re CVS Health Corp. Securities Act Litigation (formerly known as Waterford) and In
re CVS Health Corp. Securities Litigation (formerly known as City of Warren and Freundlich) have been stayed pending the outcome of the First Circuit appeal.

In August and September 2020, two class actions under the Employee Retirement Income Security Act of 1974 (“ERISA”) were filed in the U.S. District Court for the District of Connecticut against CVS Health, Aetna, and several current and former executives, directors and/or members of Aetna’s Compensation and Talent Management Committee: Radcliffe v. Aetna Inc., et al. and Flaim v. Aetna Inc., et al. The plaintiffs in these cases assert a variety of causes of action premised on allegations that the defendants breached fiduciary duties and engaged in prohibited transactions relating to participants in the Aetna 401(k) Plan’s investment in company stock between December 3, 2017 and February 20, 2019, claiming losses related to the performance of the Company’s LTC business unit. The district court consolidated the actions and the Company is defending itself against these claims. In October 2021, the consolidated case was dismissed without prejudice. Plaintiffs may seek leave to file an amended complaint. The Company also received a related document request pursuant to ERISA § 104(b), to which the Company has responded.

In December 2021, the Company received a demand for inspection of books and records pursuant to Delaware Corporation Law Section 220 (the “Demand”). The Demand purports to be related to potential breaches of fiduciary duties by the Board in relation to certain matters concerning opioids.

Other Legal and Regulatory Proceedings

The Company is also a party to other legal proceedings and is subject to government investigations, inquiries and audits and has received and is cooperating with the government in response to CIDs, subpoenas or similar process from various governmental agencies requesting information. These other legal proceedings and government actions include claims of or relating to bad faith, medical or professional malpractice, breach of fiduciary duty, claims processing, dispensing of medications, non-compliance with state and federal regulatory regimes, marketing misconduct, denial of or failure to timely or appropriately pay or administer claims and benefits, provider network structure (including the use of performance-based networks and termination of provider contracts), rescission of insurance coverage, improper disclosure or use of personal information, anticompetitive practices, general contractual matters, product liability, intellectual property litigation and employment litigation. Some of these other legal proceedings are or are purported to be class actions or derivative claims. The Company is defending itself against the claims brought in these matters.

Awards to the Company and others of certain government contracts, particularly Medicaid contracts and other contracts with government customers in the Company’s Health Care Benefits segment, frequently are subject to protests by unsuccessful bidders. These protests may result in awards to the Company being reversed, delayed or modified. The loss or delay in implementation of any government contract could adversely affect the Company’s operating results. The Company will continue to defend contract awards it receives.

There also continues to be a heightened level of review and/or audit by regulatory authorities and legislators of, and increased litigation regarding, the Company’s and the rest of the health care and related benefits industry’s business and reporting practices, including premium rate increases, utilization management, development and application of medical policies, complaint, grievance and appeal processing, information privacy, provider network structure (including provider network adequacy, the use of performance-based networks and termination of provider contracts), provider directory accuracy, calculation of minimum medical loss ratios and/or payment of related rebates, delegated arrangements, rescission of insurance coverage, limited benefit health products, student health products, pharmacy benefit management practices (including manufacturers’ rebates, pricing, the use of narrow networks and the placement of drugs in formulary tiers), sales practices, customer service practices, vendor oversight and claim payment practices (including payments to out-of-network providers).

As a leading national health solutions company, the Company regularly is the subject of government actions of the types described above. These government actions may prevent or delay the Company from implementing planned premium rate increases and may result, and have resulted, in restrictions on the Company’s businesses, changes to or clarifications of the Company’s business practices, retroactive adjustments to premiums, refunds or other payments to members, beneficiaries, states or the federal government, withholding of premium payments to the Company by government agencies, assessments of damages, civil or criminal fines or penalties, or other sanctions, including the possible suspension or loss of licensure and/or suspension or exclusion from participation in government programs.

The Company can give no assurance that its businesses, financial condition, operating results and/or cash flows will not be materially adversely affected, or that the Company will not be required to materially change its business practices, based on: (i) future enactment of new health care or other laws or regulations; (ii) the interpretation or application of existing laws or
regulations as they may relate to one or more of the Company’s businesses, one or more of the industries in which the Company competes and/or the health care industry generally; (iii) pending or future federal or state government investigations of one or more of the Company’s businesses, one or more of the industries in which the Company competes and/or the health care industry generally; (iv) pending or future government audits, investigations or enforcement actions against the Company; (v) adverse developments in any pending qui tam lawsuit against the Company, whether sealed or unsealed, or in any future qui tam lawsuit that may be filed against the Company; or (vi) adverse developments in pending or future legal proceedings against the Company or affecting one or more of the industries in which the Company competes and/or the health care industry generally.
XML 46 R26.htm IDEA: XBRL DOCUMENT v3.22.0.1
Segment Reporting
12 Months Ended
Dec. 31, 2021
Segment Reporting [Abstract]  
Segment Reporting Segment Reporting
The Company has three operating segments, Health Care Benefits, Pharmacy Services and Retail/LTC, as well as a Corporate/Other segment. The Company’s segments maintain separate financial information, and the Company’s chief operating decision maker (the “CODM”) evaluates the segments’ operating results on a regular basis in deciding how to allocate resources among the segments and in assessing segment performance. The CODM evaluates the performance of the Company’s segments based on adjusted operating income, which is defined as operating income (GAAP measure) excluding the impact of amortization of intangible assets and other items, if any, that neither relate to the ordinary course of the Company’s business nor reflect the Company’s underlying business performance. See the reconciliation of consolidated operating income (GAAP measure) to consolidated adjusted operating income below for further context regarding the items excluded from operating income in determining adjusted operating income. The Company uses adjusted operating income as its principal measure of segment performance as it enhances the Company’s ability to compare past financial performance with current performance and analyze underlying business performance and trends. Non-GAAP financial measures the Company discloses, such as consolidated adjusted operating income, should not be considered a substitute for, or superior to, financial measures determined or calculated in accordance with GAAP.

In 2021, 2020 and 2019, revenues from the federal government accounted for 17%, 16% and 16%, respectively, of the Company’s consolidated total revenues, primarily related to contracts with CMS for coverage of Medicare-eligible individuals within the Health Care Benefits segment.
The following is a reconciliation of financial measures of the Company’s segments to the consolidated totals:
In millionsHealth Care
Benefits
Pharmacy 
Services
(1)
Retail/
LTC
Corporate/
Other
Intersegment
Eliminations (2)
Consolidated
Totals
2021:
Revenues from external customers$81,515 $143,194 $66,078 $125 $— $290,912 
Intersegment revenues85 9,828 34,010 — (43,923)— 
Net investment income 586 — 17 596 — 1,199 
Total revenues82,186 153,022 100,105 721 (43,923)292,111 
  Adjusted operating income (loss) 5,012 6,859 7,623 (1,471)(711)17,312 
Depreciation and amortization1,837 576 1,884 215 — 4,512 
2020:
Revenues from external customers74,926 132,663 60,208 111 — 267,908 
Intersegment revenues58 9,275 30,990 — (40,323)— 
Net investment income483 — — 315 — 798 
Total revenues 75,467 141,938 91,198 426 (40,323)268,706 
  Adjusted operating income (loss) 6,188 5,688 6,146 (1,306)(708)16,008 
Depreciation and amortization1,832 612 1,801 196 — 4,441 
2019:
Revenues from external customers68,979 130,428 56,258 100 — 255,765 
Intersegment revenues26 11,063 30,350 — (41,439)— 
Net investment income599 — — 412 — 1,011 
Total revenues69,604 141,491 86,608 512 (41,439)256,776 
  Adjusted operating income (loss) 5,202 5,129 6,705 (1,000)(697)15,339 
Depreciation and amortization1,721 766 1,723 161 — 4,371 
_____________________________________________
(1)Total revenues of the Pharmacy Services segment include approximately $11.6 billion, $10.9 billion and $11.5 billion of retail co-payments for 2021, 2020 and 2019, respectively. See Note 1 ‘‘Significant Accounting Policies’’ for additional information about retail co-payments.
(2)Intersegment revenue eliminations relate to intersegment revenue generating activities that occur between the Health Care Benefits segment, the Pharmacy Services segment, and/or the Retail/LTC segment. Intersegment adjusted operating income eliminations occur when members of Pharmacy Services Segment clients (“PSS members”) enrolled in Maintenance Choice® elect to pick up maintenance prescriptions at one of the Company’s retail pharmacies instead of receiving them through the mail. When this occurs, both the Pharmacy Services and Retail/LTC segments record the adjusted operating income on a stand-alone basis.
The following is a reconciliation of consolidated operating income to adjusted operating income for the years ended December 31, 2021, 2020 and 2019:
In millions202120202019
Operating income (GAAP measure)$13,193 $13,911 $11,987 
Amortization of intangible assets (1)
2,259 2,341 2,436 
Acquisition-related integration costs (2)
132 332 480 
Store impairments (3)
1,358 — 231 
Goodwill impairment (4)
431 — — 
Acquisition purchase price adjustment outside of measurement period (5)
(61)— — 
(Gain) loss on divestiture of subsidiary (6)
— (269)205 
Receipt of fully reserved ACA risk corridor receivable (7)
— (307)— 
Adjusted operating income$17,312 $16,008 $15,339 
_____________________________________________
(1)The Company’s acquisition activities have resulted in the recognition of intangible assets as required under the acquisition method of accounting which consist primarily of trademarks, customer contracts/relationships, covenants not to compete, technology, provider networks and value of business acquired. Definite-lived intangible assets are amortized over their estimated useful lives and are tested for impairment when events indicate that the carrying value may not be recoverable. The amortization of intangible assets is reflected in the Company’s GAAP consolidated statements of operations in operating expenses within each segment. Although intangible assets contribute to the Company’s revenue generation, the amortization of intangible assets does not directly relate to the underwriting of the Company’s insurance products, the services performed for the Company’s customers or the sale of the Company’s products or services. Additionally, intangible asset amortization expense typically fluctuates based on the size and timing of the Company’s acquisition activity. Accordingly, the Company believes excluding the amortization of intangible assets enhances the Company’s and investors’ ability to compare the Company’s past financial performance with its current performance and to analyze underlying business performance and trends. Intangible asset amortization excluded from the related non-GAAP financial measure represents the entire amount recorded within the Company’s GAAP financial statements, and the revenue generated by the associated intangible assets has not been excluded from the related non-GAAP financial measure. Intangible asset amortization is excluded from the related non-GAAP financial measure because the amortization, unlike the related revenue, is not affected by operations of any particular period unless an intangible asset becomes impaired or the estimated useful life of an intangible asset is revised.
(2)In 2021, 2020 and 2019, acquisition-related integration costs relate to the Aetna Acquisition. The acquisition-related integration costs are reflected in the Company’s GAAP consolidated statements of operations in operating expenses within the Corporate/Other segment.
(3)During the year ended December 31, 2021, the store impairment charge relates to the write down of operating lease right-of-use assets and property and equipment in connection with the planned closure of approximately 900 retail stores between 2022 and 2024. During the year ended December 31, 2019, the store impairment charges related to the write down of operating lease right-of-use assets in connection with the planned closure of 68 underperforming retail pharmacy stores in 2019 and 2020. The store impairment charges are reflected in the Company’s GAAP consolidated statements of operations within the Retail/LTC segment.
(4)During the year ended December 31, 2021, the goodwill impairment charge relates to the LTC reporting unit within the Retail/LTC segment.
(5)In June 2021, the Company received $61 million related to a purchase price working capital adjustment for an acquisition completed during the first quarter of 2020. The resolution of this matter occurred subsequent to the acquisition accounting measurement period and is reflected in the Company’s GAAP consolidated statement of operations for the year ended December 31, 2021 as a reduction of operating expenses within the Health Care Benefits segment.
(6)In 2020, the gain on divestiture of subsidiary represents the pre-tax gain on the sale of the Workers’ Compensation business, which the Company sold on July 31, 2020 for approximately $850 million. The gain on divestiture is reflected as a reduction of operating expenses in the Company’s GAAP consolidated statement of operations within the Health Care Benefits segment. In 2019, the loss on divestiture of subsidiary represents the pre-tax loss on the sale of Onofre, which occurred on July 1, 2019. The loss on divestiture primarily relates to the elimination of the cumulative translation adjustment from accumulated other comprehensive income and is reflected in the Company’s GAAP consolidated statement of operations in operating expenses within the Retail/LTC segment.
(7)In 2020, the Company received $313 million owed to it under the ACA’s risk corridor program that was previously fully reserved for as payment was uncertain. After considering offsetting items such as the ACA’s minimum MLR rebate requirements and premium taxes, the Company recognized pre-tax income of $307 million in the Company’s GAAP consolidated statement of operations within the Health Care Benefits segment.
XML 47 R27.htm IDEA: XBRL DOCUMENT v3.22.0.1
Significant Accounting Policies (Policies)
12 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
Segment Policy
The Company has four reportable segments: Health Care Benefits, Pharmacy Services, Retail/LTC and Corporate/Other, which are described below.

Health Care Benefits Segment
The Health Care Benefits segment operates as one of the nation’s leading diversified health care benefits providers. The Health Care Benefits segment has the information and resources to help members, in consultation with their health care professionals, make more informed decisions about their health care. The Health Care Benefits segment offers a broad range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, medical management capabilities, Medicare Advantage and Medicare Supplement plans, PDPs, Medicaid health care management services and health information technology products and services. The Health Care Benefits segment also provided workers’ compensation administrative services through its Coventry Health Care Workers’ Compensation business (“Workers’ Compensation business”) prior to the sale of this business on July 31, 2020. The Health Care Benefits segment’s customers include employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers (“providers”), governmental units, government-sponsored plans, labor groups and expatriates. The Company refers to insurance products (where it assumes all or a majority of the risk for medical and dental care costs) as “Insured” and administrative services contract products (where the plan sponsor assumes all or a majority of the risk for medical and dental care costs) as “ASC.” In addition, effective January 2022, the Company entered the individual public health insurance exchanges (“Public Exchanges”) in eight states through which it sells Insured plans directly to individual consumers.

Pharmacy Services Segment
The Pharmacy Services segment provides a full range of pharmacy benefit management (“PBM”) solutions, including plan design offerings and administration, formulary management, retail pharmacy network management services and mail order pharmacy. In addition, through the Pharmacy Services segment, the Company provides specialty pharmacy and infusion services, clinical services, disease management services, medical spend management and pharmacy and/or other administrative services for providers and federal 340B drug pricing program covered entities (“Covered Entities”). The Pharmacy Services segment’s clients are primarily employers, insurance companies, unions, government employee groups, health plans, PDPs, Medicaid managed care plans, plans offered on Public Exchanges and private health insurance exchanges, other sponsors of health benefit plans throughout the United States and Covered Entities. The Pharmacy Services segment operates retail specialty pharmacy stores, specialty mail order pharmacies, mail order dispensing pharmacies, compounding pharmacies and branches for infusion and enteral nutrition services.

Retail/LTC Segment
The Retail/LTC segment sells prescription drugs and a wide assortment of health and wellness products and general merchandise, provides health care services through its MinuteClinic® walk-in medical clinics, provides medical diagnostic testing, administers vaccinations for illnesses such as influenza, COVID-19 and shingles and conducts long-term care pharmacy (“LTC”) operations, which distribute prescription drugs and provide related pharmacy consulting and other ancillary services to long-term care facilities and other care settings. As of December 31, 2021, the Retail/LTC segment operated more than 9,900 retail locations, nearly 1,200 MinuteClinic locations as well as online retail pharmacy websites, LTC pharmacies and on-site pharmacies.
Corporate/Other Segment
The Company presents the remainder of its financial results in the Corporate/Other segment, which primarily consists of:

Management and administrative expenses to support the Company’s overall operations, which include certain aspects of executive management and the corporate relations, legal, compliance, human resources, information technology and finance departments, expenses associated with the Company’s investments in its transformation and enterprise modernization programs and acquisition-related transaction and integration costs; and
Products for which the Company no longer solicits or accepts new customers such as its large case pensions and long-term care insurance products.
Basis of Presentation
Basis of Presentation

The accompanying consolidated financial statements of CVS Health and its subsidiaries have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The consolidated financial statements include the accounts of the Company and its majority-owned subsidiaries and variable interest entities (“VIEs”) for which the Company is the primary beneficiary. All material intercompany balances and transactions have been eliminated.
Reclassifications
Reclassifications

Certain prior year amounts have been reclassified to conform with the current year presentation.
Use of Estimates Use of EstimatesThe preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates.
Cash and Cash Equivalents and Restricted Cash
Cash and Cash Equivalents

Cash and cash equivalents consist of cash and temporary investments with maturities of three months or less when purchased. The Company invests in short-term money market funds, commercial paper and time deposits, as well as other debt securities that are classified as cash equivalents within the accompanying consolidated balance sheets, as these funds are highly liquid and readily convertible to known amounts of cash.

Restricted Cash

Restricted cash (included in other current assets) represents funds held on behalf of members, including health savings account (“HSA”) funds associated with high deductible health plans. Beginning in 2021, the Company began presenting these funds held on behalf of members in restricted cash and, for statement of cash flow purposes, retrospectively adjusted the 2020 and 2019 balances by the amounts shown in the table below in the line item “restricted cash (included in other current assets)” to conform with the current year presentation. Restricted cash (included in other assets) represents amounts held in a trust in one of the Company’s captive insurance companies to satisfy collateral requirements associated with the assignment of certain insurance policies. All restricted cash is invested in time deposits, money market funds or commercial paper.
Investments
Investments

Debt Securities
Debt securities consist primarily of U.S. Treasury and agency securities, mortgage-backed securities, corporate and foreign bonds and other debt securities. Debt securities are classified as either current or long-term investments based on their contractual maturities unless the Company intends to sell an investment within the next twelve months, in which case it is classified as current on the consolidated balance sheets. Debt securities are classified as available for sale and are carried at fair value. See Note 4 ‘‘Fair Value’’ for additional information on how the Company estimates the fair value of these investments.

If a debt security is in an unrealized loss position and the Company has the intent to sell the security, or it is more likely than not that the Company will have to sell the security before recovery of its amortized cost basis, the amortized cost basis of the security is written down to its fair value and the difference is recognized in net income. If a debt security is in an unrealized loss position and the Company does not have the intent to sell and it is more likely than not that the Company will not have to sell such security before recovery of its amortized cost basis, the Company bifurcates the impairment into credit-related and non-credit related components. In evaluating whether a credit related loss exists, the Company considers a variety of factors including: the extent to which the fair value is less than the amortized cost basis; adverse conditions specifically related to the issuer of a security, an industry or geographic area; the payment structure of the security; the failure of the issuer of the security to make scheduled interest or principal payments; and any changes to the rating of the security by a rating agency. The amount of the credit-related component is recorded as an allowance for credit losses and recognized in net income, and the amount of the non-credit related component is included in other comprehensive income. Interest is not accrued on debt securities when management believes the collection of interest is unlikely.

The credit-related component is determined by comparing the present value of cash flows expected to be collected from the security, considering all reasonably available information relevant to the collectability of the security, with the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis of the security, the Company records an allowance for credit losses, which is limited by the amount that the fair value is less than amortized cost basis.

For mortgage-backed and other asset-backed securities, the Company recognizes income using an effective yield based on anticipated prepayments and the estimated economic life of the securities. When estimates of prepayments change, the effective yield is recalculated to reflect actual payments to date and anticipated future payments. The Company’s investment in the security is adjusted to the amount that would have existed had the new effective yield been applied since the acquisition of the security, with adjustments recognized in net income.

Equity Securities
Equity securities with readily available fair values are measured at fair value with changes in fair value recognized in net income (loss).

Mortgage Loans
Mortgage loan investments on the consolidated balance sheets are valued at the unpaid principal balance, net of an allowance for credit losses. Mortgage loans with a maturity date or a committed prepayment date within twelve months are classified as current on the consolidated balance sheets. The Company assesses whether its loans share similar risk characteristics and, if so, groups such loans in a risk pool when measuring expected credit losses. The Company considers the following characteristics when evaluating whether its loans share similar risk characteristics: loan-to-value ratios, property type (e.g., office, retail, apartment, industrial), geographic location, vacancy rates and property condition.

Credit loss reserves are determined using a loss rate method that multiplies the unpaid principal balance of each loan within a risk pool group by an estimated loss rate percentage. The loss rate percentage considers both the expected loan loss severity and the probability of loan default. For periods where the Company is able to make or obtain reasonable and supportable forecasts of expected economic conditions (e.g., gross domestic product, employment), the Company adjusts its expected loss rates to reflect these forecasted economic conditions. For periods beyond which the Company is able to make or obtain reasonable and supportable forecasts of expected economic conditions, the Company reverts to historical loss rates in determining expected credit losses.

Interest income on a potential problem loan (i.e., high probability of default) or restructured loan is accrued to the extent it is deemed to be collectible and the loan continues to perform under its original or restructured terms. Interest income on problem loans (i.e., more than 60 days delinquent, in bankruptcy or in process of foreclosure) is recognized on a cash basis. Cash payments on loans in the process of foreclosure are treated as a return of principal.
Other Investments
Other investments consist primarily of the following:

Private equity and hedge fund limited partnerships, which are accounted for using the equity method of accounting. Under this method, the carrying value of the investment is based on the value of the Company’s equity ownership of the underlying investment funds provided by the general partner or manager of the investments, the financial statements of which generally are audited. As a result of the timing of the receipt of the valuation information provided by the fund managers, these investments are generally reported on up to a three month lag. The Company reviews investments for impairment at least quarterly and monitors their performance throughout the year through discussions with the administrators, managers and/or general partners. If the Company becomes aware of an impairment of a limited partnership’s investments through its review or prior to receiving the limited partnership’s financial statements at the financial statement date, an impairment will be recognized by recording a reduction in the carrying value of the limited partnership with a corresponding charge to net investment income.
Investment real estate, which is carried on the consolidated balance sheets at depreciated cost, including capital additions, net of write-downs for other-than-temporary declines in fair value. Depreciation is calculated using the straight-line method based on the estimated useful life of each asset. If any real estate investment is considered held-for-sale, it is carried at the lower of its carrying value or fair value less estimated selling costs. The Company generally estimates fair value using net operating income and applying a capitalization rate in conjunction with comparable sales information. At the time of the sale, the difference between the sales price and the carrying value is recorded as a realized capital gain or loss.
Privately-placed equity securities, which are carried on the consolidated balance sheets at cost less impairments, plus or minus subsequent adjustments for observable price changes. Additionally, as a member of the Federal Home Loan Bank of Boston (“FHLBB”), a subsidiary of the Company is required to purchase and hold shares of the FHLBB. These shares are restricted and carried at cost.

Net Investment Income
Net investment income on the Company’s investments is recorded when earned and is reflected in the Company’s net income (other than net investment income on assets supporting experience-rated products). Experience-rated products are products in the large case pensions business where the contract holder, not the Company, assumes investment and other risks, subject to, among other things, minimum guarantees provided by the Company. The effect of investment performance on experience-rated products is allocated to contract holders’ accounts daily, based on the underlying investment experience and, therefore, does not impact the Company’s net income (as long as the contract’s minimum guarantees are not triggered). Net investment income on assets supporting large case pensions’ experience-rated products is included in net investment income in the consolidated statements of operations and is credited to contract holders’ accounts through a charge to benefit costs. The contract holders’ accounts are reflected in policyholders’ funds on the consolidated balance sheets.

Realized capital gains and losses on investments (other than realized capital gains and losses on investments supporting experience-rated products) are included as a component of net investment income in the consolidated statements of operations. Realized capital gains and losses are determined on a specific identification basis. Purchases and sales of debt and equity securities and alternative investments are reflected on the trade date. Purchases and sales of mortgage loans and investment real estate are reflected on the closing date.

Realized capital gains and losses on investments supporting large case pensions’ experience-rated products are not included in realized capital gains and losses in the consolidated statements of operations and instead are credited directly to contract holders’ accounts. The contract holders’ accounts are reflected in policyholders’ funds on the consolidated balance sheets.

Unrealized capital gains and losses on investments (other than unrealized capital gains and losses on investments supporting experience-rated products) are reflected in shareholders’ equity, net of tax, as a component of accumulated other comprehensive income. Unrealized capital gains and losses on investments supporting large case pensions’ experience-rated products are credited directly to contract holders’ accounts. The contract holders’ accounts are reflected in policyholders’ funds on the consolidated balance sheets.
Derivative Financial Instruments
Derivative Financial Instruments

The Company uses derivative financial instruments in order to manage interest rate and foreign exchange risk and credit exposure. The Company’s use of these derivatives is generally limited to hedging risk and has principally consisted of using interest rate swaps, treasury rate locks, forward contracts, futures contracts, warrants, put options and credit default swaps.
Accounts Receivable Accounts ReceivableAccounts receivable are stated net of allowances for credit losses, customer credit allowances, contractual allowances and estimated terminations.When developing an estimate of the Company’s expected credit losses, the Company considers all available relevant information regarding the collectability of cash flows, including historical information, current conditions and reasonable and supportable forecasts of future economic conditions over the contractual life of the receivable. The Company’s accounts receivable are short duration in nature and typically settle in less than 30 days.
Inventories Inventories Inventories are valued at the lower of cost or net realizable value using the weighted average cost method. Physical inventory counts are taken on a regular basis in each retail store and LTC pharmacy, and a continuous cycle count process is the primary procedure used to validate the inventory balances on hand in each distribution center and mail facility to ensure that the amounts reflected in the consolidated financial statements are properly stated. During the interim period between physical inventory counts, the Company accrues for anticipated physical inventory losses on a location-by-location basis based on historical results and current physical inventory trends.
Reinsurance Recoverables
Reinsurance Recoverables

The Company utilizes reinsurance agreements primarily to: (a) reduce required capital and (b) facilitate the acquisition or disposition of certain insurance contracts. Ceded reinsurance agreements permit the Company to recover a portion of its losses from reinsurers, although they do not discharge the Company’s primary liability as the direct insurer of the risks reinsured. Failure of reinsurers to indemnify the Company could result in losses; however, the Company does not expect charges for unrecoverable reinsurance to have a material effect on its consolidated operating results or financial condition. The Company evaluates the financial condition of its reinsurers and monitors concentrations of credit risk arising from similar geographic regions, activities or economic characteristics of its reinsurers. At December 31, 2021, the Company’s reinsurance recoverables consisted primarily of amounts due from third parties that are rated consistent with companies that are considered to have the ability to meet their obligations. Reinsurance recoverables are recorded as other current assets or other assets on the consolidated balance sheets.
Health Care Contract Acquisition Costs Health Care Contract Acquisition CostsInsurance products included in the Health Care Benefits segment are cancellable by either the customer or the member monthly upon written notice. Acquisition costs related to prepaid health care and health indemnity contracts are generally expensed as incurred. Acquisition costs for certain long-duration insurance contracts are deferred and are recorded as other current assets or other assets on the consolidated balance sheets and are amortized over the estimated life of the contracts. The amortization of deferred acquisition costs is recorded in operating expenses in the consolidated statements of operations.
Property and Equipment
Property and Equipment

Property and equipment is reported at historical cost, net of accumulated depreciation. Property, equipment and improvements to leased premises are depreciated using the straight-line method over the estimated useful lives of the assets, or when applicable, the term of the lease, whichever is shorter. Estimated useful lives generally range from 1 to 40 years for buildings, building improvements and leasehold improvements and 3 to 10 years for fixtures, equipment and internally developed software. Repair and maintenance costs are charged directly to expense as incurred. Major renewals or replacements that
substantially extend the useful life of an asset are capitalized and depreciated. Application development stage costs for significant internally developed software projects are capitalized and depreciated.
Right-of-Use Assets and Lease Liabilities
Right-of-Use Assets and Lease Liabilities

The Company determines if an arrangement contains a lease at the inception of a contract. Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at the commencement date of the lease, renewal date of the lease or significant remodeling of the lease space based on the present value of the remaining future minimum lease payments. As the interest rate implicit in the Company’s leases is not readily determinable, the Company utilizes its incremental borrowing rate, determined by class of underlying asset, to discount the lease payments. The operating lease right-of-use assets also include lease payments made before commencement and are reduced by lease incentives.

The Company’s real estate leases typically contain options that permit renewals for additional periods of up to five years each. For real estate leases, the options to extend are not considered reasonably certain at lease commencement because the Company reevaluates each lease on a regular basis to consider the economic and strategic incentives of exercising the renewal options and regularly opens or closes stores to align with its operating strategy. Generally, the renewal option periods are not included within the lease term and the associated payments are not included in the measurement of the right-of-use asset and lease liability. Similarly, renewal options are not included in the lease term for non-real estate leases because they are not considered reasonably certain of being exercised at lease commencement. Leases with an initial term of 12 months or less are not recorded on the balance sheets, and lease expense is recognized on a straight-line basis over the term of the short-term lease.

For real estate leases, the Company accounts for lease components and nonlease components as a single lease component. Certain real estate leases require additional payments based on sales volume, as well as reimbursement for real estate taxes, common area maintenance and insurance, which are expensed as incurred as variable lease costs. Other real estate leases contain one fixed lease payment that includes real estate taxes, common area maintenance and insurance. These fixed payments are considered part of the lease payment and included in the right-of-use assets and lease liabilities.
See Note 6 ‘‘Leases’’ for additional information about right-of-use assets and lease liabilities.
Goodwill Goodwill The Company accounts for business combinations using the acquisition method of accounting, which requires the excess cost of an acquisition over the fair value of net assets acquired and identifiable intangible assets to be recorded as goodwill. Goodwill is not amortized, but is subject to impairment reviews annually, or more frequently if necessary, as further described in “Long-Lived Asset Impairment” below.
Intangible Assets
Intangible Assets

The Company’s identifiable intangible assets consist primarily of trademarks, trade names, customer contracts/relationships, covenants not to compete, technology, provider networks and value of business acquired (“VOBA”). These intangible assets arise primarily from the determination of their respective fair market values at the date of acquisition. Amounts assigned to identifiable intangible assets, and their related useful lives, are derived from established valuation techniques and management estimates.

The Company’s definite-lived intangible assets are amortized over their estimated useful lives based upon the pattern of future cash flows attributable to the asset. Other than VOBA, definite-lived intangible assets are amortized using the straight-line method. VOBA is amortized over the expected life of the acquired contracts in proportion to estimated premiums. Indefinite-lived intangible assets are not amortized but are tested for impairment annually, or more frequently if necessary, as further described in “Long-Lived Asset Impairment” below.
Long-Lived Asset Impairment
Long-Lived Asset Impairment

The Company evaluates the recoverability of long-lived assets, excluding goodwill and indefinite-lived intangible assets, which are tested for impairment using separate tests described below, whenever events or changes in circumstances indicate that the carrying value of such asset may not be recoverable. The Company groups and evaluates these long-lived assets for impairment at the lowest level at which individual cash flows can be identified. If indicators of impairment are present, the Company first compares the carrying amount of the asset group to the estimated future cash flows associated with the asset group (undiscounted). If the estimated future cash flows used in this analysis are less than the carrying amount of the asset group, an impairment loss calculation is prepared. The impairment loss calculation compares the carrying amount of the asset group to the asset group’s estimated future cash flows (discounted). If required, an impairment loss is recorded for the portion of the asset group’s carrying value that exceeds the asset group’s estimated future cash flows (discounted). During the year ended December 31, 2021, the Company recorded a store impairment charge of approximately $1.4 billion primarily related to the write down of operating lease right-of-use assets and property and equipment in connection with the planned closure of approximately 900 retail stores between 2022 and 2024. There were no material impairment charges recognized on long-lived assets in the year ended 2020. During the year ended December 31, 2019 the Company recorded a store impairment charge of $231 million primarily related to operating lease right-of-use assets. See Note 6 ‘‘Leases’’ for additional information about the right-of-use asset impairment charges.

When evaluating goodwill for potential impairment, the Company compares the fair value of its reporting units to their respective carrying amounts. The Company estimates the fair value of its reporting units using a combination of a discounted cash flow method and a market multiple method. If the carrying amount of a reporting unit exceeds its estimated fair value, an impairment loss is recognized in an amount equal to that excess. During the third quarter of 2021, the Company performed its required annual impairment tests of goodwill, the results of which indicated an impairment of the goodwill associated with the LTC reporting unit. Accordingly, during the third quarter of 2021, the Company recorded a $431 million goodwill impairment charge. The results of the impairment tests indicated that there was no impairment of goodwill of the remaining reporting units as of the testing date or during the year ended December 31, 2021. During the third quarter of both 2020 and 2019, the Company performed its required annual goodwill impairment tests and concluded there were no goodwill impairments as of the testing dates or during the years ended December 31, 2020 and 2019. See Note 5 ‘‘Goodwill and Other Intangibles’’ for additional information about the goodwill impairment charge recorded during the year ended December 31, 2021.
Indefinite-lived intangible assets are tested for impairment by comparing the estimated fair value of the asset to its carrying value. The Company estimates the fair value of its indefinite-lived trademarks using the relief from royalty method under the income approach. If the carrying value of the asset exceeds its estimated fair value, an impairment loss is recognized, and the asset is written down to its estimated fair value.
Separate Accounts
Separate Accounts

Separate Accounts assets and liabilities related to large case pensions products represent funds maintained to meet specific objectives of contract holders who bear the investment risk. These assets and liabilities are carried at fair value. Net investment income (including net realized capital gains and losses) accrue directly to such contract holders. The assets of each account are legally segregated and are not subject to claims arising from the Company’s other businesses. Deposits, withdrawals and net
investment income (including net realized and net unrealized capital gains and losses) on Separate Accounts assets are not reflected in the consolidated statements of operations or cash flows. Management fees charged to contract holders are included in services revenue and recognized over the period earned.
Health Care Costs Payable
Health Care Costs Payable

Health care costs payable consist principally of unpaid fee-for-service medical, dental and pharmacy claims, capitation costs, other amounts due to providers pursuant to risk-sharing arrangements related to the Health Care Benefits segment’s Insured Commercial, Medicare and Medicaid products and accruals for state assessments. Unpaid health care claims include an estimate of payments the Company will make for (i) services rendered to the Company’s Insured members but not yet reported to the Company and (ii) claims which have been reported to the Company but not yet paid, each as of the financial statement date (collectively, “IBNR”). Health care costs payable also include an estimate of the cost of services that will continue to be rendered after the financial statement date if the Company is obligated to pay for such services in accordance with contractual or regulatory requirements. Such estimates are developed using actuarial principles and assumptions which consider, among other things, historical and projected claim submission and processing patterns, assumed and historical medical cost trends, historical utilization of medical services, claim inventory levels, changes in Insured membership and product mix, seasonality and other relevant factors. The Company reflects changes in these estimates in benefit costs in the Company’s consolidated operating results in the period they are determined. Capitation costs represent contractual monthly fees paid to participating physicians and other medical providers for providing medical care, regardless of the volume of medical services provided to the Insured member. Amounts due under risk-sharing arrangements are based on the terms of the underlying contracts with the providers and consider claims experience under the contracts through the financial statement date.

The Company develops its estimate of IBNR using actuarial principles and assumptions that consider numerous factors. Of those factors, the Company considers the analysis of historical and projected claim payment patterns (including claims submission and processing patterns) and the assumed health care cost trend rate (the year-over-year change in per member per month health care costs) to be the most critical assumptions. In developing its IBNR estimate, the Company consistently applies these actuarial principles and assumptions each period, with consideration to the variability of related factors. There have been no significant changes to the methodologies or assumptions used to develop the Company’s estimate of IBNR in 2021.

The Company analyzes historical claim payment patterns by comparing claim incurred dates (i.e., the date services were provided) to claim payment dates to estimate “completion factors.” The Company uses completion factors predominantly to estimate the ultimate cost of claims incurred more than three months before the financial statement date. The Company estimates completion factors by aggregating claim data based on the month of service and month of claim payment and estimating the percentage of claims incurred for a given month that are complete by each month thereafter. For any given month, substantially all claims are paid within six months of the date of service, but it can take up to 48 months or longer after the date of service before all of the claims are completely resolved and paid. These historically-derived completion factors are then applied to claims paid through the financial statement date to estimate the ultimate claim cost for a given month’s incurred claim activity. The difference between the estimated ultimate claim cost and the claims paid through the financial statement date represents the Company’s estimate of claims remaining to be paid as of the financial statement date and is included in the Company’s health care costs payable. The completion factors the Company uses reflect judgments and possible adjustments based on data such as claim inventory levels, claim submission and processing patterns and, to a lesser extent, other factors such as changes in health care cost trend rates, changes in Insured membership and changes in product mix. If claims are submitted or processed on a faster (slower) pace than prior periods, the actual claims may be more (less) complete than originally estimated using the Company’s completion factors, which may result in reserves that are higher (lower) than the ultimate cost of claims.

Because claims incurred within three months before the financial statement date are less mature, the Company uses a combination of historically-derived completion factors and the assumed health care cost trend rate to estimate the ultimate cost of claims incurred for these months. The Company applies its actuarial judgment and places a greater emphasis on the assumed health care cost trend rate for the most recent claim incurred dates as these months may be influenced by seasonal patterns and changes in membership and product mix.

The Company’s health care cost trend rate is affected by changes in per member utilization of medical services as well as changes in the unit cost of such services. Many factors influence the health care cost trend rate, including the Company’s ability to manage benefit costs through product design, negotiation of favorable provider contracts and medical management programs, as well as the mix of the Company’s business. The health status of the Company’s Insured members, aging of the population and other demographic characteristics, advances in medical technology and other factors continue to contribute to rising per member utilization and unit costs. Changes in health care practices, inflation, new technologies, increases in the cost of
prescription drugs (including specialty pharmacy drugs), direct-to-consumer marketing by pharmaceutical companies, clusters of high-cost cases, claim intensity, changes in the regulatory environment, health care provider or member fraud and numerous other factors also contribute to the cost of health care and the Company’s health care cost trend rate.

For each reporting period, the Company uses an extensive degree of judgment in the process of estimating its health care costs payable. As a result, considerable variability and uncertainty is inherent in such estimates, particularly with respect to claims with claim incurred dates of three months or less before the financial statement date; and the adequacy of such estimates is highly sensitive to changes in assumed completion factors and the assumed health care cost trend rates. For each reporting period the Company recognizes the actuarial best estimate of health care costs payable considering the potential volatility in assumed completion factors and health care cost trend rates, as well as other factors. The Company believes its estimate of health care costs payable is reasonable and adequate to cover its obligations at December 31, 2021; however, actual claim payments may differ from the Company’s estimates. A worsening (or improvement) of the Company’s health care cost trend rates or changes in completion factors from those that the Company assumed in estimating health care costs payable at December 31, 2021 would cause these estimates to change in the near term, and such a change could be material.

Each quarter, the Company re-examines previously established health care costs payable estimates based on actual claim payments for prior periods and other changes in facts and circumstances. Given the extensive degree of judgment in this estimate, it is possible that the Company’s estimates of health care costs payable could develop either favorably (that is, its actual benefit costs for the period were less than estimated) or unfavorably. The changes in the Company’s estimate of health care costs payable may relate to a prior quarter, prior year or earlier periods. For a roll forward of the Company’s health care costs payable, see Note 7 ‘‘Health Care Costs Payable.’’ The Company’s reserving practice is to consistently recognize the actuarial best estimate of its ultimate liability for health care costs payable.
Other Insurance Liabilities
Other Insurance Liabilities

Unpaid Claims
Unpaid claims consist primarily of reserves associated with certain short-duration group disability and term life insurance contracts, including an estimate for IBNR as of the financial statement date. Reserves associated with certain short-duration group disability and term life insurance contracts are based upon the Company’s estimate of the present value of future benefits, which is based on assumed investment yields and assumptions regarding mortality, morbidity and recoveries from the U.S. Social Security Administration. The Company develops its estimate of IBNR using actuarial principles and assumptions which consider, among other things, contractual requirements, claim incidence rates, claim recovery rates, seasonality and other relevant factors. The Company discounts certain claim liabilities related to group long-term disability and life insurance waiver of premium contracts. The discount rates generally reflect the Company’s expected investment returns for the investments supporting all incurral years of these liabilities. The discount rates for retrospectively-rated contracts are set at contractually specified levels. The Company’s estimates of unpaid claims are subject to change due to changes in the underlying experience of the insurance contracts, changes in investment yields or other factors, and these changes are recorded in current and future benefits in the consolidated statements of operations in the period they are determined. The Company estimates its reserve for claims IBNR for life products largely based on completion factors. The completion factors used are based on the Company’s historical experience and reflect judgments and possible adjustments based on data such as claim inventory levels, claim payment patterns, changes in business volume and other factors. If claims are submitted or processed on a faster (slower) pace than historical periods, the actual claims may be more (less) complete than originally estimated using completion factors, which may result in reserves that are higher (lower) than required to cover future life benefit payments. There have been no significant changes to the methodologies or assumptions used to develop the Company’s estimate of unpaid claims IBNR in 2021. As of December 31, 2021, unpaid claims balances of $324 million and $1.3 billion were recorded in other insurance liabilities and other long-term insurance liabilities, respectively. As of December 31, 2020, unpaid claims balances of $532 million and $1.5 billion were recorded in other insurance liabilities and other long-term insurance liabilities, respectively.

Substantially all life and disability insurance liabilities have been fully ceded to unrelated third parties through indemnity reinsurance agreements; however, the Company remains directly obligated to the policyholders.

Future Policy Benefits
Future policy benefits consist primarily of reserves for limited payment pension and annuity contracts and long-term care insurance contracts. Reserves for limited payment pension and annuity contracts are computed using actuarial principles that consider, among other things, assumptions reflecting anticipated mortality, retirement, expense and interest rate experience. Such assumptions generally vary by plan, year of issue and policy duration. Assumed interest rates on such contracts ranged from 3.0% to 11.3% in the year ended December 31, 2021 and from 3.3% to 11.3% in the year ended December 31, 2020. The Company periodically reviews mortality assumptions against both industry standards and its experience. Reserves for long-
duration long-term care contracts represent the Company’s estimate of the present value of future benefits and essential maintenance expenses to be paid to or on behalf of policyholders less the present value of future gross premiums. The assumed interest rate on such contracts was 5.1% in both the years ended December 31, 2021 and 2020. The Company’s estimate of the present value of future benefits under such contracts is based upon mortality, morbidity and interest rate assumptions.
Premium Deficiency Reserves Premium Deficiency ReservesThe Company evaluates its insurance contracts to determine if it is probable that a loss will be incurred. A premium deficiency loss is recognized when it is probable that expected future claims, including maintenance costs (for example, direct costs such as claim processing costs), will exceed existing reserves plus anticipated future premiums and reinsurance recoveries. Anticipated investment income is not considered in the calculation of premium deficiency losses for short-duration contracts. For purposes of determining premium deficiency losses, contracts are grouped consistent with the Company’s method of acquiring, servicing and measuring the profitability of such contracts.
Policyholders' Funds
Policyholders’ Funds

Policyholders’ funds consist primarily of reserves for pension and annuity investment contracts and customer funds associated with certain health contracts. Reserves for such contracts are equal to cumulative deposits less withdrawals and charges plus interest credited thereon, net of experience-rated adjustments. In 2021, interest rates for pension and annuity investment contracts ranged from 3.5% to 4.8%. In 2020, interest rates for pension and annuity investment contracts ranged from 4.1% to 5.1%. Reserves for contracts subject to experience rating reflect the Company’s rights as well as the rights of policyholders and plan participants. The Company also holds funds for HSAs on behalf of members associated with high deductible health plans. These amounts are held to pay for qualified health care expenses incurred by these members. The HSA balances were approximately $2.9 billion and $2.7 billion at December 31, 2021 and 2020, respectively, and are reflected in other current assets with a corresponding liability in policyholders’ funds. These assets are considered restricted cash for cash flow statement purposes.
Policyholders’ funds liabilities that are expected to be paid within twelve months from the balance sheet date are classified as current on the consolidated balance sheets. Policyholders’ funds liabilities that are expected to be paid greater than twelve months from the balance sheet date are included in other long-term liabilities on the consolidated balance sheets.
Self-Insurance Liabilities Self-Insurance LiabilitiesThe Company is self-insured for certain losses related to general liability, workers’ compensation and auto liability. The Company obtains third party insurance coverage to limit exposure from these claims. The Company is also self-insured for certain losses related to health and medical liabilities. The Company’s self-insurance accruals, which include reported claims and claims incurred but not reported, are calculated using standard insurance industry actuarial assumptions and the Company’s historical claims experience.
Foreign Currency Translation and Transactions
Foreign Currency Translation and Transactions

For non-U.S. dollar functional currency locations, (i) assets and liabilities are translated at end-of-period exchange rates, (ii) revenues and expenses are translated at average exchange rates in effect during the period and (iii) equity is translated at historical exchange rates. The resulting cumulative translation adjustments are included as a component of accumulated other comprehensive income.

For U.S. dollar functional currency locations, foreign currency assets and liabilities are remeasured into U.S. dollars at end-of-period exchange rates, except for nonmonetary balance sheet accounts which are remeasured at historical exchange rates. Revenues and expenses are remeasured at average exchange rates in effect during each period, except for those expenses related to the nonmonetary balance sheet amounts which are remeasured at historical exchange rates. Gains or losses from foreign currency remeasurement are included in net income.
Revenue Recognition
Revenue Recognition

Health Care Benefits Segment
Health Care Benefits revenue is principally derived from insurance premiums and fees billed to customers. Revenue is recognized based on customer billings, which, in the Company’s Commercial business, reflect contracted rates per member and the number of covered members recorded in the Company’s records at the time the billings are prepared. Billings are generally sent monthly for coverage during the following month. Revenue related to the Company’s Government business is collected monthly from the U.S. federal government and various government agencies based on fixed payment rates and member eligibility.

The Company’s billings may be subsequently adjusted to reflect enrollment changes due to member terminations or other factors. These adjustments are known as retroactivity adjustments. In each period, the Company estimates the amount of future retroactivity and adjusts the recorded revenue accordingly. As information regarding actual retroactivity amounts becomes known, the Company refines its estimates and records any required adjustments to revenues in the period in which they arise.

Premium Revenue
Premiums are recognized as revenue in the month in which the enrollee is entitled to receive health care services. Premiums are reported net of an allowance for estimated terminations and uncollectible amounts. Additionally, premium revenue subject to the minimum medical loss ratio (“MLR”) rebate requirements of the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010 (as amended, collectively, the “ACA”) is recorded net of the estimated minimum MLR rebates for the current calendar year. Premiums related to unexpired contractual coverage periods (unearned premiums) are reported as other insurance liabilities on the consolidated balance sheets and recognized as revenue when earned.

Some of the Company’s contracts allow for premiums to be adjusted to reflect actual experience or the relative health status of Insured members. Such adjustments are reasonably estimable at the outset of the contract, and adjustments to those estimates are made based on actual experience of the customer emerging under the contract and the terms of the underlying contract.

Services Revenue
Services revenue relates to contracts that can include various combinations of services or series of services which generally are capable of being distinct and accounted for as separate performance obligations. The Health Care Benefits segment’s services revenue primarily consists of ASC fees received in exchange for performing certain claim processing and member services for ASC members. ASC fee revenue is recognized over the period the service is provided. Some of the Company’s administrative services contracts include guarantees with respect to certain functions, such as customer service response time, claim processing accuracy and claim processing turnaround time, as well as certain guarantees that a plan sponsor’s benefit claim experience will fall within a certain range. With any of these guarantees, the Company is financially at risk if the conditions of the arrangements are not met, although the maximum amount at risk typically is limited to a percentage of the fees otherwise payable to the Company by the customer involved. Each period the Company estimates its obligations under the terms of these guarantees and records its estimate as an offset to services revenues.

Accounting for Medicare Part D
Revenues include insurance premiums earned by the Company’s PDPs, which are determined based on the PDP’s annual bid and related contractual arrangements with the U.S. Centers for Medicare & Medicaid Services (“CMS”). The insurance premiums include a beneficiary premium, which is the responsibility of the PDP member, and can be subsidized by CMS in the case of low-income members, and a direct premium paid by CMS. Premiums collected in advance are initially recorded within other insurance liabilities and are then recognized ratably as revenue over the period in which members are entitled to receive benefits.

Revenues also include a risk-sharing feature of the Medicare Part D program design referred to as the risk corridor. The Company estimates variable consideration in the form of amounts payable to, or receivable from, CMS under the risk corridor, and adjusts revenue based on calculations of additional subsidies to be received from or owed to CMS at the end of the reporting year.
In addition to Medicare Part D premiums, the Company receives additional payments each month from CMS related to catastrophic reinsurance, low-income cost-sharing subsidies and coverage gap benefits. If the subsidies received differ from the amounts earned from actual prescriptions transferred, the difference is recorded in either accounts receivable, net or accrued expenses.

Pharmacy Services Segment
The Pharmacy Services segment sells prescription drugs directly through its mail service dispensing pharmacies and indirectly through the Company’s retail pharmacy network. The Company’s pharmacy benefit arrangements are accounted for in a manner consistent with a master supply arrangement as there are no contractual minimum volumes and each prescription is considered a separate purchasing decision and distinct performance obligation transferred at a point in time. PBM services performed in connection with each prescription claim are considered part of a single performance obligation which culminates in the dispensing of prescription drugs.

The Company recognizes revenue using the gross method at the contract price negotiated with its clients when the Company has concluded it controls the prescription drug before it is transferred to the client plan members. The Company controls prescriptions dispensed indirectly through its retail pharmacy network because it has separate contractual arrangements with those pharmacies, has discretion in setting the price for the transaction and assumes primary responsibility for fulfilling the promise to provide prescription drugs to its client plan members while also performing the related PBM services.

Revenues include (i) the portion of the price the client pays directly to the Company, net of any discounts earned on brand name drugs or other discounts and refunds paid back to the client (see “Drug Discounts” and “Guarantees” below), (ii) the price paid to the Company by client plan members for mail order prescriptions and the price paid to retail network pharmacies by client plan members for retail prescriptions (“retail co-payments”), and (iii) claims based administrative fees for retail pharmacy network contracts. Sales taxes are not included in revenues.

The Company recognizes revenue when control of the prescription drugs is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to receive in exchange for those prescription drugs. The Company has established the following revenue recognition policies for the Pharmacy Services segment:

Revenues generated from prescription drugs sold by mail service dispensing pharmacies are recognized when the prescription drug is delivered to the client plan member. At the time of delivery, the Company has performed substantially all of its performance obligations under its client contracts and does not experience a significant level of returns or reshipments.
Revenues generated from prescription drugs sold by third party pharmacies in the Company’s retail pharmacy network and associated administrative fees are recognized at the Company’s point-of-sale, which is when the claim is adjudicated by the Company’s online claims processing system and the Company has transferred control of the prescription drug and completed all of its performance obligations.

For contracts under which the Company acts as an agent or does not control the prescription drugs prior to transfer to the client plan member, revenue is recognized using the net method.

Drug Discounts
The Company records revenue net of manufacturers’ rebates earned by its clients based on their plan members’ utilization of brand-name formulary drugs. The Company estimates these rebates at period-end based on actual and estimated claims data and its estimates of the manufacturers’ rebates earned by its clients. The estimates are based on the best available data at period-end and recent history for the various factors that can affect the amount of rebates due to the client. The Company adjusts its rebates payable to clients to the actual amounts paid when these rebates are paid or as significant events occur. Any cumulative effect of these adjustments is recorded against revenues at the time it is identified. Adjustments generally result from contract changes with clients or manufacturers that have retroactive rebate adjustments, differences between the estimated and actual product mix subject to rebates, or whether the brand name drug was included in the applicable formulary. The effect of adjustments between estimated and actual manufacturers’ rebate amounts has not been material to the Company’s operating results or financial condition.

Guarantees
The Company also adjusts revenues for refunds owed to clients resulting from pricing guarantees and performance against defined service and performance metrics. The inputs to these estimates are not subject to a high degree of subjectivity or volatility. The effect of adjustments between estimated and actual pricing and performance refund amounts has not been material to the Company’s operating results or financial condition.
Retail/LTC Segment
Retail Pharmacy
The Company’s retail drugstores recognize revenue at the time the customer takes possession of the merchandise. For pharmacy sales, each prescription claim is its own arrangement with the customer and is a performance obligation, separate and distinct from other prescription claims under other retail network arrangements. Revenues are adjusted for refunds owed to third party payers resulting from pricing guarantees and performance against defined value-based service and performance metrics. The inputs to these estimates are not subject to a high degree of subjectivity or volatility. The effect of adjustments between estimated and actual pricing and performance refund amounts has not been material to the Company’s operating results or financial condition.

Revenue from Company gift cards purchased by customers is deferred as a contract liability until goods or services are transferred. Any amounts not expected to be redeemed by customers (i.e., breakage) are recognized based on historical redemption patterns.

Customer returns are not material to the Company’s operating results or financial condition. Sales taxes are not included in revenues.

Loyalty and Other Programs
The Company’s customer loyalty program, ExtraCare®, consists of two components, ExtraSavingsTM and ExtraBucks® Rewards. ExtraSavings are coupons that are recorded as a reduction of revenue when redeemed as the Company concluded that they do not represent a promise to the customer to deliver additional goods or services at the time of issuance because they are not tied to a specific transaction or spending level.

ExtraBucks Rewards are accumulated by customers based on their historical spending levels. Thus, the Company has determined that there is an additional performance obligation to those customers at the time of the initial transaction. The Company allocates the transaction price to the initial transaction and the ExtraBucks Rewards transaction based upon the relative standalone selling price, which considers historical redemption patterns for the rewards. Revenue allocated to ExtraBucks Rewards is recognized as those rewards are redeemed. At the end of each period, unredeemed ExtraBucks Rewards are reflected as a contract liability.

The Company also offers a subscription-based membership program, CarePass®, under which members are entitled to a suite of benefits delivered over the course of the subscription period, as well as a promotional reward that can be redeemed for future goods and services. Subscriptions are paid for on a monthly or annual basis at the time of or in advance of the Company delivering the goods and services. Revenue from these arrangements is recognized as the performance obligations are satisfied.

Long-term Care
Revenue is recognized when control of the promised goods or services is transferred to customers in an amount that reflects the consideration the Company expects to be entitled to receive in exchange for those goods or services. Each prescription claim represents a separate performance obligation of the Company, separate and distinct from other prescription claims under customer arrangements. A significant portion of long-term care revenue from sales of pharmaceutical and medical products is reimbursed by the federal Medicare Part D program and, to a lesser extent, state Medicaid programs. The Company monitors its revenues and receivables from these reimbursement sources, as well as long-term care facilities and other third party insurance payors, and reduces revenue at the revenue recognition date to properly account for the variable consideration due to anticipated differences between billed and reimbursed amounts. Accordingly, the total revenues and receivables reported in the Company’s consolidated financial statements are recorded at the amount expected to be ultimately received from these payors.

Patient co-payments associated with Medicare Part D, certain state Medicaid programs, Medicare Part B and certain third party payors typically are not collected at the time products are delivered or services are rendered, but are billed to the individuals as part of normal billing procedures and subject to normal accounts receivable collections procedures.

Walk-In Medical Clinics
For services provided by the Company’s walk-in medical clinics, revenue recognition occurs for completed services provided to patients, with adjustments taken for third party payor contractual obligations and patient direct bill historical collection rates.
Disaggregation of Revenue
The following table disaggregates the Company’s revenue by major source in each segment for the years ended December 31, 2021, 2020 and 2019:
In millionsHealth Care
Benefits
Pharmacy
Services
Retail/
LTC
Corporate/
Other
Intersegment
Eliminations
Consolidated
Totals
2021
Major goods/services lines:
Pharmacy$— $152,262 $76,121 $— $(43,765)$184,618 
Front Store— — 21,315 — — 21,315 
Premiums76,064 — — 68 — 76,132 
Net investment income586 — 17 596 — 1,199 
Other5,536 760 2,652 57 (158)8,847 
Total$82,186 $153,022 $100,105 $721 $(43,923)$292,111 
Pharmacy Services distribution channel:
Pharmacy network (1)
$91,715 
Mail choice (2)
60,547 
Other760 
Total$153,022 
2020
Major goods/services lines:
Pharmacy$— $141,116 $70,176 $— $(40,003)$171,289 
Front Store— — 19,655 — — 19,655 
Premiums69,301 — — 63 — 69,364 
Net investment income483 — — 315 — 798 
Other5,683 822 1,367 48 (320)7,600 
Total$75,467 $141,938 $91,198 $426 $(40,323)$268,706 
Pharmacy Services distribution channel:
Pharmacy network (1)
$85,045 
Mail choice (2)
56,071 
Other822 
Total$141,938 
2019
Major goods/services lines:
Pharmacy$— $140,896 $66,442 $— $(41,413)$165,925 
Front Store— — 19,422 — — 19,422 
Premiums63,031 — — 91 — 63,122 
Net investment income599 — — 412 — 1,011 
Other5,974 595 744 (26)7,296 
Total$69,604 $141,491 $86,608 $512 $(41,439)$256,776 
Pharmacy Services distribution channel:
Pharmacy network (1)
$88,755 
Mail choice (2)
52,141 
Other595 
Total$141,491 
_____________________________________________
(1)Pharmacy Services pharmacy network is defined as claims filled at retail and specialty retail pharmacies, including the Company’s retail pharmacies and LTC pharmacies, but excluding Maintenance Choice® activity, which is included within the mail choice category. Maintenance Choice permits eligible client plan members to fill their maintenance prescriptions through mail order delivery or at a CVS Pharmacy retail store for the same price as mail order.
(2)Pharmacy Services mail choice is defined as claims filled at a Pharmacy Services mail order facility, which includes specialty mail claims inclusive of Specialty Connect® claims picked up at a retail pharmacy, as well as prescriptions filled at the Company’s retail pharmacies under the Maintenance Choice program.

Contract Balances
Contract liabilities primarily represent the Company’s obligation to transfer additional goods or services to a customer for which the Company has received consideration, and include ExtraBucks Rewards and unredeemed Company gift cards. The consideration received remains a contract liability until goods or services have been provided to the customer. In addition, the Company recognizes breakage on Company gift cards based on historical redemption patterns.

The following table provides information about receivables and contract liabilities from contracts with customers as of December 31, 2021 and 2020:
In millions20212020
Trade receivables (included in accounts receivable, net)$7,932 $7,101 
Contract liabilities (included in accrued expenses)87 71 

During the years ended December 31, 2021 and 2020, the contract liabilities balance includes increases related to customers’ earnings in ExtraBucks Rewards or issuances of Company gift cards and decreases for revenues recognized during the period as a result of the redemption of ExtraBucks Rewards or Company gift cards and breakage of Company gift cards. Below is a summary of such changes:
Cost of Products Sold
Cost of Products Sold

The Company accounts for cost of products sold as follows:

Pharmacy Services Segment
Cost of products sold includes: (i) the cost of prescription drugs sold during the reporting period directly through the Company’s mail service dispensing pharmacies and indirectly through the Company’s retail pharmacy network, (ii) shipping and handling costs, and (iii) the operating costs of the Company’s mail service dispensing pharmacies and client service operations and related information technology support costs including depreciation and amortization. The cost of prescription drugs sold component of cost of products sold includes: (i) the cost of the prescription drugs purchased from manufacturers or distributors and shipped to members in clients’ benefit plans from the Company’s mail service dispensing pharmacies, net of any volume-related or other discounts (see “Vendor Allowances and Purchase Discounts” below) and (ii) the cost of prescription drugs sold (including retail co-payments) through the Company’s retail pharmacy network under contracts where the Company is the principal, net of any volume-related or other discounts.

Retail/LTC Segment
Cost of products sold includes: the cost of merchandise sold during the reporting period, including prescription drug costs, and the related purchasing costs, warehousing and delivery costs (including depreciation and amortization) and actual and estimated inventory losses.
Vendor Allowances And Purchase Discounts
Vendor Allowances and Purchase Discounts

The Company accounts for vendor allowances and purchase discounts as follows:

Pharmacy Services Segment
The Pharmacy Services segment receives purchase discounts on products purchased. Contractual arrangements with vendors, including manufacturers, wholesalers and retail pharmacies, normally provide for the Pharmacy Services segment to receive
purchase discounts from established list prices in one, or a combination, of the following forms: (i) a direct discount at the time of purchase, (ii) a discount for the prompt payment of invoices or (iii) when products are purchased indirectly from a manufacturer (e.g., through a wholesaler or retail pharmacy), a discount (or rebate) paid subsequent to dispensing. These rebates are recognized when prescriptions are dispensed and are generally calculated and billed to manufacturers within 30 days of the end of each completed quarter. Historically, the effect of adjustments resulting from the reconciliation of rebates recognized to the amounts billed and collected has not been material to the Company’s operating results or financial condition. The Company accounts for the effect of any such differences as a change in accounting estimate in the period the reconciliation is completed. The Pharmacy Services segment also receives additional discounts under its wholesaler contracts if it exceeds contractually defined purchase volumes. In addition, the Pharmacy Services segment receives fees from pharmaceutical manufacturers for administrative services. Purchase discounts and administrative service fees are recorded as a reduction of cost of products sold.

Retail/LTC Segment
Vendor allowances received by the Retail/LTC segment reduce the carrying cost of inventory and are recognized in cost of products sold when the related inventory is sold, unless they are specifically identified as a reimbursement of incremental costs for promotional programs and/or other services provided. Amounts that are directly linked to advertising commitments are recognized as a reduction of advertising expense (included in operating expenses) when the related advertising commitment is satisfied. Any amounts received in excess of the actual cost incurred also reduce the carrying cost of inventory. The total value of any upfront payments received from vendors that are linked to purchase commitments is initially deferred. The deferred amounts are then amortized to reduce cost of products sold over the life of the contract based upon sales volume. The total value of any upfront payments received from vendors that are not linked to purchase commitments is also initially deferred. The deferred amounts are then amortized to reduce cost of products sold on a straight-line basis over the life of the related contract. The total amortization of these upfront payments was not material to the Company’s consolidated financial statements in any of the periods presented.
Health Care Reform
Health Care Reform

Health Insurer Fee
Since January 1, 2014, the ACA has imposed an annual premium-based health insurer fee (“HIF”) for each calendar year, payable in September, which was not deductible for tax purposes. The Company has been required to estimate a liability for the HIF at the beginning of the calendar year in which the fee was payable with a corresponding deferred asset that was amortized ratably to operating expenses over the calendar year. The Company recorded the liability for the HIF in accrued expenses and recorded the deferred asset in other current assets. In December 2019, the HIF was repealed for calendar years after 2020, therefore there was no expense related to the HIF in the year ended December 31, 2021. In the year ended December 31, 2020, operating expenses included $1.0 billion related to the Company’s share of the HIF. There was no expense related to the HIF in 2019, since there was a one-year suspension of the HIF for 2019.

Risk Adjustment
The ACA established a permanent risk adjustment program to transfer funds from qualified individual and small group insurance plans with below average risk scores to plans with above average risk scores. Based on the risk of the Company’s qualified plan members relative to the average risk of members of other qualified plans in comparable markets, as defined by the ACA, the Company estimates its ultimate risk adjustment receivable (recorded in accounts receivable) or payable (recorded in accrued expenses) for the current calendar year and reflects the pro-rata year-to-date impact as an adjustment to premium revenue.

Risk Corridor
The ACA established a temporary risk corridor program, which expired at the end of 2016, for qualified individual and small group health insurance plans. Under this program, health insurance companies were to make payments to, or receive payments from, the U.S. Department of Health and Human Services (“HHS”) based on their ratio of allowable costs to target costs (as defined by the ACA).

The Company filed a lawsuit in August 2019 to recover the $313 million it was owed under the ACA’s risk corridor program, which had been stayed pending the Supreme Court decision. In April 2020, the U.S. Supreme Court ruled that health insurance companies may sue the federal government for amounts owed as calculated under the ACA’s temporary risk corridor program.

In October 2020, the Company received the $313 million it was owed under the ACA’s risk corridor program. The Company recorded the risk corridor payment as an increase to premium revenue in the year ended December 31, 2020. After considering
offsetting items such as the ACA’s minimum MLR rebate requirements and premium taxes, the Company recorded pre-tax income of $307 million and after-tax income of $223 million during the year ended December 31, 2020.
Advertising Costs Advertising Costs Advertising costs, which are reduced by the portion funded by vendors, are expensed when the related advertising takes place. Net advertising costs, which are included in operating expenses, were $523 million, $461 million and $396 million in 2021, 2020 and 2019, respectively.
Share-Based Compensation Stock-Based CompensationStock-based compensation is measured at the grant date based on the fair value of the award and is recognized as expense over the requisite service period of the stock award (generally three to five years) using the straight-line method.
Income Taxes
Income Taxes

The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year or years in which the differences are expected to reverse. The effect of a change in the tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date of such change.

The Company recognizes deferred tax assets to the extent that it believes these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies, and the Company’s recent operating results. The Company establishes a valuation allowance when it does not consider it more likely than not that a deferred tax asset will be recovered.

The Company records uncertain tax positions on the basis of a two-step process whereby (1) the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority.

Interest and/or penalties related to uncertain tax positions are recognized in the income tax provision.
Measurement of Defined Benefit Pension and Other Postretirement Employee Benefit (OPEB) Plans
Measurement of Defined Benefit Pension and Other Postretirement Employee Benefit Plans

The Company sponsors defined benefit pension plans (“pension plans”) and other postretirement employee benefit plans (“OPEB plans”) for its employees and retirees. The Company recognizes the funded status of its pension and OPEB plans on the consolidated balance sheets based on the year-end measurements of plan assets and benefit obligations. When the fair value of plan assets are in excess of the plan benefit obligations, the amounts are reported in other current assets and other assets. When the fair value of plan benefit obligations are in excess of plan assets, the amounts are reported in accrued expenses and other long-term liabilities based on the amount by which the actuarial present value of benefits payable in the next twelve months included in the benefit obligation exceeds the fair value of plan assets. The net periodic benefit cost (income) for the Company’s pension and OPEB plans do not contain a service cost component as these plans have been frozen for an extended period of time. Non-service cost components of pension and postretirement net periodic benefit cost (income) are included in other income in the consolidated statements of operations.
Earnings per Common Share
Earnings per Share

Earnings per share is computed using the two-class method. The Company calculates basic earnings per share based on the weighted average number of common shares outstanding for the period. See Note 14 ‘‘Earnings Per Share’’ for additional information.
Shares Held in Trust Shares Held in TrustThe Company maintains grantor trusts, which held approximately one million shares of its common stock at both December 31, 2021 and 2020. These shares are designated for use under various employee compensation plans. Since the Company holds these shares, they are excluded from the computation of basic and diluted shares outstanding.
Variable Interest Entities
Variable Interest Entities

The Company has investments in (i) a generic pharmaceutical sourcing entity, (ii) certain hedge fund and private equity investments and (iii) certain real estate partnerships that are considered VIEs. The Company does not have a future obligation to fund losses or debts on behalf of these investments; however, it may voluntarily contribute funds. In evaluating whether the Company is the primary beneficiary of a VIE, the Company considers several factors, including whether the Company has (a) the power to direct the activities that most significantly impact the VIE’s economic performance and (b) the obligation to absorb losses and the right to receive benefits that could potentially be significant to the VIE.

Variable Interest Entities - Primary Beneficiary
In 2014, the Company and Cardinal Health, Inc. (“Cardinal”) established Red Oak Sourcing, LLC (“Red Oak”), a generic pharmaceutical sourcing entity in which the Company and Cardinal each own 50%. The Red Oak arrangement had an initial term of ten years. In 2021, the Red Oak arrangement was amended to extend the initial term an additional five years, for a total term of 15 years. Under this arrangement, the Company and Cardinal contributed their sourcing and supply chain expertise to Red Oak and agreed to source and negotiate generic pharmaceutical supply contracts for both companies through Red Oak; however, Red Oak does not own or hold inventory on behalf of either company. No physical assets (e.g., property and equipment) were contributed to Red Oak by either company, and minimal funding was provided to capitalize Red Oak. The Company has determined that it is the primary beneficiary of this VIE because it has the ability to direct the activities of Red Oak. Consequently, the Company consolidates Red Oak in its consolidated financial statements within the Retail/LTC segment.

Cardinal is required to pay the Company quarterly payments, which began in October 2014 and will extend through June 2029. As milestones are met, the quarterly payments increase. The Company received $183 million from Cardinal during each of the years ended December 31, 2021, 2020 and 2019. The payments reduce the Company’s carrying value of inventory and are recognized in cost of products sold when the related inventory is sold. Amounts reimbursed by Cardinal for the years ended December 31, 2021, 2020 and 2019, and amounts due to or due from Cardinal at December 31, 2021 and 2020 were immaterial.

Variable Interest Entities - Other Variable Interest Holder
The Company has invested in certain VIEs for which it has determined that it is not the primary beneficiary, consisting of the following:

Hedge fund and private equity investments - The Company invests in hedge fund and private equity investments in order to generate investment returns for its investment portfolio supporting its insurance businesses.
Real estate partnerships - The Company invests in various real estate partnerships, including those that construct, own and manage low-income housing developments. For the low income housing development investments, substantially all of the projected benefits to the Company are from tax credits and other tax benefits.

The Company is not the primary beneficiary of these VIEs because the nature of the Company’s involvement with the activities of these VIEs does not give the Company the power to direct the activities that most significantly impact their economic performance. The Company records the amount of its investment in these VIEs as long-term investments on the consolidated balance sheets and recognizes its share of each VIE’s income or losses in net income (loss). The Company’s maximum exposure to loss from these VIEs is limited to its investment balances as disclosed below and the risk of recapture of previously recognized tax credits related to the real estate partnerships, which the Company does not consider significant.
Related Party Transactions
Related Party Transactions

The Company has an equity method investment in SureScripts, LLC (“SureScripts”), which operates a clinical health information network. The Company utilizes this clinical health information network in providing services to its client plan members and retail customers. The Company expensed fees for the use of this network of $52 million, $56 million and $32 million in the years ended December 31, 2021, 2020 and 2019, respectively. The Company’s investment in and equity in the earnings of SureScripts for all periods presented is immaterial.

The Company has an equity method investment in Heartland Healthcare Services, LLC (“Heartland”). Heartland operates several LTC pharmacies in four states. Heartland paid the Company $79 million, $77 million and $96 million for pharmaceutical inventory purchases during the years ended December 31, 2021, 2020 and 2019, respectively. Additionally, the Company performs certain collection functions for Heartland and then transfers those customer cash collections to Heartland. The Company’s investment in and equity in the earnings of Heartland for all periods presented is immaterial.

During the years ended December 31, 2021, 2020 and 2019, the Company made charitable contributions of $50 million, $50 million and $30 million, respectively, to the CVS Health Foundation, a non-profit entity that focuses on health, education and community involvement programs. The charitable contributions were recorded as operating expenses in the consolidated statements of operations within the Corporate/Other segment for the years ended December 31, 2021, 2020 and 2019.
Discontinued Operations Discontinued OperationsIn connection with certain business dispositions completed between 1995 and 1997, the Company retained guarantees on store lease obligations for a number of former subsidiaries, including Linens ‘n Things and Bob’s Stores, each of which subsequently filed for bankruptcy. The Company’s loss from discontinued operations includes lease-related costs that the Company believes it will likely be required to satisfy pursuant to these lease guarantees.
New Accounting Pronouncements Recently Adopted and Not Yet Adopted
New Accounting Pronouncements Recently Adopted

Simplifying the Accounting for Income Taxes
In December 2019, the Financial Accounting Standards Board (“FASB”) issued ASU 2019-12, Simplifying the Accounting for Income Taxes (Topic 740). This standard simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in Accounting Standards Codification 740 related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The standard also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The Company adopted this new accounting standard on January 1, 2021. The adoption of this standard did not have a material impact on the Company’s consolidated operating results, cash flows, financial condition or related disclosures.

New Accounting Pronouncements Not Yet Adopted

Targeted Improvements to the Accounting for Long-Duration Insurance Contracts
In August 2018, the FASB issued ASU 2018-12, Targeted Improvements to the Accounting for Long-Duration Contracts (Topic 944). This standard requires the Company to review cash flow assumptions for its long-duration insurance contracts at least annually and recognize the effect of changes in future cash flow assumptions in net income. This standard also requires the Company to update discount rate assumptions quarterly and recognize the effect of changes in these assumptions in other comprehensive income. The rate used to discount the Company’s liability for future policy benefits will be based on an estimate of the yield for an upper-medium grade fixed-income instrument with a duration profile matching that of the Company’s
liabilities. In addition, this standard changes the amortization method for deferred acquisition costs and requires additional disclosures regarding the long duration insurance contract liabilities in the Company’s interim and annual financial statements. The standard is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022. The Company will adopt the new standard on January 1, 2023, using the modified retrospective transition method as of the earliest period presented for changes to the liability for future policy benefits and deferred acquisition costs. While the Company is still evaluating the impact of the new standard on its financial statements, the Company anticipates an increase to its liability for future policy benefits with a corresponding change in accumulated other comprehensive income as a result of updating the rate used to discount the liabilities to reflect the yield for an upper-medium grade fixed-income instrument compared to the Company’s expected investment yield under the existing guidance.
XML 48 R28.htm IDEA: XBRL DOCUMENT v3.22.0.1
Significant Accounting Policies (Tables)
12 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
Schedule of reconciliation of cash and cash equivalents
The following is a reconciliation of cash and cash equivalents on the consolidated balance sheets to total cash, cash equivalents and restricted cash on the consolidated statements of cash flows as of December 31, 2021, 2020 and 2019:
In millions202120202019
Cash and cash equivalents$9,408 $7,854 $5,683 
Restricted cash (included in other current assets)3,065 2,913 2,454 
Restricted cash (included in other assets)218 276 271 
Total cash, cash equivalents and restricted cash in the consolidated statements of cash flows$12,691 $11,043 $8,408 
Schedule of accounts receivable, net Accounts receivable, net is composed of the following at December 31, 2021 and 2020:
In millions20212020
Trade receivables$7,932 $7,101 
Vendor and manufacturer receivables10,573 9,815 
Premium receivables2,537 2,628 
Other receivables3,389 2,198 
   Total accounts receivable, net $24,431 $21,742 
Schedule of property and equipment
Property and equipment consists of the following at December 31, 2021 and 2020:
In millions20212020
Land$2,038 $2,134 
Building and improvements4,225 3,950 
Fixtures and equipment13,619 13,125 
Leasehold improvements6,242 6,077 
Software7,426 6,020 
Total property and equipment33,550 31,306 
Accumulated depreciation and amortization(20,654)(18,700)
Property and equipment, net$12,896 $12,606 
Schedule of disaggregation of revenue
The following table disaggregates the Company’s revenue by major source in each segment for the years ended December 31, 2021, 2020 and 2019:
In millionsHealth Care
Benefits
Pharmacy
Services
Retail/
LTC
Corporate/
Other
Intersegment
Eliminations
Consolidated
Totals
2021
Major goods/services lines:
Pharmacy$— $152,262 $76,121 $— $(43,765)$184,618 
Front Store— — 21,315 — — 21,315 
Premiums76,064 — — 68 — 76,132 
Net investment income586 — 17 596 — 1,199 
Other5,536 760 2,652 57 (158)8,847 
Total$82,186 $153,022 $100,105 $721 $(43,923)$292,111 
Pharmacy Services distribution channel:
Pharmacy network (1)
$91,715 
Mail choice (2)
60,547 
Other760 
Total$153,022 
2020
Major goods/services lines:
Pharmacy$— $141,116 $70,176 $— $(40,003)$171,289 
Front Store— — 19,655 — — 19,655 
Premiums69,301 — — 63 — 69,364 
Net investment income483 — — 315 — 798 
Other5,683 822 1,367 48 (320)7,600 
Total$75,467 $141,938 $91,198 $426 $(40,323)$268,706 
Pharmacy Services distribution channel:
Pharmacy network (1)
$85,045 
Mail choice (2)
56,071 
Other822 
Total$141,938 
2019
Major goods/services lines:
Pharmacy$— $140,896 $66,442 $— $(41,413)$165,925 
Front Store— — 19,422 — — 19,422 
Premiums63,031 — — 91 — 63,122 
Net investment income599 — — 412 — 1,011 
Other5,974 595 744 (26)7,296 
Total$69,604 $141,491 $86,608 $512 $(41,439)$256,776 
Pharmacy Services distribution channel:
Pharmacy network (1)
$88,755 
Mail choice (2)
52,141 
Other595 
Total$141,491 
_____________________________________________
(1)Pharmacy Services pharmacy network is defined as claims filled at retail and specialty retail pharmacies, including the Company’s retail pharmacies and LTC pharmacies, but excluding Maintenance Choice® activity, which is included within the mail choice category. Maintenance Choice permits eligible client plan members to fill their maintenance prescriptions through mail order delivery or at a CVS Pharmacy retail store for the same price as mail order.(2)Pharmacy Services mail choice is defined as claims filled at a Pharmacy Services mail order facility, which includes specialty mail claims inclusive of Specialty Connect® claims picked up at a retail pharmacy, as well as prescriptions filled at the Company’s retail pharmacies under the Maintenance Choice program.
Schedule of contract with customer assets and liabilities
The following table provides information about receivables and contract liabilities from contracts with customers as of December 31, 2021 and 2020:
In millions20212020
Trade receivables (included in accounts receivable, net)$7,932 $7,101 
Contract liabilities (included in accrued expenses)87 71 

During the years ended December 31, 2021 and 2020, the contract liabilities balance includes increases related to customers’ earnings in ExtraBucks Rewards or issuances of Company gift cards and decreases for revenues recognized during the period as a result of the redemption of ExtraBucks Rewards or Company gift cards and breakage of Company gift cards. Below is a summary of such changes:
In millions20212020
Contract liabilities, beginning of period$71 $73 
Rewards earnings and gift card issuances387 357 
Redemption and breakage(371)(359)
Contract liabilities, end of period$87 $71 
Schedule of variable interest entities
The total amount of other variable interest holder VIE assets included in long-term investments on the consolidated balance sheets at December 31, 2021 and 2020 was as follows:
In millions20212020
Hedge fund investments$463 $342 
Private equity investments601 547 
Real estate partnerships225 200 
Total$1,289 $1,089 
Schedule of discontinued operations
Below is a summary of the results of discontinued operations for the year ended December 31, 2020.
In millions2020
Loss from discontinued operations$(12)
Income tax benefit
Loss from discontinued operations, net of tax$(9)
XML 49 R29.htm IDEA: XBRL DOCUMENT v3.22.0.1
Investments (Tables)
12 Months Ended
Dec. 31, 2021
Investments [Abstract]  
Total investments
Total investments at December 31, 2021 and 2020 were as follows:
20212020
In millionsCurrentLong-termTotalCurrentLong-termTotal
Debt securities available for sale$3,009 $20,231 $23,240 $2,774 $18,414 $21,188 
Mortgage loans58 844 902 226 821 1,047 
Other investments50 1,950 2,000 — 1,577 1,577 
Total investments$3,117 $23,025 $26,142 $3,000 $20,812 $23,812 
Debt securities available for sale
Debt securities available for sale at December 31, 2021 and 2020 were as follows:
In millions
Amortized
Cost (1)
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Fair
Value
December 31, 2021   
Debt securities:   
U.S. government securities$2,349 $70 $(3)$2,416 
States, municipalities and political subdivisions2,947 148 (4)3,091 
U.S. corporate securities9,093 682 (40)9,735 
Foreign securities2,821 196 (24)2,993 
Residential mortgage-backed securities870 15 (10)875 
Commercial mortgage-backed securities1,278 44 (12)1,310 
Other asset-backed securities2,791 14 (13)2,792 
Redeemable preferred securities25 — 28 
Total debt securities (2)
$22,174 $1,172 $(106)$23,240 
December 31, 2020
Debt securities:
U.S. government securities$2,341 $128 $— $2,469 
States, municipalities and political subdivisions2,556 172 — 2,728 
U.S. corporate securities7,879 1,023 (8)8,894 
Foreign securities2,595 324 (1)2,918 
Residential mortgage-backed securities673 32 — 705 
Commercial mortgage-backed securities962 84 — 1,046 
Other asset-backed securities2,369 36 (2)2,403 
Redeemable preferred securities21 — 25 
Total debt securities (2)
$19,396 $1,803 $(11)$21,188 
_____________________________________________
(1)There was no allowance for expected credit losses recorded on available-for-sale debt securities at December 31, 2021 or 2020.
(2)Investment risks associated with the Company’s experience-rated products generally do not impact the Company’s consolidated operating results. At December 31, 2021, debt securities with a fair value of $864 million, gross unrealized capital gains of $94 million and gross unrealized capital losses of $2 million and at December 31, 2020, debt securities with a fair value of $919 million, gross unrealized capital gains of $135 million and no gross unrealized capital losses were included in total debt securities, but support experience-rated products. Changes in net unrealized capital gains (losses) on these securities are not reflected in accumulated other comprehensive income.
Fair value of debt securities by contractual maturity
The amortized cost and fair value of debt securities at December 31, 2021 are shown below by contractual maturity.  Actual maturities may differ from contractual maturities because securities may be restructured, called or prepaid, or the Company intends to sell a security prior to maturity.
In millions Amortized
Cost
Fair
Value
Due to mature: 
Less than one year$1,205 $1,218 
One year through five years6,965 7,142 
After five years through ten years4,733 4,910 
Greater than ten years4,332 4,993 
Residential mortgage-backed securities870 875 
Commercial mortgage-backed securities1,278 1,310 
Other asset-backed securities2,791 2,792 
Total$22,174 $23,240 
Debt securities in an unrealized capital loss position
Summarized below are the debt securities the Company held at December 31, 2021 and 2020 that were in an unrealized capital loss position, aggregated by the length of time the investments have been in that position:
Less than 12 monthsGreater than 12 monthsTotal
In millions, except number of securitiesNumber
of
 Securities
Fair
Value
Unrealized
Losses
Number
of
 Securities
Fair
Value
Unrealized
Losses
Number
of
 Securities
Fair
Value
Unrealized
Losses
December 31, 2021
Debt securities:  
U.S. government securities43 $242 $10 $40 $53 $282 $
States, municipalities and political subdivisions233 428 13 33 246 461 
U.S. corporate securities1,610 2,296 31 165 238 1,775 2,534 40 
Foreign securities449 747 20 57 91 506 838 24 
Residential mortgage-backed securities165 593 10 36 175 629 10 
Commercial mortgage-backed securities188 462 35 112 223 574 12 
Other asset-backed securities1,011 2,030 12 26 31 1,037 2,061 13 
Redeemable preferred securities— — — 
Total debt securities3,700 $6,800 $84 317 $584 $22 4,017 $7,384 $106 
December 31, 2020
Debt securities:
U.S. government securities32 $205 $— — $— $— 32 $205 $— 
States, municipalities and political subdivisions49 83 — — — — 49 83 — 
U.S. corporate securities145 155 — — 147 155 
Foreign securities41 69 — 46 74 
Residential mortgage-backed securities23 26 — — — 26 26 — 
Commercial mortgage-backed securities22 75 — — — — 22 75 — 
Other asset-backed securities156 256 49 41 205 297 
Total debt securities468 $869 $10 59 $46 $527 $915 $11 
The maturity dates for debt securities in an unrealized capital loss position at December 31, 2021 were as follows:
 Supporting experience-
rated products
Supporting remaining
products
Total
In millionsFair
Value
Unrealized
Losses
Fair
Value
Unrealized
Losses
Fair
Value
Unrealized
Losses
Due to mature:      
Less than one year$$— $49 $$51 $
One year through five years13 2,229 32 2,242 33 
After five years through ten years33 1,332 26 1,365 27 
Greater than ten years17 — 445 10 462 10 
Residential mortgage-backed securities— 625 10 629 10 
Commercial mortgage-backed securities— 568 12 574 12 
Other asset-backed securities— 2,057 13 2,061 13 
Total$79 $$7,305 $104 $7,384 $106 
Activity in mortgage loan portfolio
The Company’s mortgage loans are collateralized by commercial real estate. During the years ended December 31, 2021 and 2020, the Company had the following activity in its mortgage loan portfolio:
In millions20212020
New mortgage loans$262 $63 
Mortgage loans fully repaid373 187 
Mortgage loans foreclosed— — 
At December 31, 2021 scheduled mortgage loan principal repayments were as follows:
In millions
2022$58 
2023100 
2024210 
202576 
2026177 
Thereafter281 
Total$902 
Mortgage loan internal credit rating
Based upon the Company’s assessments at December 31, 2021 and 2020, the amortized cost basis of the Company’s mortgage loans within each credit quality indicator by year of origination was as follows:

Amortized Cost Basis by Year of Origination
In millions, except credit quality indicator20212020201920182017PriorTotal
December 31, 2021
1$— $— $— $— $— $28 $28 
2 to 4255 48 40 72 97 349 861 
5 and 6— — — 13 
7— — — — — — — 
Total$255 $48 $40 $75 $101 $383 $902 
December 31, 2020
1$— $— $— $22 $37 $59 
2 to 446 96 91 124 595 952 
5 and 6— — 29 36 
7— — — — — — 
Total$46 $96 $94 $150 $661 $1,047 
Net investment income
Sources of net investment income for the years ended December 31, 2021, 2020 and 2019 were as follows:
In millions202120202019
Debt securities$634 $598 $589 
Mortgage loans55 60 71 
Other investments381 123 194 
Gross investment income1,070 781 854 
Investment expenses(47)(35)(42)
Net investment income (excluding net realized capital gains or losses)1,023 746 812 
Net realized capital gains (1)
176 52 199 
Net investment income (2)
$1,199 $798 $1,011 
_____________________________________________
(1)Net realized capital gains are net of yield-related impairment losses on debt securities of $42 million and $49 million for the years ended December 31, 2021 and 2020, respectively. There were no credit-related losses on debt securities in the years ended December 31, 2021 and 2020. Net realized capital gains are net of other-than-temporary impairment (“OTTI”) losses on debt securities of $24 million for the year ended December 31, 2019.
(2)Net investment income includes $38 million, $42 million and $44 million for the years ended December 31, 2021, 2020 and 2019, respectively, related to investments supporting experience-rated products.
Proceeds and related gross realized capital gains and losses from the sale of debt securities
Excluding amounts related to experience-rated products, proceeds from the sale of available-for-sale debt securities and the related gross realized capital gains and losses in the years ended December 31, 2021, 2020 and 2019 were as follows:
In millions202120202019
Proceeds from sales$3,572 $3,913 $4,773 
Gross realized capital gains72 80 146 
Gross realized capital losses14 62 17 
XML 50 R30.htm IDEA: XBRL DOCUMENT v3.22.0.1
Fair Value (Tables)
12 Months Ended
Dec. 31, 2021
Fair Value Disclosures [Abstract]  
Fair value of financial assets and liabilities Financial assets measured at fair value on a recurring basis on the consolidated balance sheets at December 31, 2021 and 2020 were as follows:
In millionsLevel 1Level 2Level 3Total
December 31, 2021    
Cash and cash equivalents$4,954 $4,454 $— $9,408 
Debt securities:    
U.S. government securities2,372 44 — 2,416 
States, municipalities and political subdivisions— 3,086 3,091 
U.S. corporate securities— 9,697 38 9,735 
Foreign securities— 2,983 10 2,993 
Residential mortgage-backed securities— 875 — 875 
Commercial mortgage-backed securities— 1,310 — 1,310 
Other asset-backed securities— 2,789 2,792 
Redeemable preferred securities— 28 — 28 
Total debt securities2,372 20,812 56 23,240 
Equity securities114 — 55 169 
Total$7,440 $25,266 $111 $32,817 
December 31, 2020    
Cash and cash equivalents$3,985 $3,869 $— $7,854 
Debt securities:
U.S. government securities2,370 99 — 2,469 
States, municipalities and political subdivisions— 2,727 2,728 
U.S. corporate securities— 8,842 52 8,894 
Foreign securities— 2,918 — 2,918 
Residential mortgage-backed securities— 705 — 705 
Commercial mortgage-backed securities— 1,046 — 1,046 
Other asset-backed securities— 2,403 — 2,403 
Redeemable preferred securities— 24 25 
Total debt securities2,370 18,764 54 21,188 
Equity securities17 — 30 47 
Total$6,372 $22,633 $84 $29,089 
Changes in level 3 financial assets
The changes in the balances of Level 3 financial assets during the year ended December 31, 2021 were as follows:
In millionsStates,
municipalities
 and political
subdivisions
U.S.
corporate
securities
Foreign
securities
Other asset-
backed
securities
Redeemable
preferred
securities
Equity
securities
Total
Beginning balance$$52 $— $— $$30 $84 
Net realized and unrealized capital gains (losses):
Included in earnings — (10)— — 13 
Included in other comprehensive income— (3)— — (1)— (4)
Purchases— — — 13 17 
Sales(1)(1)— — (2)(1)(5)
Settlements— (1)— — — — (1)
Transfers into Level 3, net— 10 — — — 15 
Ending balance$$38 $10 $$— $55 $111 
The changes in the balances of Level 3 financial assets during the year ended December 31, 2020 were as follows:
In millionsStates,
municipalities
 and political
subdivisions
U.S.
corporate
securities
Redeemable
preferred
securities
Equity
securities
Total
Beginning balance$— $37 $12 $39 $88 
Net realized and unrealized capital gains (losses):
Included in earnings — (11)18 (3)
Included in other comprehensive income— — (5)— (5)
Purchases— 27 — 30 
Sales— — (24)(9)(33)
Settlements— (1)— — (1)
Transfers into Level 3, net— — — 
Ending balance$$52 $$30 $84 

The change in unrealized capital losses included in other comprehensive income associated with Level 3 financial assets which were held as of December 31, 2020 was $4 million during the year ended December 31, 2020.

The total gross transfers into (out of) Level 3 during the years ended December 31, 2021 and 2020 were as follows:
In millions20212020
Gross transfers into Level 3$15 $
Gross transfers out of Level 3— — 
Net transfers into Level 3$15 $
Carrying value and estimated fair value of certain financial instruments
The carrying value and estimated fair value classified by level of fair value hierarchy for financial instruments carried on the consolidated balance sheets at adjusted cost or contract value at December 31, 2021 and 2020 were as follows:
Carrying
Value
 Estimated Fair Value
In millionsLevel 1Level 2Level 3Total
December 31, 2021
Assets: 
Mortgage loans$902 $— $— $907 $907 
Equity securities (1)
126 N/AN/AN/AN/A
Liabilities:
Investment contract liabilities:
With a fixed maturity— — 
Without a fixed maturity336 — — 373 373 
Long-term debt56,176 64,157 — — 64,157 
December 31, 2020
Assets:
Mortgage loans$1,047 $— $— $1,070 $1,070 
Equity securities (1)
145 N/AN/AN/AN/A
Liabilities:
Investment contract liabilities:
With a fixed maturity— — 
Without a fixed maturity322 — — 371 371 
Long-term debt64,647 75,940 — — 75,940 
_____________________________________________
(1)It was not practical to estimate the fair value of these cost-method investments as it represents shares of unlisted companies. See Note 1 ‘‘Significant Accounting Policies’’ for additional information regarding the valuation of cost method investments.
Separate account financial assets
Separate Accounts financial assets at December 31, 2021 and 2020 were as follows:
December 31, 2021December 31, 2020
In millionsLevel 1Level 2Level 3TotalLevel 1Level 2Level 3Total
Cash and cash equivalents$$186 $— $188 $$186 $— $188 
Debt securities1,233 3,048 — 4,281 1,465 2,634 — 4,099 
Equity securities— — — — 
Common/collective trusts— 547 — 547 — 563 — 563 
Total (1)
$1,235 $3,782 $— $5,017 $1,467 $3,385 $— $4,852 
_____________________________________________
(1)Excludes $70 million and $29 million of other receivables at December 31, 2021 and 2020, respectively.
XML 51 R31.htm IDEA: XBRL DOCUMENT v3.22.0.1
Goodwill and Other Intangibles (Tables)
12 Months Ended
Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
Change in goodwill
Below is a summary of the changes in the carrying amount of goodwill by segment for the years ended December 31, 2021 and 2020:
In millionsHealth Care
Benefits
Pharmacy
Services
Retail/
LTC
Total
Balance at December 31, 2019$45,361 $23,581 $10,807 $79,749 
Acquisitions274 34 — 308 
Divestiture of Workers’ Compensation business(505)— — (505)
Balance at December 31, 202045,130 23,615 10,807 79,552 
Impairment— — (431)(431)
Balance at December 31, 2021$45,130 $23,615 $10,376 $79,121 
Other intangible assets
The following table is a summary of the Company’s intangible assets as of December 31, 2021 and 2020:
In millions, except weighted average lifeGross
Carrying
Amount
Accumulated
Amortization
Net
Carrying
Amount
Weighted
Average
Life (years)
2021
Trademarks (indefinite-lived)$10,498 $— $10,498 N/A
Customer contracts/relationships and covenants not to compete25,084 (10,564)14,520 15.0
Technology1,060 (1,060)— 3.0
Provider networks4,203 (651)3,552 20.0
Value of Business Acquired 590 (173)417 20.0
Other318 (279)39 8.4
Total $41,753 $(12,727)$29,026 15.3
2020
Trademarks (indefinite-lived)$10,498 $— $10,498 N/A
Customer contracts/relationships and covenants not to compete24,952 (8,923)16,029 14.9
Technology1,060 (739)321 3.0
Provider networks4,203 (440)3,763 20.0
Value of Business Acquired 590 (119)471 20.0
Other320 (260)60 7.7
Total$41,623 $(10,481)$31,142 15.2
Estimated annual pretax amortization for other acquired intangible assets over the next five years The projected annual amortization expense for the Company’s intangible assets for the next five years is as follows:
In millions
2022$1,858 
20231,826 
20241,785 
20251,734 
20261,494 
XML 52 R32.htm IDEA: XBRL DOCUMENT v3.22.0.1
Leases (Tables)
12 Months Ended
Dec. 31, 2021
Leases [Abstract]  
Lease costs and supplemental cash flow information
The following table is a summary of the components of net lease cost for the years ended December 31, 2021, 2020 and 2019:
In millions202120202019
Operating lease cost$2,633 $2,670 $2,720 
Finance lease cost:
Amortization of right-of-use assets62 56 38 
Interest on lease liabilities62 58 44 
Total finance lease costs124 114 82 
Short-term lease costs25 22 24 
Variable lease costs604 599 581 
Less: sublease income59 55 50 
Net lease cost$3,327 $3,350 $3,357 

Supplemental cash flow information related to leases for the years ended December 31, 2021, 2020 and 2019 is as follows:
In millions202120202019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows paid for operating leases$2,714 $2,724 $2,701 
Operating cash flows paid for interest portion of finance leases62 58 44 
Financing cash flows paid for principal portion of finance leases50 34 26 
Right-of-use assets obtained in exchange for lease obligations:
Operating leases1,254 1,679 1,824 
Finance leases278 313 283 
Supplemental balance sheet information
Supplemental balance sheet information related to leases as of December 31, 2021 and 2020 is as follows:
In millions, except remaining lease term and discount rate20212020
Operating leases:
Operating lease right-of-use assets$19,122$20,729
Current portion of operating lease liabilities$1,646$1,638
Long-term operating lease liabilities18,17718,757
Total operating lease liabilities$19,823$20,395
Finance leases:
Property and equipment, gross$1,375$1,107
Accumulated depreciation(188)(106)
Property and equipment, net$1,187$1,001
Current portion of long-term debt$50$33
Long-term debt1,2501,050
Total finance lease liabilities$1,300$1,083
Weighted average remaining lease term (in years)
Operating leases12.813.3
Finance leases20.020.3
Weighted average discount rate
Operating leases4.4 %4.5 %
Finance leases5.0 %5.6 %
Maturities of operating lease liabilities
The following table summarizes the maturity of lease liabilities under finance and operating leases as of December 31, 2021:
In millionsFinance
Leases
Operating
Leases
(1)
Total
2022$122 $2,685 $2,807 
2023121 2,613 2,734 
2024111 2,398 2,509 
2025110 2,217 2,327 
2026109 2,054 2,163 
Thereafter1,495 14,103 15,598 
Total lease payments (2)
2,068 26,070 28,138 
Less: imputed interest(768)(6,247)(7,015)
Total lease liabilities$1,300 $19,823 $21,123 
_____________________________________________
(1)Future operating lease payments have not been reduced by minimum sublease rentals of $311 million due in the future under noncancelable subleases.
(2)The Company leases pharmacy and clinic space from Target Corporation. Amounts related to such finance and operating leases are reflected above. Pharmacy lease amounts due in excess of the remaining estimated economic life of the buildings of approximately $2.4 billion are not reflected in this table since the estimated economic life of the buildings is shorter than the contractual term of the pharmacy lease arrangement.
Maturities of financing lease liabilities
The following table summarizes the maturity of lease liabilities under finance and operating leases as of December 31, 2021:
In millionsFinance
Leases
Operating
Leases
(1)
Total
2022$122 $2,685 $2,807 
2023121 2,613 2,734 
2024111 2,398 2,509 
2025110 2,217 2,327 
2026109 2,054 2,163 
Thereafter1,495 14,103 15,598 
Total lease payments (2)
2,068 26,070 28,138 
Less: imputed interest(768)(6,247)(7,015)
Total lease liabilities$1,300 $19,823 $21,123 
_____________________________________________
(1)Future operating lease payments have not been reduced by minimum sublease rentals of $311 million due in the future under noncancelable subleases.
(2)The Company leases pharmacy and clinic space from Target Corporation. Amounts related to such finance and operating leases are reflected above. Pharmacy lease amounts due in excess of the remaining estimated economic life of the buildings of approximately $2.4 billion are not reflected in this table since the estimated economic life of the buildings is shorter than the contractual term of the pharmacy lease arrangement.
XML 53 R33.htm IDEA: XBRL DOCUMENT v3.22.0.1
Health Care Costs Payable (Tables)
12 Months Ended
Dec. 31, 2021
Insurance [Abstract]  
Information about incurred and paid health care claims development
The information about incurred and paid health care claims development for the year ended December 31, 2020 is presented as required unaudited supplemental information.
In millionsIncurred Health Care Claims,
Net of Reinsurance
For the Years Ended December 31,
Date of Service20202021
(Unaudited)
2020$54,529 $53,804 
202162,830 
Total$116,634 
In millionsCumulative Paid Health Care Claims,
Net of Reinsurance
For the Years Ended December 31,
Date of Service20202021
(Unaudited)
2020$47,567 $53,590 
202154,600 
Total$108,190 
All outstanding liabilities for health care costs payable prior to 2020, net of reinsurance130 
Total outstanding liabilities for health care costs payable, net of reinsurance$8,574 
Schedule of liability for unpaid claims and claims adjustment expense
The reconciliation of the December 31, 2021 health care net incurred and paid claims development tables to the health care costs payable liability on the consolidated balance sheet is as follows:
In millionsDecember 31, 2021
Short-duration health care costs payable, net of reinsurance$8,574 
Reinsurance recoverables
Premium deficiency reserve16 
Insurance lines other than short duration210 
Total health care costs payable$8,808 
Components of change in health care costs payable
The following table shows the components of the change in health care costs payable during the years ended December 31, 2021, 2020 and 2019:
In millions202120202019
Health care costs payable, beginning of period $7,936 $6,879 $6,147 
Less: Reinsurance recoverables10 
Health care costs payable, beginning of period, net7,926 6,874 6,143 
Acquisitions, net— 414 — 
Add: Components of incurred health care costs
  Current year64,761 55,835 52,723 
  Prior years(788)(429)(524)
Total incurred health care costs (1)
63,973 55,406 52,199 
Less: Claims paid
  Current year56,323 48,770 46,158 
  Prior years6,792 6,009 5,314 
Total claims paid63,115 54,779 51,472 
Add: Premium deficiency reserve16 11 
Health care costs payable, end of period, net8,800 7,926 6,874 
Add: Reinsurance recoverables10 
Health care costs payable, end of period$8,808 $7,936 $6,879 
_____________________________________________
(1)Total incurred health care costs for the years ended December 31, 2021, 2020 and 2019 in the table above exclude (i) $16 million, $11 million and $4 million, respectively, for a premium deficiency reserve related to the Company’s Medicaid products, (ii) $59 million, $41 million and $41 million, respectively, of benefit costs recorded in the Health Care Benefits segment that are included in other insurance liabilities on the consolidated balance sheets and (iii) $212 million, $221 million and $285 million, respectively, of benefit costs recorded in the Corporate/Other segment that are included in other insurance liabilities on the consolidated balance sheets.
XML 54 R34.htm IDEA: XBRL DOCUMENT v3.22.0.1
Borrowings and Credit Arrangements (Tables)
12 Months Ended
Dec. 31, 2021
Debt Disclosure [Abstract]  
Carrying value of long-term debt
The following table is a summary of the Company’s borrowings as of December 31, 2021 and 2020:
In millions20212020
Long-term debt
3.35% senior notes due March 2021
$— $2,038 
Floating rate notes due March 2021 (0.950% at December 31, 2020)
— 1,000 
4.125% senior notes due May 2021
— 222 
2.125% senior notes due June 2021
— 1,750 
4.125% senior notes due June 2021
— 203 
5.45% senior notes due June 2021
— 187 
3.5% senior notes due July 2022
1,500 1,500 
2.75% senior notes due November 2022
1,000 1,000 
2.75% senior notes due December 2022
1,250 1,250 
4.75% senior notes due December 2022
399 399 
3.7% senior notes due March 2023
— 2,336 
2.8% senior notes due June 2023
1,300 1,300 
4% senior notes due December 2023
414 414 
3.375% senior notes due August 2024
650 650 
2.625% senior notes due August 2024
1,000 1,000 
3.5% senior notes due November 2024
750 750 
5% senior notes due December 2024
299 299 
4.1% senior notes due March 2025
950 950 
3.875% senior notes due July 2025
2,828 2,828 
2.875% senior notes due June 2026
1,750 1,750 
3% senior notes due August 2026
750 750 
3.625% senior notes due April 2027
750 750 
6.25% senior notes due June 2027
372 372 
1.3% senior notes due August 2027
2,250 2,250 
4.3% senior notes due March 2028
5,000 7,050 
3.25% senior notes due August 2029
1,750 1,750 
3.75% senior notes due April 2030
1,500 1,500 
1.75% senior notes due August 2030
1,250 1,250 
1.875% senior notes due February 2031
1,250 1,250 
2.125% senior notes due September 2031
1,000 — 
4.875% senior notes due July 2035
652 652 
6.625% senior notes due June 2036
771 771 
6.75% senior notes due December 2037
533 533 
4.78% senior notes due March 2038
5,000 5,000 
6.125% senior notes due September 2039
447 447 
4.125% senior notes due April 2040
1,000 1,000 
2.7% senior notes due August 2040
1,250 1,250 
5.75% senior notes due May 2041
133 133 
4.5% senior notes due May 2042
500 500 
4.125% senior notes due November 2042
500 500 
5.3% senior notes due December 2043
750 750 
4.75% senior notes due March 2044
375 375 
5.125% senior notes due July 2045
3,500 3,500 
3.875% senior notes due August 2047
1,000 1,000 
5.05% senior notes due March 2048
8,000 8,000 
4.25% senior notes due April 2050
750 750 
Finance lease liabilities1,300 1,083 
Other320 326 
Total debt principal56,743 65,318 
Debt premiums219 238 
Debt discounts and deferred financing costs(786)(909)
56,176 64,647 
Less:
Current portion of long-term debt(4,205)(5,440)
Long-term debt$51,971 $59,207 
Schedule of maturities of long-term debt
The following is a summary of the Company’s required repayments of debt principal due during each of the next five years and thereafter, as of December 31, 2021:
In millions
2022$4,154 
20231,719 
20242,706 
20253,785 
20262,507 
Thereafter40,572 
Subtotal55,443 
Finance lease liabilities (1)
1,300 
Total debt principal$56,743 
_____________________________________________
(1)See Note 6 ‘‘Leases’’ for a summary of maturities of the Company’s finance lease liabilities.
XML 55 R35.htm IDEA: XBRL DOCUMENT v3.22.0.1
Pension Plans and Other Postretirement Benefits (Tables)
12 Months Ended
Dec. 31, 2021
Retirement Benefits [Abstract]  
Schedule of changes in benefit obligations
The following tables outline the change in pension benefit obligation and plan assets over the specified periods:
In millions20212020
Change in benefit obligation:
Benefit obligation, beginning of year$6,462 $6,239 
Interest cost110 168 
Actuarial (gain) loss(102)413 
Benefit payments(408)(358)
Settlements(53)— 
Benefit obligation, end of year6,009 6,462 
Change in plan assets:
Fair value of plan assets, beginning of year6,845 6,395 
Actual return on plan assets215 783 
Employer contributions78 25 
Benefit payments(408)(358)
Settlements(53)— 
Fair value of plan assets, end of year6,677 6,845 
Funded status$668 $383 
Schedule of changes in plan assets
The following tables outline the change in pension benefit obligation and plan assets over the specified periods:
In millions20212020
Change in benefit obligation:
Benefit obligation, beginning of year$6,462 $6,239 
Interest cost110 168 
Actuarial (gain) loss(102)413 
Benefit payments(408)(358)
Settlements(53)— 
Benefit obligation, end of year6,009 6,462 
Change in plan assets:
Fair value of plan assets, beginning of year6,845 6,395 
Actual return on plan assets215 783 
Employer contributions78 25 
Benefit payments(408)(358)
Settlements(53)— 
Fair value of plan assets, end of year6,677 6,845 
Funded status$668 $383 
Schedule of assets (liabilities) recognized in Balance Sheet
The assets (liabilities) recognized on the consolidated balance sheets at December 31, 2021 and 2020 for the defined benefit pension plans consisted of the following:
In millions20212020
Noncurrent assets reflected in other assets$946 $744 
Current liabilities reflected in accrued expenses(28)(76)
Noncurrent liabilities reflected in other long-term liabilities(250)(285)
Net assets$668 $383 
Schedule of net periodic benefit cost
The components of net periodic benefit cost (income) for the years ended December 31, 2021, 2020 and 2019 are shown below:
In millions202120202019
Components of net periodic benefit cost (income):
Interest cost$110 $168 $225 
Expected return on plan assets(317)(388)(357)
Amortization of net actuarial loss
Settlement losses16 — — 
Net periodic benefit cost (income)$(186)$(218)$(131)
Weighted average assumptions used in determining benefit obligations and net benefit costs
The Company determined its benefit obligation based on the following weighted average assumptions as of December 31, 2021 and 2020:
20212020
Discount rate2.8 %2.5 %

The Company determined its net periodic benefit cost (income) based on the following weighted average assumptions for the years ended December 31, 2021, 2020 and 2019:
202120202019
Discount rate1.8 %2.9 %4.0 %
Expected long-term rate of return on plan assets4.8 %6.3 %6.5 %
Schedule of changes in fair value of plan assets
Pension plan assets with changes in fair value measured on a recurring basis at December 31, 2021 were as follows:
In millionsLevel 1Level 2Level 3Total
Cash and cash equivalents$60 $97 $— $157 
Debt securities:
    U.S. government securities1,223 — 1,224 
    States, municipalities and political subdivisions— 150 — 150 
    U.S. corporate securities— 2,458 — 2,458 
    Foreign securities— 202 — 202 
    Residential mortgage-backed securities— 277 — 277 
    Commercial mortgage-backed securities— 76 — 76 
    Other asset-backed securities— 162 — 162 
    Redeemable preferred securities— — 
Total debt securities1,223 3,330 — 4,553 
Equity securities:
    U.S. domestic201 — — 201 
    International81 — — 81 
    Domestic real estate— — 
Total equity securities283 — — 283 
Other investments:
    Real estate— — 378 378 
    Common/collective trusts (1)
— 410 — 410 
Total other investments— 410 378 788 
Total pension investments (2)
$1,566 $3,837 $378 $5,781 
_____________________________________________
(1)The assets in the underlying funds of common/collective trusts consist of $261 million of equity securities and $149 million of debt securities.
(2)Excludes $76 million of other receivables as well as $583 million of private equity limited partnership investments and $237 million of hedge fund limited partnership investments as these amounts are measured at NAV per share or an equivalent and are not subject to leveling within the fair value hierarchy.
Pension plan assets with changes in fair value measured on a recurring basis at December 31, 2020 were as follows:
In millionsLevel 1Level 2Level 3Total
Cash and cash equivalents$118 $81 $— $199 
Debt securities:
    U.S. government securities575 36 — 611 
    States, municipalities and political subdivisions— 170 — 170 
    U.S. corporate securities— 2,006 — 2,006 
    Foreign securities— 167 — 167 
    Residential mortgage-backed securities— 287 — 287 
    Commercial mortgage-backed securities— 83 — 83 
    Other asset-backed securities— 133 — 133 
    Redeemable preferred securities— — 
Total debt securities575 2,887 — 3,462 
Equity securities:
    U.S. domestic1,046 — — 1,046 
    International537 — — 537 
    Domestic real estate15 — — 15 
Total equity securities1,598 — — 1,598 
Other investments:
    Real estate— — 343 343 
    Common/collective trusts (1)
— 266 — 266 
    Derivatives— (3)— (3)
Total other investments— 263 343 606 
Total pension investments (2)
$2,291 $3,231 $343 $5,865 
_____________________________________________
(1)The assets in the underlying funds of common/collective trusts consist of $84 million of equity securities and $182 million of debt securities.
(2)Excludes $142 million of other receivables as well as $624 million of private equity limited partnership investments and $214 million of hedge fund limited partnership investments as these amounts are measured at NAV per share or an equivalent and are not subject to leveling within the fair value hierarchy.
Schedule of change in level 3 plan assets
The changes in the balances of Level 3 pension plan assets during the year ended December 31, 2021 were as follows:
In millionsReal estateTotal
Beginning balance$343 $343 
Actual return on plan assets43 43 
Purchases, sales and settlements(8)(8)
Transfers out of Level 3— — 
Ending balance$378 $378 

The changes in the balances of Level 3 pension plan assets during the year ended December 31, 2020 were as follows:

In millionsReal estateU.S. corporate
securities
Total
Beginning balance$353 $$354 
Actual return on plan assets(2)— (2)
Purchases, sales and settlements(8)— (8)
Transfers out of Level 3— (1)(1)
Ending balance$343 $— $343 
Schedule of expected future benefits payments
The Company estimates the following future benefit payments, which are calculated using the same actuarial assumptions used to measure the pension benefit obligation as of December 31, 2021:
In millions
2022$371 
2023371 
2024371 
2025371 
2026368 
2027-20311,776 
The Company estimates the following future benefit payments, which are calculated using the same actuarial assumptions used to measure the accumulated other postretirement benefit obligation as of December 31, 2021:
In millions
2022$12 
202312 
202412 
202512 
202612 
2027-203160 
XML 56 R36.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes (Tables)
12 Months Ended
Dec. 31, 2021
Income Tax Disclosure [Abstract]  
Schedule of components of income tax expense (benefit)
The income tax provision for continuing operations consisted of the following for the years ended December 31, 2021, 2020 and 2019:
In millions202120202019
Current:
Federal$2,285 $2,615 $2,450 
State665 518 565 
2,950 3,133 3,015 
Deferred:
Federal(306)(450)(535)
State(122)(114)(114)
(428)(564)(649)
Total$2,522 $2,569 $2,366 
Schedule of effective income tax rate reconciliation
The following table is a reconciliation of the statutory income tax rate to the Company’s effective income tax rate for continuing operations for the years ended December 31, 2021, 2020 and 2019:
202120202019
Statutory income tax rate21.0 %21.0 %21.0 %
State income taxes, net of federal tax benefit4.1 3.2 4.0 
Health insurer fee— 2.2 — 
Basis difference upon disposition of subsidiary— (1.2)— 
Prior year refund claim (1.2)— — 
Other0.3 1.1 1.3 
Effective income tax rate24.2 %26.3 %26.3 %
Schedule of deferred tax assets and liabilities
The following table is a summary of the components of the Company’s deferred income tax assets and liabilities as of December 31, 2021 and 2020:
In millions20212020
Deferred income tax assets:
Lease and rents$5,563 $5,742 
Inventory99 80 
Employee benefits193 238 
Bad debts and other allowances489 395 
Net operating loss and capital loss carryforwards416 568 
Deferred income78 43 
Insurance reserves501 489 
Payroll tax deferral87 173 
Other396 500 
Valuation allowance(325)(454)
Total deferred income tax assets7,497 7,774 
Deferred income tax liabilities:
Retirement benefits(105)(29)
Investments(334)(421)
Lease and rents(4,947)(5,368)
Depreciation and amortization(8,381)(8,750)
Total deferred income tax liabilities(13,767)(14,568)
Net deferred income tax liabilities$(6,270)$(6,794)
Schedule of unrecognized tax benefits roll forward
A reconciliation of the beginning and ending balance of unrecognized tax benefits in 2021, 2020 and 2019 is as follows:
In millions202120202019
Beginning balance$768 $655 $661 
Additions based on tax positions related to the current year
Additions based on tax positions related to prior years52 182 115 
Reductions for tax positions of prior years(33)(56)(111)
Expiration of statutes of limitation(1)(2)(7)
Settlements(7)(14)(7)
Ending balance$782 $768 $655 
XML 57 R37.htm IDEA: XBRL DOCUMENT v3.22.0.1
Stock Incentive Plans (Tables)
12 Months Ended
Dec. 31, 2021
Share-based Payment Arrangement [Abstract]  
Stock-based compensation The following table is a summary of stock-based compensation for the years ended December 31, 2021, 2020 and 2019:
In millions202120202019
Stock options and stock appreciation rights (“SARs”) (1)
$80 $71 $76 
Restricted stock units and performance stock units
404 329 377 
Total stock-based compensation$484 $400 $453 
_____________________________________________
(1)Includes the ESPP.
Schedule ESPP valuation assumptions
The following table is a summary of the assumptions used to value the ESPP awards for the years ended December 31, 2021, 2020 and 2019:
202120202019
Dividend yield (1)
1.34 %1.46 %1.70 %
Expected volatility (2)
25.27 %37.21 %27.96 %
Risk-free interest rate (3)
0.08 %0.81 %2.27 %
Expected life (in years) (4)
0.50.50.5
Weighted-average grant date fair value$12.55 $13.85 $10.51 
_____________________________________________
(1)The dividend yield is calculated based on semi-annual dividends paid and the fair market value of CVS Health Corporation stock at the grant date.
(2)The expected volatility is estimated based on the historical volatility of CVS Health Corporation’s daily stock price over the previous six month period.
(3)The risk-free interest rate is selected based on the Treasury constant maturity interest rate whose term is consistent with the expected term of ESPP purchases (i.e., six months).
(4)The expected life is based on the semi-annual purchase period.
RSU and performance share unit activity
The following table is a summary of the restricted stock unit and performance stock unit activity for the year ended December 31, 2021:
In thousands, except weighted average grant date fair valueUnitsWeighted Average
Grant Date
Fair Value
Outstanding at beginning of year, nonvested14,824 $58.12 
Granted6,190 $74.39 
Vested(5,448)$74.47 
Forfeited(1,236)$63.40 
Outstanding at end of year, nonvested14,330 $63.02 
Cash proceeds received and tax benefit from share-based payment awards
The following table is a summary of stock option and SAR activity that occurred for the years ended December 31, 2021, 2020 and 2019:
In millions202120202019
Cash received from stock options exercised (including ESPP)
$549 $264 $210 
Payments for taxes for net share settlement of equity awards
168 88 112 
Intrinsic value of stock options and SARs exercised
105 24 30 
Fair value of stock options and SARs vested
224 252 467 
Schedule of valuation assumptions
The fair value of each stock option is estimated using the Black-Scholes option pricing model based on the following assumptions at the time of grant:
202120202019
Dividend yield (1)
2.68 %3.42 %3.68 %
Expected volatility (2)
27.10 %25.22 %21.76 %
Risk-free interest rate (3)
1.13 %0.61 %0.56 %
Expected life (in years) (4)
6.36.36.3
Weighted-average grant date fair value$14.57 $8.78 $6.27 
_____________________________________________
(1)The dividend yield is based on annual dividends paid and the fair market value of CVS Health Corporation stock at the grant date.
(2)The expected volatility is estimated based on the historical volatility of CVS Health Corporation’s daily stock price over a period equal to the expected life of each option grant after adjustments for infrequent events such as stock splits.
(3)The risk-free interest rate is selected based on yields from U.S. Treasury zero-coupon issues with a remaining term equal to the expected term of the options being valued.
(4)The expected life represents the number of years the options are expected to be outstanding from grant date based on historical option or SAR holder exercise experience.
Schedule of stock options and stock appreciation rights award activity
The following table is a summary of the Company’s stock option and SAR activity for the year ended December 31, 2021:
In thousands, except weighted average exercise price and remaining contractual termSharesWeighted
Average
Exercise
 Price
Weighted
Average
Remaining
Contractual
Term
Aggregate
Intrinsic
Value
Outstanding at beginning of year23,955 $69.62 
Granted3,322 $74.66 
Exercised(6,366)$63.41 
Forfeited(694)$62.66 
Expired(1,156)$87.42 
Outstanding at end of year19,061 $71.74 4.75$603,137 
Exercisable at end of year9,704 $79.99 2.61229,034 
Vested at end of year and expected to vest in the future18,709 $71.82 4.69590,514 
XML 58 R38.htm IDEA: XBRL DOCUMENT v3.22.0.1
Shareholders' Equity (Tables)
12 Months Ended
Dec. 31, 2021
Equity [Abstract]  
Share repurchase programs
The following share repurchase programs have been authorized by the Board:
In billions
Authorization Date
AuthorizedRemaining as of
December 31, 2021
December 9, 2021 (“2021 Repurchase Program”)
$10.0 $10.0 
November 2, 2016 (“2016 Repurchase Program”)15.0 — 
Schedule of regulatory Requirements The combined statutory net income for the years ended and estimated combined statutory and capital surplus at December 31, 2021, 2020 and 2019 for the Company’s insurance and HMO subsidiaries were as follows:
In millions202120202019
Statutory net income
$3,302 $3,667 $2,842 
Estimated statutory capital and surplus
14,879 13,238 10,975 
Statutory accounting practices disclosure At December 31, 2021, these amounts were as follows:
In millions
Estimated minimum statutory surplus required by regulators$7,261 
Investments on deposit with regulatory bodies794 
Estimated maximum dividend distributions permitted in 2022 without prior regulatory approval2,939 
XML 59 R39.htm IDEA: XBRL DOCUMENT v3.22.0.1
Other Comprehensive Income (Tables)
12 Months Ended
Dec. 31, 2021
Other Comprehensive Income (Loss), Net of Tax [Abstract]  
Schedule of Accumulated Other Comprehensive Income (Loss)
Shareholders’ equity included the following activity in accumulated other comprehensive income in 2021, 2020 and 2019:
At December 31,
In millions202120202019
Net unrealized investment gains (losses):
Beginning of year balance$1,214 $774 $97 
Other comprehensive income (loss) before reclassifications ($(489), $497 and $927 pretax)
(410)415 763 
Amounts reclassified from accumulated other comprehensive income ($(32), $31 and $(105) pretax) (1)
(26)25 (86)
Other comprehensive income (loss)(436)440 677 
End of year balance778 1,214 774 
Foreign currency translation adjustments:
Beginning of year balance(158)
Other comprehensive income (loss) before reclassifications(7)
Amounts reclassified from accumulated other comprehensive income (loss) (2)
— — 154 
Other comprehensive income (loss)(7)162 
End of year balance— 
Net cash flow hedges:
Beginning of year balance248 279 312 
Other comprehensive loss before reclassifications ($0, $(7) and $(25) pretax)
— (5)(18)
Amounts reclassified from accumulated other comprehensive income ($(34), $(35) and $(20) pretax) (3)
(26)(26)(15)
Other comprehensive loss(26)(31)(33)
End of year balance222 248 279 
Pension and other postretirement benefits:
Beginning of year balance(55)(38)(149)
Other comprehensive income (loss) before reclassifications ($20, $(30) and $162 pretax)
15 (22)120 
Amounts reclassified from accumulated other comprehensive loss ($6, $7 and $(12) pretax) (4)
(9)
Other comprehensive income (loss) 20 (17)111 
End of year balance(35)(55)(38)
Total beginning of year accumulated other comprehensive income1,414 1,019 102 
Total other comprehensive income (loss)(449)395 917 
Total end of year accumulated other comprehensive income$965 $1,414 $1,019 
_____________________________________________
(1)Amounts reclassified from accumulated other comprehensive income for specifically identified debt securities are included in net investment income in the consolidated statements of operations.
(2)Amounts reclassified from accumulated other comprehensive income (loss) represent the elimination of the cumulative translation adjustment associated with the sale of Onofre, which was sold on July 1, 2019. The loss on the divestiture of Onofre is reflected in operating expenses in the consolidated statements of operations.
(3)Amounts reclassified from accumulated other comprehensive income for specifically identified cash flow hedges are included within interest expense in the consolidated statements of operations. The Company expects to reclassify approximately $11 million, net of tax, in net gains associated with its cash flow hedges into net income within the next 12 months.
(4)Amounts reclassified from accumulated other comprehensive loss for specifically identified pension and other postretirement benefits are included in other income in the consolidated statements of operations.
XML 60 R40.htm IDEA: XBRL DOCUMENT v3.22.0.1
Earnings Per Share (Tables)
12 Months Ended
Dec. 31, 2021
Earnings Per Share [Abstract]  
Reconciliation of basic and diluted earnings (loss) per share
The following is a reconciliation of basic and diluted earnings per share from continuing operations for the years ended December 31, 2021, 2020 and 2019:
In millions, except per share amounts202120202019
Numerator for earnings per share calculation:
Income from continuing operations$7,898 $7,201 $6,631 
Income allocated to participating securities— — (5)
Net (income) loss attributable to noncontrolling interests12 (13)
Income from continuing operations attributable to CVS Health$7,910 $7,188 $6,629 
Denominator for earnings per share calculation:
Weighted average shares, basic1,319 1,309 1,301 
Effect of dilutive securities10 
Weighted average shares, diluted1,329 1,314 1,305 
Earnings per share from continuing operations:
Basic$6.00 $5.49 $5.10 
Diluted$5.95 $5.47 $5.08 
XML 61 R41.htm IDEA: XBRL DOCUMENT v3.22.0.1
Reinsurance (Tables)
12 Months Ended
Dec. 31, 2021
Reinsurance Disclosures [Abstract]  
Schedule of reinsurance recoverables
Reinsurance recoverables (recorded as other current assets or other assets on the consolidated balance sheets) at December 31, 2021 and 2020 were as follows:
In millions20212020
Reinsurer
Hartford Life and Accident Insurance Company$1,887 $2,364 
Lincoln Life & Annuity Company of New York395 406 
VOYA Retirement Insurance and Annuity Company 167 170 
All Other100 115 
Total$2,549 $3,055 
Schedule of direct, assumed and ceded premiums earned
Direct, assumed and ceded premiums earned for the years ended December 31, 2021, 2020 and 2019 were as follows:
In millions202120202019
Direct$76,320 $69,711 $62,968 
Assumed492 478 2,108 
Ceded(680)(825)(1,954)
Net premiums$76,132 $69,364 $63,122 
Schedule of impact of reinsurance on benefit costs
The impact of reinsurance on benefit costs for the years ended December 31, 2021, 2020 and 2019 were as follows:
In millions202120202019
Direct$64,414 $56,077 $52,592 
Assumed398 329 1,562 
Ceded(552)(727)(1,625)
Net benefit costs$64,260 $55,679 $52,529 
XML 62 R42.htm IDEA: XBRL DOCUMENT v3.22.0.1
Segment Reporting (Tables)
12 Months Ended
Dec. 31, 2021
Segment Reporting [Abstract]  
Summarized financial information of segments
In millionsHealth Care
Benefits
Pharmacy 
Services
(1)
Retail/
LTC
Corporate/
Other
Intersegment
Eliminations (2)
Consolidated
Totals
2021:
Revenues from external customers$81,515 $143,194 $66,078 $125 $— $290,912 
Intersegment revenues85 9,828 34,010 — (43,923)— 
Net investment income 586 — 17 596 — 1,199 
Total revenues82,186 153,022 100,105 721 (43,923)292,111 
  Adjusted operating income (loss) 5,012 6,859 7,623 (1,471)(711)17,312 
Depreciation and amortization1,837 576 1,884 215 — 4,512 
2020:
Revenues from external customers74,926 132,663 60,208 111 — 267,908 
Intersegment revenues58 9,275 30,990 — (40,323)— 
Net investment income483 — — 315 — 798 
Total revenues 75,467 141,938 91,198 426 (40,323)268,706 
  Adjusted operating income (loss) 6,188 5,688 6,146 (1,306)(708)16,008 
Depreciation and amortization1,832 612 1,801 196 — 4,441 
2019:
Revenues from external customers68,979 130,428 56,258 100 — 255,765 
Intersegment revenues26 11,063 30,350 — (41,439)— 
Net investment income599 — — 412 — 1,011 
Total revenues69,604 141,491 86,608 512 (41,439)256,776 
  Adjusted operating income (loss) 5,202 5,129 6,705 (1,000)(697)15,339 
Depreciation and amortization1,721 766 1,723 161 — 4,371 
_____________________________________________
(1)Total revenues of the Pharmacy Services segment include approximately $11.6 billion, $10.9 billion and $11.5 billion of retail co-payments for 2021, 2020 and 2019, respectively. See Note 1 ‘‘Significant Accounting Policies’’ for additional information about retail co-payments.
(2)Intersegment revenue eliminations relate to intersegment revenue generating activities that occur between the Health Care Benefits segment, the Pharmacy Services segment, and/or the Retail/LTC segment. Intersegment adjusted operating income eliminations occur when members of Pharmacy Services Segment clients (“PSS members”) enrolled in Maintenance Choice® elect to pick up maintenance prescriptions at one of the Company’s retail pharmacies instead of receiving them through the mail. When this occurs, both the Pharmacy Services and Retail/LTC segments record the adjusted operating income on a stand-alone basis.
Reconciliation of operating earnings to net income
The following is a reconciliation of consolidated operating income to adjusted operating income for the years ended December 31, 2021, 2020 and 2019:
In millions202120202019
Operating income (GAAP measure)$13,193 $13,911 $11,987 
Amortization of intangible assets (1)
2,259 2,341 2,436 
Acquisition-related integration costs (2)
132 332 480 
Store impairments (3)
1,358 — 231 
Goodwill impairment (4)
431 — — 
Acquisition purchase price adjustment outside of measurement period (5)
(61)— — 
(Gain) loss on divestiture of subsidiary (6)
— (269)205 
Receipt of fully reserved ACA risk corridor receivable (7)
— (307)— 
Adjusted operating income$17,312 $16,008 $15,339 
_____________________________________________
(1)The Company’s acquisition activities have resulted in the recognition of intangible assets as required under the acquisition method of accounting which consist primarily of trademarks, customer contracts/relationships, covenants not to compete, technology, provider networks and value of business acquired. Definite-lived intangible assets are amortized over their estimated useful lives and are tested for impairment when events indicate that the carrying value may not be recoverable. The amortization of intangible assets is reflected in the Company’s GAAP consolidated statements of operations in operating expenses within each segment. Although intangible assets contribute to the Company’s revenue generation, the amortization of intangible assets does not directly relate to the underwriting of the Company’s insurance products, the services performed for the Company’s customers or the sale of the Company’s products or services. Additionally, intangible asset amortization expense typically fluctuates based on the size and timing of the Company’s acquisition activity. Accordingly, the Company believes excluding the amortization of intangible assets enhances the Company’s and investors’ ability to compare the Company’s past financial performance with its current performance and to analyze underlying business performance and trends. Intangible asset amortization excluded from the related non-GAAP financial measure represents the entire amount recorded within the Company’s GAAP financial statements, and the revenue generated by the associated intangible assets has not been excluded from the related non-GAAP financial measure. Intangible asset amortization is excluded from the related non-GAAP financial measure because the amortization, unlike the related revenue, is not affected by operations of any particular period unless an intangible asset becomes impaired or the estimated useful life of an intangible asset is revised.
(2)In 2021, 2020 and 2019, acquisition-related integration costs relate to the Aetna Acquisition. The acquisition-related integration costs are reflected in the Company’s GAAP consolidated statements of operations in operating expenses within the Corporate/Other segment.
(3)During the year ended December 31, 2021, the store impairment charge relates to the write down of operating lease right-of-use assets and property and equipment in connection with the planned closure of approximately 900 retail stores between 2022 and 2024. During the year ended December 31, 2019, the store impairment charges related to the write down of operating lease right-of-use assets in connection with the planned closure of 68 underperforming retail pharmacy stores in 2019 and 2020. The store impairment charges are reflected in the Company’s GAAP consolidated statements of operations within the Retail/LTC segment.
(4)During the year ended December 31, 2021, the goodwill impairment charge relates to the LTC reporting unit within the Retail/LTC segment.
(5)In June 2021, the Company received $61 million related to a purchase price working capital adjustment for an acquisition completed during the first quarter of 2020. The resolution of this matter occurred subsequent to the acquisition accounting measurement period and is reflected in the Company’s GAAP consolidated statement of operations for the year ended December 31, 2021 as a reduction of operating expenses within the Health Care Benefits segment.
(6)In 2020, the gain on divestiture of subsidiary represents the pre-tax gain on the sale of the Workers’ Compensation business, which the Company sold on July 31, 2020 for approximately $850 million. The gain on divestiture is reflected as a reduction of operating expenses in the Company’s GAAP consolidated statement of operations within the Health Care Benefits segment. In 2019, the loss on divestiture of subsidiary represents the pre-tax loss on the sale of Onofre, which occurred on July 1, 2019. The loss on divestiture primarily relates to the elimination of the cumulative translation adjustment from accumulated other comprehensive income and is reflected in the Company’s GAAP consolidated statement of operations in operating expenses within the Retail/LTC segment.
(7)In 2020, the Company received $313 million owed to it under the ACA’s risk corridor program that was previously fully reserved for as payment was uncertain. After considering offsetting items such as the ACA’s minimum MLR rebate requirements and premium taxes, the Company recognized pre-tax income of $307 million in the Company’s GAAP consolidated statement of operations within the Health Care Benefits segment.
XML 63 R43.htm IDEA: XBRL DOCUMENT v3.22.0.1
Significant Accounting Policies - Narrative (Details)
shares in Millions, people in Millions
3 Months Ended 12 Months Ended
Oct. 22, 2020
USD ($)
Dec. 31, 2021
USD ($)
store
Sep. 30, 2020
USD ($)
Sep. 30, 2019
USD ($)
Dec. 31, 2021
USD ($)
store
state
Segment
Dec. 31, 2020
USD ($)
shares
Dec. 31, 2019
USD ($)
store
shares
Dec. 31, 2021
shares
Dec. 31, 2021
store
Dec. 31, 2021
member
Dec. 31, 2021
people
Dec. 31, 2021
patient
Dec. 31, 2021
state
Dec. 31, 2021
clinic
Aug. 31, 2019
USD ($)
Jul. 01, 2019
store
Significant Accounting Policies [Line Items]                                
Number of plan members | people                     110          
Number of patients served per year (more than) | patient                       1,000,000        
Number of people served | people                     35          
Number of reportable segments | Segment         4                      
Deferred acquisition costs   $ 895,000,000     $ 895,000,000 $ 546,000,000                    
Depreciation         2,300,000,000 2,100,000,000 $ 1,900,000,000                  
Store impairment charges         1,358,000,000 0 231,000,000                  
Goodwill impairment     $ 0 $ 0 431,000,000 0 0                  
Impairment of intangible assets, indefinite-lived         $ 0 $ 0 0                  
Assumed interest rates on long-duration group life and long-term care contracts         5.10% 5.10%                    
HSA balances   2,900,000,000     $ 2,900,000,000 $ 2,700,000,000                    
Self insurance liabilities   1,100,000,000     $ 1,100,000,000 927,000,000                    
Pharmacy rebate period         30 days                      
Health insurer fee         $ 0 1,000,000,000 0                  
Advertising costs         523,000,000 $ 461,000,000 $ 396,000,000                  
Treasury shares held in trust (in shares) | shares           1 1 1                
Expenses from transactions with related party         52,000,000 $ 56,000,000 $ 32,000,000                  
Other revenues from transactions with related party         79,000,000 77,000,000 96,000,000                  
Charitable contribution to CVS Health Foundation         $ 50,000,000 50,000,000 $ 30,000,000                  
Number of stores, planned closure | store         900   68                  
U.S. Department of Health and Human Services, ACA Risk Corridor Receivables | Settled Litigation                                
Significant Accounting Policies [Line Items]                                
Gain contingency, unrecorded amount           313,000,000                 $ 313,000,000  
Amount awarded from other party $ 313,000,000                              
Former gain contingency, recognized in current period, before tax           307,000,000                    
Former gain contingency, recognized in current period, net of tax           223,000,000                    
Heartland Healthcare Services                                
Significant Accounting Policies [Line Items]                                
Number of states in which entity operates | state                         4      
Foreign currency translation adjustments                                
Significant Accounting Policies [Line Items]                                
Cumulative translation adjustment from AOCI eliminated upon divestiture         $ 0 0 $ (154,000,000)                  
Other Insurance Liabilities                                
Significant Accounting Policies [Line Items]                                
Liability for unpaid claims   324,000,000     324,000,000 532,000,000                    
Future policy benefits   416,000,000     416,000,000 462,000,000                    
Other Long-Term Insurance Liabilities                                
Significant Accounting Policies [Line Items]                                
Liability for unpaid claims   1,300,000,000     1,300,000,000 1,500,000,000                    
Future policy benefits   5,100,000,000     $ 5,100,000,000 $ 5,500,000,000                    
Minimum                                
Significant Accounting Policies [Line Items]                                
Period after date of service a claim is paid         6 months                      
Assumed interest rates on limited payment pension contracts on large case pension business (in hundredths)         3.00% 3.30%                    
Interest rate for pension and annuity investment contracts         3.50% 4.10%                    
Award vesting period         3 years                      
Minimum | Building, building improvements and leasehold improvements                                
Significant Accounting Policies [Line Items]                                
Useful life of property plant and equipment         1 year                      
Minimum | Fixtures, equipment and internally developed software                                
Significant Accounting Policies [Line Items]                                
Useful life of property plant and equipment         3 years                      
Maximum                                
Significant Accounting Policies [Line Items]                                
Lease renewal term         5 years                      
Period after date of service a claim is paid         48 months                      
Assumed interest rates on limited payment pension contracts on large case pension business (in hundredths)         11.30% 11.30%                    
Interest rate for pension and annuity investment contracts         4.80% 5.10%                    
Award vesting period         5 years                      
Maximum | Building, building improvements and leasehold improvements                                
Significant Accounting Policies [Line Items]                                
Useful life of property plant and equipment         40 years                      
Maximum | Fixtures, equipment and internally developed software                                
Significant Accounting Policies [Line Items]                                
Useful life of property plant and equipment         10 years                      
Brazil Subsidiary | Discontinued Operations, Disposed of by Sale | Foreign currency translation adjustments                                
Significant Accounting Policies [Line Items]                                
Cumulative translation adjustment from AOCI eliminated upon divestiture             $ 154,000,000                  
Retail/ LTC                                
Significant Accounting Policies [Line Items]                                
Number of retail locations (more than) | store                 9,900              
Number of walk-in medical clinics                   1,200       1,200    
Store impairment charges   $ 1,400,000,000     $ 1,400,000,000                      
Goodwill impairment         $ 431,000,000                      
Number of stores, planned closure | store   900     900   68                  
Retail/ LTC | Property and equipment                                
Significant Accounting Policies [Line Items]                                
Store impairment charges   $ 261,000,000                            
Retail/ LTC | Brazil Subsidiary | Discontinued Operations, Disposed of by Sale                                
Significant Accounting Policies [Line Items]                                
Number of retail locations (more than) | store                               50
Health Care Benefits                                
Significant Accounting Policies [Line Items]                                
Number of states the Company has submitted regulatory filings for a January 2022 entrance into the individual public health insurance exchange | state         8                      
Goodwill impairment         $ 0                      
Health Insurance Product Line                                
Significant Accounting Policies [Line Items]                                
Premium deficiency reserve   $ 16,000,000     $ 16,000,000 $ 11,000,000 $ 4,000,000                  
XML 64 R44.htm IDEA: XBRL DOCUMENT v3.22.0.1
Significant Accounting Policies - Restricted Cash (Details) - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Accounting Policies [Abstract]        
Cash and cash equivalents $ 9,408 $ 7,854 $ 5,683  
Restricted cash (included in other current assets) 3,065 2,913 2,454  
Restricted cash (included in other assets) 218 276 271  
Total cash, cash equivalents and restricted cash in the consolidated statements of cash flows $ 12,691 $ 11,043 $ 8,408 $ 6,553
XML 65 R45.htm IDEA: XBRL DOCUMENT v3.22.0.1
Significant Accounting Policies - Accounts Receivable (Details) - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Accounting Policies [Abstract]    
Trade receivables $ 7,932 $ 7,101
Vendor and manufacturer receivables 10,573 9,815
Premium receivables 2,537 2,628
Other receivables 3,389 2,198
Total accounts receivable, net 24,431 21,742
Allowance for credit loss $ 339 $ 358
XML 66 R46.htm IDEA: XBRL DOCUMENT v3.22.0.1
Significant Accounting Policies - Property Plant and Equipment (Details) - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Property, Plant and Equipment [Line Items]    
Total property and equipment $ 33,550 $ 31,306
Accumulated depreciation and amortization (20,654) (18,700)
Property and equipment, net 12,896 12,606
Land    
Property, Plant and Equipment [Line Items]    
Total property and equipment 2,038 2,134
Building and improvements    
Property, Plant and Equipment [Line Items]    
Total property and equipment 4,225 3,950
Fixtures and equipment    
Property, Plant and Equipment [Line Items]    
Total property and equipment 13,619 13,125
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Total property and equipment 6,242 6,077
Software    
Property, Plant and Equipment [Line Items]    
Total property and equipment $ 7,426 $ 6,020
XML 67 R47.htm IDEA: XBRL DOCUMENT v3.22.0.1
Significant Accounting Policies - Disaggregation of Revenue (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Disaggregation of Revenue [Line Items]      
Revenues $ 290,912 $ 267,908 $ 255,765
Net investment income 1,199 798 1,011
Total revenues 292,111 268,706 256,776
Pharmacy      
Disaggregation of Revenue [Line Items]      
Revenues 184,618 171,289 165,925
Front Store      
Disaggregation of Revenue [Line Items]      
Revenues 21,315 19,655 19,422
Premiums      
Disaggregation of Revenue [Line Items]      
Revenues 76,132 69,364 63,122
Other      
Disaggregation of Revenue [Line Items]      
Revenues 8,847 7,600 7,296
Operating Segments | Health Care Benefits      
Disaggregation of Revenue [Line Items]      
Revenues 81,515 74,926 68,979
Net investment income 586 483 599
Total revenues 82,186 75,467 69,604
Operating Segments | Health Care Benefits | Pharmacy      
Disaggregation of Revenue [Line Items]      
Revenues 0 0 0
Operating Segments | Health Care Benefits | Front Store      
Disaggregation of Revenue [Line Items]      
Revenues 0 0 0
Operating Segments | Health Care Benefits | Premiums      
Disaggregation of Revenue [Line Items]      
Revenues 76,064 69,301 63,031
Operating Segments | Health Care Benefits | Other      
Disaggregation of Revenue [Line Items]      
Revenues 5,536 5,683 5,974
Operating Segments | Pharmacy Services      
Disaggregation of Revenue [Line Items]      
Revenues 143,194 132,663 130,428
Net investment income 0 0 0
Total revenues 153,022 141,938 141,491
Operating Segments | Pharmacy Services | Pharmacy network      
Disaggregation of Revenue [Line Items]      
Total revenues 91,715 85,045 88,755
Operating Segments | Pharmacy Services | Mail choice      
Disaggregation of Revenue [Line Items]      
Total revenues 60,547 56,071 52,141
Operating Segments | Pharmacy Services | Other      
Disaggregation of Revenue [Line Items]      
Total revenues 760 822 595
Operating Segments | Pharmacy Services | Pharmacy      
Disaggregation of Revenue [Line Items]      
Revenues 152,262 141,116 140,896
Operating Segments | Pharmacy Services | Front Store      
Disaggregation of Revenue [Line Items]      
Revenues 0 0 0
Operating Segments | Pharmacy Services | Premiums      
Disaggregation of Revenue [Line Items]      
Revenues 0 0 0
Operating Segments | Pharmacy Services | Other      
Disaggregation of Revenue [Line Items]      
Revenues 760 822 595
Operating Segments | Retail/ LTC      
Disaggregation of Revenue [Line Items]      
Revenues 66,078 60,208 56,258
Net investment income 17 0 0
Total revenues 100,105 91,198 86,608
Operating Segments | Retail/ LTC | Pharmacy      
Disaggregation of Revenue [Line Items]      
Revenues 76,121 70,176 66,442
Operating Segments | Retail/ LTC | Front Store      
Disaggregation of Revenue [Line Items]      
Revenues 21,315 19,655 19,422
Operating Segments | Retail/ LTC | Premiums      
Disaggregation of Revenue [Line Items]      
Revenues 0 0 0
Operating Segments | Retail/ LTC | Other      
Disaggregation of Revenue [Line Items]      
Revenues 2,652 1,367 744
Corporate/ Other      
Disaggregation of Revenue [Line Items]      
Revenues 125 111 100
Net investment income 596 315 412
Total revenues 721 426 512
Corporate/ Other | Pharmacy      
Disaggregation of Revenue [Line Items]      
Revenues 0 0 0
Corporate/ Other | Front Store      
Disaggregation of Revenue [Line Items]      
Revenues 0 0 0
Corporate/ Other | Premiums      
Disaggregation of Revenue [Line Items]      
Revenues 68 63 91
Corporate/ Other | Other      
Disaggregation of Revenue [Line Items]      
Revenues 57 48 9
Intersegment Eliminations      
Disaggregation of Revenue [Line Items]      
Net investment income 0 0 0
Total revenues (43,923) (40,323) (41,439)
Intersegment Eliminations | Pharmacy      
Disaggregation of Revenue [Line Items]      
Revenues (43,765) (40,003) (41,413)
Intersegment Eliminations | Front Store      
Disaggregation of Revenue [Line Items]      
Revenues 0 0 0
Intersegment Eliminations | Premiums      
Disaggregation of Revenue [Line Items]      
Revenues 0 0 0
Intersegment Eliminations | Other      
Disaggregation of Revenue [Line Items]      
Revenues $ (158) $ (320) $ (26)
XML 68 R48.htm IDEA: XBRL DOCUMENT v3.22.0.1
Significant Accounting Policies - Receivables and Contracted Balances (Details) - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Accounting Policies [Abstract]      
Trade receivables $ 7,932 $ 7,101  
Contract liabilities (included in accrued expenses) $ 87 $ 71 $ 73
XML 69 R49.htm IDEA: XBRL DOCUMENT v3.22.0.1
Significant Accounting Policies - Contract Balances (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Change in Contract with Customer, Liability [Roll Forward]    
Contract liabilities, beginning of period $ 71 $ 73
Rewards earnings and gift card issuances 387 357
Redemption and breakage (371) (359)
Contract liabilities, end of period $ 87 $ 71
XML 70 R50.htm IDEA: XBRL DOCUMENT v3.22.0.1
Significant Accounting Policies - Variable Interest Entities (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2014
Variable Interest Entity [Line Items]        
Long-term investments $ 23,025 $ 20,812    
Proceeds from VIE $ 183 183 $ 183  
Red Oak        
Variable Interest Entity [Line Items]        
VIE, ownership percentage       50.00%
Initial contractual term (in years)       10 years
Amended contract extension term 5 years      
Amended contract term (in years) 15 years      
Variable Interest Entity, Not Primary Beneficiary        
Variable Interest Entity [Line Items]        
Long-term investments $ 1,289 1,089    
Variable Interest Entity, Not Primary Beneficiary | Hedge fund investments        
Variable Interest Entity [Line Items]        
Long-term investments 463 342    
Variable Interest Entity, Not Primary Beneficiary | Private equity investments        
Variable Interest Entity [Line Items]        
Long-term investments 601 547    
Variable Interest Entity, Not Primary Beneficiary | Real estate partnerships        
Variable Interest Entity [Line Items]        
Long-term investments $ 225 $ 200    
XML 71 R51.htm IDEA: XBRL DOCUMENT v3.22.0.1
Significant Accounting Policies - Discontinued Operations (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Accounting Policies [Abstract]      
Loss from discontinued operations   $ (12)  
Income tax benefit   3  
Loss from discontinued operations, net of tax $ 0 $ (9) $ 0
XML 72 R52.htm IDEA: XBRL DOCUMENT v3.22.0.1
Divestitures - Narrative (Details)
$ in Millions
12 Months Ended
Jul. 31, 2020
USD ($)
Dec. 31, 2021
USD ($)
store
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Jul. 01, 2019
store
Business Acquisition [Line Items]          
Proceeds from sale of subsidiary   $ 0 $ 840 $ 0  
Gain (loss) on sale of subsidiaries   $ 0 269 (205)  
Retail/ LTC          
Business Acquisition [Line Items]          
Number of stores | store   9,900      
Discontinued Operations, Disposed of by Sale | Coventry Health Care Workers Compensation Business | Health Care Benefits          
Business Acquisition [Line Items]          
Proceeds from sale of subsidiary $ 850   850    
Gain (loss) on sale of subsidiaries     $ 269    
Discontinued Operations, Disposed of by Sale | Brazil Subsidiary | Retail/ LTC          
Business Acquisition [Line Items]          
Number of stores | store         50
Discontinued Operations, Disposed of by Sale | Drogaria onofre Ltda. | Retail/ LTC          
Business Acquisition [Line Items]          
Gain (loss) on sale of subsidiaries       $ (205)  
XML 73 R53.htm IDEA: XBRL DOCUMENT v3.22.0.1
Investments - Schedule of Total Investments (Details) - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Total Investments [Line Items]    
Current $ 3,117 $ 3,000
Long-term 23,025 20,812
Total 26,142 23,812
Debt securities available for sale    
Total Investments [Line Items]    
Current 3,009 2,774
Long-term 20,231 18,414
Total 23,240 21,188
Mortgage loans    
Total Investments [Line Items]    
Current 58 226
Long-term 844 821
Total 902 1,047
Other investments    
Total Investments [Line Items]    
Current 50 0
Long-term 1,950 1,577
Total $ 2,000 $ 1,577
XML 74 R54.htm IDEA: XBRL DOCUMENT v3.22.0.1
Investments - Narrative (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Debt Securities, Available-for-sale [Line Items]    
Investments related to 2012 contract conversion $ 450 $ 524
Residential mortgage-backed securities    
Debt Securities, Available-for-sale [Line Items]    
Weighted average duration of securities 4 years 8 months 12 days  
Commercial mortgage-backed securities    
Debt Securities, Available-for-sale [Line Items]    
Weighted average duration of securities 6 years 1 month 6 days  
Other asset-backed securities    
Debt Securities, Available-for-sale [Line Items]    
Weighted average duration of securities 1 year  
XML 75 R55.htm IDEA: XBRL DOCUMENT v3.22.0.1
Investments - Debt Securities (Details) - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost $ 22,174 $ 19,396
Gross Unrealized Gains 1,172 1,803
Gross Unrealized Losses (106) (11)
Fair Value 23,240 21,188
Allowance for credit loss 0 0
U.S. government securities    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 2,349 2,341
Gross Unrealized Gains 70 128
Gross Unrealized Losses (3) 0
Fair Value 2,416 2,469
States, municipalities and political subdivisions    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 2,947 2,556
Gross Unrealized Gains 148 172
Gross Unrealized Losses (4) 0
Fair Value 3,091 2,728
U.S. corporate securities    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 9,093 7,879
Gross Unrealized Gains 682 1,023
Gross Unrealized Losses (40) (8)
Fair Value 9,735 8,894
Foreign securities    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 2,821 2,595
Gross Unrealized Gains 196 324
Gross Unrealized Losses (24) (1)
Fair Value 2,993 2,918
Residential mortgage-backed securities    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 870 673
Gross Unrealized Gains 15 32
Gross Unrealized Losses (10) 0
Fair Value 875 705
Commercial mortgage-backed securities    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 1,278 962
Gross Unrealized Gains 44 84
Gross Unrealized Losses (12) 0
Fair Value 1,310 1,046
Other asset-backed securities    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 2,791 2,369
Gross Unrealized Gains 14 36
Gross Unrealized Losses (13) (2)
Fair Value 2,792 2,403
Redeemable preferred securities    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 25 21
Gross Unrealized Gains 3 4
Gross Unrealized Losses 0 0
Fair Value 28 25
Supporting experience- rated products    
Debt Securities, Available-for-sale [Line Items]    
Gross Unrealized Gains 94 135
Gross Unrealized Losses (2) 0
Fair Value $ 864 $ 919
XML 76 R56.htm IDEA: XBRL DOCUMENT v3.22.0.1
Investments - Debt Securities by Maturity (Details) - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Amortized Cost    
Less than one year $ 1,205  
One year through five years 6,965  
After five years through ten years 4,733  
Greater than ten years 4,332  
Amortized Cost 22,174 $ 19,396
Fair Value    
Less than one year 1,218  
One year through five years 7,142  
After five years through ten years 4,910  
Greater than ten years 4,993  
Total 23,240 21,188
Residential mortgage-backed securities    
Amortized Cost    
Debt securities, maturity, without single maturity date 870  
Amortized Cost 870 673
Fair Value    
Debt securities, maturity, without single maturity date 875  
Total 875 705
Commercial mortgage-backed securities    
Amortized Cost    
Debt securities, maturity, without single maturity date 1,278  
Amortized Cost 1,278 962
Fair Value    
Debt securities, maturity, without single maturity date 1,310  
Total 1,310 1,046
Other asset-backed securities    
Amortized Cost    
Debt securities, maturity, without single maturity date 2,791  
Amortized Cost 2,791 2,369
Fair Value    
Debt securities, maturity, without single maturity date 2,792  
Total $ 2,792 $ 2,403
XML 77 R57.htm IDEA: XBRL DOCUMENT v3.22.0.1
Investments - Unrealized Loss Position (Details)
$ in Millions
Dec. 31, 2021
USD ($)
security
Dec. 31, 2020
USD ($)
security
Number of Securities    
Number of Securities, Less than 12 months | security 3,700 468
Number of Securities, Greater than 12 months | security 317 59
Number of Securities | security 4,017 527
Fair Value    
Fair Value, Less than 12 months $ 6,800 $ 869
Fair Value, Greater than 12 months 584 46
Fair Value 7,384 915
Unrealized Losses    
Unrealized Losses, Less than 12 months 84 10
Unrealized Losses, Greater than 12 months 22 1
Unrealized Losses $ 106 $ 11
U.S. government securities    
Number of Securities    
Number of Securities, Less than 12 months | security 43 32
Number of Securities, Greater than 12 months | security 10 0
Number of Securities | security 53 32
Fair Value    
Fair Value, Less than 12 months $ 242 $ 205
Fair Value, Greater than 12 months 40 0
Fair Value 282 205
Unrealized Losses    
Unrealized Losses, Less than 12 months 2 0
Unrealized Losses, Greater than 12 months 1 0
Unrealized Losses $ 3 $ 0
States, municipalities and political subdivisions    
Number of Securities    
Number of Securities, Less than 12 months | security 233 49
Number of Securities, Greater than 12 months | security 13 0
Number of Securities | security 246 49
Fair Value    
Fair Value, Less than 12 months $ 428 $ 83
Fair Value, Greater than 12 months 33 0
Fair Value 461 83
Unrealized Losses    
Unrealized Losses, Less than 12 months 3 0
Unrealized Losses, Greater than 12 months 1 0
Unrealized Losses $ 4 $ 0
U.S. corporate securities    
Number of Securities    
Number of Securities, Less than 12 months | security 1,610 145
Number of Securities, Greater than 12 months | security 165 2
Number of Securities | security 1,775 147
Fair Value    
Fair Value, Less than 12 months $ 2,296 $ 155
Fair Value, Greater than 12 months 238 0
Fair Value 2,534 155
Unrealized Losses    
Unrealized Losses, Less than 12 months 31 8
Unrealized Losses, Greater than 12 months 9 0
Unrealized Losses $ 40 $ 8
Foreign securities    
Number of Securities    
Number of Securities, Less than 12 months | security 449 41
Number of Securities, Greater than 12 months | security 57 5
Number of Securities | security 506 46
Fair Value    
Fair Value, Less than 12 months $ 747 $ 69
Fair Value, Greater than 12 months 91 5
Fair Value 838 74
Unrealized Losses    
Unrealized Losses, Less than 12 months 20 1
Unrealized Losses, Greater than 12 months 4 0
Unrealized Losses $ 24 $ 1
Residential mortgage-backed securities    
Number of Securities    
Number of Securities, Less than 12 months | security 165 23
Number of Securities, Greater than 12 months | security 10 3
Number of Securities | security 175 26
Fair Value    
Fair Value, Less than 12 months $ 593 $ 26
Fair Value, Greater than 12 months 36 0
Fair Value 629 26
Unrealized Losses    
Unrealized Losses, Less than 12 months 9 0
Unrealized Losses, Greater than 12 months 1 0
Unrealized Losses $ 10 $ 0
Commercial mortgage-backed securities    
Number of Securities    
Number of Securities, Less than 12 months | security 188 22
Number of Securities, Greater than 12 months | security 35 0
Number of Securities | security 223 22
Fair Value    
Fair Value, Less than 12 months $ 462 $ 75
Fair Value, Greater than 12 months 112 0
Fair Value 574 75
Unrealized Losses    
Unrealized Losses, Less than 12 months 7 0
Unrealized Losses, Greater than 12 months 5 0
Unrealized Losses $ 12 $ 0
Other asset-backed securities    
Number of Securities    
Number of Securities, Less than 12 months | security 1,011 156
Number of Securities, Greater than 12 months | security 26 49
Number of Securities | security 1,037 205
Fair Value    
Fair Value, Less than 12 months $ 2,030 $ 256
Fair Value, Greater than 12 months 31 41
Fair Value 2,061 297
Unrealized Losses    
Unrealized Losses, Less than 12 months 12 1
Unrealized Losses, Greater than 12 months 1 1
Unrealized Losses $ 13 $ 2
Redeemable preferred securities    
Number of Securities    
Number of Securities, Less than 12 months | security 1  
Number of Securities, Greater than 12 months | security 1  
Number of Securities | security 2  
Fair Value    
Fair Value, Less than 12 months $ 2  
Fair Value, Greater than 12 months 3  
Fair Value 5  
Unrealized Losses    
Unrealized Losses, Less than 12 months 0  
Unrealized Losses, Greater than 12 months 0  
Unrealized Losses $ 0  
XML 78 R58.htm IDEA: XBRL DOCUMENT v3.22.0.1
Investments - Unrealized Loss Position Maturities (Details) - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Fair Value    
Less than one year $ 51  
One year through five years 2,242  
After five years through ten years 1,365  
Greater than ten years 462  
Fair Value 7,384 $ 915
Unrealized Losses    
Less than one year 1  
One year through five years 33  
After five years through ten years 27  
Greater than ten years 10  
Unrealized Losses 106 11
Residential mortgage-backed securities    
Fair Value    
Debt securities, maturity, without single maturity date, fair value 629  
Fair Value 629 26
Unrealized Losses    
Debt securities, maturity, without single maturity date, unrealized losses 10  
Unrealized Losses 10 0
Commercial mortgage-backed securities    
Fair Value    
Debt securities, maturity, without single maturity date, fair value 574  
Fair Value 574 75
Unrealized Losses    
Debt securities, maturity, without single maturity date, unrealized losses 12  
Unrealized Losses 12 0
Other asset-backed securities    
Fair Value    
Debt securities, maturity, without single maturity date, fair value 2,061  
Fair Value 2,061 297
Unrealized Losses    
Debt securities, maturity, without single maturity date, unrealized losses 13  
Unrealized Losses 13 $ 2
Supporting experience- rated products    
Fair Value    
Less than one year 2  
One year through five years 13  
After five years through ten years 33  
Greater than ten years 17  
Fair Value 79  
Unrealized Losses    
Less than one year 0  
One year through five years 1  
After five years through ten years 1  
Greater than ten years 0  
Unrealized Losses 2  
Supporting experience- rated products | Residential mortgage-backed securities    
Fair Value    
Debt securities, maturity, without single maturity date, fair value 4  
Unrealized Losses    
Debt securities, maturity, without single maturity date, unrealized losses 0  
Supporting experience- rated products | Commercial mortgage-backed securities    
Fair Value    
Debt securities, maturity, without single maturity date, fair value 6  
Unrealized Losses    
Debt securities, maturity, without single maturity date, unrealized losses 0  
Supporting experience- rated products | Other asset-backed securities    
Fair Value    
Debt securities, maturity, without single maturity date, fair value 4  
Unrealized Losses    
Debt securities, maturity, without single maturity date, unrealized losses 0  
Supporting remaining products    
Fair Value    
Less than one year 49  
One year through five years 2,229  
After five years through ten years 1,332  
Greater than ten years 445  
Fair Value 7,305  
Unrealized Losses    
Less than one year 1  
One year through five years 32  
After five years through ten years 26  
Greater than ten years 10  
Unrealized Losses 104  
Supporting remaining products | Residential mortgage-backed securities    
Fair Value    
Debt securities, maturity, without single maturity date, fair value 625  
Unrealized Losses    
Debt securities, maturity, without single maturity date, unrealized losses 10  
Supporting remaining products | Commercial mortgage-backed securities    
Fair Value    
Debt securities, maturity, without single maturity date, fair value 568  
Unrealized Losses    
Debt securities, maturity, without single maturity date, unrealized losses 12  
Supporting remaining products | Other asset-backed securities    
Fair Value    
Debt securities, maturity, without single maturity date, fair value 2,057  
Unrealized Losses    
Debt securities, maturity, without single maturity date, unrealized losses $ 13  
XML 79 R59.htm IDEA: XBRL DOCUMENT v3.22.0.1
Investments - Mortgage Loans (Details) - Commercial Real Estate - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Mortgage Loans on Real Estate [Line Items]    
New mortgage loans $ 262 $ 63
Mortgage loans fully repaid 373 187
Mortgage loans foreclosed $ 0 $ 0
XML 80 R60.htm IDEA: XBRL DOCUMENT v3.22.0.1
Investments - Mortgage Loans Credit Ratings Indicator (Details) - Commercial Real Estate - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Mortgage Loans on Real Estate [Line Items]    
Mortgage loans $ 902 $ 1,047
2021    
Mortgage Loans on Real Estate [Line Items]    
Mortgage loans 255  
2020    
Mortgage Loans on Real Estate [Line Items]    
Mortgage loans 48 46
2019    
Mortgage Loans on Real Estate [Line Items]    
Mortgage loans 40 96
2018    
Mortgage Loans on Real Estate [Line Items]    
Mortgage loans 75 94
2017    
Mortgage Loans on Real Estate [Line Items]    
Mortgage loans 101 150
Prior    
Mortgage Loans on Real Estate [Line Items]    
Mortgage loans 383 661
1    
Mortgage Loans on Real Estate [Line Items]    
Mortgage loans 28 59
1 | 2021    
Mortgage Loans on Real Estate [Line Items]    
Mortgage loans 0  
1 | 2020    
Mortgage Loans on Real Estate [Line Items]    
Mortgage loans 0 0
1 | 2019    
Mortgage Loans on Real Estate [Line Items]    
Mortgage loans 0 0
1 | 2018    
Mortgage Loans on Real Estate [Line Items]    
Mortgage loans 0 0
1 | 2017    
Mortgage Loans on Real Estate [Line Items]    
Mortgage loans 0 22
1 | Prior    
Mortgage Loans on Real Estate [Line Items]    
Mortgage loans 28 37
2 to 4    
Mortgage Loans on Real Estate [Line Items]    
Mortgage loans 861 952
2 to 4 | 2021    
Mortgage Loans on Real Estate [Line Items]    
Mortgage loans 255  
2 to 4 | 2020    
Mortgage Loans on Real Estate [Line Items]    
Mortgage loans 48 46
2 to 4 | 2019    
Mortgage Loans on Real Estate [Line Items]    
Mortgage loans 40 96
2 to 4 | 2018    
Mortgage Loans on Real Estate [Line Items]    
Mortgage loans 72 91
2 to 4 | 2017    
Mortgage Loans on Real Estate [Line Items]    
Mortgage loans 97 124
2 to 4 | Prior    
Mortgage Loans on Real Estate [Line Items]    
Mortgage loans 349 595
5 and 6    
Mortgage Loans on Real Estate [Line Items]    
Mortgage loans 13 36
5 and 6 | 2021    
Mortgage Loans on Real Estate [Line Items]    
Mortgage loans 0  
5 and 6 | 2020    
Mortgage Loans on Real Estate [Line Items]    
Mortgage loans 0 0
5 and 6 | 2019    
Mortgage Loans on Real Estate [Line Items]    
Mortgage loans 0 0
5 and 6 | 2018    
Mortgage Loans on Real Estate [Line Items]    
Mortgage loans 3 3
5 and 6 | 2017    
Mortgage Loans on Real Estate [Line Items]    
Mortgage loans 4 4
5 and 6 | Prior    
Mortgage Loans on Real Estate [Line Items]    
Mortgage loans 6 29
7    
Mortgage Loans on Real Estate [Line Items]    
Mortgage loans 0 0
7 | 2021    
Mortgage Loans on Real Estate [Line Items]    
Mortgage loans 0  
7 | 2020    
Mortgage Loans on Real Estate [Line Items]    
Mortgage loans 0 0
7 | 2019    
Mortgage Loans on Real Estate [Line Items]    
Mortgage loans 0 0
7 | 2018    
Mortgage Loans on Real Estate [Line Items]    
Mortgage loans 0 0
7 | 2017    
Mortgage Loans on Real Estate [Line Items]    
Mortgage loans 0 0
7 | Prior    
Mortgage Loans on Real Estate [Line Items]    
Mortgage loans $ 0 $ 0
XML 81 R61.htm IDEA: XBRL DOCUMENT v3.22.0.1
Investments - Schedule of Mortgage Loan Principal Repayments (Details) - Commercial Real Estate
$ in Millions
Dec. 31, 2021
USD ($)
Mortgage Loans on Real Estate [Line Items]  
2022 $ 58
2023 100
2024 210
2025 76
2026 177
Thereafter 281
Total $ 902
XML 82 R62.htm IDEA: XBRL DOCUMENT v3.22.0.1
Investments - Net Investment Income (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Schedule of Investment Income, Reported Amounts, by Category [Line Items]      
Gross investment income $ 1,070 $ 781 $ 854
Investment expenses (47) (35) (42)
Net investment income (excluding net realized capital gains or losses) 1,023 746 812
Net realized capital gains 176 52 199
Net investment income 1,199 798 1,011
Yield-related impairment loss (42) (49)  
Credit-related impairment loss 0 0  
OTTI losses, investments, portion recognized in earnings, net     (24)
Supporting experience- rated products      
Schedule of Investment Income, Reported Amounts, by Category [Line Items]      
Net investment income 38 42 44
Debt securities      
Schedule of Investment Income, Reported Amounts, by Category [Line Items]      
Gross investment income 634 598 589
Mortgage loans      
Schedule of Investment Income, Reported Amounts, by Category [Line Items]      
Gross investment income 55 60 71
Other investments      
Schedule of Investment Income, Reported Amounts, by Category [Line Items]      
Gross investment income $ 381 $ 123 $ 194
XML 83 R63.htm IDEA: XBRL DOCUMENT v3.22.0.1
Investments - Realized Gains (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Investments [Abstract]      
Proceeds from sales $ 3,572 $ 3,913 $ 4,773
Gross realized capital gains 72 80 146
Gross realized capital losses $ 14 $ 62 $ 17
XML 84 R64.htm IDEA: XBRL DOCUMENT v3.22.0.1
Fair Value - Fair Value Measurements (Details) - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities $ 23,240 $ 21,188
U.S. government securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities 2,416 2,469
States, municipalities and political subdivisions    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities 3,091 2,728
U.S. corporate securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities 9,735 8,894
Foreign securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities 2,993 2,918
Residential mortgage-backed securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities 875 705
Commercial mortgage-backed securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities 1,310 1,046
Other asset-backed securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities 2,792 2,403
Redeemable preferred securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities 28 25
Recurring    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial liabilities fair value on a recurring basis 0 0
Cash and cash equivalents 9,408 7,854
Debt securities 23,240 21,188
Equity securities 169 47
Total 32,817 29,089
Recurring | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents 4,954 3,985
Debt securities 2,372 2,370
Equity securities 114 17
Total 7,440 6,372
Recurring | Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents 4,454 3,869
Debt securities 20,812 18,764
Equity securities 0 0
Total 25,266 22,633
Recurring | Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents 0 0
Debt securities 56 54
Equity securities 55 30
Total 111 84
Recurring | U.S. government securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities 2,416 2,469
Recurring | U.S. government securities | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities 2,372 2,370
Recurring | U.S. government securities | Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities 44 99
Recurring | U.S. government securities | Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities 0 0
Recurring | States, municipalities and political subdivisions    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities 3,091 2,728
Recurring | States, municipalities and political subdivisions | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities 0 0
Recurring | States, municipalities and political subdivisions | Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities 3,086 2,727
Recurring | States, municipalities and political subdivisions | Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities 5 1
Recurring | U.S. corporate securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities 9,735 8,894
Recurring | U.S. corporate securities | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities 0 0
Recurring | U.S. corporate securities | Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities 9,697 8,842
Recurring | U.S. corporate securities | Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities 38 52
Recurring | Foreign securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities 2,993 2,918
Recurring | Foreign securities | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities 0 0
Recurring | Foreign securities | Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities 2,983 2,918
Recurring | Foreign securities | Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities 10 0
Recurring | Residential mortgage-backed securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities 875 705
Recurring | Residential mortgage-backed securities | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities 0 0
Recurring | Residential mortgage-backed securities | Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities 875 705
Recurring | Residential mortgage-backed securities | Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities 0 0
Recurring | Commercial mortgage-backed securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities 1,310 1,046
Recurring | Commercial mortgage-backed securities | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities 0 0
Recurring | Commercial mortgage-backed securities | Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities 1,310 1,046
Recurring | Commercial mortgage-backed securities | Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities 0 0
Recurring | Other asset-backed securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities 2,792 2,403
Recurring | Other asset-backed securities | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities 0 0
Recurring | Other asset-backed securities | Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities 2,789 2,403
Recurring | Other asset-backed securities | Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities 3 0
Recurring | Redeemable preferred securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities 28 25
Recurring | Redeemable preferred securities | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities 0 0
Recurring | Redeemable preferred securities | Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities 28 24
Recurring | Redeemable preferred securities | Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities $ 0 $ 1
XML 85 R65.htm IDEA: XBRL DOCUMENT v3.22.0.1
Fair Value - Changes in Level 3 Financial Assets (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Net realized and unrealized capital gains (losses):    
Change in unrealized capital losses included in OCI associated with Level 3 financial assets $ (4) $ (4)
Recurring    
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Beginning balance 84 88
Net realized and unrealized capital gains (losses):    
Included in earnings  5 4
Included in other comprehensive income (4) (5)
Purchases 17 30
Sales (5) (33)
Settlements (1) (1)
Transfers into Level 3, net 15 1
Ending balance 111 84
States, municipalities and political subdivisions | Recurring    
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Beginning balance 1 0
Net realized and unrealized capital gains (losses):    
Included in earnings  0 0
Included in other comprehensive income 0 0
Purchases 0 0
Sales (1) 0
Settlements 0 0
Transfers into Level 3, net 5 1
Ending balance 5 1
U.S. corporate securities | Recurring    
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Beginning balance 52 37
Net realized and unrealized capital gains (losses):    
Included in earnings  (10) (11)
Included in other comprehensive income (3) 0
Purchases 1 27
Sales (1) 0
Settlements (1) (1)
Transfers into Level 3, net 0 0
Ending balance 38 52
Foreign securities | Recurring    
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Beginning balance 0  
Net realized and unrealized capital gains (losses):    
Included in earnings  0  
Included in other comprehensive income 0  
Purchases 0  
Sales 0  
Settlements 0  
Transfers into Level 3, net 10  
Ending balance 10 0
Other asset-backed securities | Recurring    
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Beginning balance 0  
Net realized and unrealized capital gains (losses):    
Included in earnings  0  
Included in other comprehensive income 0  
Purchases 3  
Sales 0  
Settlements 0  
Transfers into Level 3, net 0  
Ending balance 3 0
Redeemable preferred securities | Recurring    
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Beginning balance 1 12
Net realized and unrealized capital gains (losses):    
Included in earnings  2 18
Included in other comprehensive income (1) (5)
Purchases 0 0
Sales (2) (24)
Settlements 0 0
Transfers into Level 3, net 0 0
Ending balance 0 1
Equity securities | Recurring    
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Beginning balance 30 39
Net realized and unrealized capital gains (losses):    
Included in earnings  13 (3)
Included in other comprehensive income 0 0
Purchases 13 3
Sales (1) (9)
Settlements 0 0
Transfers into Level 3, net 0 0
Ending balance $ 55 $ 30
XML 86 R66.htm IDEA: XBRL DOCUMENT v3.22.0.1
Fair Value - Gross Transfers Into (Out Of) Level 3 (Details) - Recurring - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Net transfers into Level 3 $ 15 $ 1
Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Gross transfers into Level 3 15 1
Gross transfers out of Level 3 0 0
Net transfers into Level 3 $ 15 $ 1
XML 87 R67.htm IDEA: XBRL DOCUMENT v3.22.0.1
Fair Value - Carrying Value and Fair Value Classified by Level (Details) - Nonrecurring - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Carrying Value    
Assets:    
Mortgage loans $ 902 $ 1,047
Equity securities 126 145
Liabilities:    
Investment contracts with a fixed maturity 5 5
Investment contracts without a fixed maturity 336 322
Long-term debt 56,176 64,647
Estimated Fair Value    
Assets:    
Mortgage loans 907 1,070
Liabilities:    
Investment contracts with a fixed maturity 5 5
Investment contracts without a fixed maturity 373 371
Long-term debt 64,157 75,940
Level 1 | Estimated Fair Value    
Assets:    
Mortgage loans 0 0
Liabilities:    
Investment contracts with a fixed maturity 0 0
Investment contracts without a fixed maturity 0 0
Long-term debt 64,157 75,940
Level 2 | Estimated Fair Value    
Assets:    
Mortgage loans 0 0
Liabilities:    
Investment contracts with a fixed maturity 0 0
Investment contracts without a fixed maturity 0 0
Long-term debt 0 0
Level 3 | Estimated Fair Value    
Assets:    
Mortgage loans 907 1,070
Liabilities:    
Investment contracts with a fixed maturity 5 5
Investment contracts without a fixed maturity 373 371
Long-term debt $ 0 $ 0
XML 88 R68.htm IDEA: XBRL DOCUMENT v3.22.0.1
Fair Value - Separate Accounts Fair Value (Details) - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Fair Value, Separate Account Investment [Line Items]    
Separate accounts assets $ 5,087 $ 4,881
Recurring    
Fair Value, Separate Account Investment [Line Items]    
Separate accounts assets 5,017 4,852
Recurring | Other receivables    
Fair Value, Separate Account Investment [Line Items]    
Separate accounts assets 70 29
Recurring | Cash and cash equivalents    
Fair Value, Separate Account Investment [Line Items]    
Separate accounts assets 188 188
Recurring | Debt securities    
Fair Value, Separate Account Investment [Line Items]    
Separate accounts assets 4,281 4,099
Recurring | Equity securities    
Fair Value, Separate Account Investment [Line Items]    
Separate accounts assets 1 2
Recurring | Common/collective trusts    
Fair Value, Separate Account Investment [Line Items]    
Separate accounts assets 547 563
Recurring | Level 1    
Fair Value, Separate Account Investment [Line Items]    
Separate accounts assets 1,235 1,467
Recurring | Level 1 | Cash and cash equivalents    
Fair Value, Separate Account Investment [Line Items]    
Separate accounts assets 2 2
Recurring | Level 1 | Debt securities    
Fair Value, Separate Account Investment [Line Items]    
Separate accounts assets 1,233 1,465
Recurring | Level 1 | Equity securities    
Fair Value, Separate Account Investment [Line Items]    
Separate accounts assets 0 0
Recurring | Level 1 | Common/collective trusts    
Fair Value, Separate Account Investment [Line Items]    
Separate accounts assets 0 0
Recurring | Level 2    
Fair Value, Separate Account Investment [Line Items]    
Separate accounts assets 3,782 3,385
Recurring | Level 2 | Cash and cash equivalents    
Fair Value, Separate Account Investment [Line Items]    
Separate accounts assets 186 186
Recurring | Level 2 | Debt securities    
Fair Value, Separate Account Investment [Line Items]    
Separate accounts assets 3,048 2,634
Recurring | Level 2 | Equity securities    
Fair Value, Separate Account Investment [Line Items]    
Separate accounts assets 1 2
Recurring | Level 2 | Common/collective trusts    
Fair Value, Separate Account Investment [Line Items]    
Separate accounts assets 547 563
Recurring | Level 3    
Fair Value, Separate Account Investment [Line Items]    
Separate accounts assets 0 0
Recurring | Level 3 | Cash and cash equivalents    
Fair Value, Separate Account Investment [Line Items]    
Separate accounts assets 0 0
Recurring | Level 3 | Debt securities    
Fair Value, Separate Account Investment [Line Items]    
Separate accounts assets 0 0
Recurring | Level 3 | Equity securities    
Fair Value, Separate Account Investment [Line Items]    
Separate accounts assets 0 0
Recurring | Level 3 | Common/collective trusts    
Fair Value, Separate Account Investment [Line Items]    
Separate accounts assets $ 0 $ 0
XML 89 R69.htm IDEA: XBRL DOCUMENT v3.22.0.1
Fair Value - Narrative (Details) - Recurring - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Transfers into Level 3, net $ 15 $ 1
Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Transfers into Level 3, net 15 1
Level 3 | Separate Accounts, financial assets    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Transfers into Level 3, net $ 0 $ 0
XML 90 R70.htm IDEA: XBRL DOCUMENT v3.22.0.1
Goodwill and Other Intangibles - Goodwill (Details) - USD ($)
3 Months Ended 12 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Goodwill [Roll Forward]          
Balance, beginning of the period     $ 79,552,000,000 $ 79,749,000,000  
Acquisitions       308,000,000  
Divestiture of Workers’ Compensation business       (505,000,000)  
Impairment $ 0 $ 0 (431,000,000) 0 $ 0
Balance, end of the period     79,121,000,000 79,552,000,000 79,749,000,000
Health Care Benefits          
Goodwill [Roll Forward]          
Balance, beginning of the period     45,130,000,000 45,361,000,000  
Acquisitions       274,000,000  
Divestiture of Workers’ Compensation business       (505,000,000)  
Impairment     0    
Balance, end of the period     45,130,000,000 45,130,000,000 45,361,000,000
Pharmacy Services          
Goodwill [Roll Forward]          
Balance, beginning of the period     23,615,000,000 23,581,000,000  
Acquisitions       34,000,000  
Divestiture of Workers’ Compensation business       0  
Impairment     0    
Balance, end of the period     23,615,000,000 23,615,000,000 23,581,000,000
Retail/ LTC          
Goodwill [Roll Forward]          
Balance, beginning of the period     10,807,000,000 10,807,000,000  
Acquisitions       0  
Divestiture of Workers’ Compensation business       0  
Impairment     (431,000,000)    
Balance, end of the period     $ 10,376,000,000 $ 10,807,000,000 $ 10,807,000,000
XML 91 R71.htm IDEA: XBRL DOCUMENT v3.22.0.1
Goodwill and Other Intangibles - Narrative (Details) - USD ($)
3 Months Ended 12 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Goodwill [Line Items]            
Goodwill impairment   $ 0 $ 0 $ 431,000,000 $ 0 $ 0
Goodwill       79,121,000,000 79,552,000,000 $ 79,749,000,000
Cumulative goodwill impairments       6,600,000,000 $ 6,100,000,000  
Long-Term Care Reporting Unit            
Goodwill [Line Items]            
Goodwill impairment $ 431,000,000          
Goodwill       0    
Long-Term Care Reporting Unit | Customer Lists            
Goodwill [Line Items]            
Intangible assets related to customer lists       $ 2,700,000,000    
XML 92 R72.htm IDEA: XBRL DOCUMENT v3.22.0.1
Goodwill and Other Intangibles - Intangible Assets (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Other Intangible Assets[Line Items]      
Indefinite-lived intangible assets, Trademarks $ 10,498 $ 10,498  
Finite-lived intangible assets, accumulated amortization (12,727) (10,481)  
Intangible assets, gross 41,753 41,623  
Intangible assets, net $ 29,026 $ 31,142  
Weighted Average Life (years) 15 years 3 months 18 days 15 years 2 months 12 days  
Amortization of intangible assets $ 2,259 $ 2,341 $ 2,436
Customer contracts/relationships and covenants not to compete      
Other Intangible Assets[Line Items]      
Finite-lived intangible assets, gross carrying amount 25,084 24,952  
Finite-lived intangible assets, accumulated amortization (10,564) (8,923)  
Finite-lived intangible assets, net carrying amount $ 14,520 $ 16,029  
Weighted Average Life (years) 15 years 14 years 10 months 24 days  
Technology      
Other Intangible Assets[Line Items]      
Finite-lived intangible assets, gross carrying amount $ 1,060 $ 1,060  
Finite-lived intangible assets, accumulated amortization (1,060) (739)  
Finite-lived intangible assets, net carrying amount $ 0 $ 321  
Weighted Average Life (years) 3 years 3 years  
Provider networks      
Other Intangible Assets[Line Items]      
Finite-lived intangible assets, gross carrying amount $ 4,203 $ 4,203  
Finite-lived intangible assets, accumulated amortization (651) (440)  
Finite-lived intangible assets, net carrying amount $ 3,552 $ 3,763  
Weighted Average Life (years) 20 years 20 years  
Value of Business Acquired      
Other Intangible Assets[Line Items]      
Finite-lived intangible assets, gross carrying amount $ 590 $ 590  
Finite-lived intangible assets, accumulated amortization (173) (119)  
Finite-lived intangible assets, net carrying amount $ 417 $ 471  
Weighted Average Life (years) 20 years 20 years  
Other      
Other Intangible Assets[Line Items]      
Finite-lived intangible assets, gross carrying amount $ 318 $ 320  
Finite-lived intangible assets, accumulated amortization (279) (260)  
Finite-lived intangible assets, net carrying amount $ 39 $ 60  
Weighted Average Life (years) 8 years 4 months 24 days 7 years 8 months 12 days  
XML 93 R73.htm IDEA: XBRL DOCUMENT v3.22.0.1
Goodwill and Other Acquired Intangibles - Future Amortization Expense (Details)
$ in Millions
Dec. 31, 2021
USD ($)
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]  
2022 $ 1,858
2023 1,826
2024 1,785
2025 1,734
2026 $ 1,494
XML 94 R74.htm IDEA: XBRL DOCUMENT v3.22.0.1
Leases - Narrative (Details)
$ in Millions
3 Months Ended 12 Months Ended
Dec. 31, 2021
USD ($)
store
Dec. 31, 2021
USD ($)
store
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
store
Operating Leased Assets [Line Items]        
Proceeds from sale-leaseback transactions   $ 0.0 $ 101.0 $ 5.0
Gains from sale-leaseback transactions     3.0 $ 0.0
Number of stores, planned closure | store   900   68
Store impairment charges   $ 1,358.0 $ 0.0 $ 231.0
Retail/ LTC        
Operating Leased Assets [Line Items]        
Number of stores, planned closure | store 900 900   68
Number of stores, planned closure period (in years) 3 years      
Number of stores, annual planned closures for closure period | store 300      
Store impairment charges $ 1,400.0 $ 1,400.0    
Distribution centers and Corporate offices | Minimum        
Operating Leased Assets [Line Items]        
Operating lease term (in years) 15 years 15 years    
Finance lease term (in years) 15 years 15 years    
Distribution centers and Corporate offices | Maximum        
Operating Leased Assets [Line Items]        
Operating lease term (in years) 25 years 25 years    
Finance lease term (in years) 25 years 25 years    
Equipment | Minimum        
Operating Leased Assets [Line Items]        
Operating lease term (in years) 3 years 3 years    
Finance lease term (in years) 3 years 3 years    
Equipment | Maximum        
Operating Leased Assets [Line Items]        
Operating lease term (in years) 10 years 10 years    
Finance lease term (in years) 10 years 10 years    
Operating lease assets | Retail/ LTC        
Operating Leased Assets [Line Items]        
Store impairment charges $ 1,100.0      
Operating lease, right-of-use asset, fair value 356.0 $ 356.0    
Property and equipment | Retail/ LTC        
Operating Leased Assets [Line Items]        
Store impairment charges 261.0      
Property and equipment, fair value $ 185.0 $ 185.0    
XML 95 R75.htm IDEA: XBRL DOCUMENT v3.22.0.1
Leases - Summary of the Components of Net Lease Cost (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Leases [Abstract]      
Operating lease cost $ 2,633 $ 2,670 $ 2,720
Finance lease cost:      
Amortization of right-of-use assets 62 56 38
Interest on lease liabilities 62 58 44
Total finance lease costs 124 114 82
Short-term lease costs 25 22 24
Variable lease costs 604 599 581
Less: sublease income 59 55 50
Lease, Cost, Total $ 3,327 $ 3,350 $ 3,357
XML 96 R76.htm IDEA: XBRL DOCUMENT v3.22.0.1
Leases - Supplemental Cash Flow Information (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Cash paid for amounts included in the measurement of lease liabilities:      
Operating cash flows paid for operating leases $ 2,714 $ 2,724 $ 2,701
Operating cash flows paid for interest portion of finance leases 62 58 44
Financing cash flows paid for principal portion of finance leases 50 34 26
Right-of-use assets obtained in exchange for lease obligations:      
Operating leases 1,254 1,679 1,824
Finance leases $ 278 $ 313 $ 283
XML 97 R77.htm IDEA: XBRL DOCUMENT v3.22.0.1
Leases - Supplemental Balance Sheet Information (Details) - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Operating leases:    
Operating lease right-of-use assets $ 19,122 $ 20,729
Current portion of operating lease liabilities 1,646 1,638
Long-term operating lease liabilities 18,177 18,757
Total operating lease liabilities 19,823 20,395
Finance leases:    
Property and equipment, gross 1,375 1,107
Accumulated depreciation (188) (106)
Property and equipment, net 1,187 1,001
Current portion of long-term debt 50 33
Long-term debt 1,250 1,050
Total finance lease liabilities $ 1,300 $ 1,083
Weighted average remaining lease term (in years)    
Operating leases 12 years 9 months 18 days 13 years 3 months 18 days
Finance leases 20 years 20 years 3 months 18 days
Weighted average discount rate    
Operating leases 4.40% 4.50%
Finance leases 5.00% 5.60%
XML 98 R78.htm IDEA: XBRL DOCUMENT v3.22.0.1
Leases - Maturities of Operating and Finance Lease Liabilities (Details) - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Finance Leases    
2022 $ 122  
2023 121  
2024 111  
2025 110  
2026 109  
Thereafter 1,495  
Total lease payments 2,068  
Less: imputed interest (768)  
Total finance lease liabilities 1,300 $ 1,083
Operating Leases    
2022 2,685  
2023 2,613  
2024 2,398  
2025 2,217  
2026 2,054  
Thereafter 14,103  
Total lease payments 26,070  
Less: imputed interest (6,247)  
Total operating lease liabilities 19,823 $ 20,395
Total    
2022 2,807  
2023 2,734  
2024 2,509  
2025 2,327  
2026 2,163  
Thereafter 15,598  
Total lease payments 28,138  
Less: imputed interest (7,015)  
Total lease liabilities 21,123  
Future noncancelable subleases, future minimum payments 311  
Leases, amount due in excess of remaining estimated economic life $ 2,400  
XML 99 R79.htm IDEA: XBRL DOCUMENT v3.22.0.1
Health Care Costs Payable - Incurred and Paid Health Care Claims Development (Details) - Health Insurance Product Line - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Claims Development [Line Items]    
Incurred Health Care Claims, Net of Reinsurance $ 116,634  
Cumulative Paid Health Care Claims, Net of Reinsurance 108,190  
All outstanding liabilities for health care costs payable prior to 2020, net of reinsurance 130  
Total outstanding liabilities for health care costs payable, net of reinsurance 8,574  
2020    
Claims Development [Line Items]    
Incurred Health Care Claims, Net of Reinsurance 53,804 $ 54,529
Cumulative Paid Health Care Claims, Net of Reinsurance 53,590 $ 47,567
2021    
Claims Development [Line Items]    
Incurred Health Care Claims, Net of Reinsurance 62,830  
Cumulative Paid Health Care Claims, Net of Reinsurance $ 54,600  
XML 100 R80.htm IDEA: XBRL DOCUMENT v3.22.0.1
Health Care Costs Payable - Narrative (Details)
$ in Billions
Dec. 31, 2021
USD ($)
Health Care Benefits  
Liability for Claims and Claims Adjustment Expense [Line Items]  
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) claims liability, net $ 6.6
XML 101 R81.htm IDEA: XBRL DOCUMENT v3.22.0.1
Health Care Costs Payable - Reconciliation of Health Care Net Incurred and Paid Claims Development to Health Care Costs Payable Liability (Details) - Health Insurance Product Line - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]        
Short-duration health care costs payable, net of reinsurance $ 8,574      
Reinsurance recoverables 8 $ 10 $ 5 $ 4
Premium deficiency reserve 16 11 4  
Insurance lines other than short duration 210      
Total health care costs payable $ 8,808 $ 7,936 $ 6,879 $ 6,147
XML 102 R82.htm IDEA: XBRL DOCUMENT v3.22.0.1
Health Care Costs Payable - Reconciliation of Health Care Costs Payable (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]      
Health care costs payable, beginning of period, net $ 7,936    
Less: Claims paid      
Health care costs payable, end of period, net 8,808 $ 7,936  
Health Care Benefits      
Less: Claims paid      
Benefit costs recorded in other insurance liabilities 59 41 $ 41
Corporate/ Other      
Less: Claims paid      
Benefit costs recorded in other insurance liabilities 212 221 285
Health Insurance Product Line      
Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]      
Health care costs payable, beginning of period 7,936 6,879 6,147
Less: Reinsurance recoverables 10 5 4
Health care costs payable, beginning of period, net 7,926 6,874 6,143
Acquisitions, net 0 414 0
Add: Components of incurred health care costs      
Current year 64,761 55,835 52,723
Decrease in prior years' healthcare costs payable (788) (429) (524)
Total incurred health care costs 63,973 55,406 52,199
Less: Claims paid      
Current year 56,323 48,770 46,158
Prior years 6,792 6,009 5,314
Total claims paid 63,115 54,779 51,472
Add: Premium deficiency reserve 16 11 4
Health care costs payable, end of period, net 8,800 7,926 6,874
Add: Reinsurance recoverables 8 10 5
Health care costs payable, end of period $ 8,808 $ 7,936 $ 6,879
XML 103 R83.htm IDEA: XBRL DOCUMENT v3.22.0.1
Borrowings and Credit Arrangements - Schedule of Debt (Details) - USD ($)
$ in Millions
Dec. 31, 2021
Aug. 18, 2021
Dec. 31, 2020
Aug. 31, 2020
Aug. 31, 2019
Debt Instrument [Line Items]          
Long-term debt $ 55,443        
Finance lease liabilities 1,300   $ 1,083    
Total debt principal 56,743   65,318    
Debt premiums 219   238    
Debt discounts and deferred financing costs (786)   (909)    
Long-term debt and lease obligations 56,176   64,647    
Current portion of long-term debt (4,205)   (5,440)    
Long-term debt $ 51,971   $ 59,207    
Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration] Long-term debt   Long-term debt    
Senior Notes | 3.35% senior notes due March 2021          
Debt Instrument [Line Items]          
Debt interest rate 3.35%       3.35%
Long-term debt $ 0   $ 2,038    
Senior Notes | 4.125% senior notes due May 2021          
Debt Instrument [Line Items]          
Debt interest rate 4.125%       4.125%
Long-term debt $ 0   222    
Senior Notes | 2.125% senior notes due June 2021          
Debt Instrument [Line Items]          
Debt interest rate 2.125%        
Long-term debt $ 0   1,750    
Senior Notes | 4.125% senior notes due June 2021          
Debt Instrument [Line Items]          
Debt interest rate 4.125%       4.125%
Long-term debt $ 0   203    
Senior Notes | 5.45% senior notes due June 2021          
Debt Instrument [Line Items]          
Debt interest rate 5.45%       5.45%
Long-term debt $ 0   187    
Senior Notes | 3.5% senior notes due July 2022          
Debt Instrument [Line Items]          
Debt interest rate 3.50%        
Long-term debt $ 1,500   1,500    
Senior Notes | 2.75% senior notes due November 2022          
Debt Instrument [Line Items]          
Debt interest rate 2.75%        
Long-term debt $ 1,000   1,000    
Senior Notes | 2.75% senior notes due December 2022          
Debt Instrument [Line Items]          
Debt interest rate 2.75%        
Long-term debt $ 1,250   1,250    
Senior Notes | 4.75% senior notes due December 2022          
Debt Instrument [Line Items]          
Debt interest rate 4.75%        
Long-term debt $ 399   $ 399    
Senior Notes | 3.7% senior notes due March 2023          
Debt Instrument [Line Items]          
Debt interest rate 3.70%   3.70% 3.70%  
Long-term debt $ 0   $ 2,336    
Senior Notes | 2.8% senior notes due June 2023          
Debt Instrument [Line Items]          
Debt interest rate 2.80%        
Long-term debt $ 1,300   $ 1,300    
Senior Notes | 4% senior notes due December 2023          
Debt Instrument [Line Items]          
Debt interest rate 4.00%   4.00% 4.00%  
Long-term debt $ 414   $ 414    
Senior Notes | 3.375% senior notes due August 2024          
Debt Instrument [Line Items]          
Debt interest rate 3.375%        
Long-term debt $ 650   650    
Senior Notes | 2.625% senior notes due August 2024          
Debt Instrument [Line Items]          
Debt interest rate 2.625%        
Long-term debt $ 1,000   1,000    
Senior Notes | 3.5% senior notes due November 2024          
Debt Instrument [Line Items]          
Debt interest rate 3.50%        
Long-term debt $ 750   750    
Senior Notes | 5% senior notes due December 2024          
Debt Instrument [Line Items]          
Debt interest rate 5.00%        
Long-term debt $ 299   $ 299    
Senior Notes | 4.1% senior notes due March 2025          
Debt Instrument [Line Items]          
Debt interest rate 4.10%   4.10% 4.10%  
Long-term debt $ 950   $ 950    
Senior Notes | 3.875% senior notes due July 2025          
Debt Instrument [Line Items]          
Debt interest rate 3.875%        
Long-term debt $ 2,828   2,828    
Senior Notes | 2.875% senior notes due June 2026          
Debt Instrument [Line Items]          
Debt interest rate 2.875%        
Long-term debt $ 1,750   1,750    
Senior Notes | 3% senior notes due August 2026          
Debt Instrument [Line Items]          
Debt interest rate 3.00%        
Long-term debt $ 750   750    
Senior Notes | 3.625% senior notes due April 2027          
Debt Instrument [Line Items]          
Debt interest rate 3.625%        
Long-term debt $ 750   750    
Senior Notes | 6.25% senior notes due June 2027          
Debt Instrument [Line Items]          
Debt interest rate 6.25%        
Long-term debt $ 372   372    
Senior Notes | 1.3% senior notes due August 2027          
Debt Instrument [Line Items]          
Debt interest rate 1.30%        
Long-term debt $ 2,250   2,250    
Senior Notes | 4.3% senior notes due March 2028          
Debt Instrument [Line Items]          
Debt interest rate 4.30%        
Long-term debt $ 5,000   7,050    
Senior Notes | 3.25% senior notes due August 2029          
Debt Instrument [Line Items]          
Debt interest rate 3.25%        
Long-term debt $ 1,750   1,750    
Senior Notes | 3.75% senior notes due April 2030          
Debt Instrument [Line Items]          
Debt interest rate 3.75%        
Long-term debt $ 1,500   1,500    
Senior Notes | 1.75% senior notes due August 2030          
Debt Instrument [Line Items]          
Debt interest rate 1.75%        
Long-term debt $ 1,250   1,250    
Senior Notes | 1.875% senior notes due February 2031          
Debt Instrument [Line Items]          
Debt interest rate 1.875%        
Long-term debt $ 1,250   1,250    
Senior Notes | 2.125% senior notes due September 2031          
Debt Instrument [Line Items]          
Debt interest rate 2.125% 2.125%      
Long-term debt $ 1,000   0    
Senior Notes | 4.875% senior notes due July 2035          
Debt Instrument [Line Items]          
Debt interest rate 4.875%        
Long-term debt $ 652   652    
Senior Notes | 6.625% senior notes due June 2036          
Debt Instrument [Line Items]          
Debt interest rate 6.625%        
Long-term debt $ 771   771    
Senior Notes | 6.75% senior notes due December 2037          
Debt Instrument [Line Items]          
Debt interest rate 6.75%        
Long-term debt $ 533   533    
Senior Notes | 4.78% senior notes due March 2038          
Debt Instrument [Line Items]          
Debt interest rate 4.78%        
Long-term debt $ 5,000   5,000    
Senior Notes | 6.125% senior notes due September 2039          
Debt Instrument [Line Items]          
Debt interest rate 6.125%        
Long-term debt $ 447   447    
Senior Notes | 4.125% senior notes due April 2040          
Debt Instrument [Line Items]          
Debt interest rate 4.125%        
Long-term debt $ 1,000   1,000    
Senior Notes | 2.7% senior notes due August 2040          
Debt Instrument [Line Items]          
Debt interest rate 2.70%        
Long-term debt $ 1,250   1,250    
Senior Notes | 5.75% senior notes due May 2041          
Debt Instrument [Line Items]          
Debt interest rate 5.75%        
Long-term debt $ 133   133    
Senior Notes | 4.5% senior notes due May 2042          
Debt Instrument [Line Items]          
Debt interest rate 4.50%        
Long-term debt $ 500   500    
Senior Notes | 4.125% senior notes due November 2042          
Debt Instrument [Line Items]          
Debt interest rate 4.125%        
Long-term debt $ 500   500    
Senior Notes | 5.3% senior notes due December 2043          
Debt Instrument [Line Items]          
Debt interest rate 5.30%        
Long-term debt $ 750   750    
Senior Notes | 4.75% senior notes due March 2044          
Debt Instrument [Line Items]          
Debt interest rate 4.75%        
Long-term debt $ 375   375    
Senior Notes | 5.125% senior notes due July 2045          
Debt Instrument [Line Items]          
Debt interest rate 5.125%        
Long-term debt $ 3,500   3,500    
Senior Notes | 3.875% senior notes due August 2047          
Debt Instrument [Line Items]          
Debt interest rate 3.875%        
Long-term debt $ 1,000   1,000    
Senior Notes | 5.05% senior notes due March 2048          
Debt Instrument [Line Items]          
Debt interest rate 5.05%        
Long-term debt $ 8,000   8,000    
Senior Notes | 4.25% senior notes due April 2050          
Debt Instrument [Line Items]          
Debt interest rate 4.25%        
Long-term debt $ 750   $ 750    
Notes Payable | Floating rate notes due March 2021          
Debt Instrument [Line Items]          
Debt interest rate     0.95%    
Long-term debt 0   $ 1,000    
Other Debt Obligations          
Debt Instrument [Line Items]          
Long-term debt $ 320   $ 326    
XML 104 R84.htm IDEA: XBRL DOCUMENT v3.22.0.1
Borrowings and Credit Arrangements - Debt Maturities (Details) - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Long-term Debt, Fiscal Year Maturity [Abstract]    
2022 $ 4,154  
2023 1,719  
2024 2,706  
2025 3,785  
2026 2,507  
Thereafter 40,572  
Subtotal 55,443  
Finance lease liabilities 1,300 $ 1,083
Total debt principal $ 56,743 $ 65,318
XML 105 R85.htm IDEA: XBRL DOCUMENT v3.22.0.1
Borrowings and Credit Arrangements - Short-term Borrowings (Details) - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Short-term Debt [Line Items]    
Federal home loan bank advances maximum amount available $ 995,000,000  
Commercial Paper    
Short-term Debt [Line Items]    
Short-term debt 0  
Line of Credit | Back-Up Credit Facilities    
Short-term Debt [Line Items]    
Short-term debt $ 0 $ 0
Commitment fee percentage 0.03%  
Line of Credit | Revolving Credit Facility, Expiring May 17, 2023    
Short-term Debt [Line Items]    
Maximum borrowing capacity $ 2,000,000,000  
Debt instrument term 5 years  
Line of Credit | Revolving Credit Facility, Expiring May 16, 2024    
Short-term Debt [Line Items]    
Maximum borrowing capacity $ 2,000,000,000  
Debt instrument term 5 years  
Line of Credit | Revolving Credit Facility, Expiring May 11, 2026    
Short-term Debt [Line Items]    
Maximum borrowing capacity $ 2,000,000,000  
Debt instrument term 5 years  
Federal Home Loan Bank Advances    
Short-term Debt [Line Items]    
Short-term debt $ 0 $ 0
XML 106 R86.htm IDEA: XBRL DOCUMENT v3.22.0.1
Borrowings and Credit Arrangements - Long-Term Borrowings (Details) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Aug. 18, 2021
Dec. 16, 2020
Aug. 21, 2020
Dec. 31, 2021
Aug. 31, 2021
Dec. 31, 2020
Aug. 31, 2020
Aug. 31, 2019
Mar. 31, 2020
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Debt Instrument [Line Items]                        
Proceeds from debt $ 987,000,000   $ 3,970,000,000                  
Proceeds from derivative instruments                 $ 7,000,000 $ 0 $ 7,000,000 $ 25,000,000
Loss on net cash flow hedges                 5,000,000      
Premium paid in excess of debt principal       $ 80,000,000 $ 332,000,000 $ 619,000,000 $ 706,000,000 $ 76,000,000        
Write off of deferred debt issuance cost       8,000,000 26,000,000 45,000,000 47,000,000          
Debt extinguishment fees       1,000,000 5,000,000 10,000,000 13,000,000 8,000,000        
Loss on early extinguishment of debt       89,000,000 $ 363,000,000 674,000,000 766,000,000 79,000,000   452,000,000 1,440,000,000 $ 79,000,000
Amount outstanding       $ 55,443,000,000           $ 55,443,000,000    
Net gain on write-off of net unamortized deferred financing premiums on early extinguishment of debt               5,000,000        
Senior Notes | 2.125% senior notes due September 2031                        
Debt Instrument [Line Items]                        
Debt face amount $ 1,000,000,000                      
Debt interest rate 2.125%     2.125%           2.125%    
Amount outstanding       $ 1,000,000,000   0       $ 1,000,000,000 0  
Senior Notes | 1.3% senior notes due August 2027                        
Debt Instrument [Line Items]                        
Debt face amount   $ 750,000,000 $ 1,500,000,000                  
Debt interest rate   1.30% 1.30%                  
Senior Notes | 1.875%, senior notes due February 2031                        
Debt Instrument [Line Items]                        
Debt face amount   $ 1,250,000,000                    
Debt interest rate   1.875%                    
Proceeds from debt   $ 1,990,000,000                    
Senior Notes | 1.75% senior notes due August 2030                        
Debt Instrument [Line Items]                        
Debt face amount     $ 1,250,000,000                  
Debt interest rate     1.75%                  
Senior Notes | 2.7% senior notes due August 2040                        
Debt Instrument [Line Items]                        
Debt face amount     $ 1,250,000,000                  
Debt interest rate     2.70%                  
Senior Notes | 3.625% senior notes due April 2027                        
Debt Instrument [Line Items]                        
Debt face amount                 $ 750,000,000      
Debt interest rate                 3.625%      
Senior Notes | 3.75% senior notes due April 2030                        
Debt Instrument [Line Items]                        
Debt face amount                 $ 1,500,000,000      
Debt interest rate                 3.75%      
Senior Notes | 4.125% senior notes due April 2040                        
Debt Instrument [Line Items]                        
Debt face amount                 $ 1,000,000,000      
Debt interest rate                 4.125%      
Senior Notes | 4.25% senior notes due April 2050                        
Debt Instrument [Line Items]                        
Debt face amount                 $ 750,000,000      
Debt interest rate                 4.25%      
Proceeds from debt                 $ 3,950,000,000      
Senior Notes | 2.625% senior notes due August 2024                        
Debt Instrument [Line Items]                        
Debt interest rate       2.625%           2.625%    
Amount outstanding       $ 1,000,000,000   1,000,000,000       $ 1,000,000,000 1,000,000,000  
Senior Notes | 3% senior notes due August 2026                        
Debt Instrument [Line Items]                        
Debt interest rate       3.00%           3.00%    
Amount outstanding       $ 750,000,000   750,000,000       $ 750,000,000 750,000,000  
Senior Notes | 3.25% senior notes due August 2029                        
Debt Instrument [Line Items]                        
Debt interest rate       3.25%           3.25%    
Amount outstanding       $ 1,750,000,000   1,750,000,000       $ 1,750,000,000 $ 1,750,000,000  
Senior Notes | Senior Notes, 4.3%, Due 2028                        
Debt Instrument [Line Items]                        
Debt interest rate         4.30%              
Aggregate principal of debt extinguished         $ 2,000,000,000              
Senior Notes | Outstanding Senior Notes                        
Debt Instrument [Line Items]                        
Aggregate principal of debt extinguished           $ 4,500,000,000 $ 6,000,000,000 $ 4,000,000,000        
Senior Notes | 4% senior notes due December 2023                        
Debt Instrument [Line Items]                        
Debt interest rate       4.00%   4.00% 4.00%     4.00% 4.00%  
Aggregate principal of debt extinguished           $ 113,000,000 $ 723,000,000          
Amount outstanding       $ 414,000,000   $ 414,000,000       $ 414,000,000 $ 414,000,000  
Senior Notes | 3.7% senior notes due March 2023                        
Debt Instrument [Line Items]                        
Debt interest rate       3.70%   3.70% 3.70%     3.70% 3.70%  
Aggregate principal of debt extinguished           $ 1,400,000,000 $ 2,300,000,000          
Amount outstanding       $ 0   $ 2,336,000,000       $ 0 $ 2,336,000,000  
Senior Notes | 4.1% senior notes due March 2025                        
Debt Instrument [Line Items]                        
Debt interest rate       4.10%   4.10% 4.10%     4.10% 4.10%  
Aggregate principal of debt extinguished           $ 1,000,000,000 $ 3,000,000,000          
Amount outstanding       $ 950,000,000   $ 950,000,000       $ 950,000,000 $ 950,000,000  
Senior Notes | 4.3% senior notes due 2028                        
Debt Instrument [Line Items]                        
Debt interest rate           4.30%         4.30%  
Aggregate principal of debt extinguished           $ 2,000,000,000            
Senior Notes | 4.125% senior notes due May 2021                        
Debt Instrument [Line Items]                        
Debt interest rate       4.125%       4.125%   4.125%    
Aggregate principal of debt extinguished               $ 328,000,000        
Amount outstanding       $ 0   222,000,000       $ 0 $ 222,000,000  
Senior Notes | 4.125% senior notes due June 2021                        
Debt Instrument [Line Items]                        
Debt interest rate       4.125%       4.125%   4.125%    
Aggregate principal of debt extinguished               $ 297,000,000        
Amount outstanding       $ 0   203,000,000       $ 0 203,000,000  
Senior Notes | 5.45% senior notes due June 2021                        
Debt Instrument [Line Items]                        
Debt interest rate       5.45%       5.45%   5.45%    
Aggregate principal of debt extinguished               $ 413,000,000        
Amount outstanding       $ 0   187,000,000       $ 0 187,000,000  
Senior Notes | 3.35% senior notes due March 2021                        
Debt Instrument [Line Items]                        
Debt interest rate       3.35%       3.35%   3.35%    
Aggregate principal of debt extinguished               $ 962,000,000        
Amount outstanding       $ 0   $ 2,038,000,000       $ 0 $ 2,038,000,000  
Senior Notes | Senior Notes, 3 Point 70 Percent, Due 2023                        
Debt Instrument [Line Items]                        
Debt interest rate       3.70%           3.70%    
Aggregate principal of debt extinguished       $ 2,300,000,000                
Senior Notes | 3.125% senior notes due March 2020                        
Debt Instrument [Line Items]                        
Debt interest rate               3.125%        
Aggregate principal of debt extinguished               $ 1,300,000,000        
Floating Rate Notes | Floating rate notes due March 2020                        
Debt Instrument [Line Items]                        
Aggregate principal of debt extinguished               $ 723,000,000        
XML 107 R87.htm IDEA: XBRL DOCUMENT v3.22.0.1
Pension Plans and Other Postretirement Benefits - Narrative (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Defined Benefit Plan Disclosure [Line Items]      
Defined contribution plan, employer contributions $ 552 $ 520 $ 550
Pension Plan      
Defined Benefit Plan Disclosure [Line Items]      
Employer contributions 78 25 25
Multiemployer plans, plan contributions 19 19 18
Benefit obligation 6,009 6,462 6,239
Net periodic benefit cost $ (186) (218) (131)
Pension Plan | Equity securities      
Defined Benefit Plan Disclosure [Line Items]      
Target investment allocations 12.00%    
Pension Plan | Debt securities      
Defined Benefit Plan Disclosure [Line Items]      
Target investment allocations 77.00%    
Pension Plan | Real Estate Investment      
Defined Benefit Plan Disclosure [Line Items]      
Target investment allocations 5.00%    
Pension Plan | Private equity investments      
Defined Benefit Plan Disclosure [Line Items]      
Target investment allocations 3.00%    
Pension Plan | Hedge Funds      
Defined Benefit Plan Disclosure [Line Items]      
Target investment allocations 3.00%    
Other Postretirement Benefits      
Defined Benefit Plan Disclosure [Line Items]      
Multiemployer plans, plan contributions $ 60 54 57
Benefit obligation 207 226  
Net periodic benefit cost $ 4 $ 12 $ 7
XML 108 R88.htm IDEA: XBRL DOCUMENT v3.22.0.1
Pension Plans and Other Postretirement Benefits - Benefit Obligations and Plan Assets (Details) - Pension Plan - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Change in benefit obligation:      
Benefit obligation, beginning of year $ 6,462 $ 6,239  
Interest cost 110 168 $ 225
Actuarial (gain) loss (102) 413  
Benefit payments (408) (358)  
Settlements (53) 0  
Benefit obligation, end of year 6,009 6,462 6,239
Change in plan assets:      
Beginning balance 6,845 6,395  
Actual return on plan assets 215 783  
Employer contributions 78 25 25
Benefit payments (408) (358)  
Settlements (53) 0  
Ending balance 6,677 6,845 $ 6,395
Funded status 668 383  
Assets (liabilities) recognized on the consolidated balance sheet      
Noncurrent assets reflected in other assets 946 744  
Current liabilities reflected in accrued expenses (28) (76)  
Noncurrent liabilities reflected in other long-term liabilities (250) (285)  
Net assets $ 668 $ 383  
XML 109 R89.htm IDEA: XBRL DOCUMENT v3.22.0.1
Pension Plans and Other Postretirement Benefits - Net Periodic Benefit Costs (Details) - Pension Plan - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]      
Interest cost $ 110 $ 168 $ 225
Expected return on plan assets (317) (388) (357)
Amortization of net actuarial loss 5 2 1
Settlement losses 16 0 0
Net periodic benefit cost (income) $ (186) $ (218) $ (131)
XML 110 R90.htm IDEA: XBRL DOCUMENT v3.22.0.1
Pension Plans and Other Postretirement Benefits - Weighted Average Assumptions Used (Details)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Assumptions used to determine benefit obligations      
Discount rate 2.80% 2.50%  
Assumptions used to determine net benefit costs      
Discount rate 1.80% 2.90% 4.00%
Expected long-term rate of return on plan assets 4.80% 6.30% 6.50%
XML 111 R91.htm IDEA: XBRL DOCUMENT v3.22.0.1
Pension Plans and Other Postretirement Benefits - Fair Value of Pension Plan Assets (Details) - Pension Plan - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets $ 6,677.0 $ 6,845.0 $ 6,395.0
Level 1      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 1,566.0 2,291.0  
Level 2      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 3,837.0 3,231.0  
Level 3      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 378.0 343.0 354.0
Total Fair Value, Inputs, Level 1, 2 and 3      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 5,781.0 5,865.0  
Cash and cash equivalents | Level 1      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 60.0 118.0  
Cash and cash equivalents | Level 2      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 97.0 81.0  
Cash and cash equivalents | Level 3      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0.0 0.0  
Cash and cash equivalents | Total Fair Value, Inputs, Level 1, 2 and 3      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 157.0 199.0  
Debt securities | Level 1      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 1,223.0 575.0  
Debt securities | Level 2      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 3,330.0 2,887.0  
Debt securities | Level 3      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0.0 0.0  
Debt securities | Total Fair Value, Inputs, Level 1, 2 and 3      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 4,553.0 3,462.0  
U.S. government securities | Level 1      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 1,223.0 575.0  
U.S. government securities | Level 2      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 1.0 36.0  
U.S. government securities | Level 3      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0.0 0.0  
U.S. government securities | Total Fair Value, Inputs, Level 1, 2 and 3      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 1,224.0 611.0  
States, municipalities and political subdivisions | Level 1      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0.0 0.0  
States, municipalities and political subdivisions | Level 2      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 150.0 170.0  
States, municipalities and political subdivisions | Level 3      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0.0 0.0  
States, municipalities and political subdivisions | Total Fair Value, Inputs, Level 1, 2 and 3      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 150.0 170.0  
U.S. corporate securities | Level 1      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0.0 0.0  
U.S. corporate securities | Level 2      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 2,458.0 2,006.0  
U.S. corporate securities | Level 3      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0.0 0.0 1.0
U.S. corporate securities | Total Fair Value, Inputs, Level 1, 2 and 3      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 2,458.0 2,006.0  
Foreign securities | Level 1      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0.0 0.0  
Foreign securities | Level 2      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 202.0 167.0  
Foreign securities | Level 3      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0.0 0.0  
Foreign securities | Total Fair Value, Inputs, Level 1, 2 and 3      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 202.0 167.0  
Residential mortgage-backed securities | Level 1      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0.0 0.0  
Residential mortgage-backed securities | Level 2      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 277.0 287.0  
Residential mortgage-backed securities | Level 3      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0.0 0.0  
Residential mortgage-backed securities | Total Fair Value, Inputs, Level 1, 2 and 3      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 277.0 287.0  
Commercial mortgage-backed securities | Level 1      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0.0 0.0  
Commercial mortgage-backed securities | Level 2      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 76.0 83.0  
Commercial mortgage-backed securities | Level 3      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0.0 0.0  
Commercial mortgage-backed securities | Total Fair Value, Inputs, Level 1, 2 and 3      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 76.0 83.0  
Other asset-backed securities | Level 1      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0.0 0.0  
Other asset-backed securities | Level 2      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 162.0 133.0  
Other asset-backed securities | Level 3      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0.0 0.0  
Other asset-backed securities | Total Fair Value, Inputs, Level 1, 2 and 3      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 162.0 133.0  
Redeemable preferred securities | Level 1      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0.0 0.0  
Redeemable preferred securities | Level 2      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 4.0 5.0  
Redeemable preferred securities | Level 3      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0.0 0.0  
Redeemable preferred securities | Total Fair Value, Inputs, Level 1, 2 and 3      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 4.0 5.0  
Equity securities | Level 1      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 283.0 1,598.0  
Equity securities | Level 2      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0.0 0.0  
Equity securities | Level 3      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0.0 0.0  
Equity securities | Total Fair Value, Inputs, Level 1, 2 and 3      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 283.0 1,598.0  
U.S. domestic | Level 1      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 201.0 1,046.0  
U.S. domestic | Level 2      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0.0 0.0  
U.S. domestic | Level 3      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0.0 0.0  
U.S. domestic | Total Fair Value, Inputs, Level 1, 2 and 3      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 201.0 1,046.0  
International | Level 1      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 81.0 537.0  
International | Level 2      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0.0 0.0  
International | Level 3      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0.0 0.0  
International | Total Fair Value, Inputs, Level 1, 2 and 3      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 81.0 537.0  
Domestic real estate | Level 1      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 1.0 15.0  
Domestic real estate | Level 2      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0.0 0.0  
Domestic real estate | Level 3      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0.0 0.0  
Domestic real estate | Total Fair Value, Inputs, Level 1, 2 and 3      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 1.0 15.0  
Other investments | Level 1      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0.0 0.0  
Other investments | Level 2      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 410.0 263.0  
Other investments | Level 3      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 378.0 343.0  
Other investments | Total Fair Value, Inputs, Level 1, 2 and 3      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 788.0 606.0  
Real estate | Level 1      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0.0 0.0  
Real estate | Level 2      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0.0 0.0  
Real estate | Level 3      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 378.0 343.0 $ 353.0
Real estate | Total Fair Value, Inputs, Level 1, 2 and 3      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 378.0 343.0  
Common/collective trusts | Level 1      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0.0 0.0  
Common/collective trusts | Level 2      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 410.0 266.0  
Common/collective trusts | Level 3      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0.0 0.0  
Common/collective trusts | Total Fair Value, Inputs, Level 1, 2 and 3      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 410.0 266.0  
Derivatives | Level 1      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets   0.0  
Derivatives | Level 2      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets   (3.0)  
Derivatives | Level 3      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets   0.0  
Derivatives | Total Fair Value, Inputs, Level 1, 2 and 3      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets   (3.0)  
Common/collective trusts, Equity Securities | Level 2      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets, investment within plan asset category, amount   84.0  
Common/collective trusts, Equity Securities | Fair Value Measured at Net Asset Value Per Share      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets, investment within plan asset category, amount 261.0    
Common/collective trusts, Debt Securities | Level 2      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets, investment within plan asset category, amount   182.0  
Common/collective trusts, Debt Securities | Fair Value Measured at Net Asset Value Per Share      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets, investment within plan asset category, amount 149.0    
Private equity investments | Fair Value Measured at Net Asset Value Per Share      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 583.0 624.0  
Hedge fund investments | Fair Value Measured at Net Asset Value Per Share      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 237.0 214.0  
Other receivables | Fair Value Measured at Net Asset Value Per Share      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets $ 76.0 $ 142.0  
XML 112 R92.htm IDEA: XBRL DOCUMENT v3.22.0.1
Pension Plans and Other Postretirement Benefits - Changes in Level 3 Pension Plan Assets (Details) - Pension Plan - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Change in plan assets:    
Beginning balance $ 6,845 $ 6,395
Ending balance 6,677 6,845
Level 3    
Change in plan assets:    
Beginning balance 343 354
Actual return on plan assets 43 (2)
Purchases, sales and settlements (8) (8)
Transfers out of Level 3 0 (1)
Ending balance 378 343
Real estate | Level 3    
Change in plan assets:    
Beginning balance 343 353
Actual return on plan assets 43 (2)
Purchases, sales and settlements (8) (8)
Transfers out of Level 3 0 0
Ending balance 378 343
U.S. corporate securities | Level 3    
Change in plan assets:    
Beginning balance 0 1
Actual return on plan assets   0
Purchases, sales and settlements   0
Transfers out of Level 3   (1)
Ending balance $ 0 $ 0
XML 113 R93.htm IDEA: XBRL DOCUMENT v3.22.0.1
Pension Plans and Other Postretirement Benefits - Defined Benefit Plans Expected Benefit (Details)
$ in Millions
Dec. 31, 2021
USD ($)
Pension Plan  
Defined Benefit Plan Disclosure [Line Items]  
2022 $ 371
2023 371
2024 371
2025 371
2026 368
2027-2031 1,776
Other Postretirement Benefits  
Defined Benefit Plan Disclosure [Line Items]  
2022 12
2023 12
2024 12
2025 12
2026 12
2027-2031 $ 60
XML 114 R94.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes - Income Tax Provision (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Current:      
Federal $ 2,285 $ 2,615 $ 2,450
State 665 518 565
Total current taxes 2,950 3,133 3,015
Deferred:      
Federal (306) (450) (535)
State (122) (114) (114)
Total deferred income taxes (428) (564) (649)
Total $ 2,522 $ 2,569 $ 2,366
XML 115 R95.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes - Narrative (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Income Tax Disclosure [Abstract]      
Net operating loss and capital loss carryforwards $ 416 $ 568  
Valuation allowance 325 454  
Income tax penalties and interest expense 40 34 $ 49
Income tax penalties and interest accrued 151 $ 121  
Unrecognized tax benefits that would impact effective tax rate $ 669    
XML 116 R96.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes - Effective Tax Rate Reconciliation (Details)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Effective Income Tax Rate Reconciliation, Amount [Abstract]      
Statutory income tax rate 21.00% 21.00% 21.00%
State income taxes, net of federal tax benefit 4.10% 3.20% 4.00%
Health insurer fee 0.00% 2.20% 0.00%
Basis difference upon disposition of subsidiary 0.00% (1.20%) 0.00%
Prior year refund claim (1.20%) 0.00% 0.00%
Other 0.30% 1.10% 1.30%
Effective income tax rate 24.20% 26.30% 26.30%
XML 117 R97.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Deferred income tax assets:    
Lease and rents $ 5,563 $ 5,742
Inventory 99 80
Employee benefits 193 238
Bad debts and other allowances 489 395
Net operating loss and capital loss carryforwards 416 568
Deferred income 78 43
Insurance reserves 501 489
Payroll tax deferral 87 173
Other 396 500
Valuation allowance (325) (454)
Total deferred income tax assets 7,497 7,774
Deferred income tax liabilities:    
Retirement benefits (105) (29)
Investments (334) (421)
Lease and rents (4,947) (5,368)
Depreciation and amortization (8,381) (8,750)
Total deferred income tax liabilities (13,767) (14,568)
Net deferred income tax liabilities $ (6,270) $ (6,794)
XML 118 R98.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes - Unrecognized Tax Benefits (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]      
Beginning balance $ 768 $ 655 $ 661
Additions based on tax positions related to the current year 3 3 4
Additions based on tax positions related to prior years 52 182 115
Reductions for tax positions of prior years (33) (56) (111)
Expiration of statutes of limitation (1) (2) (7)
Settlements (7) (14) (7)
Ending balance $ 782 $ 768 $ 655
XML 119 R99.htm IDEA: XBRL DOCUMENT v3.22.0.1
Stock Incentive Plans - Stock-Based Compensation Expense and ESPP (Details) - USD ($)
$ / shares in Units, $ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Nov. 28, 2018
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Stock-based compensation expense $ 484 $ 400 $ 453  
Shares issued employee stock purchase plan (in shares) 3,000,000      
Average purchase price of shares purchased (in dollars per share) $ 60.51      
Employee Stock Options and Stock Appreciation Rights        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Stock-based compensation expense $ 80 71 76  
Compensation not yet recognized, period for recognition 2 years      
Compensation not yet recognized, options $ 38      
Expected to vest (in shares) 9,000,000      
Restricted Stock Units and Performance Share Units        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Stock-based compensation expense $ 404 329 377  
Compensation not yet recognized, other than options $ 529      
Compensation not yet recognized, period for recognition 2 years 1 month 6 days      
Vested in period, fair value $ 406 $ 229 $ 265  
Stock Appreciation Rights (SARs)        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Award vesting period 3 years      
Expiration period 10 years      
Employee Stock Option        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Award vesting period 4 years      
Employee Stock        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Number of shares authorized 60,000,000      
Number of shares available for grant 31,000,000      
Purchase price of common stock percent 90.00%      
Minimum        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Award vesting period 3 years      
Maximum        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Award vesting period 5 years      
CVS Health 2017 Incentive Compensation Plan        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Number of shares authorized 58,000,000      
Number of shares available for grant 30,000,000      
Aetna Inc 2010 Stock Incentive Plan        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Number of shares available for grant       32,000,000
Capital shares reserved for future issuance (in shares)       22,000,000
XML 120 R100.htm IDEA: XBRL DOCUMENT v3.22.0.1
Stock Incentive Plans - Valuation and Assumptions (Details) - $ / shares
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Employee Stock      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Dividend yield 1.34% 1.46% 1.70%
Expected volatility 25.27% 37.21% 27.96%
Risk-free interest rate 0.08% 0.81% 2.27%
Expected life (in years) 6 months 6 months 6 months
Weighted-average grant date fair value (in dollars per share) $ 12.55 $ 13.85 $ 10.51
Stock Options      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Dividend yield 2.68% 3.42% 3.68%
Expected volatility 27.10% 25.22% 21.76%
Risk-free interest rate 1.13% 0.61% 0.56%
Expected life (in years) 6 years 3 months 18 days 6 years 3 months 18 days 6 years 3 months 18 days
Weighted-average grant date fair value (in dollars per share) $ 14.57 $ 8.78 $ 6.27
XML 121 R101.htm IDEA: XBRL DOCUMENT v3.22.0.1
Stock Incentive Plans - Restricted Stock Activity (Details) - Restricted Stock Units and Performance Share Units
shares in Thousands
12 Months Ended
Dec. 31, 2021
$ / shares
shares
Units  
Unvested at beginning of period (in shares) | shares 14,824
Granted (in shares) | shares 6,190
Vested (in shares) | shares (5,448)
Forfeited (in shares) | shares (1,236)
Unvested at end of period (in shares) | shares 14,330
Weighted average grant date fair value (in dollars per share)  
Unvested at beginning of year (in dollars per share) | $ / shares $ 58.12
Granted (in dollars per share) | $ / shares 74.39
Vested (in dollars per share) | $ / shares 74.47
Forfeited (in dollars per share) | $ / shares 63.40
Unvested at end of year (in dollars per share) | $ / shares $ 63.02
XML 122 R102.htm IDEA: XBRL DOCUMENT v3.22.0.1
Stock Incentive Plans - Stock Option and SAR Activity (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Cash received from stock options exercised (including ESPP) $ 549,000 $ 264,000 $ 210,000
Payments for taxes for net share settlement of equity awards $ 168,000 88,000 112,000
Stock options granted through 2018      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Expiration period 7 years    
Stock options granted subsequent to 2018      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Expiration period 10 years    
Stock Appreciation Rights (SARs)      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Expiration period 10 years    
Employee Stock Options and Stock Appreciation Rights      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Cash received from stock options exercised (including ESPP) $ 549,000 264,000 210,000
Payments for taxes for net share settlement of equity awards 168,000 88,000 112,000
Intrinsic value of stock options and SARs exercised 105,000 24,000 30,000
Fair value of stock options and SARs vested $ 224,000 $ 252,000 $ 467,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]      
Shares, Outstanding at beginning of year (in shares) 23,955    
Shares granted (in shares) 3,322    
Shares exercised (in shares) (6,366)    
Shares forfeited (in shares) (694)    
Shares expired (in shares) (1,156)    
Shares, Outstanding at end of year (in shares) 19,061 23,955  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]      
Weighted average exercise price, outstanding at beginning of year ($ per share) $ 69.62    
Weighted average exercise price, granted ($ per share) 74.66    
Weighted average exercise price, exercised ($ per share) 63.41    
Weighted average exercise price, forfeited ($ per share) 62.66    
Weighted average exercise price, expired ($ per share) 87.42    
Weighted average exercise price, outstanding at end of year ($ per share) $ 71.74 $ 69.62  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]      
Weighted average contractual term, outstanding at end of year 4 years 9 months    
Aggregate Intrinsic value outstanding at end of year $ 603,137    
Shares exercisable at end of year (in shares) 9,704    
Weighted average exercise price exercisable at end of year ($ per share) $ 79.99    
Weighted average remaining contractual term exercisable at end of year 2 years 7 months 9 days    
Aggregate intrinsic value exercisable at end of year $ 229,034    
Shares vested at end of year and expected to vest in the future (in shares) 18,709    
Weighted average exercise price vested at end of year and expected to vest in the future ($ per share) $ 71.82    
Weighted average remaining contractual term vested at end of year and expected to vest in the future 4 years 8 months 8 days    
Aggregate intrinsic value vested at end of year and expected to vest in the future $ 590,514    
XML 123 R103.htm IDEA: XBRL DOCUMENT v3.22.0.1
Shareholders' Equity - Share Repurchases (Details) - USD ($)
Dec. 31, 2021
Dec. 09, 2021
Nov. 02, 2016
2021 Repurchase Program      
Equity, Class of Treasury Stock [Line Items]      
Authorized   $ 10,000,000,000.0  
Remaining as of December 31, 2021 $ 10,000,000,000.0    
2016 Repurchase Program      
Equity, Class of Treasury Stock [Line Items]      
Authorized     $ 15,000,000,000.0
Remaining as of December 31, 2021 $ 0    
XML 124 R104.htm IDEA: XBRL DOCUMENT v3.22.0.1
Shareholders' Equity - Accelerated Share Repurchases (Details) - 2021 ASR - Subsequent Event - Barclays Bank
$ / shares in Units, shares in Millions, $ in Billions
Jan. 04, 2022
USD ($)
$ / shares
shares
Equity, Class of Treasury Stock [Line Items]  
ASR agreement, amount | $ $ 1.5
Payments for ASR, amount | $ $ 1.5
ASR percent of notional amount received in shares 80.00%
ASR, maximum amount of shares received or delivered | shares 29.0
Shares repurchased (in shares) | shares 11.6
Share price (in dollars per share) | $ / shares $ 103.34
ASR, shares to be received at the end of program as a percent of notional amount 20.00%
XML 125 R105.htm IDEA: XBRL DOCUMENT v3.22.0.1
Shareholders' Equity - Dividends (Details) - $ / shares
Dec. 31, 2022
Dec. 31, 2021
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Dividends Payable [Line Items]                  
Cash dividend declared (USD per share)   $ 0.50 $ 0.50 $ 0.50 $ 0.50 $ 0.50 $ 0.50 $ 0.50 $ 0.50
Quarterly dividends declared, percent increase   10.00%              
Forecast                  
Dividends Payable [Line Items]                  
Cash dividend declared (USD per share) $ 0.55                
XML 126 R106.htm IDEA: XBRL DOCUMENT v3.22.0.1
Shareholders' Equity - Regulatory Requirements (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Statutory Accounting Practices [Line Items]      
Estimated minimum statutory surplus required by regulators $ 7,261    
Investments on deposit with regulatory bodies 794    
Estimated maximum dividend distributions permitted in 2022 without prior regulatory approval 2,939    
Insurance and HMO      
Statutory Accounting Practices [Line Items]      
Combined statutory net income 3,302 $ 3,667 $ 2,842
Combined statutory capital and surplus 14,879 $ 13,238 $ 10,975
Dividends paid $ 1,600    
XML 127 R107.htm IDEA: XBRL DOCUMENT v3.22.0.1
Shareholders' Equity - Noncontrolling Interests (Details) - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Equity [Abstract]    
Noncontrolling interests $ 306 $ 312
XML 128 R108.htm IDEA: XBRL DOCUMENT v3.22.0.1
Other Comprehensive Income (Details) - USD ($)
$ in Millions
3 Months Ended 12 Months Ended
Mar. 31, 2020
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Changes in Accumulated Other Comprehensive Income (Loss) by Component        
Beginning of year balance $ 64,170 $ 69,701 $ 64,170 $ 58,543
Other comprehensive income (loss) before reclassifications (5)      
Other comprehensive income (loss)   (449) 395 917
End of year balance   75,381 69,701 64,170
Net unrealized investment gains (losses)        
Changes in Accumulated Other Comprehensive Income (Loss) by Component        
Beginning of year balance 774 1,214 774 97
Other comprehensive income (loss) before reclassifications   (410) 415 763
Amounts reclassified from accumulated other comprehensive loss, net of tax   (26) 25 (86)
Other comprehensive income (loss)   (436) 440 677
End of year balance   778 1,214 774
OCI before Reclass, pre-tax   (489) 497 927
Amounts reclassified, pre-tax   (32) 31 (105)
Foreign currency translation adjustments        
Changes in Accumulated Other Comprehensive Income (Loss) by Component        
Beginning of year balance 4 7 4 (158)
Other comprehensive income (loss) before reclassifications   (7) 3 8
Amounts reclassified from accumulated other comprehensive loss, net of tax   0 0 154
Other comprehensive income (loss)   (7) 3 162
End of year balance   0 7 4
Net cash flow hedges        
Changes in Accumulated Other Comprehensive Income (Loss) by Component        
Beginning of year balance 279 248 279 312
Other comprehensive income (loss) before reclassifications   0 (5) (18)
Amounts reclassified from accumulated other comprehensive loss, net of tax   (26) (26) (15)
Other comprehensive income (loss)   (26) (31) (33)
End of year balance   222 248 279
OCI before Reclass, pre-tax   0 (7) (25)
Amounts reclassified, pre-tax   (34) (35) (20)
Amount expected to be reclassified   11    
Pension and OPEB plans        
Changes in Accumulated Other Comprehensive Income (Loss) by Component        
Beginning of year balance (38) (55) (38) (149)
Other comprehensive income (loss) before reclassifications   15 (22) 120
Amounts reclassified from accumulated other comprehensive loss, net of tax   5 5 (9)
Other comprehensive income (loss)   20 (17) 111
End of year balance   (35) (55) (38)
OCI before Reclass, pre-tax   20 (30) 162
Amounts reclassified, pre-tax   6 7 (12)
AOCI Including Portion Attributable to Noncontrolling Interest        
Changes in Accumulated Other Comprehensive Income (Loss) by Component        
Beginning of year balance $ 1,019 1,414 1,019 102
End of year balance   $ 965 $ 1,414 $ 1,019
XML 129 R109.htm IDEA: XBRL DOCUMENT v3.22.0.1
Earnings Per Share (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Numerator for earnings per share calculation:      
Income from continuing operations $ 7,898 $ 7,201 $ 6,631
Income allocated to participating securities 0 0 (5)
Net (income) loss attributable to noncontrolling interests 12 (13) 3
Income from continuing operations attributable to CVS Health $ 7,910 $ 7,188 $ 6,629
Denominator for earnings per share calculation:      
Weighted average shares, basic (in shares) 1,319 1,309 1,301
Effect of dilutive securities (in shares) 10 5 4
Weighted average shares, diluted (in shares) 1,329 1,314 1,305
Earnings per share from continuing operations:      
Earnings (loss) per share from continuing operations, basic (USD per share) $ 6.00 $ 5.49 $ 5.10
Earnings (loss) per share from continuing operations, diluted (USD per share) $ 5.95 $ 5.47 $ 5.08
Employee Stock Option      
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Antidilutive securities excluded from computation of EPS (in shares) 7 15 17
XML 130 R110.htm IDEA: XBRL DOCUMENT v3.22.0.1
Reinsurance - Narrative (Details) - Subsequent Event
1 Months Ended
Jan. 31, 2022
reinsurance_agreement
Subsequent Event [Line Items]  
Number of reinsurance contracts entered into 2
Four years reinsurance agreement with unrelated insurer 4 years
XML 131 R111.htm IDEA: XBRL DOCUMENT v3.22.0.1
Reinsurance - Reinsurance Recoverables (Details) - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Ceded Credit Risk [Line Items]    
Total reinsurance recoverables $ 2,549 $ 3,055
Hartford Life and Accident Insurance Company    
Ceded Credit Risk [Line Items]    
Total reinsurance recoverables 1,887 2,364
Lincoln Life & Annuity Company of New York    
Ceded Credit Risk [Line Items]    
Total reinsurance recoverables 395 406
VOYA Retirement Insurance and Annuity Company    
Ceded Credit Risk [Line Items]    
Total reinsurance recoverables 167 170
All Other    
Ceded Credit Risk [Line Items]    
Total reinsurance recoverables $ 100 $ 115
XML 132 R112.htm IDEA: XBRL DOCUMENT v3.22.0.1
Reinsurance - Effects of Reinsurance (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Premiums Earned, Net [Abstract]      
Direct $ 76,320 $ 69,711 $ 62,968
Assumed 492 478 2,108
Ceded (680) (825) (1,954)
Net premiums 76,132 69,364 63,122
Policyholder Benefits and Claims Incurred, Net [Abstract]      
Direct 64,414 56,077 52,592
Assumed 398 329 1,562
Ceded (552) (727) (1,625)
Net benefit costs $ 64,260 $ 55,679 $ 52,529
XML 133 R113.htm IDEA: XBRL DOCUMENT v3.22.0.1
Commitments and Contingencies (Details)
$ in Millions
12 Months Ended
Dec. 31, 2012
member
Dec. 31, 2021
USD ($)
lease
Dec. 31, 2020
USD ($)
claim
Commitments and Contingencies Disclosure [Abstract]      
Guarantor obligations, maximum exposure   $ 250  
Contractual obligations underlying the guaranteed benefits   $ 1,300 $ 1,400
Number of leases guaranteed | lease   72  
Loss Contingencies [Line Items]      
Audit methodology sample size | member 200    
Radcliff and Flaim v Aetna Inc., et al | Pending Litigation      
Loss Contingencies [Line Items]      
Number of claims | claim     2
XML 134 R114.htm IDEA: XBRL DOCUMENT v3.22.0.1
Segment Reporting - Narrative (Details) - Segment
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Segment Reporting [Abstract]      
Number of operating segments 3    
US Federal Government | Customer Concentration Risk | Revenues      
Concentration Risk [Line Items]      
Concentration risk, percent 17.00% 16.00% 16.00%
XML 135 R115.htm IDEA: XBRL DOCUMENT v3.22.0.1
Segment Reporting - Reconciliation of Financial Measures of Segments to Consolidated Totals (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Segment Reporting Information [Line Items]      
Revenues from external customers $ 290,912 $ 267,908 $ 255,765
Net investment income 1,199 798 1,011
Total revenues 292,111 268,706 256,776
Adjusted operating income (loss) 17,312 16,008 15,339
Depreciation and amortization 4,512 4,441 4,371
Operating Segments | Health Care Benefits      
Segment Reporting Information [Line Items]      
Revenues from external customers 81,515 74,926 68,979
Net investment income 586 483 599
Total revenues 82,186 75,467 69,604
Adjusted operating income (loss) 5,012 6,188 5,202
Depreciation and amortization 1,837 1,832 1,721
Operating Segments | Pharmacy Services      
Segment Reporting Information [Line Items]      
Revenues from external customers 143,194 132,663 130,428
Net investment income 0 0 0
Total revenues 153,022 141,938 141,491
Adjusted operating income (loss) 6,859 5,688 5,129
Depreciation and amortization 576 612 766
Co-payments 11,600 10,900 11,500
Operating Segments | Retail/ LTC      
Segment Reporting Information [Line Items]      
Revenues from external customers 66,078 60,208 56,258
Net investment income 17 0 0
Total revenues 100,105 91,198 86,608
Adjusted operating income (loss) 7,623 6,146 6,705
Depreciation and amortization 1,884 1,801 1,723
Intersegment Eliminations      
Segment Reporting Information [Line Items]      
Revenues (43,923) (40,323) (41,439)
Net investment income 0 0 0
Total revenues (43,923) (40,323) (41,439)
Adjusted operating income (loss) (711) (708) (697)
Depreciation and amortization 0 0 0
Intersegment Eliminations | Health Care Benefits      
Segment Reporting Information [Line Items]      
Revenues 85 58 26
Intersegment Eliminations | Pharmacy Services      
Segment Reporting Information [Line Items]      
Revenues 9,828 9,275 11,063
Intersegment Eliminations | Retail/ LTC      
Segment Reporting Information [Line Items]      
Revenues 34,010 30,990 30,350
Corporate/ Other      
Segment Reporting Information [Line Items]      
Revenues from external customers 125 111 100
Net investment income 596 315 412
Total revenues 721 426 512
Adjusted operating income (loss) (1,471) (1,306) (1,000)
Depreciation and amortization $ 215 $ 196 $ 161
XML 136 R116.htm IDEA: XBRL DOCUMENT v3.22.0.1
Segment Reporting - Reconciliation from Operating Income to Adjusted Operating Income (Details)
1 Months Ended 3 Months Ended 12 Months Ended
Jul. 31, 2020
USD ($)
Jun. 30, 2021
USD ($)
Dec. 31, 2021
USD ($)
store
Sep. 30, 2020
USD ($)
Sep. 30, 2019
USD ($)
Dec. 31, 2021
USD ($)
store
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
store
Aug. 31, 2019
USD ($)
Segment Reporting [Abstract]                  
Operating income (GAAP measure)           $ 13,193,000,000 $ 13,911,000,000 $ 11,987,000,000  
Amortization of intangible assets           2,259,000,000 2,341,000,000 2,436,000,000  
Acquisition-related integration costs           132,000,000 332,000,000 480,000,000  
Store impairments           1,358,000,000 0 231,000,000  
Goodwill impairment       $ 0 $ 0 431,000,000 0 0  
Acquisition purchase price adjustments outside of measurement period           (61,000,000) 0 0  
(Gain) loss on sale of subsidiaries           0 (269,000,000) 205,000,000  
Receipt of fully reserved ACA risk corridor receivable           0 (307,000,000) 0  
Adjusted operating income           $ 17,312,000,000 16,008,000,000 $ 15,339,000,000  
Segment Reporting Information [Line Items]                  
Number of stores, planned closure | store           900   68  
Proceeds from sale of subsidiary           $ 0 840,000,000 $ 0  
U.S. Department of Health and Human Services, ACA Risk Corridor Receivables | Settled Litigation                  
Segment Reporting Information [Line Items]                  
Gain contingency, unrecorded amount             313,000,000   $ 313,000,000
Former gain contingency, recognized in current period, before tax             307,000,000    
Retail/ LTC                  
Segment Reporting [Abstract]                  
Store impairments     $ 1,400,000,000     1,400,000,000      
Goodwill impairment           $ 431,000,000      
Segment Reporting Information [Line Items]                  
Number of stores, planned closure | store     900     900   68  
Health Care Benefits                  
Segment Reporting [Abstract]                  
Goodwill impairment           $ 0      
Segment Reporting Information [Line Items]                  
Receipt related purchase price adjustment from acquisition   $ 61,000,000              
Coventry Health Care Workers Compensation Business | Health Care Benefits | Discontinued Operations, Disposed of by Sale                  
Segment Reporting [Abstract]                  
(Gain) loss on sale of subsidiaries             (269,000,000)    
Segment Reporting Information [Line Items]                  
Proceeds from sale of subsidiary $ 850,000,000           $ 850,000,000    
XML 137 cvs-20211231_htm.xml IDEA: XBRL DOCUMENT 0000064803 2021-01-01 2021-12-31 0000064803 2021-06-30 0000064803 2022-02-02 0000064803 us-gaap:ProductMember 2021-01-01 2021-12-31 0000064803 us-gaap:ProductMember 2020-01-01 2020-12-31 0000064803 us-gaap:ProductMember 2019-01-01 2019-12-31 0000064803 2020-01-01 2020-12-31 0000064803 2019-01-01 2019-12-31 0000064803 us-gaap:ServiceMember 2021-01-01 2021-12-31 0000064803 us-gaap:ServiceMember 2020-01-01 2020-12-31 0000064803 us-gaap:ServiceMember 2019-01-01 2019-12-31 0000064803 2021-12-31 0000064803 2020-12-31 0000064803 2019-12-31 0000064803 2018-12-31 0000064803 us-gaap:CommonStockMember 2018-12-31 0000064803 us-gaap:TreasuryStockMember 2018-12-31 0000064803 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2018-12-31 0000064803 us-gaap:RetainedEarningsMember 2018-12-31 0000064803 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000064803 us-gaap:ParentMember 2018-12-31 0000064803 us-gaap:NoncontrollingInterestMember 2018-12-31 0000064803 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AccountingStandardsUpdate201602Member us-gaap:RetainedEarningsMember 2018-12-31 0000064803 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:ParentMember 2018-12-31 0000064803 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2018-12-31 0000064803 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0000064803 us-gaap:ParentMember 2019-01-01 2019-12-31 0000064803 us-gaap:NoncontrollingInterestMember 2019-01-01 2019-12-31 0000064803 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0000064803 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0000064803 us-gaap:TreasuryStockMember 2019-01-01 2019-12-31 0000064803 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0000064803 us-gaap:CommonStockMember 2019-12-31 0000064803 us-gaap:TreasuryStockMember 2019-12-31 0000064803 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2019-12-31 0000064803 us-gaap:RetainedEarningsMember 2019-12-31 0000064803 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000064803 us-gaap:ParentMember 2019-12-31 0000064803 us-gaap:NoncontrollingInterestMember 2019-12-31 0000064803 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2019-12-31 0000064803 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:ParentMember 2019-12-31 0000064803 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2019-12-31 0000064803 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0000064803 us-gaap:ParentMember 2020-01-01 2020-12-31 0000064803 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-12-31 0000064803 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0000064803 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0000064803 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0000064803 us-gaap:TreasuryStockMember 2020-01-01 2020-12-31 0000064803 us-gaap:CommonStockMember 2020-12-31 0000064803 us-gaap:TreasuryStockMember 2020-12-31 0000064803 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2020-12-31 0000064803 us-gaap:RetainedEarningsMember 2020-12-31 0000064803 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000064803 us-gaap:ParentMember 2020-12-31 0000064803 us-gaap:NoncontrollingInterestMember 2020-12-31 0000064803 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0000064803 us-gaap:ParentMember 2021-01-01 2021-12-31 0000064803 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-12-31 0000064803 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0000064803 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0000064803 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0000064803 us-gaap:TreasuryStockMember 2021-01-01 2021-12-31 0000064803 us-gaap:CommonStockMember 2021-12-31 0000064803 us-gaap:TreasuryStockMember 2021-12-31 0000064803 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2021-12-31 0000064803 us-gaap:RetainedEarningsMember 2021-12-31 0000064803 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000064803 us-gaap:ParentMember 2021-12-31 0000064803 us-gaap:NoncontrollingInterestMember 2021-12-31 0000064803 us-gaap:AccountingStandardsUpdate201602Member 2018-01-01 2018-12-31 0000064803 us-gaap:AccountingStandardsUpdate201613Member 2019-01-01 2019-12-31 0000064803 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AccountingStandardsUpdate201613Member us-gaap:RetainedEarningsMember 2019-12-31 0000064803 cvs:RetailLongTermCareSegmentMember 2021-12-31 0000064803 cvs:HealthCareBenefitsSegmentMember 2021-01-01 2021-12-31 0000064803 srt:MinimumMember us-gaap:BuildingAndBuildingImprovementsMember 2021-01-01 2021-12-31 0000064803 srt:MaximumMember us-gaap:BuildingAndBuildingImprovementsMember 2021-01-01 2021-12-31 0000064803 srt:MinimumMember cvs:FixturesEquipmentAndInternallyDevelopedSoftwareMember 2021-01-01 2021-12-31 0000064803 srt:MaximumMember cvs:FixturesEquipmentAndInternallyDevelopedSoftwareMember 2021-01-01 2021-12-31 0000064803 us-gaap:LandMember 2021-12-31 0000064803 us-gaap:LandMember 2020-12-31 0000064803 us-gaap:BuildingAndBuildingImprovementsMember 2021-12-31 0000064803 us-gaap:BuildingAndBuildingImprovementsMember 2020-12-31 0000064803 us-gaap:FurnitureAndFixturesMember 2021-12-31 0000064803 us-gaap:FurnitureAndFixturesMember 2020-12-31 0000064803 us-gaap:LeaseholdImprovementsMember 2021-12-31 0000064803 us-gaap:LeaseholdImprovementsMember 2020-12-31 0000064803 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2021-12-31 0000064803 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2020-12-31 0000064803 us-gaap:PropertyPlantAndEquipmentMember cvs:RetailLongTermCareSegmentMember 2021-10-01 2021-12-31 0000064803 srt:MaximumMember 2021-01-01 2021-12-31 0000064803 cvs:RetailLongTermCareSegmentMember 2021-01-01 2021-12-31 0000064803 cvs:LongTermCareReportingUnitMember 2021-07-01 2021-09-30 0000064803 2020-07-01 2020-09-30 0000064803 2019-07-01 2019-09-30 0000064803 srt:MinimumMember 2021-01-01 2021-12-31 0000064803 cvs:OtherInsuranceLiabilitiesMember 2021-12-31 0000064803 cvs:OtherLongTermInsuranceLiabilitiesMember 2021-12-31 0000064803 cvs:OtherInsuranceLiabilitiesMember 2020-12-31 0000064803 cvs:OtherLongTermInsuranceLiabilitiesMember 2020-12-31 0000064803 srt:MinimumMember 2020-01-01 2020-12-31 0000064803 srt:MaximumMember 2020-01-01 2020-12-31 0000064803 us-gaap:HealthInsuranceProductLineMember 2021-12-31 0000064803 us-gaap:HealthInsuranceProductLineMember 2020-12-31 0000064803 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember cvs:BrazilSubsidiaryMember us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2019-01-01 2019-12-31 0000064803 us-gaap:OperatingSegmentsMember cvs:PharmacyRevenueMember cvs:HealthCareBenefitsSegmentMember 2021-01-01 2021-12-31 0000064803 us-gaap:OperatingSegmentsMember cvs:PharmacyRevenueMember cvs:PharmacyServicesSegmentMember 2021-01-01 2021-12-31 0000064803 us-gaap:OperatingSegmentsMember cvs:PharmacyRevenueMember cvs:RetailLongTermCareSegmentMember 2021-01-01 2021-12-31 0000064803 us-gaap:CorporateNonSegmentMember cvs:PharmacyRevenueMember 2021-01-01 2021-12-31 0000064803 us-gaap:IntersegmentEliminationMember cvs:PharmacyRevenueMember 2021-01-01 2021-12-31 0000064803 cvs:PharmacyRevenueMember 2021-01-01 2021-12-31 0000064803 us-gaap:OperatingSegmentsMember cvs:FrontStoreRevenueMember cvs:HealthCareBenefitsSegmentMember 2021-01-01 2021-12-31 0000064803 us-gaap:OperatingSegmentsMember cvs:FrontStoreRevenueMember cvs:PharmacyServicesSegmentMember 2021-01-01 2021-12-31 0000064803 us-gaap:OperatingSegmentsMember cvs:FrontStoreRevenueMember cvs:RetailLongTermCareSegmentMember 2021-01-01 2021-12-31 0000064803 us-gaap:CorporateNonSegmentMember cvs:FrontStoreRevenueMember 2021-01-01 2021-12-31 0000064803 us-gaap:IntersegmentEliminationMember cvs:FrontStoreRevenueMember 2021-01-01 2021-12-31 0000064803 cvs:FrontStoreRevenueMember 2021-01-01 2021-12-31 0000064803 us-gaap:OperatingSegmentsMember cvs:PremiumsMember cvs:HealthCareBenefitsSegmentMember 2021-01-01 2021-12-31 0000064803 us-gaap:OperatingSegmentsMember cvs:PremiumsMember cvs:PharmacyServicesSegmentMember 2021-01-01 2021-12-31 0000064803 us-gaap:OperatingSegmentsMember cvs:PremiumsMember cvs:RetailLongTermCareSegmentMember 2021-01-01 2021-12-31 0000064803 us-gaap:CorporateNonSegmentMember cvs:PremiumsMember 2021-01-01 2021-12-31 0000064803 us-gaap:IntersegmentEliminationMember cvs:PremiumsMember 2021-01-01 2021-12-31 0000064803 cvs:PremiumsMember 2021-01-01 2021-12-31 0000064803 us-gaap:OperatingSegmentsMember cvs:HealthCareBenefitsSegmentMember 2021-01-01 2021-12-31 0000064803 us-gaap:OperatingSegmentsMember cvs:PharmacyServicesSegmentMember 2021-01-01 2021-12-31 0000064803 us-gaap:OperatingSegmentsMember cvs:RetailLongTermCareSegmentMember 2021-01-01 2021-12-31 0000064803 us-gaap:CorporateNonSegmentMember 2021-01-01 2021-12-31 0000064803 us-gaap:IntersegmentEliminationMember 2021-01-01 2021-12-31 0000064803 us-gaap:OperatingSegmentsMember us-gaap:ProductAndServiceOtherMember cvs:HealthCareBenefitsSegmentMember 2021-01-01 2021-12-31 0000064803 us-gaap:OperatingSegmentsMember us-gaap:ProductAndServiceOtherMember cvs:PharmacyServicesSegmentMember 2021-01-01 2021-12-31 0000064803 us-gaap:OperatingSegmentsMember us-gaap:ProductAndServiceOtherMember cvs:RetailLongTermCareSegmentMember 2021-01-01 2021-12-31 0000064803 us-gaap:CorporateNonSegmentMember us-gaap:ProductAndServiceOtherMember 2021-01-01 2021-12-31 0000064803 us-gaap:IntersegmentEliminationMember us-gaap:ProductAndServiceOtherMember 2021-01-01 2021-12-31 0000064803 us-gaap:ProductAndServiceOtherMember 2021-01-01 2021-12-31 0000064803 us-gaap:OperatingSegmentsMember us-gaap:SalesChannelThroughIntermediaryMember cvs:PharmacyServicesSegmentMember 2021-01-01 2021-12-31 0000064803 us-gaap:OperatingSegmentsMember us-gaap:SalesChannelDirectlyToConsumerMember cvs:PharmacyServicesSegmentMember 2021-01-01 2021-12-31 0000064803 us-gaap:OperatingSegmentsMember cvs:SalesChannelOtherMember cvs:PharmacyServicesSegmentMember 2021-01-01 2021-12-31 0000064803 us-gaap:OperatingSegmentsMember cvs:PharmacyRevenueMember cvs:HealthCareBenefitsSegmentMember 2020-01-01 2020-12-31 0000064803 us-gaap:OperatingSegmentsMember cvs:PharmacyRevenueMember cvs:PharmacyServicesSegmentMember 2020-01-01 2020-12-31 0000064803 us-gaap:OperatingSegmentsMember cvs:PharmacyRevenueMember cvs:RetailLongTermCareSegmentMember 2020-01-01 2020-12-31 0000064803 us-gaap:CorporateNonSegmentMember cvs:PharmacyRevenueMember 2020-01-01 2020-12-31 0000064803 us-gaap:IntersegmentEliminationMember cvs:PharmacyRevenueMember 2020-01-01 2020-12-31 0000064803 cvs:PharmacyRevenueMember 2020-01-01 2020-12-31 0000064803 us-gaap:OperatingSegmentsMember cvs:FrontStoreRevenueMember cvs:HealthCareBenefitsSegmentMember 2020-01-01 2020-12-31 0000064803 us-gaap:OperatingSegmentsMember cvs:FrontStoreRevenueMember cvs:PharmacyServicesSegmentMember 2020-01-01 2020-12-31 0000064803 us-gaap:OperatingSegmentsMember cvs:FrontStoreRevenueMember cvs:RetailLongTermCareSegmentMember 2020-01-01 2020-12-31 0000064803 us-gaap:CorporateNonSegmentMember cvs:FrontStoreRevenueMember 2020-01-01 2020-12-31 0000064803 us-gaap:IntersegmentEliminationMember cvs:FrontStoreRevenueMember 2020-01-01 2020-12-31 0000064803 cvs:FrontStoreRevenueMember 2020-01-01 2020-12-31 0000064803 us-gaap:OperatingSegmentsMember cvs:PremiumsMember cvs:HealthCareBenefitsSegmentMember 2020-01-01 2020-12-31 0000064803 us-gaap:OperatingSegmentsMember cvs:PremiumsMember cvs:PharmacyServicesSegmentMember 2020-01-01 2020-12-31 0000064803 us-gaap:OperatingSegmentsMember cvs:PremiumsMember cvs:RetailLongTermCareSegmentMember 2020-01-01 2020-12-31 0000064803 us-gaap:CorporateNonSegmentMember cvs:PremiumsMember 2020-01-01 2020-12-31 0000064803 us-gaap:IntersegmentEliminationMember cvs:PremiumsMember 2020-01-01 2020-12-31 0000064803 cvs:PremiumsMember 2020-01-01 2020-12-31 0000064803 us-gaap:OperatingSegmentsMember cvs:HealthCareBenefitsSegmentMember 2020-01-01 2020-12-31 0000064803 us-gaap:OperatingSegmentsMember cvs:PharmacyServicesSegmentMember 2020-01-01 2020-12-31 0000064803 us-gaap:OperatingSegmentsMember cvs:RetailLongTermCareSegmentMember 2020-01-01 2020-12-31 0000064803 us-gaap:CorporateNonSegmentMember 2020-01-01 2020-12-31 0000064803 us-gaap:IntersegmentEliminationMember 2020-01-01 2020-12-31 0000064803 us-gaap:OperatingSegmentsMember us-gaap:ProductAndServiceOtherMember cvs:HealthCareBenefitsSegmentMember 2020-01-01 2020-12-31 0000064803 us-gaap:OperatingSegmentsMember us-gaap:ProductAndServiceOtherMember cvs:PharmacyServicesSegmentMember 2020-01-01 2020-12-31 0000064803 us-gaap:OperatingSegmentsMember us-gaap:ProductAndServiceOtherMember cvs:RetailLongTermCareSegmentMember 2020-01-01 2020-12-31 0000064803 us-gaap:CorporateNonSegmentMember us-gaap:ProductAndServiceOtherMember 2020-01-01 2020-12-31 0000064803 us-gaap:IntersegmentEliminationMember us-gaap:ProductAndServiceOtherMember 2020-01-01 2020-12-31 0000064803 us-gaap:ProductAndServiceOtherMember 2020-01-01 2020-12-31 0000064803 us-gaap:OperatingSegmentsMember us-gaap:SalesChannelThroughIntermediaryMember cvs:PharmacyServicesSegmentMember 2020-01-01 2020-12-31 0000064803 us-gaap:OperatingSegmentsMember us-gaap:SalesChannelDirectlyToConsumerMember cvs:PharmacyServicesSegmentMember 2020-01-01 2020-12-31 0000064803 us-gaap:OperatingSegmentsMember cvs:SalesChannelOtherMember cvs:PharmacyServicesSegmentMember 2020-01-01 2020-12-31 0000064803 us-gaap:OperatingSegmentsMember cvs:PharmacyRevenueMember cvs:HealthCareBenefitsSegmentMember 2019-01-01 2019-12-31 0000064803 us-gaap:OperatingSegmentsMember cvs:PharmacyRevenueMember cvs:PharmacyServicesSegmentMember 2019-01-01 2019-12-31 0000064803 us-gaap:OperatingSegmentsMember cvs:PharmacyRevenueMember cvs:RetailLongTermCareSegmentMember 2019-01-01 2019-12-31 0000064803 us-gaap:CorporateNonSegmentMember cvs:PharmacyRevenueMember 2019-01-01 2019-12-31 0000064803 us-gaap:IntersegmentEliminationMember cvs:PharmacyRevenueMember 2019-01-01 2019-12-31 0000064803 cvs:PharmacyRevenueMember 2019-01-01 2019-12-31 0000064803 us-gaap:OperatingSegmentsMember cvs:FrontStoreRevenueMember cvs:HealthCareBenefitsSegmentMember 2019-01-01 2019-12-31 0000064803 us-gaap:OperatingSegmentsMember cvs:FrontStoreRevenueMember cvs:PharmacyServicesSegmentMember 2019-01-01 2019-12-31 0000064803 us-gaap:OperatingSegmentsMember cvs:FrontStoreRevenueMember cvs:RetailLongTermCareSegmentMember 2019-01-01 2019-12-31 0000064803 us-gaap:CorporateNonSegmentMember cvs:FrontStoreRevenueMember 2019-01-01 2019-12-31 0000064803 us-gaap:IntersegmentEliminationMember cvs:FrontStoreRevenueMember 2019-01-01 2019-12-31 0000064803 cvs:FrontStoreRevenueMember 2019-01-01 2019-12-31 0000064803 us-gaap:OperatingSegmentsMember cvs:PremiumsMember cvs:HealthCareBenefitsSegmentMember 2019-01-01 2019-12-31 0000064803 us-gaap:OperatingSegmentsMember cvs:PremiumsMember cvs:PharmacyServicesSegmentMember 2019-01-01 2019-12-31 0000064803 us-gaap:OperatingSegmentsMember cvs:PremiumsMember cvs:RetailLongTermCareSegmentMember 2019-01-01 2019-12-31 0000064803 us-gaap:CorporateNonSegmentMember cvs:PremiumsMember 2019-01-01 2019-12-31 0000064803 us-gaap:IntersegmentEliminationMember cvs:PremiumsMember 2019-01-01 2019-12-31 0000064803 cvs:PremiumsMember 2019-01-01 2019-12-31 0000064803 us-gaap:OperatingSegmentsMember cvs:HealthCareBenefitsSegmentMember 2019-01-01 2019-12-31 0000064803 us-gaap:OperatingSegmentsMember cvs:PharmacyServicesSegmentMember 2019-01-01 2019-12-31 0000064803 us-gaap:OperatingSegmentsMember cvs:RetailLongTermCareSegmentMember 2019-01-01 2019-12-31 0000064803 us-gaap:CorporateNonSegmentMember 2019-01-01 2019-12-31 0000064803 us-gaap:IntersegmentEliminationMember 2019-01-01 2019-12-31 0000064803 us-gaap:OperatingSegmentsMember us-gaap:ProductAndServiceOtherMember cvs:HealthCareBenefitsSegmentMember 2019-01-01 2019-12-31 0000064803 us-gaap:OperatingSegmentsMember us-gaap:ProductAndServiceOtherMember cvs:PharmacyServicesSegmentMember 2019-01-01 2019-12-31 0000064803 us-gaap:OperatingSegmentsMember us-gaap:ProductAndServiceOtherMember cvs:RetailLongTermCareSegmentMember 2019-01-01 2019-12-31 0000064803 us-gaap:CorporateNonSegmentMember us-gaap:ProductAndServiceOtherMember 2019-01-01 2019-12-31 0000064803 us-gaap:IntersegmentEliminationMember us-gaap:ProductAndServiceOtherMember 2019-01-01 2019-12-31 0000064803 us-gaap:ProductAndServiceOtherMember 2019-01-01 2019-12-31 0000064803 us-gaap:OperatingSegmentsMember us-gaap:SalesChannelThroughIntermediaryMember cvs:PharmacyServicesSegmentMember 2019-01-01 2019-12-31 0000064803 us-gaap:OperatingSegmentsMember us-gaap:SalesChannelDirectlyToConsumerMember cvs:PharmacyServicesSegmentMember 2019-01-01 2019-12-31 0000064803 us-gaap:OperatingSegmentsMember cvs:SalesChannelOtherMember cvs:PharmacyServicesSegmentMember 2019-01-01 2019-12-31 0000064803 cvs:USDepartmentOfHealthAndHumanServicesACARiskCorridorReceivablesMember us-gaap:SettledLitigationMember 2019-08-31 0000064803 cvs:USDepartmentOfHealthAndHumanServicesACARiskCorridorReceivablesMember us-gaap:SettledLitigationMember 2020-10-22 2020-10-22 0000064803 cvs:USDepartmentOfHealthAndHumanServicesACARiskCorridorReceivablesMember us-gaap:SettledLitigationMember 2020-12-31 0000064803 cvs:RedOakMember 2014-01-01 2014-12-31 0000064803 cvs:RedOakMember 2021-01-01 2021-12-31 0000064803 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember us-gaap:HedgeFundsMember 2021-12-31 0000064803 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember us-gaap:HedgeFundsMember 2020-12-31 0000064803 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember us-gaap:PrivateEquityFundsMember 2021-12-31 0000064803 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember us-gaap:PrivateEquityFundsMember 2020-12-31 0000064803 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember us-gaap:RealEstateFundsMember 2021-12-31 0000064803 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember us-gaap:RealEstateFundsMember 2020-12-31 0000064803 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember 2021-12-31 0000064803 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember 2020-12-31 0000064803 cvs:HeartlandHealthcareServicesMember 2021-12-31 0000064803 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember cvs:CoventryHealthCareWorkersCompensationBusinessMember cvs:HealthCareBenefitsSegmentMember 2020-07-31 2020-07-31 0000064803 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember cvs:CoventryHealthCareWorkersCompensationBusinessMember cvs:HealthCareBenefitsSegmentMember 2020-01-01 2020-12-31 0000064803 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember cvs:BrazilSubsidiaryMember cvs:RetailLongTermCareSegmentMember 2019-07-01 0000064803 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember cvs:DrogariaOnofreLtdaMember cvs:RetailLongTermCareSegmentMember 2019-01-01 2019-12-31 0000064803 cvs:DebtAndEquitySecuritiesAvailableForSaleMember 2021-12-31 0000064803 cvs:DebtAndEquitySecuritiesAvailableForSaleMember 2020-12-31 0000064803 cvs:MortgageLoansMember 2021-12-31 0000064803 cvs:MortgageLoansMember 2020-12-31 0000064803 us-gaap:OtherInvestmentsMember 2021-12-31 0000064803 us-gaap:OtherInvestmentsMember 2020-12-31 0000064803 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-12-31 0000064803 us-gaap:USStatesAndPoliticalSubdivisionsMember 2021-12-31 0000064803 us-gaap:DomesticCorporateDebtSecuritiesMember 2021-12-31 0000064803 us-gaap:ForeignCorporateDebtSecuritiesMember 2021-12-31 0000064803 us-gaap:ResidentialMortgageBackedSecuritiesMember 2021-12-31 0000064803 us-gaap:CommercialMortgageBackedSecuritiesMember 2021-12-31 0000064803 cvs:OtherAssetBackedSecuritiesMember 2021-12-31 0000064803 us-gaap:RedeemablePreferredStockMember 2021-12-31 0000064803 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-12-31 0000064803 us-gaap:USStatesAndPoliticalSubdivisionsMember 2020-12-31 0000064803 us-gaap:DomesticCorporateDebtSecuritiesMember 2020-12-31 0000064803 us-gaap:ForeignCorporateDebtSecuritiesMember 2020-12-31 0000064803 us-gaap:ResidentialMortgageBackedSecuritiesMember 2020-12-31 0000064803 us-gaap:CommercialMortgageBackedSecuritiesMember 2020-12-31 0000064803 cvs:OtherAssetBackedSecuritiesMember 2020-12-31 0000064803 us-gaap:RedeemablePreferredStockMember 2020-12-31 0000064803 cvs:SupportingExperienceRatedProductsMember 2021-12-31 0000064803 cvs:SupportingExperienceRatedProductsMember 2020-12-31 0000064803 us-gaap:ResidentialMortgageBackedSecuritiesMember 2021-01-01 2021-12-31 0000064803 us-gaap:CommercialMortgageBackedSecuritiesMember 2021-01-01 2021-12-31 0000064803 cvs:OtherAssetBackedSecuritiesMember 2021-01-01 2021-12-31 0000064803 cvs:RedeemablePreferredSecuritiesMember 2021-12-31 0000064803 cvs:SupportingRemainingProductsMember 2021-12-31 0000064803 cvs:SupportingExperienceRatedProductsMember us-gaap:ResidentialMortgageBackedSecuritiesMember 2021-12-31 0000064803 cvs:SupportingRemainingProductsMember us-gaap:ResidentialMortgageBackedSecuritiesMember 2021-12-31 0000064803 cvs:SupportingExperienceRatedProductsMember us-gaap:CommercialMortgageBackedSecuritiesMember 2021-12-31 0000064803 cvs:SupportingRemainingProductsMember us-gaap:CommercialMortgageBackedSecuritiesMember 2021-12-31 0000064803 cvs:SupportingExperienceRatedProductsMember cvs:OtherAssetBackedSecuritiesMember 2021-12-31 0000064803 cvs:SupportingRemainingProductsMember cvs:OtherAssetBackedSecuritiesMember 2021-12-31 0000064803 us-gaap:CommercialRealEstateMember 2021-01-01 2021-12-31 0000064803 us-gaap:CommercialRealEstateMember 2020-01-01 2020-12-31 0000064803 us-gaap:CommercialRealEstateMember cvs:Category1Member cvs:YearOfOriginationPeriodOneMember 2021-12-31 0000064803 us-gaap:CommercialRealEstateMember cvs:Category1Member cvs:YearOfOriginationPeriodTwoMember 2021-12-31 0000064803 us-gaap:CommercialRealEstateMember cvs:Category1Member cvs:YearOfOriginationPeriodThreeMember 2021-12-31 0000064803 us-gaap:CommercialRealEstateMember cvs:Category1Member cvs:YearOfOriginationPeriodFourMember 2021-12-31 0000064803 us-gaap:CommercialRealEstateMember cvs:Category1Member cvs:YearOfOriginationPeriodFiveMember 2021-12-31 0000064803 us-gaap:CommercialRealEstateMember cvs:Category1Member cvs:YearOfOriginationPriorToPeriodFiveMember 2021-12-31 0000064803 us-gaap:CommercialRealEstateMember cvs:Category1Member 2021-12-31 0000064803 us-gaap:CommercialRealEstateMember cvs:Category2To4Member cvs:YearOfOriginationPeriodOneMember 2021-12-31 0000064803 us-gaap:CommercialRealEstateMember cvs:Category2To4Member cvs:YearOfOriginationPeriodTwoMember 2021-12-31 0000064803 us-gaap:CommercialRealEstateMember cvs:Category2To4Member cvs:YearOfOriginationPeriodThreeMember 2021-12-31 0000064803 us-gaap:CommercialRealEstateMember cvs:Category2To4Member cvs:YearOfOriginationPeriodFourMember 2021-12-31 0000064803 us-gaap:CommercialRealEstateMember cvs:Category2To4Member cvs:YearOfOriginationPeriodFiveMember 2021-12-31 0000064803 us-gaap:CommercialRealEstateMember cvs:Category2To4Member cvs:YearOfOriginationPriorToPeriodFiveMember 2021-12-31 0000064803 us-gaap:CommercialRealEstateMember cvs:Category2To4Member 2021-12-31 0000064803 us-gaap:CommercialRealEstateMember cvs:Categories5and6Member cvs:YearOfOriginationPeriodOneMember 2021-12-31 0000064803 us-gaap:CommercialRealEstateMember cvs:Categories5and6Member cvs:YearOfOriginationPeriodTwoMember 2021-12-31 0000064803 us-gaap:CommercialRealEstateMember cvs:Categories5and6Member cvs:YearOfOriginationPeriodThreeMember 2021-12-31 0000064803 us-gaap:CommercialRealEstateMember cvs:Categories5and6Member cvs:YearOfOriginationPeriodFourMember 2021-12-31 0000064803 us-gaap:CommercialRealEstateMember cvs:Categories5and6Member cvs:YearOfOriginationPeriodFiveMember 2021-12-31 0000064803 us-gaap:CommercialRealEstateMember cvs:Categories5and6Member cvs:YearOfOriginationPriorToPeriodFiveMember 2021-12-31 0000064803 us-gaap:CommercialRealEstateMember cvs:Categories5and6Member 2021-12-31 0000064803 us-gaap:CommercialRealEstateMember cvs:Category7Member cvs:YearOfOriginationPeriodOneMember 2021-12-31 0000064803 us-gaap:CommercialRealEstateMember cvs:Category7Member cvs:YearOfOriginationPeriodTwoMember 2021-12-31 0000064803 us-gaap:CommercialRealEstateMember cvs:Category7Member cvs:YearOfOriginationPeriodThreeMember 2021-12-31 0000064803 us-gaap:CommercialRealEstateMember cvs:Category7Member cvs:YearOfOriginationPeriodFourMember 2021-12-31 0000064803 us-gaap:CommercialRealEstateMember cvs:Category7Member cvs:YearOfOriginationPeriodFiveMember 2021-12-31 0000064803 us-gaap:CommercialRealEstateMember cvs:Category7Member cvs:YearOfOriginationPriorToPeriodFiveMember 2021-12-31 0000064803 us-gaap:CommercialRealEstateMember cvs:Category7Member 2021-12-31 0000064803 us-gaap:CommercialRealEstateMember cvs:YearOfOriginationPeriodOneMember 2021-12-31 0000064803 us-gaap:CommercialRealEstateMember cvs:YearOfOriginationPeriodTwoMember 2021-12-31 0000064803 us-gaap:CommercialRealEstateMember cvs:YearOfOriginationPeriodThreeMember 2021-12-31 0000064803 us-gaap:CommercialRealEstateMember cvs:YearOfOriginationPeriodFourMember 2021-12-31 0000064803 us-gaap:CommercialRealEstateMember cvs:YearOfOriginationPeriodFiveMember 2021-12-31 0000064803 us-gaap:CommercialRealEstateMember cvs:YearOfOriginationPriorToPeriodFiveMember 2021-12-31 0000064803 us-gaap:CommercialRealEstateMember 2021-12-31 0000064803 us-gaap:CommercialRealEstateMember cvs:Category1Member cvs:YearOfOriginationPeriodTwoMember 2020-12-31 0000064803 us-gaap:CommercialRealEstateMember cvs:Category1Member cvs:YearOfOriginationPeriodThreeMember 2020-12-31 0000064803 us-gaap:CommercialRealEstateMember cvs:Category1Member cvs:YearOfOriginationPeriodFourMember 2020-12-31 0000064803 us-gaap:CommercialRealEstateMember cvs:Category1Member cvs:YearOfOriginationPeriodFiveMember 2020-12-31 0000064803 us-gaap:CommercialRealEstateMember cvs:Category1Member cvs:YearOfOriginationPriorToPeriodFiveMember 2020-12-31 0000064803 us-gaap:CommercialRealEstateMember cvs:Category1Member 2020-12-31 0000064803 us-gaap:CommercialRealEstateMember cvs:Category2To4Member cvs:YearOfOriginationPeriodTwoMember 2020-12-31 0000064803 us-gaap:CommercialRealEstateMember cvs:Category2To4Member cvs:YearOfOriginationPeriodThreeMember 2020-12-31 0000064803 us-gaap:CommercialRealEstateMember cvs:Category2To4Member cvs:YearOfOriginationPeriodFourMember 2020-12-31 0000064803 us-gaap:CommercialRealEstateMember cvs:Category2To4Member cvs:YearOfOriginationPeriodFiveMember 2020-12-31 0000064803 us-gaap:CommercialRealEstateMember cvs:Category2To4Member cvs:YearOfOriginationPriorToPeriodFiveMember 2020-12-31 0000064803 us-gaap:CommercialRealEstateMember cvs:Category2To4Member 2020-12-31 0000064803 us-gaap:CommercialRealEstateMember cvs:Categories5and6Member cvs:YearOfOriginationPeriodTwoMember 2020-12-31 0000064803 us-gaap:CommercialRealEstateMember cvs:Categories5and6Member cvs:YearOfOriginationPeriodThreeMember 2020-12-31 0000064803 us-gaap:CommercialRealEstateMember cvs:Categories5and6Member cvs:YearOfOriginationPeriodFourMember 2020-12-31 0000064803 us-gaap:CommercialRealEstateMember cvs:Categories5and6Member cvs:YearOfOriginationPeriodFiveMember 2020-12-31 0000064803 us-gaap:CommercialRealEstateMember cvs:Categories5and6Member cvs:YearOfOriginationPriorToPeriodFiveMember 2020-12-31 0000064803 us-gaap:CommercialRealEstateMember cvs:Categories5and6Member 2020-12-31 0000064803 us-gaap:CommercialRealEstateMember cvs:Category7Member cvs:YearOfOriginationPeriodTwoMember 2020-12-31 0000064803 us-gaap:CommercialRealEstateMember cvs:Category7Member cvs:YearOfOriginationPeriodThreeMember 2020-12-31 0000064803 us-gaap:CommercialRealEstateMember cvs:Category7Member cvs:YearOfOriginationPeriodFourMember 2020-12-31 0000064803 us-gaap:CommercialRealEstateMember cvs:Category7Member cvs:YearOfOriginationPeriodFiveMember 2020-12-31 0000064803 us-gaap:CommercialRealEstateMember cvs:Category7Member cvs:YearOfOriginationPriorToPeriodFiveMember 2020-12-31 0000064803 us-gaap:CommercialRealEstateMember cvs:Category7Member 2020-12-31 0000064803 us-gaap:CommercialRealEstateMember cvs:YearOfOriginationPeriodTwoMember 2020-12-31 0000064803 us-gaap:CommercialRealEstateMember cvs:YearOfOriginationPeriodThreeMember 2020-12-31 0000064803 us-gaap:CommercialRealEstateMember cvs:YearOfOriginationPeriodFourMember 2020-12-31 0000064803 us-gaap:CommercialRealEstateMember cvs:YearOfOriginationPeriodFiveMember 2020-12-31 0000064803 us-gaap:CommercialRealEstateMember cvs:YearOfOriginationPriorToPeriodFiveMember 2020-12-31 0000064803 us-gaap:CommercialRealEstateMember 2020-12-31 0000064803 us-gaap:DebtSecuritiesMember 2021-01-01 2021-12-31 0000064803 us-gaap:DebtSecuritiesMember 2020-01-01 2020-12-31 0000064803 us-gaap:DebtSecuritiesMember 2019-01-01 2019-12-31 0000064803 cvs:MortgageLoansMember 2021-01-01 2021-12-31 0000064803 cvs:MortgageLoansMember 2020-01-01 2020-12-31 0000064803 cvs:MortgageLoansMember 2019-01-01 2019-12-31 0000064803 us-gaap:OtherInvestmentsMember 2021-01-01 2021-12-31 0000064803 us-gaap:OtherInvestmentsMember 2020-01-01 2020-12-31 0000064803 us-gaap:OtherInvestmentsMember 2019-01-01 2019-12-31 0000064803 cvs:SupportingExperienceRatedProductsMember 2021-01-01 2021-12-31 0000064803 cvs:SupportingExperienceRatedProductsMember 2020-01-01 2020-12-31 0000064803 cvs:SupportingExperienceRatedProductsMember 2019-01-01 2019-12-31 0000064803 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000064803 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000064803 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000064803 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000064803 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000064803 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-12-31 0000064803 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-12-31 0000064803 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-12-31 0000064803 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-12-31 0000064803 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USStatesAndPoliticalSubdivisionsMember 2021-12-31 0000064803 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USStatesAndPoliticalSubdivisionsMember 2021-12-31 0000064803 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USStatesAndPoliticalSubdivisionsMember 2021-12-31 0000064803 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USStatesAndPoliticalSubdivisionsMember 2021-12-31 0000064803 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DomesticCorporateDebtSecuritiesMember 2021-12-31 0000064803 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DomesticCorporateDebtSecuritiesMember 2021-12-31 0000064803 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DomesticCorporateDebtSecuritiesMember 2021-12-31 0000064803 us-gaap:FairValueMeasurementsRecurringMember us-gaap:DomesticCorporateDebtSecuritiesMember 2021-12-31 0000064803 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignCorporateDebtSecuritiesMember 2021-12-31 0000064803 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignCorporateDebtSecuritiesMember 2021-12-31 0000064803 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignCorporateDebtSecuritiesMember 2021-12-31 0000064803 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignCorporateDebtSecuritiesMember 2021-12-31 0000064803 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ResidentialMortgageBackedSecuritiesMember 2021-12-31 0000064803 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ResidentialMortgageBackedSecuritiesMember 2021-12-31 0000064803 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ResidentialMortgageBackedSecuritiesMember 2021-12-31 0000064803 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ResidentialMortgageBackedSecuritiesMember 2021-12-31 0000064803 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialMortgageBackedSecuritiesMember 2021-12-31 0000064803 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialMortgageBackedSecuritiesMember 2021-12-31 0000064803 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialMortgageBackedSecuritiesMember 2021-12-31 0000064803 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialMortgageBackedSecuritiesMember 2021-12-31 0000064803 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember cvs:OtherAssetBackedSecuritiesMember 2021-12-31 0000064803 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember cvs:OtherAssetBackedSecuritiesMember 2021-12-31 0000064803 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember cvs:OtherAssetBackedSecuritiesMember 2021-12-31 0000064803 us-gaap:FairValueMeasurementsRecurringMember cvs:OtherAssetBackedSecuritiesMember 2021-12-31 0000064803 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:RedeemablePreferredStockMember 2021-12-31 0000064803 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:RedeemablePreferredStockMember 2021-12-31 0000064803 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:RedeemablePreferredStockMember 2021-12-31 0000064803 us-gaap:FairValueMeasurementsRecurringMember us-gaap:RedeemablePreferredStockMember 2021-12-31 0000064803 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000064803 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000064803 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000064803 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-12-31 0000064803 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-12-31 0000064803 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-12-31 0000064803 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-12-31 0000064803 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USStatesAndPoliticalSubdivisionsMember 2020-12-31 0000064803 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USStatesAndPoliticalSubdivisionsMember 2020-12-31 0000064803 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USStatesAndPoliticalSubdivisionsMember 2020-12-31 0000064803 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USStatesAndPoliticalSubdivisionsMember 2020-12-31 0000064803 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DomesticCorporateDebtSecuritiesMember 2020-12-31 0000064803 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DomesticCorporateDebtSecuritiesMember 2020-12-31 0000064803 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DomesticCorporateDebtSecuritiesMember 2020-12-31 0000064803 us-gaap:FairValueMeasurementsRecurringMember us-gaap:DomesticCorporateDebtSecuritiesMember 2020-12-31 0000064803 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignCorporateDebtSecuritiesMember 2020-12-31 0000064803 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignCorporateDebtSecuritiesMember 2020-12-31 0000064803 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignCorporateDebtSecuritiesMember 2020-12-31 0000064803 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignCorporateDebtSecuritiesMember 2020-12-31 0000064803 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ResidentialMortgageBackedSecuritiesMember 2020-12-31 0000064803 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ResidentialMortgageBackedSecuritiesMember 2020-12-31 0000064803 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ResidentialMortgageBackedSecuritiesMember 2020-12-31 0000064803 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ResidentialMortgageBackedSecuritiesMember 2020-12-31 0000064803 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialMortgageBackedSecuritiesMember 2020-12-31 0000064803 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialMortgageBackedSecuritiesMember 2020-12-31 0000064803 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialMortgageBackedSecuritiesMember 2020-12-31 0000064803 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialMortgageBackedSecuritiesMember 2020-12-31 0000064803 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember cvs:OtherAssetBackedSecuritiesMember 2020-12-31 0000064803 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember cvs:OtherAssetBackedSecuritiesMember 2020-12-31 0000064803 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember cvs:OtherAssetBackedSecuritiesMember 2020-12-31 0000064803 us-gaap:FairValueMeasurementsRecurringMember cvs:OtherAssetBackedSecuritiesMember 2020-12-31 0000064803 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:RedeemablePreferredStockMember 2020-12-31 0000064803 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:RedeemablePreferredStockMember 2020-12-31 0000064803 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:RedeemablePreferredStockMember 2020-12-31 0000064803 us-gaap:FairValueMeasurementsRecurringMember us-gaap:RedeemablePreferredStockMember 2020-12-31 0000064803 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentShorttermDebtSecuritiesMember 2020-12-31 0000064803 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2020-12-31 0000064803 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USStatesAndPoliticalSubdivisionsMember 2021-01-01 2021-12-31 0000064803 us-gaap:FairValueMeasurementsRecurringMember us-gaap:DomesticCorporateDebtSecuritiesMember 2021-01-01 2021-12-31 0000064803 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentShorttermDebtSecuritiesMember 2021-01-01 2021-12-31 0000064803 us-gaap:FairValueMeasurementsRecurringMember cvs:OtherAssetBackedSecuritiesMember 2021-01-01 2021-12-31 0000064803 us-gaap:FairValueMeasurementsRecurringMember us-gaap:RedeemablePreferredStockMember 2021-01-01 2021-12-31 0000064803 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2021-01-01 2021-12-31 0000064803 us-gaap:FairValueMeasurementsRecurringMember 2021-01-01 2021-12-31 0000064803 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentShorttermDebtSecuritiesMember 2021-12-31 0000064803 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2021-12-31 0000064803 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USStatesAndPoliticalSubdivisionsMember 2019-12-31 0000064803 us-gaap:FairValueMeasurementsRecurringMember us-gaap:DomesticCorporateDebtSecuritiesMember 2019-12-31 0000064803 us-gaap:FairValueMeasurementsRecurringMember us-gaap:RedeemablePreferredStockMember 2019-12-31 0000064803 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2019-12-31 0000064803 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000064803 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USStatesAndPoliticalSubdivisionsMember 2020-01-01 2020-12-31 0000064803 us-gaap:FairValueMeasurementsRecurringMember us-gaap:DomesticCorporateDebtSecuritiesMember 2020-01-01 2020-12-31 0000064803 us-gaap:FairValueMeasurementsRecurringMember us-gaap:RedeemablePreferredStockMember 2020-01-01 2020-12-31 0000064803 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2020-01-01 2020-12-31 0000064803 us-gaap:FairValueMeasurementsRecurringMember 2020-01-01 2020-12-31 0000064803 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-01-01 2021-12-31 0000064803 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-01-01 2020-12-31 0000064803 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsNonrecurringMember 2021-12-31 0000064803 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsNonrecurringMember 2021-12-31 0000064803 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsNonrecurringMember 2021-12-31 0000064803 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsNonrecurringMember 2021-12-31 0000064803 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsNonrecurringMember 2021-12-31 0000064803 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsNonrecurringMember 2020-12-31 0000064803 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsNonrecurringMember 2020-12-31 0000064803 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsNonrecurringMember 2020-12-31 0000064803 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsNonrecurringMember 2020-12-31 0000064803 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsNonrecurringMember 2020-12-31 0000064803 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CashAndCashEquivalentsMember 2021-12-31 0000064803 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CashAndCashEquivalentsMember 2021-12-31 0000064803 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CashAndCashEquivalentsMember 2021-12-31 0000064803 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CashAndCashEquivalentsMember 2021-12-31 0000064803 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CashAndCashEquivalentsMember 2020-12-31 0000064803 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CashAndCashEquivalentsMember 2020-12-31 0000064803 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CashAndCashEquivalentsMember 2020-12-31 0000064803 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CashAndCashEquivalentsMember 2020-12-31 0000064803 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2021-12-31 0000064803 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2021-12-31 0000064803 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2021-12-31 0000064803 us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2021-12-31 0000064803 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2020-12-31 0000064803 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2020-12-31 0000064803 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2020-12-31 0000064803 us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2020-12-31 0000064803 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2021-12-31 0000064803 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2021-12-31 0000064803 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2021-12-31 0000064803 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2021-12-31 0000064803 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2020-12-31 0000064803 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2020-12-31 0000064803 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2020-12-31 0000064803 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2020-12-31 0000064803 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember cvs:CommonAndCollectiveTrustsMember 2021-12-31 0000064803 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember cvs:CommonAndCollectiveTrustsMember 2021-12-31 0000064803 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember cvs:CommonAndCollectiveTrustsMember 2021-12-31 0000064803 us-gaap:FairValueMeasurementsRecurringMember cvs:CommonAndCollectiveTrustsMember 2021-12-31 0000064803 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember cvs:CommonAndCollectiveTrustsMember 2020-12-31 0000064803 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember cvs:CommonAndCollectiveTrustsMember 2020-12-31 0000064803 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember cvs:CommonAndCollectiveTrustsMember 2020-12-31 0000064803 us-gaap:FairValueMeasurementsRecurringMember cvs:CommonAndCollectiveTrustsMember 2020-12-31 0000064803 us-gaap:AccountsReceivableMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000064803 us-gaap:AccountsReceivableMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000064803 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember cvs:SeparateAccountFinancialAssetsMember 2020-01-01 2020-12-31 0000064803 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember cvs:SeparateAccountFinancialAssetsMember 2021-01-01 2021-12-31 0000064803 cvs:HealthCareBenefitsSegmentMember 2019-12-31 0000064803 cvs:PharmacyServicesSegmentMember 2019-12-31 0000064803 cvs:RetailLongTermCareSegmentMember 2019-12-31 0000064803 cvs:HealthCareBenefitsSegmentMember 2020-01-01 2020-12-31 0000064803 cvs:PharmacyServicesSegmentMember 2020-01-01 2020-12-31 0000064803 cvs:RetailLongTermCareSegmentMember 2020-01-01 2020-12-31 0000064803 cvs:HealthCareBenefitsSegmentMember 2020-12-31 0000064803 cvs:PharmacyServicesSegmentMember 2020-12-31 0000064803 cvs:RetailLongTermCareSegmentMember 2020-12-31 0000064803 cvs:PharmacyServicesSegmentMember 2021-01-01 2021-12-31 0000064803 cvs:HealthCareBenefitsSegmentMember 2021-12-31 0000064803 cvs:PharmacyServicesSegmentMember 2021-12-31 0000064803 cvs:LongTermCareReportingUnitMember 2021-12-31 0000064803 us-gaap:CustomerListsMember cvs:LongTermCareReportingUnitMember 2021-12-31 0000064803 us-gaap:CustomerRelatedIntangibleAssetsMember 2021-12-31 0000064803 us-gaap:CustomerRelatedIntangibleAssetsMember 2021-01-01 2021-12-31 0000064803 us-gaap:TechnologyBasedIntangibleAssetsMember 2021-12-31 0000064803 us-gaap:TechnologyBasedIntangibleAssetsMember 2021-01-01 2021-12-31 0000064803 cvs:ProviderNetworksMember 2021-12-31 0000064803 cvs:ProviderNetworksMember 2021-01-01 2021-12-31 0000064803 cvs:ValueOfBusinessAcquiredMember 2021-12-31 0000064803 cvs:ValueOfBusinessAcquiredMember 2021-01-01 2021-12-31 0000064803 us-gaap:OtherIntangibleAssetsMember 2021-12-31 0000064803 us-gaap:OtherIntangibleAssetsMember 2021-01-01 2021-12-31 0000064803 us-gaap:CustomerRelatedIntangibleAssetsMember 2020-12-31 0000064803 us-gaap:CustomerRelatedIntangibleAssetsMember 2020-01-01 2020-12-31 0000064803 us-gaap:TechnologyBasedIntangibleAssetsMember 2020-12-31 0000064803 us-gaap:TechnologyBasedIntangibleAssetsMember 2020-01-01 2020-12-31 0000064803 cvs:ProviderNetworksMember 2020-12-31 0000064803 cvs:ProviderNetworksMember 2020-01-01 2020-12-31 0000064803 cvs:ValueOfBusinessAcquiredMember 2020-12-31 0000064803 cvs:ValueOfBusinessAcquiredMember 2020-01-01 2020-12-31 0000064803 us-gaap:OtherIntangibleAssetsMember 2020-12-31 0000064803 us-gaap:OtherIntangibleAssetsMember 2020-01-01 2020-12-31 0000064803 srt:MinimumMember us-gaap:BuildingMember 2021-12-31 0000064803 srt:MaximumMember us-gaap:BuildingMember 2021-12-31 0000064803 srt:MinimumMember us-gaap:EquipmentMember 2021-12-31 0000064803 srt:MaximumMember us-gaap:EquipmentMember 2021-12-31 0000064803 cvs:RetailLongTermCareSegmentMember 2021-10-01 2021-12-31 0000064803 us-gaap:PropertySubjectToOperatingLeaseMember cvs:RetailLongTermCareSegmentMember 2021-10-01 2021-12-31 0000064803 us-gaap:PropertySubjectToOperatingLeaseMember cvs:RetailLongTermCareSegmentMember 2021-12-31 0000064803 us-gaap:PropertyPlantAndEquipmentMember cvs:RetailLongTermCareSegmentMember 2021-12-31 0000064803 cvs:RetailLongTermCareSegmentMember 2019-01-01 2019-12-31 0000064803 us-gaap:HealthInsuranceProductLineMember us-gaap:ShortDurationInsuranceContractAccidentYear2019Member 2020-12-31 0000064803 us-gaap:HealthInsuranceProductLineMember us-gaap:ShortDurationInsuranceContractAccidentYear2019Member 2021-12-31 0000064803 us-gaap:HealthInsuranceProductLineMember us-gaap:ShortDurationInsuranceContractAccidentYear2020Member 2021-12-31 0000064803 us-gaap:HealthInsuranceProductLineMember 2019-12-31 0000064803 us-gaap:HealthInsuranceProductLineMember 2018-12-31 0000064803 us-gaap:HealthInsuranceProductLineMember 2021-01-01 2021-12-31 0000064803 us-gaap:HealthInsuranceProductLineMember 2020-01-01 2020-12-31 0000064803 us-gaap:HealthInsuranceProductLineMember 2019-01-01 2019-12-31 0000064803 cvs:HealthCareBenefitsSegmentMember 2019-01-01 2019-12-31 0000064803 us-gaap:CorporateAndOtherMember 2021-01-01 2021-12-31 0000064803 us-gaap:CorporateAndOtherMember 2020-01-01 2020-12-31 0000064803 us-gaap:CorporateAndOtherMember 2019-01-01 2019-12-31 0000064803 cvs:SeniorNotes3.35DueMarch2021Member us-gaap:SeniorNotesMember 2021-12-31 0000064803 cvs:SeniorNotes3.35DueMarch2021Member us-gaap:SeniorNotesMember 2020-12-31 0000064803 cvs:FloatingRateNotesDueMarch2021Member us-gaap:NotesPayableToBanksMember 2020-12-31 0000064803 cvs:FloatingRateNotesDueMarch2021Member us-gaap:NotesPayableToBanksMember 2021-12-31 0000064803 cvs:SeniorNotes4.125DueMay2021Member us-gaap:SeniorNotesMember 2021-12-31 0000064803 cvs:SeniorNotes4.125DueMay2021Member us-gaap:SeniorNotesMember 2020-12-31 0000064803 cvs:SeniorNotes2.125June2021Member us-gaap:SeniorNotesMember 2021-12-31 0000064803 cvs:SeniorNotes2.125June2021Member us-gaap:SeniorNotesMember 2020-12-31 0000064803 cvs:SeniorNotes4.125DueJune2021Member us-gaap:SeniorNotesMember 2021-12-31 0000064803 cvs:SeniorNotes4.125DueJune2021Member us-gaap:SeniorNotesMember 2020-12-31 0000064803 cvs:SeniorNotes5.45DueJune2021Member us-gaap:SeniorNotesMember 2021-12-31 0000064803 cvs:SeniorNotes5.45DueJune2021Member us-gaap:SeniorNotesMember 2020-12-31 0000064803 cvs:SeniorNotes3.5DueJuly2022Member us-gaap:SeniorNotesMember 2021-12-31 0000064803 cvs:SeniorNotes3.5DueJuly2022Member us-gaap:SeniorNotesMember 2020-12-31 0000064803 cvs:SeniorNotes2.75DueNovember2022Member us-gaap:SeniorNotesMember 2021-12-31 0000064803 cvs:SeniorNotes2.75DueNovember2022Member us-gaap:SeniorNotesMember 2020-12-31 0000064803 cvs:SeniorNotes2.75DueDecember2022Member us-gaap:SeniorNotesMember 2021-12-31 0000064803 cvs:SeniorNotes2.75DueDecember2022Member us-gaap:SeniorNotesMember 2020-12-31 0000064803 cvs:SeniorNotes4.75DueDecember2022Member us-gaap:SeniorNotesMember 2021-12-31 0000064803 cvs:SeniorNotes4.75DueDecember2022Member us-gaap:SeniorNotesMember 2020-12-31 0000064803 cvs:SeniorNotes3.7DueMarch2023Member us-gaap:SeniorNotesMember 2021-12-31 0000064803 cvs:SeniorNotes3.7DueMarch2023Member us-gaap:SeniorNotesMember 2020-12-31 0000064803 cvs:SeniorNotes2.8DueJune2023Member us-gaap:SeniorNotesMember 2021-12-31 0000064803 cvs:SeniorNotes2.8DueJune2023Member us-gaap:SeniorNotesMember 2020-12-31 0000064803 cvs:SeniorNotes4DueDecember2023Member us-gaap:SeniorNotesMember 2021-12-31 0000064803 cvs:SeniorNotes4DueDecember2023Member us-gaap:SeniorNotesMember 2020-12-31 0000064803 cvs:SeniorNotes3.375DueAugust2024Member us-gaap:SeniorNotesMember 2021-12-31 0000064803 cvs:SeniorNotes3.375DueAugust2024Member us-gaap:SeniorNotesMember 2020-12-31 0000064803 cvs:SeniorNotes2.625DueAugust2024Member us-gaap:SeniorNotesMember 2021-12-31 0000064803 cvs:SeniorNotes2.625DueAugust2024Member us-gaap:SeniorNotesMember 2020-12-31 0000064803 cvs:SeniorNotes3.5DueNovember2024Member us-gaap:SeniorNotesMember 2021-12-31 0000064803 cvs:SeniorNotes3.5DueNovember2024Member us-gaap:SeniorNotesMember 2020-12-31 0000064803 cvs:SeniorNotes5DueDecember2024Member us-gaap:SeniorNotesMember 2021-12-31 0000064803 cvs:SeniorNotes5DueDecember2024Member us-gaap:SeniorNotesMember 2020-12-31 0000064803 cvs:SeniorNotes4.1DueMarch2025Member us-gaap:SeniorNotesMember 2021-12-31 0000064803 cvs:SeniorNotes4.1DueMarch2025Member us-gaap:SeniorNotesMember 2020-12-31 0000064803 cvs:SeniorNotes3.875DueJuly2025Member us-gaap:SeniorNotesMember 2021-12-31 0000064803 cvs:SeniorNotes3.875DueJuly2025Member us-gaap:SeniorNotesMember 2020-12-31 0000064803 cvs:SeniorNotes2.875DueJune2026Member us-gaap:SeniorNotesMember 2021-12-31 0000064803 cvs:SeniorNotes2.875DueJune2026Member us-gaap:SeniorNotesMember 2020-12-31 0000064803 cvs:SeniorNotes3DueAugust2026Member us-gaap:SeniorNotesMember 2021-12-31 0000064803 cvs:SeniorNotes3DueAugust2026Member us-gaap:SeniorNotesMember 2020-12-31 0000064803 cvs:SeniorNotes3Point625PercentApril2027Member us-gaap:SeniorNotesMember 2021-12-31 0000064803 cvs:SeniorNotes3Point625PercentApril2027Member us-gaap:SeniorNotesMember 2020-12-31 0000064803 cvs:SeniorNotes6.25DueJune2027Member us-gaap:SeniorNotesMember 2021-12-31 0000064803 cvs:SeniorNotes6.25DueJune2027Member us-gaap:SeniorNotesMember 2020-12-31 0000064803 cvs:SeniorNotes1Point3PercentAugust2027Member us-gaap:SeniorNotesMember 2021-12-31 0000064803 cvs:SeniorNotes1Point3PercentAugust2027Member us-gaap:SeniorNotesMember 2020-12-31 0000064803 cvs:SeniorNotes4.3DueMarch2028Member us-gaap:SeniorNotesMember 2021-12-31 0000064803 cvs:SeniorNotes4.3DueMarch2028Member us-gaap:SeniorNotesMember 2020-12-31 0000064803 cvs:SeniorNotes3.25DueAugust2029Member us-gaap:SeniorNotesMember 2021-12-31 0000064803 cvs:SeniorNotes3.25DueAugust2029Member us-gaap:SeniorNotesMember 2020-12-31 0000064803 cvs:SeniorNotes3Point75PercentApril2030Member us-gaap:SeniorNotesMember 2021-12-31 0000064803 cvs:SeniorNotes3Point75PercentApril2030Member us-gaap:SeniorNotesMember 2020-12-31 0000064803 cvs:SeniorNotes1Point75PercentAugust2030Member us-gaap:SeniorNotesMember 2021-12-31 0000064803 cvs:SeniorNotes1Point75PercentAugust2030Member us-gaap:SeniorNotesMember 2020-12-31 0000064803 cvs:SeniorNotes1Point875PercentFebruary2031Member us-gaap:SeniorNotesMember 2021-12-31 0000064803 cvs:SeniorNotes1Point875PercentFebruary2031Member us-gaap:SeniorNotesMember 2020-12-31 0000064803 cvs:SeniorNotes2Point125PercentDueSeptember2031Member us-gaap:SeniorNotesMember 2021-12-31 0000064803 cvs:SeniorNotes2Point125PercentDueSeptember2031Member us-gaap:SeniorNotesMember 2020-12-31 0000064803 cvs:SeniorNotes4.875DueJuly2035Member us-gaap:SeniorNotesMember 2021-12-31 0000064803 cvs:SeniorNotes4.875DueJuly2035Member us-gaap:SeniorNotesMember 2020-12-31 0000064803 cvs:SeniorNotes6.625DueJune2036Member us-gaap:SeniorNotesMember 2021-12-31 0000064803 cvs:SeniorNotes6.625DueJune2036Member us-gaap:SeniorNotesMember 2020-12-31 0000064803 cvs:SeniorNotes6.75DueDecember2037Member us-gaap:SeniorNotesMember 2021-12-31 0000064803 cvs:SeniorNotes6.75DueDecember2037Member us-gaap:SeniorNotesMember 2020-12-31 0000064803 cvs:SeniorNotes4.78DueMarch2038Member us-gaap:SeniorNotesMember 2021-12-31 0000064803 cvs:SeniorNotes4.78DueMarch2038Member us-gaap:SeniorNotesMember 2020-12-31 0000064803 cvs:SeniorNotes6.125DueSeptember2039Member us-gaap:SeniorNotesMember 2021-12-31 0000064803 cvs:SeniorNotes6.125DueSeptember2039Member us-gaap:SeniorNotesMember 2020-12-31 0000064803 cvs:SeniorNotes4Point125PercentApril2040Member us-gaap:SeniorNotesMember 2021-12-31 0000064803 cvs:SeniorNotes4Point125PercentApril2040Member us-gaap:SeniorNotesMember 2020-12-31 0000064803 cvs:SeniorNotes2Point7PercentAugust2040Member us-gaap:SeniorNotesMember 2021-12-31 0000064803 cvs:SeniorNotes2Point7PercentAugust2040Member us-gaap:SeniorNotesMember 2020-12-31 0000064803 cvs:SeniorNotes5.75DueMay2041Member us-gaap:SeniorNotesMember 2021-12-31 0000064803 cvs:SeniorNotes5.75DueMay2041Member us-gaap:SeniorNotesMember 2020-12-31 0000064803 cvs:SeniorNotes4.5DueMay2042Member us-gaap:SeniorNotesMember 2021-12-31 0000064803 cvs:SeniorNotes4.5DueMay2042Member us-gaap:SeniorNotesMember 2020-12-31 0000064803 cvs:SeniorNotes4.125DueNovember2042Member us-gaap:SeniorNotesMember 2021-12-31 0000064803 cvs:SeniorNotes4.125DueNovember2042Member us-gaap:SeniorNotesMember 2020-12-31 0000064803 cvs:SeniorNotes5.3DueDecember2043Member us-gaap:SeniorNotesMember 2021-12-31 0000064803 cvs:SeniorNotes5.3DueDecember2043Member us-gaap:SeniorNotesMember 2020-12-31 0000064803 cvs:SeniorNotes4.75DueMarch2044Member us-gaap:SeniorNotesMember 2021-12-31 0000064803 cvs:SeniorNotes4.75DueMarch2044Member us-gaap:SeniorNotesMember 2020-12-31 0000064803 cvs:SeniorNotes5.125DueJuly2045Member us-gaap:SeniorNotesMember 2021-12-31 0000064803 cvs:SeniorNotes5.125DueJuly2045Member us-gaap:SeniorNotesMember 2020-12-31 0000064803 cvs:SeniorNotes3.875DueAugust2047Member us-gaap:SeniorNotesMember 2021-12-31 0000064803 cvs:SeniorNotes3.875DueAugust2047Member us-gaap:SeniorNotesMember 2020-12-31 0000064803 cvs:SeniorNotes5.05DueMarch2048Member us-gaap:SeniorNotesMember 2021-12-31 0000064803 cvs:SeniorNotes5.05DueMarch2048Member us-gaap:SeniorNotesMember 2020-12-31 0000064803 cvs:SeniorNotes4Point25PercentApril2050Member us-gaap:SeniorNotesMember 2021-12-31 0000064803 cvs:SeniorNotes4Point25PercentApril2050Member us-gaap:SeniorNotesMember 2020-12-31 0000064803 us-gaap:OtherDebtSecuritiesMember 2021-12-31 0000064803 us-gaap:OtherDebtSecuritiesMember 2020-12-31 0000064803 us-gaap:CommercialPaperMember 2021-12-31 0000064803 cvs:RevolvingCreditFacilityExpiringMay172023Member us-gaap:LineOfCreditMember 2021-12-31 0000064803 cvs:RevolvingCreditFacilityExpiringMay172023Member us-gaap:LineOfCreditMember 2021-01-01 2021-12-31 0000064803 cvs:RevolvingCreditFacilityExpiringMay162024Member us-gaap:LineOfCreditMember 2021-12-31 0000064803 cvs:RevolvingCreditFacilityExpiringMay162024Member us-gaap:LineOfCreditMember 2021-01-01 2021-12-31 0000064803 cvs:RevolvingCreditFacilityExpiringMay112026Member us-gaap:LineOfCreditMember 2021-12-31 0000064803 cvs:RevolvingCreditFacilityExpiringMay112026Member us-gaap:LineOfCreditMember 2021-01-01 2021-12-31 0000064803 cvs:BackUpCreditFacilitiesMember us-gaap:LineOfCreditMember 2021-01-01 2021-12-31 0000064803 cvs:BackUpCreditFacilitiesMember us-gaap:LineOfCreditMember 2020-12-31 0000064803 cvs:BackUpCreditFacilitiesMember us-gaap:LineOfCreditMember 2021-12-31 0000064803 us-gaap:FederalHomeLoanBankAdvancesMember 2021-12-31 0000064803 us-gaap:FederalHomeLoanBankAdvancesMember 2020-12-31 0000064803 cvs:SeniorNotes2Point125PercentDueSeptember2031Member us-gaap:SeniorNotesMember 2021-08-18 0000064803 2021-08-18 2021-08-18 0000064803 cvs:SeniorNotes13DueAugust2027Member us-gaap:SeniorNotesMember 2020-12-16 0000064803 cvs:SeniorNotes1875DueFebruary2031Member us-gaap:SeniorNotesMember 2020-12-16 0000064803 cvs:SeniorNotes1875DueFebruary2031Member us-gaap:SeniorNotesMember 2020-12-16 2020-12-16 0000064803 cvs:SeniorNotes13DueAugust2027Member us-gaap:SeniorNotesMember 2020-08-21 0000064803 cvs:SeniorNotes175DueAugust2030Member us-gaap:SeniorNotesMember 2020-08-21 0000064803 cvs:SeniorNotes27DueAugust2040Member us-gaap:SeniorNotesMember 2020-08-21 0000064803 2020-08-21 2020-08-21 0000064803 cvs:SeniorNotes3625DueApril2027Member us-gaap:SeniorNotesMember 2020-03-31 0000064803 cvs:SeniorNotes375DueApril2030Member us-gaap:SeniorNotesMember 2020-03-31 0000064803 cvs:SeniorNotes4125DueApril2040Member us-gaap:SeniorNotesMember 2020-03-31 0000064803 cvs:SeniorNotes425DueApril2050Member us-gaap:SeniorNotesMember 2020-03-31 0000064803 cvs:SeniorNotes425DueApril2050Member us-gaap:SeniorNotesMember 2020-01-01 2020-03-31 0000064803 2020-01-01 2020-03-31 0000064803 cvs:SeniorNotes3Point70PercentDue2023Member us-gaap:SeniorNotesMember 2021-12-01 2021-12-31 0000064803 cvs:SeniorNotes3Point70PercentDue2023Member us-gaap:SeniorNotesMember 2021-12-31 0000064803 2021-12-01 2021-12-31 0000064803 cvs:SeniorNotes4PointThreePercentDue2028Member us-gaap:SeniorNotesMember 2021-08-01 2021-08-31 0000064803 cvs:SeniorNotes4PointThreePercentDue2028Member us-gaap:SeniorNotesMember 2021-08-31 0000064803 2021-08-01 2021-08-31 0000064803 cvs:OutstandingSeniorNotesMember us-gaap:SeniorNotesMember 2020-12-01 2020-12-31 0000064803 cvs:SeniorNotes4DueDecember2023Member us-gaap:SeniorNotesMember 2020-12-01 2020-12-31 0000064803 cvs:SeniorNotes3.7DueMarch2023Member us-gaap:SeniorNotesMember 2020-12-01 2020-12-31 0000064803 cvs:SeniorNotes4.1DueMarch2025Member us-gaap:SeniorNotesMember 2020-12-01 2020-12-31 0000064803 cvs:SeniorNotes43Due2028Member us-gaap:SeniorNotesMember 2020-12-01 2020-12-31 0000064803 cvs:SeniorNotes43Due2028Member us-gaap:SeniorNotesMember 2020-12-31 0000064803 2020-12-01 2020-12-31 0000064803 cvs:OutstandingSeniorNotesMember us-gaap:SeniorNotesMember 2020-08-01 2020-08-31 0000064803 cvs:SeniorNotes4DueDecember2023Member us-gaap:SeniorNotesMember 2020-08-01 2020-08-31 0000064803 cvs:SeniorNotes4DueDecember2023Member us-gaap:SeniorNotesMember 2020-08-31 0000064803 cvs:SeniorNotes3.7DueMarch2023Member us-gaap:SeniorNotesMember 2020-08-01 2020-08-31 0000064803 cvs:SeniorNotes3.7DueMarch2023Member us-gaap:SeniorNotesMember 2020-08-31 0000064803 cvs:SeniorNotes4.1DueMarch2025Member us-gaap:SeniorNotesMember 2020-08-01 2020-08-31 0000064803 cvs:SeniorNotes4.1DueMarch2025Member us-gaap:SeniorNotesMember 2020-08-31 0000064803 2020-08-01 2020-08-31 0000064803 cvs:OutstandingSeniorNotesMember us-gaap:SeniorNotesMember 2019-08-01 2019-08-31 0000064803 cvs:SeniorNotes3.125DueMarch2020Member us-gaap:SeniorNotesMember 2019-08-01 2019-08-31 0000064803 cvs:SeniorNotes3.125DueMarch2020Member us-gaap:SeniorNotesMember 2019-08-31 0000064803 cvs:FloatingRateNotesDueMarch2020Member cvs:FloatingRateNotesMember 2019-08-01 2019-08-31 0000064803 cvs:SeniorNotes4.125DueMay2021Member us-gaap:SeniorNotesMember 2019-08-01 2019-08-31 0000064803 cvs:SeniorNotes4.125DueMay2021Member us-gaap:SeniorNotesMember 2019-08-31 0000064803 cvs:SeniorNotes4.125DueJune2021Member us-gaap:SeniorNotesMember 2019-08-01 2019-08-31 0000064803 cvs:SeniorNotes4.125DueJune2021Member us-gaap:SeniorNotesMember 2019-08-31 0000064803 cvs:SeniorNotes5.45DueJune2021Member us-gaap:SeniorNotesMember 2019-08-01 2019-08-31 0000064803 cvs:SeniorNotes5.45DueJune2021Member us-gaap:SeniorNotesMember 2019-08-31 0000064803 cvs:SeniorNotes3.35DueMarch2021Member us-gaap:SeniorNotesMember 2019-08-01 2019-08-31 0000064803 cvs:SeniorNotes3.35DueMarch2021Member us-gaap:SeniorNotesMember 2019-08-31 0000064803 2019-08-01 2019-08-31 0000064803 us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000064803 us-gaap:PensionPlansDefinedBenefitMember 2021-01-01 2021-12-31 0000064803 us-gaap:PensionPlansDefinedBenefitMember 2020-01-01 2020-12-31 0000064803 us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:PensionPlansDefinedBenefitMember 2019-01-01 2019-12-31 0000064803 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel12And3Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel12And3Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:USStatesAndPoliticalSubdivisionsMember us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:USStatesAndPoliticalSubdivisionsMember us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:USStatesAndPoliticalSubdivisionsMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:USStatesAndPoliticalSubdivisionsMember us-gaap:FairValueInputsLevel12And3Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:DomesticCorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:DomesticCorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:DomesticCorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:DomesticCorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel12And3Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:ForeignCorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:ForeignCorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:ForeignCorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:ForeignCorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel12And3Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:ResidentialMortgageBackedSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:ResidentialMortgageBackedSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:ResidentialMortgageBackedSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:ResidentialMortgageBackedSecuritiesMember us-gaap:FairValueInputsLevel12And3Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:CommercialMortgageBackedSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:CommercialMortgageBackedSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:CommercialMortgageBackedSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:CommercialMortgageBackedSecuritiesMember us-gaap:FairValueInputsLevel12And3Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:AssetBackedSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:AssetBackedSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:AssetBackedSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:AssetBackedSecuritiesMember us-gaap:FairValueInputsLevel12And3Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 cvs:RedeemablePreferredSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 cvs:RedeemablePreferredSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 cvs:RedeemablePreferredSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 cvs:RedeemablePreferredSecuritiesMember us-gaap:FairValueInputsLevel12And3Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:DebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:DebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:DebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:DebtSecuritiesMember us-gaap:FairValueInputsLevel12And3Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember us-gaap:FairValueInputsLevel12And3Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember us-gaap:FairValueInputsLevel12And3Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 cvs:EquitySecuritiesDomesticRealEstateMember us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 cvs:EquitySecuritiesDomesticRealEstateMember us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 cvs:EquitySecuritiesDomesticRealEstateMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 cvs:EquitySecuritiesDomesticRealEstateMember us-gaap:FairValueInputsLevel12And3Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel12And3Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueInputsLevel12And3Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:DefinedBenefitPlanCommonCollectiveTrustMember us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:DefinedBenefitPlanCommonCollectiveTrustMember us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:DefinedBenefitPlanCommonCollectiveTrustMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:DefinedBenefitPlanCommonCollectiveTrustMember us-gaap:FairValueInputsLevel12And3Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:OtherInvestmentsMember us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:OtherInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:OtherInvestmentsMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:OtherInvestmentsMember us-gaap:FairValueInputsLevel12And3Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:FairValueInputsLevel12And3Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 cvs:DefinedBenefitPlanCommonCollectiveTrustEquitySecuritiesMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 cvs:DefinedBenefitPlanCommonCollectiveTrustDebtSecuritiesMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:AccountsReceivableMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:PrivateEquityFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:HedgeFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel12And3Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel12And3Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:USStatesAndPoliticalSubdivisionsMember us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:USStatesAndPoliticalSubdivisionsMember us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:USStatesAndPoliticalSubdivisionsMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:USStatesAndPoliticalSubdivisionsMember us-gaap:FairValueInputsLevel12And3Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:DomesticCorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:DomesticCorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:DomesticCorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:DomesticCorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel12And3Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:ForeignCorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:ForeignCorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:ForeignCorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:ForeignCorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel12And3Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:ResidentialMortgageBackedSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:ResidentialMortgageBackedSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:ResidentialMortgageBackedSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:ResidentialMortgageBackedSecuritiesMember us-gaap:FairValueInputsLevel12And3Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:CommercialMortgageBackedSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:CommercialMortgageBackedSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:CommercialMortgageBackedSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:CommercialMortgageBackedSecuritiesMember us-gaap:FairValueInputsLevel12And3Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:AssetBackedSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:AssetBackedSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:AssetBackedSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:AssetBackedSecuritiesMember us-gaap:FairValueInputsLevel12And3Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 cvs:RedeemablePreferredSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 cvs:RedeemablePreferredSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 cvs:RedeemablePreferredSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 cvs:RedeemablePreferredSecuritiesMember us-gaap:FairValueInputsLevel12And3Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:DebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:DebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:DebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:DebtSecuritiesMember us-gaap:FairValueInputsLevel12And3Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember us-gaap:FairValueInputsLevel12And3Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember us-gaap:FairValueInputsLevel12And3Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 cvs:EquitySecuritiesDomesticRealEstateMember us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 cvs:EquitySecuritiesDomesticRealEstateMember us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 cvs:EquitySecuritiesDomesticRealEstateMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 cvs:EquitySecuritiesDomesticRealEstateMember us-gaap:FairValueInputsLevel12And3Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel12And3Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueInputsLevel12And3Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:DefinedBenefitPlanCommonCollectiveTrustMember us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:DefinedBenefitPlanCommonCollectiveTrustMember us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:DefinedBenefitPlanCommonCollectiveTrustMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:DefinedBenefitPlanCommonCollectiveTrustMember us-gaap:FairValueInputsLevel12And3Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:DefinedBenefitPlanDerivativeMember us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:DefinedBenefitPlanDerivativeMember us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:DefinedBenefitPlanDerivativeMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:DefinedBenefitPlanDerivativeMember us-gaap:FairValueInputsLevel12And3Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:OtherInvestmentsMember us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:OtherInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:OtherInvestmentsMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:OtherInvestmentsMember us-gaap:FairValueInputsLevel12And3Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:FairValueInputsLevel1Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:FairValueInputsLevel12And3Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 cvs:DefinedBenefitPlanCommonCollectiveTrustEquitySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 cvs:DefinedBenefitPlanCommonCollectiveTrustDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:AccountsReceivableMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:PrivateEquityFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:HedgeFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2021-01-01 2021-12-31 0000064803 us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2021-01-01 2021-12-31 0000064803 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000064803 us-gaap:DomesticCorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000064803 us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000064803 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2020-01-01 2020-12-31 0000064803 us-gaap:DomesticCorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2020-01-01 2020-12-31 0000064803 us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2020-01-01 2020-12-31 0000064803 us-gaap:EquitySecuritiesMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:DebtSecuritiesMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:RealEstateInvestmentMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:PrivateEquityFundsMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:HedgeFundsMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-12-31 0000064803 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2020-12-31 0000064803 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-01-01 2021-12-31 0000064803 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2020-01-01 2020-12-31 0000064803 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2019-01-01 2019-12-31 0000064803 cvs:CVSHealth2017IncentiveCompensationPlanMember 2021-12-31 0000064803 cvs:AetnaInc2010StockIncentivePlanMember 2018-11-28 0000064803 cvs:EmployeeStockOptionsandStockAppreciationRightsMember 2021-01-01 2021-12-31 0000064803 cvs:EmployeeStockOptionsandStockAppreciationRightsMember 2020-01-01 2020-12-31 0000064803 cvs:EmployeeStockOptionsandStockAppreciationRightsMember 2019-01-01 2019-12-31 0000064803 cvs:RestrictedStockUnitsandPerformanceShareUnitsMember 2021-01-01 2021-12-31 0000064803 cvs:RestrictedStockUnitsandPerformanceShareUnitsMember 2020-01-01 2020-12-31 0000064803 cvs:RestrictedStockUnitsandPerformanceShareUnitsMember 2019-01-01 2019-12-31 0000064803 us-gaap:EmployeeStockMember 2021-12-31 0000064803 us-gaap:EmployeeStockMember 2021-01-01 2021-12-31 0000064803 us-gaap:EmployeeStockMember 2020-01-01 2020-12-31 0000064803 us-gaap:EmployeeStockMember 2019-01-01 2019-12-31 0000064803 cvs:RestrictedStockUnitsandPerformanceShareUnitsMember 2021-12-31 0000064803 cvs:RestrictedStockUnitsandPerformanceShareUnitsMember 2020-12-31 0000064803 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0000064803 cvs:ShareBasedPaymentArrangementOptionGrantedPriorThrough2018Member 2021-01-01 2021-12-31 0000064803 cvs:ShareBasedPaymentArrangementOptionGrantedSubsequentTo2018Member 2021-01-01 2021-12-31 0000064803 us-gaap:StockAppreciationRightsSARSMember 2021-01-01 2021-12-31 0000064803 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0000064803 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0000064803 cvs:EmployeeStockOptionsandStockAppreciationRightsMember 2021-12-31 0000064803 cvs:EmployeeStockOptionsandStockAppreciationRightsMember 2020-12-31 0000064803 cvs:A2021RepurchaseProgramMember 2021-12-09 0000064803 cvs:A2021RepurchaseProgramMember 2021-12-31 0000064803 cvs:A2016RepurchaseProgramMember 2016-11-02 0000064803 cvs:A2016RepurchaseProgramMember 2021-12-31 0000064803 cvs:BarclaysBankMember cvs:A2021AcceleratedRepurchaseProgramMember us-gaap:SubsequentEventMember 2022-01-04 0000064803 cvs:BarclaysBankMember cvs:A2021AcceleratedRepurchaseProgramMember us-gaap:SubsequentEventMember 2022-01-04 2022-01-04 0000064803 2020-09-30 0000064803 2020-03-31 0000064803 2020-06-30 0000064803 2021-09-30 0000064803 2021-03-31 0000064803 srt:ScenarioForecastMember 2022-12-31 0000064803 cvs:InsuranceAndHmoMember 2021-01-01 2021-12-31 0000064803 cvs:InsuranceAndHmoMember 2020-01-01 2020-12-31 0000064803 cvs:InsuranceAndHmoMember 2019-01-01 2019-12-31 0000064803 cvs:InsuranceAndHmoMember 2021-12-31 0000064803 cvs:InsuranceAndHmoMember 2020-12-31 0000064803 cvs:InsuranceAndHmoMember 2019-12-31 0000064803 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2020-12-31 0000064803 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2019-12-31 0000064803 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2018-12-31 0000064803 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2021-01-01 2021-12-31 0000064803 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2020-01-01 2020-12-31 0000064803 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2019-01-01 2019-12-31 0000064803 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2021-12-31 0000064803 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2020-12-31 0000064803 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2019-12-31 0000064803 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2018-12-31 0000064803 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2021-01-01 2021-12-31 0000064803 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2020-01-01 2020-12-31 0000064803 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2019-01-01 2019-12-31 0000064803 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2021-12-31 0000064803 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2020-12-31 0000064803 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2019-12-31 0000064803 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2018-12-31 0000064803 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2021-01-01 2021-12-31 0000064803 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2020-01-01 2020-12-31 0000064803 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2019-01-01 2019-12-31 0000064803 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2021-12-31 0000064803 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2020-12-31 0000064803 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2019-12-31 0000064803 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2018-12-31 0000064803 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2021-01-01 2021-12-31 0000064803 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2020-01-01 2020-12-31 0000064803 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2019-01-01 2019-12-31 0000064803 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2021-12-31 0000064803 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2020-12-31 0000064803 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2019-12-31 0000064803 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2018-12-31 0000064803 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2021-12-31 0000064803 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0000064803 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0000064803 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0000064803 us-gaap:SubsequentEventMember 2022-01-01 2022-01-31 0000064803 cvs:HartfordLifeAndAccidentInsuranceCompanyMember 2021-12-31 0000064803 cvs:HartfordLifeAndAccidentInsuranceCompanyMember 2020-12-31 0000064803 cvs:LincolnLifeAnnuityCompanyOfNewYorkMember 2021-12-31 0000064803 cvs:LincolnLifeAnnuityCompanyOfNewYorkMember 2020-12-31 0000064803 cvs:VOYARetirementInsuranceAndAnnuityCompanyMember 2021-12-31 0000064803 cvs:VOYARetirementInsuranceAndAnnuityCompanyMember 2020-12-31 0000064803 cvs:AllOtherReinsurersMember 2021-12-31 0000064803 cvs:AllOtherReinsurersMember 2020-12-31 0000064803 2012-01-01 2012-12-31 0000064803 cvs:RadcliffAndFlaimVAetnaIncEtAlMember us-gaap:PendingLitigationMember 2020-12-31 0000064803 cvs:USFederalGovernmentMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0000064803 cvs:USFederalGovernmentMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0000064803 cvs:USFederalGovernmentMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0000064803 us-gaap:IntersegmentEliminationMember cvs:HealthCareBenefitsSegmentMember 2021-01-01 2021-12-31 0000064803 us-gaap:IntersegmentEliminationMember cvs:PharmacyServicesSegmentMember 2021-01-01 2021-12-31 0000064803 us-gaap:IntersegmentEliminationMember cvs:RetailLongTermCareSegmentMember 2021-01-01 2021-12-31 0000064803 us-gaap:IntersegmentEliminationMember cvs:HealthCareBenefitsSegmentMember 2020-01-01 2020-12-31 0000064803 us-gaap:IntersegmentEliminationMember cvs:PharmacyServicesSegmentMember 2020-01-01 2020-12-31 0000064803 us-gaap:IntersegmentEliminationMember cvs:RetailLongTermCareSegmentMember 2020-01-01 2020-12-31 0000064803 us-gaap:IntersegmentEliminationMember cvs:HealthCareBenefitsSegmentMember 2019-01-01 2019-12-31 0000064803 us-gaap:IntersegmentEliminationMember cvs:PharmacyServicesSegmentMember 2019-01-01 2019-12-31 0000064803 us-gaap:IntersegmentEliminationMember cvs:RetailLongTermCareSegmentMember 2019-01-01 2019-12-31 0000064803 cvs:HealthCareBenefitsSegmentMember 2021-06-01 2021-06-30 iso4217:USD shares iso4217:USD shares cvs:store cvs:member cvs:people cvs:patient cvs:Segment cvs:state cvs:clinic pure cvs:security cvs:reinsurance_agreement cvs:lease cvs:claim 0000064803 2021 FY false http://fasb.org/us-gaap/2021-01-31#ProductMember http://fasb.org/us-gaap/2021-01-31#ProductMember http://fasb.org/us-gaap/2021-01-31#ProductMember http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201602Member http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201613Member P3Y http://fasb.org/us-gaap/2021-01-31#LongTermDebtAndCapitalLeaseObligations http://fasb.org/us-gaap/2021-01-31#LongTermDebtAndCapitalLeaseObligations P3Y 10-K true 2021-12-31 --12-31 false 001-01011 CVS HEALTH CORPORATION DE 05-0494040 One CVS Drive, Woonsocket, RI 02895 (401) 765-1500 Common Stock, par value $0.01 per share CVS NYSE Yes No Yes Yes Large Accelerated Filer false false true false 109651334285 1312510426 <div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following materials are incorporated by reference into this Form 10-K:</span></div><div style="margin-bottom:0.8pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Information contained in the definitive proxy statement for CVS Health Corporation’s 2022 Annual Meeting of Stockholders, to be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year ended December 31, 2021 (the “Proxy Statement”), is incorporated by reference in Parts III and IV to the extent described therein.</span></div> 42 203738000000 190688000000 185236000000 76132000000 69364000000 63122000000 11042000000 7856000000 7407000000 1199000000 798000000 1011000000 292111000000 268706000000 256776000000 175803000000 163981000000 158719000000 64260000000 55679000000 52529000000 1358000000 0 231000000 431000000 0 0 37066000000 35135000000 33310000000 278918000000 254795000000 244789000000 13193000000 13911000000 11987000000 2503000000 2907000000 3035000000 -452000000 -1440000000 -79000000 182000000 206000000 124000000 10420000000 9770000000 8997000000 2522000000 2569000000 2366000000 7898000000 7201000000 6631000000 0 -9000000 0 7898000000 7192000000 6631000000 -12000000 13000000 -3000000 7910000000 7179000000 6634000000 6.00 5.49 5.10 0 -0.01 0 6.00 5.48 5.10 1319000000 1309000000 1301000000 5.95 5.47 5.08 0 -0.01 0 5.95 5.46 5.08 1329000000 1314000000 1305000000 2.00 2.00 2.00 7898000000 7192000000 6631000000 -436000000 440000000 677000000 -7000000 3000000 162000000 -26000000 -31000000 -33000000 -20000000 17000000 -111000000 -449000000 395000000 917000000 7449000000 7587000000 7548000000 -12000000 13000000 -3000000 7461000000 7574000000 7551000000 9408000000 7854000000 3117000000 3000000000 24431000000 21742000000 17760000000 18496000000 5292000000 5277000000 60008000000 56369000000 23025000000 20812000000 12896000000 12606000000 19122000000 20729000000 79121000000 79552000000 29026000000 31142000000 5087000000 4881000000 4714000000 4624000000 232999000000 230715000000 12544000000 11138000000 17330000000 15795000000 8808000000 7936000000 4301000000 4270000000 17670000000 14243000000 1303000000 1557000000 1646000000 1638000000 4205000000 5440000000 67807000000 62017000000 18177000000 18757000000 51971000000 59207000000 6270000000 6794000000 5087000000 4881000000 6402000000 7007000000 1904000000 2351000000 157618000000 161014000000 0.01 0.01 100000 100000 0 0 0 0 0 0 0.01 0.01 3200000000 3200000000 1744000000 1322000000 1733000000 1310000000 47377000000 46513000000 422000000 423000000 28173000000 28178000000 54906000000 49640000000 965000000 1414000000 75075000000 69389000000 306000000 312000000 75381000000 69701000000 232999000000 230715000000 284219000000 264327000000 248393000000 165783000000 158636000000 149655000000 63598000000 55124000000 52242000000 31652000000 29763000000 28932000000 743000000 894000000 955000000 2469000000 2904000000 2954000000 3195000000 2929000000 2717000000 18265000000 15865000000 12848000000 7246000000 6467000000 7049000000 9963000000 9639000000 7534000000 2520000000 2437000000 2457000000 0 101000000 5000000 146000000 866000000 444000000 0 840000000 0 -122000000 0 -42000000 -5261000000 -5534000000 -3339000000 0 0 -720000000 987000000 9958000000 3736000000 10254000000 15631000000 8336000000 0 7000000 25000000 2625000000 2624000000 2603000000 549000000 264000000 210000000 168000000 88000000 112000000 155000000 432000000 196000000 -11356000000 -7696000000 -7654000000 1648000000 2635000000 1855000000 11043000000 8408000000 6553000000 12691000000 11043000000 8408000000 7898000000 7192000000 6631000000 4512000000 4441000000 4371000000 1358000000 0 231000000 431000000 0 0 484000000 400000000 453000000 0 269000000 -205000000 -452000000 -1440000000 -79000000 -428000000 -570000000 -654000000 390000000 -72000000 -33000000 2703000000 1510000000 2158000000 -735000000 973000000 1075000000 3000000 -364000000 614000000 2898000000 2769000000 3550000000 169000000 -231000000 320000000 2852000000 2740000000 1476000000 18265000000 15865000000 12848000000 1720000000 -425000000 45440000000 -28228000000 40911000000 102000000 58225000000 318000000 58543000000 178000000 178000000 178000000 6634000000 6634000000 -3000000 6631000000 917000000 917000000 917000000 7000000 2000000 532000000 532000000 532000000 2000000 7000000 7000000 7000000 2615000000 2615000000 2615000000 -9000000 -9000000 1727000000 -425000000 45972000000 -28235000000 45108000000 1019000000 63864000000 306000000 64170000000 -3000000 -3000000 -3000000 7179000000 7179000000 13000000 7192000000 395000000 395000000 395000000 6000000 541000000 541000000 541000000 2000000 57000000 57000000 57000000 2644000000 2644000000 2644000000 -7000000 -7000000 1733000000 -423000000 46513000000 -28178000000 49640000000 1414000000 69389000000 312000000 69701000000 7910000000 7910000000 -12000000 7898000000 -449000000 -449000000 -449000000 11000000 864000000 864000000 864000000 1000000 5000000 5000000 5000000 2644000000 2644000000 2644000000 6000000 6000000 1744000000 -422000000 47377000000 -28173000000 54906000000 965000000 75075000000 306000000 75381000000 1000000 1000000 1000000 29000000 29000000 29000000 17000000 17000000 17000000 178000000 -3000000 Significant Accounting Policies <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CVS Health Corporation, together with its subsidiaries (collectively, “CVS Health” or the “Company”), has more than 9,900 retail locations, nearly 1,200 walk-in medical clinics, a leading pharmacy benefits manager with approximately 110 million plan members with expanding specialty pharmacy solutions and a dedicated senior pharmacy care business serving more than one million patients per year. The Company also serves an estimated 35 million people through traditional, voluntary and consumer-directed health insurance products and related services, including expanding Medicare Advantage offerings and a leading standalone Medicare Part D prescription drug plan (“PDP”). The Company believes its innovative health care model increases access to quality care, delivers better health outcomes and lowers overall health care costs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The coronavirus disease 2019 (“COVID-19”) and its emerging new variants continue to impact the economies of the U.S. and other countries around the world. The impact of COVID-19 on the Company’s businesses, operating results, cash flows and financial condition in the years ended December 31, 2021 and 2020, as well as information regarding certain expected impacts of COVID-19 on the Company, is discussed throughout this Annual Report on Form 10-K.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has four reportable segments: Health Care Benefits, Pharmacy Services, Retail/LTC and Corporate/Other, which are described below. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Health Care Benefits Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Health Care Benefits segment operates as one of the nation’s leading diversified health care benefits providers. The Health Care Benefits segment has the information and resources to help members, in consultation with their health care professionals, make more informed decisions about their health care. The Health Care Benefits segment offers a broad range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, medical management capabilities, Medicare Advantage and Medicare Supplement plans, PDPs, Medicaid health care management services and health information technology products and services. The Health Care Benefits segment also provided workers’ compensation administrative services through its Coventry Health Care Workers’ Compensation business (“Workers’ Compensation business”) prior to the sale of this business on July 31, 2020. The Health Care Benefits segment’s customers include employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers (“providers”), governmental units, government-sponsored plans, labor groups and expatriates. The Company refers to insurance products (where it assumes all or a majority of the risk for medical and dental care costs) as “Insured” and administrative services contract products (where the plan sponsor assumes all or a majority of the risk for medical and dental care costs) as “ASC.” In addition, effective January 2022, the Company entered the individual public health insurance exchanges (“Public Exchanges”) in eight states through which it sells Insured plans directly to individual consumers.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pharmacy Services Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmacy Services segment provides a full range of pharmacy benefit management (“PBM”) solutions, including plan design offerings and administration, formulary management, retail pharmacy network management services and mail order pharmacy. In addition, through the Pharmacy Services segment, the Company provides specialty pharmacy and infusion services, clinical services, disease management services, medical spend management and pharmacy and/or other administrative services for providers and federal 340B drug pricing program covered entities (“Covered Entities”). The Pharmacy Services segment’s clients are primarily employers, insurance companies, unions, government employee groups, health plans, PDPs, Medicaid managed care plans, plans offered on Public Exchanges and private health insurance exchanges, other sponsors of health benefit plans throughout the United States and Covered Entities. The Pharmacy Services segment operates retail specialty pharmacy stores, specialty mail order pharmacies, mail order dispensing pharmacies, compounding pharmacies and branches for infusion and enteral nutrition services. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Retail/LTC Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Retail/LTC segment sells prescription drugs and a wide assortment of health and wellness products and general merchandise, provides health care services through its MinuteClinic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">walk-in medical clinics, provides medical diagnostic testing, administers vaccinations for illnesses such as influenza, COVID-19 and shingles and conducts long-term care pharmacy (“LTC”) operations, which distribute prescription drugs and provide related pharmacy consulting and other ancillary services to long-term care facilities and other care settings. As of December 31, 2021, the Retail/LTC segment operated more than 9,900 retail locations, nearly 1,200 MinuteClinic locations as well as online retail pharmacy websites, LTC pharmacies and on-site pharmacies. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Corporate/Other Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company presents the remainder of its financial results in the Corporate/Other segment, which primarily consists of:</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Management and administrative expenses to support the Company’s overall operations, which include certain aspects of executive management and the corporate relations, legal, compliance, human resources, information technology and finance departments, expenses associated with the Company’s investments in its transformation and enterprise modernization programs and acquisition-related transaction and integration costs; and</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Products for which the Company no longer solicits or accepts new customers such as its large case pensions and long-term care insurance products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements of CVS Health and its subsidiaries have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The consolidated financial statements include the accounts of the Company and its majority-owned subsidiaries and variable interest entities (“VIEs”) for which the Company is the primary beneficiary. All material intercompany balances and transactions have been eliminated.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior year amounts have been reclassified to conform with the current year presentation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of cash and temporary investments with maturities of three months or less when purchased. The Company invests in short-term money market funds, commercial paper and time deposits, as well as other debt securities that are classified as cash equivalents within the accompanying consolidated balance sheets, as these funds are highly liquid and readily convertible to known amounts of cash. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash (included in other current assets) represents funds held on behalf of members, including health savings account (“HSA”) funds associated with high deductible health plans. Beginning in 2021, the Company began presenting these funds held on behalf of members in restricted cash and, for statement of cash flow purposes, retrospectively adjusted the 2020 and 2019 balances by the amounts shown in the table below in the line item “restricted cash (included in other current assets)” to conform with the current year presentation. Restricted cash (included in other assets) represents amounts held in a trust in one of the Company’s captive insurance companies to satisfy collateral requirements associated with the assignment of certain insurance policies. All restricted cash is invested in time deposits, money market funds or commercial paper.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of cash and cash equivalents on the consolidated balance sheets to total cash, cash equivalents and restricted cash on the consolidated statements of cash flows as of December 31, 2021, 2020 and 2019:</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,408 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,854 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,683 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash (included in other current assets)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,065 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,913 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,454 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash (included in other assets)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash in the consolidated statements of cash flows</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,691 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,043 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,408 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt Securities </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities consist primarily of U.S. Treasury and agency securities, mortgage-backed securities, corporate and foreign bonds and other debt securities. Debt securities are classified as either current or long-term investments based on their contractual maturities unless the Company intends to sell an investment within the next twelve months, in which case it is classified as current on the consolidated balance sheets. Debt securities are classified as available for sale and are carried at fair value. See Note 4 ‘‘Fair Value’’ for additional information on how the Company estimates the fair value of these investments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a debt security is in an unrealized loss position and the Company has the intent to sell the security, or it is more likely than not that the Company will have to sell the security before recovery of its amortized cost basis, the amortized cost basis of the security is written down to its fair value and the difference is recognized in net income. If a debt security is in an unrealized loss position and the Company does not have the intent to sell and it is more likely than not that the Company will not have to sell such security before recovery of its amortized cost basis, the Company bifurcates the impairment into credit-related and non-credit related components. In evaluating whether a credit related loss exists, the Company considers a variety of factors including: the extent to which the fair value is less than the amortized cost basis; adverse conditions specifically related to the issuer of a security, an industry or geographic area; the payment structure of the security; the failure of the issuer of the security to make scheduled interest or principal payments; and any changes to the rating of the security by a rating agency. The amount of the credit-related component is recorded as an allowance for credit losses and recognized in net income, and the amount of the non-credit related component is included in other comprehensive income. Interest is not accrued on debt securities when management believes the collection of interest is unlikely.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The credit-related component is determined by comparing the present value of cash flows expected to be collected from the security, considering all reasonably available information relevant to the collectability of the security, with the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis of the security, the Company records an allowance for credit losses, which is limited by the amount that the fair value is less than amortized cost basis. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For mortgage-backed and other asset-backed securities, the Company recognizes income using an effective yield based on anticipated prepayments and the estimated economic life of the securities. When estimates of prepayments change, the effective yield is recalculated to reflect actual payments to date and anticipated future payments. The Company’s investment in the security is adjusted to the amount that would have existed had the new effective yield been applied since the acquisition of the security, with adjustments recognized in net income.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Securities</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity securities with readily available fair values are measured at fair value with changes in fair value recognized in net income (loss).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mortgage Loans</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mortgage loan investments on the consolidated balance sheets are valued at the unpaid principal balance, net of an allowance for credit losses. Mortgage loans with a maturity date or a committed prepayment date within twelve months are classified as current on the consolidated balance sheets. The Company assesses whether its loans share similar risk characteristics and, if so, groups such loans in a risk pool when measuring expected credit losses. The Company considers the following characteristics when evaluating whether its loans share similar risk characteristics: loan-to-value ratios, property type (e.g., office, retail, apartment, industrial), geographic location, vacancy rates and property condition. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Credit loss reserves are determined using a loss rate method that multiplies the unpaid principal balance of each loan within a risk pool group by an estimated loss rate percentage. The loss rate percentage considers both the expected loan loss severity and the probability of loan default. For periods where the Company is able to make or obtain reasonable and supportable forecasts of expected economic conditions (e.g., gross domestic product, employment), the Company adjusts its expected loss rates to reflect these forecasted economic conditions. For periods beyond which the Company is able to make or obtain reasonable and supportable forecasts of expected economic conditions, the Company reverts to historical loss rates in determining expected credit losses. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income on a potential problem loan (i.e., high probability of default) or restructured loan is accrued to the extent it is deemed to be collectible and the loan continues to perform under its original or restructured terms. Interest income on problem loans (i.e., more than 60 days delinquent, in bankruptcy or in process of foreclosure) is recognized on a cash basis. Cash payments on loans in the process of foreclosure are treated as a return of principal.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Investments</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other investments consist primarily of the following:</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Private equity and hedge fund limited partnerships, which are accounted for using the equity method of accounting. Under this method, the carrying value of the investment is based on the value of the Company’s equity ownership of the underlying investment funds provided by the general partner or manager of the investments, the financial statements of which generally are audited. As a result of the timing of the receipt of the valuation information provided by the fund managers, these investments are generally reported on up to a three month lag. The Company reviews investments for impairment at least quarterly and monitors their performance throughout the year through discussions with the administrators, managers and/or general partners. If the Company becomes aware of an impairment of a limited partnership’s investments through its review or prior to receiving the limited partnership’s financial statements at the financial statement date, an impairment will be recognized by recording a reduction in the carrying value of the limited partnership with a corresponding charge to net investment income. </span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Investment real estate, which is carried on the consolidated balance sheets at depreciated cost, including capital additions, net of write-downs for other-than-temporary declines in fair value. Depreciation is calculated using the straight-line method based on the estimated useful life of each asset. If any real estate investment is considered held-for-sale, it is carried at the lower of its carrying value or fair value less estimated selling costs. The Company generally estimates fair value using net operating income and applying a capitalization rate in conjunction with comparable sales information. At the time of the sale, the difference between the sales price and the carrying value is recorded as a realized capital gain or loss. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Privately-placed equity securities, which are carried on the consolidated balance sheets at cost less impairments, plus or minus subsequent adjustments for observable price changes. Additionally, as a member of the Federal Home Loan Bank of Boston (“FHLBB”), a subsidiary of the Company is required to purchase and hold shares of the FHLBB. These shares are restricted and carried at cost. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Investment Income</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net investment income on the Company’s investments is recorded when earned and is reflected in the Company’s net income (other than net investment income on assets supporting experience-rated products). Experience-rated products are products in the large case pensions business where the contract holder, not the Company, assumes investment and other risks, subject to, among other things, minimum guarantees provided by the Company. The effect of investment performance on experience-rated products is allocated to contract holders’ accounts daily, based on the underlying investment experience and, therefore, does not impact the Company’s net income (as long as the contract’s minimum guarantees are not triggered). Net investment income on assets supporting large case pensions’ experience-rated products is included in net investment income in the consolidated statements of operations and is credited to contract holders’ accounts through a charge to benefit costs. The contract holders’ accounts are reflected in policyholders’ funds on the consolidated balance sheets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized capital gains and losses on investments (other than realized capital gains and losses on investments supporting experience-rated products) are included as a component of net investment income in the consolidated statements of operations. Realized capital gains and losses are determined on a specific identification basis. Purchases and sales of debt and equity securities and alternative investments are reflected on the trade date. Purchases and sales of mortgage loans and investment real estate are reflected on the closing date.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized capital gains and losses on investments supporting large case pensions’ experience-rated products are not included in realized capital gains and losses in the consolidated statements of operations and instead are credited directly to contract holders’ accounts. The contract holders’ accounts are reflected in policyholders’ funds on the consolidated balance sheets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized capital gains and losses on investments (other than unrealized capital gains and losses on investments supporting experience-rated products) are reflected in shareholders’ equity, net of tax, as a component of accumulated other comprehensive income. Unrealized capital gains and losses on investments supporting large case pensions’ experience-rated products are credited directly to contract holders’ accounts. The contract holders’ accounts are reflected in policyholders’ funds on the consolidated balance sheets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Financial Instruments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses derivative financial instruments in order to manage interest rate and foreign exchange risk and credit exposure. The Company’s use of these derivatives is generally limited to hedging risk and has principally consisted of using interest rate swaps, treasury rate locks, forward contracts, futures contracts, warrants, put options and credit default swaps.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are stated net of allowances for credit losses, customer credit allowances, contractual allowances and estimated terminations. Accounts receivable, net is composed of the following at December 31, 2021 and 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.432%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,932 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,101 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vendor and manufacturer receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,573 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,815 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premium receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,537 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,628 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,389 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,198 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Total accounts receivable, net </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,431 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,742 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s allowance for credit losses was $339 million and $358 million as of December 31, 2021 and 2020, respectively. When developing an estimate of the Company’s expected credit losses, the Company considers all available relevant information regarding the collectability of cash flows, including historical information, current conditions and reasonable and supportable forecasts of future economic conditions over the contractual life of the receivable. The Company’s accounts receivable are short duration in nature and typically settle in less than 30 days. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are valued at the lower of cost or net realizable value using the weighted average cost method. Physical inventory counts are taken on a regular basis in each retail store and LTC pharmacy, and a continuous cycle count process is the primary procedure used to validate the inventory balances on hand in each distribution center and mail facility to ensure that the amounts reflected in the consolidated financial statements are properly stated. During the interim period between physical inventory counts, the Company accrues for anticipated physical inventory losses on a location-by-location basis based on historical results and current physical inventory trends. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reinsurance Recoverables </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes reinsurance agreements primarily to: (a) reduce required capital and (b) facilitate the acquisition or disposition of certain insurance contracts. Ceded reinsurance agreements permit the Company to recover a portion of its losses from reinsurers, although they do not discharge the Company’s primary liability as the direct insurer of the risks reinsured. Failure of reinsurers to indemnify the Company could result in losses; however, the Company does not expect charges for unrecoverable reinsurance to have a material effect on its consolidated operating results or financial condition. The Company evaluates the financial condition of its reinsurers and monitors concentrations of credit risk arising from similar geographic regions, activities or economic characteristics of its reinsurers. At December 31, 2021, the Company’s reinsurance recoverables consisted primarily of amounts due from third parties that are rated consistent with companies that are considered to have the ability to meet their obligations. Reinsurance recoverables are recorded as other current assets or other assets on the consolidated balance sheets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Health Care Contract Acquisition Costs</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Insurance products included in the Health Care Benefits segment are cancellable by either the customer or the member monthly upon written notice. Acquisition costs related to prepaid health care and health indemnity contracts are generally expensed as incurred. Acquisition costs for certain long-duration insurance contracts are deferred and are recorded as other current assets or other assets on the consolidated balance sheets and are amortized over the estimated life of the contracts. The amortization of deferred acquisition costs is recorded in operating expenses in the consolidated statements of operations. At December 31, 2021 and 2020, the balance of deferred acquisition costs was $895 million and $546 million, respectively, comprised primarily of commissions paid on Medicare Supplement products within the Health Care Benefits segment. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is reported at historical cost, net of accumulated depreciation. Property, equipment and improvements to leased premises are depreciated using the straight-line method over the estimated useful lives of the assets, or when applicable, the term of the lease, whichever is shorter. Estimated useful lives generally range from 1 to 40 years for buildings, building improvements and leasehold improvements and 3 to 10 years for fixtures, equipment and internally developed software. Repair and maintenance costs are charged directly to expense as incurred. Major renewals or replacements that </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">substantially extend the useful life of an asset are capitalized and depreciated. Application development stage costs for significant internally developed software projects are capitalized and depreciated. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consists of the following at December 31, 2021 and 2020: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.990%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,038 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,134 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,225 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,950 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixtures and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,619 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,125 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,242 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,077 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,426 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,020 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,550 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,306 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,654)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,700)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,896 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,606 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense (which includes the amortization of property and equipment under finance or capital leases) totaled $2.3 billion, $2.1 billion and $1.9 billion for the years ended December 31, 2021, 2020 and 2019, respectively. During the year ended December 31, 2021, the Company recorded an impairment on property and equipment of $261 million in connection with the planned closure of certain retail stores. See Note 6 ‘‘Leases’’ for additional information about this impairment charge as well as the Company’s finance leases. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Right-of-Use Assets and Lease Liabilities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement contains a lease at the inception of a contract. Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at the commencement date of the lease, renewal date of the lease or significant remodeling of the lease space based on the present value of the remaining future minimum lease payments. As the interest rate implicit in the Company’s leases is not readily determinable, the Company utilizes its incremental borrowing rate, determined by class of underlying asset, to discount the lease payments. The operating lease right-of-use assets also include lease payments made before commencement and are reduced by lease incentives. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s real estate leases typically contain options that permit renewals for additional periods of up to five years each. For real estate leases, the options to extend are not considered reasonably certain at lease commencement because the Company reevaluates each lease on a regular basis to consider the economic and strategic incentives of exercising the renewal options and regularly opens or closes stores to align with its operating strategy. Generally, the renewal option periods are not included within the lease term and the associated payments are not included in the measurement of the right-of-use asset and lease liability. Similarly, renewal options are not included in the lease term for non-real estate leases because they are not considered reasonably certain of being exercised at lease commencement. Leases with an initial term of 12 months or less are not recorded on the balance sheets, and lease expense is recognized on a straight-line basis over the term of the short-term lease.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For real estate leases, the Company accounts for lease components and nonlease components as a single lease component. Certain real estate leases require additional payments based on sales volume, as well as reimbursement for real estate taxes, common area maintenance and insurance, which are expensed as incurred as variable lease costs. Other real estate leases contain one fixed lease payment that includes real estate taxes, common area maintenance and insurance. These fixed payments are considered part of the lease payment and included in the right-of-use assets and lease liabilities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 6 ‘‘Leases’’ for additional information about right-of-use assets and lease liabilities. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for business combinations using the acquisition method of accounting, which requires the excess cost of an acquisition over the fair value of net assets acquired and identifiable intangible assets to be recorded as goodwill. Goodwill is not amortized, but is subject to impairment reviews annually, or more frequently if necessary, as further described in “Long-Lived Asset Impairment” below. See Note 5 ‘‘Goodwill and Other Intangibles’’ for additional information about goodwill. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s identifiable intangible assets consist primarily of trademarks, trade names, customer contracts/relationships, covenants not to compete, technology, provider networks and value of business acquired (“VOBA”). These intangible assets arise primarily from the determination of their respective fair market values at the date of acquisition. Amounts assigned to identifiable intangible assets, and their related useful lives, are derived from established valuation techniques and management estimates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s definite-lived intangible assets are amortized over their estimated useful lives based upon the pattern of future cash flows attributable to the asset. Other than VOBA, definite-lived intangible assets are amortized using the straight-line method. VOBA is amortized over the expected life of the acquired contracts in proportion to estimated premiums. Indefinite-lived intangible assets are not amortized but are tested for impairment annually, or more frequently if necessary, as further described in “Long-Lived Asset Impairment” below.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 5 ‘‘Goodwill and Other Intangibles’’ for additional information about intangible assets. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-Lived Asset Impairment</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the recoverability of long-lived assets, excluding goodwill and indefinite-lived intangible assets, which are tested for impairment using separate tests described below, whenever events or changes in circumstances indicate that the carrying value of such asset may not be recoverable. The Company groups and evaluates these long-lived assets for impairment at the lowest level at which individual cash flows can be identified. If indicators of impairment are present, the Company first compares the carrying amount of the asset group to the estimated future cash flows associated with the asset group (undiscounted). If the estimated future cash flows used in this analysis are less than the carrying amount of the asset group, an impairment loss calculation is prepared. The impairment loss calculation compares the carrying amount of the asset group to the asset group’s estimated future cash flows (discounted). If required, an impairment loss is recorded for the portion of the asset group’s carrying value that exceeds the asset group’s estimated future cash flows (discounted). During the year ended December 31, 2021, the Company recorded a store impairment charge of approximately $1.4 billion primarily related to the write down of operating lease right-of-use assets and property and equipment in connection with the planned closure of approximately 900 retail stores between 2022 and 2024. There were no material impairment charges recognized on long-lived assets in the year ended 2020. During the year ended December 31, 2019 the Company recorded a store impairment charge of $231 million primarily related to operating lease right-of-use assets. See Note 6 ‘‘Leases’’ for additional information about the right-of-use asset impairment charges. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When evaluating goodwill for potential impairment, the Company compares the fair value of its reporting units to their respective carrying amounts. The Company estimates the fair value of its reporting units using a combination of a discounted cash flow method and a market multiple method. If the carrying amount of a reporting unit exceeds its estimated fair value, an impairment loss is recognized in an amount equal to that excess. During the third quarter of 2021, the Company performed its required annual impairment tests of goodwill, the results of which indicated an impairment of the goodwill associated with the LTC reporting unit. Accordingly, during the third quarter of 2021, the Company recorded a $431 million goodwill impairment charge. The results of the impairment tests indicated that there was no impairment of goodwill of the remaining reporting units as of the testing date or during the year ended December 31, 2021. During the third quarter of both 2020 and 2019, the Company performed its required annual goodwill impairment tests and concluded there were no goodwill impairments as of the testing dates or during the years ended December 31, 2020 and 2019. See Note 5 ‘‘Goodwill and Other Intangibles’’ for additional information about the goodwill impairment charge recorded during the year ended December 31, 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets are tested for impairment by comparing the estimated fair value of the asset to its carrying value. The Company estimates the fair value of its indefinite-lived trademarks using the relief from royalty method under the income approach. If the carrying value of the asset exceeds its estimated fair value, an impairment loss is recognized, and the asset is written down to its estimated fair value. There were no impairment losses recognized on indefinite-lived intangible assets in any of the years ended December 31, 2021, 2020 or 2019.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Separate Accounts</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separate Accounts assets and liabilities related to large case pensions products represent funds maintained to meet specific objectives of contract holders who bear the investment risk. These assets and liabilities are carried at fair value. Net investment income (including net realized capital gains and losses) accrue directly to such contract holders. The assets of each account are legally segregated and are not subject to claims arising from the Company’s other businesses. Deposits, withdrawals and net </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investment income (including net realized and net unrealized capital gains and losses) on Separate Accounts assets are not reflected in the consolidated statements of operations or cash flows. Management fees charged to contract holders are included in services revenue and recognized over the period earned.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Health Care Costs Payable</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health care costs payable consist principally of unpaid fee-for-service medical, dental and pharmacy claims, capitation costs, other amounts due to providers pursuant to risk-sharing arrangements related to the Health Care Benefits segment’s Insured Commercial, Medicare and Medicaid products and accruals for state assessments. Unpaid health care claims include an estimate of payments the Company will make for (i) services rendered to the Company’s Insured members but not yet reported to the Company and (ii) claims which have been reported to the Company but not yet paid, each as of the financial statement date (collectively, “IBNR”). Health care costs payable also include an estimate of the cost of services that will continue to be rendered after the financial statement date if the Company is obligated to pay for such services in accordance with contractual or regulatory requirements. Such estimates are developed using actuarial principles and assumptions which consider, among other things, historical and projected claim submission and processing patterns, assumed and historical medical cost trends, historical utilization of medical services, claim inventory levels, changes in Insured membership and product mix, seasonality and other relevant factors. The Company reflects changes in these estimates in benefit costs in the Company’s consolidated operating results in the period they are determined. Capitation costs represent contractual monthly fees paid to participating physicians and other medical providers for providing medical care, regardless of the volume of medical services provided to the Insured member. Amounts due under risk-sharing arrangements are based on the terms of the underlying contracts with the providers and consider claims experience under the contracts through the financial statement date.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company develops its estimate of IBNR using actuarial principles and assumptions that consider numerous factors. Of those factors, the Company considers the analysis of historical and projected claim payment patterns (including claims submission and processing patterns) and the assumed health care cost trend rate (the year-over-year change in per member per month health care costs) to be the most critical assumptions. In developing its IBNR estimate, the Company consistently applies these actuarial principles and assumptions each period, with consideration to the variability of related factors. There have been no significant changes to the methodologies or assumptions used to develop the Company’s estimate of IBNR in 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company analyzes historical claim payment patterns by comparing claim incurred dates (i.e., the date services were provided) to claim payment dates to estimate “completion factors.” The Company uses completion factors predominantly to estimate the ultimate cost of claims incurred more than three months before the financial statement date. The Company estimates completion factors by aggregating claim data based on the month of service and month of claim payment and estimating the percentage of claims incurred for a given month that are complete by each month thereafter. For any given month, substantially all claims are paid within six months of the date of service, but it can take up to 48 months or longer after the date of service before all of the claims are completely resolved and paid. These historically-derived completion factors are then applied to claims paid through the financial statement date to estimate the ultimate claim cost for a given month’s incurred claim activity. The difference between the estimated ultimate claim cost and the claims paid through the financial statement date represents the Company’s estimate of claims remaining to be paid as of the financial statement date and is included in the Company’s health care costs payable. The completion factors the Company uses reflect judgments and possible adjustments based on data such as claim inventory levels, claim submission and processing patterns and, to a lesser extent, other factors such as changes in health care cost trend rates, changes in Insured membership and changes in product mix. If claims are submitted or processed on a faster (slower) pace than prior periods, the actual claims may be more (less) complete than originally estimated using the Company’s completion factors, which may result in reserves that are higher (lower) than the ultimate cost of claims.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because claims incurred within three months before the financial statement date are less mature, the Company uses a combination of historically-derived completion factors and the assumed health care cost trend rate to estimate the ultimate cost of claims incurred for these months. The Company applies its actuarial judgment and places a greater emphasis on the assumed health care cost trend rate for the most recent claim incurred dates as these months may be influenced by seasonal patterns and changes in membership and product mix.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s health care cost trend rate is affected by changes in per member utilization of medical services as well as changes in the unit cost of such services. Many factors influence the health care cost trend rate, including the Company’s ability to manage benefit costs through product design, negotiation of favorable provider contracts and medical management programs, as well as the mix of the Company’s business. The health status of the Company’s Insured members, aging of the population and other demographic characteristics, advances in medical technology and other factors continue to contribute to rising per member utilization and unit costs. Changes in health care practices, inflation, new technologies, increases in the cost of </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">prescription drugs (including specialty pharmacy drugs), direct-to-consumer marketing by pharmaceutical companies, clusters of high-cost cases, claim intensity, changes in the regulatory environment, health care provider or member fraud and numerous other factors also contribute to the cost of health care and the Company’s health care cost trend rate.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each reporting period, the Company uses an extensive degree of judgment in the process of estimating its health care costs payable. As a result, considerable variability and uncertainty is inherent in such estimates, particularly with respect to claims with claim incurred dates of three months or less before the financial statement date; and the adequacy of such estimates is highly sensitive to changes in assumed completion factors and the assumed health care cost trend rates. For each reporting period the Company recognizes the actuarial best estimate of health care costs payable considering the potential volatility in assumed completion factors and health care cost trend rates, as well as other factors. The Company believes its estimate of health care costs payable is reasonable and adequate to cover its obligations at December 31, 2021; however, actual claim payments may differ from the Company’s estimates. A worsening (or improvement) of the Company’s health care cost trend rates or changes in completion factors from those that the Company assumed in estimating health care costs payable at December 31, 2021 would cause these estimates to change in the near term, and such a change could be material.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each quarter, the Company re-examines previously established health care costs payable estimates based on actual claim payments for prior periods and other changes in facts and circumstances. Given the extensive degree of judgment in this estimate, it is possible that the Company’s estimates of health care costs payable could develop either favorably (that is, its actual benefit costs for the period were less than estimated) or unfavorably. The changes in the Company’s estimate of health care costs payable may relate to a prior quarter, prior year or earlier periods. For a roll forward of the Company’s health care costs payable, see Note 7 ‘‘Health Care Costs Payable.’’ The Company’s reserving practice is to consistently recognize the actuarial best estimate of its ultimate liability for health care costs payable.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Insurance Liabilities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unpaid Claims</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unpaid claims consist primarily of reserves associated with certain short-duration group disability and term life insurance contracts, including an estimate for IBNR as of the financial statement date. Reserves associated with certain short-duration group disability and term life insurance contracts are based upon the Company’s estimate of the present value of future benefits, which is based on assumed investment yields and assumptions regarding mortality, morbidity and recoveries from the U.S. Social Security Administration. The Company develops its estimate of IBNR using actuarial principles and assumptions which consider, among other things, contractual requirements, claim incidence rates, claim recovery rates, seasonality and other relevant factors. The Company discounts certain claim liabilities related to group long-term disability and life insurance waiver of premium contracts. The discount rates generally reflect the Company’s expected investment returns for the investments supporting all incurral years of these liabilities. The discount rates for retrospectively-rated contracts are set at contractually specified levels. The Company’s estimates of unpaid claims are subject to change due to changes in the underlying experience of the insurance contracts, changes in investment yields or other factors, and these changes are recorded in current and future benefits in the consolidated statements of operations in the period they are determined. The Company estimates its reserve for claims IBNR for life products largely based on completion factors. The completion factors used are based on the Company’s historical experience and reflect judgments and possible adjustments based on data such as claim inventory levels, claim payment patterns, changes in business volume and other factors. If claims are submitted or processed on a faster (slower) pace than historical periods, the actual claims may be more (less) complete than originally estimated using completion factors, which may result in reserves that are higher (lower) than required to cover future life benefit payments. There have been no significant changes to the methodologies or assumptions used to develop the Company’s estimate of unpaid claims IBNR in 2021. As of December 31, 2021, unpaid claims balances of $324 million and $1.3 billion were recorded in other insurance liabilities and other long-term insurance liabilities, respectively. As of December 31, 2020, unpaid claims balances of $532 million and $1.5 billion were recorded in other insurance liabilities and other long-term insurance liabilities, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all life and disability insurance liabilities have been fully ceded to unrelated third parties through indemnity reinsurance agreements; however, the Company remains directly obligated to the policyholders.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Future Policy Benefits</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future policy benefits consist primarily of reserves for limited payment pension and annuity contracts and long-term care insurance contracts. Reserves for limited payment pension and annuity contracts are computed using actuarial principles that consider, among other things, assumptions reflecting anticipated mortality, retirement, expense and interest rate experience. Such assumptions generally vary by plan, year of issue and policy duration. Assumed interest rates on such contracts ranged from 3.0% to 11.3% in the year ended December 31, 2021 and from 3.3% to 11.3% in the year ended December 31, 2020. The Company periodically reviews mortality assumptions against both industry standards and its experience. Reserves for long-</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">duration long-term care contracts represent the Company’s estimate of the present value of future benefits and essential maintenance expenses to be paid to or on behalf of policyholders less the present value of future gross premiums. The assumed interest rate on such contracts was 5.1% in both the years ended December 31, 2021 and 2020. The Company’s estimate of the present value of future benefits under such contracts is based upon mortality, morbidity and interest rate assumptions. As of December 31, 2021, future policy benefits balances of $416 million and $5.1 billion were recorded in other insurance liabilities and other long-term insurance liabilities, respectively. As of December 31, 2020, future policy benefits balances of $462 million and $5.5 billion were recorded in other insurance liabilities and other long-term insurance liabilities, respectively. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Premium Deficiency Reserves</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its insurance contracts to determine if it is probable that a loss will be incurred. A premium deficiency loss is recognized when it is probable that expected future claims, including maintenance costs (for example, direct costs such as claim processing costs), will exceed existing reserves plus anticipated future premiums and reinsurance recoveries. Anticipated investment income is not considered in the calculation of premium deficiency losses for short-duration contracts. For purposes of determining premium deficiency losses, contracts are grouped consistent with the Company’s method of acquiring, servicing and measuring the profitability of such contracts. As of December 31, 2021 and 2020, the Company established a premium deficiency reserve of $16 million and $11 million, respectively, related to Medicaid products in the Health Care Benefits segment. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Policyholders’ Funds</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Policyholders’ funds consist primarily of reserves for pension and annuity investment contracts and customer funds associated with certain health contracts. Reserves for such contracts are equal to cumulative deposits less withdrawals and charges plus interest credited thereon, net of experience-rated adjustments. In 2021, interest rates for pension and annuity investment contracts ranged from 3.5% to 4.8%. In 2020, interest rates for pension and annuity investment contracts ranged from 4.1% to 5.1%. Reserves for contracts subject to experience rating reflect the Company’s rights as well as the rights of policyholders and plan participants. The Company also holds funds for HSAs on behalf of members associated with high deductible health plans. These amounts are held to pay for qualified health care expenses incurred by these members. The HSA balances were approximately $2.9 billion and $2.7 billion at December 31, 2021 and 2020, respectively, and are reflected in other current assets with a corresponding liability in policyholders’ funds. These assets are considered restricted cash for cash flow statement purposes.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Policyholders’ funds liabilities that are expected to be paid within twelve months from the balance sheet date are classified as current on the consolidated balance sheets. Policyholders’ funds liabilities that are expected to be paid greater than twelve months from the balance sheet date are included in other long-term liabilities on the consolidated balance sheets. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Self-Insurance Liabilities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is self-insured for certain losses related to general liability, workers’ compensation and auto liability. The Company obtains third party insurance coverage to limit exposure from these claims. The Company is also self-insured for certain losses related to health and medical liabilities. The Company’s self-insurance accruals, which include reported claims and claims incurred but not reported, are calculated using standard insurance industry actuarial assumptions and the Company’s historical claims experience. At December 31, 2021 and 2020, self-insurance liabilities totaled $1.1 billion and $927 million, respectively, and were recorded as accrued expenses on the consolidated balance sheets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation and Transactions</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For non-U.S. dollar functional currency locations, (i) assets and liabilities are translated at end-of-period exchange rates, (ii) revenues and expenses are translated at average exchange rates in effect during the period and (iii) equity is translated at historical exchange rates. The resulting cumulative translation adjustments are included as a component of accumulated other comprehensive income.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For U.S. dollar functional currency locations, foreign currency assets and liabilities are remeasured into U.S. dollars at end-of-period exchange rates, except for nonmonetary balance sheet accounts which are remeasured at historical exchange rates. Revenues and expenses are remeasured at average exchange rates in effect during each period, except for those expenses related to the nonmonetary balance sheet amounts which are remeasured at historical exchange rates. Gains or losses from foreign currency remeasurement are included in net income.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains and losses from foreign currency transactions and the effects of foreign currency remeasurements were not material in the years ended December 31, 2021 or 2020. On July 1, 2019, the Company sold its Brazilian subsidiary, Drogaria Onofre Ltda. (“Onofre”) for an immaterial amount. The Company recorded a loss on the divestiture, which included the elimination of the subsidiary’s $154 million cumulative translation adjustment from accumulated other comprehensive income during the year ended December 31, 2019.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Health Care Benefits Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health Care Benefits revenue is principally derived from insurance premiums and fees billed to customers. Revenue is recognized based on customer billings, which, in the Company’s Commercial business, reflect contracted rates per member and the number of covered members recorded in the Company’s records at the time the billings are prepared. Billings are generally sent monthly for coverage during the following month. Revenue related to the Company’s Government business is collected monthly from the U.S. federal government and various government agencies based on fixed payment rates and member eligibility. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s billings may be subsequently adjusted to reflect enrollment changes due to member terminations or other factors. These adjustments are known as retroactivity adjustments. In each period, the Company estimates the amount of future retroactivity and adjusts the recorded revenue accordingly. As information regarding actual retroactivity amounts becomes known, the Company refines its estimates and records any required adjustments to revenues in the period in which they arise.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Premium Revenue</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Premiums are recognized as revenue in the month in which the enrollee is entitled to receive health care services. Premiums are reported net of an allowance for estimated terminations and uncollectible amounts. Additionally, premium revenue subject to the minimum medical loss ratio (“MLR”) rebate requirements of the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010 (as amended, collectively, the “ACA”) is recorded net of the estimated minimum MLR rebates for the current calendar year. Premiums related to unexpired contractual coverage periods (unearned premiums) are reported as other insurance liabilities on the consolidated balance sheets and recognized as revenue when earned.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the Company’s contracts allow for premiums to be adjusted to reflect actual experience or the relative health status of Insured members. Such adjustments are reasonably estimable at the outset of the contract, and adjustments to those estimates are made based on actual experience of the customer emerging under the contract and the terms of the underlying contract.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Services Revenue</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Services revenue relates to contracts that can include various combinations of services or series of services which generally are capable of being distinct and accounted for as separate performance obligations. The Health Care Benefits segment’s services revenue primarily consists of ASC fees received in exchange for performing certain claim processing and member services for ASC members. ASC fee revenue is recognized over the period the service is provided. Some of the Company’s administrative services contracts include guarantees with respect to certain functions, such as customer service response time, claim processing accuracy and claim processing turnaround time, as well as certain guarantees that a plan sponsor’s benefit claim experience will fall within a certain range. With any of these guarantees, the Company is financially at risk if the conditions of the arrangements are not met, although the maximum amount at risk typically is limited to a percentage of the fees otherwise payable to the Company by the customer involved. Each period the Company estimates its obligations under the terms of these guarantees and records its estimate as an offset to services revenues.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Accounting for Medicare Part D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues include insurance premiums earned by the Company’s PDPs, which are determined based on the PDP’s annual bid and related contractual arrangements with the U.S. Centers for Medicare &amp; Medicaid Services (“CMS”). The insurance premiums include a beneficiary premium, which is the responsibility of the PDP member, and can be subsidized by CMS in the case of low-income members, and a direct premium paid by CMS. Premiums collected in advance are initially recorded within other insurance liabilities and are then recognized ratably as revenue over the period in which members are entitled to receive benefits.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues also include a risk-sharing feature of the Medicare Part D program design referred to as the risk corridor. The Company estimates variable consideration in the form of amounts payable to, or receivable from, CMS under the risk corridor, and adjusts revenue based on calculations of additional subsidies to be received from or owed to CMS at the end of the reporting year.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to Medicare Part D premiums, the Company receives additional payments each month from CMS related to catastrophic reinsurance, low-income cost-sharing subsidies and coverage gap benefits. If the subsidies received differ from the amounts earned from actual prescriptions transferred, the difference is recorded in either accounts receivable, net or accrued expenses.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pharmacy Services Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmacy Services segment sells prescription drugs directly through its mail service dispensing pharmacies and indirectly through the Company’s retail pharmacy network. The Company’s pharmacy benefit arrangements are accounted for in a manner consistent with a master supply arrangement as there are no contractual minimum volumes and each prescription is considered a separate purchasing decision and distinct performance obligation transferred at a point in time. PBM services performed in connection with each prescription claim are considered part of a single performance obligation which culminates in the dispensing of prescription drugs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue using the gross method at the contract price negotiated with its clients when the Company has concluded it controls the prescription drug before it is transferred to the client plan members. The Company controls prescriptions dispensed indirectly through its retail pharmacy network because it has separate contractual arrangements with those pharmacies, has discretion in setting the price for the transaction and assumes primary responsibility for fulfilling the promise to provide prescription drugs to its client plan members while also performing the related PBM services.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues include (i) the portion of the price the client pays directly to the Company, net of any discounts earned on brand name drugs or other discounts and refunds paid back to the client (see “Drug Discounts” and “Guarantees” below), (ii) the price paid to the Company by client plan members for mail order prescriptions and the price paid to retail network pharmacies by client plan members for retail prescriptions (“retail co-payments”), and (iii) claims based administrative fees for retail pharmacy network contracts. Sales taxes are not included in revenues. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when control of the prescription drugs is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to receive in exchange for those prescription drugs. The Company has established the following revenue recognition policies for the Pharmacy Services segment:</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Revenues generated from prescription drugs sold by mail service dispensing pharmacies are recognized when the prescription drug is delivered to the client plan member. At the time of delivery, the Company has performed substantially all of its performance obligations under its client contracts and does not experience a significant level of returns or reshipments.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Revenues generated from prescription drugs sold by third party pharmacies in the Company’s retail pharmacy network and associated administrative fees are recognized at the Company’s point-of-sale, which is when the claim is adjudicated by the Company’s online claims processing system and the Company has transferred control of the prescription drug and completed all of its performance obligations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For contracts under which the Company acts as an agent or does not control the prescription drugs prior to transfer to the client plan member, revenue is recognized using the net method.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Drug Discounts</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records revenue net of manufacturers’ rebates earned by its clients based on their plan members’ utilization of brand-name formulary drugs. The Company estimates these rebates at period-end based on actual and estimated claims data and its estimates of the manufacturers’ rebates earned by its clients. The estimates are based on the best available data at period-end and recent history for the various factors that can affect the amount of rebates due to the client. The Company adjusts its rebates payable to clients to the actual amounts paid when these rebates are paid or as significant events occur. Any cumulative effect of these adjustments is recorded against revenues at the time it is identified. Adjustments generally result from contract changes with clients or manufacturers that have retroactive rebate adjustments, differences between the estimated and actual product mix subject to rebates, or whether the brand name drug was included in the applicable formulary. The effect of adjustments between estimated and actual manufacturers’ rebate amounts has not been material to the Company’s operating results or financial condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Guarantees</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also adjusts revenues for refunds owed to clients resulting from pricing guarantees and performance against defined service and performance metrics. The inputs to these estimates are not subject to a high degree of subjectivity or volatility. The effect of adjustments between estimated and actual pricing and performance refund amounts has not been material to the Company’s operating results or financial condition.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Retail/LTC Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Retail Pharmacy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s retail drugstores recognize revenue at the time the customer takes possession of the merchandise. For pharmacy sales, each prescription claim is its own arrangement with the customer and is a performance obligation, separate and distinct from other prescription claims under other retail network arrangements. Revenues are adjusted for refunds owed to third party payers resulting from pricing guarantees and performance against defined value-based service and performance metrics. The inputs to these estimates are not subject to a high degree of subjectivity or volatility. The effect of adjustments between estimated and actual pricing and performance refund amounts has not been material to the Company’s operating results or financial condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from Company gift cards purchased by customers is deferred as a contract liability until goods or services are transferred. Any amounts not expected to be redeemed by customers (i.e., breakage) are recognized based on historical redemption patterns.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer returns are not material to the Company’s operating results or financial condition. Sales taxes are not included in revenues.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Loyalty and Other Programs</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s customer loyalty program, ExtraCare</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, consists of two components, ExtraSavings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and ExtraBucks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Rewards. ExtraSavings are coupons that are recorded as a reduction of revenue when redeemed as the Company concluded that they do not represent a promise to the customer to deliver additional goods or services at the time of issuance because they are not tied to a specific transaction or spending level. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ExtraBucks Rewards are accumulated by customers based on their historical spending levels. Thus, the Company has determined that there is an additional performance obligation to those customers at the time of the initial transaction. The Company allocates the transaction price to the initial transaction and the ExtraBucks Rewards transaction based upon the relative standalone selling price, which considers historical redemption patterns for the rewards. Revenue allocated to ExtraBucks Rewards is recognized as those rewards are redeemed. At the end of each period, unredeemed ExtraBucks Rewards are reflected as a contract liability.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also offers a subscription-based membership program, CarePass</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, under which members are entitled to a suite of benefits delivered over the course of the subscription period, as well as a promotional reward that can be redeemed for future goods and services. Subscriptions are paid for on a monthly or annual basis at the time of or in advance of the Company delivering the goods and services. Revenue from these arrangements is recognized as the performance obligations are satisfied.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Long-term Care</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized when control of the promised goods or services is transferred to customers in an amount that reflects the consideration the Company expects to be entitled to receive in exchange for those goods or services. Each prescription claim represents a separate performance obligation of the Company, separate and distinct from other prescription claims under customer arrangements. A significant portion of long-term care revenue from sales of pharmaceutical and medical products is reimbursed by the federal Medicare Part D program and, to a lesser extent, state Medicaid programs. The Company monitors its revenues and receivables from these reimbursement sources, as well as long-term care facilities and other third party insurance payors, and reduces revenue at the revenue recognition date to properly account for the variable consideration due to anticipated differences between billed and reimbursed amounts. Accordingly, the total revenues and receivables reported in the Company’s consolidated financial statements are recorded at the amount expected to be ultimately received from these payors. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient co-payments associated with Medicare Part D, certain state Medicaid programs, Medicare Part B and certain third party payors typically are not collected at the time products are delivered or services are rendered, but are billed to the individuals as part of normal billing procedures and subject to normal accounts receivable collections procedures.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Walk-In Medical Clinics</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For services provided by the Company’s walk-in medical clinics, revenue recognition occurs for completed services provided to patients, with adjustments taken for third party payor contractual obligations and patient direct bill historical collection rates.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disaggregation of Revenue</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table disaggregates the Company’s revenue by major source in each segment for the years ended December 31, 2021, 2020 and 2019:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:28.737%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.390%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.944%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.390%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.944%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.390%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.569%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.390%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.390%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.462%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Health Care<br/>Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pharmacy<br/>Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retail/<br/>LTC</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Corporate/<br/>Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intersegment<br/>Eliminations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consolidated<br/>Totals</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Major goods/services lines:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Pharmacy</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">152,262 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">76,121 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(43,765)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">184,618 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Front Store</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">21,315 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">21,315 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Premiums</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">76,064 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">76,132 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net investment income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">586 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">596 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,199 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,536 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">760 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,652 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8,847 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">82,186 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">153,022 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">100,105 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">721 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(43,923)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">292,111 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Pharmacy Services distribution channel:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Pharmacy network</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">91,715 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Mail choice </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">60,547 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">760 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">153,022 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Major goods/services lines:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Pharmacy</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">141,116 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">70,176 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(40,003)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">171,289 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Front Store</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">19,655 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">19,655 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Premiums</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">69,301 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">69,364 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net investment income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">483 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">315 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">798 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,683 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">822 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,367 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(320)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">75,467 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">141,938 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">91,198 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">426 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(40,323)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">268,706 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Pharmacy Services distribution channel:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Pharmacy network</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"> (1) </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">85,045 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Mail choice </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">56,071 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">822 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">141,938 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Major goods/services lines:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Pharmacy</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">140,896 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">66,442 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(41,413)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">165,925 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Front Store</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">19,422 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">19,422 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Premiums</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">63,031 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">63,122 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net investment income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">599 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">412 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,011 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,974 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">595 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">744 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7,296 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">69,604 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">141,491 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">86,608 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">512 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(41,439)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">256,776 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Pharmacy Services distribution channel:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Pharmacy network</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">88,755 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Mail choice </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">52,141 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">595 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">141,491 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Pharmacy Services pharmacy network is defined as claims filled at retail and specialty retail pharmacies, including the Company’s retail pharmacies and LTC pharmacies, but excluding Maintenance Choice</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> activity, which is included within the mail choice category. Maintenance Choice permits eligible client plan members to fill their maintenance prescriptions through mail order delivery or at a CVS Pharmacy retail store for the same price as mail order.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Pharmacy Services mail choice is defined as claims filled at a Pharmacy Services mail order facility, which includes specialty mail claims inclusive of Specialty Connect</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> claims picked up at a retail pharmacy, as well as prescriptions filled at the Company’s retail pharmacies under the Maintenance Choice</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">program. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Balances</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities primarily represent the Company’s obligation to transfer additional goods or services to a customer for which the Company has received consideration, and include ExtraBucks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rewards and unredeemed Company gift cards. The consideration received remains a contract liability until goods or services have been provided to the customer. In addition, the Company recognizes breakage on Company gift cards based on historical redemption patterns.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about receivables and contract liabilities from contracts with customers as of December 31, 2021 and 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.432%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables (included in accounts receivable, net)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,932 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,101 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities (included in accrued expenses)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2021 and 2020, the contract liabilities balance includes increases related to customers’ earnings in ExtraBucks Rewards or issuances of Company gift cards and decreases for revenues recognized during the period as a result of the redemption of ExtraBucks Rewards or Company gift cards and breakage of Company gift cards. Below is a summary of such changes:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.432%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rewards earnings and gift card issuances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redemption and breakage</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(371)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(359)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-right:4.5pt"><span><br/></span></div><div style="padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Products Sold</span></div><div style="padding-right:4.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for cost of products sold as follows:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pharmacy Services Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of products sold includes: (i) the cost of prescription drugs sold during the reporting period directly through the Company’s mail service dispensing pharmacies and indirectly through the Company’s retail pharmacy network, (ii) shipping and handling costs, and (iii) the operating costs of the Company’s mail service dispensing pharmacies and client service operations and related information technology support costs including depreciation and amortization. The cost of prescription drugs sold component of cost of products sold includes: (i) the cost of the prescription drugs purchased from manufacturers or distributors and shipped to members in clients’ benefit plans from the Company’s mail service dispensing pharmacies, net of any volume-related or other discounts (see “Vendor Allowances and Purchase Discounts” below) and (ii) the cost of prescription drugs sold (including retail co-payments) through the Company’s retail pharmacy network under contracts where the Company is the principal, net of any volume-related or other discounts. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Retail/LTC Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of products sold includes: the cost of merchandise sold during the reporting period, including prescription drug costs, and the related purchasing costs, warehousing and delivery costs (including depreciation and amortization) and actual and estimated inventory losses. </span></div><div><span><br/></span></div><div style="padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vendor Allowances and Purchase Discounts </span></div><div style="padding-right:4.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for vendor allowances and purchase discounts as follows: </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pharmacy Services Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmacy Services segment receives purchase discounts on products purchased. Contractual arrangements with vendors, including manufacturers, wholesalers and retail pharmacies, normally provide for the Pharmacy Services segment to receive </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">purchase discounts from established list prices in one, or a combination, of the following forms: (i) a direct discount at the time of purchase, (ii) a discount for the prompt payment of invoices or (iii) when products are purchased indirectly from a manufacturer (e.g., through a wholesaler or retail pharmacy), a discount (or rebate) paid subsequent to dispensing. These rebates are recognized when prescriptions are dispensed and are generally calculated and billed to manufacturers within 30 days of the end of each completed quarter. Historically, the effect of adjustments resulting from the reconciliation of rebates recognized to the amounts billed and collected has not been material to the Company’s operating results or financial condition. The Company accounts for the effect of any such differences as a change in accounting estimate in the period the reconciliation is completed. The Pharmacy Services segment also receives additional discounts under its wholesaler contracts if it exceeds contractually defined purchase volumes. In addition, the Pharmacy Services segment receives fees from pharmaceutical manufacturers for administrative services. Purchase discounts and administrative service fees are recorded as a reduction of cost of products sold. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Retail/LTC Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vendor allowances received by the Retail/LTC segment reduce the carrying cost of inventory and are recognized in cost of products sold when the related inventory is sold, unless they are specifically identified as a reimbursement of incremental costs for promotional programs and/or other services provided. Amounts that are directly linked to advertising commitments are recognized as a reduction of advertising expense (included in operating expenses) when the related advertising commitment is satisfied. Any amounts received in excess of the actual cost incurred also reduce the carrying cost of inventory. The total value of any upfront payments received from vendors that are linked to purchase commitments is initially deferred. The deferred amounts are then amortized to reduce cost of products sold over the life of the contract based upon sales volume. The total value of any upfront payments received from vendors that are not linked to purchase commitments is also initially deferred. The deferred amounts are then amortized to reduce cost of products sold on a straight-line basis over the life of the related contract. The total amortization of these upfront payments was not material to the Company’s consolidated financial statements in any of the periods presented. </span></div><div><span><br/></span></div><div style="padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Health Care Reform</span></div><div style="padding-right:4.5pt"><span><br/></span></div><div style="padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Health Insurer Fee</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since January 1, 2014, the ACA has imposed an annual premium-based health insurer fee (“HIF”) for each calendar year, payable in September, which was not deductible for tax purposes. The Company has been required to estimate a liability for the HIF at the beginning of the calendar year in which the fee was payable with a corresponding deferred asset that was amortized ratably to operating expenses over the calendar year. The Company recorded the liability for the HIF in accrued expenses and recorded the deferred asset in other current assets. In December 2019, the HIF was repealed for calendar years after 2020, therefore there was no expense related to the HIF in the year ended December 31, 2021. In the year ended December 31, 2020, operating expenses included $1.0 billion related to the Company’s share of the HIF. There was no expense related to the HIF in 2019, since there was a one-year suspension of the HIF for 2019. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Adjustment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ACA established a permanent risk adjustment program to transfer funds from qualified individual and small group insurance plans with below average risk scores to plans with above average risk scores. Based on the risk of the Company’s qualified plan members relative to the average risk of members of other qualified plans in comparable markets, as defined by the ACA, the Company estimates its ultimate risk adjustment receivable (recorded in accounts receivable) or payable (recorded in accrued expenses) for the current calendar year and reflects the pro-rata year-to-date impact as an adjustment to premium revenue. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Corridor</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ACA established a temporary risk corridor program, which expired at the end of 2016, for qualified individual and small group health insurance plans. Under this program, health insurance companies were to make payments to, or receive payments from, the U.S. Department of Health and Human Services (“HHS”) based on their ratio of allowable costs to target costs (as defined by the ACA). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company filed a lawsuit in August 2019 to recover the $313 million it was owed under the ACA’s risk corridor program, which had been stayed pending the Supreme Court decision. In April 2020, the U.S. Supreme Court ruled that health insurance companies may sue the federal government for amounts owed as calculated under the ACA’s temporary risk corridor program. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the Company received the $313 million it was owed under the ACA’s risk corridor program. The Company recorded the risk corridor payment as an increase to premium revenue in the year ended December 31, 2020. After considering </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">offsetting items such as the ACA’s minimum MLR rebate requirements and premium taxes, the Company recorded pre-tax income of $307 million and after-tax income of $223 million during the year ended December 31, 2020. </span></div><div><span><br/></span></div><div style="padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising Costs </span></div><div style="padding-right:4.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising costs, which are reduced by the portion funded by vendors, are expensed when the related advertising takes place. Net advertising costs, which are included in operating expenses, were $523 million, $461 million and $396 million in 2021, 2020 and 2019, respectively. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation is measured at the grant date based on the fair value of the award and is recognized as expense over the requisite service period of the stock award (generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJhYjlmYjcxZDY3NjQ4ZjBiNzU4ODY5ZjE2MGI3ZjRiL3NlYzpiYWI5ZmI3MWQ2NzY0OGYwYjc1ODg2OWYxNjBiN2Y0Yl8xMzAvZnJhZzoxNDIzNTEzMTYwZjM0MTdlYTIxYWEzMWM4M2FiY2IyOS90ZXh0cmVnaW9uOjE0MjM1MTMxNjBmMzQxN2VhMjFhYTMxYzgzYWJjYjI5XzcyMzEz_ea62d84c-7b65-4b23-9d75-3a8341c56a52">three</span> to five years) using the straight-line method. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year or years in which the differences are expected to reverse. The effect of a change in the tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date of such change.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes deferred tax assets to the extent that it believes these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies, and the Company’s recent operating results. The Company establishes a valuation allowance when it does not consider it more likely than not that a deferred tax asset will be recovered.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records uncertain tax positions on the basis of a two-step process whereby (1) the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and/or penalties related to uncertain tax positions are recognized in the income tax provision.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Measurement of Defined Benefit Pension and Other Postretirement Employee Benefit Plans</span></div><div style="padding-right:4.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors defined benefit pension plans (“pension plans”) and other postretirement employee benefit plans (“OPEB plans”) for its employees and retirees. The Company recognizes the funded status of its pension and OPEB plans on the consolidated balance sheets based on the year-end measurements of plan assets and benefit obligations. When the fair value of plan assets are in excess of the plan benefit obligations, the amounts are reported in other current assets and other assets. When the fair value of plan benefit obligations are in excess of plan assets, the amounts are reported in accrued expenses and other long-term liabilities based on the amount by which the actuarial present value of benefits payable in the next twelve months included in the benefit obligation exceeds the fair value of plan assets. The net periodic benefit cost (income) for the Company’s pension and OPEB plans do not contain a service cost component as these plans have been frozen for an extended period of time. Non-service cost components of pension and postretirement net periodic benefit cost (income) are included in other income in the consolidated statements of operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earnings per Share</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings per share is computed using the two-class method. The Company calculates basic earnings per share based on the weighted average number of common shares outstanding for the period. See Note 14 ‘‘Earnings Per Share’’ for additional information.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shares Held in Trust</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains grantor trusts, which held approximately one million shares of its common stock at both December 31, 2021 and 2020. These shares are designated for use under various employee compensation plans. Since the Company holds these shares, they are excluded from the computation of basic and diluted shares outstanding. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Variable Interest Entities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has investments in (i) a generic pharmaceutical sourcing entity, (ii) certain hedge fund and private equity investments and (iii) certain real estate partnerships that are considered VIEs. The Company does not have a future obligation to fund losses or debts on behalf of these investments; however, it may voluntarily contribute funds. In evaluating whether the Company is the primary beneficiary of a VIE, the Company considers several factors, including whether the Company has (a) the power to direct the activities that most significantly impact the VIE’s economic performance and (b) the obligation to absorb losses and the right to receive benefits that could potentially be significant to the VIE. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities - Primary Beneficiary</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2014, the Company and Cardinal Health, Inc. (“Cardinal”) established Red Oak Sourcing, LLC (“Red Oak”), a generic pharmaceutical sourcing entity in which the Company and Cardinal each own 50%. The Red Oak arrangement had an initial term of ten years. In 2021, the Red Oak arrangement was amended to extend the initial term an additional five years, for a total term of 15 years. Under this arrangement, the Company and Cardinal contributed their sourcing and supply chain expertise to Red Oak and agreed to source and negotiate generic pharmaceutical supply contracts for both companies through Red Oak; however, Red Oak does not own or hold inventory on behalf of either company. No physical assets (e.g., property and equipment) were contributed to Red Oak by either company, and minimal funding was provided to capitalize Red Oak. The Company has determined that it is the primary beneficiary of this VIE because it has the ability to direct the activities of Red Oak. Consequently, the Company consolidates Red Oak in its consolidated financial statements within the Retail/LTC segment. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardinal is required to pay the Company quarterly payments, which began in October 2014 and will extend through June 2029. As milestones are met, the quarterly payments increase. The Company received $183 million from Cardinal during each of the years ended December 31, 2021, 2020 and 2019. The payments reduce the Company’s carrying value of inventory and are recognized in cost of products sold when the related inventory is sold. Amounts reimbursed by Cardinal for the years ended December 31, 2021, 2020 and 2019, and amounts due to or due from Cardinal at December 31, 2021 and 2020 were immaterial.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities - Other Variable Interest Holder</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has invested in certain VIEs for which it has determined that it is not the primary beneficiary, consisting of the following:</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Hedge fund and private equity investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The Company invests in hedge fund and private equity investments in order to generate investment returns for its investment portfolio supporting its insurance businesses.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Real estate partnerships</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The Company invests in various real estate partnerships, including those that construct, own and manage low-income housing developments. For the low income housing development investments, substantially all of the projected benefits to the Company are from tax credits and other tax benefits.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is not the primary beneficiary of these VIEs because the nature of the Company’s involvement with the activities of these VIEs does not give the Company the power to direct the activities that most significantly impact their economic performance. The Company records the amount of its investment in these VIEs as long-term investments on the consolidated balance sheets and recognizes its share of each VIE’s income or losses in net income (loss). The Company’s maximum exposure to loss from these VIEs is limited to its investment balances as disclosed below and the risk of recapture of previously recognized tax credits related to the real estate partnerships, which the Company does not consider significant.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total amount of other variable interest holder VIE assets included in long-term investments on the consolidated balance sheets at December 31, 2021 and 2020 was as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.990%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedge fund investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private equity investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">601 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate partnerships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,289 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,089 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Related Party Transactions</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an equity method investment in SureScripts, LLC (“SureScripts”), which operates a clinical health information network. The Company utilizes this clinical health information network in providing services to its client plan members and retail customers. The Company expensed fees for the use of this network of $52 million, $56 million and $32 million in the years ended December 31, 2021, 2020 and 2019, respectively. The Company’s investment in and equity in the earnings of SureScripts for all periods presented is immaterial.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an equity method investment in Heartland Healthcare Services, LLC (“Heartland”). Heartland operates several LTC pharmacies in four states. Heartland paid the Company $79 million, $77 million and $96 million for pharmaceutical inventory purchases during the years ended December 31, 2021, 2020 and 2019, respectively. Additionally, the Company performs certain collection functions for Heartland and then transfers those customer cash collections to Heartland. The Company’s investment in and equity in the earnings of Heartland for all periods presented is immaterial.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2021, 2020 and 2019, the Company made charitable contributions of $50 million, $50 million and $30 million, respectively, to the CVS Health Foundation, a non-profit entity that focuses on health, education and community involvement programs. The charitable contributions were recorded as operating expenses in the consolidated statements of operations within the Corporate/Other segment for the years ended December 31, 2021, 2020 and 2019.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Discontinued Operations</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with certain business dispositions completed between 1995 and 1997, the Company retained guarantees on store lease obligations for a number of former subsidiaries, including Linens ‘n Things and Bob’s Stores, each of which subsequently filed for bankruptcy. The Company’s loss from discontinued operations includes lease-related costs that the Company believes it will likely be required to satisfy pursuant to these lease guarantees. See “Lease Guarantees” in Note 16 ‘‘Commitments and Contingencies’’ for additional information. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of the results of discontinued operations for the year ended December 31, 2020. </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:88.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.573%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations, net of tax</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Results from discontinued operations were immaterial for the years ended December 31, 2021 and 2019.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New Accounting Pronouncements Recently Adopted </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Simplifying the Accounting for Income Taxes </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Financial Accounting Standards Board (“FASB”) issued ASU 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Simplifying the Accounting for Income Taxes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 740). This standard simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in Accounting Standards Codification 740 related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The standard also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The Company adopted this new accounting standard on January 1, 2021. The adoption of this standard did not have a material impact on the Company’s consolidated operating results, cash flows, financial condition or related disclosures.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New Accounting Pronouncements Not Yet Adopted</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Targeted Improvements to the Accounting for Long-Duration Insurance Contracts</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU 2018-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Targeted Improvements to the Accounting for Long-Duration Contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 944). This standard requires the Company to review cash flow assumptions for its long-duration insurance contracts at least annually and recognize the effect of changes in future cash flow assumptions in net income. This standard also requires the Company to update discount rate assumptions quarterly and recognize the effect of changes in these assumptions in other comprehensive income. The rate used to discount the Company’s liability for future policy benefits will be based on an estimate of the yield for an upper-medium grade fixed-income instrument with a duration profile matching that of the Company’s </span></div>liabilities. In addition, this standard changes the amortization method for deferred acquisition costs and requires additional disclosures regarding the long duration insurance contract liabilities in the Company’s interim and annual financial statements. The standard is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022. The Company will adopt the new standard on January 1, 2023, using the modified retrospective transition method as of the earliest period presented for changes to the liability for future policy benefits and deferred acquisition costs. While the Company is still evaluating the impact of the new standard on its financial statements, the Company anticipates an increase to its liability for future policy benefits with a corresponding change in accumulated other comprehensive income as a result of updating the rate used to discount the liabilities to reflect the yield for an upper-medium grade fixed-income instrument compared to the Company’s expected investment yield under the existing guidance. 9900 1200 110000000 1000000 35000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has four reportable segments: Health Care Benefits, Pharmacy Services, Retail/LTC and Corporate/Other, which are described below. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Health Care Benefits Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Health Care Benefits segment operates as one of the nation’s leading diversified health care benefits providers. The Health Care Benefits segment has the information and resources to help members, in consultation with their health care professionals, make more informed decisions about their health care. The Health Care Benefits segment offers a broad range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, medical management capabilities, Medicare Advantage and Medicare Supplement plans, PDPs, Medicaid health care management services and health information technology products and services. The Health Care Benefits segment also provided workers’ compensation administrative services through its Coventry Health Care Workers’ Compensation business (“Workers’ Compensation business”) prior to the sale of this business on July 31, 2020. The Health Care Benefits segment’s customers include employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers (“providers”), governmental units, government-sponsored plans, labor groups and expatriates. The Company refers to insurance products (where it assumes all or a majority of the risk for medical and dental care costs) as “Insured” and administrative services contract products (where the plan sponsor assumes all or a majority of the risk for medical and dental care costs) as “ASC.” In addition, effective January 2022, the Company entered the individual public health insurance exchanges (“Public Exchanges”) in eight states through which it sells Insured plans directly to individual consumers.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pharmacy Services Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmacy Services segment provides a full range of pharmacy benefit management (“PBM”) solutions, including plan design offerings and administration, formulary management, retail pharmacy network management services and mail order pharmacy. In addition, through the Pharmacy Services segment, the Company provides specialty pharmacy and infusion services, clinical services, disease management services, medical spend management and pharmacy and/or other administrative services for providers and federal 340B drug pricing program covered entities (“Covered Entities”). The Pharmacy Services segment’s clients are primarily employers, insurance companies, unions, government employee groups, health plans, PDPs, Medicaid managed care plans, plans offered on Public Exchanges and private health insurance exchanges, other sponsors of health benefit plans throughout the United States and Covered Entities. The Pharmacy Services segment operates retail specialty pharmacy stores, specialty mail order pharmacies, mail order dispensing pharmacies, compounding pharmacies and branches for infusion and enteral nutrition services. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Retail/LTC Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Retail/LTC segment sells prescription drugs and a wide assortment of health and wellness products and general merchandise, provides health care services through its MinuteClinic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">walk-in medical clinics, provides medical diagnostic testing, administers vaccinations for illnesses such as influenza, COVID-19 and shingles and conducts long-term care pharmacy (“LTC”) operations, which distribute prescription drugs and provide related pharmacy consulting and other ancillary services to long-term care facilities and other care settings. As of December 31, 2021, the Retail/LTC segment operated more than 9,900 retail locations, nearly 1,200 MinuteClinic locations as well as online retail pharmacy websites, LTC pharmacies and on-site pharmacies. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Corporate/Other Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company presents the remainder of its financial results in the Corporate/Other segment, which primarily consists of:</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Management and administrative expenses to support the Company’s overall operations, which include certain aspects of executive management and the corporate relations, legal, compliance, human resources, information technology and finance departments, expenses associated with the Company’s investments in its transformation and enterprise modernization programs and acquisition-related transaction and integration costs; and</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Products for which the Company no longer solicits or accepts new customers such as its large case pensions and long-term care insurance products.</span></div> 4 8 9900 1200 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements of CVS Health and its subsidiaries have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The consolidated financial statements include the accounts of the Company and its majority-owned subsidiaries and variable interest entities (“VIEs”) for which the Company is the primary beneficiary. All material intercompany balances and transactions have been eliminated.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior year amounts have been reclassified to conform with the current year presentation.</span></div> Use of EstimatesThe preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates. <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of cash and temporary investments with maturities of three months or less when purchased. The Company invests in short-term money market funds, commercial paper and time deposits, as well as other debt securities that are classified as cash equivalents within the accompanying consolidated balance sheets, as these funds are highly liquid and readily convertible to known amounts of cash. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash (included in other current assets) represents funds held on behalf of members, including health savings account (“HSA”) funds associated with high deductible health plans. Beginning in 2021, the Company began presenting these funds held on behalf of members in restricted cash and, for statement of cash flow purposes, retrospectively adjusted the 2020 and 2019 balances by the amounts shown in the table below in the line item “restricted cash (included in other current assets)” to conform with the current year presentation. Restricted cash (included in other assets) represents amounts held in a trust in one of the Company’s captive insurance companies to satisfy collateral requirements associated with the assignment of certain insurance policies. All restricted cash is invested in time deposits, money market funds or commercial paper.</span></div> <div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of cash and cash equivalents on the consolidated balance sheets to total cash, cash equivalents and restricted cash on the consolidated statements of cash flows as of December 31, 2021, 2020 and 2019:</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,408 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,854 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,683 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash (included in other current assets)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,065 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,913 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,454 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash (included in other assets)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash in the consolidated statements of cash flows</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,691 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,043 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,408 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 9408000000 7854000000 5683000000 3065000000 2913000000 2454000000 218000000 276000000 271000000 12691000000 11043000000 8408000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt Securities </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities consist primarily of U.S. Treasury and agency securities, mortgage-backed securities, corporate and foreign bonds and other debt securities. Debt securities are classified as either current or long-term investments based on their contractual maturities unless the Company intends to sell an investment within the next twelve months, in which case it is classified as current on the consolidated balance sheets. Debt securities are classified as available for sale and are carried at fair value. See Note 4 ‘‘Fair Value’’ for additional information on how the Company estimates the fair value of these investments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a debt security is in an unrealized loss position and the Company has the intent to sell the security, or it is more likely than not that the Company will have to sell the security before recovery of its amortized cost basis, the amortized cost basis of the security is written down to its fair value and the difference is recognized in net income. If a debt security is in an unrealized loss position and the Company does not have the intent to sell and it is more likely than not that the Company will not have to sell such security before recovery of its amortized cost basis, the Company bifurcates the impairment into credit-related and non-credit related components. In evaluating whether a credit related loss exists, the Company considers a variety of factors including: the extent to which the fair value is less than the amortized cost basis; adverse conditions specifically related to the issuer of a security, an industry or geographic area; the payment structure of the security; the failure of the issuer of the security to make scheduled interest or principal payments; and any changes to the rating of the security by a rating agency. The amount of the credit-related component is recorded as an allowance for credit losses and recognized in net income, and the amount of the non-credit related component is included in other comprehensive income. Interest is not accrued on debt securities when management believes the collection of interest is unlikely.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The credit-related component is determined by comparing the present value of cash flows expected to be collected from the security, considering all reasonably available information relevant to the collectability of the security, with the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis of the security, the Company records an allowance for credit losses, which is limited by the amount that the fair value is less than amortized cost basis. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For mortgage-backed and other asset-backed securities, the Company recognizes income using an effective yield based on anticipated prepayments and the estimated economic life of the securities. When estimates of prepayments change, the effective yield is recalculated to reflect actual payments to date and anticipated future payments. The Company’s investment in the security is adjusted to the amount that would have existed had the new effective yield been applied since the acquisition of the security, with adjustments recognized in net income.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Securities</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity securities with readily available fair values are measured at fair value with changes in fair value recognized in net income (loss).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mortgage Loans</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mortgage loan investments on the consolidated balance sheets are valued at the unpaid principal balance, net of an allowance for credit losses. Mortgage loans with a maturity date or a committed prepayment date within twelve months are classified as current on the consolidated balance sheets. The Company assesses whether its loans share similar risk characteristics and, if so, groups such loans in a risk pool when measuring expected credit losses. The Company considers the following characteristics when evaluating whether its loans share similar risk characteristics: loan-to-value ratios, property type (e.g., office, retail, apartment, industrial), geographic location, vacancy rates and property condition. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Credit loss reserves are determined using a loss rate method that multiplies the unpaid principal balance of each loan within a risk pool group by an estimated loss rate percentage. The loss rate percentage considers both the expected loan loss severity and the probability of loan default. For periods where the Company is able to make or obtain reasonable and supportable forecasts of expected economic conditions (e.g., gross domestic product, employment), the Company adjusts its expected loss rates to reflect these forecasted economic conditions. For periods beyond which the Company is able to make or obtain reasonable and supportable forecasts of expected economic conditions, the Company reverts to historical loss rates in determining expected credit losses. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income on a potential problem loan (i.e., high probability of default) or restructured loan is accrued to the extent it is deemed to be collectible and the loan continues to perform under its original or restructured terms. Interest income on problem loans (i.e., more than 60 days delinquent, in bankruptcy or in process of foreclosure) is recognized on a cash basis. Cash payments on loans in the process of foreclosure are treated as a return of principal.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Investments</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other investments consist primarily of the following:</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Private equity and hedge fund limited partnerships, which are accounted for using the equity method of accounting. Under this method, the carrying value of the investment is based on the value of the Company’s equity ownership of the underlying investment funds provided by the general partner or manager of the investments, the financial statements of which generally are audited. As a result of the timing of the receipt of the valuation information provided by the fund managers, these investments are generally reported on up to a three month lag. The Company reviews investments for impairment at least quarterly and monitors their performance throughout the year through discussions with the administrators, managers and/or general partners. If the Company becomes aware of an impairment of a limited partnership’s investments through its review or prior to receiving the limited partnership’s financial statements at the financial statement date, an impairment will be recognized by recording a reduction in the carrying value of the limited partnership with a corresponding charge to net investment income. </span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Investment real estate, which is carried on the consolidated balance sheets at depreciated cost, including capital additions, net of write-downs for other-than-temporary declines in fair value. Depreciation is calculated using the straight-line method based on the estimated useful life of each asset. If any real estate investment is considered held-for-sale, it is carried at the lower of its carrying value or fair value less estimated selling costs. The Company generally estimates fair value using net operating income and applying a capitalization rate in conjunction with comparable sales information. At the time of the sale, the difference between the sales price and the carrying value is recorded as a realized capital gain or loss. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Privately-placed equity securities, which are carried on the consolidated balance sheets at cost less impairments, plus or minus subsequent adjustments for observable price changes. Additionally, as a member of the Federal Home Loan Bank of Boston (“FHLBB”), a subsidiary of the Company is required to purchase and hold shares of the FHLBB. These shares are restricted and carried at cost. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Investment Income</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net investment income on the Company’s investments is recorded when earned and is reflected in the Company’s net income (other than net investment income on assets supporting experience-rated products). Experience-rated products are products in the large case pensions business where the contract holder, not the Company, assumes investment and other risks, subject to, among other things, minimum guarantees provided by the Company. The effect of investment performance on experience-rated products is allocated to contract holders’ accounts daily, based on the underlying investment experience and, therefore, does not impact the Company’s net income (as long as the contract’s minimum guarantees are not triggered). Net investment income on assets supporting large case pensions’ experience-rated products is included in net investment income in the consolidated statements of operations and is credited to contract holders’ accounts through a charge to benefit costs. The contract holders’ accounts are reflected in policyholders’ funds on the consolidated balance sheets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized capital gains and losses on investments (other than realized capital gains and losses on investments supporting experience-rated products) are included as a component of net investment income in the consolidated statements of operations. Realized capital gains and losses are determined on a specific identification basis. Purchases and sales of debt and equity securities and alternative investments are reflected on the trade date. Purchases and sales of mortgage loans and investment real estate are reflected on the closing date.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized capital gains and losses on investments supporting large case pensions’ experience-rated products are not included in realized capital gains and losses in the consolidated statements of operations and instead are credited directly to contract holders’ accounts. The contract holders’ accounts are reflected in policyholders’ funds on the consolidated balance sheets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized capital gains and losses on investments (other than unrealized capital gains and losses on investments supporting experience-rated products) are reflected in shareholders’ equity, net of tax, as a component of accumulated other comprehensive income. Unrealized capital gains and losses on investments supporting large case pensions’ experience-rated products are credited directly to contract holders’ accounts. The contract holders’ accounts are reflected in policyholders’ funds on the consolidated balance sheets.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Financial Instruments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses derivative financial instruments in order to manage interest rate and foreign exchange risk and credit exposure. The Company’s use of these derivatives is generally limited to hedging risk and has principally consisted of using interest rate swaps, treasury rate locks, forward contracts, futures contracts, warrants, put options and credit default swaps.</span></div> Accounts ReceivableAccounts receivable are stated net of allowances for credit losses, customer credit allowances, contractual allowances and estimated terminations.When developing an estimate of the Company’s expected credit losses, the Company considers all available relevant information regarding the collectability of cash flows, including historical information, current conditions and reasonable and supportable forecasts of future economic conditions over the contractual life of the receivable. The Company’s accounts receivable are short duration in nature and typically settle in less than 30 days. Accounts receivable, net is composed of the following at December 31, 2021 and 2020:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.432%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,932 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,101 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vendor and manufacturer receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,573 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,815 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premium receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,537 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,628 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,389 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,198 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Total accounts receivable, net </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,431 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,742 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 7932000000 7101000000 10573000000 9815000000 2537000000 2628000000 3389000000 2198000000 24431000000 21742000000 339000000 358000000 Inventories Inventories are valued at the lower of cost or net realizable value using the weighted average cost method. Physical inventory counts are taken on a regular basis in each retail store and LTC pharmacy, and a continuous cycle count process is the primary procedure used to validate the inventory balances on hand in each distribution center and mail facility to ensure that the amounts reflected in the consolidated financial statements are properly stated. During the interim period between physical inventory counts, the Company accrues for anticipated physical inventory losses on a location-by-location basis based on historical results and current physical inventory trends. <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reinsurance Recoverables </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes reinsurance agreements primarily to: (a) reduce required capital and (b) facilitate the acquisition or disposition of certain insurance contracts. Ceded reinsurance agreements permit the Company to recover a portion of its losses from reinsurers, although they do not discharge the Company’s primary liability as the direct insurer of the risks reinsured. Failure of reinsurers to indemnify the Company could result in losses; however, the Company does not expect charges for unrecoverable reinsurance to have a material effect on its consolidated operating results or financial condition. The Company evaluates the financial condition of its reinsurers and monitors concentrations of credit risk arising from similar geographic regions, activities or economic characteristics of its reinsurers. At December 31, 2021, the Company’s reinsurance recoverables consisted primarily of amounts due from third parties that are rated consistent with companies that are considered to have the ability to meet their obligations. Reinsurance recoverables are recorded as other current assets or other assets on the consolidated balance sheets.</span></div> Health Care Contract Acquisition CostsInsurance products included in the Health Care Benefits segment are cancellable by either the customer or the member monthly upon written notice. Acquisition costs related to prepaid health care and health indemnity contracts are generally expensed as incurred. Acquisition costs for certain long-duration insurance contracts are deferred and are recorded as other current assets or other assets on the consolidated balance sheets and are amortized over the estimated life of the contracts. The amortization of deferred acquisition costs is recorded in operating expenses in the consolidated statements of operations. 895000000 546000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is reported at historical cost, net of accumulated depreciation. Property, equipment and improvements to leased premises are depreciated using the straight-line method over the estimated useful lives of the assets, or when applicable, the term of the lease, whichever is shorter. Estimated useful lives generally range from 1 to 40 years for buildings, building improvements and leasehold improvements and 3 to 10 years for fixtures, equipment and internally developed software. Repair and maintenance costs are charged directly to expense as incurred. Major renewals or replacements that </span></div>substantially extend the useful life of an asset are capitalized and depreciated. Application development stage costs for significant internally developed software projects are capitalized and depreciated. P1Y P40Y P3Y P10Y <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consists of the following at December 31, 2021 and 2020: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.990%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,038 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,134 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,225 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,950 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixtures and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,619 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,125 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,242 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,077 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,426 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,020 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,550 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,306 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,654)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,700)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,896 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,606 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2038000000 2134000000 4225000000 3950000000 13619000000 13125000000 6242000000 6077000000 7426000000 6020000000 33550000000 31306000000 20654000000 18700000000 12896000000 12606000000 2300000000 2100000000 1900000000 261000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Right-of-Use Assets and Lease Liabilities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement contains a lease at the inception of a contract. Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at the commencement date of the lease, renewal date of the lease or significant remodeling of the lease space based on the present value of the remaining future minimum lease payments. As the interest rate implicit in the Company’s leases is not readily determinable, the Company utilizes its incremental borrowing rate, determined by class of underlying asset, to discount the lease payments. The operating lease right-of-use assets also include lease payments made before commencement and are reduced by lease incentives. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s real estate leases typically contain options that permit renewals for additional periods of up to five years each. For real estate leases, the options to extend are not considered reasonably certain at lease commencement because the Company reevaluates each lease on a regular basis to consider the economic and strategic incentives of exercising the renewal options and regularly opens or closes stores to align with its operating strategy. Generally, the renewal option periods are not included within the lease term and the associated payments are not included in the measurement of the right-of-use asset and lease liability. Similarly, renewal options are not included in the lease term for non-real estate leases because they are not considered reasonably certain of being exercised at lease commencement. Leases with an initial term of 12 months or less are not recorded on the balance sheets, and lease expense is recognized on a straight-line basis over the term of the short-term lease.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For real estate leases, the Company accounts for lease components and nonlease components as a single lease component. Certain real estate leases require additional payments based on sales volume, as well as reimbursement for real estate taxes, common area maintenance and insurance, which are expensed as incurred as variable lease costs. Other real estate leases contain one fixed lease payment that includes real estate taxes, common area maintenance and insurance. These fixed payments are considered part of the lease payment and included in the right-of-use assets and lease liabilities.</span></div>See Note 6 ‘‘Leases’’ for additional information about right-of-use assets and lease liabilities. P5Y Goodwill The Company accounts for business combinations using the acquisition method of accounting, which requires the excess cost of an acquisition over the fair value of net assets acquired and identifiable intangible assets to be recorded as goodwill. Goodwill is not amortized, but is subject to impairment reviews annually, or more frequently if necessary, as further described in “Long-Lived Asset Impairment” below. <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s identifiable intangible assets consist primarily of trademarks, trade names, customer contracts/relationships, covenants not to compete, technology, provider networks and value of business acquired (“VOBA”). These intangible assets arise primarily from the determination of their respective fair market values at the date of acquisition. Amounts assigned to identifiable intangible assets, and their related useful lives, are derived from established valuation techniques and management estimates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s definite-lived intangible assets are amortized over their estimated useful lives based upon the pattern of future cash flows attributable to the asset. Other than VOBA, definite-lived intangible assets are amortized using the straight-line method. VOBA is amortized over the expected life of the acquired contracts in proportion to estimated premiums. Indefinite-lived intangible assets are not amortized but are tested for impairment annually, or more frequently if necessary, as further described in “Long-Lived Asset Impairment” below.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-Lived Asset Impairment</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the recoverability of long-lived assets, excluding goodwill and indefinite-lived intangible assets, which are tested for impairment using separate tests described below, whenever events or changes in circumstances indicate that the carrying value of such asset may not be recoverable. The Company groups and evaluates these long-lived assets for impairment at the lowest level at which individual cash flows can be identified. If indicators of impairment are present, the Company first compares the carrying amount of the asset group to the estimated future cash flows associated with the asset group (undiscounted). If the estimated future cash flows used in this analysis are less than the carrying amount of the asset group, an impairment loss calculation is prepared. The impairment loss calculation compares the carrying amount of the asset group to the asset group’s estimated future cash flows (discounted). If required, an impairment loss is recorded for the portion of the asset group’s carrying value that exceeds the asset group’s estimated future cash flows (discounted). During the year ended December 31, 2021, the Company recorded a store impairment charge of approximately $1.4 billion primarily related to the write down of operating lease right-of-use assets and property and equipment in connection with the planned closure of approximately 900 retail stores between 2022 and 2024. There were no material impairment charges recognized on long-lived assets in the year ended 2020. During the year ended December 31, 2019 the Company recorded a store impairment charge of $231 million primarily related to operating lease right-of-use assets. See Note 6 ‘‘Leases’’ for additional information about the right-of-use asset impairment charges. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When evaluating goodwill for potential impairment, the Company compares the fair value of its reporting units to their respective carrying amounts. The Company estimates the fair value of its reporting units using a combination of a discounted cash flow method and a market multiple method. If the carrying amount of a reporting unit exceeds its estimated fair value, an impairment loss is recognized in an amount equal to that excess. During the third quarter of 2021, the Company performed its required annual impairment tests of goodwill, the results of which indicated an impairment of the goodwill associated with the LTC reporting unit. Accordingly, during the third quarter of 2021, the Company recorded a $431 million goodwill impairment charge. The results of the impairment tests indicated that there was no impairment of goodwill of the remaining reporting units as of the testing date or during the year ended December 31, 2021. During the third quarter of both 2020 and 2019, the Company performed its required annual goodwill impairment tests and concluded there were no goodwill impairments as of the testing dates or during the years ended December 31, 2020 and 2019. See Note 5 ‘‘Goodwill and Other Intangibles’’ for additional information about the goodwill impairment charge recorded during the year ended December 31, 2021. </span></div>Indefinite-lived intangible assets are tested for impairment by comparing the estimated fair value of the asset to its carrying value. The Company estimates the fair value of its indefinite-lived trademarks using the relief from royalty method under the income approach. If the carrying value of the asset exceeds its estimated fair value, an impairment loss is recognized, and the asset is written down to its estimated fair value. 1400000000 900 0 231000000 431000000 0 0 0 0 0 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Separate Accounts</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separate Accounts assets and liabilities related to large case pensions products represent funds maintained to meet specific objectives of contract holders who bear the investment risk. These assets and liabilities are carried at fair value. Net investment income (including net realized capital gains and losses) accrue directly to such contract holders. The assets of each account are legally segregated and are not subject to claims arising from the Company’s other businesses. Deposits, withdrawals and net </span></div>investment income (including net realized and net unrealized capital gains and losses) on Separate Accounts assets are not reflected in the consolidated statements of operations or cash flows. Management fees charged to contract holders are included in services revenue and recognized over the period earned. <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Health Care Costs Payable</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health care costs payable consist principally of unpaid fee-for-service medical, dental and pharmacy claims, capitation costs, other amounts due to providers pursuant to risk-sharing arrangements related to the Health Care Benefits segment’s Insured Commercial, Medicare and Medicaid products and accruals for state assessments. Unpaid health care claims include an estimate of payments the Company will make for (i) services rendered to the Company’s Insured members but not yet reported to the Company and (ii) claims which have been reported to the Company but not yet paid, each as of the financial statement date (collectively, “IBNR”). Health care costs payable also include an estimate of the cost of services that will continue to be rendered after the financial statement date if the Company is obligated to pay for such services in accordance with contractual or regulatory requirements. Such estimates are developed using actuarial principles and assumptions which consider, among other things, historical and projected claim submission and processing patterns, assumed and historical medical cost trends, historical utilization of medical services, claim inventory levels, changes in Insured membership and product mix, seasonality and other relevant factors. The Company reflects changes in these estimates in benefit costs in the Company’s consolidated operating results in the period they are determined. Capitation costs represent contractual monthly fees paid to participating physicians and other medical providers for providing medical care, regardless of the volume of medical services provided to the Insured member. Amounts due under risk-sharing arrangements are based on the terms of the underlying contracts with the providers and consider claims experience under the contracts through the financial statement date.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company develops its estimate of IBNR using actuarial principles and assumptions that consider numerous factors. Of those factors, the Company considers the analysis of historical and projected claim payment patterns (including claims submission and processing patterns) and the assumed health care cost trend rate (the year-over-year change in per member per month health care costs) to be the most critical assumptions. In developing its IBNR estimate, the Company consistently applies these actuarial principles and assumptions each period, with consideration to the variability of related factors. There have been no significant changes to the methodologies or assumptions used to develop the Company’s estimate of IBNR in 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company analyzes historical claim payment patterns by comparing claim incurred dates (i.e., the date services were provided) to claim payment dates to estimate “completion factors.” The Company uses completion factors predominantly to estimate the ultimate cost of claims incurred more than three months before the financial statement date. The Company estimates completion factors by aggregating claim data based on the month of service and month of claim payment and estimating the percentage of claims incurred for a given month that are complete by each month thereafter. For any given month, substantially all claims are paid within six months of the date of service, but it can take up to 48 months or longer after the date of service before all of the claims are completely resolved and paid. These historically-derived completion factors are then applied to claims paid through the financial statement date to estimate the ultimate claim cost for a given month’s incurred claim activity. The difference between the estimated ultimate claim cost and the claims paid through the financial statement date represents the Company’s estimate of claims remaining to be paid as of the financial statement date and is included in the Company’s health care costs payable. The completion factors the Company uses reflect judgments and possible adjustments based on data such as claim inventory levels, claim submission and processing patterns and, to a lesser extent, other factors such as changes in health care cost trend rates, changes in Insured membership and changes in product mix. If claims are submitted or processed on a faster (slower) pace than prior periods, the actual claims may be more (less) complete than originally estimated using the Company’s completion factors, which may result in reserves that are higher (lower) than the ultimate cost of claims.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because claims incurred within three months before the financial statement date are less mature, the Company uses a combination of historically-derived completion factors and the assumed health care cost trend rate to estimate the ultimate cost of claims incurred for these months. The Company applies its actuarial judgment and places a greater emphasis on the assumed health care cost trend rate for the most recent claim incurred dates as these months may be influenced by seasonal patterns and changes in membership and product mix.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s health care cost trend rate is affected by changes in per member utilization of medical services as well as changes in the unit cost of such services. Many factors influence the health care cost trend rate, including the Company’s ability to manage benefit costs through product design, negotiation of favorable provider contracts and medical management programs, as well as the mix of the Company’s business. The health status of the Company’s Insured members, aging of the population and other demographic characteristics, advances in medical technology and other factors continue to contribute to rising per member utilization and unit costs. Changes in health care practices, inflation, new technologies, increases in the cost of </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">prescription drugs (including specialty pharmacy drugs), direct-to-consumer marketing by pharmaceutical companies, clusters of high-cost cases, claim intensity, changes in the regulatory environment, health care provider or member fraud and numerous other factors also contribute to the cost of health care and the Company’s health care cost trend rate.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each reporting period, the Company uses an extensive degree of judgment in the process of estimating its health care costs payable. As a result, considerable variability and uncertainty is inherent in such estimates, particularly with respect to claims with claim incurred dates of three months or less before the financial statement date; and the adequacy of such estimates is highly sensitive to changes in assumed completion factors and the assumed health care cost trend rates. For each reporting period the Company recognizes the actuarial best estimate of health care costs payable considering the potential volatility in assumed completion factors and health care cost trend rates, as well as other factors. The Company believes its estimate of health care costs payable is reasonable and adequate to cover its obligations at December 31, 2021; however, actual claim payments may differ from the Company’s estimates. A worsening (or improvement) of the Company’s health care cost trend rates or changes in completion factors from those that the Company assumed in estimating health care costs payable at December 31, 2021 would cause these estimates to change in the near term, and such a change could be material.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each quarter, the Company re-examines previously established health care costs payable estimates based on actual claim payments for prior periods and other changes in facts and circumstances. Given the extensive degree of judgment in this estimate, it is possible that the Company’s estimates of health care costs payable could develop either favorably (that is, its actual benefit costs for the period were less than estimated) or unfavorably. The changes in the Company’s estimate of health care costs payable may relate to a prior quarter, prior year or earlier periods. For a roll forward of the Company’s health care costs payable, see Note 7 ‘‘Health Care Costs Payable.’’ The Company’s reserving practice is to consistently recognize the actuarial best estimate of its ultimate liability for health care costs payable.</span></div> P6M P48M <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Insurance Liabilities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unpaid Claims</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unpaid claims consist primarily of reserves associated with certain short-duration group disability and term life insurance contracts, including an estimate for IBNR as of the financial statement date. Reserves associated with certain short-duration group disability and term life insurance contracts are based upon the Company’s estimate of the present value of future benefits, which is based on assumed investment yields and assumptions regarding mortality, morbidity and recoveries from the U.S. Social Security Administration. The Company develops its estimate of IBNR using actuarial principles and assumptions which consider, among other things, contractual requirements, claim incidence rates, claim recovery rates, seasonality and other relevant factors. The Company discounts certain claim liabilities related to group long-term disability and life insurance waiver of premium contracts. The discount rates generally reflect the Company’s expected investment returns for the investments supporting all incurral years of these liabilities. The discount rates for retrospectively-rated contracts are set at contractually specified levels. The Company’s estimates of unpaid claims are subject to change due to changes in the underlying experience of the insurance contracts, changes in investment yields or other factors, and these changes are recorded in current and future benefits in the consolidated statements of operations in the period they are determined. The Company estimates its reserve for claims IBNR for life products largely based on completion factors. The completion factors used are based on the Company’s historical experience and reflect judgments and possible adjustments based on data such as claim inventory levels, claim payment patterns, changes in business volume and other factors. If claims are submitted or processed on a faster (slower) pace than historical periods, the actual claims may be more (less) complete than originally estimated using completion factors, which may result in reserves that are higher (lower) than required to cover future life benefit payments. There have been no significant changes to the methodologies or assumptions used to develop the Company’s estimate of unpaid claims IBNR in 2021. As of December 31, 2021, unpaid claims balances of $324 million and $1.3 billion were recorded in other insurance liabilities and other long-term insurance liabilities, respectively. As of December 31, 2020, unpaid claims balances of $532 million and $1.5 billion were recorded in other insurance liabilities and other long-term insurance liabilities, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all life and disability insurance liabilities have been fully ceded to unrelated third parties through indemnity reinsurance agreements; however, the Company remains directly obligated to the policyholders.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Future Policy Benefits</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future policy benefits consist primarily of reserves for limited payment pension and annuity contracts and long-term care insurance contracts. Reserves for limited payment pension and annuity contracts are computed using actuarial principles that consider, among other things, assumptions reflecting anticipated mortality, retirement, expense and interest rate experience. Such assumptions generally vary by plan, year of issue and policy duration. Assumed interest rates on such contracts ranged from 3.0% to 11.3% in the year ended December 31, 2021 and from 3.3% to 11.3% in the year ended December 31, 2020. The Company periodically reviews mortality assumptions against both industry standards and its experience. Reserves for long-</span></div>duration long-term care contracts represent the Company’s estimate of the present value of future benefits and essential maintenance expenses to be paid to or on behalf of policyholders less the present value of future gross premiums. The assumed interest rate on such contracts was 5.1% in both the years ended December 31, 2021 and 2020. The Company’s estimate of the present value of future benefits under such contracts is based upon mortality, morbidity and interest rate assumptions. 324000000 1300000000 532000000 1500000000 0.030 0.113 0.033 0.113 0.051 0.051 416000000 5100000000 462000000 5500000000 Premium Deficiency ReservesThe Company evaluates its insurance contracts to determine if it is probable that a loss will be incurred. A premium deficiency loss is recognized when it is probable that expected future claims, including maintenance costs (for example, direct costs such as claim processing costs), will exceed existing reserves plus anticipated future premiums and reinsurance recoveries. Anticipated investment income is not considered in the calculation of premium deficiency losses for short-duration contracts. For purposes of determining premium deficiency losses, contracts are grouped consistent with the Company’s method of acquiring, servicing and measuring the profitability of such contracts. 16000000 11000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Policyholders’ Funds</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Policyholders’ funds consist primarily of reserves for pension and annuity investment contracts and customer funds associated with certain health contracts. Reserves for such contracts are equal to cumulative deposits less withdrawals and charges plus interest credited thereon, net of experience-rated adjustments. In 2021, interest rates for pension and annuity investment contracts ranged from 3.5% to 4.8%. In 2020, interest rates for pension and annuity investment contracts ranged from 4.1% to 5.1%. Reserves for contracts subject to experience rating reflect the Company’s rights as well as the rights of policyholders and plan participants. The Company also holds funds for HSAs on behalf of members associated with high deductible health plans. These amounts are held to pay for qualified health care expenses incurred by these members. The HSA balances were approximately $2.9 billion and $2.7 billion at December 31, 2021 and 2020, respectively, and are reflected in other current assets with a corresponding liability in policyholders’ funds. These assets are considered restricted cash for cash flow statement purposes.</span></div>Policyholders’ funds liabilities that are expected to be paid within twelve months from the balance sheet date are classified as current on the consolidated balance sheets. Policyholders’ funds liabilities that are expected to be paid greater than twelve months from the balance sheet date are included in other long-term liabilities on the consolidated balance sheets. 0.035 0.048 0.041 0.051 2900000000 2700000000 Self-Insurance LiabilitiesThe Company is self-insured for certain losses related to general liability, workers’ compensation and auto liability. The Company obtains third party insurance coverage to limit exposure from these claims. The Company is also self-insured for certain losses related to health and medical liabilities. The Company’s self-insurance accruals, which include reported claims and claims incurred but not reported, are calculated using standard insurance industry actuarial assumptions and the Company’s historical claims experience. 1100000000 927000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation and Transactions</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For non-U.S. dollar functional currency locations, (i) assets and liabilities are translated at end-of-period exchange rates, (ii) revenues and expenses are translated at average exchange rates in effect during the period and (iii) equity is translated at historical exchange rates. The resulting cumulative translation adjustments are included as a component of accumulated other comprehensive income.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For U.S. dollar functional currency locations, foreign currency assets and liabilities are remeasured into U.S. dollars at end-of-period exchange rates, except for nonmonetary balance sheet accounts which are remeasured at historical exchange rates. Revenues and expenses are remeasured at average exchange rates in effect during each period, except for those expenses related to the nonmonetary balance sheet amounts which are remeasured at historical exchange rates. Gains or losses from foreign currency remeasurement are included in net income.</span></div> 154000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Health Care Benefits Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health Care Benefits revenue is principally derived from insurance premiums and fees billed to customers. Revenue is recognized based on customer billings, which, in the Company’s Commercial business, reflect contracted rates per member and the number of covered members recorded in the Company’s records at the time the billings are prepared. Billings are generally sent monthly for coverage during the following month. Revenue related to the Company’s Government business is collected monthly from the U.S. federal government and various government agencies based on fixed payment rates and member eligibility. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s billings may be subsequently adjusted to reflect enrollment changes due to member terminations or other factors. These adjustments are known as retroactivity adjustments. In each period, the Company estimates the amount of future retroactivity and adjusts the recorded revenue accordingly. As information regarding actual retroactivity amounts becomes known, the Company refines its estimates and records any required adjustments to revenues in the period in which they arise.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Premium Revenue</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Premiums are recognized as revenue in the month in which the enrollee is entitled to receive health care services. Premiums are reported net of an allowance for estimated terminations and uncollectible amounts. Additionally, premium revenue subject to the minimum medical loss ratio (“MLR”) rebate requirements of the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010 (as amended, collectively, the “ACA”) is recorded net of the estimated minimum MLR rebates for the current calendar year. Premiums related to unexpired contractual coverage periods (unearned premiums) are reported as other insurance liabilities on the consolidated balance sheets and recognized as revenue when earned.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the Company’s contracts allow for premiums to be adjusted to reflect actual experience or the relative health status of Insured members. Such adjustments are reasonably estimable at the outset of the contract, and adjustments to those estimates are made based on actual experience of the customer emerging under the contract and the terms of the underlying contract.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Services Revenue</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Services revenue relates to contracts that can include various combinations of services or series of services which generally are capable of being distinct and accounted for as separate performance obligations. The Health Care Benefits segment’s services revenue primarily consists of ASC fees received in exchange for performing certain claim processing and member services for ASC members. ASC fee revenue is recognized over the period the service is provided. Some of the Company’s administrative services contracts include guarantees with respect to certain functions, such as customer service response time, claim processing accuracy and claim processing turnaround time, as well as certain guarantees that a plan sponsor’s benefit claim experience will fall within a certain range. With any of these guarantees, the Company is financially at risk if the conditions of the arrangements are not met, although the maximum amount at risk typically is limited to a percentage of the fees otherwise payable to the Company by the customer involved. Each period the Company estimates its obligations under the terms of these guarantees and records its estimate as an offset to services revenues.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Accounting for Medicare Part D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues include insurance premiums earned by the Company’s PDPs, which are determined based on the PDP’s annual bid and related contractual arrangements with the U.S. Centers for Medicare &amp; Medicaid Services (“CMS”). The insurance premiums include a beneficiary premium, which is the responsibility of the PDP member, and can be subsidized by CMS in the case of low-income members, and a direct premium paid by CMS. Premiums collected in advance are initially recorded within other insurance liabilities and are then recognized ratably as revenue over the period in which members are entitled to receive benefits.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues also include a risk-sharing feature of the Medicare Part D program design referred to as the risk corridor. The Company estimates variable consideration in the form of amounts payable to, or receivable from, CMS under the risk corridor, and adjusts revenue based on calculations of additional subsidies to be received from or owed to CMS at the end of the reporting year.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to Medicare Part D premiums, the Company receives additional payments each month from CMS related to catastrophic reinsurance, low-income cost-sharing subsidies and coverage gap benefits. If the subsidies received differ from the amounts earned from actual prescriptions transferred, the difference is recorded in either accounts receivable, net or accrued expenses.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pharmacy Services Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmacy Services segment sells prescription drugs directly through its mail service dispensing pharmacies and indirectly through the Company’s retail pharmacy network. The Company’s pharmacy benefit arrangements are accounted for in a manner consistent with a master supply arrangement as there are no contractual minimum volumes and each prescription is considered a separate purchasing decision and distinct performance obligation transferred at a point in time. PBM services performed in connection with each prescription claim are considered part of a single performance obligation which culminates in the dispensing of prescription drugs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue using the gross method at the contract price negotiated with its clients when the Company has concluded it controls the prescription drug before it is transferred to the client plan members. The Company controls prescriptions dispensed indirectly through its retail pharmacy network because it has separate contractual arrangements with those pharmacies, has discretion in setting the price for the transaction and assumes primary responsibility for fulfilling the promise to provide prescription drugs to its client plan members while also performing the related PBM services.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues include (i) the portion of the price the client pays directly to the Company, net of any discounts earned on brand name drugs or other discounts and refunds paid back to the client (see “Drug Discounts” and “Guarantees” below), (ii) the price paid to the Company by client plan members for mail order prescriptions and the price paid to retail network pharmacies by client plan members for retail prescriptions (“retail co-payments”), and (iii) claims based administrative fees for retail pharmacy network contracts. Sales taxes are not included in revenues. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when control of the prescription drugs is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to receive in exchange for those prescription drugs. The Company has established the following revenue recognition policies for the Pharmacy Services segment:</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Revenues generated from prescription drugs sold by mail service dispensing pharmacies are recognized when the prescription drug is delivered to the client plan member. At the time of delivery, the Company has performed substantially all of its performance obligations under its client contracts and does not experience a significant level of returns or reshipments.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Revenues generated from prescription drugs sold by third party pharmacies in the Company’s retail pharmacy network and associated administrative fees are recognized at the Company’s point-of-sale, which is when the claim is adjudicated by the Company’s online claims processing system and the Company has transferred control of the prescription drug and completed all of its performance obligations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For contracts under which the Company acts as an agent or does not control the prescription drugs prior to transfer to the client plan member, revenue is recognized using the net method.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Drug Discounts</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records revenue net of manufacturers’ rebates earned by its clients based on their plan members’ utilization of brand-name formulary drugs. The Company estimates these rebates at period-end based on actual and estimated claims data and its estimates of the manufacturers’ rebates earned by its clients. The estimates are based on the best available data at period-end and recent history for the various factors that can affect the amount of rebates due to the client. The Company adjusts its rebates payable to clients to the actual amounts paid when these rebates are paid or as significant events occur. Any cumulative effect of these adjustments is recorded against revenues at the time it is identified. Adjustments generally result from contract changes with clients or manufacturers that have retroactive rebate adjustments, differences between the estimated and actual product mix subject to rebates, or whether the brand name drug was included in the applicable formulary. The effect of adjustments between estimated and actual manufacturers’ rebate amounts has not been material to the Company’s operating results or financial condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Guarantees</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also adjusts revenues for refunds owed to clients resulting from pricing guarantees and performance against defined service and performance metrics. The inputs to these estimates are not subject to a high degree of subjectivity or volatility. The effect of adjustments between estimated and actual pricing and performance refund amounts has not been material to the Company’s operating results or financial condition.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Retail/LTC Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Retail Pharmacy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s retail drugstores recognize revenue at the time the customer takes possession of the merchandise. For pharmacy sales, each prescription claim is its own arrangement with the customer and is a performance obligation, separate and distinct from other prescription claims under other retail network arrangements. Revenues are adjusted for refunds owed to third party payers resulting from pricing guarantees and performance against defined value-based service and performance metrics. The inputs to these estimates are not subject to a high degree of subjectivity or volatility. The effect of adjustments between estimated and actual pricing and performance refund amounts has not been material to the Company’s operating results or financial condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from Company gift cards purchased by customers is deferred as a contract liability until goods or services are transferred. Any amounts not expected to be redeemed by customers (i.e., breakage) are recognized based on historical redemption patterns.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer returns are not material to the Company’s operating results or financial condition. Sales taxes are not included in revenues.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Loyalty and Other Programs</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s customer loyalty program, ExtraCare</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, consists of two components, ExtraSavings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and ExtraBucks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Rewards. ExtraSavings are coupons that are recorded as a reduction of revenue when redeemed as the Company concluded that they do not represent a promise to the customer to deliver additional goods or services at the time of issuance because they are not tied to a specific transaction or spending level. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ExtraBucks Rewards are accumulated by customers based on their historical spending levels. Thus, the Company has determined that there is an additional performance obligation to those customers at the time of the initial transaction. The Company allocates the transaction price to the initial transaction and the ExtraBucks Rewards transaction based upon the relative standalone selling price, which considers historical redemption patterns for the rewards. Revenue allocated to ExtraBucks Rewards is recognized as those rewards are redeemed. At the end of each period, unredeemed ExtraBucks Rewards are reflected as a contract liability.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also offers a subscription-based membership program, CarePass</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, under which members are entitled to a suite of benefits delivered over the course of the subscription period, as well as a promotional reward that can be redeemed for future goods and services. Subscriptions are paid for on a monthly or annual basis at the time of or in advance of the Company delivering the goods and services. Revenue from these arrangements is recognized as the performance obligations are satisfied.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Long-term Care</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized when control of the promised goods or services is transferred to customers in an amount that reflects the consideration the Company expects to be entitled to receive in exchange for those goods or services. Each prescription claim represents a separate performance obligation of the Company, separate and distinct from other prescription claims under customer arrangements. A significant portion of long-term care revenue from sales of pharmaceutical and medical products is reimbursed by the federal Medicare Part D program and, to a lesser extent, state Medicaid programs. The Company monitors its revenues and receivables from these reimbursement sources, as well as long-term care facilities and other third party insurance payors, and reduces revenue at the revenue recognition date to properly account for the variable consideration due to anticipated differences between billed and reimbursed amounts. Accordingly, the total revenues and receivables reported in the Company’s consolidated financial statements are recorded at the amount expected to be ultimately received from these payors. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient co-payments associated with Medicare Part D, certain state Medicaid programs, Medicare Part B and certain third party payors typically are not collected at the time products are delivered or services are rendered, but are billed to the individuals as part of normal billing procedures and subject to normal accounts receivable collections procedures.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Walk-In Medical Clinics</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For services provided by the Company’s walk-in medical clinics, revenue recognition occurs for completed services provided to patients, with adjustments taken for third party payor contractual obligations and patient direct bill historical collection rates.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disaggregation of Revenue</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table disaggregates the Company’s revenue by major source in each segment for the years ended December 31, 2021, 2020 and 2019:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:28.737%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.390%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.944%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.390%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.944%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.390%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.569%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.390%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.390%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.462%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Health Care<br/>Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pharmacy<br/>Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retail/<br/>LTC</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Corporate/<br/>Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intersegment<br/>Eliminations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consolidated<br/>Totals</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Major goods/services lines:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Pharmacy</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">152,262 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">76,121 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(43,765)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">184,618 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Front Store</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">21,315 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">21,315 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Premiums</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">76,064 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">76,132 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net investment income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">586 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">596 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,199 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,536 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">760 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,652 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8,847 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">82,186 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">153,022 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">100,105 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">721 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(43,923)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">292,111 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Pharmacy Services distribution channel:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Pharmacy network</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">91,715 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Mail choice </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">60,547 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">760 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">153,022 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Major goods/services lines:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Pharmacy</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">141,116 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">70,176 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(40,003)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">171,289 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Front Store</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">19,655 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">19,655 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Premiums</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">69,301 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">69,364 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net investment income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">483 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">315 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">798 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,683 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">822 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,367 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(320)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">75,467 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">141,938 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">91,198 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">426 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(40,323)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">268,706 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Pharmacy Services distribution channel:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Pharmacy network</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"> (1) </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">85,045 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Mail choice </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">56,071 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">822 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">141,938 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Major goods/services lines:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Pharmacy</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">140,896 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">66,442 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(41,413)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">165,925 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Front Store</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">19,422 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">19,422 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Premiums</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">63,031 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">63,122 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net investment income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">599 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">412 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,011 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,974 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">595 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">744 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7,296 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">69,604 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">141,491 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">86,608 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">512 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(41,439)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">256,776 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Pharmacy Services distribution channel:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Pharmacy network</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">88,755 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Mail choice </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">52,141 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">595 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">141,491 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Pharmacy Services pharmacy network is defined as claims filled at retail and specialty retail pharmacies, including the Company’s retail pharmacies and LTC pharmacies, but excluding Maintenance Choice</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> activity, which is included within the mail choice category. Maintenance Choice permits eligible client plan members to fill their maintenance prescriptions through mail order delivery or at a CVS Pharmacy retail store for the same price as mail order.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Pharmacy Services mail choice is defined as claims filled at a Pharmacy Services mail order facility, which includes specialty mail claims inclusive of Specialty Connect</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> claims picked up at a retail pharmacy, as well as prescriptions filled at the Company’s retail pharmacies under the Maintenance Choice</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">program. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Balances</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities primarily represent the Company’s obligation to transfer additional goods or services to a customer for which the Company has received consideration, and include ExtraBucks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rewards and unredeemed Company gift cards. The consideration received remains a contract liability until goods or services have been provided to the customer. In addition, the Company recognizes breakage on Company gift cards based on historical redemption patterns.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about receivables and contract liabilities from contracts with customers as of December 31, 2021 and 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.432%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables (included in accounts receivable, net)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,932 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,101 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities (included in accrued expenses)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2021 and 2020, the contract liabilities balance includes increases related to customers’ earnings in ExtraBucks Rewards or issuances of Company gift cards and decreases for revenues recognized during the period as a result of the redemption of ExtraBucks Rewards or Company gift cards and breakage of Company gift cards. Below is a summary of such changes:</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table disaggregates the Company’s revenue by major source in each segment for the years ended December 31, 2021, 2020 and 2019:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:28.737%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.390%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.944%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.390%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.944%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.390%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.569%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.390%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.390%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.462%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Health Care<br/>Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pharmacy<br/>Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retail/<br/>LTC</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Corporate/<br/>Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intersegment<br/>Eliminations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consolidated<br/>Totals</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Major goods/services lines:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Pharmacy</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">152,262 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">76,121 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(43,765)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">184,618 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Front Store</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">21,315 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">21,315 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Premiums</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">76,064 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">76,132 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net investment income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">586 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">596 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,199 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,536 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">760 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,652 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8,847 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">82,186 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">153,022 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">100,105 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">721 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(43,923)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">292,111 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Pharmacy Services distribution channel:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Pharmacy network</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">91,715 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Mail choice </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">60,547 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">760 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">153,022 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Major goods/services lines:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Pharmacy</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">141,116 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">70,176 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(40,003)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">171,289 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Front Store</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">19,655 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">19,655 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Premiums</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">69,301 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">69,364 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net investment income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">483 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">315 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">798 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,683 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">822 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,367 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(320)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">75,467 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">141,938 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">91,198 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">426 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(40,323)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">268,706 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Pharmacy Services distribution channel:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Pharmacy network</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"> (1) </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">85,045 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Mail choice </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">56,071 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">822 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">141,938 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Major goods/services lines:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Pharmacy</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">140,896 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">66,442 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(41,413)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">165,925 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Front Store</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">19,422 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">19,422 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Premiums</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">63,031 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">63,122 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net investment income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">599 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">412 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,011 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,974 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">595 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">744 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7,296 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">69,604 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">141,491 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">86,608 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">512 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(41,439)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">256,776 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Pharmacy Services distribution channel:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Pharmacy network</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">88,755 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Mail choice </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">52,141 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">595 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">141,491 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Pharmacy Services pharmacy network is defined as claims filled at retail and specialty retail pharmacies, including the Company’s retail pharmacies and LTC pharmacies, but excluding Maintenance Choice</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> activity, which is included within the mail choice category. Maintenance Choice permits eligible client plan members to fill their maintenance prescriptions through mail order delivery or at a CVS Pharmacy retail store for the same price as mail order.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Pharmacy Services mail choice is defined as claims filled at a Pharmacy Services mail order facility, which includes specialty mail claims inclusive of Specialty Connect</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> claims picked up at a retail pharmacy, as well as prescriptions filled at the Company’s retail pharmacies under the Maintenance Choice</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span>program. 0 152262000000 76121000000 0 -43765000000 184618000000 0 0 21315000000 0 0 21315000000 76064000000 0 0 68000000 0 76132000000 586000000 0 17000000 596000000 0 1199000000 5536000000 760000000 2652000000 57000000 -158000000 8847000000 82186000000 153022000000 100105000000 721000000 -43923000000 292111000000 91715000000 60547000000 760000000 153022000000 0 141116000000 70176000000 0 -40003000000 171289000000 0 0 19655000000 0 0 19655000000 69301000000 0 0 63000000 0 69364000000 483000000 0 0 315000000 0 798000000 5683000000 822000000 1367000000 48000000 -320000000 7600000000 75467000000 141938000000 91198000000 426000000 -40323000000 268706000000 85045000000 56071000000 822000000 141938000000 0 140896000000 66442000000 0 -41413000000 165925000000 0 0 19422000000 0 0 19422000000 63031000000 0 0 91000000 0 63122000000 599000000 0 0 412000000 0 1011000000 5974000000 595000000 744000000 9000000 -26000000 7296000000 69604000000 141491000000 86608000000 512000000 -41439000000 256776000000 88755000000 52141000000 595000000 141491000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about receivables and contract liabilities from contracts with customers as of December 31, 2021 and 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.432%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables (included in accounts receivable, net)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,932 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,101 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities (included in accrued expenses)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2021 and 2020, the contract liabilities balance includes increases related to customers’ earnings in ExtraBucks Rewards or issuances of Company gift cards and decreases for revenues recognized during the period as a result of the redemption of ExtraBucks Rewards or Company gift cards and breakage of Company gift cards. Below is a summary of such changes:</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.432%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rewards earnings and gift card issuances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redemption and breakage</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(371)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(359)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 7932000000 7101000000 87000000 71000000 71000000 73000000 387000000 357000000 371000000 359000000 87000000 71000000 <div style="padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Products Sold</span></div><div style="padding-right:4.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for cost of products sold as follows:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pharmacy Services Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of products sold includes: (i) the cost of prescription drugs sold during the reporting period directly through the Company’s mail service dispensing pharmacies and indirectly through the Company’s retail pharmacy network, (ii) shipping and handling costs, and (iii) the operating costs of the Company’s mail service dispensing pharmacies and client service operations and related information technology support costs including depreciation and amortization. The cost of prescription drugs sold component of cost of products sold includes: (i) the cost of the prescription drugs purchased from manufacturers or distributors and shipped to members in clients’ benefit plans from the Company’s mail service dispensing pharmacies, net of any volume-related or other discounts (see “Vendor Allowances and Purchase Discounts” below) and (ii) the cost of prescription drugs sold (including retail co-payments) through the Company’s retail pharmacy network under contracts where the Company is the principal, net of any volume-related or other discounts. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Retail/LTC Segment</span></div>Cost of products sold includes: the cost of merchandise sold during the reporting period, including prescription drug costs, and the related purchasing costs, warehousing and delivery costs (including depreciation and amortization) and actual and estimated inventory losses. <div style="padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vendor Allowances and Purchase Discounts </span></div><div style="padding-right:4.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for vendor allowances and purchase discounts as follows: </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pharmacy Services Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmacy Services segment receives purchase discounts on products purchased. Contractual arrangements with vendors, including manufacturers, wholesalers and retail pharmacies, normally provide for the Pharmacy Services segment to receive </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">purchase discounts from established list prices in one, or a combination, of the following forms: (i) a direct discount at the time of purchase, (ii) a discount for the prompt payment of invoices or (iii) when products are purchased indirectly from a manufacturer (e.g., through a wholesaler or retail pharmacy), a discount (or rebate) paid subsequent to dispensing. These rebates are recognized when prescriptions are dispensed and are generally calculated and billed to manufacturers within 30 days of the end of each completed quarter. Historically, the effect of adjustments resulting from the reconciliation of rebates recognized to the amounts billed and collected has not been material to the Company’s operating results or financial condition. The Company accounts for the effect of any such differences as a change in accounting estimate in the period the reconciliation is completed. The Pharmacy Services segment also receives additional discounts under its wholesaler contracts if it exceeds contractually defined purchase volumes. In addition, the Pharmacy Services segment receives fees from pharmaceutical manufacturers for administrative services. Purchase discounts and administrative service fees are recorded as a reduction of cost of products sold. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Retail/LTC Segment</span></div>Vendor allowances received by the Retail/LTC segment reduce the carrying cost of inventory and are recognized in cost of products sold when the related inventory is sold, unless they are specifically identified as a reimbursement of incremental costs for promotional programs and/or other services provided. Amounts that are directly linked to advertising commitments are recognized as a reduction of advertising expense (included in operating expenses) when the related advertising commitment is satisfied. Any amounts received in excess of the actual cost incurred also reduce the carrying cost of inventory. The total value of any upfront payments received from vendors that are linked to purchase commitments is initially deferred. The deferred amounts are then amortized to reduce cost of products sold over the life of the contract based upon sales volume. The total value of any upfront payments received from vendors that are not linked to purchase commitments is also initially deferred. The deferred amounts are then amortized to reduce cost of products sold on a straight-line basis over the life of the related contract. The total amortization of these upfront payments was not material to the Company’s consolidated financial statements in any of the periods presented. P30D <div style="padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Health Care Reform</span></div><div style="padding-right:4.5pt"><span><br/></span></div><div style="padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Health Insurer Fee</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since January 1, 2014, the ACA has imposed an annual premium-based health insurer fee (“HIF”) for each calendar year, payable in September, which was not deductible for tax purposes. The Company has been required to estimate a liability for the HIF at the beginning of the calendar year in which the fee was payable with a corresponding deferred asset that was amortized ratably to operating expenses over the calendar year. The Company recorded the liability for the HIF in accrued expenses and recorded the deferred asset in other current assets. In December 2019, the HIF was repealed for calendar years after 2020, therefore there was no expense related to the HIF in the year ended December 31, 2021. In the year ended December 31, 2020, operating expenses included $1.0 billion related to the Company’s share of the HIF. There was no expense related to the HIF in 2019, since there was a one-year suspension of the HIF for 2019. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Adjustment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ACA established a permanent risk adjustment program to transfer funds from qualified individual and small group insurance plans with below average risk scores to plans with above average risk scores. Based on the risk of the Company’s qualified plan members relative to the average risk of members of other qualified plans in comparable markets, as defined by the ACA, the Company estimates its ultimate risk adjustment receivable (recorded in accounts receivable) or payable (recorded in accrued expenses) for the current calendar year and reflects the pro-rata year-to-date impact as an adjustment to premium revenue. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Corridor</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ACA established a temporary risk corridor program, which expired at the end of 2016, for qualified individual and small group health insurance plans. Under this program, health insurance companies were to make payments to, or receive payments from, the U.S. Department of Health and Human Services (“HHS”) based on their ratio of allowable costs to target costs (as defined by the ACA). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company filed a lawsuit in August 2019 to recover the $313 million it was owed under the ACA’s risk corridor program, which had been stayed pending the Supreme Court decision. In April 2020, the U.S. Supreme Court ruled that health insurance companies may sue the federal government for amounts owed as calculated under the ACA’s temporary risk corridor program. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the Company received the $313 million it was owed under the ACA’s risk corridor program. The Company recorded the risk corridor payment as an increase to premium revenue in the year ended December 31, 2020. After considering </span></div>offsetting items such as the ACA’s minimum MLR rebate requirements and premium taxes, the Company recorded pre-tax income of $307 million and after-tax income of $223 million during the year ended December 31, 2020. 0 1000000000 0 313000000 313000000 307000000 223000000 Advertising Costs Advertising costs, which are reduced by the portion funded by vendors, are expensed when the related advertising takes place. Net advertising costs, which are included in operating expenses, were $523 million, $461 million and $396 million in 2021, 2020 and 2019, respectively. 523000000 461000000 396000000 Stock-Based CompensationStock-based compensation is measured at the grant date based on the fair value of the award and is recognized as expense over the requisite service period of the stock award (generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJhYjlmYjcxZDY3NjQ4ZjBiNzU4ODY5ZjE2MGI3ZjRiL3NlYzpiYWI5ZmI3MWQ2NzY0OGYwYjc1ODg2OWYxNjBiN2Y0Yl8xMzAvZnJhZzoxNDIzNTEzMTYwZjM0MTdlYTIxYWEzMWM4M2FiY2IyOS90ZXh0cmVnaW9uOjE0MjM1MTMxNjBmMzQxN2VhMjFhYTMxYzgzYWJjYjI5XzcyMzEz_ea62d84c-7b65-4b23-9d75-3a8341c56a52">three</span> to five years) using the straight-line method. P5Y <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year or years in which the differences are expected to reverse. The effect of a change in the tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date of such change.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes deferred tax assets to the extent that it believes these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies, and the Company’s recent operating results. The Company establishes a valuation allowance when it does not consider it more likely than not that a deferred tax asset will be recovered.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records uncertain tax positions on the basis of a two-step process whereby (1) the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and/or penalties related to uncertain tax positions are recognized in the income tax provision.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Measurement of Defined Benefit Pension and Other Postretirement Employee Benefit Plans</span></div><div style="padding-right:4.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors defined benefit pension plans (“pension plans”) and other postretirement employee benefit plans (“OPEB plans”) for its employees and retirees. The Company recognizes the funded status of its pension and OPEB plans on the consolidated balance sheets based on the year-end measurements of plan assets and benefit obligations. When the fair value of plan assets are in excess of the plan benefit obligations, the amounts are reported in other current assets and other assets. When the fair value of plan benefit obligations are in excess of plan assets, the amounts are reported in accrued expenses and other long-term liabilities based on the amount by which the actuarial present value of benefits payable in the next twelve months included in the benefit obligation exceeds the fair value of plan assets. The net periodic benefit cost (income) for the Company’s pension and OPEB plans do not contain a service cost component as these plans have been frozen for an extended period of time. Non-service cost components of pension and postretirement net periodic benefit cost (income) are included in other income in the consolidated statements of operations.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earnings per Share</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings per share is computed using the two-class method. The Company calculates basic earnings per share based on the weighted average number of common shares outstanding for the period. See Note 14 ‘‘Earnings Per Share’’ for additional information.</span></div> Shares Held in TrustThe Company maintains grantor trusts, which held approximately one million shares of its common stock at both December 31, 2021 and 2020. These shares are designated for use under various employee compensation plans. Since the Company holds these shares, they are excluded from the computation of basic and diluted shares outstanding. 1000000 1000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Variable Interest Entities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has investments in (i) a generic pharmaceutical sourcing entity, (ii) certain hedge fund and private equity investments and (iii) certain real estate partnerships that are considered VIEs. The Company does not have a future obligation to fund losses or debts on behalf of these investments; however, it may voluntarily contribute funds. In evaluating whether the Company is the primary beneficiary of a VIE, the Company considers several factors, including whether the Company has (a) the power to direct the activities that most significantly impact the VIE’s economic performance and (b) the obligation to absorb losses and the right to receive benefits that could potentially be significant to the VIE. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities - Primary Beneficiary</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2014, the Company and Cardinal Health, Inc. (“Cardinal”) established Red Oak Sourcing, LLC (“Red Oak”), a generic pharmaceutical sourcing entity in which the Company and Cardinal each own 50%. The Red Oak arrangement had an initial term of ten years. In 2021, the Red Oak arrangement was amended to extend the initial term an additional five years, for a total term of 15 years. Under this arrangement, the Company and Cardinal contributed their sourcing and supply chain expertise to Red Oak and agreed to source and negotiate generic pharmaceutical supply contracts for both companies through Red Oak; however, Red Oak does not own or hold inventory on behalf of either company. No physical assets (e.g., property and equipment) were contributed to Red Oak by either company, and minimal funding was provided to capitalize Red Oak. The Company has determined that it is the primary beneficiary of this VIE because it has the ability to direct the activities of Red Oak. Consequently, the Company consolidates Red Oak in its consolidated financial statements within the Retail/LTC segment. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardinal is required to pay the Company quarterly payments, which began in October 2014 and will extend through June 2029. As milestones are met, the quarterly payments increase. The Company received $183 million from Cardinal during each of the years ended December 31, 2021, 2020 and 2019. The payments reduce the Company’s carrying value of inventory and are recognized in cost of products sold when the related inventory is sold. Amounts reimbursed by Cardinal for the years ended December 31, 2021, 2020 and 2019, and amounts due to or due from Cardinal at December 31, 2021 and 2020 were immaterial.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities - Other Variable Interest Holder</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has invested in certain VIEs for which it has determined that it is not the primary beneficiary, consisting of the following:</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Hedge fund and private equity investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The Company invests in hedge fund and private equity investments in order to generate investment returns for its investment portfolio supporting its insurance businesses.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Real estate partnerships</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The Company invests in various real estate partnerships, including those that construct, own and manage low-income housing developments. For the low income housing development investments, substantially all of the projected benefits to the Company are from tax credits and other tax benefits.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is not the primary beneficiary of these VIEs because the nature of the Company’s involvement with the activities of these VIEs does not give the Company the power to direct the activities that most significantly impact their economic performance. The Company records the amount of its investment in these VIEs as long-term investments on the consolidated balance sheets and recognizes its share of each VIE’s income or losses in net income (loss). The Company’s maximum exposure to loss from these VIEs is limited to its investment balances as disclosed below and the risk of recapture of previously recognized tax credits related to the real estate partnerships, which the Company does not consider significant.</span></div> 0.50 P10Y P5Y P15Y 183000000 183000000 183000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total amount of other variable interest holder VIE assets included in long-term investments on the consolidated balance sheets at December 31, 2021 and 2020 was as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.990%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedge fund investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private equity investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">601 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate partnerships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,289 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,089 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 463000000 342000000 601000000 547000000 225000000 200000000 1289000000 1089000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Related Party Transactions</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an equity method investment in SureScripts, LLC (“SureScripts”), which operates a clinical health information network. The Company utilizes this clinical health information network in providing services to its client plan members and retail customers. The Company expensed fees for the use of this network of $52 million, $56 million and $32 million in the years ended December 31, 2021, 2020 and 2019, respectively. The Company’s investment in and equity in the earnings of SureScripts for all periods presented is immaterial.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an equity method investment in Heartland Healthcare Services, LLC (“Heartland”). Heartland operates several LTC pharmacies in four states. Heartland paid the Company $79 million, $77 million and $96 million for pharmaceutical inventory purchases during the years ended December 31, 2021, 2020 and 2019, respectively. Additionally, the Company performs certain collection functions for Heartland and then transfers those customer cash collections to Heartland. The Company’s investment in and equity in the earnings of Heartland for all periods presented is immaterial.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2021, 2020 and 2019, the Company made charitable contributions of $50 million, $50 million and $30 million, respectively, to the CVS Health Foundation, a non-profit entity that focuses on health, education and community involvement programs. The charitable contributions were recorded as operating expenses in the consolidated statements of operations within the Corporate/Other segment for the years ended December 31, 2021, 2020 and 2019.</span></div> 52000000 56000000 32000000 4 79000000 77000000 96000000 50000000 50000000 30000000 Discontinued OperationsIn connection with certain business dispositions completed between 1995 and 1997, the Company retained guarantees on store lease obligations for a number of former subsidiaries, including Linens ‘n Things and Bob’s Stores, each of which subsequently filed for bankruptcy. The Company’s loss from discontinued operations includes lease-related costs that the Company believes it will likely be required to satisfy pursuant to these lease guarantees. <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of the results of discontinued operations for the year ended December 31, 2020. </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:88.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.573%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations, net of tax</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> -12000000 -3000000 -9000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New Accounting Pronouncements Recently Adopted </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Simplifying the Accounting for Income Taxes </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Financial Accounting Standards Board (“FASB”) issued ASU 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Simplifying the Accounting for Income Taxes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 740). This standard simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in Accounting Standards Codification 740 related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The standard also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The Company adopted this new accounting standard on January 1, 2021. The adoption of this standard did not have a material impact on the Company’s consolidated operating results, cash flows, financial condition or related disclosures.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New Accounting Pronouncements Not Yet Adopted</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Targeted Improvements to the Accounting for Long-Duration Insurance Contracts</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU 2018-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Targeted Improvements to the Accounting for Long-Duration Contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 944). This standard requires the Company to review cash flow assumptions for its long-duration insurance contracts at least annually and recognize the effect of changes in future cash flow assumptions in net income. This standard also requires the Company to update discount rate assumptions quarterly and recognize the effect of changes in these assumptions in other comprehensive income. The rate used to discount the Company’s liability for future policy benefits will be based on an estimate of the yield for an upper-medium grade fixed-income instrument with a duration profile matching that of the Company’s </span></div>liabilities. In addition, this standard changes the amortization method for deferred acquisition costs and requires additional disclosures regarding the long duration insurance contract liabilities in the Company’s interim and annual financial statements. The standard is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022. The Company will adopt the new standard on January 1, 2023, using the modified retrospective transition method as of the earliest period presented for changes to the liability for future policy benefits and deferred acquisition costs. While the Company is still evaluating the impact of the new standard on its financial statements, the Company anticipates an increase to its liability for future policy benefits with a corresponding change in accumulated other comprehensive income as a result of updating the rate used to discount the liabilities to reflect the yield for an upper-medium grade fixed-income instrument compared to the Company’s expected investment yield under the existing guidance. Divestitures<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Divestiture of Workers’ Compensation Business</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 31, 2020, the Company sold its Workers’ Compensation business for approximately $850 million. The results of this business were reported within the Health Care Benefits segment. The Company recorded a pre-tax gain on the divestiture of $269 million in the year ended December 31, 2020, which is reflected as a reduction in operating expenses in the Company’s consolidated statement of operations within the Health Care Benefits segment.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Divestiture of Brazilian Subsidiary</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 1, 2019, the Company sold its Brazilian subsidiary, Onofre, for an immaterial amount. Onofre operated 50 retail pharmacy stores, the results of which historically had been reported within the Retail/LTC segment. The Company recorded a pre-tax loss on the divestiture of $205 million in the year ended December 31, 2019, which primarily relates to the elimination of the cumulative translation adjustment from accumulated other comprehensive income and is reflected in operating expenses in the Company’s consolidated statement of operations within the Retail/LTC segment.</span></div> 850000000 269000000 50 -205000000 Investments<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total investments at December 31, 2021 and 2020 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.309%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.016%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available for sale</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,009 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,231 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,240 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,774 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,414 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,188 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage loans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">844 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">902 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">821 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,047 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,950 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,577 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,577 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,117 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,025 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,142 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,812 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,812 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2021 and 2020, the Company held investments of $450 million and $524 million, respectively, related to the 2012 conversion of an existing group annuity contract from a participating to a non-participating contract. These investments are included in the total investments of large case pensions supporting non-experience-rated products. Although these investments are not accounted for as Separate Accounts assets, they are legally segregated and are not subject to claims that arise out of the Company’s business and only support future policy benefits obligations under that group annuity contract. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Securities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities available for sale at December 31, 2021 and 2020 were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.701%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.014%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,349 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,416 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,947 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,091 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. corporate securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,093 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">682 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,735 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,821 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,993 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">870 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">875 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,278 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,310 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,791 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,792 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable preferred securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,174 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,172 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,240 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,341 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,469 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,556 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,728 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. corporate securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,879 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,023 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,894 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,595 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,918 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">705 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">962 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,046 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,369 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,403 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable preferred securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,396 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,803 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,188 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">There was no allowance for expected credit losses recorded on available-for-sale debt securities at December 31, 2021 or 2020.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Investment risks associated with the Company’s experience-rated products generally do not impact the Company’s consolidated operating results. At December 31, 2021, debt securities with a fair value of $864 million, gross unrealized capital gains of $94 million and gross unrealized capital losses of $2 million and at December 31, 2020, debt securities with a fair value of $919 million, gross unrealized capital gains of $135 million and no gross unrealized capital losses were included in total debt securities, but support experience-rated products. Changes in net unrealized capital gains (losses) on these securities are not reflected in accumulated other comprehensive income.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost and fair value of debt securities at December 31, 2021 are shown below by contractual maturity.  Actual maturities may differ from contractual maturities because securities may be restructured, called or prepaid, or the Company intends to sell a security prior to maturity.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"> Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair <br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due to mature:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than one year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,205 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,218 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One year through five years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,965 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,142 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After five years through ten years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,733 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,910 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater than ten years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,332 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,993 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">870 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">875 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,278 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,310 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,791 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,792 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,174 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,240 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mortgage-Backed and Other Asset-Backed Securities</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company’s residential mortgage-backed securities at December 31, 2021 were issued by the Government National Mortgage Association, the Federal National Mortgage Association or the Federal Home Loan Mortgage Corporation and carry agency guarantees and explicit or implicit guarantees by the U.S. Government. At December 31, 2021, the Company’s residential mortgage-backed securities had an average credit quality rating of AAA and a weighted average duration of 4.7 years.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s commercial mortgage-backed securities have underlying loans that are dispersed throughout the United States. Significant market observable inputs used to value these securities include loss severity and probability of default. At December 31, 2021, these securities had an average credit quality rating of AAA and a weighted average duration of 6.1 years.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s other asset-backed securities have a variety of underlying collateral (e.g., automobile loans, credit card receivables, home equity loans and commercial loans). Significant market observable inputs used to value these securities include the unemployment rate, loss severity and probability of default. At December 31, 2021, these securities had an average credit quality rating of AA and a weighted average duration of 1.0 year.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized below are the debt securities the Company held at December 31, 2021 and 2020 that were in an unrealized capital loss position, aggregated by the length of time the investments have been in that position:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Less than 12 months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Greater than 12 months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions, except number of securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of<br/> Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of<br/> Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of<br/> Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">461 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. corporate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,610 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,296 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,775 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,534 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">838 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">593 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">629 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">574 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,011 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,030 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,037 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,061 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable preferred securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,700 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,800 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">584 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,017 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,384 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. corporate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">869 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">527 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">915 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviewed the securities in the table above and concluded that they are performing assets generating investment income to support the needs of the Company’s business. In performing this review, the Company considered factors such as the quality of the investment security based on research performed by the Company’s internal credit analysts and external rating agencies and the prospects of realizing the carrying value of the security based on the investment’s current prospects for recovery. Unrealized capital losses at December 31, 2021 were generally caused by interest rate increases and not by unfavorable changes in the credit quality associated with these securities. As of December 31, 2021, the Company did not intend to sell these securities, and did not believe it was more likely than not that it would be required to sell these securities prior to the anticipated recovery of their amortized cost basis.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maturity dates for debt securities in an unrealized capital loss position at December 31, 2021 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.818%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.432%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supporting experience-<br/>rated products</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supporting remaining<br/>products</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due to mature:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than one year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One year through five years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,229 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,242 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After five years through ten years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,332 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,365 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater than ten years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">445 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">629 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">568 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">574 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,057 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,061 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,305 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,384 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mortgage Loans</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s mortgage loans are collateralized by commercial real estate. During the years ended December 31, 2021 and 2020, the Company had the following activity in its mortgage loan portfolio:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.432%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New mortgage loans</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage loans fully repaid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage loans foreclosed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses mortgage loans on a regular basis for credit impairments, and assigns a credit quality indicator to each loan. The Company’s credit quality indicator is internally developed and categorizes each loan in its portfolio on a scale from 1 to 7. These indicators are based upon several factors, including current loan-to-value ratios, current and future property cash flow, property condition, market trends, creditworthiness of the borrower and deal structure. </span></div><div><span><br/></span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Category 1 - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Represents loans of superior quality.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Categories 2 to 4 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- Represent loans where credit risk is minimal to acceptable; however, these loans may display some susceptibility to economic changes.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Categories 5 and 6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Represent loans where credit risk is not substantial, but these loans warrant management’s close attention.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Category 7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Represents loans where collections are potentially at risk; if necessary, an impairment is recorded.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based upon the Company’s assessments at December 31, 2021 and 2020, the amortized cost basis of the Company’s mortgage loans within each credit quality indicator by year of origination was as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.100%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.943%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.943%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.943%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.943%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.943%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.943%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.950%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost Basis by Year of Origination</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions, except credit quality indicator</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2017</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Prior</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 to 4</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">861 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 and 6</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">902 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 to 4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">595 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">952 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 and 6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,047 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2021 scheduled mortgage loan principal repayments were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:88.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.842%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">902 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Investment Income</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sources of net investment income for the years ended December 31, 2021, 2020 and 2019 were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">634 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage loans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross investment income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">781 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">854 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment income (excluding net realized capital gains or losses)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,023 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">746 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">812 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net realized capital gains </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,199 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">798 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,011 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Net realized capital gains are net of yield-related impairment losses on debt securities of $42 million and $49 million for the years ended December 31, 2021 and 2020, respectively. There were no credit-related losses on debt securities in the years ended December 31, 2021 and 2020. Net realized capital gains are net of other-than-temporary impairment (“OTTI”) losses on debt securities of $24 million for the year ended December 31, 2019.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Net investment income includes $38 million, $42 million and $44 million for the years ended December 31, 2021, 2020 and 2019, respectively, related to investments supporting experience-rated products. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capital gains and losses recognized during the year ended December 31, 2021 related to investments in equity securities held as of December 31, 2021 were not material.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluding amounts related to experience-rated products, proceeds from the sale of available-for-sale debt securities and the related gross realized capital gains and losses in the years ended December 31, 2021, 2020 and 2019 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,572 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,913 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,773 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross realized capital gains</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross realized capital losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total investments at December 31, 2021 and 2020 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.309%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.016%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available for sale</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,009 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,231 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,240 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,774 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,414 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,188 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage loans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">844 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">902 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">821 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,047 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,950 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,577 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,577 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,117 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,025 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,142 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,812 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,812 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 3009000000 20231000000 23240000000 2774000000 18414000000 21188000000 58000000 844000000 902000000 226000000 821000000 1047000000 50000000 1950000000 2000000000 0 1577000000 1577000000 3117000000 23025000000 26142000000 3000000000 20812000000 23812000000 450000000 524000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities available for sale at December 31, 2021 and 2020 were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.701%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.014%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,349 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,416 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,947 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,091 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. corporate securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,093 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">682 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,735 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,821 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,993 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">870 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">875 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,278 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,310 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,791 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,792 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable preferred securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,174 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,172 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,240 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,341 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,469 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,556 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,728 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. corporate securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,879 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,023 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,894 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,595 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,918 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">705 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">962 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,046 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,369 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,403 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable preferred securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,396 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,803 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,188 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">There was no allowance for expected credit losses recorded on available-for-sale debt securities at December 31, 2021 or 2020.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Investment risks associated with the Company’s experience-rated products generally do not impact the Company’s consolidated operating results. At December 31, 2021, debt securities with a fair value of $864 million, gross unrealized capital gains of $94 million and gross unrealized capital losses of $2 million and at December 31, 2020, debt securities with a fair value of $919 million, gross unrealized capital gains of $135 million and no gross unrealized capital losses were included in total debt securities, but support experience-rated products. Changes in net unrealized capital gains (losses) on these securities are not reflected in accumulated other comprehensive income.</span></div> 2349000000 70000000 3000000 2416000000 2947000000 148000000 4000000 3091000000 9093000000 682000000 40000000 9735000000 2821000000 196000000 24000000 2993000000 870000000 15000000 10000000 875000000 1278000000 44000000 12000000 1310000000 2791000000 14000000 13000000 2792000000 25000000 3000000 0 28000000 22174000000 1172000000 106000000 23240000000 2341000000 128000000 0 2469000000 2556000000 172000000 0 2728000000 7879000000 1023000000 8000000 8894000000 2595000000 324000000 1000000 2918000000 673000000 32000000 0 705000000 962000000 84000000 0 1046000000 2369000000 36000000 2000000 2403000000 21000000 4000000 0 25000000 19396000000 1803000000 11000000 21188000000 0 0 864000000 94000000 2000000 919000000 135000000 0 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost and fair value of debt securities at December 31, 2021 are shown below by contractual maturity.  Actual maturities may differ from contractual maturities because securities may be restructured, called or prepaid, or the Company intends to sell a security prior to maturity.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"> Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair <br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due to mature:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than one year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,205 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,218 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One year through five years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,965 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,142 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After five years through ten years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,733 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,910 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater than ten years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,332 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,993 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">870 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">875 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,278 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,310 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,791 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,792 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,174 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,240 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1205000000 1218000000 6965000000 7142000000 4733000000 4910000000 4332000000 4993000000 870000000 875000000 1278000000 1310000000 2791000000 2792000000 22174000000 23240000000 P4Y8M12D P6Y1M6D P1Y <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized below are the debt securities the Company held at December 31, 2021 and 2020 that were in an unrealized capital loss position, aggregated by the length of time the investments have been in that position:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Less than 12 months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Greater than 12 months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions, except number of securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of<br/> Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of<br/> Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of<br/> Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">461 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. corporate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,610 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,296 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,775 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,534 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">838 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">593 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">629 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">574 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,011 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,030 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,037 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,061 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable preferred securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,700 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,800 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">584 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,017 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,384 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. corporate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">869 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">527 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">915 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maturity dates for debt securities in an unrealized capital loss position at December 31, 2021 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.818%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.432%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supporting experience-<br/>rated products</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supporting remaining<br/>products</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due to mature:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than one year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One year through five years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,229 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,242 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After five years through ten years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,332 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,365 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater than ten years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">445 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">629 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">568 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">574 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,057 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,061 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,305 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,384 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 43 242000000 2000000 10 40000000 1000000 53 282000000 3000000 233 428000000 3000000 13 33000000 1000000 246 461000000 4000000 1610 2296000000 31000000 165 238000000 9000000 1775 2534000000 40000000 449 747000000 20000000 57 91000000 4000000 506 838000000 24000000 165 593000000 9000000 10 36000000 1000000 175 629000000 10000000 188 462000000 7000000 35 112000000 5000000 223 574000000 12000000 1011 2030000000 12000000 26 31000000 1000000 1037 2061000000 13000000 1 2000000 0 1 3000000 0 2 5000000 0 3700 6800000000 84000000 317 584000000 22000000 4017 7384000000 106000000 32 205000000 0 0 0 0 32 205000000 0 49 83000000 0 0 0 0 49 83000000 0 145 155000000 8000000 2 0 0 147 155000000 8000000 41 69000000 1000000 5 5000000 0 46 74000000 1000000 23 26000000 0 3 0 0 26 26000000 0 22 75000000 0 0 0 0 22 75000000 0 156 256000000 1000000 49 41000000 1000000 205 297000000 2000000 468 869000000 10000000 59 46000000 1000000 527 915000000 11000000 2000000 0 49000000 1000000 51000000 1000000 13000000 1000000 2229000000 32000000 2242000000 33000000 33000000 1000000 1332000000 26000000 1365000000 27000000 17000000 0 445000000 10000000 462000000 10000000 4000000 0 625000000 10000000 629000000 10000000 6000000 0 568000000 12000000 574000000 12000000 4000000 0 2057000000 13000000 2061000000 13000000 79000000 2000000 7305000000 104000000 7384000000 106000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s mortgage loans are collateralized by commercial real estate. During the years ended December 31, 2021 and 2020, the Company had the following activity in its mortgage loan portfolio:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.432%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New mortgage loans</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage loans fully repaid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage loans foreclosed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2021 scheduled mortgage loan principal repayments were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:88.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.842%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">902 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 262000000 63000000 373000000 187000000 0 0 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based upon the Company’s assessments at December 31, 2021 and 2020, the amortized cost basis of the Company’s mortgage loans within each credit quality indicator by year of origination was as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.100%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.943%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.943%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.943%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.943%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.943%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.943%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.950%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost Basis by Year of Origination</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions, except credit quality indicator</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2017</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Prior</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 to 4</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">861 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 and 6</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">902 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 to 4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">595 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">952 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 and 6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,047 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0 0 0 0 0 28000000 28000000 255000000 48000000 40000000 72000000 97000000 349000000 861000000 0 0 0 3000000 4000000 6000000 13000000 0 0 0 0 0 0 0 255000000 48000000 40000000 75000000 101000000 383000000 902000000 0 0 0 22000000 37000000 59000000 46000000 96000000 91000000 124000000 595000000 952000000 0 0 3000000 4000000 29000000 36000000 0 0 0 0 0 0 46000000 96000000 94000000 150000000 661000000 1047000000 58000000 100000000 210000000 76000000 177000000 281000000 902000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sources of net investment income for the years ended December 31, 2021, 2020 and 2019 were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">634 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage loans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross investment income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">781 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">854 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment income (excluding net realized capital gains or losses)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,023 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">746 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">812 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net realized capital gains </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,199 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">798 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,011 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Net realized capital gains are net of yield-related impairment losses on debt securities of $42 million and $49 million for the years ended December 31, 2021 and 2020, respectively. There were no credit-related losses on debt securities in the years ended December 31, 2021 and 2020. Net realized capital gains are net of other-than-temporary impairment (“OTTI”) losses on debt securities of $24 million for the year ended December 31, 2019.</span></div>(2)Net investment income includes $38 million, $42 million and $44 million for the years ended December 31, 2021, 2020 and 2019, respectively, related to investments supporting experience-rated products. 634000000 598000000 589000000 55000000 60000000 71000000 381000000 123000000 194000000 1070000000 781000000 854000000 47000000 35000000 42000000 1023000000 746000000 812000000 176000000 52000000 199000000 1199000000 798000000 1011000000 -42000000 -49000000 0 0 -24000000 38000000 42000000 44000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluding amounts related to experience-rated products, proceeds from the sale of available-for-sale debt securities and the related gross realized capital gains and losses in the years ended December 31, 2021, 2020 and 2019 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,572 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,913 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,773 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross realized capital gains</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross realized capital losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 3572000000 3913000000 4773000000 72000000 80000000 146000000 -14000000 -62000000 -17000000 Fair Value<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Company’s consolidated financial statements in accordance with GAAP requires certain assets and liabilities to be reflected at their fair value and others to be reflected on another basis, such as an adjusted historical cost basis. In this note, the Company provides details on the fair value of financial assets and liabilities and how it determines those fair values. The Company presents this information for those financial instruments that are measured at fair value for which the change in fair value impacts net income attributable to CVS Health or other comprehensive income separately from other financial assets and liabilities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Instruments Measured at Fair Value on the Consolidated Balance Sheets</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company’s financial instruments are measured at fair value on the consolidated balance sheets. The fair values of these instruments are based on valuations that include inputs that can be classified within one of three levels of a hierarchy established by GAAP.  The following are the levels of the hierarchy and a brief description of the type of valuation information (“valuation inputs”) that qualifies a financial asset or liability for each level:</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 – Unadjusted quoted prices for identical assets or liabilities in active markets.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 – Valuation inputs other than Level 1 that are based on observable market data. These include: quoted prices for similar assets in active markets, quoted prices for identical assets in inactive markets, valuation inputs that are observable that are not prices (such as interest rates and credit risks) and valuation inputs that are derived from or corroborated by observable markets.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 – Developed from unobservable data, reflecting the Company’s assumptions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets and liabilities are classified based upon the lowest level of input that is significant to the valuation. When quoted prices in active markets for identical assets and liabilities are available, the Company uses these quoted market prices to determine the fair value of financial assets and liabilities and classifies these assets and liabilities in Level 1. In other cases where a quoted market price for identical assets and liabilities in an active market is either not available or not observable, the Company estimates fair value using valuation methodologies based on available and observable market information or by using a matrix pricing model. These financial assets and liabilities are classified in Level 2. If quoted market prices are not available, the Company determines fair value using broker quotes or an internal analysis of each investment’s financial performance and cash flow projections. Thus, financial assets and liabilities may be classified in Level 3 even though there may be some significant inputs that may be observable.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a description of the valuation methodologies used for the Company’s financial assets and liabilities that are measured at fair value, including the general classification of such assets and liabilities pursuant to the valuation hierarchy.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">–</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of cash and cash equivalents approximates fair value as maturities are less than three months. When quoted prices are available in an active market, cash equivalents are classified in Level 1 of the fair value hierarchy. Fair values of cash equivalent instruments that do not trade on a regular basis in active markets are classified as Level 2.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> –</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Where quoted prices are available in an active market, debt securities are classified in Level 1 of the fair value hierarchy. The Company’s Level 1 debt securities consist primarily of U.S. Treasury securities.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the Company’s Level 2 debt securities are obtained using models, such as matrix pricing, which use quoted market prices of debt securities with similar characteristics or discounted cash flows to estimate fair value. The </span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company reviews these prices to ensure they are based on observable market inputs that include quoted prices for similar assets in active markets, quoted prices for identical assets in inactive markets and inputs that are observable that are not prices (such as interest rates and credit risks). The Company also reviews the methodologies and the assumptions used to calculate prices from these observable inputs. On a quarterly basis, the Company selects a sample of its Level 2 debt securities’ prices and compares them to prices provided by a secondary source. Variances over a specified threshold are identified and reviewed to confirm the price provided by the primary source represents an appropriate estimate of fair value. In addition, the Company’s internal investment team consistently compares the prices obtained for select Level 2 debt securities to the team’s own independent estimates of fair value for those securities. The Company obtained one price for each of its Level 2 debt securities and did not adjust any of those prices at December 31, 2021 or 2020. </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also values certain debt securities using Level 3 inputs. For Level 3 debt securities, fair values are determined by outside brokers or, in the case of certain private placement securities, are priced internally. Outside brokers determine the value of these debt securities through a combination of their knowledge of the current pricing environment and market flows. The Company did not have any broker quoted debt securities for the years ended December 31, 2021 and 2020. For some private placement securities, the Company’s internal staff determines the value of these debt securities by analyzing spreads of corporate and sector indices as well as interest spreads of comparable public bonds. Examples of these private placement Level 3 debt securities include certain U.S. and foreign securities and certain tax-exempt municipal securities.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> –</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company currently has two classifications of equity securities: those that are publicly traded and those that are privately placed. Publicly-traded equity securities are classified in Level 1 because quoted prices are available for these securities in an active market. For privately placed equity securities, there is no active market; therefore, these securities are classified in Level 3 because the Company prices these securities through an internal analysis of each investment’s financial statements and cash flow projections. Significant unobservable inputs consist of earnings and revenue multiples, discount for lack of marketability and comparability adjustments. An increase or decrease in any of these unobservable inputs would have resulted in a change in the fair value measurement. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no financial liabilities measured at fair value on a recurring basis on the consolidated balance sheets at December 31, 2021 or 2020. Financial assets measured at fair value on a recurring basis on the consolidated balance sheets at December 31, 2021 and 2020 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.699%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,954 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,454 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,408 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,372 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,416 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,086 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,091 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. corporate securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,697 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,735 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,983 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,993 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">875 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">875 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,310 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,310 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,789 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,792 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable preferred securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,372 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,812 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,240 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,440 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,266 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,817 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,985 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,869 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,854 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,370 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,469 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,727 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,728 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. corporate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,842 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,894 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,918 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,918 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">705 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">705 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,046 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,046 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,403 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,403 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable preferred securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,370 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,764 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,188 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,372 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,633 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,089 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the balances of Level 3 financial assets during the year ended December 31, 2021 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:20.683%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.434%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">States, <br/>municipalities<br/> and political <br/>subdivisions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S.<br/>corporate<br/>securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign<br/>securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other asset-<br/>backed<br/>securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Redeemable<br/>preferred<br/>securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Equity<br/>securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net realized and unrealized capital gains (losses):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in earnings </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfers into Level 3, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in unrealized capital losses included in other comprehensive income associated with Level 3 financial assets which were held as of December 31, 2021 was $4 million during the year ended December 31, 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the balances of Level 3 financial assets during the year ended December 31, 2020 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.859%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">States, <br/>municipalities<br/> and political <br/>subdivisions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S.<br/>corporate<br/>securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Redeemable<br/>preferred<br/>securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Equity<br/>securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net realized and unrealized capital gains (losses):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in earnings </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfers into Level 3, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in unrealized capital losses included in other comprehensive income associated with Level 3 financial assets which were held as of December 31, 2020 was $4 million during the year ended December 31, 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total gross transfers into (out of) Level 3 during the years ended December 31, 2021 and 2020 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.867%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross transfers into Level 3</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross transfers out of Level 3</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net transfers into Level 3</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Instruments Not Measured at Fair Value on the Consolidated Balance Sheets</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value and estimated fair value classified by level of fair value hierarchy for financial instruments carried on the consolidated balance sheets at adjusted cost or contract value at December 31, 2021 and 2020 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.584%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.700%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"> Estimated Fair Value</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage loans</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">902 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">907 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">907 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment contract liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">With a fixed maturity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Without a fixed maturity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,176 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,157 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,157 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage loans</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,047 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment contract liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">With a fixed maturity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Without a fixed maturity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,647 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,940 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,940 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">It was not practical to estimate the fair value of these cost-method investments as it represents shares of unlisted companies. See Note 1 ‘‘Significant Accounting Policies’’ for additional information regarding the valuation of cost method investments. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Separate Accounts Measured at Fair Value on the Consolidated Balance Sheets</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separate Accounts assets relate to the Company’s large case pensions products which represent funds maintained to meet specific objectives of contract holders. Since contract holders bear the investment risk of these assets, a corresponding Separate Accounts liability has been established equal to the assets. These assets and liabilities are carried at fair value. Net investment income and capital gains and losses on Separate Accounts assets accrue directly to such contract holders. The assets of each account are legally segregated and are not subject to claims arising from the Company’s other businesses. Deposits, withdrawals, net investment income and realized and unrealized capital gains and losses on Separate Accounts assets are not reflected in the consolidated statements of operations, shareholders’ equity or cash flows.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separate Accounts assets include debt and equity securities. The valuation methodologies used for these assets are similar to the methodologies described above in this Note 4 ‘‘Fair Value.’’ Separate Accounts assets also include investments in common/collective trusts that are carried at fair value. Common/collective trusts invest in other investment funds otherwise known as the underlying funds. The Separate Accounts’ interests in the common/collective trust funds are based on the fair values of the investments of the underlying funds and therefore are classified in Level 2. The assets in the underlying funds primarily consist of equity securities. Investments in common/collective trust funds are valued at their respective net asset value (“NAV”) per share/unit on the valuation date.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separate Accounts financial assets at December 31, 2021 and 2020 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.953%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,233 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,048 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,281 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,465 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,634 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,099 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common/collective trusts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,235 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,782 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,017 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,467 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,385 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,852 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Excludes $70 million and $29 million of other receivables at December 31, 2021 and 2020, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2021 and 2020, the Company had no gross transfers of Separate Accounts financial assets into or out of Level 3.</span></div> 0 0 Financial assets measured at fair value on a recurring basis on the consolidated balance sheets at December 31, 2021 and 2020 were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.699%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,954 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,454 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,408 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,372 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,416 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,086 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,091 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. corporate securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,697 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,735 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,983 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,993 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">875 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">875 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,310 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,310 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,789 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,792 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable preferred securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,372 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,812 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,240 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,440 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,266 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,817 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,985 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,869 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,854 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,370 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,469 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,727 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,728 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. corporate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,842 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,894 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,918 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,918 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">705 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">705 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,046 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,046 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,403 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,403 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable preferred securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,370 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,764 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,188 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,372 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,633 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,089 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 4954000000 4454000000 0 9408000000 2372000000 44000000 0 2416000000 0 3086000000 5000000 3091000000 0 9697000000 38000000 9735000000 0 2983000000 10000000 2993000000 0 875000000 0 875000000 0 1310000000 0 1310000000 0 2789000000 3000000 2792000000 0 28000000 0 28000000 2372000000 20812000000 56000000 23240000000 114000000 0 55000000 169000000 7440000000 25266000000 111000000 32817000000 3985000000 3869000000 0 7854000000 2370000000 99000000 0 2469000000 0 2727000000 1000000 2728000000 0 8842000000 52000000 8894000000 0 2918000000 0 2918000000 0 705000000 0 705000000 0 1046000000 0 1046000000 0 2403000000 0 2403000000 0 24000000 1000000 25000000 2370000000 18764000000 54000000 21188000000 17000000 0 30000000 47000000 6372000000 22633000000 84000000 29089000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the balances of Level 3 financial assets during the year ended December 31, 2021 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:20.683%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.434%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">States, <br/>municipalities<br/> and political <br/>subdivisions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S.<br/>corporate<br/>securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign<br/>securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other asset-<br/>backed<br/>securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Redeemable<br/>preferred<br/>securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Equity<br/>securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net realized and unrealized capital gains (losses):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in earnings </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfers into Level 3, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the balances of Level 3 financial assets during the year ended December 31, 2020 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.859%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">States, <br/>municipalities<br/> and political <br/>subdivisions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S.<br/>corporate<br/>securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Redeemable<br/>preferred<br/>securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Equity<br/>securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net realized and unrealized capital gains (losses):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in earnings </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfers into Level 3, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in unrealized capital losses included in other comprehensive income associated with Level 3 financial assets which were held as of December 31, 2020 was $4 million during the year ended December 31, 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total gross transfers into (out of) Level 3 during the years ended December 31, 2021 and 2020 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.867%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross transfers into Level 3</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross transfers out of Level 3</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net transfers into Level 3</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1000000 52000000 0 0 1000000 30000000 84000000 0 -10000000 0 0 2000000 13000000 5000000 0 -3000000 0 0 -1000000 0 -4000000 0 1000000 0 3000000 0 13000000 17000000 1000000 1000000 0 0 2000000 1000000 5000000 0 1000000 0 0 0 0 1000000 5000000 0 10000000 0 0 0 15000000 5000000 38000000 10000000 3000000 0 55000000 111000000 -4000000 0 37000000 12000000 39000000 88000000 0 -11000000 18000000 -3000000 4000000 0 0 -5000000 0 -5000000 0 27000000 0 3000000 30000000 0 0 24000000 9000000 33000000 0 1000000 0 0 1000000 1000000 0 0 0 1000000 1000000 52000000 1000000 30000000 84000000 -4000000 15000000 1000000 0 0 15000000 1000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value and estimated fair value classified by level of fair value hierarchy for financial instruments carried on the consolidated balance sheets at adjusted cost or contract value at December 31, 2021 and 2020 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.584%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.700%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"> Estimated Fair Value</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage loans</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">902 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">907 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">907 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment contract liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">With a fixed maturity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Without a fixed maturity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,176 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,157 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,157 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage loans</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,047 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment contract liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">With a fixed maturity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Without a fixed maturity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,647 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,940 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,940 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div>(1)It was not practical to estimate the fair value of these cost-method investments as it represents shares of unlisted companies. See Note 1 ‘‘Significant Accounting Policies’’ for additional information regarding the valuation of cost method investments. 902000000 0 0 907000000 907000000 126000000 5000000 0 0 5000000 5000000 336000000 0 0 373000000 373000000 56176000000 64157000000 0 0 64157000000 1047000000 0 0 1070000000 1070000000 145000000 5000000 0 0 5000000 5000000 322000000 0 0 371000000 371000000 64647000000 75940000000 0 0 75940000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separate Accounts financial assets at December 31, 2021 and 2020 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.953%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,233 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,048 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,281 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,465 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,634 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,099 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common/collective trusts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,235 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,782 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,017 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,467 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,385 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,852 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Excludes $70 million and $29 million of other receivables at December 31, 2021 and 2020, respectively.</span></div> 2000000 186000000 0 188000000 2000000 186000000 0 188000000 1233000000 3048000000 0 4281000000 1465000000 2634000000 0 4099000000 0 1000000 0 1000000 0 2000000 0 2000000 0 547000000 0 547000000 0 563000000 0 563000000 1235000000 3782000000 0 5017000000 1467000000 3385000000 0 4852000000 70000000 29000000 0 0 Goodwill and Other Intangibles<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of the changes in the carrying amount of goodwill by segment for the years ended December 31, 2021 and 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.946%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.455%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Health Care<br/>Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pharmacy<br/>Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retail/<br/>LTC</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,361 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,581 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,807 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,749 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divestiture of Workers’ Compensation business</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(505)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(505)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,130 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,615 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,807 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,552 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(431)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(431)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,130 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,615 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,376 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,121 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, the decrease in the carrying amount of goodwill was primarily driven by a goodwill impairment charge related to the LTC reporting unit within the Retail/LTC segment. During the year ended December 31, 2020, the decrease in the carrying amount of goodwill was primarily driven by the divestiture of the Workers’ Compensation business, partially offset by goodwill associated with immaterial acquisitions. See Note 2 ‘‘Divestitures’’ for further discussion regarding the Workers’ Compensation business divestiture.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2021, the Company performed its required annual impairment tests of goodwill. The results of the impairment tests indicated an impairment of the goodwill associated with the LTC reporting unit, as the reporting unit’s carrying value exceeded its fair value as of the testing date. The results of the impairment tests of the remaining reporting units indicated that there was no impairment of goodwill as of the testing date. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, the LTC reporting unit has continued to face challenges that have impacted the Company’s ability to grow the LTC reporting unit’s business at the rate estimated when its 2020 goodwill impairment test was performed. These challenges include lower net facility admissions, net long-term care facility customer losses and the prolonged adverse impact of the COVID-19 pandemic and the emerging new variants, which resulted in more significant declines in occupancy rates experienced by the Company’s long-term care facility customers than previously anticipated. During the third quarter of 2021, LTC management updated their 2021 annual forecast and submitted their long-term plan which showed deterioration in the financial results for the remainder of 2021 and beyond. The Company utilized these updated projections in performing its annual impairment test, which indicated that the fair value of the LTC reporting unit was lower than its carrying value, resulting in a $431 million goodwill impairment charge in the third quarter of 2021. The fair value of the LTC reporting unit was determined using a combination of a discounted cash flow method and a market multiple method. As of December 31, 2021, there was no remaining goodwill balance in the LTC reporting unit. During the third quarter of 2021, the Company also performed an impairment test of the intangible assets of the LTC reporting unit and concluded these assets were not impaired. As of December 31, 2021, there was $2.7 billion of intangible assets related to customer lists in the LTC reporting unit. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2020, the Company performed its required annual impairment tests of goodwill. The results of the impairment tests indicated that there was no impairment of goodwill. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2021 and 2020, cumulative goodwill impairments were $6.6 billion and $6.1 billion, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the Company’s intangible assets as of December 31, 2021 and 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.577%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions, except weighted average life</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Life (years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks (indefinite-lived)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,498 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,498 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer contracts/relationships and covenants not to compete</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,084 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,564)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,520 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,060 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,060)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider networks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,203 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(651)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,552 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value of Business Acquired </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(173)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(279)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,753 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,727)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,026 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.3</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks (indefinite-lived)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,498 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,498 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer contracts/relationships and covenants not to compete</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,952 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,923)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,029 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,060 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(739)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider networks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,203 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(440)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,763 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value of Business Acquired </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">471 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(260)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,623 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,481)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,142 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense for intangible assets totaled $2.3 billion, $2.3 billion and $2.4 billion for the years ended December 31, 2021, 2020 and 2019, respectively. The projected annual amortization expense for the Company’s intangible assets for the next five years is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:88.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.842%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,858 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,826 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,785 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,734 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,494 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of the changes in the carrying amount of goodwill by segment for the years ended December 31, 2021 and 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.946%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.455%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Health Care<br/>Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pharmacy<br/>Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retail/<br/>LTC</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,361 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,581 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,807 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,749 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divestiture of Workers’ Compensation business</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(505)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(505)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,130 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,615 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,807 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,552 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(431)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(431)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,130 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,615 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,376 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,121 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 45361000000 23581000000 10807000000 79749000000 274000000 34000000 0 308000000 505000000 0 0 505000000 45130000000 23615000000 10807000000 79552000000 0 0 431000000 431000000 45130000000 23615000000 10376000000 79121000000 431000000 0 2700000000 6600000000 6100000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the Company’s intangible assets as of December 31, 2021 and 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.577%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions, except weighted average life</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Life (years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks (indefinite-lived)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,498 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,498 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer contracts/relationships and covenants not to compete</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,084 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,564)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,520 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,060 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,060)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider networks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,203 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(651)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,552 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value of Business Acquired </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(173)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(279)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,753 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,727)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,026 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.3</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks (indefinite-lived)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,498 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,498 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer contracts/relationships and covenants not to compete</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,952 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,923)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,029 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,060 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(739)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider networks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,203 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(440)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,763 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value of Business Acquired </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">471 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(260)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,623 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,481)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,142 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2</span></td></tr></table></div> 10498000000 10498000000 25084000000 10564000000 14520000000 P15Y 1060000000 1060000000 0 P3Y 4203000000 651000000 3552000000 P20Y 590000000 173000000 417000000 P20Y 318000000 279000000 39000000 P8Y4M24D 41753000000 12727000000 29026000000 P15Y3M18D 10498000000 10498000000 24952000000 8923000000 16029000000 P14Y10M24D 1060000000 739000000 321000000 P3Y 4203000000 440000000 3763000000 P20Y 590000000 119000000 471000000 P20Y 320000000 260000000 60000000 P7Y8M12D 41623000000 10481000000 31142000000 P15Y2M12D 2300000000 2300000000 2400000000 The projected annual amortization expense for the Company’s intangible assets for the next five years is as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:88.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.842%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,858 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,826 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,785 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,734 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,494 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 1858000000 1826000000 1785000000 1734000000 1494000000 Leases<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases most of its retail stores and mail order facilities and certain distribution centers and corporate offices under operating or finance leases, typically with initial terms of 15 to 25 years. The Company also leases certain equipment and other assets under operating or finance leases, typically with initial terms of 3 to 10 years. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company leases pharmacy space at the stores of another retail chain for which the noncancelable contractual term of the pharmacy lease arrangement exceeds the remaining estimated economic life of the buildings. For these pharmacy lease arrangements, the Company concluded that for accounting purposes the lease term was the remaining estimated economic life of the buildings. Consequently, most of these individual pharmacy leases are finance leases.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the components of net lease cost for the years ended December 31, 2021, 2020 and 2019:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.160%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,633 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,670 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,720 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: sublease income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net lease cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,327 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,350 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,357 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases for the years ended December 31, 2021, 2020 and 2019 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.160%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows paid for operating leases</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,714 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,724 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,701 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows paid for interest portion of finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows paid for principal portion of finance leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,254 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,679 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,824 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases as of December 31, 2021 and 2020 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.800%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.159%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions, except remaining lease term and discount rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating leases:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,122</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,729</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt 0 7pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,646</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,638</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,177</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,757</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,823</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,395</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance leases:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,375</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,107</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(188)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,187</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,001</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,050</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,300</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,083</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average remaining lease term </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in years)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.3</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the maturity of lease liabilities under finance and operating leases as of December 31, 2021:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.453%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Finance<br/>Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Operating<br/>Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,685 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,807 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,613 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,734 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,398 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,509 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,217 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,327 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,054 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,163 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,495 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,103 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,598 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease payments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,068 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,070 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,138 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(768)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,247)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,015)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,300 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,823 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,123 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Future operating lease payments have not been reduced by minimum sublease rentals of $311 million due in the future under noncancelable subleases.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The Company leases pharmacy and clinic space from Target Corporation. Amounts related to such finance and operating leases are reflected above. Pharmacy lease amounts due in excess of the remaining estimated economic life of the buildings of approximately $2.4 billion are not reflected in this table since the estimated economic life of the buildings is shorter than the contractual term of the pharmacy lease arrangement.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sale-Leaseback Transactions</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company finances a portion of its store development program through sale-leaseback transactions. The properties are generally sold at net book value, which generally approximates fair value, and the resulting leases generally qualify and are accounted for as operating leases. The operating leases that resulted from these transactions are included in the tables above. The Company does not have any retained or contingent interests in the stores and does not provide any guarantees, other than a </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">guarantee of lease payments, in connection with the sale-leaseback transactions. There were no sale-leaseback transactions in 2021. Proceeds from sale-leaseback transactions totaled $101 million and $5 million in the years ended December 31, 2020 and 2019, respectively. Gains from sale-leaseback transactions totaled $3 million in the year ended December 31, 2020. There were no material gains from sale-leaseback transactions in the year ended December 31, 2019.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Store Impairment Charges</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its retail store right-of-use and property and equipment assets for impairment at the retail store level, which is the lowest level at which cash flows can be identified. For retail stores where there is an indicator of impairment present, the Company first compares the carrying amount of the asset group to the estimated future cash flows associated with the asset group (undiscounted). If the estimated undiscounted future cash flows used in the analysis are less than the carrying amount of the asset group, an impairment loss calculation is prepared. The impairment loss calculation compares the carrying amount of the asset group to its estimated fair value which is the greater of the asset group’s estimated future cash flows (discounted), or the consideration of what a market participant would pay to lease the assets, net of leasing costs. The Company’s estimate of fair value considers historical results, current operating trends, consolidated sales, profitability and cash flow results and forecasts. For assets which the Company has determined it will be able to sublease, the estimated future cash flows include the estimated sublease income, net of estimated leasing costs. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the carrying value of an asset group exceeds its estimated fair value, an impairment loss is recorded to reduce the value of the asset group to its estimated fair value. As the impaired assets are measured at fair value on a nonrecurring basis primarily using unobservable inputs as of the measurement date, the assets are classified in Level 3 of the fair value hierarchy.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2021, the Company completed a strategic review of its retail business and announced the creation of new formats for its stores to continue to drive higher engagement with customers. As part of this review, the Company evaluated changes in population, consumer buying patterns and future health needs to ensure it has the right kinds of stores in the right locations for consumers and for the business. In connection with this initiative, on November 17, 2021, the Board of Directors of CVS Health Corporation (the “Board”) authorized the closing of approximately 900 retail stores over the next three years. The Company expects to close approximately 300 stores each year between 2022 and 2024. As a result, management determined that there were indicators of impairment with respect to the impacted stores’ asset groups, including the associated operating lease right-of-use assets and property and equipment. A long-lived asset impairment test was performed during the fourth quarter of 2021 and the results of the impairment test indicated that the fair value of certain retail store asset groups was lower than their respective carrying values. Accordingly, in the three months ended December 31, 2021, the Company recorded a store impairment charge of approximately $1.4 billion, consisting of a write down of approximately $1.1 billion related to operating lease right-of-use assets and $261 million related to property and equipment, within the Retail/LTC segment. Subsequent to the impairment loss, the fair value of the associated operating lease right-of use assets and property and equipment were $356 million and $185 million, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, the Company performed reviews of its retail stores and determined it would close 68 underperforming retail pharmacy stores. As a result, management determined that there were indicators of impairment with respect to the impacted stores, including the associated operating lease right-of-use assets. Long-lived asset impairment tests were performed and the results indicated that the fair value of those underperforming retail stores were lower than their respective carrying values. Accordingly, the Company recorded store impairment charges of $231 million during the year ended December 31, 2019, primarily related to these operating lease right-of-use asset impairment charges, within the Retail/LTC segment.</span></div> Leases<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases most of its retail stores and mail order facilities and certain distribution centers and corporate offices under operating or finance leases, typically with initial terms of 15 to 25 years. The Company also leases certain equipment and other assets under operating or finance leases, typically with initial terms of 3 to 10 years. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company leases pharmacy space at the stores of another retail chain for which the noncancelable contractual term of the pharmacy lease arrangement exceeds the remaining estimated economic life of the buildings. For these pharmacy lease arrangements, the Company concluded that for accounting purposes the lease term was the remaining estimated economic life of the buildings. Consequently, most of these individual pharmacy leases are finance leases.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the components of net lease cost for the years ended December 31, 2021, 2020 and 2019:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.160%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,633 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,670 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,720 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: sublease income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net lease cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,327 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,350 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,357 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases for the years ended December 31, 2021, 2020 and 2019 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.160%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows paid for operating leases</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,714 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,724 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,701 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows paid for interest portion of finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows paid for principal portion of finance leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,254 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,679 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,824 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases as of December 31, 2021 and 2020 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.800%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.159%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions, except remaining lease term and discount rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating leases:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,122</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,729</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt 0 7pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,646</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,638</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,177</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,757</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,823</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,395</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance leases:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,375</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,107</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(188)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,187</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,001</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,050</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,300</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,083</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average remaining lease term </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in years)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.3</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the maturity of lease liabilities under finance and operating leases as of December 31, 2021:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.453%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Finance<br/>Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Operating<br/>Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,685 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,807 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,613 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,734 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,398 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,509 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,217 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,327 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,054 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,163 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,495 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,103 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,598 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease payments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,068 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,070 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,138 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(768)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,247)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,015)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,300 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,823 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,123 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Future operating lease payments have not been reduced by minimum sublease rentals of $311 million due in the future under noncancelable subleases.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The Company leases pharmacy and clinic space from Target Corporation. Amounts related to such finance and operating leases are reflected above. Pharmacy lease amounts due in excess of the remaining estimated economic life of the buildings of approximately $2.4 billion are not reflected in this table since the estimated economic life of the buildings is shorter than the contractual term of the pharmacy lease arrangement.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sale-Leaseback Transactions</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company finances a portion of its store development program through sale-leaseback transactions. The properties are generally sold at net book value, which generally approximates fair value, and the resulting leases generally qualify and are accounted for as operating leases. The operating leases that resulted from these transactions are included in the tables above. The Company does not have any retained or contingent interests in the stores and does not provide any guarantees, other than a </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">guarantee of lease payments, in connection with the sale-leaseback transactions. There were no sale-leaseback transactions in 2021. Proceeds from sale-leaseback transactions totaled $101 million and $5 million in the years ended December 31, 2020 and 2019, respectively. Gains from sale-leaseback transactions totaled $3 million in the year ended December 31, 2020. There were no material gains from sale-leaseback transactions in the year ended December 31, 2019.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Store Impairment Charges</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its retail store right-of-use and property and equipment assets for impairment at the retail store level, which is the lowest level at which cash flows can be identified. For retail stores where there is an indicator of impairment present, the Company first compares the carrying amount of the asset group to the estimated future cash flows associated with the asset group (undiscounted). If the estimated undiscounted future cash flows used in the analysis are less than the carrying amount of the asset group, an impairment loss calculation is prepared. The impairment loss calculation compares the carrying amount of the asset group to its estimated fair value which is the greater of the asset group’s estimated future cash flows (discounted), or the consideration of what a market participant would pay to lease the assets, net of leasing costs. The Company’s estimate of fair value considers historical results, current operating trends, consolidated sales, profitability and cash flow results and forecasts. For assets which the Company has determined it will be able to sublease, the estimated future cash flows include the estimated sublease income, net of estimated leasing costs. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the carrying value of an asset group exceeds its estimated fair value, an impairment loss is recorded to reduce the value of the asset group to its estimated fair value. As the impaired assets are measured at fair value on a nonrecurring basis primarily using unobservable inputs as of the measurement date, the assets are classified in Level 3 of the fair value hierarchy.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2021, the Company completed a strategic review of its retail business and announced the creation of new formats for its stores to continue to drive higher engagement with customers. As part of this review, the Company evaluated changes in population, consumer buying patterns and future health needs to ensure it has the right kinds of stores in the right locations for consumers and for the business. In connection with this initiative, on November 17, 2021, the Board of Directors of CVS Health Corporation (the “Board”) authorized the closing of approximately 900 retail stores over the next three years. The Company expects to close approximately 300 stores each year between 2022 and 2024. As a result, management determined that there were indicators of impairment with respect to the impacted stores’ asset groups, including the associated operating lease right-of-use assets and property and equipment. A long-lived asset impairment test was performed during the fourth quarter of 2021 and the results of the impairment test indicated that the fair value of certain retail store asset groups was lower than their respective carrying values. Accordingly, in the three months ended December 31, 2021, the Company recorded a store impairment charge of approximately $1.4 billion, consisting of a write down of approximately $1.1 billion related to operating lease right-of-use assets and $261 million related to property and equipment, within the Retail/LTC segment. Subsequent to the impairment loss, the fair value of the associated operating lease right-of use assets and property and equipment were $356 million and $185 million, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, the Company performed reviews of its retail stores and determined it would close 68 underperforming retail pharmacy stores. As a result, management determined that there were indicators of impairment with respect to the impacted stores, including the associated operating lease right-of-use assets. Long-lived asset impairment tests were performed and the results indicated that the fair value of those underperforming retail stores were lower than their respective carrying values. Accordingly, the Company recorded store impairment charges of $231 million during the year ended December 31, 2019, primarily related to these operating lease right-of-use asset impairment charges, within the Retail/LTC segment.</span></div> P15Y P15Y P25Y P25Y P3Y P3Y P10Y P10Y <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the components of net lease cost for the years ended December 31, 2021, 2020 and 2019:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.160%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,633 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,670 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,720 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: sublease income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net lease cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,327 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,350 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,357 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases for the years ended December 31, 2021, 2020 and 2019 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.160%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows paid for operating leases</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,714 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,724 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,701 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows paid for interest portion of finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows paid for principal portion of finance leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,254 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,679 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,824 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 2633000000 2670000000 2720000000 62000000 56000000 38000000 62000000 58000000 44000000 124000000 114000000 82000000 25000000 22000000 24000000 604000000 599000000 581000000 59000000 55000000 50000000 3327000000 3350000000 3357000000 2714000000 2724000000 2701000000 62000000 58000000 44000000 50000000 34000000 26000000 1254000000 1679000000 1824000000 278000000 313000000 283000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases as of December 31, 2021 and 2020 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.800%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.159%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions, except remaining lease term and discount rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating leases:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,122</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,729</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt 0 7pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,646</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,638</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,177</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,757</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,823</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,395</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance leases:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,375</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,107</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(188)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,187</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,001</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,050</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,300</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,083</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average remaining lease term </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in years)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.3</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 19122000000 20729000000 1646000000 1638000000 18177000000 18757000000 19823000000 20395000000 1375000000 1107000000 188000000 106000000 1187000000 1001000000 50000000 33000000 1250000000 1050000000 1300000000 1083000000 P12Y9M18D P13Y3M18D P20Y P20Y3M18D 0.044 0.045 0.050 0.056 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the maturity of lease liabilities under finance and operating leases as of December 31, 2021:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.453%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Finance<br/>Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Operating<br/>Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,685 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,807 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,613 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,734 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,398 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,509 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,217 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,327 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,054 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,163 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,495 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,103 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,598 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease payments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,068 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,070 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,138 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(768)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,247)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,015)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,300 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,823 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,123 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Future operating lease payments have not been reduced by minimum sublease rentals of $311 million due in the future under noncancelable subleases.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The Company leases pharmacy and clinic space from Target Corporation. Amounts related to such finance and operating leases are reflected above. Pharmacy lease amounts due in excess of the remaining estimated economic life of the buildings of approximately $2.4 billion are not reflected in this table since the estimated economic life of the buildings is shorter than the contractual term of the pharmacy lease arrangement.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the maturity of lease liabilities under finance and operating leases as of December 31, 2021:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.453%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Finance<br/>Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Operating<br/>Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,685 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,807 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,613 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,734 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,398 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,509 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,217 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,327 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,054 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,163 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,495 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,103 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,598 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease payments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,068 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,070 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,138 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(768)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,247)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,015)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,300 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,823 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,123 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Future operating lease payments have not been reduced by minimum sublease rentals of $311 million due in the future under noncancelable subleases.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The Company leases pharmacy and clinic space from Target Corporation. Amounts related to such finance and operating leases are reflected above. Pharmacy lease amounts due in excess of the remaining estimated economic life of the buildings of approximately $2.4 billion are not reflected in this table since the estimated economic life of the buildings is shorter than the contractual term of the pharmacy lease arrangement.</span></div> 122000000 2685000000 2807000000 121000000 2613000000 2734000000 111000000 2398000000 2509000000 110000000 2217000000 2327000000 109000000 2054000000 2163000000 1495000000 14103000000 15598000000 2068000000 26070000000 28138000000 768000000 6247000000 7015000000 1300000000 19823000000 21123000000 311000000 2400000000 101000000 5000000 3000000 0 900 P3Y 300 1400000000 1100000000 261000000 356000000 185000000 68 231000000 Health Care Costs Payable<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is information about incurred and cumulative paid health care claims development as of December 31, 2021, net of reinsurance, and the total IBNR liabilities plus expected development on reported claims included within the net incurred claims amounts. See Note 1 ‘‘Significant Accounting Policies’’ for information on how the Company estimates IBNR reserves and health care costs payable as well as changes to those methodologies, if any. The Company’s estimate of IBNR liabilities is primarily based on trend and completion factors. Claim frequency is not used in the calculation of the Company’s liability. In addition, it is impracticable to disclose claim frequency information for health care claims due to the Company’s inability to gather consistent claim frequency information across its multiple claims processing systems. Any claim frequency count disclosure would not be comparable across the Company’s different claim processing systems and would not be consistent from period to period based on the volume of claims processed through each system. As a result, health care claim count frequency is not included in the disclosures below.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information about incurred and paid health care claims development for the year ended December 31, 2020 is presented as required unaudited supplemental information.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.367%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.376%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Incurred Health Care Claims,<br/>Net of Reinsurance<br/>For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date of Service</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Unaudited)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,529 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,804 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,830 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,634 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cumulative Paid Health Care Claims,<br/>Net of Reinsurance<br/>For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date of Service</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Unaudited)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,567 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,590 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,190 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All outstanding liabilities for health care costs payable prior to 2020, net of reinsurance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total outstanding liabilities for health care costs payable, net of reinsurance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,574 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2021, the Company’s liabilities for IBNR plus expected development on reported claims totaled approximately $6.6 billion. Substantially all of the Company’s liabilities for IBNR plus expected development on reported claims at December 31, 2021 related to the current calendar year.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of the December 31, 2021 health care net incurred and paid claims development tables to the health care costs payable liability on the consolidated balance sheet is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.695%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.105%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-duration health care costs payable, net of reinsurance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,574 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reinsurance recoverables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premium deficiency reserve</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance lines other than short duration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total health care costs payable</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,808 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the components of the change in health care costs payable during the years ended December 31, 2021, 2020 and 2019:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.160%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care costs payable, beginning of period </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,936 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,879 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,147 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Reinsurance recoverables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care costs payable, beginning of period, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,926 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,874 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,143 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions, net</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">414 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Components of incurred health care costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,761 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,835 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,723 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(788)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(429)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(524)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total incurred health care costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,973 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,406 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,199 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Claims paid</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,323 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,770 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,158 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,792 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,009 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,314 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total claims paid</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,115 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,779 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,472 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Premium deficiency reserve</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care costs payable, end of period, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,800 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,926 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,874 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Reinsurance recoverables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care costs payable, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,808 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,936 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,879 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Total incurred health care costs for the years ended December 31, 2021, 2020 and 2019 in the table above exclude (i) $16 million, $11 million and $4 million, respectively, for a premium deficiency reserve related to the Company’s Medicaid products, (ii) $59 million, $41 million and $41 million, respectively, of benefit costs recorded in the Health Care Benefits segment that are included in other insurance liabilities on the consolidated balance sheets and (iii) $212 million, $221 million and $285 million, respectively, of benefit costs recorded in the Corporate/Other segment that are included in other insurance liabilities on the consolidated balance sheets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s estimates of prior years’ health care costs payable decreased by $788 million, $429 million and $524 million in 2021, 2020 and 2019, respectively, because claims were settled for amounts less than originally estimated (i.e., the amount of claims incurred was lower than originally estimated), primarily due to lower health care cost trends as well as the actual claim submission time being faster than originally assumed (i.e., the Company’s completion factors were higher than originally assumed) in estimating health care costs payable at the end of the prior year. This development does not directly correspond to an increase in the Company’s operating results as these reductions were offset by estimated current period health care costs when the Company established the estimate of the current year health care costs payable.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information about incurred and paid health care claims development for the year ended December 31, 2020 is presented as required unaudited supplemental information.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.367%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.376%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Incurred Health Care Claims,<br/>Net of Reinsurance<br/>For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date of Service</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Unaudited)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,529 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,804 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,830 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,634 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cumulative Paid Health Care Claims,<br/>Net of Reinsurance<br/>For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date of Service</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Unaudited)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,567 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,590 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,190 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All outstanding liabilities for health care costs payable prior to 2020, net of reinsurance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total outstanding liabilities for health care costs payable, net of reinsurance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,574 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 54529000000 53804000000 62830000000 116634000000 47567000000 53590000000 54600000000 108190000000 130000000 8574000000 6600000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of the December 31, 2021 health care net incurred and paid claims development tables to the health care costs payable liability on the consolidated balance sheet is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.695%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.105%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-duration health care costs payable, net of reinsurance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,574 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reinsurance recoverables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premium deficiency reserve</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance lines other than short duration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total health care costs payable</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,808 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 8574000000 8000000 16000000 210000000 8808000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the components of the change in health care costs payable during the years ended December 31, 2021, 2020 and 2019:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.160%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care costs payable, beginning of period </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,936 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,879 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,147 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Reinsurance recoverables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care costs payable, beginning of period, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,926 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,874 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,143 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions, net</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">414 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Components of incurred health care costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,761 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,835 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,723 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(788)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(429)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(524)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total incurred health care costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,973 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,406 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,199 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Claims paid</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,323 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,770 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,158 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,792 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,009 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,314 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total claims paid</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,115 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,779 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,472 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Premium deficiency reserve</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care costs payable, end of period, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,800 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,926 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,874 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Reinsurance recoverables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care costs payable, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,808 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,936 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,879 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Total incurred health care costs for the years ended December 31, 2021, 2020 and 2019 in the table above exclude (i) $16 million, $11 million and $4 million, respectively, for a premium deficiency reserve related to the Company’s Medicaid products, (ii) $59 million, $41 million and $41 million, respectively, of benefit costs recorded in the Health Care Benefits segment that are included in other insurance liabilities on the consolidated balance sheets and (iii) $212 million, $221 million and $285 million, respectively, of benefit costs recorded in the Corporate/Other segment that are included in other insurance liabilities on the consolidated balance sheets.</span></div> 7936000000 6879000000 6147000000 10000000 5000000 4000000 7926000000 6874000000 6143000000 0 414000000 0 64761000000 55835000000 52723000000 -788000000 -429000000 -524000000 63973000000 55406000000 52199000000 56323000000 48770000000 46158000000 6792000000 6009000000 5314000000 63115000000 54779000000 51472000000 16000000 11000000 4000000 8800000000 7926000000 6874000000 8000000 10000000 5000000 8808000000 7936000000 6879000000 16000000 11000000 4000000 59000000 41000000 41000000 212000000 221000000 285000000 -788000000 -429000000 -524000000 Borrowings and Credit Agreements<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the Company’s borrowings as of December 31, 2021 and 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.215%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.452%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Long-term debt</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.35% senior notes due March 2021</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,038 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Floating rate notes due March 2021 (0.950% at December 31, 2020)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.125% senior notes due May 2021</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">222 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.125% senior notes due June 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.125% senior notes due June 2021</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">203 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.45% senior notes due June 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">187 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.5% senior notes due July 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.75% senior notes due November 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.75% senior notes due December 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.75% senior notes due December 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">399 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">399 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.7% senior notes due March 2023</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,336 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8% senior notes due June 2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4% senior notes due December 2023</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">414 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">414 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.375% senior notes due August 2024</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">650 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">650 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.625% senior notes due August 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.5% senior notes due November 2024</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5% senior notes due December 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">299 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">299 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.1% senior notes due March 2025</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">950 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">950 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.875% senior notes due July 2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,828 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,828 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.875% senior notes due June 2026</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3% senior notes due August 2026</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.625% senior notes due April 2027</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.25% senior notes due June 2027</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">372 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">372 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.3% senior notes due August 2027</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.3% senior notes due March 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,050 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.25% senior notes due August 2029</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.75% senior notes due April 2030</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.75% senior notes due August 2030</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.875% senior notes due February 2031</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.125% senior notes due September 2031</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.875% senior notes due July 2035</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">652 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">652 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.625% senior notes due June 2036</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">771 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">771 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.75% senior notes due December 2037</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">533 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">533 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.78% senior notes due March 2038</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.125% senior notes due September 2039</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">447 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">447 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.125% senior notes due April 2040</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.7% senior notes due August 2040</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.75% senior notes due May 2041</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5% senior notes due May 2042</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.125% senior notes due November 2042</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.3% senior notes due December 2043</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.75% senior notes due March 2044</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">375 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">375 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.125% senior notes due July 2045</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.875% senior notes due August 2047</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.05% senior notes due March 2048</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.25% senior notes due April 2050</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJhYjlmYjcxZDY3NjQ4ZjBiNzU4ODY5ZjE2MGI3ZjRiL3NlYzpiYWI5ZmI3MWQ2NzY0OGYwYjc1ODg2OWYxNjBiN2Y0Yl8xNTEvZnJhZzo2ZjlhMmQyYmUzZGQ0NWZiOTlmMWQ5NWFhOGM2NWZlYy90YWJsZTo4MGRmOWZjYmM2NmU0ZjMwODYxOWQzNDhkMmMyZWZlMi90YWJsZXJhbmdlOjgwZGY5ZmNiYzY2ZTRmMzA4NjE5ZDM0OGQyYzJlZmUyXzU2LTAtMS0xLTE5NjM1_55ac48cb-f36e-4b9d-8b69-3e86d1c383ef"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJhYjlmYjcxZDY3NjQ4ZjBiNzU4ODY5ZjE2MGI3ZjRiL3NlYzpiYWI5ZmI3MWQ2NzY0OGYwYjc1ODg2OWYxNjBiN2Y0Yl8xNTEvZnJhZzo2ZjlhMmQyYmUzZGQ0NWZiOTlmMWQ5NWFhOGM2NWZlYy90YWJsZTo4MGRmOWZjYmM2NmU0ZjMwODYxOWQzNDhkMmMyZWZlMi90YWJsZXJhbmdlOjgwZGY5ZmNiYzY2ZTRmMzA4NjE5ZDM0OGQyYzJlZmUyXzU2LTAtMS0xLTE5NjM1_fc260d98-5cca-40f0-8e2a-2fb2b3ac6249">Finance lease liabilities</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,083 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">320 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">326 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt principal</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56,743 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65,318 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt premiums</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">219 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">238 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt discounts and deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(786)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(909)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56,176 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64,647 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,205)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,440)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51,971 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59,207 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company’s required repayments of debt principal due during each of the next five years and thereafter, as of December 31, 2021:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:88.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.842%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,154 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,719 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,706 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,785 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,507 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,572 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,443 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt principal</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,743 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">See Note 6 ‘‘Leases’’ for a summary of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">maturities of the Company’s finance lease liabilities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Short-term Borrowings</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commercial Paper and Back-up Credit Facilities</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have any commercial paper outstanding as of December 31, 2021 or 2020. In connection with its commercial paper program, the Company maintains a $2.0 billion, five-year unsecured back-up revolving credit facility, which expires on May 17, 2023, a $2.0 billion, five-year unsecured back-up revolving credit facility, which expires on May 16, 2024, and a $2.0 billion, five-year unsecured back-up revolving credit facility, which expires on May 11, 2026. The credit facilities allow for borrowings at various rates that are dependent, in part, on the Company’s public debt ratings and require the Company to pay a weighted average quarterly facility fee of approximately 0.03%, regardless of usage. As of December 31, 2021 and 2020, there were no borrowings outstanding under any of the Company’s back-up credit facilities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Federal Home Loan Bank of Boston (“FHLBB”)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A subsidiary of the Company is a member of the FHLBB. As a member, the subsidiary has the ability to obtain cash advances, subject to certain minimum collateral requirements. The maximum borrowing capacity available from the FHLBB as of December 31, 2021 was approximately $995 million. At both December 31, 2021 and 2020, there were no outstanding advances from the FHLBB.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-term Borrowings</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Notes</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 18, 2021, the Company issued $1.0 billion aggregate principal amount of 2.125% unsecured senior notes due September 15, 2031 for total proceeds of $987 million, net of discounts, underwriting fees and offering expenses. The net proceeds of this offering were used for the purchase of senior notes in connection with the Company’s cash tender offer in August 2021 as described below.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Notes</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 16, 2020, the Company issued $750 million aggregate principal amount of 1.3% unsecured senior notes due August 21, 2027 and $1.25 billion aggregate principal amount of 1.875% unsecured senior notes due February 28, 2031 for total proceeds of approximately $1.99 billion, net of discounts and underwriting fees. The $750 million aggregate principal amount of 1.3% unsecured senior notes represent a further issuance of the Company’s 1.3% unsecured senior notes due August 21, 2027 initially issued in an aggregate principal amount of $1.5 billion on August 21, 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 21, 2020, the Company issued $1.5 billion aggregate principal amount of 1.3% unsecured senior notes due August 21, 2027, $1.25 billion aggregate principal amount of 1.75% unsecured senior notes due August 21, 2030 and $1.25 billion aggregate principal amount of 2.7% unsecured senior notes due August 21, 2040 (collectively, the “August 2020 Notes”) for total proceeds of approximately $3.97 billion, net of discounts and underwriting fees.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 31, 2020, the Company issued $750 million aggregate principal amount of 3.625% unsecured senior notes due April 1, 2027, $1.5 billion aggregate principal amount of 3.75% unsecured senior notes due April 1, 2030, $1.0 billion aggregate principal amount of 4.125% unsecured senior notes due April 1, 2040 and $750 million aggregate principal amount of 4.25% </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unsecured senior notes due April 1, 2050 (collectively, the “March 2020 Notes”) for total proceeds of approximately $3.95 billion, net of discounts and underwriting fees.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net proceeds of these offerings were used for general corporate purposes, which may include working capital, capital expenditures, as well as the repurchase and/or repayment of indebtedness.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During March 2020, the Company entered into several interest rate swap transactions to manage interest rate risk. These agreements were designated as cash flow hedges and were used to hedge the exposure to variability in future cash flows resulting from changes in interest rates related to the anticipated issuance of the March 2020 Notes. In connection with the issuance of the March 2020 Notes, the Company terminated all outstanding cash flow hedges. The Company paid a net amount of $7 million to the hedge counterparties upon termination, which was recorded as a loss, net of tax, of $5 million in accumulated other comprehensive income and will be reclassified as interest expense over the life of the March 2020 Notes. See Note 13 ‘‘Other Comprehensive Income’’ for additional information. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Early Extinguishments of Debt</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the Company redeemed for cash the remaining $2.3 billion of its outstanding 3.7% senior notes due 2023. In connection with the early redemption of such senior notes, the Company paid a make-whole premium of $80 million in excess of the aggregate principal amount of the senior notes that were redeemed, wrote-off $8 million of unamortized deferred financing costs and incurred $1 million in fees, for a total loss on early extinguishment of debt of $89 million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, the Company purchased approximately $2.0 billion of its outstanding 4.3% senior notes due 2028 through a cash tender offer. In connection with the purchase of such senior notes, the Company paid a premium of $332 million in excess of the aggregate principal amount of the senior notes that were purchased, wrote-off $26 million of unamortized deferred financing costs and incurred $5 million in fees, for a total loss on early extinguishment of debt of $363 million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Company purchased $4.5 billion of its outstanding senior notes through cash tender offers. The senior notes purchased included the following: $113 million of its 4.0% senior notes due 2023, $1.4 billion of its 3.7% senior notes due 2023, $1.0 billion of its 4.1% senior notes due 2025 and $2.0 billion of its 4.3% senior notes due 2028. In connection with the purchase of such senior notes, the Company paid a premium of $619 million in excess of the aggregate principal amount of the senior notes that were purchased, wrote-off $45 million of unamortized deferred financing costs and incurred $10 million in fees, for a total loss on early extinguishment of debt of $674 million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company purchased $6.0 billion of its outstanding senior notes through cash tender offers. The senior notes purchased included the following: $723 million of its 4.0% senior notes due 2023, $2.3 billion of its 3.7% senior notes due 2023 and $3.0 billion of its 4.1% senior notes due 2025. In connection with the purchase of such senior notes, the Company paid a premium of $706 million in excess of the aggregate principal amount of the senior notes that were purchased, wrote-off $47 million of unamortized deferred financing costs and incurred $13 million in fees, for a total loss on early extinguishment of debt of $766 million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Company purchased $4.0 billion of its outstanding senior notes through cash tender offers. The senior notes purchased included the following: $1.3 billion of its 3.125% senior notes due 2020, $723 million of its floating rate notes due 2020, $328 million of its 4.125% senior notes due 2021, $297 million of 4.125% senior notes due 2021 issued by Aetna Inc. (“Aetna”), $413 million of 5.45% senior notes due 2021 issued by Coventry Health Care, Inc., a wholly-owned subsidiary of Aetna, and $962 million of its 3.35% senior notes due 2021. In connection with the purchase of such senior notes, the Company paid a premium of $76 million in excess of the aggregate principal amount of the senior notes that were purchased, incurred $8 million in fees and recognized a net gain of $5 million on the write-off of net unamortized deferred financing premiums, for a net loss on early extinguishment of debt of $79 million. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Covenants</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s back-up revolving credit facilities, unsecured senior notes and unsecured floating rate notes contain customary restrictive financial and operating covenants. These covenants do not include an acceleration of the Company’s debt maturities in the event of a downgrade in the Company’s credit ratings. The Company does not believe the restrictions contained in these covenants materially affect its financial or operating flexibility. As of December 31, 2021, the Company was in compliance with all of its debt covenants.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the Company’s borrowings as of December 31, 2021 and 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.215%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.452%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Long-term debt</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.35% senior notes due March 2021</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,038 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Floating rate notes due March 2021 (0.950% at December 31, 2020)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.125% senior notes due May 2021</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">222 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.125% senior notes due June 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.125% senior notes due June 2021</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">203 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.45% senior notes due June 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">187 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.5% senior notes due July 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.75% senior notes due November 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.75% senior notes due December 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.75% senior notes due December 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">399 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">399 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.7% senior notes due March 2023</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,336 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8% senior notes due June 2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4% senior notes due December 2023</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">414 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">414 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.375% senior notes due August 2024</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">650 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">650 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.625% senior notes due August 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.5% senior notes due November 2024</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5% senior notes due December 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">299 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">299 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.1% senior notes due March 2025</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">950 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">950 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.875% senior notes due July 2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,828 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,828 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.875% senior notes due June 2026</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3% senior notes due August 2026</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.625% senior notes due April 2027</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.25% senior notes due June 2027</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">372 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">372 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.3% senior notes due August 2027</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.3% senior notes due March 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,050 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.25% senior notes due August 2029</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.75% senior notes due April 2030</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.75% senior notes due August 2030</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.875% senior notes due February 2031</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.125% senior notes due September 2031</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.875% senior notes due July 2035</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">652 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">652 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.625% senior notes due June 2036</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">771 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">771 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.75% senior notes due December 2037</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">533 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">533 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.78% senior notes due March 2038</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.125% senior notes due September 2039</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">447 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">447 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.125% senior notes due April 2040</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.7% senior notes due August 2040</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.75% senior notes due May 2041</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5% senior notes due May 2042</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.125% senior notes due November 2042</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.3% senior notes due December 2043</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.75% senior notes due March 2044</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">375 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">375 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.125% senior notes due July 2045</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.875% senior notes due August 2047</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.05% senior notes due March 2048</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.25% senior notes due April 2050</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJhYjlmYjcxZDY3NjQ4ZjBiNzU4ODY5ZjE2MGI3ZjRiL3NlYzpiYWI5ZmI3MWQ2NzY0OGYwYjc1ODg2OWYxNjBiN2Y0Yl8xNTEvZnJhZzo2ZjlhMmQyYmUzZGQ0NWZiOTlmMWQ5NWFhOGM2NWZlYy90YWJsZTo4MGRmOWZjYmM2NmU0ZjMwODYxOWQzNDhkMmMyZWZlMi90YWJsZXJhbmdlOjgwZGY5ZmNiYzY2ZTRmMzA4NjE5ZDM0OGQyYzJlZmUyXzU2LTAtMS0xLTE5NjM1_55ac48cb-f36e-4b9d-8b69-3e86d1c383ef"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJhYjlmYjcxZDY3NjQ4ZjBiNzU4ODY5ZjE2MGI3ZjRiL3NlYzpiYWI5ZmI3MWQ2NzY0OGYwYjc1ODg2OWYxNjBiN2Y0Yl8xNTEvZnJhZzo2ZjlhMmQyYmUzZGQ0NWZiOTlmMWQ5NWFhOGM2NWZlYy90YWJsZTo4MGRmOWZjYmM2NmU0ZjMwODYxOWQzNDhkMmMyZWZlMi90YWJsZXJhbmdlOjgwZGY5ZmNiYzY2ZTRmMzA4NjE5ZDM0OGQyYzJlZmUyXzU2LTAtMS0xLTE5NjM1_fc260d98-5cca-40f0-8e2a-2fb2b3ac6249">Finance lease liabilities</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,083 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">320 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">326 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt principal</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56,743 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65,318 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt premiums</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">219 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">238 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt discounts and deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(786)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(909)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56,176 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64,647 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,205)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,440)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51,971 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59,207 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0.0335 0 2038000000 0.00950 0 1000000000 0.04125 0 222000000 0.02125 0 1750000000 0.04125 0 203000000 0.0545 0 187000000 0.035 1500000000 1500000000 0.0275 1000000000 1000000000 0.0275 1250000000 1250000000 0.0475 399000000 399000000 0.037 0 2336000000 0.028 1300000000 1300000000 0.04 414000000 414000000 0.03375 650000000 650000000 0.02625 1000000000 1000000000 0.035 750000000 750000000 0.05 299000000 299000000 0.041 950000000 950000000 0.03875 2828000000 2828000000 0.02875 1750000000 1750000000 0.03 750000000 750000000 0.03625 750000000 750000000 0.0625 372000000 372000000 0.013 2250000000 2250000000 0.043 5000000000 7050000000 0.0325 1750000000 1750000000 0.0375 1500000000 1500000000 0.0175 1250000000 1250000000 0.01875 1250000000 1250000000 0.02125 1000000000 0 0.04875 652000000 652000000 0.06625 771000000 771000000 0.0675 533000000 533000000 0.0478 5000000000 5000000000 0.06125 447000000 447000000 0.04125 1000000000 1000000000 0.027 1250000000 1250000000 0.0575 133000000 133000000 0.045 500000000 500000000 0.04125 500000000 500000000 0.053 750000000 750000000 0.0475 375000000 375000000 0.05125 3500000000 3500000000 0.03875 1000000000 1000000000 0.0505 8000000000 8000000000 0.0425 750000000 750000000 1300000000 1083000000 320000000 326000000 56743000000 65318000000 219000000 238000000 786000000 909000000 56176000000 64647000000 4205000000 5440000000 51971000000 59207000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company’s required repayments of debt principal due during each of the next five years and thereafter, as of December 31, 2021:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:88.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.842%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,154 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,719 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,706 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,785 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,507 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,572 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,443 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt principal</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,743 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">See Note 6 ‘‘Leases’’ for a summary of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">maturities of the Company’s finance lease liabilities.</span></div> 4154000000 1719000000 2706000000 3785000000 2507000000 40572000000 55443000000 1300000000 56743000000 0 2000000000 P5Y 2000000000 P5Y 2000000000 P5Y 0.0003 0 0 995000000 0 0 1000000000 0.02125 987000000 750000000 0.013 1250000000 0.01875 1990000000 750000000 0.013 0.013 1500000000 1500000000 0.013 1250000000 0.0175 1250000000 0.027 3970000000 750000000 0.03625 1500000000 0.0375 1000000000 0.04125 750000000 0.0425 3950000000 7000000 -5000000 2300000000 0.037 -80000000 8000000 1000000 -89000000 2000000000 0.043 -332000000 26000000 5000000 -363000000 4500000000 113000000 0.040 1400000000 0.037 1000000000 0.041 2000000000 0.043 -619000000 45000000 10000000 -674000000 6000000000 723000000 0.040 2300000000 0.037 3000000000 0.041 -706000000 47000000 13000000 -766000000 4000000000 1300000000 0.03125 723000000 328000000 0.04125 297000000 0.04125 413000000 0.0545 962000000 0.0335 -76000000 8000000 5000000 -79000000 Pension Plans and Other Postretirement Benefits<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Defined Contribution Plans</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the Company sponsors several active 401(k) savings plans that cover all employees who meet plan eligibility requirements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company makes matching contributions consistent with the provisions of the respective plans. At the participant’s option, account balances, including the Company’s matching contribution, can be invested among various investment options under each plan. The CVS Health Future Fund 401(k) Plan offers CVS Health Corporation’s common stock fund as an investment option. The Company also maintains nonqualified, unfunded deferred compensation plans for certain key employees. The plans provide participants the opportunity to defer portions of their eligible compensation and for certain nonqualified plans, participants receive matching contributions equivalent to what they could have received under the CVS Health Future Fund 401(k) Plan absent certain restrictions and limitations under the Internal Revenue Code. The Company’s contributions under its defined contribution plans were $552 million, $520 million and $550 million in the years ended December 31, 2021, 2020 and 2019, respectively. The Company’s contributions for the year ended December 31, 2019 include contributions to the Aetna 401(k) Plan, which was merged into the CVS Health Future Fund 401(k) Plan on January 1, 2020. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Defined Benefit Pension Plans</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors a tax-qualified defined benefit pension plan that was frozen in 2010 and a nonqualified supplemental pension plan that was frozen in 2007. The Company also sponsors several other defined benefit pension plans that are unfunded nonqualified supplemental retirement plans.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pension Benefit Obligation and Plan Assets</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables outline the change in pension benefit obligation and plan assets over the specified periods:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.867%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in benefit obligation:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit obligation, beginning of year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,462 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,239 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial (gain) loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(408)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(358)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit obligation, end of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,009 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,462 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in plan assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets, beginning of year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,845 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,395 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">783 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employer contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(408)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(358)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets, end of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,677 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,845 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funded status</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the pension benefit obligation during the years ended December 31, 2021 and 2020 was primarily driven by the change in the discount rate during each respective period.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets (liabilities) recognized on the consolidated balance sheets at December 31, 2021 and 2020 for the defined benefit pension plans consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.867%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent assets reflected in other assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">946 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">744 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities reflected in accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent liabilities reflected in other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(250)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(285)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Periodic Benefit Cost (Income)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net periodic benefit cost (income) for the years ended December 31, 2021, 2020 and 2019 are shown below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.869%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of net periodic benefit cost (income):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(317)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(388)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(357)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of net actuarial loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlement losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost (income)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(186)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(218)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(131)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pension Plan Assumptions</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses a series of actuarial assumptions to determine its benefit obligation and net periodic benefit cost (income), the most significant of which include discount rates and expected return on plan assets assumptions. </span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Discount Rates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discount rate is determined using a yield curve as of the annual measurement date. The yield curve consists of a series of individual discount rates, with each discount rate corresponding to a single point in time, based on high-quality bonds. Projected benefit payments are discounted to the measurement date using the corresponding rate from the yield curve that is consistent with the maturity profile of the expected liability cash flows.</span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Return on Plan Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected long-term rate of return on plan assets is determined by using the plan’s target allocation and return expectations based on many factors including forecasted long-term capital market real returns and the inflationary outlook on a plan by plan basis. See “Pension Plan Assets” below for additional details regarding the pension plan assets as of December 31, 2021 and 2020.</span></div><div style="padding-left:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also considers other assumptions including mortality, interest crediting rate, termination and retirement rates and cost of living adjustments. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined its benefit obligation based on the following weighted average assumptions as of December 31, 2021 and 2020:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.867%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined its net periodic benefit cost (income) based on the following weighted average assumptions for the years ended December 31, 2021, 2020 and 2019:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.869%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected long-term rate of return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pension Plan Assets</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s pension plan assets primarily include debt and equity securities held in separate accounts, common/collective trusts and real estate investments. The valuation methodologies used to value these debt and equity securities and common/collective trusts are similar to the methodologies described in Note 4 “Fair Value.” Pension plan assets also include investments in other assets that are carried at fair value. The following is a description of the valuation methodologies used to value real estate investments and these additional investments, including the general classification pursuant to the fair value hierarchy.</span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Real Estate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Real estate investments are valued by independent third party appraisers. The appraisals comply with the Uniform Standards of Professional Appraisal Practice, which include, among other things, the income, cost, and sales comparison approaches to estimating property value. Therefore, these investments are classified in Level 3.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Private equity and hedge fund limited partnerships</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Private equity and hedge fund limited partnerships are carried at fair value which is estimated using the NAV per unit as reported by the administrator of the underlying investment fund as a practical expedient to fair value. Therefore, these investments have been excluded from the fair value table below.</span></div><div style="padding-left:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pension plan assets with changes in fair value measured on a recurring basis at December 31, 2021 were as follows: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.870%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    U.S. government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,223 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,224 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    States, municipalities and political subdivisions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    U.S. corporate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,458 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,458 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Foreign securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Other asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Redeemable preferred securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,223 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,330 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,553 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    U.S. domestic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Domestic real estate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other investments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Real estate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Common/collective trusts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total pension investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,566 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,837 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,781 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The assets in the underlying funds of common/collective trusts consist of $261 million of equity securities and $149 million of debt securities. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Excludes $76 million of other receivables as well as $583 million of private equity limited partnership investments and $237 million of hedge fund limited partnership investments as these amounts are measured at NAV per share or an equivalent and are not subject to leveling within the fair value hierarchy. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pension plan assets with changes in fair value measured on a recurring basis at December 31, 2020 were as follows: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.870%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    U.S. government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">611 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    States, municipalities and political subdivisions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    U.S. corporate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,006 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,006 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Foreign securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Other asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Redeemable preferred securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,887 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,462 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    U.S. domestic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,046 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,046 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Domestic real estate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,598 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,598 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other investments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Real estate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Common/collective trusts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Derivatives</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">606 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total pension investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,291 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,231 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,865 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The assets in the underlying funds of common/collective trusts consist of $84 million of equity securities and $182 million of debt securities. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Excludes $142 million of other receivables as well as $624 million of private equity limited partnership investments and $214 million of hedge fund limited partnership investments as these amounts are measured at NAV per share or an equivalent and are not subject to leveling within the fair value hierarchy. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the balances of Level 3 pension plan assets during the year ended December 31, 2021 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:74.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.759%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.761%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Real estate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases, sales and settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfers out of Level 3</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the balances of Level 3 pension plan assets during the year ended December 31, 2020 were as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.326%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.038%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Real estate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. corporate<br/>securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases, sales and settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfers out of Level 3</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s pension plan invests in a diversified mix of assets designed to generate returns that will enable the plan to meet its future benefit obligations. The risk of unexpected investment and actuarial outcomes is regularly evaluated. This evaluation is performed through forecasting and assessing ranges of investment outcomes over short- and long-term horizons and by assessing the pension plan’s liability characteristics. Complementary investment styles and strategies are utilized by professional investment management firms to further improve portfolio and operational risk characteristics. Public and private equity investments are used primarily to increase overall plan returns. Real estate investments are viewed favorably for their diversification benefits and above-average dividend generation. Fixed income investments provide diversification benefits and liability hedging attributes that are desirable, especially in falling interest rate environments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2021, target investment allocations for the Company’s pension plan were: 12% in equity securities, 77% in fixed income and debt securities, 5% in real estate, 3% in private equity limited partnerships and 3% in hedge funds. Actual asset allocations may differ from target allocations due to tactical decisions to overweight or underweight certain assets or as a result of normal fluctuations in asset values. Asset allocations are consistent with stated investment policies and, as a general rule, periodically rebalanced back to target asset allocations. Asset allocations and investment performance are formally reviewed periodically throughout the year by the pension plan’s Investment Subcommittee. Forecasting of asset and liability growth is performed at least annually.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flows</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally contributes to its tax-qualified pension plan based on minimum funding requirements determined under applicable federal laws and regulations. Employer contributions related to the nonqualified supplemental pension plans generally represent payments to retirees for current benefits. The Company contributed $78 million, $25 million and $25 million to its pension plans during 2021, 2020 and 2019, respectively. No contributions are required for the tax-qualified pension plan in 2022. The Company expects to make an immaterial amount of contributions for all other pension plans in 2022. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the following future benefit payments, which are calculated using the same actuarial assumptions used to measure the pension benefit obligation as of December 31, 2021: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027-2031</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,776 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Multiemployer Pension Plans</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also contributes to a number of multiemployer pension plans under the terms of collective-bargaining agreements that cover its union-represented employees. The risks of participating in these multiemployer plans are different from single-employer pension plans in the following respects: (i) assets contributed to the multiemployer plan by one employer may be used to provide benefits to employees of other participating employers, (ii) if a participating employer stops contributing to the plan, the unfunded obligations of the plan may be borne by the remaining participating employers, and (iii) if the Company chooses to stop participating in some of its multiemployer plans, the Company may be required to pay those plans an amount based on the underfunded status of the applicable plan, which is referred to as a withdrawal liability. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of the multiemployer pension plans in which the Company participates are individually significant to the Company. The Company’s contributions to multiemployer pension plans were $19 million, $19 million and $18 million in 2021, 2020 and 2019, respectively. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Postretirement Benefits</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides postretirement health care and life insurance benefits to certain retirees who meet eligibility requirements. The Company’s funding policy is generally to pay covered expenses as they are incurred. For retiree medical plan accounting, the Company reviews external data and its own historical trends for health care costs to determine the health care cost trend rates. As of December 31, 2021 and 2020, the Company’s other postretirement benefits had an accumulated postretirement benefit obligation of $207 million and $226 million, respectively. Net periodic benefit costs related to these other postretirement benefits were $4 million, $12 million and $7 million in 2021, 2020 and 2019, respectively. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the following future benefit payments, which are calculated using the same actuarial assumptions used to measure the accumulated other postretirement benefit obligation as of December 31, 2021: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:86.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.695%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027-2031</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>Pursuant to various collective bargaining agreements, the Company also contributes to multiemployer health and welfare plans that cover certain union-represented employees. The plans provide postretirement health care and life insurance benefits to certain employees who meet eligibility requirements. The Company’s contributions to multiemployer health and welfare plans totaled $60 million, $54 million and $57 million in 2021, 2020 and 2019, respectively. 552000000 520000000 550000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables outline the change in pension benefit obligation and plan assets over the specified periods:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.867%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in benefit obligation:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit obligation, beginning of year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,462 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,239 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial (gain) loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(408)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(358)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit obligation, end of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,009 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,462 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in plan assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets, beginning of year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,845 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,395 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">783 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employer contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(408)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(358)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets, end of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,677 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,845 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funded status</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables outline the change in pension benefit obligation and plan assets over the specified periods:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.867%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in benefit obligation:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit obligation, beginning of year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,462 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,239 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial (gain) loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(408)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(358)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit obligation, end of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,009 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,462 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in plan assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets, beginning of year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,845 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,395 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">783 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employer contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(408)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(358)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets, end of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,677 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,845 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funded status</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 6462000000 6239000000 110000000 168000000 102000000 -413000000 408000000 358000000 53000000 0 6009000000 6462000000 6845000000 6395000000 215000000 783000000 78000000 25000000 408000000 358000000 53000000 0 6677000000 6845000000 668000000 383000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets (liabilities) recognized on the consolidated balance sheets at December 31, 2021 and 2020 for the defined benefit pension plans consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.867%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent assets reflected in other assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">946 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">744 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities reflected in accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent liabilities reflected in other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(250)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(285)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 946000000 744000000 28000000 76000000 250000000 285000000 668000000 383000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net periodic benefit cost (income) for the years ended December 31, 2021, 2020 and 2019 are shown below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.869%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of net periodic benefit cost (income):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(317)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(388)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(357)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of net actuarial loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlement losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost (income)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(186)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(218)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(131)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 110000000 168000000 225000000 317000000 388000000 357000000 -5000000 -2000000 -1000000 -16000000 0 0 -186000000 -218000000 -131000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined its benefit obligation based on the following weighted average assumptions as of December 31, 2021 and 2020:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.867%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined its net periodic benefit cost (income) based on the following weighted average assumptions for the years ended December 31, 2021, 2020 and 2019:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.869%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected long-term rate of return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 0.028 0.025 0.018 0.029 0.040 0.048 0.063 0.065 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pension plan assets with changes in fair value measured on a recurring basis at December 31, 2021 were as follows: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.870%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    U.S. government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,223 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,224 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    States, municipalities and political subdivisions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    U.S. corporate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,458 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,458 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Foreign securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Other asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Redeemable preferred securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,223 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,330 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,553 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    U.S. domestic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Domestic real estate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other investments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Real estate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Common/collective trusts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total pension investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,566 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,837 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,781 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The assets in the underlying funds of common/collective trusts consist of $261 million of equity securities and $149 million of debt securities. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Excludes $76 million of other receivables as well as $583 million of private equity limited partnership investments and $237 million of hedge fund limited partnership investments as these amounts are measured at NAV per share or an equivalent and are not subject to leveling within the fair value hierarchy. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pension plan assets with changes in fair value measured on a recurring basis at December 31, 2020 were as follows: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.870%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    U.S. government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">611 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    States, municipalities and political subdivisions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    U.S. corporate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,006 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,006 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Foreign securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Other asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Redeemable preferred securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,887 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,462 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    U.S. domestic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,046 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,046 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Domestic real estate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,598 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,598 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other investments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Real estate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Common/collective trusts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Derivatives</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">606 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total pension investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,291 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,231 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,865 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The assets in the underlying funds of common/collective trusts consist of $84 million of equity securities and $182 million of debt securities. </span></div>(2)Excludes $142 million of other receivables as well as $624 million of private equity limited partnership investments and $214 million of hedge fund limited partnership investments as these amounts are measured at NAV per share or an equivalent and are not subject to leveling within the fair value hierarchy. 60000000 97000000 0 157000000 1223000000 1000000 0 1224000000 0 150000000 0 150000000 0 2458000000 0 2458000000 0 202000000 0 202000000 0 277000000 0 277000000 0 76000000 0 76000000 0 162000000 0 162000000 0 4000000 0 4000000 1223000000 3330000000 0 4553000000 201000000 0 0 201000000 81000000 0 0 81000000 1000000 0 0 1000000 283000000 0 0 283000000 0 0 378000000 378000000 0 410000000 0 410000000 0 410000000 378000000 788000000 1566000000 3837000000 378000000 5781000000 261000000 149000000 76000000 583000000 237000000 118000000 81000000 0 199000000 575000000 36000000 0 611000000 0 170000000 0 170000000 0 2006000000 0 2006000000 0 167000000 0 167000000 0 287000000 0 287000000 0 83000000 0 83000000 0 133000000 0 133000000 0 5000000 0 5000000 575000000 2887000000 0 3462000000 1046000000 0 0 1046000000 537000000 0 0 537000000 15000000 0 0 15000000 1598000000 0 0 1598000000 0 0 343000000 343000000 0 266000000 0 266000000 0 -3000000 0 -3000000 0 263000000 343000000 606000000 2291000000 3231000000 343000000 5865000000 84000000 182000000 142000000 624000000 214000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the balances of Level 3 pension plan assets during the year ended December 31, 2021 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:74.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.759%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.761%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Real estate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases, sales and settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfers out of Level 3</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the balances of Level 3 pension plan assets during the year ended December 31, 2020 were as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.326%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.038%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Real estate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. corporate<br/>securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases, sales and settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfers out of Level 3</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 343000000 343000000 43000000 43000000 -8000000 -8000000 0 0 378000000 378000000 353000000 1000000 354000000 -2000000 0 -2000000 -8000000 0 -8000000 0 -1000000 -1000000 343000000 0 343000000 0.12 0.77 0.05 0.03 0.03 78000000 25000000 25000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the following future benefit payments, which are calculated using the same actuarial assumptions used to measure the pension benefit obligation as of December 31, 2021: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027-2031</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,776 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the following future benefit payments, which are calculated using the same actuarial assumptions used to measure the accumulated other postretirement benefit obligation as of December 31, 2021: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:86.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.695%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027-2031</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 371000000 371000000 371000000 371000000 368000000 1776000000 19000000 19000000 18000000 207000000 226000000 4000000 12000000 7000000 12000000 12000000 12000000 12000000 12000000 60000000 60000000 54000000 57000000 Income Taxes<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax provision for continuing operations consisted of the following for the years ended December 31, 2021, 2020 and 2019:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.698%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,285 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,615 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,450 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">665 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">518 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,950 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,133 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,015 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(306)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(450)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(535)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(122)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(428)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(564)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(649)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,522 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,569 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,366 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a reconciliation of the statutory income tax rate to the Company’s effective income tax rate for continuing operations for the years ended December 31, 2021, 2020 and 2019:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.698%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statutory income tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health insurer fee</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basis difference upon disposition of subsidiary</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior year refund claim </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the components of the Company’s deferred income tax assets and liabilities as of December 31, 2021 and 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:78.695%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.711%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease and rents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,563 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,742 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bad debts and other allowances</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss and capital loss carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">568 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll tax deferral</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(325)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(454)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,497 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,774 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retirement benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(334)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(421)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease and rents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,947)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,368)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,381)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,750)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,767)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,568)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,270)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,794)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the Company had net operating and capital loss carryovers of $416 million, which expire between 2022 and 2041. The Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and the Company’s recent operating results. The Company established a valuation allowance of $325 million as of December 31, 2021 because it does not consider it more likely than not that these deferred tax assets will be recovered.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending balance of unrecognized tax benefits in 2021, 2020 and 2019 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.698%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">768 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">655 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to the current year</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions for tax positions of prior years</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expiration of statutes of limitation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">782 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">768 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">655 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CVS Health Corporation and most of its subsidiaries are subject to U.S. federal income tax as well as income tax of numerous state and local jurisdictions. CVS Health Corporation participated in the Compliance Assurance Process through 2019, which is a program made available by the U.S. Internal Revenue Service (“IRS”) to certain qualifying large taxpayers, under which participants work collaboratively with the IRS to identify and resolve potential tax issues through open, cooperative and transparent interaction prior to the annual filing of their federal income tax returns. The IRS has completed its examinations of the Company’s consolidated U.S. federal income tax returns for tax years through and including 2013 and 2018. The IRS has substantially completed its examinations of the Company’s consolidated U.S. federal income tax returns for tax years 2014 through 2017 and 2019.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CVS Health Corporation and its subsidiaries are also currently under income tax examinations by a number of state and local tax authorities. As of December 31, 2021, no examination has resulted in any proposed adjustments that would result in a material change to the Company’s operating results, financial condition or liquidity.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all material state and local income tax matters have been concluded for fiscal years through 2014. Certain state exams are likely to be concluded and certain state statutes of limitations will lapse in 2022, but the change in the balance of the Company’s uncertain tax positions is projected to be immaterial. In addition, it is reasonably possible that the Company’s unrecognized tax benefits could change within the next twelve months due to the anticipated conclusion of various examinations with the IRS for various years. An estimate of the range of the possible change cannot be made at this time.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records interest expense related to unrecognized tax benefits and penalties in the income tax provision. The Company accrued interest expense of approximately $40 million, $34 million and $49 million in 2021, 2020 and 2019, respectively. The Company had approximately $151 million and $121 million accrued for interest and penalties as of December 31, 2021 and 2020, respectively. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the total amount of unrecognized tax benefits that, if recognized, would affect the Company’s effective income tax rate is approximately $669 million, after considering the federal benefit of state income taxes.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax provision for continuing operations consisted of the following for the years ended December 31, 2021, 2020 and 2019:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.698%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,285 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,615 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,450 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">665 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">518 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,950 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,133 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,015 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(306)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(450)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(535)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(122)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(428)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(564)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(649)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,522 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,569 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,366 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2285000000 2615000000 2450000000 665000000 518000000 565000000 2950000000 3133000000 3015000000 -306000000 -450000000 -535000000 -122000000 -114000000 -114000000 -428000000 -564000000 -649000000 2522000000 2569000000 2366000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a reconciliation of the statutory income tax rate to the Company’s effective income tax rate for continuing operations for the years ended December 31, 2021, 2020 and 2019:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.698%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statutory income tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health insurer fee</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basis difference upon disposition of subsidiary</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior year refund claim </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 0.210 0.210 0.210 0.041 0.032 0.040 0 0.022 0 0 -0.012 0 -0.012 0 0 0.003 0.011 0.013 0.242 0.263 0.263 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the components of the Company’s deferred income tax assets and liabilities as of December 31, 2021 and 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:78.695%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.711%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease and rents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,563 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,742 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bad debts and other allowances</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss and capital loss carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">568 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll tax deferral</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(325)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(454)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,497 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,774 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retirement benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(334)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(421)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease and rents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,947)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,368)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,381)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,750)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,767)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,568)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,270)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,794)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 5563000000 5742000000 99000000 80000000 193000000 238000000 489000000 395000000 416000000 568000000 78000000 43000000 501000000 489000000 87000000 173000000 396000000 500000000 325000000 454000000 7497000000 7774000000 105000000 29000000 334000000 421000000 4947000000 5368000000 8381000000 8750000000 13767000000 14568000000 6270000000 6794000000 416000000 325000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending balance of unrecognized tax benefits in 2021, 2020 and 2019 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.698%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">768 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">655 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to the current year</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions for tax positions of prior years</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expiration of statutes of limitation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">782 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">768 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">655 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 768000000 655000000 661000000 3000000 3000000 4000000 52000000 182000000 115000000 33000000 56000000 111000000 1000000 2000000 7000000 7000000 14000000 7000000 782000000 768000000 655000000 40000000 34000000 49000000 151000000 121000000 669000000 Stock Incentive Plans<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of the CVS Health 2017 Incentive Compensation Plan (“ICP”) provide for grants of annual incentive and long-term performance awards to executive officers and other officers and employees of the Company or any subsidiary of the Company, as well as equity compensation to outside directors of CVS Health Corporation. Payment of such annual incentive and long-term performance awards will be in cash, stock, other awards or other property, at the discretion of the Management Planning and Development Committee (the “MP&amp;D Committee”) of the Board. The ICP allows for a maximum of 58 million shares of CVS Health Corporation common stock to be reserved and available for grants. As of December 31, 2021, there were approximately 30 million shares of CVS Health Corporation common stock available for future grants under the ICP.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the acquisition of Aetna (the “Aetna Acquisition”) on November 28, 2018, approximately 22 million shares of Aetna common stock subject to awards outstanding under the Amended Aetna Inc. 2010 Stock Incentive Plan (“SIP”) were assumed by CVS Health Corporation. In addition, in accordance with the merger agreement, shares which were available for future issuance under the SIP were converted into approximately 32 million shares of CVS Health Corporation common stock reserved and available for issuance pursuant to future awards. Subsequent to the expiration of the SIP on May 21, 2020, the ICP is the only compensation plan under which the Company grants stock options, restricted stock and other stock-based awards to its employees.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation is measured at the grant date based on the fair value of the award and is recognized as expense over the requisite service period of the stock award (generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJhYjlmYjcxZDY3NjQ4ZjBiNzU4ODY5ZjE2MGI3ZjRiL3NlYzpiYWI5ZmI3MWQ2NzY0OGYwYjc1ODg2OWYxNjBiN2Y0Yl8xNjMvZnJhZzozYTI1ZjUxNmVjOTM0NmIxYWE2MWZhNGE4NmU2MzZkOS90ZXh0cmVnaW9uOjNhMjVmNTE2ZWM5MzQ2YjFhYTYxZmE0YTg2ZTYzNmQ5XzE3MDk_ea62d84c-7b65-4b23-9d75-3a8341c56a52">three</span> to five years) using the straight-line method. The following table is a summary of stock-based compensation for the years ended December 31, 2021, 2020 and 2019:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.698%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options and stock appreciation rights (“SARs”) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units and performance stock units</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">484 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">453 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes the ESPP.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ESPP</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s Employee Stock Purchase Plan (“ESPP”) provides for the purchase of up to 60 million shares of CVS Health Corporation common stock. Under the ESPP, eligible employees may purchase common stock at the end of each six month offering period at a purchase price equal to 90% of the lower of the fair market value on the first day or the last day of the offering period. During 2021, approximately 3 million shares of common stock were purchased under the provisions of the ESPP at an average price of $60.51 per share. As of December 31, 2021, approximately 31 million shares of common stock were available for issuance under the ESPP.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock-based compensation associated with the ESPP is estimated on the date of grant (the first day of the six month offering period) using the Black-Scholes option pricing model.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the assumptions used to value the ESPP awards for the years ended December 31, 2021, 2020 and 2019:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.869%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.34 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.46 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.70 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.27 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.21 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.96 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.08 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.81 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.55 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.85 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.51 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The dividend yield is calculated based on semi-annual dividends paid and the fair market value of CVS Health Corporation stock at the grant date.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The expected volatility is estimated based on the historical volatility of CVS Health Corporation’s daily stock price over the previous six month period.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The risk-free interest rate is selected based on the Treasury constant maturity interest rate whose term is consistent with the expected term of ESPP purchases (i.e., six months).</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The expected life is based on the semi-annual purchase period.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units and Performance Stock Units</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s restricted stock units and performance stock units are considered nonvested share awards and require no payment from the employee. The fair value of the restricted stock units is based on the market price of CVS Health Corporation common stock on the grant date and is recognized on a straight-line basis over the vesting period. For each restricted stock unit granted, employees receive one share of common stock, net of taxes, at the end of the vesting period. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s performance stock units contain performance vesting conditions in addition to a service vesting condition. Vesting of the Company’s performance stock units is dependent upon the degree to which the Company achieves its performance goals, which are generally set for a three-year performance period and are approved at the time of grant by the MP&amp;D Committee. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of performance stock units granted with service and performance vesting conditions is based on the market price of CVS Health Corporation common stock on the grant date and is recognized over the vesting period. Certain of the performance stock units also contain a market vesting condition based on the performance of CVS Health Corporation common stock relative to a comparator group. The fair value of these performance stock units is determined using a Monte Carlo simulation as of the grant date and is recognized over the vesting period. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, there was $529 million of total unrecognized compensation cost related to the Company’s restricted stock units and performance stock units that are expected to vest. These costs are expected to be recognized over a weighted-average period of 2.1 years. The total fair value of restricted stock units vested during 2021, 2020 and 2019 was $406 million, $229 million and $265 million, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the restricted stock unit and performance stock unit activity for the year ended December 31, 2021:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In thousands, except weighted average grant date fair value</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at beginning of year, nonvested</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,824 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.12 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,190 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.39 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,448)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,236)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.40 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at end of year, nonvested</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,330 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.02 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options and SARs</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All stock option grants are awarded at fair value on the date of grant. The fair value of stock options is estimated using the Black-Scholes option pricing model, and stock-based compensation is recognized on a straight-line basis over the requisite </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">service period. Stock options granted generally become exercisable over a four-year period from the grant date. Stock options granted through 2018 generally expire seven years after the grant date. Stock options granted subsequent to 2018 generally expire ten years after the grant date.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All unvested Aetna SARs outstanding upon the acquisition of Aetna were converted into replacement CVS Health Corporation SARs. The replacement SARs granted are settled in CVS Health Corporation common stock, net of taxes, based on the appreciation of the stock price on the exercise date over the market price on the date of grant. The fair value of SARs is estimated using the Black-Scholes option pricing model, and stock-based compensation is recognized on a straight-line basis over the requisite service period. SARs generally become exercisable over a three-year period from the grant date. SARs generally expire ten years after the grant date. No SARs have been granted subsequent to the Aetna Acquisition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of stock option and SAR activity that occurred for the years ended December 31, 2021, 2020 and 2019:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash received from stock options exercised (including ESPP)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments for taxes for net share settlement of equity awards</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intrinsic value of stock options and SARs exercised </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of stock options and SARs vested </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">467 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each stock option is estimated using the Black-Scholes option pricing model based on the following assumptions at the time of grant:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.68 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.42 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.68 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.10 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.22 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.76 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.57 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.78 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The dividend yield is based on annual dividends paid and the fair market value of CVS Health Corporation stock at the grant date.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The expected volatility is estimated based on the historical volatility of CVS Health Corporation’s daily stock price over a period equal to the expected life of each option grant after adjustments for infrequent events such as stock splits.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The risk-free interest rate is selected based on yields from U.S. Treasury zero-coupon issues with a remaining term equal to the expected term of the options being valued.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The expected life represents the number of years the options are expected to be outstanding from grant date based on historical option or SAR holder exercise experience.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, unrecognized compensation expense related to unvested stock options totaled $38 million, which the Company expects to be recognized over a weighted-average period of 2.0 years. After considering anticipated forfeitures, the Company expects approximately 9 million of the unvested stock options to vest over the requisite service period.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the Company’s stock option and SAR activity for the year ended December 31, 2021:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.724%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.747%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In thousands, except weighted average exercise price and remaining contractual term</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise<br/> Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at beginning of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,955 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.62 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,322 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.66 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,366)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(694)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.66 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,156)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.42 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at end of year</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,061 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.74 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.75</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">603,137 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at end of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,704 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.99 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.61</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,034 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested at end of year and expected to vest in the future</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,709 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.82 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.69</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590,514 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 58000000 30000000 22000000 32000000 P5Y The following table is a summary of stock-based compensation for the years ended December 31, 2021, 2020 and 2019:<div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.698%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options and stock appreciation rights (“SARs”) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units and performance stock units</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">484 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">453 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes the ESPP.</span></div> 80000000 71000000 76000000 404000000 329000000 377000000 484000000 400000000 453000000 60000000 0.90 3000000 60.51 31000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the assumptions used to value the ESPP awards for the years ended December 31, 2021, 2020 and 2019:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.869%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.34 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.46 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.70 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.27 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.21 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.96 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.08 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.81 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.55 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.85 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.51 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The dividend yield is calculated based on semi-annual dividends paid and the fair market value of CVS Health Corporation stock at the grant date.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The expected volatility is estimated based on the historical volatility of CVS Health Corporation’s daily stock price over the previous six month period.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The risk-free interest rate is selected based on the Treasury constant maturity interest rate whose term is consistent with the expected term of ESPP purchases (i.e., six months).</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The expected life is based on the semi-annual purchase period.</span></div> 0.0134 0.0146 0.0170 0.2527 0.3721 0.2796 0.0008 0.0081 0.0227 P0Y6M P0Y6M P0Y6M 12.55 13.85 10.51 529000000 P2Y1M6D 406000000 229000000 265000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the restricted stock unit and performance stock unit activity for the year ended December 31, 2021:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In thousands, except weighted average grant date fair value</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at beginning of year, nonvested</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,824 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.12 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,190 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.39 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,448)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,236)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.40 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at end of year, nonvested</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,330 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.02 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 14824000 58.12 6190000 74.39 5448000 74.47 1236000 63.40 14330000 63.02 P4Y P7Y P10Y P3Y P10Y <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of stock option and SAR activity that occurred for the years ended December 31, 2021, 2020 and 2019:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash received from stock options exercised (including ESPP)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments for taxes for net share settlement of equity awards</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intrinsic value of stock options and SARs exercised </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of stock options and SARs vested </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">467 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 549000000 264000000 210000000 168000000 88000000 112000000 105000000 24000000 30000000 224000000 252000000 467000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each stock option is estimated using the Black-Scholes option pricing model based on the following assumptions at the time of grant:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.68 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.42 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.68 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.10 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.22 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.76 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.57 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.78 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The dividend yield is based on annual dividends paid and the fair market value of CVS Health Corporation stock at the grant date.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The expected volatility is estimated based on the historical volatility of CVS Health Corporation’s daily stock price over a period equal to the expected life of each option grant after adjustments for infrequent events such as stock splits.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The risk-free interest rate is selected based on yields from U.S. Treasury zero-coupon issues with a remaining term equal to the expected term of the options being valued.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The expected life represents the number of years the options are expected to be outstanding from grant date based on historical option or SAR holder exercise experience.</span></div> 0.0268 0.0342 0.0368 0.2710 0.2522 0.2176 0.0113 0.0061 0.0056 P6Y3M18D P6Y3M18D P6Y3M18D 14.57 8.78 6.27 38000000 P2Y 9000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the Company’s stock option and SAR activity for the year ended December 31, 2021:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.724%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.747%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In thousands, except weighted average exercise price and remaining contractual term</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise<br/> Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at beginning of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,955 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.62 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,322 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.66 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,366)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(694)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.66 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,156)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.42 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at end of year</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,061 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.74 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.75</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">603,137 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at end of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,704 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.99 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.61</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,034 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested at end of year and expected to vest in the future</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,709 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.82 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.69</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590,514 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 23955000 69.62 3322000 74.66 6366000 63.41 694000 62.66 1156000 87.42 19061000 71.74 P4Y9M 603137000 9704000 79.99 P2Y7M9D 229034000 18709000 71.82 P4Y8M8D 590514000 Shareholders’ Equity<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchases</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following share repurchase programs have been authorized by the Board:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In billions</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Authorization Date</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Authorized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining as of<br/>December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 9, 2021 (“2021 Repurchase Program”)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2, 2016 (“2016 Repurchase Program”)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the share Repurchase Programs was effective immediately. The 2016 Repurchase program was terminated effective December 9, 2021. The 2021 Repurchase Program permits the Company to effect repurchases from time to time through a combination of open market repurchases, privately negotiated transactions, accelerated share repurchase (“ASR”) transactions, and/or other derivative transactions. The 2021 Repurchase Program can be modified or terminated by the Board at any time.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2021, 2020 and 2019, the Company did not repurchase any shares of common stock pursuant to the 2016 or 2021 Repurchase Programs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the authorization under the 2021 Repurchase Program, the Company entered into a $1.5 billion fixed dollar ASR with Barclays Bank PLC (“Barclays”). Upon payment of the $1.5 billion purchase price on January 4, 2022, the Company received a number of shares of CVS Health Corporation’s common stock equal to 80% of the $1.5 billion notional amount of the ASR or approximately 11.6 million shares at a price of $103.34 per share, which were placed into treasury stock in January 2022. At the conclusion of the ASR, the Company may receive additional shares equal to the remaining 20% of the $1.5 billion notional amount. The ultimate number of shares the Company may receive will depend on the daily volume-weighted average price of the Company’s stock over an averaging period, less a discount. It is also possible, depending on such weighted average price, that the Company will have an obligation to Barclays which, at the Company’s option, could be settled in additional cash or by issuing shares. Under the terms of the ASR, the maximum number of shares that could be delivered to the Company is 29.0 million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The quarterly cash dividend declared by the Board was $0.50 per share in 2021 and 2020. In December 2021, the Board authorized a 10% increase in the quarterly cash dividend to $0.55 per share effective in 2022. CVS Health Corporation has paid cash dividends every quarter since becoming a public company. Future dividend payments will depend on the Company’s earnings, capital requirements, financial condition and other factors considered relevant by the Board.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Requirements</span></div><div><span><br/></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s insurance business operations are conducted through subsidiaries that principally consist of health maintenance organizations (“HMOs”) and insurance companies. The Company’s HMO and insurance subsidiaries report their financial </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">statements in accordance with accounting practices prescribed by state regulatory authorities which may differ from GAAP. The combined statutory net income for the years ended and estimated combined statutory and capital surplus at December 31, 2021, 2020 and 2019 for the Company’s insurance and HMO subsidiaries were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statutory net income </span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,302 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,667 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,842 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated statutory capital and surplus</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,879 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,238 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,975 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s insurance and HMO subsidiaries paid $1.6 billion of gross dividends to the Company for the year ended December 31, 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to general state law restrictions on payments of dividends and other distributions to stockholders applicable to all corporations, HMOs and insurance companies are subject to further regulations that, among other things, may require those companies to maintain certain levels of equity and restrict the amount of dividends and other distributions that may be paid to their equity holders. In addition, in connection with the Aetna Acquisition, the Company made certain undertakings that require prior regulatory approval of dividends by certain of its HMOs and insurance companies. At December 31, 2021, these amounts were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:88.196%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.604%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated minimum statutory surplus required by regulators</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,261 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments on deposit with regulatory bodies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">794 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated maximum dividend distributions permitted in 2022 without prior regulatory approval</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,939 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Noncontrolling Interests</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2021 and 2020, noncontrolling interests were $306 million and $312 million, respectively, primarily related to third party interests in the Company’s operating entities. The noncontrolling entities’ share is included in total shareholders</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> equity on the consolidated balance sheets.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following share repurchase programs have been authorized by the Board:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In billions</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Authorization Date</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Authorized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining as of<br/>December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 9, 2021 (“2021 Repurchase Program”)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2, 2016 (“2016 Repurchase Program”)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 10000000000.0 10000000000.0 15000000000.0 0 1500000000 1500000000 0.80 1500000000 11600000 103.34 0.20 1500000000 29000000 0.50 0.50 0.50 0.50 0.50 0.50 0.50 0.50 0.10 0.55 The combined statutory net income for the years ended and estimated combined statutory and capital surplus at December 31, 2021, 2020 and 2019 for the Company’s insurance and HMO subsidiaries were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statutory net income </span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,302 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,667 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,842 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated statutory capital and surplus</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,879 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,238 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,975 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 3302000000 3667000000 2842000000 14879000000 13238000000 10975000000 1600000000 At December 31, 2021, these amounts were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:88.196%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.604%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated minimum statutory surplus required by regulators</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,261 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments on deposit with regulatory bodies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">794 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated maximum dividend distributions permitted in 2022 without prior regulatory approval</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,939 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 7261000000 794000000 2939000000 306000000 312000000 Other Comprehensive Income<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shareholders’ equity included the following activity in accumulated other comprehensive income in 2021, 2020 and 2019:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.853%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.529%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">At December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net unrealized investment gains (losses):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of year balance</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,214 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">774 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">($(489), $497 and $927 pretax)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(410)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">763 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">($(32), $31 and $(105) pretax)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(436)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">677 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of year balance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">778 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,214 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">774 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency translation adjustments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of year balance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of year balance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of year balance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss before reclassifications </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">($0, $(7) and $(25) pretax)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">($(34), $(35) and $(20) pretax)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of year balance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension and other postretirement benefits:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of year balance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">($20, $(30) and $162 pretax)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive loss </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">($6, $7 and $(12) pretax)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of year balance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total beginning of year accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,414 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,019 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(449)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">917 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total end of year accumulated other comprehensive income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">965 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,414 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,019 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Amounts reclassified from accumulated other comprehensive income for specifically identified debt securities are included in net investment income in the consolidated statements of operations. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Amounts reclassified from accumulated other comprehensive income (loss) represent the elimination of the cumulative translation adjustment associated with the sale of Onofre, which was sold on July 1, 2019. The loss on the divestiture of Onofre is reflected in operating expenses in the consolidated statements of operations.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Amounts reclassified from accumulated other comprehensive income for specifically identified cash flow hedges are included within interest expense in the consolidated statements of operations. The Company expects to reclassify approximately $11 million, net of tax, in net gains associated with its cash flow hedges into net income within the next 12 months.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Amounts reclassified from accumulated other comprehensive loss for specifically identified pension and other postretirement benefits are included in other income in the consolidated statements of operations.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shareholders’ equity included the following activity in accumulated other comprehensive income in 2021, 2020 and 2019:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.853%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.529%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">At December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net unrealized investment gains (losses):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of year balance</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,214 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">774 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">($(489), $497 and $927 pretax)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(410)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">763 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">($(32), $31 and $(105) pretax)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(436)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">677 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of year balance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">778 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,214 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">774 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency translation adjustments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of year balance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of year balance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of year balance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss before reclassifications </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">($0, $(7) and $(25) pretax)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">($(34), $(35) and $(20) pretax)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of year balance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension and other postretirement benefits:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of year balance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">($20, $(30) and $162 pretax)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive loss </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">($6, $7 and $(12) pretax)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of year balance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total beginning of year accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,414 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,019 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(449)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">917 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total end of year accumulated other comprehensive income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">965 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,414 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,019 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Amounts reclassified from accumulated other comprehensive income for specifically identified debt securities are included in net investment income in the consolidated statements of operations. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Amounts reclassified from accumulated other comprehensive income (loss) represent the elimination of the cumulative translation adjustment associated with the sale of Onofre, which was sold on July 1, 2019. The loss on the divestiture of Onofre is reflected in operating expenses in the consolidated statements of operations.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Amounts reclassified from accumulated other comprehensive income for specifically identified cash flow hedges are included within interest expense in the consolidated statements of operations. The Company expects to reclassify approximately $11 million, net of tax, in net gains associated with its cash flow hedges into net income within the next 12 months.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Amounts reclassified from accumulated other comprehensive loss for specifically identified pension and other postretirement benefits are included in other income in the consolidated statements of operations.</span></div> 1214000000 774000000 97000000 -489000000 497000000 927000000 -410000000 415000000 763000000 -32000000 31000000 -105000000 26000000 -25000000 86000000 -436000000 440000000 677000000 778000000 1214000000 774000000 7000000 4000000 -158000000 -7000000 3000000 8000000 0 0 -154000000 -7000000 3000000 162000000 0 7000000 4000000 248000000 279000000 312000000 0 -7000000 -25000000 0 -5000000 -18000000 -34000000 -35000000 -20000000 26000000 26000000 15000000 -26000000 -31000000 -33000000 222000000 248000000 279000000 -55000000 -38000000 -149000000 20000000 -30000000 162000000 15000000 -22000000 120000000 6000000 7000000 -12000000 -5000000 -5000000 9000000 20000000 -17000000 111000000 -35000000 -55000000 -38000000 1414000000 1019000000 102000000 -449000000 395000000 917000000 965000000 1414000000 1019000000 11000000 Earnings Per Share<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings per share is computed using the two-class method. SARs and options to purchase 7 million, 15 million, and 17 million shares of common stock were outstanding, but were excluded from the calculation of diluted earnings per share for the years ended December 31, 2021, 2020 and 2019, respectively, because their exercise prices were greater than the average market price of the common shares and, therefore, the effect would be antidilutive. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of basic and diluted earnings per share from continuing operations for the years ended December 31, 2021, 2020 and 2019:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.712%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.576%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions, except per share amounts</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator for earnings per share calculation:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,898 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,201 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,631 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income allocated to participating securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (income) loss attributable to noncontrolling interests</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations attributable to CVS Health</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,910 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,188 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,629 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator for earnings per share calculation:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares, basic</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,319 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,309 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,301 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares, diluted</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,329 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,314 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,305 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share from continuing operations:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.00 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.49 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.95 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.47 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.08 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 7000000 15000000 17000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of basic and diluted earnings per share from continuing operations for the years ended December 31, 2021, 2020 and 2019:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.712%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.576%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions, except per share amounts</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator for earnings per share calculation:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,898 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,201 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,631 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income allocated to participating securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (income) loss attributable to noncontrolling interests</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations attributable to CVS Health</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,910 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,188 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,629 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator for earnings per share calculation:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares, basic</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,319 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,309 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,301 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares, diluted</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,329 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,314 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,305 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share from continuing operations:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.00 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.49 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.95 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.47 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.08 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 7898000000 7201000000 6631000000 0 0 5000000 -12000000 13000000 -3000000 7910000000 7188000000 6629000000 1319000000 1309000000 1301000000 10000000 5000000 4000000 1329000000 1314000000 1305000000 6.00 5.49 5.10 5.95 5.47 5.08 Reinsurance<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes reinsurance agreements primarily to: (a) reduce required capital and (b) facilitate the acquisition or disposition of certain insurance contracts. Ceded reinsurance agreements permit the Company to recover a portion of its losses from reinsurers, although they do not discharge the Company’s primary liability as the direct insurer of the risks reinsured.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 30, 2018, the Company completed the sale of Aetna’s standalone Medicare Part D prescription drug plans to a subsidiary of WellCare Health Plans, Inc. (“WellCare”), effective December 31, 2018. In connection with that sale, subsidiaries of WellCare and Aetna entered into reinsurance agreements under which WellCare ceded to Aetna 100% of the insurance risk related to the divested standalone Medicare Part D prescription drug plans for the 2019 PDP plan year.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the Company entered into two four-year reinsurance agreements with an unrelated reinsurer that allow it to reduce required capital and provide collateralized excess of loss reinsurance coverage on a portion of the Health Care Benefits segment’s group Commercial Insured business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reinsurance recoverables (recorded as other current assets or other assets on the consolidated balance sheets) at December 31, 2021 and 2020 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.235%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Reinsurer</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hartford Life and Accident Insurance Company</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,887 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,364 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lincoln Life &amp; Annuity Company of New York</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VOYA Retirement Insurance and Annuity Company </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,549 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,055 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Direct, assumed and ceded premiums earned for the years ended December 31, 2021, 2020 and 2019 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.236%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Direct</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,320 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,711 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,968 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,108 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ceded</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(680)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(825)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,954)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net premiums</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,132 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,364 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,122 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The impact of reinsurance on benefit costs for the years ended December 31, 2021, 2020 and 2019 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.236%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Direct</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,414 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,077 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,592 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,562 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ceded</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(552)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(727)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,625)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net benefit costs</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,260 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,679 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,529 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is not a material difference between premiums on a written basis versus an earned basis.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has various agreements with unrelated reinsurers that do not qualify for reinsurance accounting under GAAP, and consequently are accounted for using deposit accounting. The Company entered into these contracts to reduce the risk of catastrophic loss which in turn reduces the Company’s capital and surplus requirements. Total deposit assets and liabilities related to reinsurance agreements that do not qualify for reinsurance accounting under GAAP were not material as of December 31, 2021 or 2020.</span></div> 2 P4Y <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reinsurance recoverables (recorded as other current assets or other assets on the consolidated balance sheets) at December 31, 2021 and 2020 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.235%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Reinsurer</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hartford Life and Accident Insurance Company</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,887 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,364 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lincoln Life &amp; Annuity Company of New York</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VOYA Retirement Insurance and Annuity Company </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,549 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,055 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1887000000 2364000000 395000000 406000000 167000000 170000000 100000000 115000000 2549000000 3055000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Direct, assumed and ceded premiums earned for the years ended December 31, 2021, 2020 and 2019 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.236%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Direct</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,320 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,711 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,968 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,108 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ceded</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(680)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(825)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,954)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net premiums</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,132 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,364 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,122 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 76320000000 69711000000 62968000000 492000000 478000000 2108000000 680000000 825000000 1954000000 76132000000 69364000000 63122000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The impact of reinsurance on benefit costs for the years ended December 31, 2021, 2020 and 2019 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.236%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Direct</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,414 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,077 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,592 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,562 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ceded</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(552)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(727)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,625)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net benefit costs</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,260 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,679 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,529 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 64414000000 56077000000 52592000000 398000000 329000000 1562000000 552000000 727000000 1625000000 64260000000 55679000000 52529000000 Commitments and Contingencies<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic continues to evolve. The Company believes COVID-19’s impact on its businesses, operating results, cash flows and/or financial condition primarily will be driven by the geographies impacted and the severity and duration of the pandemic; the pandemic’s impact on the U.S. and global economies and consumer behavior and health care utilization patterns; and the timing, scope and impact of stimulus legislation as well as other federal, state and local governmental responses to the pandemic. Those primary drivers are beyond the Company’s knowledge and control. As a result, the impact COVID-19 will have on the Company’s businesses, operating results, cash flows and/or financial condition is uncertain, but the impact could be adverse and material. COVID-19 also may result in legal and regulatory proceedings, investigations and claims against the Company.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Guarantees</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has the following significant guarantee arrangements at December 31, 2021:</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ASC Claim Funding Accounts - The Company has arrangements with certain banks for the processing of claim payments for its ASC customers. The banks maintain accounts to fund claims of the Company’s ASC customers. The customer is responsible for funding the amount paid by the bank each day. In these arrangements, the Company guarantees that the banks will not sustain losses if the responsible ASC customer does not properly fund its account. The aggregate maximum exposure under these arrangements is generally limited to $250 million. The Company can limit its exposure to these guarantees by suspending the payment of claims for ASC customers that have not adequately funded the amount paid by the bank. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Separate Accounts Assets - Certain Separate Accounts assets associated with the large case pensions business in the Corporate/Other segment represent funds maintained as a contractual requirement to fund specific pension annuities that the Company has guaranteed. Minimum contractual obligations underlying the guaranteed benefits in these Separate Accounts were approximately $1.3 billion and $1.4 billion at December 31, 2021 and 2020, respectively. See Note 1 ‘‘Significant Accounting Policies’’ for additional information on Separate Accounts. Contract holders assume all investment and mortality risk and are required to maintain Separate Accounts balances at or above a specified level. The level of required funds is a function of the risk underlying the Separate Account’s investment strategy. If contract holders do not maintain the required level of Separate Accounts assets to meet the annuity guarantees, the Company would </span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">establish an additional liability. Contract holders’ balances in the Separate Accounts at December 31, 2021 exceeded the value of the guaranteed benefit obligation. As a result, the Company was not required to maintain any additional liability for its related guarantees at December 31, 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lease Guarantees</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between 1995 and 1997, the Company sold or spun off a number of subsidiaries, including Bob’s Stores and Linens ‘n Things, each of which subsequently filed for bankruptcy, and Marshalls. In many cases, when a former subsidiary leased a store, the Company provided a guarantee of the former subsidiary’s lease obligations for the initial lease term and any extension thereof pursuant to a renewal option provided for in the lease prior to the time of the disposition. When the subsidiaries were disposed of and accounted for as discontinued operations, the Company’s guarantees remained in place, although each initial purchaser agreed to indemnify the Company for any lease obligations the Company was required to satisfy. If any of the purchasers or any of the former subsidiaries fail to make the required payments under a store lease, the Company could be required to satisfy those obligations, and any significant adverse impact of COVID-19 on such purchasers and/or former subsidiaries increases the risk that the Company will be required to satisfy those obligations. As of December 31, 2021, the Company guaranteed 72 such store leases (excluding the lease guarantees related to Linens ‘n Things, which have been recorded as a liability on the consolidated balance sheets), with the maximum remaining lease term extending through 2030.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Guaranty Fund Assessments, Market Stabilization and Other Non-Voluntary Risk Sharing Pools</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under guaranty fund laws existing in all states, insurers doing business in those states can be assessed (in most states up to prescribed limits) for certain obligations of insolvent insurance companies to policyholders and claimants. The life and health insurance guaranty associations in which the Company participates that operate under these laws respond to insolvencies of long-term care insurers and life insurers as well as health insurers. The Company’s assessments generally are based on a formula relating to the Company’s health care premiums in the state compared to the premiums of other insurers. Certain states allow assessments to be recovered over time as offsets to premium taxes. Some states have similar laws relating to HMOs and/or other payors such as not-for-profit consumer-governed health plans established under the ACA.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2009, the Pennsylvania Insurance Commissioner placed long-term care insurer Penn Treaty Network America Insurance Company and one of its subsidiaries (collectively, “Penn Treaty”) in rehabilitation, an intermediate action before insolvency, and subsequently petitioned a state court to convert the rehabilitation into a liquidation. Penn Treaty was placed in liquidation in March 2017. The Company has recorded a liability for its estimated share of future assessments by applicable life and health insurance guaranty associations. It is reasonably possible that in the future the Company may record a liability and expense relating to other insolvencies which could have a material adverse effect on the Company’s operating results, financial condition and cash flows, and the risk is heightened by any significant adverse impact of the COVID-19 pandemic on the solvency of other insurers, including long-term care and life insurers. While historically the Company has ultimately recovered more than half of guaranty fund assessments through statutorily permitted premium tax offsets, significant increases in assessments could lead to legislative and/or regulatory actions that limit future offsets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HMOs in certain states in which the Company does business are subject to assessments, including market stabilization and other risk-sharing pools, for which the Company is assessed charges based on incurred claims, demographic membership mix and other factors. The Company establishes liabilities for these assessments based on applicable laws and regulations. In certain states, the ultimate assessments the Company pays are dependent upon the Company’s experience relative to other entities subject to the assessment, and the ultimate liability is not known at the financial statement date. While the ultimate amount of the assessment is dependent upon the experience of all pool participants, the Company believes it has adequate reserves to cover such assessments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s total guaranty fund assessments liability was immaterial at both December 31, 2021 and 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation and Regulatory Proceedings</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has been involved or is currently involved in numerous legal proceedings, including litigation, arbitration, government investigations, audits, reviews and claims. These include routine, regular and special investigations, audits and reviews by</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CMS, state insurance and health and welfare departments, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the U.S. Department of Justice (the “DOJ”), </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">state attorneys general, the U.S. Drug Enforcement Administration (the “DEA”) and other governmental authorities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal proceedings, in general, and securities, class action and multi-district litigation, in particular, and governmental special investigations, audits and reviews can be expensive and disruptive. Some of the litigation matters may purport or be determined </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to be class actions and/or involve parties seeking large and/or indeterminate amounts, including punitive or exemplary damages, and may remain unresolved for several years. The Company also may be named from time to time in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> actions initiated by private third parties that could also be separately pursued by a governmental body. The results of legal proceedings, including government investigations, are often uncertain and difficult to predict, and the costs incurred in these matters can be substantial, regardless of the outcome.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records accruals for outstanding legal matters when it believes it is probable that a loss will be incurred and the amount can be reasonably estimated. The Company evaluates, on a quarterly basis, developments in legal matters that could affect the amount of any accrual and developments that would make a loss contingency both probable and reasonably estimable. If a loss contingency is not both probable and reasonably estimable, the Company does not establish an accrued liability. None of the Company’s accruals for outstanding legal matters are material individually or in the aggregate to the Company’s financial condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as otherwise noted, the Company cannot predict with certainty the timing or outcome of the legal matters described below, and the Company is unable to reasonably estimate a possible loss or range of possible loss in excess of amounts already accrued for these matters. The Company believes that its defenses and assertions in pending legal proceedings have merit and does not believe that any of these pending matters, after consideration of applicable reserves and rights to indemnification, will have a material adverse effect on the Company’s financial position. Substantial unanticipated verdicts, fines and rulings, however, do sometimes occur, which could result in judgments against the Company, entry into settlements or a revision to its expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on its results of operations. In addition, as a result of governmental investigations or proceedings, the Company may be subject to damages, civil or criminal fines or penalties, or other sanctions including possible suspension or loss of licensure and/or exclusion from participating in government programs. The outcome of such governmental investigations of proceedings could be material to the Company.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Usual and Customary Pricing Litigation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and certain current and former directors and officers are named as a defendant in a number of lawsuits that allege that the Company’s retail pharmacies overcharged for prescription drugs by not submitting the correct usual and customary price during the claims adjudication process. These actions are brought by a number of different types of plaintiffs, including plan members, private payors, government payors, and shareholders based on different legal theories. Some of these cases are brought as putative class actions, and in some instances, classes have been certified. The Company is defending itself against these claims.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">PBM Litigation and Investigations</span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is named as a defendant in a number of lawsuits and is subject to a number of investigations concerning its PBM practices.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is facing multiple lawsuits, including by a State Attorney General, governmental subdivisions and several putative class actions, regarding drug pricing and its rebate arrangements with drug manufacturers. These complaints, brought by a number of different types of plaintiffs under a variety of legal theories, generally allege that rebate agreements between the drug manufacturers and PBMs caused inflated prices for certain drug products. The Company is defending itself against these claims. The Company has also received subpoenas, civil investigative demands (“CIDs”) and other requests for documents and information from, and is being investigated by, Attorneys General of multiple states and the District of Columbia regarding its PBM practices, including pricing and rebates. The Company has been providing documents and information in response to these subpoenas, CIDs and requests for information.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United States ex rel. Behnke v. CVS Caremark Corporation, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">et al. (U.S. District Court for the Eastern District of Pennsylvania). In April 2018, the Court unsealed a complaint filed in February 2014. The government has declined to intervene in this case. The relator alleges that the Company submitted, or caused to be submitted, to Part D of the Medicare program Prescription Drug Event data and/or Direct and Indirect Remuneration reports that misrepresented true prices paid by the Company’s PBM to pharmacies for drugs dispensed to Part D beneficiaries with prescription benefits administered by the Company’s PBM. The Company is defending itself against these claims.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Controlled Substances Litigation, Audits and Subpoenas</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, the U.S. Judicial Panel on Multidistrict Litigation consolidated numerous cases filed against various defendants by plaintiffs such as counties, cities, hospitals, Indian tribes and third-party payors, alleging claims generally concerning the impacts of widespread prescription opioid abuse. The consolidated multidistrict litigation captioned In re National Prescription Opiate Litigation (MDL No. 2804) is pending in the U.S. District Court for the Northern District of Ohio. This multidistrict litigation presumptively includes hundreds of relevant federal court cases that name the Company as a defendant. A significant number of similar cases that name the Company as a defendant in some capacity are pending in state courts. In addition, the Company has been named as a defendant in similar cases brought by certain state Attorneys General. The Company is defending itself against all such claims. Additionally, the Company has received subpoenas, CIDs and/or other requests for information regarding opioids from state Attorneys General and insurance and other regulators of several U.S. jurisdictions. The Company has been cooperating with the government with respect to these subpoenas, CIDs and other requests for information. In November 2021, the Company was among the chain pharmacies found liable by a jury in a trial in federal court in Ohio; the remedy pursuant to that verdict has not been determined and the Company plans to appeal.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the DOJ served the Company with a DEA administrative subpoena. The subpoena seeks documents relating to practices with respect to prescription opioids and other controlled substances at CVS Pharmacy locations concerning potential violations of the federal Controlled Substances Act and the federal False Claims Act. In January 2022, the DOJ served the Company with a CID regarding similar subjects. The Company is providing documents and information in response to these matters.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Prescription Processing Litigation and Investigations</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is named as a defendant in a number of lawsuits and is subject to a number of investigations concerning its prescription processing practices, including the following:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ex rel.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Bassan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> v. Omnicare, Inc. and CVS Health Corp. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(U.S. District Court for the Southern District of New York). In December 2019, the U.S. Attorney’s Office for the Southern District of New York (the “SDNY”) filed a complaint-in-intervention in this previously sealed </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> case. The complaint alleges that for certain non-skilled nursing facilities, Omnicare improperly filled prescriptions beyond one year where a valid prescription did not exist and that these dispensing events violated the federal False Claims Act. The Company is defending itself against these claims.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2017, the Company also received a subpoena from the California Department of Insurance requesting documents concerning the Company’s Omnicare pharmacies’ cycle fill process for assisted living facilities. The Company has been cooperating with the California Department of Insurance and providing documents and information in response to this subpoena.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2016, the Company received a CID from the U.S. Attorney’s Office for the Northern District of New York requesting documents and information in connection with a federal False Claims Act investigation concerning whether the Company’s retail pharmacies improperly submitted certain insulin claims to Part D of the Medicare program rather than Part B of the Medicare program. The Company has been cooperating with the government and providing documents and information in response to this CID.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Provider Proceedings</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is named as a defendant in purported class actions and individual lawsuits arising out of its practices related to the payment of claims for services rendered to its members by providers with whom the Company has a contract and with whom the Company does not have a contract (“out-of-network providers”). Among other things, these lawsuits allege that the Company paid too little to its health plan members and/or providers for out-of-network services and/or otherwise allege that the Company failed to timely or appropriately pay or administer out-of-network claims and benefits (including the Company’s post payment audit and collection practices and reductions in payments to providers due to sequestration). Other major health insurers are the subject of similar litigation or have settled similar litigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has received subpoenas and/or requests for documents and other information from, and been investigated by, state Attorneys General and other state and/or federal regulators, legislators and agencies relating to, and the Company is involved in other litigation regarding, its out-of-network benefit payment and administration practices. It is reasonably possible that others could initiate additional litigation or additional regulatory action against the Company with respect to its out-of-network benefit payment and/or administration practices.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">CMS Actions</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS regularly audits the Company’s performance to determine its compliance with CMS’s regulations and its contracts with CMS and to assess the quality of services it provides to Medicare beneficiaries. CMS uses various payment mechanisms to allocate and adjust premium payments to the Company’s and other companies’ Medicare plans by considering the applicable health status of Medicare members as supported by information prepared, maintained and provided by providers. The Company collects claim and encounter data from providers and generally relies on providers to appropriately code their submissions to the Company and document their medical records, including the diagnosis data submitted to the Company with claims. CMS pays increased premiums to Medicare Advantage plans and Medicare PDP plans for members who have certain medical conditions identified with specific diagnosis codes. Federal regulators review and audit the providers’ medical records to determine whether those records support the related diagnosis codes that determine the members’ health status and the resulting risk-adjusted premium payments to the Company. In that regard, CMS has instituted risk adjustment data validation (“RADV”) audits of various Medicare Advantage plans, including certain of the Company’s plans, to validate coding practices and supporting medical record documentation maintained by providers and the resulting risk adjusted premium payments to the plans. CMS may require the Company to refund premium payments if the Company’s risk adjusted premiums are not properly supported by medical record data. The Office of the Inspector General of the HHS (the “OIG”) also is auditing the Company’s risk adjustment-related data and that of other companies. The Company expects CMS and the OIG to continue these types of audits.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2012, CMS revised its audit methodology for RADV audits to determine refunds payable by Medicare Advantage plans for contract year 2011 and forward. Under the revised methodology, among other things, CMS will extrapolate the error rate identified in the audit sample of approximately 200 members to all risk adjusted premium payments made under the contract being audited. For contract years prior to 2011, CMS did not extrapolate sample error rates to the entire contract. As a result, the revised methodology may increase the Company’s exposure to premium refunds to CMS based on incomplete medical records maintained by providers. Since 2013, CMS has selected certain of the Company’s Medicare Advantage contracts for various contract years for RADV audit, and the number of RADV audits continues to increase. The Company is currently unable to predict which of its Medicare Advantage contracts will be selected for future audit, the amounts of any retroactive refunds of, or prospective adjustments to, Medicare Advantage premium payments made to the Company, the effect of any such refunds or adjustments on the actuarial soundness of the Company’s Medicare Advantage bids, or whether any RADV audit findings would require the Company to change its method of estimating future premium revenue in future bid submissions to CMS or compromise premium assumptions made in the Company’s bids for prior contract years, the current contract year or future contract years. Any premium or fee refunds or adjustments resulting from regulatory audits, whether as a result of RADV, Public Exchange related or other audits by CMS, the OIG or otherwise, including audits of the Company’s MLR rebates, methodology and/or reports, could be material and could adversely affect the Company’s operating results, cash flows and/or financial condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Medicare and Medicaid CIDs</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has received CIDs from the Civil Division of the DOJ in connection with a current investigation of the Company’s patient chart review processes in connection with risk adjustment data submissions under Parts C and D of the Medicare program. The Company has been cooperating with the government and providing documents and information in response to these CIDs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017, the Company received a CID from the SDNY requesting documents and information concerning possible false claims submitted to Medicare in connection with reimbursements for prescription drugs under the Medicare Part D program. The Company has been cooperating with the government and providing documents and information in response to this CID.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Stockholder Matters</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in February 2019, multiple class action complaints, as well as a derivative complaint, were filed by putative plaintiffs against the Company and certain current and former officers and directors. The plaintiffs in these cases assert a variety of causes of action under federal securities laws that are premised on allegations that the defendants made certain omissions and misrepresentations relating to the performance of the Company’s LTC business unit. The Company and its current and former officers and directors are defending themselves against these claims. Since filing, several of the cases have been consolidated, and the first-filed federal case, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">City of Miami Fire Fighters’ and Police Officers’ Retirement Trust, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">et al. (formerly known as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Anarkat</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), was dismissed with prejudice in February 2021. Plaintiffs have appealed that decision to the First Circuit after their motion for reconsideration was denied. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re CVS Health Corp. Securities Act Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (formerly known as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Waterford</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">re CVS Health Corp. Securities Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (formerly known as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">City of Warren</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Freundlich</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) have been stayed pending the outcome of the First Circuit appeal. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August and September 2020, two class actions under the Employee Retirement Income Security Act of 1974 (“ERISA”) were filed in the U.S. District Court for the District of Connecticut against CVS Health, Aetna, and several current and former executives, directors and/or members of Aetna’s Compensation and Talent Management Committee: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Radcliffe v. Aetna Inc., </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Flaim v. Aetna Inc., </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">et al. The plaintiffs in these cases assert a variety of causes of action premised on allegations that the defendants breached fiduciary duties and engaged in prohibited transactions relating to participants in the Aetna 401(k) Plan’s investment in company stock between December 3, 2017 and February 20, 2019, claiming losses related to the performance of the Company’s LTC business unit. The district court consolidated the actions and the Company is defending itself against these claims. In October 2021, the consolidated case was dismissed without prejudice. Plaintiffs may seek leave to file an amended complaint. The Company also received a related document request pursuant to ERISA § 104(b), to which the Company has responded.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the Company received a demand for inspection of books and records pursuant to Delaware Corporation Law Section 220 (the “Demand”). The Demand purports to be related to potential breaches of fiduciary duties by the Board in relation to certain matters concerning opioids.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Legal and Regulatory Proceedings</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also a party to other legal proceedings and is subject to government investigations, inquiries and audits and has received and is cooperating with the government in response to CIDs, subpoenas or similar process from various governmental agencies requesting information. These other legal proceedings and government actions include claims of or relating to bad faith, medical or professional malpractice, breach of fiduciary duty, claims processing, dispensing of medications, non-compliance with state and federal regulatory regimes, marketing misconduct, denial of or failure to timely or appropriately pay or administer claims and benefits, provider network structure (including the use of performance-based networks and termination of provider contracts), rescission of insurance coverage, improper disclosure or use of personal information, anticompetitive practices, general contractual matters, product liability, intellectual property litigation and employment litigation. Some of these other legal proceedings are or are purported to be class actions or derivative claims. The Company is defending itself against the claims brought in these matters.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Awards to the Company and others of certain government contracts, particularly Medicaid contracts and other contracts with government customers in the Company’s Health Care Benefits segment, frequently are subject to protests by unsuccessful bidders. These protests may result in awards to the Company being reversed, delayed or modified. The loss or delay in implementation of any government contract could adversely affect the Company’s operating results. The Company will continue to defend contract awards it receives.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There also continues to be a heightened level of review and/or audit by regulatory authorities and legislators of, and increased litigation regarding, the Company’s and the rest of the health care and related benefits industry’s business and reporting practices, including premium rate increases, utilization management, development and application of medical policies, complaint, grievance and appeal processing, information privacy, provider network structure (including provider network adequacy, the use of performance-based networks and termination of provider contracts), provider directory accuracy, calculation of minimum medical loss ratios and/or payment of related rebates, delegated arrangements, rescission of insurance coverage, limited benefit health products, student health products, pharmacy benefit management practices (including manufacturers’ rebates, pricing, the use of narrow networks and the placement of drugs in formulary tiers), sales practices, customer service practices, vendor oversight and claim payment practices (including payments to out-of-network providers).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a leading national health solutions company, the Company regularly is the subject of government actions of the types described above. These government actions may prevent or delay the Company from implementing planned premium rate increases and may result, and have resulted, in restrictions on the Company’s businesses, changes to or clarifications of the Company’s business practices, retroactive adjustments to premiums, refunds or other payments to members, beneficiaries, states or the federal government, withholding of premium payments to the Company by government agencies, assessments of damages, civil or criminal fines or penalties, or other sanctions, including the possible suspension or loss of licensure and/or suspension or exclusion from participation in government programs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company can give no assurance that its businesses, financial condition, operating results and/or cash flows will not be materially adversely affected, or that the Company will not be required to materially change its business practices, based on: (i) future enactment of new health care or other laws or regulations; (ii) the interpretation or application of existing laws or </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulations as they may relate to one or more of the Company’s businesses, one or more of the industries in which the Company competes and/or the health care industry generally; (iii) pending or future federal or state government investigations of one or more of the Company’s businesses, one or more of the industries in which the Company competes and/or the health care industry generally; (iv) pending or future government audits, investigations or enforcement actions against the Company; (v) adverse developments in any pending </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> lawsuit against the Company, whether sealed or unsealed, or in any future </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> lawsuit that may be filed against the Company; or (vi) adverse developments in pending or future legal proceedings against the Company or affecting one or more of the industries in which the Company competes and/or the health care industry generally.</span> 250000000 1300000000 1400000000 72 200 2 Segment Reporting<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has three operating segments, Health Care Benefits, Pharmacy Services and Retail/LTC, as well as a Corporate/Other segment. The Company’s segments maintain separate financial information, and the Company’s chief operating decision maker (the “CODM”) evaluates the segments’ operating results on a regular basis in deciding how to allocate resources among the segments and in assessing segment performance. The CODM evaluates the performance of the Company’s segments based on adjusted operating income, which is defined as operating income (GAAP measure) excluding the impact of amortization of intangible assets and other items, if any, that neither relate to the ordinary course of the Company’s business nor reflect the Company’s underlying business performance. See the reconciliation of consolidated operating income (GAAP measure) to consolidated adjusted operating income below for further context regarding the items excluded from operating income in determining adjusted operating income. The Company uses adjusted operating income as its principal measure of segment performance as it enhances the Company’s ability to compare past financial performance with current performance and analyze underlying business performance and trends. Non-GAAP financial measures the Company discloses, such as consolidated adjusted operating income, should not be considered a substitute for, or superior to, financial measures determined or calculated in accordance with GAAP.</span></div><div><span><br/></span></div><div style="padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, 2020 and 2019, revenues from the federal government accounted for 17%, 16% and 16%, respectively, of the Company’s consolidated total revenues, primarily related to contracts with CMS for coverage of Medicare-eligible individuals within the Health Care Benefits segment.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of financial measures of the Company’s segments to the consolidated totals:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.308%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.389%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.827%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.746%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.003%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Health Care<br/>Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pharmacy <br/>Services </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retail/<br/>LTC</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Corporate/<br/>Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intersegment</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Eliminations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consolidated<br/>Totals</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues from external customers</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,515 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,194 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,078 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290,912 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,828 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,010 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,923)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment income </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">586 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">596 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,199 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,186 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,022 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,105 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">721 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,923)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292,111 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Adjusted operating income (loss) </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,012 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,859 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,623 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,471)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(711)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,312 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,837 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,884 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,512 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues from external customers</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,926 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,663 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,208 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267,908 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,275 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,990 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,323)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">798 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,467 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,938 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,198 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,323)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268,706 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Adjusted operating income (loss) </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,188 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,688 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,146 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,306)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(708)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,008 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,832 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">612 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,801 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,441 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues from external customers</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,979 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,428 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,258 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,765 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,063 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,350 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,439)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,011 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,604 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,491 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,608 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">512 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,439)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,776 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Adjusted operating income (loss) </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,202 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,129 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,705 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(697)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,339 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,721 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,723 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,371 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:13.5pt;text-indent:-11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:1.93pt">Total revenues of the Pharmacy Services segment include approximately $11.6 billion, $10.9 billion and $11.5 billion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">of retail co-payments for 2021, 2020 and 2019, respectively. See Note 1 ‘‘Significant Accounting Policies’’ for additional information about retail co-payments.</span></div><div style="padding-left:13.5pt;text-indent:-11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:1.93pt">Intersegment revenue eliminations relate to intersegment revenue generating activities that occur between the Health Care Benefits segment, the Pharmacy Services segment, and/or the Retail/LTC segment. Intersegment adjusted operating income eliminations occur when members of Pharmacy Services Segment clients (“PSS members”) enrolled in Maintenance Choice</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> elect to pick up maintenance prescriptions at one of the Company’s retail pharmacies instead of receiving them through the mail. When this occurs, both the Pharmacy Services and Retail/LTC segments record the adjusted operating income on a stand-alone basis.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of consolidated operating income to adjusted operating income for the years ended December 31, 2021, 2020 and 2019:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.712%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.576%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (GAAP measure)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,193 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,911 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,987 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,259 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,341 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,436 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related integration costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Store impairments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,358 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition purchase price adjustment outside of measurement period </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Gain) loss on divestiture of subsidiary </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(269)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receipt of fully reserved ACA risk corridor receivable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(307)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted operating income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,312 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,008 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,339 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:13.5pt;text-indent:-11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:1.93pt">The Company’s acquisition activities have resulted in the recognition of intangible assets as required under the acquisition method of accounting which consist primarily of trademarks, customer contracts/relationships, covenants not to compete, technology, provider networks and value of business acquired. Definite-lived intangible assets are amortized over their estimated useful lives and are tested for impairment when events indicate that the carrying value may not be recoverable. The amortization of intangible assets is reflected in the Company’s GAAP consolidated statements of operations in operating expenses within each segment. Although intangible assets contribute to the Company’s revenue generation, the amortization of intangible assets does not directly relate to the underwriting of the Company’s insurance products, the services performed for the Company’s customers or the sale of the Company’s products or services. Additionally, intangible asset amortization expense typically fluctuates based on the size and timing of the Company’s acquisition activity. Accordingly, the Company believes excluding the amortization of intangible assets enhances the Company’s and investors’ ability to compare the Company’s past financial performance with its current performance and to analyze underlying business performance and trends. Intangible asset amortization excluded from the related non-GAAP financial measure represents the entire amount recorded within the Company’s GAAP financial statements, and the revenue generated by the associated intangible assets has not been excluded from the related non-GAAP financial measure. Intangible asset amortization is excluded from the related non-GAAP financial measure because the amortization, unlike the related revenue, is not affected by operations of any particular period unless an intangible asset becomes impaired or the estimated useful life of an intangible asset is revised. </span></div><div style="padding-left:13.5pt;text-indent:-11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:1.93pt">In 2021, 2020 and 2019, acquisition-related integration costs relate to the Aetna Acquisition. The acquisition-related integration costs are reflected in the Company’s GAAP consolidated statements of operations in operating expenses within the Corporate/Other segment. </span></div><div style="padding-left:13.5pt;text-indent:-11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:1.93pt">During the year ended December 31, 2021, the store impairment charge relates to the write down of operating lease right-of-use assets and property and equipment in connection with the planned closure of approximately 900 retail stores between 2022 and 2024. During the year ended December 31, 2019, the store impairment charges related to the write down of operating lease right-of-use assets in connection with the planned closure of 68 underperforming retail pharmacy stores in 2019 and 2020. The store impairment charges are reflected in the Company’s GAAP consolidated statements of operations within the Retail/LTC segment. </span></div><div style="padding-left:13.5pt;text-indent:-11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:1.93pt">During the year ended December 31, 2021, the goodwill impairment charge relates to the LTC reporting unit within the Retail/LTC segment. </span></div><div style="padding-left:13.5pt;text-indent:-11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:1.93pt">In June 2021, the Company received $61 million related to a purchase price working capital adjustment for an acquisition completed during the first quarter of 2020. The resolution of this matter occurred subsequent to the acquisition accounting measurement period and is reflected in the Company’s GAAP consolidated statement of operations for the year ended December 31, 2021 as a reduction of operating expenses within the Health Care Benefits segment. </span></div><div style="padding-left:13.5pt;text-indent:-11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:1.93pt">In 2020, the gain on divestiture of subsidiary represents the pre-tax gain on the sale of the Workers’ Compensation business, which the Company sold on July 31, 2020 for approximately $850 million. The gain on divestiture is reflected as a reduction of operating expenses in the Company’s GAAP consolidated statement of operations within the Health Care Benefits segment. In 2019, the loss on divestiture of subsidiary represents the pre-tax loss on the sale of Onofre, which occurred on July 1, 2019. The loss on divestiture primarily relates to the elimination of the cumulative translation adjustment from accumulated other comprehensive income and is reflected in the Company’s GAAP consolidated statement of operations in operating expenses within the Retail/LTC segment. </span></div><div style="padding-left:13.5pt;text-indent:-11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:1.93pt">In 2020, the Company received $313 million owed to it under the ACA’s risk corridor program that was previously fully reserved for as payment was uncertain. After considering offsetting items such as the ACA’s minimum MLR rebate requirements and premium taxes, the Company recognized pre-tax income of $307 million in the Company’s GAAP consolidated statement of operations within the Health Care Benefits segment.</span></div> 3 0.17 0.16 0.16 <div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.308%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.389%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.827%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.746%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.003%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Health Care<br/>Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pharmacy <br/>Services </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retail/<br/>LTC</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Corporate/<br/>Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intersegment</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Eliminations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consolidated<br/>Totals</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues from external customers</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,515 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,194 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,078 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290,912 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,828 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,010 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,923)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment income </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">586 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">596 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,199 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,186 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,022 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,105 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">721 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,923)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292,111 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Adjusted operating income (loss) </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,012 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,859 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,623 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,471)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(711)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,312 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,837 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,884 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,512 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues from external customers</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,926 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,663 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,208 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267,908 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,275 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,990 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,323)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">798 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,467 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,938 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,198 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,323)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268,706 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Adjusted operating income (loss) </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,188 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,688 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,146 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,306)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(708)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,008 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,832 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">612 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,801 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,441 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues from external customers</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,979 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,428 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,258 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,765 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,063 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,350 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,439)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,011 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,604 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,491 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,608 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">512 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,439)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,776 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Adjusted operating income (loss) </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,202 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,129 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,705 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(697)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,339 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,721 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,723 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,371 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:13.5pt;text-indent:-11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:1.93pt">Total revenues of the Pharmacy Services segment include approximately $11.6 billion, $10.9 billion and $11.5 billion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">of retail co-payments for 2021, 2020 and 2019, respectively. See Note 1 ‘‘Significant Accounting Policies’’ for additional information about retail co-payments.</span></div><div style="padding-left:13.5pt;text-indent:-11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:1.93pt">Intersegment revenue eliminations relate to intersegment revenue generating activities that occur between the Health Care Benefits segment, the Pharmacy Services segment, and/or the Retail/LTC segment. Intersegment adjusted operating income eliminations occur when members of Pharmacy Services Segment clients (“PSS members”) enrolled in Maintenance Choice</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> elect to pick up maintenance prescriptions at one of the Company’s retail pharmacies instead of receiving them through the mail. When this occurs, both the Pharmacy Services and Retail/LTC segments record the adjusted operating income on a stand-alone basis.</span></div> 81515000000 143194000000 66078000000 125000000 290912000000 85000000 9828000000 34010000000 -43923000000 586000000 0 17000000 596000000 0 1199000000 82186000000 153022000000 100105000000 721000000 -43923000000 292111000000 5012000000 6859000000 7623000000 -1471000000 -711000000 17312000000 1837000000 576000000 1884000000 215000000 0 4512000000 74926000000 132663000000 60208000000 111000000 267908000000 58000000 9275000000 30990000000 -40323000000 483000000 0 0 315000000 0 798000000 75467000000 141938000000 91198000000 426000000 -40323000000 268706000000 6188000000 5688000000 6146000000 -1306000000 -708000000 16008000000 1832000000 612000000 1801000000 196000000 0 4441000000 68979000000 130428000000 56258000000 100000000 255765000000 26000000 11063000000 30350000000 -41439000000 599000000 0 0 412000000 0 1011000000 69604000000 141491000000 86608000000 512000000 -41439000000 256776000000 5202000000 5129000000 6705000000 -1000000000 -697000000 15339000000 1721000000 766000000 1723000000 161000000 0 4371000000 11600000000 10900000000 11500000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of consolidated operating income to adjusted operating income for the years ended December 31, 2021, 2020 and 2019:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.712%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.576%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (GAAP measure)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,193 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,911 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,987 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,259 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,341 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,436 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related integration costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Store impairments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,358 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition purchase price adjustment outside of measurement period </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Gain) loss on divestiture of subsidiary </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(269)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receipt of fully reserved ACA risk corridor receivable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(307)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted operating income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,312 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,008 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,339 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:13.5pt;text-indent:-11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:1.93pt">The Company’s acquisition activities have resulted in the recognition of intangible assets as required under the acquisition method of accounting which consist primarily of trademarks, customer contracts/relationships, covenants not to compete, technology, provider networks and value of business acquired. Definite-lived intangible assets are amortized over their estimated useful lives and are tested for impairment when events indicate that the carrying value may not be recoverable. The amortization of intangible assets is reflected in the Company’s GAAP consolidated statements of operations in operating expenses within each segment. Although intangible assets contribute to the Company’s revenue generation, the amortization of intangible assets does not directly relate to the underwriting of the Company’s insurance products, the services performed for the Company’s customers or the sale of the Company’s products or services. Additionally, intangible asset amortization expense typically fluctuates based on the size and timing of the Company’s acquisition activity. Accordingly, the Company believes excluding the amortization of intangible assets enhances the Company’s and investors’ ability to compare the Company’s past financial performance with its current performance and to analyze underlying business performance and trends. Intangible asset amortization excluded from the related non-GAAP financial measure represents the entire amount recorded within the Company’s GAAP financial statements, and the revenue generated by the associated intangible assets has not been excluded from the related non-GAAP financial measure. Intangible asset amortization is excluded from the related non-GAAP financial measure because the amortization, unlike the related revenue, is not affected by operations of any particular period unless an intangible asset becomes impaired or the estimated useful life of an intangible asset is revised. </span></div><div style="padding-left:13.5pt;text-indent:-11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:1.93pt">In 2021, 2020 and 2019, acquisition-related integration costs relate to the Aetna Acquisition. The acquisition-related integration costs are reflected in the Company’s GAAP consolidated statements of operations in operating expenses within the Corporate/Other segment. </span></div><div style="padding-left:13.5pt;text-indent:-11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:1.93pt">During the year ended December 31, 2021, the store impairment charge relates to the write down of operating lease right-of-use assets and property and equipment in connection with the planned closure of approximately 900 retail stores between 2022 and 2024. During the year ended December 31, 2019, the store impairment charges related to the write down of operating lease right-of-use assets in connection with the planned closure of 68 underperforming retail pharmacy stores in 2019 and 2020. The store impairment charges are reflected in the Company’s GAAP consolidated statements of operations within the Retail/LTC segment. </span></div><div style="padding-left:13.5pt;text-indent:-11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:1.93pt">During the year ended December 31, 2021, the goodwill impairment charge relates to the LTC reporting unit within the Retail/LTC segment. </span></div><div style="padding-left:13.5pt;text-indent:-11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:1.93pt">In June 2021, the Company received $61 million related to a purchase price working capital adjustment for an acquisition completed during the first quarter of 2020. The resolution of this matter occurred subsequent to the acquisition accounting measurement period and is reflected in the Company’s GAAP consolidated statement of operations for the year ended December 31, 2021 as a reduction of operating expenses within the Health Care Benefits segment. </span></div><div style="padding-left:13.5pt;text-indent:-11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:1.93pt">In 2020, the gain on divestiture of subsidiary represents the pre-tax gain on the sale of the Workers’ Compensation business, which the Company sold on July 31, 2020 for approximately $850 million. The gain on divestiture is reflected as a reduction of operating expenses in the Company’s GAAP consolidated statement of operations within the Health Care Benefits segment. In 2019, the loss on divestiture of subsidiary represents the pre-tax loss on the sale of Onofre, which occurred on July 1, 2019. The loss on divestiture primarily relates to the elimination of the cumulative translation adjustment from accumulated other comprehensive income and is reflected in the Company’s GAAP consolidated statement of operations in operating expenses within the Retail/LTC segment. </span></div><div style="padding-left:13.5pt;text-indent:-11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:1.93pt">In 2020, the Company received $313 million owed to it under the ACA’s risk corridor program that was previously fully reserved for as payment was uncertain. After considering offsetting items such as the ACA’s minimum MLR rebate requirements and premium taxes, the Company recognized pre-tax income of $307 million in the Company’s GAAP consolidated statement of operations within the Health Care Benefits segment.</span></div> 13193000000 13911000000 11987000000 2259000000 2341000000 2436000000 132000000 332000000 480000000 1358000000 0 231000000 431000000 0 0 -61000000 0 0 0 269000000 -205000000 0 307000000 0 17312000000 16008000000 15339000000 900 68 61000000 850000000 313000000 307000000 Ernst & Young LLP Boston, Massachusetts Common stock and capital surplus includes the par value of common stock of $17 million as of December 31, 2021, 2020 and 2019. Reflects the adoption of ASU 2016-13, Financial Instruments - Credit Losses (Topic 326), which resulted in a reduction to retained earnings of $3 million during the year ended December 31, 2020. Treasury shares include 1 million shares held in trust for each of the years ended December 31, 2021, 2020 and 2019. Treasury stock includes $29 million related to shares held in trust for each of the years ended December 31, 2021, 2020 and 2019. See Note 1 ‘‘Significant Accounting Policies’’ for additional information. Reflects the adoption of Accounting Standards Update (“ASU”) 2016-02, Leases (Topic 842), which resulted in an increase to retained earnings of $178 million during the year ended December 31, 2019. EXCEL 138 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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
  •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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 140 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 141 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.0.1 html 965 789 1 true 235 0 false 15 false false R1.htm 000010001 - Document - Cover Page Sheet http://www.cvshealth.com/role/CoverPage Cover Page Cover 1 false false R2.htm 000020002 - Document - Audit Information Sheet http://www.cvshealth.com/role/AuditInformation Audit Information Notes 2 false false R3.htm 100010003 - Statement - Consolidated Statements of Operations Sheet http://www.cvshealth.com/role/ConsolidatedStatementsofOperations Consolidated Statements of Operations Uncategorized 3 false false R4.htm 100020004 - Statement - Consolidated Statements of Comprehensive Income Sheet http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome Consolidated Statements of Comprehensive Income Statements 4 false false R5.htm 100030005 - Statement - Consolidated Balance Sheets Sheet http://www.cvshealth.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 5 false false R6.htm 100040006 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.cvshealth.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 6 false false R7.htm 100050007 - Statement - Consolidated Statements of Cash Flows Sheet http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows Consolidated Statements of Cash Flows Statements 7 false false R8.htm 100060008 - Statement - Consolidated Statements of Shareholders' Equity Sheet http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity Consolidated Statements of Shareholders' Equity Statements 8 false false R9.htm 100070009 - Statement - Consolidated Statements of Shareholders' Equity (Parentheticals) Sheet http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquityParentheticals Consolidated Statements of Shareholders' Equity (Parentheticals) Statements 9 false false R10.htm 210011001 - Disclosure - Significant Accounting Policies Sheet http://www.cvshealth.com/role/SignificantAccountingPolicies Significant Accounting Policies Notes 10 false false R11.htm 210131002 - Disclosure - Divestitures Sheet http://www.cvshealth.com/role/Divestitures Divestitures Notes 11 false false R12.htm 210151003 - Disclosure - Investments Sheet http://www.cvshealth.com/role/Investments Investments Notes 12 false false R13.htm 210281004 - Disclosure - Fair Value Sheet http://www.cvshealth.com/role/FairValue Fair Value Notes 13 false false R14.htm 210361005 - Disclosure - Goodwill and Other Intangibles Sheet http://www.cvshealth.com/role/GoodwillandOtherIntangibles Goodwill and Other Intangibles Notes 14 false false R15.htm 210421006 - Disclosure - Leases Sheet http://www.cvshealth.com/role/Leases Leases Notes 15 false false R16.htm 210491007 - Disclosure - Health Care Costs Payable Sheet http://www.cvshealth.com/role/HealthCareCostsPayable Health Care Costs Payable Notes 16 false false R17.htm 210551008 - Disclosure - Borrowings and Credit Arrangements Sheet http://www.cvshealth.com/role/BorrowingsandCreditArrangements Borrowings and Credit Arrangements Notes 17 false false R18.htm 210611009 - Disclosure - Pension Plans and Other Postretirement Benefits Sheet http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefits Pension Plans and Other Postretirement Benefits Notes 18 false false R19.htm 210701010 - Disclosure - Income Taxes Sheet http://www.cvshealth.com/role/IncomeTaxes Income Taxes Notes 19 false false R20.htm 210771011 - Disclosure - Stock Incentive Plans Sheet http://www.cvshealth.com/role/StockIncentivePlans Stock Incentive Plans Notes 20 false false R21.htm 210831012 - Disclosure - Shareholders' Equity Sheet http://www.cvshealth.com/role/ShareholdersEquity Shareholders' Equity Notes 21 false false R22.htm 210901013 - Disclosure - Other Comprehensive Income Sheet http://www.cvshealth.com/role/OtherComprehensiveIncome Other Comprehensive Income Notes 22 false false R23.htm 210931014 - Disclosure - Earnings Per Share Sheet http://www.cvshealth.com/role/EarningsPerShare Earnings Per Share Notes 23 false false R24.htm 210961015 - Disclosure - Reinsurance Sheet http://www.cvshealth.com/role/Reinsurance Reinsurance Notes 24 false false R25.htm 211011016 - Disclosure - Commitments and Contingencies Sheet http://www.cvshealth.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 25 false false R26.htm 211031017 - Disclosure - Segment Reporting Sheet http://www.cvshealth.com/role/SegmentReporting Segment Reporting Notes 26 false false R27.htm 220022001 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) Policies http://www.cvshealth.com/role/SignificantAccountingPolicies 27 false false R28.htm 230033001 - Disclosure - Significant Accounting Policies (Tables) Sheet http://www.cvshealth.com/role/SignificantAccountingPoliciesTables Significant Accounting Policies (Tables) Tables http://www.cvshealth.com/role/SignificantAccountingPolicies 28 false false R29.htm 230163002 - Disclosure - Investments (Tables) Sheet http://www.cvshealth.com/role/InvestmentsTables Investments (Tables) Tables http://www.cvshealth.com/role/Investments 29 false false R30.htm 230293003 - Disclosure - Fair Value (Tables) Sheet http://www.cvshealth.com/role/FairValueTables Fair Value (Tables) Tables http://www.cvshealth.com/role/FairValue 30 false false R31.htm 230373004 - Disclosure - Goodwill and Other Intangibles (Tables) Sheet http://www.cvshealth.com/role/GoodwillandOtherIntangiblesTables Goodwill and Other Intangibles (Tables) Tables http://www.cvshealth.com/role/GoodwillandOtherIntangibles 31 false false R32.htm 230433005 - Disclosure - Leases (Tables) Sheet http://www.cvshealth.com/role/LeasesTables Leases (Tables) Tables http://www.cvshealth.com/role/Leases 32 false false R33.htm 230503006 - Disclosure - Health Care Costs Payable (Tables) Sheet http://www.cvshealth.com/role/HealthCareCostsPayableTables Health Care Costs Payable (Tables) Tables http://www.cvshealth.com/role/HealthCareCostsPayable 33 false false R34.htm 230563007 - Disclosure - Borrowings and Credit Arrangements (Tables) Sheet http://www.cvshealth.com/role/BorrowingsandCreditArrangementsTables Borrowings and Credit Arrangements (Tables) Tables http://www.cvshealth.com/role/BorrowingsandCreditArrangements 34 false false R35.htm 230623008 - Disclosure - Pension Plans and Other Postretirement Benefits (Tables) Sheet http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsTables Pension Plans and Other Postretirement Benefits (Tables) Tables http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefits 35 false false R36.htm 230713009 - Disclosure - Income Taxes (Tables) Sheet http://www.cvshealth.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.cvshealth.com/role/IncomeTaxes 36 false false R37.htm 230783010 - Disclosure - Stock Incentive Plans (Tables) Sheet http://www.cvshealth.com/role/StockIncentivePlansTables Stock Incentive Plans (Tables) Tables http://www.cvshealth.com/role/StockIncentivePlans 37 false false R38.htm 230843011 - Disclosure - Shareholders' Equity (Tables) Sheet http://www.cvshealth.com/role/ShareholdersEquityTables Shareholders' Equity (Tables) Tables http://www.cvshealth.com/role/ShareholdersEquity 38 false false R39.htm 230913012 - Disclosure - Other Comprehensive Income (Tables) Sheet http://www.cvshealth.com/role/OtherComprehensiveIncomeTables Other Comprehensive Income (Tables) Tables http://www.cvshealth.com/role/OtherComprehensiveIncome 39 false false R40.htm 230943013 - Disclosure - Earnings Per Share (Tables) Sheet http://www.cvshealth.com/role/EarningsPerShareTables Earnings Per Share (Tables) Tables http://www.cvshealth.com/role/EarningsPerShare 40 false false R41.htm 230973014 - Disclosure - Reinsurance (Tables) Sheet http://www.cvshealth.com/role/ReinsuranceTables Reinsurance (Tables) Tables http://www.cvshealth.com/role/Reinsurance 41 false false R42.htm 231043015 - Disclosure - Segment Reporting (Tables) Sheet http://www.cvshealth.com/role/SegmentReportingTables Segment Reporting (Tables) Tables http://www.cvshealth.com/role/SegmentReporting 42 false false R43.htm 240044001 - Disclosure - Significant Accounting Policies - Narrative (Details) Sheet http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails Significant Accounting Policies - Narrative (Details) Details 43 false false R44.htm 240054002 - Disclosure - Significant Accounting Policies - Restricted Cash (Details) Sheet http://www.cvshealth.com/role/SignificantAccountingPoliciesRestrictedCashDetails Significant Accounting Policies - Restricted Cash (Details) Details 44 false false R45.htm 240064003 - Disclosure - Significant Accounting Policies - Accounts Receivable (Details) Sheet http://www.cvshealth.com/role/SignificantAccountingPoliciesAccountsReceivableDetails Significant Accounting Policies - Accounts Receivable (Details) Details 45 false false R46.htm 240074004 - Disclosure - Significant Accounting Policies - Property Plant and Equipment (Details) Sheet http://www.cvshealth.com/role/SignificantAccountingPoliciesPropertyPlantandEquipmentDetails Significant Accounting Policies - Property Plant and Equipment (Details) Details 46 false false R47.htm 240084005 - Disclosure - Significant Accounting Policies - Disaggregation of Revenue (Details) Sheet http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails Significant Accounting Policies - Disaggregation of Revenue (Details) Details 47 false false R48.htm 240094006 - Disclosure - Significant Accounting Policies - Receivables and Contracted Balances (Details) Sheet http://www.cvshealth.com/role/SignificantAccountingPoliciesReceivablesandContractedBalancesDetails Significant Accounting Policies - Receivables and Contracted Balances (Details) Details 48 false false R49.htm 240104007 - Disclosure - Significant Accounting Policies - Contract Balances (Details) Sheet http://www.cvshealth.com/role/SignificantAccountingPoliciesContractBalancesDetails Significant Accounting Policies - Contract Balances (Details) Details 49 false false R50.htm 240114008 - Disclosure - Significant Accounting Policies - Variable Interest Entities (Details) Sheet http://www.cvshealth.com/role/SignificantAccountingPoliciesVariableInterestEntitiesDetails Significant Accounting Policies - Variable Interest Entities (Details) Details 50 false false R51.htm 240124009 - Disclosure - Significant Accounting Policies - Discontinued Operations (Details) Sheet http://www.cvshealth.com/role/SignificantAccountingPoliciesDiscontinuedOperationsDetails Significant Accounting Policies - Discontinued Operations (Details) Details 51 false false R52.htm 240144010 - Disclosure - Divestitures - Narrative (Details) Sheet http://www.cvshealth.com/role/DivestituresNarrativeDetails Divestitures - Narrative (Details) Details 52 false false R53.htm 240174011 - Disclosure - Investments - Schedule of Total Investments (Details) Sheet http://www.cvshealth.com/role/InvestmentsScheduleofTotalInvestmentsDetails Investments - Schedule of Total Investments (Details) Details 53 false false R54.htm 240184012 - Disclosure - Investments - Narrative (Details) Sheet http://www.cvshealth.com/role/InvestmentsNarrativeDetails Investments - Narrative (Details) Details 54 false false R55.htm 240194013 - Disclosure - Investments - Debt Securities (Details) Sheet http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails Investments - Debt Securities (Details) Details 55 false false R56.htm 240204014 - Disclosure - Investments - Debt Securities by Maturity (Details) Sheet http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails Investments - Debt Securities by Maturity (Details) Details 56 false false R57.htm 240214015 - Disclosure - Investments - Unrealized Loss Position (Details) Sheet http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails Investments - Unrealized Loss Position (Details) Details 57 false false R58.htm 240224016 - Disclosure - Investments - Unrealized Loss Position Maturities (Details) Sheet http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails Investments - Unrealized Loss Position Maturities (Details) Details 58 false false R59.htm 240234017 - Disclosure - Investments - Mortgage Loans (Details) Sheet http://www.cvshealth.com/role/InvestmentsMortgageLoansDetails Investments - Mortgage Loans (Details) Details 59 false false R60.htm 240244018 - Disclosure - Investments - Mortgage Loans Credit Ratings Indicator (Details) Sheet http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails Investments - Mortgage Loans Credit Ratings Indicator (Details) Details 60 false false R61.htm 240254019 - Disclosure - Investments - Schedule of Mortgage Loan Principal Repayments (Details) Sheet http://www.cvshealth.com/role/InvestmentsScheduleofMortgageLoanPrincipalRepaymentsDetails Investments - Schedule of Mortgage Loan Principal Repayments (Details) Details 61 false false R62.htm 240264020 - Disclosure - Investments - Net Investment Income (Details) Sheet http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails Investments - Net Investment Income (Details) Details 62 false false R63.htm 240274021 - Disclosure - Investments - Realized Gains (Details) Sheet http://www.cvshealth.com/role/InvestmentsRealizedGainsDetails Investments - Realized Gains (Details) Details 63 false false R64.htm 240304022 - Disclosure - Fair Value - Fair Value Measurements (Details) Sheet http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails Fair Value - Fair Value Measurements (Details) Details 64 false false R65.htm 240314023 - Disclosure - Fair Value - Changes in Level 3 Financial Assets (Details) Sheet http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails Fair Value - Changes in Level 3 Financial Assets (Details) Details 65 false false R66.htm 240324024 - Disclosure - Fair Value - Gross Transfers Into (Out Of) Level 3 (Details) Sheet http://www.cvshealth.com/role/FairValueGrossTransfersIntoOutOfLevel3Details Fair Value - Gross Transfers Into (Out Of) Level 3 (Details) Details 66 false false R67.htm 240334025 - Disclosure - Fair Value - Carrying Value and Fair Value Classified by Level (Details) Sheet http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails Fair Value - Carrying Value and Fair Value Classified by Level (Details) Details 67 false false R68.htm 240344026 - Disclosure - Fair Value - Separate Accounts Fair Value (Details) Sheet http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails Fair Value - Separate Accounts Fair Value (Details) Details 68 false false R69.htm 240354027 - Disclosure - Fair Value - Narrative (Details) Sheet http://www.cvshealth.com/role/FairValueNarrativeDetails Fair Value - Narrative (Details) Details 69 false false R70.htm 240384028 - Disclosure - Goodwill and Other Intangibles - Goodwill (Details) Sheet http://www.cvshealth.com/role/GoodwillandOtherIntangiblesGoodwillDetails Goodwill and Other Intangibles - Goodwill (Details) Details 70 false false R71.htm 240394029 - Disclosure - Goodwill and Other Intangibles - Narrative (Details) Sheet http://www.cvshealth.com/role/GoodwillandOtherIntangiblesNarrativeDetails Goodwill and Other Intangibles - Narrative (Details) Details 71 false false R72.htm 240404030 - Disclosure - Goodwill and Other Intangibles - Intangible Assets (Details) Sheet http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails Goodwill and Other Intangibles - Intangible Assets (Details) Details 72 false false R73.htm 240414031 - Disclosure - Goodwill and Other Acquired Intangibles - Future Amortization Expense (Details) Sheet http://www.cvshealth.com/role/GoodwillandOtherAcquiredIntangiblesFutureAmortizationExpenseDetails Goodwill and Other Acquired Intangibles - Future Amortization Expense (Details) Details 73 false false R74.htm 240444032 - Disclosure - Leases - Narrative (Details) Sheet http://www.cvshealth.com/role/LeasesNarrativeDetails Leases - Narrative (Details) Details 74 false false R75.htm 240454033 - Disclosure - Leases - Summary of the Components of Net Lease Cost (Details) Sheet http://www.cvshealth.com/role/LeasesSummaryoftheComponentsofNetLeaseCostDetails Leases - Summary of the Components of Net Lease Cost (Details) Details 75 false false R76.htm 240464034 - Disclosure - Leases - Supplemental Cash Flow Information (Details) Sheet http://www.cvshealth.com/role/LeasesSupplementalCashFlowInformationDetails Leases - Supplemental Cash Flow Information (Details) Details 76 false false R77.htm 240474035 - Disclosure - Leases - Supplemental Balance Sheet Information (Details) Sheet http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails Leases - Supplemental Balance Sheet Information (Details) Details 77 false false R78.htm 240484036 - Disclosure - Leases - Maturities of Operating and Finance Lease Liabilities (Details) Sheet http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails Leases - Maturities of Operating and Finance Lease Liabilities (Details) Details 78 false false R79.htm 240514037 - Disclosure - Health Care Costs Payable - Incurred and Paid Health Care Claims Development (Details) Sheet http://www.cvshealth.com/role/HealthCareCostsPayableIncurredandPaidHealthCareClaimsDevelopmentDetails Health Care Costs Payable - Incurred and Paid Health Care Claims Development (Details) Details 79 false false R80.htm 240524038 - Disclosure - Health Care Costs Payable - Narrative (Details) Sheet http://www.cvshealth.com/role/HealthCareCostsPayableNarrativeDetails Health Care Costs Payable - Narrative (Details) Details 80 false false R81.htm 240534039 - Disclosure - Health Care Costs Payable - Reconciliation of Health Care Net Incurred and Paid Claims Development to Health Care Costs Payable Liability (Details) Sheet http://www.cvshealth.com/role/HealthCareCostsPayableReconciliationofHealthCareNetIncurredandPaidClaimsDevelopmenttoHealthCareCostsPayableLiabilityDetails Health Care Costs Payable - Reconciliation of Health Care Net Incurred and Paid Claims Development to Health Care Costs Payable Liability (Details) Details 81 false false R82.htm 240544040 - Disclosure - Health Care Costs Payable - Reconciliation of Health Care Costs Payable (Details) Sheet http://www.cvshealth.com/role/HealthCareCostsPayableReconciliationofHealthCareCostsPayableDetails Health Care Costs Payable - Reconciliation of Health Care Costs Payable (Details) Details 82 false false R83.htm 240574041 - Disclosure - Borrowings and Credit Arrangements - Schedule of Debt (Details) Sheet http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails Borrowings and Credit Arrangements - Schedule of Debt (Details) Details 83 false false R84.htm 240584042 - Disclosure - Borrowings and Credit Arrangements - Debt Maturities (Details) Sheet http://www.cvshealth.com/role/BorrowingsandCreditArrangementsDebtMaturitiesDetails Borrowings and Credit Arrangements - Debt Maturities (Details) Details 84 false false R85.htm 240594043 - Disclosure - Borrowings and Credit Arrangements - Short-term Borrowings (Details) Sheet http://www.cvshealth.com/role/BorrowingsandCreditArrangementsShorttermBorrowingsDetails Borrowings and Credit Arrangements - Short-term Borrowings (Details) Details 85 false false R86.htm 240604044 - Disclosure - Borrowings and Credit Arrangements - Long-Term Borrowings (Details) Sheet http://www.cvshealth.com/role/BorrowingsandCreditArrangementsLongTermBorrowingsDetails Borrowings and Credit Arrangements - Long-Term Borrowings (Details) Details 86 false false R87.htm 240634045 - Disclosure - Pension Plans and Other Postretirement Benefits - Narrative (Details) Sheet http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNarrativeDetails Pension Plans and Other Postretirement Benefits - Narrative (Details) Details 87 false false R88.htm 240644046 - Disclosure - Pension Plans and Other Postretirement Benefits - Benefit Obligations and Plan Assets (Details) Sheet http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails Pension Plans and Other Postretirement Benefits - Benefit Obligations and Plan Assets (Details) Details 88 false false R89.htm 240654047 - Disclosure - Pension Plans and Other Postretirement Benefits - Net Periodic Benefit Costs (Details) Sheet http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNetPeriodicBenefitCostsDetails Pension Plans and Other Postretirement Benefits - Net Periodic Benefit Costs (Details) Details 89 false false R90.htm 240664048 - Disclosure - Pension Plans and Other Postretirement Benefits - Weighted Average Assumptions Used (Details) Sheet http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsWeightedAverageAssumptionsUsedDetails Pension Plans and Other Postretirement Benefits - Weighted Average Assumptions Used (Details) Details 90 false false R91.htm 240674049 - Disclosure - Pension Plans and Other Postretirement Benefits - Fair Value of Pension Plan Assets (Details) Sheet http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails Pension Plans and Other Postretirement Benefits - Fair Value of Pension Plan Assets (Details) Details 91 false false R92.htm 240684050 - Disclosure - Pension Plans and Other Postretirement Benefits - Changes in Level 3 Pension Plan Assets (Details) Sheet http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsChangesinLevel3PensionPlanAssetsDetails Pension Plans and Other Postretirement Benefits - Changes in Level 3 Pension Plan Assets (Details) Details 92 false false R93.htm 240694051 - Disclosure - Pension Plans and Other Postretirement Benefits - Defined Benefit Plans Expected Benefit (Details) Sheet http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsDefinedBenefitPlansExpectedBenefitDetails Pension Plans and Other Postretirement Benefits - Defined Benefit Plans Expected Benefit (Details) Details 93 false false R94.htm 240724052 - Disclosure - Income Taxes - Income Tax Provision (Details) Sheet http://www.cvshealth.com/role/IncomeTaxesIncomeTaxProvisionDetails Income Taxes - Income Tax Provision (Details) Details 94 false false R95.htm 240734053 - Disclosure - Income Taxes - Narrative (Details) Sheet http://www.cvshealth.com/role/IncomeTaxesNarrativeDetails Income Taxes - Narrative (Details) Details 95 false false R96.htm 240744054 - Disclosure - Income Taxes - Effective Tax Rate Reconciliation (Details) Sheet http://www.cvshealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails Income Taxes - Effective Tax Rate Reconciliation (Details) Details 96 false false R97.htm 240754055 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details) Sheet http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails Income Taxes - Deferred Tax Assets and Liabilities (Details) Details 97 false false R98.htm 240764056 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Details) Sheet http://www.cvshealth.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails Income Taxes - Unrecognized Tax Benefits (Details) Details 98 false false R99.htm 240794057 - Disclosure - Stock Incentive Plans - Stock-Based Compensation Expense and ESPP (Details) Sheet http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails Stock Incentive Plans - Stock-Based Compensation Expense and ESPP (Details) Details 99 false false R100.htm 240804058 - Disclosure - Stock Incentive Plans - Valuation and Assumptions (Details) Sheet http://www.cvshealth.com/role/StockIncentivePlansValuationandAssumptionsDetails Stock Incentive Plans - Valuation and Assumptions (Details) Details 100 false false R101.htm 240814059 - Disclosure - Stock Incentive Plans - Restricted Stock Activity (Details) Sheet http://www.cvshealth.com/role/StockIncentivePlansRestrictedStockActivityDetails Stock Incentive Plans - Restricted Stock Activity (Details) Details 101 false false R102.htm 240824060 - Disclosure - Stock Incentive Plans - Stock Option and SAR Activity (Details) Sheet http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails Stock Incentive Plans - Stock Option and SAR Activity (Details) Details 102 false false R103.htm 240854061 - Disclosure - Shareholders' Equity - Share Repurchases (Details) Sheet http://www.cvshealth.com/role/ShareholdersEquityShareRepurchasesDetails Shareholders' Equity - Share Repurchases (Details) Details 103 false false R104.htm 240864062 - Disclosure - Shareholders' Equity - Accelerated Share Repurchases (Details) Sheet http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails Shareholders' Equity - Accelerated Share Repurchases (Details) Details 104 false false R105.htm 240874063 - Disclosure - Shareholders' Equity - Dividends (Details) Sheet http://www.cvshealth.com/role/ShareholdersEquityDividendsDetails Shareholders' Equity - Dividends (Details) Details 105 false false R106.htm 240884064 - Disclosure - Shareholders' Equity - Regulatory Requirements (Details) Sheet http://www.cvshealth.com/role/ShareholdersEquityRegulatoryRequirementsDetails Shareholders' Equity - Regulatory Requirements (Details) Details 106 false false R107.htm 240894065 - Disclosure - Shareholders' Equity - Noncontrolling Interests (Details) Sheet http://www.cvshealth.com/role/ShareholdersEquityNoncontrollingInterestsDetails Shareholders' Equity - Noncontrolling Interests (Details) Details 107 false false R108.htm 240924066 - Disclosure - Other Comprehensive Income (Details) Sheet http://www.cvshealth.com/role/OtherComprehensiveIncomeDetails Other Comprehensive Income (Details) Details http://www.cvshealth.com/role/OtherComprehensiveIncomeTables 108 false false R109.htm 240954067 - Disclosure - Earnings Per Share (Details) Sheet http://www.cvshealth.com/role/EarningsPerShareDetails Earnings Per Share (Details) Details http://www.cvshealth.com/role/EarningsPerShareTables 109 false false R110.htm 240984068 - Disclosure - Reinsurance - Narrative (Details) Sheet http://www.cvshealth.com/role/ReinsuranceNarrativeDetails Reinsurance - Narrative (Details) Details 110 false false R111.htm 240994069 - Disclosure - Reinsurance - Reinsurance Recoverables (Details) Sheet http://www.cvshealth.com/role/ReinsuranceReinsuranceRecoverablesDetails Reinsurance - Reinsurance Recoverables (Details) Details 111 false false R112.htm 241004070 - Disclosure - Reinsurance - Effects of Reinsurance (Details) Sheet http://www.cvshealth.com/role/ReinsuranceEffectsofReinsuranceDetails Reinsurance - Effects of Reinsurance (Details) Details 112 false false R113.htm 241024071 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.cvshealth.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://www.cvshealth.com/role/CommitmentsandContingencies 113 false false R114.htm 241054072 - Disclosure - Segment Reporting - Narrative (Details) Sheet http://www.cvshealth.com/role/SegmentReportingNarrativeDetails Segment Reporting - Narrative (Details) Details 114 false false R115.htm 241064073 - Disclosure - Segment Reporting - Reconciliation of Financial Measures of Segments to Consolidated Totals (Details) Sheet http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails Segment Reporting - Reconciliation of Financial Measures of Segments to Consolidated Totals (Details) Details 115 false false R116.htm 241074074 - Disclosure - Segment Reporting - Reconciliation from Operating Income to Adjusted Operating Income (Details) Sheet http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails Segment Reporting - Reconciliation from Operating Income to Adjusted Operating Income (Details) Details 116 false false All Reports Book All Reports cvs-20211231.htm cvs-20211231.xsd cvs-20211231_cal.xml cvs-20211231_def.xml cvs-20211231_lab.xml cvs-20211231_pre.xml exhibit1010-2021.htm exhibit1025-2021.htm exhibit1055-2021.htm exhibit211-2021.htm exhibit231-2021.htm exhibit311-2021.htm exhibit312-2021.htm exhibit321-2021.htm exhibit322-2021.htm exhibit423-2021.htm cvs-20211231_g1.jpg cvs-20211231_g2.jpg http://fasb.org/srt/2021-01-31 http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true JSON 144 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "cvs-20211231.htm": { "axisCustom": 2, "axisStandard": 44, "contextCount": 965, "dts": { "calculationLink": { "local": [ "cvs-20211231_cal.xml" ] }, "definitionLink": { "local": [ "cvs-20211231_def.xml" ] }, "inline": { "local": [ "cvs-20211231.htm" ] }, "labelLink": { "local": [ "cvs-20211231_lab.xml" ] }, "presentationLink": { "local": [ "cvs-20211231_pre.xml" ] }, "schema": { "local": [ "cvs-20211231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 1179, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 9, "http://xbrl.sec.gov/dei/2021q4": 4, "total": 13 }, "keyCustom": 124, "keyStandard": 665, "memberCustom": 122, "memberStandard": 96, "nsprefix": "cvs", "nsuri": "http://www.cvshealth.com/20211231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000010001 - Document - Cover Page", "role": "http://www.cvshealth.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210011001 - Disclosure - Significant Accounting Policies", "role": "http://www.cvshealth.com/role/SignificantAccountingPolicies", "shortName": "Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R100": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "ie549abdb9cf943f6acd4a4f0dc937118_D20210101-20211231", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240804058 - Disclosure - Stock Incentive Plans - Valuation and Assumptions (Details)", "role": "http://www.cvshealth.com/role/StockIncentivePlansValuationandAssumptionsDetails", "shortName": "Stock Incentive Plans - Valuation and Assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "ie549abdb9cf943f6acd4a4f0dc937118_D20210101-20211231", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R101": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "if7c3db8973f246b592a6bdc7ae66c5d4_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240814059 - Disclosure - Stock Incentive Plans - Restricted Stock Activity (Details)", "role": "http://www.cvshealth.com/role/StockIncentivePlansRestrictedStockActivityDetails", "shortName": "Stock Incentive Plans - Restricted Stock Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "if7c3db8973f246b592a6bdc7ae66c5d4_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R102": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ProceedsFromStockOptionsExercised", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240824060 - Disclosure - Stock Incentive Plans - Stock Option and SAR Activity (Details)", "role": "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails", "shortName": "Stock Incentive Plans - Stock Option and SAR Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i69a67aadd34647f781446b1f63119ac5_D20210101-20211231", "decimals": null, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R103": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfTreasuryStockByClassTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i432b0c5043074ae0812170d09abfa592_I20211209", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240854061 - Disclosure - Shareholders' Equity - Share Repurchases (Details)", "role": "http://www.cvshealth.com/role/ShareholdersEquityShareRepurchasesDetails", "shortName": "Shareholders' Equity - Share Repurchases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfTreasuryStockByClassTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i432b0c5043074ae0812170d09abfa592_I20211209", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R104": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i910e0cab88ca49569118b221e7416e1d_I20220104", "decimals": "-8", "first": true, "lang": "en-US", "name": "cvs:AcceleratedShareRepurchasesAgreementAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240864062 - Disclosure - Shareholders' Equity - Accelerated Share Repurchases (Details)", "role": "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails", "shortName": "Shareholders' Equity - Accelerated Share Repurchases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i910e0cab88ca49569118b221e7416e1d_I20220104", "decimals": "-8", "first": true, "lang": "en-US", "name": "cvs:AcceleratedShareRepurchasesAgreementAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R105": { "firstAnchor": { "ancestors": [ "us-gaap:DividendsPayableAmountPerShare", "us-gaap:DividendsPayableAmountPerShare", "us-gaap:DividendsPayableAmountPerShare", "us-gaap:DividendsPayableAmountPerShare", "us-gaap:DividendsPayableAmountPerShare", "us-gaap:DividendsPayableAmountPerShare", "us-gaap:DividendsPayableAmountPerShare", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i48425c9c7d6d41fe9f23b091c65a31d4_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DividendsPayableAmountPerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240874063 - Disclosure - Shareholders' Equity - Dividends (Details)", "role": "http://www.cvshealth.com/role/ShareholdersEquityDividendsDetails", "shortName": "Shareholders' Equity - Dividends (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:DividendsPayableAmountPerShare", "us-gaap:DividendsPayableAmountPerShare", "us-gaap:DividendsPayableAmountPerShare", "us-gaap:DividendsPayableAmountPerShare", "us-gaap:DividendsPayableAmountPerShare", "us-gaap:DividendsPayableAmountPerShare", "us-gaap:DividendsPayableAmountPerShare", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i48425c9c7d6d41fe9f23b091c65a31d4_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DividendsPayableAmountPerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R106": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i48425c9c7d6d41fe9f23b091c65a31d4_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240884064 - Disclosure - Shareholders' Equity - Regulatory Requirements (Details)", "role": "http://www.cvshealth.com/role/ShareholdersEquityRegulatoryRequirementsDetails", "shortName": "Shareholders' Equity - Regulatory Requirements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i48425c9c7d6d41fe9f23b091c65a31d4_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R107": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i48425c9c7d6d41fe9f23b091c65a31d4_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:MinorityInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240894065 - Disclosure - Shareholders' Equity - Noncontrolling Interests (Details)", "role": "http://www.cvshealth.com/role/ShareholdersEquityNoncontrollingInterestsDetails", "shortName": "Shareholders' Equity - Noncontrolling Interests (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R108": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "ifcbe414ba05c4538bc76281ff3ac3fa4_I20191231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240924066 - Disclosure - Other Comprehensive Income (Details)", "role": "http://www.cvshealth.com/role/OtherComprehensiveIncomeDetails", "shortName": "Other Comprehensive Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i84a0c7a5f87a43ea863b4f7e44c6d8c2_I20181231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R109": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240954067 - Disclosure - Earnings Per Share (Details)", "role": "http://www.cvshealth.com/role/EarningsPerShareDetails", "shortName": "Earnings Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210131002 - Disclosure - Divestitures", "role": "http://www.cvshealth.com/role/Divestitures", "shortName": "Divestitures", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R110": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i9b7aa9f9810b45008c9d9fed20ef83c3_D20220101-20220131", "decimals": "INF", "first": true, "lang": "en-US", "name": "cvs:NumberofReinsuranceContractsEnteredInto", "reportCount": 1, "unique": true, "unitRef": "reinsurance_agreement", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240984068 - Disclosure - Reinsurance - Narrative (Details)", "role": "http://www.cvshealth.com/role/ReinsuranceNarrativeDetails", "shortName": "Reinsurance - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i9b7aa9f9810b45008c9d9fed20ef83c3_D20220101-20220131", "decimals": "INF", "first": true, "lang": "en-US", "name": "cvs:NumberofReinsuranceContractsEnteredInto", "reportCount": 1, "unique": true, "unitRef": "reinsurance_agreement", "xsiNil": "false" } }, "R111": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCededCreditRiskByReinsurerTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i48425c9c7d6d41fe9f23b091c65a31d4_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ReinsuranceRecoverablesOnPaidAndUnpaidLosses", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240994069 - Disclosure - Reinsurance - Reinsurance Recoverables (Details)", "role": "http://www.cvshealth.com/role/ReinsuranceReinsuranceRecoverablesDetails", "shortName": "Reinsurance - Reinsurance Recoverables (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCededCreditRiskByReinsurerTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i48425c9c7d6d41fe9f23b091c65a31d4_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ReinsuranceRecoverablesOnPaidAndUnpaidLosses", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R112": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "srt:SupplementalScheduleOfReinsurancePremiumsForInsuranceCompaniesTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DirectPremiumsEarned", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241004070 - Disclosure - Reinsurance - Effects of Reinsurance (Details)", "role": "http://www.cvshealth.com/role/ReinsuranceEffectsofReinsuranceDetails", "shortName": "Reinsurance - Effects of Reinsurance (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "srt:SupplementalScheduleOfReinsurancePremiumsForInsuranceCompaniesTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DirectPremiumsEarned", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R113": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i48425c9c7d6d41fe9f23b091c65a31d4_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:GuaranteeObligationsMaximumExposure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241024071 - Disclosure - Commitments and Contingencies (Details)", "role": "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i48425c9c7d6d41fe9f23b091c65a31d4_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:GuaranteeObligationsMaximumExposure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R114": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241054072 - Disclosure - Segment Reporting - Narrative (Details)", "role": "http://www.cvshealth.com/role/SegmentReportingNarrativeDetails", "shortName": "Segment Reporting - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R115": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241064073 - Disclosure - Segment Reporting - Reconciliation of Financial Measures of Segments to Consolidated Totals (Details)", "role": "http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails", "shortName": "Segment Reporting - Reconciliation of Financial Measures of Segments to Consolidated Totals (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i9d8f78677d6943988b31d555638bbaf9_D20210101-20211231", "decimals": "-6", "lang": "en-US", "name": "cvs:AdjustedOperatingIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R116": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OperatingIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241074074 - Disclosure - Segment Reporting - Reconciliation from Operating Income to Adjusted Operating Income (Details)", "role": "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails", "shortName": "Segment Reporting - Reconciliation from Operating Income to Adjusted Operating Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:BusinessCombinationIntegrationRelatedCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210151003 - Disclosure - Investments", "role": "http://www.cvshealth.com/role/Investments", "shortName": "Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210281004 - Disclosure - Fair Value", "role": "http://www.cvshealth.com/role/FairValue", "shortName": "Fair Value", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210361005 - Disclosure - Goodwill and Other Intangibles", "role": "http://www.cvshealth.com/role/GoodwillandOtherIntangibles", "shortName": "Goodwill and Other Intangibles", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeFinanceLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210421006 - Disclosure - Leases", "role": "http://www.cvshealth.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeFinanceLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShortDurationInsuranceAndDepositContractsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210491007 - Disclosure - Health Care Costs Payable", "role": "http://www.cvshealth.com/role/HealthCareCostsPayable", "shortName": "Health Care Costs Payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShortDurationInsuranceAndDepositContractsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210551008 - Disclosure - Borrowings and Credit Arrangements", "role": "http://www.cvshealth.com/role/BorrowingsandCreditArrangements", "shortName": "Borrowings and Credit Arrangements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210611009 - Disclosure - Pension Plans and Other Postretirement Benefits", "role": "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefits", "shortName": "Pension Plans and Other Postretirement Benefits", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210701010 - Disclosure - Income Taxes", "role": "http://www.cvshealth.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:AuditorName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "false", "longName": "000020002 - Document - Audit Information", "role": "http://www.cvshealth.com/role/AuditInformation", "shortName": "Audit Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:AuditorName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210771011 - Disclosure - Stock Incentive Plans", "role": "http://www.cvshealth.com/role/StockIncentivePlans", "shortName": "Stock Incentive Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210831012 - Disclosure - Shareholders' Equity", "role": "http://www.cvshealth.com/role/ShareholdersEquity", "shortName": "Shareholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210901013 - Disclosure - Other Comprehensive Income", "role": "http://www.cvshealth.com/role/OtherComprehensiveIncome", "shortName": "Other Comprehensive Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210931014 - Disclosure - Earnings Per Share", "role": "http://www.cvshealth.com/role/EarningsPerShare", "shortName": "Earnings Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ReinsuranceTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210961015 - Disclosure - Reinsurance", "role": "http://www.cvshealth.com/role/Reinsurance", "shortName": "Reinsurance", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ReinsuranceTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "211011016 - Disclosure - Commitments and Contingencies", "role": "http://www.cvshealth.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "211031017 - Disclosure - Segment Reporting", "role": "http://www.cvshealth.com/role/SegmentReporting", "shortName": "Segment Reporting", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "220022001 - Disclosure - Significant Accounting Policies (Policies)", "role": "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies", "shortName": "Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230033001 - Disclosure - Significant Accounting Policies (Tables)", "role": "http://www.cvshealth.com/role/SignificantAccountingPoliciesTables", "shortName": "Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "cvs:TotalInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230163002 - Disclosure - Investments (Tables)", "role": "http://www.cvshealth.com/role/InvestmentsTables", "shortName": "Investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "cvs:TotalInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "srt:SupplementalScheduleOfReinsurancePremiumsForInsuranceCompaniesTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:PremiumsEarnedNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100010003 - Statement - Consolidated Statements of Operations", "role": "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations", "shortName": "Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230293003 - Disclosure - Fair Value (Tables)", "role": "http://www.cvshealth.com/role/FairValueTables", "shortName": "Fair Value (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230373004 - Disclosure - Goodwill and Other Intangibles (Tables)", "role": "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesTables", "shortName": "Goodwill and Other Intangibles (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230433005 - Disclosure - Leases (Tables)", "role": "http://www.cvshealth.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230503006 - Disclosure - Health Care Costs Payable (Tables)", "role": "http://www.cvshealth.com/role/HealthCareCostsPayableTables", "shortName": "Health Care Costs Payable (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230563007 - Disclosure - Borrowings and Credit Arrangements (Tables)", "role": "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsTables", "shortName": "Borrowings and Credit Arrangements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230623008 - Disclosure - Pension Plans and Other Postretirement Benefits (Tables)", "role": "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsTables", "shortName": "Pension Plans and Other Postretirement Benefits (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230713009 - Disclosure - Income Taxes (Tables)", "role": "http://www.cvshealth.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230783010 - Disclosure - Stock Incentive Plans (Tables)", "role": "http://www.cvshealth.com/role/StockIncentivePlansTables", "shortName": "Stock Incentive Plans (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfTreasuryStockByClassTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230843011 - Disclosure - Shareholders' Equity (Tables)", "role": "http://www.cvshealth.com/role/ShareholdersEquityTables", "shortName": "Shareholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfTreasuryStockByClassTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230913012 - Disclosure - Other Comprehensive Income (Tables)", "role": "http://www.cvshealth.com/role/OtherComprehensiveIncomeTables", "shortName": "Other Comprehensive Income (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100020004 - Statement - Consolidated Statements of Comprehensive Income", "role": "http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome", "shortName": "Consolidated Statements of Comprehensive Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230943013 - Disclosure - Earnings Per Share (Tables)", "role": "http://www.cvshealth.com/role/EarningsPerShareTables", "shortName": "Earnings Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCededCreditRiskByReinsurerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230973014 - Disclosure - Reinsurance (Tables)", "role": "http://www.cvshealth.com/role/ReinsuranceTables", "shortName": "Reinsurance (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCededCreditRiskByReinsurerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "231043015 - Disclosure - Segment Reporting (Tables)", "role": "http://www.cvshealth.com/role/SegmentReportingTables", "shortName": "Segment Reporting (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i48425c9c7d6d41fe9f23b091c65a31d4_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "cvs:NumberOfPlanMembers", "reportCount": 1, "unique": true, "unitRef": "people", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240044001 - Disclosure - Significant Accounting Policies - Narrative (Details)", "role": "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails", "shortName": "Significant Accounting Policies - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i48425c9c7d6d41fe9f23b091c65a31d4_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "cvs:NumberOfPlanMembers", "reportCount": 1, "unique": true, "unitRef": "people", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i48425c9c7d6d41fe9f23b091c65a31d4_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240054002 - Disclosure - Significant Accounting Policies - Restricted Cash (Details)", "role": "http://www.cvshealth.com/role/SignificantAccountingPoliciesRestrictedCashDetails", "shortName": "Significant Accounting Policies - Restricted Cash (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "ifcbe414ba05c4538bc76281ff3ac3fa4_I20191231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i48425c9c7d6d41fe9f23b091c65a31d4_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetNetCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240064003 - Disclosure - Significant Accounting Policies - Accounts Receivable (Details)", "role": "http://www.cvshealth.com/role/SignificantAccountingPoliciesAccountsReceivableDetails", "shortName": "Significant Accounting Policies - Accounts Receivable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i48425c9c7d6d41fe9f23b091c65a31d4_I20211231", "decimals": "-6", "lang": "en-US", "name": "cvs:VendorandManufacturerReceivables", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i48425c9c7d6d41fe9f23b091c65a31d4_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240074004 - Disclosure - Significant Accounting Policies - Property Plant and Equipment (Details)", "role": "http://www.cvshealth.com/role/SignificantAccountingPoliciesPropertyPlantandEquipmentDetails", "shortName": "Significant Accounting Policies - Property Plant and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i48425c9c7d6d41fe9f23b091c65a31d4_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240084005 - Disclosure - Significant Accounting Policies - Disaggregation of Revenue (Details)", "role": "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails", "shortName": "Significant Accounting Policies - Disaggregation of Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i58bb9dd9de57438c8823cb7f0f5b7456_D20210101-20211231", "decimals": "-6", "lang": "en-US", "name": "cvs:PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i48425c9c7d6d41fe9f23b091c65a31d4_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetNetCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240094006 - Disclosure - Significant Accounting Policies - Receivables and Contracted Balances (Details)", "role": "http://www.cvshealth.com/role/SignificantAccountingPoliciesReceivablesandContractedBalancesDetails", "shortName": "Significant Accounting Policies - Receivables and Contracted Balances (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "ic9bbc3798d714a95928e301134f0a8b4_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerLiabilityCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240104007 - Disclosure - Significant Accounting Policies - Contract Balances (Details)", "role": "http://www.cvshealth.com/role/SignificantAccountingPoliciesContractBalancesDetails", "shortName": "Significant Accounting Policies - Contract Balances (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": "-6", "lang": "en-US", "name": "cvs:ContractWithCustomerLiabilityLoyaltyProgramEarningsAndGiftCardIssuance", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i48425c9c7d6d41fe9f23b091c65a31d4_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100030005 - Statement - Consolidated Balance Sheets", "role": "http://www.cvshealth.com/role/ConsolidatedBalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i48425c9c7d6d41fe9f23b091c65a31d4_I20211231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:InventoryNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "cvs:TotalInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i48425c9c7d6d41fe9f23b091c65a31d4_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LongTermInvestments", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240114008 - Disclosure - Significant Accounting Policies - Variable Interest Entities (Details)", "role": "http://www.cvshealth.com/role/SignificantAccountingPoliciesVariableInterestEntitiesDetails", "shortName": "Significant Accounting Policies - Variable Interest Entities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "cvs:ProceedsFromVariableInterestEntity", "span", "div", "us-gaap:ConsolidationVariableInterestEntityPolicy", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": "-6", "lang": "en-US", "name": "cvs:ProceedsFromVariableInterestEntity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i7c0970400e154d55993f70f521cd55da_D20200101-20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240124009 - Disclosure - Significant Accounting Policies - Discontinued Operations (Details)", "role": "http://www.cvshealth.com/role/SignificantAccountingPoliciesDiscontinuedOperationsDetails", "shortName": "Significant Accounting Policies - Discontinued Operations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i7c0970400e154d55993f70f521cd55da_D20200101-20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ProceedsFromDivestitureOfBusinesses", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240144010 - Disclosure - Divestitures - Narrative (Details)", "role": "http://www.cvshealth.com/role/DivestituresNarrativeDetails", "shortName": "Divestitures - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i7fd8613bfc0d4364b6e49aa6a8b2d288_D20190101-20191231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:GainLossOnSaleOfBusiness", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "cvs:TotalInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i48425c9c7d6d41fe9f23b091c65a31d4_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ShortTermInvestments", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240174011 - Disclosure - Investments - Schedule of Total Investments (Details)", "role": "http://www.cvshealth.com/role/InvestmentsScheduleofTotalInvestmentsDetails", "shortName": "Investments - Schedule of Total Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "cvs:TotalInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i48425c9c7d6d41fe9f23b091c65a31d4_I20211231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:Investments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i48425c9c7d6d41fe9f23b091c65a31d4_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RestrictedInvestmentsAtFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240184012 - Disclosure - Investments - Narrative (Details)", "role": "http://www.cvshealth.com/role/InvestmentsNarrativeDetails", "shortName": "Investments - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i48425c9c7d6d41fe9f23b091c65a31d4_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RestrictedInvestmentsAtFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i48425c9c7d6d41fe9f23b091c65a31d4_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "cvs:DebtSecuritiesAvailableForSaleAmortizedCostNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240194013 - Disclosure - Investments - Debt Securities (Details)", "role": "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails", "shortName": "Investments - Debt Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i48425c9c7d6d41fe9f23b091c65a31d4_I20211231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i48425c9c7d6d41fe9f23b091c65a31d4_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "cvs:DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateWithinOneYearAmortizedCostNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240204014 - Disclosure - Investments - Debt Securities by Maturity (Details)", "role": "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails", "shortName": "Investments - Debt Securities by Maturity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i48425c9c7d6d41fe9f23b091c65a31d4_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "cvs:DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateWithinOneYearAmortizedCostNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i48425c9c7d6d41fe9f23b091c65a31d4_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions", "reportCount": 1, "unique": true, "unitRef": "security", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240214015 - Disclosure - Investments - Unrealized Loss Position (Details)", "role": "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails", "shortName": "Investments - Unrealized Loss Position (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i48425c9c7d6d41fe9f23b091c65a31d4_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions", "reportCount": 1, "unique": true, "unitRef": "security", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i48425c9c7d6d41fe9f23b091c65a31d4_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240224016 - Disclosure - Investments - Unrealized Loss Position Maturities (Details)", "role": "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails", "shortName": "Investments - Unrealized Loss Position Maturities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i48425c9c7d6d41fe9f23b091c65a31d4_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "cvs:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "cvs:ActivityInMortgageLoanPortfolioTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i81f297d193504b64a77dc2ee3da88ccb_D20210101-20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:MortgageLoansOnRealEstateNewMortgageLoans", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240234017 - Disclosure - Investments - Mortgage Loans (Details)", "role": "http://www.cvshealth.com/role/InvestmentsMortgageLoansDetails", "shortName": "Investments - Mortgage Loans (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "cvs:ActivityInMortgageLoanPortfolioTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i81f297d193504b64a77dc2ee3da88ccb_D20210101-20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:MortgageLoansOnRealEstateNewMortgageLoans", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i48425c9c7d6d41fe9f23b091c65a31d4_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100040006 - Statement - Consolidated Balance Sheets (Parenthetical)", "role": "http://www.cvshealth.com/role/ConsolidatedBalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i48425c9c7d6d41fe9f23b091c65a31d4_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "cvs:ScheduleOfMortgageLoanInternalCreditRatingsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "if07ab5ed5fe44735bee0f7db6106013d_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:MortgageLoansOnRealEstate", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240244018 - Disclosure - Investments - Mortgage Loans Credit Ratings Indicator (Details)", "role": "http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails", "shortName": "Investments - Mortgage Loans Credit Ratings Indicator (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "cvs:ScheduleOfMortgageLoanInternalCreditRatingsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "if07ab5ed5fe44735bee0f7db6106013d_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:MortgageLoansOnRealEstate", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "if07ab5ed5fe44735bee0f7db6106013d_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "cvs:MortgageLoansOnRealEstateCollectionsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240254019 - Disclosure - Investments - Schedule of Mortgage Loan Principal Repayments (Details)", "role": "http://www.cvshealth.com/role/InvestmentsScheduleofMortgageLoanPrincipalRepaymentsDetails", "shortName": "Investments - Schedule of Mortgage Loan Principal Repayments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "if07ab5ed5fe44735bee0f7db6106013d_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "cvs:MortgageLoansOnRealEstateCollectionsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentIncomeTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:InvestmentIncomeInterestAndDividend", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240264020 - Disclosure - Investments - Net Investment Income (Details)", "role": "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails", "shortName": "Investments - Net Investment Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentIncomeTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:InvestmentIncomeInterestAndDividend", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "cvs:ProceedsAndRelatedGrossRealizedCapitalGainsLossesFromSaleOfDebtSecuritiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240274021 - Disclosure - Investments - Realized Gains (Details)", "role": "http://www.cvshealth.com/role/InvestmentsRealizedGainsDetails", "shortName": "Investments - Realized Gains (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "cvs:ProceedsAndRelatedGrossRealizedCapitalGainsLossesFromSaleOfDebtSecuritiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i48425c9c7d6d41fe9f23b091c65a31d4_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240304022 - Disclosure - Fair Value - Fair Value Measurements (Details)", "role": "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails", "shortName": "Fair Value - Fair Value Measurements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:FinancialLiabilitiesFairValueDisclosure", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i91e5f841bc1148249e50546c6b0c4b62_I20211231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:FinancialLiabilitiesFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetRecurringBasisStillHeldUnrealizedGainLossOci", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240314023 - Disclosure - Fair Value - Changes in Level 3 Financial Assets (Details)", "role": "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails", "shortName": "Fair Value - Changes in Level 3 Financial Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetRecurringBasisStillHeldUnrealizedGainLossOci", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4f78308e3c32426bb0c2ca2138e491d2_D20210101-20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240324024 - Disclosure - Fair Value - Gross Transfers Into (Out Of) Level 3 (Details)", "role": "http://www.cvshealth.com/role/FairValueGrossTransfersIntoOutOfLevel3Details", "shortName": "Fair Value - Gross Transfers Into (Out Of) Level 3 (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i870c8f372f074816aa15ac75a237b726_D20210101-20211231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "ie5ff79f6ea7640da8266c10697cb62dc_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:MortgagesHeldForSaleFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240334025 - Disclosure - Fair Value - Carrying Value and Fair Value Classified by Level (Details)", "role": "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails", "shortName": "Fair Value - Carrying Value and Fair Value Classified by Level (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "ie5ff79f6ea7640da8266c10697cb62dc_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:MortgagesHeldForSaleFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i48425c9c7d6d41fe9f23b091c65a31d4_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:SeparateAccountAssets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240344026 - Disclosure - Fair Value - Separate Accounts Fair Value (Details)", "role": "http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails", "shortName": "Fair Value - Separate Accounts Fair Value (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i91e5f841bc1148249e50546c6b0c4b62_I20211231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:SeparateAccountAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4f78308e3c32426bb0c2ca2138e491d2_D20210101-20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240354027 - Disclosure - Fair Value - Narrative (Details)", "role": "http://www.cvshealth.com/role/FairValueNarrativeDetails", "shortName": "Fair Value - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "icfcc06f892d44fcead268e6e21698a4a_D20210101-20211231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ProceedsFromCustomers", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100050007 - Statement - Consolidated Statements of Cash Flows", "role": "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ProceedsFromCustomers", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "ic9bbc3798d714a95928e301134f0a8b4_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240384028 - Disclosure - Goodwill and Other Intangibles - Goodwill (Details)", "role": "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesGoodwillDetails", "shortName": "Goodwill and Other Intangibles - Goodwill (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i7c0970400e154d55993f70f521cd55da_D20200101-20201231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:GoodwillAcquiredDuringPeriod", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i2350df645dc04e808a96e20dad3a3fba_D20200701-20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:GoodwillImpairmentLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240394029 - Disclosure - Goodwill and Other Intangibles - Narrative (Details)", "role": "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesNarrativeDetails", "shortName": "Goodwill and Other Intangibles - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i48425c9c7d6d41fe9f23b091c65a31d4_I20211231", "decimals": "-8", "lang": "en-US", "name": "us-gaap:GoodwillImpairedAccumulatedImpairmentLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "cvs:FinitelivedandindefinitelivedintangibleassetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i48425c9c7d6d41fe9f23b091c65a31d4_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240404030 - Disclosure - Goodwill and Other Intangibles - Intangible Assets (Details)", "role": "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails", "shortName": "Goodwill and Other Intangibles - Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "cvs:FinitelivedandindefinitelivedintangibleassetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i48425c9c7d6d41fe9f23b091c65a31d4_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i48425c9c7d6d41fe9f23b091c65a31d4_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240414031 - Disclosure - Goodwill and Other Acquired Intangibles - Future Amortization Expense (Details)", "role": "http://www.cvshealth.com/role/GoodwillandOtherAcquiredIntangiblesFutureAmortizationExpenseDetails", "shortName": "Goodwill and Other Acquired Intangibles - Future Amortization Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i48425c9c7d6d41fe9f23b091c65a31d4_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240444032 - Disclosure - Leases - Narrative (Details)", "role": "http://www.cvshealth.com/role/LeasesNarrativeDetails", "shortName": "Leases - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i7c0970400e154d55993f70f521cd55da_D20200101-20201231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:SaleAndLeasebackTransactionGainLossNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240454033 - Disclosure - Leases - Summary of the Components of Net Lease Cost (Details)", "role": "http://www.cvshealth.com/role/LeasesSummaryoftheComponentsofNetLeaseCostDetails", "shortName": "Leases - Summary of the Components of Net Lease Cost (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240464034 - Disclosure - Leases - Supplemental Cash Flow Information (Details)", "role": "http://www.cvshealth.com/role/LeasesSupplementalCashFlowInformationDetails", "shortName": "Leases - Supplemental Cash Flow Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "cvs:LesseeLeaseTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i48425c9c7d6d41fe9f23b091c65a31d4_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240474035 - Disclosure - Leases - Supplemental Balance Sheet Information (Details)", "role": "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails", "shortName": "Leases - Supplemental Balance Sheet Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "cvs:LesseeLeaseTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i48425c9c7d6d41fe9f23b091c65a31d4_I20211231", "decimals": "-6", "lang": "en-US", "name": "cvs:FinanceLeaseRightOfUseAssetGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i48425c9c7d6d41fe9f23b091c65a31d4_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240484036 - Disclosure - Leases - Maturities of Operating and Finance Lease Liabilities (Details)", "role": "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails", "shortName": "Leases - Maturities of Operating and Finance Lease Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i48425c9c7d6d41fe9f23b091c65a31d4_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i2d081ebfc3b747a899e5a8ee7f9179b0_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240514037 - Disclosure - Health Care Costs Payable - Incurred and Paid Health Care Claims Development (Details)", "role": "http://www.cvshealth.com/role/HealthCareCostsPayableIncurredandPaidHealthCareClaimsDevelopmentDetails", "shortName": "Health Care Costs Payable - Incurred and Paid Health Care Claims Development (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i2d081ebfc3b747a899e5a8ee7f9179b0_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i13739c11655d4b66b619ac881014f765_I20181231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100060008 - Statement - Consolidated Statements of Shareholders' Equity", "role": "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity", "shortName": "Consolidated Statements of Shareholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i13739c11655d4b66b619ac881014f765_I20181231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i6355e336e53c4e8f9fad360d96598544_I20211231", "decimals": "-8", "first": true, "lang": "en-US", "name": "us-gaap:ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240524038 - Disclosure - Health Care Costs Payable - Narrative (Details)", "role": "http://www.cvshealth.com/role/HealthCareCostsPayableNarrativeDetails", "shortName": "Health Care Costs Payable - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i6355e336e53c4e8f9fad360d96598544_I20211231", "decimals": "-8", "first": true, "lang": "en-US", "name": "us-gaap:ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i2d081ebfc3b747a899e5a8ee7f9179b0_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240534039 - Disclosure - Health Care Costs Payable - Reconciliation of Health Care Net Incurred and Paid Claims Development to Health Care Costs Payable Liability (Details)", "role": "http://www.cvshealth.com/role/HealthCareCostsPayableReconciliationofHealthCareNetIncurredandPaidClaimsDevelopmenttoHealthCareCostsPayableLiabilityDetails", "shortName": "Health Care Costs Payable - Reconciliation of Health Care Net Incurred and Paid Claims Development to Health Care Costs Payable Liability (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i2d081ebfc3b747a899e5a8ee7f9179b0_I20211231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R82": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "ic9bbc3798d714a95928e301134f0a8b4_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240544040 - Disclosure - Health Care Costs Payable - Reconciliation of Health Care Costs Payable (Details)", "role": "http://www.cvshealth.com/role/HealthCareCostsPayableReconciliationofHealthCareCostsPayableDetails", "shortName": "Health Care Costs Payable - Reconciliation of Health Care Costs Payable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "idf62411f04644ec5a62a251e4c8f705a_D20210101-20211231", "decimals": "-6", "lang": "en-US", "name": "cvs:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidExcludedFromTotalIncurredHealthCareCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R83": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i48425c9c7d6d41fe9f23b091c65a31d4_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240574041 - Disclosure - Borrowings and Credit Arrangements - Schedule of Debt (Details)", "role": "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails", "shortName": "Borrowings and Credit Arrangements - Schedule of Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i48425c9c7d6d41fe9f23b091c65a31d4_I20211231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DebtInstrumentUnamortizedPremium", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R84": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i48425c9c7d6d41fe9f23b091c65a31d4_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240584042 - Disclosure - Borrowings and Credit Arrangements - Debt Maturities (Details)", "role": "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsDebtMaturitiesDetails", "shortName": "Borrowings and Credit Arrangements - Debt Maturities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i48425c9c7d6d41fe9f23b091c65a31d4_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R85": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i48425c9c7d6d41fe9f23b091c65a31d4_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:FederalHomeLoanBankAdvancesGeneralDebtObligationsDisclosuresMaximumAmountAvailable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240594043 - Disclosure - Borrowings and Credit Arrangements - Short-term Borrowings (Details)", "role": "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsShorttermBorrowingsDetails", "shortName": "Borrowings and Credit Arrangements - Short-term Borrowings (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i48425c9c7d6d41fe9f23b091c65a31d4_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:FederalHomeLoanBankAdvancesGeneralDebtObligationsDisclosuresMaximumAmountAvailable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R86": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i2a2c1f6bdf614434afbf804874bfc4c5_D20210818-20210818", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ProceedsFromDebtNetOfIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240604044 - Disclosure - Borrowings and Credit Arrangements - Long-Term Borrowings (Details)", "role": "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsLongTermBorrowingsDetails", "shortName": "Borrowings and Credit Arrangements - Long-Term Borrowings (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i2a2c1f6bdf614434afbf804874bfc4c5_D20210818-20210818", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ProceedsFromDebtNetOfIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R87": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240634045 - Disclosure - Pension Plans and Other Postretirement Benefits - Narrative (Details)", "role": "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNarrativeDetails", "shortName": "Pension Plans and Other Postretirement Benefits - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R88": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock", "us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4d6e9082a5464b3c81907ef022a3e221_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanBenefitObligation", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240644046 - Disclosure - Pension Plans and Other Postretirement Benefits - Benefit Obligations and Plan Assets (Details)", "role": "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails", "shortName": "Pension Plans and Other Postretirement Benefits - Benefit Obligations and Plan Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock", "us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i91e3b1a50898436e96566b8b401ba50a_D20210101-20211231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanActuarialGainLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R89": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i91e3b1a50898436e96566b8b401ba50a_D20210101-20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanInterestCost", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240654047 - Disclosure - Pension Plans and Other Postretirement Benefits - Net Periodic Benefit Costs (Details)", "role": "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNetPeriodicBenefitCostsDetails", "shortName": "Pension Plans and Other Postretirement Benefits - Net Periodic Benefit Costs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i91e3b1a50898436e96566b8b401ba50a_D20210101-20211231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "cvs:TreasuryStockSharesHeldinTrust", "link:footnote", "span", "div", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "ifcbe414ba05c4538bc76281ff3ac3fa4_I20191231", "decimals": "-6", "first": true, "lang": "en-US", "name": "cvs:TreasuryStockSharesHeldinTrust", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100070009 - Statement - Consolidated Statements of Shareholders' Equity (Parentheticals)", "role": "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquityParentheticals", "shortName": "Consolidated Statements of Shareholders' Equity (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "cvs:TreasuryStockValueSharesHeldInTrust", "link:footnote", "span", "div", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "ifcbe414ba05c4538bc76281ff3ac3fa4_I20191231", "decimals": "-6", "lang": "en-US", "name": "cvs:TreasuryStockValueSharesHeldInTrust", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R90": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i48425c9c7d6d41fe9f23b091c65a31d4_I20211231", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240664048 - Disclosure - Pension Plans and Other Postretirement Benefits - Weighted Average Assumptions Used (Details)", "role": "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsWeightedAverageAssumptionsUsedDetails", "shortName": "Pension Plans and Other Postretirement Benefits - Weighted Average Assumptions Used (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i48425c9c7d6d41fe9f23b091c65a31d4_I20211231", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R91": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock", "us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i42e14e6ecf0d4519bad91c300172ce00_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240674049 - Disclosure - Pension Plans and Other Postretirement Benefits - Fair Value of Pension Plan Assets (Details)", "role": "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails", "shortName": "Pension Plans and Other Postretirement Benefits - Fair Value of Pension Plan Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i1308d93a146c4c8488b59a3c5a030c08_I20211231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R92": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock", "us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4d6e9082a5464b3c81907ef022a3e221_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240684050 - Disclosure - Pension Plans and Other Postretirement Benefits - Changes in Level 3 Pension Plan Assets (Details)", "role": "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsChangesinLevel3PensionPlanAssetsDetails", "shortName": "Pension Plans and Other Postretirement Benefits - Changes in Level 3 Pension Plan Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DefinedBenefitPlanPlanAssetsCategoryTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i7de4764ce7104e8cb8330af8da0f29b3_D20210101-20211231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R93": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i42e14e6ecf0d4519bad91c300172ce00_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240694051 - Disclosure - Pension Plans and Other Postretirement Benefits - Defined Benefit Plans Expected Benefit (Details)", "role": "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsDefinedBenefitPlansExpectedBenefitDetails", "shortName": "Pension Plans and Other Postretirement Benefits - Defined Benefit Plans Expected Benefit (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i42e14e6ecf0d4519bad91c300172ce00_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R94": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240724052 - Disclosure - Income Taxes - Income Tax Provision (Details)", "role": "http://www.cvshealth.com/role/IncomeTaxesIncomeTaxProvisionDetails", "shortName": "Income Taxes - Income Tax Provision (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R95": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i48425c9c7d6d41fe9f23b091c65a31d4_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240734053 - Disclosure - Income Taxes - Narrative (Details)", "role": "http://www.cvshealth.com/role/IncomeTaxesNarrativeDetails", "shortName": "Income Taxes - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R96": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240744054 - Disclosure - Income Taxes - Effective Tax Rate Reconciliation (Details)", "role": "http://www.cvshealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails", "shortName": "Income Taxes - Effective Tax Rate Reconciliation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R97": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i48425c9c7d6d41fe9f23b091c65a31d4_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240754055 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details)", "role": "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails", "shortName": "Income Taxes - Deferred Tax Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i48425c9c7d6d41fe9f23b091c65a31d4_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R98": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "ic9bbc3798d714a95928e301134f0a8b4_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240764056 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Details)", "role": "http://www.cvshealth.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails", "shortName": "Income Taxes - Unrecognized Tax Benefits (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i23e34e947aac44fc9f5cf5448f94f452_I20181231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R99": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240794057 - Disclosure - Stock Incentive Plans - Stock-Based Compensation Expense and ESPP (Details)", "role": "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails", "shortName": "Stock Incentive Plans - Stock-Based Compensation Expense and ESPP (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cvs-20211231.htm", "contextRef": "i4fa4f86ecd2d49489934d0916692e4b7_D20210101-20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } } }, "segmentCount": 235, "tag": { "cvs_A2016RepurchaseProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2016 Repurchase Program [Member]", "label": "2016 Repurchase Program [Member]", "terseLabel": "2016 Repurchase Program" } } }, "localname": "A2016RepurchaseProgramMember", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityShareRepurchasesDetails" ], "xbrltype": "domainItemType" }, "cvs_A2021AcceleratedRepurchaseProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2021 Accelerated Repurchase Program", "label": "2021 Accelerated Repurchase Program [Member]", "terseLabel": "2021 ASR" } } }, "localname": "A2021AcceleratedRepurchaseProgramMember", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails" ], "xbrltype": "domainItemType" }, "cvs_A2021RepurchaseProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2021 Repurchase Program", "label": "2021 Repurchase Program [Member]", "terseLabel": "2021 Repurchase Program" } } }, "localname": "A2021RepurchaseProgramMember", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityShareRepurchasesDetails" ], "xbrltype": "domainItemType" }, "cvs_AcceleratedShareRepurchaseProgramMaximumNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accelerated Share Repurchase Program, Maximum Number of Shares", "label": "Accelerated Share Repurchase Program, Maximum Number of Shares", "terseLabel": "ASR, maximum amount of shares received or delivered" } } }, "localname": "AcceleratedShareRepurchaseProgramMaximumNumberOfShares", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails" ], "xbrltype": "sharesItemType" }, "cvs_AcceleratedShareRepurchasesAgreementAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accelerated Share Repurchases Agreement, Amount", "label": "Accelerated Share Repurchases Agreement, Amount", "terseLabel": "ASR agreement, amount" } } }, "localname": "AcceleratedShareRepurchasesAgreementAmount", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails" ], "xbrltype": "monetaryItemType" }, "cvs_AcceleratedShareRepurchasesPercentOfNotionalAmountInSharesToBeReceivedAtEndOfProgram": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accelerated Share Repurchases, Percent of Notional Amount in Shares to be Received at End of Program", "label": "Accelerated Share Repurchases, Percent of Notional Amount in Shares to be Received at End of Program", "terseLabel": "ASR, shares to be received at the end of program as a percent of notional amount" } } }, "localname": "AcceleratedShareRepurchasesPercentOfNotionalAmountInSharesToBeReceivedAtEndOfProgram", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails" ], "xbrltype": "percentItemType" }, "cvs_AcceleratedShareRepurchasesPercentOfNotionalAmountReceivedInShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accelerated Share Repurchases, Percent of Notional Amount Received in Shares", "label": "Accelerated Share Repurchases, Percent of Notional Amount Received in Shares", "terseLabel": "ASR percent of notional amount received in shares" } } }, "localname": "AcceleratedShareRepurchasesPercentOfNotionalAmountReceivedInShares", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails" ], "xbrltype": "percentItemType" }, "cvs_ActivityInMortgageLoanPortfolioTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Table representing activities in mortgage loan portfolio during the period.", "label": "Activity in mortgage loan portfolio [Table Text Block]", "verboseLabel": "Activity in mortgage loan portfolio" } } }, "localname": "ActivityInMortgageLoanPortfolioTableTextBlock", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "cvs_AdjustedOperatingIncomeLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjusted Operating Income (Loss)", "label": "Adjusted Operating Income (Loss)", "terseLabel": "Adjusted operating income", "verboseLabel": "Adjusted operating income (loss)" } } }, "localname": "AdjustedOperatingIncomeLoss", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails", "http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails" ], "xbrltype": "monetaryItemType" }, "cvs_AetnaInc2010StockIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aetna Inc 2010 Stock Incentive Plan [Member]", "label": "Aetna Inc 2010 Stock Incentive Plan [Member]", "terseLabel": "Aetna Inc 2010 Stock Incentive Plan" } } }, "localname": "AetnaInc2010StockIncentivePlanMember", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails" ], "xbrltype": "domainItemType" }, "cvs_AllOtherReinsurersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All Other Reinsurers [Member]", "label": "All Other Reinsurers [Member]", "terseLabel": "All Other" } } }, "localname": "AllOtherReinsurersMember", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/ReinsuranceReinsuranceRecoverablesDetails" ], "xbrltype": "domainItemType" }, "cvs_AssumedInterestRatesOnLongDurationGroupLifeAndLongTermCareContracts": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assumed Interest Rates On Long Duration Group Life And Long Term Care Contracts", "label": "Assumed Interest Rates On Long Duration Group Life And Long Term Care Contracts", "terseLabel": "Assumed interest rates on long-duration group life and long-term care contracts" } } }, "localname": "AssumedInterestRatesOnLongDurationGroupLifeAndLongTermCareContracts", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "percentItemType" }, "cvs_AuditorInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Auditor Information [Abstract]", "label": "Auditor Information [Abstract]" } } }, "localname": "AuditorInformationAbstract", "nsuri": "http://www.cvshealth.com/20211231", "xbrltype": "stringItemType" }, "cvs_BackUpCreditFacilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Back-Up Credit Facilities [Member]", "label": "Back-Up Credit Facilities [Member]", "terseLabel": "Back-Up Credit Facilities" } } }, "localname": "BackUpCreditFacilitiesMember", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsShorttermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cvs_BarclaysBankMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Barclays Bank", "label": "Barclays Bank [Member]", "terseLabel": "Barclays Bank" } } }, "localname": "BarclaysBankMember", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails" ], "xbrltype": "domainItemType" }, "cvs_BrazilSubsidiaryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Brazil Subsidiary [Member]", "label": "Brazil Subsidiary [Member]", "terseLabel": "Brazil Subsidiary" } } }, "localname": "BrazilSubsidiaryMember", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/DivestituresNarrativeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "cvs_BusinessCombinationPurchasePriceAdjustmentOutsideOfMeasurementPeriod": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Purchase Price Adjustment, Outside of Measurement Period", "label": "Business Combination, Purchase Price Adjustment, Outside of Measurement Period", "terseLabel": "Acquisition purchase price adjustments outside of measurement period" } } }, "localname": "BusinessCombinationPurchasePriceAdjustmentOutsideOfMeasurementPeriod", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails" ], "xbrltype": "monetaryItemType" }, "cvs_CVSHealth2017IncentiveCompensationPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CVS Health 2017 Incentive Compensation Plan [Member]", "label": "CVS Health 2017 Incentive Compensation Plan [Member]", "terseLabel": "CVS Health 2017 Incentive Compensation Plan" } } }, "localname": "CVSHealth2017IncentiveCompensationPlanMember", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails" ], "xbrltype": "domainItemType" }, "cvs_CashFlowLesseeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash Flow, Lessee [Abstract]", "label": "Cash Flow, Lessee [Abstract]", "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:" } } }, "localname": "CashFlowLesseeAbstract", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/LeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "stringItemType" }, "cvs_Categories5and6Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mortgage loan credit quality indicator - Categories 5 and 6", "label": "Categories 5 and 6 [Member]", "terseLabel": "5 and 6" } } }, "localname": "Categories5and6Member", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails" ], "xbrltype": "domainItemType" }, "cvs_Category1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mortgage Loan Credit Quality Indicator - Category 1 [Member].", "label": "Category 1 [Member]", "terseLabel": "1" } } }, "localname": "Category1Member", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails" ], "xbrltype": "domainItemType" }, "cvs_Category2To4Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mortgage Loan Credit Quality Indicator - Category 2 to 4 [Member].", "label": "Category 2 to 4 [Member]", "terseLabel": "2 to 4" } } }, "localname": "Category2To4Member", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails" ], "xbrltype": "domainItemType" }, "cvs_Category7Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mortgage loan credit quality indicator - Category 7", "label": "Category 7 [Member]", "terseLabel": "7" } } }, "localname": "Category7Member", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails" ], "xbrltype": "domainItemType" }, "cvs_ChangeInContractWithCustomerLiabilityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Change in Contract with Customer, Liability", "label": "Change in Contract with Customer, Liability [Roll Forward]", "terseLabel": "Change in Contract with Customer, Liability [Roll Forward]" } } }, "localname": "ChangeInContractWithCustomerLiabilityRollForward", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesContractBalancesDetails" ], "xbrltype": "stringItemType" }, "cvs_CommonAndCollectiveTrustsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The total amount of Common/Collective Trusts held by the company, primarily related to investment funds otherwise known as underlying funds.", "label": "Common and Collective Trusts [Member]", "terseLabel": "Common/collective trusts" } } }, "localname": "CommonAndCollectiveTrustsMember", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails" ], "xbrltype": "domainItemType" }, "cvs_ContractWithCustomerLiabilityLoyaltyProgramEarningsAndGiftCardIssuance": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in contract liability recognized for loyalty program earnings and gift card issuance.", "label": "Contract With Customer Liability Loyalty Program Earnings And Gift Card Issuance", "terseLabel": "Rewards earnings and gift card issuances" } } }, "localname": "ContractWithCustomerLiabilityLoyaltyProgramEarningsAndGiftCardIssuance", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesContractBalancesDetails" ], "xbrltype": "monetaryItemType" }, "cvs_ContractWithCustomerLiabilityRedemptionAndBreakage": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Contract With Customer Liability Redemption And Breakage", "label": "Contract With Customer Liability Redemption And Breakage", "negatedTerseLabel": "Redemption and breakage" } } }, "localname": "ContractWithCustomerLiabilityRedemptionAndBreakage", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesContractBalancesDetails" ], "xbrltype": "monetaryItemType" }, "cvs_ContractualObligationsToMaintainLevelsOfSeparateAccounts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the contractual obligation to maintain the required level of funding in Separate Accounts necessary to fund specific guaranteed pensions annuities.", "label": "Contractual Obligations To Maintain Levels Of Separate Accounts", "terseLabel": "Contractual obligations underlying the guaranteed benefits" } } }, "localname": "ContractualObligationsToMaintainLevelsOfSeparateAccounts", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "cvs_CoventryHealthCareWorkersCompensationBusinessMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Coventry Health Care Workers Compensation Business", "label": "Coventry Health Care Workers Compensation Business [Member]", "terseLabel": "Coventry Health Care Workers Compensation Business" } } }, "localname": "CoventryHealthCareWorkersCompensationBusinessMember", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/DivestituresNarrativeDetails", "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails" ], "xbrltype": "domainItemType" }, "cvs_CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Credit Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings", "label": "Credit Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings", "terseLabel": "Credit-related impairment loss" } } }, "localname": "CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails" ], "xbrltype": "monetaryItemType" }, "cvs_DebtAndEquitySecuritiesAvailableForSaleMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Investments in debt and equity securities which are categorized neither as trading securities nor held-to-maturity securities. Such securities are reported at fair value; unrealized gains and losses related to Available-for-sale securities are excluded from earnings and reported in a separate component of shareholders' equity (other comprehensive income)", "label": "Debt And Equity Securities Available For Sale [Member]", "terseLabel": "Debt securities available for sale" } } }, "localname": "DebtAndEquitySecuritiesAvailableForSaleMember", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/InvestmentsScheduleofTotalInvestmentsDetails" ], "xbrltype": "domainItemType" }, "cvs_DebtExtinguishmentFees": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Extinguishment Fees", "label": "Debt Extinguishment Fees", "terseLabel": "Debt extinguishment fees" } } }, "localname": "DebtExtinguishmentFees", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsLongTermBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "cvs_DebtInstrumentUnamortizedDiscountandDebtIssuanceCostsNet": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Unamortized Discount and Debt Issuance Costs, Net", "label": "Debt Instrument, Unamortized Discount and Debt Issuance Costs, Net", "negatedTerseLabel": "Debt discounts and deferred financing costs" } } }, "localname": "DebtInstrumentUnamortizedDiscountandDebtIssuanceCostsNet", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails" ], "xbrltype": "monetaryItemType" }, "cvs_DebtSecuritiesAvailableForSaleAllocatedAndSingleMaturityDateMaturityAfter10YearsAmortizedCostNet": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails": { "order": 4.0, "parentTag": "cvs_DebtSecuritiesAvailableForSaleAmortizedCostNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-For-Sale, Allocated And Single Maturity Date, Maturity, After 10 Years, Amortized Cost, Net", "label": "Debt Securities, Available-For-Sale, Allocated And Single Maturity Date, Maturity, After 10 Years, Amortized Cost, Net", "terseLabel": "Greater than ten years" } } }, "localname": "DebtSecuritiesAvailableForSaleAllocatedAndSingleMaturityDateMaturityAfter10YearsAmortizedCostNet", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails" ], "xbrltype": "monetaryItemType" }, "cvs_DebtSecuritiesAvailableForSaleAmortizedCostNet": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available For Sale, Amortized Cost, Net", "label": "Debt Securities, Available For Sale, Amortized Cost, Net", "totalLabel": "Amortized Cost" } } }, "localname": "DebtSecuritiesAvailableForSaleAmortizedCostNet", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails", "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails" ], "xbrltype": "monetaryItemType" }, "cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYears": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, After Five Through Ten Years", "label": "Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, After Five Through Ten Years", "terseLabel": "After five years through ten years" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYears", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYearsAccumulatedLoss": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, After Five Through Ten Years, Accumulated Loss", "label": "Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, After Five Through Ten Years, Accumulated Loss", "terseLabel": "After five years through ten years" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYearsAccumulatedLoss", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYears": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, After One Through Five Years", "label": "Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, After One Through Five Years", "terseLabel": "One year through five years" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYears", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYearsAccumulatedLoss": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, After One Through Five Years, Accumulated Loss", "label": "Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, After One Through Five Years, Accumulated Loss", "terseLabel": "One year through five years" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYearsAccumulatedLoss", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYears": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, After Ten Years", "label": "Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, After Ten Years", "terseLabel": "Greater than ten years" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYears", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYearsAccumulatedLoss": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, After Ten Years, Accumulated Loss", "label": "Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, After Ten Years, Accumulated Loss", "terseLabel": "Greater than ten years" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYearsAccumulatedLoss", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYear": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails": { "order": 4.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, Within One Year", "label": "Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, Within One Year", "terseLabel": "Less than one year" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYear", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "cvs_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYearAccumulatedLoss": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails": { "order": 4.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, Within One Year, Accumulated Loss", "label": "Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Allocated And Single Maturity Date, Within One Year, Accumulated Loss", "terseLabel": "Less than one year" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYearAccumulatedLoss", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "cvs_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughFiveYearsAmortizedCostNet": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails": { "order": 2.0, "parentTag": "cvs_DebtSecuritiesAvailableForSaleAmortizedCostNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-For-Sale, Maturity, Allocated And Single Maturity Date, After One Through Five Years, Amortized Cost, Net", "label": "Debt Securities, Available-For-Sale, Maturity, Allocated And Single Maturity Date, After One Through Five Years, Amortized Cost, Net", "terseLabel": "One year through five years" } } }, "localname": "DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughFiveYearsAmortizedCostNet", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails" ], "xbrltype": "monetaryItemType" }, "cvs_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateWithinOneYearAmortizedCostNet": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails": { "order": 1.0, "parentTag": "cvs_DebtSecuritiesAvailableForSaleAmortizedCostNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-For-Sale, Maturity, Allocated And Single Maturity Date, Within One Year, Amortized Cost, Net", "label": "Debt Securities, Available-For-Sale, Maturity, Allocated And Single Maturity Date, Within One Year, Amortized Cost, Net", "terseLabel": "Less than one year" } } }, "localname": "DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateWithinOneYearAmortizedCostNet", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails" ], "xbrltype": "monetaryItemType" }, "cvs_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateafterFiveThroughTenYearsAmortizedCostNet": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails": { "order": 3.0, "parentTag": "cvs_DebtSecuritiesAvailableForSaleAmortizedCostNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-For-Sale, Maturity, Allocated And Single Maturity Date, after Five Through Ten Years, Amortized Cost, Net", "label": "Debt Securities, Available-For-Sale, Maturity, Allocated And Single Maturity Date, after Five Through Ten Years, Amortized Cost, Net", "terseLabel": "After five years through ten years" } } }, "localname": "DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateafterFiveThroughTenYearsAmortizedCostNet", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails" ], "xbrltype": "monetaryItemType" }, "cvs_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-For-Sale, Unrealized Loss Position, Fair Value [Abstract]", "label": "Debt Securities, Available-For-Sale, Unrealized Loss Position, Fair Value [Abstract]", "terseLabel": "Fair Value" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails" ], "xbrltype": "stringItemType" }, "cvs_DebtSecuritiesAvailableForSaleWeightedAverageDurationOfSecurities": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-For-Sale, Weighted Average Duration Of Securities", "label": "Debt Securities, Available-For-Sale, Weighted Average Duration Of Securities", "terseLabel": "Weighted average duration of securities" } } }, "localname": "DebtSecuritiesAvailableForSaleWeightedAverageDurationOfSecurities", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "durationItemType" }, "cvs_DebtSecuritiesAvailableForsaleMaturityWithoutSingleMaturityDateAmortizedCostNet": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails": { "order": 5.0, "parentTag": "cvs_DebtSecuritiesAvailableForSaleAmortizedCostNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-For-sale, Maturity, Without Single Maturity Date, Amortized Cost, Net", "label": "Debt Securities, Available-For-sale, Maturity, Without Single Maturity Date, Amortized Cost, Net", "terseLabel": "Debt securities, maturity, without single maturity date" } } }, "localname": "DebtSecuritiesAvailableForsaleMaturityWithoutSingleMaturityDateAmortizedCostNet", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails" ], "xbrltype": "monetaryItemType" }, "cvs_DebtSecuritiesAvailableforsaleContinuousUnrealizedLossPositionwithoutSingleMaturityDateAmortizedCost": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails": { "order": 5.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, without Single Maturity Date, Amortized Cost", "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, without Single Maturity Date, Amortized Cost", "terseLabel": "Debt securities, maturity, without single maturity date, unrealized losses" } } }, "localname": "DebtSecuritiesAvailableforsaleContinuousUnrealizedLossPositionwithoutSingleMaturityDateAmortizedCost", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "cvs_DebtSecuritiesAvailableforsaleContinuousUnrealizedLossPositionwithoutSingleMaturityDateFairValue": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails": { "order": 5.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, without Single Maturity Date, Fair Value", "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, without Single Maturity Date, Fair Value", "terseLabel": "Debt securities, maturity, without single maturity date, fair value" } } }, "localname": "DebtSecuritiesAvailableforsaleContinuousUnrealizedLossPositionwithoutSingleMaturityDateFairValue", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "cvs_DeferredTaxAssetsPayrollTaxDeferral": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred Tax Assets, Payroll Tax Deferral", "label": "Deferred Tax Assets, Payroll Tax Deferral", "terseLabel": "Payroll tax deferral" } } }, "localname": "DeferredTaxAssetsPayrollTaxDeferral", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "cvs_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsBadDebtsAndOtherAllowances": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred Tax Assets, Tax Deferred Expense, Reserves And Accruals, Bad Debts And Other Allowances", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves And Accruals, Bad Debts And Other Allowances", "terseLabel": "Bad debts and other allowances" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsBadDebtsAndOtherAllowances", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "cvs_DeferredTaxLiabilitiesDepreciationAndAmortization": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred Tax Liabilities, Depreciation and Amortization - Amount of deferred tax liability attributable to taxable temporary differences from depreciation and amortization", "label": "Deferred Tax Liabilities, Depreciation and Amortization", "negatedTerseLabel": "Depreciation and amortization" } } }, "localname": "DeferredTaxLiabilitiesDepreciationAndAmortization", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "cvs_DeferredTaxLiabilitiesRetirementBenefits": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred Tax Liabilities, Retirement Benefits", "label": "Deferred Tax Liabilities, Retirement Benefits", "negatedTerseLabel": "Retirement benefits" } } }, "localname": "DeferredTaxLiabilitiesRetirementBenefits", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "cvs_DefinedBenefitPlanCommonCollectiveTrustDebtSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Defined Benefit Plan, Common Collective Trust, Debt Securities [Member]", "label": "Defined Benefit Plan, Common Collective Trust, Debt Securities [Member]", "terseLabel": "Common/collective trusts, Debt Securities" } } }, "localname": "DefinedBenefitPlanCommonCollectiveTrustDebtSecuritiesMember", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "cvs_DefinedBenefitPlanCommonCollectiveTrustEquitySecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Defined Benefit Plan, Common Collective Trust, Equity Securities [Member]", "label": "Defined Benefit Plan, Common Collective Trust, Equity Securities [Member]", "terseLabel": "Common/collective trusts, Equity Securities" } } }, "localname": "DefinedBenefitPlanCommonCollectiveTrustEquitySecuritiesMember", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "cvs_DenominatorForEarningsPerShareCalculationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Denominator For Earnings Per Share Calculation [Abstract]", "label": "Denominator For Earnings Per Share Calculation [Abstract]", "terseLabel": "Denominator for earnings per share calculation:" } } }, "localname": "DenominatorForEarningsPerShareCalculationAbstract", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/EarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "cvs_DividendsPayableQuarterlyDividendsDeclaredIncreaseAmountPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Dividends Payable, Quarterly Dividends Declared, Increase Amount, Percent", "label": "Dividends Payable, Quarterly Dividends Declared, Increase Amount, Percent", "terseLabel": "Quarterly dividends declared, percent increase" } } }, "localname": "DividendsPayableQuarterlyDividendsDeclaredIncreaseAmountPercent", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityDividendsDetails" ], "xbrltype": "percentItemType" }, "cvs_DrogariaOnofreLtdaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Drogaria onofre Ltda.", "label": "Drogaria onofre Ltda. [Member]", "terseLabel": "Drogaria onofre Ltda." } } }, "localname": "DrogariaOnofreLtdaMember", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/DivestituresNarrativeDetails" ], "xbrltype": "domainItemType" }, "cvs_ESPPIssuanceNetOfTreasuryStockSharesAcquiredCostMethod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ESPP Issuance, Net of Treasury Stock, Shares, Acquired, Cost Method", "label": "ESPP Issuance, Net of Treasury Stock, Shares, Acquired, Cost Method", "terseLabel": "ESPP issuances, net of purchase of treasury shares (in shares)" } } }, "localname": "ESPPIssuanceNetOfTreasuryStockSharesAcquiredCostMethod", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "sharesItemType" }, "cvs_ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "ESPP Issuance, Net of Treasury Stock, Value, Acquired, Cost Method", "label": "ESPP Issuance, Net of Treasury Stock, Value, Acquired, Cost Method", "terseLabel": "ESPP issuances, net of purchase of treasury shares" } } }, "localname": "ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "cvs_EmployeeStockOptionsandStockAppreciationRightsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee Stock Options and Stock Appreciation Rights [Member]", "label": "Employee Stock Options and Stock Appreciation Rights [Member]", "terseLabel": "Employee Stock Options and Stock Appreciation Rights" } } }, "localname": "EmployeeStockOptionsandStockAppreciationRightsMember", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails", "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails", "http://www.cvshealth.com/role/StockIncentivePlansValuationandAssumptionsDetails" ], "xbrltype": "domainItemType" }, "cvs_EquitySecuritiesDomesticRealEstateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This category includes information about ownership interests or the right to acquire ownership interests in domestic real estate whose ownership interest is represented by shares of common or preferred stock (which is neither mandatorily redeemable no redeemable at the option of the holder), convertible securities, stock rights, or stock warrants categorized by other type.", "label": "Equity Securities Domestic Real Estate [Member]", "terseLabel": "Domestic real estate" } } }, "localname": "EquitySecuritiesDomesticRealEstateMember", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "cvs_FairValueAssetsMeasuredOnRecurringBasisUnobservableUnputReconciliationNetRealizedAndUnrealizedCapitalGainesLossesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fair Value, Assets Measured On Recurring Basis, Unobservable Unput Reconciliation, Net Realized And Unrealized Capital Gaines (Losses) [Abstract]", "label": "Fair Value, Assets Measured On Recurring Basis, Unobservable Unput Reconciliation, Net Realized And Unrealized Capital Gaines (Losses) [Abstract]", "terseLabel": "Net realized and unrealized capital gains (losses):" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableUnputReconciliationNetRealizedAndUnrealizedCapitalGainesLossesAbstract", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails" ], "xbrltype": "stringItemType" }, "cvs_FinanceLeaseAssetsAndLiabilitiesLesseeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Finance Lease, Assets And Liabilities, Lessee [Abstract]", "label": "Finance Lease, Assets And Liabilities, Lessee [Abstract]", "terseLabel": "Finance leases:" } } }, "localname": "FinanceLeaseAssetsAndLiabilitiesLesseeAbstract", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "cvs_FinanceLeaseCost": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/LeasesSummaryoftheComponentsofNetLeaseCostDetails": { "order": 4.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Finance Lease Cost", "label": "Finance Lease Cost", "totalLabel": "Total finance lease costs" } } }, "localname": "FinanceLeaseCost", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/LeasesSummaryoftheComponentsofNetLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "cvs_FinanceLeaseRightOfUseAssetAccumulatedDepreciation": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails": { "order": 2.0, "parentTag": "cvs_FinanceLeaseRightOfUseAssetNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Finance Lease, Right-Of-Use Asset, Accumulated Depreciation", "label": "Finance Lease, Right-Of-Use Asset, Accumulated Depreciation", "negatedTerseLabel": "Accumulated depreciation" } } }, "localname": "FinanceLeaseRightOfUseAssetAccumulatedDepreciation", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "cvs_FinanceLeaseRightOfUseAssetGross": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails": { "order": 1.0, "parentTag": "cvs_FinanceLeaseRightOfUseAssetNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Finance Lease, Right-Of-Use Asset, Gross", "label": "Finance Lease, Right-Of-Use Asset, Gross", "terseLabel": "Property and equipment, gross" } } }, "localname": "FinanceLeaseRightOfUseAssetGross", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "cvs_FinanceLeaseRightOfUseAssetNet": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Finance Lease, Right-Of-Use Asset, Net", "label": "Finance Lease, Right-Of-Use Asset, Net", "totalLabel": "Property and equipment, net" } } }, "localname": "FinanceLeaseRightOfUseAssetNet", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "cvs_FinitelivedandindefinitelivedintangibleassetsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the cost, accumulated amortization and net balance of intangibles assets and amortization period, in total and by major class. Finite-lived intangible assets have a stated useful life over which their gross carrying value is amortized. Indefinite intangible assets have a projected indefinite period of benefit (hence are not amortized).", "label": "Finite lived and indefinite lived intangible assets [Table Text Block]", "terseLabel": "Other intangible assets" } } }, "localname": "FinitelivedandindefinitelivedintangibleassetsTableTextBlock", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesTables" ], "xbrltype": "textBlockItemType" }, "cvs_FixturesEquipmentAndInternallyDevelopedSoftwareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fixtures, Equipment And Internally Developed Software [Member]", "label": "Fixtures, Equipment And Internally Developed Software [Member]", "terseLabel": "Fixtures, equipment and internally developed software" } } }, "localname": "FixturesEquipmentAndInternallyDevelopedSoftwareMember", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "cvs_FloatingRateNotesDueMarch2020Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Floating Rate Notes Due March 2020 [Member]", "label": "Floating Rate Notes Due March 2020 [Member]", "terseLabel": "Floating rate notes due March 2020" } } }, "localname": "FloatingRateNotesDueMarch2020Member", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsLongTermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cvs_FloatingRateNotesDueMarch2021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Floating Rate Notes Due March 2021 [Member]", "label": "Floating Rate Notes Due March 2021 [Member]", "terseLabel": "Floating rate notes due March 2021" } } }, "localname": "FloatingRateNotesDueMarch2021Member", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "cvs_FloatingRateNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Floating Rate Notes", "label": "Floating Rate Notes [Member]", "terseLabel": "Floating Rate Notes" } } }, "localname": "FloatingRateNotesMember", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsLongTermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cvs_FormerGainContingencyRecognizedInCurrentPeriodBeforeTax": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Former Gain Contingency, Recognized in Current Period, Before Tax", "label": "Former Gain Contingency, Recognized in Current Period, Before Tax", "terseLabel": "Former gain contingency, recognized in current period, before tax" } } }, "localname": "FormerGainContingencyRecognizedInCurrentPeriodBeforeTax", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cvs_FormerGainContingencyRecognizedInCurrentPeriodNetOfTax": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Former Gain Contingency, Recognized in Current Period, Net of Tax", "label": "Former Gain Contingency, Recognized in Current Period, Net of Tax", "terseLabel": "Former gain contingency, recognized in current period, net of tax" } } }, "localname": "FormerGainContingencyRecognizedInCurrentPeriodNetOfTax", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cvs_FourYearsReinsuranceAgreementWithUnrelatedInsurer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This line item represents the four years of a reinsurance agreement with an unrelated insurer.", "label": "Four Years Reinsurance Agreement With Unrelated Insurer", "terseLabel": "Four years reinsurance agreement with unrelated insurer" } } }, "localname": "FourYearsReinsuranceAgreementWithUnrelatedInsurer", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/ReinsuranceNarrativeDetails" ], "xbrltype": "durationItemType" }, "cvs_FrontStoreRevenueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Front Store Revenue [Member]", "label": "Front Store Revenue [Member]", "terseLabel": "Front Store" } } }, "localname": "FrontStoreRevenueMember", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "cvs_GuarantorObligationsNumberofLeases": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Guarantor Obligations, Number of Leases", "label": "Guarantor Obligations, Number of Leases", "terseLabel": "Number of leases guaranteed" } } }, "localname": "GuarantorObligationsNumberofLeases", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "integerItemType" }, "cvs_HartfordLifeAndAccidentInsuranceCompanyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Hartford Life And Accident Insurance Company [Member]", "label": "Hartford Life And Accident Insurance Company [Member]", "terseLabel": "Hartford Life and Accident Insurance Company" } } }, "localname": "HartfordLifeAndAccidentInsuranceCompanyMember", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/ReinsuranceReinsuranceRecoverablesDetails" ], "xbrltype": "domainItemType" }, "cvs_HealthCareBenefitsSegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Health Care Benefits Segment [Member]", "label": "Health Care Benefits Segment [Member]", "terseLabel": "Health Care Benefits" } } }, "localname": "HealthCareBenefitsSegmentMember", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/DivestituresNarrativeDetails", "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesGoodwillDetails", "http://www.cvshealth.com/role/HealthCareCostsPayableNarrativeDetails", "http://www.cvshealth.com/role/HealthCareCostsPayableReconciliationofHealthCareCostsPayableDetails", "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails", "http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "cvs_HealthCareCostsPayablePeriodAfterDateOfServicesClaimsArePaid": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Health Care Costs Payable, Period After Date Of Services Claims Are Paid", "label": "Health Care Costs Payable, Period After Date Of Services Claims Are Paid", "terseLabel": "Period after date of service a claim is paid" } } }, "localname": "HealthCareCostsPayablePeriodAfterDateOfServicesClaimsArePaid", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "cvs_HealthInsurerFee": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the estimated amount of the health insurer fee accrued during the reporting period, as required by Health Care Reform.", "label": "Health Insurer Fee", "terseLabel": "Health insurer fee" } } }, "localname": "HealthInsurerFee", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cvs_HealthInsurerFeeTaxEffectPercent": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails": { "order": 4.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Represents the tax effect of the health care reform's non-tax deductible health insurer fee.", "label": "Health Insurer Fee Tax Effect, Percent", "terseLabel": "Health insurer fee" } } }, "localname": "HealthInsurerFeeTaxEffectPercent", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "cvs_HeartlandHealthcareServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Heartland Healthcare Services [Member]", "label": "Heartland Healthcare Services [Member]", "terseLabel": "Heartland Healthcare Services" } } }, "localname": "HeartlandHealthcareServicesMember", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "cvs_HeathSavingsAccountBalance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Heath Savings Account Balance", "label": "Heath Savings Account Balance", "terseLabel": "HSA balances" } } }, "localname": "HeathSavingsAccountBalance", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cvs_IndividualPublicHealthInsuranceExchangesSubmittedRegulatoryFilingsNumberOfStates": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Individual Public Health Insurance Exchanges, Submitted Regulatory Filings, Number of States", "label": "Individual Public Health Insurance Exchanges, Submitted Regulatory Filings, Number of States", "terseLabel": "Number of states the Company has submitted regulatory filings for a January 2022 entrance into the individual public health insurance exchange" } } }, "localname": "IndividualPublicHealthInsuranceExchangesSubmittedRegulatoryFilingsNumberOfStates", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "cvs_Initialcontractualterm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Variable Interest Entity, Initial Contractual Term", "label": "Initial contractual term", "terseLabel": "Initial contractual term (in years)" } } }, "localname": "Initialcontractualterm", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesVariableInterestEntitiesDetails" ], "xbrltype": "durationItemType" }, "cvs_InsuranceAndHmoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Insurance and HMO subsidiaries [Member].", "label": "Insurance and HMO [Member]", "terseLabel": "Insurance and HMO" } } }, "localname": "InsuranceAndHmoMember", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityRegulatoryRequirementsDetails" ], "xbrltype": "domainItemType" }, "cvs_InsurancePremiumDeficiencyReservePolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Insurance Premium Deficiency Reserve [Policy Text Block]", "label": "Insurance Premium Deficiency Reserve [Policy Text Block]", "terseLabel": "Premium Deficiency Reserves" } } }, "localname": "InsurancePremiumDeficiencyReservePolicyTextBlock", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "cvs_InvestmentContractsWithFixedMaturityFairValueDisclosure": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Investment Contracts With Fixed Maturity, Fair Value Disclosure.", "label": "Investment Contracts With Fixed Maturity, Fair Value Disclosure", "terseLabel": "Investment contracts with a fixed maturity" } } }, "localname": "InvestmentContractsWithFixedMaturityFairValueDisclosure", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails" ], "xbrltype": "monetaryItemType" }, "cvs_InvestmentContractsWithoutFixedMaturityFairValueDisclosure": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Investment Contracts Without A Fixed Maturity, Fair Value Disclosure.", "label": "Investment Contracts Without A Fixed Maturity, Fair Value Disclosure", "terseLabel": "Investment contracts without a fixed maturity" } } }, "localname": "InvestmentContractsWithoutFixedMaturityFairValueDisclosure", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails" ], "xbrltype": "monetaryItemType" }, "cvs_InvestmentIncomeExcludingCapitalGainsorLosses": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails": { "order": 1.0, "parentTag": "us-gaap_InvestmentIncomeNet", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Investment Income, Excluding Capital Gains or Losses", "label": "Investment Income, Excluding Capital Gains or Losses", "totalLabel": "Net investment income (excluding net realized capital gains or losses)" } } }, "localname": "InvestmentIncomeExcludingCapitalGainsorLosses", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails" ], "xbrltype": "monetaryItemType" }, "cvs_LeaseLiability": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": { "order": 2.0, "parentTag": "cvs_LesseeLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lease, Liability", "label": "Lease, Liability", "totalLabel": "Total lease liabilities" } } }, "localname": "LeaseLiability", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "cvs_LeasesWeightedAverageDiscountRateAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Leases, Weighted Average Discount Rate [Abstract]", "label": "Leases, Weighted Average Discount Rate [Abstract]", "terseLabel": "Weighted average discount rate" } } }, "localname": "LeasesWeightedAverageDiscountRateAbstract", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "cvs_LesseeLeaseTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Lease [Table Text Block]", "label": "Lessee, Lease [Table Text Block]", "terseLabel": "Supplemental balance sheet information" } } }, "localname": "LesseeLeaseTableTextBlock", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "cvs_LesseeLeasesLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Leases Liabilities Payments Due [Abstract]", "label": "Lessee, Leases Liabilities Payments Due [Abstract]", "terseLabel": "Total" } } }, "localname": "LesseeLeasesLiabilitiesPaymentsDueAbstract", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "cvs_LesseeLiabilityPaymentsDue": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, Liability, Payments, Due", "label": "Lessee, Liability, Payments, Due", "totalLabel": "Total lease payments" } } }, "localname": "LesseeLiabilityPaymentsDue", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "cvs_LesseeLiabilityPaymentsDueAfterYearFive": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": { "order": 6.0, "parentTag": "cvs_LesseeLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, Liability, Payments, Due After Year Five", "label": "Lessee, Liability, Payments, Due After Year Five", "totalLabel": "Thereafter" } } }, "localname": "LesseeLiabilityPaymentsDueAfterYearFive", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "cvs_LesseeLiabilityPaymentsDueYearFive": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": { "order": 5.0, "parentTag": "cvs_LesseeLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, Liability, Payments, Due Year Five", "label": "Lessee, Liability, Payments, Due Year Five", "totalLabel": "2026" } } }, "localname": "LesseeLiabilityPaymentsDueYearFive", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "cvs_LesseeLiabilityPaymentsDueYearFour": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": { "order": 4.0, "parentTag": "cvs_LesseeLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, Liability, Payments, Due Year Four", "label": "Lessee, Liability, Payments, Due Year Four", "totalLabel": "2025" } } }, "localname": "LesseeLiabilityPaymentsDueYearFour", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "cvs_LesseeLiabilityPaymentsDueYearThree": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": { "order": 3.0, "parentTag": "cvs_LesseeLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, Liability, Payments, Due Year Three", "label": "Lessee, Liability, Payments, Due Year Three", "totalLabel": "2024" } } }, "localname": "LesseeLiabilityPaymentsDueYearThree", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "cvs_LesseeLiabilityPaymentsDueYearTwo": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "cvs_LesseeLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, Liability, Payments, Due Year Two", "label": "Lessee, Liability, Payments, Due Year Two", "totalLabel": "2023" } } }, "localname": "LesseeLiabilityPaymentsDueYearTwo", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "cvs_LesseeLiabilityPaymentsYearOne": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "cvs_LesseeLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, Liability, Payments, Year One", "label": "Lessee, Liability, Payments, Year One", "totalLabel": "2022" } } }, "localname": "LesseeLiabilityPaymentsYearOne", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "cvs_LesseeLiabilityUndiscountedExcessAmount": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": { "order": 1.0, "parentTag": "cvs_LesseeLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, Liability, Undiscounted Excess Amount", "label": "Lessee, Liability, Undiscounted Excess Amount", "negatedTotalLabel": "Less: imputed interest" } } }, "localname": "LesseeLiabilityUndiscountedExcessAmount", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "cvs_LesseeOperatingAndFinanceLeasesRenewalTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating And Finance Leases, Renewal Term", "label": "Lessee, Operating And Finance Leases, Renewal Term", "terseLabel": "Lease renewal term" } } }, "localname": "LesseeOperatingAndFinanceLeasesRenewalTerm", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "cvs_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidExcludedFromTotalIncurredHealthCareCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Liability For Unpaid Claims And Claims Adjustment Expense, Claims Paid, Excluded From Total Incurred Health Care Costs", "label": "Liability For Unpaid Claims And Claims Adjustment Expense, Claims Paid, Excluded From Total Incurred Health Care Costs", "terseLabel": "Benefit costs recorded in other insurance liabilities" } } }, "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidExcludedFromTotalIncurredHealthCareCosts", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableReconciliationofHealthCareCostsPayableDetails" ], "xbrltype": "monetaryItemType" }, "cvs_LiabilityforUnpaidClaims": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the total liability on the balance sheet for unpaid claims for both short-duration and long-duration insurance contracts after reinsurance.", "label": "Liability for Unpaid Claims", "terseLabel": "Liability for unpaid claims" } } }, "localname": "LiabilityforUnpaidClaims", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cvs_LimitedPaymentsContracts": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum assumed interest rates on limited payment contracts on large case pensions business.", "label": "Limited Payments Contracts", "terseLabel": "Assumed interest rates on limited payment pension contracts on large case pension business (in hundredths)" } } }, "localname": "LimitedPaymentsContracts", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "percentItemType" }, "cvs_LincolnLifeAnnuityCompanyOfNewYorkMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lincoln Life & Annuity Company Of New York [Member]", "label": "Lincoln Life & Annuity Company Of New York [Member]", "terseLabel": "Lincoln Life & Annuity Company of New York" } } }, "localname": "LincolnLifeAnnuityCompanyOfNewYorkMember", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/ReinsuranceReinsuranceRecoverablesDetails" ], "xbrltype": "domainItemType" }, "cvs_LongTermCareReportingUnitMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long-Term Care Reporting Unit [Member]", "label": "Long-Term Care Reporting Unit [Member]", "terseLabel": "Long-Term Care Reporting Unit" } } }, "localname": "LongTermCareReportingUnitMember", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesNarrativeDetails" ], "xbrltype": "domainItemType" }, "cvs_LongtermDebtGrossAndLeaseObligation": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Long-term Debt, Gross And Lease Obligation", "label": "Long-term Debt, Gross And Lease Obligation", "terseLabel": "Total debt principal", "totalLabel": "Total debt principal" } } }, "localname": "LongtermDebtGrossAndLeaseObligation", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsDebtMaturitiesDetails", "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails" ], "xbrltype": "monetaryItemType" }, "cvs_LossContingencyAuditMethodologySampleSize": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Audit Methodology Sample Size", "label": "Loss Contingency, Audit Methodology Sample Size", "terseLabel": "Audit methodology sample size" } } }, "localname": "LossContingencyAuditMethodologySampleSize", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "integerItemType" }, "cvs_MortgageLoansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents mortgage loans for the reporting period measured at carrying value. We carry the value of our mortgage loan investments on our balance sheet at the unpaid principal balance, net of impairment reserves.", "label": "Mortgage Loans [Member]", "terseLabel": "Mortgage loans" } } }, "localname": "MortgageLoansMember", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails", "http://www.cvshealth.com/role/InvestmentsScheduleofTotalInvestmentsDetails" ], "xbrltype": "domainItemType" }, "cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalAfterYearFive": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/InvestmentsScheduleofMortgageLoanPrincipalRepaymentsDetails": { "order": 6.0, "parentTag": "us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Mortgage Loans On Real Estate Collections Of Principal After Year Five", "label": "Mortgage Loans On Real Estate Collections Of Principal After Year Five", "terseLabel": "Thereafter" } } }, "localname": "MortgageLoansOnRealEstateCollectionsOfPrincipalAfterYearFive", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/InvestmentsScheduleofMortgageLoanPrincipalRepaymentsDetails" ], "xbrltype": "monetaryItemType" }, "cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInNextTwelveMonths": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/InvestmentsScheduleofMortgageLoanPrincipalRepaymentsDetails": { "order": 1.0, "parentTag": "us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Mortgage Loans On Real Estate Collections Of Principal In Next Twelve Months", "label": "Mortgage Loans On Real Estate Collections Of Principal In Next Twelve Months", "terseLabel": "2022" } } }, "localname": "MortgageLoansOnRealEstateCollectionsOfPrincipalInNextTwelveMonths", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/InvestmentsScheduleofMortgageLoanPrincipalRepaymentsDetails" ], "xbrltype": "monetaryItemType" }, "cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearFive": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/InvestmentsScheduleofMortgageLoanPrincipalRepaymentsDetails": { "order": 5.0, "parentTag": "us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Mortgage Loans On Real Estate Collections Of Principal In Year Five", "label": "Mortgage Loans On Real Estate Collections Of Principal In Year Five", "terseLabel": "2026" } } }, "localname": "MortgageLoansOnRealEstateCollectionsOfPrincipalInYearFive", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/InvestmentsScheduleofMortgageLoanPrincipalRepaymentsDetails" ], "xbrltype": "monetaryItemType" }, "cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearFour": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/InvestmentsScheduleofMortgageLoanPrincipalRepaymentsDetails": { "order": 4.0, "parentTag": "us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Mortgage Loans On Real Estate Collections Of Principal In Year Four", "label": "Mortgage Loans On Real Estate Collections Of Principal In Year Four", "terseLabel": "2025" } } }, "localname": "MortgageLoansOnRealEstateCollectionsOfPrincipalInYearFour", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/InvestmentsScheduleofMortgageLoanPrincipalRepaymentsDetails" ], "xbrltype": "monetaryItemType" }, "cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearThree": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/InvestmentsScheduleofMortgageLoanPrincipalRepaymentsDetails": { "order": 3.0, "parentTag": "us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Mortgage Loans On Real Estate Collections Of Principal In Year Three", "label": "Mortgage Loans On Real Estate Collections Of Principal In Year Three", "terseLabel": "2024" } } }, "localname": "MortgageLoansOnRealEstateCollectionsOfPrincipalInYearThree", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/InvestmentsScheduleofMortgageLoanPrincipalRepaymentsDetails" ], "xbrltype": "monetaryItemType" }, "cvs_MortgageLoansOnRealEstateCollectionsOfPrincipalInYearTwo": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/InvestmentsScheduleofMortgageLoanPrincipalRepaymentsDetails": { "order": 2.0, "parentTag": "us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Mortgage Loans On Real Estate Collections Of Principal In Year Two", "label": "Mortgage Loans On Real Estate Collections Of Principal In Year Two", "terseLabel": "2023" } } }, "localname": "MortgageLoansOnRealEstateCollectionsOfPrincipalInYearTwo", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/InvestmentsScheduleofMortgageLoanPrincipalRepaymentsDetails" ], "xbrltype": "monetaryItemType" }, "cvs_MortgageLoansOnRealEstateLoansFullyRepaid": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Pertains to amount of mortgage loans fully repaid.", "label": "Mortgage Loans on Real Estate, Loans Fully Repaid", "terseLabel": "Mortgage loans fully repaid" } } }, "localname": "MortgageLoansOnRealEstateLoansFullyRepaid", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/InvestmentsMortgageLoansDetails" ], "xbrltype": "monetaryItemType" }, "cvs_MortgageLoansOnRealEstateYearOfOriginationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mortgage Loans On Real Estate Year Of Origination", "label": "Mortgage Loans On Real Estate Year Of Origination [Axis]", "terseLabel": "Mortgage Loans On Real Estate Year Of Origination [Axis]" } } }, "localname": "MortgageLoansOnRealEstateYearOfOriginationAxis", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails" ], "xbrltype": "stringItemType" }, "cvs_MortgageLoansOnRealEstateYearOfOriginationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mortgage Loans On Real Estate Year Of Origination", "label": "Mortgage Loans On Real Estate Year Of Origination [Domain]", "terseLabel": "Mortgage Loans On Real Estate Year Of Origination [Domain]" } } }, "localname": "MortgageLoansOnRealEstateYearOfOriginationDomain", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails" ], "xbrltype": "domainItemType" }, "cvs_NetGainFromWriteOffOfDeferredDebtIssuanceCosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Net Gain from Write Off of Deferred Debt Issuance Costs", "label": "Net Gain from Write Off of Deferred Debt Issuance Costs", "terseLabel": "Net gain on write-off of net unamortized deferred financing premiums on early extinguishment of debt" } } }, "localname": "NetGainFromWriteOffOfDeferredDebtIssuanceCosts", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsLongTermBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "cvs_NetRevenuesRetailCoPayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Net Revenues, Retail CoPayments", "label": "Net Revenues, Retail CoPayments", "terseLabel": "Co-payments" } } }, "localname": "NetRevenuesRetailCoPayments", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails" ], "xbrltype": "monetaryItemType" }, "cvs_NoncontrollinginterestOtherPeriodIncreaseDecrease": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Noncontrolling interest, Other Period Increase (Decrease)", "label": "Noncontrolling interest, Other Period Increase (Decrease)", "terseLabel": "Other increases (decreases) in noncontrolling interest" } } }, "localname": "NoncontrollinginterestOtherPeriodIncreaseDecrease", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "cvs_NumberOfPeopleServed": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of People Served", "label": "Number Of People Served", "terseLabel": "Number of people served" } } }, "localname": "NumberOfPeopleServed", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "cvs_NumberOfPlanMembers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Plan Members", "label": "Number Of Plan Members", "terseLabel": "Number of plan members" } } }, "localname": "NumberOfPlanMembers", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "cvs_NumberOfStoresAnnualPlannedClosuresForClosurePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Stores, Annual Planned Closures For Closure Period", "label": "Number of Stores, Annual Planned Closures For Closure Period", "terseLabel": "Number of stores, annual planned closures for closure period" } } }, "localname": "NumberOfStoresAnnualPlannedClosuresForClosurePeriod", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/LeasesNarrativeDetails" ], "xbrltype": "integerItemType" }, "cvs_NumberOfStoresPlannedClosure": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Stores, Planned Closure", "label": "Number of Stores, Planned Closure", "terseLabel": "Number of stores, planned closure" } } }, "localname": "NumberOfStoresPlannedClosure", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/LeasesNarrativeDetails", "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "cvs_NumberOfStoresPlannedClosurePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Stores, Planned Closure Period", "label": "Number of Stores, Planned Closure Period", "terseLabel": "Number of stores, planned closure period (in years)" } } }, "localname": "NumberOfStoresPlannedClosurePeriod", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "cvs_NumberofPatientsServedperYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Patients Served per Year", "label": "Number of Patients Served per Year", "terseLabel": "Number of patients served per year (more than)" } } }, "localname": "NumberofPatientsServedperYear", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "cvs_NumberofReinsuranceContractsEnteredInto": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of reinsurance contracts entered into with an unrelated insurer.", "label": "Number of Reinsurance Contracts Entered Into", "terseLabel": "Number of reinsurance contracts entered into" } } }, "localname": "NumberofReinsuranceContractsEnteredInto", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/ReinsuranceNarrativeDetails" ], "xbrltype": "integerItemType" }, "cvs_NumberofWalkInMedicalClinics": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Walk In Medical Clinics", "label": "Number of Walk In Medical Clinics", "terseLabel": "Number of walk-in medical clinics" } } }, "localname": "NumberofWalkInMedicalClinics", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "cvs_NumeratorForEarningsPerShareCalculationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Numerator For Earnings Per Share Calculation [Abstract]", "label": "Numerator For Earnings Per Share Calculation [Abstract]", "terseLabel": "Numerator for earnings per share calculation:" } } }, "localname": "NumeratorForEarningsPerShareCalculationAbstract", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/EarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "cvs_OperatingAndCapitalLeasesAmountDueInExcessOfRemainingEstimatedEconomicLife": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating And Capital Leases, Amount Due In Excess Of Remaining Estimated Economic Life", "label": "Operating And Capital Leases, Amount Due In Excess Of Remaining Estimated Economic Life", "terseLabel": "Leases, amount due in excess of remaining estimated economic life" } } }, "localname": "OperatingAndCapitalLeasesAmountDueInExcessOfRemainingEstimatedEconomicLife", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "cvs_OperatingExpensesExcludingStoreImpairmentsAndGoodwillImpairments": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating Expenses, Excluding Store Impairments and Goodwill Impairments", "label": "Operating Expenses, Excluding Store Impairments and Goodwill Impairments", "terseLabel": "Operating expenses" } } }, "localname": "OperatingExpensesExcludingStoreImpairmentsAndGoodwillImpairments", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "cvs_OperatingLeaseAssetsAndLiabilitiesLesseeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating Lease, Assets And Liabilities, Lessee [Abstract]", "label": "Operating Lease, Assets And Liabilities, Lessee [Abstract]", "terseLabel": "Operating leases:" } } }, "localname": "OperatingLeaseAssetsAndLiabilitiesLesseeAbstract", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "cvs_OperatingLeaseRightOfUseAssetFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating lease, Right-of-Use Asset, Fair Value Disclosure", "label": "Operating lease, Right-of-Use Asset, Fair Value Disclosure", "terseLabel": "Operating lease, right-of-use asset, fair value" } } }, "localname": "OperatingLeaseRightOfUseAssetFairValueDisclosure", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cvs_OtherAcquiredIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "-- None. No documentation exists for this element. --", "label": "Other Acquired Intangible Assets [Line Items]", "terseLabel": "Other Intangible Assets[Line Items]" } } }, "localname": "OtherAcquiredIntangibleAssetsLineItems", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "cvs_OtherAcquiredIntangibleAssetsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "-- None. No documentation exists for this element. --", "label": "Other Acquired Intangible Assets [Table]", "terseLabel": "Other Intangible Assets [Table]" } } }, "localname": "OtherAcquiredIntangibleAssetsTable", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "cvs_OtherAssetBackedSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Securities collateralized by a variety of assets such as automobile loans, credit card receivables, home equity loans, etc.", "label": "Other Asset-Backed Securities [Member]", "terseLabel": "Other asset-backed securities" } } }, "localname": "OtherAssetBackedSecuritiesMember", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails", "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails", "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails", "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails", "http://www.cvshealth.com/role/InvestmentsNarrativeDetails", "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails", "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails" ], "xbrltype": "domainItemType" }, "cvs_OtherInsuranceLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other Insurance Liabilities, Current", "label": "Other Insurance Liabilities, Current", "terseLabel": "Other insurance liabilities" } } }, "localname": "OtherInsuranceLiabilitiesCurrent", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "cvs_OtherInsuranceLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Insurance Liabilities [Member]", "label": "Other Insurance Liabilities [Member]", "terseLabel": "Other Insurance Liabilities" } } }, "localname": "OtherInsuranceLiabilitiesMember", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "cvs_OtherInsuranceLiabilitiesNoncurrent": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other Insurance Liabilities, Noncurrent", "label": "Other Insurance Liabilities, Noncurrent", "terseLabel": "Other long-term insurance liabilities" } } }, "localname": "OtherInsuranceLiabilitiesNoncurrent", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "cvs_OtherLongTermInsuranceLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Long-Term Insurance Liabilities [Member]", "label": "Other Long-Term Insurance Liabilities [Member]", "terseLabel": "Other Long-Term Insurance Liabilities" } } }, "localname": "OtherLongTermInsuranceLiabilitiesMember", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "cvs_OutstandingSeniorNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding Senior Notes [Member]", "label": "Outstanding Senior Notes [Member]", "terseLabel": "Outstanding Senior Notes" } } }, "localname": "OutstandingSeniorNotesMember", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsLongTermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cvs_PaymentsForAcceleratedShareRepurchasesAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments for Accelerated Share Repurchases, Amount", "label": "Payments for Accelerated Share Repurchases, Amount", "terseLabel": "Payments for ASR, amount" } } }, "localname": "PaymentsForAcceleratedShareRepurchasesAmount", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails" ], "xbrltype": "monetaryItemType" }, "cvs_PaymentsforInsuranceBenefits": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows_1": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments for Insurance Benefits", "label": "Payments for Insurance Benefits", "negatedTerseLabel": "Insurance benefits paid" } } }, "localname": "PaymentsforInsuranceBenefits", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "cvs_PaymentsforInventoryandPrescriptionsDispensedbyRetailNetworkPharmacies": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows_1": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments for Inventory and Prescriptions Dispensed by Retail Network Pharmacies", "label": "Payments for Inventory and Prescriptions Dispensed by Retail Network Pharmacies", "negatedTerseLabel": "Cash paid for inventory and prescriptions dispensed by retail network pharmacies" } } }, "localname": "PaymentsforInventoryandPrescriptionsDispensedbyRetailNetworkPharmacies", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "cvs_PensionAndAnnuityInvestmentContractsInterest": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pension And Annuity Investment Contracts Interest", "label": "Pension And Annuity Investment Contracts Interest", "terseLabel": "Interest rate for pension and annuity investment contracts" } } }, "localname": "PensionAndAnnuityInvestmentContractsInterest", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "percentItemType" }, "cvs_PharmacyClaimsandDiscountsPayableCurrent": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Pharmacy Claims and Discounts Payable, Current", "label": "Pharmacy Claims and Discounts Payable, Current", "terseLabel": "Pharmacy claims and discounts payable" } } }, "localname": "PharmacyClaimsandDiscountsPayableCurrent", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "cvs_PharmacyRebatePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pharmacy Rebate Period", "label": "Pharmacy Rebate Period", "terseLabel": "Pharmacy rebate period" } } }, "localname": "PharmacyRebatePeriod", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "cvs_PharmacyRevenueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pharmacy Revenue [Member]", "label": "Pharmacy Revenue [Member]", "terseLabel": "Pharmacy" } } }, "localname": "PharmacyRevenueMember", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "cvs_PharmacyServicesSegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pharmacy Services Segment [Member]", "label": "Pharmacy Services Segment [Member]", "terseLabel": "Pharmacy Services" } } }, "localname": "PharmacyServicesSegmentMember", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesGoodwillDetails", "http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "cvs_PremiumDeficiencyReserveLiability": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/HealthCareCostsPayableReconciliationofHealthCareNetIncurredandPaidClaimsDevelopmenttoHealthCareCostsPayableLiabilityDetails": { "order": 4.0, "parentTag": "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of reserves related to expected future claims, including maintenance costs (for example, direct costs such as claim processing costs), in excess of existing reserves plus anticipated future premiums and reinsurance recoveries.", "label": "Premium Deficiency Reserve Liability", "terseLabel": "Add: Premium deficiency reserve", "verboseLabel": "Premium deficiency reserve" } } }, "localname": "PremiumDeficiencyReserveLiability", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableReconciliationofHealthCareCostsPayableDetails", "http://www.cvshealth.com/role/HealthCareCostsPayableReconciliationofHealthCareNetIncurredandPaidClaimsDevelopmenttoHealthCareCostsPayableLiabilityDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Premiums Earned, Net And Revenue From Contract With Customer, Excluding Assessed Tax", "label": "Premiums Earned, Net And Revenue From Contract With Customer, Excluding Assessed Tax", "terseLabel": "Revenues from external customers", "verboseLabel": "Revenues" } } }, "localname": "PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails" ], "xbrltype": "monetaryItemType" }, "cvs_PremiumsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Premiums [Member]", "label": "Premiums [Member]", "terseLabel": "Premiums" } } }, "localname": "PremiumsMember", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "cvs_ProceedsAndRelatedGrossRealizedCapitalGainsLossesFromSaleOfDebtSecuritiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This item includes proceeds from the sale of debt securities and the related gross realized capital gains and losses, excluding amounts related to experience-rated and discontinued products.", "label": "Proceeds And Related Gross Realized Capital Gains Losses From Sale Of Debt Securities [Table Text Block]", "verboseLabel": "Proceeds and related gross realized capital gains and losses from the sale of debt securities" } } }, "localname": "ProceedsAndRelatedGrossRealizedCapitalGainsLossesFromSaleOfDebtSecuritiesTableTextBlock", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "cvs_ProceedsFromVariableInterestEntity": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Variable Interest Entity", "label": "Proceeds From Variable Interest Entity", "terseLabel": "Proceeds from VIE" } } }, "localname": "ProceedsFromVariableInterestEntity", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesVariableInterestEntitiesDetails" ], "xbrltype": "monetaryItemType" }, "cvs_ProviderNetworksMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Acquired in a business combination or other transaction. This item represents the value ascribed to the relationships with the acquiree's physicians, hospitals and other health care providers network.", "label": "Provider networks [Member]", "terseLabel": "Provider networks" } } }, "localname": "ProviderNetworksMember", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "cvs_RadcliffAndFlaimVAetnaIncEtAlMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Radcliff and Flaim v Aetna Inc., et al", "label": "Radcliff and Flaim v Aetna Inc., et al [Member]", "terseLabel": "Radcliff and Flaim v Aetna Inc., et al" } } }, "localname": "RadcliffAndFlaimVAetnaIncEtAlMember", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "cvs_ReceiptFromBusinessCombinationPurchasePriceAdjustmentOutsideOfMeasurementPeriod": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Receipt from Business Combination, Purchase Price Adjustment, Outside of Measurement Period", "label": "Receipt from Business Combination, Purchase Price Adjustment, Outside of Measurement Period", "terseLabel": "Receipt related purchase price adjustment from acquisition" } } }, "localname": "ReceiptFromBusinessCombinationPurchasePriceAdjustmentOutsideOfMeasurementPeriod", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails" ], "xbrltype": "monetaryItemType" }, "cvs_RedOakMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Red Oak", "label": "Red Oak [Member]", "terseLabel": "Red Oak" } } }, "localname": "RedOakMember", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesVariableInterestEntitiesDetails" ], "xbrltype": "domainItemType" }, "cvs_RedeemablePreferredSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Redeemable Preferred Securities [Member]", "label": "Redeemable Preferred Securities [Member]", "terseLabel": "Redeemable preferred securities" } } }, "localname": "RedeemablePreferredSecuritiesMember", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "cvs_RelatedPartyTransactionCharitableContributionToNonProfitEntity": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Charitable Contribution To Non-Profit Entity", "label": "Related Party Transaction, Charitable Contribution To Non-Profit Entity", "terseLabel": "Charitable contribution to CVS Health Foundation" } } }, "localname": "RelatedPartyTransactionCharitableContributionToNonProfitEntity", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cvs_RestrictedStockUnitsandPerformanceShareUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted Stock Units and Performance Share Units [Member]", "label": "Restricted Stock Units and Performance Share Units [Member]", "terseLabel": "Restricted Stock Units and Performance Share Units" } } }, "localname": "RestrictedStockUnitsandPerformanceShareUnitsMember", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansRestrictedStockActivityDetails", "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails" ], "xbrltype": "domainItemType" }, "cvs_RetailLongTermCareSegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Retail Long-Term Care Segment [Member]", "label": "Retail Long-Term Care Segment [Member]", "terseLabel": "Retail/ LTC" } } }, "localname": "RetailLongTermCareSegmentMember", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/DivestituresNarrativeDetails", "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesGoodwillDetails", "http://www.cvshealth.com/role/LeasesNarrativeDetails", "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails", "http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "cvs_RevolvingCreditFacilityExpiringMay112026Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revolving Credit Facility, Expiring May 11, 2026", "label": "Revolving Credit Facility, Expiring May 11, 2026 [Member]", "terseLabel": "Revolving Credit Facility, Expiring May 11, 2026" } } }, "localname": "RevolvingCreditFacilityExpiringMay112026Member", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsShorttermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cvs_RevolvingCreditFacilityExpiringMay162024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revolving Credit Facility, Expiring May 16, 2024 [Member]", "label": "Revolving Credit Facility, Expiring May 16, 2024 [Member]", "terseLabel": "Revolving Credit Facility, Expiring May 16, 2024" } } }, "localname": "RevolvingCreditFacilityExpiringMay162024Member", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsShorttermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cvs_RevolvingCreditFacilityExpiringMay172023Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revolving Credit Facility, Expiring May 17, 2023 [Member]", "label": "Revolving Credit Facility, Expiring May 17, 2023 [Member]", "terseLabel": "Revolving Credit Facility, Expiring May 17, 2023" } } }, "localname": "RevolvingCreditFacilityExpiringMay172023Member", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsShorttermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cvs_RightOfUseAssetObtainedInExchangeForLeaseLiabilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right-Of-Use Asset Obtained In Exchange For Lease Liability [Abstract]", "label": "Right-Of-Use Asset Obtained In Exchange For Lease Liability [Abstract]", "terseLabel": "Right-of-use assets obtained in exchange for lease obligations:" } } }, "localname": "RightOfUseAssetObtainedInExchangeForLeaseLiabilityAbstract", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/LeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "stringItemType" }, "cvs_SalesChannelOtherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sales Channel, Other [Member]", "label": "Sales Channel, Other [Member]", "terseLabel": "Other" } } }, "localname": "SalesChannelOtherMember", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "cvs_ScheduleOfMortgageLoanInternalCreditRatingsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule detailing credit quality information related to financing receivables by credit quality indicator and by class of financing receivable.", "label": "Schedule Of Mortgage Loan Internal Credit Ratings [Table Text Block]", "verboseLabel": "Mortgage loan internal credit rating" } } }, "localname": "ScheduleOfMortgageLoanInternalCreditRatingsTableTextBlock", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "cvs_SeniorNotes13DueAugust2027Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 1.3%, Due August 2027", "label": "Senior Notes, 1.3%, Due August 2027 [Member]", "terseLabel": "1.3% senior notes due August 2027" } } }, "localname": "SeniorNotes13DueAugust2027Member", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsLongTermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes175DueAugust2030Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 1.75%, Due August 2030", "label": "Senior Notes, 1.75%, Due August 2030 [Member]", "terseLabel": "1.75% senior notes due August 2030" } } }, "localname": "SeniorNotes175DueAugust2030Member", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsLongTermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes1875DueFebruary2031Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 1.875%, Due February 2031", "label": "Senior Notes, 1.875%, Due February 2031 [Member]", "terseLabel": "1.875%, senior notes due February 2031" } } }, "localname": "SeniorNotes1875DueFebruary2031Member", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsLongTermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes1Point3PercentAugust2027Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 1 Point 3 Percent, August 2027", "label": "Senior Notes, 1 Point 3 Percent, August 2027 [Member]", "terseLabel": "1.3% senior notes due August 2027" } } }, "localname": "SeniorNotes1Point3PercentAugust2027Member", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes1Point75PercentAugust2030Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 1 Point 75 Percent, August 2030", "label": "Senior Notes, 1 Point 75 Percent, August 2030 [Member]", "terseLabel": "1.75% senior notes due August 2030" } } }, "localname": "SeniorNotes1Point75PercentAugust2030Member", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes1Point875PercentFebruary2031Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 1 Point 875 Percent, February 2031", "label": "Senior Notes, 1 Point 875 Percent, February 2031 [Member]", "terseLabel": "1.875% senior notes due February 2031" } } }, "localname": "SeniorNotes1Point875PercentFebruary2031Member", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes2.125June2021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 2.125%, June 2021 [Member]", "label": "Senior Notes, 2.125%, June 2021 [Member]", "terseLabel": "2.125% senior notes due June 2021" } } }, "localname": "SeniorNotes2.125June2021Member", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes2.625DueAugust2024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 2.625%, Due August 2024 [Member]", "label": "Senior Notes, 2.625%, Due August 2024 [Member]", "terseLabel": "2.625% senior notes due August 2024" } } }, "localname": "SeniorNotes2.625DueAugust2024Member", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsLongTermBorrowingsDetails", "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes2.75DueDecember2022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 2.75%, Due December 2022 [Member]", "label": "Senior Notes, 2.75%, Due December 2022 [Member]", "terseLabel": "2.75% senior notes due December 2022" } } }, "localname": "SeniorNotes2.75DueDecember2022Member", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes2.75DueNovember2022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 2.75%, Due November 2022 [Member]", "label": "Senior Notes, 2.75%, Due November 2022 [Member]", "terseLabel": "2.75% senior notes due November 2022" } } }, "localname": "SeniorNotes2.75DueNovember2022Member", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes2.875DueJune2026Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 2.875%, Due June 2026 [Member]", "label": "Senior Notes, 2.875%, Due June 2026 [Member]", "terseLabel": "2.875% senior notes due June 2026" } } }, "localname": "SeniorNotes2.875DueJune2026Member", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes2.8DueJune2023Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 2.8%, Due June 2023 [Member]", "label": "Senior Notes, 2.8%, Due June 2023 [Member]", "terseLabel": "2.8% senior notes due June 2023" } } }, "localname": "SeniorNotes2.8DueJune2023Member", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes27DueAugust2040Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 2.7%, Due August 2040", "label": "Senior Notes, 2.7%, Due August 2040 [Member]", "terseLabel": "2.7% senior notes due August 2040" } } }, "localname": "SeniorNotes27DueAugust2040Member", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsLongTermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes2Point125PercentDueSeptember2031Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 2 Point 125 Percent, Due September 2031", "label": "Senior Notes, 2 Point 125 Percent, Due September 2031 [Member]", "terseLabel": "2.125% senior notes due September 2031" } } }, "localname": "SeniorNotes2Point125PercentDueSeptember2031Member", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsLongTermBorrowingsDetails", "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes2Point7PercentAugust2040Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 2 Point 7 Percent, August 2040", "label": "Senior Notes, 2 Point 7 Percent, August 2040 [Member]", "terseLabel": "2.7% senior notes due August 2040" } } }, "localname": "SeniorNotes2Point7PercentAugust2040Member", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes3.125DueMarch2020Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 3.125%, Due March 2020 [Member]", "label": "Senior Notes, 3.125%, Due March 2020 [Member]", "terseLabel": "3.125% senior notes due March 2020" } } }, "localname": "SeniorNotes3.125DueMarch2020Member", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsLongTermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes3.25DueAugust2029Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 3.25%, Due August 2029 [Member]", "label": "Senior Notes, 3.25%, Due August 2029 [Member]", "terseLabel": "3.25% senior notes due August 2029" } } }, "localname": "SeniorNotes3.25DueAugust2029Member", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsLongTermBorrowingsDetails", "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes3.35DueMarch2021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 3.35%, Due March 2021 [Member]", "label": "Senior Notes, 3.35%, Due March 2021 [Member]", "terseLabel": "3.35% senior notes due March 2021" } } }, "localname": "SeniorNotes3.35DueMarch2021Member", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsLongTermBorrowingsDetails", "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes3.375DueAugust2024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 3.375%, Due August 2024 [Member]", "label": "Senior Notes, 3.375%, Due August 2024 [Member]", "terseLabel": "3.375% senior notes due August 2024" } } }, "localname": "SeniorNotes3.375DueAugust2024Member", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes3.5DueJuly2022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 3.5%, Due July 2022 [Member]", "label": "Senior Notes, 3.5%, Due July 2022 [Member]", "terseLabel": "3.5% senior notes due July 2022" } } }, "localname": "SeniorNotes3.5DueJuly2022Member", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes3.5DueNovember2024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 3.5%, Due November 2024 [Member]", "label": "Senior Notes, 3.5%, Due November 2024 [Member]", "terseLabel": "3.5% senior notes due November 2024" } } }, "localname": "SeniorNotes3.5DueNovember2024Member", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes3.7DueMarch2023Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 3.7%, Due March 2023 [Member]", "label": "Senior Notes, 3.7%, Due March 2023 [Member]", "terseLabel": "3.7% senior notes due March 2023" } } }, "localname": "SeniorNotes3.7DueMarch2023Member", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsLongTermBorrowingsDetails", "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes3.875DueAugust2047Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 3.875%, Due August 2047 [Member]", "label": "Senior Notes, 3.875%, Due August 2047 [Member]", "terseLabel": "3.875% senior notes due August 2047" } } }, "localname": "SeniorNotes3.875DueAugust2047Member", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes3.875DueJuly2025Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 3.875%, Due July 2025 [Member]", "label": "Senior Notes, 3.875%, Due July 2025 [Member]", "terseLabel": "3.875% senior notes due July 2025" } } }, "localname": "SeniorNotes3.875DueJuly2025Member", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes3625DueApril2027Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 3.625%, Due April 2027", "label": "Senior Notes, 3.625%, Due April 2027 [Member]", "terseLabel": "3.625% senior notes due April 2027" } } }, "localname": "SeniorNotes3625DueApril2027Member", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsLongTermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes375DueApril2030Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 3.75%, Due April 2030", "label": "Senior Notes, 3.75%, Due April 2030 [Member]", "terseLabel": "3.75% senior notes due April 2030" } } }, "localname": "SeniorNotes375DueApril2030Member", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsLongTermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes3DueAugust2026Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 3%, Due August 2026 [Member]", "label": "Senior Notes, 3%, Due August 2026 [Member]", "terseLabel": "3% senior notes due August 2026" } } }, "localname": "SeniorNotes3DueAugust2026Member", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsLongTermBorrowingsDetails", "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes3Point625PercentApril2027Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 3 Point 625 Percent, April 2027", "label": "Senior Notes, 3 Point 625 Percent, April 2027 [Member]", "terseLabel": "3.625% senior notes due April 2027" } } }, "localname": "SeniorNotes3Point625PercentApril2027Member", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes3Point70PercentDue2023Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 3 Point 70 Percent, Due 2023", "label": "Senior Notes, 3 Point 70 Percent, Due 2023 [Member]", "terseLabel": "Senior Notes, 3 Point 70 Percent, Due 2023" } } }, "localname": "SeniorNotes3Point70PercentDue2023Member", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsLongTermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes3Point75PercentApril2030Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 3 Point 75 Percent, April 2030", "label": "Senior Notes, 3 Point 75 Percent, April 2030 [Member]", "terseLabel": "3.75% senior notes due April 2030" } } }, "localname": "SeniorNotes3Point75PercentApril2030Member", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes4.125DueJune2021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 4.125%, Due June 2021 [Member]", "label": "Senior Notes, 4.125%, Due June 2021 [Member]", "terseLabel": "4.125% senior notes due June 2021" } } }, "localname": "SeniorNotes4.125DueJune2021Member", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsLongTermBorrowingsDetails", "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes4.125DueMay2021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 4.125%, Due May 2021 [Member]", "label": "Senior Notes, 4.125%, Due May 2021 [Member]", "terseLabel": "4.125% senior notes due May 2021" } } }, "localname": "SeniorNotes4.125DueMay2021Member", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsLongTermBorrowingsDetails", "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes4.125DueNovember2042Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This item represents senior notes due 2042 with a coupon rate of 4.125%.", "label": "Senior Notes, 4.125%, Due November 2042 [Member]", "terseLabel": "4.125% senior notes due November 2042" } } }, "localname": "SeniorNotes4.125DueNovember2042Member", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes4.1DueMarch2025Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 4.1%, Due March 2025 [Member]", "label": "Senior Notes, 4.1%, Due March 2025 [Member]", "terseLabel": "4.1% senior notes due March 2025" } } }, "localname": "SeniorNotes4.1DueMarch2025Member", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsLongTermBorrowingsDetails", "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes4.3DueMarch2028Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 4.3%, Due March 2028 [Member]", "label": "Senior Notes, 4.3%, Due March 2028 [Member]", "terseLabel": "4.3% senior notes due March 2028" } } }, "localname": "SeniorNotes4.3DueMarch2028Member", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes4.5DueMay2042Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 4.5%, Due May 2042 [Member]", "label": "Senior Notes, 4.5%, Due May 2042 [Member]", "terseLabel": "4.5% senior notes due May 2042" } } }, "localname": "SeniorNotes4.5DueMay2042Member", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes4.75DueDecember2022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 4.75%, Due December 2022 [Member]", "label": "Senior Notes, 4.75%, Due December 2022 [Member]", "terseLabel": "4.75% senior notes due December 2022" } } }, "localname": "SeniorNotes4.75DueDecember2022Member", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes4.75DueMarch2044Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 4.75%, Due March 2044 [Member]", "label": "Senior Notes, 4.75%, Due March 2044 [Member]", "terseLabel": "4.75% senior notes due March 2044" } } }, "localname": "SeniorNotes4.75DueMarch2044Member", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes4.78DueMarch2038Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 4.78%, Due March 2038 [Member]", "label": "Senior Notes, 4.78%, Due March 2038 [Member]", "terseLabel": "4.78% senior notes due March 2038" } } }, "localname": "SeniorNotes4.78DueMarch2038Member", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes4.875DueJuly2035Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 4.875%, Due July 2035 [Member]", "label": "Senior Notes, 4.875%, Due July 2035 [Member]", "terseLabel": "4.875% senior notes due July 2035" } } }, "localname": "SeniorNotes4.875DueJuly2035Member", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes4125DueApril2040Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 4.125%, Due April 2040", "label": "Senior Notes, 4.125%, Due April 2040 [Member]", "terseLabel": "4.125% senior notes due April 2040" } } }, "localname": "SeniorNotes4125DueApril2040Member", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsLongTermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes425DueApril2050Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 4.25%, Due April 2050", "label": "Senior Notes, 4.25%, Due April 2050 [Member]", "terseLabel": "4.25% senior notes due April 2050" } } }, "localname": "SeniorNotes425DueApril2050Member", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsLongTermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes43Due2028Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 4.3%, Due 2028", "label": "Senior Notes, 4.3%, Due 2028 [Member]", "terseLabel": "4.3% senior notes due 2028" } } }, "localname": "SeniorNotes43Due2028Member", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsLongTermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes4DueDecember2023Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 4%, Due December 2023 [Member]", "label": "Senior Notes, 4%, Due December 2023 [Member]", "terseLabel": "4% senior notes due December 2023" } } }, "localname": "SeniorNotes4DueDecember2023Member", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsLongTermBorrowingsDetails", "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes4Point125PercentApril2040Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 4 Point 125 Percent, April 2040", "label": "Senior Notes, 4 Point 125 Percent, April 2040 [Member]", "terseLabel": "4.125% senior notes due April 2040" } } }, "localname": "SeniorNotes4Point125PercentApril2040Member", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes4Point25PercentApril2050Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 4 Point 25 Percent, April 2050", "label": "Senior Notes, 4 Point 25 Percent, April 2050 [Member]", "terseLabel": "4.25% senior notes due April 2050" } } }, "localname": "SeniorNotes4Point25PercentApril2050Member", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes4PointThreePercentDue2028Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 4 Point Three Percent, Due 2028", "label": "Senior Notes, 4 Point Three Percent, Due 2028 [Member]", "terseLabel": "Senior Notes, 4.3%, Due 2028" } } }, "localname": "SeniorNotes4PointThreePercentDue2028Member", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsLongTermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes5.05DueMarch2048Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 5.05%, Due March 2048 [Member]", "label": "Senior Notes, 5.05%, Due March 2048 [Member]", "terseLabel": "5.05% senior notes due March 2048" } } }, "localname": "SeniorNotes5.05DueMarch2048Member", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes5.125DueJuly2045Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 5.125%, Due July 2045 [Member]", "label": "Senior Notes, 5.125%, Due July 2045 [Member]", "terseLabel": "5.125% senior notes due July 2045" } } }, "localname": "SeniorNotes5.125DueJuly2045Member", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes5.3DueDecember2043Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 5.3%, Due December 2043 [Member]", "label": "Senior Notes, 5.3%, Due December 2043 [Member]", "terseLabel": "5.3% senior notes due December 2043" } } }, "localname": "SeniorNotes5.3DueDecember2043Member", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes5.45DueJune2021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This item represents senior notes due 2021 with a coupon rate of 5.45%.", "label": "Senior Notes, 5.45%, Due June 2021 [Member]", "terseLabel": "5.45% senior notes due June 2021" } } }, "localname": "SeniorNotes5.45DueJune2021Member", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsLongTermBorrowingsDetails", "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes5.75DueMay2041Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 5.75%, Due May 2041 [Member]", "label": "Senior Notes, 5.75%, Due May 2041 [Member]", "terseLabel": "5.75% senior notes due May 2041" } } }, "localname": "SeniorNotes5.75DueMay2041Member", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes5DueDecember2024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 5%, Due December 2024 [Member]", "label": "Senior Notes, 5%, Due December 2024 [Member]", "terseLabel": "5% senior notes due December 2024" } } }, "localname": "SeniorNotes5DueDecember2024Member", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes6.125DueSeptember2039Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 6.125%, Due September 2039 [Member]", "label": "Senior Notes, 6.125%, Due September 2039 [Member]", "terseLabel": "6.125% senior notes due September 2039" } } }, "localname": "SeniorNotes6.125DueSeptember2039Member", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes6.25DueJune2027Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 6.25%, Due June 2027 [Member]", "label": "Senior Notes, 6.25%, Due June 2027 [Member]", "terseLabel": "6.25% senior notes due June 2027" } } }, "localname": "SeniorNotes6.25DueJune2027Member", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes6.625DueJune2036Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 6.625%, Due June 2036 [Member]", "label": "Senior Notes, 6.625%, Due June 2036 [Member]", "terseLabel": "6.625% senior notes due June 2036" } } }, "localname": "SeniorNotes6.625DueJune2036Member", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "cvs_SeniorNotes6.75DueDecember2037Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 6.75%, Due December 2037 [Member]", "label": "Senior Notes, 6.75%, Due December 2037 [Member]", "terseLabel": "6.75% senior notes due December 2037" } } }, "localname": "SeniorNotes6.75DueDecember2037Member", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "cvs_SeparateAccountFinancialAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Separate Account, Financial Assets", "label": "Separate Account, Financial Assets [Member]", "terseLabel": "Separate Accounts, financial assets" } } }, "localname": "SeparateAccountFinancialAssetsMember", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/FairValueNarrativeDetails", "http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails" ], "xbrltype": "domainItemType" }, "cvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsVestedInPeriodFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Vested In Period, Fair Value", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Vested In Period, Fair Value", "terseLabel": "Fair value of stock options and SARs vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsVestedInPeriodFairValue", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails" ], "xbrltype": "monetaryItemType" }, "cvs_ShareBasedPaymentArrangementOptionGrantedPriorThrough2018Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Payment Arrangement, Option, Granted Prior Through 2018", "label": "Share-Based Payment Arrangement, Option, Granted Prior Through 2018 [Member]", "terseLabel": "Stock options granted through 2018" } } }, "localname": "ShareBasedPaymentArrangementOptionGrantedPriorThrough2018Member", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails" ], "xbrltype": "domainItemType" }, "cvs_ShareBasedPaymentArrangementOptionGrantedSubsequentTo2018Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Payment Arrangement, Option, Granted Subsequent to 2018", "label": "Share-Based Payment Arrangement, Option, Granted Subsequent to 2018 [Member]", "terseLabel": "Stock options granted subsequent to 2018" } } }, "localname": "ShareBasedPaymentArrangementOptionGrantedSubsequentTo2018Member", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails" ], "xbrltype": "domainItemType" }, "cvs_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Number", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Number", "terseLabel": "Expected to vest (in shares)" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails" ], "xbrltype": "sharesItemType" }, "cvs_SharesHeldInTrustPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares Held In Trust [Policy Text Block]", "label": "Shares Held In Trust [Policy Text Block]", "terseLabel": "Shares Held in Trust" } } }, "localname": "SharesHeldInTrustPolicyTextBlock", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "cvs_StockIssuedDuringPeriodEmployeeStockPurchasePlanAveragePurchasePriceofSharesPurchased": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period, Employee Stock Purchase Plan, Average Purchase Price of Shares Purchased", "label": "Stock Issued During Period, Employee Stock Purchase Plan, Average Purchase Price of Shares Purchased", "terseLabel": "Average purchase price of shares purchased (in dollars per share)" } } }, "localname": "StockIssuedDuringPeriodEmployeeStockPurchasePlanAveragePurchasePriceofSharesPurchased", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails" ], "xbrltype": "perShareItemType" }, "cvs_StoreImpairmentCharges": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": { "order": 5.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Store Impairment Charges", "label": "Store Impairment Charges", "terseLabel": "Store impairments", "verboseLabel": "Store impairment charges" } } }, "localname": "StoreImpairmentCharges", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows", "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations", "http://www.cvshealth.com/role/LeasesNarrativeDetails", "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cvs_SupportingExperienceRatedProductsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Supporting discontinued and experience-rated products.", "label": "Supporting Experience Rated Products [Member]", "terseLabel": "Supporting experience- rated products" } } }, "localname": "SupportingExperienceRatedProductsMember", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails", "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails", "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails" ], "xbrltype": "domainItemType" }, "cvs_SupportingRemainingProductsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt securities in an unrealized capital loss position supporting remaining products.", "label": "Supporting Remaining Products [Member]", "terseLabel": "Supporting remaining products" } } }, "localname": "SupportingRemainingProductsMember", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails" ], "xbrltype": "domainItemType" }, "cvs_TotalInvestmentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Total Investments [Axis]", "terseLabel": "Total Investments [Axis]" } } }, "localname": "TotalInvestmentsAxis", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/InvestmentsScheduleofTotalInvestmentsDetails" ], "xbrltype": "stringItemType" }, "cvs_TotalInvestmentsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Total Investments [Domain]", "terseLabel": "Total Investments [Domain]" } } }, "localname": "TotalInvestmentsDomain", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/InvestmentsScheduleofTotalInvestmentsDetails" ], "xbrltype": "domainItemType" }, "cvs_TotalInvestmentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Total Investments [Line Items]", "terseLabel": "Total Investments [Line Items]" } } }, "localname": "TotalInvestmentsLineItems", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/InvestmentsScheduleofTotalInvestmentsDetails" ], "xbrltype": "stringItemType" }, "cvs_TotalInvestmentsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Total Investments [Table]", "terseLabel": "Total Investments [Table]" } } }, "localname": "TotalInvestmentsTable", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/InvestmentsScheduleofTotalInvestmentsDetails" ], "xbrltype": "stringItemType" }, "cvs_TotalInvestmentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This item includes total investments, both current and long-term.", "label": "Total Investments [Table Text Block]", "verboseLabel": "Total investments" } } }, "localname": "TotalInvestmentsTableTextBlock", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "cvs_TreasuryStockSharesAcquiredCostMethodNetOfESPPIssuance": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Treasury Stock, Shares, Acquired, Cost Method, Net Of ESPP Issuance", "label": "Treasury Stock, Shares, Acquired, Cost Method, Net Of ESPP Issuance", "terseLabel": "Purchase of treasury shares, net of ESPP issuances (in shares)" } } }, "localname": "TreasuryStockSharesAcquiredCostMethodNetOfESPPIssuance", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "sharesItemType" }, "cvs_TreasuryStockSharesHeldinTrust": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Treasury Stock, Shares, Held in Trust", "label": "Treasury Stock, Shares, Held in Trust", "terseLabel": "Treasury shares held in trust (in shares)" } } }, "localname": "TreasuryStockSharesHeldinTrust", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquityParentheticals", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "sharesItemType" }, "cvs_TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Treasury Stock, Value, Acquired, Cost Method, Net Of ESPP Issuance", "label": "Treasury Stock, Value, Acquired, Cost Method, Net Of ESPP Issuance", "negatedTerseLabel": "Purchase of treasury shares, net of ESPP issuances" } } }, "localname": "TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "cvs_TreasuryStockValueSharesHeldInTrust": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Treasury Stock, Value, Shares Held In Trust", "label": "Treasury Stock, Value, Shares Held In Trust", "terseLabel": "Treasury shares held in trust" } } }, "localname": "TreasuryStockValueSharesHeldInTrust", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquityParentheticals" ], "xbrltype": "monetaryItemType" }, "cvs_USDepartmentOfHealthAndHumanServicesACARiskCorridorReceivablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "U.S. Department of Health and Human Services, ACA Risk Corridor Receivables", "label": "U.S. Department of Health and Human Services, ACA Risk Corridor Receivables [Member]", "terseLabel": "U.S. Department of Health and Human Services, ACA Risk Corridor Receivables" } } }, "localname": "USDepartmentOfHealthAndHumanServicesACARiskCorridorReceivablesMember", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "cvs_USFederalGovernmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "US Federal Government", "label": "US Federal Government [Member]", "terseLabel": "US Federal Government" } } }, "localname": "USFederalGovernmentMember", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "domainItemType" }, "cvs_VOYARetirementInsuranceAndAnnuityCompanyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "VOYA Retirement Insurance And Annuity Company [Member]", "label": "VOYA Retirement Insurance And Annuity Company [Member]", "terseLabel": "VOYA Retirement Insurance and Annuity Company" } } }, "localname": "VOYARetirementInsuranceAndAnnuityCompanyMember", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/ReinsuranceReinsuranceRecoverablesDetails" ], "xbrltype": "domainItemType" }, "cvs_ValueOfBusinessAcquiredMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Value Of Business Acquired [Member]", "label": "Value Of Business Acquired [Member]", "terseLabel": "Value of Business Acquired" } } }, "localname": "ValueOfBusinessAcquiredMember", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "cvs_VariableInterestEntityAmendedContractExtensionTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Variable Interest Entity, Amended Contract Extension Term", "label": "Variable Interest Entity, Amended Contract Extension Term", "terseLabel": "Amended contract extension term" } } }, "localname": "VariableInterestEntityAmendedContractExtensionTerm", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesVariableInterestEntitiesDetails" ], "xbrltype": "durationItemType" }, "cvs_VariableInterestEntityAmendedContractTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Variable Interest Entity, Amended Contract Term", "label": "Variable Interest Entity, Amended Contract Term", "terseLabel": "Amended contract term (in years)" } } }, "localname": "VariableInterestEntityAmendedContractTerm", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesVariableInterestEntitiesDetails" ], "xbrltype": "durationItemType" }, "cvs_VendorAllowancesAndPurchaseDiscountsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vendor Allowances And Purchase Discounts", "label": "Vendor Allowances And Purchase Discounts [Policy Text Block]", "terseLabel": "Vendor Allowances And Purchase Discounts" } } }, "localname": "VendorAllowancesAndPurchaseDiscountsPolicyTextBlock", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "cvs_VendorandManufacturerReceivables": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/SignificantAccountingPoliciesAccountsReceivableDetails": { "order": 4.0, "parentTag": "us-gaap_AccountsReceivableNetCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Vendor and Manufacturer Receivables", "label": "Vendor and Manufacturer Receivables", "terseLabel": "Vendor and manufacturer receivables" } } }, "localname": "VendorandManufacturerReceivables", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesAccountsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "cvs_WeightedAverageRemainingLeaseTermAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted Average Remaining Lease Term [Abstract]", "label": "Weighted Average Remaining Lease Term [Abstract]", "terseLabel": "Weighted average remaining lease term (in years)" } } }, "localname": "WeightedAverageRemainingLeaseTermAbstract", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "cvs_YearOfOriginationPeriodFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Year Of Origination Period Five", "label": "Year Of Origination Period Five [Member]", "terseLabel": "2017" } } }, "localname": "YearOfOriginationPeriodFiveMember", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails" ], "xbrltype": "domainItemType" }, "cvs_YearOfOriginationPeriodFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Year Of Origination Period Four", "label": "Year Of Origination Period Four [Member]", "terseLabel": "2018" } } }, "localname": "YearOfOriginationPeriodFourMember", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails" ], "xbrltype": "domainItemType" }, "cvs_YearOfOriginationPeriodOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Year Of Origination Period One", "label": "Year Of Origination Period One [Member]", "terseLabel": "2021" } } }, "localname": "YearOfOriginationPeriodOneMember", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails" ], "xbrltype": "domainItemType" }, "cvs_YearOfOriginationPeriodThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Year Of Origination Period Three", "label": "Year Of Origination Period Three [Member]", "terseLabel": "2019" } } }, "localname": "YearOfOriginationPeriodThreeMember", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails" ], "xbrltype": "domainItemType" }, "cvs_YearOfOriginationPeriodTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Year Of Origination Period Two", "label": "Year Of Origination Period Two [Member]", "terseLabel": "2020" } } }, "localname": "YearOfOriginationPeriodTwoMember", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails" ], "xbrltype": "domainItemType" }, "cvs_YearOfOriginationPriorToPeriodFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Year Of Origination Prior To Period Five", "label": "Year Of Origination Prior To Period Five [Member]", "terseLabel": "Prior" } } }, "localname": "YearOfOriginationPriorToPeriodFiveMember", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails" ], "xbrltype": "domainItemType" }, "cvs_YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Yield Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings", "label": "Yield Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings", "terseLabel": "Yield-related impairment loss" } } }, "localname": "YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings", "nsuri": "http://www.cvshealth.com/20211231", "presentation": [ "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails" ], "xbrltype": "monetaryItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r1076", "r1077", "r1078" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID", "terseLabel": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cvshealth.com/role/AuditInformation" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r1076", "r1077", "r1078" ], "lang": { "en-us": { "role": { "label": "Auditor Location", "terseLabel": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cvshealth.com/role/AuditInformation" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r1076", "r1077", "r1078" ], "lang": { "en-us": { "role": { "label": "Auditor Name", "terseLabel": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cvshealth.com/role/AuditInformation" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r1076", "r1077", "r1078" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r1079" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1074" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]", "terseLabel": "Documents Incorporated by Reference" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1073" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityRegulatoryRequirementsDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1073" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r1073" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r1088" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1073" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r1073" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r1073" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1073" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r1115" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r1076", "r1077", "r1078" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityRegulatoryRequirementsDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1072" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1075" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "srt_ConsolidatedEntitiesAxis": { "auth_ref": [ "r176", "r400", "r405", "r413", "r704", "r705", "r713", "r714", "r825", "r1066", "r1091", "r1103", "r1112", "r1113" ], "lang": { "en-us": { "role": { "documentation": "Information by consolidated entity or group of entities.", "label": "Consolidated Entities [Axis]", "terseLabel": "Consolidated Entities [Axis]" } } }, "localname": "ConsolidatedEntitiesAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesVariableInterestEntitiesDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidatedEntitiesDomain": { "auth_ref": [ "r176", "r400", "r405", "r413", "r704", "r705", "r713", "r714", "r825", "r1066", "r1091", "r1103", "r1112", "r1113" ], "lang": { "en-us": { "role": { "documentation": "Entity or group of entities consolidated into reporting entity.", "label": "Consolidated Entities [Domain]", "terseLabel": "Consolidated Entities [Domain]" } } }, "localname": "ConsolidatedEntitiesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesVariableInterestEntitiesDetails" ], "xbrltype": "domainItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r176", "r230", "r249", "r250", "r251", "r252", "r254", "r256", "r260", "r400", "r401", "r402", "r403", "r404", "r405", "r407", "r408", "r410", "r412", "r413", "r1103", "r1104", "r1105", "r1106", "r1107", "r1108", "r1109", "r1110", "r1111", "r1112", "r1113" ], "lang": { "en-us": { "role": { "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.", "label": "Consolidation Items [Axis]", "terseLabel": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [ "r176", "r230", "r249", "r250", "r251", "r252", "r254", "r256", "r260", "r400", "r401", "r402", "r403", "r404", "r405", "r407", "r408", "r410", "r412", "r413", "r1103", "r1104", "r1105", "r1106", "r1107", "r1108", "r1109", "r1110", "r1111", "r1112", "r1113" ], "lang": { "en-us": { "role": { "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.", "label": "Consolidation Items [Domain]", "terseLabel": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r86", "r88", "r173", "r174", "r419", "r455", "r1114" ], "lang": { "en-us": { "role": { "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.", "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": { "auth_ref": [ "r2", "r182", "r190", "r196", "r313", "r639", "r640", "r641", "r679", "r680", "r739", "r742", "r744", "r745", "r1118" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) to financial statements for cumulative-effect adjustment in period of adoption of amendment to accounting standards.", "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]", "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity", "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquityParentheticals" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAxis": { "auth_ref": [ "r2", "r182", "r190", "r196", "r313", "r639", "r640", "r641", "r679", "r680", "r739", "r742", "r744", "r745", "r1118" ], "lang": { "en-us": { "role": { "documentation": "Information by cumulative-effect adjustment to financial statements in period of adoption of amendment to accounting standards.", "label": "Cumulative Effect, Period of Adoption [Axis]", "terseLabel": "Cumulative Effect, Period of Adoption [Axis]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity", "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquityParentheticals" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionDomain": { "auth_ref": [ "r2", "r182", "r190", "r196", "r313", "r639", "r640", "r641", "r679", "r680", "r739", "r742", "r744", "r745", "r1118" ], "lang": { "en-us": { "role": { "documentation": "Cumulative-effect adjustment to financial statements in period of adoption of amendment to accounting standards.", "label": "Cumulative Effect, Period of Adoption [Domain]", "terseLabel": "Cumulative Effect, Period of Adoption [Domain]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity", "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquityParentheticals" ], "xbrltype": "domainItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of investment including named security. Excludes entity that is consolidated.", "label": "Investment, Name [Domain]", "terseLabel": "Investment, Name [Domain]" } } }, "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesVariableInterestEntitiesDetails" ], "xbrltype": "domainItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of judicial proceeding, alternative dispute resolution or claim.", "label": "Litigation Case [Axis]", "terseLabel": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails", "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Judicial proceeding, alternative dispute resolution or claim. For example, but not limited to, name of case, category of litigation, or other differentiating information.", "label": "Litigation Case [Domain]", "terseLabel": "Litigation Case [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails", "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r266", "r492", "r496", "r980" ], "lang": { "en-us": { "role": { "documentation": "Information by name or description of a single external customer or a group of external customers.", "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r418", "r454", "r592", "r599", "r837", "r838", "r839", "r840", "r841", "r842", "r861", "r978", "r982", "r1067", "r1068" ], "lang": { "en-us": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/LeasesNarrativeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails", "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r418", "r454", "r592", "r599", "r837", "r838", "r839", "r840", "r841", "r842", "r861", "r978", "r982", "r1067", "r1068" ], "lang": { "en-us": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/LeasesNarrativeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails", "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails" ], "xbrltype": "domainItemType" }, "srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis": { "auth_ref": [ "r1045", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065", "r1090", "r1092" ], "lang": { "en-us": { "role": { "documentation": "Information by type of real estate property.", "label": "Real Estate, Type of Property [Axis]", "terseLabel": "Real Estate, Type of Property [Axis]" } } }, "localname": "MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails", "http://www.cvshealth.com/role/InvestmentsMortgageLoansDetails", "http://www.cvshealth.com/role/InvestmentsScheduleofMortgageLoanPrincipalRepaymentsDetails" ], "xbrltype": "stringItemType" }, "srt_MortgageLoansOnRealEstateLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]", "terseLabel": "Mortgage Loans on Real Estate [Line Items]" } } }, "localname": "MortgageLoansOnRealEstateLineItems", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails", "http://www.cvshealth.com/role/InvestmentsMortgageLoansDetails", "http://www.cvshealth.com/role/InvestmentsScheduleofMortgageLoanPrincipalRepaymentsDetails" ], "xbrltype": "stringItemType" }, "srt_MortgageLoansOnRealEstateNamePropertyTypeDomain": { "auth_ref": [ "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065", "r1090", "r1093", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099", "r1100" ], "lang": { "en-us": { "role": { "documentation": "Land and any structures permanently fixed to it.", "label": "Real Estate [Domain]", "terseLabel": "Real Estate [Domain]" } } }, "localname": "MortgageLoansOnRealEstateNamePropertyTypeDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails", "http://www.cvshealth.com/role/InvestmentsMortgageLoansDetails", "http://www.cvshealth.com/role/InvestmentsScheduleofMortgageLoanPrincipalRepaymentsDetails" ], "xbrltype": "domainItemType" }, "srt_MortgageLoansOnRealEstateScheduleTable": { "auth_ref": [ "r1047", "r1102" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in mortgage loan on real estate by entity with substantial portion of business acquiring and holding investment real estate or interest in real estate.", "label": "SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate Schedule [Table]", "terseLabel": "Mortgage Loans on Real Estate [Table]" } } }, "localname": "MortgageLoansOnRealEstateScheduleTable", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails", "http://www.cvshealth.com/role/InvestmentsMortgageLoansDetails", "http://www.cvshealth.com/role/InvestmentsScheduleofMortgageLoanPrincipalRepaymentsDetails" ], "xbrltype": "stringItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r266", "r492", "r496", "r980" ], "lang": { "en-us": { "role": { "documentation": "Single external customer or group of external customers.", "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r263", "r492", "r494", "r863", "r975", "r979" ], "lang": { "en-us": { "role": { "documentation": "Information by product and service, or group of similar products and similar services.", "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations", "http://www.cvshealth.com/role/HealthCareCostsPayableIncurredandPaidHealthCareClaimsDevelopmentDetails", "http://www.cvshealth.com/role/HealthCareCostsPayableReconciliationofHealthCareCostsPayableDetails", "http://www.cvshealth.com/role/HealthCareCostsPayableReconciliationofHealthCareNetIncurredandPaidClaimsDevelopmenttoHealthCareCostsPayableLiabilityDetails", "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails", "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails", "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r263", "r492", "r494", "r863", "r975", "r979" ], "lang": { "en-us": { "role": { "documentation": "Product or service, or a group of similar products or similar services.", "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations", "http://www.cvshealth.com/role/HealthCareCostsPayableIncurredandPaidHealthCareClaimsDevelopmentDetails", "http://www.cvshealth.com/role/HealthCareCostsPayableReconciliationofHealthCareCostsPayableDetails", "http://www.cvshealth.com/role/HealthCareCostsPayableReconciliationofHealthCareNetIncurredandPaidClaimsDevelopmenttoHealthCareCostsPayableLiabilityDetails", "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails", "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails", "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r418", "r454", "r531", "r592", "r599", "r837", "r838", "r839", "r840", "r841", "r842", "r861", "r978", "r982", "r1067", "r1068" ], "lang": { "en-us": { "role": { "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/LeasesNarrativeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails", "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r418", "r454", "r531", "r592", "r599", "r837", "r838", "r839", "r840", "r841", "r842", "r861", "r978", "r982", "r1067", "r1068" ], "lang": { "en-us": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/LeasesNarrativeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails", "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r87", "r88", "r173", "r174", "r419", "r455" ], "lang": { "en-us": { "role": { "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.", "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r191", "r593", "r1089" ], "lang": { "en-us": { "role": { "documentation": "Information reported for future period. Excludes information expected to be reported in future period for effect on historical fact.", "label": "Forecast [Member]", "terseLabel": "Forecast" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityDividendsDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r191", "r196", "r593" ], "lang": { "en-us": { "role": { "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.", "label": "Scenario [Domain]", "terseLabel": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityDividendsDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r306" ], "lang": { "en-us": { "role": { "documentation": "Information by name of investment including named security. Excludes entity that is consolidated.", "label": "Investment, Name [Axis]", "terseLabel": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesVariableInterestEntitiesDetails" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r191", "r196", "r383", "r593", "r830" ], "lang": { "en-us": { "role": { "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.", "label": "Scenario [Axis]", "terseLabel": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityDividendsDetails" ], "xbrltype": "stringItemType" }, "srt_SupplementalScheduleOfReinsurancePremiumsForInsuranceCompaniesTextBlock": { "auth_ref": [ "r955", "r1101" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the supplemental schedule of reinsurance information. Reinsurance schedule includes, but is not limited to, the type of insurance, gross amount of premiums, premiums ceded to other entities, premiums assumed from other entities, net amount of premium revenue, and the percentage of the premiums assumed to net premium revenue.", "label": "SEC Schedule, 12-17, Insurance Companies, Reinsurance [Text Block]", "terseLabel": "Schedule of direct, assumed and ceded premiums earned" } } }, "localname": "SupplementalScheduleOfReinsurancePremiumsForInsuranceCompaniesTextBlock", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ReinsuranceTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201602Member": { "auth_ref": [ "r797" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).", "label": "Accounting Standards Update 2016-02 [Member]", "terseLabel": "ASU 2016-02" } } }, "localname": "AccountingStandardsUpdate201602Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquityParentheticals" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201613Member": { "auth_ref": [ "r309" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2016-13 Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.", "label": "Accounting Standards Update 2016-13 [Member]", "terseLabel": "ASU 2016-13" } } }, "localname": "AccountingStandardsUpdate201613Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquityParentheticals" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdateExtensibleList": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r183", "r184", "r185", "r186", "r277", "r278", "r310", "r311", "r312", "r313", "r314", "r315", "r399", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r679", "r680", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r823", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r1116", "r1117", "r1118", "r1119", "r1120" ], "lang": { "en-us": { "role": { "documentation": "Indicates amendment to accounting standards.", "label": "Accounting Standards Update [Extensible Enumeration]", "terseLabel": "Accounting Standards Update [Extensible List]" } } }, "localname": "AccountingStandardsUpdateExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquityParentheticals" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_AccountsPayableTradeCurrent": { "auth_ref": [ "r35", "r66" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Trade, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableTradeCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r1051" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Other receivables" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r31", "r53", "r268", "r269" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.cvshealth.com/role/SignificantAccountingPoliciesAccountsReceivableDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net", "totalLabel": "Total accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets", "http://www.cvshealth.com/role/SignificantAccountingPoliciesAccountsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r70" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember": { "auth_ref": [ "r95", "r100", "r108", "r109", "r110", "r710" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) related to gain (loss) component of defined benefit plans including the portion attributable to the noncontrolling interest.", "label": "Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Including Portion Attributable to Noncontrolling Interest [Member]", "terseLabel": "Pension and OPEB plans" } } }, "localname": "AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/OtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r64", "r372" ], "calculation": { "http://www.cvshealth.com/role/SignificantAccountingPoliciesPropertyPlantandEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedTerseLabel": "Accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPropertyPlantandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": { "auth_ref": [ "r90", "r100", "r108", "r109", "r110", "r710" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, including the portion attributable to the noncontrolling interest.", "label": "Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]", "terseLabel": "Foreign currency translation adjustments" } } }, "localname": "AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/OtherComprehensiveIncomeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember": { "auth_ref": [ "r100", "r108", "r109", "r110", "r709" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, including portion attributable to noncontrolling interest.", "label": "Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member]", "terseLabel": "Net cash flow hedges" } } }, "localname": "AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/OtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember": { "auth_ref": [ "r92", "r93", "r94", "r100", "r108", "r109", "r110" ], "lang": { "en-us": { "role": { "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), including portion attributable to noncontrolling interest.", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Including Noncontrolling Interest [Member]", "terseLabel": "Net unrealized investment gains (losses)" } } }, "localname": "AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/OtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r56", "r98", "r99", "r100", "r923", "r991", "r995" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "verboseLabel": "Accumulated other comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r97", "r100", "r108", "r109", "r110", "r179", "r180", "r181", "r710", "r986", "r987", "r1120" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r183", "r184", "r185", "r186", "r196", "r277", "r278", "r310", "r311", "r312", "r313", "r314", "r315", "r399", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r677", "r678", "r679", "r680", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r823", "r865", "r866", "r867", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r1116", "r1117", "r1118", "r1119", "r1120" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Accounting Standards Update [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquityParentheticals" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments required to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "auth_ref": [ "r646" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for advertising cost.", "label": "Advertising Cost [Policy Text Block]", "terseLabel": "Advertising Costs" } } }, "localname": "AdvertisingCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdvertisingExpense": { "auth_ref": [ "r647" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.", "label": "Advertising Expense", "terseLabel": "Advertising costs" } } }, "localname": "AdvertisingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r602", "r631", "r644" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocationsToPolicyholdersPolicies": { "auth_ref": [ "r996" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining amounts of income and expenses allocated to policyholders and contract holders, excluding the method for determining dividends payable to policyholders and accounting policies pertaining to separate accounts for variable annuity contracts.", "label": "Allocations to Policyholders, Policies [Policy Text Block]", "terseLabel": "Policyholders' Funds" } } }, "localname": "AllocationsToPolicyholdersPolicies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "auth_ref": [ "r272", "r316", "r318", "r320" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable.", "label": "Accounts Receivable, Allowance for Credit Loss", "terseLabel": "Allowance for credit loss" } } }, "localname": "AllowanceForDoubtfulAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesAccountsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries": { "auth_ref": [ "r319" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in allowance for credit loss on accounts receivable, from recovery.", "label": "Accounts Receivable, Allowance for Credit Loss, Recovery", "negatedTerseLabel": "Receipt of fully reserved ACA risk corridor receivable" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableRecoveries", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r156", "r356", "r363" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails", "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r205" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "verboseLabel": "Antidilutive securities excluded from computation of EPS (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/EarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r205" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/EarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/EarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r205" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/EarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": { "auth_ref": [ "r97", "r100", "r108", "r109", "r110", "r710" ], "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]", "terseLabel": "AOCI Including Portion Attributable to Noncontrolling Interest" } } }, "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/OtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetBackedSecuritiesMember": { "auth_ref": [ "r293", "r532" ], "lang": { "en-us": { "role": { "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.", "label": "Asset-backed Securities [Member]", "terseLabel": "Other asset-backed securities" } } }, "localname": "AssetBackedSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r168", "r238", "r251", "r258", "r308", "r400", "r401", "r402", "r404", "r405", "r406", "r407", "r409", "r411", "r413", "r414", "r704", "r713", "r772", "r826", "r828", "r874", "r920" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r32", "r33", "r85", "r168", "r308", "r400", "r401", "r402", "r404", "r405", "r406", "r407", "r409", "r411", "r413", "r414", "r704", "r713", "r772", "r826", "r828" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r748" ], "calculation": { "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsHeldByInsuranceRegulators": { "auth_ref": [ "r1022" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of cash and investment securities on deposit with state regulatory authorities in connection with capital requirements.", "label": "Assets Held by Insurance Regulators", "terseLabel": "Investments on deposit with regulatory bodies" } } }, "localname": "AssetsHeldByInsuranceRegulators", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityRegulatoryRequirementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssumedPremiumsEarned": { "auth_ref": [ "r936", "r953", "r1007", "r1010" ], "calculation": { "http://www.cvshealth.com/role/ReinsuranceEffectsofReinsuranceDetails": { "order": 2.0, "parentTag": "us-gaap_PremiumsEarnedNet", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of earned premiums assumed from other entities.", "label": "Assumed Premiums Earned", "terseLabel": "Assumed" } } }, "localname": "AssumedPremiumsEarned", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ReinsuranceEffectsofReinsuranceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r285" ], "calculation": { "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails": { "order": 1.0, "parentTag": "cvs_DebtSecuritiesAvailableForSaleAmortizedCostNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Gross Unrealized Gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r286" ], "calculation": { "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails": { "order": 2.0, "parentTag": "cvs_DebtSecuritiesAvailableForSaleAmortizedCostNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Gross Unrealized Losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]", "terseLabel": "Unrealized Losses" } } }, "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails", "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": { "auth_ref": [ "r287", "r290", "r900" ], "calculation": { "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10", "terseLabel": "After five years through ten years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": { "auth_ref": [ "r287", "r289", "r899" ], "calculation": { "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five", "terseLabel": "One year through five years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue": { "auth_ref": [ "r287", "r291", "r901" ], "calculation": { "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails": { "order": 4.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10", "terseLabel": "Greater than ten years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-sale, Fair Value, Fiscal Year Maturity [Abstract]", "terseLabel": "Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]", "terseLabel": "Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]", "terseLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "auth_ref": [ "r287", "r288", "r898" ], "calculation": { "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One", "terseLabel": "Less than one year" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue": { "auth_ref": [ "r292", "r902" ], "calculation": { "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails": { "order": 5.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), without single maturity date and not allocated over maturity grouping.", "label": "Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value", "terseLabel": "Debt securities, maturity, without single maturity date" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r279", "r283", "r328", "r882" ], "calculation": { "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 }, "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails": { "order": 3.0, "parentTag": "cvs_DebtSecuritiesAvailableForSaleAmortizedCostNet", "weight": 1.0 }, "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale", "terseLabel": "Debt securities", "totalLabel": "Total", "verboseLabel": "Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails", "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails", "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Number of Positions [Abstract]", "terseLabel": "Number of Securities" } } }, "localname": "AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r603", "r633" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansRestrictedStockActivityDetails", "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails", "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails", "http://www.cvshealth.com/role/StockIncentivePlansValuationandAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r730", "r731" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r178" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "verboseLabel": "Significant Accounting Policies" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BuildingAndBuildingImprovementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.", "label": "Building and Building Improvements [Member]", "terseLabel": "Building, building improvements and leasehold improvements", "verboseLabel": "Building and improvements" } } }, "localname": "BuildingAndBuildingImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesPropertyPlantandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BuildingMember": { "auth_ref": [ "r371" ], "lang": { "en-us": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.", "label": "Building [Member]", "terseLabel": "Distribution centers and Corporate offices" } } }, "localname": "BuildingMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/DivestituresNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationIntegrationRelatedCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.", "label": "Business Combination, Integration Related Costs", "verboseLabel": "Acquisition-related integration costs" } } }, "localname": "BusinessCombinationIntegrationRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy": { "auth_ref": [ "r956" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for deferred policy acquisition costs, including the nature, type, and amount of capitalized costs incurred to write or acquire insurance contracts, and the basis for and methodologies applied in capitalizing and amortizing such costs.", "label": "Deferred Policy Acquisition Costs, Policy [Policy Text Block]", "terseLabel": "Health Care Contract Acquisition Costs" } } }, "localname": "CapitalizationOfDeferredPolicyAcquisitionCostsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "auth_ref": [ "r767", "r768" ], "lang": { "en-us": { "role": { "documentation": "Measured as reported on the statement of financial position (balance sheet).", "label": "Reported Value Measurement [Member]", "terseLabel": "Carrying Value" } } }, "localname": "CarryingReportedAmountFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r29", "r60", "r158" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.cvshealth.com/role/SignificantAccountingPoliciesRestrictedCashDetails": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets", "http://www.cvshealth.com/role/SignificantAccountingPoliciesRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Member]", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r38", "r159", "r871" ], "lang": { "en-us": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents and Restricted Cash" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r148", "r158", "r162" ], "calculation": { "http://www.cvshealth.com/role/SignificantAccountingPoliciesRestrictedCashDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash at the end of the period", "periodStartLabel": "Cash, cash equivalents and restricted cash at the beginning of the period", "totalLabel": "Total cash, cash equivalents and restricted cash in the consolidated statements of cash flows" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows", "http://www.cvshealth.com/role/SignificantAccountingPoliciesRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r148", "r781" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries": { "auth_ref": [ "r177" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents disclosure of the aggregate cash dividends paid to the entity by consolidated subsidiaries.", "label": "SEC Schedule, 12-04, Cash Dividends Paid to Registrant, Consolidated Subsidiaries", "terseLabel": "Dividends paid" } } }, "localname": "CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityRegulatoryRequirementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock": { "auth_ref": [ "r634" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cash received from exercise of stock options and similar instruments granted under share-based payment arrangements and tax benefit from exercise of stock options.", "label": "Cash Proceeds Received and Tax Benefit from Share-based Payment Awards [Table Text Block]", "terseLabel": "Cash proceeds received and tax benefit from share-based payment awards" } } }, "localname": "CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_CededCreditRiskAxis": { "auth_ref": [ "r1024" ], "lang": { "en-us": { "role": { "documentation": "Information by reinsurer or group of reinsurers of concentrated credit risk arising from a reinsurance arrangement.", "label": "Ceded Credit Risk, Reinsurer [Axis]", "terseLabel": "Ceded Credit Risk, Reinsurer [Axis]" } } }, "localname": "CededCreditRiskAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ReinsuranceReinsuranceRecoverablesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CededCreditRiskLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Ceded Credit Risk [Line Items]", "terseLabel": "Ceded Credit Risk [Line Items]" } } }, "localname": "CededCreditRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ReinsuranceReinsuranceRecoverablesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CededCreditRiskReinsurerDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reinsurer or group of reinsurers for whom the entity has a concentration of credit risk.", "label": "Ceded Credit Risk, Reinsurer [Domain]", "terseLabel": "Ceded Credit Risk, Reinsurer [Domain]" } } }, "localname": "CededCreditRiskReinsurerDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ReinsuranceReinsuranceRecoverablesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CededCreditRiskTable": { "auth_ref": [ "r1024" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about reinsurer or group of reinsurers for whom the entity has a concentration of credit risk.", "label": "Ceded Credit Risk [Table]", "terseLabel": "Ceded Credit Risk [Table]" } } }, "localname": "CededCreditRiskTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ReinsuranceReinsuranceRecoverablesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CededPremiumsEarned": { "auth_ref": [ "r936", "r952", "r1004", "r1005", "r1008", "r1010" ], "calculation": { "http://www.cvshealth.com/role/ReinsuranceEffectsofReinsuranceDetails": { "order": 3.0, "parentTag": "us-gaap_PremiumsEarnedNet", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of earned premiums ceded to other entities.", "label": "Ceded Premiums Earned", "negatedTerseLabel": "Ceded" } } }, "localname": "CededPremiumsEarned", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ReinsuranceEffectsofReinsuranceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ChangeInContractWithCustomerLiabilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Change in Contract with Customer, Liability [Abstract]", "terseLabel": "Change in Contract with Customer, Liability [Abstract]" } } }, "localname": "ChangeInContractWithCustomerLiabilityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesContractBalancesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClaimsDevelopmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Claims Development [Line Items]", "terseLabel": "Claims Development [Line Items]" } } }, "localname": "ClaimsDevelopmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableIncurredandPaidHealthCareClaimsDevelopmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfTreasuryStockTable": { "auth_ref": [ "r474", "r475", "r476", "r477" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.", "label": "Class of Treasury Stock [Table]", "terseLabel": "Class of Treasury Stock [Table]" } } }, "localname": "ClassOfTreasuryStockTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails", "http://www.cvshealth.com/role/ShareholdersEquityShareRepurchasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommercialMortgageBackedSecuritiesMember": { "auth_ref": [ "r292", "r532" ], "lang": { "en-us": { "role": { "documentation": "Securities collateralized by commercial real estate mortgage loans.", "label": "Commercial Mortgage Backed Securities [Member]", "terseLabel": "Commercial mortgage-backed securities" } } }, "localname": "CommercialMortgageBackedSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails", "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails", "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails", "http://www.cvshealth.com/role/InvestmentsNarrativeDetails", "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails", "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r396" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial Paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsShorttermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommercialRealEstateMember": { "auth_ref": [ "r325", "r532" ], "lang": { "en-us": { "role": { "documentation": "Property that is solely used for business purposes.", "label": "Commercial Real Estate [Member]", "terseLabel": "Commercial Real Estate" } } }, "localname": "CommercialRealEstateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails", "http://www.cvshealth.com/role/InvestmentsMortgageLoansDetails", "http://www.cvshealth.com/role/InvestmentsScheduleofMortgageLoanPrincipalRepaymentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r76", "r382", "r884", "r930" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 16)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r379", "r380", "r381", "r391", "r1053" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "verboseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r77" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Capital shares reserved for future issuance (in shares)" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r473" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Declared", "terseLabel": "Dividends declared per share (in dollars per share)" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock held by shareholders with par value plus amounts in excess of par value or issuance value (in cases of no-par value stock).", "label": "Common Stock Including Additional Paid in Capital [Member]", "terseLabel": "Common Stock and Capital Surplus" } } }, "localname": "CommonStockIncludingAdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r179", "r180", "r744" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Shares" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r52" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r52" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r52" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r52", "r468" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r52", "r828" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquityParentheticals" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStocksIncludingAdditionalPaidInCapital": { "auth_ref": [ "r52", "r54", "r473" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of par value plus amounts in excess of par value or issuance value for common stock issued.", "label": "Common Stocks, Including Additional Paid in Capital", "terseLabel": "Common stock, par value $0.01: 3,200 shares authorized; 1,744 shares issued and 1,322 shares outstanding at December\u00a031, 2021 and 1,733 shares issued and 1,310 shares outstanding at December\u00a031, 2020 and capital surplus" } } }, "localname": "CommonStocksIncludingAdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]", "terseLabel": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Components of Deferred Tax Assets [Abstract]", "terseLabel": "Deferred income tax assets:" } } }, "localname": "ComponentsOfDeferredTaxAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Components of Deferred Tax Assets and Liabilities [Abstract]", "terseLabel": "Components of Deferred Tax Assets and Liabilities [Abstract]" } } }, "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Components of Deferred Tax Liabilities [Abstract]", "terseLabel": "Deferred income tax liabilities:" } } }, "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]" } } }, "localname": "ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesIncomeTaxProvisionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r103", "r105", "r106", "r120", "r892", "r943" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income attributable to CVS Health" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r103", "r105", "r119", "r702", "r725", "r891", "r942" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r118", "r128", "r890", "r940" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]", "terseLabel": "Other Comprehensive Income" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/OtherComprehensiveIncome" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r219", "r220", "r266", "r769", "r770", "r1051" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r219", "r220", "r266", "r769", "r770", "r1024", "r1051" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r219", "r220", "r266", "r769", "r770", "r1024", "r1051" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]", "terseLabel": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r219", "r220", "r266", "r769", "r770" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration risk, percent" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r217", "r219", "r220", "r221", "r769", "r771", "r1051" ], "lang": { "en-us": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]", "terseLabel": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r219", "r220", "r266", "r769", "r770", "r1051" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationVariableInterestEntityPolicy": { "auth_ref": [ "r712", "r716", "r718" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).", "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]", "terseLabel": "Variable Interest Entities" } } }, "localname": "ConsolidationVariableInterestEntityPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r482" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "terseLabel": "Schedule of contract with customer assets and liabilities" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetNetCurrent": { "auth_ref": [ "r479", "r481", "r493" ], "calculation": { "http://www.cvshealth.com/role/SignificantAccountingPoliciesAccountsReceivableDetails": { "order": 3.0, "parentTag": "us-gaap_AccountsReceivableNetCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.", "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current", "verboseLabel": "Trade receivables" } } }, "localname": "ContractWithCustomerAssetNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesAccountsReceivableDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesReceivablesandContractedBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r479", "r480", "r493" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "periodEndLabel": "Contract liabilities, end of period", "periodStartLabel": "Contract liabilities, beginning of period", "terseLabel": "Contract liabilities (included in accrued expenses)" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesContractBalancesDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesReceivablesandContractedBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerSalesChannelAxis": { "auth_ref": [ "r492", "r500" ], "lang": { "en-us": { "role": { "documentation": "Information by sales channel for delivery of good or service in contract with customer.", "label": "Contract with Customer, Sales Channel [Axis]", "terseLabel": "Contract with Customer, Sales Channel [Axis]" } } }, "localname": "ContractWithCustomerSalesChannelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContractWithCustomerSalesChannelDomain": { "auth_ref": [ "r492", "r500" ], "lang": { "en-us": { "role": { "documentation": "Sales channel for delivery of good or service in contract with customer. Includes, but is not limited to, directly to consumer and through intermediary.", "label": "Contract with Customer, Sales Channel [Domain]", "terseLabel": "Contract with Customer, Sales Channel [Domain]" } } }, "localname": "ContractWithCustomerSalesChannelDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateAndOtherMember": { "auth_ref": [ "r225" ], "lang": { "en-us": { "role": { "documentation": "Component of an entity that provides financial and operational oversight and administrative support for other segments and other segments not separately reported due to size or nature of business activities. Excludes intersegment elimination and reconciling items.", "label": "Corporate and Other [Member]", "terseLabel": "Corporate/ Other" } } }, "localname": "CorporateAndOtherMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableReconciliationofHealthCareCostsPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateNonSegmentMember": { "auth_ref": [ "r249", "r250", "r251", "r252", "r254", "r260", "r262" ], "lang": { "en-us": { "role": { "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.", "label": "Corporate, Non-Segment [Member]", "terseLabel": "Corporate/ Other" } } }, "localname": "CorporateNonSegmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r124", "r863" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of products sold" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesPolicyTextBlock": { "auth_ref": [ "r502" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.", "label": "Cost of Goods and Service [Policy Text Block]", "terseLabel": "Cost of Products Sold" } } }, "localname": "CostOfSalesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r122" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total operating costs" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r169", "r673", "r683" ], "calculation": { "http://www.cvshealth.com/role/IncomeTaxesIncomeTaxProvisionDetails": { "order": 1.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Federal Tax Expense (Benefit)", "terseLabel": "Federal" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r169", "r673", "r683", "r685" ], "calculation": { "http://www.cvshealth.com/role/IncomeTaxesIncomeTaxProvisionDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "Current Income Tax Expense (Benefit)", "totalLabel": "Total current taxes" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Current:" } } }, "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesIncomeTaxProvisionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r169", "r673", "r683" ], "calculation": { "http://www.cvshealth.com/role/IncomeTaxesIncomeTaxProvisionDetails": { "order": 2.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current State and Local Tax Expense (Benefit)", "terseLabel": "State" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r218", "r266" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerListsMember": { "auth_ref": [ "r697" ], "lang": { "en-us": { "role": { "documentation": "Information about customers such as their name and contact information; it may also be an extensive database that includes other information about the customers such as their order history and demographic information.", "label": "Customer Lists [Member]", "terseLabel": "Customer Lists" } } }, "localname": "CustomerListsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRelatedIntangibleAssetsMember": { "auth_ref": [ "r696" ], "lang": { "en-us": { "role": { "documentation": "Customer-related asset, including, but not limited to, customer lists, and noncontractual customer relationships.", "label": "Customer-Related Intangible Assets [Member]", "terseLabel": "Customer contracts/relationships and covenants not to compete" } } }, "localname": "CustomerRelatedIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r165", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r432", "r439", "r440", "r442", "r450" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "verboseLabel": "Borrowings and Credit Arrangements" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangements" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r44", "r46", "r47", "r167", "r176", "r415", "r416", "r417", "r418", "r419", "r420", "r422", "r428", "r429", "r430", "r431", "r433", "r434", "r435", "r436", "r437", "r438", "r444", "r445", "r446", "r447", "r795", "r875", "r877", "r915" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsLongTermBorrowingsDetails", "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails", "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsShorttermBorrowingsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r47", "r443", "r877", "r915" ], "calculation": { "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsDebtMaturitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails": { "order": 1.0, "parentTag": "cvs_LongtermDebtGrossAndLeaseObligation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term Debt, Gross", "terseLabel": "Long-term debt", "totalLabel": "Subtotal", "verboseLabel": "Amount outstanding" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsDebtMaturitiesDetails", "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsLongTermBorrowingsDetails", "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r415", "r444", "r445", "r793", "r795", "r796" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Debt face amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsLongTermBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFairValue": { "auth_ref": [ "r430", "r444", "r445", "r766" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.", "label": "Debt Instrument, Fair Value Disclosure", "terseLabel": "Long-term debt" } } }, "localname": "DebtInstrumentFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r73", "r416" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Debt interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsLongTermBorrowingsDetails", "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsLongTermBorrowingsDetails", "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r74", "r167", "r176", "r415", "r416", "r417", "r418", "r419", "r420", "r422", "r428", "r429", "r430", "r431", "r433", "r434", "r435", "r436", "r437", "r438", "r444", "r445", "r446", "r447", "r795" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsLongTermBorrowingsDetails", "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails", "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsShorttermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r74", "r167", "r176", "r415", "r416", "r417", "r418", "r419", "r420", "r422", "r428", "r429", "r430", "r431", "r433", "r434", "r435", "r436", "r437", "r438", "r441", "r444", "r445", "r446", "r447", "r469", "r470", "r471", "r472", "r792", "r793", "r795", "r796", "r907" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsLongTermBorrowingsDetails", "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Debt instrument term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsShorttermBorrowingsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DebtInstrumentUnamortizedPremium": { "auth_ref": [ "r428", "r792", "r796" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt premium.", "label": "Debt Instrument, Unamortized Premium", "terseLabel": "Debt premiums" } } }, "localname": "DebtInstrumentUnamortizedPremium", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": { "auth_ref": [ "r284", "r328", "r336", "r337" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Allowance for Credit Loss", "negatedTerseLabel": "Allowance for credit loss" } } }, "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": { "auth_ref": [ "r300", "r334", "r339" ], "calculation": { "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails": { "order": 1.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer", "terseLabel": "Fair Value, Greater than 12 months" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": { "auth_ref": [ "r300", "r334" ], "calculation": { "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails": { "order": 1.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss", "terseLabel": "Unrealized Losses, Greater than 12 months" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions": { "auth_ref": [ "r332" ], "calculation": { "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails": { "order": 1.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions", "terseLabel": "Number of Securities, Greater than 12 months" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": { "auth_ref": [ "r300", "r334", "r339" ], "calculation": { "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails": { "order": 2.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months", "verboseLabel": "Fair Value, Less than 12 months" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": { "auth_ref": [ "r300", "r334" ], "calculation": { "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails": { "order": 2.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss", "verboseLabel": "Unrealized Losses, Less than 12 months" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions": { "auth_ref": [ "r332" ], "calculation": { "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails": { "order": 2.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions", "terseLabel": "Number of Securities, Less than 12 months" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": { "auth_ref": [ "r301" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Realized Gain", "terseLabel": "Gross realized capital gains" } } }, "localname": "DebtSecuritiesAvailableForSaleRealizedGain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/InvestmentsRealizedGainsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss": { "auth_ref": [ "r301" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Realized Loss", "negatedTerseLabel": "Gross realized capital losses" } } }, "localname": "DebtSecuritiesAvailableForSaleRealizedLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/InvestmentsRealizedGainsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "auth_ref": [ "r302" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale [Table]", "terseLabel": "Debt Securities, Available-for-sale [Table]" } } }, "localname": "DebtSecuritiesAvailableForSaleTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails", "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails", "http://www.cvshealth.com/role/InvestmentsNarrativeDetails", "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails", "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "auth_ref": [ "r302" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale [Table Text Block]", "terseLabel": "Debt securities available for sale" } } }, "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": { "auth_ref": [ "r296", "r330", "r339" ], "calculation": { "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.", "label": "Debt Securities, Available-for-sale, Unrealized Loss Position", "totalLabel": "Fair Value" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails", "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": { "auth_ref": [ "r297", "r331" ], "calculation": { "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss", "totalLabel": "Unrealized Losses" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails", "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": { "auth_ref": [ "r298", "r332" ], "calculation": { "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions", "totalLabel": "Number of Securities" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtSecuritiesMember": { "auth_ref": [ "r302" ], "lang": { "en-us": { "role": { "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions.", "label": "Debt Securities [Member]", "terseLabel": "Debt securities" } } }, "localname": "DebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails", "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r169", "r674", "r683" ], "calculation": { "http://www.cvshealth.com/role/IncomeTaxesIncomeTaxProvisionDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Federal Income Tax Expense (Benefit)", "terseLabel": "Federal" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r156", "r169", "r674", "r683", "r684", "r685" ], "calculation": { "http://www.cvshealth.com/role/IncomeTaxesIncomeTaxProvisionDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "totalLabel": "Total deferred income taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Deferred:" } } }, "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesIncomeTaxProvisionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r49", "r50", "r666", "r876", "r914" ], "calculation": { "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred Tax Liabilities, Gross", "negatedTotalLabel": "Total deferred income tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r651", "r652" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxesAndTaxCredits": { "auth_ref": [ "r157" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.", "label": "Deferred Income Taxes and Tax Credits", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxesAndTaxCredits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredPolicyAcquisitionCosts": { "auth_ref": [ "r928", "r957", "r958", "r959", "r989", "r1021" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred policy acquisition cost capitalized on contract remaining in force.", "label": "Deferred Policy Acquisition Cost", "terseLabel": "Deferred acquisition costs" } } }, "localname": "DeferredPolicyAcquisitionCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r169", "r674", "r683" ], "calculation": { "http://www.cvshealth.com/role/IncomeTaxesIncomeTaxProvisionDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred State and Local Income Tax Expense (Benefit)", "terseLabel": "State" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsDeferredIncome": { "auth_ref": [ "r671", "r672" ], "calculation": { "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.", "label": "Deferred Tax Assets, Deferred Income", "terseLabel": "Deferred income" } } }, "localname": "DeferredTaxAssetsDeferredIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsInventory": { "auth_ref": [ "r671", "r672" ], "calculation": { "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.", "label": "Deferred Tax Assets, Inventory", "terseLabel": "Inventory" } } }, "localname": "DeferredTaxAssetsInventory", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r668" ], "calculation": { "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Total deferred income tax assets" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r671", "r672" ], "calculation": { "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 9.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "terseLabel": "Net operating loss and capital loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails", "http://www.cvshealth.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r671", "r672" ], "calculation": { "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 8.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Deferred Tax Assets, Other", "terseLabel": "Other" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation": { "auth_ref": [ "r671", "r672" ], "calculation": { "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 7.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation", "terseLabel": "Employee benefits" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent": { "auth_ref": [ "r671", "r672" ], "calculation": { "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 10.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred rent.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Deferred Rent", "terseLabel": "Lease and rents" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves": { "auth_ref": [ "r671", "r672" ], "calculation": { "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves, classified as other.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Reserves", "terseLabel": "Insurance reserves" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r667" ], "calculation": { "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedTerseLabel": "Valuation allowance", "verboseLabel": "Valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails", "http://www.cvshealth.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilities": { "auth_ref": [ "r652", "r668" ], "calculation": { "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "label": "Deferred Tax Liabilities, Net", "negatedTotalLabel": "Net deferred income tax liabilities" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesInvestments": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from investments (excludes investments in subsidiaries and equity method investments).", "label": "Deferred Tax Liabilities, Investments", "negatedLabel": "Investments" } } }, "localname": "DeferredTaxLiabilitiesInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": { "auth_ref": [ "r671", "r672" ], "calculation": { "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.", "label": "Deferred Tax Liabilities, Leasing Arrangements", "negatedTerseLabel": "Lease and rents" } } }, "localname": "DeferredTaxLiabilitiesLeasingArrangements", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets": { "auth_ref": [ "r521", "r578" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses.", "label": "Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)", "terseLabel": "Actual return on plan assets" } } }, "localname": "DefinedBenefitPlanActualReturnOnPlanAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld": { "auth_ref": [ "r536", "r578" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, measured using unobservable inputs, of increase (decrease) in plan assets of defined benefit plan from actual return (loss) on assets still held.", "label": "Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Actual Return (Loss) on Plan Assets Still Held", "terseLabel": "Actual return on plan assets" } } }, "localname": "DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsChangesinLevel3PensionPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanActuarialGainLoss": { "auth_ref": [ "r514" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.", "label": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)", "negatedTerseLabel": "Actuarial (gain) loss" } } }, "localname": "DefinedBenefitPlanActuarialGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": { "auth_ref": [ "r507", "r547", "r572", "r578", "r579" ], "calculation": { "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNetPeriodicBenefitCostsDetails": { "order": 2.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.", "label": "Defined Benefit Plan, Amortization of Gain (Loss)", "negatedTerseLabel": "Amortization of net actuarial loss" } } }, "localname": "DefinedBenefitPlanAmortizationOfGainsLosses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNetPeriodicBenefitCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet": { "auth_ref": [ "r505", "r529" ], "calculation": { "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset (liability), recognized in statement of financial position, for defined benefit pension and other postretirement plans.", "label": "Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position", "totalLabel": "Net assets" } } }, "localname": "DefinedBenefitPlanAmountsRecognizedInBalanceSheet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract]", "terseLabel": "Assets (liabilities) recognized on the consolidated balance sheet" } } }, "localname": "DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": { "auth_ref": [ "r42", "r505", "r506", "r529", "r578", "r873", "r918" ], "calculation": { "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.", "label": "Assets for Plan Benefits, Defined Benefit Plan", "terseLabel": "Noncurrent assets reflected in other assets" } } }, "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate": { "auth_ref": [ "r554" ], "lang": { "en-us": { "role": { "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate", "terseLabel": "Discount rate" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsWeightedAverageAssumptionsUsedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate": { "auth_ref": [ "r554" ], "lang": { "en-us": { "role": { "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate", "terseLabel": "Discount rate" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsWeightedAverageAssumptionsUsedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets": { "auth_ref": [ "r555", "r577" ], "lang": { "en-us": { "role": { "documentation": "Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets", "terseLabel": "Expected long-term rate of return on plan assets" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsWeightedAverageAssumptionsUsedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanBenefitObligation": { "auth_ref": [ "r509" ], "calculation": { "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.", "label": "Defined Benefit Plan, Benefit Obligation", "periodEndLabel": "Benefit obligation, end of year", "periodStartLabel": "Benefit obligation, beginning of year", "terseLabel": "Benefit obligation" } } }, "localname": "DefinedBenefitPlanBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid": { "auth_ref": [ "r516", "r584" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.", "label": "Defined Benefit Plan, Benefit Obligation, Benefits Paid", "negatedTerseLabel": "Benefit payments" } } }, "localname": "DefinedBenefitPlanBenefitObligationBenefitsPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement": { "auth_ref": [ "r511" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of payment, which decreases benefit obligation of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract. Excludes decreases to benefit obligation for remeasurement due to settlement.", "label": "Defined Benefit Plan, Benefit Obligation, Payment for Settlement", "negatedTerseLabel": "Settlements" } } }, "localname": "DefinedBenefitPlanBenefitObligationPaymentForSettlement", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis": { "auth_ref": [ "r531", "r532", "r534", "r535", "r536", "r537", "r538", "r539", "r558", "r578" ], "lang": { "en-us": { "role": { "documentation": "Information by defined benefit plan asset investment.", "label": "Defined Benefit Plan, Plan Assets, Category [Axis]", "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Axis]" } } }, "localname": "DefinedBenefitPlanByPlanAssetCategoriesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsChangesinLevel3PensionPlanAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember": { "auth_ref": [ "r532" ], "lang": { "en-us": { "role": { "documentation": "Cash and cash equivalent in which defined benefit plan asset is invested.", "label": "Defined Benefit Plan, Cash and Cash Equivalents [Member]", "terseLabel": "Cash and cash equivalents" } } }, "localname": "DefinedBenefitPlanCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]", "terseLabel": "Change in benefit obligation:" } } }, "localname": "DefinedBenefitPlanChangeInBenefitObligationRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]", "terseLabel": "Change in plan assets:" } } }, "localname": "DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsChangesinLevel3PensionPlanAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanCommonCollectiveTrustMember": { "auth_ref": [ "r532" ], "lang": { "en-us": { "role": { "documentation": "Regulated trust, responsible for collective investment and reinvestment of asset from employee benefit plan maintained by more than one employer, in which defined benefit plan asset is invested.", "label": "Defined Benefit Plan, Common Collective Trust [Member]", "verboseLabel": "Common/collective trusts" } } }, "localname": "DefinedBenefitPlanCommonCollectiveTrustMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DefinedBenefitPlanContributionsByEmployer": { "auth_ref": [ "r523", "r532", "r534", "r576", "r578", "r579" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets.", "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer", "terseLabel": "Employer contributions", "verboseLabel": "Employer contributions" } } }, "localname": "DefinedBenefitPlanContributionsByEmployer", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanDerivativeMember": { "auth_ref": [ "r532" ], "lang": { "en-us": { "role": { "documentation": "Financial instrument or other contract with one or more underlyings, notional amount or payment provision or both; can be settled net by means outside contract or delivery of asset; and with minimal or no initial net investment, in which defined benefit plan asset is invested.", "label": "Defined Benefit Plan, Derivative [Member]", "terseLabel": "Derivatives" } } }, "localname": "DefinedBenefitPlanDerivativeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plan Disclosure [Line Items]", "terseLabel": "Defined Benefit Plan Disclosure [Line Items]" } } }, "localname": "DefinedBenefitPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsDefinedBenefitPlansExpectedBenefitDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNarrativeDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNetPeriodicBenefitCostsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember": { "auth_ref": [ "r532", "r534", "r578" ], "lang": { "en-us": { "role": { "documentation": "Security representing ownership in corporation or other legal entity, not domiciled in United States of America (US), for which ownership is represented by share of stock; in which defined benefit plan asset is invested. Includes, but is not limited to, common stock, preferred stock, convertible security, stock right and stock warrant.", "label": "Defined Benefit Plan, Equity Securities, Non-US [Member]", "terseLabel": "International" } } }, "localname": "DefinedBenefitPlanEquitySecuritiesNonUsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember": { "auth_ref": [ "r532", "r534", "r578" ], "lang": { "en-us": { "role": { "documentation": "Security representing ownership in corporation or other legal entity, domiciled in United States of America (US), for which ownership is represented by share of stock; in which defined benefit plan asset is invested. Includes, but is not limited to, common stock, preferred stock, convertible security, stock right and stock warrant.", "label": "Defined Benefit Plan, Equity Securities, US [Member]", "terseLabel": "U.S. domestic" } } }, "localname": "DefinedBenefitPlanEquitySecuritiesUsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter": { "auth_ref": [ "r541" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years", "terseLabel": "2027-2031" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsDefinedBenefitPlansExpectedBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths": { "auth_ref": [ "r541" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year One", "terseLabel": "2022" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsDefinedBenefitPlansExpectedBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive": { "auth_ref": [ "r541" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Five", "terseLabel": "2026" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsDefinedBenefitPlansExpectedBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour": { "auth_ref": [ "r541" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Four", "terseLabel": "2025" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsDefinedBenefitPlansExpectedBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree": { "auth_ref": [ "r541" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Three", "terseLabel": "2024" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsDefinedBenefitPlansExpectedBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo": { "auth_ref": [ "r541" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Two", "terseLabel": "2023" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsDefinedBenefitPlansExpectedBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": { "auth_ref": [ "r507", "r546", "r571", "r578", "r579" ], "calculation": { "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNetPeriodicBenefitCostsDetails": { "order": 1.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.", "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets", "negatedLabel": "Expected return on plan assets" } } }, "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNetPeriodicBenefitCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanFairValueOfPlanAssets": { "auth_ref": [ "r520", "r532", "r534", "r535", "r578" ], "calculation": { "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.", "label": "Defined Benefit Plan, Plan Assets, Amount", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "terseLabel": "Fair value of plan assets" } } }, "localname": "DefinedBenefitPlanFairValueOfPlanAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsChangesinLevel3PensionPlanAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanFundedStatusOfPlan": { "auth_ref": [ "r505", "r529", "r578" ], "calculation": { "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.", "label": "Defined Benefit Plan, Funded (Unfunded) Status of Plan", "totalLabel": "Funded status" } } }, "localname": "DefinedBenefitPlanFundedStatusOfPlan", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanInterestCost": { "auth_ref": [ "r507", "r512", "r545", "r570", "r578", "r579" ], "calculation": { "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNetPeriodicBenefitCostsDetails": { "order": 4.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.", "label": "Defined Benefit Plan, Interest Cost", "terseLabel": "Interest cost" } } }, "localname": "DefinedBenefitPlanInterestCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNetPeriodicBenefitCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": { "auth_ref": [ "r543", "r568", "r578", "r579" ], "calculation": { "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNetPeriodicBenefitCostsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)", "terseLabel": "Net periodic benefit cost", "totalLabel": "Net periodic benefit cost (income)" } } }, "localname": "DefinedBenefitPlanNetPeriodicBenefitCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNarrativeDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNetPeriodicBenefitCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]", "terseLabel": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]" } } }, "localname": "DefinedBenefitPlanNetPeriodicBenefitCostAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNetPeriodicBenefitCostsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid": { "auth_ref": [ "r525", "r584" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.", "label": "Defined Benefit Plan, Plan Assets, Benefits Paid", "negatedTerseLabel": "Benefit payments" } } }, "localname": "DefinedBenefitPlanPlanAssetsBenefitsPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPlanAssetsCategoryTableTextBlock": { "auth_ref": [ "r532", "r534" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of defined benefit plan asset investment. Includes, but is not limited to, fair value of category of plan asset and its level within fair value hierarchy.", "label": "Defined Benefit Plan, Plan Assets, Category [Table Text Block]", "terseLabel": "Schedule of change in level 3 plan assets" } } }, "localname": "DefinedBenefitPlanPlanAssetsCategoryTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount": { "auth_ref": [ "r532" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment within defined benefit plan asset category.", "label": "Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount", "terseLabel": "Plan assets, investment within plan asset category, amount" } } }, "localname": "DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage": { "auth_ref": [ "r531", "r578" ], "lang": { "en-us": { "role": { "documentation": "Percentage of target investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan.", "label": "Defined Benefit Plan, Plan Assets, Target Allocation, Percentage", "terseLabel": "Target investment allocations" } } }, "localname": "DefinedBenefitPlanPlanAssetsTargetAllocationPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements": { "auth_ref": [ "r537", "r578" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, measured using unobservable input, of increase (decrease) in plan asset of defined benefit plan from purchase, sale and settlement of trade associated with underlying investment.", "label": "Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Purchase, Sale, and Settlement", "verboseLabel": "Purchases, sales and settlements" } } }, "localname": "DefinedBenefitPlanPurchasesSalesAndSettlements", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsChangesinLevel3PensionPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanRealEstateMember": { "auth_ref": [ "r532", "r578" ], "lang": { "en-us": { "role": { "documentation": "Property composed of building, land and land improvement; in which defined benefit plan asset is invested.", "label": "Defined Benefit Plan, Real Estate [Member]", "terseLabel": "Real estate" } } }, "localname": "DefinedBenefitPlanRealEstateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsChangesinLevel3PensionPlanAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1": { "auth_ref": [ "r508", "r550", "r575" ], "calculation": { "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNetPeriodicBenefitCostsDetails": { "order": 3.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk related to obligation and assets used to effect settlement.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement", "negatedTerseLabel": "Settlement losses" } } }, "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNetPeriodicBenefitCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanSettlementsPlanAssets": { "auth_ref": [ "r528" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of payment, which decreases plan assets of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract.", "label": "Defined Benefit Plan, Plan Assets, Payment for Settlement", "negatedTerseLabel": "Settlements" } } }, "localname": "DefinedBenefitPlanSettlementsPlanAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels": { "auth_ref": [ "r538", "r578" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, measured using unobservable inputs, of increase (decrease) in plan assets of defined benefit plan, for assets transferred into (out of) Level 3 of fair value hierarchy. Includes, but is not limited to, transfer due to change in observability of significant inputs.", "label": "Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Assets Transferred into (out of) Level 3", "terseLabel": "Transfers out of Level 3" } } }, "localname": "DefinedBenefitPlanTransfersBetweenMeasurementLevels", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsChangesinLevel3PensionPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]", "terseLabel": "Assumptions used to determine benefit obligations" } } }, "localname": "DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsWeightedAverageAssumptionsUsedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract]", "terseLabel": "Assumptions used to determine net benefit costs" } } }, "localname": "DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsWeightedAverageAssumptionsUsedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable": { "auth_ref": [ "r564", "r565", "r566", "r567", "r578" ], "lang": { "en-us": { "role": { "documentation": "Disclosures and provisions pertaining to defined benefit pension plans or other postretirement defined benefit plans. The arrangements are generally based on terms and conditions stipulated by the entity, and which contain a promise by the employer to pay certain amounts or awards at designated future dates, including a period after retirement, upon compliance with stipulated requirements. Excludes disclosures pertaining to defined contribution plans.", "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]", "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]" } } }, "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsChangesinLevel3PensionPlanAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]", "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]" } } }, "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsChangesinLevel3PensionPlanAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.", "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount", "terseLabel": "Defined contribution plan, employer contributions" } } }, "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r156", "r370" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r156", "r233" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows", "http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r175", "r726", "r727", "r728", "r729", "r733" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivatives, Policy [Policy Text Block]", "terseLabel": "Derivative Financial Instruments" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DirectPremiumsEarned": { "auth_ref": [ "r936", "r951", "r1006", "r1009" ], "calculation": { "http://www.cvshealth.com/role/ReinsuranceEffectsofReinsuranceDetails": { "order": 1.0, "parentTag": "us-gaap_PremiumsEarnedNet", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before premiums ceded to other entities and premiums assumed by the entity, of premiums earned.", "label": "Direct Premiums Earned", "terseLabel": "Direct" } } }, "localname": "DirectPremiumsEarned", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ReinsuranceEffectsofReinsuranceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r492", "r494", "r495", "r496", "r497", "r498", "r499", "r500" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r492" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Schedule of disaggregation of revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r645" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Stock Incentive Plans" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": { "auth_ref": [ "r8", "r9", "r10", "r11", "r12", "r20", "r116", "r938" ], "calculation": { "http://www.cvshealth.com/role/SignificantAccountingPoliciesDiscontinuedOperationsDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.", "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax", "terseLabel": "Loss from discontinued operations" } } }, "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_EarningsPerShareBasic", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation.", "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share", "terseLabel": "Loss from discontinued operations attributable to CVS Health (in dollars per share)" } } }, "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_EarningsPerShareDiluted", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation.", "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share", "terseLabel": "Loss from discontinued operations attributable to CVS Health (in dollars per share)" } } }, "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation": { "auth_ref": [ "r9", "r10", "r11", "r12", "r20", "r23", "r653", "r682", "r689" ], "calculation": { "http://www.cvshealth.com/role/SignificantAccountingPoliciesDiscontinuedOperationsDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.", "label": "Discontinued Operation, Tax Effect of Discontinued Operation", "negatedTerseLabel": "Income tax benefit" } } }, "localname": "DiscontinuedOperationTaxEffectOfDiscontinuedOperation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DiscontinuedOperationsDisposedOfBySaleMember": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Component or group of components disposed of by sale and representing a strategic shift that has or will have a major effect on operations and financial results.", "label": "Discontinued Operations, Disposed of by Sale [Member]", "terseLabel": "Discontinued Operations, Disposed of by Sale" } } }, "localname": "DiscontinuedOperationsDisposedOfBySaleMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/DivestituresNarrativeDetails", "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DiscontinuedOperationsPolicyTextBlock": { "auth_ref": [ "r14", "r27" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for discontinued operations. Includes, but is not limited to, method of interest allocation to a discontinued operation.", "label": "Discontinued Operations, Policy [Policy Text Block]", "terseLabel": "Discontinued Operations" } } }, "localname": "DiscontinuedOperationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisposalGroupClassificationAxis": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Information by disposal group classification.", "label": "Disposal Group Classification [Axis]", "terseLabel": "Disposal Group Classification [Axis]" } } }, "localname": "DisposalGroupClassificationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/DivestituresNarrativeDetails", "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.", "label": "Disposal Group Classification [Domain]", "terseLabel": "Disposal Group Classification [Domain]" } } }, "localname": "DisposalGroupClassificationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/DivestituresNarrativeDetails", "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "auth_ref": [ "r587", "r594" ], "lang": { "en-us": { "role": { "documentation": "Name of disposal group.", "label": "Disposal Group Name [Domain]", "terseLabel": "Disposal Group Name [Domain]" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/DivestituresNarrativeDetails", "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DividendsCommonStock": { "auth_ref": [ "r473", "r905" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).", "label": "Dividends, Common Stock", "negatedTerseLabel": "Common stock dividends" } } }, "localname": "DividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPayableAmountPerShare": { "auth_ref": [ "r161" ], "lang": { "en-us": { "role": { "documentation": "The per share amount of a dividend declared, but not paid, as of the financial reporting date.", "label": "Dividends Payable, Amount Per Share", "terseLabel": "Cash dividend declared (USD per share)" } } }, "localname": "DividendsPayableAmountPerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityDividendsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_DividendsPayableLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Dividends Payable [Line Items]", "terseLabel": "Dividends Payable [Line Items]" } } }, "localname": "DividendsPayableLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityDividendsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DividendsPayableTable": { "auth_ref": [ "r161" ], "lang": { "en-us": { "role": { "documentation": "A table that contains information regarding dividends that have been declared but not paid as of the financial reporting date. This information may contain the amount, amount per share, declared date, and date to be paid.", "label": "Dividends Payable [Table]", "terseLabel": "Dividends Payable [Table]" } } }, "localname": "DividendsPayableTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityDividendsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DomesticCorporateDebtSecuritiesMember": { "auth_ref": [ "r282", "r532", "r578" ], "lang": { "en-us": { "role": { "documentation": "Debt security issued by corporation domiciled in United States of America (US).", "label": "Debt Security, Corporate, US [Member]", "terseLabel": "U.S. corporate securities", "verboseLabel": "U.S. corporate securities" } } }, "localname": "DomesticCorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails", "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails", "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails", "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsChangesinLevel3PensionPlanAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r121", "r188", "r189", "r190", "r191", "r192", "r197", "r199", "r202", "r203", "r204", "r208", "r209", "r745", "r746", "r893", "r944" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "totalLabel": "Net income attributable to CVS Health (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic [Abstract]", "verboseLabel": "Basic earnings per share:" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic and Diluted [Abstract]", "terseLabel": "Earnings per share from continuing operations:" } } }, "localname": "EarningsPerShareBasicAndDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/EarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r121", "r188", "r189", "r190", "r191", "r192", "r199", "r202", "r203", "r204", "r208", "r209", "r745", "r746", "r893", "r944" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "totalLabel": "Net income attributable to CVS Health (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted [Abstract]", "terseLabel": "Diluted earnings per share:" } } }, "localname": "EarningsPerShareDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r205", "r206" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Earnings per Common Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r205", "r206", "r207", "r210" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "verboseLabel": "Earnings Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/EarningsPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r654" ], "calculation": { "http://www.cvshealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "totalLabel": "Effective income tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r170", "r654", "r686" ], "calculation": { "http://www.cvshealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails": { "order": 3.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "Statutory income tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness": { "auth_ref": [ "r654", "r686" ], "calculation": { "http://www.cvshealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails": { "order": 1.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to disposition of a business not qualifying as a discontinued operation.", "label": "Effective Income Tax Rate Reconciliation, Disposition of Business, Percent", "terseLabel": "Basis difference upon disposition of subsidiary" } } }, "localname": "EffectiveIncomeTaxRateReconciliationDispositionOfBusiness", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "auth_ref": [ "r654", "r686" ], "calculation": { "http://www.cvshealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails": { "order": 5.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent", "terseLabel": "Other" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r654", "r686" ], "calculation": { "http://www.cvshealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails": { "order": 6.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "terseLabel": "State income taxes, net of federal tax benefit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsDomestic": { "auth_ref": [ "r654", "r686" ], "calculation": { "http://www.cvshealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails": { "order": 2.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to domestic income tax settlement.", "label": "Effective Income Tax Rate Reconciliation, Tax Settlement, Domestic, Percent", "terseLabel": "Prior year refund claim" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxSettlementsDomestic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectsOfReinsuranceTableTextBlock": { "auth_ref": [ "r1012" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the effects of reinsurance, for example, but not limited to, disclosure of direct, assumed, and ceded insurance.", "label": "Effects of Reinsurance [Table Text Block]", "terseLabel": "Schedule of impact of reinsurance on benefit costs" } } }, "localname": "EffectsOfReinsuranceTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ReinsuranceTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r632" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Compensation not yet recognized, period for recognition" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r632" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "terseLabel": "Compensation not yet recognized, other than options" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r632" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Compensation not yet recognized, options" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "terseLabel": "Employee Stock" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails", "http://www.cvshealth.com/role/StockIncentivePlansValuationandAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r629" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Employee Stock Option", "verboseLabel": "Stock Options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/EarningsPerShareDetails", "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails", "http://www.cvshealth.com/role/StockIncentivePlansValuationandAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]", "terseLabel": "Equipment" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityClassOfTreasuryStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Equity, Class of Treasury Stock [Line Items]", "terseLabel": "Equity, Class of Treasury Stock [Line Items]" } } }, "localname": "EquityClassOfTreasuryStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails", "http://www.cvshealth.com/role/ShareholdersEquityShareRepurchasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r2", "r108", "r109", "r110", "r179", "r180", "r181", "r184", "r193", "r195", "r212", "r313", "r468", "r473", "r639", "r640", "r641", "r679", "r680", "r744", "r782", "r783", "r784", "r785", "r786", "r788", "r986", "r987", "r988", "r1120" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity", "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquityParentheticals", "http://www.cvshealth.com/role/OtherComprehensiveIncomeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentsPolicy": { "auth_ref": [ "r61", "r147", "r307", "r772" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.", "label": "Equity Method Investments [Policy Text Block]", "terseLabel": "Related Party Transactions" } } }, "localname": "EquityMethodInvestmentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquitySecuritiesFvNi": { "auth_ref": [ "r764" ], "calculation": { "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails": { "order": 3.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.", "label": "Equity Securities, FV-NI, Current", "terseLabel": "Equity securities" } } }, "localname": "EquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesMember": { "auth_ref": [ "r39", "r45", "r302", "r916", "r1040", "r1041", "r1042" ], "lang": { "en-us": { "role": { "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.", "label": "Equity Securities [Member]", "terseLabel": "Equity securities" } } }, "localname": "EquitySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails", "http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "auth_ref": [ "r303" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "terseLabel": "Equity securities" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "auth_ref": [ "r430", "r444", "r445", "r766" ], "lang": { "en-us": { "role": { "documentation": "Measured as an estimate of fair value.", "label": "Estimate of Fair Value Measurement [Member]", "terseLabel": "Estimated Fair Value" } } }, "localname": "EstimateOfFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ExtinguishmentOfDebtAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross amount of debt extinguished.", "label": "Extinguishment of Debt, Amount", "verboseLabel": "Aggregate principal of debt extinguished" } } }, "localname": "ExtinguishmentOfDebtAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsLongTermBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetRecurringBasisStillHeldUnrealizedGainLossOci": { "auth_ref": [ "r758" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) recognized in other comprehensive income (OCI) from asset measured at fair value on recurring basis using unobservable input (level 3) and still held.", "label": "Fair Value, Asset, Recurring Basis, Still Held, Unrealized Gain (Loss), OCI", "terseLabel": "Change in unrealized capital losses included in OCI associated with Level 3 financial assets" } } }, "localname": "FairValueAssetRecurringBasisStillHeldUnrealizedGainLossOci", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails", "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails", "http://www.cvshealth.com/role/FairValueGrossTransfersIntoOutOfLevel3Details", "http://www.cvshealth.com/role/FairValueNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r748", "r749", "r750", "r761" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails", "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails", "http://www.cvshealth.com/role/FairValueGrossTransfersIntoOutOfLevel3Details", "http://www.cvshealth.com/role/FairValueNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r753", "r761" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Changes in level 3 financial assets" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/FairValueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]" } } }, "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "auth_ref": [ "r748", "r767", "r768" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table]", "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]" } } }, "localname": "FairValueByBalanceSheetGroupingTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTextBlock": { "auth_ref": [ "r748", "r767" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]", "terseLabel": "Carrying value and estimated fair value of certain financial instruments" } } }, "localname": "FairValueByBalanceSheetGroupingTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/FairValueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r430", "r444", "r445", "r532", "r534", "r535", "r536", "r537", "r538", "r539", "r578", "r749", "r834", "r835", "r836" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails", "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails", "http://www.cvshealth.com/role/FairValueGrossTransfersIntoOutOfLevel3Details", "http://www.cvshealth.com/role/FairValueNarrativeDetails", "http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsChangesinLevel3PensionPlanAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementBasisAxis": { "auth_ref": [ "r430", "r444", "r445", "r748", "r762" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement basis.", "label": "Measurement Basis [Axis]", "terseLabel": "Measurement Basis [Axis]" } } }, "localname": "FairValueByMeasurementBasisAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r748", "r749", "r751", "r752", "r763" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails", "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails", "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails", "http://www.cvshealth.com/role/FairValueGrossTransfersIntoOutOfLevel3Details", "http://www.cvshealth.com/role/FairValueNarrativeDetails", "http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "auth_ref": [ "r430", "r444", "r445" ], "lang": { "en-us": { "role": { "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.", "label": "Fair Value Measurement [Domain]", "terseLabel": "Fair Value Measurement [Domain]" } } }, "localname": "FairValueDisclosureItemAmountsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r760" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "verboseLabel": "Fair Value" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/FairValue" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel12And3Member": { "auth_ref": [ "r534" ], "lang": { "en-us": { "role": { "documentation": "Fair value measurement input including quoted price in active market for identical asset or liability reporting entity can access at measurement date (level 1), input other than quoted price included within level 1 either directly or indirectly observable for asset or liability (level 2) and unobservable input reflecting entity's own assumption (level 3).", "label": "Fair Value, Inputs, Level 1, 2 and 3 [Member]", "terseLabel": "Total Fair Value, Inputs, Level 1, 2 and 3" } } }, "localname": "FairValueInputsLevel12And3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r430", "r532", "r534", "r539", "r578", "r749", "r834" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails", "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails", "http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r430", "r444", "r445", "r532", "r534", "r539", "r578", "r749", "r835" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails", "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails", "http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r430", "r444", "r445", "r532", "r534", "r535", "r536", "r537", "r538", "r539", "r578", "r749", "r836" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails", "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails", "http://www.cvshealth.com/role/FairValueGrossTransfersIntoOutOfLevel3Details", "http://www.cvshealth.com/role/FairValueNarrativeDetails", "http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsChangesinLevel3PensionPlanAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember": { "auth_ref": [ "r534", "r747", "r763" ], "lang": { "en-us": { "role": { "documentation": "Fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Measured at Net Asset Value Per Share [Member]", "terseLabel": "Fair Value Measured at Net Asset Value Per Share" } } }, "localname": "FairValueMeasuredAtNetAssetValuePerShareMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails", "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails", "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails", "http://www.cvshealth.com/role/FairValueGrossTransfersIntoOutOfLevel3Details", "http://www.cvshealth.com/role/FairValueNarrativeDetails", "http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1": { "auth_ref": [ "r754" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings", "terseLabel": "Included in earnings" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss": { "auth_ref": [ "r755" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in other comprehensive income (OCI) from asset measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss)", "terseLabel": "Included in other comprehensive income" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases": { "auth_ref": [ "r756" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of purchases of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases", "terseLabel": "Purchases" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales": { "auth_ref": [ "r756" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of sale of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Sales", "negatedTerseLabel": "Sales" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements": { "auth_ref": [ "r756" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of settlement of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements", "negatedTerseLabel": "Settlements" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3": { "auth_ref": [ "r757" ], "calculation": { "http://www.cvshealth.com/role/FairValueGrossTransfersIntoOutOfLevel3Details": { "order": 1.0, "parentTag": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3", "terseLabel": "Gross transfers into Level 3" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/FairValueGrossTransfersIntoOutOfLevel3Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/FairValueGrossTransfersIntoOutOfLevel3Details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transfer of financial instrument classified as an asset into (out of) level 3 of the fair value hierarchy.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net", "terseLabel": "Transfers into Level 3, net", "totalLabel": "Net transfers into Level 3" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails", "http://www.cvshealth.com/role/FairValueGrossTransfersIntoOutOfLevel3Details", "http://www.cvshealth.com/role/FairValueNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3": { "auth_ref": [ "r757" ], "calculation": { "http://www.cvshealth.com/role/FairValueGrossTransfersIntoOutOfLevel3Details": { "order": 2.0, "parentTag": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3", "negatedTerseLabel": "Gross transfers out of Level 3" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/FairValueGrossTransfersIntoOutOfLevel3Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": { "auth_ref": [ "r753" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r430", "r444", "r445", "r532", "r534", "r535", "r536", "r537", "r538", "r539", "r578", "r834", "r835", "r836" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails", "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails", "http://www.cvshealth.com/role/FairValueGrossTransfersIntoOutOfLevel3Details", "http://www.cvshealth.com/role/FairValueNarrativeDetails", "http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsChangesinLevel3PensionPlanAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsNonrecurringMember": { "auth_ref": [ "r748", "r749", "r751", "r752", "r759", "r763" ], "lang": { "en-us": { "role": { "documentation": "Infrequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, not frequently measured at fair value.", "label": "Fair Value, Nonrecurring [Member]", "terseLabel": "Nonrecurring" } } }, "localname": "FairValueMeasurementsNonrecurringMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r760", "r763" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails", "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails", "http://www.cvshealth.com/role/FairValueGrossTransfersIntoOutOfLevel3Details", "http://www.cvshealth.com/role/FairValueNarrativeDetails", "http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FederalHomeLoanBankAdvancesGeneralDebtObligationsDisclosuresMaximumAmountAvailable": { "auth_ref": [ "r72", "r883", "r906" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of maximum advances or credit lines available from the Federal Home Loan Bank (FHLB).", "label": "Federal Home Loan Bank, Advances, General Debt Obligations, Maximum Amount Available", "terseLabel": "Federal home loan bank advances maximum amount available" } } }, "localname": "FederalHomeLoanBankAdvancesGeneralDebtObligationsDisclosuresMaximumAmountAvailable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsShorttermBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FederalHomeLoanBankAdvancesMember": { "auth_ref": [ "r883" ], "lang": { "en-us": { "role": { "documentation": "Borrowings from the Federal Home Loan Bank, which are primarily used to cover shortages in the required reserve balance and also in times of liquidity shortages. The member institution executes a promissory note, which is generally collateralized by government securities to the Federal Reserve or loans.", "label": "Federal Home Loan Bank Advances [Member]", "terseLabel": "Federal Home Loan Bank Advances" } } }, "localname": "FederalHomeLoanBankAdvancesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsShorttermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeaseInterestExpense": { "auth_ref": [ "r801", "r807", "r819" ], "calculation": { "http://www.cvshealth.com/role/LeasesSummaryoftheComponentsofNetLeaseCostDetails": { "order": 1.0, "parentTag": "cvs_FinanceLeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense on finance lease liability.", "label": "Finance Lease, Interest Expense", "terseLabel": "Interest on lease liabilities" } } }, "localname": "FinanceLeaseInterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/LeasesSummaryoftheComponentsofNetLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseInterestPaymentOnLiability": { "auth_ref": [ "r803", "r813" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest paid on finance lease liability.", "label": "Finance Lease, Interest Payment on Liability", "terseLabel": "Operating cash flows paid for interest portion of finance leases" } } }, "localname": "FinanceLeaseInterestPaymentOnLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/LeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, Payment, Due [Abstract]", "terseLabel": "Finance Leases" } } }, "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r799", "r818" ], "calculation": { "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails": { "order": 2.0, "parentTag": "cvs_LongtermDebtGrossAndLeaseObligation", "weight": 1.0 }, "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "cvs_LeaseLiability", "weight": 1.0 }, "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 }, "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Finance Lease, Liability", "terseLabel": "Total finance lease liabilities", "totalLabel": "Total finance lease liabilities", "verboseLabel": "Finance lease liabilities" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsDebtMaturitiesDetails", "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails", "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails", "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r799" ], "calculation": { "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Finance Lease, Liability, Current", "terseLabel": "Current portion of long-term debt" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r818" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.", "label": "Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]", "terseLabel": "Maturities of financing lease liabilities" } } }, "localname": "FinanceLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r799" ], "calculation": { "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease, Liability, Noncurrent", "terseLabel": "Long-term debt" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "auth_ref": [ "r818" ], "calculation": { "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Payment, Due", "totalLabel": "Total lease payments" } } }, "localname": "FinanceLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r818" ], "calculation": { "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r818" ], "calculation": { "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "cvs_LesseeLiabilityPaymentsYearOne", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year One", "terseLabel": "2022" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r818" ], "calculation": { "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Five", "terseLabel": "2026" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r818" ], "calculation": { "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Four", "terseLabel": "2025" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r818" ], "calculation": { "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Three", "terseLabel": "2024" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r818" ], "calculation": { "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Two", "terseLabel": "2023" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r800" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes finance lease liability.", "label": "Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]" } } }, "localname": "FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r818" ], "calculation": { "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "cvs_LesseeLiabilityUndiscountedExcessAmount", "weight": 1.0 }, "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: imputed interest" } } }, "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r802", "r813" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "terseLabel": "Financing cash flows paid for principal portion of finance leases" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/LeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "auth_ref": [ "r801", "r807", "r819" ], "calculation": { "http://www.cvshealth.com/role/LeasesSummaryoftheComponentsofNetLeaseCostDetails": { "order": 2.0, "parentTag": "cvs_FinanceLeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, Amortization", "terseLabel": "Amortization of right-of-use assets" } } }, "localname": "FinanceLeaseRightOfUseAssetAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/LeasesSummaryoftheComponentsofNetLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r816", "r819" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for finance lease calculated at point in time.", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Finance leases" } } }, "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r815", "r819" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Finance Lease, Weighted Average Remaining Lease Term", "terseLabel": "Finance leases" } } }, "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r293", "r294", "r303", "r304", "r305", "r317", "r321", "r322", "r323", "r324", "r333", "r335", "r338", "r339", "r441", "r466", "r735", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r1080", "r1081", "r1082", "r1083", "r1084", "r1085", "r1086" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails", "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails", "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails", "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails", "http://www.cvshealth.com/role/InvestmentsNarrativeDetails", "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails", "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]", "terseLabel": "Assets:" } } }, "localname": "FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financial Instruments, Financial Liabilities, Balance Sheet Groupings [Abstract]", "terseLabel": "Liabilities:" } } }, "localname": "FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancialLiabilitiesFairValueDisclosure": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.", "label": "Financial Liabilities Fair Value Disclosure", "terseLabel": "Financial liabilities fair value on a recurring basis" } } }, "localname": "FinancialLiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension": { "auth_ref": [ "r367" ], "lang": { "en-us": { "role": { "documentation": "Weighted average period before the next renewal or extension (both explicit and implicit) for intangible assets that have been renewed or extended, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Weighted Average Period before Next Renewal or Extension", "terseLabel": "Weighted Average Life (years)" } } }, "localname": "FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r362" ], "calculation": { "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedTerseLabel": "Finite-lived intangible assets, accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five", "terseLabel": "2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherAcquiredIntangiblesFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r364" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "terseLabel": "2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherAcquiredIntangiblesFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r364" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "terseLabel": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherAcquiredIntangiblesFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r364" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "terseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherAcquiredIntangiblesFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r364" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "terseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherAcquiredIntangiblesFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r357", "r358", "r362", "r366", "r864", "r868" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails", "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]", "terseLabel": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]" } } }, "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherAcquiredIntangiblesFutureAmortizationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r362", "r868" ], "calculation": { "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Finite-lived intangible assets, gross carrying amount", "verboseLabel": "Intangible assets related to customer lists" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails", "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r357", "r361" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails", "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r362", "r864" ], "calculation": { "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Finite-lived intangible assets, net carrying amount" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCorporateDebtSecuritiesMember": { "auth_ref": [ "r282", "r532" ], "lang": { "en-us": { "role": { "documentation": "Debt security issued by corporation not domiciled in United States of America (US).", "label": "Debt Security, Corporate, Non-US [Member]", "terseLabel": "Foreign securities" } } }, "localname": "ForeignCorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails", "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails", "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r790" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency Translation and Transactions" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ForeignGovernmentShorttermDebtSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Short-term debt securities issued by a national, local, or municipal government not within the country of domicile of the reporting entity.", "label": "Foreign Government Short-term Debt Securities [Member]", "terseLabel": "Foreign securities" } } }, "localname": "ForeignGovernmentShorttermDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Fixtures and equipment" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPropertyPlantandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainContingencyUnrecordedAmount": { "auth_ref": [ "r390" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount or range of possible amounts of gain that could be realized upon the resolution of a contingency.", "label": "Gain Contingency, Unrecorded Amount", "terseLabel": "Gain contingency, unrecorded amount" } } }, "localname": "GainContingencyUnrecordedAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfBusiness": { "auth_ref": [ "r156", "r711" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.", "label": "Gain (Loss) on Disposition of Business", "negatedTerseLabel": "(Gain) loss on sale of subsidiaries", "terseLabel": "Gain (loss) on sale of subsidiaries" } } }, "localname": "GainLossOnSaleOfBusiness", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows", "http://www.cvshealth.com/role/DivestituresNarrativeDetails", "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r156", "r448", "r449" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedTerseLabel": "Loss on early extinguishment of debt" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsLongTermBorrowingsDetails", "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows", "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost": { "auth_ref": [ "r448", "r449" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reflects the difference between the fair value of payments made to legally extinguish a debt and its carrying value at that time. This item excludes the write-off of amounts previously capitalized as debt issuance costs.", "label": "Gain (Loss) on Extinguishment of Debt, before Write off of Debt Issuance Cost", "negatedTerseLabel": "Premium paid in excess of debt principal" } } }, "localname": "GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsLongTermBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r343", "r345", "r828", "r872" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Balance, end of the period", "periodStartLabel": "Balance, beginning of the period", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets", "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesGoodwillDetails", "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAcquiredDuringPeriod": { "auth_ref": [ "r347" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.", "label": "Goodwill, Acquired During Period", "terseLabel": "Acquisitions" } } }, "localname": "GoodwillAcquiredDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]", "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r369" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "verboseLabel": "Goodwill and Other Intangibles" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherIntangibles" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "auth_ref": [ "r351" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.", "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]", "terseLabel": "Goodwill" } } }, "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.", "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": { "auth_ref": [ "r346", "r350" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impaired, Accumulated Impairment Loss", "terseLabel": "Cumulative goodwill impairments" } } }, "localname": "GoodwillImpairedAccumulatedImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r156", "r344", "r349", "r353" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impairment Loss", "negatedTerseLabel": "Impairment", "terseLabel": "Goodwill impairment" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows", "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations", "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesGoodwillDetails", "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesNarrativeDetails", "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Goodwill [Line Items]", "terseLabel": "Goodwill [Line Items]" } } }, "localname": "GoodwillLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesGoodwillDetails", "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Goodwill [Roll Forward]", "terseLabel": "Goodwill [Roll Forward]" } } }, "localname": "GoodwillRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit": { "auth_ref": [ "r348" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Written off Related to Sale of Business Unit", "negatedTerseLabel": "Divestiture of Workers\u2019 Compensation business" } } }, "localname": "GoodwillWrittenOffRelatedToSaleOfBusinessUnit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GuaranteeObligationsMaximumExposure": { "auth_ref": [ "r395" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee or each group of similar guarantees before reduction for potential recoveries under recourse or collateralization provisions.", "label": "Guarantor Obligations, Maximum Exposure, Undiscounted", "terseLabel": "Guarantor obligations, maximum exposure" } } }, "localname": "GuaranteeObligationsMaximumExposure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_HealthCareCostsPolicyPolicyTextBlock": { "auth_ref": [ "r1052", "r1054" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for accruing health care costs for a prepaid health care service provider.", "label": "Health Care Costs, Policy [Policy Text Block]", "terseLabel": "Health Care Costs Payable" } } }, "localname": "HealthCareCostsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_HealthCareEntitiesPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for all health care policies.", "label": "Health Care Entities, Policy [Policy Text Block]", "terseLabel": "Health Care Reform" } } }, "localname": "HealthCareEntitiesPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_HealthInsuranceProductLineMember": { "auth_ref": [ "r983" ], "lang": { "en-us": { "role": { "documentation": "Product line consisting of insurance against loss by illness or injury.", "label": "Health Insurance Product Line [Member]", "terseLabel": "Health Insurance Product Line" } } }, "localname": "HealthInsuranceProductLineMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableIncurredandPaidHealthCareClaimsDevelopmentDetails", "http://www.cvshealth.com/role/HealthCareCostsPayableReconciliationofHealthCareCostsPayableDetails", "http://www.cvshealth.com/role/HealthCareCostsPayableReconciliationofHealthCareNetIncurredandPaidClaimsDevelopmenttoHealthCareCostsPayableLiabilityDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_HedgeFundsMember": { "auth_ref": [ "r532" ], "lang": { "en-us": { "role": { "documentation": "Investments in registered hedge funds.", "label": "Hedge Funds [Member]", "terseLabel": "Hedge Funds", "verboseLabel": "Hedge fund investments" } } }, "localname": "HedgeFundsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNarrativeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesVariableInterestEntitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": { "auth_ref": [ "r156", "r368" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.", "label": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)", "terseLabel": "Impairment of intangible assets, indefinite-lived" } } }, "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Long-Lived Asset Impairment" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperations": { "auth_ref": [ "r123", "r157", "r188", "r189", "r190", "r191", "r200", "r204", "r701" ], "calculation": { "http://www.cvshealth.com/role/EarningsPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.", "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent", "totalLabel": "Income from continuing operations attributable to CVS Health" } } }, "localname": "IncomeLossFromContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/EarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r115", "r238", "r250", "r254", "r257", "r260", "r869", "r887", "r896", "r946" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Income before income tax provision" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r168", "r183", "r238", "r250", "r254", "r257", "r260", "r308", "r400", "r401", "r402", "r405", "r406", "r407", "r409", "r411", "r413", "r414", "r702", "r746", "r772" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 }, "http://www.cvshealth.com/role/EarningsPerShareDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.", "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Income from continuing operations", "verboseLabel": "Income from continuing operations" } } }, "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations", "http://www.cvshealth.com/role/EarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": { "auth_ref": [ "r112", "r121", "r183", "r188", "r189", "r190", "r191", "r199", "r202", "r203", "r746", "r885", "r888", "r893", "r937" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_EarningsPerShareBasic", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.", "label": "Income (Loss) from Continuing Operations, Per Basic Share", "terseLabel": "Income from continuing operations attributable to CVS Health (in dollars per share)", "verboseLabel": "Earnings (loss) per share from continuing operations, basic (USD per share)" } } }, "localname": "IncomeLossFromContinuingOperationsPerBasicShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations", "http://www.cvshealth.com/role/EarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": { "auth_ref": [ "r112", "r121", "r183", "r188", "r189", "r190", "r191", "r199", "r202", "r203", "r204", "r746", "r893", "r937", "r940", "r944" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_EarningsPerShareDiluted", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Income (Loss) from Continuing Operations, Per Diluted Share", "terseLabel": "Income from continuing operations attributable to CVS Health (in dollars per share)", "verboseLabel": "Earnings (loss) per share from continuing operations, diluted (USD per share)" } } }, "localname": "IncomeLossFromContinuingOperationsPerDilutedShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations", "http://www.cvshealth.com/role/EarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": { "auth_ref": [ "r8", "r9", "r10", "r11", "r12", "r23", "r26", "r690", "r938" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 }, "http://www.cvshealth.com/role/SignificantAccountingPoliciesDiscontinuedOperationsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.", "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Loss from discontinued operations, net of tax", "totalLabel": "Loss from discontinued operations, net of tax" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations", "http://www.cvshealth.com/role/SignificantAccountingPoliciesDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "auth_ref": [ "r587", "r594" ], "lang": { "en-us": { "role": { "documentation": "Information by name of disposal group.", "label": "Disposal Group Name [Axis]", "terseLabel": "Disposal Group Name [Axis]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/DivestituresNarrativeDetails", "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r170", "r655", "r664", "r670", "r681", "r687", "r691", "r692", "r693" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r171", "r194", "r195", "r236", "r653", "r682", "r688", "r947" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": -1.0 }, "http://www.cvshealth.com/role/IncomeTaxesIncomeTaxProvisionDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "totalLabel": "Total", "verboseLabel": "Income tax provision" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations", "http://www.cvshealth.com/role/IncomeTaxesIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Amount [Abstract]", "terseLabel": "Effective Income Tax Rate Reconciliation, Amount [Abstract]" } } }, "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesEffectiveTaxRateReconciliationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r107", "r649", "r650", "r664", "r665", "r669", "r675" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r160" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows_1": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "negatedTerseLabel": "Income taxes paid" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r155" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable and pharmacy claims and discounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r155" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedTerseLabel": "Accounts receivable, net" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInsuranceLiabilities": { "auth_ref": [ "r155" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in insurance liability balances during the period.", "label": "Increase (Decrease) in Insurance Liabilities", "terseLabel": "Health care costs payable and other insurance liabilities" } } }, "localname": "IncreaseDecreaseInInsuranceLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r155" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedTerseLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Change in operating assets and liabilities, net of effects from acquisitions:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "auth_ref": [ "r155" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets classified as other.", "label": "Increase (Decrease) in Other Operating Assets", "negatedTerseLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "auth_ref": [ "r155" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Liabilities", "terseLabel": "Other liabilities" } } }, "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r365" ], "calculation": { "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)", "terseLabel": "Indefinite-lived intangible assets, Trademarks" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InsuranceAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Insurance [Abstract]", "terseLabel": "Insurance [Abstract]" } } }, "localname": "InsuranceAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.", "label": "Intangible Assets, Gross (Excluding Goodwill)", "totalLabel": "Intangible assets, gross" } } }, "localname": "IntangibleAssetsGrossExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r355", "r360" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net", "totalLabel": "Intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets", "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r113", "r232", "r791", "r794", "r894" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "verboseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r145", "r152", "r160" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows_1": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "negatedTerseLabel": "Interest paid" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet": { "auth_ref": [ "r734" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The estimated net amount of unrealized gains or losses on interest rate cash flow hedges as of the balance sheet date expected to be reclassified to earnings within the next twelve months.", "label": "Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net", "terseLabel": "Amount expected to be reclassified" } } }, "localname": "InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/OtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InternalCreditAssessmentAxis": { "auth_ref": [ "r271", "r324", "r326", "r327", "r394", "r732" ], "lang": { "en-us": { "role": { "documentation": "Information by entity-defined rating.", "label": "Internal Credit Assessment [Axis]", "terseLabel": "Internal Credit Assessment [Axis]" } } }, "localname": "InternalCreditAssessmentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InternalCreditAssessmentDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Entity defined credit risk rating.", "label": "Internal Credit Assessment [Domain]", "terseLabel": "Internal Credit Assessment [Domain]" } } }, "localname": "InternalCreditAssessmentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IntersegmentEliminationMember": { "auth_ref": [ "r230", "r249", "r250", "r251", "r252", "r254", "r256", "r260" ], "lang": { "en-us": { "role": { "documentation": "Eliminating entries used in operating segment consolidation.", "label": "Intersegment Eliminations [Member]", "terseLabel": "Intersegment Eliminations" } } }, "localname": "IntersegmentEliminationMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r30", "r82", "r828" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r36", "r83", "r163", "r211", "r340", "r341", "r342", "r862" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentIncomeInterestAndDividend": { "auth_ref": [ "r125" ], "calculation": { "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails": { "order": 1.0, "parentTag": "cvs_InvestmentIncomeExcludingCapitalGainsorLosses", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.", "label": "Investment Income, Interest and Dividend", "terseLabel": "Gross investment income" } } }, "localname": "InvestmentIncomeInterestAndDividend", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInvestmentExpense": { "auth_ref": [ "r127", "r948" ], "calculation": { "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails": { "order": 2.0, "parentTag": "cvs_InvestmentIncomeExcludingCapitalGainsorLosses", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses related to the generation of investment income.", "label": "Investment Income, Investment Expense", "negatedLabel": "Investment expenses" } } }, "localname": "InvestmentIncomeInvestmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeNet": { "auth_ref": [ "r125", "r126" ], "calculation": { "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.", "label": "Investment Income, Net", "totalLabel": "Net investment income" } } }, "localname": "InvestmentIncomeNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeTextBlock": { "auth_ref": [ "r125", "r126", "r127", "r948" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of investment income, including, but not limited to, interest and dividend income and amortization of discount (premium) derived from debt and equity securities. Excludes realized and unrealized gain (loss) on investments.", "label": "Investment Income [Table Text Block]", "verboseLabel": "Net investment income" } } }, "localname": "InvestmentIncomeTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentPolicyTextBlock": { "auth_ref": [ "r307", "r945" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment in financial asset.", "label": "Investment, Policy [Policy Text Block]", "terseLabel": "Investments" } } }, "localname": "InvestmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1037", "r1038", "r1039", "r1040", "r1041", "r1042" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]", "terseLabel": "Investment Type [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesVariableInterestEntitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1037", "r1038", "r1039", "r1040", "r1041", "r1042" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investments [Domain]", "terseLabel": "Investments [Domain]" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesVariableInterestEntitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Investments": { "auth_ref": [ "r933" ], "calculation": { "http://www.cvshealth.com/role/InvestmentsScheduleofTotalInvestmentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.", "label": "Investments", "totalLabel": "Total" } } }, "localname": "Investments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/InvestmentsScheduleofTotalInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments [Abstract]", "terseLabel": "Investments [Abstract]" } } }, "localname": "InvestmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.", "label": "Investments Classified by Contractual Maturity Date [Table Text Block]", "verboseLabel": "Fair value of debt securities by contractual maturity" } } }, "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]", "terseLabel": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r302", "r870", "r903", "r1043", "r1087" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "terseLabel": "Investments" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/Investments" ], "xbrltype": "textBlockItemType" }, "us-gaap_LandMember": { "auth_ref": [ "r494" ], "lang": { "en-us": { "role": { "documentation": "Part of earth's surface not covered by water.", "label": "Land [Member]", "terseLabel": "Land" } } }, "localname": "LandMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPropertyPlantandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r817", "r819" ], "calculation": { "http://www.cvshealth.com/role/LeasesSummaryoftheComponentsofNetLeaseCostDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Lease, Cost, Total" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/LeasesSummaryoftheComponentsofNetLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lease, Cost [Abstract]", "terseLabel": "Finance lease cost:" } } }, "localname": "LeaseCostAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/LeasesSummaryoftheComponentsofNetLeaseCostDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r817" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Lease costs and supplemental cash flow information" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r371" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPropertyPlantandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]", "terseLabel": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeFinanceLeaseTermOfContract1": { "auth_ref": [ "r806" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Finance Lease, Term of Contract", "terseLabel": "Finance lease term (in years)" } } }, "localname": "LesseeFinanceLeaseTermOfContract1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeFinanceLeasesTextBlock": { "auth_ref": [ "r820" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.", "label": "Lessee, Finance Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeFinanceLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r805" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Right-of-Use Assets and Lease Liabilities" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r818" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Maturities of operating lease liabilities" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r818" ], "calculation": { "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r818" ], "calculation": { "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "cvs_LesseeLiabilityPaymentsDueAfterYearFive", "weight": 1.0 }, "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r818" ], "calculation": { "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "cvs_LesseeLiabilityPaymentsYearOne", "weight": 1.0 }, "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r818" ], "calculation": { "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "cvs_LesseeLiabilityPaymentsDueYearFive", "weight": 1.0 }, "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "terseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r818" ], "calculation": { "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "cvs_LesseeLiabilityPaymentsDueYearFour", "weight": 1.0 }, "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r818" ], "calculation": { "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "cvs_LesseeLiabilityPaymentsDueYearThree", "weight": 1.0 }, "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r818" ], "calculation": { "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "cvs_LesseeLiabilityPaymentsDueYearTwo", "weight": 1.0 }, "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r818" ], "calculation": { "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "cvs_LesseeLiabilityUndiscountedExcessAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r806" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Operating lease term (in years)" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r820" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceived": { "auth_ref": [ "r821" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payments to be received by lessor for operating lease.", "label": "Lessor, Operating Lease, Payments to be Received", "terseLabel": "Future noncancelable subleases, future minimum payments" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceived", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r69", "r168", "r252", "r308", "r400", "r401", "r402", "r405", "r406", "r407", "r409", "r411", "r413", "r414", "r705", "r713", "r714", "r772", "r826", "r827" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities [Abstract]", "terseLabel": "Liabilities:" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r59", "r168", "r308", "r772", "r828", "r879", "r927" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and shareholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r71", "r168", "r308", "r400", "r401", "r402", "r405", "r406", "r407", "r409", "r411", "r413", "r414", "r705", "r713", "r714", "r772", "r826", "r827", "r828" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense": { "auth_ref": [ "r963", "r966" ], "calculation": { "http://www.cvshealth.com/role/HealthCareCostsPayableReconciliationofHealthCareNetIncurredandPaidClaimsDevelopmenttoHealthCareCostsPayableLiabilityDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.", "label": "Liability for Claims and Claims Adjustment Expense", "periodEndLabel": "Health care costs payable, end of period", "periodStartLabel": "Health care costs payable, beginning of period", "totalLabel": "Total health care costs payable" } } }, "localname": "LiabilityForClaimsAndClaimsAdjustmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableReconciliationofHealthCareCostsPayableDetails", "http://www.cvshealth.com/role/HealthCareCostsPayableReconciliationofHealthCareNetIncurredandPaidClaimsDevelopmenttoHealthCareCostsPayableLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Liability for Claims and Claims Adjustment Expense [Line Items]", "terseLabel": "Liability for Claims and Claims Adjustment Expense [Line Items]" } } }, "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableNarrativeDetails", "http://www.cvshealth.com/role/HealthCareCostsPayableReconciliationofHealthCareCostsPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the liability for claims and claims adjustment expense.", "label": "Liability for Claims and Claims Adjustment Expense [Table]", "terseLabel": "Liability for Claims and Claims Adjustment Expense [Table]" } } }, "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableNarrativeDetails", "http://www.cvshealth.com/role/HealthCareCostsPayableReconciliationofHealthCareCostsPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilityForFuturePolicyBenefits": { "auth_ref": [ "r912", "r976", "r977", "r981", "r989" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before effect of reinsurance, of present value of future benefit to be paid to or on behalf of policyholder and related expense less present value of future net premium receivable under insurance contract.", "label": "Liability for Future Policy Benefit, before Reinsurance", "terseLabel": "Future policy benefits" } } }, "localname": "LiabilityForFuturePolicyBenefits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the cost of settling unpaid claims after deduction of reinsurance recoveries related to the acquisition of a business. Includes, but is not limited to, claims which have been incurred but not reported.", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Business Acquisitions", "verboseLabel": "Acquisitions, net" } } }, "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableReconciliationofHealthCareCostsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid [Abstract]", "terseLabel": "Less: Claims paid" } } }, "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableReconciliationofHealthCareCostsPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1": { "auth_ref": [ "r965" ], "calculation": { "http://www.cvshealth.com/role/HealthCareCostsPayableReconciliationofHealthCareCostsPayableDetails": { "order": 1.0, "parentTag": "us-gaap_PaymentsForLossesAndLossAdjustmentExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs.", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year", "terseLabel": "Current year" } } }, "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableReconciliationofHealthCareCostsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1": { "auth_ref": [ "r965" ], "calculation": { "http://www.cvshealth.com/role/HealthCareCostsPayableReconciliationofHealthCareCostsPayableDetails": { "order": 2.0, "parentTag": "us-gaap_PaymentsForLossesAndLossAdjustmentExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs.", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years", "terseLabel": "Prior years" } } }, "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableReconciliationofHealthCareCostsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1": { "auth_ref": [ "r964" ], "calculation": { "http://www.cvshealth.com/role/HealthCareCostsPayableReconciliationofHealthCareCostsPayableDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process.", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims", "totalLabel": "Total incurred health care costs" } } }, "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableReconciliationofHealthCareCostsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims [Abstract]", "terseLabel": "Add: Components of incurred health care costs" } } }, "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableReconciliationofHealthCareCostsPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet": { "auth_ref": [ "r913", "r963", "r966" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Liability as of the balance sheet date for amounts representing estimated cost of settling unpaid claims under the terms of the underlying insurance policies, less estimated reinsurance recoveries on such claims. This includes an estimate for claims which have been incurred but not reported. Claim adjustment expenses represent the costs estimated to be incurred in the settlement of unpaid claims.", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Net", "periodEndLabel": "Health care costs payable, end of period, net", "periodStartLabel": "Health care costs payable, beginning of period, net", "terseLabel": "Health care costs payable" } } }, "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets", "http://www.cvshealth.com/role/HealthCareCostsPayableReconciliationofHealthCareCostsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]", "terseLabel": "Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]" } } }, "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableReconciliationofHealthCareCostsPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.", "label": "Line of Credit Facility, Commitment Fee Percentage", "terseLabel": "Commitment fee percentage" } } }, "localname": "LineOfCreditFacilityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsShorttermBorrowingsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r67" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsShorttermBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "terseLabel": "Line of Credit" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsShorttermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LitigationSettlementAmountAwardedFromOtherParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount awarded from other party in judgment or settlement of litigation.", "label": "Litigation Settlement, Amount Awarded from Other Party", "terseLabel": "Amount awarded from other party" } } }, "localname": "LitigationSettlementAmountAwardedFromOtherParty", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationStatusAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by status of pending, threatened, or settled litigation.", "label": "Litigation Status [Axis]", "terseLabel": "Litigation Status [Axis]" } } }, "localname": "LitigationStatusAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails", "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LitigationStatusDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Status of pending, threatened, or settled litigation.", "label": "Litigation Status [Domain]", "terseLabel": "Litigation Status [Domain]" } } }, "localname": "LitigationStatusDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails", "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligations": { "auth_ref": [ "r47" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.", "label": "Long-term Debt and Lease Obligation", "terseLabel": "Long-term debt" } } }, "localname": "LongTermDebtAndCapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails", "http://www.cvshealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": { "auth_ref": [ "r70" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt and lease obligation, classified as current.", "label": "Long-term Debt and Lease Obligation, Current", "negatedTerseLabel": "Current portion of long-term debt", "verboseLabel": "Current portion of long-term debt" } } }, "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails", "http://www.cvshealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt and lease obligation, including portion classified as current.", "label": "Long-term Debt and Lease Obligation, Including Current Maturities", "terseLabel": "Long-term debt and lease obligations" } } }, "localname": "LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtByMaturityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long-term Debt, Fiscal Year Maturity [Abstract]", "terseLabel": "Long-term Debt, Fiscal Year Maturity [Abstract]" } } }, "localname": "LongTermDebtByMaturityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsDebtMaturitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": { "auth_ref": [ "r176", "r397", "r434" ], "calculation": { "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsDebtMaturitiesDetails": { "order": 5.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsDebtMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r176", "r397", "r434" ], "calculation": { "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsDebtMaturitiesDetails": { "order": 4.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year One", "terseLabel": "2022" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsDebtMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "auth_ref": [ "r176", "r397", "r434" ], "calculation": { "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsDebtMaturitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Five", "terseLabel": "2026" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsDebtMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r176", "r397", "r434" ], "calculation": { "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsDebtMaturitiesDetails": { "order": 6.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Four", "terseLabel": "2025" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsDebtMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r176", "r397", "r434" ], "calculation": { "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsDebtMaturitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Three", "terseLabel": "2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsDebtMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r176", "r397", "r434" ], "calculation": { "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsDebtMaturitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Two", "terseLabel": "2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsDebtMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermInvestments": { "auth_ref": [ "r61" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.cvshealth.com/role/InvestmentsScheduleofTotalInvestmentsDetails": { "order": 2.0, "parentTag": "us-gaap_Investments", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).", "label": "Long-term Investments", "terseLabel": "Long-term", "verboseLabel": "Long-term investments" } } }, "localname": "LongTermInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets", "http://www.cvshealth.com/role/InvestmentsScheduleofTotalInvestmentsDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesVariableInterestEntitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r74" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsLongTermBorrowingsDetails", "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r74", "r398" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsLongTermBorrowingsDetails", "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r382", "r383", "r384", "r386", "r387", "r388", "r389", "r392", "r393" ], "lang": { "en-us": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyPendingClaimsNumber": { "auth_ref": [ "r385" ], "lang": { "en-us": { "role": { "documentation": "Number of pending claims pertaining to a loss contingency.", "label": "Loss Contingency, Pending Claims, Number", "terseLabel": "Number of claims" } } }, "localname": "LossContingencyPendingClaimsNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": { "auth_ref": [ "r28", "r698" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.", "label": "Mergers, Acquisitions and Dispositions Disclosures [Text Block]", "verboseLabel": "Divestitures" } } }, "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/Divestitures" ], "xbrltype": "textBlockItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r81", "r168", "r308", "r400", "r405", "r406", "r407", "r413", "r414", "r772", "r878", "r926" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "terseLabel": "Noncontrolling interests" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets", "http://www.cvshealth.com/role/ShareholdersEquityNoncontrollingInterestsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MortgageLoansOnRealEstate": { "auth_ref": [ "r1044" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in mortgage loan on real estate by entity with substantial portion of business acquiring and holding investment real estate or interest in real estate.", "label": "SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate", "terseLabel": "Mortgage loans" } } }, "localname": "MortgageLoansOnRealEstate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/InvestmentsMortgageLoansCreditRatingsIndicatorDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet": { "auth_ref": [ "r932" ], "calculation": { "http://www.cvshealth.com/role/InvestmentsScheduleofMortgageLoanPrincipalRepaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The balance represents the amount of loans that are secured by real estate mortgages, offset by the reserve to cover probable credit losses on the loan portfolio.", "label": "Mortgage Loans on Real Estate, Commercial and Consumer, Net", "totalLabel": "Total" } } }, "localname": "MortgageLoansOnRealEstateCommercialAndConsumerNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/InvestmentsScheduleofMortgageLoanPrincipalRepaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MortgageLoansOnRealEstateForeclosures": { "auth_ref": [ "r1046" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in investment in mortgage loan on real estate by entity with substantial portion of business acquiring and holding investment real estate or interest in real estate, from foreclosure.", "label": "SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate, Foreclosure", "terseLabel": "Mortgage loans foreclosed" } } }, "localname": "MortgageLoansOnRealEstateForeclosures", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/InvestmentsMortgageLoansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MortgageLoansOnRealEstateNewMortgageLoans": { "auth_ref": [ "r1046" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in mortgage loan on real estate by entity with substantial portion of business acquiring and holding investment real estate or interest in real estate, from new investment.", "label": "SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate, New Mortgage Loan", "terseLabel": "New mortgage loans" } } }, "localname": "MortgageLoansOnRealEstateNewMortgageLoans", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/InvestmentsMortgageLoansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MortgagesHeldForSaleFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of mortgage loans held-for-sale.", "label": "Mortgages Held-for-sale, Fair Value Disclosure", "terseLabel": "Mortgage loans" } } }, "localname": "MortgagesHeldForSaleFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MultiemployerPlanPensionInsignificantPlanContribution": { "auth_ref": [ "r597" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of contribution received by multiemployer pension plan from all employers participating in multiemployer pension plan determined to be individually insignificant.", "label": "Multiemployer Plan, Pension, Insignificant, Plan Contribution", "terseLabel": "Multiemployer plans, plan contributions" } } }, "localname": "MultiemployerPlanPensionInsignificantPlanContribution", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r148" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r148" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r148", "r154", "r157" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 }, "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]", "terseLabel": "Reconciliation of net income to net cash provided by operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r26", "r101", "r104", "r110", "r117", "r157", "r168", "r183", "r188", "r189", "r190", "r191", "r194", "r195", "r200", "r238", "r250", "r254", "r257", "r260", "r308", "r400", "r401", "r402", "r405", "r406", "r407", "r409", "r411", "r413", "r414", "r746", "r772", "r889", "r939" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net income attributable to CVS Health" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r101", "r104", "r110", "r194", "r195", "r707", "r724" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0 }, "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 }, "http://www.cvshealth.com/role/EarningsPerShareDetails": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "negatedLabel": "Net (income) loss attributable to noncontrolling interests", "negatedTerseLabel": "Comprehensive (income) loss attributable to noncontrolling interests" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome", "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations", "http://www.cvshealth.com/role/EarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetInvestmentIncome": { "auth_ref": [ "r941" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after investment expense, of income earned from investments in securities and real estate. Includes, but is not limited to, real estate investment, policy loans, dividends, and interest. Excludes realized gain (loss) on investments.", "label": "Net Investment Income", "terseLabel": "Net investment income" } } }, "localname": "NetInvestmentIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations", "http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "verboseLabel": "Significant Accounting Policies [Line Items]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r182", "r183", "r184", "r185", "r186", "r187", "r190", "r196", "r208", "r277", "r278", "r310", "r311", "r312", "r313", "r314", "r315", "r399", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r677", "r678", "r679", "r680", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r823", "r865", "r866", "r867", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r1116", "r1117", "r1118", "r1119", "r1120" ], "lang": { "en-us": { "role": { "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.", "label": "Accounting Standards Update and Change in Accounting Principle [Table]", "verboseLabel": "Significant Accounting Policies [Table]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "New Accounting Pronouncements Recently Adopted and Not Yet Adopted" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r179", "r180", "r181", "r473", "r699" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Noncontrolling Interests" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_NotesPayableToBanksMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A written promise to pay a note to a bank.", "label": "Notes Payable to Banks [Member]", "terseLabel": "Notes Payable" } } }, "localname": "NotesPayableToBanksMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsLongTermBorrowingsDetails", "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r226" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r226" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of reportable segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfStatesInWhichEntityOperates": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of states the entity operates in as of the balance sheet date.", "label": "Number of States in which Entity Operates", "terseLabel": "Number of states in which entity operates" } } }, "localname": "NumberOfStatesInWhichEntityOperates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfStores": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of stores.", "label": "Number of Stores", "terseLabel": "Number of retail locations (more than)", "verboseLabel": "Number of stores" } } }, "localname": "NumberOfStores", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/DivestituresNarrativeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OffsettingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Offsetting [Abstract]", "terseLabel": "Offsetting [Abstract]" } } }, "localname": "OffsettingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating costs:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r238", "r250", "r254", "r257", "r260" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "netLabel": "Operating income (GAAP measure)", "totalLabel": "Operating income" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations", "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r808", "r819" ], "calculation": { "http://www.cvshealth.com/role/LeasesSummaryoftheComponentsofNetLeaseCostDetails": { "order": 3.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/LeasesSummaryoftheComponentsofNetLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]", "terseLabel": "Operating Leases" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r799" ], "calculation": { "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 }, "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Total operating lease liabilities", "totalLabel": "Total operating lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails", "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r799" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Current portion of operating lease liabilities", "verboseLabel": "Current portion of operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets", "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r799" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Long-term operating lease liabilities", "verboseLabel": "Long-term operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets", "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r804", "r813" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating cash flows paid for operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/LeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r798" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets", "verboseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets", "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r816", "r819" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Operating leases" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r815", "r819" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Operating leases" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLeasedAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Leased Assets [Line Items]", "terseLabel": "Operating Leased Assets [Line Items]" } } }, "localname": "OperatingLeasedAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [ "r249", "r250", "r251", "r252", "r254", "r260" ], "lang": { "en-us": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating Segments [Member]", "terseLabel": "Operating Segments" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r84", "r828" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r65" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r702", "r703", "r709" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.", "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Net unrealized investment gains (losses)" } } }, "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax": { "auth_ref": [ "r100", "r108", "r109", "r782", "r784", "r788" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), before Reclassifications, before Tax", "terseLabel": "OCI before Reclass, pre-tax" } } }, "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/OtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": { "auth_ref": [ "r100", "r108", "r109", "r111", "r782", "r784", "r788" ], "calculation": { "http://www.cvshealth.com/role/OtherComprehensiveIncomeDetails": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax", "negatedTerseLabel": "Loss on net cash flow hedges", "verboseLabel": "Other comprehensive income (loss) before reclassifications" } } }, "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsLongTermBorrowingsDetails", "http://www.cvshealth.com/role/OtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": { "auth_ref": [ "r91", "r98" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax", "terseLabel": "Net cash flow hedges" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r89" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation adjustments" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r102", "r105", "r108", "r109", "r111", "r118", "r468", "r782", "r787", "r788", "r890", "r940" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 }, "http://www.cvshealth.com/role/OtherComprehensiveIncomeDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "totalLabel": "Other comprehensive income (loss)", "verboseLabel": "Other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome", "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity", "http://www.cvshealth.com/role/OtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive income (loss), net of tax:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": { "auth_ref": [ "r96", "r98" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 4.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax", "negatedTerseLabel": "Pension and other postretirement benefits" } } }, "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherDebtSecuritiesMember": { "auth_ref": [ "r295", "r329", "r532", "r760" ], "lang": { "en-us": { "role": { "documentation": "Investments in debt securities classified as other.", "label": "Other Debt Obligations [Member]", "terseLabel": "Other Debt Obligations" } } }, "localname": "OtherDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherIntangibleAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Intangible assets classified as other.", "label": "Other Intangible Assets [Member]", "terseLabel": "Other" } } }, "localname": "OtherIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherInvestmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other investments.", "label": "Other Investments [Member]", "terseLabel": "Other investments" } } }, "localname": "OtherInvestmentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails", "http://www.cvshealth.com/role/InvestmentsScheduleofTotalInvestmentsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r75" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r157" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedTerseLabel": "Other noncash items" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r127" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "negatedTerseLabel": "Other income" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherPolicyholderFunds": { "auth_ref": [ "r934" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount due to policyholders for funds held that are returnable under the terms of insurance contracts, classified as other.", "label": "Other Policyholder Funds", "terseLabel": "Policyholders\u2019 funds" } } }, "localname": "OtherPolicyholderFunds", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": { "auth_ref": [ "r504", "r505", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r531", "r532", "r534", "r535", "r536", "r537", "r538", "r539", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r554", "r555", "r556", "r558", "r561", "r565", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r585", "r586", "r587", "r588", "r589", "r590" ], "lang": { "en-us": { "role": { "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits.", "label": "Other Postretirement Benefits Plan [Member]", "terseLabel": "Other Postretirement Benefits" } } }, "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsDefinedBenefitPlansExpectedBenefitDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherReceivablesNetCurrent": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/SignificantAccountingPoliciesAccountsReceivableDetails": { "order": 2.0, "parentTag": "us-gaap_AccountsReceivableNetCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.", "label": "Other Receivables, Net, Current", "terseLabel": "Other receivables" } } }, "localname": "OtherReceivablesNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesAccountsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings": { "auth_ref": [ "r281" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings.", "label": "Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Recognized in Earnings", "terseLabel": "OTTI losses, investments, portion recognized in earnings, net" } } }, "localname": "OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ParentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.", "label": "Parent [Member]", "terseLabel": "Total CVS Health Shareholders\u2019 Equity" } } }, "localname": "ParentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted": { "auth_ref": [ "r201" ], "calculation": { "http://www.cvshealth.com/role/EarningsPerShareDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of earnings (loss) distributed and earnings (loss) allocated to participating securities for the diluted earnings (loss) per share or per unit calculation under the two-class method.", "label": "Participating Securities, Distributed and Undistributed Earnings (Loss), Diluted", "negatedTerseLabel": "Income allocated to participating securities" } } }, "localname": "ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/EarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForLossesAndLossAdjustmentExpense": { "auth_ref": [ "r153", "r965" ], "calculation": { "http://www.cvshealth.com/role/HealthCareCostsPayableReconciliationofHealthCareCostsPayableDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after effects of reinsurance, of payments to settle insured claims and pay costs incurred in the claims settlement process.", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid", "totalLabel": "Total claims paid" } } }, "localname": "PaymentsForLossesAndLossAdjustmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableReconciliationofHealthCareCostsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net cash outflow or inflow from derivative instruments during the period, which are classified as financing activities, excluding those designated as hedging instruments.", "label": "Payments for (Proceeds from) Derivative Instrument, Financing Activities", "negatedTerseLabel": "Derivative settlements", "terseLabel": "Proceeds from derivative instruments" } } }, "localname": "PaymentsForProceedsFromDerivativeInstrumentFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsLongTermBorrowingsDetails", "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "auth_ref": [ "r132", "r135" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.", "label": "Payments for (Proceeds from) Other Investing Activities", "negatedTerseLabel": "Other" } } }, "localname": "PaymentsForProceedsFromOtherInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividends": { "auth_ref": [ "r139" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.", "label": "Payments of Dividends", "negatedLabel": "Dividends paid" } } }, "localname": "PaymentsOfDividends", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r139" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-based Payment Arrangement", "negatedTerseLabel": "Payments for taxes related to net share settlement of equity awards", "terseLabel": "Payments for taxes for net share settlement of equity awards" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows", "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r133" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedLabel": "Acquisitions (net of cash acquired)" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInvestments": { "auth_ref": [ "r135" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.", "label": "Payments to Acquire Investments", "negatedLabel": "Purchases of investments" } } }, "localname": "PaymentsToAcquireInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r134" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToSuppliersAndEmployees": { "auth_ref": [ "r143", "r144", "r151" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows_1": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash payments to suppliers for goods and services provided and to employees for services provided.", "label": "Payments to Suppliers and Employees", "negatedTerseLabel": "Cash paid to other suppliers and employees" } } }, "localname": "PaymentsToSuppliersAndEmployees", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PendingLitigationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process.", "label": "Pending Litigation [Member]", "terseLabel": "Pending Litigation" } } }, "localname": "PendingLitigationMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r531", "r533", "r539", "r557", "r559", "r560", "r561", "r562", "r563", "r578", "r580", "r583", "r585", "r600" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for retirement benefits.", "label": "Retirement Benefits [Text Block]", "verboseLabel": "Pension Plans and Other Postretirement Benefits" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefits" ], "xbrltype": "textBlockItemType" }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities": { "auth_ref": [ "r46", "r505", "r506", "r529", "r578" ], "calculation": { "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current.", "label": "Liability, Defined Benefit Plan, Current", "negatedTerseLabel": "Current liabilities reflected in accrued expenses" } } }, "localname": "PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent": { "auth_ref": [ "r48", "r505", "r506", "r529", "r578" ], "calculation": { "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.", "label": "Liability, Defined Benefit Plan, Noncurrent", "negatedTerseLabel": "Noncurrent liabilities reflected in other long-term liabilities" } } }, "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementPlansPolicy": { "auth_ref": [ "r564", "r581", "r582", "r585", "r591" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for pension and other postretirement benefit plans. This accounting policy may address (1) the types of plans sponsored by the entity, and the benefits provided by each plan (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived.", "label": "Pension and Other Postretirement Plans, Policy [Policy Text Block]", "terseLabel": "Measurement of Defined Benefit Pension and Other Postretirement Employee Benefit (OPEB) Plans" } } }, "localname": "PensionAndOtherPostretirementPlansPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PensionPlansDefinedBenefitMember": { "auth_ref": [ "r503", "r505", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r531", "r532", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r554", "r555", "r556", "r558", "r561", "r565", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r585", "r586", "r594", "r595", "r596", "r598" ], "lang": { "en-us": { "role": { "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.", "label": "Pension Plan [Member]", "terseLabel": "Pension Plan" } } }, "localname": "PensionPlansDefinedBenefitMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsChangesinLevel3PensionPlanAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsDefinedBenefitPlansExpectedBenefitDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNarrativeDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNetPeriodicBenefitCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PlanAssetCategoriesDomain": { "auth_ref": [ "r531", "r532", "r534", "r535", "r536", "r537", "r538", "r539", "r558", "r578" ], "lang": { "en-us": { "role": { "documentation": "Defined benefit plan asset investment.", "label": "Defined Benefit Plan, Plan Assets, Category [Domain]", "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Domain]" } } }, "localname": "PlanAssetCategoriesDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsChangesinLevel3PensionPlanAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r603", "r633" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PolicyholderAccountsPolicy": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for contracts reported in separate accounts, including the extent and terms of minimum guarantees, basis of presentation for separate account assets and liabilities and related separate account activity, the liability valuation method and assumptions used in valuing each type of policyholder and contract holder account maintained by the entity.", "label": "Policyholder Accounts, Policy [Policy Text Block]", "terseLabel": "Separate Accounts" } } }, "localname": "PolicyholderAccountsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PolicyholderBenefitsAndClaimsIncurredGross": { "auth_ref": [ "r950" ], "calculation": { "http://www.cvshealth.com/role/ReinsuranceEffectsofReinsuranceDetails": { "order": 1.0, "parentTag": "us-gaap_PolicyholderBenefitsAndClaimsIncurredNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before effect of policies assumed or ceded, of expense related to provision for policy benefits and costs incurred.", "label": "Policyholder Benefits and Claims Incurred, Direct", "terseLabel": "Direct" } } }, "localname": "PolicyholderBenefitsAndClaimsIncurredGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ReinsuranceEffectsofReinsuranceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare": { "auth_ref": [ "r950" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after effect of policies assumed or ceded, of expense related to provision for policy benefits and costs incurred for health insurance contracts.", "label": "Policyholder Benefits and Claims Incurred, Net, Health", "terseLabel": "Benefit costs" } } }, "localname": "PolicyholderBenefitsAndClaimsIncurredHealthCare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PolicyholderBenefitsAndClaimsIncurredNet": { "auth_ref": [ "r908", "r950" ], "calculation": { "http://www.cvshealth.com/role/ReinsuranceEffectsofReinsuranceDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after effects of policies assumed or ceded, of expense related to the provision for policy benefits and costs incurred.", "label": "Policyholder Benefits and Claims Incurred, Net", "totalLabel": "Net benefit costs" } } }, "localname": "PolicyholderBenefitsAndClaimsIncurredNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ReinsuranceEffectsofReinsuranceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PolicyholderBenefitsAndClaimsIncurredNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Policyholder Benefits and Claims Incurred, Net [Abstract]", "terseLabel": "Policyholder Benefits and Claims Incurred, Net [Abstract]" } } }, "localname": "PolicyholderBenefitsAndClaimsIncurredNetAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ReinsuranceEffectsofReinsuranceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "auth_ref": [ "r765" ], "lang": { "en-us": { "role": { "documentation": "Measured at fair value for financial reporting purposes.", "label": "Portion at Fair Value Measurement [Member]", "terseLabel": "Portion at Fair Value Measurement" } } }, "localname": "PortionAtFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/FairValueCarryingValueandFairValueClassifiedbyLevelDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r51", "r452" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r51" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r51", "r452" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r51" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r51", "r828" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, par value $0.01: 0.1 shares authorized; none issued or outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PremiumsEarnedNet": { "auth_ref": [ "r886", "r936", "r954", "r1011" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 }, "http://www.cvshealth.com/role/ReinsuranceEffectsofReinsuranceDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after premiums ceded to other entities and premiums assumed by the entity, of premiums earned.", "label": "Premiums Earned, Net", "terseLabel": "Premiums", "totalLabel": "Net premiums" } } }, "localname": "PremiumsEarnedNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations", "http://www.cvshealth.com/role/ReinsuranceEffectsofReinsuranceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PremiumsReceivableAtCarryingValue": { "auth_ref": [ "r931" ], "calculation": { "http://www.cvshealth.com/role/SignificantAccountingPoliciesAccountsReceivableDetails": { "order": 1.0, "parentTag": "us-gaap_AccountsReceivableNetCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The carrying amount as of the balance sheet date due the entity from (a) agents and insureds, (b) uncollected premiums and (c) others, net of the allowance for doubtful accounts.", "label": "Premiums Receivable, Net", "terseLabel": "Premium receivables" } } }, "localname": "PremiumsReceivableAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesAccountsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.", "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "terseLabel": "Reclassifications" } } }, "localname": "PriorPeriodReclassificationAdjustmentDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PrivateEquityFundsMember": { "auth_ref": [ "r532" ], "lang": { "en-us": { "role": { "documentation": "Investments held in private equity funds.", "label": "Private Equity Funds [Member]", "verboseLabel": "Private equity investments" } } }, "localname": "PrivateEquityFundsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNarrativeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesVariableInterestEntitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromCustomers": { "auth_ref": [ "r149" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows_1": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash receipts from customers during the current period which are usually for sales of goods and services.", "label": "Proceeds from Customers", "terseLabel": "Cash receipts from customers" } } }, "localname": "ProceedsFromCustomers", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": { "auth_ref": [ "r137" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.", "label": "Proceeds from Debt, Net of Issuance Costs", "terseLabel": "Proceeds from debt" } } }, "localname": "ProceedsFromDebtNetOfIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsLongTermBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromDivestitureOfBusinesses": { "auth_ref": [ "r131" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.", "label": "Proceeds from Divestiture of Businesses", "terseLabel": "Proceeds from sale of subsidiary" } } }, "localname": "ProceedsFromDivestitureOfBusinesses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows", "http://www.cvshealth.com/role/DivestituresNarrativeDetails", "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromInterestAndDividendsReceived": { "auth_ref": [ "r142", "r150" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows_1": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received for dividends and interest on the entity's equity and debt investments during the current period.", "label": "Proceeds from Interest and Dividends Received", "terseLabel": "Interest and investment income received" } } }, "localname": "ProceedsFromInterestAndDividendsReceived", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "auth_ref": [ "r137" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.", "label": "Proceeds from Issuance of Long-term Debt", "terseLabel": "Proceeds from issuance of long-term debt" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity": { "auth_ref": [ "r895" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from principal payment received from sales-type and direct financing leases classified as investing activity.", "label": "Proceeds from Lease Payment, Sales-Type and Direct Financing Leases, Investing Activity", "terseLabel": "Proceeds from sale-leaseback transactions" } } }, "localname": "ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows", "http://www.cvshealth.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "auth_ref": [ "r138", "r141" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.", "label": "Proceeds from (Payments for) Other Financing Activities", "terseLabel": "Other" } } }, "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfShortTermDebt": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The net cash inflow or outflow for borrowing having initial term of repayment within one year or the normal operating cycle, if longer.", "label": "Proceeds from (Repayments of) Short-term Debt", "terseLabel": "Net repayments of short-term debt" } } }, "localname": "ProceedsFromRepaymentsOfShortTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds from Sale and Maturity of Marketable Securities", "terseLabel": "Proceeds from sales and maturities of investments" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r129", "r130", "r280" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Sale of Debt Securities, Available-for-sale", "terseLabel": "Proceeds from sales" } } }, "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/InvestmentsRealizedGainsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r136", "r634" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options", "verboseLabel": "Cash received from stock options exercised (including ESPP)" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows", "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductAndServiceOtherMember": { "auth_ref": [ "r494" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.", "label": "Product and Service, Other [Member]", "terseLabel": "Other" } } }, "localname": "ProductAndServiceOtherMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r494" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Products" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "domainItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r26", "r101", "r104", "r110", "r146", "r168", "r183", "r194", "r195", "r238", "r250", "r254", "r257", "r260", "r308", "r400", "r401", "r402", "r405", "r406", "r407", "r409", "r411", "r413", "r414", "r702", "r706", "r708", "r724", "r725", "r746", "r772", "r896" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 }, "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net income", "totalLabel": "Net income" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows", "http://www.cvshealth.com/role/ConsolidatedStatementsofComprehensiveIncome", "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations", "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]", "terseLabel": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r64", "r373" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/LeasesNarrativeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesPropertyPlantandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentFairValueDisclosure": { "auth_ref": [ "r748" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant, and Equipment, Fair Value Disclosure", "terseLabel": "Property and equipment, fair value" } } }, "localname": "PropertyPlantAndEquipmentFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r63", "r371" ], "calculation": { "http://www.cvshealth.com/role/SignificantAccountingPoliciesPropertyPlantandEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "verboseLabel": "Total property and equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPropertyPlantandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPropertyPlantandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment [Member]", "terseLabel": "Property and equipment" } } }, "localname": "PropertyPlantAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/LeasesNarrativeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r40", "r41", "r373", "r828", "r904", "r929" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.cvshealth.com/role/SignificantAccountingPoliciesPropertyPlantandEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets", "http://www.cvshealth.com/role/SignificantAccountingPoliciesPropertyPlantandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r62", "r373", "r1055", "r1056" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r40", "r373" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of property and equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r40", "r371" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/LeasesNarrativeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesPropertyPlantandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Useful life of property plant and equipment" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_PropertySubjectToOperatingLeaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Property subject to an operating lease.", "label": "Property Subject to Operating Lease [Member]", "terseLabel": "Operating lease assets" } } }, "localname": "PropertySubjectToOperatingLeaseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RealEstateFundsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Investments in funds that invest in commercial or residential real estate.", "label": "Real Estate Funds [Member]", "verboseLabel": "Real estate partnerships" } } }, "localname": "RealEstateFundsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesVariableInterestEntitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RealEstateInvestmentMember": { "auth_ref": [ "r1039", "r1040", "r1041", "r1042" ], "lang": { "en-us": { "role": { "documentation": "This element represents direct equity investments in real estate projects (Land, buildings and improvements owned for income production and capital accretion potential) and certain loans accounted for as real estate investments. For loans accounted for as real estate investments, the entity (lender) has virtually the same risks and rewards as those of owners or joint venture participants. Such arrangements are treated as if the entity actually has an ownership interest in the property. In such arrangements, the entity (lender) participates in expected residual profits, which may be in the form of an equity kicker or a higher than usual effective interest rate. At the outset and during the construction and development of the property, the borrower generally has little or no equity in the property and the entity's (lender's) only source of repayment is the property. The entity (lender) generally (a) agrees to provide substantially all funds to acquire, develop, and construct the property, (b) funds the commitment or origination fees or both, and (c) funds interest during the development and construction of the property.", "label": "Real Estate Investment [Member]", "terseLabel": "Real Estate Investment" } } }, "localname": "RealEstateInvestmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RealizedInvestmentGainsLosses": { "auth_ref": [ "r949" ], "calculation": { "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails": { "order": 2.0, "parentTag": "us-gaap_InvestmentIncomeNet", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) on investment.", "label": "Realized Investment Gains (Losses)", "terseLabel": "Net realized capital gains" } } }, "localname": "RealizedInvestmentGainsLosses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivablesPolicyTextBlock": { "auth_ref": [ "r270", "r274", "r275", "r276" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.", "label": "Receivable [Policy Text Block]", "terseLabel": "Accounts Receivable" } } }, "localname": "ReceivablesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]", "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]" } } }, "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/OtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax": { "auth_ref": [ "r100", "r108", "r109", "r782", "r786", "r788" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss).", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax", "terseLabel": "Amounts reclassified, pre-tax" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/OtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "auth_ref": [ "r100", "r108", "r109", "r111", "r782", "r786", "r788" ], "calculation": { "http://www.cvshealth.com/role/OtherComprehensiveIncomeDetails": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "negatedTerseLabel": "Amounts reclassified from accumulated other comprehensive loss, net of tax", "verboseLabel": "Cumulative translation adjustment from AOCI eliminated upon divestiture" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/OtherComprehensiveIncomeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]", "terseLabel": "Changes in Accumulated Other Comprehensive Income (Loss) by Component" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/OtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": { "auth_ref": [ "r110" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/OtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": { "auth_ref": [ "r250", "r254" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]", "terseLabel": "Reconciliation of operating earnings to net income" } } }, "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]", "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]" } } }, "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RedeemablePreferredStockMember": { "auth_ref": [ "r37", "r168", "r308", "r400", "r405", "r406", "r407", "r413", "r414", "r451", "r772" ], "lang": { "en-us": { "role": { "documentation": "Description of type or class of redeemable preferred stock. For instance, cumulative preferred stock, noncumulative preferred stock, convertible or series.", "label": "Redeemable Preferred Stock [Member]", "terseLabel": "Redeemable preferred securities" } } }, "localname": "RedeemablePreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails", "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails", "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReinsuranceAccountingPolicy": { "auth_ref": [ "r908", "r909", "r1013", "r1014" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of reinsurance accounting policy, for example, but not limited to, description of the methodologies and assumptions underlying determination of reinsurance recoverables, reinsurance payables and retention policy.", "label": "Reinsurance Accounting Policy [Policy Text Block]", "terseLabel": "Reinsurance Recoverables" } } }, "localname": "ReinsuranceAccountingPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReinsuranceDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Reinsurance Disclosures [Abstract]", "terseLabel": "Reinsurance Disclosures [Abstract]" } } }, "localname": "ReinsuranceDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed": { "auth_ref": [ "r908" ], "calculation": { "http://www.cvshealth.com/role/ReinsuranceEffectsofReinsuranceDetails": { "order": 2.0, "parentTag": "us-gaap_PolicyholderBenefitsAndClaimsIncurredNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of policy benefits and costs incurred for policies assumed.", "label": "Policyholder Benefits and Claims Incurred, Assumed", "terseLabel": "Assumed" } } }, "localname": "ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ReinsuranceEffectsofReinsuranceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded": { "auth_ref": [ "r908" ], "calculation": { "http://www.cvshealth.com/role/ReinsuranceEffectsofReinsuranceDetails": { "order": 3.0, "parentTag": "us-gaap_PolicyholderBenefitsAndClaimsIncurredNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of reduction of provision for policy benefits and costs incurred for policies ceded.", "label": "Policyholder Benefits and Claims Incurred, Ceded", "negatedTerseLabel": "Ceded" } } }, "localname": "ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ReinsuranceEffectsofReinsuranceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentNetAmountAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Premiums Earned, Net [Abstract]", "terseLabel": "Premiums Earned, Net [Abstract]" } } }, "localname": "ReinsurancePremiumsForInsuranceCompaniesByProductSegmentNetAmountAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ReinsuranceEffectsofReinsuranceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments": { "auth_ref": [ "r910", "r961", "r963", "r966" ], "calculation": { "http://www.cvshealth.com/role/HealthCareCostsPayableReconciliationofHealthCareNetIncurredandPaidClaimsDevelopmenttoHealthCareCostsPayableLiabilityDetails": { "order": 2.0, "parentTag": "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after valuation allowance, recoverable under reinsurance contracts for losses reported to the ceding insurer but not yet paid and amounts expected for incurred losses and settlement expenses, which have not yet been reported to the ceding insurer.", "label": "Reinsurance Recoverable for Unpaid Claims and Claims Adjustments", "periodEndLabel": "Add: Reinsurance recoverables", "periodStartLabel": "Less: Reinsurance recoverables", "terseLabel": "Reinsurance recoverables" } } }, "localname": "ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableReconciliationofHealthCareCostsPayableDetails", "http://www.cvshealth.com/role/HealthCareCostsPayableReconciliationofHealthCareNetIncurredandPaidClaimsDevelopmenttoHealthCareCostsPayableLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReinsuranceRecoverablesOnPaidAndUnpaidLosses": { "auth_ref": [ "r910", "r960", "r961", "r1023" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after valuation allowance, recoverable under reinsurance contracts. Examples include, but are not limited to, settled and unsettled claims, incurred but not reported losses, loss adjustment expense, policy benefits and policy reserves. Excludes premiums paid under reinsurance contracts.", "label": "Reinsurance Recoverable for Paid and Unpaid Claims and Claims Adjustments", "terseLabel": "Total reinsurance recoverables" } } }, "localname": "ReinsuranceRecoverablesOnPaidAndUnpaidLosses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ReinsuranceReinsuranceRecoverablesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReinsuranceTextBlock": { "auth_ref": [ "r1025" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure pertaining to the existence, magnitude and information about insurance that has been ceded to or assumed from another insurance company, including the methodologies and assumptions used in determining recorded amounts.", "label": "Reinsurance [Text Block]", "terseLabel": "Reinsurance" } } }, "localname": "ReinsuranceTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/Reinsurance" ], "xbrltype": "textBlockItemType" }, "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": { "auth_ref": [ "r824" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.", "label": "Related Party Transaction, Expenses from Transactions with Related Party", "terseLabel": "Expenses from transactions with related party" } } }, "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reflects the sum of all other revenue and income realized from sales and other transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party during the period.", "label": "Related Party Transaction, Other Revenues from Transactions with Related Party", "terseLabel": "Other revenues from transactions with related party" } } }, "localname": "RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r140" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-term Debt", "negatedLabel": "Repayments of long-term debt" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReportingUnitAxis": { "auth_ref": [ "r352", "r353" ], "lang": { "en-us": { "role": { "documentation": "Information by reporting unit.", "label": "Reporting Unit [Axis]", "terseLabel": "Reporting Unit [Axis]" } } }, "localname": "ReportingUnitAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReportingUnitDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Level of reporting at which goodwill is tested for impairment.", "label": "Reporting Unit [Domain]", "terseLabel": "Reporting Unit [Domain]" } } }, "localname": "ReportingUnitDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResidentialMortgageBackedSecuritiesMember": { "auth_ref": [ "r282", "r532" ], "lang": { "en-us": { "role": { "documentation": "Securities collateralized by residential real estate mortgage loans.", "label": "Residential Mortgage Backed Securities [Member]", "terseLabel": "Residential mortgage-backed securities" } } }, "localname": "ResidentialMortgageBackedSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails", "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails", "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails", "http://www.cvshealth.com/role/InvestmentsNarrativeDetails", "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails", "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashCurrent": { "auth_ref": [ "r29", "r38", "r162" ], "calculation": { "http://www.cvshealth.com/role/SignificantAccountingPoliciesRestrictedCashDetails": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Current", "terseLabel": "Restricted cash (included in other current assets)" } } }, "localname": "RestrictedCashCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r34", "r42", "r162", "r1049" ], "calculation": { "http://www.cvshealth.com/role/SignificantAccountingPoliciesRestrictedCashDetails": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Noncurrent", "terseLabel": "Restricted cash (included in other assets)" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedInvestmentsAtFairValue": { "auth_ref": [ "r1026", "r1036", "r1048", "r1050" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate value of all restricted investments.", "label": "Restricted Investments, at Fair Value", "terseLabel": "Investments related to 2012 contract conversion" } } }, "localname": "RestrictedInvestmentsAtFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r55", "r473", "r642", "r828", "r924", "r990", "r995" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r2", "r179", "r180", "r181", "r184", "r193", "r195", "r313", "r639", "r640", "r641", "r679", "r680", "r744", "r986", "r988" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity", "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquityParentheticals" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanTypeAxis": { "auth_ref": [ "r503", "r504", "r505", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r531", "r532", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r554", "r555", "r556", "r558", "r561", "r565", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r585", "r586", "r587", "r588", "r589", "r590", "r594", "r595", "r596", "r598" ], "lang": { "en-us": { "role": { "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Axis]", "terseLabel": "Retirement Plan Type [Axis]" } } }, "localname": "RetirementPlanTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsChangesinLevel3PensionPlanAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsDefinedBenefitPlansExpectedBenefitDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNarrativeDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNetPeriodicBenefitCostsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanTypeDomain": { "auth_ref": [ "r503", "r504", "r505", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r531", "r532", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r554", "r555", "r556", "r558", "r561", "r565", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r585", "r586", "r587", "r588", "r589", "r590", "r594", "r595", "r596", "r598" ], "lang": { "en-us": { "role": { "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Domain]", "terseLabel": "Retirement Plan Type [Domain]" } } }, "localname": "RetirementPlanTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsChangesinLevel3PensionPlanAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsDefinedBenefitPlansExpectedBenefitDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNarrativeDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNetPeriodicBenefitCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r229", "r230", "r249", "r255", "r256", "r263", "r264", "r266", "r491", "r492", "r863" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": { "order": 3.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Revenues", "verboseLabel": "Revenues" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations", "http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r164", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r501" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r114", "r168", "r229", "r230", "r249", "r255", "r256", "r263", "r264", "r266", "r308", "r400", "r401", "r402", "r405", "r406", "r407", "r409", "r411", "r413", "r414", "r772", "r896" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "totalLabel": "Total revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations", "http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenues:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "auth_ref": [ "r814", "r819" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability", "terseLabel": "Finance leases" } } }, "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/LeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r814", "r819" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Operating leases" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/LeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleAndLeasebackTransactionGainLossNet": { "auth_ref": [ "r812", "r819", "r822" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale and leaseback transaction from transfer of asset accounted for as sale.", "label": "Sale and Leaseback Transaction, Gain (Loss), Net", "terseLabel": "Gains from sale-leaseback transactions" } } }, "localname": "SaleAndLeasebackTransactionGainLossNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesChannelDirectlyToConsumerMember": { "auth_ref": [ "r500" ], "lang": { "en-us": { "role": { "documentation": "Contract with customer in which good or service is transferred directly to consumer.", "label": "Sales Channel, Directly to Consumer [Member]", "terseLabel": "Mail choice" } } }, "localname": "SalesChannelDirectlyToConsumerMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SalesChannelThroughIntermediaryMember": { "auth_ref": [ "r500" ], "lang": { "en-us": { "role": { "documentation": "Contract with customer in which good or service is transferred through intermediary.", "label": "Sales Channel, Through Intermediary [Member]", "terseLabel": "Pharmacy network" } } }, "localname": "SalesChannelThroughIntermediaryMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r219", "r266" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]", "terseLabel": "Revenues" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "auth_ref": [ "r80" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]", "terseLabel": "Schedule of accounts receivable, net" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r100", "r787", "r788" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/OtherComprehensiveIncomeTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock": { "auth_ref": [ "r530" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the major categories of plan assets of pension plans and/or other employee benefit plans. This information may include, but is not limited to, the target allocation of plan assets, the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall.", "label": "Schedule of Allocation of Plan Assets [Table Text Block]", "terseLabel": "Schedule of changes in fair value of plan assets" } } }, "localname": "ScheduleOfAllocationOfPlanAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock": { "auth_ref": [ "r529" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts that are recognized in the balance sheet (or statement of financial position) for pension plans and/or other employee benefit plans, showing separately the assets and current and noncurrent liabilities (if applicable) recognized.", "label": "Schedule of Amounts Recognized in Balance Sheet [Table Text Block]", "terseLabel": "Schedule of assets (liabilities) recognized in Balance Sheet" } } }, "localname": "ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r205" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/EarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": { "auth_ref": [ "r553" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.", "label": "Defined Benefit Plan, Assumptions [Table Text Block]", "terseLabel": "Weighted average assumptions used in determining benefit obligations and net benefit costs" } } }, "localname": "ScheduleOfAssumptionsUsedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-sale [Line Items]", "terseLabel": "Debt Securities, Available-for-sale [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails", "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails", "http://www.cvshealth.com/role/InvestmentsNarrativeDetails", "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails", "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r694", "r695" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/DivestituresNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.", "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]", "terseLabel": "Schedule of reconciliation of cash and cash equivalents" } } }, "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCededCreditRiskByReinsurerTextBlock": { "auth_ref": [ "r1024" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of reinsurer or group of reinsurers for whom the entity has a concentration of credit risk.", "label": "Ceded Credit Risk [Table Text Block]", "terseLabel": "Schedule of reinsurance recoverables" } } }, "localname": "ScheduleOfCededCreditRiskByReinsurerTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ReinsuranceTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock": { "auth_ref": [ "r520" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation of beginning and ending balances of the fair value of plan assets of pension plans and/or other employee benefit plans showing separately, if applicable, the effects during the period attributable to each of the following: actual return on plan assets, foreign currency exchange rate changes, contributions by the employer, contributions by plan participants, benefits paid, business combinations, divestitures, and settlements.", "label": "Schedule of Changes in Fair Value of Plan Assets [Table Text Block]", "terseLabel": "Schedule of changes in plan assets" } } }, "localname": "ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock": { "auth_ref": [ "r509" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in the benefit obligation of pension plans and/or other employee benefit plans from the beginning to the end of the period, showing separately, if applicable, the effects of the following: service cost, interest cost, contributions by plan participants, actuarial gains and losses, foreign currency exchange rate changes, benefits paid, plan amendments, business combinations, divestitures, curtailments, settlements, and special and contractual termination benefits.", "label": "Schedule of Changes in Projected Benefit Obligations [Table Text Block]", "terseLabel": "Schedule of changes in benefit obligations" } } }, "localname": "ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r675" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Schedule of components of income tax expense (benefit)" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r74", "r176", "r444", "r446", "r469", "r470", "r471", "r472", "r792", "r793", "r796", "r907" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-term Debt Instruments [Table Text Block]", "terseLabel": "Carrying value of long-term debt" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r668" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Schedule of deferred tax assets and liabilities" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "auth_ref": [ "r564", "r565", "r566", "r567", "r578" ], "lang": { "en-us": { "role": { "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Defined Benefit Plans Disclosures [Table]", "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]" } } }, "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsBenefitObligationsandPlanAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsDefinedBenefitPlansExpectedBenefitDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNarrativeDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsNetPeriodicBenefitCostsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "auth_ref": [ "r6", "r14", "r15", "r16", "r17", "r18", "r19", "r21", "r24", "r25", "r26", "r375", "r376" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "terseLabel": "Schedule of discontinued operations" } } }, "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r204" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "verboseLabel": "Reconciliation of basic and diluted earnings (loss) per share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/EarningsPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r654" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Schedule of effective income tax rate reconciliation" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r602", "r630", "r644" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r602", "r630", "r644" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Stock-based compensation" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock": { "auth_ref": [ "r541" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter.", "label": "Schedule of Expected Benefit Payments [Table Text Block]", "terseLabel": "Schedule of expected future benefits payments" } } }, "localname": "ScheduleOfExpectedBenefitPaymentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r748", "r749" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "verboseLabel": "Fair value of financial assets and liabilities" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/FairValueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Separate Account Investment [Line Items]", "terseLabel": "Fair Value, Separate Account Investment [Line Items]" } } }, "localname": "ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable": { "auth_ref": [ "r911", "r1016", "r1019" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about fair value of asset supporting separate account.", "label": "Fair Value, Separate Account Investment [Table]", "terseLabel": "Fair Value, Separate Account Investment [Table]" } } }, "localname": "ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTextBlock": { "auth_ref": [ "r911", "r1016", "r1019" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of fair value of asset supporting separate account.", "label": "Fair Value, Separate Account Investment [Table Text Block]", "verboseLabel": "Separate account financial assets" } } }, "localname": "ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/FairValueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTable": { "auth_ref": [ "r351", "r354" ], "lang": { "en-us": { "role": { "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.", "label": "Schedule of Goodwill [Table]", "terseLabel": "Schedule of Goodwill [Table]" } } }, "localname": "ScheduleOfGoodwillTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesGoodwillDetails", "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r351", "r354" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Change in goodwill" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Net Investment Income [Line Items]", "terseLabel": "Schedule of Investment Income, Reported Amounts, by Category [Line Items]" } } }, "localname": "ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable": { "auth_ref": [ "r125", "r126", "r948" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment income, including, but not limited to, interest and dividend income and amortization of discount (premium) derived from debt and equity securities. Excludes realized and unrealized gain (loss) on investments.", "label": "Investment Income [Table]", "terseLabel": "Schedule of Investment Income, Reported Amounts, by Category [Table]" } } }, "localname": "ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/InvestmentsNetInvestmentIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense": { "auth_ref": [ "r967" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims.", "label": "Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]", "terseLabel": "Schedule of liability for unpaid claims and claims adjustment expense" } } }, "localname": "ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r397" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.", "label": "Schedule of Maturities of Long-term Debt [Table Text Block]", "terseLabel": "Schedule of maturities of long-term debt" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": { "auth_ref": [ "r543" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.", "label": "Schedule of Net Benefit Costs [Table Text Block]", "terseLabel": "Schedule of net periodic benefit cost" } } }, "localname": "ScheduleOfNetBenefitCostsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock": { "auth_ref": [ "r616" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested shares.", "label": "Schedule of Nonvested Share Activity [Table Text Block]", "terseLabel": "RSU and performance share unit activity" } } }, "localname": "ScheduleOfNonvestedShareActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOperatingLeasedAssetsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Schedule of Operating Leased Assets [Table]", "terseLabel": "Schedule of Operating Leased Assets [Table]" } } }, "localname": "ScheduleOfOperatingLeasedAssetsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r64", "r373" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPropertyPlantandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRegulatoryAssetsTextBlock": { "auth_ref": [ "r1069", "r1070", "r1071" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets that are created when regulatory agencies permit public utilities to defer certain costs included in rate-setting to the balance sheet.", "label": "Schedule of Regulatory Assets [Table Text Block]", "terseLabel": "Schedule of regulatory Requirements" } } }, "localname": "ScheduleOfRegulatoryAssetsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r238", "r241", "r253", "r351" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails", "http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r238", "r241", "r253", "r351" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Summarized financial information of segments" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r603", "r633" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansRestrictedStockActivityDetails", "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails", "http://www.cvshealth.com/role/StockIncentivePlansValuationandAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock": { "auth_ref": [ "r609" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for stock options and stock appreciation rights that were outstanding at the beginning and end of the year, exercisable at the end of the year, and the number of stock options and stock appreciation rights that were granted, exercised or converted, forfeited, and expired during the year.", "label": "Share-based Payment Arrangement, Option and Stock Appreciation Rights, Activity [Table Text Block]", "terseLabel": "Schedule of stock options and stock appreciation rights award activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": { "auth_ref": [ "r624" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule ESPP valuation assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r624" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of valuation assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShortTermDebtTable": { "auth_ref": [ "r68" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.", "label": "Schedule of Short-term Debt [Table]", "terseLabel": "Schedule of Short-term Debt [Table]" } } }, "localname": "ScheduleOfShortTermDebtTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsShorttermBorrowingsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfTreasuryStockByClassTextBlock": { "auth_ref": [ "r474", "r475", "r476", "r477" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.", "label": "Class of Treasury Stock [Table Text Block]", "terseLabel": "Share repurchase programs" } } }, "localname": "ScheduleOfTreasuryStockByClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "For all investments in an unrealized loss position, including those for which other-than-temporary impairments have not been recognized in earnings (including investments for which a portion of an other-than-temporary impairment has been recognized in other comprehensive income), a tabular disclosure of the aggregate related fair value of investments with unrealized losses and the aggregate amount of unrealized losses (that is, the amount by which amortized cost basis exceeds fair value).", "label": "Schedule of Unrealized Loss on Investments [Table Text Block]", "verboseLabel": "Debt securities in an unrealized capital loss position" } } }, "localname": "ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "auth_ref": [ "r663", "r676" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in unrecognized tax benefits.", "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]", "terseLabel": "Schedule of unrecognized tax benefits roll forward" } } }, "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfVariableInterestEntitiesTable": { "auth_ref": [ "r704", "r705", "r713", "r714", "r715", "r717", "r720", "r721", "r722" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.", "label": "Schedule of Variable Interest Entities [Table]", "terseLabel": "Schedule of Variable Interest Entities [Table]" } } }, "localname": "ScheduleOfVariableInterestEntitiesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesVariableInterestEntitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfVariableInterestEntitiesTextBlock": { "auth_ref": [ "r715", "r717", "r720", "r721", "r722" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.", "label": "Schedule of Variable Interest Entities [Table Text Block]", "terseLabel": "Schedule of variable interest entities" } } }, "localname": "ScheduleOfVariableInterestEntitiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "verboseLabel": "Estimated annual pretax amortization for other acquired intangible assets over the next five years" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r225", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r249", "r250", "r251", "r252", "r254", "r255", "r256", "r257", "r258", "r260", "r266", "r377", "r378", "r975" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/DivestituresNarrativeDetails", "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesGoodwillDetails", "http://www.cvshealth.com/role/HealthCareCostsPayableNarrativeDetails", "http://www.cvshealth.com/role/HealthCareCostsPayableReconciliationofHealthCareCostsPayableDetails", "http://www.cvshealth.com/role/LeasesNarrativeDetails", "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails", "http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]", "terseLabel": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r225", "r227", "r228", "r238", "r242", "r254", "r258", "r259", "r260", "r261", "r263", "r265", "r266", "r267" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "verboseLabel": "Segment Reporting" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SegmentReporting" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails", "http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r243", "r244", "r245", "r246", "r247", "r248", "r264" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segment Policy" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SelfInsuranceReserve": { "auth_ref": [ "r75" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount (including both current and noncurrent portions) of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property.", "label": "Self Insurance Reserve", "terseLabel": "Self insurance liabilities" } } }, "localname": "SelfInsuranceReserve", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SelfInsuranceReservePolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for self-insurance reserves, including, but not limited to incurred but not reported reserves (IBNR).", "label": "Self Insurance Reserve [Policy Text Block]", "terseLabel": "Self-Insurance Liabilities" } } }, "localname": "SelfInsuranceReservePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SeniorNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.", "label": "Senior Notes [Member]", "terseLabel": "Senior Notes" } } }, "localname": "SeniorNotesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsLongTermBorrowingsDetails", "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsScheduleofDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeparateAccountAssetCategoryAxis": { "auth_ref": [ "r1016", "r1019" ], "lang": { "en-us": { "role": { "documentation": "Information by separate account asset investment.", "label": "Separate Account Asset Category [Axis]", "terseLabel": "Separate Account Asset Category [Axis]" } } }, "localname": "SeparateAccountAssetCategoryAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/FairValueNarrativeDetails", "http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SeparateAccountAssetCategoryDomain": { "auth_ref": [ "r1016", "r1019" ], "lang": { "en-us": { "role": { "documentation": "Separate account asset investment.", "label": "Separate Account Asset Category [Domain]", "terseLabel": "Separate Account Asset Category [Domain]" } } }, "localname": "SeparateAccountAssetCategoryDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/FairValueNarrativeDetails", "http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeparateAccountAssets": { "auth_ref": [ "r919", "r1015", "r1016", "r1019" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset at fair value held for benefit of separate account policyholder.", "label": "Separate Account Asset", "terseLabel": "Separate accounts assets" } } }, "localname": "SeparateAccountAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets", "http://www.cvshealth.com/role/FairValueSeparateAccountsFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SeparateAccountsLiability": { "auth_ref": [ "r922", "r1015", "r1017", "r1018", "r1020" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability for variable contract in which all or portion of contract holder's funds is allocated to specific separate account and supported by assets held in separate account.", "label": "Separate Account, Liability", "terseLabel": "Separate accounts liabilities" } } }, "localname": "SeparateAccountsLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ServiceMember": { "auth_ref": [ "r494" ], "lang": { "en-us": { "role": { "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.", "label": "Service [Member]", "terseLabel": "Services" } } }, "localname": "ServiceMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "domainItemType" }, "us-gaap_SettledLitigationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreement reached between parties in a litigation that occurs without judicial intervention, supervision or approval.", "label": "Settled Litigation [Member]", "terseLabel": "Settled Litigation" } } }, "localname": "SettledLitigationMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r155" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r604" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Award vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails", "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r614" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedTerseLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r620" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r618" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r618" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted (in dollars per share)", "verboseLabel": "Weighted-average grant date fair value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansRestrictedStockActivityDetails", "http://www.cvshealth.com/role/StockIncentivePlansValuationandAssumptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r617" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Unvested at end of period (in shares)", "periodStartLabel": "Unvested at beginning of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Units" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r617" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Unvested at end of year (in dollars per share)", "periodStartLabel": "Unvested at beginning of year (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted average grant date fair value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r619" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "auth_ref": [ "r621" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "terseLabel": "Vested in period, fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r619" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r627" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "verboseLabel": "Dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansValuationandAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r626" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "verboseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansValuationandAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r628" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "verboseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansValuationandAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansRestrictedStockActivityDetails", "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails", "http://www.cvshealth.com/role/StockIncentivePlansValuationandAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r606" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Number of shares authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r633" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Number of shares available for grant" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r612" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Shares exercisable at end of year (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r612" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price exercisable at end of year ($ per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r621" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Intrinsic value of stock options and SARs exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r615" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period", "negatedTerseLabel": "Shares expired (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r614" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedTerseLabel": "Shares forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Shares granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r633" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate Intrinsic value outstanding at end of year" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r611", "r633" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Shares, Outstanding at end of year (in shares)", "periodStartLabel": "Shares, Outstanding at beginning of year (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r610" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted average exercise price, outstanding at end of year ($ per share)", "periodStartLabel": "Weighted average exercise price, outstanding at beginning of year ($ per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r622" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Aggregate intrinsic value vested at end of year and expected to vest in the future" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r623" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Shares vested at end of year and expected to vest in the future (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r623" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price vested at end of year and expected to vest in the future ($ per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r601", "r607" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansRestrictedStockActivityDetails", "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails", "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails", "http://www.cvshealth.com/role/StockIncentivePlansValuationandAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, exercised ($ per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, expired ($ per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, forfeited ($ per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, granted ($ per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r603", "r608" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Payment Arrangement [Policy Text Block]", "terseLabel": "Share-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Share price (in dollars per share)" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareRepurchaseProgramAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by share repurchase program.", "label": "Share Repurchase Program [Axis]", "terseLabel": "Share Repurchase Program [Axis]" } } }, "localname": "ShareRepurchaseProgramAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails", "http://www.cvshealth.com/role/ShareholdersEquityShareRepurchasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareRepurchaseProgramDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the share repurchase program.", "label": "Share Repurchase Program [Domain]", "terseLabel": "Share Repurchase Program [Domain]" } } }, "localname": "ShareRepurchaseProgramDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails", "http://www.cvshealth.com/role/ShareholdersEquityShareRepurchasesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r605" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "terseLabel": "Expiration period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails", "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r625", "r643" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "verboseLabel": "Expected life (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansValuationandAssumptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r633" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Aggregate intrinsic value exercisable at end of year" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r633" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining contractual term exercisable at end of year" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r623" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average contractual term, outstanding at end of year" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r623" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining contractual term vested at end of year and expected to vest in the future" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase price of common stock expressed as a percentage of its fair value.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent", "terseLabel": "Purchase price of common stock percent" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance at end of period (in shares)", "periodStartLabel": "Balance at beginning of period (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortDurationInsuranceAndDepositContractsTextBlock": { "auth_ref": [ "r1025" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for insurance products considered to be short-duration contracts because the contract provides insurance protection for a fixed period of short duration and enables the insurer to cancel the contract or to adjust the provisions of the contract at the end of any contract period, such as adjusting the amount of premiums charged or coverage provided, and on contracts on which amounts are paid but insurance risk is not transferred.", "label": "Short-Duration Insurance and Deposit Contracts [Text Block]", "terseLabel": "Health Care Costs Payable" } } }, "localname": "ShortDurationInsuranceAndDepositContractsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShortDurationInsuranceContractAccidentYear2019Member": { "auth_ref": [ "r971" ], "lang": { "en-us": { "role": { "documentation": "Accident year 2019 in which covered event occurs under terms of short-duration insurance contract.", "label": "Short-Duration Insurance Contract, Accident Year 2019 [Member]", "terseLabel": "2020" } } }, "localname": "ShortDurationInsuranceContractAccidentYear2019Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableIncurredandPaidHealthCareClaimsDevelopmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShortDurationInsuranceContractAccidentYear2020Member": { "auth_ref": [ "r971" ], "lang": { "en-us": { "role": { "documentation": "Accident year 2020 in which covered event occurs under terms of short-duration insurance contract.", "label": "Short-Duration Insurance Contract, Accident Year 2020 [Member]", "terseLabel": "2021" } } }, "localname": "ShortDurationInsuranceContractAccidentYear2020Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableIncurredandPaidHealthCareClaimsDevelopmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShortTermBorrowings": { "auth_ref": [ "r43", "r828", "r875", "r921" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.", "label": "Short-term Debt", "terseLabel": "Short-term debt" } } }, "localname": "ShortTermBorrowings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsShorttermBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermDebtLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Short-term Debt [Line Items]", "terseLabel": "Short-term Debt [Line Items]" } } }, "localname": "ShortTermDebtLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsShorttermBorrowingsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r68" ], "lang": { "en-us": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short-term Debt, Type [Axis]", "terseLabel": "Short-term Debt, Type [Axis]" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsShorttermBorrowingsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r66" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.", "label": "Short-term Debt, Type [Domain]", "terseLabel": "Short-term Debt, Type [Domain]" } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsShorttermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r45", "r880", "r881", "r917" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.cvshealth.com/role/InvestmentsScheduleofTotalInvestmentsDetails": { "order": 1.0, "parentTag": "us-gaap_Investments", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short-term Investments", "terseLabel": "Investments", "verboseLabel": "Current" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets", "http://www.cvshealth.com/role/InvestmentsScheduleofTotalInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r809", "r819" ], "calculation": { "http://www.cvshealth.com/role/LeasesSummaryoftheComponentsofNetLeaseCostDetails": { "order": 5.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-term Lease, Cost", "terseLabel": "Short-term lease costs" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/LeasesSummaryoftheComponentsofNetLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortdurationInsuranceContractsAccidentYearAxis": { "auth_ref": [ "r971" ], "lang": { "en-us": { "role": { "documentation": "Information by accident year in which a covered event occurs under the terms of the short-duration insurance contract.", "label": "Short-duration Insurance Contracts, Accident Year [Axis]", "terseLabel": "Short-duration Insurance Contracts, Accident Year [Axis]" } } }, "localname": "ShortdurationInsuranceContractsAccidentYearAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableIncurredandPaidHealthCareClaimsDevelopmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortdurationInsuranceContractsAccidentYearDomain": { "auth_ref": [ "r971" ], "lang": { "en-us": { "role": { "documentation": "Accident year in which a covered event occurs under the terms of the short-duration insurance contract.", "label": "Short-duration Insurance Contracts, Accident Year [Domain]", "terseLabel": "Short-duration Insurance Contracts, Accident Year [Domain]" } } }, "localname": "ShortdurationInsuranceContractsAccidentYearDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableIncurredandPaidHealthCareClaimsDevelopmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable": { "auth_ref": [ "r971" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about undiscounted information about claims development by accident year for short-duration insurance contracts.", "label": "Short-duration Insurance Contracts, Claims Development [Table]", "terseLabel": "Short-duration Insurance Contracts, Claims Development [Table]" } } }, "localname": "ShortdurationInsuranceContractsClaimsDevelopmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableIncurredandPaidHealthCareClaimsDevelopmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock": { "auth_ref": [ "r971" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted information about claims development by accident year for short-duration insurance contracts.", "label": "Short-duration Insurance Contracts, Claims Development [Table Text Block]", "terseLabel": "Information about incurred and paid health care claims development" } } }, "localname": "ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet": { "auth_ref": [ "r970" ], "calculation": { "http://www.cvshealth.com/role/HealthCareCostsPayableIncurredandPaidHealthCareClaimsDevelopmentDetails": { "order": 1.0, "parentTag": "us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after reinsurance, of paid claims and allocated claim adjustment expense used in claims development for short-duration insurance contracts. Excludes unallocated claim adjustment expense.", "label": "Short-duration Insurance Contracts, Cumulative Paid Claims and Allocated Claim Adjustment Expense, Net", "terseLabel": "Cumulative Paid Health Care Claims, Net of Reinsurance" } } }, "localname": "ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableIncurredandPaidHealthCareClaimsDevelopmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet": { "auth_ref": [ "r973", "r974" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Undiscounted amount, after reinsurance, of incurred-but-not-reported (IBNR) liabilities plus expected development on reported claims, for claims and allocated claim adjustment expense for short-duration insurance contracts. Excludes unallocated claim adjustment expense.", "label": "Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net", "verboseLabel": "Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) claims liability, net" } } }, "localname": "ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet": { "auth_ref": [ "r969" ], "calculation": { "http://www.cvshealth.com/role/HealthCareCostsPayableIncurredandPaidHealthCareClaimsDevelopmentDetails": { "order": 3.0, "parentTag": "us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Undiscounted amount, after reinsurance, of incurred claims and allocated claim adjustment expense used in claims development for short-duration insurance contracts. Excludes unallocated claim adjustment expense.", "label": "Short-duration Insurance Contracts, Incurred Claims and Allocated Claim Adjustment Expense, Net", "terseLabel": "Incurred Health Care Claims, Net of Reinsurance" } } }, "localname": "ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableIncurredandPaidHealthCareClaimsDevelopmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet": { "auth_ref": [ "r971", "r972" ], "calculation": { "http://www.cvshealth.com/role/HealthCareCostsPayableIncurredandPaidHealthCareClaimsDevelopmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.cvshealth.com/role/HealthCareCostsPayableReconciliationofHealthCareNetIncurredandPaidClaimsDevelopmenttoHealthCareCostsPayableLiabilityDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Undiscounted amount, after reinsurance, of the liability for unpaid claims and allocated claim adjustment expense for short-duration insurance contracts. Excludes unallocated claim adjustment expense.", "label": "Short-duration Insurance Contracts, Liability for Unpaid Claims and Allocated Claim Adjustment Expense, Net", "terseLabel": "Short-duration health care costs payable, net of reinsurance", "totalLabel": "Total outstanding liabilities for health care costs payable, net of reinsurance" } } }, "localname": "ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableIncurredandPaidHealthCareClaimsDevelopmentDetails", "http://www.cvshealth.com/role/HealthCareCostsPayableReconciliationofHealthCareNetIncurredandPaidClaimsDevelopmenttoHealthCareCostsPayableLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNetNotSeparatelyPresented": { "auth_ref": [ "r971" ], "calculation": { "http://www.cvshealth.com/role/HealthCareCostsPayableIncurredandPaidHealthCareClaimsDevelopmentDetails": { "order": 2.0, "parentTag": "us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Undiscounted amount, after reinsurance, of the liability for unpaid claims and allocated claim adjustment expense for short-duration insurance contracts for accident years not separately presented in claim development information. Excludes unallocated claim adjustment expense.", "label": "Short-duration Insurance Contracts, Liability for Unpaid Claims and Allocated Claim Adjustment Expense, Net, Not Separately Presented", "terseLabel": "All outstanding liabilities for health care costs payable prior to 2020, net of reinsurance" } } }, "localname": "ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNetNotSeparatelyPresented", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableIncurredandPaidHealthCareClaimsDevelopmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem": { "auth_ref": [ "r972" ], "calculation": { "http://www.cvshealth.com/role/HealthCareCostsPayableReconciliationofHealthCareNetIncurredandPaidClaimsDevelopmenttoHealthCareCostsPayableLiabilityDetails": { "order": 3.0, "parentTag": "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of reconciling item for the reconciliation of the liability in the disclosure of claims development (in excess of) less than the liability for unpaid claims and claims adjustment expense for short-duration insurance contracts, classified as other.", "label": "Short-duration Insurance Contracts, Liability for Unpaid Claims and Claim Adjustment Expense, Other Reconciling Item", "terseLabel": "Insurance lines other than short duration" } } }, "localname": "ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableReconciliationofHealthCareNetIncurredandPaidClaimsDevelopmenttoHealthCareCostsPayableLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]", "terseLabel": "Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]" } } }, "localname": "ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableReconciliationofHealthCareNetIncurredandPaidClaimsDevelopmenttoHealthCareCostsPayableLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable": { "auth_ref": [ "r972" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the reconciliation of claims development to the liability for unpaid claims and claim adjustment expense for short-duration insurance contracts.", "label": "Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table]", "terseLabel": "Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table]" } } }, "localname": "ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableReconciliationofHealthCareNetIncurredandPaidClaimsDevelopmenttoHealthCareCostsPayableLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock": { "auth_ref": [ "r972" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for the reconciliation of claims development to the liability for unpaid claims and claim adjustment expense for short-duration insurance contracts.", "label": "Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table Text Block]", "terseLabel": "Components of change in health care costs payable" } } }, "localname": "ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.", "label": "Software and Software Development Costs [Member]", "terseLabel": "Software" } } }, "localname": "SoftwareAndSoftwareDevelopmentCostsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPropertyPlantandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r13", "r225", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r249", "r250", "r251", "r252", "r254", "r255", "r256", "r257", "r258", "r260", "r266", "r351", "r374", "r377", "r378", "r975" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/DivestituresNarrativeDetails", "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesGoodwillDetails", "http://www.cvshealth.com/role/HealthCareCostsPayableNarrativeDetails", "http://www.cvshealth.com/role/HealthCareCostsPayableReconciliationofHealthCareCostsPayableDetails", "http://www.cvshealth.com/role/LeasesNarrativeDetails", "http://www.cvshealth.com/role/SegmentReportingReconciliationfromOperatingIncometoAdjustedOperatingIncomeDetails", "http://www.cvshealth.com/role/SegmentReportingReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesDisaggregationofRevenueDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r2", "r79", "r108", "r109", "r110", "r179", "r180", "r181", "r184", "r193", "r195", "r212", "r313", "r468", "r473", "r639", "r640", "r641", "r679", "r680", "r744", "r782", "r783", "r784", "r785", "r786", "r788", "r986", "r987", "r988", "r1120" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity", "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquityParentheticals", "http://www.cvshealth.com/role/OtherComprehensiveIncomeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations", "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity", "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquityParentheticals" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r179", "r180", "r181", "r212", "r863" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations", "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity", "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquityParentheticals" ], "xbrltype": "stringItemType" }, "us-gaap_StatutoryAccountingPracticesDisclosureTextBlock": { "auth_ref": [ "r935", "r999", "r1000", "r1001", "r1002", "r1003" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of how the entity's reporting under GAAP as of the balance sheet date differs from the results based on prescribed and permitted accounting practices of the state or country of domicile in which a relevant statutory filing is made, or differences in results based on the National Association of Insurance Commissioners (NAIC) prescribed practices, or a combination thereof. Describes the accounting practices used and the related monetary effect on statutory surplus, net income, and risk-based capital. If an insurance enterprise's risk-based capital would have triggered a regulatory event had it not used a permitted practice, that fact is disclosed in the financial statements. Permitted statutory accounting practices include practices not prescribed but allowed by the domiciliary state insurance department regulatory authority.", "label": "Statutory Accounting Practices Disclosure [Table Text Block]", "terseLabel": "Statutory accounting practices disclosure" } } }, "localname": "StatutoryAccountingPracticesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatutoryAccountingPracticesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statutory Accounting Practices [Line Items]", "terseLabel": "Statutory Accounting Practices [Line Items]" } } }, "localname": "StatutoryAccountingPracticesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityRegulatoryRequirementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPaymentsWithoutRegulatoryApproval": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of dividends that can be declared or paid without approval of regulatory agency.", "label": "Statutory Accounting Practices, Statutory Amount Available for Dividend Payments without Regulatory Approval", "terseLabel": "Estimated maximum dividend distributions permitted in 2022 without prior regulatory approval" } } }, "localname": "StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPaymentsWithoutRegulatoryApproval", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityRegulatoryRequirementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance": { "auth_ref": [ "r925", "r997" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of statutory capital and surplus (stockholders' equity) as of the balance sheet date using prescribed or permitted statutory accounting practices (rather than GAAP, if different) of the state or country.", "label": "Statutory Accounting Practices, Statutory Capital and Surplus, Balance", "terseLabel": "Combined statutory capital and surplus" } } }, "localname": "StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityRegulatoryRequirementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired": { "auth_ref": [ "r998" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of statutory capital required to be maintained as of the balance sheet date under prescribed or permitted statutory accounting practices.", "label": "Statutory Accounting Practices, Statutory Capital and Surplus Required", "terseLabel": "Estimated minimum statutory surplus required by regulators" } } }, "localname": "StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityRegulatoryRequirementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StatutoryAccountingPracticesStatutoryNetIncomeAmount": { "auth_ref": [ "r925" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of net income for the period determined using accounting principles prescribed or permitted by insurance regulators.", "label": "Statutory Accounting Practices, Statutory Net Income Amount", "terseLabel": "Combined statutory net income" } } }, "localname": "StatutoryAccountingPracticesStatutoryNetIncomeAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityRegulatoryRequirementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StatutoryAccountingPracticesTable": { "auth_ref": [ "r935", "r999", "r1000", "r1001", "r1002", "r1003" ], "lang": { "en-us": { "role": { "documentation": "Detail by state, country, or other jurisdiction of domicile in which financial statements are filed reflecting statutory capital and surplus, net income and the differences between financial reports which are in conformity with generally accepted accounting principles and the statutory financial statements which also use state permitted or prescribed accounting practices.", "label": "Statutory Accounting Practices [Table]", "terseLabel": "Statutory Accounting Practices [Table]" } } }, "localname": "StatutoryAccountingPracticesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityRegulatoryRequirementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StockAppreciationRightsSARSMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period.", "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)" } } }, "localname": "StockAppreciationRightsSARSMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails", "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r51", "r52", "r468", "r473" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Shares issued employee stock purchase plan (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/StockIncentivePlansStockBasedCompensationExpenseandESPPDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r51", "r52", "r468", "r473", "r613" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedTerseLabel": "Shares exercised (in shares)", "verboseLabel": "Stock option activity, stock awards and other (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity", "http://www.cvshealth.com/role/StockIncentivePlansStockOptionandSARActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r79", "r468", "r473" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Stock option activity, stock awards and other" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Authorized" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityShareRepurchasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount remaining of a stock repurchase plan authorized.", "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount", "terseLabel": "Remaining as of December 31, 2021" } } }, "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityShareRepurchasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r52", "r57", "r58", "r168", "r273", "r308", "r772", "r828" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total CVS Health shareholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r2", "r3", "r109", "r168", "r179", "r180", "r181", "r184", "r193", "r308", "r313", "r473", "r639", "r640", "r641", "r679", "r680", "r699", "r700", "r723", "r744", "r772", "r782", "r783", "r788", "r987", "r988", "r1120" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "End of year balance", "periodStartLabel": "Beginning of year balance", "terseLabel": "Cumulative adjustment to retained earnings as a result of new accounting standard adoption", "totalLabel": "Total shareholders\u2019 equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets", "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity", "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquityParentheticals", "http://www.cvshealth.com/role/OtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]", "terseLabel": "Shareholders\u2019 equity:" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r166", "r453", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r467", "r473", "r478" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "verboseLabel": "Shareholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubleaseIncome": { "auth_ref": [ "r811", "r819" ], "calculation": { "http://www.cvshealth.com/role/LeasesSummaryoftheComponentsofNetLeaseCostDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of sublease income excluding finance and operating lease expense.", "label": "Sublease Income", "terseLabel": "Less: sublease income" } } }, "localname": "SubleaseIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/LeasesSummaryoftheComponentsofNetLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ReinsuranceNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r789", "r829" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ReinsuranceNarrativeDetails", "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r789", "r829" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ReinsuranceNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r789", "r829" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ReinsuranceNarrativeDetails", "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r789", "r829" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ReinsuranceNarrativeDetails", "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense": { "auth_ref": [ "r964" ], "calculation": { "http://www.cvshealth.com/role/HealthCareCostsPayableReconciliationofHealthCareCostsPayableDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after effects of reinsurance, of expense for claims incurred in the current reporting period and related claims settlement costs.", "label": "Current Year Claims and Claims Adjustment Expense", "terseLabel": "Current year" } } }, "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableReconciliationofHealthCareCostsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense": { "auth_ref": [ "r964" ], "calculation": { "http://www.cvshealth.com/role/HealthCareCostsPayableReconciliationofHealthCareCostsPayableDetails": { "order": 2.0, "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.", "label": "Prior Year Claims and Claims Adjustment Expense", "verboseLabel": "Decrease in prior years' healthcare costs payable" } } }, "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/HealthCareCostsPayableNarrativeDetails", "http://www.cvshealth.com/role/HealthCareCostsPayableReconciliationofHealthCareCostsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TechnologyBasedIntangibleAssetsMember": { "auth_ref": [ "r696" ], "lang": { "en-us": { "role": { "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights.", "label": "Technology-Based Intangible Assets [Member]", "terseLabel": "Technology" } } }, "localname": "TechnologyBasedIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/GoodwillandOtherIntangiblesIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r293", "r294", "r303", "r304", "r305", "r441", "r466", "r735", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r1080", "r1081", "r1082", "r1083", "r1084", "r1085", "r1086" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails", "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails", "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails", "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesbyMaturityDetails", "http://www.cvshealth.com/role/InvestmentsNarrativeDetails", "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails", "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionMaturitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockCommonShares": { "auth_ref": [ "r474" ], "lang": { "en-us": { "role": { "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common, Shares", "terseLabel": "Shares repurchased (in shares)" } } }, "localname": "TreasuryStockCommonShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r78", "r474" ], "lang": { "en-us": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury Shares" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r78", "r474" ], "lang": { "en-us": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock, Shares", "terseLabel": "Treasury stock, shares (in shares)" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r78", "r474", "r477" ], "calculation": { "http://www.cvshealth.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedTerseLabel": "Treasury stock, at cost: 422 and 423 shares at December\u00a031, 2021 and 2020" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r183", "r184", "r185", "r186", "r196", "r277", "r278", "r310", "r311", "r312", "r313", "r314", "r315", "r399", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r677", "r678", "r679", "r680", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r823", "r865", "r866", "r867", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r1116", "r1117", "r1118", "r1119", "r1120" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards.", "label": "Accounting Standards Update [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofShareholdersEquityParentheticals" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfCostGoodOrServiceExtensibleList": { "auth_ref": [ "r494" ], "lang": { "en-us": { "role": { "documentation": "Indicates type of cost from product sold and service rendered.", "label": "Cost, Product and Service [Extensible Enumeration]", "terseLabel": "Cost, Product and Service [Extensible List]" } } }, "localname": "TypeOfCostGoodOrServiceExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "auth_ref": [ "r172", "r532", "r897" ], "lang": { "en-us": { "role": { "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).", "label": "US Government Agencies Debt Securities [Member]", "terseLabel": "U.S. government securities" } } }, "localname": "USGovernmentAgenciesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails", "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails", "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USStatesAndPoliticalSubdivisionsMember": { "auth_ref": [ "r532", "r1016" ], "lang": { "en-us": { "role": { "documentation": "Bonds or similar securities issued by state, city, or local US governments or the agencies operated by state, city, or local governments. Debt securities issued by state governments may include bond issuances of US state authorities including, for example, but not limited to, housing authorities, dormitory authorities, and general obligations while debt securities issued by political subdivisions of US states would include, for example, debt issuances by county, borough, city, or municipal governments.", "label": "US States and Political Subdivisions Debt Securities [Member]", "terseLabel": "States, municipalities and political subdivisions", "verboseLabel": "States, municipalities and political subdivisions" } } }, "localname": "USStatesAndPoliticalSubdivisionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/FairValueChangesinLevel3FinancialAssetsDetails", "http://www.cvshealth.com/role/FairValueFairValueMeasurementsDetails", "http://www.cvshealth.com/role/InvestmentsDebtSecuritiesDetails", "http://www.cvshealth.com/role/InvestmentsUnrealizedLossPositionDetails", "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasuryAndGovernmentMember": { "auth_ref": [ "r532", "r897", "r1016" ], "lang": { "en-us": { "role": { "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).", "label": "US Treasury and Government [Member]", "terseLabel": "U.S. government securities" } } }, "localname": "USTreasuryAndGovernmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/PensionPlansandOtherPostretirementBenefitsFairValueofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy": { "auth_ref": [ "r962", "r968" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for estimating the ultimate cost of settling insurance claims relating to insured events that have occurred on or before a particular date (ordinarily, the statement of financial position date). The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claims adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims.", "label": "Unpaid Policy Claims and Claims Adjustment Expense, Policy [Policy Text Block]", "terseLabel": "Other Insurance Liabilities" } } }, "localname": "UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r648", "r657" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r658" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions", "negatedTerseLabel": "Reductions for tax positions of prior years" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": { "auth_ref": [ "r660" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities", "negatedTerseLabel": "Settlements" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "auth_ref": [ "r656" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "terseLabel": "Income tax penalties and interest accrued" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": { "auth_ref": [ "r656" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense", "terseLabel": "Income tax penalties and interest expense" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r659" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "terseLabel": "Additions based on tax positions related to the current year" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r658" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions", "terseLabel": "Additions based on tax positions related to prior years" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": { "auth_ref": [ "r661" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.", "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations", "negatedTerseLabel": "Expiration of statutes of limitation" } } }, "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "auth_ref": [ "r662" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.", "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "terseLabel": "Unrecognized tax benefits that would impact effective tax rate" } } }, "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r213", "r214", "r215", "r216", "r222", "r223", "r224" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableInterestEntityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Variable Interest Entity [Line Items]", "terseLabel": "Variable Interest Entity [Line Items]" } } }, "localname": "VariableInterestEntityLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesVariableInterestEntitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Variable Interest Entities (VIE) in which the entity does not have a controlling financial interest (as defined) and of which it is therefore not the primary beneficiary. VIEs of which the entity is not the primary beneficiary because it does not have the power to direct the activities of the VIE that most significantly impact the VIE's economic performance and for which it does not have the obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE are not included in the consolidated financial statements of the entity.", "label": "Variable Interest Entity, Not Primary Beneficiary [Member]", "terseLabel": "Variable Interest Entity, Not Primary Beneficiary" } } }, "localname": "VariableInterestEntityNotPrimaryBeneficiaryMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesVariableInterestEntitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_VariableInterestEntityOwnershipPercentage": { "auth_ref": [ "r719" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly).", "label": "Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage", "terseLabel": "VIE, ownership percentage" } } }, "localname": "VariableInterestEntityOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/SignificantAccountingPoliciesNarrativeDetails", "http://www.cvshealth.com/role/SignificantAccountingPoliciesVariableInterestEntitiesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r810", "r819" ], "calculation": { "http://www.cvshealth.com/role/LeasesSummaryoftheComponentsofNetLeaseCostDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "terseLabel": "Variable lease costs" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/LeasesSummaryoftheComponentsofNetLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r204" ], "calculation": { "http://www.cvshealth.com/role/EarningsPerShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Weighted Average Number Diluted Shares Outstanding Adjustment", "terseLabel": "Effect of dilutive securities (in shares)" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/EarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r198", "r204" ], "calculation": { "http://www.cvshealth.com/role/EarningsPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average diluted shares outstanding (in shares)", "totalLabel": "Weighted average shares, diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations", "http://www.cvshealth.com/role/EarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r197", "r204" ], "calculation": { "http://www.cvshealth.com/role/EarningsPerShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average basic shares outstanding (in shares)", "verboseLabel": "Weighted average shares, basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/ConsolidatedStatementsofOperations", "http://www.cvshealth.com/role/EarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WriteOffOfDeferredDebtIssuanceCost": { "auth_ref": [ "r126" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt.", "label": "Write off of Deferred Debt Issuance Cost", "terseLabel": "Write off of deferred debt issuance cost" } } }, "localname": "WriteOffOfDeferredDebtIssuanceCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cvshealth.com/role/BorrowingsandCreditArrangementsLongTermBorrowingsDetails" ], "xbrltype": "monetaryItemType" } }, "unitCount": 15 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "3B", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r1000": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6486098&loc=d3e24746-158529" }, "r1001": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6486098&loc=d3e24790-158529" }, "r1002": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "505", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=82848697&loc=d3e24938-158530" }, "r1003": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "55", "SubTopic": "505", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=82848697&loc=d3e24959-158530" }, "r1004": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "605", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=84167274&loc=d3e27175-158546" }, "r1005": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "605", "Subparagraph": "(a)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6486672&loc=d3e27261-158547" }, "r1006": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "605", "Subparagraph": "(b)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6486672&loc=d3e27261-158547" }, "r1007": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "605", "Subparagraph": "(b)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6486672&loc=d3e27261-158547" }, "r1008": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "605", "Subparagraph": "(b)(3)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6486672&loc=d3e27261-158547" }, "r1009": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "605", "Subparagraph": "(c)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6486672&loc=d3e27261-158547" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r1010": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "605", "Subparagraph": "(c)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6486672&loc=d3e27261-158547" }, "r1011": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "605", "Subparagraph": "(c)(3)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6486672&loc=d3e27261-158547" }, "r1012": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "605", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6486672&loc=d3e27261-158547" }, "r1013": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "605", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99379264&loc=d3e27758-158548" }, "r1014": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "605", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99379264&loc=d3e27830-158548" }, "r1015": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "80", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6484091&loc=d3e19268-158472" }, "r1016": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473" }, "r1017": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=SL117422267-158473" }, "r1018": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=SL117422267-158473" }, "r1019": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124505678&loc=SL117422397-158474" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r1020": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124505678&loc=SL117422401-158474" }, "r1021": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506110&loc=d3e32546-158582" }, "r1022": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=123600598&loc=SL75763979-209797" }, "r1023": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r1024": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r1025": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "944", "URI": "http://asc.fasb.org/topic&trid=2303980" }, "r1026": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12.6(c))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611133-123010" }, "r1027": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r1028": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r1029": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r1030": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r1031": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r1032": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r1033": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r1034": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r1035": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r1036": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Footnote 11(c)))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r1037": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r1038": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r1039": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r1040": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r1041": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r1042": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r1043": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "http://asc.fasb.org/subtopic&trid=2324412" }, "r1044": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Column G))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r1045": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r1046": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 6))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r1047": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29)", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r1048": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL6242262-115580" }, "r1049": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r1050": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413209&loc=SL6242269-115581" }, "r1051": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594" }, "r1052": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "405", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491204&loc=d3e4879-115612" }, "r1053": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r1054": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "720", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=49178521&loc=d3e9162-115647" }, "r1055": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r1056": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r1057": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r1058": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r1059": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r1060": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r1061": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r1062": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r1063": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r1064": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r1065": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r1066": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r1067": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r1068": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r1069": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "980", "URI": "http://asc.fasb.org/extlink&oid=6499975&loc=d3e44250-110382" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r1070": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "980", "URI": "http://asc.fasb.org/extlink&oid=6499975&loc=d3e44264-110382" }, "r1071": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "715", "Topic": "980", "URI": "http://asc.fasb.org/extlink&oid=6501251&loc=d3e52485-110419" }, "r1072": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1073": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r1074": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r1075": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r1076": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r1077": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r1078": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r1079": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r1080": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r1081": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r1082": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r1083": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r1084": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r1085": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r1086": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r1087": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1403" }, "r1088": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r1089": { "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "11", "Subsection": "03" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r1090": { "Footnote": "2", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r1091": { "Footnote": "4", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r1092": { "Footnote": "4", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "29" }, "r1093": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column B", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r1094": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column C", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r1095": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column D", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r1096": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column E", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r1097": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column F", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r1098": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column G", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r1099": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column H", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r1100": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column I", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r1101": { "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "17" }, "r1102": { "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "29" }, "r1103": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(i)", "Subsection": "01" }, "r1104": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(i)", "Subsection": "02" }, "r1105": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(ii)", "Subsection": "01" }, "r1106": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iii)", "Subsection": "01" }, "r1107": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iii)(A)", "Subsection": "01" }, "r1108": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iii)(A)", "Subsection": "02" }, "r1109": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iii)(B)", "Subsection": "01" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581" }, "r1110": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iii)(B)", "Subsection": "02" }, "r1111": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iii)(C)", "Subsection": "02" }, "r1112": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iv)", "Subsection": "01" }, "r1113": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iv)", "Subsection": "02" }, "r1114": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(m)", "Publisher": "SEC", "Section": "4", "Subparagraph": "(1)(iii)", "Subsection": "08" }, "r1115": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r1116": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848" }, "r1117": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848" }, "r1118": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848" }, "r1119": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(13))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868656-224227" }, "r1120": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(14))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(22))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.13)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r128": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "http://asc.fasb.org/topic&trid=2134417" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3337-108585" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "21D", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=SL94080555-108585" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(n))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(b))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r178": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r210": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8475-108599" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r267": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=26872618&loc=d3e7436-122677" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953659-111524" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562" }, "r28": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/subtopic&trid=2122178" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "8A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=SL6284422-111562" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL6283291-111563" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aaa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27337-111563" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563" }, "r302": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL82887624-210437" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(d)(2)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124267575&loc=SL82921835-210448" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124267575&loc=SL82921842-210448" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "79", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124267575&loc=SL82922352-210448" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(i)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r342": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r369": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(27)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r381": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=6397426&loc=d3e17499-108355" }, "r391": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(4)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12069-110248" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12069-110248" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S65", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23309-112656" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r478": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130533-203044" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r501": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r502": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "705", "URI": "http://asc.fasb.org/topic&trid=2122478" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=d3e1731-114919" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(10)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(8)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(9)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(8)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(o)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(p)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=6412939&loc=d3e15145-114933" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=66047640&loc=d3e39622-114963" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39716-114964" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=d3e29149-114947" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450678-114947" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r600": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r645": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(b)", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109227538&loc=d3e44648-109337" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r693": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5227-128473" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473" }, "r698": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r700": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4613673-111683" }, "r702": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r703": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683" }, "r704": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r705": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r706": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r707": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r708": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r709": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r710": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r711": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684" }, "r712": { "Name": "Accounting Standards Codification", "Paragraph": "2AA", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "a", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6759068-111685" }, "r713": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r714": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r715": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r716": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685" }, "r717": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685" }, "r718": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685" }, "r719": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22 (b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r720": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685" }, "r721": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5747-111685" }, "r722": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6228884-111685" }, "r723": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r724": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r725": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r726": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959" }, "r727": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r728": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r729": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r730": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r731": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r732": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5708775-113959" }, "r733": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959" }, "r734": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994" }, "r735": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008" }, "r736": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r737": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r738": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r739": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r740": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r741": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r742": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r743": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r744": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r745": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r746": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r747": { "Name": "Accounting Standards Codification", "Paragraph": "54B", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=122636397&loc=SL7495116-110257" }, "r748": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r749": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r750": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r751": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r752": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r753": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r754": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r755": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r756": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r757": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r758": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r759": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r760": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r761": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r762": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258" }, "r763": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258" }, "r764": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740" }, "r765": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610" }, "r766": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611" }, "r767": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611" }, "r768": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611" }, "r769": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r770": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r771": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r772": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r773": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r774": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r775": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r776": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r777": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r778": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r779": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r780": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r781": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r782": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r783": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r784": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r785": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r786": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r787": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r788": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r789": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r790": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "http://asc.fasb.org/topic&trid=2175825" }, "r791": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r792": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r793": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r794": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r795": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r796": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r797": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123341672&loc=SL77916155-209984" }, "r798": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r799": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r800": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977" }, "r801": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r802": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r803": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r804": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r805": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980" }, "r806": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r807": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r808": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r809": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r810": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r811": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r812": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r813": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r814": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r815": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r816": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r817": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r818": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r819": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r820": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r821": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL77919396-209981" }, "r822": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123417830&loc=SL77919786-209982" }, "r823": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846" }, "r824": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r825": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764" }, "r826": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r827": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r828": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r829": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r830": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r831": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r832": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r833": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r834": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r835": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r836": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r837": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r838": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r839": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r840": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r841": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r842": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r843": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r844": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r845": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r846": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r847": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r848": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r849": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r850": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r851": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r852": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r853": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r854": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r855": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r856": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r857": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r858": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r859": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r860": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r861": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r862": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411" }, "r863": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r864": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r865": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r866": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r867": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r868": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r869": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r870": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "http://asc.fasb.org/subtopic&trid=2176304" }, "r871": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r872": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r873": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r874": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r875": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r876": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r877": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r878": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r879": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r880": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r881": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r882": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r883": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.13(3)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r884": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r885": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r886": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(c))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r887": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r888": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(20))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r889": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r890": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r891": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(24))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r892": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r893": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r894": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r895": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123398031&loc=SL120154370-112784" }, "r896": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r897": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803" }, "r898": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(a)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803" }, "r899": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r900": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(c)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803" }, "r901": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(d)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803" }, "r902": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803" }, "r903": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/subtopic&trid=2209399" }, "r904": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r905": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817" }, "r906": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6479118&loc=d3e64650-112822" }, "r907": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r908": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99397103&loc=d3e6811-158387" }, "r909": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99397103&loc=d3e6816-158387" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r910": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99397103&loc=d3e6824-158387" }, "r911": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504833&loc=d3e7104-158389" }, "r912": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(13)(a)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r913": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(13)(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r914": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r915": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r916": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(b))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r917": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r918": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r919": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(11))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r920": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r921": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r922": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r923": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r924": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r925": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(c))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r926": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r927": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r928": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(7))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r929": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r930": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r931": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),5)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r932": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(c))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r933": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(h))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r934": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.14)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r935": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.23(c))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r936": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r937": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(11))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r938": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r939": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r940": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r941": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r942": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(20))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r943": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r944": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r945": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(b))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r946": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r947": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r948": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r949": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.3(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r950": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.5)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r951": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column B))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120401096&loc=d3e574992-122915" }, "r952": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column C))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120401096&loc=d3e574992-122915" }, "r953": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column D))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120401096&loc=d3e574992-122915" }, "r954": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column E))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120401096&loc=d3e574992-122915" }, "r955": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120401096&loc=d3e574992-122915" }, "r956": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=35755530&loc=d3e11264-158415" }, "r957": { "Name": "Accounting Standards Codification", "Paragraph": "2B", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124505477&loc=SL117422543-158416" }, "r958": { "Name": "Accounting Standards Codification", "Paragraph": "2B", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124505477&loc=SL117422543-158416" }, "r959": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504731&loc=d3e11522-158419" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i-k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r960": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99404803&loc=d3e21409-158489" }, "r961": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99404803&loc=d3e21412-158489" }, "r962": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14754-158437" }, "r963": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437" }, "r964": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437" }, "r965": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437" }, "r966": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(cc)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437" }, "r967": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437" }, "r968": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14784-158437" }, "r969": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671311-158438" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r970": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671311-158438" }, "r971": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671311-158438" }, "r972": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671315-158438" }, "r973": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671317-158438" }, "r974": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671321-158438" }, "r975": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r976": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=d3e14931-158439" }, "r977": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=d3e14931-158439" }, "r978": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r979": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r980": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r981": { "Name": "Accounting Standards Codification", "Paragraph": "29E", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819541-158441" }, "r982": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r983": { "Name": "Accounting Standards Codification", "Paragraph": "9C", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=122147696&loc=SL65671395-207642" }, "r984": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r985": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r986": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r987": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r988": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r989": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r990": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r991": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r992": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r993": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r994": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r995": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r996": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6483535&loc=d3e16392-158451" }, "r997": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6486098&loc=d3e24708-158529" }, "r998": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6486098&loc=d3e24708-158529" }, "r999": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6486098&loc=d3e24708-158529" } }, "version": "2.1" } ZIP 145 0000064803-22-000008-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000064803-22-000008-xbrl.zip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

    Q7X50(&E./E'%@7"49D9.&(\L<]\H3KYA:VQ2W!IX5]BKZ14BY-'>G".B* M!'2I9U3D\V;R.1_B4<0H'S4(9& @G[FIF#<8!4><)AZ62(#SH_FM/9\BH$]? M0(M@_KI@SI\Q2<4Y9TD@SP4%JYTI9!AA2&),4B3*4P>":?!B/](BF$]&,)-E MEAJEK;"66Y5TY$+0D&ATF-L@;G=T4B3T9A(ZKSJ=HX:0B#2CN> X@E7+=4+, M2ZI%TIC%3&-%99'0(J'%MKU[ 9T/[&-.N?><(^&U0MQ8@8RU$?E I9$2A^0S M^R&]=0I:$="G+Z E7GU7'NE\O#HFZ7F(#!2IUX@+YQ&H68(2>"#$.ZNMQVN; M9!USU2+!?0ZU2[L5KU=WEH7G%X+22U[\Z<$.I58'ZX,TX%('8ZR)S#COJ8_6 M:L]*4/K>(.;=0E Z!S8\$PFE2!WB&@=DA3'(.(E5-,19XY;R0/[::5B+#O2+ M@*Y:0$NZSET+[YS;S:2@R;F$=)($S(,DD:9!(2FM#,K$((7.YH$I\EODM]CU M#R:W\P'MZ)QGQ%HDH\*@=,&V=]P0I)2F!B=80X)S,C'LL"*W3U=N.1.<2BF# MQ))CQ2TXXYI3PCFW3$BVNFJ NEG6:1P.BNS>5'9/Y@UF+HU*'$7M*.+18V0B M <4K+8W1$4:X7]NL:)KI;T5ZB_06J_F!)7@^%AX$&$B)6T1<$(C;9)"3-B%/ M/'?!6IF\R%:S4+<.JA7Y??KR6^3VKKS=^6BXQDDH02-R..4:/(>1-8&!X+(4 ME*4.1]P^P5U1?G;U;+6A1,L#XPMLWC<]@6@2YAN2;09O'@:33 HV'?NSK;19 M_00]'3 'Y!;>>!5DX"1%DRASV!"?&X23P L+6#M0_>/" 8200@9"#))1![#& M-$&61(P2ISS@W#Q5A,P"1LBJCCA7)S\/G-E0D+0@:6N1M+BU=PVD)_-,/"'W MSV:(, S6,78.:4,ETMR)8 D1Q*>*B0?3Q2%@2](P2=/Y;C MFEE*HD6*$XPX)0HY&2+*V>LR.2,YR52-Z-): Z7S!4%!DN0E1DV*0%20N2/A8D+0AZ5W'1^;0!$XR*P48$X FVJ'48.6PP!@6LVRKS\(=;0>&@"[^>?JEC<[>81S%"U!DA_EWWYN$F#&J M&M%X/C\JCZEGAP>QXRU\_SCV\TA'G='D^'@PK)Z1GQI_' .@QKZ/:%B]X?%P M$"9^/-KH;/7&AX/)P6&^_Y(1] ?CCO4>U%3^6FZM:$>=#Q%> ^[3V:JOP$=' MHS@>5>!Z4GVO%P]LKW?2&<6#(?R8OYR%;'K+T<1]@7G/\^)[MGLT@F]:>-*P M"V,83,;YO6: NLJ(5[^-.FXR M ?C:J;#?KY ?6;=M)D/(&;'X,R]"<=%_LQ M=?/\.-!O5>_H4:=J'ET_:/G:;70NZK&\;_*U;G]2W>*Z:J]%%Z<:N%&3/&< M'@]&W:J;=K7?8>__-NT]7YFS,]]J;!!\_A7KP-R8C"__RD*KU/NWRBM3@% ] MMY@S_QX.I\,YM@<1N6&T7Y%-,-H7MO?=GHS6_G7AI8ZZ?30[@_,O?_D2U/_. M[:,:KHW4/'(E"+&.4PUJP]-(,&7):44%K74.?">&K:P!*$],)>$#=9(;KG2@ MQ$KBG8!ORZ#6[M;PJNYXK<;M]*P_ZX>S_JPWV+47+,TY>RM9GK2,, TM*0R-W:O]5MK M&_BOSTZO^M/=/;]O#0LF,8FPC0X,JLSWXS"#G2,,-PHN:K[6B6!]'&>!'X*= M\H V_\\; 7?L3]V"SO<(R@-46QKT>H/OHQ=+]FOE#YTC8^6#P4OV[/$HOIC^ M\%OHCHY[]N1%MU\-M?K2;T>@H@%"&CC-"#+G?U6H65\^!Y<-7 -,D__=/+FY MO%%=FO,IZVN";BA,+KV,-RY<6Q(LF[X#B&%LS2>O_?H$)HY<^_5O<(UI_DO? M+(-]L,%>[[8_J;)H!;60N;D>!O2HQPH.XV!861XO*ALX?VIM\VU_Z@==SC_4 MF^%@-*K, M\(]]\(-Z><=5O[ZQW6LAP[.;F'_#W^-SGID;M61-?8Z+]>=+ZJ0;9KBRT_4UY^W0)LR8V7&[@V"K^ I(72#MITLY./&AXW.P0"&U,_GU3/( M_%B!^28K]=2R1I>]XI/)^PR,$DUULA0G+B-U!GO.O0K.DJ@D^5F>F/\V^LG! MY5FP,,?B=N+X:6<.-6FAWW>^;,,XWIU\W@O=3_0=_OSF<_?3T6NVL[=%=M^\ MQ3M[,/Z];;Z]D!:Z1;=/#_C.JS][._3/+Y]?O?_Z^>C/[J<]3[9??>2?OKPC MVT=_',)G3I/!!4H915'E5N<.?C):!02_,4F4E$GEED7KC)L6D4FMR.4I M*%50ZLJLQGELFD,N[R='DRK1KHJPG@=7<\#Y]PBX%??LCX)1-\6HN2I*B;V( M+'B4!":(!VR12Y8@%W+?'D(\4WQM4SU!DN@"4(\)H/[QB! JG_P4A/I5A)HO M3V2<4R&I1$Q@C+AD&%G) *L<"=Q)JYAS:YML :#^6;"I1?+[E+&I!=!T#DL7 M0:HX>*N$IH6Z/P*+ADD@B*E@<]V?0X8IB0)/+C$J*+&Y='J=DUNWI6TI7?!C M" %^&(.2'JUWCD PJ$*0:9ZXU"=UOW=&32'1[]GU(78PR8:>] ME;E+--4&8R'E2HYV)/P>HDDN!(!:TSG:Q&FB6!>&+)8,N) ML&IMDW!=1/J1B?1-HC4/+=,E6G,;F9Z/UG@9,=&6H21Y DG.S7ZY$,@Z&H6B M5%L%BGJQV/[ZT9HBS,]//Y?PQGW(\D)X0W+I2* )L:@QXDP99 QVR 1K%%5& MQ2S,;!T;TB(5_2PSG/Q@>#RHV#8>?X+3M?#T6320\YH[GJCST7JPCY6S*C,R M"N&MY9'Y$L9H,Z(NTK\S[QCGT:#(#/@Y)# U."1XLIPJ0-@JE[;- "HB^=9 MC_[ O8CUJL2ZA#$>5*CG4VBB2)IZCH@Q"JPDKY#1F"*E+9=&2PQKN;8I]:V9 M'XM(MSB,\= R7<(8MY'I^3"&BXX)BQD"5S8A3EE$FEB/O!%!,HTUEWYMDR^F MQ3WFK),G+LTM$.82Q[@/85Z(8W!JN8].(Q5Y! V- S*4)N2,L28Z)Z6-V>Q6 M[-9MZTJ:QB_+)\@(_-I_+@&,9Q$05LPS0[%@FA"NJ34:M*K$D2OX3\"EI*G5 M4/II(8"A. :$$PF1(%S.PR#(1"(1"\90@:D27.<\#$W;%!$NYSPM$^L2P'A0 MH9[/PQ!!8ZX$8CPJQ*.0R$B#X2<9-:>$44S6-HFY=0YK$>D6!S >6J9+ .,V M,CT?P-#)4>.915HQAKBP$FF/*>)>"*%=<"#PH*A+(L8CDN86"',)8-R',"\$ M,"(CD0>G4=2T2L2@R)H8D6!!P-+ZK,"K].?;GQN61(Q?EL_W<=0-L3_NVEXG M>Z4'5=<(>,L8GDM0XUE$AVW"(C<_\$DF'BBXOEICIC!/@KG(Y5T$-0J"W@!! M_4+2T"(H09A>V]1/D>>@R.VJY+9$+1Y4I.>B M%D9F@A*ED521(QY(0,X1B92DU L>F=%T;9.TZ42G2/2J@Q8/+=(E:'$;D5[H M1$X$>#HR(%@PAK@U"FGJ$U*"8:\HMD[D0&3)NGA$TMP"8;X\:%'D]4;RNA"7 MT,Y;(\&8#MC)7.VED$DDH928EYX(9;C)9G6;E/!S2ZMX.3@ZBD/_C(,2SR+B MZV3@P8>HB>%+#)>I("Q<0S%X +B/ JE,<7L2XQBW8*]5S,@G(P8[DAR&#/ M1#LGHO+%4]DBT>V6Z!L17CRP2)>8Q6U$>CYF897C/$2!F \<<4DLTH$H%"D/ MS 8'(I]C%HO%7R71HK72W )A+HD6]R',BY4BW >%A4"1,Y!F2@.R6GJD@I J M8@YZ.Q\JK+,E011S8$"X5=D(+#<8RILXD M:9)7W%G*;"RL%ZU&U:\+H0PI!+'4.V2TD6 BZ03^3W*($FJ),#HFZG+VFKH] MC5 YWGFZ8EU"&0\JU'.AC)A[+T0=D%.&(:X-A9]REP:N!"RQC=94Y)U%HA^9 M1-\DE/'0(EU"&;<1Z?E0AC)*L,RO+7DPB.-DD".6P:^,!F.=B$F"2#^M5BM/ M7)I;(,PEE'$?PKS8F\0:$;3E*-H8$(\&I%D;C4(2#&O#HU.-U=TF8JKGEIWQ M/H88C[*T=(Z',<7A\/D$,YY%@-@22H0DEGLCN231)8*=8BJ&@$T*NA2+/#!T MOO[^[[V/%Z&341Z$<@8EE^NLMG*P\W3EMD0K M'E:D_461SG5>))F C,HQ2$4%LA&L(<*DI;"PFB:SK(MDD>@BT7<3K)AU?E+W M!]CHIW$X*))^8TG_.B?IC KG"$$)2XVXY1HY0BTRQD8EJ1Y'W4D[R8*+[NHX_@OCN[GTZW7FW3Y1BD4N+,!8$<2X98&Q[("EN/!.@Z$RG?*4CDAOB&D/Z[7@PZN;5 M?S&,H'"[W^)OX\'Q"\2J;\_/GQW%?(.US7_0\WAU-9DM"YG\]),_VUEN, QQ MB/)U"!=)VH51VN7T]F'OB@ M[I=?XKD#7\&^>XK1%5A<)2S.!?"XDUA;Y9$2/ ?PO$6.68RXU\%:YH3"/&=F M$[6JX\QK"U0!Q@*,+4O,>FAD+(E9MP._N9@F+)IC+D8D50+(H]$@0Q7-398Q M-H8'JW FQEEDZ+YQ:E9!O8)Z;7KQ%H!>26"[']!;B ;G) SO-,M%7C*GL'ED ML.!(@#FG@PC*, &N,%NG2SJQM=3H:\+%TX%,][JHP&W59T M#V3>Y%UG%H;! MU(?!).?,70A27&,:5C&5OS#$,LI[&.5]'\3B+)RV$*P3UIX"7P6^'CE\ ME=/J^X&IA=-J[:)PL(:9TMT#4!F!K(9_L%;$*,*292D[@ER:%L'49])9'(JP2@6&CH@\\I*1*R*W56$L70FZ)*4^3)4@0P1%/1")GM$$4,T(C MU^#H5D@KQ&)"9"GP+G)=8E2MD.KY"@])1338(^&]0["@!AGA(](RB,0(-Y3X MM6ZA[@+V%M-H),8"DQ+M:#6F MLH5HATL1,T85T@"?B NID''2HI!P8,E@EYQ:VU3K6K4IKESH^5LFUX7LHL4B M/Q<*\2P$SPQ'B@:*. 4CRA+PD9Q,DG!NN$LADUU@>FO&VB+R+:9Q>&B9+S0. MMQ/KN:B']-)X0C$BFAK$G8Y(:ZH1Q=&G8!,WQ*QM+OI%I;].:Z6Y!<)<0AWW M(\P+H8YH2.#**IA3!^(L&4:.1H) CG-2&B>.@&&NU[5I4Q>\YY;P 5("O_:? M2XSC>42-(],Q<"HTX]P3JW6PU##AL&8BD5AB'*T&4[X0X^#1L&@,1DRRB+C1 M CF" U(:BUSQ9DI!V69R#"\AZ3Q$6 M,@R9'MB#F%DQOSZ?;L'/(D8LB&#: M6:HE"]PRX[Q4Q'L9(]&*>GX7@8V"H3?!4+$0NS"4,RX518$Q#091DB"9R2!M ME!$2-&/ >&U3JG)46P2W1"Y:*M-SD0NM2!""6H2E]@BD&\19!8%L;BKJP,D1 M,>7(11'I(M*E%.5QB?I\OV I'?$R(2NB0]PHA2S!')&HF+'$:\K%$^87*?)^ MU_)>^@6O3'07HA=4>NT5X8@JFILERHB,QQA%QK!GB45BW=JFPK<^-2P)&+\L M@B\'1T=QZ)]QZ.)91(:YC"102D&-)HZE-Y1AX16XPAQ;%4KHXJ$!].WWQ5ZS MF1:2<8TDU;E8+W)D8=V0M0EL(NJ8RZ4E1I:2^R*X)7314IF>"UV8%*W@7B&E M#4><6H\<=@09$Z+6W+A$]=JF+CD71:1+Z.*1B?H\BX:#==:1H&"H13QAC[3S M$7DAG&02'" 1"HM&D?<["%V4K(Q5RO5"7$,9F;0Q&JDD,.(Q4F2YRG:ZY(P* MZB,F50$H;Q/#W7/+RM@='\9AQXY&A.?P MXMA:Z4RI,FDUKOY8"'=(HIE+22*ODD:<)8Z6@ MIV5R70(>#RO59 M/+1,ER*3V\GT?-.7*!2-.*$8,^>5LA)9'T!Q>^JXYD8SCT%3%Z:,QR/-+1#F M$LZX'V%>#&=P*UPD"@G.&>)<)F2H%B@0XSD72B9:&=X+#)C MB$!PD!QIGJD @\/(,FT1)8X*F8A4A@)TWKJW<#G>>;IR6P(6#RO29T#<@&PA!$AL=J*7:!+>V61(TBD27!(U')NGS80R2(B,:_!Z2"3^E M\<+PD:1=Y_6=Y+;X.Q[8&DN/%,@*(SG?*5CDANB&L, MZ;?CP:B;5__%,(+"[7Z+OXT'QR\0J[X]/W]V%/,-UC;_0<\CUM5DMBQD\M-/ M_FQGN<$PQ"&J=\P+!OLZ#"8YPI179'HUSU3>\J-!KQOJ*\^@K?E*IN;):$AO MG/-,@0>D"+=&&*HCPX0PGK#5[D[*ATK4?V4*]'2Q26_DL)Z)(:HXV+Y$&U"D MCJ+$:/".4R&%7MLD9IV951W-KT*B'O@0\%:O>.5;%E2]Z005;"VM@]H/N_/! M1U="?_S MX%LRTVZ'KW,A7>PI-212)#/(\N XLBDHE.-Y3!$;)9. K[?A/RZX6G#U>>)J M"V"UY C>#ZPN$E$3)GA@"06MJ^9X#-F(';*2^N@3V*N9AXV2=:)OS43=&H2M M O;_&N?]-XT KSZF?HT(-OWE"/;^3?[G8JP;_IF^8S.7*&/U"Z*G -[M9]+K M%RC_9=60I*\Q)V#ID7_>R:G"=9[^VX59T1NRFH6]PSB,G>]VU+E)@;CF5'CC M59"!DQ1-HLQA0[P4EI&F0)S\'"U_$F'M]0;?;=_GWU\.8^B.L_'YT_0"_$A! M\_-_#[$_^JMO_S83 $!XWOO#;?C6SIO/7[9?O?NQ_>6KV/T;QK/W]"),\LT4&KMKD.>]$W\<1P]^8,=7"]+IP8H (@VCS]HL=&#?V.DR(O@"&L&:+)REVG'G M5?3QR,5AK5P96>]DD.C (_+6V7B$8$[;!N9O^]_B:'P$\](9=D=?1YE,8."[ MV8WO?.^.#SOCP]AY.3B"T9Y4:4+JMU&UP,-NA/5&P^J3Q\-!F/CQJ',0^W$( MN^$$#)E.?S#N=.&;?KST+H 6E3U3W6$ =P2=WS^ ;3*:],:CC7K1MR[;!>L+ M&Z8:KNTDVQUVOMG>)'8&J?,_-]%1(1IBL 9PLCPDH9G35&)&C&=W/BQH'M]D=MV1_E%&.EFV?G=&L_$=!LN3.84!XC+@CX M*&><0Q$\@$39"BT@1)>:"6+RO_O;!]+K-@\%WH+DND\MJ)Y"*7+AH:DL0* M!T]L9-25:-0];1^^\V5KGTF3 C4*20P*C$LPE)P'((J6"Z>-Y4EA@!^RR/)R M9[KKCO9'T5TKW3R[>P?[1*3$$Y@[,>$$NLO"YB%)($QS>TO0'33"YB%L,>_W M OH\HLUQLV*0Y^>[P[U>?=PG8"CPZ!VBBD3$'75(P[H@P[7S'*Z :;/47_^I M'?,]!_2Z?=^;9/>\V^^,EV4WKW?=!Z=R& ]C?]3] M5KW#X"C.!0::Z=B9',& ??U[WO[=_L36\8RSB/?F_^N&_]I7'JQ#>N M-L_!ZL5(]O=N&!].#YEFOM6$_O'Y5ZP#KW@ROOPK,P%^#WY['-[_65D5S"#4 MS$WTS+^'P_-@3&ZW %O@*[()1OO"]K[;D]':ORZ\U%&WCV9GYX4H'2JPDW@E.M0RJAD'X3@Q;&6] 8PMEN8E&! X6NO54 M$,&]4 PL/F//XI_-7II#T01Z7Q'T:@9N!FO1XX/LT]3^ KW?SAP?G8+P7< M(SL\ -3(9X2B"NA6IYCGP%J=G,+"]NSQ*+Z8_O#;M(ZDVZ^6I_K2;\V]&C1> MS2RWB#7'KMJML2O"&, M^*7;7GV-:7XW@]77NNU/BLI^M79LI?)OIN)?W?!%MG*Z_@(@J&5%6]580SX8 MJ=36BTD?-FU]KOVV/S7GKT-\<\4DU$;"/4_#%2^]UB1+G)7#5$H]U\3@6J;XKZ\<4U-L+/G.W__V?M$WYULOYS/&_WZ M8X=^9-NGG^'[OW_9V7O?V]T#%W3/GVR?_G7T^=4V^73TUY?/K]Y^_^_IVVDJ M_GA[[RO=!O=3*&HUT0(ER1SBW%BD%99(6!5]L)&()'*U$[U]!]#VT:L48"O M=HO3Q.VSV,(% ,NF<&4$%^1:*7*=7$2NH(1R3&9"**$1-XXB*XU$"7MAG0E! MD*I.DY);9[NWCV#FL1B7NXU)"08FO-7!82?E8X[\E\N# L^>O;LM9ME6/NZ M%=RKU^X/6+J,;Z-BH=T=SFTO6&A!\)0TCSF5!RPT@S728+$AR:7BD7&LE%W; ME.M&MJE'>Z'T;QDHW-2DN4SXBW5S-U(_9]TD1G @SB$ADT(<1Y4[DTH4<'#! MQ$BYTFN;:IWP6[<6;RGA_R.P;BH9F3%ISJR<<>S?PLAY%H2>;3%RJIR.C&X- MT.W%?C%R[ACNWBT8.3Y812T)R&I*$+=2(2>403: =Q=)9(ZEM4V^KMBM27?: M%X8JH/"@1LX2X2]&SMU(_9R18[VQ5B6!2/"Y9I=+Y#P32#&E0Z*4,JNRU!N" M6R3USRR$\V88;39SJB/"VQDVQ5%;B6%SM4%S9O9D;".X&#-W#&L?%XP9@DF4 MV%J4B[ 0-X(B:V,$W\U*3G'"!N,,:XRUR7B@)>#HZ,X]'=@@CP+!\J!WQ1\B!JT%9=!6\48QDP;IQB1,CZ("5*\J57A MF%^T3W2T@& )898RD2/3R(H4D?>!$"XX9516*7UJ502V)7#R!.7^+BR4(O8K M%/LY\R77N <3!7*"8<2-9,C@G.M&M*(T6Y:YR".B.9LM.&+!9*W%_M8'O27RB)%8N6-DH/F>Y33+D[P_2O MBP7QSC+%@T=28(4XTQ*92"D"+*>8J&AMT(#I=)VH1?;MQ]I%J?2I*P#[5 &V M,(,_*+S.FN4KRK8]_#PNJ1) MW3RI[_4H?.] 3"_E^UM. +H]/#H=@XD=6L#5_"IP+?XXAA7OCO-MNT?-SS.?:5[DX\:'C9FW^7E7HUO, M\*'-^ZECX6'Y;9KN6_\W@:TY/NDT[95@$;>VMNK^%)UZR?,V;+X3)LWKP\>N MXCIF@C$E?3!46>Z"-DH)YQ3H%:] M]B]@Y+FPXI&JE5]G07XK0.7L,X9MLHDA25Q$W+. 3&[FIY+45(/ZE[EW*=]0 M\\!95Z,LDNP^#)C^E#MYL8?8-3)$0#"^Q4Y-K7J29: '4E]Q]HTK!N7,"!R' M(_A.4W\\F-0=RSZ"597!>&S'<;31^0":J9M 2P$J'=GAUPC"[^!EOE6\P]W^ M\60\ZDRJ^PP:-N<%6ON&9;]BWH>_PP[/LIFE\7@X<-9U*UFM2*"3G?2N!Q@7 M'W&/," #N'O.:Q>EY5QQ+167R0;+ Q/$%1BXO_:.)SNGK_=UDE$R3E#4F0Q= M.8)L[F@<$X65\'%E$?PC M;AQLK'?L!$S/ 4ABK(%B?2I"8 Z$W,4R=BN)APN'V8:(_S?)@E6#2F4VG(-2 M]<=_KA8Z,C)-^A%LCL%)W;@1QK_>#D2Y+: 0YD028$6$2#-5CZ54"BA+&K'< MK/'*\^VMPG#;>ZO\K%?*7&\5DB38HM8D"Q)M@C2.8\6B#\IXJ4RX\]XJ'_QA M#)->W$T7&T_M]F>ZKCS[EBHPCGV926N]3,CRW(#,.1!Z; UX%"QE,K7@4II? M7L6"5K#ZB3O)85F="RI1'6+0F'O#VM."Y?F MT-?:'#O5!%0>^R!5_ZD]DB7GQK>!YPB'$1XX>>UB+&]R#&3ZN::?DL3*/VG6G OO27 M+8,L@RR#+(-LTR"? R/(JXN'S+_6Z?RZA +W?(_',/_+2V#*C#V6&2OW*/=X M=/=X9AU/JIJG@_,*KL+5.5^EV\S(R5RI;F"4:*J3I3AQ&:DSV'/N57"61"7) M\E+=MSM_S.GUT M5L6+'VF&9%W%>]S=?O/YX>/&OO\,OG/7C6WE]'.T?]E9[Z*]^CM]\]'KW]\VOOK<.=H6VQ_>2=@7(>[;W9Z^;UV_OY$/^_M M='?>;.-E[=H,-HJKY) G4B(N#$/.)8F$MH:%Z+#&] _B,/B5-U:X!>HD1C3+C)D.;.( M,VF15DP@:[SFCEH=/5G;;!4'>K%4BJ72?DME'KJ*:7)#I-J=,TVPUYXSGE#" MBB(>/4;&*H4<2TGZZ 3-2+4R K>"5 6IGB=2%9_JEM&@#%HU>,'GMLE^8()) MIG*DFDG$"7A6VAM +IU!&0J+*&4'",9. *<4X#TLP1L#9$B$:ZF&B.WNHG&+\MB%00:>6(5#RAVP*4 MOPA0-F)"+>:(RIS"$PT#;(H6Y?5EQDLKDUK;;)/!M*+T^L>2A5BS-J]WCD B M??2QF\4EZNPD$I@MX606^W MW5[RWU8N\'.Z72MK V8"$8U%5O "Z2@E$LY'KB)FU-G<6:!(_%.1^+:J]I(P M=DO17D@8PQXDV3@DC(C@EU.,-&$1>:HD%8ECESSH\B+:1;1+AM6CDO2%#"M# M#"$J<60<&.L\1(*TT0X1);5W0F,7V0HRK(JDMT72']9L+QE6=R77:XC^L6TN:;HSQT&*F_ MAB$4$SSJ3[8@^P ME0IQB2/2%!ND=**&":I \L&REZ*(_%,1^;8J]Y+LZ'T:9MLSU/Z<)$X3;DEGY:(IQ"0"9DXE3#FG,&)!KRVJ;@J MLEUDN^3Y/"91G\_S4<$8@8-&T0J!.#4&.:$ILB#')"@3&0EKF_36+DB1]+9( M>KL-]Y+GLW*)GU/N+D4"ZTL1<9(@#C\CAXU "G,N J%"!KVV*8IN?S(2WU;= M7M)\;BG:\VD^5D@J3"0H,I<) 03XY,(I)"4!Z58^!L[7-DTI)BZB7;)\'I6D M+V3YL(C!-N<4"9XL@L7UR.96U)J)8!0)WC+9KC+C(NF/V&POG#YW)==SB3R2 MXRAI\BAH91"W22-#4D*:>II)(3CQ%*QS7#A]GHQD/Y0.+YP^*Q+AN4P=P7CD MQGL4M6:("^F1$PDCRJW5W&*F#:AF??MD^R+"181+GLY=2/1V#1^/E3*G*$^>D,G5D3W*<9.PO*3P:%FU)]%"4'?G7 MWP8E^;%I)9)%25L4PT VMDU1ZAI^+QA*Q"A-T";G:BD65 M$+P7//.Q&IT(;=?NW$E">[6BW<%$SF54D%W('&3$"H']$4 4:*I4Q(:J'_7= M*,BO>BC?AO:NW1D;M@?;>UE9774VH"4RMI4*D(0P4$WRTEERRN6M;1[YCNV. M[:[=N4M0'VIW)%+A80T@72MH3LZ#+Q@@>XR%DA,NNG[2=X. /FZ_O4MWU@[X M88H>"E*TBN A%,7>NM40G+9@A*CLRH>2FW2G9][<',2/U;1WZ\]:*VM#RV5=Y3 MTD%R[<_@JR7227NSAG)<'>EC0?KMNNU=NG-=N!Y(=Z2P[(U+A*H"FW#G$D0> M3)!%YZ2CH]B2[,F>@6=SD'U;-KQ+=]8$X8%T1\KBH](9C$MLFK-G"+=RF4(9 M9]&3]Q2VMJWJ:VH=PEVZ,TI$#Z0[UIN8@U)0A5=LE(MBM]L6L#6%S&,<8]0C M6S*[9REVOI_M[],\7X-R9P.%AN=5]K4%2R[D94"T;,.PJ.C0'ZN/WVKMQ9.^"'&?5BMB$I RK[ MT#+J90B.W?AJT2F,F2J9K6U]Y:V!COBQ('ZLIKTK=ZX([:%R1QLM+-D MO # MEEC!!^G 9)-%P$S.*P[)97?;.[:[=.=.07VUME9A>">&N<.V_&9$@6!UA&"" M= M^:UMI:Y\:*XC>RS(OBT;WJ4[:X+PKZL;_2JW]-7)$D?8.8 708'-U@O;BB:9 MV-+:CBE)1X?P!D&X.]M71?1 NB-)ZU2S RM*V^L6",E)!'1&1QLQQ-!.NXTI MKKYG67>>+79I/HF'A[3HR78N&4($B=:)9+SQEN>V2J':P+,=4U0ZTKK*\ZY! MLM,+]ZZ+Y'YX_Z_ABH(,WI% S9.RK2AH&2&HRG]Z7:A:9-<%6^%>(?N!H(VA MA%7'Y=O8X/HE/;VD[SJQ/UAU"$T%T!)VB%HSH"<-J8H"PN0BC)8>O6XE?84> MDSRY8_]>8+^',U=%^[" =RJB\'0&5[0$%/S (4T&*B$IH=G24UE'.-.A/A:H MC]OS[Z*?]4-^L(*AD\RJ6@.8;&I%.A 29;;W0L:*,:,D=NY53^JQ,9 ?JW7O MJI\K8_O-('!WNB97>3*K& &-=Y \.^\^"N-19Z]$W-K6/6KOV.ZJGSL&]1_^ M/%NGX]_X\/3G/[R0.5I1(>6H S8(Z[?KNE]8]].7 MYM<*^P\#V%.6@D))(&QD_]V["HT)P'@RP;'U=TDN%^?UE8_J=.B/!?JW9>;/ M$P;U)?BU8EP.,%Z]5ZF8",D(-NTN!(BN9B#,VF=IA(\GB_"VF_>.\:X<&B>J M]0#5*5'U05:0U3*JK;'@JQ=@C$!$7[RC=BAG3$4P[EG:GU^H$.TW;$S>SJG2 M?-X3_EP\$"DA86XYZ7)RJ),-QF1E$OI0LL"TKK*_/>'/#7/9GY\$0LQCSW\X M_D,(PJJ-AQI$Y!A$6(BJ%M UY"H\:K%DLA&)(+NJ>!O>?[&1VT=[Z$ M=N4AJ]6VY065 $4KYV&D!^],S-I("L9RZ-&AW:%]R]J?S]<@ZO1/*O"!YK/. M )=F@%^_9(! .25O;:O@50"#(8@>'2CC6!3>&#< M3GT7!JT?]WE@^76@6DT"1?R D1CW.A)X$Y0#")5?-PZ;! M:^$ C1(03:H0DDA"Y6*53SV37X?P34E^NC.^+J3K =*#):^],9"I!."!3N S M:3!2^ZBJS;K:,3KC:\HE-&H1T//9(NXQN-)B38F#TFQ>: Z+V=M'[;X?SO:F M9=+ZL5%<=DZ@@9Y#S1RR*[:@K!2JTDD$=DI-U++@>$1!_=S"=2B&3D\F$D7K MC0Z03*TD;P M$B,W*KY<]?V^C2I[OJ6[18R#?$O>)&6:VL)[IP"C,A!,EB UZ1R"5E3>C%UK:_ MZC&]M,KZS6%&4J&0IH*QFYK-% P^J Y.^D3-?CQ37IF8\RZ5@E(ND48.VC@ -LV!RKH"74=?,_Q:G6G&T M^\2$/58<5ZS8,Z;=KC+RC"NTH(H)/1A=V[J251!$1@B&C PVJ8QF:QL?B!XR M=L>I.T[7Z#CU='(WJBL](T EJM'1:R!O F J 1(*"S(IXJ&VUMB\M>T>Z!XY M=@+L!'CC!-CCP[4);,\HKR1'U3H'2FOV^8@">.U:\>R8:O:QNA*WMJ585YF+ MZR6\4]GM62O.YKA9TMFZ-?@7N,9GO=7&[4FG@UX?_?CAY->,F'>S3P;I. M&M^#O7N**@8I9$Y4$'4((5HOI6\IZ2F+M%RG%6,X3]PW[B^SB"M7C@P;K3 ; M64!@%H#5M7)((8$LKE2MG;.A%3/=P-KD5X;YZ.CNTMM/F[G)]&WDU8LFC(ZJ MAH=XO=+.U !.H0=$+R'%XB"DI$/.1=?8BB:(*Z=NZES5N>I>80.LB 4MM]>UBAN!3;M6UGUX;OX2E6M+58'2.@:!ET M;6:?17H+WGDR*$JROO;ML.ZSW';?1N>S]'HEZZ*DX;G2BE8H'C:0H69 24Q) MR02P(M6<$!V:U+>].B?=>M_N""?U:.G:J&OE?*@J,IODP2V7LP5JB$%%\#H0 MAI!%7F.1\S72UYJTZG=%)OGO!8/A\,%DGQ&;IV^Y10U-DWA0)F]G[0]NY^3P M*)7IN^EABS2^23WYE7NTH6%AQA2%3D+;')&DBI)#3S.F0V9= 8Y7,0PHN)2O9C5L=;)F:]OW>NX=VUV>MR$4,)#GD8TF&.E M8V4*"#Y!2D6"4U9Q1!-U4GF,!20[#VRP6]_E>3?'!P-YGDO26R4L%*T+(++/ M'S(E=@EB(BM5EE5V/M@X/ABK7]#U;-<&_(&>C5*M9&T X;T%)*' HR6P122! M%ID3NB/0@7];P.\!P;6M]PT%8#IX0]8CR*H%M&4^"+(H*-;E4'2P*H?.!!O' M!+<;$G0!V+7A>R@ 2Y*L*K: M5D!.I> !Y6@)F5DD9@PI+ZBOTG0OBTCWQ53 MZ\+P4#&5+0HM*+![[C2@,1F"-A6J1FN%,2U-?U^Y[QCN"J,[!_6AP@B5==JK M"CX5#LQ5,A"KR"!RT-F67&J#^OC<\?N8B"W/YF]GO W_V M:C?4 RDMC"&O08F6G<&+"H%?@FJ"D-40SX3U28([$XR%"6[7Z>]ZH&O#]U / MI#49##I CK8"QHP0L11^%K3D,!]#2_@FT75L;PJV;\O*=T'0ND \% 1Y*XCM M,P(:20Q=%)"R]\#3&87+KKIL^_I[!_'-*8(ZIB^+Z:'RQXO,+K5',.QF UHI M(&H.;$A4_J^,Q58QKG7V>Y95B '!?QY<5>RS@6K%\PX3D/944!FO$;.,WI>H M@C9)>&VJI"[VN9OLA2MBG\RF1R2G(;G8] "4P1M?(,B$7OG&.&IK&^6(!(M= MH+QN@?(WH;UK?4:'[6':( H^>VIK!$3GIKV_8#1!W; M7>ISQZ ^D/I8E1,F(K!)%D"5&>K%"RA%>UDP.>G3UG:WXAN#]'$[[EWJLW[$ M#Z0^*61CM6.P9VT!G3 0,S^PS8]5%6-$*5O;5UY&[(@?"^+':MM7I3[=F%\2 MV@-)CU;.R! #*&KKB:$$B%(&0(F2C/(^F=JAW:'=Q3P;PP K8IZFU,W"12"M M$V#%!-$$#RY:G[4J9(H8XVGBS@1WV*WO8IYKP_=0S.-TL-Y$":&T@-VC!&]S MVS.,)BIT46);=[<=VIL"[=LR\EW+LRX,KR3WT1R#QQ@;:!N&A06O",$J'Y(3 M6:DHM[8==@QW#'R^>BX8211OL4E;>Z8-0A9>MDSI9( M>J6"#W?HN_ED_ M[H?B'V>QU?SCR+<@XQXC>.4,Z%"D"-5+8=/6=O?J-P;Q8[7\/<_/M4%^( JR M0?+($J,]I!WE__:5O2&TB"IK146VV$> M&0%C(X'J*B"Y5$E9FU-G@LUC@MMU^KLTZ-KP/90&*4*I@JE IJ06U'M(ON7V M&A](@:643#!A0I@7H(B&-E#G>$ZL@99D44I%0Q6%S:&EG,TN1?XKNM)U0W>3UGYZOYH62+/Q MJB%"-:H"&LP02"3F..N+3]DXV;0%5ZXDT*7-8X'\JO_R;6CONJ'187N@&PHZ M4PD:.2)IV8.]]^!U"2!B8L^4759LQXM=/U\\&FR'^P'M'K1<%P,,9$-:NH@V MJR86:O(!%R E5\';4$V)/BJ7^N'BT=' 9GOU%Y -_0T?=&__HGPPD!.ABEI& M3U!L2TIN98 8DP&A"NH@@Y7%=C[8.#X8JU_01477!OR!J*B5#9$Q)_!5!,"$ M_,RB!U&2UASI1ZS=$1@?\#T&!%U2=&WP'DJ*R%9*J4C(2;5*X);A+:R&;$-L)0,Q-O%P M7\[?&&3?EHGOBJ)U07BH* I(7L62H6K#,3I)=M6+5!"4<:(ZG6W!OFK?(=P% M17<-Z2OEQ!"3*R3!:8/-6$L(+FLH.6G,)6:?\AA]\7N6B>C98I?FDWAX2(N> M@.B2$88V!J-VP3JT*+$FA\5DY-Z+&&T*74AT-^GLSQ4A41)$1E GUN2$L]! M1S2IM$ D%!0\[+$5+39=";TQF%]U7+X-[EU)-#IP#Y1$WI%+LE9P47!,$K*' M)%NI,1="\E2\L6IK6W5P=W#?NI:H8_V26!]HAI*A5)RM("7;<"Q10;2E0#'6 M6FUJR@;7D!FU(WTL2!^WZ]Z3#*T?\0-5D//":&<( AD)6&N"J(6 4!H7J(RN MVJUMO'+YT [YL4!^K,:]EQB[,K8'PA_R'IUB,,=06V8!&R $1GGFL4TR64UJ M+66_.[8[MJ\H^NE0O^P*W(JXQXJH-#OLR4C;T@0%2)82R,3_-&F/-;:[[AN$ M]=MUW;NNY]J0/=3UY$@.T7O0PC&RI6=D"^+(/"(Z::+*L6QM*W%E54#']EBP M?5MVO"M[U@7BE5Q!.5$IN8*0OJ4-4:F%V!$8PB0HY"($,8B#ZR#N(.YUQ$:) MZ:&&1Z.L5J@(ILH,&+T#GX*#+$E7EQ6IMEI^9;WMS:4#*M/#MWOQN#66_IH$ M^B?[)^_:)]>4"VO4>K7GLT7<8]N1%FM*>)5F\T)S..G4(\V\4V9';&LFK2]G M[RYF;Q\U2CJ<[4W+R3N;9,C/J]<=4LILS7UQ$F,P07G20DJ-;,Y]ZHFR[JBI M_["B;Z/B3%56@O.* +5I1;B(/?@D4HC\-/C:ZGC[-0EUUP&Z6];SWQJOC(Z2 M_^,V1O\2HSXJJOU*[>5O8MDN*QP=IPYDA=*E*+V.@*DE3ZY"0U!6092:DLA2 M6^^VMKV]LO*@7 H"9&Q[TS4IX.&6$'RF:&I0HI:M M;=.=N.[$=2=N$YVXKMJ],J4.5+M5.&E(6%"9VF':C!!*0% RD=7M7RO:8F.G MU$ZIG5+O :7VN/C*VSE#L72,6F?2%K+%RFYKR9!0&M J&JRH371^#6+IS:'8 M'AC?I<"XB[.OC4E6Q-G%D30<]D:D *@4/RLV@E0EQY!)9<_>FE%7UG5N#I=T M=ZV[:W?(7>N:^'5QYU 3[TS0R/^ MBUM5%(#*G=U-Z3V6RX!<_*;4GTX/E*\O>36*:O>/'@V8Z#O+>45E^/B[: M1XXG<4Z3MS1O*7KYEI[D*#VV5Z\(X.%_MTL."G>;;/EYU-#H_> MOIW-EY>8'!"5P\FL+O\X;=DRXZS[[G"2C@ZY!X>'#T]FR$\'G__88G=Z>-J' M!Y]_NS7T<,J#SRVM/,-F\T/^Q;S+K5M^[/^.>$07QV>_^5D+SP+F28J'_&4F MKSD=4ISS=T]_EU]-QU]MZI1Y;7X0]R:9?W>ZX#L6]XX/^6;PK3MI/4^PDT^< MWIK(MRFW^]UN;KODV_GL\"WEQ?)VG'#623]IDN-\?MS^>!?WCNBLZ:OM_;)# M'QO''YNW#G[Z!>X,_T3FL9T?/YQ\HDC^I;?3)M_?8U)L;5M,GE"F%K2?]$++ M!Q-F93EYSS?X=*3W]OBFQZ/#D[NSO!/<@M;/UAJ^(?'PM)L'LT7[R-%!C>]F M\^4$R[OQX-6G67=Z^\X&B6?4+$\;2T_>3Q>[[2.'GT_6AY/'R]OU]49^.2_* M]*0!K8'MEO-$I+V]E4L^6+;T[,.)]J;$". VO><)M#_C7N]-W]!>FP:,W_:9 M)1[:!V9'>WP+B._L_QU-V_P[[S=X)*8\ OQV:V \8*:9OEWV\FQ03L=X.I_$ M5D7\9&QF?%=YK*>'#[^DD\8]^61%-RX9]6_9YXQW3LD!6P[DMZ>F\=&#>??:X M.S]KSMMEU7:>N6\@5F[MH[CW/AX?;OWCBTXQ#\'G=W#8^?.'X.1Q,&PGGH>L MMEH?0XW*8B@V)!1.$\"]P!STUBV;J?VX.&&WPL X8:S!F:+& M&;%YF%]EK\G9Y/P[$HOMXGM[L_>'C\[%R7ZG3WY[NP(V/1@V13O/8?ZO3DY2OU%_^\4 MXI<7?-0\LFG^V]Z>M+5P_#-?>JF/C@[8J6J?VMKFR)\;L-OJ^OGHF03;^&GM8WEC?S7KS[<^W_I\ MNU.W\._GVYK*I8UZ)_;)T7)G8;EF1(\N,I'.Z_6WSHS1W9*_B:C6D4ROW\Y^ M._OM[+>SW\Y^.R]Y.]>4".^NU'!M>29.-HQG!S0YICB_2N'<#57';:;*#0L% M&83W"2.6:KQ.7EFA9KW++[PZO>)CK\=[>++?EYL<'Y=]\@_=H MYW1O]0F_^OMTL3L]>'9 +WA6;H@.;O;GR^<_R!?[+\S.\[W]EZ^S>*%:>W\^ M?OG[CGFA7KS?>?U#:^_KG>.!#N[U/_=VGO\V??GZS9_\N_M//_SR^L7^/Z=/ MG_PW]X%_\_7CXYWGN_L[/^Y\^-\/'_-)+7:>OU$['W[]([8B%TJ&5GQ6 ";* MX)T(@,+9:MHT(+&&?+Q_P88C505W_AI3WS:5OU9DO4VU%YM,YL_%HSK]DPI\ MH/FLT]QE:>[X2YJ3 DOF20$DFM8W662:BP0U9;18BE1*-K_/*ZF^ZV37R>Z. MD)U,T02VU;Y2P"IK$BH*1RYD+WR0."JRZRQV219[.G#6JC48E3>MY$^E]:44Z736Z>S:@T^/RN207;$%)7-:53J)(+,U4J.*!$K!6"3QHB650VEN[&2QR[UZM3NI MTWTL9NG<\NQV<_KVQNNH*Q\$@# M,7D!QIP@8 F0O5'&EDAD5^MDT,GA^XGC(P. M!GX">2]E4A5$]AE01@FAQ@+1V""S,TDXM[6MKZR([%PP7BX8^R)H=Q1N@AF& MNST&C4"A'?C0JN^:D,#+8"&;:F014;JVFL". G9RZ.0P.G+HCL(5%Q2&FR7" M1Z.B)BBV'9U0*,%76T!7DA%EJ>B(/84QK2[>LU-L2RA\MD7R<==D00=7V#2Y MZ![WW::YN[!NVLCME.>>TT'?-+D\K_VZLFEBHA$\V J*$@DPD(.0@P=7A%>N MLN&+;AVT-CY12P?_70=_]W&NR 5#@2XY4:JKH%1V@!(5^!P1DLF6E$<&_&8* M=#L5W*EUT:_Z 7TM9'W$,-PTX2%WVI<*KKH,6*N%H(N @D';P!,&;65B>*"O MOE#:R:&30_<31D8' S_!)9F%PF6XD!H=2(A6>:BE*,QH4S!E:UNMJ_YZYX(1 MMJVR3+[W]4V2N['?O!=6"OMNR/?1& O5G9',BIKR1CPH1TI,28R?Y$$$T(R MN9+2U/R9*_-75X!TQ*\%\3W#W#41PV )Q$M;:^+(QBB#@#$*""D%($4VN1BD MB&EM&>8Z.XR7'>[$FFCW![X1]BLIV2A&ITL%K[&E /$5$L>S$&**(K,]J!:W MMA&OO+K1(=\A?ST.06> RS' 4",1-(GD$;0KH1G^ EXE TE)3;EBDK%%!*(3 MP.82P)U8WNPV_QL1/]S34#54&VT%F4-31>4(23#BBZ[6FUQEU()MONW'0#KD MQP'Y;O.O&.P/MS$H.8Q>_ MT.&T$,,F[DWV9_/%J_B*H/6,^!Y_!%H_]'$>J267JS>$F*K#D-F:F8@F9Q6B M*<+F*Y!:G+W=G18I7/6NG59=753EZ7(J^\LH6A'!E'@MV7D"(@ M#R@D:0H4JTG78GC4%;LO(]J![7*,^X/SQXVWVZ>_GQTN^F[%NCA@N%OAC,M! M,0?$BH".V2 H?G!!INIY>DA5-K@>3F>"CTR 1@42-E@=>1KD2,E*5ZJQP9$5 M5]G+[!;_MM ^W*2(,HK@A 553$OK6]CB9PQ 5?"(&QM%P:UMJ[H$LR-]!#:_ MH_UR:!_6NG/H2]0%FC?7\E((B%(F,#4[&8LBHW =:Q,=[.,%>ZS"!%U"KK9B M424$[X5V JO1B;";];L(].$^1+$B2RP"4I$M(94MX!/ZMN#5DC6@9!IH9GT# MZ\%UI-\!I'>S?J60?;CGT#)45U$E9(OLQ=N0('EMP7EA$BE4!<=FU]=T=&+4 M>P[?S_;W:9ZO8K6Z MY2 ])>T*$ \N8'(> MH(F2U7]$JP_Z+84QG1;FG72]P?G/D=Z3?OLWO:+\< MV@>VG6UXSC8LLV";5@B9;7N4#F(H*IHLF]YH:UMV0?1&@[U@R86\;-G_BH]. M:R&T#\EI:6TWZW<1Z,,MATC1:%D+Z*@D8$9DLRXT2.)1)TQ21 [DC;NR>K C MO2.]F_6;#MF'6PXU"4RI:-"6"+!&@M0V']IX"V4T1;(CL^OWX9C#L\4NS2?Q M\) 6_73#Q7G+L(=:*H7L,2 [K(F>C\$_Z5L-Z.&"X'-'TCZHJR*%%*:E8B,XE M\$E&H854U:XO%U-G@O$R@0BH#/^#40LD1PFC$$5[00J#364<%K_GGUX?%0SW M(6SRU60D$+XN"^T,$?]>MT&@SU(M$XDXYGB,0B50K6A9H^K^9BJ\E$:#SJH5H!*6?"2O7ZM>?PE^WA%B9&9_?MP-N+Y;!'W+KL+ ME&;S0G,X:?@CS;>WS(X80TP75[QT73!+<]? -<- M@:L:<'=.LSM._C7CZY[3S*_UX60PGQ[M'N^FB^.?#LX:U]KV/_R\\EC.GK<;_YQ_[+_V M9OG-'07NR__=%7G_MX/X>SAZ]OHQ_]XONSO\K:<_OGR]\^3G/W=>OS'/?N?V M/'_#X/[I__[XCQB<3]I8,-8:P*H%Q. ]N(0I4Q08 MHSOA79Z25!XWYY(95DJ?I M>=9D.2F?[]+D^]D^__+Q\CR3^^[P8QK2R5Z;J),XI^;B-"J?G_#\)!WS*Q_3 MEC;ZYPXM^ ,/3YCF"9N*@U>3!5_\N-4/G-!!X:\]H4S[B>83+1],VGR-F2R&\OR;YZ$>[/W[4KQ=*).I@>3Z6+0Q,G;LPG[: 559_=S/\Y? M30^65&66CM>25#Y2X F1+7OY]I >G3WYKDP/W^[%XT?3@^6M6W[IN]-KG?(B M7VY(8DN2.WG[N_?3LMAMIONA.#'?IY*MTU\^??OA\JT!,9^\Y_Q#U.K>Y[?W59_]#C^=_\JZO^]7OLVU]+6_6%KOHWHKA1:-_"Y>T'SYR3MK*7-ILO M[=XCMM_Z3>O'A!>[L_R0Y-)4[SW\UJZ'M3_K%A]V]%_N_\?5_%B^>_RQ?/OG9 M['!0^_3UJ^,7KW]]_^+#KW\^??ZFA;8K*3<(175.:U#)BI84K$!*VK5\06A< M+4Z*P%2XMGKH&[8FV%GN_K"<51SH)^V#26UYW47GJY&R2EF(C/!+EA-G+"?+ ME9!ZM+=W/)G3VS@M/4W:M7MB;87R7'Y:OO#/-B"_+,>C\].E^.FG%2_,9)>( M4@$>N QMM1*2]0A!^E0IVV!#V=K6;DQG(/N)Y['Z%QV[UXK=@6]A@_(5,4-& M$0!-L! -^Q94(GGE6]Y"O[4M_9AR%-V'E:RA_S";4]Z;'=*W>0_W(CGTS:WC M_/-T-([F=+CIJ11OB)EV5KP*ES.'-D%#HM(.-AB"8(P'X5"3%;IF1[UJTSW M]NAWG2O*U%)0,YYL31@B7P6A%(C#HGY7VH=HRX/D=1]$E?4YDN)E/^\G2^3P>+PP=+ MX05?AF_0(7_G]!/_=\2W;"FR*'P#%_S5Q6Q",>\NKW^J[?B:8N3<[W,+IFU/ M]2"VE9-"[VAO]I;*\N?Y$_1J-N=[=6J)U4N>S_8ELC7*? M&G-(GW[O1*S"/>>?.'K+WSSD7YS'O4GEB<=O/^"/YKVC-HLF^6@^YWNQ_%58 MS.!=2ZLV66ZN\^?.WFT-K4<+YI+)VSDW?<[=R_%P=U+W9N\??/;:C-O0YO:# MR7Z+^5%N M/_5P<@EUV*K(Y9-@[PPRT#SC1]*?V1.^8=RY1]!>N7G3L9S/;>XH^Y$#;EJB M][5&#>X6/EPJA;X_F:;'//%@,(=MJ],TW3)],T^,/7-]ILP M=3<>O*+#/@5O:PJ:I2FQMSD%)Q><@P>S!4^EQ/[ZP6(:]QY,TM'BBXGW/L[G M_!Y/P /V;YK3\LG9:"LHD[A8\(ML<,^?;WUVK<_XN;',JL,OI]5L;X^6,<6) MZ_=VMIP52V\SGDRW[R;3.CF@S*Y7G!\WS__\8X^J87_WZTOOG7*F>+35V(ZG.T=+<[_RHJN\9;F MNM1J<&,_>]R=?P+K*X(TI_@&8N76/HI[[^/QX=8_OC0A;#\^OX/#SI\_!!^/ M4GP^IB>QO[4NRH**@P3"I&W2IB8G0@VA9.'24-V/)60O&"0=8^(G11JO M6X4@:[>N\\C&O_,NE:,]>E8_7P#YZ33(^GY)L[]PYPY>'=[WXQMBY\GC/[2J M5N5"( 4N91<58E$:2K6AU%9Y$.UXCF/\UZ?0=?&5./LD\%^&\(W>SLY3G,3" MYQRJB&>9@GD:'BY.EP5.8]"_.?G1L@]S/+X,SL\-\=/Q\HQ'NR2[(>S@G2#K M?6S-/3W"<;AZ,.-OF/3.',]0YN$I_:SYR$.XX)&'RQ[/N(ZC)+VMO:V]K=?4 M5G,Q=KG@T:?S3\B$NWE$YF,F_$E+A3_YKZ5]8Z/TXM0H/?MDE"YSDF84,H-K M/2KV8$)_MK6<1\.WJT0YI6/Y8RNBQ<_[ORU+FZ,+EAIJVV(WOA@T><8 M"0E%Q!"0HLGNHCD*SY4#;[X$^/7N[H[ZX?W.Z\?FZ?X/8N?US_K9DY?[+_=_ M.'[Q^K%\\;R\?KK_V_[+?Z](@-6S'W_X\.+Y8[[N&_7B^<_'3Y]D?,K?Y#9, M=Y[\MOM4[:B7O[_<^YJT/^ADL]<(Q68"3(H@F1H@B:2MR_RJ-&N3 (_OT&!G MI UEI.I,,6BK"Q51)Y4P:&&D12V<2.%O:[UW1KHQ1AH>@XS6UU9 Q0AAF9$P M0XHU0Q'*H2M2:-T9J3/2./IV"49R1:=2@Y-9$1H=8\Q*DS;)I)HI4V>DL3#2 MTX&/Q&8D%\P!PK*N4ZZ&?232(),/T1E=2*_O^&-GI,Y(-\1(N@8R4N=$3F$P ME')%LKHDGM1.6-T9:32,-/"1E,>D?H/,Z)BU)5(>19_8E:DC^!2-U MYKG<>M'S'[XL6.:\KU*:"C;(Y>&0!"DQ">GD+/-02DGYK6WE.^MTUKDCK"-M M-*;49"0&Q$RI"B]CS26YD*6SG75NGG5V!L6^HRO!5@F&+(=@D2P$6Q18S-5J MF76Q8V.=S1)M?1UD)QD<>F:^V_QVE(T8I8K(J-4=)1N+DIEE))4%=E[#LYT]-I4:Y01TAM"W5W>FT?I MP)9J1^11."M'A-/[<&IUD(#Y4MQR+\K+41:1 M34DJ5!Q&C-XE93%:7Z*0"7T7Z8V#!PM@HU[$DUB&\'@@/ELJD,,J7 M(AFS[.(S_19(-3N01A@*9&R1H4/X'D XFL01N+'!)X.*9*RE6N_06G*ZQG7L M/74(KP7"PSTIEW+-N2@0(6MHKCZDH",XF2ES7*[U&JLI=@B/%\+66(VV>M(U MHY<84I;!6VO8'"&6&%"]IG@9Y,JE'[6*.P[!+'M>0?ZR"]7-RZ MLBUE4\8FO8JQ&D!E#023'-B8"#EX-=K@UK;M*-U6"%\9*!:9H#\@&%&+R")Z**Y[C4Q5UJP8W(IC>AU-- MYR=\O_<[W<50,L95%5Q"$X/7)$35T5***>5UZ,;Z.M@:R.;%RFY4%JKX%"L8 M,@[09_;;BTN@+>G I*.,LFM;!^MBE1%#.+0E,&.]% :3PT@D*[%WB(XMCNFY M.L<#X<'Z6!2Y\J!ER-8$0'X*28< IBKEO".?K>X0O@<0CAF-44X9)S):#L"C MSBH+(VLH1?K4(3P6" ]WHTP03A<&KI'$$$Y&,X1+DXCHH$(B5YSK$+X'$$:. M_4*+S"T'Y+;:*$((FF)4'@.)GI]V/! >9H/$6JV4 8C'"M#X $$H"TXK@T$* MJ=SZ-"$=PN.%L,DQ>U=E##IBT(D=ZA*T$U@+D8G="H\&PL,]+*ED(&N; 1;( MCG26X(TQ(%+6D7UL7>7ZTB=V"(\7PL$P6(L,0=F );LH:XV%'X-@ UU[)9W1 M0'AEAPN=$23;*E9UC&$M52M<$<&@KC:''%Q*'/1:'3#D1E+QI#DU=K*T!C9F\J.D5YE-'P?3B8M5J% M]@([C!=S[F1V[\B,R 69;%'2 MQI:C-45OG",C5:1*KBL;;Y[,AJNO!F-TPD#5;>E&:789/;N,+E/3,4V?J2VH'%2.R74<9UQ,6=RR[%92N5#JLUEDB" MT]8#NBHA*5]!RSF%\R&0@E= M9#0<]8.(F@ U$QG[:0*D%L61T]'5EE7#K^N486>SSF9CZOAEI"3"Q62HF$J( M3IM$K?AL298=,R'U.HY&=3:[))L-CTP;6TM*!GQN>7R%X3A3) G.*FV.Q42W+6D+.I:Y9IS([2'JWT^"J_T%O9 M6]E;><=:N5F2-_=53^$)9=I/-)]H^6#"EEZ']_\:AK^F5"F*DJ!(9$"I X0FA"-=?3!&:A$V.05(IZ1- MI21%WB!6S5R$&6V47LJB(\J@$.C6IF;W%;D*@2/ MWINJ>215IZ1.2:/HVV6R'&>!T6BCV2-:'FRRA:F)_RS2R51+IZ3Q4%+^DI*D MLS9:DI"D(L"J K1S'* #8F(/M]F63DF=DD;1M\N:4-(1B9OFJR? MI[70'E&M@9(Z]5R2>MY\23U!!&N3EV"$YP#-Y0+)Z59]R 9)ULL2_-:VNO+V M9&>=SCHWE>_[BP].? M_PCHO$)50884 8TM'(#QGXZD$HF4L"YO;6O7>:?SSAWA'FO;A!'Q MSF9)&;X.,S59S"8X>OW"O2_2DW/5.6;EG7#8ZF<%4V042EI-EJ+I''?#'/?G MRI9;3I+8L?)@J'!$1XX@9I$XHI-!5&L*MBTW[+6T-ABFP996V4[;% U*2REA MI,HH9:NG8DD=ICIWG#<:I54FH(EJY8(O!A>0H,VRU M2Z1M5>L0976<7A*G*PO_,NIJE<\0=>;PU$AJ1R,EQ&*"*DC]3:0.EPJQY2L5U: )U\ *7B(P@9^ MP$I9!(_2L>MKUG5TN9=[OAC.S"0>E(D=ZS&<"['M54>SR:4@$6B,K5C>#P8'JRP6X[]2[06!$4"+%6#3ZE M*(:R9U(VM,D'/3J&/ZX+."&C$"2EKD@&@^>@(R7DN)-R7@N&.U8OB=7!,GL) M;7?2:-#9:D ?,G@M"UC%T4;P7ONV?G?EE&\=I>-%J:NQN))CTL%@"398DZ25 MJ-EA;@NZ':4WC]+!*KNS2F$,"531#C 4 9Y](2C,K"DIG;6L6]M77F/O*!TO M2K/0$AW;4<$A;""*;$9]<2U_:J(0NLCU%E"ZLL;.L8IN 0K8E 4@FL#1JVE' MG$T0J=127#O4,R:1:P?JNC>M(P;E;&Y11QEJ5TTHSU\F :AT*U[XNMP[:^["RMEY*P6I"!%3! XID(%I5044G M37;:!;6^=;FN A@OAJD*%#+;@@S;J$J0);/;:KQ/UCK3,3PB# _6U@N9H"@; MT,438) 5DA<27$A)DV=JIMPQ? \PS+$_J:R,(TCN$U87BX(B]KL%IZ4%C;BGQTD!19,,I&;45!LNO+K]HQ/%X, MRY!\R)FM<(E8=8U562F%:Q#.T?3L?R/"\,IZO5:^QJ ;BG4+BXT$GSE -BIY M'E!E@S(=Q?< Q:M5+%YMM54ZQPXTF M*E-#=<;+S#&T[FEB;X$FARO*9C M*1?Y/^6Z;OMLWX]/=IGP.3M_UR^>-*I-/_']L<.+E_GSS8(3 ^. MXA(=RXDGL]7124HR.12ZK?DZ+(8?([I"<>NSB]X@G%6#\^/%Y EEVD\T/QDP M+1],&):2T;-+Y6B/RF3_%'^3/0;@Y.U\>I"G;^/>9$YOX_$^'2P.)^]I3I-X MR'C67_KN]%JGRA.>.Q4+W+Z MRZ=O/UR^-9BL)^]Y_S 8?^[;XJ$\][V_O.Q#C^I"5_T;EOO[IF/VM/W?4;Z^?/=\Q.].!?[7_R^Z+#R_?/'W^BGVL7X^; M?[7SX]/=I^R;[;#O]8+]J9>_\_<^O#EF_^IL*6^Q\_R-VOGPZQ]11:V%T4#. MR[::1^!3JY^C9,JE:*-JRR/N>^J$FV92?:ZEN??Z[ENAGA<4Y\_?;XK$^Z88 MYZ=5QF'>0.T=Z$(6,,D*4>C,@5VVP;MB51/M\9SHVNZ;IISS*X?>^SQ0MTTH5@UN&P<8 D>$B8'54JMBRLQH-G:=F,J M37I/_)SSB[YT/^?6*&?ZKKLYEZ.<7U[2G$W!@N;=V1D1\SQN(]+)YYO(Y\7JPH[V5J;@(+<" M[$C>M?0;+1N6YG=\Q9HLFU\_IB+/:W)XEK_MQDY"7SN\?WU2B"ZXNNP-ZE1^ M42;WI8I[2HG/XI3@\KW"X*J1%"1%$M8LMOI<0/4W4BZJ<%SA6Z*%(H*T-BC"Y/YXTC M^'_P M"=Q?POE3RTX:]IPO_E][L_SFCH+UY?_NBKS_VT'\/1P]>_V8?^^7W1W^UM,? M7[[>>?+SGSNOWYAGOW-[GK_Y\^7SG][O_/C?TYT??]EEX'UX]N3Q'WS_=!%> M0_6Q16L5V]Y[6J8OHV4:.JE.F)5G(I7'36+J^;9+AS9;X]!'BB'6[(S762D= M@MB:$%/@6[[KB_D1W::H[]^SHWGFR\WJY("GY?33M)PN1[_)9B>+79H M^[9>;+2Z2/+B(LFOW(3,)$'S&[X-?]'IY9JQ_%;AYV9T7]SK[LOP1??OPS;) M$TKL;E,^FD\74UI!] 4=^_N^+'"?HGYA:M*Y8F*G%$LNP0@77;4BI!2]P*]& M"'\5_@_CA9\:,? K'/,_F;Z;%G89-R3@GTF.'?9>_/[;FV?/,P?\/XEG3W[B MW_E5M2/W+Y^\^?!4\7L__GS\\OOA^:K?]E_^^-ONR]]_-MR7XQ?E_K5YS MUI/KB^=O]A1JY[?[PV_)EVA5X/9(BR1]**BH4#)25>.-E*0VKPN1@0V>;D9$S)X=:V">LZX-#YK?/;F#I^&7[+ M9!QJ%)802W A\G^2T5XJ[X0KC=]D..4W&3J_W0:_/1UNV*"0'D4%DZ4 ##I M*$J#]B&0J2'88MOYK745J;Z9_9@-EP/M?'Z6_?S%LGLO"4*9E,E":>)&L4(A9V$6((,8M$E;25W=&_==I9/5.-@D<-BP)C:P*TJBT] MY "5?*A>%RUEV-K65]?[K_&PT;K+U=U[Y!(EBE':9,@A&YND7':HLW8,7&%5 M]_3'@-R!IY]15Y%]!J<2>_JU!&"/+X!U'KW225(M6]NRI2#JR-U4Y$;TQ@9M M330"EV6OM=?MP:?H/(\IP641G.#+ MD#18C&%*J$Y4HV3FOTKL<<884#\47Y%R7J<"7K;,_80.@LT)8LC)I(!18-K: M=FO+"'"O,+_A@*\^YIIJ#=%C6\B.0:;T_[/WYDUQY%C[Z%>IX+YQ8]X(Y-%R MM+E_041/VST_WQCPN)ON'O<_#BU'IFR@F"JPV_[T]RB+8LD"&^S"3@K-@J&6 M3*6DYSFKSB%50( UJ- W\V0 @.^;)Y6/O321J20# =X \SY'!B)D:S()>N4V MMIS^:O/D5N!H08KK$7GAM#C^=82'L^6C/FON,OG;L R3Q=]/YZO1*.E6E+1< M$BT9AT[I6FG:$R5!K?PJHV$RH)&*I$O.86/KBM9!_]N\G.L V6]@.#3(?B5D M/_2=G D%F0:L !0&5@<6N;5,NFA0EYQ45AM;:CF#L$%V+2#[#53_!MFO@VQ? M\3?1*2M(RB)79.EKFU@HB%U"@ (N98Z:I.QRV:CO MF'$)'8N;+FSM_PK[1_ M4A^B*\HS11KI1Z19"$>U LCH=1@?SD:3Z6A_,B-38&EUFK?RV]H)M:AIG[V> M+I;PI_FB_;.NV63ZKV[%6AAC=32W7.(4@W; #6G3CQ$E^;Z$\/*K)$O((:&_=MAOV>5<)Y(&;6&">X(\8JT&Z"Z* C2T+J^KG\*"0O^:P7YE%TV!_U[!?.ERA9*WY$1AW 1E8%9CS3C'G M0$)$;D,AV#OQU15QUS*D\3VJCYZ9/]=8-XL56>FPS"-]@W']<#29C;NZB5/< M#\?C=_A#76BF'EU1:S2&&S*P_--,RN M%+,] RBD'(/1B14=' /AD$7)%56N !MD!0G;EH9D&V55" MMF^\Q*"BC+8P+FI)!UHI%M!QEB0HHW2T,G7'1595'>H^!F>^JXFR'*&YA]:) MO,8ZN:&IVWI+?8,)6AL)=.%T;J19$6Y50>KUD^V45@Y=0F%:N, B)A%*1 MG(5&+4QZO#-\"L9M9'F[4BSGQ,I3;:!>V95 MD+5"&[( GC,)'*TJTCMN-K;LU]>Q;I1YX4&_)F"YYF1YTZE9&YJ\\ZS4IGBN MF$/[WA!5A/46,L-8J^,E+9FW7C,=P1<1K97.==E;8L4'4K\*02ML;+IZ5\<- M' ORBQT+KV[SGZ5&D+U68ZSR\6/A%B0]/LR$O,>LOK)J\G$W:I!Y(:K[S>_^ MPZ59<8],-PN?")J'*789PY,R^C#&_;#F.<,CHM%\N7E8 M_=;_W,;&=R!U\LEFDT$4]$6J2#9^,CHHD>'Z_M$SVD'TV\5TF9=UN+_,1_OL M;+#5P5Q;G/UZ-L@?WX7Q?D7+SY/IK\2SOV":O#Z<^Z:?ANDAS=::9]=^>3_; MEW3=IZ_0&!U]%DSI3#HJ*#+LK?!,NE14]CF[@E<> ECTC>S:O-YFHR0?8U*D M]68K('CMI4-%]*V@\.#B?*-<:;&TC?)=-LK3]\]WWPK:+"207^J=)\]>650@ MA$@,EA;&0-?3CQMZ;_MT@>(/&9L$,PDHA8T)0M3-K8.)TO\LDPXJ5NP,\WG>G5G?'A;0GHTNIGN-:DUI=GQ M7CADQWAP-)F&Z8>+*MC?_M__QTG)?WB^N_NL^U7\\+^KT\M68 +WY.["%NYJ M9>_28^TNGJI)X&\@@=7VFZ>O2D<2R30 KB2=1$;6W*Y M9LN5$KBWWT?SK2[\HUZ,>'ZMG9,#LE[2_3#8*E(J'L:')UWS\_G6<9X4& N& MI+X%%S#X4)+5)&.D5-[S.8;H.YA_K+M1*5#2Z2*M*< U=]R0QJ LK\@2QIX& MU'OWVAJ8J7CU7'S^V:Y.>J!_]D\R#?@V;(28M:L% MSQ5FOI[#(JE#PML)S>GN:*7(M;?4:@)5;<&O6_#T*G)NBK&2:5G[!$7'F=OC$TI M\)(8F3JU-U0"%G/B3('6)GGT&#.M^0W5@[X^/%JHPMU/?JH0"W_90J]_S97N MX\G%CBJCV-A0C;M/GHTG>23=#Q[M"Q,1\O*R&5A>^8I MW_H_XLPU(5OG08+^/E70IQ-]D^. MK__*AFYPK>:V21C)VW+!0:[>.P_SY\F&W\ M_=)#'8P/V<49[#_\]4LP_WFE@@+9)R>2%XYK0!4"49C.@K0U(PLWYCOE@W:S M]]-EH^_PS,* Q-P#W3XQ'Q(SU6V']T"RQ07 M3\+.4\E_GDX.JJGXO%PV)7>K&;E+P_K'_B2]?7 4GSX^?T(6H$U*E2Q9*9$S ML$(STN4\4U(* P)]L&%CA"0(CRK;3$_P>^+D[+SS*!Q,3NJVOK#;KY4"F_6W M;L^,"NV%#D(SVA!UVX>%/X&1J&+=JWU/285C_SO3][/'E\K8 ["]#6Q9(VEZLXHZZ*]YX*D"R_3LNR'HQD^7OSR M0Q[/CO;#A\?CPVYRNR_]<'JM4^ES15RV$S+SM\^Y^!&?\_%IOO[IG4_??M2] MU8N5S]\S]I'G^MJW^2-Q[7N?NJQ[Y.#Z;W[JJI]^3SEX\&.]V6I]YO3&("IH M^07-=!=\7($[3I>(QUYU.J(;*UD%DVFG4#P^(31/YYD*SPX7RN[UU7-O- ES M]>T;3\,G'GICJQ+4+9[IVJ-S]_?Q^8-^?.$O/?Y#J(G][TN*0E4'EE#]N<=] ML'GVMW[^MT>??\FWZQO/=?[S9 MWOV-OO.;?O[D!=^1V[#SYO5[&H/:/OA]O/UK+WF4;*+GNR\^O/RXK;?_N?W7 MSNX+^O];V'GR0KW\2.-\\B,];_KPYQ_/_OK/QZ=+IY8TYN!!*U:TBV0C(3 ' MJ537M\\J8L@(&UMJ4]M5'8 ?3(;]9T['-RYL7'C71XH:%WY7+NP=1C(9DA7! M,:NR8L!!,A)\D@4TA1;>!-$5:-_T8E4=9->>"Q\T$:XI"Z[\Q%!CP>_)@DO' MB5)4Q8!@$$(M",LM\SHF!@8XT2$7VM2:]YO6WCD+WLO"*]\#O?_\A-O^:VK= MKW?5IY6;MI]+YYPO3PW?-9:Z%4L]6^Y_%:'D;!1#Y3@#7[J4'<-H1:.DUXQ3 MI*M]O=%Z-1GK94=J)!1,86*M S4GD7K ].R8(H8 MI+&U_O2JVF8W_ X0ORLW)!I^[PR_?2M!BR)X"H4Y;7@V00/R-P=RSSA(/B.(7)C& M&HA1.3%7!+!LB]5)96.LW]@RK23[&@/Y[@YE-R#?&9#[5D*.WI7@$C.&.P;> M>C(0#(EES8V3AGZOAV?%7[ES/"_E479G%N#1G9S?OM'=+Q_@%OZ1 M7AS@OH/#.0ON^#F,I[^'_1-\,IXE,JI.IC@;SC&;MPN2('#NO]GY^)I __N; M/W>?\91 H-[9WW[SRYOM M-\]H?"_TSIN7'U^^>5U/3XJ=W;VNZ,+.[K9ZE0/:DKQD4@3.@*?(''+)A+68 M9%1.6KM4+J Z& MJ.B!%L9)I,4![B(WB13V_KF<.O&C;N:7X7B;@UM7'.[_ M[$@NC]Q[M D4^)@X?G MR0$-YD.MG"+L#[/Z0%V0M3OR4\:'X3"-PSX-EEXX.U$74II,,[V%H_?CX[W1 M/W_\\=^C:3UG1WM^E(A#0_W4;(;'IT>#QB&.]^?GBHXGHUA/%95]3/4FX;@. MA):PU'5\5]>Q^TY7^&7YX]V)ZNZ]40RS\6QS-#M)>_7P$,UIR&].9O53>^/9 M\61:F9R>:'8\_^BCN>AX5@\HC6?UC!]N7IR$>E[JW;@69T&/0@>Y/9Q4LMAK-[:0 XZR:Y&^#X<)[, M<'ZBN+O"V>W'AS-"P,'I%V@>:]F< PR5>KIYO3#N^OWW>V.:J?I :2\#(_9$4K\=/OOX[^+VE!M.9TO?DJT =IV'MX M.!N_P\479_.-AOL?YBGE\X]^;N9N<]+R+H%T\U,R';1^/GNL9Q=69/O"0IQ3 MU&)+_7019_\(^QV8?MU#FI6!3,*G3^Z>8OP:%KEZCWYB>Y[.RB7VB:>S,NMF MY0):+F#H= S7+I1+:K:L47]8(>A4Y"<5EZA?X].%L!)-(/$,FF?]N6XC.F+ ME=?J\QWB_!93Q-$^OL/][I:!" :G89KV/I PJO 8TRAIR!\Z+CP=ZX41=^<: MNP.<-+3ZI.?7JG^=7ZTB(HSB=(R%R&.6IN.CBW1]_.&H&]#90UTBB44MK(OO MUH<\JXO5/>Q_3VA?EXZH^HBLJ%[@\4/'&1B(,KK!+A_*O%%)@,NG+%4M#/#M MJQW=<%=W\V1^^#:*Z^3^9'?<<)9 MMV#C.HN=X#OEV M+>EJI+70U)D:T,F_Q^ K2;4NWXJ639TOW>P^9IX*QEK<; M+9;Y3)2?4=@DTI#>=4)XOF@C8LAPSHBSLWI2CZ_8$;,Q/6R8+O;#T@;8O,DN M&M<1][_7YYGSH5\8\=EKM:;"Z2W^MM#9QO7X'S'HJ"H+PN@?MJ-%\U MT+.2$)=MHI-99[M4CCF]U2D%G=Z1QG9FY'RIL70V1XL[7?/9\1E)GIMRIT9( MJ,-\WQ4U#E<-]&;S4*>O-X-U+7#^3Z MPL$DX_XE.?'Y];B\9\^F7"ZFO%R]#Q8,?\TVNF (+\U'G$[>TO1VE^WTE7 X M%PR'=9CTXP,9[W4S=76?*\R-(YQV4U/MAFYGA=G>J!#2JFW_!M.<7!83 MWM1%^UZ>_$ZI]&GW1N;I_K/0K*\QD,RJ/;/%BV= M^;Q.%8\K;W)T,IV=7,6WY_;9#=4'932\33DSL\42 U]?5(-HLXI?(7*U!L8 M3"Y+='OSX:[4X[,7JQ*.)]WMN?5UN6/,9+*LC"4W/5 MBDUB=797VVUVIE5?"#Q=5KHW3^,L)]=93).R=),NBK;PTZ2]4',=Z&G)A$B= M0IS'LU0+_^$%C;8SO196QH4G['J[W*3S%78GTTN3EC/REH4[;S@2IM;7C2=] SII-;R/'N\TZJ@ MLTN#G3_'H]'SP\Z3$J8T/!(=I\'VBS;]#*LWK]J!LW!P-"\L.CZ^EDI/J?9, M>M8'K5>:SMT^!W6,I^^=!N(['VZHEY@Y-:X)?N-/IF!R6\71>%G7N(KIXU]-7#\[O M2E\^"\]705_5:/I$G<\S%JX.KPM$_*QF).2.'3>O%#IG7HX+#2*.,1PL1#?] M35-_<9;.A,A")'7[NEN(:T78J3E;+WQVY\G[NHTS'F'GW[[@KKKT#!?R#BZH M"LN)"V?#J0'34.A M==9@+N'_5)-9)-KT9W2NI2Q<5*=XGD_:SS19BS=Z7]N\I"7-HRNG/KMY+(6N M0N@X]=95M61S4>NW>E\[6^QT0+1D[SJ>V0^IRQJZ=)MZZ6Y1\]G^WU_HN,][ M-[GL6CZS;N>DM;3/]Z:=(RY4Q$0BZ0M^*7JRMX>3]_N87R^N,*(O3NO@%MY2 M/'PWGDX.NP'777DJ6SIEZXH]O]BT>^$==EOVHA\S+XWN"YKVD;%;T5U=B9^> MTD]RR^PXE'(Y$^FS4UEYMSI>/]9YF1'OA3RWMB?3HRZ\UHV1OG!<1>1AGD.4 M%%G_&/Z%)"A'!R>'M F.ZG2MA4ET2W/_Z;Q&?C/XS\9P M$>FG1$&B>(_V]O'[2<^Q/ ].]-L,/)YO[+D4.U,!YUN?+M4YI/*IQG;Y(_.- M3Y_IMGX^1N]"Q!0N&*17.C!.">J2J+_*JW%!E/1'NCRF MS=.P2)=O>?DZ/\S?JAC=7+[Q=<^BSI[EV?K<>-*MOZY?F,[9( MS#I7G<]>Z12G;IB/1C_6ATW5Q=-%*3.>_MZMY8=S@KUJH.\G)Z0Z=R*-^)M& M-9_[<"%EM.>F.HW(U'OW5;!/NAUNR:&M_\S5K@P]<%?&9UT3/5>&( "J",)% MC: CQNQS+?NAC>%>8OK..?1?T#19" ,\<2-1:5 V.$ 7<]82> Y>NL]USCT[ M8++@I'^=QRRO.'3RV;ZX_,$=1MG^\'SWM=C^^ +H-;WS,;U221C:9()E!9:! MYIS5XX,L98@%.*!)[E9G$KU 71R(F(0 VNH>-=>U16:LS?N,_%QG[+;(JU]D M<)H'69 E50L)U9;K+A3%@LXHK0@BNWC#1LCG^L"EU)!KD]EKD+%JC5UZ2Q=F M_'R&^XU<''=[ANW7M(?YI);9/-MS/W9>SQ\/\X4-N3C:\/SPE\53_J,^Y,!: M2WV/,V\O/KQR-M-2!,>*J=S"=6!!"C9]YO!=+ZW\O(?3E7K#9V?D'O5^TO:1 M-W?1H\CX+^LH]3WZ*;6QWM58?>M3]1#[5)WZ=AYPKZ;3D-*#GP'U@&=@=T(D ML<8-NZY^ZJ6.FC?8 2MI-3&06;FZAM#5I6%66GRI36>;SC:= YW.A]#/X:?K M$ON_IFSNNK7?N>H1UZ;\739&Y!H3*25"5C(ZJ[.E5SC/4IMX4U=SW4D_'N;Z MSX73/9]U-@^WJ/]_= MUMN[+]7+@VWZ[HL/+\>]0GAO7O_U\N.?>R_ELX_;3^C^NR_H[_V]G=T?-8V) MQIC'+S_2)Y[\?^.KVE7D:"3ZD)B+63!0,K-@,C >A&I)2$[#5/0G,)D<=HN0)P1%;%BY+2'9/4 M%6'[QD\WXZ=^-6$N:2V=Y RS<0R*%2QH'YC3D(WD3NI@3P^/RQ\:0S6&NB<, MM:JTHJ9&?1^:ZJE1 D-V.A>F. ]DZXG,?#:9(1BN+$<-R#>V_"9P-R"26J^ MRM68?'+Y2,GC5;AI!]9WX>I(TC"\TFW*VI2U*?M&\8VY B@?23UP4N[.\;VN M1[P/>T<>6^?J:]O5:1%#+$I!(FW"VQA-])$7X;GB)L!--<9^\YOSHX&7F^0T MA7%U"N.+Y;YU""Z'8%B60I/"J#@+(G'Z#;T*3J;L8&-+;JK6SGJ=01UL3IY' M;E$A '!?K,TZ12$)V-:+U8.ZX?9VN.T9>L7Q B)SADD! Q,L"]Q;9K,7QKE2 M ,S&%JRAL[R!]LR[G-&8*+P"+&"5CL6'*(BU;1+&H+E;2=R \H(\EF;;D# MY$VW'C2L>S+:Q80QY,!,S"2C/23F=$@L&5I-K7*1,5?=&L0:=JJ_-SZ 7VO] MC=GF>8&>\S(^1Y/Z1RW--SN)>?QN//OD,9\'WS=7&8S9A,15\5!L=0OX+!$D M1BEINS>%9)#,]=N25X",P"@,&18R"JA-L 4+$171%PFC8JRV0JQ,(6F=L(>+ M:(-%&BZDUZF <>"-T-I+E6165O(;)[ TA>2[P+JGD*@@I2U1,TC5V5=B8%ZZ MQ'BAQ5008TQ\8TMM^4$5])JJ%@/!N_ @]]P M>RO<]OT#I9#TK2G[TEO'($)A3BK%>%(I1!E43F%C2S?,KB]FXU-ZB:XC%H6/<4#R^EQXS(LLB9% _ZX8TT+(3HR9:P+AA;\\.-MPW4ZPOJ MJ&4J$, 1M &=C>B\(\:W47($=0=NO8;;6^&V[P$@='+PTC,=;3P]?@9D,*A@ M!)H"JBA/!L.0#G4TT*X8M$5+ITOV,9 (YBX'X*@@Z"(MIARQ2>)!([HGB5$[ MK;Q3+)FD&-!JLI@)UMHBJ=T^:X)VE<16?;5?KR4'?#$\?U[J[].B_]>V(4#A M/!;M/ =0/KIDO,A&,JK9_8=Y&S7)"2YJ(-U:%FHY(2DD#]?J"V@H-2@A((5I0(<;HK

    ])' -GH1C'HLXB^&""TWIC2_ &VO4% MK0HR.0R)4!F@QOPU^FBD]#PKD40[=#ML1/?S\$KDA%ID&$)FH+-D'FQA)=:6 M;9@]HNPDL1^2)'YHX?]?<#;O[A[V1P>3Z?'KKL04O8_> M93! &J:WP8!4JJ"1[HXYJ_D#OI"N7B_7"# !E'6*^5ASAR6/S)E0&*TD:(G9 M>EM:+L #0#0G"U+28HNH$D2E@S!.D.'@"D>3=[I]"XCGJJ&*JD>,@:%>$9&JE[*BP MY>0-% C/""9+#LK"0,+!2-"U@S )Y:'+X 2"Z&.,)N$:1[@7! M29>Y,B;Z7%N: ]Q!I*TA]W;([5<"L-DIVCXL9F,8B*"9EZ:6N%E3V5H M$!7'$VY^*&)Z8?6FK \^,]G([";(;'+2/@-LH'C[H$C22B M0.H<%9 $0_ 94LSECJN)->7C"UGJZ?N.H>8*B-YYLRU>B1!*,+63L+2608U" MA&(CRPY1.JF"AM4Y"5HH8KB0-EICD"&BA0R W@GM!#K@("(ON1T1&#BNMR_C MVNE"BUF0<9](Z;"U$KFM6<9T3 M%*6S"QZ"O8,ZY VXMP3N;Y>!B\&06L4=TR[5QH]9,L<-_;#%UX:0UFFYL?75 MZ<0-M,,%+2'6R)3!:ZZ@8*BYM@%T4XZW[:)XJ]%=+J,:(L /)#L#9Z:%D#O]1J2@<5+:.C*1:<3EN^P,WU9I&QF#DUA5HFL M(QCGT^K2$ELD8KB0=B4%PX70B1< D,Z[($U"XS#Q8.\@8:!!]Y;0[9G[TD/6 ML@BFLZX9Q84S5Y1DP42IBN A0S7WO[JL6$/M<%$;M,U<5J<\*K!!1H\\(WCE M8M5 VS&]X:*YYP,(@)'@:QA&2V@N%9;:M$CAD!GKPY+53Z9=#IB U31Q!IH'LAI<9-I* M,OF555) =4\JNRKWY(VQ M57?SAO>UPKL7J(L#$9,0X"1XU%R#22;R!-'<<;?PI@!\+1GT7!A*U-,) AAJ MAPR,%"SFP%E!),6@9 ^Q%C54FQ*^^NC"MR*$%64S#-K'\?2_)^/C#RUGX1NZ M,.93?LY,/[_;&3<"NAT!?5SR2(#6J6@T3&09&'B1F?=.LBATT$JAB+J>*0BAG@D"YD!6Q[]"I8+4V55[_ZNKF#6$ M#A>AJ[+:&T)7@M#^H0&C'9 ESF*2F@2ILBP441A7*GH>I0^QZL#FJT_OM42" MVR<2W)E[XTJ6&=P<_,_=/?_:L.O*DB1J:8K9SV$\_3WLG^"3\2SM3V8G4VQ. MT!7R+U_.BG!=XH,C#:E&05-1S&OZ4;57512FE//&EMV$^^,#75%0I)%=([N[ MR@!I9/=MR*Y_>B3XA"4(YKDVM;N$9%$69#*E%(VP'HW>V))Z4YJ'%@)N;-?8 M[J[26ZYGNT9HMR2TGG^KH#:*"TO:6Q:,1%)DL1YG52$EFT71"*I&D$1CL\9F M#YO-5I:\TW2W;T-U/4=ADMQ'6D"6K$0&62KF0N1,B6B!2V5#@(TM)3>=L/>% M[4X=B8N!++:V[KALU8& &USCP@,K>J0\.:EE0OI/_#5W:*.\]Z-<+^^WO5*N M/,&$!Q&G(R4V1R07^+4I9E_WX,.3J% M*!S2 ]9?\+\GXW>D1Q\>+R7]?G62P^ >_>96W56/..S=?)N"S2F)P%%:< 9" M <>+Y#RI@$8D%^9.=_YYPZWNI!\/<_WGZ?DV:H;C\1HPF*AUXL+:H#5: MZQM+#9VE>J%"F[(H2BGF$N<,:GTJK\ P%0R*$F3$$BI+N4%EIC66:BSUR=)Y M1COD5OC"#7@/05FI2W!(VUT'5^Z8I=H)E*\@J%[HSPJKG4F&%1L+J5'&,%?S MN%R7F5($\F37^ 1*HZ@UI2@A#/#$C42E0=G@ %W,64O@.7CIFB(U<)[JQ>UB MT%%H4I]4XH&!1;+T4$52J83W+C@.4M0$4Z>'=,QUO8(<5X/RR>4J@8^'XHYM MU[CC:SRTEA>_/?KUT>CUA(9T>$!"H%6.N($8!L,!BD2N=8+.1@ AO159HO=9 M\9N*X5;KYCM(8;WD=)4I.^5JN2N3+ ,7.7/@#?/HM0:30PQY7OQR2%UZVUG8 M5:?T#3R$[V=3K8>.ZY^0B7;I$9X&E4)O98D$6R'3JCE(;(V,L"JMZ#8.* M%J[(R75O_ "_'H=CG&V.#@B8:7Q$(ZK0Z+++CB;U#QKG:'82\_C=>$9+\U6- M,]:;OWPFPQ$M%B\D)(4AZF12D@4+%%7NV#W05)(OI*YG[Y<\ U9*(,5#LF)+ M)K,"%'-D'K*29$I!))F=6)E*\@D"N0>EK]<;TLY$X$H+4#7F5DK0QDJ70&+@ M.L*-(E:1)=4C!M;JSK1WT [0-!R+@WW#FPFQI;:.F6B!&Y,B<4V!A9* M%BRI8DKRI#8ZW0(3#P#2A4O:!R%YCPA!U+J&R6:-JFB? (Q& MFEK[ONA:\1!C9BX:P7(JNKH'0L"PL>4V'7QUC\N&ZN&B.D>.629;+,^T&W0T MQ=&O(6K"&E$\=X5VY($!@[IGAL 2]6>2V'J"B=XAD/TJ5 ML>3,[]A8:/;_EW+3AR7[G\2*Y^@3*]8@ R5JT $MBT6B#QE=#+QE 3P$2-LL M2,5PF5N $L%;$!S)3#0&A8K0=(YAX[IG_\><:?F49"$&6JZ'SKQ* I$J0KH7$(B69U 6C09HKJ#7B"^J'E"/R"LW'& MP^-QV!\=3*;'K\-K9/4I,;>$@1N=/S8I9)M4U,14201'NFDDP@K>)*VQZ2'# MY*N/2PX#[KPR$H$)HPJ#D!/AP!<6C?*00,>44TL8> "03EK&*'(JJGA0%F.V M)G.+/%R90XSQQ)=]D%N;%F^AN67 M&VS/\GR\11ME4I#I?Q:]YZG$6 "RS@9;ZMYPX=SW"$ 0.BC+=!+(@%<7GTR! M996$TBHX^JM)XH< :=0EF>B<#@:*=B&;XHPI)1&7@]9-$G]WZ/:,?LUUMMH M4]X1=*VV+$2AF8LUWU9$$X)1>S+YTQV?*FYZQI>2%5].$2!K 9-/3,FL&,C,62!#GQE$1]L$P.#J MC@BTR,-P(>T]*9DJ9%1*UQ)T7JFD#"=MTX>H?"L4,'!<]]P!Q5A7/;),8Y0, M4#L6:R-QGM&2%E(BE[BQ)38YF(;J]46U=%EE+X-.I?8%(0!NGA0CJ@BZBM!#(S M:4/X6JN+9Z-EM%@BWG&TK0GJK\5USUM@E" =2PKF4''"M9',A6(9Y\4J6S+A M.@Q/4#^T%('GQWLX'879#(];9L MTIFDM\'IZ(01H!+&2'LZT7X'%2PO+3-@ MH#0EEOP$'GRV7%@6D1L&-5%,I>D@@ AT!T'SF:%"1Z(W7S$PP7T#T_ :TBSU!S]D!J!E8XYIUW M+'H,5AD5BH"4R+23-?TI"N:*D\P$8Z0H MGOZ5+5#Q "#MMLD##YI9 MCL! 1L-B"9P)FX15(:9H/>D87UW(J*%VN*A59",*94(FG@9M'6T M-G$""8F MVA\-M=\=M3V+W]7VD:$8QE7T#+R7S,F S-LDBQ,H+&)K+;#6H.488R2%BK1F M Y$;AUE(KXO,,O-0[D![;J"])6A[YCPX]%9H8%'(KK>@JHU\#-/66*F*,C$H M$K5??49@>#'_0=OONY/CL$\0B<9]-]L=YM'B.]28E MDY(('*4%9T@^@>-%B9DTG8;&R* M%C:V=,-[P_L5>!?" $_<2%0:E*T-B5W,6=?S"\%+UQ2 89-!SX7A4S% Z\6\ M<(X!*F!!>F ^I1AM*DC6'AD$8I/>OB^$L*)\A4'[.)[^]V1\_*%E)7Q#%\9\ MRL^9Z>=W.^-&0+58\5R*IF()*9(&T3NAK MC-!5.16N1FC+$5H1$+ U>C'R%FYJ-TC#0%;S!%@=ZT'*$' -]5 MN0":@%T)3'OFOG=)H>:2FL<()<8RL86#$D%?C!I!%_HW)@/ M_+&BZKW,=#FZ2_N<[3M#:T//*DBQJ:8O9SV$\_3WLG^"3\2SM M3V8G4VQ.U!42N%[R80B>E2U"LU2,8R!R8DX",)%DL1@+ZEKGV6R27KQ:'^H* M4/2=HRZ-3QN?#M:?U/CT&_%IOS6FDA%+]HSG&J$./+ H4F9>\XC9YJ2EV=B2 MNWN=?BR>_!1+4*N_'$UFX_KMQU/C_/QW@)H%[YU.A_\ M_"LATJ.?'%__E0M/G9! .?WV?"'KF(0RER?CXL^]Z6(X1UW;FBF&MRP4&NWC ML/\^?)AM_/W20QV,#]G%&>P__/5+,/_96[8Y+P@IK(H@7-18BQ'%[(E"(FIC MN)>8YJQ&W\'\XW'7Q@HX2J5,")%H33I%Q":3+26C=<&?<>3.R0'-6>H5G2P! MBC.8LLS@P7FO(',OC*%[0;2OGA I"D[_9?67.3M>YL,S)IP3XS:&2H;Y^>$O M-20U)03\(\S&L]\.)Y$6[5W=RL\.CTYH #22--X?=P^_2T/ZQ_XDO;VG]/CG M?_9X.OC],/SA3YZ_R6^>_[&MGC]Y\>'//W;VM]_\\F;[S3,:WPNB,B*Y-Z_5 M\]T78F=W;^\_'Y^^W]G=AE>)EV2#3$RH$!ED[YA3)K+DBP977$+I^FL/6M"G ML]?)!T =G?8Z:Y]R@!PDAHT1DM0YJOB;GN#%3?FM<;>[AZ.T%PY?TR7'AZ-C M^C.&_7"8Z.])&?T+W^'^2(W*^)!>J\VCNHK0LU$^J1NH^_P'#-,1'F;,HR>8 M\"#B=,[J2FR.ZN8P=A^IJP6VE;=XIG1[#G]-:1 M.DW-?CB:X>/%+S_D\>QH/WQX/#[L'K#[T@^GUSKEQ$H#/4+OJ&_^]CE#/.)S MEC@-UYW>^?3M1]U;/2$U?T_R1\:I:]_FC\2U[WWJLH(_ O!?=-E/OT=DM/+! M^D<@31MK&VL;ZUV,5=WLJI_)-AA$4H%?R*;N@H_'QW2S=$E:V2NLROE82>F: M3#O5Y#$9!CBMG]K8>G8XH@'LTZO7)_??:!+F6O WGH9///3&UJ_'X1AGFZ-. M73T@0SJ-CVA4W3F&^M) M_?JHFP_:-T=UZ^!\=CY_&F3]Y^;GR93^/&P35AOYU)Z^LY.?ZQTJ>4B1$,ZEX=Z!S:& MU+;ZF21P8Y)3R:1TTTC(F>?OU.=W0)SPQ_AX;\G5-[OLZ[OL&.S_UY^[3]\]W\YLN[O'FEX.7\BG\^>3G-]M+,9+M]R\_ MTOB?O%4[3Q(]UR_[V[L_ZAVY_7[[X.>#G7_^^>;E[M[;[3^V/_SGXUG"X_'V M[ENY_?&W5RBU<;1E&2^<,T"AF?>E]ISVFB=M)'=F!04K[UD1B<: C0%[#.B4 MP"BS-TYHX$DXH[%X:43QWA4K&P/>%P;\<)D!K17&:Q]9BL(R )Y9,+'&4[3B M0942:Y!8KSCENU'@L)B@4> -\K$%N@(>> P>,'G/41E(5BB:$ZUOG(^]>@I< M[]H WXP:=TZ5PYTW3S]L/WGVBLC/0TR"J5A2+2NH6'3),VD]R*AR*F%U?3])LA5M<9H-O1W)\+MU\23)9Q7T+I-P?"GQQ@0*W MX955$K0E$QEE$ S *J) T=G.6:7!5R#O[FT'3EP[>#R:(@WD M(^913=D].3S[,X6CF@@]>AW&A[/1W_8G!)G9_SZ^0>;8EQ=[;-=HUVC7^/0U M5I2M.%>LU".K!\Y1SP[3_DD]S3<^'&&8UAS&V=6BXVPV;M %9KUKQG)CM"># MT[NB (IPEA%OMV"&HD26J0A) MYA@D58), < 'SIUU4:0;,,.,'IA^^UX4T:C@=E30RWPK,>J0@V6AJ,* HV$! M-3(%&&P)-F/GM%_V6/UO(X"A$L!M\,\]1!,\K;L&!.F-1Z0?0? 2P33-8,WI MH)_M)9+R4D7)0BS :EL)%KS+M7!G<2I)#P&;9O B,'Z9&60F T$T-8ZU ZX M+$7H2.20&S&L-S'TTIST*UL*EU9IED H8@9I:HJ\8H9'Y4L JWULS/ F(&C M$\9G'1$U1"L\F0_YA,(%#)89&@/8DO0 M2@19V\LGJ%'=;)CS4C-(.OK8Y3]C+9/9P+^^X(=BG>(.55(2I(F1)YF"%,HA M>)%E _]Z@+^?T<&S<2"L8"%%0]B/FCFA,E/9Q&),/0\M-K;T@*"_RIR-^Q83 MG70EHM+DX&B*>W@X&[]#>IG^7BKQQ ]->]7?+0K O;3Q05^UJUO_53S M?ZR$!%\LA4QYX59*LG8TKT>]O"S,08DL!X,H'01=5N?^:/UW6\CTV[)&8X?; ML4,OBHJ8DC1D'B5OR3R*B@PE[S5M@!1+"3EB#!M;R];1S8.HC1*&JS[_IH1^' MM;IX'1/#HFS-Q'#,">$90$0']-^,5Y9K;<;&8#EA;4.P38'X)@S1B]9&0WO" M*L&2[8J8AL"\=\B43SZE@%PIU12(^TH6MU$@5A"S;0K$/:>'?CPW)0$^Z,(\ MQNJ+$,!H6S@F:^T%H7FMQ+"QM7Q _[OH#ZL\WCKTX_?_/IFFO3#[1#N6!Y^# M,N1([=GR-<5F);&5H.>@/@ 96 M$(/]%C30X'X[N/>[,@23HY>!":,=*2HHF.@# M#JTV>;]J NA'38/*,J!%QFTI#(1PS)=:L4)X(8, (^WJHJ:-!H9+ T..FC9Y M_\7R_E+@,\E7#FG'H;1,AAP80"U&89)G(0E1K,&BB[DJC:HA?6V0/N33I4W@ MKYX!>K%-)R+WR2MF@R(Y7Z.>Y%* MG6IS11-8LMHP,(C,J919UD4JE4@6<-G.E:XWU(=\KK1!_4NAWH\Z*HQ%&V&9 M3Y*0+F5A02E@Q1FNK0HY!2"DVP$A_2&5_OZ5-O>7Q1T?1B+%D ./W=HU@KH5 M0;U<#BZJ;*U$P= H0025!8O R?10B&1MI*3ARFA#2ZM<"X /.:38 /Y% .^' M$XM%)Z5GO/C"P$I@T1/*?1*Q!.6%Y*$!_%X!?$TBB:?X;D[%E>!^J:9M+,DI MITBPDW0'8X&Y HEI+J,F>OT1? M57.VG5&\ZS@A'A_O=_AHIQ3O9[#P? &;NV$E[)660HE".@-$6L19D=>LIL)( M3P'&750)0;AB6A;CO26"M8DJ7F2"AOC;(?Y#/[M)D$I:-#,!D &Q/HLQ"):R M=4:0GIJT_#J#I,%\N/)^T+'%)N]7COY^A)&;6$*,BJED,P.2[K5@HV8N,]!"(8=(2Q$<'JU8!^G#%Y+4D7\,S)[!DDL,QY)^L)Q@2:!>#84'(R,"XS)P*@9DD X0(A?9$8X('P 2# M#D%JN%(Q "C,JPPL!>ZYB)Q>MH/Q!CZD4XZ[4_IRP>EL-#X\GHS^ MA>]P?Z0V1X=X_,#./JY)-/-L07?PN-'6K6CK]5+8DM998<%4XQ>:@7.!14B" M<92Z.*=-R6D%C7Y;:M5PL3[D>.5EK#=K9349,*B[0M0L3@H+26 M40^!"H8-"NZ$"GJA2Q'0!:7E/(8!P!T+O 3Q1?2%F3PJC0J> !4,.3(9?,&? 7D M^Z%+C$@J?W L^V+)#M""A: =$U%98:5)*=?FTD,* JSH^.6@ Y=/#^M01S'L MA\.$MPT3Q\DTXY3-G^"QHGG.DQ,"V&@Q\-,/'$^.'M=5F$WVQ_GLS<\RV^!F MZW^^XP2M#>5GI4%%GTN6 K3 R(,!)0VD%*V-[M6S;\[TW64:Q=^*XM\NGT[E MLN0H/%&\(HJO[34BH&4Y%ZD* ;>>Q9@X"Q+I=U&BP]K* MS#66;2S;6/:.6;9V"LW1<.V] [)K'? 2:+)L*1"A-%7VOK!L/WAL6QCV<:RGW,8Z&!DRN U5U P! ,R@"[* M.2."@\:R]X1EEY)#;(C>"XPL*9L8Z""(84$PP:WT2DECM%M=7][&LHUE&\M> M'Y3//%J?P'L.J=J1*D;C'& ,(. [ZK(M"+\B]NWEX^1B#1DPEGD1@-A7<>9E M\:Q(EXK12HNX\DH"C8,;!S<.OHZ#M1$I6*/01 X@75 V9I4L\;+,-&]-T[TW M7-M+>++1\1C!,(&@&!C.&=$J9RG7E!<426N^L:5;<*S1;*/9.U=U!>KB0,0D M2+&5X%%S#281ZR:(1C::O2;>?D@("4MOY/]^+\N>+T[UMGS]B]?O;F M-X2K["IF[.$H[87#US@:5[!.D1[O(Y+4"$?CX[ _VI\0+FH]C;1_DNEU^M3D M> ^G!.6#HRGNX>%L_*Y^F?[&49C-)HG011]\3PA<5. 8E?%A(.#1]4*%V6ST M?F^<]D;O<8JC/=S/]/)H4D9/,.%!Q.E\&RBQ.:H,,'I/[_[/K;)9 Q1G,&69 MP8/S7I%5[84Q7B)$>X-LUAFM,?UV+=5T;'&90'X]'N_O_U]ZF-_.9O&?87SX M+YK YVE\V7X^/#E@>7+,3F]Z[QGGS__L\73P^V'XPY\\?Y/?//]C6SU_\N+# MGW_L[&^_^>7-]IMG-#YBHC?$*V]>J^>[+\3.[M[>?SZF#]L??WR59=&R9,<4 M3YH!&L6"M9[EDD@P\*IWQXTM6.*+$4%BO^Z&?%+7840[<_0!PW2$AW6S7KV? M'HVN =]5R*0;UKTU/CSI9,9\>4 +H4+V.OD J*/37F?M4PZ0@\2P,0A$5]1V M,W*:5MI![%I$WF(&^1RXA,HRV=^?O)\]7IK0Q5,?A.GK\6''O+K3*#N./&/T M.2_3U.R'HQD^7OSR0Q[/CO;#A\?CP^X!NR_]<'JM4YJGR_4YN>/L^=L_O!_G MX[VJDSSB<[WD-(/X],ZG;S_JWNK)F?E[P!_1LE[[-G\DKGWO4Y<5_)$%^467 M_?1[RL'*!^L?.?-E5VUC7:.QVIN-YS.)^H/(Q_<+#NTN^+BJ..-TB57M%6;- M?*PDK"?33@H\)AT4I_53&UO/#A="Z/J.23>:A$1F"TZ_\31\XJ$WMGX])DUN MMCGJQ.(!*5QI?$2C.A[CK'MI+A3"81X=3>K+-.KY9V';+2;GV?-8] MG;_?'OWZJ)L/VC='=>O@?':JVCB?Q8<[-[]@1CRHA>1'OMS]Q]OG?SQ]O_WFK7BYF_CVQ[V] M.JZ7N_GMSC]WZ#J_'_SYYK4X^\["X7KPR][V/U_0YW[\\'SW][V=CR\^/O_G M4]AYL[^W(U_PEW)G?^>//P^>/_E][S\?GRX=^?):%C+4/5.EGN-/1K!8C_67 MQ$4*QBD7W1VE$*Q+Z*KQX\/A1VUT*#M M>+!W*BM'Y8K7GN7L#(,B$_-)"5:D-]%$M"&4C2UE&P4V"GS8%(@.2!W,QG(C M01;O7$J<%TC>ZJ)C:!1X3RAPIT>!W@;+DT<6A8@,/$@68O$,:FF?@$DFY3>V MA&P4V"CP85.@%]P7D$;K+,&JX$PH+GOEDU'1D MC8FLF$C6L!:567)[DCO,K M'T@3LQT\'IVE8=;@^A59F:_#^' V^ML\.?-_']\@*OCEQ5';-=HU^M=84>1U MKDBH1U8/')//+J0_8YC6>.SL:JH\FXWU;(=Z&_O*Y&B]!LL]@"DF@%12AT2* M19(@YDU'^"(+FW]3+6.1F+U8UV>'3T]75;0@Y4ITDNVE("4J]$X79)!D[9/L M%/.UHH])W@C:(,XC;WV2[RLQW*9/LLO!^ZA*LE: TL';$H*G7<&1!XSE!LSP MN?,9=TP1C0IN1P7]ZHG1<(>*Z&"&*QFT&!_*]CW8U,Y9H)V<4R*( CV*K, M/#&%*?FHHQ"FQJ96Y95HV!^B\"]1&C($8K(!010=1"TC9UP063GTT(3_FK% M/SR3>(REU(+TT<=:;0YJ>"8PH9(+W,JL$:^J-M=D_V#Q?YO$$X'.H55>H0 > MDC..3 $9O47'2U1-]J\7ZA>ROV#2FC1]9E,-RF)&%DK]TQ2=DW85WAGRXN\+-N?>NGF@MT)23X8MD% M6G(2*#0##IF!D(9YX)J59#@9Q!:5B:W?X@/@BA5X0!M7K!E7])TEF6M;LB>N M\(E!\H6%2#^<3R",ED%JT[CBOG+%;3PF*W"7?@^/R:=9H['#K=BA[TJ5*D>2 M(9JIXDH]Z03,!^68$0E4B:9X)Z]J\G=S)TJCA.&J#ROPH0Z&")KZL!*"6/*R M!A(6G"/9%B@9Q"29X\DR;8,$C3[DM+HCX8TK!JP^K,#CVM2'-6&'A?I@+&:) M1;/H)+&#]9Y%(3-SJ5@PDELGRV#4AU4FFPX]^?O?)].T%V:?*/3TX"-(0_:S MGBU?TVM6PER_75'J!GWRW#-N(C(PHM1>9=696KVGO$A1YJHHN#>D#1/J0TT6; MP%\U _0]G=P(H8LI#(VI[?%L8%Y(S8274<:LO8FJ"?P'0 -#=GHV@?^E<._[ M+7V@978Y,>KGD@ Q)1:E*80:QEE4D!2628L*BEB2@O'/9A!98?0 4,&0'9*. ME5) SR4A0A9U09G%(AED2:J+(0HPTJE(=HLLJJ5FWEL*^,:IF7?- 0WKM\)Z MW_VHM?.J.,6*SF2FB)R9TRXSE0"\RXE4 =C8DLL'UUJFY5H@?,A>QX;P+T%X MW^,H,SHEP3/EO65 ZAQS("S3W"F+5A4O<&-KN5IP _A: 'S(WL8&\*\!^%FR MHX:2"<2L@"*+G10V%D60#,E0>B!#!69M35J%&/*XL$3QPWLR'88**^-LA?M[G8)R+ A(Q,00" MCDKB?-EL**9(B$ZXH#>V:G;,%8+YNO@4J[Q?.OKG/8Y)4V>0WDO9CA(!Q2BQ MGD7B./.R%&=!O:_*^T= !*UV/58B6#H1+#@FDY1"1T-,EIE !"!>9=0*9(+D MK/2!+F^;L1)!BQ7_5OLHJ^)_9\2?F?HH^@%U/Y*S$"6P@!&G8B!9.4IM+D: M:XWB_YBB(?>&^.6=/Z=OJ1>1SSI]-.XQDBNHN/R;$)WTKC2UJUH MZ]."A])#I$Z@HN)B+GG]J2)>,(,LYHP1";AG_BK:JI%0:X/U-KLF+V.]&BO+ MX8#3^4U6)<"$1(23FD!*G!C-,\DL>&U<,6-K3.1C8((VNR\K$]P#$\S[+]%0 M93I&1:3W:,0X%XEEJ!YF@S?[+R@3WP 0+9[D]YTZG M7,*F*8$02NQTJ?K'=$GB AS_JDSP")B@S?[+Z@E8 N)GLE]P"%G:0(1.B@#7 M: 6DC 0@8]*>)17%E0[,GX?U)85;MMI[^;)?FMKQKN?Z8:&"S_=ZZ@?#F(9D MTH.G L27952'9A00#5(L$C-!$+8$D/?&&2] M-YQ9;A5XJDR*C%N9>>21NIPKRZX(RRYFEHU.A^2(Y+P4(J>.&!""2*I2B("V MBV%5E:TD6TGV_DG6F9R4I-8PD4%9YI,&:6P./&A!;?47K K)SN\!(8\""YH2 MA89)J33DB-7&$R8"U9)[DQ(L,DN M!QJ=Y::R[(JQ[%D$;K"9@HJ$,>162$X1&Z4EAGI@6='DO-K8,HM9RE:599MM MNU_&9:'A_V/WR];_-#\F_?##7[;.^G3YX@.BDS&.NF/7Z_0&"(-RKF!2^+#<-2BE#Q&Y%VH?ENN#P]1QH]$@()CPQA,$ MW.PD0B=W^PYQAL]S!56CSLE^-^QW3M(P=?93+^+'G4'NO$@A'?HTG$R[8$\Z M!?"=$[SZ7[?@$1VHU;24%V42HI36BJQIEIP%_"NZ)924;,CA,E_\.>[V>O\/ M._/V;!1G92-W0_=R%$__^)#$P9A,7[KR!//A[WT:#O_JNW?V>/<@'NR^VQ:[ M+UZ??GBWT]L^>'.P?? *V_=:[AR\__K^X)/8W7O-=O;VD2Q>GNSN?6;;>]CN MKY_$SM[VQV@,U?@/D3%0 CB-Q)N82-8A6&.$X\6[>!U7($9Z97G$XS(Q'5RJ MG=/DAIW4+ZOWZ@6V>0T86X?4\:! $CEO-.J,+Y_Y^=?@>(P0^N\SR,T-P.A; M(\ ZKA^G6"N01+SE0:\W.!D]7>C]K-^';OBIVV\X5#:J8<-V9]P\85@Q>[HJ.=.GW;[31>;+SV;/FM*V/BX>79MV'=R^=E)-X[WBW*Q22<* MQC0\8OKFZ>7-YM*!B^T>F-K0+W6_3IVJC!U>T^O=3]QQ!A]<=5$F,J M*'Y0N7[LAOMCLLN-IL%DH7FF&@Q3SC'I@I:HB6FON6KT:3;3I]G/B8]]A6NZ M6=)BY;7IF;F.G[,/+Y[3G8/R[TNZO1< KW5WT11'TQIV]EZ=?BAM7C#77Z.6 M_=?G[1>O\=GX[][K?W;0U']_^ H^O/C\S^[>)[9]\+^'.R_V>ZB!+P1107;4 M1!])-FBD@\HEB,H%(DUB5%GEDX.-+;98?_U.YOJZ^#PK,SX>9A09 2&2-UI1 M*%FZ;W91WSY'2:AJ;UWTG?I+KM-]Z*&JEE+[=X_%NGG';FA^3?!C.>[6H M#8;,?,R69&H2:H.4$@,:*3 P2[T5-NM:4>XQ,,)**#N5$>Z!$>:3J43K/)6) M,$\U@:A*T(S-A'-PCO-DF9)M9(2EUJ[8U++EFL].&B_7Y_<#&^J/R.Z]\^BL MC:!8"=5QG<[3/XP@V%Y0#0WC@261B5=!$F!.EB+IG!C#*201M*-N^8["NP)M M-=R(E6PKV:Z-5E[)]@?(=K[P@I.2@U9%ZP8"AGMB9&0D"I8T9*?M4I*7M(-K MKPB@+/TJ*[_;/V[6VU6?W"QTZYJ+LS&9(A&*?G\T&'6;X)!AZN$[OJ3S\*," MTPO?FHX4/?^*\S@HQ^/KO[(0*/'P;-.$EC&A+P_&Q9_[P_,XCT^)^&%RGXG+ MV-JGKG?B3D<;OUR."^OVR<41G._\]5,P^3DWIQ.NR EHXD*@*ND!%4LC#"0> M=,XQ:>/LA!/Q.RD^+_:^**7/6:)6 8.,; A!)Y=I#"6]7TGU>:^!?#>/0VK& M__>SZ-A7_=%X>-QDJ^_L#,:=*07'CAMW"B]W&F+NX+"4N+[?!OT&=DV\[:^3 M]#F=/_=3NE"O\/LK?T(7._C683?,)[X?"TA*)^:=9NB31-HS&J'V75YK*H)Q="SXU&W=S%3_UII]=X*@;Y MXAW[W31TP[!_6AQ[%V+*NQ=04]Y6'C&%2+@(D6F&J$30] MIU RF,#^A^-MA\@O1=&_D8HG&;;:$+3I([ M!.JM0G>OWGM9:EAB?<9Z/>.1!:EM#X;C3^Y3ZO0&;M&NNTVGUS3@83VC%I+, M6=NLDM.J9'@- MR@;:F@0?#&#[C_=?/[QXRW;?[>Q_.'A+\;VG[_?V>SM??_W\X8^=P]V]W_<_ M'+[I;7?G@@\./IU\.-CYC,^3[_GOASM[;["/_[N_^\=;L?W'F\_O^7NY_>[W MPP]_O#W]^^OKA4@OIA)3$)2:5UTEFUL6;JLG,\K%*]5 M.:A-?;L%!RGN)0>ELK :@HM&**DRA:1]H!26ST%K?1SA ;EIOJ*CBR6'IR", M1D; >U<21BGBN8XAE21@')9V'*'R4^6GA^(GH8 '9R$YI"F?O+-<9VD3%X8+:*'@&8+3:<#^9A^;T)&^2SM$Z@NJ2)B"Y)3;$1$J"5*_! M!"9]L>%TY:#*02O"02I$&4%$32&"C-8ZZ9GUSH-&7F*IH#E7',LI^ZQ$;%X1"NW=*$T"R/[%_GONQ$G- M\7%/?OG)^"E BY7+4K,\1/W7E<"P#N_/&]+#$$= MKSI>=;SFQFN] C:O[O._N\YW>XTP_['PK27&UM5G/+)G+,D$6Y6@J%?]+VDT M+@=:SP^D]NZ*OU4(?JO/:.4"O0?@R>GK.>;]-*:]Q&OQ>IF![.@/5(WM7?\&G!7^!UN!9B>SC MPB<"UF1B$]?$20%,YJBU8AM;RTKAUJ(]H0K?907"W0F^->AD.;">SQ8&U@$X M1;AREI1$/L29;(CE.@CA760\K''0207WLJ+(*KA_/KCG(\HDSXH:G4CRPA/P M((F5P(G)3D4:0$5O*K@? ;CO&H)5%>\'!/%\%GVOC05F"$1=)+0.Q'H12-"* M9IL< ZZJXKW6\+UK]%*%[\/!=SZ2*2F6@T/X"F$HPCBKXL0KU;Z6XL>KT3]W\^/A1%1*6BHE?5YPY='(0N":$T5M)L R(U[) M1(P&I[VG7'*]L27$.H?^/'H,WZ,S[T88KB;_W_?HTJLZ^#W@>+Y"N!5*"(XX1H%-P 9*3%"!,,]8HB IC1)U M<"TJAM<7P_?HUZL87CZ&YUU[COL4&;,D18YV-$=CVHD8"%>,@K66.FK;AN%' MEC;PWX/^)U(.D2%^_+A&YMWW>;X7.,KGQ:G.2.>R.= _/B1QT*3O+P^J/'0K M'GIYTG#0A(ODSL$V^UARP\CL%5$@* '!BC)A#1$237]I#1B&1K]43]!*:-%& M0]TG;)E/KZ+X05&\?1G%3C#G6,@D!9T(),^("QR(%4$99.?@#*)8P1,FVY3V MH**X99Z[6Z&XNN;N ."WEP&,"(Q*R$A28@S%L )BA-IYI)D YR 45L"IXPB3A.G&<1USE%;$7PLO.%54WZ M06#\^3*,59#.FT")RJ58!:R93U&>U\QB/;(JV5U6[3Q;6Q M<(6-5%FOF=(6M-;&9:=]\"%XZC+EC85+[ZEJ2+5X[V3QTH4=8,[!"L,YR1R- M7?#,$>^5)6C*2D6- 2O3QA9[0J%-!F_-VE\YZEL<%8*"%(,R(!4$P1U'7OE:.J7_T.]+0]OS.F8G9<$JV#(A B$_*$2-B,I:[Y,&OL5^]$M2: M$I0S66@AK&6&@P.P5+J4)9?6Z6QCK@355H*:V[K/U$H.+!&D(]2?N"CU1KS" M'P&43CX[*BI!58)J1=]N05 V.F-\=,D9!3QG'\ (:1A+.;$,KEIYK6:IN? $ MDYE0489271N0I4KQVN@=41"9 F:8#+&Q\C2M'%4Y:D4X*GIJG*3!>\7 &F:] M :'!Z\R\M[ER5+LY:B[V0B,A"0B:6.LI 6<$_H:4E_UFY[())E"^Y^HU-"K=Z@YI=52>Q*B>,N$$NUR")'8V(A6;AS M6KD6GQY?]V)1=;SJ>-7Q:L]XK5=@8RW>5I_1LF?4XFVU>%M]QGK$/:Y*WN=: MO.W!W 8U"?V#.0Q@T6'@K6>FY)XW/I,22T5,#H+X0#-.('@N>+NRT-U%]UTCT2JZ MVX#NN:@T!TQG)021EBD"UEOB/8(]04@L)N6$I17=CP#==PWCJKKW0Z)X/FI+ MX[^26B+!&@(:9;3STA,NDXZ2.A3:INK>:XW?NX8X5?P^)'[G(IJ"-$E:+XFS M6A+@3C4%5(D&4-%JEB.O%=Q^NB>O5G!KB3.O9IY?.B?)!7]>"&C>*Y&(<0HM M@\@#\>7X"LZ?]\D*D:+8V!*D@/"T9! @%-# MO,F<>$5],#'2+)=WVK0"O+T OT>_7E7#[P/($-C$Q21C:RP0L V*MLB1EG50R M8)U/;0/Q(\M16,NX/>S1OIJV_MZ)Z-5B&3?.%"BI ]&\$)$4@-H$_G#2&LUR MXJK8_0J>J'7,XE=1O.RT=Q7%#X+B>>^==XHFS4@(T1 H!:"0BS/)#"3KG,VQ(GC9 MJ<6J)OT@,)YSS"4FJ=8(8^X]8CF@4>R-I@1G,#!IO16@6ZA)-[ZY7\8E\=$L M"57SXZ&3:/$?3J+U\3;_S*7;FDS##@)EV W7)SIC9D8SW7Y$3#TEY9-E,XJY MP1A-"*701K=_[!I&:> JJ-)).NJE\L"M-,!EUMP$EX7U(DVH!K^3XO/" )FB MOI!4D"&5 YI [7!B0R"TH"_3'.3S;UKZUY2K-VDW\\NS8?95)/QOW(LOM^W M5^/.B1MU^H-QYZB!(*ZKSGC02:,QDN$X=<;[J9.1.#M?"G-V!KE\,DHXB*,Q M.4SC_4'L=,]V048=?%AWW!FFHR'>53X8[3O\M7SQN-_KCL:I"+I#'+5N&FUV M_DRILS/ ][!.(]?5L^G__L2EW=,BREZ]B!;G]"\&4@ANF3&Y8!:[I2>C'Y'!M4^M!9[,/FXFQW+J/EC!>V M_L-0CY,QVY89G%Z0B..MO)E=VGV''C M3I&'G;\FT]IO1N>W07^$ QQ=F:5?7<_U0^K\N9_2>-22 ?@F(2QVUS6UR#H- MBZ:RKB>]+,OO=+IV1IV>&W["!8TTVCE*_1'.]PC!,(C' ;]ZLM\-^^?KN9-1 M^(PZAZ[;'^-_.$SXT$,]F(:CS8F M^[-;AG;^8L+X<.\/NZ/,Y[B8]>M)Q^.4AMNEHT&\6]V+?9TE)3CO[ MKCPY]0NJ4;QU1_O8[O1_QQ.HE]=-GCIMV]Z%%W5E4IGINUXD1H)CO-TTAWOQZ$[ M00WU2:=_[> ,$T+ZZ[0]Q_VS/W]LT*;]&:;-8 M#8[2L.$Z;&9#V=.!G3%LFB0919Y%H.QWE$JN70:]T>"LEQ=E-+X-%][AH/\+3D)O0E8= M-))&>&V\[\;? 'D!P-5?G+R@/'N"B0OK?,*9S<6GA0%.4GG_%>:2[X_'U7[E@(8945M;#^T8:DF+"S WLA9_[PW-3[%,B M'H7#9^(RMO:IZYVXT]'&+YEN/L?0'C;F MU]X@?%Y1M\Z'O_=I./RK[][9X]V#>+#[;EOLOGA]^N'=3F_[X,W!]L$K;-]K MN7/P_NO[@T]B=^\UV]G;W__[Z\N3G;UM^C%F;W.PD@A7-C@]_F:NYHE)[.?GD6NZ.C MGCM]VNTW/6B^]&SZK"D=7>&Q:5AGNO?>NQ:M/"]5>_]=1O7Q,&:EM7IJT*S,JT=97&M;;UGMHJQ8V> M^ITXW._OT+&%>Z_8@YNHE ^S"6?GI.J"0["1+C-YV9F)RAMDJWTT@T%ODS>\ M%>G![>W]PJ5$2]/6F,)@XO%Y.K%0FRVD5_T.-J!7_$ W260\T8N*UE1VW1K? M4F?6GY5:"Q/[_29PN%&?;Y+D=\W&CM>Q^^&Q$W7L?F#L]@;(=\L08.LX.)70 M*J%50ENML5LDM,=0O.:WLI\XV2#&7\H^R!?7*YL>MPT"N_%"6-,RLS?O_]H$ MBK+,F8Q!.LH5. 6>2^$UCY!5#E'H)E"4?3]0=&X?X7GC8%Z32-"CWH<706R_ MB+W=O4^ ;<-[/W_=???7_ON]SVS[ZRO8_OK7X>Z[MWSGS[E(T,._/N]\#2<[ M_*TL[=IY\5KN[FW+#^]^W]_=>_MU^^#3UYUWV+^]]^SOKZ]F4:#C[;W/?/OK MVX^. ="(G: M6A#&9[0^N1;4>I\BK=K:@Y+9G+;F.7@/RA%F)2.0LB<>"8Q(YIUTQ@OC!5DE((%PVRB3-_TF'4ELF40V>Z<5F9-25_! M W&N5!&3"8@SVA.&6IDW-#'.5/6>51JK-&:S<.!1Y:(6%'>6IQ# B6*&4KQ2 M:>Q!O6?SZ1%M8#RYQ F/)A)@/A,;HR)!1&V#--(S7]UGE]K&IQ%,66AN= :SD/K,@5!8V9N#>V"7N M,U0$WPW!\U$AJ"X%A:1+'!6(8*9"P3+"F#J90F29\EB,8%"R(GB-$:PTRT$S M8Y6'X#-.OZ,LN]2<)**B(K@U"%X(B.#,)^V$)E3D2$"[2)S5F5C.O<"YE(FB M%SE\'%P!@4[X?)X)W6D>>8$,(W+A=9K>#[1>_<9C^C&22E MC@CJ. &?#7%*,N),D! C,"%9-8,? 7Y#"9?600F5 GC!#3 *V3#'D-:IO>LV M=A7!RP3QW!ZWTR"8Y8S( (I DI)8EB3)6MND$YK$NK&#J;4M@O!CR ;SH_:/ MLU8.VT;BC;=:*)6R7GJP8(OB 2M\9_#UTG''2J(B24%JZC.EH&BF,3(C,]1C MI \*TSE/.:@ 04E+O->B&.F4.$"M7ZELK"]&FBG!)A6@ZPM0AU8>T)R%, Z4 M<$8S8[(P4CJJG%-5OK8!N//;U![M;PDL$QK*-K6RDCB?';&>AAATXH+&*E\? M 7P]XU[0H&C2&NURY[+G+C O+:I@0=!N#.;T K184V M*A!AK25@)8K6&"AAR6EX67V79:Q[C"W!+GS.\Q6*M"(5V.+AQCPA_/&$LE+V(C(%&RH M$O81X%>A$LQ]$DYD"9H*ZU)PD>M,4Q#1Q2IA'Q:GZAJ']@C@*Z,(AH(/ M05F@4CAP%A#/*7J:HJ[[R \+TSD_=_0Q:N<5*O/1$>!&$5MB/@)CE'O-?8YF M8PO5NPK1]84HEYE&R82GQ@)7S",T>>"14B9H,LM,.E(E[ ]#=WXGF6D0QD5! M.)2Z+P;Q6ZPOHGS0$<6K:;:HJH1=>_@:GJSF&JS4##(SGO, T6?M$<3.BRIA M'Q2F,C5U=T&Z,[O);.$%FQ \]4:(PD4X>JXY,0DU)@":*=XM6$? WQQ MPK.@(9E@-6C#31962HDK F4O97<-!:DPO9T-.[^7G)/SG I&0K:,(+]JXA65 MQ/HL(@K<1',Q8E7-N[?&&+40HU6EKG*,8(.VY92"IP[5X4@-DU7$M@.[<[O) M$1+PR!QA*E$"V7MBC XD.* )G(F@>)6QCP"_#K+BP)T"(T'H9*)C6CN6I:?9 MRBIC'QBG<[O)P7B9LT=B,RV3<8^]('DV/TR>_;T M$:3<_U1M:MF@_F= <&\P=KW.;/B7V@*U*6_0A&='@U&WK(2GP]1S9E#=#: M2)^H%(LH5CQR'$3!O=$R:OR$TLBE\C5I9$M$T_N%2 .OHM-""2*20RYRR,SHW"?"U67)=UTJEE4HK ME2Y0J> 0K:2!2S. 5252BN55BK]WJ'/ M$)BCB6LP"EP&0S/:]@&->\6"<;4V1WNH=#Z<3=HH?72).(7:*$@>B+5:$9V% M"9QS*I.:U.:H5%JIM%+IO9^,"\HD9[A75D)RRDL9:(EYD#)I;2N5MH=*%T(. MM94,HLT$)[!D: ] +%42!UAE)K4QOJ29$D^$J9M.E4LKE]Y[])B2)E'-;*8* MK 4G-)?9F:1#E,[4 Q8MH=&YZ,_@4?!IPXAU.*: 2Y,XKQR1WCJ<.,&BRM55 M6HFT$NF#5>YC"FB@BB=1PG"=@61\C)(#CSPI;- T>;'0P>Z\A\.=/UXFW\N MA\1>%W#,S(RJN_V8^N.GI'RR;/(Q-QB32W&\#_[V9Y=&Q6RJ9A1>_A-ZQQ%? M\5^WJ69$);-):"]$J2HNC**@.#@6=.0S7JQ;2%?QXH>_]VDX_*OOWMGCW8-X ML/MN6^R^>'WZX=U.;_O@S<'VP2MLWVODL/=?WQ]\$KM[K]G.WO[^WU]?(@=^ M/MTY"/BL5U]W7VQ_]#Z"C]03JZDA()PMY0TE"4J+*#@K%L#&EJ8+_-;!M=4K M<^SZ\583KW)R^.2 ]@2%3*-EF3F(7B87DF=WS2-<)_ZJB7]_LO,B?$5SH1%L MVR]>?P3K66(49SJHDLV06^)=8%_'OHTG-PMV)-.@7.S6,KT/L'[1T>3A'V]T\VY@PF3-^X< M'R)%A0OR9^M__/"7K07*?G =L.'A%\=#9,(.=KYSFMQPU$DH&N)9QSM7]+G< M^]O@$!M[VMEWL7,;U"2;41E)-,H,,64755 )M* \1 #X^**\@C):"HW=!#Z_ MN^[P+]<[3MO)C8Z'Z1#%VKON>/]M?^!Q1)J9?-4_.AZ/WB1L2>CVNJXT\DVI MU%=Z_JL;=4<-ZO:&.(PY#4<[:?Q=TYX^.NQ]ECM?GW],W"CG)",^E'.9LECF MB0G"'6?2! M=D7D" DE+)"H9C7EAY M)AX[4_DXZN1NW^&LN5['-;*RT^V/!YW!L#,X'I=O_#LA%W?$%61'4]FTSMOL]2V,4RA:%OV;P'QGPC>_IW5S/Z]WEDWLW^O65 MA"\W[T7OOM';+RO>S&Y.SC]>$I27Z0&R@VQ4"A'YP8*Q5@"N+J:4Y0F\OI(> M+A/"'X-!/$$Y_[P?7_7'KO^IBPPPT;->=$>A-R@LL8=O_+4W")]_,HIW7KR: MHOBHNWWXDKW?^_WSAS]>P_N]EW3G:V#X+$!T?WY_\ :-_P^?=[[N=W=.YU!\ M^.KT_=Y?^]OOWGS^\&)_?WOOM=CY^A>V>Q_1_::[\\=+N7/X6NQB.__^^OJ? M[1?//TJ-!HL-0'APFH".BGAA,M'*11=HLEK2"7,C@E)\7GA0-*5PA'$(!S1Z M7)D5%[7*F@DIL]WH).3&(YR*\? 8+=K91#2JQ&ZC;IU/R&A!7[I:/[H*K7/8 MGLS@]ULWUYM<3J(P\#E:4/B'\I$%' D!BJ:4-NY726N>^+0[=KUNN &*9V-Y MNU&Z1Y3]&?93/.ZEW3QKVN.&U*N/2D2-EJ A)5\FJDHY$J- D)2\]\#1,#5Q M'B(_SP[X-?4&)YTN6CV=T?'AH1N>%F%:5/VPCQ!-1^YW,%ZTHF&!O+Q%+-HFFK6@7#H:-#O#T&,EF./&DO^I?KOAO28Q^--&KMN[Y=F./Z]]]LC'HDF[\VE_C]T.J"? ML=/_J^NY?D@77=I3SRZS/[BY^]C#0QY3](>TD(3*E,IB#8OLF+ \**^L%D+( MIA( L]_WS_OCE\O_?K(3Z#;<\'?!S\?K!S^!+*71_^V.F^__KF8'=O?W_G\-4_ M[_G[KSM_?-C?QO_>'[S]Y^^O+\\SWQR\Y3L'KSX&L-ESS4@T+A,( HBW29,0 MK!&,>ZF5WM@"^42H956J7K/8N,IMCXC;0$GKF58N.!#:V@@QN^R92Y0)GRNW MM8+;9DD4@-'(DR3&&X;V16V#89Q+6[GMIW+;?-$UI8*D.1 >G25 ?2+>24NXXI[+:$5H M,A;2)X8N^21NY;9V0;QRVPWJOP:/RD!)HR0#2&%\T(H;EK-P 2U4J-SV,[GM MBG)7U(HD4%&+K-3,,03UZTBL88S3()T$M[&E[1,-U\5JMH[;EE27NGFW;G*! MMYJ4GH?_.^Y.3C+4LM37TI+W(3B5702J($KE4PI9F(A:5] @PZTC7,_"E\KP M#U.R :L91*4=4XL&;$M M3_.P,DB>]W=HJ77,BFBF(@%=4I#EF @S+$JC0V",U1I?CP#..E"K*3XF(8"C M1 DLLJ:E/'+ OZ*K OAGPG;>E/<,F*9<$$%I*3 O#+%6.HP"F MID6075*,SZJ8ZB^Z7])HW!T?#U.)SWXW&'Y.PU'#I/I93LQ+^>(1? M'_V817_%**T(._VK#2;]NV%W/$[]W9S?E,P0*>X-_G3E",6OTTEYBXVJ?'4K MOMI>M/$96)ZH)2KPLF7L,O$Y"F*]X!S-.S3\Y,:6I(L9^?[[MB['%NV8K#E^ MVV#>WQ"^U7I8+JRG:HA.B;%L%7$^HAJBW,&5'P_*+[G*SP8F;3T@:#2Q8O8UHCOI$ARR>-46Q>#J_A>57S?1O^^-_= MU;_O \CS_H*8$LV))<(AEKI7-!$K)"4XHY8QY0.3H47Z]W=2I4<[Y)L3M7D*E(7R^D6QML=#8'20,P MZDW Y9,YN!2S5_S&A:,JTN\%Z7-F,0KQ1)UEA)J2E3](1;SVG.28O++"TDC= MLD[[5*2O%]*#13$AM#51,W!66FZ2H(P)R-09#Q7I/Q/I\PZP%)E"&\L0KAS* M=&6 >)8,"3F(4A.^Q+HU9U_DW0MP/ C2JR>G+9ZG5XY+K#DB[RD44? MW29Z(2L.C&4*"B %Z11W7+($P61-Y>WSH\\X_WSP_ST8M;^6W6J0_Z?%Z"-4 MP:G"T70RE%)V-!$/W)(L30[4.\^\JMN8CP#(5%.F!',T)@K"&UN*/)& M!@K,X<3+3%E4/DAFM8A+0W)%[.T0.V=W9:>%,E(291-#T5ORX'D*1*1H(>#J M!8N:-XC%1%$U\'*N$.E M"7PI]]P:H%;W1UO<'^L5R,)^T,MW=9G=NSC'6S=J-T^(M$YK0T$AH9*C,[B?E'(CAEG(P:82O:'M$\;O7&ZD!6S9 M.&!_:4KD;DT+\,Y7Y?YFB>F?5KUXDN"MJ4]<:@U_L]3PD^8VA,@PN5&Z25GC M$S?J' T144-L>2<.NU]2O]0Z=N>W=,]VA$J]Y.&GU!E.CI1WQH/F^?_>^PT_ M.AK@Z.-+"D-T3KKC_>G;I_49RTW3 LJ;G5OTB2ZO3\US+JDY#AGR%DZWPTL74HMO=OY,J;,S&*<. M[S3O4\^F_[N0UFS6DEF#2KGI?#QLBLK'[B@=HS0L @/GH#L>X?!,\B-V7+]_ M["ZMXC$.PNCBBMGL[.V753TZ[DTNE,<.NF?D%*<]BWCJZ>?N[/VED:6^R.^^68=FGX^3(>N MVR]?O=R4BST>[[MQN1E14]#5'\P-P(7.7]V>%5INYROK"F+;QPX6K:?;/YX0 M8':AJ2/?ZZ6FE'PS4OONRV2\PV3PSA;IV?0ZW^UUQZ?E"2@J3ZYYW=GM9Q"> M3$-GB(/:*0-\.%EG^\AP9<8*85[)W&4V)L0X0TFS1D:7VM[MA]YQ3)W>X 1! MUD>2P]Y-VNGB8;?A':3"B')Z-!N>V6KY;?>O5R\(L\BS* L.N^'LFPF?]JD,2!]G^0MRNNN/ ML1$G^]VP/UWB!1;]SN$ &S)"R=_-N&JQSR@SRB27?G4&(1SCH\-I,W0CQ!,. M1#?U WYW*AKFI^A[76SFNH\]2U^Z@^,12@9\:3=TC\J47))QUY!7F6]C,W3X.1)%-,X(H$N:<">)Y&YL7^G0ZZ$^6RQG7'H]Q++Y.VH!S M.6LZSO)!:C3$9M"G:ZT,0UF<5S/Q;"H7R>8BSTV7R56JAAM-%VPS'>5%E[GS MR;2?33/ZJ-G\UVVV%U7440H-H"E$&JV0CN>4/9HWRD@QC;/1TS@;:@6]>VCK MNMDZ'_[>I^'PK[Y[9X]W#U^=OM_[:W_[W9O/'U[L[V_OO18[7__"=N\?[+Y[ MT]WY ^V3P]=B%]N)=@O?>?'Y=.<@T)V]E__L?'WUT2LGLG::>!O1;(F>$9L2 M(Q$-2VUM-BR$JP-J)FHERHU>F?-OJ+=3G%R)V@D,;KPP&P B '!5%P9'=167 MUZ%'!#8+#[_L&IVNZ+!X#X)\OY-Q-7<.TWA_$!O\.20)5.[&G<.RB(_07)I< MW.P\;X3M-TR!J;B^3<:Y)2]HYB#+GI"T 12XH!,DP>]DQ*-@#F5QGZ"E M-TK]Q[Z:]\+'8**B/I0DC\H0")82EZDE+%K/@C242;>QU1\L+.8+6MO92O;3 M^)OI^EUD6RSQVW"Z,3KQ))BV.>.:Q@4>J<'U;3++"82Y M9HV;^37^.X[_./T;C:KXZFP GC==^6-X8U*WCPX&GV%W[RW??H%M.WA]LG/P M]B-X9[BCF@21!0&+/YRTGO L4U 0A#%B8XMO+IX6[_@IG^,J65R%%QP5YXII M=V+,78N1R]9(>>%4X6\X^_O&R\QLF=H64(XJ'@TF+H"G38MPQ3P[Z<;Q_LS) M>N%;4^<8/?^*\Z-![WA\_5B?N=+3QRZ5.H= D%T=POO/73\'DY]RT33"&J\LEQ\#G:$'A M'\I'%D!' 8JFE#9^OO5Y'373G^7LN*GIOQHV_O/Q-<*DD4N3<0['J&DU*+U* M2YR*J=L(G!_<&5D0.)=MAQ2?AVE340#]@#GQN"7/-FR_>/XQ4LED-((P+Q(! MKP7Q03CBM96H]'(FF-_84IN+&\9GDJ^+0[1B4A M7"))?25)GFNSG8DZ>XMN7-I36\*9IKW!2:,'E0GL=$<=UQD='QZZX>F9JWC.3[NH]KMO M&(UG>39\UU>J+(CNW2]TH[Y/+YSKN)IWHN=,#0],W3R]O-I?F]MPGUR3?-*"O MO4PWV;77OO58NRDU_Z&G?ON:,+#TMC*V*;A:D<;:35BAMDI]LZ7UG;-NK3C2 M9F\O&A&2D[:BYC3=4GEZ7'9+REU%:%YR,(^>-'NV1^/.Y'G%.,.>H>W;Z75S MNC8KT(W&:6+F/_!(?6-<-K8:AU>C#OPVW7QI_GC>1&?T7&YH)3/ M!@3;]K59/8]X6';2N"Z6A5%Y-V6*R6A,V*+Y_=_(&)U_E5"IT>5CX4O*JM:2 ML-RK1^6JX\.WZ>NU<8470PMOL)1^/%U%;62K&_D8SN;O#5U,91]YU/G7N>E, M&MOYYIDF;EJRN77=OW5H?PW1_];N_JNS%73E[N?+?\KN+@[?XPKEWW[Q4NZ\ M>-/]\,=;MOWN%=W=^]_/[P^WR\%WV#GXT,/G[7_8>PF+H?PO3[;W/M.=/_[W M\X>]M_^\/W@MMP_?=-]_+7D6/_&=P^+V^;VWO?=I4FQ^+GT;,.G &$:$!$6 M6DF<#XD():-U01FIH#GW!+9-A:L?Z/Q2):LV]6V:1+"NNKKJJHBL(O*^1.3. MG(BT4GMM-"?<N>7YVOL#KFZS[_- M MD*;94E.OIE$E0VZ(_VNT>C:8#EE]0O!R6:<,H2_E8.A(VO=SNO9T;-VV3& MT='IG$S.*I6*S#9(Y'\(UL=,D[8WY?WE!(56GK\)SV\OF$*K MO.4A*4JHU9* #H%831W1*; HM*'9BD:1DVH1X#7W=6NQW2YH[Z1QA?$R83QO MCYE@HJ3,$\T9((R]1'L,+&%6<)JL!*4UPAB>2'[G-* MQO+=3)/6HOC*Z$\M M @B.F"WV-C!A0KO#E_^,4W\T+Z6;%@VV"N@;P;HT_D]"&$4#8H@'4<".21BJ+($A%*! M*4XM1\6;R4VZD';G3@;\*F[%IK#?QW=].OTA:_RF#N;6LL.-CFCF&%BBV27P MX+BR1C$;E#'*:>88J]9X^TCA]>+&I!!)BY2)=I (T,R( Q,)348:RZ7P@B(I M/*%J6;F^V^AT74\PW\88?P T5V/\(?"]4(5**5"2$H8:/$&=G1.TRAA1P3O/ M Q@OQ77XOE/0487VXY'3"[;X&A9^?"@ +VR+QH12V"B2%/X '00Q6LER!-8( M04/@B2^M\&.+<;QN^Z+?LL,]>$]S@:JSP(,T7D&@W'MC+$W<5#M\I1 ];X<' MI<%F-,$U9P3_LL0(:@F%7#*JI"BDWM@2RS;#5W ?_3_#P9=NG.0Y/!D,/X_J MWOAU4IY188U(I1IP! ?64J>#C,DFEZWTJ5KC[:.&MPO6N.?9>F<-29P*Y(<, MQ'$4^SXHYBA5!A)L;,$3O+K&+O?U!/-MK/$'0/.UUGB%\.T@/"?=;0:AA(Z$ M98,BW@"JZIQJ L(9JTT(FH>-+25;4DVV8G?U!''=^EXRAN=M[LR3!*"99)H, MBF%IB'4N$F%B@"08 Y500W\B)5]C,?R8=KXIC512C5I69!!X1*[..7MO1522 M&UXM[I7"\YQ,-F B>.5)U)D2R!P0SU83E4T2R4J%NG4YQ%YWOK?^FF7,_G56 MSN!YF":NK%OAUV:@CRCQ@3K.%0BLE5)JKN/RC.\JV&]!!.\7[.N@ M(O4A*9*H902\<\3J5%))"F!> I>6;6Q)6_>Z5PVMM[&N'P"NU;I>$H#G)+G/ M"F=&,:*514^ID!M;3"^ZQ^IF=FNQVR[H-M9UA>FM8#IO M0',*'B5H>!EO:N#X:J%YWJ7-05WK'=+%8:Z2WV=^/9H8R6NK!,&I;C))G('TGA.' M$H#G9+8$)37.&N%"H@8.+J/,]IEPC@HXI0IU-(XR6]NZ#;TZV&T7=*NA?'N8 M+NPT"^M"\(8XEQ@!90Q!XRD3:Y+06@ '9E'.+J)T?<3L8]IF%@[0,@;E!01@ M0CFKJ9(I*9QFQVRL=O)*@7E.YL;,9'9H&'NE7#FJP8G/VA"5HK01!*22P4D(%-H!QJ;">,@!,]WIK?;9YQFSZM! LLNQIU=9>UCPKFM!_GDC?4:>)* M]@/@+)1:#Y%H:K*E#,H6=)./4-S$7S9;M[/%!9.RT#^UN)U :,;!<:E,W>(2 M?+65#]_*]3I*=&U14/I#14'O(<*R/N.>G_$8@ON64Z#SIN$'K>O^S0W5J[JX M$EKH36S18+T/0EL3-0-GI>4F"7'VA>-4=EJE=CJQRITUE575UV5 MD55&WD)&OKTL([/.3L3BLO4*"$@KB/<9I:7WFGE'K6KVJ]941JYMQ.*=2W2V MVCG1EA*=C^)\=J8J.YJ28U*#2LIQ*8)$[3E%'XV*-R7^FH;T 8G^=,$8TLRD M"-*1E!/2NY&4F"0S"5IP)IUUNB1 X_#$WCT#6HN/<*\GG&\3>?0 >*Z11P^" M\.TY=T=&>'MIB.+)$G Z$5..H%"N3?1&:@N(2 IN&A!&@9&H46FGE!^YS-D+0;SH\JUHJ.3FF9A MO(!DJ.&0E?8^BF05I:P)BJ&SH!A:@V):CNAP&=&H7@MAHR.L!,1 RH88BX(Y MQ^0SJ&C 0BF[NVD??;*5.U;I?!3GP*,/B2<*T4@/0J/*%Y [DC*1JR"EJP9Y M"UGAZX)!+I03J+!!B9C-!*+VQ$))RJ(9Y8I'"'!M&;_U<;RN)YIO8X\_ )QK M1I9E87C.Y):HJ^6H# DB"P*,)^*BTT1I+J*C-' :-[;T%:DJ6UH*W7=BM M*5E^!*=S-K5V7'.M,A'2&)2U41%'=2 :DN+96\^\V]@2?+&"S_I(VG7;XOR6 M01U%#IYI%KFTD*EQP7,7L\1_LA4R5(-ZM> \9U K:F.BF:/8]8F 3((X\(AI M'XQ@67.CV#V4VUS!/?'EE-M\%,YS)V)D+- 4M (;N:<\J60H],ZL-D$J+1D07@H.@(% C!>*0!#4*BN$M DQ#(N.L;J/W5KPM@N[=1][ MZ2">L[DC%9'C3!+#2\5-YQGQ+%'B<815@IRBH*7BIE;K+(@?TS:V3%)9PZ,1 MT8"/S@A/J1.ED\D8F:K5O5J GK.Z:2Y!9%01;@U*9>T,\3PF0JV6UEJF3)'* MM6;(/9309X%>VW80*V8&/'H!-' M[8SPY!W:V+J(=I.0&#@W.%/1I;24FILM=J>O)UQO8V$_ %ZKA;TL!,]9V-I( MYWB61(O@":X%03P-EO@L%8L6.-5Z8XNQNG&]0N!M%W;KQO6/X'3.B!9!.:5, M)EX;C9(6!'%9"X2MTA08QREC&UN@Z\;U>IC0G**M'+G,'B(D:8UD+B9G*5.V M%&BL)O1JP7G.A+8B42&")$&*5/(C1 -.1 M>(Y"G"F?T7825AB!4ON*%9SBYY02&D38';I/7-!@5>;65 M5PO-<[:R9!$434 43MVD7KT+SI# ;+*1)>,I2EV]J1]BMWFE2F_>UNDW378_ M:?A5^>X?;7FFY0_02M#MP^8#K;4['YAKQ8*/@E)EDHN44*<2@2 #\28I0F7P M0C"J=99-\4YU1>ZH']MI6!ZF6I[QN+)K9=?;^XN61:\U2]_/IMKM^?-)BC%& M([&&EI0!D1-73BK)%$R$Z%WR=I)PV2QNZMXZ^**R;&791\:R+=!A:PW2^Z?5 M^0P/6DL>I"+@HD=:E8QXY1EI3A(E78XAP,:68$\8W#F]\;IQZVV>L=1.KP21 M7)VQ,5"K*7XO,0E12FM%UC1+S@+^%5WU/:X6F\SY'D5$SM 6Z4,)B?9P\JBD M.4.,%(I)3CU,ZYCR[SL??QD[G%C\?^Q^V5JXO?EP\A4__.7\Z\WG9Q[92.ZX1=9UQ\3BFV/FOV]3^_I$BP!<$L)G'TL7V M[N9Y<7PST6M7%"P?_MZGX?"OOGMGCW[\@0O\\+78Q7;^_74;=O?>?^2"\\R-(L)$0W Z7"D,X(E646J9 MG<8;-K;XYJ+CI^-1K\%?GMQJ\G^(.NOD+WWRY?:+YQ\]]:DDFR0E\3 !JC-Q M(3GB025I98E"E=^>_*:JRFWF/QL7,EJ\UAD 'HRSS'OD 9:)9%LF7]FI_// M;)W_^YO_\!'9E4?.,M$AH.XL#! G,R=1.YT,6"Z!EOF'Z^>_B(7Q?NH4?6/4 M2?V(PN!%"NG0IV$'%>Y.H?#F)VW62IG4)YUA&ATE?-*7U#O=[-QSQ?@_PWZ* MQ[TTR-]PA_U^/#X>IHN+Z>5$\.T5^;V'[?FU-PB?']U">7VRN[?]4667K$Z: M4!8I@2P4\1D5))=SM!:H1!Q/@-[M'Z/J6O!FF-$I@&$N,TB0G((48\PZ@HC@ M^$8G(?R.<*+&P^.TL;6'J^AH.#C =8%KR/7[QZ[7<=>I(F7-_38X1.WHM"F> MJ)^-KE!/9G?V=]8NM-%FMWA+?A+;W>X&3T]%I5;J:+S;2P0S?\U.TW M)HYL#"G\WK3GDV8V*^2[O4?;JZRL,Y-K8CBABM=S1Z/T=/;+L]@='?76MXM*4]EM>TWK+"'WK9;Q%;KUVYV.W-*=S/?4> M-_Y:!+:;D6A=//!= ^3BAI\0MF]JJEZ.%?A1IUL@<\=N_M;&]J=V>5I; M)=3>7KQM=B7>7"=OP'Y:->Q^(\U(.>"&\,:K( ,G*9I$F0.9P$MA&0FEX796 M;US(.S8K"&3CR_YY;/X3ZS"8DS=1R>_L%)Y_>;#_2Z/^VW^:NZT#7&_]=0J2 MP26\&]Y;/Z_O?[C8;7T5N]-&F%8=YK)[ F,_/VA]I8>GGR\.O]7YP6D=Y@GO MOWS_H[[_B1[N?R=_7UX%)/3K^]]I_?+K46(1=C &!/JAS)U)!2@I.*'(A);< M8ZQTML%L:K%.C4E? J.:'U'9' E8KSOV^WF0Y@#$T_WS3@4PRP.83S, XP.C M%&./3% Y&3, P!#&$8O>DZ02)S86 $/E8@#S!#CR6D0V7I5#6D/D.>G&6&'/ M\K"G/H,]3$8;E:?(!\403]0B)RU&T@4:29*4L)2Q1VE1"39_ZL5O@#]Q0X<_R\.?K#/Y0G:C37"$KK,R>98:>; M%-H5-POBS^HEG*N(G2F_SG@,S^3G]T7QE$?(66>24R1();E.V"FAM30))NM MW71')#O;9_U-PXFA#''OJ!JA0*,=8KO_#N5/5D[P,ZZ+(DY(;HVF^O1O_WEB M68C9NO+%K="3_'L$:(D .K;MX^_1]F)O?3S#7X= T0$B_<_)[F7]8I?N BA\ MPGO?/HN#;U_YX;>O=&\'")K^=5*__"X.?YWR#)^>9)!A]BQ[NG[X]PS,7X,XD189)S@" M9$^"8Y*8:>XT4%3"M\T,FA%E--:>\DY""9RVC/\)+NZ=Q:S"ZY]7.WK M[NG7(\>C",D9@&VK$=>PI0XSCX3$VJKDL7-Q>E]%,BH0F["ACG.-'=?2)RJM MA6,!_T[O:[G2LX[W>QSQMV/MS9[X>T_;Y"RX3TX*DXM)1,ZT=3&X8&EPG.JH M#;W-XW__["??XYST0!^8668XH]A9.*?*AA04B\F2C6>, -V_CJZH-8M=JK4Z MO7ZN:=[H]VK=V+>-)@RJTX4K.:RGE?\N0AAJR?I&L]%O#*]X8+BVT:Z%1J_? M;;A!L6 >6%?L#K_0Z9YE[W>NF)X:'FXK?."USH@@X;FU5&+N<#";M?[%6>;B MS8O:>:-_4LMB8,,V:_#05B^/\D[(X,HYY8--0G/FA,%P$F"?N:14PEZ-"Y_W MX?\^O' O_0J/S](+6=]0[*=&D0_G>R :@G@)XN#!^>[E]R,C@L T&024E!!/ M2B#-M4.$:<:-@$W(6<:KW+A)B)_ZW?N)$PJ8(=9PM8$RBGL,-.>V6 TL_IQC/(W>N@M0';9R/ M(%_+:)&VN3\:M1P9 $.0=!GA! 06'-7&-KV?,(N R*W:.-NWS5YGQ/M'/#S^ M[Z!QU@+>73#N3J[1.HJT7#'/]D$1:J5C 1/.@K<*^P!"?B"&J)AT!0W+A_X< M^&L( ]I6%L$! _6.4IP[!0@DH@)]3R4>W#T*VF-WKH*&A:$!GGL$_%K;Z#12 MSN=V31ZV, 6+I#;>1&-0$92SB%*)UN0#(O"Q[ >O(LUD3/K5KV5C;+Y(%^[.FA;,3 M"\?%7]1@<" OV'[QI:%U 00#VRY%C:'9P9]D622G=IR?-/Q)F>#1:?M\')M% M3H4?GL3!4+S(#\G?NGI1\>*:[79M^S@6 DW\X6,,O>)KW=B"-V0I)O;ZC58N MD5.+\,Q."XBHV4AQ]#PW:#2S$1KVX6.9:=*[ZR6]R=G#$W.5"'AX_P3FG"=D MO>\,VH4 =3;HGG7RZN1;RD<54SFW#Q\D4&@/9#@82O-B\\JB4PZ[T8;ST0AY MR29GT(,IQ"EA;FOR9-W@*EG82?+PBZ/C/#QS/*?#P-(5Y^U=%XY$SC.[SH+Y MOQL3=PUS:/#U+=;U.LU!__9;QIQ*I2'KZ1VN!5V1W )Y8A_&?IYTKQU(QQ&Y M;K3?002 T;ZSS7-[T=OX:3*MJ=%&XRLX/?G;M^ .V^N]MM0IFVBB*1@?!*'& M%, #=5K4&X9#P%&F//;G*06,VIS\-7* M?0Y 1K\" :Y9>N$S.!LNWQ_!(0F>6(F4\11Q:S"RBDK$F+>6$>MM=C9,.86> MU3A>9@UF]"VS^'(N8:TW:+5L]V($O!YPOM/.N)\_:BQ=U]CFE>#E;=?GGKL#3%>HT,'$!L7_^9+ MB$1=13YH[0&IH#=.H_=.?Z68\2J" M3J^L:6.2Q@/KVKWU2IEOJ1#F8PMRS83E3EIULYKS4J)M'Z;_7%6LV_]ZN?L- M_G\GG!SN?,"'.Y_IWF^?S_=VWN.]'7^^>_KIO)XKVC5F*M;]V-VOD\/].MZE M'[_7][]\W]TYX(<[[WE]YS,''8G63]^?[_[VG]9-R=)<\>0LT4C@W***88T, M5@3!]A&AHV7"Y2)>FY(MN7[[VA>W?/ \WC34O5*<>VSMN0KGGAKG+J;R)A7G M6-F4^]8#SE$>D#&8HA@",X8+*20K<$X]NLO70B12@5P%TE[[VRESD->W'_1+8XVSM%&.LTDP)%$P.5F<<@P[ +>+9 MA8Q=5)3QC6VYK#8?:R3F5\2[,D6^(MX5$>^4 N^I2NH%?&NAG@G%--,O)A8FT)"#FM03#'#R(J< M"R@P4SYH92D0+UNG>JS/KWN^%&7B4PX*B#D@N#U419L-ZX:)W%6IM%5J"Z.E M'U8IJG!J(9R:K7V&K<66R(@T88!342MD?.*@*Z1$ TF 87AQ#6%U<+2 R/"Z MJ6RE8GU%98^DLFE?G!$F,"41U5+GEIL6V=PNSW+"N(B",0%Z^*+5V2LJ>]GR M=T5ECZ.R29G[^"ARR9P'-@;[H1#W+)=FXP+"@3FB]L4WHLJJ OI2XQ*40]RNG[*6I Q5E+X.RI^1_ MGCPC D1_PW/O4 @ED/:YP M[.Y\.$K(L9^8ULOR[U>A9X](]'^>=+I]E%1 M560Q/>1U ]32C?W%.N<:215,/0RF#F;T"DF%YS(0I*1QB <2P)<, M.DHR7OGPN>TBE?5Q53;^BK@>3UQ3HKUA3(3 +'+,D)QF8^ WD8O+L0278A"< M W%5#K1U(ZZEF_8KXGHT<4T*V)^/!-$XYLPU3F/V3A.)8",HHM1[ZTS,E:N MN"J+_HL1H_^RW491:6E)QOS7C5%+EZY'RU]!U,,@RL\(U]9;3&*B %',Y1JE M'#D5&6+>,RT52-?$;&Q+O$ZMNZHPW747U"LZ?32=3D?3VURIF8$HH0)&G)B MG 51PCI& DL\4*XVMF'G*CI]O72Z=)F_HM/'TNFDR.^/F J"2*^1)4HB+F5$ ME@N/C"'$8D](\"F'RI&UI],JUWL"5XG^C[3NM6!G1EVY$'R[P MIV)]*TQ:")..9V3\8#AGP3@4E8D@Z,,/IX-&RCIO4Q3&ZT)V6!.E+="K ?FEJR554;P5@/_W&74%5!4>G>%( M)ZT1ET0C'9)'G#MB8G+>85!7V":C:KF1B4N@GI=1'?3FB5:U0Q^]-*\&.Y>N M>5;8N1KLG-)(:3"AB#@A"K:&$RV19MHCE8+#AK% B2ZP:5T4Z'FFB!$ MA9KK95:H4',EJ#EI;J@?8:H(DY(@381!W%*!G$D"20!0;J.TD?D2-9]$XGRI MF3(_%?T$M]>Z/_&?@[.S9M&AUS9KWO9.:JG9.:\UVB5]90(OVLCF3KV=45/< M!S=P+'I%]H8=)'M5.\>Y'_OB.B2^J,%6[1RK=HY5.\>JG6/5SG%MM(Q?LRAR M9D'.R\*&;<%T^KT<8-0<9&FCT2X$D!;((X-N(;[D+@ SQ3OG:2?QN'HJX/JWKWAO_P-\__#TX'2WN;O?/#G< M__ZC/FU5:7W]4=_Y3^N UN&YGR]@7C\.]S^+^OX!WVWM-NKT*]G[]K$)S[KX M^_+3;-Z^<\3)J! HB"*G%F%D8N"(.DN=)M%C470J58O6#7KZ *D*-EX$;*RX MZ6<%&RN!C2D7EJ:>.\$M"@*P@Y-$D&&.($F],=X:RX4I>^)5L%'!QEJZ;2K8 M6#UL3/AP3C\?Q>B%%Y0CKX-#(#TRY*Q-B%BO.$X^2EVVTL0+IEZMM%3, M>"25!<33WB$70T26>,Z5 *V+IJH[XNNFW2=IHU+1[N-I=TK) 2F$2FTI4DXG MD%:219J+@ )6RC'A<>1F\8XJ%>V^)-I]DN8L%>T^FG:G-8T<8XN]2\@Z&1%W MSB'K&49*ZQ"\I3BIM'B?EJK"PUK0;TE#MZD99]T&7#RSS4?I&:\;UE:J3OPQ MVH!KHTJ%9@N@V6P'1:*DT030+'IG$1>"(\NY1]YI$:7UWA6%I=8FU;;*87\* MT;^BLT?3V72M""9!OK,!*8$9XD9I9!S.,>8^L."<90%8*UM[G\:;H[.5BND5 MG3V6SJ:ELKQQ0&=V8YO*=:&SM7 "K+5(_B7_ MCCH)#7JQ9GN]V._5.JYOX8M%8&3\X4]L^S@6$GH9$MEQ,.PB"OMQ(9'K$E#X M I]1*9=W^; J77$UNF*!%7OI:R^^ST"Q-X2)3^T/0Y#XV.E.>N?'[&*5>WY9 M;/F&)CX!F#!5#I$H"3!C$9'S.B%'4L)2:DV\W]@FFU14$O"Z4>G2-% M2J>4U&BQXS%BQ#"EB$>16Y!SCBS543B@8>I)IE*IJF*AZT:E2]=3*RI=$RJ= M5'']D=6)6A44,C:!BFM%0EI:@GR*PDL-@I01F4KU^D3(KH66^U+4A(]5X-KZ M:@_CUKO*I_XP2)MM0R15D-JEB!C7 00/[I&A4B&-O5(:6T)U;D.HJH"85TS/ MSZ)G5/2\%'J>KD.G(E$L4.2998C3D) -CB!MN0M)1!!?Z,8V(ZRBY]=+S\^B MD53TO QZGE8Y/)4V@=:!HLWT+"Q%5C*,C$@&8Z!CJ7)VC5Y_>EYZG;/AA'<' M+2 H7_Z=R:#1'A0>J)L^F:\VVBT71^,;DB7/ZLQ9I]W6-?K- ?]VV^9J4#S]-!3U&XCG$PNQOC/D^ZU%GLM&^QW9 M!*-]9YOG]J*W\=-DR;5&&XVOX/3D;]^"\N?4GI:PDF@*!H050HT!IN=-9(H9 MJJPF!,.G)4#"/3&\S\81*SV.3LJH;>0A6.VLH %TEIA(\E9OW/(>G@+3WFMJ M!*@\01AEHU%.4HL9M2Q-OP:"-8P(2930+ 7IU16L#T_Q$O2L M$KG]/[UWN6E6+ %Y/Q/./CSXEV;'?W^A6'SX]PGVK;_:]IL9[)V>-.JM#ZQ^ M^8D=T ^B?OI9'.YD##YI'@*VUD]_.3W\]N%R;[_Y_>_+KQB0^X@Z39F,#@$7 M%" ;48RT- QA9ZP,T286U$8M LGMS/_;%U1P49J['OOGZ@)LYGB6"R-.-+9!N MKX(%:L#)6@7=P*'VN3Q8#9YS>_/!%UM0KBHG.#[]UQ7@-3-I>E-8S!NN8G?S MTQ<^!*GX;TT/P5RQ4;7N;-3?W$KD#=-_H757YC(FW3!=M;C.O.;&)*XY%=YX M%63@)$63*'.@A'@I+".!'WUZ2"6X*8O26_!;=_#A#CSK]+!UN/,='WZKX\-6 MG<&X+NJMPY/=G>.+^G[]$L;!#_^<+K/_Y3N,F^ZV#K_O[7^!<7]I'5QZOGOZ MZ>*P]0'#^W[ G3#GD^:-!>&,@<.K)1+6$L1C810&%4BIH(6CGE.70,LWFX3. M%BUX$$^8HHRY&W]4 /+Z ,0;YSQ31@=%N#7"4!T9)H3QA*UV)8 L7!.N I!5 M LB45PD'37GB&*E(.0*X(,AAYY$0)&@5. XX6Z'QIJ*S\6DWB=53IE0RM"T\ MJT!X0_NY-11;IUN63#P>P%*]+>GUUT&WFXMRCZ6%3Y4B'B_370FR;Y@/K4:0 MO7)U#D]BQ8B6QXAFD^8U)8Q@11&U5B#..4-64XNTA-XF:[5.Y+FGPKY7&5LR5*QI;$8U-!R[SI(D" M\HH.:\1IHDC[D&5\YHDE+OJ "QI3-_2"?1QGOMGL\5*2EO8[.4!HB4:/N1RY M;T2AF7LM7I^VLV+9I4+3Y:'I;-4'KYGF$DND(\YJCL+(D(21-8QJ*1G\M(7' M3]/9R/'G,)3,V;'^#2/.*X>;%8MQ%=PL%6ZFA+?$M;(.>Y1PKF4:?$!.4(L4 MQDY3[DU0MO /,B,J_^#S^0>?RS/X!$'T-T_=C9OYNK:3?]AXM =UJO7(_0\5L?*65[C>;=305&_Y0-623[+DWR^SRA: M)B1E$A8H."\13Y$AQY-!/E$K.3&&!)/]24S=(_@L26JHX.,-P<=C=:8*/IX< M/J84IQ"UMC9,Y=^KL-]6-/5T?+>BJ6715'V2IIP% M*&08(Y:H0YQZC+1G 6%L8E!)P G+P5]X-G;TWZN(_7HI'N;;[!?MV%_4>E'Y MEA^P%J]/<5FQ4+);Y8,M%4E_S$@G%&"44",1]]@ DA*!C" $,>IR%29L&-&% MWJ*?)B#N\7G_;QUT7CGBK%ADJQ!GZ8@S);L%*32)N;"I$ [@09DA4_(4$>U M- ([7UA*,"9/X&%>HK:T0@_SDXSR[?KU;L@];5YE3(3H%I:.WQ@O>MT<9UGQ MDS?6U;W*%:O8RB)LY7)&D-5",N&<1E(R$&2C< M5?BP%@&/%3XL%1^FQ$X0-JEQBH+$J7ANGR>1EMPAYE1D"4?&N=W89O<$4;\% M[]SO=XH^K]Y_L"Z2096OMA)DP+,..NH5DX*AR'/DCQ48.8,5"HH*9HF!3VC9 M6'-)PL-;]]"M"V^M*&Q5%%:?ELV%"HQ&I' N]I)_:)D8DH:12'.]%V8+D\]] M%/;&_'5E1F@:#WU_4#YHY;.K?'9/)+542+I$)"4SLHIATAF/+?(!!!:N2:[? M&!2BGFD5!/%,%.XZAM?#T%&YZRIWW>H$N ILE@LV4V*;M8 MQBCD?:Z6DW+: MN1 414MXXIIF&:X0VVYH6E9YZEZ]I^XYSC4;V_]JM&L7T79[_WY$'N@*BDDM_1EOP4(ZW6YE63;2EV*YN;G' MW0)JQ5V5'D;4_;XD[B\CVB[;WP%EDPFV#U/Q[\*@FXFK8O3S,'H^HU6HQ+S6 MP-Z%D1IQ4#*0M=PCZ7B4/E*G:EG2DPV MQF&.I4-$B(AX= E9@$%0T5GRBF&+O0?J85OL3NIY"X%6DU4\EE5P]D43_L/9 MYKA*7)']BLE>S#)-#[N31$!21YZ9)D%. J8X"C&U"H90RZ5M(67PC175$CV M1=/.PYEF13M/2SM3+!/PS&LI0> D@2+NK$'.@\"I.:=,>:T4Q07MS,4RU\:N MM-;/>%WRQ9R6H44[_58VE^??VD?:7!;L;G*C[VEMV>"LRZ4]R,WAE^+B90NI MECM#TOH"E/5'[/KQ*%5$*\XX3W^^BQFIDG#C8:LLTC$YQ+7"R"E+D<;*6^JM MX21N;/,M/N-Q^>__0R3^^3&-T*C3MH*/9X"/*<&:2V(] MB0YAJ27B*A)DL8W(&>[/9?RX$%QB7R&-&$8=M0XXICE(@WA G)%S'0'% M+PKWEJVZ5N"Q-+&I H]5@\>4T)1T##XRBY1G.340?K-8* 0[A16CR7L3,GC, M5A-[H^!1"$T_]:UKQJLXIBDS[55PV/;_N.Y/VY-!3W>YPY+E2_#ZWYI=OSW%THQAW^? M8-_ZJVV_F<'>Z4FCWOK ZI>?V '](.JGG\7A3O/D;A_P.NGOYP>?OMP MN;??_/[WY5<, H^C;L7\2:ZG3;';.L^FV@(Q:;]!JV2X\I%?KP^76<'>+LBO3.4[ MC7;R[?N1!\S4RXQF9'-6CYK[R:1!WZ,5@"&<-QH%^&U M0X=1.;@A>)?!M[!,37O6B^]&O_P<&KVSIKUXUV@7DRUN^GGXK!*BW]W0!Z0 M]_+RS^>-T#_)N+J%2R%CJ'X.WSR\O%5LA=G!/"@&NAPKR+V=;E$%]UU!V65SG$_MDFIA M%$VX-$]DT!TKD<7BV'WBM;C3+SD420I1Z/=Y8Y\6YM'=O9Q!WX8W[Y['Y3ZS#ZT]ZKR0O\JQY>/K^Q\'IYXO=_6.^ MM_\=PUA/]_9_^5Z,:Z?9V-MYCP]/_]/:;4S9BUI_M>H['QN[.Y_RN,3>_I?& MWK>ZJ/_VI57?/SC?^_:)UW?@]]8!_?ORPTRG*!R3B\YQ1+F,V:BN6GC ;:DM<@%KS"NPKB[,>Y.Z]"=6/?Z$\2?$ BG>EYQ M%H0A!C 0YY)ZC.>VY$0CC'DD 4';AL)G^H")JCSE!ABL%B$?@MT0$DMQ%$QVW)!9@IV]H\+>F M8/<6PL:!J%@5*O[<.FA&J/WS3@5""X'0IQG54XOD3-(.>6H(XMY[9&D2\*=* MBBO'@LZ]!.ELYXQG">^L K37F6CG5:JNB+<2+Y9(V5.Z%%/<)6PM*7BF9,76)(?K+3GF>)7]L!:ZP$DWQ@II%D*:^HPVP$#0]S0X M))/+89R@"#BO,8HV.N&]$MAE;8 \6AM83MQRE7>PSF2[D#90DF\E12R1MJ?T M 1)BE,02I K:QM8@+55 EC/'(R-X&-GT*V 9B&@ M^3RC$"3A,8'-0I%:C+C1!&E/+2+4:>Z\-\2FK! \.@NZ,B&^?JI=1"$HJ;>2 M(99(VE/Z $TL4,P,"CKD]L84(P=_(^F#]4ZZY%C,,@0ECPX_J(C[]1+W_?I M1@70+TS&/(Z:0I(F.4(I(*G&R16$#DHR/_ M*N_ 8NW73V(WVM2/WDE2<:Y Q"!$:<8LY M,C+_:9+G#'XDIH'"^2;!5;9!1>(/5!\J@EX904_K$!%3[P3P:&ES.0;).+!L MZQ!W'ENMDY!! 4&+3?'X<,$7[%,8*W\.[N>G?TOGIW#"WBE91_S*I M?UHK\S*&8!Q&Q%G0RD@$84!0AJ1TT0IL58H>J%]O$O9BI($E^7U*.J5;5*RY M#RC3SKM:HW4VR&VE&[G"=NSUWY@_Z%_KHL=\;8\:>L?PX8>'O7G?RG]54+40 M5!W/Z"T!>VVD,@"MH'C4SEL)@HJZ06OY=V4)KLAV3KWC=O*M MQ) ETO:TMR=H+ F3*"@/M,VC0M:3@' R1$NG@W,@ALA-RF?CS2OJKJC[9BVB MHN6GH.69W!'GDA$6H^@D1MP!QW:4$R1\U(P'+:S0P* ZY8WC)9N(E$-#+:+5006D% MI4\/I;?HP168+A5,I_5=(SW)"J[C&O1=80C*.X=TTEQ[I9U2%,#4;&JZK(R* M"DTK-*W0=+76API 5P6@,T:&8!F/7*.0B$-<28,Z,0Q QZNY MBUJKT6ZT!JU:+Q_Q?$L7O@^@5^NDVG\]D].FTYT45D=1(ON=7^*7Z".SW4SZJ1E]OL6ZSC]QJ_;'Z.4E--CA M@X='(Q:NE@P4^9!T8\O"Z.")L=<'(LR/B0 1G1:,N-E(/2W)7,/.^'7ZU9PT O@)PAOZCG4'\U"X=2GOIRVA^'T;3 M^S"\PN?G@R+PY./IT4=]_?Z2398;Y7&;, !QYFBN,61#JO(,-I-IAFJ6X MK=D"(34WA*-\/C/_NCZC!3@U>K5^"42-?+3S^9K[^,&]O9-.MP^@UC^Q)=3E M(Y;?/;#-&EQHC>XZFZ*$;M>VCV/F2E/ -YS [J %J.!G_WX0,&[_C^O^M#V# ML"O3MHHGOLODT/!S .F?<+A103A9J*[MP]KTROWK/=V8[TYL&@/6(0P"Y-4 M,PN8@4UN *[U^ATX92'^$YN=L[RW-0"GXZYMP1$ 3>'XI-;+,VU>S;0_-M.M M6GX)W'"6A>(AHA['-B!,$Z -M 2 U7ZM#6CM.IWOM7]L?&_F,_!F./;C\RW> $37'(01,<:2%GLC]C&^ZJ$#GV<"+B31_$DW M]@%0X5X86R8[&$!>\E%<8V_TS&)7>L6DKAX":_1/(Y3/.1Y8&%8_QMYFK0,W M#*G9UF8)LWS-H."3-WTR1IS#X\.SFC.K YTW0O]D9'T8NVNH-.+K6ZR#G1_T M;[]E3#7T,<_]F7+_"*=3"S;V\Z1[#5K'$;ENM-]148[DG6V>VXO>QD\3DP*M M HVOX/3D;X>U\N?4SI1[< H,":8H/S+_1KB:+@?8;3CZF'F0KW]B[,(PMQ.HPNK5GJ/ M1UID[U/[GRP;@+0'@_[GU9ON'J%#GN_M?R?U?1CWY>?+^NFG(Q&P\H1@Y(($ M+3+G1B8DCGH1'5B>,0-+43DD670*!L=VYX>" RM9M MV&;M>#[8N?> $3-K5'T9]H!"C_X$BE^C6ZC1OYYD,^4Z&@-BUJX+7;M16$Q! M)6T.[0"%HPYU$AKT2IOI4+OXOX-&:2.PO5Z$>[.*W;B>,FC0I;8^]L1F MMBR,5/YLN8(O-#OG(%R4E_)-Y45O>R>U!-=Z\&N[YD#3SD:A1FK$L%7["*\: M?W /[LH0U"]^-K*N#*S>/FU2:0+8_#YKVXLQ^5M MMWN1;0*ET7=D!RLF6\M^T[-L5YZTMPW]!&.#AZ]W?*.X>*6^C#_B7X.QT/U_ M;]4^I:E'CE^_X?FP-5>V!]NVS8M>HS1,-+-E^MJJ=^]D-HLUNUZF)D FW-;T M@^90D^SEIV5\X^X[__CZ9$_=R[ M^&+:6?,A<^ 6A,@5AFD47I/1@LQ>F3Q*=!MA"MY MI!\+*UE!S>6JC]/(B>T!#\XVX<)HU8#5 $DADV9A?RZ<+*4O;/->LAB:S::^ M=^6"ALP"Q;=7>EW16OB8[PLKCD"&E!8L_*#[KCY_9K-IF MIR@, \YGGJ"SO0(MX/%=6% J?SIH-UQL(;_%*>ET3X;Y,=>><^&#R\FEH_Q MYAAA%6_W3?BCP/^,=[\7[(*-[AX;SDD#B*/K3R[617:X\W3L#(H5*^;0&72! M0_SOP':'")>M4Y-\*N-J,Q8.2A@I@$ \;GC8]'\:,)RA$7_(&%U>]BI.8072(=6VXL92*AQQ\Y ;(:N'0+#THJ#MT0:N$Y3W.%N;8/K:E M^Z?D:WX -[4 N(H3E"&SW)KB>.;13'(2;1->W2Z(!@88V_D$96#*4%4('WFE:]]!%"C.V7!> M0W997FQVO"W%T52:X8O77B'CT&-6+B6PYYL,DHW\R$:_45C&-S,][';^*>58 MHC;'=O&7CNV&/)#2RM+I%J/Z]:\_:_^OG,J8%[OVKWQ'YA<4_US<6/Q.?OYW MS0[Z)\ :+D>["3B0EVC&F7RK0E:LPY1*)A(E5,)_FG).&+;4,ANECM@F02PM M]'E"<*G/S[J5Z;A;>7>09[^7"CFX]T<3CE\,O\(X!]WXAI6M.@./;.\KP1IV M(3XC!GS:_7C[27G?;@]L<_*\]$#>G#HZ%38,L>'K$?4)ML' 09&>()X21SI: M!E#!X )+UBN]L7U3%MH(%*(%$;XPK[C8/\]QC[!M=&@MIKQ@U7:H"VR"NM,> ML?0Q,;]PA?>OK7Q7:G5O2J\NF.'0_#S2C//E(E2E'-!0^QD71@LG7]8%1E+0 MF,(\'+-+9\$P)SJGD8KVVT)ZTCX\M2C"R;1JY#O^E#:1Q2Z? MM0#XI'FQ>16-4*!("VC\Y#;GP92 >:5+V.&@QJ;F"R/6XX+6'BMF3$2O%;R^WE]_\,1,""2&*4(,^R %3F!7. 1)2JH%4)+1G*FZPU1 M:65BP3 TK936&X6'L#@=M?-NHQ]KH7/>?MQI"?;+">!^D3%H' M:;2L3LL3\2.8PQ%E24M*.8K"6,0%H2U][\7T>[D>8[5]YLCN-GA^IY]79 MON]L'U_NGOHCSF/D#.1S:0CH[M8%9".C"# F>@\01"C@(1/RGK.]*,#1Z)EF M5$9G'/!L8N!P4*U$M-9*+-4MIT+<$ Y4G-*LD_7?M\.'T4&M3L4#3\7>SHCV^>]"\5WK;2K+&0(4-*ZKQ/"MB/X518&R.L./4$"$8I:>^) M+[G3D%%9,V\Z^RQ;,Y5TR7A#D6=%TIW42$=A40 D3!*8/V#6QO8-=4O+S+KA M.:!6XP#"V?-+BT2K)+6'T6_8G?__1'($X*9H$&E(\"[B#/(:6]S M"UQNE0W2YV:3L 5W)F=#NBNO:'/,.C\GV99+-_:1UP\&[3P&HZ.",\),G=G9U,UG828/UGY M)J@;-T%MK20[>ZZW3Z9G$[-5]F2[PZ_(D^5)R^@##=P A&=C"\C"4AH:N5.E MW644$#[A5[R*XLW)J"!&%@3X*7OSW#6W]I=OSW9P?M MXQ%H S"'YMYO7QH NC\.O]7QWO[GBX/65_C]$,9P?'&X[\GN9?-[_<]IT#[@ MNQ3 _;=/%[L['V$,G\7NSG\:A_L?FX>MCXV]G?\T8;P,F,"/#-KU_?J1)RH2 M%Q7RBF-0/3DH&V1R$).?;FUQQN5?O#7N38G=D,W[EUDQNST^X?V.1$ MK$P>! 2<>[%SJIAU/GD:F _:,!_INHR8(6YE]%8$AI?!1*/JN,\B^ MH2*,KY3U_* U*+E(#1A:&(6T^&' 4Z/5F\C&+<.E1MRT5!BO_3C#:+EN;(Q( MYSIIMDCQJ'WZ9??+>"GYKF.<-K_S M:D;#[PVK)&S5_HRQMMOIQQHI EF(_'GXSY_ X!H))%MXT?LR1S>OUQ^=9L,W MKOR$(W=A$98TMH[POY/.^60\T3"6K5=.,8?X=O\9ZI03:UH1E: M!8IU/IBMLT)X\Z/@S5 :>X;G;OSM8TN?M^*F,UI&B-TTBD9[%($*7SBV17KR MT%U42&]WO,SZ;A'A"#O6RAG?L$ZC%Y[E5+9>$?;4NX GM;+2DN/CIAY7'*W1 MU')P6&E2*.L #:.4RZ-0ONNF&81&2K%[/=C9=Q<;.?7DJQD6:1!G17A#8;XN M?[L^"3E2$X3"5ND7GIA>H?:5>?>%*[]\W906/+,=PTG/')_I5/7K5>G!D &R M%K$R/8$@$*8%@2OV7]!';^<:K?;S'KYMH>#S$0F8"^PE@M5WB$>MD9,AHA2M MQD%0+ZB99O+/RRGO88[S<,11B.8-RN8$>\3#_(6<^E%88VJ9/(H(YT';#@ ; MB_CS,\"85E'_:WQPMY=V EP_!NTF5X0K!>1A+9:1 EC4R8,E;=JS7GPW^N5G M(+VSIKUXUV@7"U/<]//P64.M\8;J
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ÐUI>Y0?7@6^_LU0I'5.6&56HOE1ON@QOF-1B&;.!RMJ0D7!!0F1.C!!!& MG7"*1:&2:0TWK)G797>(7\YI..H,CL9G F6JQ^4>/2ZGB_)K&G]-J;\]"=TK M;-0LSV.O+GY75/5V08U)TD6J.2>1QDA (&EYJR-A3F7G67*@5]>KM+ICUHLY M[L =4YGCKIACP4WC-/,JNI)W1I$YO"(6@B=1.\:LDDX5 ZA]S+$.T5(O^O'F MH5*UQ,<=3-"CX7KAG*?)Z9@Y:H:96J]< F1WKI1):I([?"V*K]$#-Z?OO<4C M. #4XP4G*@JD;P6">,H]H:4FBP2T44V)'M"+5NJ-H@=:5R"I%4ZPRLB5D5?. MR#0'Q9/V4J(!'Y2PF9L4#'> %KV/K#+R_3+R@MLM&S*G6)/!5>K MSSC#-P56KN7Q7?;3'EG?W]NE?3_$AAH=E\5/#P-_K M):WQO-1\Q)J/6!-LKI:/J'S6WI=$1%"!>U_2VBQS+F0+DP0;9JM!-E_H=N_= M6_K^8.=@^R1VT1BCK[;>?]H[>"&W3[;+>R=H=(GW!V_I]D*AV[_WW^^^.=CC M>R<[_"4:8Z]AYV"GN[?[^63[I+RW@X9:/'B_^_KXHGQ$P;075@%1AB>TRKPG M+FA!& JULB"<2AX-,OE@$FQJ[F"EMEOJ[963B6 2".V !^,"3T)D =Y(QZRN MU';/U'9\GMI ,0%".()\9@D(%8F-R1'MHO=<6$.]V]B\<6^92FR5V!XVL27! M;%;.RA X>!^]B5H$QZ('RJ+)E=CNE]CFG>A2!2&H8,0Z9DB)6\3?*"=1J;"FUK5EX;DV*OE;J@#*!JYQ*8&X$YIGU" ,/*6DC=8ZYB;2C MLTB["XLX7#EU8%TR(.^*Q!;3HR$%9FQ21 81T?!TBIC,-('H-;=<>,5*_=0; MY _<>B1NC9J]MLIAG&7">,C,,& V<%@+2)L12!ZRM@>040?M11LW<([3G# MR_BLC.6EOT<2:'AIB=#6BN@L4C;"EG3G-D;-5I2O>LL.684DM$.%E2*\A7.< M!L'NR,P;30UA7@ !;Q3Q*1KBHL%-/*LVS*]8@)?FN^&FQ7 $RD.,9(DE9%X>OX\2"DH0Q*34M*QIE:U*2:VF!AV=2 M_!B]U9I8#:KGK D$-22: PE., *.*F*Y3B1GGA*'F(&FE5D3%> MWJCOTIJH M&_4*(;U@2%B6A$'+07&%AH23DACE+''>&X"<52H)^2W9J-?L<*+6#EFZIO3- M[8=: : =5+58.T11)JS4C"CM!0&9#/$T2*)QQ851@84HJB_SH:)\&>UC!?;% ME;6/*^"]XGHY7,]9%<)DER771!N5407)C+@D'6'2N628#"[IBX+#ZO'CHP#S M79H2%8R0DK,2^:52J0$A!+$1#(G229&M94RF6^CIT?-95_?EZ,:_;0 M4\Q .=L\'(RZ3=V@8>KA9;ZD[X6T"J#.?&LZ%?3[5YS'ISX:7_Z5A2(Q=\\+ M3:TT)OGYR3C[]LXY:Y.?L!=^)\7G12MS'+)%ZTMK M # 6;>G(LLH\=#XBOY8:1],LO%%GO._&G:_=7J^3^DV% MN5+-KKDZ?OH@I7&GBY?(1_CIU/$3=NX,/,IB,^NCIYTRS&%W]+G<\:B?OAVF M,,:;3097O+U-3*XK8>K#KNN5\_4P*-/4'>$H/A[UW+!WW$E?D.IQ8+%<$-^9 M_MTL;'GL85&DRS/L(\M\W"]Z=0IN-"[^MN;Z^*RC4?EK.*GEAZ,Y,X33FPYP MECJC_<%P3)KO]0;]CP1E]*"#KW5/\(F:E_WQF2LV4W)FXD]7H]=UOMOKCH]+ M!<'"D[C0.*2 LU(6;A(WXX;'9T?2"-$T3GEEF6:6&H?R(?=T/SX<-A]TN1CO1_1^6IOM]X.L)1:CYS@"N):X;W[O8# MXGR4FGEU*$6-Z$R%ZVGG3'FQA8M]Z::O>+GLO@R&*'G'94G+5'>'WV4Y3"1@ M*G>367,>[T513M7IDQ?*!>KWRI6X@:[]QI\);Z M7[K#0;\9QM-E:S_>!_L\'U]= M2_7,_E&Y[WS16RZ]2:"H0E43:=OZJ>;[_]SX-!W_WW3M[].K@+=_[]!*O_YR_VGIQ_/[3 MZ^/MK6W ^\+[/U O???B9'OWM=QYMR?_?1)@^^3C!\6<24VS3ED*V2K%B]]X$EXG[TDJ%\K DG@ M?ARC*WQ@@Z8Z64XW-N7%LC#\KA,LN^P1-P#CHN%*<$#)!H,"UZ#IIEGU,M>]V#;C$3 M#MUPC(K;:+][.-&^EB0"'$ER@B>?%80,-GO<'JS5DAJ5DJT2<6L2@=?_ -8I MH%&2[*&44904+7XA"&5&H#H0I;+V4HDHVG5"ZZ4?T5*8%H=I3-9SZN2!.T9U M/6TFCN^ZU $D9]&1[TF!+Q?SFYZG=P[*H.;W&OV^4ZQ3U,9^,*(BW6 0CI" M^ZKHQE^[X_U.0W?GC.)#M-!"=V()/IG<>6+"H)EV5*P*M-NZ@U@>".V*89H& ME:!UZ,+GR>-.)F+^_A<.J7_^WA-SNERO&6WSQ^0V4ZOLW,VG-G<)C#^M=>^/ M+S>+7WZ_TU]''O=\A/HX);3+SACM,__$G,GU<3CXBO-USN9'BZN'1F;Y:/^H MC*@M!M2E%<8O-JE^2.O$*387YQ<%A;W",WS@=5B/1C9MUXM,J^E M=VZPHS-/.4R'B/0&#>YX,DB\UC"-<OO91]QW"\^2-RPLJ""F.P# <,CL3RBF1.]CDGC3Y!HX2RF9\V: M SQ92@R8E#X%';5T%AA(@S"(#(4#55SIJ5A!^DP5@Z7%X.T'Y9SBW";"(&D4 M@PC$*!/0V@T^,4=U=*7:QZ)Q,Q.#AL*6D027&55"&9,8&C'<6V8RYY(%F7R( MK@G*9G8J"=#HWZC_9Z_=;E;\>\/FJ.& M\T]T>ILEU+)SA[#G\0#904;K+42.IAP8:P5$:IE2EB?P^L(-\CP"_@IH7* 6 M_2J_F)Y'S< PW>MWB^:QB[?\%97DSVLGX"^^O=H*)Q^H!,^X4D0S0 EG/!&G MLB8P6N6'1Y?D34Q\1$Y"!!:Z!"VJU.)LKFT>EQX,@51^;I MF29:,D<'AQ.D-(=DS>%ID^]RSDQ:/$ MEA^"[>*CEF>+B#H]/9_T]"IA$[*) M[[K;_F#6/C527*<]F%%/F>*WT<1*U296*V]B=2YZ,I&=I-R"X\T[O%Q M!B\"3ZCEHZ:1:03)K'?1LB#0ZM(\)$JOWT9UIG;\WNPO<\K'#@Y@]VOJ?4G; M.)K]1Q/4B/]NLYVM(+=Y::WZG&[_\9:_^N.MV'GWDN/]V=ZG/?;^T_O>]E_S M08UO]O=.WM*=D\\G>[NOV?;6ZZ_O=U%QV0WE._BL?W=W/OU]L'/P]ALJ+PNI M-'NUT>3@G)'I+/80BQ$BN*M4&9CM 1"%L08)TE.*;K@A*<^K81T:A+VLJ0# M:U;V]8&0SOXPI4H[2]'.8@,)YXTUR1MB@M0$! 7BF.V$=596=-K).]TO5=99CG<4JE-%'BU:6)$$ FE@Z>>(XC<2Z)(!;"CR6+LUJ M,2:CZCJWS#J:<"I857A:1CV%=G[O%MHI)#3:W4_#U.3@/NY0C[LEJL7:3CD% MFC(( BQ) C%3XE$M(CGXY(%9:;G8V&1/M%9M4Y!^G!S_4$)KMX]ZXVZ:A8K^ M.3UN+W!I8ZPM8GTP'V;K.I,$AQ(-<'#N:\HS8^O&5>3$]O$Z3?)R254OT1+]!*YY$$F5SL3BS$-?AH]Z_Q7 M]Q^SJ/RS4;;36-_%NY=H]$$_=4Y?+$D#/IV&8LS2?D_3?/&UTT'! W8QK=/%'4)8&AV?&VD2)#$Y3Z9\TOQWU2V1TB97^GCU?[GV: M<#\=M!\,\5&F\?7#=#!=SDL'5Z+'<("3$8[/!BCO#P:CB7"5\2TNYJADXY4\ M>9R1"Y;TR;FK34=W&GY6IM650>(]9B+0GX6/G0:%3QX<)7;Z["4/XNCTL<\$ M@4_F:1)UTQ0&0$&:WJ;)C2A9%''HOI8X\5FRP%(!9_<&_)TBF=,'_A&P<4$F MCW]VUK^OV;1(0+??9+PW:1!-+=XFB1VG?"IOTR^>"_D[3WG2+U)RIH,\&7_S(//A[<^;D7G!B%_7[=/ O\0F)$6HB*X,@$UE5+_ MQ^I K)?::^64@**IV+9&N5>96+%,?/SZ00B<"L\DD8JQ4DQ/$6-X()E%S:3A M5F3W0YFX_Y#W*A:K%@OQP?N<%P> EYFXJSW*!O1.N,9-*7"V.4),=/ M\)^%N;=D$[]ZI&6SK;]J5,8_!Z/Q)&>L27><6N.7V1RMTDO.&B13!7G4.3S_ M//O)]<;[G5 TCTF>9BXJR.AHV.2.GM6G9]FTIQET7_>G!:02JKO=:7KGV:3 MBW646?I@DQ][7'3![SE[4YVSL62*U?*M:"Q%,6K"NH^G"E*3MA>;;-/9:' @ M33+K1-%V(10M%>]R7L6=9+^.\+IH6I5Z2=&-W21WMN0'?^UW]KNH20^;*^$T M]>,D+^+L+(7!:#(?IQF/S2WF/S+Y>E,:J$G8O3P&? H;3I]<6%5G:KF<7[;3 M==EWL3-YX*.#:0S[Q1\]&Y&.0UF&RXT,44KA:80$D5)#=<1Q>RJY=3GXZWNZ MIK^^.AU:)>S+TCFVM][*#Z44?/+"$1>U)V D(\Y01ZA$%8Q+X;B!XKQ=+-)R M[8U6V,<-$E:5>0(XU/]^?TX::O_H:CKT)VJ9#M[IU\0/-0 M6I\248J6LMN"$A>8(PJ-1UP@R3-#ZQ%69#Q:<,(DHQ4S:#QZ;X,"%APPW&(2 M2WP%*=)5"I:6 O&!XI(SZU LD:JT302QQ,:C9 \1>K/6?H+*\%=>YO)R5CJ MLD(Y$,"# ML%>['_GVP>^?=GZ;#R +)^^W4#L^V#O9V>T=O-I]_77[W1YL;[W]]FHWB.W= MMQ*?[WCOW3:]*(,Y*R59SH)PICC!C:FT8R!H@$DBE(V@),V9KX1S:DI/S5]^%)SS MF/*7[XAU%O.74XX@I6$D428(9/S-VI2+\QABU!Z4JYI.35^NK/,(TY?OB'06 MTY?!*U1M1&FV+B(!'SQQP7+"D[>EHF]PVE55IV8O5])Y?-G+=T0ZB]G+TL< M'/F&@Z($4JFNZZPBCDIAE,R\:9=3-9V:O%R9YV?)RY6*EJ"BQ?SDE(S,-E*2 M0XG;-347;IO\L)B>?#_Q8/A3D?D[X+XY)^'DLPY]' MP]'1-+OOBQMV!T>C,]F^G0NS?<_'M%^4:GP^ZV\:FEYB;[ZF7BZ1!),$P#-9 MP[/@_I]F#D^^.=1JS6I:<<^# MY]\^:!N4U"(3;BT0),%(# =+$G>9>X^68"G;>0$5MB2&MNJC%+)D2.8UP=!Z5!LVBT@I,IEY+8Y3-J,!Y MG<%_P%\V+HC#FRIKI!AJS[B>F3'=?L1=]1DIK]RZQ7)QBB6CIXT>[_[VOYR; M%P9/)T&*M]NWZ&73(7O7?=M",Z@W*&&9K6E2].GY#(6?T SAV_Q-;^=D^^OV M']OTU59 =+U'4Z:'*-S__&KW3??]ULMO[W^;1^$V?_]I[^3]'V_%]LGSKWLG MKV'GY'T7KP>OWN'W_T $_O&_G[<__?[YWR>OCW'<'[SAAJ?,B=&EQ2R5DOCH M\4_+P# O<3>-\T'"(@! EIJRD 7UU+JA70<2D-1) M3:6?B^/!YW;"9VV-#F>4/J43M]FRX>'*/$4U;*T>'+O2=,'6OM&_:C MJ/L)@J\1>G_!3$RRH>YX+G[PY,UQP.4G 3]))W@)D948DY[[,/ 1QNGD^X6>Q^_L,CXU6<#"^GH53^>!#\H0.UFN)E$I,0 M92DBE37-DK,2BA+=TN=DE3_NDC^.YYJ4&:\MS8ED[9$_LO+$""J(S@&W!EQK M,+3PAV*5/RI_K((_LG$A^YRM,P \&&>9]U .";1*(MFE#U0K?]PA?^S,]U8- M-&@#D5 5!0&7.?' '(G*9D-%8)PW_ %RR9"U%D7F/Q2[[*^Q&Z<:I7_7AD\S M[<_[\5^#<"']5(99@F$6TQ"U%3Y%(PF4X"]@@A-GT<)!RP>BCL@^3F]L*K6D M?G*KT?FK=DZM/79OR^BHV%TM=N>L"VD\%S$"JEL:L>N$)U[Z3#1/3#MEI842 MEW5!9?J*W4>#W=M2^"MV5XK=>J>1034)]/F9%(%A&G"HYMUP%JU+TM/?F2P+1JGZ\.Q1?DTW-C2W@QT5( JM A$Q-1 M>W;".:N#\$HVYP-V6?O\R@"Y&^=?A?!=J,L5PG^@5')' M]&8IB-3:6)<89(4;L7C"A*@0?C00OBVMN4+X#B \KTL;JK)7 8C0)961L41< MT)XPU*B5IE$ -,B?3O6E>V/=_I;8_A:+FD@ HP0:H=&&X@;.FGA7BBRI**E, MAED5%787>7L)LW]E@(GBI$G*%,E2;MB1@%GCAJC0]1 M).?MQJ84BZ;>;<*NQD(]^C/9=NG4YXYG*]>L@FO"@F9M+-<*K"%9@R9@0!*3 M5"+49.:#TAE5MU*Y=+%TZ65<4V,K'A2.;U])KSB^#1S/J>JHBUOIHB">>D? M\T",R8*@OB><<$E191#';+&P6<7QH\#Q[6O]%<>W@.-YW3^QH')VGD@+@D"2 MGIB0&$&!P'U:TNB3:Q&.:[S4P]"E*UQ7 =>/"^JS*R6=DRBVN2NFNK+$" 7$ MV'*U)7@]1Y%3BF**BEJ/CF9%$%UB6# M .W9Z*,SWF85LMC85&#;@]1U"'+:+6T2EK4QIC,_K<?7!Y64 M#\&FDC@B+SA;N%X"V.JP=,]NS$-D"99(55A5J,,'^HK'I)U\VS_7!^U@+G3EK3O,AYTC_K%!EO MW#B]27C'T.UUFRX&M3?-UNS"M6G*WKNPZ=&(.$/5 &>6H%H_863O4]%\?T;+;EM MBN/ZAO=!"^\E*K]OQ0[_?7][%RV[XWDK$*V_DYWNSFXXV7GW&K9/7HN=W1?X M3*_9]J>/\OUN$'OO7GS#,8E_G[Q8/+&PU*/YS@@%9PEXE0G^'4C1JV7@27$/ M2"*X :_6"+P5&^\^4/2?-ZE_L8H8[_6FI1MZ^"LMM826YK.P%3!CO"&:>;3K MLP7BN6$$< 61F5(**E1:JK345EJZH8N\TE([:&G>9YZU52HI1J)3"K4E:XD! M+TG26EC-J=*Z:DM7IZ6E3='<_.?!F:)G_;%I]*333^/BX\T3L#;&J9\<>5W+ M/KU@5AXEJ=[0!!77H=2+$P#3J'+I./ZUHKK5J+ZA 511?:^HGK=[-%,^!9U(@.*$ MB4$2RYTB/K"0>8J& RM[]8W-GA6B>AW.N?XGN=YX'ZV+T=$P#=&@6+?J7?=C M0(0OHV>3J7\YF?G?4Q.]V'#4GVE83H'/!R_F[K<4R4D:#BH9+4=&B]U9;+;4 M9*0@"%(0H#P@#SD@AB%+96EUI&%CLPF*XK^TJ,]2K?_37N/A:HBNR%T2N?-- M62A85XI\IFP,0?Z5Q&A01-&H)-=*9E7PZ940S#03W7D&8E+@5)P/10AOWX74X=?C5C;JC3NPB$H:I'U+GZ!!1 M68*K!Z/N+,9\=.1'W=AUP^-Z[-"R8X>M[ROU*O]Z-,)'&(TJE:V&RA9[;: " M(DP4FMC,4#%AJ*(XAK,+1GLAK E,I9516?5@FCC-KX.1Q5_#KN#8:.S=$+/=0\Z:W9@L:0N^D@]<>C+?S8".>QTM1R-/7V MU-K8P>?8V?W\022I("$YL9Q+_Q%6[ Z.NHFFPB?G(>8;*R/5 ]IJ9>0^@IXN M@W/51E8$\^,YF'/) SA)K'6) "*;.%Q(8E-"(@#\-ZRE'RTXY MFE5Y'C\=C<8-1U4.6HZ#%EL;,NJ,8383H4$2D#821T,FA@6)Y)0#U7%CDSX5 M+?)^5&?GX[ O*IIOC.;Y_BTTQ01H,B0K(VH4V2*:O2:9R621F*T4I5%I39%Z MY&B^#^NAHOFF:)X_G:!>L:R9)2922B!85C"\H+E->_,ZG$R\ MN*QJY@J*A=U68>V'SFAW8VW\=EKQ]-5IP=/*8\OQV&+_1\4MHTD&$EE&'A-, M(J.E0*0L(53-_TN3$UA9&/>]UHV^_RH9]U>\I[+7?5I7E;U6PEYS-E4L9S(L M,R*5S&A3F4AL3))D'B( B.!\:2:B;JZ&5?:J[-5&]KH;:[*RURK8:]Z&A J M,Y^(2I03,*KDW"3\$]7HJ(.T6H;*7BNN4/;CAB'E[VEKA4;*?])"9(W>G"W= M='ZA-&Z8A<,^&Z:>*Z3QO5_#?VZ<^]94Y.CWKSB/TG4TOOPK"X78[UZ&FCX? MJ!6>GXRS/_>'W^O(?TS$#Y/[3%S&T3YSO:_N>+3QS_.--+I]>C41J/2L67KO/='DI)&JU]6QPUMK'UJI+A.=QM]_=XN M/^["HJF]E8XQMS)6=K7Q7+%CS+UZN4_;@#07?-8=X\W"3QN#3,:*6OU@HIL_ M0]4O#4!](2I3;$6;>.,%N7[@S/;N*NN)+UTT^U;+EP_"NY46HV_6'1+FYRT/K8VN!>](CM-N"7:&0+ M!K@,-NBH(K"<;.;"HUT2E'2"1?CP\J+#Q\7^M0LF"?XR>VW:TO9-PL?YDHJQ M\CR$X1%>:?:)-PM5:AYIJUNZ_6F/[IQ\EGOO_O[4_/[IY;>]W1??=D[>?-HY M>4'1S&GN_?ZO>:\9FC6?7HM7N[W]]^^VR^\/;;&]^^:@&>?) MW[V+2DT[8X50AA4W62D;IX&8;"@1D7N?F$W.ZXU-^42J-L5>K"B2JK+7(V6O M8+T/0EL3-0-GI>4F"O::.['D*F;I'"-9249 "" ^ M146$%C$Z):/F#7MI:%-1[149%0]%A7S9_X) &%RSE-8C3(.[0VWK=.XKU2Q% M-=L+BE)0W@OE@4BF2QTL1XFC-N.?,5/OLC0,J<;:%F6OU6S5AZ)65)A>&Z;S M>2$@J#8T$BV-(F A$*-8)HJID" 'IJG?V#2K:D+6HB33AZ(.O#@X[ V.4YKU M];K)V%!* M:L9$B?=HQ"!/9<8,XUSEC4UF'Z''I6+['EP4%=NWB.TY_<. HUQ%36@L;5!Y M$JA_Z$ $-;B4.7%<[8U-+DR+L+UF_HA?741$^6G@RZ DX+5H"B4MB@BGEAYBG3B293>G+SE2+C+OJN&F9LE2!>P? G=.%K!(Q^I"( MHHD1 ,N(-3Z2G)3,@M/H*5HY4E6O3%NBT*L;YLX5A]D+DUSURCE+<FJY0L7HSK,[I!TP( MSD02Y3 VH7[ *7':2$)#8,X:#B)S5.Q753FB1HU<(XAT=#0LCL'.<.I%K*Z% M%H2-7.#2G;U426DI4OJ\Z&V(0=J42JUR[XH"(8B/!H@-1FD>,LN"HM%":XGC M1XSE^\UDJ5B^+I;G%0PN'40N"%<1M0PO+?$.46TL*$H=YX[;E1RS5@?$M;LP MNN/AH-=KTM\GQ5)CHG2@.C*)F1-^$*],99K-5;<%VT_>UZTZ+!IZDC:^8L^*\V: 6G MRW :.%[99SGV.5Y0$8PRAJ'%0;C3Y434)>)Y,H2)F$HW-C"E4:K@BX'C_ZC> M@L> UEM3#RI:5X#6.5U!!,>\U(-M=.K+F3M+/-.?ZO@ZS^DQUZUENZV$+:F<.)>[( 8 MA0IHX+A&3CFK*&QL,GH33U8]YVHQ7%<<^%+ANEJXSFF*D2>;1$C$..T(>&:) M!^F)22ZHD+3"-=S8Y(LQLO>"UC4[\"HEBD?C@XN: %77^6WZJ,Z0SIDUJ&RS M'-OP!>7 114$RX9P(04!#24D'Y6#["WE!A)-3FQL"M$2QWD]YFJ;GM8 MG=,,%,^N* >$F40)!)#$RAR(8E[(I*TSU&QL E],A7O(AUP/137X28_ :H_< MD7I0U@$G[_EPZ/H?TY1ZJF][9;PD%J-IHP0K'"?,:UNZ33#B !0J$E)RF5AV M6B,O/;&P>*Y570R/ M*WJT542-\ZI.=4#9^5C$8PHJE*!+)QQ)C,":7)2IV] MTC25EG+B@F)AU0]Q%^=2AT.4]6GL+>H<[F" HSMI7JB>B7LXN3B[(J5VP)GU MJ%RU0JZ"!?4C!(>+I]$.\N5HW7-+#)."<"^SPI5U,2!7F2?"M,0PJDZ,MJD? M%=8M@/5\2*_)GJ<,"&OA"<0 :%583C@DFR $!#LKL-9R,0'H(?L[6JUW7![4 M>R8JID;VML,O,BF+>)[/*FFMD+3D8M90RBI;)HB4@:$NDASQ+$@2I:". L\@ MU<8F$T^T6H$OI(;W/BX"6+47I1+ [1/ G-;"60I!RD0HR%PZWV7B*0AB/=-6 MR1B]*U%.ZHFV*XA)O'\B;33L?XX=WA3_C=TOF[.GVCDZ0*B$S?]N7IP\ MEQ_^<_/T&9O73]^\0T#R LCGH\X@=[922 <^#2( )ZJYZ'^T(1_^1XW('C,!O/_W/@T'?_?=.WOTZF"; M(]!/WO_Q5FR?//^Z=_(:=D[>=_%Z\.H=?O^/UW+GC__]C #_7-)>M[=>WJ ] M8 >EM(>_/.E\W>^&_4[Z=M@=IHY/XZ\I]8M@\49R. 7VM+-[1L)0(D;=6*3' M]7H=]\5U>P50GD<%PIU\-#X:EK8: M10911(H8IF_=42.N: TVEQNG@\/!T V/.[&;45S*149/.H?#P:<4QF@]3J\R M^_S$F'S26).'/=?OEXN-QBA6Z2-N),VHS@#E____#&?ZEQ&.(I1,Q.]X&:;1 M46\\.O_0:518HSO:QQN[SI?%4ERM@=)%%6\JA"Z$$,?/W*#VU Q"'?<#=D9$ M!7?%@@$+Z_ M]@;A\]K)'^IN)^&#$3DK@$P,=:7RHG'$@5&(3RYUU$*A;&X@_^ 6CM,\'AZ5 M3M#WIX@T,M-Z[WHP:C\X(0R/)L\QOY.VI M%E/,A.F6PVRG.RJPRH-"8F=2_V?B/7ON S?$&SJVI?EJBTN:4R4;9G+S]R]=N'.\7<^DIG506 MF3INIW>>OOVT>6M.09Z\I\Q3 7#IV_0IN_2]'UW6/%567NNJ/WY/F#I6"Y^\.0;FX6CEGBF*]0(>6B/3]?Z\9D]]_CK<%;WZ^F> M/MW(K^GP67=_\8-W!]^#-_@2X^'!6ZM3C^^WG9./8N?=F][[=SB.K8]T9_<- M?G[O9/O@Q;?M/W[_M+?[9O_5[LOC5[_->WQ?"+P^>__'W[V]W;VOK[9>LYT_ M]F#GT_;QWNZ+KWOO=O9W_G@AMS^]!+1P%SH\,LA>&Z6(DM83X"X0GU,B@5O# M5,Y&4+ZQJ6_>EGY9"#R,L[%*9>M#93GX! R\HS* %,8'K;AA.0L71'8-E3%; MJ>S.J&RNP25/@BOO#(%4?C!)B2L=+++.GFO)@O1R8U/)1<==I;)*96M%95PD M )1B!T'7G#8V!Y_EY6'J MN7(T.1XT3O%P-"SE23K'R5VE?]\##+A?YL#S.F=+UR"CE_TP+-5A2B?QHUXY MT?U].#CX;;(4?^)C#LJG_YRM6>6NI;CKY8)%*;C)F3--J(F4@)6*>(YJ&%J3 M"9Q+&E=T8W/)]J&WITXMD3;SN/&H [6:XF42DQ"E1#QF3;/D+.!?T35XI#,\ M7M]E4_%XRWB<,XM*LJ[+W!"F#1#05A*3?"8>E3YKJ)(BTHK']N$Q&Q>RS]DZ M \"#<99YC]LD ZV22+;@D=DI'F_@=ZAXO%T\SNOVDN4DP5$2I0T$9,K$":-) M!L982IHK83HO!\B"H:-VKYNE8 M:YU9%(I(YB4!$8%80'5>4D6%*8&JUF]L2KXB3T2+_*85V>TP#2JR5X3L.<- M.$4A9D;06E<$J/+$2$E)T2FI$I1J*S8VF:G0?L30OE\KHT)[-=">MS&\\Y$[ M90BJ8&CS)Z9)T<8(6AX9I)-H@S"$-EO546@](KB\MUD\"A-[(J,)<=["&.0E M+8L'R$5+U6"X(PMB*U4RNBTR>KU@0425#==6$1^+ ])YI*4L#)$A:X^[C?8Q ME2XG5TXHKL['VX?B7:G\%8JW"L4YE=]R3B-EC@09_43EMZYX(;U', 9;>F2C M,;^8'5RA>']0O"L5O4+Q-J$XKZ+3((Q5.1&=2I%_2C/QN+I$*6/0,,]@N"PJ M^M7+9M^FNR@*_ROTY7KQ+5-WB?'YU(G %',!M8\L,H&4'3%,.%1&8K*@6!0) M,;YX$% Q_B@P?E<61L7X'6)\WN 0BAK"2;GM?*@>%(V M29(CQVU2^4B,U8PDJTSPSB7%U5UOD^M0R^K%N8J4M<5,[8QP^_D1*ZKP7(LN MK(**PX+%XK/G#K0D4>1"Q4D3DYD@B5('AA7%MU#QRN*A[[_]0>TC4]FRK6Q9 M"P>VC"WGC,D(*EN#QB1GUA(H/F47M",B4\NM\D[:= N% RM;5K:L;%EK$[:< M+>?-?.X-..,8R1YM?>"@B(W*D9!E,IYKH72XA=J$M;76\ATM?OO[K\[_)-<; M[W=^&PP/IZ7MFT84!X/1N 0'EC85HR,_ZL:N&S:]A(:IO% :$95R 6^?_O6T MDQ-.L.N=;6KK1IVOJ?1(&IU]%2_8+U,R.!HU(8B3ADF] - M6<.GTF"C=%/Z?^R]>U,;2;(^_%44O&=/S$10G+I?/!%$,(,]AXV?8.S!]L'_ M$'4%82&QDK '/OV;U=T2NMH(Q$70L[$8)'6KJRKSJO:\<6Y#'&OE MY*Z*>Q;CVLM<[!UXM@_Q6^QM!3?_);=0HOBWO0]_%[^1WW[-D^%! M2BP\U'\N04S258ZZM&WOI!C[A;V*O?YFH^@;4#W':#"=W-BFV_O:*+ITN&*P MWW)7G.\M&']^'OBF_ VYH=0 ;EW,6R^"+'_+W:<&^55XSCS'+9B">#/N[D7L M;,)]JR9/58^J 4P22%Q!T=;*HZQPMZS1JCC<;*<# VFD5CN/I.QVTNK-6^U> M'%SV.E7?J/RHI[#N/B]++-8)AA?_ 0GNV%$UV+Q^5+DW4-;.8G$725;U7:,: MLZ*@;#38\IPD,B_#>%"P?( $W#5S^M3%Q586A^.82ZV"0EX/% ME\RT+GA\ Z* ,I+WDXFY&_MYVKN)&9]$Y'K1?D4VP=.^L>WO]JJ_\3^3G75: M'30^@].#7[P$HS93X\M6VA'8)!.Y4=)XQH-A)A'IL&.",/#[HG[*UD8_V CF M;@!@4G6'%(^@/26FCC^-^L5O<'+-L-7[<\+'3';][ MHQY87/#'(3Q%/[+;>_BIT\!1ES&J:JM%-QON]NULES:?K<#5L55ODV_ M5;1VK+K;S?G:15W"?"&TU1BR05"-HP/0VQB E06+< XK?=IOA,MXLWG?V$GE M?/:KVH]OH,?9 )M0T@E#(Z_A\%/%(H)2=G(?R%8>[W#B>L4#57^,!E@]IP?C MH3O(DU3:5WG0,"5PA[@6BC'> #,O3"_T2T,)9B$W#(V=?ARGS5J\?%F$X>, MKAD]J[4;4R80JF^MO#:373>M][W+ M.FOA0FW%[ 1?\4BP&RM53KS<K8!(R\C&(Q+GU+)Q=]DX>WML%.,Q $I(3RCBGAKDN L(.\ 2 MA770./?$-HME8WY+TLUL]EZ Z5-$)28WJMQU_1X;TL-F"OQ0I';*+;86J44B M!<]][+!,SF218BY3IW&.P&+%2-'HI:*>,IYK(L5L5>2=\>:!ST-KF;B73!PV MCP6C0F$A$"'&(JZ\0C:E3+9-G.9)\I!R=BW]D4Q4YFUV-48F[J2I_,/6XB4R M43R-3.O@6_PXP)'=@T%W /ZS/>]>=@8_;B&=_4GP-U/CY@.;59@#EJ0(TL]Q M-F/Q5@X&CPQ;;#9*$*F1>2[%4#T.R>%< WC MWI5,WL3X;F0K]N\?V2Y6S5EGDE,D2"6Y3M@IH;7,H53X-7%W3"3;F!,/KX[Y M4$X)>$/5,$^@U?_EZ\/>4_I[MGS;//IWO'[ZE7SZ#Z7[]'O3^W>G1X=$_7\[?XJ/#$_KE M\.AZ__R]^+]\C'_X\1BT%HP?+%"2+" >?>Y>"FY?2@GLL "N6?0E'(-.Q;"3 M89#ZZ)R01EO"N2+4 #"#V::\U)1;H3<:$5#Q(A_CP&:\L?WW .:W ?91/DZ$ MS>&OMLW=S*?.LF^_P\X]!_GY0TT. FL;F0$/1D;.@^1.4(TI$Z#Q3D7&GO+< M)/M! (GG-Z>$-PS5R.2WHQL3>'R'_\-3I$+H*!(19FT4FO.!?.\;[R M(+8UNED9E0>]S5\.)E.OV/ER4-M^MSE4.'+$GYE:;MV).B+*A8M:(G>'Z*W0@&9_>B> .FX[PU M&,38^"5?4JUK\Z__MN<7O^W>O#U:YNK>OW?A<:ICZ3_^RL_E87$^F (3 M[/(\?W2A!=;/*-F?,L)(Q-A;(P6 E?1ZQPQ]")22VRT7LTWPO;VWTWC] T& MC\ON3J^(^^=Q_WXU ],[>8+WB[.^@U2\VZ]*J*[7QZEZ;( _NCYX#_:989Y% M@EB,'G&6.0N,\9X_5Z!\>8(%%\3> MM^J@[28)Y@9^?G8>AUITYXNN M)\V38Q(E28D;I!AF(+I.(<=2A"W7<"Z-%MSP3M!YVT'YKN/GLQ$''3FPHY2L[-Q^[V4\ZC?WNMT)! M&U1O%NE.F_=22- Y80UF/"K/<7*:6LY\HO RF%\.5VUS"=4_5L@_BH4K#,L_ M[$5K8-NEAGVH@ <4[%VQ@'O]_F7>R&M-6^ %\"9L$N#S*L)S'POG,WE50-:" MJT6L]#QXXBBA&]MTMFQKCJ:5TC2A6&-YG4-+":RW@2T+2&]4:P=@,V=GE+< M&WW RJ:*(&G9[H;#W1@D+X)6< M9-/NI!<+A-\A"3ODMS]^[ST*3ZJWM<17N M[3\'N^^/K9*!)9QYHU-F= >+S(&6H>A"I#$& 4XX[&VWTKC;[&T_,,A&\GIQ MV-"W.=PQ<_PW_]KM MM*=[&92UR M;X?.Z'/9O(L[OLD[5\O?(IY78" JE'#2YZ\.L)_)J'Z<%3BV.A-" -)Q'FT. MW86AQUPL?2.G08\U%\Q18=O*263MRU&*6+'.94YI?^RXHH@=#'.;OE5 W(NE MD1,;_2KE_J+@Y1[>JY*GXHZ_G,1.#D!G9!Z?+1B]1ZU_T&DKA-AY\YJ@BS5W MOQY'*VG0W"/E!")..L!:<^)V.$"&L\?8208YFIFP.9A>@4QDM1;@6V M_GD50>XOVEZ*,IG36,:8RNSQTM%8%'V:2%)Z\^.3BKF'$3\=WF1=B.V=M#I% M)6%Y4%:.;U0]4]09%B5<%_WX9OC+;Z'5!^OIZDVK4VRUQ46_5?>J2FYRE*MJ;K)\CVIMQCG"]_&6V3A>S^ZK=Z2 M1MSIKC]^C^GZ6?6M[KH<>^S35,>;Y4UID/+R64/.O2\4]DWA?.1/;6SO=4HD MJ'RLQ12SMYJ)LG#MD>?B!R/?V,[HML28%E('KN_P\:L>/C$3PW]LEKK9+6]8 M&;J%Q2-DRBR@E!Z/+A2[?N4%7ER -]DJ=_6B7+]_$W3<^= ?11T?),]&YIR9 MGS[]G"+<;$4@MC5GY\^648ESOY!?I_*FEB-%>.W$*:^)%X7BQ!GX5UX&SK$( MVGC-O ]8"BHL#4N7=E7^5 SSW:U10<::1XA+OI2+]M'G)M\_^_*U^>>[UI>S M'5QX5(?O3L%S(@>''Z_VZ:_ MG#8_OR7[9Q_%_B&,Z?,^>&:GK?^[?CO#Q9=LC)12AACV H';(9&C'KPRQ2-+ MRL>@\,:VGCT]O1==RDOACJH1[O4@G!:!*6.(#D1P;K0.#!/)5-*<:,;UTC6* M-<(]#,)-\>$>**KX/.,*'Z;3%+*"#GD[;A+,Q]Z;[Y._C(8=2Z 5 MIEX+CB5AFG-/N7.,,FI-)I PVB]/)E*CU0.@U=Z-T M&-!*),J9SV6;F5IDED+BAW!5M\AY^+X*C''%-1><$:X5U5BJY)D0B3B/O:L] MH&>B<=,>D*41;#F,&(X8<>,",DHD%!.SL'A@)$29LPAGBV]KC7MBC8N1$1VP ML1YSQ:36C'K'@@?KVQ 9:XO\>6C8T5A\)N)T<)VX4."IZ24?E&;<2J!NOU"CZ7%%TY12A M-8H^#(I..Y])>V]<1#3D$C81$C*)2?CAK91>>*-Y#O>L.,.@1M$:16L4?7@R MW1I%'P1%IP,*-E&#(K.:6NU^HK4 M6Z3/TCNGSQXO\]_"7CJ3''EZFCLPO[)JV-&W*M,=RPY^]&^?9 [46[*8A;VR M;T=90_[V[[^F&5B6IWU\+F7=>3#K4+I].(?M=5@]6?%S_'79\Z>@(Y/T''F MTS1T_6%%7J8<**_)9+078W7"MR3!,,R+(ET/B\ =]L9S33FA/@8M@C(U*=ES M*QG=N]J_?G_LP+&++CKD<]8>AXT.@>&2D%#$EL2U M%9T 7&%O;G;1RTP#,;?O^Z&(E\VLIG.W!#?6!6=\,IPEF2-5EB<M##?\KCZ<@61UR,/T5>[G>:237B+X^P<;[NT?'WH-$!\>0 M)AB,."\8 A-<(TU9LHQ'BZ78V#:S@OVO(05%N_N];&@V8KLXM[VO<3 DO:AH M,%J]?J;'*,@TB\OL\._RRBF)W&KL7O;*UH6YP/D^Q$,KCWH7$I1YNF(H'[*L MK2\1=52B7XC94 S@6R-L L$$?R.K\>4,DX$2)Z7T2+ "XJ\U(6R!AIV'!EK8G0R2$]W](_P[K M7RS^:@6/#N7.?^LODKF%TK93#F " ;O5IC]\,8R$#K\^H:/[9T>%T F*/<*! M@=!)DY"3GB+J**=)VRBQR-OZUKRV'A>9ORE/Z,^X0>\#7G7+];< M?7^LC;#4)8]\\AQQJB72QE*D8[ V&:=#/KAC/^@/\B-46T"+=CEA.M:M=._> M2E<^]U:Z/Z.$GR*Q<=QB'H)*%$QSHK!-DAI#$@MYP^LC]LMB[V[U1\TY1_QKH>K46?*S_3)EBU8L:C]TCL;YGWYO6WBFO_UI MMYVU\F+8+-SG#YQW0VPO0]?W6+11\Y%]H>WP"5:@W!XR,VG),W"8<>95$T>= M-8]=#%0;FF!_(PEQQQUR5":$'67,,X&9H--$4$^L43^AH"KX"&]6&22];.-: M*N&-45Q24]Z;EVI&,]:'.(IO:78WVJ0?W=9L:7DWVJ3')V-:MVGG< M.C6STFL>?LVL-&=:=EOYM >VJZM6;(>7Q),TIU[E@>KMUR@IY2&.+_C* B_O MP!G*EG@F4EK.O_S3//[2:^=H_W[6:AQ].]S_#6*^; M5T?7[]H'\)U'<$^XS]4\YB%-&%'>&:0MR03WUB,G!$$IRA!5Y%1E;GNR-:>7 M^/.K6W\*#?O7+;;2I;,.5P)9KP"O&&.$4R^IC%RHI)V"VUKOF7(TXOB3;.0: MK]8 KZ82F266BFM"D!8Q(4Z<*%O84FML5,HG;TC&*_[@/!LU6-5@M0Q844N5 MMT&9%&-F]7.<)$:L("P8+2S]2=)O#5;/'ZRF\X4I]X39I!#1V").HT0 4KE] MK[ VUR 'PS)8J0/A?"]_Z MTTC' M\YIRYD4XMS5@W!,PIMQ;P@AL#T7?Y!00US@@ S\1LYXF2JUW26?*FBVZ)%-N M#1@O'C#6PL&L >-^@#%3DAJ9Q4881 T+N<$? (8+$6FJ0LZ#\RYD"T-MF24# M8FL/&/6Q;D%LV^I_1:D78VYB'7,WWD8O9P6NH3?)5G"^^^(W@6?M9F9A? >R MN%>)8KT%++\%S#)DF: =4=H@S:)&W!B'G# 6I%%$@5/24J2-;4 AO:(HX]IO M#4]P\/'R@>*:<58\I2T0 W#B<$%>:(:VB0DH3(RFC7,60@4>O MJJM+#3PU\*R7VUL#SRJ 9^9%[GZ6F[E6+CEU:G4=3K/ Q1TBW8A.8_Y3JZX/QG+O@"D6*5SJS+UC.W M+/%.KO6*V%Q^%%(]C+US,E&+#J/W;\)E+XM]O<7<8HMY/^-44YHL\=@C%K-3 MK8A$QF.3/6LII/1,LL*I%L,=IA*9[0>LK'D96G07/['6HC71HFD/T3 AO;=( M!WPMEZ7XA M/-L+R,CN>2A&5Q8B>ON?R];@:J_3'_0N\XO]@\%I[!V>VLY!B:,%KU1_KU,R MG W%N2(T*][(?#:DY@]+K1^G#'SI0V"*P-F"8L*<:H4LE@G%)F-7G.K M&<4;VX1N"?$\0DF/V=N@QKWG-+:[X-[]SN1JW'LYN#?EF%G'%)?>(>V=0%RR M;%(&C!(EWB3#,)4)<(]MZ1KW:MQ;-]R[YY%@C7LO!O>F76ENK131&J0#SJ2D M(B&#F4"66H]MT(R33'KN[#\O M+)D ,DY1.K7X#EL9? MM@N*T));-)/JQO,6LIU.;G@PO*+?N+"M4+ 7+F"V7]C*8:(+PTWX998:]/DO M*GV.BQKGE 9/<+^.%C8OP&D+UJ.757+\\PM7;]0N)E@84+66%0_\MQ%W?/S6 MZE[VIYECJ]X%:[C.[#FN0 )\&(8$UN"$4'LE8\2&0EH((==A(H-_XI;45MS:G M!*#_ZSJN/7^.:Q\G$EA@D286>ARP;]K6S-.^Z>. =6FT]0%D%1XXST#9KNHC MV/S]8CL"0[DX7,ID[V/OK6M;KM[-2$NPO1R-]&)LI!/O]6*IM %T.C1@?;_! M3?(-L@LRI"O.=^A%<#_@I4X7MO/"*6FD7O>\5/&* 'NK,4L^GM]?\LE@9 M!:-6(;?H[S2\=.QH)C]L*T^&[YYT=//*Q=ZWUKS/;C4^52]5 M,WC;)X&E#_$B%AM&X_)B2' ?3_(."=_Y_;3E3\?OV !9:$5X@$:^?/RV)UWP M\C>K*_*RG\0.^-OM;/# >F>B;PMW@ANC?&@]<>VP91B(0*%LN;O)MQB&H@$V MV!CAOKLJ7FS^]=_V_.*WW?QDYZW!("O=N@C*)# L6IQ*N4H#8KCVTQ@V3VX> M"TT6@<8?X*]F^:Z$<2'DMOO=D2[8D2?8'R\X2PVFXVURN M@TC_N%=1CLV!>0P3\<..5U/!1F:HXE%8B97A7&#-9"(J:D:3%#2FVW8I&K6D M*/5G?LQQ?[C;%^'%_F$73*KQ]__H]@?[W<%1A(<;+MG-G]QM; MJ%O_3N3757@BC^U&F&J9>"XXE89IS3[ESC#)JC>!!&.UOT\SEP32CC+J#Y5B] ME#_WXK+7[J$ \!QOCR,LG ^!(A(SPT2*%KG@#6+46,PP,1%GAHDM,NUNEE47 MY:Y5RO_DWK5 GBMO)HRWP)SHI;(T0M])!!^DH=Q/SX,^%8,?G@<50CQV^%/C M]%PQI3"&8TIQ3-)$9!) -!=>(9=L JFEP>N @TMR8QND8"%.;RXE5)PQKKCF M@C/"M:(:2Y4\$R(1Y[%W/\FMJ(7J^0O5R;&P5BNC!8J9MI4;BI$FL 4JDJ33 MW&##-&#?CS;_C%I+R56,C("\&NLQ5TQJ,"2]8\$3 _^3\2=GU[5DP%83'HA"S&"G%G7$[H-\ACH;3WDB85UJ^7WOS ZV+W MI&$KF9CMK??#UGJSO?2F:I!S0D)9?;PV+?84V2*4/D K.*'N=M?';UM'Q!:_ MY10\4#7[2I7++'_VE0NSBV>%;;**#[XI&AJ7.31[.:[8O81O"_U-\-=]O!B, MO/+&4A4OZ][#;?+,[_7UL!LF"I; 6*4+%GM]D3-8OIPS!XO7LE%6OO1I1AA> M0U78P>4@)T2$(OP]:+@(P-ZISJ#R;K-YSQW9620[E'QQ^Q0>[H7WT^=-Y$Y[[RYF__G+69%_.FWPFT?:\>=7\\V-^ M1KY__5X<',*_]-/IE\]'5T?G[\[WP:!M7H?SH^N3N7WE!!-$:T^15U3F%CF_!-3=>AL]QCEA_<#T>>'?HN79MP^_&O*7XN+ERX&X@^ M8KW""$-?2ZG"(R+H3"L $8BD"?E@%>+8<61HB"@RDUB4!/-2^ M1[FK2;(:H R,P6BB5EX2HPU F=PD9LE&> ]GU?W$>'LY9MC+-JCN"4AU)>C+ MP:0I\\I%JCW3!&D=.>)&).0258AXJ[ S!G/K-[85WV*SA[L/CDDKBLJMBP7U MZ=ZQMS6TK'YYL:;59%Y ;5JM#L9FFW\X08))@B(&Z(6XY )IZ0T2BE%-C2!8 M&_ 2-SF?[?[QZ[(.XAH%T5Z.@?9*.3S6QW*;A+O:*(B,\+4B:M8E$*R,*RXT_$_K_%QS[>M?MI=AZL=&OEVNCC1:N-M-6CUFS M=/+:<!0:TZ212%HC'G)%8[0.12&=XRDF)JW;%BNTY5>PEX.,L![CGQVB:*HF0, M_$D1D'6$(0:>)572>ZUV\P$8#GBVF+DB#O)+RK!+^HK/M[ MY\-:<-_MM-M#OJ;BZU/NVT84_4(F68J?^"\&V)[LYC.XF:HI'&:X&=9EIVNH-[K MM^#99QD9,[ZV.I?%C2?*%ZL9XSGH.TNS/*HQ_-=DX]5AQ]6;2ZP#>^%RL/B2 MF=JFQ]^/"JD@0DU-S]C/T]Z-7WD2D>M%^Q79!$_[QK:_VZO^QO],%G^V.FA\ M!J<'OU@K1G71XRM3;A&.6\Q#4(DFPXG"-DEJ#$DL<)6B<>5N"=? OI/-\V!= MM!C<:6433]QIK*7VBA+'$M>)/V4=[Y"8;4C8]?>$Y@PYW&[(\!P(_'DF!HH] MW^H7E;05%= /^SL&QDAPFC.3.([,B%Q3;CBC4GIGY6V[I-[%6"A^5 2#951[ M/IO/=["N^[&SIF; O:K/#_>.LX%,#4YAP]>DS XC\7F9[T1](DC94*'B@P M+D'CE":<2T>29(08Z\5#]MQ]FQ^O^/"<$Y+7+DI'5_N''X_!&<#). <"Y"WB M03C8/+%!+)J(O182G(4,/-]BU8-[1I@*0+^E&/4O71_VU

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�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�#Q\B)ST5J508A[+ -[LVTT\JG/%KW4T4'V];#RQ'__.%W,R>2Q\#))O:! MG'7R%L%Y;T$GYSEYTL4:U607&TQBAYO:GKA8'D-)$P>^'Y99_<'/%V=GW][A MES#/,^\S4\X8<%;0.N9X3R&[!@$Y#72G2SM^-Q!=G006*V$UVT*YP>1-\W]_)0[U][* M&0UQQXK#OB("Y^?O0NT3N?YUD><;0(\?G7W\/6UCMCOPV#"2ZV(D;;,"I7 D MTRY+"#8((-BRH$7FS(4F:WR:2"[MT[IP\H<,VEQS]QU$18ZXE22(K+FS=M!H MJ6<=R=T%$WM$2!C!)KBV/9N_'ZX3_W2.Y. M.#D@DKN+TCIP*!Z)&CIG>)!DF=;V=^0:88 0Z$@1DH7B95;1M.D,]QPBN3O! M8'@D=Q>==("N7Q?TK$4XNS29:X_%]?I[+V99BF?*!L!$'"BED80ER5HILN:C MH-&VS4STQZCJ,!QR^/$ZNCHZAM;5^N.NSGX3"I+TY&5+7[=[,HI%LEP$YT,N M;3:OQ^F:VF<82_\#@;6',B8.U+ZB!?=QN?K&KS9<4XO"0RC =)WVE0J1GI2% MI W](&GD9M$6RL^ST%V(?ZY[C689'-%0.1,9.#96!+9*"\+!!\ M4"25DI$5@44.J0+?^O!I:]3:@N ,?:!@V_V>O"!":4X7KMQ9H*P- G(^+:$ MXVR4#KP$JW;8 ^P.NF]6,-5X ]A'=+W>S=9JJ[?E[6K^<;ZXU$^UDXR4G/:N M!#%(LI-$(,\N10=%NRR*DJCOQ@AWNZ#=^M8.[\P.=TL:"_]D8'4=,O#1VH(, M#!>1?/OBP<>H043'!"HE/!M2![KK>Z>Q15OK?B^([:&(B4%VCX7?<35?YK>+ MZX 1CXD<-V$A*&OJE5 BH94,63 N.5E4^]YQ1 M(]VEXU$W2=L/ORY MO#;:,#')C !I96V>H33Q@K7=7Y;(>3).E?UA\_T]T_A"/K*V:D MYM8JF-]\D73>. ]0"=/87=*7+F7[\?O1@< ME[4;LQ<;[T."=\R 25F$8%A2@^9_/_FB:?HU=(&<_83='7*(E]6'Y3V>T%K4 MDDY=GHNM38V).\E(;D(GC2SY$.U> -K^OFEZ&TR,HQ%$WVL"SYOO^<.\,-H^ M30"SJ> 2T8!C](7KY *3Q*@9-#W\F,5)HQ]U4V:+[:>*#BZT'^1HID)"PY0 MEZTC&?$$P04/R*,4BGR$C&WNLA\DJ<,\G#WU/C2%?RK7;'D\9%F288-WCH_ U@:4V[C=6 M@A4,8P@EJ/3?:H Q47)X-< N*NL5E ]E%.? F1<6<--*5R('7UP=-1T4HI(J MFD%%G?^M!M@5)X=4 ^R@M Y\D, ME4@"$]�#H!E"P<0BYT%N@DLO=1,LX.R;L92DB'V]F>B!B2?--$/:>&Q1HD M__#G?LHXR0!5_,' M9LIJD1-JL*HN*^OJ>*H<('LEO>"13I:#L@V?I*##E-:I0+>S0DX1=C7W8.8$ M&A>-!AX"K:T2!/AJ#8NB,16;O&%#,NKW)J##^[")0+>S.DX2<_.O. N88U2T MG,@)\V0GLPR!20G"H_64T; M>)$UP4H'13Y_"F ,^6TH1!&F@4WW PW3I)GTA;S]E=)!/.X17J^#0B\6^15Q M?$'?_H;G,^19LUP2:,](JHY9"#)),#(Y886V/K09\+ SJ8/ :4\(G,=1VBF, M9B&>;K[[=4%_@J-D$3SRW-'S!8;RT+#%7^8.DZL]BHP.H&36$#/!$2TKBGN= M%6--UO*(+?[NCTR_*]5W^(46#.87GY<7],*7WZY+22^CG$8949CSM0)5@/+" M@#?<@'#&EI2ME'%00MW.0MB7XF[R _;"T=W-["AZZ^"DO>&N7MML[@BKS"+3 M!DH1M2&*K>VE70!MG)7.&;)B6V?@7-,R+::.@X%[+64.4DAWD+INCO"?C=JN M+_"T%UR2+V0*,W3PHX>@R1-WL10R &2=['D$B&VCK9=M;#_M/PJF@U71 ;A^ MG AXS8-"ED,)D"SR.NA<@\^D_R1<\6@%FM3FK-Q&34\ .ESCCPYDW$/\/44V MKLC7F4D=I0%$1^0;JR":H"$9GB3G1HDPI(AJRZ.G;GG4! ICB+&#C>3M^2=< MW6YU?E58ZI1 KC1@+V^F9NE]2T\UD!!5,G-WS M^VJ9+]+YV]5[7'V=I\L#6V&I380D>&\U*&X+!$ZK(>>H(]+W#L=+G]U&P;3; MSE&MYE&4T >(UB\6^8J#]57ZG/.*61],O2-P=8*5@V"] 6YLULPDRQ\F!XIY8OOE_<67NH;FBX^O__T%5W-<)'Q'JRA?UAP:I M'5E?$ABF!"K0.4S;9P9AN4ZTDEAF0WKX#7S=Y @Y5*G+MA+NP-S98U>^N160 M3!=E;0+)2B%9I@)1N Q,*EF<-.24MG'7#Z%Z6M-IDMC1T93< :#O<9%GKDH/&T_H :2?G M*K1"X2$JVQV#_A*#"_Q8+8N#K<*[[+S^=SJ[R&3"O I?YN?A[!2.^7\PWS"Y8>>*&9VB2(&V(Q&5 :5]S38J&DJ)C,OB12QM@FB/DC5M_^G) M]KKQ5-7A65NSB()4Q+?"=FFIS7R3%V MJ%HFW-$V/;OF>);?X5D]C'_]_"7,5Y65ND)^O.]Z\37,SZJ7]O-R]3[4++&T M_+BX7%ROPVI1!Z/.E&8^U6[_7N4 *OD SH<"W"<>@DZ.ZSS@>!V3IFGR82<] M?2=3Z=2C'"Z']([$.%I5HB?;%Z-4H(PA3\Q9.B)B]NA$*#X-P?*H1$V3/SLI MF*=3:@='_N:6\,.GL/B GTG"8?7M8 G(Q'-(V@&KC6"5<<2\CYRS:KH1-0G$*CNVN[?V/MCY*&OO6)HR>@/TUWP]1S31NCM"J" M#37T:#.#P+R%'++C,?FD6?/NY*Z6]I-CMAYN[>UE3/75P@#^U%]\L M]UGQ$;GT FI_93H2:D]D%.0S1I2*P..P#&I[>& BYV,T]I+3-P[V&NGF9%!7 M;8699T(A>@G6>S*(<]%TZ->;?2M#EJ@\-FKQ-9S&7O( CXFZG75SZ#W,A\;& MV<]DH/XSG%W@'F;8S;\=Q^!Z@):13*OO3_]IODYGR_7%ZG9_5F:C-BX"UZ8. M_HD:?+"6^,W>>VTS]Z')BE2 &GJ1:K-!J(IM99=2X%&%&7:>' M=Y>;.,OWM]0)MIN\ MQS?S$.=G5_4XH;XVU^)[.EU7\\7'EV$]7V]T<;,$F/-U%D +1C62(>&$,BF M"R+7>?>RL+L) *.G\XW 1L>[URX8?#B'[]BJ'G&W&V%M7S+]$)O_6"SC&E=? M*[>_+KY0WB*1<#8(N!% DM;;X S4OK"D .+=D0%)KHMS.5F?N&X3ZAV9 MD6G=SF9HGU+='3BIW]E_^>UE. N+A.\_(9[_LEI>?"'>;ZWC[)@P9 5EIQFH M:@I%)L@R,B1C$11CV,9%'4KAM YJ>WR.J: .@+?EE'E;WB-)FQSA%RE=7=K\ M/?R?Y>KZYN;V)<\-X^C)WZ_-MPUW%E2,";RI(S=J(STO;2S#VO./84SLQ\*T M>6''-"2.H.)3<)F^?[@Z;@X<]S3LN2.[5\-Y.(;3)8)4P1,P;4)11]37ENQ9 M0A3"\)"\P5).SNG:U?ZF/_AMN5C=-\=G3F-F)BM:,74,@G !G) (0FC+I-,E M'<<(W9^%CIVM7;#WA/EY)!5W(ZP2/QX7-P[;I*#KL"9;;&+J>*6.B5=J3 MC%PB2XBH@.B0 [>HLS.<2]ZFV<\ XCJ!Y5B > AP(VFG4\"MOZ_;JU+O8J.( M)1+83U$G(<=HS=@1==0"Y M#ZNP6-.;;_IDD(C>EBW%QD.@GP$FKA+YD9R5-C[-4 JGQ>5T&%H>0:%= /5][8A?Y?O[LIYE*9R] MOXAY_G6^K@,7,0$72+8.F>K1M0FJ#Z-O6LN@(Y". MKLP.($J"P37Q\FJYJI4U=:+PEG6GDLNVU/LNP^FDXI*,>N846)FX(;Z2;]2> M?A!YT]Y&=@/0\579 3Y_7JYP_G'Q.$^)AZ0,&?F6:4V&E"Q /Q"0.<\*0^:H M1!M?:@!UTUXX=H/.T179 3C?X;KVL#HG85WW2'X9TA^8[S%&+JF2CCFP#A49 M+D5 M,D"'0BL8.2EI#8IP8-)G+:713B45M;5#SUGFF[3DP.L=%5T<'^]PZ)H,\U1/S[-07O MSY?ICRMN,#H=BA 0!,NU(YN!$","RS%(\NA<-*K1 ?T87=,V?)@OH:]S]_5NB[:N;OS2:\@J\KE 6= MR=.75IJC04ST<"LS+<3VT4NG$)/787FR4JU7!7*2540H(&:90$3/G(Q.!MZX M3<)]HCJQ\":!V#YZZ0EB!YC%;[[W[,.4K$DZ /)8D^UU 2=Y]?.59S8D87*; MB^E1V>BDXJL/1^7HN.AA45P')6[QO*7(9&:)+<>4KW$#6NM*2M,<49\=P/156'\BH=7_>_T_%_.OX>R'$^\68Y%; MR4.40"N>71U*+HF:$:U/5I[#X MB.OYXC+"\=V,ON1_A)88PUXPK$ MG4B!/)&VL9.NFV1XY\FJC0FB-/6J*]5)9"&!B3H[G5PVNO&MS3-NDK$+]MHU MR=A%Q1V\!C M8*'N+KKJ '*CYE=E%RPF],!L7?15 )X1[Z'V3E=.ZVC:Y&$\_T+=G6#5LE!W M%QUW@.^!)7-9D>4NHP-3D@?%JWB#<^"]L2P*5#RUN?LE__[1BY$9PQK1M8ZSN M1.YG3'_V]7R',:Q;?[ M &UT572P(SY1"Q*+,B%G#T$EHE+D>6E&3AA?N(84DP\%XUM\B2?1RO?G2"Q3RO?7?33$^9& MR5CA,BNA=0)!@B1O/GGPM78E*!-C9%*45O>*1R^NZ#I[&U?WV1!H(H!IR@K8&9$DA8QU@C MHW+5R<9_?+ VF08X G)Z6D6WCLM_S<\_W6-^_2/W/XIJ(\C-8V;1IQ""LX#> MD&),=A %,B#VO#/!&6X:CW,9B9.N5LN$&!U@7QT-,'LOF"^XFB_S^_.P.C_X MBF$/U?SCOFI^0_I!.)O_!S/M=/^@C>[RFU?AR_P\G/U"=C"NWRSI%3?I=1YY M9BXG4$K(VH6:; 72'A2AE%2,?LCO9')OO;N8C(&N8C#3+ZG3 =/S.JBJ.*HP M?EVDLXN,^=?%Z[!:T)^L^ZQC\+? M-(?:"0&]W6DW%NJ>^UK<7!N_6GXFYC[A8CW_2H]*R\]8_VKF=-9D*TBHPXY! M647&0M$.O$&?BR658N/8Q;%9GN;,_.^*;8O-Y[6(?[]8I4^!-#BSW(7HO("L M:Y*;%(XV,A>J,9]]TB89[-[[^\Y-5R'&Z>H_'15'_\\U]">X'F6 M*^E[IAS9ZK.$0?B0(S#EZ]T[9G"1])5,0*VT"\EW;\'=9FC:),2_PEK:&S[/ MRXZ[O,T0@8M86 21#/&?0NT$DA%8DD5EZ:.*C3OV'O/ZJ]DDDK_"NMD=, => M?[U>Y :9%S]R]OY\?G;V-SR[%>FY#J.\3?-9,KJ.!"I@F*&SUJ [W2 &(.( M7/IB?*-.EWO3W-6E53=9$\VT/MJAT*R;T2\K8NO[H??KXGSY]N+\;;GL C1" M,Z-!SQ^YE]'N/!VCE9$V6+(@D*:Z02JE!#A#GZ07,68G+-K&65A=MS*2ELF0 M9 8=G (5R=8*IVBPYY@^4C-@6/HP,F$9"35(CW)6#+'<]Q.KDAH)T#L422TBW8Z!=R](A3%DU)1(7"5 MR1A/1I+G)P+9YBEP;I,7>,3Y92=7)+03)/8I$MI%/SUA[HE1;SH$9QRQD16G MHR%S\,0E&&]]XB:(PAO;U("P@YCT7;12T\0&R5\JV)*7#('PL@$BM?N M<4[4#B).\Y($+ZTOE_Y;N3OR$7]T7/2T*$:\>ZXAZ\N-@NQV%IT/M$4H:ZI> M$OC,(V!V2C#%M0V-M^XF?'6R^Q\?L$?(7-@3/<]T+=VZ^ID5R1FJDH";ZENS M1$XP&@/1!F:TM3F ,5%BMOA&SFV_"(M_\XBRLU_,RQQPO MXQ9CC(3:^65CCX1HF5_Q M\MO+JE6?^?_;>K+FM8TD7_2LW M[GNZ:QXBSHLL6[M]P[8I. &B1EJW_]R0)G$"2Q@%58!9^[ M!TD4*50.7U5E9N4 GD4$D106;[+GFUV@QX^"/TM=)Y;^H8AY(:P]CF)Z,K]? M>!LMFM&](@-DF\FC4'66'V(&3U]JK[R+1;?&6N<)#Z,A8H]1 M>1EUX*$@,,$4B6B=)PEU:;Q_4DE-1SAEAU+23U!;Z?W3A.244E8 MD#6$H&RV$"-GP*.62)L*+1XO??"T\Q4&X>2@?(4A2NL)D0_>Q?G-N6Z) R4( M'D[+F@T7. 2+-27.2,2B1':-^Y8]):H3M(T/A1WR%?;12Z<0$S>LZ!R3XF@A M<5>;E+$"3LB:X9&5S\KD&!HWM7]*5"AZ5%0:LI8VB MBO/D>BD!*17&E8C%V<;MW?;,NFK_QC$)Q/;12T\0>^3E7[^Q5 LC<^FQ. W: M*5FG?27PCBMPC!N+9&Q(VS@^LIVP3J!VW&CHZ\1 &P,.ST%M+-UT@+<_EJNU M:B[OF-O"Y>UP.9."PX3@I8V@&*.+H-0-*[FDC1QU M=8#$VZ?M#_B5F,1\+;3GV8O(4PEDH4I7 Q-ULK4-)$=C%/$6K4>,):HV M-9A#J)S6R3T6+)OIK0-,WILZ6PSKN[&S'TFI:QOH;?A:1?X@.:U()EUD D3M MC*M$8N"L3(!%1/1%"<-:YZOL1WDG[6#;NS1'4&P/0-XR(OGN[Z[3,+=)XD%; M%>]5J7$)9@+QJZR"&,BH][9@4=J6PAL5O1](>2?6ZE%PM@GR8RJ] Y#_1C?> MY_ 9+VI'LW?+56VXO.4JFJ%U,FB6@%M?AX+7T8WKGN69S@WK"H;0)N-A1P(G MANQ14;-LK\(.D+DY2K[FF"]KU\N0YV???T):Z9Q$'!\P>VW=S[P53@5=@)?L M:I-C7K/;?0T41^6==2*VJ:??F^2)GW:F1.]QU-P!GE^4\H-BCI=%3:Z%,XX9 M$"5K4"@Y>,\T%)9+CD8$)1NEL8]!?B=/F-T9%DW4/R'FZTBE7Q;?\.)R+F^_F_^%^;=P6;?[]VW7E-":RQ#HFN(U!*/K$^\Z&"F3"UF5XO/&@]76 MP8][+M^Q'=$&),OC:JQ/4-*%\RJ7W H39?)0@I9TW? $42D/3H2HN:I/Q@?@ M<@<*.C82IH+FV'KKP$SX">/EO8CO&)H%SEE)S()D]840G06?*QL\B\R85BZV MB8H]0]#$[_>3H7%,/?7?__LCDC[('GJ3TOJM\'Z#'5ZU^NIGCURD.HR78]2D MJN2XU+4[/;DK=12J@9#)>1(I:A8C3S:>7DWJQ_0%\]79P[>-]V53]C]^_RW\ MUW+UEO[J\W+U_7VY/^"O ]4><^2.+ EN4WWT0$>B(330L"Q.0M6G=. KY MG010#\72G6T-!0!DA2^68CB4D[8Z89-=1 MV>L$D-FC+G:(_GJ"Y L%=M8+S5"$ZW"<[E"CIIT7L4";BLW?@MDT!^?88=KULH-P=F2([:.73B%V6Y?I=%;9 M6:0#GQ?:+85<,FXT1,?)=BV:"=4XQG+B];(C0VP?O70 L0WK=YW>=&OZKDT, M)YBR/BKPT9"U*X4 G^B0-@I#0:M2:>3&OD;9M&";WI4857.=(_%FSS*!TDEE M@9LZ=D&7 M['"-Y$IQ/3*JWFC_2<7Z-B79VZB9. 37 M%DH'B[\#"&VF@-_Z+EHZQI@ QR0G6X&L5JB8VO]K" M: 053)S9^79Y?DZJH%-U>7:&Z7+^#3^MKB[NCE7/M+&2)RBV6%"\&(C)29"( M3#L5HF,;1]+6],U7EIFV!+012,86[\1(V9#21J7+#3\FFJINIP\&A9]% '7X M3^)(&P C1)VDHUM71=&F*>IS%$U\%$T>+AA%4YTB[K:)=E"H8^00BW&@O*!# MMX0 C.0FLXXNQ#9%N<_3-*W?-H[.=P#2'@KH $JW^^X#)IRO!S7=^IS))R61 M 0NRQG")#\\5 UF"+8&AY+)-N]/G*.H/1OMH?-E _!W Z-"S_=>[@DJ6#(M9 M*O"E%@YC,O5/$03=_UB9YASI*I MS.J3O@P*7&U/ZPICT>0@DFK3FGPK.:>=^KTG-'8(Y@_34_]56K^'%;%(+OD( M55E//FOD*JR7:1VIZNI]*:3FRSH'\[;N)0KNC4X.Z#?R,X6WX$-@Y-,&*=&( MHFR;](&GM(R6)7'P6'('F0T9'C8*""2'"!AB59S.O\;M4X=C85IC[@# MR&U;EW(K 4[G4.V6G#!8+E/CP3.'YWIW/;5^ M#_#LF>\]0),]X7.G3"MO!9DE4@-Z4U]-@J@940G05M."66U3XTRUOT^^]Q"< M')3O/41I/2%R2T:>R59EGR($(QE=0;4?2T8!&@4+F@O'W?&&UPS)E.PDWWL0 M% 9D2@[12T\0>Z%.DGDFC'2T(;6GJT+5>HP< Q3.#4N,<5/C,QRPD,< U*)TDQ!P,\.1+EIHI8]K4]/5=I=#'K3NJ]CI'X^T&EE84 MDV6=P4?[2WH#46 &PSSW#(L5J8W/]?'"-C DWB MY)LSVI0\,O"Q,)#,)V*\Q+C9A+BCAY%AR0GM!]+TX0$?'1<];8H'IG'MF_O/ MQ3)>X&J=@W0=J"+^EW0&G,W7\/CPB/VUY#ZMPN*"F+CX'2]G%@WZD!F4E 4= M$)D.'CH0R&8// 16,&H\FK4XBV2?AXJ5/&R?E8F=Z1TJZN%V/X'F_U#6D[QN1WKV3(T/E MO3002DFU3W(";XR&($7(,LFH3)M,J4%D'GH [[38)U+ C_2O_C63,C+O:8L( M3QZ \J'V*B]URD36F:-VTK0)IP^C<]KCLAW.-H_#AMK;^Y3[AJNXG.J<6YMC M(Y]V-Y_9_,S;1OLD)U^=E22=UR#HA@:E,H)'R>K,C)1"S2XW;8RGHYY\]]F? MM\O>;Q3+E$*N/ AK:4^ZI,$%VI@F"UM4,IG%-@D2+Q!U2F?:$ 0]G[!]F%XF MCA6]FR_FEW@V_X:9]OJ<-G&Y_YOYG0C#6H3KK7_/9BRA,&\R")2UT-"3^ 3S M8+5DNOAD2)8[A) .(&':I^GV8#NFACIPLV_WU+)<,_UK97%3M.^N+JM8S^N( MZ?]9Z_KGO[[BX@(W>,]U$&.H0YYCG:;$=( 0A:.=J% 4LE8BMGE)').+:5^! MCG^:'EWSIVD_WGYK_SJ% 1_>W*)\D9M)3$LK=42M,A1R-4!E+\&AXB"D"_0W M&55JD_8LO:0MU*8<^AF"3LFD'(*< M'4S*P?KHX1:_'?SYX]7%?($7%Q_Q\SJ79/U,:Z)..9%L+*])H:EV4N79DEU2 MLA2R:,X;7Y$/O*>F)7]M_7%L=;$M^/N" GZ?)6)C7L#H/Z?M' M7'V;)]Q@A GT*8<"!=6ZNZF&R# 2(U$[[WCQ.N\ B1<7F;IMXAB &$^*$\/A MP]K%^'6Y^/P)5^<5X8]9(>M,DZ^8H# 90&D1(01BRL?D'=-21NEV ,0KRTS= M G$,2(PIR0XLC%O#Z]>[]W^K> J%CC89:SA#U@)D;LD6,UZ)2&89SZ&I#_CK MH/2C(\P^&L\X/4S:'<'EP_+L[-UR]6=8Y1F7JLX!$Q"TKN5N2"Q$9R$S5G0V M')EM,[MC"S%]N,Q[JO<9L.PKZX[@,K.A<".8!J\,DAPPTU5IZR@YG3!*U#+' MIACI QA[J_(9: R2Z]YX^(JK^3*3Y[6Z'!45;])_7\V)B)^N:NK7'^M59LP* MY[5.8*ROS:2<@AB5@11S\4A;B:SNMB'(+53U\=XV-GH.EG]')\Q_K.:7E[AX M7\H'/ N7F#\M/X9Z>=_&"?ZYF%_. C?>YR (W>@4L)JER%D6P,'+@O3: ;0 M(#+[>/P:&VWC:V@X_/PU_!;X>4W Z"C\Y?QKF*_6S<>6%W3[2Q-4R %D<(9\ M#)7 A2#!8DA<9B^B:YNI\YB>:=/Y6^'J )GW!Z"9IPM=>[K&!3G6A']7,Q<\ M YY8%DDE+*I-7>8@0ZE90\IFAM(0N1YH*/V\R-.\CH_0QF_(IS=_'S]*J[^! MN1Y1.5FK*Z6NUY.*"3QR7H>[2U54EJ7\C1_(B^2&*23N41=0/"MR9%6@G63I MHM;:2FPTVN[T'\B'(&?7!_(A^NC 5O^ 7VL*T^)SM?36[W6%.3J]N0#R5NNL MJH@0F+"@@^9:),^";^/L/2&ESX?P00I>CBGMWN!R$[4O3J5, M2QTHQ# IX6,.K$T<:0LQTT+F0/6^!)8]9#WQ\];#YYA'K-S6HL>2F"7#CZ/S M0&<" &&4)281=,K9?6:8C0.RCPF4;>79PDKR06WO;/_PL7%RGD(@2 MF=>^/M@Q)+FI]2 J7^[D3V^3!VR&752D-]@^^>L=_#.=[L MV2@D%AX""!?)4#18P,D4H#AA@_#2\T9!HX&$3ESSW@HPNP/S8.UU ,ZW5Q>7 MRW-<_3J_'\4G=4Z>#G)P6,M00U 0@T/(*+.1BHYWUR8!8 LQW8+L<.5OSO0] M4!,=@.GI\W=V4NNL!90ZD%C%^ORMR&) RX@;'[P3;9*>]\LE:9=ZU.#*/$S: M'<%E(X!O3(I)E@31ZYI?HWFM@@_@K&3"N)"D;#.S_H!'DR-FE Q2\FY/)D,D MWA%N9L+78CNZR$5A@G:/-$2RH>-16N9D0<98V\2C/M("QL7&(*EV@(87[NA_ MK"JZ-;G W#A&AZHD1UBC!E^*IYLT"8$N>H>-IBF\0ED?S_SCH&=4+8Q8FSK6 M[83Y34I7YU?KQ(6-XS.Y8IQ-"*B5 N5T!I?I( W2",-U4ERTS5AZE<0^'OY; MW&%CZ>44FX8]>71J\>K[W"+-'W]WXFZ2-V >4"ARY\!BYF0NU7""4Q)8B-R1 M^Y<3:S-%ZBAOP#7\N];%;7;@YE+7GHN17#M-!@*9A_FZX;KWZWI?Y9,2EGFK M7T'=;BOU87^/CXR'X?:1Y=VW5?8D/%>R]2'(5)L[AFIP2CJGBP$=O/="6:-, M&S-^[(C[Z"AL@8T# N]#%-4W!K=&[U)4QMB< ;UGH)*UM'M]]8,R4]G2]BUM M.DK^;0/O@P!S8.!]B/8Z .=MN/*D8,"NXH@O#!;-+)?KV3Y]XN- 1X#*29"?&QKJ'_'UE MT*WY>\,(>FY]K'+NX#[; MB" ].A>%UU)J\HDRJ]EP* 5X;>AMR%3-A94V]_'+=$WC MJDZ/O:$JV?\07%Z&LY%,P"TG^5,+0JB(-2H#(97:QM9$DI4+((52L7A3G&MS M\.U&WS2.Z]',O=%5U"'P:.]L,5QE%,ZB Q-4S0.6$GS0'H)T/* 3Y)"W,?1V MH6XGT)F_">@.5D\'D'O^Y/X/G'_^4BV&;[@*G_&Z\=B/6)8K_!W_NOR "_PS MG+U?_5RSNRZJ.1%8B5'I6F!J:;?Y2&)-%J'4IMXE>ZN.7I0YF(F= &Q/%,!3 M*;L#Q^:AW?N^;(IW9KEDQ1$/EKF:ZRH%Q, %<)UE0>NB2&W>3U^F:R>XSV^Q.1 6S1N=K0[^B:@ A0^!H((521&!*QLU,X_9>]ZM4GU+6 M\A ,#G#/Q]5L!Q?]2V&PIUQ6X^;3GWCV#7];+BZ_7,R*%8G$RD'H&JH(7H,G M#B%X([-,):MP]/32'>CN-LEO9'P-B'F.K.R3@_9_8EA]^G,Y8ZBC$SF I1," M5-(Y(H?K>\6LU2+KJ@TZ!X\219;<&Q MP !33%8%3O\]^OO\"_1VFUG9&X8'*_?D(/RFT,IK5ND?S 3+2A<2+-E(Q&^2 MKD9\#-E,D@MYA)J.G";L02/Z3CT>/H5":-(Z V+ MA-7G_%>MX@L7G36Y*R-9XR8!ED>EDM1Z"+I',SERXH-N;^Y9 M>HZN:1W@T:$TBO@[OV#6:?3[7S,W_WS,RV8;16VN'*]0\OH 2'9N-7\Q@?>N M #K'A8A*B$9M(<:^2NTL$&D"U%RT M[+053[J3;V]D_]P"7=T1^Z!@//%U:F?\.@]Q?C:__/Y;( ^/?M]@L?9/PSI_ M.FE>>Q#5U[QJ2GG/8XY%&%W:M-S=@]AIPYFCGCEM%=4!%A]:[J^QYKUA7$4! M06E'QIVL:3M1@HS"QNRS1MXLDK,KD=.&(4?$7BO%=&X:CS#L[ID/&M-!:&^>) M5UL3]^_T0?L>Y?Q@H7QL8 ,3H)RKD$P2I&'@2W.DFR&&.; ME[4=B.ME8-U8B%BV54_/B*L,W739,)$IC*:VYPD(RFM%NS1HX%*PHDNQRK0) M'>Y W+2(&QT0NP)N3^UT +@?KTBBM#-O.JTHLO2"DNN6!!%49+0QM;=D.&_.Q30NL""4'6=G("(0B=(65$&27# M4MK,3M@@9-JP5&O,'"+U#D!S*YZ/5_&_,%U^6CXV"6Z8()%PKKV%-# M LO!,64=1V./;$KUT%GP6% ;0RL3@NQB=3G[$!:?K^U*HX2FFYJ#5T2JTAS! M)Q_!V&(B+YQ9L=,U2)_Z $;TU2:$'BW;RY37D3V\_47; QYNNQ:2@\&L%<"* M8^1I%")[G6W 0[8V&RG33J\LNR-B2N/Y )5M*GT/^4VL]M_FB_GYU?D-X74\ MHU>% :I,AUBF/P6A+#"1!#(CF'$[F3$[*?[1TA.K?A_%+<>0XM3J#W\]()PE M9@C>&4J(M3;.L (.G;:EAA_*3C[T;NI_N/0TM\%HZM];BAU8FA])SK@. M-=WT2?Z(G^N7UT,NF,2@D]50?!UFAH%NPY0D!$S%<"P.>9L:HA?)ZF7>;:/P M\'@JZ0%?U[3?6-_>1R-TJ:.CB /EG 0ODJ$=EZ)$E=#Y-JG6C\B8^'EA//5N M F=O64^<$_9A_8#\ZW+Q^1.NSM^2&&]8N8TT2IT1K04>1*WBYP*"J4.E3=$B M*B9%W"C&W9H9]LHR$\-B?^4MVTBR@]-CZPG[ZUT?'9.]Y+0M2-4UHFCIU@U9 M&-HQT?% USB)L^=]>;MNT37MFC8F$';(.#U!+-T![F-'VF!\^T\@\ M)S\!E$SUT/=T.#NMP.:<251!.=6FY\2KI$T;KFL.L[&4T@'*_E@M$V*^>$=2 M7//S1_A>[_^/X0POULD$B_S3?(7I\IKINQJC7Q;?\*(*^4VZG'^;7WZ?68PH M"DMD(60$E6O^+FTJ<)Q90W*5*39[9!B)AVD]Q8:XG4C-'0"\FV=G%S@)$"&R^B##B@5GE8"2E/B9V3G^_JI[3^_*1?@0OZMO? O/;ZSYS,^-+N5INDB/B%0]A!P5W!YLUAH8RWS8RQ)XB]O3N;8 3\[+3U-5^^C FI\%4R,L#5;OYQ_#?-5 MM0???@FKSW@QX-A6^XBLLQACH^$LV'VJS^??GGQ74WHW?$V7I&ZGW;W%F)QFHO(@C%R=G- M(8"+BL2F1=928^!6[@"3H>ON!"!_8@!J*OP.'+%GL^&V\688KPWI!5BL/6/K M">IBLI"+R]IE$T6C_D-#J-PMF,I."(?-==5Y(>W'J_/SL/J^+)=?\.WR_.MR M41]:EX5,::6"L4A,ASMJ@= M(:=1\'K,RMS'F[#*F,=K/J#Y=7!&,N/7^BXJPD/]QPPGUDP9'8E2_)0I1; 1+JW466; M24[)8IL6:T]IZ:"+U6@'Q(&2[N!Z^=]A-:^I@P\82,B<-P*86<]14633J2#! M!F>RU9HYV28M[@DITSZ1CHN4P^3< 5 ^7A'UZWLP+<]Q%DQ0W*&%:'0$)6LW M?+5NQ:\BW8S*J="HA.01'=,^CHY\F.POX0[P<0]LJ8G1D#/(7#./BC#UX;9 M%O2-)'C]7UN'>=H7SG%1L9]<1[-"6@5POWX]6U?+A+.WX>++N[/EG[\LRG)U MOE[A\-CM3A\_;MAV.$>-YEY$JXNV$CCCOOJW"3PZ"X7,#\FXJ8^9'4=LJP%^ M*\#K--X[SF))*HJDP7A!IE5F$IRC#<6C4\+2=;I;)^GMG]Y!*&0_'3[T7$80 M7 =7R>,H\DT*[,5,Y)@YMS6%U03RN)T'7VNQ&1)#20=E&AFFV^F9!C!C:?G% MP/U>(N\ .-OB-3>\O%_<-1J>6:-2SC: Y2731:IT;5UL:G-U%] HYT.;.0:[ MT3=-!*T1L!JHI#.@_;&:+]+\:SB[VS4H73*ISFD(ABSW0G]R)@80O%BE5"Y* MM8_Z/R%KFNC<$6!UF *FKI%^_%+Q/I*=N*@CZG[^*WVI72S>+5>/^Z3?R2\G M59@1'I@+O"861?(OB@"T(0:A!"MIE^2__2F8)I(W,J*.J(0.#JY=.'UF)@2Q MBLJSS(!, E^+.U*5;G5J%5/66\Y2&_OK **G,]*.A:GE- H^$2QOG30QB['X M7%P!%P3=#\9GB$YRL%*9G IWNE'E]]XD3V<3=HSCPY7;?9[C?5#IQW!6F?WX M!?&R4:CLE25:A/+&5O(@L.)"Z^EFJU@<+*6I=7HE(_TTQ[F ]#EVWJS#;$+T_ M7P,PLK [N%E?K'&8D4F07(X,4B*'77%K(7*%8%!9)I5(SA\C#K=!UG267ELT MO!BH.T0UW>'L[@I_>[6J,I\E3K>U#098-K6ILW7@:W\KHVR.VIM@3)M6_B_3 M-9TM-B'2#E).OU#[?;E(-PQYGESD4H&QHH *LO8N8)%<((%'"T#=5T,>H/!GF7#:)X_6 MKT'JF#"[12S$*#S+5&PVL-CMSP^F71"KGS-NQ@XP];M8,$\,,M M_(:"[B@9?,-\_,=J>7$QB]XGNKXE$-WT"^T'\(4QT 0+7:0T/._2F.*U=::S MUUOJ]AD('2SH?D'S)J6K\ZNS<(GY)R3:TORZS(;\#9TT)P>$<5=9-!!]5F Q M%Z-UMM*ZPV#TS,K3F>?3 VL,90R'FK^&V@(_UX4_M49<;306@Q!:$!NB%MXH MU(SVCJS=')TR,<8DDS@,7;MVMSP*V[6EC6AJPYB(Y\ M5N6RA_I:#,KD$IR3/H0V!3 O436=X7T$@(VNE@X\NJV\/')0/7HI&)18!VA& M%.!\K'-=LX@Y9IERFZJ(5PB;II*F!Z#MJ9Q>L38SAK9,LG6"0*Q5(<2)BR9# M<20=-'4.39OBBOV?I4<$.*H8/CQ6T$6\')]#C@-FK M;/(97>12)!7(8"SUA"TD/!8]T(9 P3AF[=ITNA]*Z73!AT9@>3'4.;+F.D#F MPR-Y!^X2:B6M)MFQ6%N?&0U!N *\N/I<)3'G]@G9(Z&R2>3B.*ALJ+6)XV/7 M-\D&3[7WWO)J9:4!(Q?DYI!)XF0@KX>Y2/P$KO,NG<5W7K"# M;@N'W[!MQ-O!.?;B.?V0P3]PE=;^JKD.D/G"6;V-.\?)%5(R$7*BI6NA1/ )(QCNF&2:H1!M MITK^%RZO5VO-?W@_("XN\S7FG'SHT;7K/Y<9,H1Z# MXT;IU,81A'V=;EKK2#C7$ EG8%4I*J%T6;3)VQLGG?JEN \)\K;*\*>K^SW+ M"UK-)-+.272X"]JXZ]RX(,E[0J9S=NTKBE^FL:_$ZP$(V24<-X):.KMS[P*- M#_CZG;;KIS_Q[!O^MEQ.E88[$F"2K,4A7^>-0LM$16=$8V@Q*'4KI MM.!KA9A=XL1CJ>\$X/F?&%:?_ES.;+19)YDA"V7K?$5BRY/-:XKE 8LQ)K3O M2OH"@=,FJ'4"QGV4=2H8)% AV;:8K2!I2<;HBK&,U:%T$="K;+6,5J0C/I1M M(W':QX^><#A882>"Q'?+J]4LH$@6A03K:C,*3V9.E)G3+S&A=XIQW::N8%<* MIPT1=H3#P>HZ%1C.O^$L&:*?HX$2?:@]43P$,KPA:(S&'+1D9PN=)I.>&2&[%U9('/:3"5'5)LOP2VQ M]QR9TPX!G1*(HRCNT&**AIFDVI-7)0*2F+"6'Q4&7J U+F8E)G"'(Z'OVEG MA4Z)LT&*Z.!2W5Y&^XRT"C>*=@0Y];%.MU1%@@M)@$\^D12SYJS-P\@0*ONJ M6#W@::29:CJ W75"]S,UW"]%V;-T3CCOP3A.?&;BV-F,(*T.FA<3M6E3^;,O MQ=,^EK3#T)/!!D=0Z D!]S8B[VS2&;$ V;>.#@"I(-2JS>*5HH,@!-'H46\@ MH=.>FMW!=!_UG1HZUW%ZDY620EJPW'!01I-3ALE"JL-,O(S*\#8SOP>3.NT# M2Y\(':S"$\/H.H8?4\+BT8/UM?%HJ _K161 3P(;:-42&=3]P28:VLB59E@).>XQV]%S3'53W5^4)X746G&.\ MUE)HA750EE"UKIN!]R664@*7N4U\:5<*IWW(Z0Z5@Q36P9/.BWP]^T+ 8M(% M$X%&< ;*:@8QZ@2&*<69-AA%FV?%OZW+)M:*M5X>6 M6\+->J2@4S8!TXK$Y@73OK^FH\T>?(Z&NC'4,7EQ<]TXU\\4KTB**1%LJJ\5 M,M6L)5G &^Y!&VNU$QZMV(@-/5/=O.N*?340V>/IIJ& ^X#-IA%03=+W"_*@ M).THS 98"99<_-I(@&P"X#P[89AQ.;]6BO?Z*E-6(;?1Z5/8C"'@B1L4/7354?!U M)D%6%KS0!FR=>&7[@,U007<+F\<16I.I<1R M$'"F"6%/CI5!@NT+'L]&,TM)(@EBA)E"YZ:5#!S+#H@?9K5Q,H@]+JB^ LO3 M &<4D1\\>F$D,#V*5#IEO0NUR"&18Z@,DD_H)4(1B7DC2\F![829Z:._1X/& MW@+LY,EK3WI?D[+Q?)\GGZ=%YS94IRV.D&JS\E*T)^<$ C9!E&L$702Y1U.J/$H MFC9K:J17B8D4]+?L,SC;*$AHWFEPQCOH-;C)]5VWP7_;6PG_OO[Z+>V#M\N+ MRWIKAWB&>PCWF0\:1VB[4#E2Z\5?%A=7JZJ#^U$7RC(;4(+,M3S55*LET2\J MQL@C;3Z#;>I'GI!RJ"7R\?,:JV"^T]?U-EFRXOYY=OE8KW.Q2<2YH_T M+_\U*TY85;NW1&7JG(]H(48I020;DT07=*/^R,-IG;;,ZS#<;!HHC375[9VP M?:-_JK_LTUOVQ8]K>31MH[C9 >5LCB9& P(#><0^,?!9$>Y0&8&:-*_:%)ZW M.:#R)NSOP/[V+,S/Z3+\AF?+K]587XOY?@M(+@//(9.U[NL4T.0AE&J\1QVD ML\5RI=L=5GO3W=O!-01/6P^NXVBP@[3JC^D+YJLS?%_NHA/OEJM_+KZ&>;YF MM=KZUW_(_W5U<5E9_OFOK[BXP%GARA0KB-=0(BA=.T4R'D%'72*YFE&P-M4 MAU ];9'JR%@]EO9Z0.K+^_(#DGN92 3K[[\O3_?I\DY&FULV**]$0C(TI %5 MM 1GE0.R=S(9'BPEW28/MAE+T^9 'O4\/I+>3\S>_.5ZQ&4FA_P/.@L>_-"F M>/8?>S#6RBVMV /ET,[@Y2'FX!!DH@-8F4QG;^WX3?Y6$=X50F ;.Z\/@W<6 M(V85;0+G39TC'0RX$HE:;X2LVS&D-@;_7N1V9]X.0,\HYNT@?4UH*URL+F=_ MK);Y*EV^7WW$U;VO^<4L,^9L#!Z,M8%L'G+$370!X*J[7S#P<5/R_J:,8M999%$A"B#K"_W!0+Y M>^3<*9ET\=;JG1I'#8'14S*FP=(XFGT*DP/%W(%GUC&VC0KO7*)L<28-P1SO-CR& M'D\+IC>;7'-=I&,%4.E$F[S0=G=%03$<:8<;JUV;1*'!I'9MN!T&G/U!NH<6 M>X'IDR?)6P8?\B<8]S@)2ZYP4 YK\[YL024>HSS)@W0= .STPCZC-$T.L8#<\6P(2(W4N;'2#VB?%4C>]?+O'\8N9\CM'E"/8ZZ9E)B*$$VHHY,FZR;=5= M_GF:IGTG.;X=.I)V.L#9*[*[C?O?/8*^.5M_YLW?/'D,_1TO9UH0HUX@>!2L MW@VRCA9!$ HU,PDU]Y/$I/?@95H[8"R4#;-/6ZN\?]"_O3J_.J/O?<,_'K[_ M[R"'VOW7,XZ0G5.U2("!LV0E)9[K"/C HV\S>*851].:%=-L@..HO_]M\$(J MS.NR^'UY^1%)R_1#9]__N,8-YEF*A=>B!)"%C@>5R&^(/M9S(WDZ(T0I?)*[ MH0&OT]I$TVR=J2'S-]]4,U^$\L(4NEUC;"T!]]J=U\F+G!4'EV*L+24T!"$T6,V" MD#;SHAIU5!]*:F]94$-0\Z1\NJF>>KC.23-8F?CQZH(NAHN+C_AY71R^?B:* M7'LCBH-D8[TA7((@K8=,!["D_RN%C?R]E\B:%F"-(;%YSXZFGQ[ =DW[38C< M\NS0E0*>B 7EK09BAI'A:V/2O"#+C=X?'I(Q\5/8>.K=!,[>LIZXN\.]Q?$C M+K#,+V]EEM=:\S9,DUT]9$'=IDT.]%[L3S9(]ZM;77 M9P>@W?$QXL>K&A[Z@%_IIS'_$A7WM^'BBBZI[W>2^>>"$/#G:EYWX!^K^7+=++Y?8/O0/#V!',XU#;,BPZ@;R;Q5JEUX59IL$HVL**' /R"U0= M^1N$E9@QL39/,<>N/!U<&#Z+@G'F%7GD:[><9PU.F@CD+D4C%;GHRDQAAPWF MI+=([1#,M2[_'Z3E/@H1'Y?;N8(R!><@)[:>,^LA1%53_(.2A2ZZC&(7E/X] M2UD;X^&U*MU3K"%P$SE#H\5F).[_@BK7 M09K=JT*2Q+"Z,&%&(F?H%QAT7'?9L3I*5:Y#E+^ MT"K7(9KH %DC'NGW7FIR1FN6-*"L/3)R%. 2G>V8+7$'M<_5.P6;=$[/' MS/(; J .-M,'G-\*H"KB&Z[J&?5Z&\6+64B2U>L:O,8Z#4@9\)Z@;50L)C C MV2<;7 O+M1UM>7QT#>^4OIX%-S[3ME^ ME;R__(*K.ZTL/E>!SXK2*4I.]J+.$52P=+=(RT!&'I-5S/#26R'![MQ-6U#0 MS?[H%E =&"M#7FQGPIKDH]<@DG.U362!:+0 E3++ON9'BS;=H(90.>U@I.Y MWTS!)U9/\_R3Z\.?.MY3];95IWER?I7_=F.$'$^<:02M4LTK+0Z\$!%J4REE M,"%3;2;I=%"FHR)WTK,")B'M:2YIJZDZ I+5.?9%ZL#:C% Z^3*=(:@YO$QG MB)[Z>(![_,P4@G"&!P5H" M*)G$]%X_XTD9I89G[.S5H2'K$F:$,17('2GD/,2D/TP8G@N?6X4P#W;_5\.TBS.SW?#A%S!Y[#JX^& MUDFFE$M >Z:FYA3RA!P)S.MD4#!',FN3A7Z*S[>#E#_T^7:()CI ULNU;B00 M0WZ(!U:J,V0M"2GJ4%N$B\"L+04;16P.+C7M(N]Z_UMN?/WT +;'%70QQ.PE M!RT4(T^[;A*;$]C"9691HI:-!I"=2JGI(/6^7&HZ0-:=EYJ6K*U+/ *GRY^, M@U41.=M^MP\ T; M.495+#JP2M:!Z(*.5UXK7,ADE,PQ9T0;[_X9@B9^IST8.F/*NP/8[%IWK7EOKQ>AX[7N444<5&;8)E[6K4&[V.'M!V+D;:--W@0V:<3O-H35B\ N:V..P/TJT]C MF+S+GF5 YD4=PVS &;)[+1T;6I!MPEB;L0VCOWT>!:Z-P7/((^<03>Z-TJ^X MFB\SN5*KRXF3"D51.=?,,E?G4JE")X%WC$'V0<62/:I&K3)/-*EP.A0?1\?= M0'HO0<](ODR60&ACW)&#N&X6D"04EY.7EG/&=IJ8>!P[HA\C>+H#N8UN3QC& MMW&U-^F_K^87\XJ&BUE)6LWJ))2F"%+I1<\>Q.)@V MW_"4D#\" CKP&@_L./2VBN!Z*-?KZ9@ZZIR2@I+05/]=@E?DJ6B3=?%99I4: M-3X]&H^GYK&.@>%Q6UBU M3I;[7=FWN1?I37RH"SC'0HDH;@A:CS:ISGB*3+ M1L^^_]>UA3O5;=8&3'\+6X[/9#1*>^_ QDS:8,:!=Y$<-QZ$RHD5C^T+0_8B M_=0<] 8;X[CJ'ZULY)AXO_[KVHWO3N)%^F2S'*CY#HRH0WA^8%ORF8@);:T=9II85K)(<,HRX-ZC M898'E.W3#P[AX-1\C4.Q-R+X]P;"B6^ .ZN/;CF!7.5B B#6=W41"CCF/,@Z M&@&5*:6H[O#_@(%3\P$Z@O^^,.@ _7^$[^LW0N+ZU^7%!59^ZQ^>^BU.T7^B M3F3%223&A >?;0*M#2HI$HNI39^FG4D\-6-]9 2W4>6$!OENC4MX,D+41ID\ M%JQO(QP<+Q8P)R/)R8F8-A(8&G:3L?V@ZU"C>'SI=W#<[??P7(S67A-_6=5N M!\P0DR5K*!HC.=!<>=6+,[=K4H'[^P#U>+H],*G@YT6>.-DKQT#[LF2Z7EP& MY5(!GSB#S-'0_1)\;E1WT#;9R__]P'P<'7<"Z$'YF9IK9T6)(!2)5LEH()AB MP$6FM-.9H9N^S&&W6 +[^^&VF2HGAFJUA@ZQ\'_^*YU=9?ENLWINL@ M^4:CG5F,RH<<-)GEC('B7H$SK 7*%U")BS?I3GB,6CM)V+P&F^_'E3]T*7N M1S.FQ^ZO]>-RM5K^.5]\O@@D&Z)J?OEF11?99[R^T!_1OU/OK-<^<9R^6(/H M'JGGU4\8+W^:7Z2S)=WU#R:-.W*=R"P%EF0=-YX5!(4)I$03A!>!->HEOYV> M0Z_WQY_ZB63W(WW[7S.F+)DDW( V%?.FUHICKC/31$R23&\9VT1,GR%HV@> M$;"P>1F/(?B.A]6]LF/7=9L-SIN;SSW*J;.-A[9GCX]96Y]O.\TXLLZ"B0R2 MTL9YYQ+YRR=T]GQ,7S!?G>'[4C__EP5]ZM6U9.]V@R [DZ[_4CL?6]IAS(%G MM!N25(KS),@L:-0QYE7:NCR1AB#D29;5N.KH(*)XS]%OX?)J-;^@^9Y0*J,AE"8'0">UDLE\R5-EW\AU(ZK7G?%'P- M5'6J]OBM4);K';E_@]N]ECG*';H#AVVOU%+/,T.>)H_5W/(<(0CE 'VT+ 4M MC6F3/MS.G+\_N:^[8Y 9RJ4)!HRW"$K6\<=<*JC'M6'1R]RH]\@68KJ\-(=@ M8)L9?XC .[@EZR%[>7O(TK^Y&7&8?43)P9F8H4XR 2<,0L88$WVGE$:C@;=1 M,SUJ#E+Q9ACV4'EWB)F;_E Y:N>LER!#39'@+$! 1?ZQYX)++PT3QT%-#\WX M#M?S*\#90^@=0._+2[RXZ0#&?<"B-2DU$=E*VP(N&@XHD?'(/-.\ MD9.W24I?@-E'OT_:-AXB[ [0LB;]9L+!I^6/8?&O6T8*L9$9MT!NA0&50H)8 MB@3!@\ HG(BY3>'*LR1-_.8R/GK&$7X'*%KW&ZR"^8CIQKF\881D(J&*(D@='5N 1,'-/44_NU7!-OPBQT"ELZLMC,1Y"T);<""F#3]&JO)$LN#43Y=6%>H+&OKI(DQ*>95!LDPTI$K.=")*T JERSW*-#L4JGQ MVCK3&KV2TQ,CA8NT'(O*':U;.ZH4I;E@A-6?%48-GL=K?ED$T'L&ADCH7$<)F/.YU MQ^;I,M/6B[9U:PX4:C_X$#_8RLOORV]K+A[PX[U3H:@Z%"_40>V)TYWI(CEI MVD7.Z&0<:JP^N]:T!9MM+9(QQ-L=7'["M,F/X$SDE".8J.I =.[(12.)F20- MUXY8]6PON#Q=:]J2R"/ Y4#Q]@,7]2P_6EHLN4[QQ$AF>4!.MRD97"E)7P@3 M/-O7$NYV76OB4L2VUNP8\NT'+_('^R $)&^-7YYNKSU<7E\2.ND6]]]&Z9,%* M5Z6E'03E-;CZW,!0H.4#39/GEMH-*B<9BAU%NOV 1?Q@Q%9V,)F"+@=P%ND. M==R %[58U4668D[HU< WXN>6V@TL)QF4'46Z_8#E.CSTP.>_92+K4;6$XR.CN*=/L!RX;_=LN,+4EY(1D4 M4:.)TDCP4DK0D3OR^3UQ-/"E9_M"NP'E)*.T(TBV'YBH'_@##T[?\&*D-Z'4 M3L.NYIEG4_/,"?><;/-DLQ3H!KH]6]?9#20G&: ]7*[]8$3^X.R#AXE;9K++ M7.HZ_+(^<"IM%<3JU 6=R7^S6FN1AMXZVQ;:#24G&9<=0;+]P$3<,;-V]LVM M88Z"/#7&@,"/9&LQ#U$Q!(F,Y9I\GG;*8GMUH=URV$XR'#N"9/N!B7QHD-^R MPK(M)7,%PI,9KF1M[IV$ 9UU"(H.2O+L!IXE6Y;9#2*G&8D]5*H= >2/Y7QQ M29[;'[A*-:O\ZVI^1ES9NR<(0=872BC>U=.Q/D$4V@#1^&*)L8)F:);!RRON M!IN3#,^.*>M^$&1^>)B+9>_\.*:P&E_:UNZ;&B-$YB1DH45))6:I!N8O;5UG M-[2<9)SV<+GV@Q&^1KZ\Q?WMT7G+E! HC!4)O%$:%.<:7"!SW3JCZ.P4ADLZNX'E)$.VA\NU'XS('QY'G_UMBI:T3,3H0.K:LH9*RZMSI;88)*#LO4%0V1# MUG$+RVZ&XY.,O0[LL3[@9)8,\;O0@IT2W_$KY+0;+]P,3< MI/Q7ML7V@TF)QDJ'D&R M/<%DH\!!WH:C3#3(E9:@F$AUR+(&Y\F5I,NXMG?41>J!"3+/KK4;6$XT4CR& M?/O!B_K!NONXE+R-2^68K":DUS.2)&6EH>-1:Z@AJ9116KF(7EFE:"#$M7@*^C9 MU78#S$E&B,>2<3^H41MV^TU02MV&%*S)P@7O(>G]V(2=TQ):)4W%L)J?#:0B#R:L77X9,Z">?0 MA3CPY?OE!7?#STG&CT>4=#_PT=?6VKK[E;KK2U*0P$XV&D^U2,\D!BYP!G3& M,LRV5OL.?*7:MLQN4#G)2/'!4NT'(.J'>TYN*\$E=\D5+VO_7UDY*>",C^NF MTM:+:%$/MGV?K+(;/$XR 'RH3'M"Q[5%=E\[<\>0%DE:G13P4KL(:QYKOT4# M!/2HDM-,^*&FR[.+[=9_[B0CNR-)N!_(Z'6:QWUX0-W6_$H=4XF"#*Y,II?* M]7QDRH%.)"67LLAI8.7)3C.B.(MU^P*)N+])UB$#=%EPQALAYXE!8 MJFWMB2-G,]GK"9G.TB4^/-EJVT*[ >4D8[HC2+8?F.B[%HSU'4/=OF,P+72R M==H%1L)\G3KH+-VIP1,[QEIAAV9R;E]H-YB<9#1W!,GV Y/;FJL[W^TV,DU4 M!>FR!31Z[?H3.Z%62P1KE8G.!C?02WYNJ=V@7-:9%Q])-YAOMDCXC+-2HJ)354#!FDGH4@1G. .AT#*- MSBG69E#:[C3V-*QF3TB\"+/1]-,=\MZ&U>K[?/'YS?GR:G$Y8RK)+!,"J[D= MRA8#T3))K@$K64GCC!1'P-ICJGH:<-,"70?HH ,\O9LOPB+AKQCH ^D*' =!ATM];^A\PU5< MCF""/QQX^8_5\N+BS2*O^7D?S^:?U]J92_(Z7,Y\T$U$HR"HX4$P9$J 6P%/03BOIO-JEL'/? M]7L:M7/X@744+0Q'FK]&V@(_5Z/_TVA&4SV?/]VKJI3?PN7-&.>9$$%GJQ ,I@1*U5A)T;6;%!WK*>F4\#@,8Y#(^JRPX,_MWXO6%S%J)FC"D+J=#YKWC.$!+'FN) @BWHE)H2J#=D M]C1LZ)BHW$=+IW:*S@06'9PQ('U-VRO"@S-,0XA)94'W1 E^0@CV-+GHF-@; MI)<.SKVM+OSOY87LPKAS__=8F+BWD\HQ^_N)Q)8M,:5FH+ M'-ICGA?P4180 4U&F^FOV_@G!Q+>U:BDAM&31JH<#;G_Z]^>*("D\:_UM];? MJ?_J Y;_I_[^SP^_//I\LK&_8#B[_/)#6IY??_Z/R]5J^2=9)!=D6[\EJN:7 M;U:KL/B\%L)%E?N]D?(37H;YV<5CIB[FYU_/7HN_[+7,O]USM7*WP320TAW0Y$PI+Y,:"ST:!TG4R5Y&!K+^:YXL:\CG_\?B/9[W?<1HF:-D:=.69IPT81P*N (%620KDLM"S-K^&G M=$W_=G4@,EZZ?0]40P>W[D-N[C?K!_P:OJ\W\?ORQVI.9_77!.E9S\$$Y<(E));C1^0BW^.[T3OORVQ5$ M!ZOO%$'Z;GFUFF7+C!.605#$GTHA@;E=#)*5K)G?8!NRN$#E7>:2'T M3:%E[_A,(NH<1H9H32YB$ M@&1)V4HB@M/5_W=:6JZSMGR7'K9C9:@V36(>"2$M1'NJKVP?ORQ7EU40]S_7 M[*GMA;6.\MZV*Z]M']UXXH'^GP"QCOJU*M9W8TUGD9!1!RX<:W/LMWET^YB^ M8+XZP_=E+=Y;:^"ZT"Z2;$M GEVQRBN/;4H0 MMY(S+8#&T_8FC X6?8_XN:D>SR*SK.K<;*SC;HMA$'4MEY2U0A*1E=CH)-I. MT,08.ES5KX%G#[EW )^WR_-S7*TSK\)77-VU'XFL5M."S&1ITA;3$.H3,!=> MFA"LEKY-M'0K.9U!9Q]%+\>6>@?0(5N5SN1KJ_.&@\!MR"HS\"K5$T#=8T *;X.8I+=.Z]RU 0>8N9,Q0,Z&&!+DXOJ(M:&T)%LQ,*E9F\SQ5TF;-AC0 D_C:J,#>#V. MH*YO>(?"8=98=X2NT1(!/O &B-S7L3@71LKZ"DM$Q](K8SH X7>'6P>- M0:)#9B!CJ=VG;09?C(3 7&1!EB#ON\XU!,\]1=,[\H=H^D7@["GVB4N9?PSI M7__\>GTEOPNI1MSG=Z>G947S0!NJMO(#%6V!:&(A/X-QR74J#G=I>_?2&CT! M8E\-+AN(!SKA:7AY%Y/V#R1!GM]V(E8C%T$E< M\9% <9/ I51H*S+,C#,IXBXMP8>M.HUM,R68]A5Y_V#BQ,7MN$+C2LJ9;G6R M U4=\(W@)2=&@Q/>V\BEWV44]K!5I_&TI@33OB+OP'A^Y$W\>ETQRR2W&7<B@B:1%5]7D7R"L$%'6/04KAPH'2CN M#@"S;3/41\#Y9>7H'>*#]L:1[OWB"BDZ:DNLD=9#S@K(J"XQ"1V,R$<[KIXA M8%WU9V'"$M^/FE MCI(5O".GC9.",7"K&((LY.PJ81!\J"VTN1,H(M)EWJ[O_?A)P=N&;CB&6KJ8 MH60309;!I6S %G1%A6R8;C/+9ALUTZ/F(!5OJ>D\2-X=8N;FP56J$NN\ M=)">,U"6=E*(.8-1C#.ZO)T+;=+%M],S?3NEP_3\"G#V$'H'T'DP%NQV(J7@ M0107Z-0-))-2$CCA31U>$;/E.LG2IO71$U+Z LP^^MT,L1XD[ [0LB;]C_"] MGKJ?EM6)N&4DT!D+SW6$U\.-4)(4.MH(1M34"Y$L"8:.X\B4KIU<<]C,$=_ZIOS, MQT_??FHD+(PEP@[.DBV)@W3;,IEL L\%F?XL./ 6D3@P H,AF31JQ]-;7N[8 M1NZ!LNX.+0^R"KV5.:1"J.>2Q.*BAN"\ I&D8BDGHW.;G(*32<<=I.E=TW&' MB+V?&<-B/?F6WXV^_>D*/^+7R_7Y*9CD-R>IL,FI&!B4M<0L1_#,$H<%.8O. M:)5V27 :O'!/T-E7U]M'#C<0?#^HXO+!L'9Q.ZS=&J&+T+3MM F@C! 00VW) MP71DL;#XI(7L:R#:NDY/%]6XF#EYJ5PJMWJ7QC6[K#5]YYIF4!E%O/^'O2]M;C.YU?U%2/6^?/1X M[!/?FHQ=MI/4_<3J!6WS1B8=DG+&Y]=?-+5+E,3E;;Y-34Y.>6Q9%AO S2 MQM(17-;D7&%?7FUF=]D*YTH!HXE=2M>(0:M"-WD.Q0N#6:H=L;+Q@WI:PCDP M4 YG;#\H$?86+>J*%L;1J>P3%!2%PD!KB PNP1#NG2V,IZUVM3[W.3UMTQS8 M5SF8K?U 1)*!J]1\7TS/;EVBS 6.7FB@J[1N:RP<=(>?,' M];08XG)48FL4X=+86'H"QSSN_H MMS[R45UM4AS8=QV"N_V Y4X&Z*H7T@4,WBD# 4U]-[,!HD,.GO$BN"<.FAVC MX$T?LQU(3C(9>S!7.P+(7^["W5]2(U.,&AD">=R)N$1(]X5'0/*^F,9D3-XU MP-G\2=O!Y"3SKT/PMA^DJ/4+Q'K[TLT;!%'EKL;L,4\.N2/ NT)N.4,)3A'_ MLI*N6&$9YWI')^7I3]P..2>9CAV2UR,CZ/WY:KD*LSR=?7E8O84V>&4H@//< ME+K8(8/7TH.I QN]#*[$;:S,4Y^Q'4I.)Q<[&#\[LBP$[E\Q7;YE7@^3<5Z( MPIB!8H,ACTM0G+^&NS%!4RBG34D[&I2-'[0=0DXR$SL 9_N!B?Q+S2O_C8[R M]?;(H:18L:869]2.U4@.6#3%01 R9^]REG+'5^*-G[,=2$XS$WLP7_O!B/H+ MOT6+OGKR]D5YKVI[G?.$=_3@O2X@63*HA-;%[YB(W?@YVV'D)#.QA_.U(XS( MN\Z4Y=D43NZXSIFLH8\18J8[E+&8,OT1C78[HD/NX:B>9O+U %YVA(B_7.20 M_Q9^5K%>U5+I)(2I#PM"U!5/+H*3/(/3!45=2";9[E;CX>=LAX[33+L>S-?^ M,/)_SF=XBYC$M.]SC_6;C!VU7I7:2*=?/)/&\/OMI\^A9./G; >2DTRY'L[7 M?C B_R+U+6_JBAC#>%1):\@JURV7'"$P44 (Z3AFIG6,NX%D\P=MAY(3S;@> MS-F.8+). EIV)P-X%9Z)*"79Q5K>74>$*\:4TB?4H2@>8DVN.!9WM7 ;/RD M[>!R.CG7@7G;6P?I!G*(&PZE<2!4*:"D(N[:QW\[7J7$D)/ O)>NNUYFV61QYPZ)Z: M-8?!Z[$DN#M8_0589_BE^@Z?!\/LFS]J7'X^77ZM7'Q?*E!Y3'R^T,]^UVE>HOD 7O-BT''P:)F1 %W$(H-4!QS$B5= M ;A-5]KFG]Y3:^MAF!B(@QW$$,]:V4GT7'M4M2,W%_(SN83@7:Z-W$;[Q%UL M-'_[V:-UU0%[I$MO)W'T-IF,Z^,'(W0QTAJU+-@>L, MB"A908^FT37VU*FZZIQMD2$^0 BC>O_5]E(07#6EYG:>OY:7$^X<=YE'R#H0 M;04+N.0%2.-,C7FT<]O47.SVJ5WUU!Y^W35D>;=KE3[4G,Q\]N$LS.JZH76V MY@.1M\#5=+%>./0+SK!,5_LL4MKAAP^S.FE?:@9:EE337'2""PV8Y8_7G[IA M>TZT"=')1%Y3(D?:>P5.N@2LL"15,87S-C['#H<\^,WA0AROGI3$S<=^)C'\ M0O_^7Q.#BEE/9_?!2])@,M).%@'9:8HSHC/&MYDOON^)QWW3;X6[!V\/QY#G M@#?O>,9R79;3UF1>?L2Q#>A86E%H$23Z_+\R XB9#M+5% M6G-5BK(L\#;[2;<\X+CU6L<'Y7#2Z@J$= ^V:/GG <8NP1K",@TFK+Q">K;^;R'K*.8DNLQ 5 M&(FICF]F$(L3$*2R&94RJ;2IJM[MG.-6:8T R:%EUP$R?R4S/[N.\"I5-Y2] M#BO\,E_\O'\!>.MSCEN==2R$-I9A M!RB]T<$W?WR_G9*X*CR_1Y[.3.B,/\/2P6ZR:)7W$5IF=M$_0//NS8J?JGJ1TA:<^]UL)8!S$6 M!"4\(=M4>">"=. I6M7F66^4I/W#N^+6V]B%(DZDC1A]72^34VTBXP$GM L0Q4 MR 6B9(%0DUDTQ4ICVS2D;#[/N$!K"(#YX-+H$E.7,TUX\B[YNLA:)05**80@ MM #KI>..9^2AC4_XV(G&Q=40TGX60'NPO@,(W79F[BK=U:#70MKD$WF_/M84 M:%T0FXP Y)*)PK+C]R?W#UL)].C)>H/4/O+?7-XSC# Z -?CKO'C)"+CQBF> M07,=0159=YJS MIX8X(S1=B&3<.['7;<5^7ZBHC1^2KK0\Y+@J/Y[.UDEL'D-Q MQJ4N9\ND4/G&C< KHV.!J$^UV,\_DKYB]XAX*8@M.R ,^$ M?J4QDH^("G)R0NOHN$]MVECNGV3VW,[,"ALNH'@*_GL]5B&L]7E\GA M-]^^G\U_XJ)26/-T\UE8_+S]39?S%JRHK?:6@(.UACYE 3'55XZD7+0.27F; M5J_M>>[>,@P' VDS5(\AU7XPO+%B[W-8?,'53:WIK?G16I@H0L@0M*MK2%<89$[1CD@Q1]%J:OP^YQU[UO>1,-M2BEUB];;^+7_Y>:6C$Y9XXK)V@?H0 MZM808J.6!M!%G8.+7$AY)'@^TCM[0._$^!B%# 5,-#79O:ZY$K*.5\5,'GL2HDT@O-=QQQX+WAJ< M[678 5 WO,7<;YZ?8$E*R^2A&$=,E,&#DUD2A2IIY9$+; /++0XW]JSOXUO( MP^33)>1^QQ7Y&]-YGJ9;C9P3IJU4TECPZ&JN7'((463@*)CA1G%FVI21;'O" ML<=^'Q]\ TCJ!71 /)PO0M]_XTL?HR]BRR,&'-1;Q9S3?)JQT1]"M"Z#4=> M: _%+@@[K(=B%\EU $L\!T9"X7AS*W:2$__1Z* MG0"P70_%+M+H$E.7#U^2&]0,$S!)#%$\&P@:,[B4T7L9,_)C=>;T4'@WA+2W M[:'8A?4=0.C9LGTE1-"J**@=)Z#J["T?2.FBR=8)KY4(;>,@\%"'$I*WX+C0(+7EDJ523*-Q?<.]07=2H7[(C3B\ MK+H$X,7PP7+_X1%GA@O$DMUB$(TOEX,#GRR6+=S)N%$\M(< MZ_UNF_.>PIOS3L!Y_K5D:"EVB=6'&<_DM"C.1# B">)B]. S*Q"C4B4K+W*C MBJ^A,M)'1.'P&-DC1;V+P/;&X/=U9O+3*BQ6C9!XM2U[G?1T7M5%F@@\*Z+) M<$VJG"R8G%U6,9&+TB9D??I8N)#]ID(QDPK,D$Z7+-(PAR5;S.7#B4MLUTC#T/W%O)0P_P/5BP M)P7C268J._*B@7-/]XD.%J(4 8J7$7EB+KECI8KVBW^.6!31 SQW$MB!\<^; M66Z<,]JXK^(V-P,+'F-)@)QH5,5K\'1U@"$>ZQ)JDW2;@0?[G[FWJ.EXN:-! MI=EE +61P@D3SG+K/"1>NY5D5!"<*N!Y#MH7A1J/!=*-!^PUCS0L7IZ%Z>'" MZSB?M(X4SS[BZGPQ>W^K&V-2LA*Q9 T\^)JTJ$I/#@L4RW*27CC=:*3I]F?L MS6*.A,]!1-BEV7RL%4.%@$E'"8(KTCWE%<1@4MTL+G2=6\;]L7IE3Z1M9B1H M#B' +CK^GVIH@FC+ _::5SHR-@\7 M7L_0W.Q.)RN<-T%09%DG"?$<(1CR6J+B18@HM<%C/2CM'PN-D%/J(A;:17C= MYI;JA!FLL=;J?'E!W01M3-XBN2F^,%(YPR R(BY)K736)BM]K+S\P]/UYF*V MSQ<=**']0YSY*IRUBK^?7F=ZWC\PY*%#I+U)$;?B0H M;GGDWAS-]OAL(?#9>\N*'@/21Y9X/^'5 MKH3?HOB6?J/0RN;@01M%,0+%F> II 24@?@N2BF-!C$/'.$> 7^XW/O! M_,XY-Z=Y)']D0'D.%O6-N.YT MX\B3HPSY>.:CC[X*=0=.C##4(TI;3"(_.?HZ!HFCAUA" .ERR)F<")?;=*MU M.]1#E1)0%0]%*_VBAGKL@K##AGKL(KD.8KY' M!@OHFN3F24$4@JC(*@(=7H*Q@OXJ"B="FYO_](=Z[ 2 [89Z["*-+C%U.5D@ M)"2I"P07;%WMKG0MK"E@I&2:U64\H)#O782?Z[#O7811@=@&N[-PZ+QA53 M%Q)S1<$2YPBA/G3(D*.P25D7C_6R?N)#/0ZY$8>759< W!R@7;NOWM,%((PF M?]4J4$(4B($QX%$6E:0K6AVK8- M9?G9H?3::G*$95VL75]3E>&0F"]<"Z6,.E;KY..G[.T5\:A0'$AXASZ9M'LM M6:RF_[L6YOM2)T0LZX@(7$Z"#"[47A&3G .ELP%?"E8')_+L95#'+#+:?,C> M7ON."LQA1-?S4][-FP\Q]FIZR:_G^'E^JRJ:3TK4P5IM 7FQ-0QDX#/2_1 4 MUT&P0/':D9"ZW8E[>]@[*FP;"+5G##^RHH![RU+=3F SCZ"*8Q!Y6:VZ.U7UQP#*)([9?'!6C PCM!3PU_Q.G7[Z2>KSZ@8OP!GU$$74?*@ Y:@,J:#*ADKKX.:JG)-Q6J3;_"$=^? M'VKNT[)Y-WL=SM+Y&9UM]N7!6)1KUG&OF2M,0A:\]DI[ T%J!,V3-%D7S_2Q M^C:'H.=T7K1WP>SS5OSH6.@R^7"/[*>(KA*IQ58?R2F:V( \E^Q!&&1$.*[W M;'J@P)9G*8-A^5CIV3U)Z"V#=GP\;E/LWQP<76K%#K)XQO,D[Y)YGD@,V690 MM= Q>J= %!Y-\(:A.):>#$;4N F_D[@Q!D1%EPKRN&783/D=\Z"4E*A5?8.* M)!69!7@6+-2]?,Y8XRB$'_WN>)Z.$[Y AH3G ;?(P%AY$9IR]:#PVWSVY3,N MOET]+%SUST=MBP@)K#.Z#@B/$)6J#:DI!+I?(Y-'R[L/2EEOKT@O19L&Q-,+ M6(9Z/91B7F[]H^-M0MWF\X^=L-J9)R.DJ[*SDJ(7!4'7^72Q2/"%!0A"H<>2 M77!M*M.Z;9=(: O%>@EB'9^B2L;:D">!F.$%*2[]VH8C+[1=8A>$'=8NL8OD M.G!I'BG9SBY[RYVM^04#E4?@M,I@)3'*Q5RX^^\.U $ L%V[Q"[2Z!)3ES7; M+!BDT)P.;J(%Y3/Y2LEQ<,DZJ3#P&-ND2TZJ76(G:6_;+K$+ZSN T+,5^J5X MS#%IL%I*BAR#@(C6 >?!J:0DR_J_.U#WE?^N[1*["*,#<&W8DO#SVBE^'5;X M9;Z8XG*MC$FH@"90/.>(98I) 4YQ#X7+$!S];&6/-?WZT4.>4NO$(;=C*[EU M ,D-9%PJKF".HS2D3*6.5(R1072\%D25(EVD.+[1G?GHD7K+C X$@OM&;Q") M= "M#2-#P_(K!4SU/V_^?3[]$N$KNLQ*5**U@*WJ)4O M6JA&%^MNYQP7A .!X_FQZ4-)J@L+]?"A2QJ M2-A(,6A--T1I5[[[\#3CWJ.M,'4@USM SM\_?5Y@("?B)^G"_\Q_X&)6/=Q+ M8K)@2M=Z"!19@7)"@BLYD< ERH*9)=[&8#UYK+$OR4.E/F\E@B[P5$<'DX\P MRQ_F=19:"F>?SF.>_IC6..>*7SI25,.< I]$!E4GH_FL$7).J+7G2I@VO8'; MG6_L)[7!$3:X4/I8&#+_ADNBYO5\\7V^( HWYGACMUH-#+7A1=*!47L[7^#TR^QIFI(LLC@O@?L80 7M(6BD MJ$BGE"E&$E&UN2NW.=W8G5$#HVQP@70 LH^XG&9BYC2<_6V^6'T)7_"7D/Z% M^0%A112A=54<$2@X<9F#8YXB<4F&.]024M5F\O?61QR[R6E@N+4130>8>SW_ M]@T7Z7FZC.ZDTAD8SE)XXU%:PLB<#JZ'8/R*2 MTH\EV>.,^*V^>7RX^O2'+J;-03!?GW9]75H3ZUY.-&"=9SGQ8).YAZ8'Q6E; M?M16&''=8Z0%8SNP.#6WN_KY@ JF2I9>:"C6D-T4]:U,8NUTD [1>,--F[?' MS><9-PILDQX=@/,=X&?#X)I[=/W]BC+!K/:661!!8IW%2#]/I]=$R<+*YRX!C'7P -3A*B5@%"0%R=3 MXDR.A+U;QQPWKSH*_/85TL@NUGTRKO)Z'S&ZWI&WTL[;]O'$OR@$1U(S)'9BN=52Y(B'$=&E5O-A;>!N7RL4IJ]3%0S'VL(!&PQ:^P <70)L)IPF].O M9V>85M,?^'EQOKQZ@K?33#L:&5;CQ]S7-_J M*+ ;2DA]/%X_(.]77$Q_A$K8E5\1M(F!0A13E*\KOP/X2$XCXSG%Q%06NT<<#78'2Z,#I^[#VESCA0:]/9_E*SI0"6%+**"C);M-U(!G/D$AW0E! MVI!EHSW3CYQHW%?%-I'G(-SOPC'[*^8O>)L"PX)-G.6Z)T&#RCF#TSI X1Z- M*#(SV29OUNQ$6^''GQ9^!N%^![?7]2R97WY>__:O4US0H;[^_ U_ MX-FZ[:Y0E!$R.8*6\UJC;0)$F2U08&*\=<6GT.;=>KOSC1L6'J]=MH&T>L+@ MW];]*!Y N70*,7'E0Q@3C=%T)["ZB$H'1SY)3N"M)"?"87*-(L!S)367D"C-IB$L251#'LV*RA^3^ MN!#;1RZ=0HR+5[-\14\.4292&HJC"0M*:P>N.$'.+S&/1(DE M&(O)M@E@AUO:WLPNCCEY[%!9=0G :X5[7VYMNM71IR0#AYRR!L4Q@[-8 &,I MS&LE2J.2R"T/./:HE<&A\2SX#I=3E_"[H>6F;.:?T]77Z>Q^6O[GJV\UH3X) M.DI3IUH*73M+51;@:E655L;DD$JR\EB[1G8^_-CS6XX/V[;R?0'["UY_#;,O MN)S.+J*\4788;'N&8^\QV(LW(^PRX%'&4+B&S )!5M<=;1X3L-J\98U)V;6) M(49=O5G'-CTNO,T.F8N.4P2I0!8M00GKP0=.MB9K0>&E]JY1>^L@QS^=W0>[ M(/)Y(]Y:TEUZ)H^/F,T*%8\Q4;R9Z(8,CIRNG(C7B3-OO'8YMTE9#3T?^H@. MA=Y=@#5Q^M5F!(:9;&0-"\7 ]]#T@ZT45X&7\.#1@6%IS\W>B<0 M;#TW>A>)= "M+3JJ0M$^"._ QAH>($.(W#%(*#$@UUG91E,+.V]P&P@$N_>X M[2*1'C"VU21&H5 JYTG_?*T\*8I#M-Q!-$EZYY*A_[6!V6##,4>8>0T@:7 M2Q=5L%M6.DE;HK(^@$#!B"ZK(6)68)1.@=CG1*/E:P/6+QXQ<71L=ZZ!%#LP MA;L]JY%VE82&M+F0=5>>^!=]U%"8C2('Y@6V*=M^>76-.^'DH+K&7836$R(W M5)X8HW/*C($0TH.*0H/G+H+7-@OOA12RS1BI0RN".JEKW D*.U0$[2*7#B#V MR 8\FXWQ(EI C'6G,G)P@B>@X*LH6YT+7YJ@ZX#MDPW'GX]]X0X@I2ZQ=M79 MXS$X+@0H5>>"9&/K+F\+/$0O@@^RE%:CJD]H*^5.TMYV*^4NK.\ 0L\N0A2* M:10A0.*6@Y), ,5'$DI(MO 4/05E;9)NI[F5S\VKA_ MQC]6O]"/^M?-P[TMVHK@4FUC)G.O6 87C )1;,HANE(:[6\>DHJQ%T*,?>^. MAH@NM>&B .#=YN*GC_.SL[?SQ7_"(D\L2I<$T1=#3>$;(R$8IR&+&# R:X0Y M%O:W/7-O3R/'PMGST[1:"+U+>&^NZ>/&!E,KGE*MG%;24R@GZZ88';R)1K,L MVE23G&CM91N\[%F0N8OP]L;D=UQ,Y_G3*BQ6C9#Y*JW.PQGY<.>+V?M;%5>? M5M.SL[_B&3$S!!63UR"RI=A T2^NZ PR!.O1H.3I6$40SQZVM^SY2(@=5JA= M6M0/YXOT-2QQ^2F8MTC:*6U=%69 MHSD)3YVSM]332&@=3)1=/$,^I._S@CPJ.LWR%US]!W%V*X>\3N\N)\2R6JN' M8+RKP6RRI(WD8%GO6<%DBL)C-6$\>]C>XK:10#NL4+LTL9O]'J&)BYG(\CP1 M&Z-5X#*1Y64),M+_F=)JJ?=P3FO#S7^=X/-PX1WHM+Z9Y2[:+C;$OV_^^(YI M=?VU8S1>;'^*8[=>[,F?$9HOG&(E:EOSR76XLL,,/BL/OFBT)4OF99LIZ$=L MOMBMZ[78@K6'J_9-U2M&"@@LF;I5B$3C/%+@B[;X+;2:X# MY^"19\/ C9:."1"A%CKH8L K^IW(7!D7DN6L3:'( 4_YS8#6$ #;/=GO(HTN M,77Y;I@%.PX^;*FT"PM<@Z0.5VHQVX M(WTJ08 ,F1S9.N3!"4^JEE4I/"MFRK&6<>X[6*@9\H[GIPTOJRX!>)4N>'N^ M(L*N_B+\7"?P?\<_5I__@V<_\&_SV>HK^2TB&2Z\!&;K-@9/O'3,:N"N-K"I MH%6C<9,''KRWQ_"#H?3\(MEF2BZ U6FO2DL)(48$ MKH)+0D='%T@/Z+T\;V_OX2.#=A\IGBA6"7PXR:QNG3#D;(?ZRH_TBR\V I?: MY)0,Q8M'VP>_U8E[>Q'O :\[2_(T$?MV?KZ8&)2"H6- T: BYU\G"(:[O\AX/L/7 O3V&=X#7G>5XHG"=_L )FJ@T"@W$8:38$2VX0)<)*E ]PW56.IP?72N);XG0XJP0O/W_%!8:RJDTTR;/$0@*C M7@XHCKG[_AJ3K&R)2H1>?D%E((4].6EGF0SA=T@4O,;<:8/'&H M0^W:AA]]W8,RP5@(J]K7X4>%;'1 \H"%H<#-.)9B"H*WF1/TU*G&30H-A8_[ M5F0^T)Y<_8W"KLNEL1[ MR+4MK) R""LIXLP(,00+/J&7+CK6 MJF>^H6VYR?K7@J#YK%Z7[\OU!]9K=;:\ND_OMK]-ZIAJ;H(&F0(%WZG.7A<> M01N.0KC(6\VR/>#0_5JF7=#U>)%56REVX.3?D/JFE(M%Z==T?@PKLG9I/DO3 ML^E:J/=H-62$;:T&T0')2$O%(4B6@6/.P=K,8_/"P-U//6ZRNCUD&\NQ*\S^ M>GD (O*B]/S5+/\V#9'HK#,&[Y&IM>41>8"8N"5GA=?2=Z7 F^1-<8%9V68D MT)X''C=-W1ZI[:37%4C_/EN0\GV93?]W3>I51?RMIHQ[E'IM1&">@S!8-U:( M#($;0=I9;$@H'%TCC7&ZZYG'S5"WAVI3&9Y"_'+]VP^+^8]IK<#;OY]EJQ\[ M>)2S)05'"'R89L+IP"HV4MTB5L ELF1!"ZN=2$Z8-O=0P\!G"T?Y]7RVFL[. MI[,O[[_C8BW-Y35/I&!&9"6 +#P'%94!IU*D7X+2Z.HK3QN;=^#!^PV =D'9 M?<-W3&EV<%>_/E]4;N]#*1-!AX!DY[E7H+Q ",IX(/.N@C21R=AFB.[^9QZ_ M4>IHT+H/Z^/(N1]$OT429CA[0.J$>29E2>24&/*%%')%;C4Y2Y\#: M="P\<["1L7DD?&R&Y2#"Z@=[G^I*B1K1T3_80)0QBGF5:J:A3AFVI,?1>DW7 M4]9HB9>ET52JK8XW;I)H7!P.*+A^T/@(+R=!&!>#LN"B)"\IHP+OK07-,NF5 M8YK;-H\03Y]KW-3/N/@;0E3[ V^^"F=#E<^L/W8?+F89T.LHP 2?00E?ZB." M VE0E!!US*S1MIK]#SVRR1S1K3R6I#NPIE>D7OHJCZDJ,I^]T1$"Z@#*,*+* M,7);G',:)\HS?9' 7HW32CHG-P.7:$TAZ[ X>64D?.V#5I M=7[IA<#.SN;_";.$DZ =14%%0A:R3FO)Y&FJF$ $P@B MV3KA692D"KFW;2!XP*'[+5@\!)K'DF('MG$?4E^EM#C'/)$F14XJ""S*VMT: M.02?"%Z9HBUDB*[12\H!A^ZW;/'8@-U'BOT"]O/7L/KG_/PLO_OVG;AY71)_ M60P_J:OKE9<:-->DC!2D08RV -;%]CJ8PGR;\H?]SCMN0_V183JD[$ZALO8^ M@7<[-08)E;?[B,'CYSTH.T)075Q"7,]?S(G"%>,UQ,(+"%NL,E)9;4^N^G:' MC-5-5] =:5RS)\A@I%:.7.NZ\=1S%*FX+&X6CH-R3?!7M; M9@E;R[B#2WZ;CK975^5S]?WHG'[>SSO?/!'()";#@;-<'P0"$<]CA&)"YR/C;CXN"$X$]YN?2W$YR1B<1'*3D!QZJ).P(,I$IB;D4HRI MLS+;3.XXY-2=Y+;Z1_H@8A\1XN0X3OZZ]AS?S>H-N7B+:\:O2?^ BT3BFEBF M3,$;_,YG62MQ@'=X((X$;M)SMGW^7): M?_N^_'*^G,YPN9Q(YHMS0H)WH6[F"74JO%%01(F*)>>B:>/\[GWD3C)8_5O, MPP5^(LBF+][:;/HK?=MR-4T3SWC*T2$XFS6HF!F$X#A$BK:#+3KZU.8M>?\S M=Y+VZA_; XC\1,"]7KWQ*O^_\^7J8G&OERFB4 P2,Q(43X9<>H[$9-0E%VYR MHWEM^YQVW#F2)P3H@\3<+90W<7KB,S(;)#E3P4=0+"?P)5H(HF263>'*M:G] MW/Z,6\'6_BEA>[!(3Z%N[T%M1K@SIV>0)XHM/V/P-XI]:#M&Y9\2)3"N0=HZ M2-?Y )X,'NADK$8"J\3&6?BV(T*>&?UTS016 ;+KUWZ/A])K(L?Z\*==<%. M.+N^P#[61%TJ@1P:&4'&FJ@SG-QDKP;P7H!ZKL"U MK71[Q/.[V0\B8[[X.;%)Y!#H_"G6':U22PB^SC:)3*-D6DD\$DZOS]1/^_J1 M\+>?-'K$U4--JNRD_UZ(;W:UV&+YAF*2^4^\\]<3)H64!C-8G0VH@)5Z%."X M,=DE;1.RL6SF#G3TTSXWFOUL)?61WTGWNSE^"?E7C&OOZR*;=M5&L9Q@TIY[ M1K37ED+EDX*(W )WIM:C1_1QFW?5H<\U[E-6.P2/+L,>;?83_62<(U-<))!H M54V?,8I61;V.4$B3K'6Z[9"&+0XY[M/4"-9V('GU",6[_?Z3HKC3B1G00@8@ MP@)X9CD@TSZ+$GTT1VHZO7NP<1^/1H#< 7+I$69;6?RK+TU\R:JN?0>93 2% MV4',I0"9?90NQ"14VY$@^YU[W*>B+KS0H:3:F]?Y(?RD'W]V37 XFUC&LQ,\ M0G0BU^U?=0]8R4 >B+*Y\"!*V<>1?/A16^'*G1ZN6G"Z1^.W=E\G/F*PVGD@ M4XV@3"9ZN$3P+F,DY\'GW&R1[8;S; 4J?WJ@&E */6)IPV0 D0QY #E#,A;K M Y]W7$W0 MYN1+K1]A2=(=[EAM>:UK%JQ4VDME&\\0O'V:[<#UDIY-=A5!!Q/8'N'2ID=1 M3_8WQXA@4G"@E'40N-+ +4O>2%OG?QWSD7G?,H>1'DJ.]M)\J.SZ<>YO4?(1 M5]/%NH;X*G4^2=Q(7C=X(Q.^YG8RQ*@EV)*-92+EH,QN'OZ3G]?E(_#!LM[L MZP_'^"XOS%ODU9?&JT+>R)RG"#B *:K:[[J)+1M&C)/,^A(1&Q6V/7NT+NW: M4-AK(Z!#@=<0<[]A6$YG7UY1]#S[5/D$;&WX8A=/N(>!X.'"FQ\(_BX??\5Z4AI>O4P_>K;?+&:_N_%0W0L.C'& M+3C/&:CL+,1@(EA%"J<-,\;[O6_8)SZXR]?6]E?M4*(8'V[WU>FZ /@6M1/A M?)1U>G"0,H*R#"'8C.#)"4X\^")RVT4,FT[5I95K%D$,)I^#(3?X:IM[Q&BO MD_ R0#'!@/*&0V22-,F&0G*2I%5MP;8'S$:J)VD'LP-D,C3 &K8D/3([;I!6 MI&=^]N M2+O0'S_,T?X=MTMOYV"M?/%[/;R[\GH18, M6A8AU!$"RA%UD5,0)9@LTJ/FV;5YV6I-6;]-3;O@]+ZQ[ H/';RQ/4+_Q AA ME/$"2M0<%)I:VN4\:)&=DB6B=6ULP2,'&A>-?:%FNVFJ.XEP;R1^Q\5T7E(MI; J1?,[V9Z@]$[6(#S2X&IRP7H&5A M=9@7!U]?YAWSUENI<\&CSK[>Z?3CI@Y>CDH, 8Y^%>)7W(5FP8NV=;J=**X^ MM4D#,61"L,:4F2W,FZ,N+MCI].,F.4Y1(=J!HY^<\".D?\1\GM9TW:']M_!] MB>_+J^_?SZ8IQ#.\&)]+7_IM^FVZNIQJDX1"900#3$&"JF-THK(!F,C%6V82 M9VTJTAL0,V[[SBEJS=&@T[T2;;8?M^;O_7.Z^DK?7P5WOOHZ7UPD8JU@*3K+ MP)A<9ZB2JQD+(W_3D161')/W;0;5#4K&N$U(IZ@X1X!+]RHSL9&)Q'0 JX@& M)36"USE!=,9%NEDQAZ."?]PVI5.$\4XB/#"/]&:6&[XB?5K-T[\H*J(?-OV! M'\[";)_WHDT_99B7H6?/-] ;T$U*_7VY/1KA(YY5H_!ZOEPM/WTE0$>R7OE# M^+FV5C>K3 +=W$I88*5$4$HQ\$E:\,7DVD>BM6B31CCLW <_?6_[Z;_<_O3/ M)+-?Z,?\:X),,ZN"@)Q3G>%33'WK=X"<>UXHHA"A4?? 80%<_ MHL"[75>VP29]KM[^0);S\F3[AXL.U=W*1K5F? M]$;=BLJ9/J^ UIE"368-N.("\(A.6&=(V=LPM!E))VUY=\'W?=C4*SP-OY(0Z+&?3?M0F/&!4I7.O/[?-W=@GG-DU=UAOMT M]?,>=8K"6"'(0RR"(:B8% 3.#&2G(WHZH/!M^BYW.^>XSY]=('MP<78 UM=A M^?7#8IX0\Y*N+B2_-;^:W4J_K%.&&U7ZOIJJ4"(J"C(0E0$E>820I00K60XZ M!*=SF_ZZX6@8]TES1)"/!(,.%."YBVM]8;V_N)>VN*N0:QVB]*""IKNJH(68 M? &/+)2$,B3;IA%A6#K&?:7LPMH?'0Z=*L-M =RFGLS#^H^OOM^TM7VN1Z3,5;(Q1"YJ7.:90:G)8<4&/BR0B*E7;49TM%.F;K&-4C*LV$_";D'/2 M^=)=<-T\7[HS.#IPGJIQ^SU\PU=_3)<3'D1DS"#P7*\L61OZI13@A(Y*>Q^= M:U-V7Y"##V8.[(X]1>_^/37]\:IW/4S^P#(/G*='X')(X/G%:YF@>@A MLMA#1_V2'K3K,I4(?.T7&%D@NNC!R6"]9%PH$[8 S3:?->[KV4!@&9RI(X)D MN5A-/M:A6&L+BW1,@G,$+R*"2EJ0A24S2X2@8L4[NI:WN7/HI]ZZ;^A/]^^: M.Q\[+BCZ<6+VET4/ +K$O4O2:FX,2-(E4 P%^. ]V4JF>!%6J++5&]'V$!KS M&CI 9/>%O@?_1A;[WZ:SZ;?S;Y<'-RE))Z4&X1'KW.1Z*Y)Q5<)X':R04@YG M.^Y\],BBWT=P\R&X.+;XPQ^W#NY"D;P@ QX27::6G"+RR!7$E.BO OGI8JL\ MSW;BO_W1XUP?@XE_;RYV$+*N4_J?Z9O7YJ]P;S1C 80CZA5&!EX*!(=>EJQ5 MM/=7_PT4L=XYQKAE+/UX$X?+J . /<*U6W-Y(< M#/.D9-DS<,XCB!14UB8RS=L,'FI!S;CA]P'@NI]@'EO2(T?J=\HG+]]2PZ-O MJ9?7!1^568HX>LM*D94QH M\*XDR (YE_07*MLV5_US1QO93>T%J&U$V0$V-UP*5YEAC63C,8'QKJXK(W7S M/B 4GR/6:JR";39%/'JD<8NBN\/B,*+K#8-7CU=UOT]4#C(W'$B5$@3F(Y'@ MLG8QH&FT!&S#8<:M0>X;=WN(JR?$'93T^&TZPW2N\,\SX1F660Y,R;F)A5&#NFA)KBI(7I"8_ MPO2LFJRW\\7_T+]=3:3B1L?$@0=+<:XL#J*C2Y8[5"H*)7)J,Y6U%47CICU> MHM(H_W;9F?,Z?)^NPMD%81\)&HL?F(FNM^>K\P6^6R[/UVNT"]=) M6>(U60%%KBNSX#27X+E 9YP0K%%!\\Y''3=WTA/:VTJY QCOK<[K7_Z!RSH4 M\X+M?&)X,8EI!,84T8Z:@Z.('4)*41P#\:-CK0BTL6 M7TZJ>*S7;L*93CP29Z,P1)6N>XR8R2 I1'-!9^5"F_SW=N<;-P'4$Y8;R+,# ME-XTHSVMH?&^AE[/#UJ08-;-;E?7''&^%EM/)-/6"Q_!"0R@%)I:;V7J0-J4 M+7HE3)L1H>UH&K>_O"=MZ 0W/6C0NK^ G#?,OYXOKN^K"R_OT9%;RXG-W'I; M*0R_C<_<#C#LWN"OM'D/C(!26/D/@H<:]^X")\ MP3O*/;\,U*^^F.EN% 5M@&AF8Z!W#KF[J5 -]:<-#G<5O!V M+QG>?(F&@V9UPH*'SB$P$B*+&E-\K2.FR9WPF@D;Z5V_B6KW>@BV EU M+UD]+T3Z=KZX_%+]/CYQ*95H:CM[UA30)>\@EFS!&VZ"+:;H[=IF^M')C71N M]ZC'_JN)HP+L):O?[>+L"4N169L\!"YJ;UW-\SED4$HHPFGM-+9Y_SL*>=LI MVY_B";T_.'6@8WOGS=_\^WRZ^OENMEPMSM<%G=3@O_^R;?!^!Z4+<3[\]5R%69UW>%%E<_$AZ!3, &B M-Y&D0EP(+$8H*3ACG9,JW7L7W9PK;'O,[;3@1;_U]P:&4QH^?#V]G*B]-2LHF:HFX!UWR;FTQJ$LQ-"MFABWD5*$ DDM-KE%=J^-T0##9*2<\P^"VR28T&\-T6O-N]D'?4437FS&\,YI" M9.YL#@6<=Z1C@ERB:-!#0N\0.;E'NLWKRF%314YKPLU@AG%OT>V-P1^XB/.Q M'Q!OR[CR,>.G(R.@ \N[ M-\77[Y&WTI17&>E?IS^F&6?Y8UCA),E4? AD30K/Q! >ZB9)57^',HAB0^FL M.W%;TCIWD0?&ZE"JT@0XIWU_/,62?\S/Z,><35<_UTQQDH)KZ12DHG/=RYH@ M* .GR$TK)[L^5?)?H;XMV@I67/?$:STK)=:.NC MM"QSDTT(OI8MDK98KB&BS."R,B&Z)#1OT\[T4DK+LD>564:0S)*CZG2Z&(HF M4G:!;(UFK::G_K>T;$?\MBLMVP4$'22D[U>9:,6+\8#(L*Z;91!%,: =ZJ*D M9.C_6UK6!@K/E)9M+Y<.0-7DU30&%S-#3(##8"B406FP..G+?_>M M[5=:M@.XCE%:MHND3V^IE;%9>:<1..?U=46056"^-E$YCLE+CS8_X^8V7&IU M6B5F.R'EL*56NXCM%$SP\]&S8Z@TJ[,A32U328:!+[*.-F6)$1BU")V]?;VX MXHI#/(@C(^"4,?]LRN9ZML/'^=G9V_FB_J.),%*+6!P8%FIVR5'D8;P#';PN M%&Z(J%U?^K$7G9U?&P.C^&A9P(,A]>=0N,OF6KI>'3->D/B0T44?"W@9"FAC MI"A!:J;;E.H?C<035;,CX/SX*KD'Z/;6QN\7Y5\BZ%)UH?]9(T\@#(O>CK\>[ HHFSQ!6F M+? 2*#8U9*-B,B0\:84WJ8[':+-SYU@4GFAQU4M2Q0,@M[LJ^@M5G.&7<%'* MTKU&DO *3F]S*&N7;)&9@HTZ4-J@AJA* J$QLX#5?3BU^_$!D2=:MO62]/(P MX/T95/.^6U_JZX9W!;A1$90RMF9RR94HC@09N7;FSQ!+]E>X]9+4\A#0'1A+ MOIGE4]'(9XO?;@O:40G;#,TA_-R5VH>S'B1./2DTG( M-@/EBPY)MV??))10>(X:I'.\3M1%",5DT!0Y:.EYMJFS)J !J7_Q>=YVZM.A M*=@)RW^Z'/'S[+/D4N7&Y7,]L*"$[W-_U3V MH"6J7[13<#=I^#SC4&B*A+RJ,Y1]W?(D*98K# +7 9.SUL2&(^=[8,&+SW2_ M '/0$M4OVAQ94"906%J)B$C!9H[Q73)C.R@\'I?_% MI]9?@"%HAN<7;05VB*ZD\#&JDDE+BP05E8"P'OGI&--)2!W%RTWYO?@L_@NP M (VP/.@+P!$:N6]-HZRS4E]];-+*_>RG-&OFWHV^/MJY)0O")V](31)YG2)' MB)G"T:234L89U*;-(,"7TL[M7=;<9@$RU_)/U 5<+@E2C,SY;!53;?KA_]O. MO2M^V[5S[P*"#KRVNYV=G,XN;2J@T9'+R9@E9BH/@ON"3F/V]_>3_;>=>R H M/-G.O8M<.@!5D];-Q)'\-N*AX1+)GY.\%D08,-%K'K4N,8Y4A7/B[=P[@>L8 M[=R[2+J'A9%W:+LA_<+]6SOV]-?D9E,73<(I,!F20\@B";JS M;,WYQT!!"A9)Y-?_;M';?> Q.G]B;HZA^TL?CR304\'NI_.XQ'^?TY<_SV^3 MRDJQF1M@IOI;B>R&4PK!!FZ4):NBMYI+<. Q.G\.[1*[ PBT!R]C\X85"K8_ M71$D^#BH)0GDGB_;:-)K(^-S1.G^U.Q9JVXCR%'AZ,)N'U^-B#,%: MXFQ6=?.##1F<0 L^)..X=SJ5SHJP?GMI@UX.R2T<&0&]8#X^3W&\3_&;/[Y/ M%^MOONR5\MXD)4G9+1.1^$Y74$Q!00B"AVR",E&V@_X0)'0>[ V,O:$FIQ\$ MA XTX,-BGA#S\BU)Y/;M]N8/7*0I$3NA@PO"7MV666SU_A.X(&N#+O,\JIQY MHVF^SQZM\Q"O+6*'%5P7(_NO7FXNWW4^SS^'/_XY77W].C_+T]F7M_/%9IY/ M?%0V\BP!BPBUAUP!?87(=<(DIRVZTJ8/9-\3=Q[F-4;N,<3<@6G=F\WW-/FZ M7OSS?!7.WLU6B^EL.4T7Q2#.)ETP"8B:U4DFF8(,;A@DZ[A+U@K$SESN':CK M/ (]@DO2$WRZ24OOQX]7LUT+LF]OSA#1N\3 ZUIX+3""SYB@J.031JER"7>U M[)F4]M%).-$:P,-4Z91@\P(NK/?GJ^4JS.HE?KO@,GBMI!$(G&4%JM@ D>L( MLFB-47,75&=#I9ZD9RM-,B],DSJ"R,M2E,NI'DE@*%Y9B$)S4%PA.(KN '6, M6;,@F.K3C7M RHFFD0;$9SN5V0,LI]\JOK%U]G\6\R59,D6HCL$#JE"3W6C M"Q1@5 G*2V]<[&S^P^/$G&@RJU^].10P/=PSZP:"Y?(<\Z_G%+9]N:!E3?9R M<]+/E%)0&[(-NHY39,@@6D%L]S+%R*.QK29X[GS6$TV"-41\6W&_@!%]#]LE M;T;Z1K2!_@=%$#Z5P0(^!0'<(#+AI12ASRAC S$GFO?J]RXX%# O1W5NWBMO M..$,.M1)@_,&Z5:,=:":*I!CE,A-4*QTMG_D<6).-,_5K^H<"IB7HSH/ [%B MA#&I1"C*1E Z&' R*;#<.172YE9%GVQKH"0PM3N? Y.2 ,Y,E< M=XGD%M#J(?@_#H!BI4(*SBH+R.X")&B-J8& SZ(AH- M1CLRI2_F5>(DU+0E#$]!30>*T4-)021O 1E*4,@R1$6>!D7NDCGZ&I=]OJ@/ MF1@ZA3>/+I1R!-"]D%>25SE/ZV_"VCY;L^8\ MG'W&Q3%( MN.M%-8>Y\^^UG7)RM$VNHS&D(>M9?(+HZPYXPZ7DP7J-#:>EM"#IM-\R&JO9 MZ!AZ C#IC#.2X6P]6>4&V)),WSV, ES,+(GLC>9]59UL2>-K/!">A M8(/AJQ>U.\ W?IPMC_G&?,)=D8%9"[:0@TP><1U<2!Q3*B3FN0G9=C9 ;W]B M3_LYH-^8K#7N7I9JWO6G^<1KIRD^=>!8\779L +OG ?NHQ/9VI!=]QIXCZ;3 M3O&?A*(=@J)>].D &5V,_JE#@O[XCFD]SJY^Z6'[1RQ"\A0X^%)$'=K@P"?T M(#!YK$YY3",5= Y$X8FV,W3O8S9!V)]"\YYTR;D-1)3)X#'(6IL3( 8E0&/1 M.16O8QRI]J0IW2?Z\/8"M'0P-/:BNP?X#SMSZW'_/=H@BS<6@N,&5/ 6/-<" M4BX*8Q;)RH9ZW 4/MM)I_R?5Z2XDM!-*>]'OIM;PU9Z-F?5'V[!^%@VCKX=O7*FSI3G3[G M8H+MW2-OMSS]X0\9:#?Z,Z<;:/7YQ8^^AF.*VJ24++A4!_)F[2!:DR 6IXTR M+(309M+-W7,,,A?N#O-^GZ_P1O\^$_=^H7_PKXDRR3D6#(BZR%4E#.!S4N"$ M]EQJ%C W&NVS[1''K4\Z !\;I[<-+I0!%W.T-S#K%53+00H7&H5CVQVP*W.S"S8>F)L& NDA\K@F MZR-^.3^KW_WSU7*)JULD"67MQ6)RCS59VP6ODT3;C<=$_K()4W*D#4@H*7$"T%+YZ" M%QER9HXN[E:SJ'8[Z+CEF4ZVF")HER*!A4+Q1$FD/GU&&/1KO#2YDGYT2-UY5WM(O_[EF@8IO=PY]W5 MOP^+^9=%^/;JC^ERPGC0@E/<&2.KMW5*$G+600Y#"V2[5N/-.X^!E( MZ)O2F(=+H%LL7:Y6UT'IX)!!7=%(][Z0$+BF7V)*G%L>E2E'1-/%J3IH?AM M\EL!:@\QC+S0[U45Z ,Z_H;K8A;OHU61&2BA1%"IV+KF,P O,:*3(C'%GW%^ MGON,'L&QCQ3G#5@Z/C2X>8R.;'0J]24)9:ZZPPH$[1&"_73?H!QVS0E_ *4XD<;JW8S#$ME081BNY;12\ M;W&X<>'5QLT96B8=P&Q]^H?W]_GJZWPQ_5_,K[[5) 6G0,/E*+2 0I85E%(" M8K(6E#9.6E&D:K6&;+L#]A"5#0B,3>]N TNI6_!=5QC=T'?S/5>48@H^,AF! MF^! ,:' D3D'2W]1K'"EE$:-''N?N8>T^;$A.K@L3RC%^2HE/,-%7?#2,MNY MQ<>T2GSN2F&;'*@AGU^@ST"^O03E";"Q" _,ZN)]G1/+VCS''BL'FE&CR%E! MYC)5M>3DM$8-$JU!X3)%UFW2#J>1 ]U%_MOG0'=A>@]7Z>-Y&%1&%\441&GK MN#GIR:J3H4W)!AFBR=XVK!X_J1SH3D+?/@>ZBP2ZQ=)E;*Z<=%8B0EV[2=HF M,[&HB%KG):,S0NC4<&+FJ>5 =Y+\+CG07<0P?J)+\%NNPF,)FL(BBA@B,%25 M5ZB!HAE/OP0,F@?+<&26W,J-?%KAN_[M/TJ4R^6PS<:@N820_;RV&D8.P7^B3S\+/Y2]A]J^K!W$>4HDQ0V*: M3J\,!V^#!RQ")JZ*HW!CBWCKX4\>#P>-1#A:[V\>/R;,*POTS* M\5G7H1&"/$*GH=2),%EK[6WY_<,P@>,XH&'"!?MTFA;C+9_;_JK\OGIIQOE_K] $7B4A^ M7WZ?7\S[N*#N(R:<_L#\;K;^!\N)K5G82.2I2&9>V2 @),V@: I(=:00-]G# MK-:6)^FA+>[HUJR%E+K%Y%7J/OPQ_7;^[6(,XOMR22'3VEJ5/%AI'9')(_A4 MWYCJ/FNNN?9,'83#ISY]7$=L'.P-)HT. H$[3'L]__9M?J,XI#I>433D3*G) M7HJ<%5O'-LIK+7/@;79'/7JD<:>)M\+:L)+H %+K4U],>_2,!<:]!ZNR"59H$W[)7Z_]U]67-;1Y+N^_TO>6_MR\M$4)1D*T*6-)8]'?V$ MJ)5"-XBCP:*V^M??+ #<0(+$<@JGV _M%BD;R.6KK,RL7!I8?ED;-$?*NMF+ M;M>U?G.=_]&]23=7_,7BW31^SAMK/.)<,QMR@.RD Y%UZ>H@&,YDFE*.BH:< MJ[AC+],V[,3HMARTGC7YBDJ!WXY_C&.:QEX+?Q]]:*TRW^>IKU/4ZZ6/6ED* M/I1]U2P;0(N6RTH9(AE)R?HZ+DB_1;VWHL-@NF0)UZE"IZ4Q,1"(CB/*O2]+ MBA6>.Q><"=PD%^N\&#])3@L9L:/TOGTCGB[L@1\ RVR859KN*YI/-QMWF](+ MS81@%J(N^\PLRV %\B.L]38H%M&"]_;8]R0)PR*D![5V? MPCB/4]R\:24KC+$J@C3>EIF+$6S$8"&2*(,3W,6T5T'@9#K6=&H9.N(2!)=]DH=5CM)&O;5 MI;\;J5_9-PBB=>2' >$JK!B5>50Y"PG"*/R'"GC"N$H@$_&$>6&DK#.O['FZ MVG)PCE3^"Y Z01,#YXRV.?GOI9OA)T_N!Z9A@DS%#]-0DAQWO)8TQ$A3SAQG M&K(SZ $H)L%+JH'E%'C63@>R3WKH1#+:,EFG8>S<6GE%J9Z[2;*_)_S%;.60 M]IKW>?X;:B6!#N"K3D:(6&-S*H-0+2\+*Q"LUJXF ^EH!-$BD3H3'_K>:[![ M_NO:C_!>*4]I BXTABDJ$S#26N#H0*"#D5GBE?H)7B*MJ4S1(7@X9 COX4H8 M\'J,:3SZF*[GOC2@;M.^E5GUX]L!X;%FNI-9&LP]@A.EJ(L M7296$P^V%#[3X U/F5"^[0(=@8G[WS@,($Y66=>#_ ;VEC],Y\N9FX9T,8V_ M7G>;7(1R,1AA%:!31\KB5 _.\0QX,(QA/,=DPAX^\),?/IRNC]=1UZ? &HB[ MGS.!=[Y^RD:D,DP^L#+@J8S!\R)&2(83A9X_8:I.^+T7>0-/I*QRB=333^.@ MN_V[3VF! 6!WO0G_1I[:9$VPH!05(())X+0,0$1(3$D\JO[\[NTN:MOU:XX$ MS0&P[$6#KP6EE^[[>.$F> 5\7?C.':S<:D?M9GQF-1Z9XS(/())@8(45KA I(W;/9Y]C8X[ MFN9A6QKJ0_=,VFP M\<=TDUZ,8X,#\1S9< C?QBX40Z>"0$R2\F2H4%M-S<, M:GEOZ!ZV+:)5TWN45AO \'H=W*]I$M_\O T4;W/A\Q$)W =-."@O?5G/)<%* MHT$[DB,7F7A99S_1"X0-VS!1'X5]ZJ4!F.UUJ-;N]\4/-YZ4>/1]-[NY1VY: M-?\V7GSKEHM[VPR_?Y]U/]QD)#Q3P1H*6J 41/2^K&6)$#SUCE!N)#G_GK\^ M.!NVR:,1U8$K:KW$'L)9G:=8 MIWQ<#^^2&?',8P"3M03$>2(B6>JJ[AWIZRGVM_&TF^'GW8APE(T-2D0#1#J& MEX9.X D-H#USVGH94JBS27Z;DJ8>6@_1]K;U.DG$S5J;SXMO:5;"-3R9:3H? M_TCK_-@15F7G1_5C/?:CM"O+/G;S^:>T^)S_<']]2;-Q=UL1]#9M*H-N ML%;&YF1C&!B--Q)>FAE,5 *R=-YHGY52LLH)/)WVD[,\C[_\4[>XMPE8&"YU M1@W46;_4P=HPW M]<('UK5^3U'=C@W4F2 J+ &I0YE;F"C8S!4$04CP7)>5./^A-O!K^);BLBNA.)/S5 M6]!#,/LHPCVCTE^=@3T^7GWI$^N:V)K1: ]X592P5-J,N38<\4HT6*(C6,&# M$9(K+NOX4L/;V-]+5?Y\/L[CL%+XY^5BKY.WKH$1FCMC>08E;<9X?%$:KL?734 O"T>-C6I3AO" MHXE \9R"T#H#"L2 99+S**A5K,Z.FB?)&;Z:K2=U/ST^^039-P"@>T=N57#W M(\T715J_("_EIL!3-UG&\OS3S58J6RQF8[]3RUDR$\"W/9[=AO:;^LVK*5@@/%J4 T5,,GA2+IM(B\[I\-3&&NLYY&!H% M;9V)&X-0R@C?3[I__9KB5;J5Q/-,)R9LR!)XL J$=PQL<@J(L]X9YZG<;^'0 M*= _GOPF1EW70?B9=-H6D-^F/)ZF^"9-\0^++Q,WG=\=;;P#>[CY-(]TM<4> MSS0&)[X\-G,KP$NK?/0.=51GB.!9V6QB#G>=@]$81EHX0%T8G\!MH)YFS1ED M)C'*8[H[POKFFS].W M:3;^@?_UC_MUE3)*K4-YJ$^K)5Y:E][? %D(R?'JB[7BVEH<#>O%#Y<); (A M#9Z4]ZBC/9A?AT:+]1O"S8O"[=M!F6AH(X;^21A1XO^(L8Y/( ,QQ#HG&*^3 M]*[!35NY\F%P^L+A.3MH&C@XJYGV#ZJDC[E>1\S*Y&@I<*41U6 R1E,.%8)W MNG'4>IEI'?>H'_K;.ASGQ^&C]Z6S@^+HH_!]Q?[7A9LM>CD0S[TYOTFY*_L: M'JKK]BEZI&UDF@D*V:N2, X4HZ&R+)!02SA5*/0ZC9@US1*-%FO4ED[0 *ZL'*1]:I!&66GE?-!@O:4@\-2#%X8 %3P(H[7$$&^PJKAA MTYS-8;IWA1[OQ7<+-VG)BP\R&$*3!.4SGE!CT%>+S(!S4D267#:F3HWB&;WX M:LG.YH ^ "A.].+?3>-0/OSZU^7H"\>\3-1!9NC B>QIF;/!(8ID:!)$VTJ% MNJ=0W987WT1VYVP@:""+TX?MN6/>B^0%=P0<]67=#\,(W@D"*FA'T"!YE$"S MGOQA1^)LKGP31V(XF#1P1FXNM-^1U0?U(C=OX9OMFAL)I?AV.2M%).FO!66_ MX<7XK;B'(V=EEA:Y9AR5(#@-F[H1JY.W2B=KZJSG[8?^MH*!)D[% ,!HMION MG9M-D;?Y[7Z?!P3OU3[WZ"/ZZ9=[GK*^QK5L?(K$/#1 M"?#6R.Q]RN@AU&E'V$'1R5T76Y][UQ5JDA,V:@^$,0?"673U9># @Z9&*<43 MJ5/GNY.D@4O6^\#$H\:+7L3?8Q*YMB$Y>M[!C@^J8U0JSC?8"2,G+8V!IS)) MEX%0*8 K"Q<21OC,16LE>UVFY:XM??L;WKCY.%Q,X]OQ9%F2M _;T8/P67-B M(!D30! AP/K2TN2BZWH/SSX=1W"C9ND0/.V>*%!/=:_(:!T_0V#7 M)]4Q6U4GV.W"&1!3N3YS<^G/V#5BQQ]\(<)H]0Y_<==KT. 2:9>3) M@6&EICMH!48SE'-63AH60JPTBNPERH9%U^YG2Z@GX M\_;@M$+BM74M9.%D\,*9\6;I5EG=0 BE: MZ8O(I=MG<^Z!7SOP/)<^\Q6UA=Z -;TKR5H?F;*F98D\?OY>N"XU64?5+$I" M B_3R*5@N?1Y1W"!>W!6&Z<3..?TWCW\XUFBNPV#S0CJZUC+J,F8M(@++IUWIF, M<0N:5X=N7Z@TL;,7\H>QXN=&_/DUW4Y?S>UNY,+*7@?9&6E-I!Z,('B0N?!@ MK;.02"8A<2H"J;.#_6!2ARD]/3=ZZVKP5*2>R3T9!9&-SMQ"P&@:@PB#CIU# MQKB+BG(C@A)U-B>\3-LPM9[MN0T'Z6C ;JXBN;=IVEV/IX?(SF8B6=F,R!D' M(20>+TX(!*:4\S3$*,0>8=;!7SSP6,&^ ZVZ@F\@U/I;&E]]*RX%^JKN*N$1 M]6GV.:_8FW]>+N8+-RV^]:K29T2XU,39#)FAKRQ*&[OAPH().22MJ(N5$E0' MD3E<8%09+MVY=-=$Q/,D>QOW]A&/=ST#HXBB]#Y:X 1O#*&8!\\2!6,M<3KZ M\B1X/I"^3/!P44T#<.U9G^U:U%V,CKS(40N4IH\E$Q%,*+M(,I"4N>$YT)3J M/'X=2.APX4L#,.U)?PT,!7BAA/=6A%9GB0ZP Y%UQ/8HJ:L)#! S]4(2D'&.C4**94Q)2 MTC8/E:9_0&A;-;"]@.7@(/IXS37A8N[%X'W+C^=;>T>;3V&NY(^3V-I_/ES$W#,:VX]__K?CI/=M+34[?) MO<]_.YZ'28<_I/DMABC/)&3"@=* 8(N><(8*; 8LXO>6,7J5"\^3]?IXSMN M/_VNIRI:0M&N:@@J2/0O. -/$="$E4&"AGO/:LW3>TS-T -2>T/%XY$8)XJ^ MV5;^^YP=VWS[^#-Z-R,56VY?@(W(F7@J\(I@Y4)"G8)ET8).5DLMLS2BS@5? MUYC)I3A)>)QO/A]//_GFY^;+TZS.Z@3%IW4A@#Z; ZAGC,8)P48F73 M_YQ+7L<%/XC,ILW/(3C:W8K6M[(&# ?GL\7HZ_([FI>2U7.3.R;O2?+++%V/ ME]?S]]WLP\WO2LFDFX[3_(YE$6BT:,5!:Y) 1&7 :&'!1FJ=(BG[L->-CS3= MPR;^M(W+'HD>>AA;[V@=2J$-I#3>Y9S"8OZ TZWF=Y>CX@5;-;O:LEM?@Q'URL]EJ[-7Q4PF>^[3>';OGZ3V/ MBR<]196+#,Q$@\;&:W >[T\1I>&6$N]L>HTNWM+/T_\N44?O?N _ULT\R2:O M?&9(2L;C1#(%2XQ!UG4@,6C-29V=?4]1T[3#=@@J'CELIXJ^@3MMFP?\SU8= MM"YGERA'@RP2LJ&$ T<" Y26CRX9IEV=B1X["!JX\_YD3;\ G6/$WB9Z-JVR M6E&EDB?HT!ET[9QG8#DMHX!,%C0J+\UY+- M26TAZ"B%OPRB(Z3?'HPV?=%< M,<853\/H"/DWAYX/MZV=!*6 M$E-XH0>1!0@;-!C.(P1)K5&$*$,JS9#;0=' _>*5[[#C!#\@@#;%Z0CY[G[H M6%X4BVLX?[=J58@?IHMN%(--1#@#FCH\926*Q'"UU*B+J+3.E-"MROY=_:O[ M?%U3MN9(O79UA3PP;MYWR]G?DYO-[_%T<35+JZ38W\:+;W].9VDUO/K#.G$[ MHH9(*:T!*VG&BUY%,.4Q*:?H?-8ZT,3W0-#!7]R4T3D=2W4%_QIR/P_^&+I2 MKUA>S7K)!+WPV;WGA0[AY3Q9(N="$&79DXPTH V2 E:[G[*WR5J1M%5U$KAU MLT1;+TKKRS]&FXV6%DDRK-3+HA-9EJ]GY9TS0F9-ZK2K/45-TUFB0U"Q[2:= M+/H&?.PM'E:1*]IL*YREX#GZCX('"FAI(TA-J9#">UWIJ>,)8H8%S^D:?AXR M!XN[/<30XQ"DNR,3Q46J?^/%U-X>APM3\/ MHU-T,+"[_:N;+3**_^,XIXMIO AA'%&@6V_+/S<)#&-DC%E'H*P4)#N&'I\4 M"K*3GF3./77[N-H'?6E3R#E)T]TYQ#XPGM!C#=UDNN9K6M8A;ECYG#^E?_V] MF_WS9C:CXLQFC=&")0Y$0/'YF!48C$DSER''N,__7_R>%N/9*NZ\/1#ED#Q@<<.9DBQSI4*9R&)!)*/ $;GJ3(MHR9/7>EH7#"40. ;QR$B(C47I/ M!"-R#_#L^OQA6^HJP:078;;G1M_ESU2(B;%((98!*>@)1K \"9!.1$\I49J= M)?IJY'&C=@AVG. ; -".#-OGZ1]Z>R*4_[2%SL;CSI5TFO(9^]*=]\\#S42S+[N0_N/9.] M-Q?G26,S6=H:%0-F5 ;ADP5K2[- 9%8H_%LCR"M,8^];8O[FYY=9%Y=A\35= M%3_Q4UJLIRS?=:!&*;1B#!P+&*S: LIE0(@9@*8@/&3TB[GS 1GODXI M^B-2ADVUM8&TT_33P"BU+]UD''Y^ZR:HK3=IFO)X,<<8_7+BQM=E*\&RT%1D M=B.MTD9$*#4@2&D^--F#Y\$ FO#DLK?2"ED'?P=2VLR-VW=$455E#=RP>_'W MRZR;ST>,E]0GGBX?_6K9$1[BLJ<[;ABFL MDH]28Y^G:ZZ0O1M.;QCWF60%['K6^2ORN7.A1#I*BUVR!*FM!E/&SUF>+GA*RK2VG3M>QKT<2 M/&SPTSAV#U=I0W'0GJ(=)1*8(L* 9UR!R G9"]X E8Z&E&GPV[4I9W9/AXV: MVO,'#E5:;S%3WX^ &'%>CU?3WN<.F5Q-\KQ*TS ^:C[=# M?XR.TFGO0":+YZ2,G+4\J3)FR"4I-%.J4IWY070.7--0#6>/THSUM-?PX-YG M[,;QA0Y[?&AUJU>SP.$P4&J$7F1XZ3KE?7D2T65;" ,1';>>>RUDI?>$EQCU)8@_B7I.9.P11VV:N;ST-7)E\TZR_=)-[#/W1_>;&J+[Q]&/Z MD2;SS_EK0D5@%',10HF>YB/F.54Y"N "(2.X"+"JO36.1NVX-Y2_9.9.^?Z! M2U*KP^ULNAD8?YOCU,WN<7@S4^)C_:>"FBK-@JF=Y-Y#-*Z6S#Z2U+A#7QKF0? FRQ"*3-'\&DG*+"Y# MLHI:I#KUSD_3,W GQMFNQQZT,?!$ZX_CQ>9@7.)Q6#7J\A"S(=J =2& "#2! ML0Z/!7>6:!MS"'L]6^PUG/KQ]P_K6O6AT:XW\38%CGNCVHR*7@C*(:YYB PP MNF50PNF8<]94[)6,. (B0X]![$.K.P%RI(@']FI^=S%,QCFCL7U?\KO_(W/]TYO(&X3-YF#EZ'5B3(/BH912*0D^B@S)92K+L#0GZO2^/$W/P*[+R7I^ M 3A'"+T!Z'Q)JSVW=\QL#*7*BU^ MFJ"VP'.,KK>?@'L0? /X>621/]YVRIK@LF0F@<1[%P/&F,$*O'N53%JG++S< MS@K6BKH_'M2\7BVK4^/VZD?\S0'IY^9XK"LBUDFI$1XPPKQ1H"B>.>&L!^]S MQ%""Y.R4CSG5>?QYF;;&PO(C4? LN$Y6R="SH!YR<[&,X\5O:?&MB]VDN_KY MU97'V*_C?Z>14DGZTIF0*"?(%+'@%%W%$-DS0Q156_OQGAX&M>\7-N93GP:> M>J)N=LC!IG_F]_2]FQ6>CWCE?_01_;SI/T]93R_XVU]RMZ.5>L^-B,!B&13' M2^Y8,@$F)'2ZK0N9U'$ =E%T\@J"K<]]JI8%W306LTB00RC==&5C@XH6*'VE.8F7LHM,,"7JVT[4?-<:\%M+<-SNWQS^QL^3',WNUXIZLW/S5_>(1_O MY]7F>U#.10PF[:J!TT.FJMSL2?-8IR7Q2((;-5"'X&GWMM]ZJFL@?"OSK-![ MG(Q7_'S.G[^GL@ER>O5EUN7QHGB$[U'@&S;G?W3H'\Z[R3BNNR%NN&:$TTB, M0R&S!,)G"KXD0[C09=H!IT;5J6KKA_Z!EW#4P.\ BGTUCGX/ZUE?_,@ZM_)9 M%K7NQ*-AQ%H>++ R!5@(9<&7*3K&"(>_DE8D]:KNYW4VY-[AN#D.(^*SCAG# MVDR%!A&(!Q=,&4SKJ/:"1:;K=&OL)*G1._803&S;J'[$W\ MBK8SI%+H6=1Q M-^#44HNA$9INSD(L7'!P2#D8I@(A@3#)ZDPV>9J>1F^Y4Q#4@^ 'KD;ZS?VC MFUTNYXON&C]O];III&%&EHU;AF#<:R0#JR1ZE)QPI5TBT>X%F[WJD!Y__]!= M *=KM.M-O .#XY.[Q@#D 0^;)TR1;?0$#23^GT5Y. >FU.)X8D-B)D3B]KJ* M]\+(3C*&JTHZ5:]=WT(>^)7DSZ_O$TK;37XIXXFGQ=)N'J8=X3:E4@GLD7Y1 M^O/0K%)DA[/D I&2YCU>179^P7 8Z$EQ7=]2;-$A>?/S=J4U,3P'ES+0*,I. MV4# LAPA:BW+3UZ;.EFV9X@:NA6HMSNG;P6TB*5[-:!)(\$^&0BRI >D5^ E M>G&,!87LB(BGXTP>;B.+Y'M3_(N>[G%:: %0&V/]B*6-K:6!JFPI@[(;'83C M&8PR"J),.B9K/:-UVGY>(*PQ8!T+@&U@]:B-%L#U^/R]2=/P[=K-UAO[='8N M:QM!AEEEQ:/,&L/-S"ME=EZB;.C6Q7/<@<>KHDEHW7"S.8:6:LVM M5<"-*1&(+Z,WA +"N;..FYCBN3RKAY0U9KE.PL&+(#M!*0V [*N;I/GOZ4>: M+M.G=!M^Y"0QBHU@43H8?M (^"L%"OT)$U)P6=4IZWZ2G-;@=(K&MY]]3Q9_ M QAZ)*&/MZ6!643K?-3@O0L@/"?@;-E3%&P.Q,7 ]9D<]H\'%7=7;*NN?^\= M)_X6@?0ES>H:LPT':GY MEP!UK!I>S0O]P^J%+K\?3QW^[":_);>:.][=E.5@\/*@VS M'N;@!!&9!" HNW+O.# E4Q23E,X3IO>L<-_KR?!I&@;&4FVU=[WJH#D4W3RN M66=$QO"<\I! ).3!)NG1IS&,.IH$R?T]/>^B8KA7QSXT^RQ0CA!S Z'"HQJN M3>ALG5(:'5S@D5H0LFP/XI:"YJD4M[J,0JIRU>T@J"7@'*/IKG^Q-X">#]/5 M9ZU8>#<97Z,C>Z^W/H0@E(X"6!1EI;(58'V@&(Q;+04+F9HZ#T+/DC7,FW4U M)/6G@@;P=-G-\&K'4.=3-]V.A01Y>@RINR!,F=8H"2S6,<> M[21IF'>?:CCJ1_0-8*B,#$F%_#?+^7B:YO,;$[M^R_>,*6D$!"OR:JPB&.HU M1!,2T3&P("OUBSY'UL EOF=RL/O74 MP6]-^,UR-$B=U+DMMM"D3CB2:VJP1 M%#1'Y2QCIE('X'TR!H[7^E/OT]W'1\AZX#+/7U<9P4L4W\WZF8]^B/-K@O"'[)"J?4\.0VN5$@+B=> S^ M9MAJIGX@T:,1A:* <MKZ'MJ>[7XQ31N2FU**_K-JHR_C?%>WA2EOOLK3)9E>MG%?(X. M8(I_N+]&66(,ZC0![CTMJUE0IHY;2"$F/,X$ ;:/D],3.4TX0SUBI!M680W8 MR6-8I#3&E)4H0])+$ZLT8%3I/8K.&DV)4+R.V:R%V+/U ?>&V'.IK\=14R=, M+DB+#],?:;Y:"/)A&I"S$9=>VUAFL9O"!+6Q/$&%,M010Q=F*9.Y"@:?(*8) M]Z\>QDX5?SM6;CYR-EOF1 9EI$3$)P^>YT\I5VK)S0\&P!:#GLD>' M";JWI<#'N6H7\1]H+E.\?5Y<8[Q,#1K9LL*840&4EOK%Z"38)!)*12?N2\6A MWB>A\,Q7[ 4(^>H T:=@F[B$WB;\[K"N/L0_3])*1=.RG1TE]^_5[TT:@H:.(+$:_?&FJYS,Y?= M%_=S/3(H):NSU1(5/^08ZG;\B_! < M["RC.U+DA]L]NSY[T[3HQ16[?Z-_SA]0'].KL9^DDN1 &RZUS](9#3[DB $' M12D)6>9U.YNDX%ZP.IW)S]/55B:J%R3UJ(@&D@0WE1>7W;7?% 26.L&K32M: MFI1NHLMNCIP)F;PH<_M<].7!O+R0VNR!>(7AC$PJBSI^_OXTMI64Z@5NE10T M:'A9'-*O^%?IP_5W-YX5H5U^<[.K-!]%88U4E *C 7U1)R+8J"U"0YK,&"5Y M>WC'DT[^TY_>5A[J)'CT),(&+- O71?_-9Y,[AA97-L^5W7])LW,51E-IJ8S.&T"7Z)=F "40"-U):*:,1:I^T0A^T MM)6L.MD^G5T]+5@S-YZ68_1Y6@:-?,XW,AA%9M'\J@34&@PQA)%@J.,0<[0) M;7(.<:_=XX?;LQT4M97LZL>B]2'\$R*]J_5JA;ZP=#&9=/]RTY#>=[.WW=(O M\G)R$4*WG"[FOZ>0QC]*!5))YJ!3-L:;'P4D> X*F"UCEH*U8!S>_,DP[P0E M5K,Z[\.'4KH7]LRKPEY590V/R9>>MG(,1@=" )U,AV;:$; A6LC<9LH%8S:] ME#WMX\W0O@K,]"G,!NZ\8\HFA4M>12L!V2P3X?!/+K&RA88$*K+U/KHZ.=U: M S+(JX#>N736 "S7!^JNQ\A-BGG^^BVMRAPO8AP7'MWD;C/A_,U/_.%[-W>3 M7V;=\OLU.7MB>VFZS8E3U'43@H03*)4>!DDIH7&LZNBY]1P M0>MD7L_#W^N;Z'$03!_U2#>'F09.TD$,EJ']-UW&1#F2G07K29%_:2=79;"^ M)=PJS8,BE2I#CB-X6*RWB+WMSG7?O@W[K9/_&C+[OK M[VDZ7UN<36"Y:1,BB2253+F#DT21EAQ%F1[*G"/<""FRVB=I?<17#XO8L\"A M.Y]N&C"US[=$QU36+G,/GJ329[&JV3'X8[16>ILHRY6\YO^LF02GN C]::@% MN#UHH]26T*1E!"/*.E+K!%X-5$,I'B3",!T$J0.OUS*3X"#U/CN3X!!9-]YO MS -7D:@ E*G246,">,D=>"J2IMZ8Y/T>UU\?_<9GFDEPD/(.Z#<^1)*-#ZIP M08B0702G:2W L*/J49 -7R@.G\'+B MYO-Q'H>U3HH)M38PZU=E*4:!4":"3\1 5)X:RHP.V\V]-8+"QX2]OM;S4[R8 M/K74-NAN8@XJK%&<0K >XP K%=B2+%4<#Q BQNETAES$4Z0U%,.="H3]07:$ M5MJ V1.1[9I-_$W& ^HFZ2;R5&BT2[NHSZ42U%N,=WEP8*E2W+.1*E\7NM#]IK9//C[Q^XL/),=VC,] M[>+RHBRJN>QFLW'L9G)5\9<\)$%T":C $U*:$NU B<9SUH'+[<+WG:L MI3Z=EE: =2P:N@%5TX#7=2?$DIQ;SC=^*1*O X$H& /!E05O2(00#?[@",W4 M5_&NGJ)FX.KP,\>.)^NC04QMCF6VEE"#AY&3L@=0J>(%HN-)9.#)4>'\?BM4 M3D95"Z'AZ7I^ 3A'"+T!Z'Q-B\4$O_66F8U57>T!H3[AD9()! L"K&,>:$2S MZE0P3M>IOMU!4%O@.4;7CQY03A=\$_C98\X#^@>99.6!"!%03C&BG"AJ/S$M M#:-1Y*I/<:=/Z:S7IW+N!]^^]37TC)5E.34HO=(^./\R<=-IBI?KBJ*1#)<<2%XI9EN4>7OMSW]'$0UZ/VNPJB';P%U\,&;XORH3% M7IJXM+=>4<,A<5X.'5I]HU2 G!./R;L0R3X3Q7HFJXG'PSI '%*!#5RQ7V9= M2"G."_]OQV6,XWB!#-UUA*7Y2!)&\-P9"$(A2V+]P)J 9L:0*R5\KK.BD=:G6@:^D]^C9-)LBZ'23W@U'?\[ MQ0_3R^5L=FNQWR249"J3CZU*,EBF4%[H>PA#.;BL(MIOEHG _S&C][A[C_SZ MMN8F]'K'GD,A]__/+/G>-? M?CFY/2%_W'XY)[O=7I__P*UV?_&"(&)=)W;>_?8K?,+_EU'GM__SZ_]]_YZO\XYW;ZQW1G8-#UNM1NLMVCVA_,.F-QN,C M=G!TP YW_Z?/!_D+_[FX)HH?/?:/=S/7?S]E\/P/!X-Y_/'!=>+IAWZO]V_O MK-_-J>/PT;_WV"3^L+/?XS^-V??X/?7<._\#O@"_8!+PUY57C ,O"#_\U,,_ M'^&;]Q,Z<[W'#_\^#%WJ_7LGXE/]/F*A.Q%?1^[_,OYH?FO\YX,<%K_:>L%=,.K^ M:W[WCD3AN.0+\0+R>8.=^?>/,QK>\9D:!7$LS!VQ]23,X"3(;Y6 M<[C7GW]_9PU'C'(4_F8/N/VNUM\5JM!@T 4I4I^%0M3$AX9BC;G>LU!\XOH. M_]>']X.#^0OIVF!_)5T[_O.&_'$Z/+_]@QQ?7E]=7@]OSRXO2M\S-WP^V)B. M/*9^, I"AX7O^: ].H_8!_67CXX;S3WZ^,'U<1!XT7-4[VBON[,W L6\_6( M'?5@J9A=-&Z_Q$[^NZ/#[E&O_&MN;/1WO^"]PXRUV,&UX=?QEXKFU/_'NYUW MF?>6;]*?\^4+/-KTX@:ED%R=#Y\FBLMGJ!7@5Q;@*EIGN4IQ,.>3M*=%^PFZ=-3+:=)1 MKTB/7DEK=@NU9LA=1X<[G]1WR#6+8O1$3R<3-H[=>T;^@_H)#1])OX/^Y\:7 MH_WN^2)L^O'S0)QB/H3,H[#2I9Z]U.9>>@D=<;5.XOPE+R*W1RN)[548S$.7 MQ5PVB[S[]-U7._OL:D=\&J;*>\?>C_C9[-M[.N%J^8%Z#_0QLF?'.!_M'^"V M6#PI!2M3P7UE=_^PV^L)"U^\L:2F._OE[OZ^NK;P>^OBXKVEO[=@=1?70Q66#YE[%=?P=+3QRN<(ZKN MEO^(^=S9[1[LK6@]GV:7>T^PRT_Z=P>?^M&1]#W.CVW]Q:RZ-B5*?]:WJ\/KV M[/C\E)R1GW\Z'/3['\\N;J\O3[X>P^[<7>.?@BW@=3?0C4WYKY1,0S;YQ[N? M5O'IUS$F,8<.&PQH=#"[315K\"['O0^W@9S\@>-\5_]C^2*^1'$0#XQ MGTW<> TJU^I6;75KMZFZ]3GQ80"OJSBM8(=ND#]J:@=8,5,$,-#:1 M/IQ,7,_=9"HB_=,:@]885,$8-#;S/_3]A'KDF$93[77O<;"Y_X1"-&;JA'P\=75?36#K1VX W8@<:" M/0P[L)Z=OS4!K0FHI EH+#A%U,^,W0V[ JTAJ)XA.&BB(3AJK"$(:.ALU 2H M/ZTI:$U!%4R!P1S>,%MP/*7^'2.N3X[Y;\-@S8>"U@BT1J R1J"Q^,'CP*D" M4J#;)%MPT#CU:BPH[SB8S=P(."PV!\IK%:N^BM58F)NA6)L(:KJK6HW%80&C._4?R<;*M5JMJJ]6-1;AI+0*XY?N*%DS34RK M4_75J<:BA: /S3$-V8R&W\@UBP$R#%U(Z"/TGVTUZ0>G][!QFM18T(T*2[24 M,*UVO9IV-1;)HK1KJ5K$6M093U$L[\U=J1*DN*6A!O]Z.8'Q(W9X8UE,[ M]>X,NH.=G94Z]5;EMKM/Z2O\0OH@IOM==?J/OBA'V#,F88'LKV]VZ!TC/__4 M'^Q^).Z3S4/)R$M;J+:-6]O.@^77UMK'&S06H5C<$/74 \+U5XWTM8Y=?;6I ML5"_$S>B(]=SX\W6 +7Z56_]:BS6[P1:%<@LU,::@;2:55_-:BS8K^VQT^K6 M*^M68T%_XC1ED$)M(EW5:E9]-:NQF+]3/E87 H2GW]DX63/S8JM9]=>LQN+^ M3F=S+WC<,$Z]U:TZZU9C\7^GUVGG5VFDL$N/WD/K.A,93IN 8ZZAF;%6IOJK46!B& MK4KKA+&WZE1?=6HLZN(\B&+RA<;C*1^&50F\AD16JU'UU:C&HBVN* S:Y:^Z MX;;"K7;55[L:B[> !KUDZ,Q<'^""- ["5K%:Q7HYQ6HLW (5ZR]&-Z!/K78U M1;L:"[GXKX2/=N(RAQA1]N)S5ZM'K1XMTZ/&PBNN6>R&[!6IE%K=:KIN-19< M<3-G8[%';0@@V!RM,KKF-$6M&@NKD&HU5I[?!LY8K6+55[%V&PNJN&7AS/4% MJ44PD9O6FES#YFC4F^F\!:K?O-9;NXT%@MP&,?6 6'<-ZM[:@M86O %;T%@4 MRU??Y>..N#W8[1T- 17F^JX@$@G&R:OY!*WFMYI?#77ZZ&%W_Q_U[<7I]]^@I'XYM669?-[&:5M6A,9E =>L[\36?84@0._N+';L^Q&J^NMKE=" MUQM[2/\2.% F(D_I(5?Z^V"79T8REH.:FXI-;=\9']F*JWBK_6U#^ MO47*_PLVNU>?&Q.LPO([(-%!A*4.'T+F4>B-(/O=RYDPKAH%<1S,/O322^@H M"KPD+K_$6'E<3+ \,*;TEJ'#PO=\YCPZC]@']9>/CAO-/?KXP?5Q)O"BCS,: MWKG^>SD.4,>L),'CQ-?ID+H],2PTA_DV]O]F)!*L[W:@Y^=.Z=>];K_TNTW= M=G>EV\J-X86T5TRW6/87T=&CE53T*@SFHTTG,P@_4>Z"/ MD3T_?+=2@]X_Z((V9ZW(DJ<6#WC,?/[$M1N:W?U#;FB$;U5L:"R1LW5W5VUQ M96K_S"]W>_MJ4"]\YT&_.UAUR$U.NZ99U^'Q\>77B]MG)U;?C->V(7?YK2=I M#YIWC-MK;I+V-(*=QHVF"D[Y*0B^?6-L#OD:V8SBI1.X3;$$;_U,UTA+T-@< M[4TRHJ^C[ZUI:$U#'4Q#8U.Z?SS.@WC*<.#D@B+]'W<57LD]: U":Q#>AD%H M;,+W3Q;%KYOC6?5/:Q]:^U!9^] FAX]#YKA@*LCE?$W-^%JCT!J%*AN%QO:. ML4X1OU/7CP >>AY$$7MUL]!:A+=A$0[;-2\W7V_N8G$$^ACJB"@NH1+&P3I>2IUFNW%M:KL;E/VRA\G4/%6UD'-UG_>CNE/DE;_G:$Z8#H9^HDM:CDGKLKQQ:6FF%6MLYO7-R.7G M()R9,>*-V+#6B+T-86FF$3MHC5C%Y5*Z8A A*LJ)O;I1:\W7FQ"300-[%^QW M#UOS57&YE%4]).U(FD",BUK6[)6,6&NZWH2(#!K(Z+K?/6I-5\7E\H1%?%9U M'/X3\]G$';LT?%S;2;*U8&]"4IIIP:"%;&O"*BV87_VQ1]T9Q.RTE CUEB(]9L1S#]HZ$13=T[^Z<93)Z0/0/V]9CO6VK W(2I/M6'U $_U M&XL*?S.":<7N^6'R]Y#ZSH0"GHL[9[K 747+@ 4=T*'VSU1C!/FK$E%OE[]Z MRS]X6@>3MA*U+8A<&EC7);-IS>SPY,O9!=3-#J%JM@U2M0)CVJ &=E0Y:&X% M[9O9&Z\\ZI.A,W-]\)%H'(0MV+05E]:,66:L/>%572Y_9SZ#(]Q5\,!"[$=K MV+37!FJUMNM-R$@S;5=;F5QUN3P.HGC=)JNU86]35IIIPQI;G_QFY/+,=]C, MU[W"-U3LTQJR-R,PS31D;>UUU>5RMW?;DA5]>7QZ_!Q.)\SZJ'(OI4W68>I?4O3T58BO)FU:N;FT*9O MJRZ78D,01/@;?KXE):X_4FA.2)QJO-V+Z)+-Q!%3*V9_^M\[5?SFZ.3\_/AQ>GEU]OUN9( M-<4$O7%Y&32P4_I1F[7=C%P^86N\"&+1;X2.8[OST7K.@DTQ7V]<3)IIOMH\ M;=7E\B+PWP\CY(R5G6HU:VR\'BQ*:\#>A* L-F"_Q'3D,?6Y,>GJ1+@#DQU$ M+MXQ9!Z_]3W[^. Z\53-A''5*(CC8/:AEUY"1U'@)7'Y)88TX&*"]80QI;<, M'1:^YS/GT7G$/JB_?'3<:.[1QP^NCS.!%WV^3H?4 M[8EAH4EWU)/EUUW\2LFW]=W.H#O8V2G]NM?MEWZWJ=ONKG1;N;F]D$:+Z1;+ M_B(Z>K22BEZ%P3QT64S#IW>H?$+HXAF3L$#VUS<[]([Q$WQ_L/N1N*[[9 -1 M,O;??AV%66MC_.\T3*?OCKT?A8Q^>T\G,0L_4.^!/D;V!,VX+BM+=- %=7?5'E>F]\_\WKP;UPG<> M]+N#58=<:V^Z10M5W4D"LM]IX,%L(1WF"7,2S*#@OV[I=_9*/G7K1+\)^6AF M%* %LE1=+H7=;U:H_4FA&-PV$2CU;9YK[I<7@3D-DRBF!R'C,;,:1E3 M6FEIK9AMQ=H^[U67RZ]^!,X6]7E$BL=-DVVV=JR-R4SS;1E;:_WJLOE%46<,8D#\L7U@U#$N\[\ M<3";LYA_\UH OM9NO0GY:*;=:CN\5UXPA^,Q\YCX"$Z(_+AXPCSZ2%R?2*,6 M/95,9*,O]/(F]LED*IM]_Y9,Y"HD;M"6TE7=<&\87Q^917*Q@_GK3%[ M$S+34&/6UM5573!_#_C\^DBD\M+(D]:,U4Y:&FK&VH*&J@OF)]?'8H;3R82- MU\1HT)JRMRPQ3S1EE::*&NRV5%$5H/X97EV=7IR<_3<9:JJHJ^O+/\]NSBXO M;@C_]OSL>/CI_)3<7O*?7 V!6>KL:GAQB[\^^'A#?K\>7IQ\'M[^<7I]>D). M3C^?7E\/S\GP^/CRZ\4MX5]F?G)\^87?X"_UBU7M7E-LU!L7J)W>T]RM=9@! M7,G#=K=Y8B8!)M=C)&WZ=<(FKH^<$=%&8TA-,05O7(!:4U"7E=2FX$_3%K P MI)X 1D"=$/4?!5N;.TI>PT:T6O\F9.6I6K\.RMA6ZW]$ZU.E_T)=/V8^U@,& M$S(4-%;[7^[,M-J?UU64FM_ZO\K4&1*8[C68T!K MZ$X#S1!+11 MRC:HM'*4\M-SHY0J'/GUXN3TFMS^<4HNOUSPBZY/.^3LXK@K Y(;@N\&]WCC_98/"R*7;@C4M/ M:P?JLI+*#NP(.V %*+DSL7.8AC+)J8G9WV"%,! MSU(?88Z)\=<7.\T,3V\OAN3F*[_X],OIQ>WPG.SV^EO_N8U'&$1AB)^4G'.N M+W^_'GY9LV/T6M:PB,>]/1?]T+EHYUD=*JQ)W^WFY_S]D9[Q GYXDV7>HG+' M5WG5F\N/N,'C0F<)G":F7W[?MD%'VZ"C;=#1E 8=]VOJSP$W<)U_O%N^9?1[ M^^_45<_OZG$ !O#Y/3TREC1CHN'DG+>NXA/7=_B_U.'Z)7;EP4J[\E"U3]7N MV=G%[?7ER==C\)5^8!>Q=JR=??O-_Y5$L3MYM%[]_<[^^CR2 ;Q[/VV+N:Z' MVM,R&'3[:#8NZ Q!!E<>];NO/.GK.@7C%!__>4/^8-2+I^0X".?2T2);\92A MP UZ'R6<"O_5_[A-IBQDHT="G6 >1P1^:-Q$A"^8 &$Q/Q*W@VDC-"(4Z.?Y MEX#2"ED4 R$J?,YG]C^HGW"[3OH=,N@-!M8(X'+U^->>_8V+_* B(G^5<'&( MZBGUMURVYNG[@:BAB+H1<"S-P^#>=1@9\_V>NCYA?)PN.+!,$EQ&ZB*%- Q" M+M)D.)FXGLMEFM DG@8A'Y!#N*;(7\[<.&8,'Z#C_PR84/3CX2_!G"MAG/C0 MH9'_U %]XB-@R)4"SYWR0?+G =?YV-2QAZD[GI(9O"7Q@Y@$0(?^X/(W'#%Q MFQ"]\(2+=BB^)=S=]B,R R 5___6:(O?B^LM']2,?M.WE)C+D(T9/T?P(9DA MS7A*8_(0))X#@PA&\!1C$!G;\3F)DY#Q__#[0;S@V[:8EBUI!HSOM3&2T\=P?[N4X]L3T&X2,<@SD+LP2.9PLQGU MN4LND%7X^IH>&7I4:0WP\?%C)^*]8A?+ NJ%8L-GE4?CV6!]?SP BP M[_P&,9F$P0SSH!$9=,@.CFT7GG_KQECFD;Z7.5]@V-('!.3OA*_CY%':DQN1 M,4'C0;=3(]T G=ZMB$Z#<>:?UE9AE3)UR1#E6?1/UM(]IZXC9!LD[TYR9=,H M8G'6:>BF, #8V4T_()I2?KLIY?LI?!9IAFUUPT33<8\E#7?N[G47^+V*"+PH MF ?7YX2;QWK*_0,\&3+]R[NC6/SHZZ* Q+SSJ<2$';>$RXX8L MSM_IA'N1LQ&WY#MX#.P==L#(P^[#'XL]?T#$T3^/T(_CUZ1&_VBHE*#0KY-# MN4L\Z03R^\P2[PY'AMN8V$5P]/9P^@_P4_V MQ=O;I]D>O 7?)7&G5?ZIPZ 9NWB:,W-]E[NK&(LGXRGU[_C^"K\(*U#^KO:0>5$12 M+Q*T0&!*?@>K&]9*6/\)IOD>WF\^QP001"+@,]?OD(<@=+A7%@GA0V^)#YZ; M^#"5[3$W]JZ#DLWML.N/O<01GM7<2] _XQ.7OY'\*L\J,1N,$7@/< M-0<.9 \P6A@^HR&WV'\V)6[]X2!8NJ;B4=D/ORQ)V3'6WNU/:R( MVO[!*'P:U4I;03RG\L6P+%/L!R($)WVU2*HOH2%3HNB0*/ 8=_,@+,%5C?MM M+H3TA#_E3H2'!D

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end

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�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�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